,nct_id,primaryOutcomes,secondaryOutcomes,startDate,status,study_type,phases,otherOutcomes
0,NCT00115570,Change in total glycated hemoglobin measured as HbA1c equivalents (GHb )from baseline to endpoint,Change from Baseline in basal insulin dose,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
1,NCT02275845,incidence of gestational diabetes mellitus in both groups,Neonatal outcomes,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2,NCT02682121,The primary outcome will be gene expression levels of mitofusin 2 and uncoupling protein 2,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
3,NCT01814735,"Changes in fasting blood glucose, lipids, and blood pressure",Feasibility and cultural appropriateness,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
4,NCT01271231,Glycated hemoglobin,Probing depth,2010-04,COMPLETED,INTERVENTIONAL,['NA'],
5,NCT04729985,Emergency room visit and rehospitalization,Patient satisfaction,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
6,NCT02058160,Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30,Percentage of Participants With Severe Symptomatic Hypoglycemia,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
7,NCT03176472,Change in Mean Average Pain Intensity (NRS),Change in Non-pain Neuropathic Signs (UENS),2020-12-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
8,NCT05755555,HbA1C(%),,2022-08-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
9,NCT01140542,Mean change in HbA1c [percent] from baseline to the last study visit (Vlast),"Time to event (study withdrawal, time to study withdrawal due to an adverse event (AE) and time to lack of efficacy (LOE)",2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
10,NCT01275820,Glucose blood level,Dosage of Insulin,2010-06,COMPLETED,OBSERVATIONAL,['NA'],
11,NCT03878758,Injection Site Pain for BD Nano PRO Needle Compared to Each of Three (3) Commercially Available Comparators,Compare BD Nano™ PRO vs Each of 3 Comparator Pen Needles (Force),2019-02-07,COMPLETED,INTERVENTIONAL,['NA'],Compare BD Nano™ PRO vs Each of 3 Comparator Pen Needles (Total Injection Time)
12,NCT02148861,Number of treatment emergent adverse events,area under the glucose infusion rate - time curve at steady-state,2014-05-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
13,NCT00948168,Improvement in HbA1c,"Non-invasive modeling of glucose homeostasis determinants, including insulin sensitivity",2008-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
14,NCT01001104,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks,Percentage of Participants With Self-Reported Hypoglycemic Episodes During the 12-week Treatment Period,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
15,NCT02157480,Mean CGM glucose from a 6-day CGM recording,HbA1c,2014-09,COMPLETED,INTERVENTIONAL,['NA'],cardiometabolic stress test
16,NCT04841720,Tmax,AE/serious AE,2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
17,NCT04734158,corneal epithelial thickness,,2019-08-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
18,NCT04407819,prevalence of sarcopenia in patients with T2D and in the control group,fat mass,2018-03-20,COMPLETED,OBSERVATIONAL,['NA'],
19,NCT00520065,Positive area under the curve (AUC) for plasma glucose and mean glucose level,Adjusted peak values for plasma glucose and serum insulin concentrations and positive AUC for serum insulin concentration,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
20,NCT03378635,Time to Plasma Glucose Recovery,Time to First Rescue Infusion of IV Glucose,2017-12-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
21,NCT03662997,% of Participants With No Strike-through After 7 Days Wear Time at Day 7 and 21,Mean Difference in Score in SF12 Health-Related Quality-of-Life Questionnaire,2019-03-19,COMPLETED,INTERVENTIONAL,['NA'],
22,NCT03205436,Time to initial closure of diabetic foot ulcer,Mean cost to heal,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],
23,NCT02158078,Change in glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood) from baseline at Week 12,Change in measures of PROs from baseline at Week 12,2014-06,TERMINATED,OBSERVATIONAL,['NA'],
24,NCT03580330,Mean HbA1c,,2014-04-17,COMPLETED,INTERVENTIONAL,['NA'],
25,NCT00526513,Glycosylated Haemoglobin (HbA1c),Control of Post-Prandial Glycemia (PPBG),2007-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
26,NCT01307904,Dates Glycemic Index,,2010-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
27,NCT03741660,change in systolic blood pressure,change in apoB:ApoA-1,1991-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
28,NCT01302327,beta cell function,,2011-03-01,WITHDRAWN,INTERVENTIONAL,['NA'],
29,NCT05123963,Change in glucose control.,Change in plasma cytokine levels,2021-09-15,RECRUITING,INTERVENTIONAL,['NA'],
30,NCT03878706,Comparison of Global Longitudinal Strain (GLS) difference among treatment groups.,Comparison of liver steatosis level between treatment groups,2017-11-03,RECRUITING,OBSERVATIONAL,['NA'],
31,NCT01053728,- Pharmacodynamics (Glucose infusion rate) time-action profile,- anti-insulin antibody production,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
32,NCT00657800,Quality of Life (QoL),Emergency Room visits; admissions,2007-12,COMPLETED,INTERVENTIONAL,['NA'],
33,NCT02802644,Neointimal coverage assessed by optical coherence tomography,Biomarkers,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],
34,NCT04659330,glucose variability,Insulin dose in patients with and without lipohypertrophy,2018-06-01,COMPLETED,INTERVENTIONAL,['NA'],
35,NCT01051674,Weight,Hemoglobin A1c,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
36,NCT00721084,Total energy expenditure,Physical activity related energy expenditure,2008-07,COMPLETED,OBSERVATIONAL,['NA'],
37,NCT04442334,Detailed Characterisation of the NAFLD Patient Phenotype,Health Related Quality of Life: NASH-CHECK,2015-05-01,RECRUITING,OBSERVATIONAL,['NA'],
38,NCT00849576,Postprandial time course of Asymmetric dimethyl arginine (ADMA) after injection of insulin VIAjectTM compared with regular human insulin and insulin lispro.,"The secondary objectives are to evaluate the postprandial time course of arterial elasticity (pulse wave analysis; PWA), blood glucose, insulin, intact proinsulin, nitrotyrosine, glucagon, ICAM-1, VCAM, E-selectin.",2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
39,NCT03761446,Mitochondrial Respiration,Physical function,2019-03-18,RECRUITING,INTERVENTIONAL,['NA'],
40,NCT00973830,Diabetes knowledge,Change in HbA1c reading,2008-08,COMPLETED,INTERVENTIONAL,['NA'],
41,NCT01027871,Fasting Blood Glucose (FBG) Level at Week 12 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles,Glycemic Variability in Fasting Blood Glucose at Baseline and Week 12 - Subgroup Analysis of LY2605541 Dosing Algorithms,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
42,NCT02644590,"blood pressure monitoring , pre and post treatment with melatonin",,2016-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
43,NCT00607139,Glucose level at which counter-regulatory hormone response is achieved,Accuracy of the Guardian-RT continuous glucose monitoring device,2006-12,COMPLETED,OBSERVATIONAL,['NA'],
44,NCT02225379,Positive Predictive Value of the hypo-Sense,,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
45,NCT01044017,Effect on postprandial plasma glucose concentration,"Safety and tolerability: AEs, laboratory parameters",2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
46,NCT00240019,The amount of protein in the urine after 8 weeks of treatment.,The estimated glomerular filtration rate after 8 weeks of treatment.,2003-12,COMPLETED,INTERVENTIONAL,['NA'],
47,NCT01784289,Measure of blood Interleukin 7,Count of blood lymphocytes T,2010-06,COMPLETED,OBSERVATIONAL,['NA'],
48,NCT04014023,Change from baseline in HbA1c,"The proportion of patients who achieve HbA1c < 7.0%, HbA1c < 6.5% and HbA1c reduction >0.5% from baseline",2019-07-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
49,NCT04853537,gestational diabetes,any associated comorbidities questionnaires,2021-08,UNKNOWN,INTERVENTIONAL,['NA'],
50,NCT00769275,"Overall cardiac event rate (cardiac death, myocardial infarction) was 3.0%, not different in screened and not screened cohort",,2000-08,COMPLETED,OBSERVATIONAL,['NA'],
51,NCT00733577,"Safety measures including: AEs daily; laboratory testing: day -1,2,5,7 and follow up; ECG: day -1, 2, 5, 6, 7 and follow-up; vital signs: daily; PK parameters day -1,5, and 6.",Subject reports of hunger and craving as reported on the Hunger and Craving questionnaire,2008-08-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
52,NCT01479933,Insulin sensitivity,Adipose tissue gene expression,2011-09,COMPLETED,INTERVENTIONAL,['NA'],
53,NCT01293318,Association between copeptin level and severity of pancreatitis (according to Atlanta classification),"Determine whether change in copeptin level from day 0 to 2 is associated with organ failure, necrosis and/or superinfection",2011-03,COMPLETED,OBSERVATIONAL,['NA'],
54,NCT04019938,Serum Cystatin C,Bone mineral density,2019-07-04,UNKNOWN,OBSERVATIONAL,['NA'],
55,NCT02653599,Change in HbA1c from baseline at 12 weeks,Pulse,2015-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in glucagon-like peptide-1 levels from baseline at 12 weeks
56,NCT02220296,Incidence of adverse events,"t1/2, the terminal half-life of insulin 338",2014-08-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
57,NCT01103284,Change From Baseline in Glucagon-Stimulated C-Peptide AUC at 24 Months,Mean Number of Days With at Least One Hypoglycemic Event,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of Subjects Requiring a Daily Insulin Dose ≤ 0.5 IU/kg at End of Study
58,NCT02340260,Glycosylated hemoglobin (HbA1c),,2013-08,COMPLETED,INTERVENTIONAL,['NA'],
59,NCT04812262,Number of participants with clinically significant abnormalities in 12-lead ECGs,Number of participants with antidrug antibodies (ADAs),2021-02-24,RECRUITING,INTERVENTIONAL,['PHASE1'],
60,NCT03722225,"The percentage of the glucose values spent in target range, defined as 72-180 mg/dl.",,2016-01-20,COMPLETED,INTERVENTIONAL,['NA'],
61,NCT00674986,Change From Baseline in Hemoglobin A1c (HbA1c) at Month 12,Glycemic Variability Pre and Post-Prandial Excursions at Each Meal,2008-03,COMPLETED,INTERVENTIONAL,['NA'],
62,NCT06020664,Proportion of subjects with complete wound closure during the 12 weeks of the Treatment Phase,Changes in Wound-Q Health-Related Quality of Life outcome during the 12 weeks of the Treatment Phase as measured by changes in the subject response to the Wound-Q Health-Related Quality of Life scale,2023-08-16,SUSPENDED,INTERVENTIONAL,['PHASE1'],
63,NCT04124354,Change in Shannon Index (Alpha-Diversity) as Reflected in Change in Operational Taxonomic Units,Change in Body Fat Percentage,2020-02-10,TERMINATED,INTERVENTIONAL,['NA'],
64,NCT03859193,Change in nutritional knowledge,Patient Satisfaction with Care,2019-09-27,COMPLETED,INTERVENTIONAL,['NA'],
65,NCT03574935,Wound healing rate,,2018-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
66,NCT00553020,To assess the duration of the metabolic effect of a sc injected single dose of either insulin glargine (LantusT) or NPH-insulin (ProtaphanT) on blood glucose control in patients with type 2 diabetes,"To evaluate the effect of insulin glargine (LantusT) and NPH-insulin (ProtaphanT) on suppression of endogenous glucose production, endogenous insulin secretion, and lipolysis",2004-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
67,NCT01642394,Change in Glycated hemoglobin,Change in the diet composition,2011-10-01,COMPLETED,INTERVENTIONAL,['NA'],
68,NCT01789190,We aimed to study the influence of regular physical activity on the prolongation of the honeymoon period in type 1 diabetic patients by determining circulating parameters.,To study the influence of regular physical activity on the control of the inflammation process associated to type 1 diabetes.,2011-01,TERMINATED,OBSERVATIONAL,['NA'],
69,NCT00069615,Feasibility of collecting data from home computers,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
70,NCT01029288,"Decisional quality (knowledge, decisional conflict, and satisfaction)",Patient medication adherence,2010-04,COMPLETED,INTERVENTIONAL,['NA'],
71,NCT02471404,Change in Haemoglobin A1c (HbA1c) From Baseline to Week 52,Number of Patients Rescued,2015-09-21,COMPLETED,INTERVENTIONAL,['PHASE4'],
72,NCT06171412,Mean hours per week CGM worn,Mean count Barriers to Device Use,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
73,NCT03117543,Percentage of hOGTT venous plasma equivalent glucose (hOGTT-VPEqG) results within ±10% of paired venous plasma glucose measured on a YSI analyser (VPG-YSI) (reference standard).,Specificity of HbA1c for screening for GDM versus gold standard of 75g OGTT and VPG-YSI measurement (IADPSG 2010 criteria).,2016-03,UNKNOWN,OBSERVATIONAL,['NA'],Serum insulin concentration at 60 min after 75g oral glucose in pregnant women of Black (Black African and Black Caribbean) compared to White European ethnicity.
74,NCT06282055,Identify different trajectories of insulin sensitivity throughout the menstrual cycle,Correlations between insulin sensitivity trajectories and confounders,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
75,NCT05574023,Less time spent in hypoglycaemia using Predictive Alarm vs Alarm on Threshold,Better glycemic metrics using Predictive Alarm vs Alarm on Threshold,2021-05-10,COMPLETED,INTERVENTIONAL,['NA'],
76,NCT01676116,"Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)",Change From Baseline in Patient Reported Outcomes (PROs) Based on Diabetes Treatment Satisfaction Questionnaire (DTSQ).,2012-08-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
77,NCT02631148,Change in Systemic Renin-aldosterone-angiotensin System (RAAS) Activity,Change in Central Blood Pressure,2016-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
78,NCT04144920,Glucose variability (mean amplitude glycemic excursions),Physical and Emotional feeling states,2018-08-01,COMPLETED,INTERVENTIONAL,['NA'],
79,NCT01932866,Change in abdominal circumference,Change in diabetes risk score,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
80,NCT01059812,Change in HbA1c (Glycosylated Haemoglobin) After 26 Weeks of Treatment,Change in Body Weight,2010-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
81,NCT00119041,A1c,Patient Satisfaction,2005-09,COMPLETED,INTERVENTIONAL,['NA'],
82,NCT01754337,Percentage of time of plasma glucose levels spent in target range.,Percentage of overnight time of plasma glucose levels spent in the high range,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
83,NCT00213109,,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],
84,NCT02812030,Change in Best-Corrected Visual Acuity (BCVA),Non-ocular adverse events,2016-09,WITHDRAWN,OBSERVATIONAL,['NA'],
85,NCT01741467,Differences in blood glucose,Changes in medication use,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
86,NCT02562326,Pharmacokinetics: AUClis 0-30min,Local tolerability,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
87,NCT06280729,Primary Endpoint,Exploratory Objectives,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
88,NCT01354262,Change in serum levels of Hemoglobin A1c.,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
89,NCT01051102,Area under the Glucose Infusion Rate curve after a single dose,Area under the insulin aspart concentration-time curve after a single dose,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
90,NCT05616026,Change in HbA1c,Appointment Adherence,2023-02-07,RECRUITING,INTERVENTIONAL,['NA'],
91,NCT05922280,Douleur Neuropathique 4 Questionnaire DN4,,2023-02-15,COMPLETED,INTERVENTIONAL,['NA'],
92,NCT01742208,Percent Change From Baseline in Total Daily Bolus Amount of Exogenous Insulin Required Calculated Over Days 3 to 27 (Treatment Outpatient Period),Change From Day 1 in 3-hour Urinary Glucose Excretion Following a Mixed Meal Tolerance Test (MMTT) to Day 29: Expansion Groups,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
93,NCT05124457,Prolonged neonatal hypoglycemia,5 Minute APGAR,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
94,NCT00666718,Change From Baseline in Hemoglobin A1c (HbA1c) to Week 24,Number of Injections of Insulin at Week 24,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
95,NCT02579148,Improvements in IIEF scores,Safety and Tolerability assessed by Adverse Events,2015-09,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
96,NCT00889668,Clarke Error Grid,User Satisfaction,2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
97,NCT00707031,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Quality of Life: Change From Baseline in Patient's Satisfaction to Treatment (PAGI-QOL) at Week 24
98,NCT03939000,International normalized ratio,,2016-03,COMPLETED,OBSERVATIONAL,['NA'],
99,NCT05762471,"Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM",Identification of GSBR-1290 metabolites following oral administration of multiple doses in plasma,2023-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
100,NCT00877929,Change From Baseline in Trough Seated Systolic Blood Pressure to Week 8,Change From Baseline in Urine Albumin:Creatinine Ratio (UACR),2009-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
101,NCT03685253,Thigh Intraepidermal Nerve Fiber Density,Distal lower limb intraepidermal nerve fiber density,2019-01-24,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Cardiac Autonomic Neuropathy
102,NCT00287456,,,2006-02-02,WITHDRAWN,INTERVENTIONAL,['NA'],
103,NCT06035367,Value of absolute photoacoustic signal on the participant arm,assess the tolerability of the investigational device by a usability questionnaire,2023-07-06,RECRUITING,INTERVENTIONAL,['NA'],
104,NCT02180334,Area under the curve (AUC) of plasma total GLP-1 levels,Area under the curve (AUC) of plasma active GLP-1 levels,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4'],The time to peak concentration of plasma paracetamol
105,NCT05013229,Change in HbA1c,Weekly insulin dose (total),2021-11-30,COMPLETED,INTERVENTIONAL,['PHASE3'],
106,NCT05118061,Analytical verification of StatStrip glucose/ketone meter system - ketone comparison,,2022-05-25,COMPLETED,OBSERVATIONAL,['NA'],
107,NCT03800875,Total percentage of time (22:00-22:00) that the glucose concentration remained within 3.9 and 10.0 mmol/L,Mean glucose level,2019-02-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
108,NCT05399446,Change in Eating Disorder Symptoms,Change over time in Diabetes-Related Quality of Life,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],
109,NCT05416580,Change in inflammation marker level: high sensitivity CRP,Change in body weight,2022-09-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],
110,NCT05414409,Changes in the gut microbial metabolites in obese youth with type 1 in response to metformin,Changes in measures of beta cell function using a timed mixed meal tolerance test,2022-09-30,RECRUITING,INTERVENTIONAL,['PHASE2'],
111,NCT02739906,BG1h,Local tolerability (Number of injection site reactions),2016-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
112,NCT00171717,% of patients whose diabetes resolves 6 months after the conversion (fasting glucose < 1.26 g/L without hypoglycemic treatment).,Incidence of acute and chronic rejection treated at 6 months and at 1 year.,2004-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
113,NCT05849714,"proportion of patients with glycaemia level within target from arrival to departure from the endoscopy unit, i.e. between 4 - 10 mmol/L. (Part 2 of study)","Proportion of participants who experienced: episode of hypoglycemia <3 and < 4 mmol/L, episode of hyperglycemia >10, > 15 and >20 mmol/L, episode of ketoacidosis. (Part 2 of study)",2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],
114,NCT00862875,Changes in total fat mass (in kg),"Epicardial fat, trunk fat, total fat free mass, weight & waist circumference, HbA1c, fasting glucose, RMR, TEF,PAEE & TEE, energy intake.",2009-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
115,NCT01337440,the difference of haemoglobin A1c (HbA1c) and glycoalbumin (GA),change from baseline in autonomic nerve function,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
116,NCT00715221,"Physiological measurement; Differences in tissue insulin-stimulated glucose uptake used by PET imaging among normal weight, obese and patients with type 2 diabetes",,2007-07,COMPLETED,OBSERVATIONAL,['NA'],
117,NCT02492763,Change From Baseline in Heart Rate at Week 12,Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12,2015-07-27,TERMINATED,INTERVENTIONAL,['PHASE2'],
118,NCT05671679,Percentage of time with sensor glucose in the target range,Percentage of postprandial time with sensor glucose in hypoglycaemia,2023-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
119,NCT02002221,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks Between Treatment Groups,"Number of Participants With Adverse Events, Serious Adverse Events and Death",2013-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
120,NCT02585778,Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs),Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Weeks 12 and 24 - On-Treatment Analysis,2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
121,NCT00659477,The change in blood glucose variability,Comparison of dose of insulins NPH vs Lantus,2008-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
122,NCT03785236,Hepatic uptake of 68Ga-NODAGA-exendin-4,Islet graft function,2016-06-06,TERMINATED,OBSERVATIONAL,['NA'],
123,NCT01213784,Left ventricular function,Muscle strength and mass,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
124,NCT02804620,Change in HbA1c%,ApoB,2014-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Weight
125,NCT03474601,Treatment outcome of pituitary diseases,Complications of pituitary disease,2015-03-15,RECRUITING,OBSERVATIONAL,['NA'],
126,NCT05872009,Number of neonates with adverse neonatal outcome,Percentage of participants with pathological placenta histology findings in case and control groups,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
127,NCT04527107,"Mean change in best-corrected visual acuity (BCVA) ETDRS letter score from Baseline, in subjects in Part B of the study",Incidence of systemic and ocular adverse events (AEs) and serious adverse events (SAEs),2020-07-31,COMPLETED,INTERVENTIONAL,['PHASE2'],
128,NCT05125185,Change of VCAM-1,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA'],
129,NCT03568630,"Result of MMTT which may indicate type 3c diabetes, which may be a risk factor for pancreas cancer.",,2018-07-26,RECRUITING,OBSERVATIONAL,['NA'],
130,NCT03700528,Committed Action Questionnaire (CAQ-8),Work and Social Adjustment Scale (WSAS),2018-10-01,UNKNOWN,INTERVENTIONAL,['NA'],
131,NCT01030601,Central Retinal Thickness,Best corrected visual acuity and incidence of laser treatments,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
132,NCT05647083,Means of diabetic foot risk score,,2022-09-09,RECRUITING,INTERVENTIONAL,['NA'],
133,NCT06063759,Accuracy of the Vital USA VitalDetectTM for assessment of microcirculation (in AU),,2023-09-25,SUSPENDED,INTERVENTIONAL,['NA'],
134,NCT01237119,Liver Histological improvement,NAFLD Activity Score,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
135,NCT02848833,Percentage of Participants With Adverse Events Leading to Discontinuation of the Drug,Number of Participants Per Final Effectiveness Assessment Category at Last Visit,2016-08-10,COMPLETED,OBSERVATIONAL,['NA'],
136,NCT00993473,"Event Rate of ""All Hypoglycemia"" Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)",Average Daily Blood Glucose (BG) Based on CGMS Values: End of Treatment and Change From Baseline to End of Treatment,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Nocturnal Blood Glucose Variability Based on All On-treatment CGMS Values
137,NCT04306848,Blood glucose profile,participant survey,2021-01-01,WITHDRAWN,INTERVENTIONAL,['NA'],
138,NCT02829593,Change in Euglycemic GABA level in hypothalamus using MRI,,2019-10-31,COMPLETED,INTERVENTIONAL,['NA'],
139,NCT04615910,Pancreatic 68Ga-exendin uptake,relative 68Ga-exendin uptake,2021-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
140,NCT05391984,SPADI for pain and disability,,2022-06-07,RECRUITING,INTERVENTIONAL,['NA'],
141,NCT00851201,"BMI percentile for age and sex, biomarkers e.g, glucose, insulin, lipids","dietary intake, and physical activity measures",2009-08,COMPLETED,INTERVENTIONAL,['NA'],
142,NCT01606904,change in weight,change in incretins,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
143,NCT03449199,Changes in Log-transformed Urinary Albumin-to-creatinine Ratio (UACR) at Week 12,Changes in Exploratory Renal Biomarkers (Creatinine-Corrected N-acetyl-beta-D-glucosaminidase),2018-04-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
144,NCT02834715,Glycaemic profile in response to mixed meal test,Liver enzymes,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
145,NCT04064996,Pain assessment With Visual Analog Scale,Albumin levels,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],
146,NCT03937453,Early Stage Pancreatic Cancer or Precursor Lesions,Relative Risk of Pancreatic Cancer Among Individuals with Detiorating diabetes,2018-01-19,RECRUITING,OBSERVATIONAL,['NA'],
147,NCT05473767,Change in postpartum weight retention,Change in physical activity,2022-11-18,RECRUITING,INTERVENTIONAL,['NA'],
148,NCT04974333,HbA1C,Waist circumference,2021-10-04,UNKNOWN,INTERVENTIONAL,['NA'],
149,NCT04316429,Change in Endothelial Function (EF) Assessment:,Change in Physical Activity,2020-06-09,COMPLETED,INTERVENTIONAL,['NA'],
150,NCT00203632,The primary end-point of the study is the percent change in forearm blood flow to acetylcholine in patients randomized to rosiglitazone compared with placebo.,"Secondary end-points include (i) the percent change in forearm blood flow to verapamil and the absolute change to both acetylcholine and verapamil and (ii) the relationship between HOMA-IR, CRP and endothelial function.",2003-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
151,NCT03552991,Quantitative insulin sensitivity check index (QUICKI),Lipopolysaccharide (LPS),2014-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
152,NCT02081989,glucose uptake into peripheral skeletal muscle,,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
153,NCT04152915,"Cmax,sema,1mg: Maximum observed semaglutide concentration after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period","t½,sema,1mg: terminal elimination half-life of semaglutide after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period",2019-11-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
154,NCT06269419,Urinary creatinine ACR,,2024-02-25,RECRUITING,OBSERVATIONAL,['NA'],
155,NCT03174522,Complete healing of all ischemic ulcers on the index leg.,,2017-04-25,TERMINATED,INTERVENTIONAL,['PHASE3'],
156,NCT02627287,Injection success (full dose delivered s.c.) (yes/no),"Grading of bleeding, redness, bruising and swelling at the site of injection",2015-12-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
157,NCT02774876,Area under the curve of sensor glucose levels,Coefficient of variation of glucose levels,2016-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
158,NCT05653050,Time in target glucose range,"Total, basal, and bolus insulin dose",2023-02-20,RECRUITING,INTERVENTIONAL,['NA'],Human Factor assessment
159,NCT02594033,Maximum concentration of insulin aspart measured in serum,,2015-10-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
160,NCT01705899,Change in measured creatinine clearance,Change in glycemic lability score,2006-11,SUSPENDED,INTERVENTIONAL,['PHASE1'],
161,NCT04155996,Data collection - Sleep hours,Data collection - Medical treatment information,2019-01-20,TERMINATED,OBSERVATIONAL,['NA'],
162,NCT03635671,Perfusion density,Retinal layer thickness,2018-09-01,TERMINATED,OBSERVATIONAL,['NA'],
163,NCT00738088,HbA1c reduction,insulin secretory response to glucose and tolbutamide,2007-06,TERMINATED,INTERVENTIONAL,['PHASE4'],
164,NCT04075110,Visceral Adiposity Index,leukotriene B4,2019-07-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
165,NCT03085251,System accuracy criteria,,2017-03-16,COMPLETED,INTERVENTIONAL,['NA'],
166,NCT02093702,Mean Change in Diastolic Blood Pressure,Mean Change in Adherence to the Canadian Diabetes Association's Clinical Practice Guidelines Resistance Exercise Recommendations,2014-04,COMPLETED,INTERVENTIONAL,['NA'],
167,NCT01689142,Change from baseline in HbA1c,Number of patients with various types of hypoglycemia events,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
168,NCT03237455,Inflammatory changes in the spine and/or sacroiliac joints,,2018-08-01,RECRUITING,INTERVENTIONAL,['NA'],
169,NCT03686436,measuring visual acuity by snellen chart,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],
170,NCT06056167,The percentage of blood glucose readings at the target glycemic control 140- 180 mg/dL (7.8 -10 mmol/L).,Intensive care unit (ICU) length of stay,2023-05-17,RECRUITING,INTERVENTIONAL,['NA'],
171,NCT00427401,The primary end point is glucose lowering (24 hour mean glucose concentration).,Fasting blood glucose,2007-02,TERMINATED,INTERVENTIONAL,['PHASE2'],
172,NCT02368704,Show an increase in markers of ER stress in fasting patients with type 2 diabetes,Lipolysis on insulin,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],
173,NCT05764850,Cluster analysis to decipher underlying mechanisms of type 1 diabetes,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA'],
174,NCT03901248,"Interrelationship of adipokines such as adiponectin, apelin, visfatin and vaspin in different glycaemic stages",Change in HbA1c,2015-07,COMPLETED,OBSERVATIONAL,['NA'],
175,NCT00911625,Average Blood Glucose Over 6 Days,The Number of Participants Who Experience at Least One Blood Glucose Level Below 70 Milligrams Per Deciliter,2009-01-21,COMPLETED,INTERVENTIONAL,['PHASE4'],
176,NCT00395148,Metabolic parameters,,2006-03,COMPLETED,INTERVENTIONAL,['NA'],
177,NCT01089205,,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],
178,NCT00059254,Oxygen consumption,excess Post exercise oxygen consumption (EPOC),2000-09,COMPLETED,INTERVENTIONAL,['NA'],
179,NCT01765894,"Glucose homeostasis in controls, type 2 diabetics without medication and type 2 diabetics in metformin treatment.",IL-6 and incretins,2012-10,COMPLETED,OBSERVATIONAL,['NA'],
180,NCT05260931,Ventricular sphericity indices,,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA'],
181,NCT03251079,Safety Endpoint,,2017-07-25,COMPLETED,INTERVENTIONAL,['NA'],
182,NCT05618756,Postprandial Triglyceridaemia,Postprandial Insulinaemia,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
183,NCT02661165,The self-management Interviews to identify if and how patients' spirituality influences their diet and exercise.,,2016-06,COMPLETED,OBSERVATIONAL,['NA'],
184,NCT05629806,Blood glucose fluctuation,,2022-04-10,RECRUITING,INTERVENTIONAL,['PHASE3'],
185,NCT03736668,Measurement of left ventricular ejection fraction,Comparing the volume of the left atrium in Simpson biplane and in 3D,2018-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
186,NCT01263132,Mean Neuropathic Pain Score at Visit 6 (Week 4),Quality of Life Survey Assessed Using Short Form 36 (SF-36) Questionnaire,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
187,NCT04291703,Progression to Stage 3 T1D,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
188,NCT03802877,Recruitment,Completion of evaluation procedures,2019-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Breastfeeding
189,NCT02121717,Change in HbA1c from baseline after 24 weeks of treatment,Percentage of patients who use rescue therapy,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
190,NCT04358263,Percentage of time in hypoglycemic ranges,Changes in glycated haemoglobin (HbA1c),2018-09-01,UNKNOWN,INTERVENTIONAL,['NA'],
191,NCT05299177,"% time spent in target glucose range measured by continuous glucose monitoring (3.9-10mmol/L, 70-180mg/dL)",Change in weight (kg),2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],Productivity lost
192,NCT03406897,MMTT (Mixed Meal Tolerance Test),Incidence of Adverse Events (AE),2018-07-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
193,NCT05755360,Absolute change in glycated haemoglobin (HbA1c) (millimoles per mole [mmol/mol]),Absolute change in diabetes distress survey (DDS) scores (points),2023-02-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
194,NCT00206349,,,2004-06,COMPLETED,OBSERVATIONAL,['NA'],
195,NCT02068638,Amount of exogenous glucose required to maintain glycemia within a range between 7-10mM,Heart rate variability,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
196,NCT06081231,proportion of time spent in the target glucose range,concentration of HbA1c,2021-06-01,RECRUITING,OBSERVATIONAL,['NA'],
197,NCT01169090,Change in HbA1c from baseline to Week 16.,Change from baseline in Fasting Plasma Glucose (FPG),2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
198,NCT00359775,Impact on Family measured by the Impact of Family Scale.,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
199,NCT05036343,Glucose,Change in Self-Efficacy for Managing Chronic Conditions - Managing Medications and Treatment Score,2021-09-14,COMPLETED,INTERVENTIONAL,['NA'],
200,NCT04117763,Arrhythmogenic burden,,2019-10-04,RECRUITING,INTERVENTIONAL,['PHASE4'],
201,NCT04029103,self-efficacy,,2017-06-01,COMPLETED,INTERVENTIONAL,['NA'],
202,NCT00001985,,,2000-01,COMPLETED,OBSERVATIONAL,['NA'],
203,NCT03307850,"Impact of Stress and Exercise on CGM Glucose Levels, determining how these factors affect time within target glucose range 70-180 mg/dl",CGM Glucose Levels greater than 180 mg/dl,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],
204,NCT05611944,SSI rate,patient satisfaction,2017-04-01,COMPLETED,INTERVENTIONAL,['NA'],
205,NCT00001368,,,1993-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
206,NCT05941286,"Time in range (3.9~10.0mmol/L, %)",Glycemia risk index (GRI),2024-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
207,NCT00168857,Change from baseline after one year of treatment in proteinuria (ratio of protein to creatinine as measure in spot urine sample).,Change from baseline after one year of treatment in the following: glomerular filtration rate; serum creatinine; macroalbuminuria; sodium excretion; high sensitive C-reactive protein; serum aldosterone; and other renal and cardiovascular measures.,2003-07-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
208,NCT03617393,Survival at 1 Year,Humoral Immunoserologic Indexes,2017-07-10,UNKNOWN,OBSERVATIONAL,['NA'],
209,NCT00499707,Change from baseline in hemoglobin A1c (HbA1c) at week 32.,"Key Secondary Measures: Change in FPG HbA1c and FPG responders Change in insulin, C-peptide, free fatty acids, lipids, insulin sensitivity and beta cell function Adverse Events Vital Signs Weight 32 weeks",2003-10-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
210,NCT01039896,"Css,max and AUCinf","AUCtau, AUCt, Tmax",2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
211,NCT00042042,,,na,UNKNOWN,INTERVENTIONAL,['NA'],
212,NCT00859755,Characterize the pharmacokinetics (PK) of the study drug and metabolites in terms of plasma concentrations.,Assess the excretion of the study drug and metabolites in urine following dosing.,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
213,NCT05801614,non diabetic HbA1c,Changes in Insulin secretion,2022-02-28,RECRUITING,INTERVENTIONAL,['NA'],
214,NCT03253562,benefit of improving the condition of elevated blood pressure in patients through neovascularization,comparing the anti-hyperglycemic effect of each drug for diabetic hypertensive patients,2017-02-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
215,NCT01244152,Weight change,Hemoglobin A1C,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
216,NCT05556161,HbA1c change,Social support,2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
217,NCT04115917,Discomfort During Scleral Depression with Schocket Depressor and Cotton Tipped Applicator,Retinal pathology,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],
218,NCT04356898,Area under the curve (AUC); ((mmol/L)*h),High blood glucose index (HBGI),2018-04-15,COMPLETED,OBSERVATIONAL,['NA'],
219,NCT03786146,Retinal nerve fiber layer thickness measured by Optical Coherence Tomography (OCT) and expressed in micrometers.,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
220,NCT02827708,Change in HbA1c,Change in Urinalysis,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE3'],
221,NCT05417841,HbA1c,Time Above Range,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
222,NCT03805191,The extent of change in MAGE,The control rate of HbA1c,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Gene polymorphism
223,NCT00361907,Primary: Assessment of effect of Pulsatile Intravenous Insulin therapy on circulating blood markers for diabetic patients.,,2005-02,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
224,NCT00668785,Mean Change From Pre-PRP Best Corrected Visual Acuity (BCVA) at 3 Months as Expressed as an Early Treatment Diabetic Retinopathy Study (ETDRS) Score (Number of Letters Correctly Read.),Percentage of Patients That Maintain Pre-PRP Visual Acuity at the 3 Month Time Point,2007-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
225,NCT05446493,Serum YKL-40 and platelets indices in erectile dysfunction,Effect of tadalafil on Erectile dysfucntion patients,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
226,NCT01603940,Endothelial Function,Vascular Stiffness by Augmentation Index,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
227,NCT01473953,Number of Treatment Emergent Adverse Events (TEAEs),Number of Subjects With Antibodies (Positive) or Without Antibodies (Negative) Against Liraglutide Observed at Pre-dose and at Last Follow-up,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
228,NCT03214367,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26,Change From Baseline in HbA1c at Week 52,2017-07-17,COMPLETED,INTERVENTIONAL,['PHASE3'],
229,NCT03557541,type 2 diabetes new onset,HOMA-B (homeostasis model assessment B cell function),2014-05,COMPLETED,INTERVENTIONAL,['NA'],
230,NCT03244579,Fasting blood glucose,Shoulder dystocia,2017-08-20,UNKNOWN,INTERVENTIONAL,['NA'],
231,NCT06295913,LDL-ox as marker of oxidative status,Aspartate aminotransferase (transaminase AST),2024-03,RECRUITING,INTERVENTIONAL,['NA'],
232,NCT02735044,Change From Baseline in HbA1c to Month 6,Percentage of Participants With Any Hyperglycemia With Ketosis at Month 12,2016-04-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
233,NCT04552600,To evaluate safety of Nuvastatic - Letter Score,To evaluate short-term visual outcomes on DRSS,2019-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
234,NCT04670198,Glycated haemoglobin (HbA1c),Acceptability of Intervention Measure (AIM),2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],
235,NCT00054925,Change in Weight,,2003-01,COMPLETED,INTERVENTIONAL,['NA'],
236,NCT05753436,Heart Rate,Serum Ferritin,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
237,NCT02035644,change in HbA1c levels,blood pressures,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
238,NCT00862602,Glucose tolerance,Insulin,2009-07,COMPLETED,INTERVENTIONAL,['NA'],
239,NCT01462864,we aim for a 2000 steps increase in Number of steps per day,Brief Illness Perception,2011-09,COMPLETED,INTERVENTIONAL,['NA'],
240,NCT00623610,Evidence of clinically relevant beta cell function.,,2000-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
241,NCT05007977,Change in glucagon between euglycemia and hypoglycemia,Change in cortisol between euglycemia and hypoglycemia,2021-07-08,TERMINATED,INTERVENTIONAL,['PHASE1'],Symptom score during hypoglycemia
242,NCT01302639,postprandial fat oxidation,,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
243,NCT03423589,Alterations in Plasma-Induced Transcriptional Analysis,Intestinal Microbiota,2018-04-23,COMPLETED,INTERVENTIONAL,['NA'],
244,NCT04867629,Proteomic biomarkers,Oxidative stress biomarkers,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
245,NCT00171496,Incidence of biopsy-proven acute rejection (BPAR) or graft loss or death within the first 6 months post-transplantation.,"incidence of BPAR or graft loss or death within the first 3 months post-transplantation, as well as the incidence of each individual event within 3 and 6 months post-transplantation.",2003-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
246,NCT06330194,Percent time in sensor glucose target range (3.9-10.0 mmol/L),Frailty,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
247,NCT00453817,"Semi-quantitative assessment of intrahepatic MRI signal on T2*-weighted sequences, at 6 days, 6 weeks, 6 months and 1 year after transplantation","Islet graft function assessed by exogenous insulin requirements, HbA1c, mean amplitude of glucose excursions (MAGE) and fasting C-peptide.",2005-06,TERMINATED,INTERVENTIONAL,['PHASE1'],
248,NCT04019821,Postprandial Glycemia,Time in postprandial glucose range between 70 to 180 mg/dl (4.0-10.0 mmol/L),2020-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
249,NCT01665989,Change in weight (percent weight loss from baseline to 6 months),Cost effectiveness and savings,2012-08,COMPLETED,INTERVENTIONAL,['NA'],
250,NCT04305587,Number of Participants With Abnormal Electrocardiogram (ECG),Renal Clearance (CLr) for PF-07081532,2020-03-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
251,NCT06152042,To assess the effect on endogenous insulin secretion,Incidence of adverse events,2023-12-28,RECRUITING,INTERVENTIONAL,['PHASE2'],
252,NCT00982358,The primary objective of the study was to evaluate the anti-inflammatory effect of VAL by analyzing the reduction of the inflammatory markers interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFα) in serum after 16 weeks of treatment.,"To explore the effect of 160/320 mg valsartan on coronary perfusion, in the group of patients with angiographically documented CAD",2004-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
253,NCT01644201,HbA1c,,2012-10,TERMINATED,INTERVENTIONAL,['PHASE3'],
254,NCT06186245,Length of stay in the medical intensive care unit (in days).,mortality,2023-12-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
255,NCT00606034,Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c),Patient Satisfaction With Insulin Delivery Method Via Insulin Delivery Rating System Questionnaire (IDRSQ),2007-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
256,NCT06226727,Cmax,,2024-02-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
257,NCT01951183,Change from baseline in HbA1c,Safety: Incidence of adverse events,2013-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
258,NCT00095056,Safety and Tolerability of Sitagliptin After 12 Weeks of Treatment,Safety and Tolerability of Sitagliptin Over 54 Weeks,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
259,NCT01095822,How therapy with valsartan (160mg/daily) in combination with aliskiren (150-300mg/daily) affects platelet/coagulation/fibrinolytic biomarkers in recently diagnosed hypertensive patients with type 2 diabetes mellitus.,"Whether combination therapy is superior over monotherapy with aliskiren with regard to the improvement of hemostatic biomarkers (platelet aggregation, expression of GP IIb/IIIa, and plasma levels of antithrombin-III).",2010-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
260,NCT06157684,Infant birthweight percentile,need for insulin or metformin during pregnancy,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],feasibility and acceptability
261,NCT03920683,Toe-brachial index,Coronary angiography,2019-07-08,COMPLETED,OBSERVATIONAL,['NA'],
262,NCT03497390,Change in glycemic control,Change in waist-hip ratio [WHR],2012-07,COMPLETED,INTERVENTIONAL,['NA'],mortality
263,NCT02990299,Hemoglobin A1c,Diabetes Self-efficacy,2017-03-24,COMPLETED,INTERVENTIONAL,['NA'],Health Coach Satisfaction
264,NCT03546062,Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],
265,NCT00628056,The primary end point of the Perhexiline intervention study will be the change in cardiac PCr/ATP ratio.,,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
266,NCT05056376,Achievement of CDC's benchmark for type 2 diabetes risk reduction as a binary outcome (yes/no),Correlation between self-reported and measured physical activity,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
267,NCT01490151,Safety and Feasibility of TTR Closed-loop Control System as Measure by the Count of Successful Hospital Admissions,,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
268,NCT03343366,Glycated Hemoglobin (HbA1c),HOMA-IR,2018-01-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
269,NCT04603885,BDNF DNA demethylation in percentage,Processing speed,2020-10-27,UNKNOWN,INTERVENTIONAL,['NA'],
270,NCT01916694,Glycosylated haemogloblin,Neonatal hypoglycaemia,2013-09,COMPLETED,INTERVENTIONAL,['NA'],Economic evaluation
271,NCT02777060,Change in Balance,Change in average of longest walking bout,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],
272,NCT00254124,"- prespecified per protocol analysis: same outcomes as above, looking at patients who were >=80% compliant with the intervention",- change in blood pressure,2004-04,COMPLETED,INTERVENTIONAL,['NA'],
273,NCT04943692,Change in HbA1c,Incidence of adverse events,2021-08,SUSPENDED,INTERVENTIONAL,['PHASE3'],
274,NCT00821379,,,2008-04,COMPLETED,OBSERVATIONAL,['NA'],
275,NCT05476016,Accuracy of the Glyconics-SX System in detection of DM status based on dichotomised outcomes as per the chemometric model (HbA1c measurements as internal control),"Analysis of safety outcomes, included suspected de novo DM diagnosis based on HbA1c",2022-08-29,COMPLETED,INTERVENTIONAL,['NA'],
276,NCT00596973,Treatment sucess based on patients' glycemic control,,2008-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
277,NCT05237271,CPV-measured cost difference,CPV-measured Assessment of use case types,2022-03-15,COMPLETED,INTERVENTIONAL,['NA'],
278,NCT03341312,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to Seven Hours (AUC0-7hr),Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Curve (BGΔAUC) for Each Treatment Arm,2017-11-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
279,NCT04919499,Part B: Number of subjects with drug related Adverse Events (AEs) from drug administration until end of study (EOS),Part B: Number of subjects with any ocular Adverse Events (AEs) (eye disorders) from drug administration until end of study (EOS),2021-07-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
280,NCT00798915,"The effects of GIP, xenin-25, or a combination of GIP plus xenin-25 on insulin secretion and blood glucose levels",The effects of xenin-25 on GIP action in persons with type 2 diabetes,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
281,NCT02796248,Presence of stigma,Well-Being Index,2016-05,COMPLETED,OBSERVATIONAL,['NA'],
282,NCT01403961,Compare incidence of immediate post surgery complications in diabetic patients with HbA1c > 7 and patients with HbA1c ≤ 7,,2011-07,COMPLETED,OBSERVATIONAL,['NA'],
283,NCT00229268,,,2005-09,COMPLETED,OBSERVATIONAL,['NA'],
284,NCT01046994,Diabetes control as defined by FSG and HbA1c,Assessment of patient BMI,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],
285,NCT01997424,Steatosis,Steatosis (serum),2013-05,COMPLETED,INTERVENTIONAL,['NA'],
286,NCT00379652,"Potential outcomes for the future intervention include systolic blood pressure, diastolic blood pressure, and hemoglobin A1c",,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
287,NCT04786340,"Incidence of Treatment Emergent Adverse Events as assessed by dermal assessment (Draize score 0.0-4.0) score of skin erythema, edema pruritus and dryness score) of the dosing area",Neuropathy Total Symptom Score-6 (NTSS-6),2020-11-20,COMPLETED,INTERVENTIONAL,['PHASE2'],
288,NCT00809705,"Tmax, log (AUC), log(Cmax)of paracetamol",Multiple dose pharmacokinetics of Taspoglutide,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
289,NCT06201806,Glycemic Responses (GR),Assessment of Appetite:,2019-01-02,COMPLETED,INTERVENTIONAL,['NA'],
290,NCT04893148,Changes in glycated hemoglobin (HbA1c),Changes in weight,2020-05-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
291,NCT05152121,AUC,hypoglycemia epizode,2017-07-01,COMPLETED,INTERVENTIONAL,['NA'],
292,NCT01104701,Mean Change in HbA1c From Baseline to End of Treatment (Week 20) - Evaluable Population,Number of Chemistry Laboratory Values of Potential Clinical Importance Observed During Treatment Period - ITT Population,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
293,NCT00970567,"glucose metabolism, time course of positive ketone bodies",,2007-11,COMPLETED,INTERVENTIONAL,['NA'],
294,NCT01572389,Change in Patient Health Questionnaires-9 During Intervention,,2012-11-01,COMPLETED,INTERVENTIONAL,['NA'],
295,NCT04416841,Global cognition-Montreal Cognitive Assessment at 36 Weeks,"Quality of life-Medical Outcomes Study 36-item Short-Form Health Survey at 24, 36 weeks",2020-06-03,COMPLETED,INTERVENTIONAL,['NA'],functional Magnetic Resonance Imaging (fMRI)
296,NCT03513939,"To assess the safety of the Cell Pouch following implantation, and islet transplantation, by evaluating the incidence and severity of adverse events (AEs) determined to be probable or highly probable to the Cell Pouch",Proportion of participants with a reduction in HbA1c >1mg%,2019-02-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
297,NCT03186560,Microcirculatory flux in the lower limb of the different subgroups with geko device on.,Adverse Events,2018-02-12,TERMINATED,INTERVENTIONAL,['NA'],
298,NCT02020850,Toe-Brachial Index,Ankle-Brachial Index,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],
299,NCT05233592,Total Daily Insulin Resistance (TDIR),Change in Time in Hyperglycemia,2022-03-08,COMPLETED,OBSERVATIONAL,['NA'],Post-hoc t-test
300,NCT01565733,Frequency of severe hypoglycaemic episodes,Average plasma glucose level at bedtime and at night,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
301,NCT02177643,Hepatic Function Panel,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
302,NCT00529191,Efficacy of a Daily Dose of Atorvastatin to Maintain Islet Cell Function as Measured by a 4-hour C-peptide Area Under Curve (AUC) in Patients With Newly Diagnosed Type 1 Diabetes Mellitus,HDL and LDL Cholesterol Levels in Participants Stratified by the Preservation of Islet Cell Function,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
303,NCT04616391,Between group TIR difference,Between group difference in the Diabetes Quality of Life (QoL) questionnaire score,2020-11-02,UNKNOWN,INTERVENTIONAL,['NA'],Number of Severe Hyperglycemia episodes
304,NCT04014582,Change in diabetes self-care,Change in diabetes specific self-efficacy,2019-07-20,COMPLETED,INTERVENTIONAL,['NA'],Daily self-efficacy
305,NCT05599477,Reduction in HbA1c,Costs and cost-effectiveness.,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
306,NCT00687999,"Sustained virological response (SVR) rate, HCV RNA seronegative by PCR throughout 24-week off-treatment period; biochemical, virological and histological characteristics of CHC patients; HOMA-IR change after combination therapy",,2005-12,COMPLETED,INTERVENTIONAL,['NA'],
307,NCT02657213,Assessment of the Minimed 640G insulin pump with Smartguard activation in preventing the number of severe and non-severe hypoglycaemia in patients with diabetes type 1 at risk of severe hypoglycemia,Study of average cost per patient for each therapeutic strategy supported from the point of view of society,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
308,NCT04569994,Number of treatment-emergent adverse events (AEs),Maximum observed serum NNC0363-0845 concentration after a single dose,2020-09-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
309,NCT03542370,Blood Pressure - Systolic Blood Pressure (randomized and non-randomized controlled trials),Inflammation - C-Reactive Protein (randomized and non-randomized controlled trials),2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],
310,NCT03751735,Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaires,,2017-01-27,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
311,NCT01497561,Area under the glucose infusion rate curve,Terminal half-life,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
312,NCT04809311,Patient with at least 70% unblinded FGM (flash glucose monitoring) data,Coefficient of variation (CV),2024-03-18,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
313,NCT01824264,Change from baseline in glycated hemoglobin (HbA1c) after 12 weeks,Change from baseline in renal threshold for glucose excretion,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
314,NCT00315939,Frequency of Severe Hypoglycemia,,2006-01,COMPLETED,INTERVENTIONAL,['NA'],
315,NCT00117026,Lower-limb nerve conduction velocity,"Serum advanced glycation end products (AGEs) and markers of inflammation (CRP, IL-6, VCAM-1)",2005-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
316,NCT03184662,Renal Function Decline,Safety of HIPA performed by e-coaching in the context of COVID infection,2018-02-12,UNKNOWN,INTERVENTIONAL,['NA'],
317,NCT05121844,Change in weight,Time in range,2021-11-02,RECRUITING,INTERVENTIONAL,['NA'],
318,NCT05951270,Apple polyphenols and glucose homeostasis in prediabetics,Apple polyphenols and fecal microbiota composition,2022-01-14,TERMINATED,INTERVENTIONAL,['NA'],
319,NCT05988957,Describe CGM data use,Describe overall experience of receiving a NFA during CGM initiation,2023-08-01,COMPLETED,OBSERVATIONAL,['NA'],
320,NCT01950676,Change in glycemic control (HbA1c) between the intervention and the control group,Treatment satisfaction as measured by DTSCs and DTSQc,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
321,NCT00541775,Hemoglobin A1C (A1C) at Week 18,2-hour Post-meal Glucose (PMG) at Week 18,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
322,NCT03782636,Differences in slopes of DBS (Dried Blood Spot) C-peptide over the 6 month-treatment period between the active and placebo groups.,Change in HbA1c and daily insulin requirements during the trial period.,2019-01-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],
323,NCT00845559,Whether treatment with exenatide attenuates post-prandial glycemic excursions as assessed by oral glucose tolerance testing (OGTT) and continuous monitoring system (CGMS) technology.,Change in body mass index (BMI).,2008-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
324,NCT02246400,Change in measure of Health-related quality of life from baseline to 6-months follow up.,Body weight,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
325,NCT01735643,HbA1c,weight,2011-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
326,NCT00602953,Disposition Index (DI),,2007-09,COMPLETED,OBSERVATIONAL,['NA'],
327,NCT01496365,Mean Change From Baseline to Week 5 in Average Daily Pain Score (ADPS) Following Treatment With DS-5565 Compared to Pregabalin and Placebo,Drug-related Treatment-Emergent Adverse Events (n ≥2 Participants in Any Treatment Group) Following Treatment With DS-5565 Compared to Pregabalin and Placebo,2011-11-28,COMPLETED,INTERVENTIONAL,['PHASE2'],
328,NCT05385575,Number of participants with abnormal clinically significant electrocardiogram (ECG),The efficacy of KN056 by analyzing HbA1c (Glycosylated hemoglobin) changes,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],
329,NCT01510223,Gastric emptying by 13C octanoic acid breath test,Food intake by buffet meal,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
330,NCT00863954,Reduction in blood glucose and A1c levels at endpoint compared to start,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
331,NCT04045184,Compare hemoglobin A1c levels between groups with high versus low dietary fiber intake,,2018-10-20,RECRUITING,OBSERVATIONAL,['NA'],
332,NCT05186389,Metagenomic analysis,Clinical associations with metagenomic analysis,2022-01-26,UNKNOWN,OBSERVATIONAL,['NA'],
333,NCT04007640,fibroinflammatory lesions at histology in obese patients,Biomarkers of pathways activation measured by immunohistochemistry on resected pancreatic parenchyma,2019-06-18,RECRUITING,INTERVENTIONAL,['NA'],
334,NCT00134524,Subject tolerance to the MME procedure,"Quality of Life assessments at baseline, post-procedure and 6 month follow-up",2005-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],
335,NCT00974090,Change From Baseline in HbA1c at Week 12,Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
336,NCT02967406,Dementia,Blood lipids,2016-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Cognitive function
337,NCT00157586,"The rate of decline of glomerular filtration rate (GFR).GFR is measured at baseline,and at 6,12,18,24,30 and 36 months after randomization",Major cardiovascular events,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
338,NCT00676767,Glycemic Response,,2006-08,COMPLETED,INTERVENTIONAL,['NA'],
339,NCT01349114,Change in Flow-mediated Dilation,Mean Central Aortic Pressure at 3 Months,2011-06,TERMINATED,INTERVENTIONAL,['PHASE4'],
340,NCT03475108,Hemoglobin A1c,Quality of life (primary care giver),2018-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
341,NCT02993614,CVD REAL1 Incidence of hospitalization for heart failure. / CVD REAL 2 All-cause mortality,"CVD REAL1 All-cause mortality; CVD REAL 2: Hospitalization for heart failure (HHF), stroke, myocardial infarction (MI) and including composite endpoints",2017-11-30,COMPLETED,OBSERVATIONAL,['NA'],
342,NCT05852054,Primary care visit (PCV) completion,Dysglycemia and hypertension cases detected,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
343,NCT02767336,Marketing Claims Evaluation questionnaire.,,2016-04,COMPLETED,INTERVENTIONAL,['NA'],
344,NCT05166447,Major adverse cardiovascular events (MACE) (Register data),Chronic Kidney Disease (CKD) Stage 3/4/5 (Blood samples),2021-09-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
345,NCT01399346,"tmax(ins), time to maximum observed serum insulin aspart concentration","t10%max(ins), time to reach 10% of maximum observed serum insulin aspart concentration",2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
346,NCT04993482,Change in 24-hour movement composition from baseline over one year and two-year follow-up,Change in Advanced Glycation Endproducts from baseline to one and two-year follow-up,2021-08-29,RECRUITING,OBSERVATIONAL,['NA'],Explanatory variables: physical environmental factors
347,NCT03330548,Change in Low-density lipoprotein (LDL),Change in Hemoglobin A1C (HgbA1c),2015-07-09,COMPLETED,INTERVENTIONAL,['NA'],
348,NCT02977130,Glycated hemoglobin (HbA1c),,2014-05,COMPLETED,INTERVENTIONAL,['NA'],
349,NCT05814393,HbA1c (24 Weeks) lowering effect,HbA1c lowering effect,2023-01-03,RECRUITING,INTERVENTIONAL,['PHASE3'],
350,NCT00438321,Insulin sensitivity,Intramyocellular fat,2006-09,TERMINATED,INTERVENTIONAL,['PHASE1'],
351,NCT06246175,Area Under the Concentration Versus Time Curve (AUC) of HRS9531 From Time Zero to Infinity (AUC0-inf),Incidence and severity of adverse events,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE1'],
352,NCT04978376,Body weight,HbA1c,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],
353,NCT04195191,Adherence to treatment,Satisfaction with the service,2019-01-18,UNKNOWN,INTERVENTIONAL,['NA'],
354,NCT03389607,SCUBE-1,total antioxidant capacity,2018-01-08,COMPLETED,OBSERVATIONAL,['NA'],
355,NCT01885208,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Subjects Who Achieve HbA1c Equal to or Below 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target: (Yes/no),2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
356,NCT03844126,Transition preparedness,,2018-04-13,COMPLETED,INTERVENTIONAL,['NA'],
357,NCT05223556,Accuracy in the diagnosis of referral retinal lesions,Satisfaction of participants as measured by questionnaire,2022-02-01,COMPLETED,OBSERVATIONAL,['NA'],
358,NCT00044395,Reduction in neuropathic symptoms,"Vibration sensation;Neurological signs;Electrophysiology of peroneal, tibial and sural nerves;Relief of symptoms as measured by VAS;Composite scores of nerve function;Clinical global impression of change",2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
359,NCT02465021,Food intake,Blood insulin,2015-03,COMPLETED,INTERVENTIONAL,['NA'],Food Recall
360,NCT02939118,Incidence of adverse events reported during the study.,,2016-11-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
361,NCT04021602,Introduction of Solid Food,Baby's Height,2019-09-18,COMPLETED,INTERVENTIONAL,['NA'],
362,NCT03713996,Change in Insomnia Severity Index,Change in Random Glucose Level,2019-01-16,COMPLETED,INTERVENTIONAL,['NA'],
363,NCT00279084,Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period.,Quality of life: SF 36 auto-questionnaire,2004-01,UNKNOWN,INTERVENTIONAL,['NA'],
364,NCT02048904,Change in Microalbuminuria Level,,2014-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
365,NCT04769765,"Number of patients on the basic diabetic program, included in the study, who have completed at least three of the four scheduled follow-up visits.",Logistic feasability of managing these patients (who have had at least one unscheduled hospitalization during the year) by tele-expertise. Number of follow-up visits per patient per center.,2022-05-04,RECRUITING,INTERVENTIONAL,['NA'],Complications
366,NCT05215210,change in fasting plasma glucose concentrations,change in HOMA-B levels,2022-03-23,COMPLETED,INTERVENTIONAL,['NA'],change in creatinine
367,NCT03555994,To assess the effect of MEDI0382 on hepatic glycogen levels versus placebo after 28 days (Part A) and 35 days (Part B) of treatment,Measures of safety and tolerability of daily SC doses of MEDI0382 titrated up to a dose level of 300μg (Parts A and B) by assessment of changes in haematology and clinical chemistry parameters,2018-05-31,COMPLETED,INTERVENTIONAL,['PHASE2'],
368,NCT01510522,Change from Baseline of Patient self-reported subjective compliance as assessed by Haynes-Sackett test at Month 6,Rate of reported adverse events,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
369,NCT01175486,Diabetic nephropathy,Diabetic nephropathy,2010-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],
370,NCT02488278,Operating the GlucoMe device: obtaining a glucose reading and recording the results,Documenting specific user errors and inefficiencies related to the use of the device and application,2015-07,WITHDRAWN,INTERVENTIONAL,['NA'],
371,NCT05989256,Inpatient hypoglycemia event rates,Number of Inpatient hospitalizations with a hyperglycemic event,2024-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
372,NCT04828512,Survival,major complications of cirrhosis,2007-01-02,UNKNOWN,OBSERVATIONAL,['NA'],
373,NCT04979130,Differences in lactulose mannitol ratio (LMR) test as a measure of intestinal permeability between treatment groups,Differences between treatment groups in plasma hs-CRP,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],Exploratory: determine the effect of semaglutide as compared to placebo on intestinal microbiota in relation to changes in intestinal permeability and inflammatory markers
374,NCT01000545,macroalbuminuria and serum creatinine,adverse events,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],
375,NCT03915990,the diagnostic value of Umbilical artery Doppler indices [Resistance index (RI)& pulsatility index (PI)] in predicting the adverse neonatal outcome among diabetic patients.,he diagnostic value of MCA Doppler indices [Resistance index (RI)& pulsatility index (PI)] in predicting the adverse neonatal outcome among diabetic patients.,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
376,NCT01330121,Adherence with discharge diabetes medications up to 120 days following pharmacist counseling during hospital stay about diabetes self management,Change in lipids after 90 days,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
377,NCT01214590,Diabetic neuropathic pain,Nerve conduction velocity,2011-03,UNKNOWN,INTERVENTIONAL,['NA'],
378,NCT06016478,Change in total peripheral resistance during acute hyperglycemia,Change in 24-hour ambulatory blood pressure monitoring,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],
379,NCT05478252,Change in Glycated Haemoglobin (HbA1c),Anti-semaglutide Antibodies Level (Measured as Titre),2022-08-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
380,NCT05647798,Initial neonatal glucose post delivery,Mother's childbirth experience score,2023-05-22,RECRUITING,INTERVENTIONAL,['NA'],Intrapartum insulin dose (total)
381,NCT02500303,Further surgery,Co-morbidities,2014-03,UNKNOWN,OBSERVATIONAL,['NA'],
382,NCT03338010,Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®),Rate of Total Symptomatic and Nocturnal Hypoglycemia Events (Adjusted by 1 Year),2018-03-22,COMPLETED,INTERVENTIONAL,['PHASE3'],
383,NCT03307486,Occurrence of type 2 DM after GDM,Fetal weight at birth vs eating habits,2015-09-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
384,NCT04071977,Changes in concentration of total antioxidant capacity (TAC) after intervention from baseline.,"Correlate the levels of total antioxidant capacity (TAC) in systemic samples, aqueous humor and vitreous humor with the glycosylated hemoglobin value of patients with proliferative diabetic retinopathy.",2020-03-25,COMPLETED,INTERVENTIONAL,['PHASE2'],
385,NCT01835431,Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%),Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill With Ketosis (Blood Ketones Above 1.5 mmol/L),2013-10-17,COMPLETED,INTERVENTIONAL,['PHASE3'],
386,NCT01928329,Change From Baseline in HbA1c Levels,Major Hypoglycemic Event Rate Off Drug,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
387,NCT02407132,"Glycemic Control, Measured by Change in Adjusted Mean HbA1c (%) From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention.","Change in Mean Triglycerides From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention",2015-06,COMPLETED,INTERVENTIONAL,['NA'],
388,NCT05415683,Data Collection,,2022-06-22,RECRUITING,OBSERVATIONAL,['NA'],
389,NCT01690091,insulin sensitivity,heart function,2012-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
390,NCT02811575,Number of lymphocyte TCD4 Th17 in colon sample,Bacteria production,2016-12,COMPLETED,OBSERVATIONAL,['NA'],
391,NCT01399645,To determine liver fat fraction evolution induced by liraglutide and insulin,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
392,NCT02053103,Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo,Change from baseline in very low density lipoprotein (VLDL),2014-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
393,NCT00339703,,,2004-11,COMPLETED,OBSERVATIONAL,['NA'],
394,NCT02900417,The changes of the composition of gut microbiota before and after the use of sitagliptin,"Changes of fasting plasma glucose levels, lipids levels and insulin sensitivity",2016-09,UNKNOWN,INTERVENTIONAL,['NA'],
395,NCT03228420,Composite of Safety and Effectiveness,Hemoglobin A1c,2017-07-20,UNKNOWN,INTERVENTIONAL,['NA'],
396,NCT00760578,Change From Baseline in Averaged Postprandial Glucose in Response to a MMT Test,Change From Baseline in HDL,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
397,NCT06129994,Ecological Momentary Assessment (EMA) methods for measuring depression,Hemoglobin A1c,2023-11-07,RECRUITING,OBSERVATIONAL,['NA'],
398,NCT03077386,Acute care utilization,Acute care costs,2018-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
399,NCT00235196,Clinical effectiveness of CAM in DFU by comparing the reduction in wound area between 2 treatment groups.,Wound characteristics,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
400,NCT02162901,Body weight,,2014-03-13,COMPLETED,INTERVENTIONAL,['NA'],
401,NCT00684528,The efficacy and safety of Metformin VS Metformin + Janufer in the community setting,,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],
402,NCT01570946,Progression to diabetes,Improvements in Quality of Life,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
403,NCT04994327,Glycemic control,Compliance,2021-05-07,COMPLETED,INTERVENTIONAL,['NA'],
404,NCT00755287,Absolute change from baseline in HbA1c,"Safety: Adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies",2008-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
405,NCT00225264,Absolute change from Baseline in carotid intima-media thickness.,"Incidence of cardiovascular events as a composite of cardiovascular mortality, nonfatal MI, nonfatal stroke, coronary revascularization, carotid endarterectomy/stenting, hospitalization for unstable angina and hospitalization for CHF",2003-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
406,NCT00239538,Changes from baseline in the mean SBP and DBP as measured by ambulatory blood pressure monitoring (ABPM),Metabolic and inflammatory marker changes from baseline,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
407,NCT01089790,"To demonstrate safety and tolerability of dutogliptin as assessed by vital signs, adverse event reporting, routine clinical laboratory assessments, and ECG",To demonstrate maintenance or lowering of HbA1c and fasting plasma glucose.,2010-03,TERMINATED,INTERVENTIONAL,['PHASE3'],
408,NCT01022619,apnea-hypopnea index,growth and development during the 1st year of life,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],
409,NCT04938557,The time spent with glucose levels between 3.5-7.8 mmol/L based on CGM measures (Time In Range TIR 3.5-7.8mmol/L),Hospital length of stay (infant).,2019-09-26,COMPLETED,INTERVENTIONAL,['NA'],
410,NCT00823992,Absolute change from baseline in HbA1c,"Safety:Adverse events,clinical laboratory tests, vital signs,physical examination, ECG, anti-taspoglutide antibodies\n",2009-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
411,NCT04071535,Assessment of small fiber neuropathy in Chinese patients with diabetes by calculating intraepidermal nerve fiber density (IENFD) via skin biopsy,Evaluation of diagnostic sensitivity and specificity of sudoscan in Chinese diabetic patients with small fiber neuropathy compared with intraepidermal nerve fiber density (IENFD),2015-12-01,UNKNOWN,OBSERVATIONAL,['NA'],
412,NCT04547023,Number of Participants With a Positive Gestational Diabetes Mellitus (GDM) Screen (>= 140 mg/dL) on the 1 Hour 50-g Oral Glucose Tolerance Test (OGTT),Number of Neonates Exclusively Breastfeeding at Time of Hospital Discharge,2020-11-02,COMPLETED,INTERVENTIONAL,['NA'],
413,NCT03137316,intact parathyroid level,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],
414,NCT02123901,Change from baseline in vascular reactivity,Change from baseline in blood chemistry,2013-12,COMPLETED,INTERVENTIONAL,['NA'],
415,NCT05405244,Change in Voxel-wise Blood Oxygen Level-Dependent (BOLD) Brain Activation in Response to Milkshake Anticipation and Receipt vs. Water,Change in Voxel-wise Blood Oxygen Level-Dependent (BOLD) Brain Activation in Response to Milkshake Anticipation and Receipt vs. Water by TaqIA Allele Status (A1 vs. A2/A2),2017-09-19,COMPLETED,INTERVENTIONAL,['PHASE3'],
416,NCT04034511,Change in hemoglobin A1c,Change in Hemoglobin A1c,2020-01-21,COMPLETED,INTERVENTIONAL,['NA'],
417,NCT04094662,Average Daily Pain Score (ADPS),Five Level EuroQol-5D (EQ-5D) version,2019-09-18,COMPLETED,INTERVENTIONAL,['PHASE3'],Actigraphy signal collected from a wrist-worn medical-grade sensor
418,NCT03960463,Change in tissue oxygenation from baseline to 4 weeks,Presence of scar tissue,2017-05-18,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
419,NCT01493115,Glucose infusion rate,"Safety-related parameters including electrocardiogram, vital signs and laboratory tests",2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
420,NCT00276471,Ability to communicate between patient wand and the device.,Improvement in co-morbid parameters,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
421,NCT05783700,BIOIMPEDANCEMETRY,Resting heart rate,2023-10-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
422,NCT03299010,Factors that have sufficient power to classify Chinese DM patients in primary care into risk group in terms of total CVD and all-cause mortality,,2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],
423,NCT05105620,Fréchet inception distance (FID) score.,,2018-08-01,COMPLETED,OBSERVATIONAL,['NA'],
424,NCT03681054,Child: Neonatal body fat%,Percentage of participants on GDM medication,2018-12-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
425,NCT02467881,Actigraph Accelerometry,EQ-5D Quality of Life Survey,2015-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
426,NCT00344136,,,2000-09,COMPLETED,OBSERVATIONAL,['NA'],
427,NCT06330948,Hematology Test,,2024-03,RECRUITING,INTERVENTIONAL,['NA'],
428,NCT04869605,"the role of 1,5 anhydroglucitol and 1,5 anhydroglucitol / HbA1c ratio as a potential biomarker for islet β-cell function and insulin resistance among patients with type 2 diabetes",,2021-05-06,UNKNOWN,OBSERVATIONAL,['NA'],
429,NCT02240420,Behavior change,Weight loss,2014-12,COMPLETED,INTERVENTIONAL,['NA'],
430,NCT04032197,Change in maximum target-to-background ratio (TBR) for 18F-fluorodeoxyglucose (FDG) in the carotid arteries,Change in average fibrous cap thickness (FCT) of the atherosclerotic plaque in the most diseased carotid artery,2019-08-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
431,NCT02459561,HbA1c reduced by 20%,To estimate the cost-effectiveness of the EndoBarrier device compared with conventional treatment.,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],
432,NCT01407640,Validation of cutaneous insulin tests,Immunogenetic of patients with IA (Insulin Allergy),2012-02-06,COMPLETED,INTERVENTIONAL,['NA'],
433,NCT05842993,Change in glycosylated hemoglobin (HbA1c),Safety measurement,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],
434,NCT02772679,Survival of Tregs,"Analysis of general immune response as assessed by, for example, viral tetramer+ CD8 cells and effects of Treg infusions on peripheral blood cells measured by flow cytometry including T cell subsets, B cells and other innate cell subsets",2016-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
435,NCT03342495,Health services utilization,Variation in SF-12 Scores,2018-02-06,COMPLETED,INTERVENTIONAL,['NA'],Youth/Caregiver Satisfaction
436,NCT04442529,Perceived stress,Mothers and Babies Skill Utilization,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA'],
437,NCT03484741,Adverse events,Blood insulin level,2017-04-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
438,NCT03638362,TCJ and hsCRP,fasting triglycerides,2009-08-21,COMPLETED,INTERVENTIONAL,['NA'],
439,NCT03959501,Change in serum ketone levels after treatment,Change in homeostasis model assessment 2 steady-state beta-cell function,2017-08-16,COMPLETED,INTERVENTIONAL,['PHASE4'],
440,NCT02309424,Muscle glucose uptake following meal ingestion (area under the glucose uptake versus time curve-AUC),Number of participants with adverse events,2008-07,COMPLETED,INTERVENTIONAL,['NA'],
441,NCT04351880,Anxiety and Depression measured through the Hospital Anxiety and Depression Scale,Re-hospitalization and Emergency Department Visits,2020-04-16,COMPLETED,INTERVENTIONAL,['NA'],
442,NCT06184568,Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥10% weight loss,"Percent Change from Baseline in Triglycerides, Total Cholesterol, LDL-c, HDL-c, non-HDL-c",2024-02-29,RECRUITING,INTERVENTIONAL,['PHASE3'],
443,NCT00575159,Mean of Derived Plasma Glucose Parameters,"The Metabolite to Parent AUC Ratio, AUCmetabolite/AUCparent Ratio for GSK279782 Over Period",2008-03-31,COMPLETED,INTERVENTIONAL,['PHASE2'],
444,NCT03940482,Change in glycaemic control of patients as measured by >= 5% reduction in glycosylated haemoglobin (HbA1C) over a 12 week period.,Change in a levels of ketonemia (Serum Beta-Hydroxybutyrate 0.5-3.0 mmol/L) over a 12 week period.,2019-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
445,NCT03428945,Change from Treatment Assignment Glucose Tolerance to Abnormal Glucose Tolerance or Diabetes,,2018-08-15,TERMINATED,INTERVENTIONAL,['PHASE2'],
446,NCT01418911,,,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],
447,NCT02357043,Accuracy - Blood Glucose Level Obtained by Layperson With the Dario Meter Compared to Blood Glucose Level on Yellow Springs Instrument Obtained by Nurse/Technician,,2014-12,COMPLETED,INTERVENTIONAL,['NA'],
448,NCT00438126,increased self-reported leisure physical activity,resting blood pressure,2002-01,COMPLETED,INTERVENTIONAL,['NA'],
449,NCT00198926,caloric compensation,,2000-05,COMPLETED,INTERVENTIONAL,['NA'],
450,NCT02597127,Percentage Change in LDL-C From Baseline to Day 180,Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
451,NCT00671008,Glycaemic control as measured by HbA1c,Change in body weight,2007-12,COMPLETED,OBSERVATIONAL,['NA'],
452,NCT05702463,"Among initial ASA non-responder participants, define the proportion of participants that remain ASA non-responders with different formulations and dosing regimens of ASA.","Platelet response levels to various agonists not directly related to the pharmacological target of ASA, including ADP, collagen, epinephrine and thrombin receptor-activating peptide (TRAP).",2023-06-13,RECRUITING,INTERVENTIONAL,['PHASE1'],
453,NCT02135549,Postprandial serum glucose area under the curve in mg*hr/dL over four hours,Peak blood serum excursion at 2 hours from baseline in mg/dL,2014-05,COMPLETED,INTERVENTIONAL,['NA'],
454,NCT02354235,Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c),Change From Baseline in 2-hour Postprandial Plasma Glucose Level,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
455,NCT00855608,The main outcome measure will be visual acuity improvement (3 lines),central foveal thickness and angiographic lesion size,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],
456,NCT03804658,Glucose variability,Health Literacy,2019-01-13,RECRUITING,OBSERVATIONAL,['NA'],
457,NCT05530356,Spatial Metabolomics,Age-corrected composite fluid cognition score,2022-09-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
458,NCT02455414,Change in regional brain volume,Change in disease severity score,2012-04,COMPLETED,OBSERVATIONAL,['NA'],
459,NCT01753934,Memory score on ImPACT testing,White matter volume on MRI using diffusion tensor imaging,2011-05,COMPLETED,OBSERVATIONAL,['NA'],
460,NCT01487382,Hypoglycaemic events,Adverse events,2002-04,COMPLETED,OBSERVATIONAL,['NA'],
461,NCT01698112,Fasting fructosamine,adiponectin,2006-07,COMPLETED,INTERVENTIONAL,['NA'],
462,NCT02327429,Change in Cholesterol Intake (3-day Food Record),Change in Fasting High-density Lipoprotein Cholesterol,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
463,NCT01075282,Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c),"Number of Participants With LY2189265 Antibodies at 26, 52, 78 Weeks and 4 Weeks After Last Dose of Study Drug (83 Weeks Maximum)",2010-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
464,NCT01351701,Risk factors associated with different grades of severity of DFI,Percentage sensitivity to different empiric antibiotics,2011-06,UNKNOWN,OBSERVATIONAL,['NA'],
465,NCT04957173,The primary outcome of this study will be weight loss in the participants.,,2021-10-14,WITHDRAWN,INTERVENTIONAL,['NA'],
466,NCT06330233,Electrophysiological examination of the peroneal nerve of the lower limb,infrared thermography testing,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
467,NCT00818142,Adherence to insulin regimen.,,2008-01,COMPLETED,OBSERVATIONAL,['NA'],
468,NCT02130687,Norepinephrine (NE) Concentrations,24hr Urinary Testing for Sodium,2014-06,COMPLETED,INTERVENTIONAL,['NA'],"Aldosterone, Angiotensin II, and Plasma Renin Activity (PRA)"
469,NCT03959306,Effect on Markers of Endothelial Dysfunction(The change in the level of soluble intercellular adhesion molecule ( ICAM) in serum using ELISA kit),Effect on Quality of Life ( Using Diabetes-39 questionnaire ),2019-04-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],
470,NCT05487352,gestational diabetes mellitus,"neonatal weight, height and head circumference",2021-05-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
471,NCT00541710,homeostasis model assessment for insulin resistance (HOMA-IR),Adverse events,2007-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
472,NCT01196546,HbA1c reduction,"To evaluate the effect of combination therapy of vildagliptin (50 mg) plus metformin (500 or 1000 mg) twice daily on FPG and BMI, safety and tolerability profiles",2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
473,NCT04831216,"Hemoglobin A1c (HbA1c), %",,2021-08-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
474,NCT04600128,Change in blood glucose levels,,2019-11-18,COMPLETED,INTERVENTIONAL,['NA'],Insulin
475,NCT05873322,The extent of beta cell function at week 22/23/28,,2022-08-30,RECRUITING,OBSERVATIONAL,['NA'],
476,NCT01395290,nasal staphylococcus colonisation,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
477,NCT00935441,Glycemic control (HbA1c),Systolic blood pressure control in patients with elevated blood pressure at baseline,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
478,NCT00108524,Change From Baseline in Body Weight at 48 Weeks,Change From Baseline in Blood Sugar at 48 Weeks,2004-07,COMPLETED,INTERVENTIONAL,['NA'],
479,NCT03269799,sulcus bleeding index,,2017-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],
480,NCT02178501,Change from Baseline in endothelial function status 3 months,Change from Baseline in glycometabolic control at 3 months,2013-01,COMPLETED,INTERVENTIONAL,['NA'],Safety Measures
481,NCT04790604,Acute care service use,Medication adherence,2021-01-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
482,NCT01093651,Plasma HIV Viremia (Viral Load),Self-reported Symptoms,2010-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
483,NCT01412710,Blood Lipid,Glycemic Control,2011-07,COMPLETED,INTERVENTIONAL,['NA'],
484,NCT05131139,Safety Objective: To demonstrate safety of the Eversense 524 CGM System and ROME CGM System.,,2021-10-20,RECRUITING,INTERVENTIONAL,['NA'],
485,NCT02276742,Urinary sodium will be determined from a time 24-hour urine sample,,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
486,NCT03403699,Differentiate iPSCs into CD34+ cells and mesoderm,,2018-01-11,RECRUITING,OBSERVATIONAL,['NA'],
487,NCT04219787,Primary endpoint,Secondary endpoints,2020-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
488,NCT01350102,Hgb A1c Level,Wound Area Measurements,2012-02,TERMINATED,INTERVENTIONAL,['PHASE4'],
489,NCT01802034,Change in disease progression,,2013-02,RECRUITING,OBSERVATIONAL,['NA'],
490,NCT02457130,Platelet reactivity,,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
491,NCT06067399,To assess the correlation between RDW and HbA1C levels in patients with T2DM before and after glycemic control.,To determine if changes in RDW levels correlate with the presence of other comorbidities and complications.,2024-04-01,RECRUITING,OBSERVATIONAL,['NA'],
492,NCT01494987,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24,2012-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
493,NCT00840307,Pancreatic and Liver Triglyceride (Fat) Content,,2008-08,COMPLETED,OBSERVATIONAL,['NA'],
494,NCT01332149,Change From Baseline in Mean Pain Score at Endpoint,Change From Baseline in HADS Depression Total Score at Endpoint,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
495,NCT01060059,Percentage of Patients Who Achieved Glycemic Target of HbA1c ≤ 7.0% With Minimal Weight Gain (≤ 1 Kg) at Month 12.,"Factors of Higher Creatinine, Higher Fasting High Density Lipoprotein (HDL) Cholesterol, Higher Fasting Cholesterol, and Higher Fasting Triglycerides Which Were Associated With Treatment Choice at Baseline",2010-04,COMPLETED,OBSERVATIONAL,['NA'],
496,NCT00737269,,,2008-06,COMPLETED,OBSERVATIONAL,['NA'],
497,NCT03418415,Changes in glucose metabolism from baseline to 6 months,Changes in renal function up to 2 years,2018-01-18,UNKNOWN,INTERVENTIONAL,['NA'],
498,NCT03633266,Mean change from baseline in best-corrected visual acuity (BCVA),chang from baseline in retinal neovascularization,2018-09-01,UNKNOWN,INTERVENTIONAL,['NA'],
499,NCT04487678,Change in venous blood pH,Gastro-intestinal distress symptoms via a questionnaire,2023-08,WITHDRAWN,INTERVENTIONAL,['NA'],
500,NCT02068989,Percentage of Subjects with an HbA1c greater than or equal to 6.5%,,2013-02,TERMINATED,OBSERVATIONAL,['NA'],
501,NCT00707993,Change From Baseline in Glycosylated Hemoglobin at Week 52.,Incidence of Glycosylated Hemoglobin Decrease From Baseline.,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
502,NCT03785522,Change in HbA1c (mmol/mol),"Reason(s) for discontinuing treatment with Tresiba® during the treatment period, if applicable",2018-12-23,COMPLETED,OBSERVATIONAL,['NA'],
503,NCT03150030,Part 2: Difference in MAGE,Part 2: Correlation between plasma glucose variation and risk of clinical relevant arrhythmias,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],
504,NCT04362540,The primary outcome measure for the study will be the mean difference in values of the HOMA-IR (as a surrogate for insulin resistance) in those with NAFLD vs. those without NAFLD 6-12 weeks post partum,MRI scan to confirm the presence of NAFLD at 6-12 weeks post partum.,2019-05-05,RECRUITING,OBSERVATIONAL,['NA'],
505,NCT05346250,Incidence of type 2 diabetes,Serum lipid change,2011-07-01,COMPLETED,OBSERVATIONAL,['NA'],
506,NCT05666596,Body mass index(kg/m2),,2021-01-07,COMPLETED,OBSERVATIONAL,['NA'],
507,NCT01710553,"Cmax, Tmax, AUC0-t, AUC0-∞, AUC%_Extrap, Kel and t1/2",Safety profile,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
508,NCT00992641,Glucose metabolism,Transcriptomics and metabolomics data,2009-08,COMPLETED,INTERVENTIONAL,['NA'],
509,NCT03842813,The primary endpoint is Target Lesion Failure (TLF) rate at 1 year,Stent thrombosis at 1 year in the sub-group of patients with a short planned dual-therapy,2019-04-09,UNKNOWN,OBSERVATIONAL,['NA'],
510,NCT05567692,Type 2 diabetes incidence in Descendance population,Study of interactions between risk factors on type 2 diabetes incidence,2023-02-10,RECRUITING,OBSERVATIONAL,['NA'],
511,NCT01499108,Change in ambulatory blood pressure,Washout analysis,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
512,NCT06221969,Relative change in body weight,"Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold",2024-01-16,RECRUITING,INTERVENTIONAL,['PHASE3'],
513,NCT03838900,Measure of Loop Safety by Self-Report of Hospitalization Events,Measure of Loop Safety by Self-Report of Hospitalization Events,2019-01-17,COMPLETED,OBSERVATIONAL,['NA'],Loop Follow-Up General Data Collection
514,NCT01907399,quantification of Treg,,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
515,NCT00354341,Change From Baseline in Left Ventricle Mass Index (LVMI) at Month 15,Percentage of Participants With Stable Hb Levels Between 13 to 15 g/dL,2002-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
516,NCT05909046,Rate of postpartum diabetes mellitus screening,Prediabetes or type 2 diabetes,2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],
517,NCT03081598,"To evaluate the efficacy of PBI-4050 400 mg, 800 mg, and 1200 mg",To evaluate the effect of PBI-4050 on frequency of hypoglycaemia events,2017-05-29,TERMINATED,INTERVENTIONAL,['PHASE2'],
518,NCT04219215,Change in rate of glucose disappearance,,2020-02-01,COMPLETED,INTERVENTIONAL,['NA'],
519,NCT03618420,Glomerular Filtration Rate (GFR),Renal Oxygenation,2018-10-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
520,NCT02453685,Change in HbA1c (Glycosylated Haemoglobin),Total Daily Insulin Dose,2015-08-31,COMPLETED,INTERVENTIONAL,['PHASE4'],
521,NCT01754181,Time spent in glucose reference intervals,"Measuring glucose sensor 2h, 3h and 4h post-prandial and AUC, in every situation tested to evaluate the efficacy and safety (time spent in hypoglycemia)",2013-03,COMPLETED,INTERVENTIONAL,['PHASE3'],"Comparison of glucose sensor 2h, 3h and 4h post-prandial and AUC in conditions identical meals for each trigger level (50 or 75%). Measuring AUC during and 2 hours after physical activity, then to lunch time, during dinner and throughout the night."
522,NCT01492465,Subject incidence of anti-AMG 876 antibodies.,Pharmacodynamic parameters:,2011-11,TERMINATED,INTERVENTIONAL,['PHASE1'],
523,NCT05663606,TIR,HbA1c,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
524,NCT06197360,Hypoglycemia fear worry,The self-management attitude scale for diabetes patients,2021-08-01,COMPLETED,INTERVENTIONAL,['NA'],
525,NCT05831644,Pharmacodynamic effect,,2023-04-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
526,NCT03260881,EAT inflammation,EAT GLP-1R,2018-09-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
527,NCT01474603,body weight change from baseline (non-diabetic patients),change from baseline of inflammatory and metabolic parameters,2011-11,COMPLETED,OBSERVATIONAL,['NA'],
528,NCT01783210,Gestational diabetes mellitus.,Mode and timing of delivery,2012-07,UNKNOWN,INTERVENTIONAL,['NA'],
529,NCT05372809,Incidence of index ulcers closed,Wound infection,2022-04-28,TERMINATED,INTERVENTIONAL,['PHASE3'],Incidence of adverse events of the index ulcer
530,NCT02916251,PD endpoint: Plasma glucose profiles above baseline: tmax,Safety endpoints: Antidrug antibodies incidences,2016-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
531,NCT06017089,Primary Safety Endpoint (Hypoglycemia),Basal Insulin,2023-11-10,RECRUITING,INTERVENTIONAL,['NA'],
532,NCT03349840,Comparison of the glycemic control of insulin glargine U100 with insulin degludec in patients with type 2 diabetes from baseline to end of Ramadan.,Incidence of Treatment-Emergent Adverse Events,2018-01-07,TERMINATED,INTERVENTIONAL,['PHASE4'],
533,NCT02213549,Change in 2h glucose concentration after the oral glucose tolerance test (OGTT) from baseline,Change in serum triglyceride from baseline,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
534,NCT02359617,Mean absolute relative difference between sensor readings and capillary glucose readings,,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
535,NCT01459601,FBS (fasting blood sugar),HbA1C,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],
536,NCT00120328,"To determine the effect of each dose of avosentan on time to doubling of serum creatinine, end stage renal disease (ESRD) or death when administered on top of standard treatment in subjects with type 2 diabetes mellitus and diabetic nephropathy.",unstable angina,2005-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
537,NCT04404556,Barriers to Diabetes Adherence questionnaire - Youth report Time Pressure/Planning Subscale,Type 1 Diabetes and Life -Parent Report,2020-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
538,NCT01196533,Comparison of the TensorTip Accuracy Against Hospital Periodical Readings.,,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
539,NCT00928876,"to determine the effect of Interleukin-1 receptor antagonist on insulin sensitivity, as derived from glucose infusion rate measured by euglycemic hyperinsulinemic clamp",systemic inflammation,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
540,NCT05943886,AUC,Assessment of the incidence of anti drug antibodies (ADA) developed against HEC88473 after dosing,2021-08-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
541,NCT06185348,Body mass index (BMI) variation after 6 months of treatment with hybrid closed loop (HCL),description of metabolic parameters at 24 months,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
542,NCT05645653,Medication Adherence,Treatment burden,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
543,NCT04409171,incidence & risk factors of worsened DM,characteristics of new-onset and worsened DM,2015-09-01,COMPLETED,OBSERVATIONAL,['NA'],
544,NCT00846300,Change in blood pressure,,2001-08,COMPLETED,INTERVENTIONAL,['NA'],
545,NCT03745157,Change in local laboratory measured glycosylated haemoglobin (HbA1c),Change in selected patient reported outcomes: Diabetes Therapy Related Quality of Life (DTR-QoL),2018-11-21,COMPLETED,OBSERVATIONAL,['NA'],
546,NCT03093298,Altered gene expression in the endocrine secretome following Roux-en-Y gastric bypass surgery,,2014-12-12,COMPLETED,INTERVENTIONAL,['NA'],
547,NCT00252876,"Adverse events, laboratory variables, physical examination, cardiac evaluation, hypoglycemic events, electrocardiogram, vital signs (blood pressure and pulse), body weight","Central obesity (waist circumference, hip circumference, waist/hip ratio)",2005-03,TERMINATED,INTERVENTIONAL,['PHASE3'],
548,NCT03085771,Endothelial precursor cell account (EPC),,2017-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
549,NCT01129258,PD Endpoint: glucose excursion (change from Day -1 baseline) in response to a liquid meal test (MMTT) on Days 1 and 14.,"Lactate (change from Day -1 baseline), at times specified in the SOA.",2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
550,NCT01457911,Absolute change in HbA1c,"Hematology, Serum chemistry and lipids",2011-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
551,NCT02392117,Change in the number of any hypoglycaemic episodes,"Change from baseline in HR-QoL (health-related quality of life) questionnaire scores (PROs (patient reported outcome): SF-36 (short form 36), and DTSQ(Diabetes Treatment Satisfaction Questionnaire ))",2015-03-16,COMPLETED,OBSERVATIONAL,['NA'],
552,NCT02513641,Insulin Sensitivity,2-hour Insulin Area-under-the-curve Via Oral Glucose Tolerance Test,2015-12,COMPLETED,INTERVENTIONAL,['NA'],
553,NCT05918068,Glycated Hemoglobin (HbAlc),"Indoleamine 2,3 dioxygenase (IDO)",2022-11-01,COMPLETED,INTERVENTIONAL,['NA'],
554,NCT01547156,Change in Hba1c(for diabetes patients),Change in FÍNSIK scores,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
555,NCT02212951,Post-standardized meal glucose exposure (AUC),Draize injection site erythema and edema scoring,2014-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
556,NCT01201278,"Insulin tolerability, PK, and PD",,na,UNKNOWN,INTERVENTIONAL,['PHASE1'],
557,NCT06141278,Change of SBP at baseline and at 12 month,Treatment rate at baseline and at 12 month,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
558,NCT04779164,Femoral cartilage thickness,radiographic knee osteoarthritis,2020-09-04,COMPLETED,INTERVENTIONAL,['NA'],
559,NCT04814147,Weight loss (kg) at 12 months of sleeve gastrectomy,Pre and post-operative hip circumference,2021-03-13,RECRUITING,OBSERVATIONAL,['NA'],
560,NCT00762736,Change from Baseline in glycosylated hemoglobin.,Change from Baseline in matrix metalloproteinase-9.,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
561,NCT05699759,Adverse Events,Mean change in best-corrected visual acuity (BCVA) at other study timepoints,2023-02-28,RECRUITING,INTERVENTIONAL,['PHASE1'],
562,NCT06130215,Time above Range (>180mg/dl and >250mg/dl),Diabetic Ketoacidosis,2023-11-15,RECRUITING,INTERVENTIONAL,['NA'],Ped Quality of Life Survey
563,NCT03955107,time in range at Week 8 after enrollment,adverse pregnancy outcomes,2019-04-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
564,NCT02185755,HbA1c Levels before and after intervention,HbA1c levels remain at 8% or higher,2014-08,COMPLETED,INTERVENTIONAL,['NA'],
565,NCT01186562,Insulin Independence,Acute C-peptide Response (ACR) to Glucose,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
566,NCT01345500,Total weight loss,Biochemical/social outcomes,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
567,NCT01165983,Skin Blood Flow Before and After Iontophoresis With Acetylcholine and Sodium Nitroprusside,"Absolute Change in Inflammatory Cytokines and Growth Factors, TNFα, pg/mL",2009-11,COMPLETED,INTERVENTIONAL,['NA'],
568,NCT05115747,Mean changes in the glycosylated hemoglobin level (HbA1c) at six months.,Mean changes in the health-related quality of life at six months.,2021-01-15,COMPLETED,INTERVENTIONAL,['NA'],
569,NCT03070106,Number of subjects in each study arm discontinuing insulin use with Hemoglobin A1c <7%,Change in the subject's score on the Medical Symptom Questionnaire (MSQ) in each study arm,2017-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
570,NCT04227431,Change in glycosylated haemoglobin (HbA1c),"Reason(s) for starting Tresiba®, at time of switch/add-on, if available",2020-01-17,COMPLETED,OBSERVATIONAL,['NA'],
571,NCT02899390,Body weight change,Change in the Perceived Stress Scale (PSS) -14 score,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
572,NCT00094991,The change from baseline in insulin medicated glucose disposal after 16 weeks of treatment with Muraglitazar,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
573,NCT02161094,Change in HbA1c,Score on the Diabetes Quality Of Life,2013-04,UNKNOWN,INTERVENTIONAL,['NA'],
574,NCT05303857,Central (aortic) pulse pressure assessed by Sphygmocor XCEL,Renal perfusion of both kidneys assessed by Arterial Spin Labeling MRI,2022-03-03,RECRUITING,INTERVENTIONAL,['PHASE4'],
575,NCT04652999,Patient satisfaction with the relaxation intervention,Heart rate,2019-03-19,COMPLETED,INTERVENTIONAL,['NA'],Clinical Data
576,NCT00700765,Major hypoglycaemic events,Variability in fasting blood glucose (FBG) and average plasma glucose level,2008-01,COMPLETED,OBSERVATIONAL,['NA'],
577,NCT01299246,Number of the residents in detecting the early neurovasculopathy,,2009-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
578,NCT02160275,Mean sensor glucose concentration,Time that the control algorithm is inactive,2014-06,COMPLETED,INTERVENTIONAL,['NA'],Glucagon use
579,NCT03297879,The change of HbA1c,,2013-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
580,NCT03975556,Change in levels of metabolic risk factors,Changes in diet satisfaction: diet satisfaction scale,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],
581,NCT03347890,Change of Bold Oxygenation Level Dependent (BOLD) signal (%) in brain regions involved in the reward system,BOLD in brain regions involved in the reward system,2018-03-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
582,NCT02040337,Sensitivity and specificity of T cell repertoire analysis to classify Type I Diabetes,,2014-04,COMPLETED,OBSERVATIONAL,['NA'],
583,NCT00316537,Assessment of ulcer size as determined by weekly ulcer tracings,"Assessment for complete wound closure. ""Complete wound closure"" will be defined as full epithelialization of the wound with the absence of drainage and lack of dressing requirement for an interval of at least 2 weeks.",2006-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
584,NCT04003194,Change in Glucose,Change in Hemoglobin A1c,2009-03-01,COMPLETED,INTERVENTIONAL,['NA'],
585,NCT00238550,"Improvement in pain symptoms, including pain perception and sleep quality, utilising daily diaries and validated pain questionnaires during 12 week treatment period and after 3 month cessation of treatment",MR spectroscopy of the chemical constituents in the deep nuclei of the brain will be analysed before and after 12 week treatment period.,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
586,NCT02071979,Wound Size,Wound recurrence,2014-04,TERMINATED,INTERVENTIONAL,['NA'],
587,NCT00481286,Change in systolic blood pressure; change in Hemoglobin A1C; change in low density lipoprotein,"Attainment of benchmark levels for SBP, A1C, LDL; self-management performance (self-report); completion of group clinic",2007-04,COMPLETED,INTERVENTIONAL,['NA'],
588,NCT01778556,Total Body Insulin Sensitivity,Endogenous Rate of Appearance of Palmitate,2013-01-26,COMPLETED,INTERVENTIONAL,['PHASE2'],
589,NCT05275400,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Diabetes Treatment Satisfaction Questionnaire-Status Version (DTSQ),2022-03-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
590,NCT00440284,glycosylated hemoglobin (GHb),"mild and severe hypoglycemia, insulin dosage, blood pressure and body-mass-index (BMI).",2004-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
591,NCT00916604,"Safety by assessment of adverse events, BP, pulse rate, plasma glucose, safety laboratory variables and ECG","Pharmacodynamic variables (P-Glucose, S-Insulin and S-C-peptide).",2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
592,NCT02215408,The mean percent of applicable Guideline Advantage standards of care that are met at 12 months,The percent of intervention group patients who rate the intervention as helpful (versus not helpful),2015-01-20,COMPLETED,INTERVENTIONAL,['NA'],
593,NCT04080518,To demonstrate that SGLT-2 inhibition induces urea-dominated renal water conservation within the renal concentration mechanism. ( Change from baseline in urinary osmolyte concentration,Analysis of glycogen and fat content in skeletal muscle and liver,2019-11-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
594,NCT04024631,Glucose response to an oral glucose load,Disposition index,2019-06-17,RECRUITING,INTERVENTIONAL,['NA'],
595,NCT05815342,Change in HbA1c,Coefficient of variation,2023-04-11,COMPLETED,INTERVENTIONAL,['NA'],
596,NCT02019082,The plasma level of VEGF(pg/ml) and NO (microM),Wound surface area(cm2),2011-03,COMPLETED,INTERVENTIONAL,['NA'],
597,NCT03769701,Proportion of women who achieve glycemic control.,,2018-12-07,UNKNOWN,INTERVENTIONAL,['NA'],
598,NCT03978286,Effect of antidepressant treatment (sertraline versus vortioxetine) in triglycerides control in depressed type 2 diabetic patients.,Effect of antidepressant treatment (sertraline versus vortioxetine) in anthropometric variables in depressed type 2 diabetic patients.,2016-06-30,COMPLETED,INTERVENTIONAL,['PHASE4'],
599,NCT04590703,Evaluation of incidence of adverse events,,2020-06-24,COMPLETED,OBSERVATIONAL,['NA'],
600,NCT05235425,Change in HbA1c,Change in HbA1c,2022-03-20,RECRUITING,INTERVENTIONAL,['NA'],
601,NCT00236210,The percentage of patients who attained a significant reduction in their global cardiovascular risk at 6 and 12 months. This was determined a priori by the investigators to be an increase in the ACTION Score of 5 or more.,"Secondary outcomes were change in the average ACTION Score, change in individual risk domains as measured by the ACTION Score, patient satisfaction, and quality of life, all after 6 months and 12 months, comparing intervention versus control.",2004-08,COMPLETED,INTERVENTIONAL,['NA'],
602,NCT00355680,Regression of new vessels,Bruch's membrane rupture,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
603,NCT01039324,Emergency department encounter rates among patients in the study population.,Provider satisfaction among providers with contact with patients for whom intervention was appropriate.,2009-12,COMPLETED,INTERVENTIONAL,['NA'],
604,NCT04535960,Proximal tubular natriuresis,"Urinary EGF,FGF2,Eotaxin,TGFa,G-CSF,Flt-3L,GM-CSF,Fractalkine,IFNa2,IFNy,GRO,IL10,MCP-3,IL-12P40,MDC,IL-12P70,PDGF-AA,IL-13,PDGF-BB,IL-15,sCD40L,IL-17A,IL-1RA,IL1a,IL9,IL1B,IL2,IL3,IL4,IL5,IL6,IL7,IL8,IL10,MCP-1,MIP-1a,MIP-1B,RANTES,TNFalpha,TNFB,VEGF",2019-01-24,RECRUITING,INTERVENTIONAL,['PHASE2'],
605,NCT03683368,Time to infusion set failure due to an occlusion,Glucose variability,2018-10-09,COMPLETED,INTERVENTIONAL,['NA'],
606,NCT01339520,Change in total score,HbA1c,2008-11,COMPLETED,INTERVENTIONAL,['NA'],
607,NCT01728740,AUC(0-tn) of metformin,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
608,NCT06271382,Ankle Brachial Index,,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
609,NCT00657605,Change in Weight,Change in Glucose Levels,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
610,NCT03358797,Change in physical activity engagement,Change in Self-Rated health,2016-12-29,RECRUITING,INTERVENTIONAL,['NA'],
611,NCT01743014,Reduction in albumine to creatine ratio after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy,Change from baseline in carotid intima-media thickness after combined therapy with ramipril and clopidogrel and after ramipril monotherapy,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],
612,NCT04361552,30-day mortality rate,Length of hospital stay,2020-04-07,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
613,NCT00553475,Change From Baseline at Week 13 in Mean Weekly Pain Scores,Patient Global Impression of Change,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
614,NCT04327713,Total cardiovascular disease (CVD) incidence,Arrhythmia incidence,2020-03-28,UNKNOWN,OBSERVATIONAL,['NA'],
615,NCT02789722,Evaluation of transcriptome analysis.,Clinical evaluation: weight.,2016-08-15,COMPLETED,INTERVENTIONAL,['NA'],
616,NCT02213003,procedural complications,,2014-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
617,NCT01186107,Angiographic in-segment late loss,target-vessel revascularization,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
618,NCT05114590,Change from baseline to week 16 in the percentage of Time in Range (TIR),Number of participants with adverse events,2022-01-27,COMPLETED,INTERVENTIONAL,['PHASE4'],
619,NCT01657474,Mean time to healing,Percent change in wound area,2012-09,COMPLETED,INTERVENTIONAL,['NA'],
620,NCT02617732,Change from baseline in mean amplitude of glycemic excursions (MAGE) and mean of daily differences (MODD) at 12 weeks.,Renal Function Examination,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],
621,NCT01606930,Adherence to anti-hypertensive drug treatment at three months,Systolic and Diastolic Blood Pressure at three months,2010-11,COMPLETED,INTERVENTIONAL,['NA'],
622,NCT03378271,Accuracy of CGM and FGM,The evaluation of patients preferences and experience of the two glucose monitoring systems.,2016-05-05,COMPLETED,INTERVENTIONAL,['NA'],
623,NCT02484209,Difference in hypoglycaemia occurrence (mild-moderate category) between treatment arms,Duration of Hypoglycaemia,2016-02,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
624,NCT01435603,Percent Change in Body Weight,Percent Change in Physical Activity,2011-08,COMPLETED,INTERVENTIONAL,['NA'],
625,NCT01954147,HbA1C,Fasting Blood Glucose,2013-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
626,NCT01554293,"Pharmacokinetics Variables (Cmax, tmax, AUC, t1/2, kel, CL/F & Vz/F)",Exploratory markers (plasma DPP-IV activity and GLP-1 levels),2012-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],
627,NCT00820378,,,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],
628,NCT01121029,C-peptide levels before and after the hematopoietic stem cell transplantation,Serum levels of Hb A1C before and after the hematopoietic stem cell transplantation,2010-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
629,NCT04101604,Peripheral blood mononuclear cell (PBMC) signatures,PBMC cell types frequencies,2019-09-26,UNKNOWN,OBSERVATIONAL,['NA'],
630,NCT02733302,IPAQ-SF questionnaire for measure of Physical Activity,,2016-04-04,UNKNOWN,INTERVENTIONAL,['NA'],
631,NCT01068730,Metformin PK Parameter Observed Maximum Plasma Concentration (Cmax),Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Urinalysis,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])
632,NCT03819127,Evaluation of cognitive decline,Rate of Glycated hemoglobin (%),2015-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
633,NCT04646941,the new onset and types of tumor in T2DM patients,,2020-06-10,RECRUITING,OBSERVATIONAL,['NA'],
634,NCT00698932,Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c),Proportion of Patients Achieving a Therapeutic Glycemic Response Defined as HbA1c <7.0% at Week 24,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
635,NCT01774500,"Combined hospital admission, seizure recurrence, or death at day 7",Recurrence of seizure,2013-01,COMPLETED,OBSERVATIONAL,['NA'],
636,NCT02099981,The vascular response to flicker,Contrast sensitivity,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
637,NCT03248401,Change of carotid artery atherosclerosis,Change of carotid artery atherosclerosis 3,2016-09-26,COMPLETED,INTERVENTIONAL,['PHASE4'],Body composition
638,NCT03524404,Program engagement,,2018-03-28,COMPLETED,INTERVENTIONAL,['NA'],
639,NCT01348568,change in serum lipids,cancer cell proliferation (in vitro),2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
640,NCT04916093,Changes in HbA1c (%),Changes in Renal function tests,2019-12-20,COMPLETED,INTERVENTIONAL,['PHASE4'],
641,NCT06242106,Perceived stress scale:,,2023-03-15,RECRUITING,INTERVENTIONAL,['NA'],
642,NCT02715258,Change in HbA1c From Baseline at Week 24,Change in Body Weight From Baseline at Week 24 in Subjects With a BMI ≥ 25 Kg/m2,2016-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Proportion of Subjects Who Achieve an HbA1c < 7%
643,NCT03805412,Percent Body Fat Change at 14 Weeks,MAGE Mean Amplitude of Glycemic Excursion,2019-01-10,COMPLETED,INTERVENTIONAL,['NA'],
644,NCT05760118,Revised Osteoporosis Knowledge Test,Osteoporosis Health Belief Scale,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
645,NCT05463705,"Rate of prescriptions for SGLT-2i or GLP-1RA among eligible patients in each arm, compared across study arms","Change in Hemoglobin A1c (A1c) over the 6-month intervention period among eligible patients, compared across study arms",2023-05-04,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
646,NCT02607566,Feasibility as measured by study completion,Diabetes Self-Care,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
647,NCT01296412,Change From Baseline in Hemoglobin A1c (A1C),Percentage of Participants Reaching A1C Goal of <6.5%,2011-03-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
648,NCT02917902,Change in HbA1c (measured as part of routine care),"Change in Body Mass Index, measured in kg/m^2, weight in kilograms, height in meters",2015-01,COMPLETED,INTERVENTIONAL,['NA'],
649,NCT02444156,Change in Cardiac function,Change in Sample size in a full-scale trial,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
650,NCT02015429,Blood glucose,Subjective appetite,2007-12,COMPLETED,INTERVENTIONAL,['NA'],Palatability of treatments
651,NCT00587132,Number of Subjects With Evidence of Pancreatic Tumor or Any Secondary Findings of Pancreatic Tumor as Shown by CT.,,2006-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
652,NCT06192251,Participant Feedback,Participant Feedback,2023-11-06,RECRUITING,OBSERVATIONAL,['NA'],
653,NCT00679042,Number of Subjects Reaching the Efficacy Goal,Reduction in Hypoglycemic Severity Measured by %Reduction in HYPO Score,2007-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
654,NCT00195884,hemoglobin A1c (HbA1c),quality of life (QOL),1999-09,COMPLETED,INTERVENTIONAL,['NA'],
655,NCT04473326,Medication Adherence,Glycemic Control,2021-02-04,COMPLETED,INTERVENTIONAL,['NA'],
656,NCT01252524,Change in Hemoglobin A1c from baseline,Adverse outcomes,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
657,NCT02269735,Number of participants who discontinued study drug due to an adverse event,Number of participants with anti-drug antibody (ADA) formation,2014-11-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
658,NCT00846716,Onset and progression of diabetic nephropathy,Progression of diabetes mellitus change from the baseline in HbA1c change from the baseline in albumine/creatinine ratio change from the baseline in cystatin C onset and progression of diabetic retinopathy safety assessment,2008-03,UNKNOWN,INTERVENTIONAL,['NA'],
659,NCT01794052,Change in compliance to therapy and follow-up rate among people with hypertension and/or diabetes.,,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
660,NCT01059799,Change in Glycosylated Haemoglobin (HbA1c),Mean of 9-point Self Measured Plasma Glucose Profile (SMPG),2010-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
661,NCT02597101,Insulin Sensitivity at 6 Months From Baseline,Change From Baseline in the Serum Levels of Inflammatory Markers,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
662,NCT01505036,"Rate of patients who attain,Hemoglobin A1C ≤ 7.0% and Blood pressure ≤ 130/80 and LDL-Cholesterol ≤ 100 or LDL-Cholesterol ≤ 70, all at 12 months.",Changes in Blood Pressure,2010-12,COMPLETED,INTERVENTIONAL,['NA'],
663,NCT06160817,Healing time,Clinical characteristics of the ulcer: Local Clinical Signs of Infection,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],SINBAD classification of diabetic foot ulcers
664,NCT01215968,Time Required for 50% of Radioactivity To Be Emptied From the Stomach by Scintigraphy,Number of Participants With Clinically Significant Effects,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
665,NCT04615351,Prediabetes or Diabetes,Prediabetes or diabetes at 15 months postpartum,2020-11-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],
666,NCT03437551,prevalence (percentages) of the stages of diabetic retinopathy (DR),mean NEI-VFQ 25 score,2012-09,COMPLETED,OBSERVATIONAL,['NA'],
667,NCT04907838,Leg blood flow,,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA'],
668,NCT02777073,Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin,Change in Ghrelin Concentrations,2016-03-01,COMPLETED,INTERVENTIONAL,['NA'],
669,NCT05897372,urine albumin/creatinin-ratio (UACR) reduction to less than 50% of baseline,incidence of symptomatic hypotension,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
670,NCT03186300,"Change in the percentage of time spent in hypoglycaemia (glucose level below 3, 9 mmol/L or 70 mg/dl)",Evaluation of usability and the treatment satisfaction of PEPPER system by using non-validated questionnaires.,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],
671,NCT00855374,,,2008-06,COMPLETED,OBSERVATIONAL,['NA'],
672,NCT01484457,Restoration of Euglycemia,Average percent-of-time-in-range (80 - 180 mg/dL),2008-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
673,NCT03220425,The change in the level of glycosylated haemoglobin(HbA1c),,2001-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
674,NCT04805853,the change level of cardiac extracellular volume (ECV),Changes in score of Patient Health Questionnaire-9(PHQ-9),2020-02-20,UNKNOWN,OBSERVATIONAL,['NA'],
675,NCT01524809,Area under the serum insulin curve 6-14 hours after dinner at day 15,Adverse events,2001-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
676,NCT06167616,LADA,Type 2 diabetes,2010-09-01,COMPLETED,OBSERVATIONAL,['NA'],
677,NCT05031000,Analysis of system accuracy based on DIN EN ISO 15197,,2021-09-03,COMPLETED,INTERVENTIONAL,['NA'],
678,NCT06043843,Compare first incidence rate of hypoglycaemia or severe hypoglycemia between intervention and control groups in Ramadan,Compare the weight changes after Ramadan as compared to pre-Ramadan weight,2021-02-16,RECRUITING,INTERVENTIONAL,['NA'],
679,NCT03997773,Change in quality of life,Change in moderate to vigorous physical activity patterns,2019-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Changes in health literacy
680,NCT01468181,Percentage of Participants With Hypoglycemic Episodes,Change From Baseline in Updated Homeostasis Model Assessment (HOMA2),2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
681,NCT06293742,Midazolam PK parameters: Cmax,ECC5004 PK parameters: Ctau,2024-02-09,RECRUITING,INTERVENTIONAL,['PHASE1'],
682,NCT03804892,IMTG utilisation during exercise,,2019-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
683,NCT00806975,"HbA1c change rate from the start to 12 and 24 weeks are investigated and compared. Furthermore, using a questionnaire sheet ""IDSQ-J"" related to the insulin infusion device, the patient's usability and satisfaction with KwikPen® or FlexPen® are performed.","As the secondary endpoints, the incidence of hypoglycemia, changes in body weight (BMI) and blood pressure, and the dose of insulin are investigated and compared before and after the changeover.",2009-01,UNKNOWN,INTERVENTIONAL,['NA'],
684,NCT04140201,The 80 participants will be evaluated through reduction of macular edema,The 80 participants will be evaluated through reduction of cardiovascular risk,2020-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
685,NCT04304729,Vascular structure (Pulse-wave velocity),Hypertension,2017-01-12,SUSPENDED,OBSERVATIONAL,['NA'],
686,NCT05202002,"Rate of type II Diabetes Mellitus (DM) diagnosis, as diagnosed by the 75gm oral glucose tolerance test (OGTT)",Rate of exclusive breastfeeding,2021-03-01,UNKNOWN,INTERVENTIONAL,['NA'],
687,NCT04646746,Postprandial glycemic response,Postprandial GIP (Glucose-dependent insulinotropic polypeptide) response,2021-02-08,COMPLETED,INTERVENTIONAL,['NA'],
688,NCT02485132,Total incidence rate of hypoglycemia episode,,2016-03,TERMINATED,OBSERVATIONAL,['NA'],
689,NCT00433069,Early virological response,Improvement (vs. baseline) of glucose tolerance parameters after 12 and 48 weeks of therapy and after 24 weeks of follow-up,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
690,NCT05575206,Insulin secretion capacity,Glucose tolerance status,2023-09-15,RECRUITING,OBSERVATIONAL,['NA'],
691,NCT05887271,Change in the distance walked during 6 minute walk test (6MWT),Exploratory outcome: change in fibroinflammatory biomarker panel,2023-03-29,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
692,NCT03962686,methylase status,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],
693,NCT01566110,Metabolic Control,Continuous Glucose Monitoring,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
694,NCT05478291,Effects of vitamin D supplementation on physiology of atherosclerosis,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
695,NCT02876393,Presence of DMO evaluated from the optical coherence tomography (OCT) images,,2014-11,COMPLETED,OBSERVATIONAL,['NA'],
696,NCT03403556,Mean percent change from baseline to week 24 in low-density lipoprotein cholesterol (LDL-C),Mean change from baseline to week 24 in HOMA-B,2018-03-27,UNKNOWN,INTERVENTIONAL,['PHASE4'],
697,NCT00106340,Time to HbA1c >8%,Change from baseline in body weight at 5 years,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
698,NCT03212950,Time within range 3.9 - 10 mmol/l (70 - 180 mg/dl),,2017-07-10,COMPLETED,INTERVENTIONAL,['NA'],
699,NCT05692388,Self-Care Behavior,,2023-01-23,RECRUITING,OBSERVATIONAL,['NA'],
700,NCT03040414,Non-inferiority for Percent of Time <54 mg/dL (3.0 mmol/L) During the Entire 24-hour Period.,Key Safety Outcome 3) Number of Severe Hypoglycemia Events,2019-06-03,COMPLETED,INTERVENTIONAL,['NA'],Human Factors and Diabetes Technology Attitude and Human Factors Questionnaires
701,NCT00224237,,,2005-12,COMPLETED,OBSERVATIONAL,['NA'],
702,NCT05820295,Number of emergency department visits or hospital admissions,"Efficiency, as measured by the total number of care-coordinator hours used",2023-05-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
703,NCT03848793,HbA1c,Change in Body Weight,2019-03-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
704,NCT01475734,Glucagon Concentration (Nanomoles Per Liter [Nmol/L]) During the Hypoglycemic Periods of the Glucose Clamp Procedure,Number of Participants With Any Treatment-emergent Serious Adverse Event (SAE) and Treatment-emergent Non-serious Adverse Event (AE) During the Clamp Period,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
705,NCT00974740,C-peptide after a liquid mixed meal stimulation,plasma CRP,2004-03,TERMINATED,INTERVENTIONAL,['PHASE1'],
706,NCT01334034,Number of adverse events,Area under the glucose infusion rate-time curve,2011-04-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
707,NCT03470961,Incidence and severity of adverse event,,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
708,NCT05101473,4x10-meter fast-paced walk test,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],
709,NCT03072901,Evaluation of Effectiveness of the EndoBarrier GI Liner upon weight loss,,2010-12,TERMINATED,OBSERVATIONAL,['NA'],
710,NCT02655770,Change in diastolic properties as assessed by CMR.,Echocardiographic indices of diastolic dysfunction,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
711,NCT04547790,Change in HbA1c,Change in weight,2020-12-23,COMPLETED,INTERVENTIONAL,['NA'],
712,NCT04905485,Difference in VIOME's Type 2 diabetes risk score,,2021-05-21,UNKNOWN,INTERVENTIONAL,['NA'],
713,NCT01010100,The principal objective was to determine if the administration of small doses of Acarbose could prevent or delay the appearance of Type 2 DM in a population of subjects with impaired glucose homeostasis.,Delay in the conversion to diabetes mellitus,2000-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
714,NCT01597843,Registration for MHV,,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
715,NCT04060056,Adverse birth outcomes,Number of participants developing type 2 diabetes,2019-08-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
716,NCT04765982,Incidence of developing pre diabetes in patient with post operative stress hyperglycemia,other morbidity measures,2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],
717,NCT03667300,UACR percent change at Week 24,eGFR change at Week 12,2017-03-16,COMPLETED,INTERVENTIONAL,['PHASE2'],
718,NCT02542722,Incidence of type 2 diabetes in subjects at risk,,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
719,NCT00832390,Change From Baseline in A1C at Week 24,,2007-02-14,COMPLETED,INTERVENTIONAL,['PHASE4'],
720,NCT05024656,Incidence of complete wound closure,,2021-09,WITHDRAWN,INTERVENTIONAL,['NA'],
721,NCT05866497,CAVI measurements,,2022-06-10,COMPLETED,OBSERVATIONAL,['NA'],
722,NCT03435328,salivary volume,Eight-item visual analogue scale xerostomia questionnaire,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],
723,NCT00448487,"same as in ICARE: composite major CVD outcomes (non fatal MI, Stroke and CVD death)",,2005-04,COMPLETED,OBSERVATIONAL,['NA'],
724,NCT00589680,Hospital length of stay,Time to correction of glucose level and anion gap,2007-12,COMPLETED,OBSERVATIONAL,['NA'],
725,NCT00434538,Percentage of subjects with closed ulcers at week 12,Reduction of incidence of clinical signs of infection.,2007-02,TERMINATED,INTERVENTIONAL,['PHASE3'],
726,NCT03352596,insulin,Blood pressure,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
727,NCT01237301,Percentage Change in Hemoglobin A1c,Change From Baseline in CGM Glucose Variability,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
728,NCT00933101,Determine the impact of glycemic control on vascular oxidative stress/inflammation in adolescents with Type 1 diabetes mellitus,To determine the impact of glycemic control and vascular oxidative stress/inflammation on vascular health in adolescents with T1DM,2010-01,COMPLETED,OBSERVATIONAL,['NA'],
729,NCT01299844,Hemoglobin A1c,Diabetes Knowledge Test Score,2006-12,COMPLETED,INTERVENTIONAL,['NA'],
730,NCT05999773,SGLT-2 inhibitors related adverse events,Adverse events classification,2023-07-15,RECRUITING,OBSERVATIONAL,['NA'],
731,NCT03826290,Per-patient change in Hemoglobin A1c (HbA1c) levels from beginning to end of evaluation period,Cost of diabetes medications prescribed,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],User opinions of the diabetes dashboard
732,NCT01486290,Hemoglobin A1c,Economic impact,2007-07,COMPLETED,INTERVENTIONAL,['NA'],
733,NCT00532610,Continuous holter monitor & ECG each treatment period:,"12-lead ECGs, vital signs, adverse events, and clinical laboratory tests.",2007-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
734,NCT02624908,Self monitoring and continuous monitoring blood glucose levels,,2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
735,NCT00923975,Number of Participants Out of 50 Rated Successful (<=3) by Healthcare Professionals When Participants Performed Specific Software Tasks,Number of Participants Out of 50 Who Rated Their Satisfaction With The Following as Good to Excellent (>=3),2009-06,COMPLETED,INTERVENTIONAL,['NA'],
736,NCT02119754,Clinical Response,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
737,NCT04977427,Intraocular Inflammation,Macular Edema,2021-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],
738,NCT01408095,Change from baseline to 12 week endpoint in glycosylated fraction of hemoglobin A (HbA1c),"Pharmacokinetics: Area under the curve of concentration-time curve for one dosing interval at steady state (AUC0-tau, ss) of LY2608204",2011-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
739,NCT04444570,Rate and type of complications,Cardiovascular events and/or surgical site or implants complications,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA'],
740,NCT05245825,Hemoglobin A1C,Stool classification,2021-11-20,RECRUITING,INTERVENTIONAL,['NA'],
741,NCT02355197,neonatal outcome assessed by neonatal ICU admission,oxidative stress parameters: non enzymatic and enzymatic oxidative stress parameters in neonatal blood in women with GDM named malondialdahyde and superoxide dismutase,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
742,NCT01938807,Diabetes Management,Hemoglobin A1c,2013-10,COMPLETED,INTERVENTIONAL,['NA'],Satisfaction and usability of the mobile application
743,NCT02899949,change in HbA1c value,Evidence of urinary tract infection (UTI) documented,2016-10,COMPLETED,OBSERVATIONAL,['NA'],
744,NCT00240422,Change from baseline of renal plasma flow (RPF) in response to L-NMMA infusion at the end of treatment.,Changes from screening in ECG at the end of the study,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
745,NCT05407233,Change in Pain assessment,Analyze cost-utility,2019-10-14,COMPLETED,INTERVENTIONAL,['NA'],
746,NCT01555788,Percentage of time spent with blood glucose between 3.9 and 8.0 mmol/L (79 - 144 mg/dl),Percentage of time spent in hyperglycemia,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
747,NCT03579797,Eye health management,,2015-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
748,NCT04464772,System Performance,,2020-07-10,COMPLETED,OBSERVATIONAL,['NA'],
749,NCT06334484,change in time spent in tighter glucose range after 24 months of hybrid closed loop system,,2024-03-26,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
750,NCT02874612,Evidence of a correlation between negative diabetes health outcomes and psychosocial functioning over a 1 year period,Number of participating rating themselves as having diabetes quality of life as assessed by the PedsQL Diabetes 3.2 measure,2015-08,COMPLETED,OBSERVATIONAL,['NA'],
751,NCT00535886,"The primary outcome measure will be the ratio of total to high density lipoprotein (HDL) cholesterol. Blood draws will take place at screening, three weeks, and five weeks.","Related secondary outcome measures include concentrations of low density lipoprotein (LDL) cholesterol, HDL cholesterol, triglyceride (TG) and Lp(a) measured at screening, three weeks, and five weeks.",2005-11,COMPLETED,INTERVENTIONAL,['NA'],
752,NCT00342992,Cancer,Causes of mortality,1995-03-03,COMPLETED,OBSERVATIONAL,['NA'],
753,NCT00816010,"Composite endpoint of death and/or CVD related hospitalisations (acute myocardial infarction, revascularisation procedures, heart failure or unstable angina or arrhythmia requiring hospital admissions, lower extremity amputation and stroke) by 24 months.","Number of hospital admissions, total number of days of hospitalization",2008-07,TERMINATED,INTERVENTIONAL,['NA'],
754,NCT01473576,Muscle protein fractional synthetic rate,Plasma nitrate,2011-08,COMPLETED,INTERVENTIONAL,['NA'],
755,NCT00790088,Percentage of Patients Achieving HbA1c < 7.5%,Diabetes Treatment Satisfaction Questionnaire Status Version (DTSQs),2009-02,COMPLETED,OBSERVATIONAL,['NA'],
756,NCT00412906,"Gene expression evaluated by measuring mRNA via RT-PCR. Plasma cytokine content, PLasma PAI-1 content, endotoxemia score","Mean Arterial Pressure, heart rate, Temperature,",2006-11,COMPLETED,INTERVENTIONAL,['NA'],
757,NCT03195400,Hepatic glucose fluxes,,2017-03-01,COMPLETED,OBSERVATIONAL,['NA'],
758,NCT02666807,Change from Baseline in NF-KB at 10 weeks,Change from Baseline in insulin (µlU/ml) at 10 weeks,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
759,NCT03689738,Change in the Matsuda insulin sensitivity index (MISI),Change in the total AUC for breath hydrogen,2018-09-24,COMPLETED,INTERVENTIONAL,['NA'],
760,NCT04071808,Blood norepinephrine content,,2019-10-01,COMPLETED,OBSERVATIONAL,['NA'],
761,NCT04050098,bioequivalence study,,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
762,NCT01272973,Frequency of adverse events (AEs),Terminal phase elimination half-life,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
763,NCT03106246,Determine whether these EVs contain islet-specific antigens,Mutivariate analysis will be performed with patient parameters and EV parameters,2016-12,UNKNOWN,OBSERVATIONAL,['NA'],
764,NCT03845868,Incidence of cardiovascular diseases,,2013-04-16,RECRUITING,OBSERVATIONAL,['NA'],
765,NCT01397279,M Value in hyperinsulinemic euglycemic clamp,Insulin-suppressed endogenous glucose production (liver insulin sensitivity),2011-07,COMPLETED,INTERVENTIONAL,['NA'],
766,NCT00541450,Change in Hemoglobin A1c (A1C) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks,Change in Fasting Plasma Glucose (FPG) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks,2008-01-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
767,NCT05849701,Wound volume,Wound volume,2022-03-10,COMPLETED,INTERVENTIONAL,['NA'],
768,NCT00760292,,,2008-05,UNKNOWN,OBSERVATIONAL,['NA'],
769,NCT02377076,HbA1c,,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
770,NCT02709629,Change from baseline in diabetes self management as reflected in the diabetes self-management questionnaire,Change from baseline in diabetes self-management as reflected in scores on the diabetes self-management questionnaire at 35 weeks,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
771,NCT06273020,Blood-Brain-Barrier Permeability after 10-14days of cerebrolysin in patients with AIS of the middle cerebral artery,"Comparison of cognitive impairment, using Montreal Cognitive Assessment in patients with and withouth cerebrolysin",2022-11-17,RECRUITING,INTERVENTIONAL,['PHASE4'],
772,NCT00569959,LDL-Cholesterol,Other lipid parameters,2006-11,COMPLETED,INTERVENTIONAL,['NA'],
773,NCT02682680,Proportion of subjects who achieve target HbA1c and LDL cholesterol,Absolute change in creatine kinase (CK),2016-01-11,COMPLETED,INTERVENTIONAL,['PHASE4'],Mean dose of colesevelam
774,NCT01252810,Comparison of Overall Image Quality Between Ioforminol and Iopamidol-enhanced Images as Determined by an Independent Reader.,Assessing the Incidence of Renal Biomarker-based Contrast-induced Acute Kidney Injury (CI-AKI) in Subjects Post Administration of Ioforminol or Iopamidol Injections,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
775,NCT03729479,Systolic blood pressure,Weight loss,2018-11-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
776,NCT03116009,Large for gestational age or macrosomia,Glycemic control,2017-03-19,TERMINATED,INTERVENTIONAL,['PHASE3'],
777,NCT02556398,area under the curve (AUC) above target (> 180 mg/dL),,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
778,NCT00806520,,,2008-04,COMPLETED,OBSERVATIONAL,['NA'],
779,NCT05351190,A1c,Quality of Life - GMSS T2DM Version,2022-05-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
780,NCT02157155,Insulin signaling expressed as a CHANGE in phosphorylation of intracellular target proteins and CHANGE in mRNA expression of target genes in muscle- and fat-tissue.,Cytokines and stress hormones,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
781,NCT01589757,SUB-STUDY (n=75): Oxygen Radical Absorbance Capacity (ORAC) (Antioxidant Capacity) of transitional and mature breast milk.,MAIN STUDY: Change in behaviour from baseline (pre-class) to 6-8 weeks after delivery.,2011-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
782,NCT05118945,Time in glucose range 70 - 180mg/dl (%),mean daily insulin amount before study start,2021-03-03,COMPLETED,OBSERVATIONAL,['NA'],
783,NCT05866536,Change in HbA1c values,Change in insulin usage,2023-05-04,RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory: Change in hypoglycemia
784,NCT05646017,Change in Time in range,Change in Hypoglycemia frequency,2022-12-15,COMPLETED,OBSERVATIONAL,['NA'],Change in Percentage of patients attaining the the International Consensus on Time in Range (ICTR) goals
785,NCT03863535,Change in best-corrected visual acuity (BCVA),Foveal avascular zone,2019-01-18,UNKNOWN,INTERVENTIONAL,['NA'],
786,NCT06268977,Effect of adding SGLTi on BMI,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
787,NCT01786564,Oral Disposition Index,,2011-12-06,COMPLETED,OBSERVATIONAL,['NA'],
788,NCT04863872,Self-reported severe hypoglycemia,,2022-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
789,NCT04204733,Moderate to vigorous physical activity (subjective),,2020-01-06,COMPLETED,INTERVENTIONAL,['NA'],
790,NCT04131582,Change from basal fasting and post2h OGTT glucose levels at 6 and 12 months,Change from basal Weight at 6 and 12 months,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
791,NCT00775684,Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (pg/mL),PG 50 (the Plasma Glucose Level at Which Half-maximal Insulin Secretion is Achieved During the Glucose-potentiated Arginine Test) at Baseline and 6 Months,2008-10,COMPLETED,INTERVENTIONAL,['NA'],
792,NCT01696266,Incidence of any hypoglycaemic event,Incidence of probable symptomatic hypoglycaemic events,2012-09-05,COMPLETED,OBSERVATIONAL,['NA'],
793,NCT00370084,Gastric emptying assessment,"Glycemia, relief of upper gastrointestinal symptoms, intragastric meal distribution",2005-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
794,NCT03929601,C-Peptide Response to 2-hr MMTT at 24 months post-randomization,Analysis of changes in immune responses to known diabetes antigens and a neoantigen over time by treatment group,2023-10-30,RECRUITING,INTERVENTIONAL,['PHASE2'],
795,NCT03643692,Time in Range (%),,2019-02-26,COMPLETED,INTERVENTIONAL,['NA'],
796,NCT01673204,Changes in renal function with proteinuria,changes in sTNFR and TNF-related proteins,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
797,NCT01479062,Change from baseline in diabetes risk markers,Change from baseline in physical activity and dietary factors,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
798,NCT06187493,prevention of the development of DKD and alter its natural progression.,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
799,NCT02663661,Test the hypothesis that immunological abnormalities are associated with abnormally high glucagon responses to a meal and reduced glucagon responses to insulin induced hypoglycemia.,Correlate metrics derived from a minimally-invasive Continuous Glucose Monitor (CGM) home test with glucagon responses to a meal and hypoglycemia measured in the hospital.,2016-03-16,COMPLETED,INTERVENTIONAL,['NA'],
800,NCT00645528,Barriers to Insulin Treatment Total Sum Score Visit 2 (Week 2),Number of Patients Experiencing a Severe Hypoglycemic Event,2008-04,COMPLETED,INTERVENTIONAL,['NA'],
801,NCT04082000,Adverse Events (AEs) and Serious Adverse Events (SAEs),Improvement in sleep disturbance,2019-04-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
802,NCT04607915,Feasibility - Delivery of Intervention (Coach strategies),Virtual Care Team experience and satisfaction via semi-structured interview,2021-05-04,COMPLETED,INTERVENTIONAL,['NA'],Exploratory Outcome - Diabetes self-management
803,NCT04663659,length of stay in intensive care,,2020-03-15,COMPLETED,OBSERVATIONAL,['NA'],
804,NCT01025973,Foetal HbA1c,Foetal acetylated Hb,2009-10,COMPLETED,OBSERVATIONAL,['NA'],
805,NCT00184626,HbA1c,Fasting plasma glucose value,2004-09-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
806,NCT00476710,Bile Acid Pool Size and Kinetic Parameters,Resting Metabolic Rate,2007-05,COMPLETED,OBSERVATIONAL,['NA'],
807,NCT01667614,Urinary albumin excretion,Serum potassium concentrations,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
808,NCT03751007,Incidence of Treatment-emergent Adverse Events (TEAE),C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 2 Hour Mixed Meal Tolerance Test (MMTT) at 12 Months,2018-10-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of Treatment Emergent Adverse Events up to 12 Months
809,NCT01248286,Homeostatic model assessment (HOMA) index.,Sirtuin 1,2010-11,COMPLETED,INTERVENTIONAL,['NA'],
810,NCT04306406,A high-sensitivity C-reactive protein (hs-CRP) measured in milligrams per liter,"3,4-Dihydroxyphenylacetic acid (DOPAC) measured in nanograms per milliliter",2015-01-07,COMPLETED,INTERVENTIONAL,['NA'],
811,NCT01872611,Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0),Percentage of Participants With With a > 10-letter Loss in BCVA From Day 7 to Any Visit,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
812,NCT00338949,Change in Visceral Fat Mass From Baseline to Week 26,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
813,NCT04981808,CGM time in range,Time above CGM range,2021-08-18,COMPLETED,INTERVENTIONAL,['NA'],Health-related quality of life
814,NCT01187576,"to examine whether an extended multi-professional PAR intervention, based on SDT, is effective in increasing and maintaining the self-reported physical activity level in patients with newly diagnosed type 2 diabetes or hypertension or both.",,2010-11,WITHDRAWN,INTERVENTIONAL,['NA'],
815,NCT02418884,the Density Score of Coronary Artery Calcification in CAD patients with Diabetes Mellitus,the volume score of CAC in CAD patients with diabetes mellitus,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
816,NCT05654831,"Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations",Pharmacodynamic Parameters: Fasting plasma insulin homeostatic model assessment,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE1'],
817,NCT01295775,Hard exudates,Intraretinal microvascular abnormalities (IRMA),2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
818,NCT04207853,plantar pressure,,2019-08-08,UNKNOWN,INTERVENTIONAL,['NA'],
819,NCT05986253,Postprandial blood glucose area under the curve (AUC),Postprandial serum insulin concentration,2023-08-07,RECRUITING,INTERVENTIONAL,['NA'],
820,NCT00898950,"Change in markers of oxidative stress, endothelial function, glycaemic control, and insulin resistance",Change in inflammatory markers,2004-08,COMPLETED,INTERVENTIONAL,['NA'],
821,NCT02094534,"Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements","Mean Nighttime, Daytime, and Fasting Glucose Levels",2014-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
822,NCT02718950,Evaluate the effect of liraglutide administration on brown adipose tissue (BAT) activation in humans,Evaluate the effect of liraglutide administration on body composition in humans,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],
823,NCT01024244,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 12 Weeks,Change From Baseline in Heart Rate at 12 Weeks and 16 Weeks,2009-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
824,NCT00542633,change in HbA1c,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
825,NCT06181227,Safety of AVD-104,Treatment effect - vision,2023-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
826,NCT02877186,Taxa abundance before and after one-week of three times daily diet soda consumption,,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
827,NCT00004983,,,1999-09,COMPLETED,INTERVENTIONAL,['NA'],
828,NCT00101712,Change from baseline in HbA1c at 52 weeks,Coefficient of failure for HbA1c between 24 weeks and 52 weeks,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
829,NCT05134129,Differential lipid compounds,,2021-04-25,RECRUITING,OBSERVATIONAL,['NA'],
830,NCT01774968,Change From Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c),Change From Baseline to Week 24 in Body Weight Based on Baseline TDD Insulin ≥2.0 Units/kg and <2.0 Units/kg,2013-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
831,NCT05294653,Occurrence of Atherosclerotic Cardiovascular Disease(ASCVD) high risk rating,Occurrence of subclinical ASCVD(coronary artery calcium),2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Occurrence of rheumatic diseases
832,NCT04599920,Changes in the intake of nutrients and nutritional status of participants as a measure of diet modification.,Changes in the concentrations of N-nitroso compounds in feces.,2020-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
833,NCT05152589,Hearing Loss,diabetic mother,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
834,NCT04972175,Incidence of adverse event,,2021-07-28,UNKNOWN,INTERVENTIONAL,['PHASE1'],
835,NCT02621008,blood pressure,stress mindset scale,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],
836,NCT02972996,Blood Pressure,Hemoglobin A1C,2017-01-19,COMPLETED,INTERVENTIONAL,['NA'],
837,NCT04591015,Glycosylated Hemoglobin (HbA1c) - Change From Baseline to 180 Days,"Knowledge, Attitudes and Practice Toward COVID-19 Survey - Change From Baseline to 180 Days",2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
838,NCT04714411,Clostridioides difficile Infection,,2020-11-05,RECRUITING,OBSERVATIONAL,['NA'],
839,NCT02228122,A measure of the presence/absence of biofilms in over five weeks when exposed to Aquacel Ag+ Extra dressing.,Size of the wound and an indicator of healing,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
840,NCT01683409,Change From Baseline in Urinary Albumin/Creatinine Ratio (UACR) at Week 24,"Pharmacokinetics (PK): Area Under the Concentration-Time Curve at Steady State (AUC,ss)",2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
841,NCT04940897,Measure incidence of adverse events,,2021-10-25,COMPLETED,INTERVENTIONAL,['NA'],
842,NCT02575937,Change in Glycosylated hemoglobin (HbA1c),Food Frequency Questionnaire（FFQ）,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],
843,NCT02102958,Frequency of foot examination at home,New foot problems discovered at home,2011-07,COMPLETED,INTERVENTIONAL,['NA'],Total new foot problems
844,NCT01334684,Fasting glucose change after metformin treatment in respect to mRNA and miRNA expression profiles in white blood cells,Change in fasting insulin levels after metformin treatment in respect to mRNA and miRNA expression profiles in white blood cells,2011-05,UNKNOWN,INTERVENTIONAL,['NA'],
845,NCT05902546,Insulin Resistance (Homa-IR),,2023-01-07,COMPLETED,INTERVENTIONAL,['NA'],
846,NCT02344329,Time to closure of a Diabetic Foot Ulcer using Human Amnion Allograft and Total Contact Casting vs Standard Wound Care and Total Contact Casting.,,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
847,NCT02783469,Neuropathic Pain,,2004-10,COMPLETED,OBSERVATIONAL,['NA'],
848,NCT06061991,GDM diagnosis,Stillbirth,2024-01-30,RECRUITING,INTERVENTIONAL,['NA'],
849,NCT00454662,"Composite of following events: Sudden death, Cerebrovascular events, Coronary events, Renal dysfunction","All deaths, Death from cardiovascular events, Glucose metabolism, Incidence of primary outcomes events, New onset of atrial fibrillation, Safety, Withdrawal rate",2007-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
850,NCT02730741,Compare number of treated patients who have had diarrhoea in the verum group and in the placebo group between Visit 2 and Visit 5. Diarrhoea evaluated using the Bristol stool scale (types 5 to 7),,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
851,NCT03462589,Number of participants with treatment-related adverse events as assessed by CTCAE v4.03,C-peptide secretion following single dose of SY-008,2018-08-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
852,NCT02235519,Blood pressure,Renal function improvement.,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
853,NCT01514838,Change in HbA1c from baseline to end of treatment,"Safety assessed by the incidence of adverse events, vital signs safety labo-tests and 12-lead ECG",2012-04-23,TERMINATED,INTERVENTIONAL,['PHASE3'],
854,NCT06256523,Changes from baseline in hemoglobin A1c (HbA1c) at the end of the study,HbA1c control rate (proportions of subjects with HbA1c < 6.5 % and HbA1c < 7.0 %),2022-06-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
855,NCT00978744,Gaps in care; compliance with quality measures,Costs of care,2008-12,UNKNOWN,OBSERVATIONAL,['NA'],
856,NCT03519217,Evaluate possible risk factors among diabetic infants,Detection of gene mutation responsible for infantile diabetes through gene sequencing,2020-06-05,UNKNOWN,OBSERVATIONAL,['NA'],
857,NCT05633810,"First event of the composite of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, or urgent hospitalization for angina requiring coronary revascularization.",MoCA Scores Assessed Over Time,2022-12-21,RECRUITING,INTERVENTIONAL,['PHASE3'],
858,NCT00480779,Change in Weight,Change in Triglycerides,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
859,NCT05255497,The effect of biodex balance training on motor nerves,,2017-09-02,COMPLETED,INTERVENTIONAL,['NA'],
860,NCT01662193,change in adipocytokines from baseline at 8 weeks,change in blood pressure from baseline at 8 weeks,2012-02,UNKNOWN,INTERVENTIONAL,['NA'],
861,NCT03968055,Contacts with the care provider,Hemoglobin A1c,2019-03-25,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
862,NCT05415826,CRT,Intraretinal hemorrhage,2022-06-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
863,NCT01171248,Ambulatory blood pressure (AMBP),Diabetic late complications,2009-09,COMPLETED,OBSERVATIONAL,['NA'],
864,NCT01804049,Change in Total Lean Mass From Baseline,Change in Muscle Characteristics,2014-04-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
865,NCT01131650,Prevalence of diabetic retinopathy,associated risk factors of diabetic retinopathy,2009-03,COMPLETED,OBSERVATIONAL,['NA'],
866,NCT04700436,"Triglyceride (TG) change rate (percent, %)",Electrocardiogram (12-lead ECG),2020-01-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
867,NCT01619332,Area under the effect curve (AUC0-4h) over the 4-hour post-dose period to measure glucose response following a standard mixed meal test,Change from baseine in Gastric inhibit polypeptide (GIP) (Part III),2012-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
868,NCT02769884,CGM percent time < 60 mg/dl,% of subjects with mean CGM <169 (eHbA1C < 7.5%),2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety Criteria 4: No seizures or loss of consciousness while system is on and functional
869,NCT01820273,changes in incretines in the bariatric patient,Diabetes control,2013-04,WITHDRAWN,OBSERVATIONAL,['NA'],
870,NCT02473991,Placental Thickness at 3rd Trimester,,2015-03,COMPLETED,OBSERVATIONAL,['NA'],
871,NCT03816761,Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage) - Median,Total Insulin Dose Per Day,2019-02-25,COMPLETED,INTERVENTIONAL,['PHASE2'],
872,NCT03700801,HbA1c,Rate of hypoglycemia,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
873,NCT06250049,Number of individuals with diabetes who have received individual education related to diabetic foot care.,"Number of diabetic individuals referred to podiatry, vascular surgery, and traumatology and orthopedics.",2023-03-01,COMPLETED,INTERVENTIONAL,['NA'],
874,NCT03030729,"Comparison between retinal measurements, done by the RTOCT device and a commercial OCT",,2017-03-14,COMPLETED,OBSERVATIONAL,['NA'],
875,NCT01712594,Amount of time spent in the target range defined as 3.8-8.8 mmol/l (70 to 160 mg/dL) YSI glucose during in-clinic overnight visits,Glucose AUC above 8.8mmol/l (160 mg/dL) YSI glucose obtained during in-clinic overnight visits,2013-05,COMPLETED,INTERVENTIONAL,['NA'],All descriptive endpoints stratified by the accuracy of the sensor based on mean absolute relative difference (MARD) overnight
876,NCT02354222,Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c),Change From Baseline in 2-hour Postprandial Plasma Glucose Level,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
877,NCT04924673,HbA1c,Stress,2020-06-17,COMPLETED,OBSERVATIONAL,['NA'],
878,NCT02536820,glycosylated hemoglobin (HbAc1 %),Follow-up lost,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],
879,NCT04516018,area under the curve (AUC) of the glucose tolerance test,skeletal muscle GLUT4 translocation,2020-09-01,COMPLETED,INTERVENTIONAL,['NA'],Shivering activity
880,NCT03481361,The relationship between OSA and cardiac autonomic neuropathy (CAN) in patients with T1D.,The potential mechanisms for the relationship between OSA and diabetic-related complications,2018-02-14,COMPLETED,OBSERVATIONAL,['NA'],
881,NCT05703152,Change from baseline in quality of life on the short form-36 questionnaire (SF-36) at 8 weeks,Body Mass Index (BMI) measurement,2022-10-31,COMPLETED,INTERVENTIONAL,['NA'],
882,NCT03415139,Plasma IL-33 levels will be measured among patients who do or do not develop PTDM (multivariable analysis).,,2019-03-12,RECRUITING,OBSERVATIONAL,['NA'],
883,NCT01253733,Health related self-efficacy,Quality of Life,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
884,NCT05979779,"Percent change from baseline in liver fat, as assessed by magnetic resonance imaging liver proton density fat fraction (MRI-Liver PDFF) at 6 months (26 weeks)",Change from baseline in HbA1c at 6 months (26 weeks).,2023-09-05,RECRUITING,INTERVENTIONAL,['PHASE2'],
885,NCT06081387,Vitamin D,Food consumption and adherence to the Mediterranean diet,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
886,NCT03742219,Triglycerides,24 hour dietary recall,2017-06-05,TERMINATED,INTERVENTIONAL,['NA'],
887,NCT05180721,Change in A1C value,Health care engagement - negative,2022-10-03,RECRUITING,INTERVENTIONAL,['NA'],
888,NCT01925248,Blood Glucose Level,Change in Urine glucose level,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
889,NCT00657930,Efficacy (HbA1c),Insulin dose change,2008-03,COMPLETED,OBSERVATIONAL,['NA'],
890,NCT00638872,reduction of ulcer rate,safety and tolerability of the compound,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
891,NCT01903356,Incidence Rate of Adverse Events (AE),Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment.,2013-07-11,COMPLETED,OBSERVATIONAL,['NA'],
892,NCT02721888,Effects of liraglutide on High Density Lipoprotein (HDL) apolipoprotein A1 (apoA1) fractional catabolic rate,Modification of visceral fat by Magnetic Resonance Imaging (MRI),2012-07-10,TERMINATED,INTERVENTIONAL,['PHASE4'],
893,NCT03394456,Glycemic control,longitudinal outcomes,2018-01-13,COMPLETED,INTERVENTIONAL,['NA'],Access to care
894,NCT01951651,Hepatic Fat Content,Monocyte Inflammatory Protein Nuclear Factor Kappa-B (NFkappaB) (%),2010-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
895,NCT06163482,Concentration of Glucose,Concentration of fatty acids,2023-03-28,RECRUITING,OBSERVATIONAL,['NA'],
896,NCT00206362,,,2004-07,COMPLETED,OBSERVATIONAL,['NA'],
897,NCT03881254,Percentage of index ulcers healed at 12 weeks,"Changes in peripheral neuropathy using Semmes Weinstein Monofilament ""10""point discrimination test",2019-04-02,COMPLETED,INTERVENTIONAL,['NA'],Visible Graft Take at each visit
898,NCT00417989,Change in A1c From Baseline to 52 Weeks,Quality of Life - Insulin Delivery System Rating Questionnaire (IDSRQ) for Subject Satisfaction With Type of Insulin Therapy,2007-01,COMPLETED,INTERVENTIONAL,['NA'],
899,NCT05367024,Change in glycated haemoglobin (HbA1c) after broccoli and courgette soup interventions,Treatment effects on whole blood gene expression from RNAseq,2021-09-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
900,NCT00357890,Beta Cell Function,Percent Body Fat,2005-12,COMPLETED,INTERVENTIONAL,['NA'],
901,NCT02449603,Change of mean amplitude of glycemic excursions,Number of participants with clinical hypoglycemia,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
902,NCT00870818,"The Number of Participants Who Experience an Adverse Event, Serious Adverse Event or Adverse Event of Special Interest.",Human Anti-human Antibody (HAHA) Levels,2009-02,TERMINATED,INTERVENTIONAL,['NA'],
903,NCT02077803,Plasma concentration of metformin following the single dose of drug administration,Number of participants with adverse events as a measure of safety and tolerability,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
904,NCT01265537,Number of Participants With New Onset Diabetes After Transplant (NODAT) or Acute Rejection,eGFR at 6 Months,2011-06-24,COMPLETED,INTERVENTIONAL,['NA'],
905,NCT03870971,measurement performance,,2019-02-04,COMPLETED,INTERVENTIONAL,['NA'],
906,NCT04489043,Oral glucose tolerance test (OGTT),Anthropometric measures,2019-09-05,UNKNOWN,INTERVENTIONAL,['NA'],
907,NCT02536248,Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period,Measurement of ICAM-1 Production Rate With Stable Isotope During Postprandial Period,2015-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
908,NCT05990205,Change in weigth loss,Change in HbA1c,2018-04-17,RECRUITING,INTERVENTIONAL,['PHASE2'],
909,NCT01945060,Low Blood Glucose Index (LBGI),,2013-09,COMPLETED,INTERVENTIONAL,['NA'],
910,NCT05504785,Observe correlation of glucose control and post-operative adverse clinical events,Compare the CGM and Accu-Chek time-match glucose measurements,2020-08-01,TERMINATED,INTERVENTIONAL,['NA'],
911,NCT06285396,Motility index,Integrated area under response curve (AUC),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
912,NCT06034574,%MARD lab phase,%MARD home phase,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
913,NCT05322369,: Prevalence of Periodontitis in diabetics of Egyptian outpatients of faculty of dentistry cairo university.,,2022-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
914,NCT00678886,Change From Baseline in 2-hour Mixed Meal Stimulated C-peptide Area Under Curve [AUC] (Normalized for 120-minute Time Interval) at Month 12,"Percent Change From Baseline in CD3/TCR Modulation on CD4+ T Cells and CD8+ T Cells at Day 1, Day 4, Day 8",2008-07-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
915,NCT01079637,treatment failure rate,Foot temperature,2010-05,TERMINATED,INTERVENTIONAL,['NA'],
916,NCT01435642,Mean HbA1c (glycosylated haemoglobin),To quantify quality of life,2011-09,COMPLETED,OBSERVATIONAL,['NA'],
917,NCT01825382,Patient Reported Outcomes as it relates to hypoglycemia fear and quality of life.,Improvement in glucose control and indices off glucose variability from SMBG and CGM data.,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
918,NCT03573102,decrease in proteinuria,,2018-06-20,UNKNOWN,INTERVENTIONAL,['PHASE4'],
919,NCT01154933,Fasting Insulin,Intranuclear NFκB Binding Activity,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
920,NCT03908606,clinical attachment level,,2018-04-11,COMPLETED,INTERVENTIONAL,['NA'],
921,NCT00634673,postprandial serum fatty acids,serum endothelin serum fibrinogen,2006-06,COMPLETED,INTERVENTIONAL,['NA'],
922,NCT03979352,Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L on 4- weeks automated AP on empagliflozin when compared to 4-weeks conventional pump therapy with placebo,Number of technical adverse events,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
923,NCT03955952,Composite of All-Cause Mortality and Cardiovascular Outcomes,Incidence of Atrial Fibrillation,2019-06-05,COMPLETED,OBSERVATIONAL,['NA'],Percentage Change in Triglycerides
924,NCT01284634,Percent Change From Baseline To The End Of Treatment (EOT) In Mean Liver Triglyceride Levels,Change From Baseline To The EOT In Mean Serum Triglyceride Levels,2011-05-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
925,NCT05199636,Blood pressure,HbA1C,2022-01-20,COMPLETED,INTERVENTIONAL,['NA'],
926,NCT01300273,"monitor podocyte loss by detecting nephrin, podocin, and synaptopodin mRNA in urine particulates with quantitative reverse transcriptase-PCR.",,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
927,NCT01056887,,,2008-03,COMPLETED,OBSERVATIONAL,['NA'],
928,NCT02711124,The level of preoperative HbA1c that will be a predictor of the higher prevalence of platelet resistance to the aspirin,"The level of HbA1c, that will represent the reliable predictor of platelet hyperreactivity and MAACE",2014-02,UNKNOWN,OBSERVATIONAL,['NA'],
929,NCT02610530,Reduction in glycated hemoglobin (HbA1c),Weight Control,2015-12,UNKNOWN,OBSERVATIONAL,['NA'],
930,NCT01968044,HbA1c change,Albuminuria,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
931,NCT02758522,Glycemic control,Differences in hospital stay days,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
932,NCT03530644,Performance evaluation,Safety by paucity of adverse events,2018-08-28,COMPLETED,INTERVENTIONAL,['NA'],
933,NCT00474630,Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease,Change in Food Craving Inventory Carbohydrates Subscale Score,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
934,NCT00980746,"Change From Baseline to Endpoint in Mean Pain, Scored Daily on a on an 11-point (0-10) Numeric Rating Pain Scale (NRPS), Where 0 = no Pain and 10 = Worst Possible Pain",,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
935,NCT01113658,Frequency of complaints about device use and operation,,2010-03,WITHDRAWN,INTERVENTIONAL,['NA'],
936,NCT03172247,Combined endpoint of diabetic hospitalized patients,,2016-12-01,COMPLETED,OBSERVATIONAL,['NA'],
937,NCT06182852,HbA1c,Body fat,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
938,NCT05283538,Statin prescription indication based on the patient's LDL cholesterol value and the LDL cholesterol target determined according to the cardiovascular risk level according to the ESC/ESA 2019 recommendations,,2022-03-28,RECRUITING,INTERVENTIONAL,['NA'],
939,NCT02678676,Percentage of Participants With First Occurrence of Macro-vascular Event or Death,Incidences With Malignancies,2004-11,COMPLETED,OBSERVATIONAL,['NA'],
940,NCT03377699,Last Planned Glycosylated Haemoglobin (HbA1c) Prior to Delivery,Neonatal Hypoglycaemic Episodes Defined as Plasma Glucose Below or Equal to 1.7 mmol/L (31 mg/dL) or Below or Equal to 2.5 mmol/L (45 mg/dl) (Yes/no),2017-11-22,COMPLETED,INTERVENTIONAL,['PHASE3'],
941,NCT00470262,Insulin Sensitivity,IMCL,2007-01,COMPLETED,INTERVENTIONAL,['NA'],
942,NCT05901831,Change in Urinary albumin-to-creatinine ratio (UACR),Number of participants with Hyperkalaemia,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE3'],
943,NCT02227303,Weekly changes over 8 weeks as compared to baseline in quality of life as measured by the PROMIS® Global Health questionnaire (global physical health and global mental health subscale scores and social and overall health scores).,,2014-08,COMPLETED,INTERVENTIONAL,['NA'],Changes from baseline to 4 and 8 weeks in compliance with exercise goals as measured by active minutes (provided by the Fitbit Flex; requires subject input of data).
944,NCT03062592,Blood glucose,c-peptid,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
945,NCT02866539,Number of pre-diabetes achieving euglycemic status,,2016-12,COMPLETED,INTERVENTIONAL,['NA'],
946,NCT04377321,colchicine for treatment of type diabetes patients,,2019-10-10,COMPLETED,OBSERVATIONAL,['NA'],
947,NCT03752567,Percent of Participants With Adherence to the PDTA,Economic Impact,2018-11-01,COMPLETED,OBSERVATIONAL,['NA'],
948,NCT04313088,Proportion of days with improved bowel movements,Nocturnal diarrhea,2022-07-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
949,NCT04293731,insulin sensitivity (%S),cytokines levels,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],
950,NCT02748434,Blood glucose levels,,2016-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
951,NCT05718375,Change rate of urinary albumin/creatinine ratio (UACR) at 24 weeks compared to baseline,,2023-01-25,RECRUITING,INTERVENTIONAL,['PHASE2'],
952,NCT05987410,Six Minute Walking Test (6MWT) distance in meters,Peak Oxygen Uptake (VO2),2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],
953,NCT05556291,Change from baseline in bodyweight & BMI,Percentage of patients who discontinued investigational drug due to adverse events,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],
954,NCT03950245,iAUC glucose,Beta-cell glucose sensitivity (β-GS),2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],
955,NCT00703755,"The percentage of normalized patients at V4 (fasting glucose < 6.1 mmol/L, TG < 1.69 mmol/L and HDL-C >= 1.03 mmol/L in males and >= 1.29 mmol/L in females)",Blood pressure.,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
956,NCT06140030,Anxiety Symptoms,Glycemic control,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],
957,NCT00575471,Change in HbA1c from baseline for rivoglitazone compared to placebo,Change in Fasting Plasma Glucose from baseline for rivoglitazone HCl compared to placebo,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
958,NCT03165084,HbA1c,eHealth literacy,2017-05-05,UNKNOWN,INTERVENTIONAL,['NA'],
959,NCT04655690,Number of adverse events (AEs),"t½, NNC0471-0119: Terminal half-life for NNC0471-0119",2020-11-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
960,NCT02565940,dermal sample,,2014-12,UNKNOWN,OBSERVATIONAL,['NA'],
961,NCT04009980,Changes of Retinal sensitivity and contrast sensitivity function after topical citicoline use in patients with diabetic retinopathy,Morphological retinal changes after topical citicoline use in patients with diabetic retinopathy,2015-09-23,COMPLETED,INTERVENTIONAL,['NA'],
962,NCT06236750,Safety Endpoint: Incidence of Adverse Events,,2023-08-04,RECRUITING,INTERVENTIONAL,['NA'],Safety Endpoint: Incidence of Device Deficiencies
963,NCT02332824,Change From End of Pre-treatment Period (Week 0) in Log-transformed Urine Albumin/Creatinine Ratio (UACR) at the End of Treatment Period (Week 12),Progression Rate From Early-Stage Nephropathy (Stage 2) to Overt Nephropathy (Stage 3) During the Treatment Period (Week 12),2014-10-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)
964,NCT04847778,Number of daily insulin injections irregularities,Change in Insulin Treatment Satisfaction Questionnaire (ITSQ-change) Score.,2021-03-01,COMPLETED,INTERVENTIONAL,['NA'],
965,NCT03630458,Glycemic response,Appetitive response,2018-06-11,COMPLETED,INTERVENTIONAL,['NA'],
966,NCT01574508,Glycated albumin levels,Number of participants with adverse events,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
967,NCT02247596,Change from baseline in Resting Energy Expenditure via indirect calorimetry at 2 weeks,Change from baseline in Glycated hemoglobin at 2 weeks,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
968,NCT02548299,Investigator-Designed Cooking Skills Questionnaire - Change from Baseline to 6 months,"Dietary Fiber, Fruit and Vegetable Consumption Questionnaire - Change from Baseline to 6 months",2015-05,COMPLETED,INTERVENTIONAL,['NA'],
969,NCT02824874,"Css,max of Lobeglitazone","swing[(Css,max-Css,min)/Css,min] of Lobeglitazone",2016-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
970,NCT00666094,HbA1C,"body composition, C-peptid, BP, Cholesterol (LDL, HDL), Triglycerides",2008-08,COMPLETED,INTERVENTIONAL,['NA'],
971,NCT03388697,Gestational Diabetes,NICU admission,2017-12-15,COMPLETED,OBSERVATIONAL,['NA'],
972,NCT04304261,Changes of cognitive function assessed by cognitive function scale after 12 weeks,,2020-04-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
973,NCT05326958,average weighted corneal nerve fiber thickness (CNFTh),,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
974,NCT05446753,Change in cardiovascular health risk indicators,Change in body composition,2022-06-17,RECRUITING,INTERVENTIONAL,['NA'],
975,NCT02122926,Cardiac medication adherence,Hospital Readmissions,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
976,NCT05507892,Kidney Transcript Changes,Renal Plasma Flow (RPF),2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],
977,NCT05240274,Diagnosis of post-transplant diabetes,diagnosis of PTDM in OGTT screen fails,2019-01-25,COMPLETED,INTERVENTIONAL,['PHASE2'],
978,NCT02169167,Wound healing,Eradication of bacteria,2014-06,COMPLETED,INTERVENTIONAL,['NA'],Wound healing and infection
979,NCT01631929,Time to Achieve Patient Stabilization,,2012-08,TERMINATED,INTERVENTIONAL,['NA'],
980,NCT00721617,Change in Diastolic Blood Pressure From Baseline to 8 Hours,C-peptides Levels for Intralipid/Dextrose Infusion,2009-04,COMPLETED,INTERVENTIONAL,['NA'],
981,NCT03720080,Adjustments of basal rate insulin infusion 670G,,2019-05-16,TERMINATED,OBSERVATIONAL,['NA'],
982,NCT05260281,does AI augment diagnostic performance of resident,does physical consultation augment diagnostic performance of AI,2022-03-01,UNKNOWN,OBSERVATIONAL,['NA'],
983,NCT04285151,Visual acuity improvement,,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
984,NCT02470260,Cognition,Depressive symptoms,2012-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
985,NCT00458133,Hemoglobin A1C,"metabolic measures, including serum cholesterol and triglycerides",2007-04,COMPLETED,INTERVENTIONAL,['NA'],
986,NCT02850224,Number of participants with improved health-related quality of life as assessed by the PEDsQL.,,2017-04-20,COMPLETED,INTERVENTIONAL,['NA'],
987,NCT03998436,"Proportion of Subjects Achieving Target Ulcer Closure Within 12-week Treatment Phase, as Assessed by Blinded Investigator","Proportion of Subjects Achieving Target Ulcer Closure Till End of Study, as Assessed by the Blinded Investigator.",2018-12-26,COMPLETED,INTERVENTIONAL,['PHASE3'],Proportion of Subjects With Treatment Emergent Adverse Events (TEAEs)
988,NCT05481021,Identify any self-reported stressors associated with burnout,To compare any change in presence of burnout from previous cross-sectional study (5 years ago),2022-07-05,COMPLETED,OBSERVATIONAL,['NA'],
989,NCT00129792,weight loss,Cortisol levels,2005-01,COMPLETED,INTERVENTIONAL,['NA'],
990,NCT03815006,HbA1c Level at 24 Weeks,Glucose Monitoring Satisfaction Survey Score,2020-01-09,COMPLETED,INTERVENTIONAL,['NA'],
991,NCT00961025,To characterize the pharmacokinetic/pharmacodynamic of DA-1229 in healthy male subjects,To evaluate the safety and tolerance of DA-1229,2009-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],
992,NCT04255433,"Time to First Occurrence of Death from Cardiovascular (CV) Causes, Myocardial Infarction (MI), or Stroke (MACE-3)",Cumulative Number of Primary Composite Events of CV Death and Total (First and Recurrent) MI and/or Stroke,2020-05-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
993,NCT04545567,Percentage of Time From Dinner Time Until Midnight With Blood Glucose in Range 70-180 mg/dL in the Unannounced Meal,Units of Insulin Injected Outside of the Study Dinner Sessions,2020-12-16,COMPLETED,INTERVENTIONAL,['NA'],
994,NCT03196895,change in medication,change in psychological functioning (attitude towards glucose monitoring questionnaire),2017-06-28,COMPLETED,INTERVENTIONAL,['NA'],
995,NCT05281029,Change from Baseline of HbA1c at 24 weeks,The rate of subjects who reached the target value of less than 7% (reasonable HbA1c goal) of HbA1c.,2021-06-24,UNKNOWN,OBSERVATIONAL,['NA'],
996,NCT02947828,Presence of painful diabetic polyneuropathy,,2016-10,COMPLETED,OBSERVATIONAL,['NA'],
997,NCT03394859,Impact of return of clinically actionable results on patient treatment,,2015-09-01,COMPLETED,OBSERVATIONAL,['NA'],
998,NCT03648554,Responder's proportion difference between the two groups (dulaglutide (TRULICITY®) on top of dietary reinforcement vs. dietary reinforcement alone),Weight,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
999,NCT02883829,"Changes in attitudes, beliefs, and intentions about alcohol",,2017-04-04,COMPLETED,INTERVENTIONAL,['NA'],
1000,NCT03942081,Foot Ulcer Size,Quality of Photos: 1 - 5 scale,2017-09-05,RECRUITING,INTERVENTIONAL,['NA'],
1001,NCT05533996,Diagnosis of gestational diabetes (GDM),Labor dystocia,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1002,NCT02230137,HbA1c level,Satisfaction survey,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
1003,NCT03510000,Comparison of mean glucose levels between AP with empagliflozin with simple meal announcement strategy and AP without empagliflozin with carb-counting.,Morning capillary ketone concentration,2018-05-15,COMPLETED,INTERVENTIONAL,['NA'],
1004,NCT00563875,Platelet aggregation,,2007-11,COMPLETED,INTERVENTIONAL,['NA'],
1005,NCT02922296,Metabolic status of adult SCD subjects,Genetic and genomic predictors in SCD subjects,2015-05-01,RECRUITING,OBSERVATIONAL,['NA'],
1006,NCT01125215,"Pain relief from pain score reduction, using visual analog scale (VAS)",,2009-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1007,NCT05159570,Differences in lipolysis rate,Changes in signaling in muscle and adipose tissue,2023-02-01,COMPLETED,INTERVENTIONAL,['NA'],
1008,NCT06161701,Incidence of steroid diabetes in nephrotic patients after glucocorticoid use,"Cumulative use time of glucocorticoid, cumulative dose of glucocorticoid and drugs that may affect blood glucose in combination with steroid diabetes",2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1009,NCT01708694,Insulin Sensitivity and Secretion,Hunger,2012-08,COMPLETED,INTERVENTIONAL,['NA'],
1010,NCT04653545,What is the prevalence of glucose intolerance (diabetes and IGT) in patients presenting to an acute medical emergency department?,Diabetes control in those with known diabetes,2022-02-01,RECRUITING,OBSERVATIONAL,['NA'],
1011,NCT02384265,Change from Baseline in Hemoglobin A1c at 12-months,Change from Baseline in Systolic and Diastolic Blood Pressure at 12-months,2012-06-21,COMPLETED,INTERVENTIONAL,['NA'],
1012,NCT03071016,To record the mean change in HbA1C from baseline,To record the change in blood pressure,2017-03-04,COMPLETED,OBSERVATIONAL,['NA'],
1013,NCT05560412,Change in GLP-1 AUC,Insulin Levels,2023-01-10,COMPLETED,INTERVENTIONAL,['NA'],Blood Pressure
1014,NCT02009995,Testing of Strength,EuroQOL EQ-5D questionnaire,2014-02,UNKNOWN,INTERVENTIONAL,['NA'],
1015,NCT00327015,"Change From Baseline in A1C at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy","Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy",2006-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
1016,NCT01317979,,,2011-01,UNKNOWN,OBSERVATIONAL,['NA'],
1017,NCT02920801,flow-mediated dilation,renal function test,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
1018,NCT03170544,GIRmax After a Single Dose Administration of Subcutaneous MK-1092 or Glargine to Adult Participants With Type 1 Diabetes Mellitus (T1DM) (Part 3),Time to Reach a 50% Decrease In Plasma Insulin Glargine Concentration (t1/2) Part 4,2017-08-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
1019,NCT05074849,A Change in Adherence to prescribed footwear is being assessed,A change in Perception of Benefits is being assessed,2024-10-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],A change in Acceptability and Ease of Use is being assessed
1020,NCT03678831,Expression levels in femoral spinal adipocytes of mRNAs of 18 genes compared to those of adipocytes isolated from the subcutaneous adipose tissue in the same patient,the intra patients difference of the expression level of medullary adipocytes mRNA compared to that of subcutaneous adipocytes according to presence or absence of metabolic syndrome,2020-06-30,RECRUITING,OBSERVATIONAL,['NA'],
1021,NCT02207712,The number of intravitreal injections of ranibizumab required by each study eye at 48 weeks,Adverse events rates,2014-11,TERMINATED,INTERVENTIONAL,['NA'],Changes in sleep pattern.
1022,NCT03341559,Perfusion in lower extremities,,2018-03-20,COMPLETED,OBSERVATIONAL,['NA'],
1023,NCT02288273,Change in 24-hour Mean Weighted Glucose,Change in HbA1c From Baseline to Day 22 and Baseline to Day 70,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
1024,NCT03724526,"Combined changes in HbA1C, SBP and LDL-cholesterol levels, simultaneous modeled using a scaled marginal model.",Change in ACC/AHA Risk Score of CVD,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],
1025,NCT00553592,Pain and Safety,"Clinical Global Impression of Improvement, McGill Pain Questionnaire, Amount of Rescue Medication Used for Pain, Quality of Life Survey (SF-36), Patient Global Impression of Change",2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1026,NCT01176201,"Metabolic profiling and identification of 14C-labeled parent compound and metabolites of SLV337 in plasma, urine and feces (Part 2)","Safety and tolerability assessments including adverse events, clinical laboratory tests, ECG and vital signs (Part 1 and Part 2)",2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
1027,NCT00547274,,,2003-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
1028,NCT03415880,The effect of a LiPA intervention program on increasing carotid distensibility in patients with type 2 diabetes.,The effect of a LiPA intervention program on microvascular function,2018-11-08,COMPLETED,INTERVENTIONAL,['NA'],
1029,NCT01999361,allosensitization after complete islet graft loss,,2009-01,RECRUITING,INTERVENTIONAL,['NA'],
1030,NCT01128894,Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32,Mean Change From Baseline in Body Weight at Week 32,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
1031,NCT01381926,Determine Changes in Bone Turnover Markers by Tartrate-Resistant Acid Phosphatase 5b (TRACP5b) During the Treatment With a GLP-1 Receptor Agonist (Exenatide) Compared to Placebo in Patients With T2DM.,,2011-02,TERMINATED,INTERVENTIONAL,['PHASE4'],
1032,NCT03434288,Time for identification of bacteria responsible for foot osteomyelitis,Time for identification of sensitivity/resistance to antibiotics of the bacteria responsible for foot osteomyelitis,2018-02-08,COMPLETED,OBSERVATIONAL,['NA'],
1033,NCT02587741,The incidence of diabetic retinopathy,oxidative stress,2015-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Metabolic indices
1034,NCT04307875,Prevalence of hypertension,CAPS-5,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA'],
1035,NCT03840850,"Feasibility of implementing the intervention in primary care: Binary outcome (feasible / not feasible), as judged by the investigators",Change in self-management behaviour,2017-09-15,COMPLETED,INTERVENTIONAL,['NA'],Rate of missing data
1036,NCT01128374,HbA1c percentage,gene polymorphisms,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
1037,NCT01775059,Safety endpoint,Accuracy endpoint,2013-03,UNKNOWN,INTERVENTIONAL,['NA'],Accuracy endpoint
1038,NCT01813708,disease control,Self-Efficacy,2004-11,COMPLETED,INTERVENTIONAL,['NA'],
1039,NCT04939038,Number of patients with delayed diabetic foot ulcer healing,Number of patients with all-cause death,2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Number of serious adverse events
1040,NCT02001766,Glucose metabolism,,2013-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1041,NCT03354286,Time spent in blood glucose range,Health care utilization,2017-11-07,COMPLETED,INTERVENTIONAL,['NA'],
1042,NCT05378282,Differential Expression in blood and urine of diabetic patiens with and without diabetic nephropathy assesed by RNA seq,"Molecular data, Whole messenger RNA sequencing",2021-09-03,COMPLETED,OBSERVATIONAL,['NA'],
1043,NCT04299763,HbA1c,,2018-06-19,COMPLETED,INTERVENTIONAL,['PHASE2'],
1044,NCT05297045,Change in HbA1c from baseline to end of treatment in the modified intent-to-treat population,"Proportion of patients who report AEs of Special Interest (AESI) including GI intolerability, hypoglycemia, drug hypersensitivity reactions, acute pancreatitis, thyroid C-cell hyperplasia and C-cell neoplasms, and cardiovascular (CV) events",2022-03-29,TERMINATED,INTERVENTIONAL,['PHASE2'],
1045,NCT00567047,• Pharmacokinetic measures,• Safety and tolerability measures,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
1046,NCT01026688,Patient is receiving a statin,Change in treatment recommended following an LDL-cholesterol level above 2.0 mmol/L,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
1047,NCT05560568,Sleep efficiency,,2023-01-20,RECRUITING,OBSERVATIONAL,['NA'],
1048,NCT01381887,Plasma concentrations of glucose,Adverse events,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
1049,NCT00970528,Glycosylated hemoglobin (HbA1c),High Sensitivity C-reactive protein (hs-CRP),2009-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
1050,NCT01868698,Doppler ultrasound,,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
1051,NCT04539769,Diabetes remission rate,,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
1052,NCT00579813,Changes in Fat Inflammation Following Pioglitazone,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
1053,NCT01709929,Incidence of serious adverse drug reactions (SADRs) including major hypoglycaemic events,Treatment satisfaction as assessed by Insulin Treatment Satisfaction Questionnaire (ITSQ-22),2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1054,NCT02358408,Evaluation of System Accuracy according to ISO 15197 (see description),,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
1055,NCT05523362,Change in glucose variability as measured by continuous glucose monitor,Glucose Monitoring Satisfaction Survey,2022-01-15,COMPLETED,INTERVENTIONAL,['NA'],
1056,NCT04227379,HbA1c percent time in control,blood pressure control,2023-01-30,RECRUITING,INTERVENTIONAL,['NA'],
1057,NCT02581488,Mean Percent Change in Ulcer Area From Baseline to the End of the Treatment.,Target Ulcer Infection Rates in Each Treatment Group During the Treatment Period as Determined by Investigator-reported Adverse Events,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Time to Closure for Ulcers Achieving Closure by End of Follow-up
1058,NCT05983120,Determining the effect of SCLT-based education on Quality of Life,Determination of Body Mass Index (BMI),2021-08-19,COMPLETED,INTERVENTIONAL,['NA'],
1059,NCT06189417,Mean and proportion increase in glycemic control,Acceptability of a community-based club intervention led by Health Extension Workers,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1060,NCT05324488,Biomarker identification,Biomarker validation,2015-10-21,RECRUITING,OBSERVATIONAL,['NA'],
1061,NCT01336751,Change from baseline in hemoglobin A1c (HbA1c) levels at week 24,Number and severity of hypoglycemic events and time of occurrence of hypoglycemic events,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
1062,NCT00798486,Number of A1C Results Either Equal To Or Within +/- 13.5% of the Laboratory Method (ACCURACY),Number of Participants Who Provided These Ratings For Overall Testing Experience With A1C Test Kit,2008-11,COMPLETED,INTERVENTIONAL,['NA'],
1063,NCT00598013,Insulin Resistance and Insulin Secretion,carotid intima-media thickness,2004-11,COMPLETED,INTERVENTIONAL,['NA'],
1064,NCT03254446,Change in Joint British Society recommendations on the prevention of cardiovascular disease 3rd iteration (JBS3) risk score,Change in HbA1c,2018-03-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],Safety profile of TRC150094
1065,NCT02664233,Change in weight measures from baseline to 3 months,Usability of the connected interface technology as indicated by a System Usability Scale,2015-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
1066,NCT03200795,Cholesterol level Change is being assessed,Quality of life Change is being assessed,2018-03-15,UNKNOWN,INTERVENTIONAL,['NA'],
1067,NCT02390050,Change in HbA1c After 12 Weeks of Treatment,Change in HbA1c Over Time,2015-05-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
1068,NCT05041816,Changes in NIS,,2021-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],
1069,NCT02585622,Number and severity of all pre-specified infusion-associated events and the overall number and frequency of adverse events.,Cost-effectiveness of cell therapy,2017-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1070,NCT00555217,"A Composite Endpoint of Reduction in Estimated GFR of 30ml/Min/1.73m*m in Individuals w/a Baseline Estimated GFR >= 60 ml/Min/1.73m*m, Reduction in Estimated GFR >50% in Individuals w/ Baseline Estimated GFR <60ml/Min/1.73m*m; ESRD or Death","A Renal Composite Endpoint, Defined as; Reduction in Estimated GFR of >50% (for Individuals With Baseline GFR <60) or Reduction in GFR of >30 (for Individuals With Baseline GFR >= GFR 60) or ESRD.",2008-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
1071,NCT03111004,Change in length of the hospital stay,Carer perception of service utility according to eCCIS (selected questions),2014-09-01,COMPLETED,OBSERVATIONAL,['NA'],
1072,NCT05870293,Diabetes potentiation scale,,2023-05-01,COMPLETED,INTERVENTIONAL,['NA'],
1073,NCT00918801,,,2007-04,COMPLETED,OBSERVATIONAL,['NA'],
1074,NCT01766245,"Cmax, the maximum plasma semaglutide concentration",Hypoglycaemic episodes,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
1075,NCT03798080,Change in HbA1c,Immunogenicity (antibody variables),2019-02-19,COMPLETED,INTERVENTIONAL,['PHASE3'],
1076,NCT06097065,Number and types of proteins/peptides differential characteristic peaks,ROC curve and area under curve AUC of clinical predictive diagnostic model,2022-05-20,RECRUITING,OBSERVATIONAL,['NA'],
1077,NCT00529399,The Primary Outcome is the Area Under the Stimulated C-peptide Curve (AUC) at the One Year Visit,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
1078,NCT00473733,,,na,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1079,NCT01210001,HbA1c Change From Baseline for Pio and Met Background Medication Patients,Body Weight Change From Baseline,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Hypoglycaemic Events
1080,NCT01838122,Prevalence of HbA1C in both arms of the cohort of subjects,,2013-04,UNKNOWN,OBSERVATIONAL,['NA'],
1081,NCT02839174,Hemoglobin A1C,patient-physician relationship,2016-09,COMPLETED,OBSERVATIONAL,['NA'],
1082,NCT00039013,Change in HbA1c (glycosylated hemoglobin) from baseline to study termination (Week 30),Change in body weight from Baseline to each intermediate visit and Week 30,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
1083,NCT04962139,The proportion of subjects with complete closure of Target Ulcer,The proportion of patients with Target Ulcer recurrence,2021-08-10,RECRUITING,INTERVENTIONAL,['PHASE3'],
1084,NCT04369001,Change of Depression Scores,Change of Diabetes Quality of Life,2020-12,WITHDRAWN,INTERVENTIONAL,['NA'],
1085,NCT02997319,Disposition index,Plasma Melatonin,2017-02-24,COMPLETED,OBSERVATIONAL,['NA'],Depression
1086,NCT04503239,Collect Device Data - Activity Tracker,Collect Current Subject Lifestyle and Treatment Regimen,2020-07-22,UNKNOWN,OBSERVATIONAL,['NA'],
1087,NCT05704075,Wound Size,Identification of regulatory cytokines for peripheral blood mesenchymal stem cells (PB-MSCs) mobilization,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1088,NCT05659147,Frequency of genetic mutations in patients progressing to diabetes vs. those not,,2023-01-18,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4'],
1089,NCT02099513,"Perception of perceived usefulness, attitudes, and experiences",,2014-03,COMPLETED,INTERVENTIONAL,['NA'],
1090,NCT00814190,The primary endpoint is the A1c level or the change in A1c level.,"The secondary endpoints include severe hypoglycemia defined as requiring external aid, hospital admissions for any CVD related intervention, and adverse events such as unplanned hospitalizations for any cause that last more than 24 hours.",2009-01,COMPLETED,INTERVENTIONAL,['NA'],
1091,NCT01488383,change in capillary blood glucose levels,"Adverse reactions of treatments (nausea, diarrhea, vomiting, allergic signs)",2013-09,WITHDRAWN,INTERVENTIONAL,['NA'],
1092,NCT03857191,Difference in OSA risk before and after nutritional and psychocomportemental rehabilitation,To assess the effect of Weight loss on OSA,2019-03-22,COMPLETED,OBSERVATIONAL,['NA'],
1093,NCT01580904,Fasting Glycemia,LDL Cholesterol,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
1094,NCT00160160,Blood pressure reduction,Comparison of responder rates,2004-10,COMPLETED,INTERVENTIONAL,['NA'],
1095,NCT03387683,Adjusted Mean Change From Baseline in Global Longitudinal Strain of the Left Ventricle (GLSLV) at End of Treatment.,Adjusted Mean Change From Baseline in Myocardial Efficiency at End of Treatment.,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE4'],
1096,NCT01606475,,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],
1097,NCT01268696,,,2010-12,UNKNOWN,OBSERVATIONAL,['NA'],
1098,NCT02279524,Change From Baseline in Mean Liver Fat,Change From Baseline to Week 52/Termination in ALT,2015-04-29,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline to Termination/Early Termination in HbA1C
1099,NCT01195259,Time to first occurrence of a serious adverse event of malignancy (excluding non-melanomatous skin cancers),,2009-10,COMPLETED,OBSERVATIONAL,['NA'],
1100,NCT04373265,Dose-limiting Toxicity (DLT),Plasma Concentrations of Relacorilant in Combination with Pembrolizumab in Patients with Advanced ACC and Glucocorticoid Excess,2020-09-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
1101,NCT03527368,Weight Change,Glycated albumin,2018-09-24,COMPLETED,INTERVENTIONAL,['NA'],
1102,NCT00044746,,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
1103,NCT00916188,"Insulin Sensitivity, oxidative Stress, lipid Profile",,2006-10,COMPLETED,INTERVENTIONAL,['NA'],
1104,NCT01498939,Area under the insulin detemir concentration curve,Adverse events,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1105,NCT04916457,The incidence of developing into diabetic foot among the groups,,2020-12-18,RECRUITING,OBSERVATIONAL,['NA'],
1106,NCT01515384,Pancreatic uptake and clearance of 18F-AV-133 tracer as determined by SUVR,,2010-06,TERMINATED,INTERVENTIONAL,['PHASE1'],
1107,NCT01561976,Area Under Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time [AUC (0-infinity)],Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),2012-01-30,COMPLETED,INTERVENTIONAL,['NA'],
1108,NCT04175665,Change in HbA1c,Proportion of patients who achieve weight loss ≥10%,2020-01-06,COMPLETED,OBSERVATIONAL,['NA'],Weight change in patients prescribed semaglutide as fourth line therapy (excluding insulin use)
1109,NCT04228822,Dyslipidemia,Glucose variability,2020-11-10,COMPLETED,INTERVENTIONAL,['NA'],
1110,NCT04801199,Change in HbA1c level,Frequency of adverse events,2020-01-26,COMPLETED,INTERVENTIONAL,['PHASE3'],
1111,NCT01374594,GLP-1 secretion,,2011-06,COMPLETED,OBSERVATIONAL,['NA'],
1112,NCT01220089,weight change,cost effectiveness,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
1113,NCT01828931,HbA1c levels,,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
1114,NCT01544309,Change in HbA1c Level,"Change From Baseline in 1,5-AG Level",2012-03,COMPLETED,INTERVENTIONAL,['NA'],
1115,NCT01867502,Change in Glycemic variability,"Change in Hemodynamic response to exercise: Cardiac output (Q), Stroke Volume (SV) and blood pressure (BP)",2014-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],Change in Oxidative stress (F2 isoprostane 8-iso prostaglandin F2α);
1116,NCT03641170,Blood glucose,,2018-04-03,COMPLETED,INTERVENTIONAL,['NA'],
1117,NCT04784650,"Presence of foot problems (no = 0, yes = 1)",Indication of peripheral arterial disease (PAD),2021-01-31,COMPLETED,INTERVENTIONAL,['NA'],
1118,NCT01578980,Percent Time of Active CTR,Frequency of Unplanned System Resets or Restarts,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
1119,NCT01257776,"Major adverse event (death, target limb amputation)",University of Texas Classification at target limb,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1120,NCT02818322,time of ulcer healing,,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],
1121,NCT02097615,Unlike the ultimate determinations for the initial surface of the ulcer obtained in square millimeters.,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
1122,NCT06128265,Change in glucose homeostasis measured by Continuous Glucose Monitor (CGM),"Weight in kg, measured from screening through study completion.",2024-01-03,RECRUITING,INTERVENTIONAL,['NA'],
1123,NCT00252525,The primary outcome measures are cardiovascular morbidity and mortality.,,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
1124,NCT02510521,insulin sensitivity measured by the reference euglycemic hyperinsulinemic clamp technique,,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
1125,NCT01357876,"To investigate the relationship between the glucose lowering action of metformin and lipid metabolism including, but not limited to, fasting lipids and prandial TGs",To measure sparse metformin profiles on the days when the PD endpoints are measured,2010-10-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
1126,NCT00870831,OGTT will be performed every 6 months for 5 years in subjects with a functioning Islet Transplant,The OGTT reflects the function of the Islet transplant and could be used as an indication of Islet Transplant function,2000-10,TERMINATED,OBSERVATIONAL,['NA'],
1127,NCT03164785,Change in urine albumin creatine ratio (ACR).,Incidence of Treatment-Emergent Adverse Events,2017-07-24,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1128,NCT01307371,Number of patient death during the follow up period,six-min walk distance (6MWD),2007-03,UNKNOWN,OBSERVATIONAL,['NA'],
1129,NCT01895179,Change in Glucose Tolerance,Change in Inflammation and Metabolic Markers,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
1130,NCT04810026,Change in mean glucose time in range from baseline at Week 16,Change in self-reported blood pressure,2021-05-03,COMPLETED,INTERVENTIONAL,['NA'],Change from baseline in abbreviated Medical Outcomes Study Sleep Scale
1131,NCT04141241,hs-CRP (high-sensitivity C-reactive protein),Body Temperature,2016-03-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1132,NCT00723411,Meal stimulated C-peptide (area under the curve),Insulin Dose,2008-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
1133,NCT01854593,Reoperation,Silicon Oil Tamponade,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
1134,NCT05687474,Feasibility - reliability,To improve the detection technique for disease related mutations that are not detected in classical screening by improving the classification of unspecified variants.,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],
1135,NCT00845897,Plantar Flexor Muscle Strength,Barefoot Plantar Pressure,2005-03,COMPLETED,INTERVENTIONAL,['NA'],
1136,NCT00842556,Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs,To assess the safety and tolerability in healthy subjects,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
1137,NCT01766570,Change in cardiometabolic statute from baseline to the end of intervention.,Change in anthropometric measurements from baseline to the end of the intervention.,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
1138,NCT05346978,Lipid profile,Atherogenic Coefficient (AC),2018-06-01,COMPLETED,INTERVENTIONAL,['NA'],
1139,NCT05476861,Insulin omission,Waist circumference,2022-11-01,COMPLETED,OBSERVATIONAL,['NA'],
1140,NCT01161797,glucose variability,,2008-02,COMPLETED,OBSERVATIONAL,['NA'],
1141,NCT04531176,Change in A1C,Mean total cost of care,2020-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
1142,NCT03204552,Change in BMI,,2007-10-15,COMPLETED,OBSERVATIONAL,['NA'],
1143,NCT00760110,Death,Macrovascular complications,1997-11,COMPLETED,OBSERVATIONAL,['NA'],
1144,NCT03369067,Percent time spent in glycemic zone (70-180mg/dl),,2017-12-18,COMPLETED,INTERVENTIONAL,['NA'],
1145,NCT01787617,Change in insulin response to an oral glucose tolerance test over 5 months.,Quality of Life Measures,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],
1146,NCT00105846,,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],
1147,NCT04625595,Change in total daily insulin use,Cytokine level from in vitro presentation of antigen by HLA-DQ8,2020-11-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
1148,NCT03747471,Change from baseline Diabetes distress (DD) 3 months:,Change from baseline HbA1C at 3 months:,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],
1149,NCT03460964,Glucose measurements,Acceptability of sensor,2018-05-01,TERMINATED,INTERVENTIONAL,['NA'],
1150,NCT02421198,Change in percentage overweight,Waist circumference,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
1151,NCT02745015,Metabolic,Periodontal 3,2014-12,COMPLETED,INTERVENTIONAL,['NA'],
1152,NCT02320461,Myocardial infarction (Incident cases),,2008-08,UNKNOWN,OBSERVATIONAL,['NA'],
1153,NCT02868788,change in plasma dipeptidyl peptidase IV enzyme level from baseline,change in plasma incretin level from baseline,2016-06-14,UNKNOWN,INTERVENTIONAL,['NA'],
1154,NCT04124848,To determine the severity of obstructive sleep apnea,Body composition,2019-10-25,RECRUITING,OBSERVATIONAL,['NA'],
1155,NCT05585983,Change in fasting residual β cell (C-peptide) function.,Variation of blood glucose.,2022-12-14,RECRUITING,INTERVENTIONAL,['PHASE4'],Treatment-emergent events of diabetic ketoacidosis (safety outcome)
1156,NCT01844479,Plantar Foot Temperature Changes in Regions-of-interest in Response to Walking,Gait Speed Variability Dual Task,2012-12,COMPLETED,INTERVENTIONAL,['NA'],Sudomotor Function
1157,NCT01028287,Percentage of patients achieving less than 300 mg protein per 24 hours after 6 months of Acthar Gel.,Percentage of patients achieving greater than 50% reduction in urinary proteinuria after 6 months of Acthar Gel.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
1158,NCT04960514,Referrals,,2021-11-22,RECRUITING,OBSERVATIONAL,['NA'],
1159,NCT03335371,Sentinel - Time to Maximum Concentration (Tmax),Change From Baseline in Basal Insulin Use,2017-10-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1160,NCT00353587,Evaluate safety of MBX-102 with particular emphasis on endpoints of weight gain and edema,,2006-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1161,NCT03704389,Diabetes overtreatment in the elderly,,2019-01-17,COMPLETED,INTERVENTIONAL,['NA'],
1162,NCT01244646,Impact of Weight on Quality of Life (IWQOL-Lite) questionnaire,"Investigator-asked Symptoms of Hypoglycemia, hypoglycemic events, weight, compliance",2010-12,TERMINATED,OBSERVATIONAL,['NA'],
1163,NCT03527277,Endogenous glucose production,non-high density lipoprotein cholesterol (non-HDL-C),2018-06-01,COMPLETED,INTERVENTIONAL,['NA'],Eating motivation
1164,NCT05744232,Global score of disordered eating psychopathology,Weight,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],Safety/ New cases needing referral to specialist services
1165,NCT05134025,"Comparison of TIR in blood glucose values during, and 1-hour after, dynamic physical exercise.",,2021-09-14,COMPLETED,INTERVENTIONAL,['NA'],Comparison of the maximum iG concentration
1166,NCT02318108,Hemoglobin A1c,,2012-07,UNKNOWN,INTERVENTIONAL,['NA'],
1167,NCT00849017,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,Albiglutide Plasma Concentration at Weeks 8 and 24,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1168,NCT00006305,Number of Participants With All-Cause Mortality,"Number of Participants With Death, Myocardial Infarction, or Stroke",2000-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
1169,NCT04877730,Time in Range (TIR) 70-180 mg/dL From Breakfast Time + 5 Hours,Units of Insulin Injected Between 2 Hours Before and 5 Hours After Dinner,2021-05-21,COMPLETED,INTERVENTIONAL,['NA'],
1170,NCT03689530,Change in Body Weight at 6 Months,Change in Controlled Motivation to Prevent Diabetes Using the Treatment Self-Regulation Questionnaire (TSRQ - Controlled),2018-10-02,COMPLETED,INTERVENTIONAL,['NA'],
1171,NCT05433584,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in the IWQOL-Lite-CT - Physical Functioning Domain,2022-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
1172,NCT05908708,Time spent in range (70-180 mg/dL) as assessed from closed-loop Medtronic 780G system,Sleep quality as assessed by a questionnaire,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],
1173,NCT05459285,Area under the plasma concentration-time curve from time zero to ∞ (AUC0-∞),Elimination constants (λz),2022-05-31,COMPLETED,INTERVENTIONAL,['PHASE1'],
1174,NCT04889157,Maximum observed plasma concentration,Number of participants with laboratory abnormalities,2021-07-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
1175,NCT01926457,Umbilical Cord C-Peptide >90th percentile,Return to prepregnancy weight,2013-07,COMPLETED,INTERVENTIONAL,['NA'],Diagnosis of Preeclampsia
1176,NCT00950040,Percentage heavy drinking days,HbA1c levels,2009-07,COMPLETED,INTERVENTIONAL,['NA'],
1177,NCT03436498,Infusion set occlusions,Number of patients with hypoglycemic events,2018-05-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
1178,NCT01072565,Evaluate the efficacy of SMBG for clinical decisions related to the management of type 2 diabetes.,Determine the incremental benefit of CGM for clinical decision-making.,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
1179,NCT03938740,Basal/bolus ratios during the last 2 weeks of the treatment period,,2019-03-18,COMPLETED,INTERVENTIONAL,['PHASE2'],
1180,NCT01755572,Change in plasma ANP level at 21 Days,Office-measured heart rate;Treatment difference for liraglutide compared to crossover with placebo,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Change in HDL
1181,NCT04579900,Microbial signature,,2021-02-01,RECRUITING,INTERVENTIONAL,['NA'],
1182,NCT03043859,Change in Hb A1C,Changes in BMI(kg/m^2),2017-05-09,COMPLETED,INTERVENTIONAL,['NA'],
1183,NCT05637749,Flow Short Scale (FSS) scores,,2023-02-01,COMPLETED,INTERVENTIONAL,['NA'],
1184,NCT05778370,Correlation between HBA1c level and thickness of both macula and choroid in patients with type II diabetes mellitus,,2023-04-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1185,NCT01230632,intravenous glucose tolerance test (IVGTT),insulin sensitivity,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
1186,NCT05261373,Assessed changes from Body composition: Fatmass and Fat-free mass.,Assessed changes from blood pressure,2022-03-10,RECRUITING,INTERVENTIONAL,['NA'],
1187,NCT05929066,Change from Baseline in Apnea-Hypopnea Index (AHI) Events Per Hour for GSA1 Subset,Percentage of Participants with AHI <5 or with AHI 5-14 with Epworth Sleepiness Scale (ESS) ≤10 for GSA1 Subset,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE3'],
1188,NCT01217905,Investigate the safety and tolerability of AZD7687 following administration of single and multiple doses,Evaluate the pharmacokinetics (PK) (plasma and urine) of AZD7687 and it´s glucuronic acid metabolite (AZ13128940) after single and multiple doses,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1189,NCT03571139,Detecting changes in the retinal vascular plexuses and choriocapillaris after cataract surgery in type 2 diabetes mellitus patients with and without diabetic retinopathy using OCT angiography.,,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA'],
1190,NCT01752985,Percent Change From Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) Across 12 Weeks of Treatment With BMS-813160,Dose-Response Relationship Using Change in Baseline Urinary Albumin-to-Creatinine Ratio (UACR) Across 12 Weeks of Treatment,2013-03-18,TERMINATED,INTERVENTIONAL,['PHASE2'],
1191,NCT03288740,Area under the semaglutide plasma concentration time curve at steady state (semaglutide 1.0 mg),Incidence of anti-semaglutide antibodies (positive/negative) at follow-up,2017-09-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
1192,NCT02065791,"Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End-stage Kidney Disease (ESKD), and Renal or Cardiovascular (CV) Death",CV Composite Endpoint,2014-02-17,COMPLETED,INTERVENTIONAL,['PHASE3'],
1193,NCT03865901,Negative predictive value (NPV) and positive predictive value (PPV) of the Mellitus GCD59 ELISA for gestational diabetes mellitus screening,Sensitivity and specificity of the GCD59 ELISA to that of glucose load test (GLT) using two or more abnormal oral glucose tolerance test (OGTT) results,2019-05,WITHDRAWN,OBSERVATIONAL,['NA'],Sensitivity and specificity of the GCD59 ELISA across relevant subgroups
1194,NCT01829464,Change From Baseline in HbA1c at Week 24,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,2013-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
1195,NCT04769141,Medication dosing optimization,(CURATE.AI) pilot deployment using prospective data,2021-08,UNKNOWN,OBSERVATIONAL,['NA'],
1196,NCT02846233,Change in A1c at the End of Study Period,Changes in Treatment Satisfaction Scores (DM-SAT Total Score),2016-08,COMPLETED,INTERVENTIONAL,['NA'],
1197,NCT00157924,LDL-C lowering efficacy,Safety,2005-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
1198,NCT03296800,AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity),Urinary Glucose Excretion 0-48 hr,2017-09-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
1199,NCT01035320,"Compare the effects of simvastatin + ezetimibe with those of simvastatin alone, on thrombogenic mechanisms, in patients with diabetes mellitus type 2.",Compare effects of simvastatin alone with those of placebo on thrombogenic mechanisms. Compare the effects of simvast. + ezetim. with those of simvast. alone on inflammatory variables. Assess how the treatment effect relate to renal function.,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1200,NCT00621608,"Freedom from having, or meeting the criteria for, a major amputation (below knee amputation, or metatarsal level) up to 12 weeks after randomization.",Cost effectiveness of HBOT: calculate the incremental cost per amputation avoided and the incremental cost per quality-adjusted life-year (QALY) gained,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
1201,NCT05488002,Cholesterol LDL-cholesterol Triglycerides Cholesterol LDL-cholesterol Triglycerides,Medication adherance,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1202,NCT01029704,Pharmacokinetics of EGT0001442 (AUC 0-t and 0-24) at 4 Dose Levels at Week 4,Change in FPG Following Cessation of Treatment,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
1203,NCT04257370,Wound healing at Week 16,Percentage of ulcers healed 50% or more at 12 weeks,2020-07-09,COMPLETED,INTERVENTIONAL,['NA'],
1204,NCT00394524,Mean Blood Glucose (BG) in mg/dl Among Glucommander Group Compared to Standard Insulin Infusion,Mean Hospital Length of Stay in Days Among the Glucommander Group Compared to Standard Insulin Infusion,2006-06,COMPLETED,INTERVENTIONAL,['NA'],
1205,NCT01313975,Incidence of sodium-fluid disturbances,Associated changes in natriuretic peptide levels,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
1206,NCT01736124,Diabetes Self-management,Prospective Memory,2015-04-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
1207,NCT04798937,Transition Readiness Assessment Questionnaire (TRAQ) scores,Hemoglobin glycated values,2020-01-01,COMPLETED,INTERVENTIONAL,['NA'],
1208,NCT02853630,Changes in Insulin secretion rate,Number of participant treated related to adverse event,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
1209,NCT00200018,Mean excess weight loss and percent excess weight loss,Diabetes status and use of diabetes medication,2005-06,COMPLETED,INTERVENTIONAL,['NA'],
1210,NCT02477163,Changes in the value of laboratory investigations,,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
1211,NCT01791907,HbA1c,Health economics,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
1212,NCT02989142,"prevalence of participants with at least one of the following four complications: pregnancy-induced hypertension, gestational diabetes mellitus, caesarean section, large-for-gestational age baby",Number of women who gave at least 6 months breast feeding,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
1213,NCT04380584,prediction of diabetic nephropathy,,2019-11-30,COMPLETED,OBSERVATIONAL,['NA'],
1214,NCT00300287,Change from baseline in HbA1c at 108 weeks,Change from baseline in body weight at week 108,2006-02-20,COMPLETED,INTERVENTIONAL,['PHASE3'],
1215,NCT04690270,Insulin secretion,,2021-01-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
1216,NCT02718547,Change of at least 50 micron in Macular edema,,2017-03-26,UNKNOWN,INTERVENTIONAL,['NA'],
1217,NCT04027062,"Percent of change of knowledge, attitude and practice of primary healthcare physicians",,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA'],
1218,NCT04807374,Change in CGM Time in Range (TIR),Semi-structured interviews with youth and parents exploring the overall experience and barriers to expanding access to hybrid closed loop technology,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],
1219,NCT02024750,"Change in Parent Quality of Life (QOL) for Usual Care and Tailored Resources (Intervention) Arms, During and Post-Intervention","Change In Parent Fear of Hypoglycemia (FOH) for Usual Care and Tailored Resources (Intervention) Arms, During and Post-Intervention",2014-09,COMPLETED,INTERVENTIONAL,['NA'],
1220,NCT00356109,To test that preprandial AIR Insulin is non-inferior to preprandial injectable insulin (insulin lispro) with respect to mean change in HbA1c from baseline to endpoint.,To assess rate and incidence of hypoglycemia,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
1221,NCT01496339,Glycosylated hemoglobin (HbA1c),The random glucose level,2012-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1222,NCT06004219,Diabetes Distress Screening Scale (DDS17),,2023-11-21,RECRUITING,INTERVENTIONAL,['NA'],
1223,NCT01827826,Program feasibility: Attendance,Physical activity level,2010-07,COMPLETED,INTERVENTIONAL,['NA'],
1224,NCT01219803,HbA1c,"Ins(0h,1h,2h),blood lipids",2010-08,UNKNOWN,INTERVENTIONAL,['NA'],
1225,NCT02501616,Reactive hyperemic index to measure endothelial function,Urine β2 microglobulin,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1226,NCT00082316,,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],
1227,NCT04328896,CGM-Tele-monitoring effects on hypoglycemia,CGM - Tele-monitoring effects on HbA1c,2018-06-15,COMPLETED,INTERVENTIONAL,['NA'],
1228,NCT02318693,Change From Baseline in Mean Amplitude of Glycemic Excursions (MAGE) at Day 13,"Change From Baseline in Percentage of Hypoglycemic Values (Glucose Sensor Readings: < 70, <60, <50 mg/dL)",2015-02-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
1229,NCT03049709,agreement of diastolic central blood pressure measurements,,2015-05-01,COMPLETED,OBSERVATIONAL,['NA'],
1230,NCT00388518,Absolute change from baseline in Hemoglobin A1c (HbA1c),"Adverse Events (AEs), laboratory parameters.",2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
1231,NCT04098549,Positive incremental area under the glucose curve (PI-AUC) (using the plasma glucose concentration before glucagon administration as basal level),Number of subjects experiencing vomiting,2019-09-12,COMPLETED,INTERVENTIONAL,['NA'],
1232,NCT01814995,percentage change in weight in participant,Change in mindful eating,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
1233,NCT04101396,Clinical characteristics of participants,Participants' satisfaction,2019-10-25,COMPLETED,INTERVENTIONAL,['NA'],
1234,NCT01219959,Change From the Baseline Value in HbA1c at Month 3 and 6,Change From Baseline of Left Ventricular (LV) Ejection Fraction as Determined by MRI at Month 6,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1235,NCT00348179,Vascular abnormalities as measured by the SyphmgnoCor equipment,,2004-04,COMPLETED,INTERVENTIONAL,['NA'],
1236,NCT01812122,Cardiovascular disease risk factor,hypoglycemic index,2013-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
1237,NCT03707379,HbA1c,LDL-C,2016-03-01,RECRUITING,OBSERVATIONAL,['NA'],
1238,NCT03529903,Change in Physical Activity,,2018-08-10,COMPLETED,INTERVENTIONAL,['NA'],
1239,NCT00786019,"Ejection Fraction: Percentage of Blood Leaving the Heart Before and After Exercise at Baseline, After a Vitamin C Infusion, and After Exercise Training",,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
1240,NCT00494715,Progression to ESRD (i.e. need for renal replacement therapy by chronic dialysis or renal transplantation),"Doubling of serum creatinine (versus baseline), Rate of GFR decline, Incidence of fatal and non-fatal cardiovascular events (stroke, acute myocardial infarction, sudden death), Albumin to creatinine ratio and 24-hour urinary protein excretion.",2007-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
1241,NCT00901472,Improvement in glucose tolerance,,2007-02,COMPLETED,OBSERVATIONAL,['NA'],
1242,NCT02932475,Number of Participants With Composite Adverse Neonatal Outcome,Neonatal Safety Based on Treatment Emergent Adverse Events,2017-05-25,TERMINATED,INTERVENTIONAL,['PHASE3'],
1243,NCT03491930,Change in weight,"Change in quality of life by ""SF-12v2"" questionnaire",2018-06,WITHDRAWN,INTERVENTIONAL,['NA'],
1244,NCT01585948,The incidence and extent of coronary artery disease between diabetics and non-diabetic patients.,TCF7L2 gene polymorphims and the incidence and extent of coronary artery disease.,2009-11,COMPLETED,OBSERVATIONAL,['NA'],
1245,NCT02003872,Excess weight loss,liver fat infiltration,2015-01,TERMINATED,INTERVENTIONAL,['NA'],
1246,NCT04068272,Epitheliopathy,Anterior segment inflammation,2019-09-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
1247,NCT02156349,The mean HbA1c change by means of Generalized Estimating Equations (GEE) methods,Effects of integrated Personalized Diabetes Management (PDM) by means of Generalized Estimating Equations [GEE] methods,2014-05-14,COMPLETED,INTERVENTIONAL,['NA'],
1248,NCT03253328,Stump Healing using the Bates-Jensen Wound Assessment Tool,Determine effect size to power a larger trial,2016-12-15,SUSPENDED,INTERVENTIONAL,['NA'],Stump Healing
1249,NCT02784275,Change of Body Weight From Baseline,Change of Score in Audit of Diabetes-Dependent Quality of Life Questionnaire From Baseline,2016-06-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1250,NCT00294723,Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 156,Hypoglycaemic Episodes,2006-02,TERMINATED,INTERVENTIONAL,['PHASE3'],
1251,NCT04959071,Comparison of mean healing time of wounds in diabetic foot ulcers among Vac and conventional dressings,,2020-02-28,COMPLETED,INTERVENTIONAL,['NA'],
1252,NCT00786721,Near Infrared Spectroscopy to assess muscle mitochondrial OXPHOS function.,,2006-11,COMPLETED,OBSERVATIONAL,['NA'],
1253,NCT04132401,Area under the receiver operating characteristic curve of the algorithm,,2021-05-01,COMPLETED,INTERVENTIONAL,['NA'],
1254,NCT02496390,Improvement in Homeostasis model assessment [HOMA] score.,Modulation of lipid and hormone metabolism,2016-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1255,NCT03049631,Changes in gut microbiome composition as measured by 16S rRNA gene sequencing in 12-week intervention of active treatment vs Experimental,Changes in blood pressure in 12-week intervention of active treatment vs Experimental,2017-05-18,COMPLETED,INTERVENTIONAL,['NA'],Changes in plasma HDL cholesterol in 12-week intervention of active treatment vs Experimental
1256,NCT03456271,fracture,,2017-07-01,TERMINATED,OBSERVATIONAL,['NA'],
1257,NCT02765399,Change in ApoCIII Level,Mean Fractional Catabolic Rate of VLDL2-apoB100,2015-02-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1258,NCT00390273,Lactate production following exogenous lactate overload,Parameters modelizing elimination of lactate following muscular exercise test (bi-exponential model).,2006-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1259,NCT01957696,Surgical complications,Non-surgical complications,2013-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],"Scheduled, conventional, percutaneous, ultrasound-guided pancreas graft biopsies at 6 weeks and 12 months post-Tx [Amendment 2; Approved by Regional Ethics Commitee]"
1260,NCT05629221,Haemoglobin glycated (Hb1Ac) mean changes,Time spent for telemedicine visits,2022-12-30,RECRUITING,INTERVENTIONAL,['NA'],
1261,NCT00522327,Adherence with care,care parameters,2004-11,COMPLETED,INTERVENTIONAL,['NA'],
1262,NCT00965991,Number of Participants Assessed for Glucose Control,Failure Rate of the Drug to Control Blood Glucose,2003-07,COMPLETED,INTERVENTIONAL,['NA'],
1263,NCT01677299,Within Treatment Comparison Based on Ratios of AUCs of PYY,,2012-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1264,NCT03131232,The effect of empagliflozine on glucose metabolism,- echocardiographic parameters (if collected) with determination of the systolic and diastolic left ventricular function,2015-12-10,UNKNOWN,OBSERVATIONAL,['NA'],
1265,NCT02577900,Number of Participants With Complete Healing of Ulcer During the Observation Period,the Change in Concentration of Interleukin-1 Alpha (IL-1α) Level Inside Wound Fluid at Week 1 and Week 4,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
1266,NCT00313001,Superiority as assessed by HbA1c reduction,Patient satisfaction,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
1267,NCT01392677,Adjusted Mean Change From Baseline in HbA1c Levels,Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1268,NCT05602441,Change in glycated haemoglobin from baseline to 12 months post intervention,Change in diabetes distress measured by Diabetes Distress - Screening Scale 17 (DDS-17) from baseline,2021-01-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1269,NCT02824003,Change in fasting hepatic lipid content,"Safety and Tolerability will be assessed by determining the incidence, severity, dose relationship of adverse effects, and changes in laboratory evaluations",2016-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1270,NCT05367622,Medication compliance,Diabetes health literacy assessment scale,2022-12-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
1271,NCT00904020,"Average daily pain intensity (Brief Pain Inventory [BPI] Questions 3, 4, 5, and 6)",QoL: Patient Global Assessment of Patch Satisfaction,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
1272,NCT04241575,Action on suspected advanced liver fibrosis,Confirmed diagnosis of advanced liver fibrosis,2020-05-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1273,NCT06112925,"Change in percentage of of glycemic control, blood pressure control and medication adherence among adult patients comorbid with diabetes mellitus and hypertension at outpatient clinics in Southwest Ethiopia",,2022-03-27,COMPLETED,INTERVENTIONAL,['NA'],
1274,NCT02987348,Changes from baseline in composite outcomes of HbA1c<=7.0% and weight reduction,Health care utilization,2015-06-30,COMPLETED,OBSERVATIONAL,['NA'],
1275,NCT00279201,ADDENDUM: 24-Week Endpoint HbA1c,ADDENDUM: HbA1c at Specified Visits and Endpoint,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
1276,NCT05803421,"Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death]",Pharmacokinetics (PK): Plasma Serum Concentrations of Orforglipron,2023-04-03,RECRUITING,INTERVENTIONAL,['PHASE3'],
1277,NCT01994746,Increase in Plasma Glucose Level to >=70mg/dL or an Increase of >=20mg/dL From Glucose Nadir,Time to Maximum Change From Baseline Concentration (Tmax) of Glucose,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
1278,NCT06240273,Fasting glucose level will be assessed before and after the trial.,,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1279,NCT01050868,To compare the difference between the self-monitoring blood glucose (SMBG) value achieved at 6 hours after meals with induced post-prandial hyperglycemia and the mean target value of 110 mg/dL. Target post-prandial range is 80-140 mg/dL.,"To compare the absolute relative difference (RAD, multiplied by 100) between the SMBG value and the target value between the calculators",2009-06,COMPLETED,INTERVENTIONAL,['NA'],
1280,NCT04084418,Daily blood glucose standard deviation,Effects on physical activity (steps/day),2019-10-15,TERMINATED,INTERVENTIONAL,['NA'],
1281,NCT02351232,Change in HbA1c,Change in anxiety and depression as measured by Hospital Anxiety and Depression Scale,2015-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1282,NCT05939271,- What is the incident amputation rate in persons with and without DM in the Netherlands in the period 2011-2020?,"- Does the presence of a formal multidisciplinary foot clinic / team in a hospital make a difference, especially when comparing previous and actual macrovascular complication rates?",2022-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1283,NCT05354245,Peripheral insulin sensitivity,Stool consistency,2022-09-08,RECRUITING,INTERVENTIONAL,['NA'],
1284,NCT02003677,Area under the glucose infusion rate curve,Maximum observed serum insulin aspart concentration,2013-11-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
1285,NCT03917784,Matsuda index,total bilirubin,2019-02-25,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1286,NCT02290067,User performance of blood glucose monitoring systems indicated by patient [questionnaire],,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
1287,NCT02826759,"serum concentration of sphingosine-1-phosphate, micromol per liter","serum concentration of ceramide, micromol per liter",2016-07,UNKNOWN,OBSERVATIONAL,['NA'],
1288,NCT03337828,Homeostatic model assessment (HOMA) index change after each alcohol-free beer phase.,Micriobota change after each alcohol-free beer phase.,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],
1289,NCT03776227,AUC 0-72h (area under the curve),Area under the curve (AUC),2019-01-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
1290,NCT05227105,Objective accelerometry,Objective accelerometry,2023-05-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
1291,NCT04263311,Change in BP control,Barriers and Facilitators to Implementation Adoption and Implications for Scalability,2020-07-20,COMPLETED,INTERVENTIONAL,['NA'],
1292,NCT01115621,Effect of dietary intervention on the development of islet autoantibodies,Effect of dietary intervention on the development of Type 1 diabetes.,2001-02,UNKNOWN,INTERVENTIONAL,['NA'],
1293,NCT05947370,Differences of blood glucose levels between BBR and placebo treatment groups during the glucose tolerance test.,Differences of serum calcium levels between BBR and placebo treatment groups during the glucose tolerance test.,2022-10-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Differences of QT-interval duration between BBR and placebo treatment groups during the glucose tolerance test.
1294,NCT02851745,Increase in LV systolic function,Changes in diastolic LV function,2015-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
1295,NCT03660553,Hemoglobin A1c (HbA1c),Incidence of Severe Hypoglycemia,2018-10-10,TERMINATED,INTERVENTIONAL,['PHASE4'],
1296,NCT00094263,,,2004-09,COMPLETED,OBSERVATIONAL,['NA'],
1297,NCT01779609,Flow mediated dilation,Maximal Oxygen Uptake,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
1298,NCT06007014,HbA1C,Fasting C-Peptide,2023-10-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1299,NCT03393715,24-hour blood pressure profile,Night time blood pressure dip,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
1300,NCT03037918,Whole body insulin sensitivity index,Microbiome analysis,2017-02-03,COMPLETED,INTERVENTIONAL,['NA'],
1301,NCT02157298,Adjusted Mean Change in HbA1c Levels,Proportion of Participants With Mean Daily Insulin Dose Reduction of Greater Than or Equal 10%,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
1302,NCT03481530,Hypoglycemia rate,Comparison hypoglycemia rate,2018-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1303,NCT00149331,Preference for Insulin therapy,Satisfaction with the education session,2005-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
1304,NCT00475371,Determine the safety and tolerability of ascending doses of MKC253 Inhalation Powder,Pharmacokinetic (PK) parameters of plasma GLP-1,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
1305,NCT04682067,Number of participants with >80% completion of daily ecological momentary assessments (EMA) completed,Number of participants with biochemically verified abstinence at 4 weeks post quit,2021-01-08,COMPLETED,INTERVENTIONAL,['NA'],
1306,NCT02436551,prevalence of gestational diabetes,,2015-09,COMPLETED,OBSERVATIONAL,['NA'],
1307,NCT02974413,Glycemic control,Weight,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],
1308,NCT00825695,functional transcranial doppler measures,,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
1309,NCT02701257,Insulin Area Under the Curve in the 3.5 Hours Following the Insulin Bolus,PG AUC in the 3.5 Hours Following the Meal,2016-03,TERMINATED,INTERVENTIONAL,['NA'],
1310,NCT06195566,"Validation of the Mission T2D (MT2D) algorithm outputs, that predicts the real time risk for developing pre-diabetes.",,2024-01-29,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1311,NCT03437798,Correlation of CDC-AAP periodontal condition questions vs. periodontal disease diagnosis,,2018-01-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1312,NCT01234597,Changes in Hemoglobin A1c (HbA1c) level,Changes in insulin glulisine dose,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
1313,NCT04127890,Weight loss,,2017-03-07,COMPLETED,INTERVENTIONAL,['NA'],
1314,NCT04664764,to compare the effectiveness of insulin degludec to insulin glargine and NPH,,2019-02-21,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1315,NCT05066152,HOMA-IR,Dietary cholesterol,2016-02-01,COMPLETED,INTERVENTIONAL,['NA'],
1316,NCT02974309,HbA1c,Sleep Duration,2017-09-15,RECRUITING,INTERVENTIONAL,['NA'],Cortisol
1317,NCT01562782,Fold Change in Plasma Very Low Density Lipoprotein (VLDL) Triglyceride Palmitate,Peak Glucose in 2 Study Groups,2012-04-02,COMPLETED,INTERVENTIONAL,['NA'],
1318,NCT03605329,study of heart rate variability (HRV),monitoring of blood pressure,2018-09-05,TERMINATED,INTERVENTIONAL,['NA'],
1319,NCT01647542,Change From Baseline in HbA1c at Week 24,Change From Baseline in 2-hour Postprandial Glucose (PPG) Following Oral Glucose Tolerance Test (OGTT) at Week 24,2012-10,TERMINATED,INTERVENTIONAL,['PHASE3'],
1320,NCT00191282,Number of Participants Who Experienced a Primary Combined Outcome,Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 18,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Summary of Reasons for Deaths
1321,NCT02551835,HbA1c,Two-hour glucose,2015-04,UNKNOWN,OBSERVATIONAL,['NA'],
1322,NCT02559479,Change in insulin resistance (HOMA index).,"Change in lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, non HDL cholesterol, triglycerides and apolipoproteins).",2015-09,UNKNOWN,INTERVENTIONAL,['NA'],
1323,NCT03652480,Glycemia,Subjective Outcomes Determination (SOD) score,2013-03,COMPLETED,OBSERVATIONAL,['NA'],
1324,NCT00005419,,,1992-03,COMPLETED,OBSERVATIONAL,['NA'],
1325,NCT01565564,The Rate of Macrosomia.,The Rate of Pregnancy-induced Hypertension.,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
1326,NCT05298735,Pancreatic calcium-handling: Rate of change of pancreatic T1 values with manganese-enhanced magnetic resonance imaging,,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],
1327,NCT01759823,Reduction of insulin requirement by ≥ 50% by the end of 6 months of autologous bone marrow derived stem cell transplantation and Improvement in Glucagon stimulated C - peptide levels and hyperglycemic clamp for assessment of beta cell function,,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1328,NCT04605991,Change From Baseline in Percentage of Time With Continuous Glucose Monitoring (CGM) Sensor Glucose Values Between 70-180 Milligrams/Deciliter (mg/dL) (3.9-10.0 Millimoles/Liter [mmol/L]) (Both Inclusive) During Daytime Period at Week 12,Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) - Glycemic Control Domain Score at Week 12,2020-11-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
1329,NCT04688359,Measurements behind the Icelandic heart association risk calculator,Hip-to-Waist ratio,2021-11-01,COMPLETED,INTERVENTIONAL,['NA'],LDL cholesterol changes from start point to endpoint in both groups
1330,NCT00067626,Homeostasis Model Assessment for Insulin Resistance (HOMA-IR),endothelial function measures as percent flow-mediated dilitation (FMD).,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1331,NCT00382564,,,2006-09-25,COMPLETED,OBSERVATIONAL,['NA'],
1332,NCT00789711,"Number of all (Major/Minor/Nocturnal) hypoglycaemic events, reported as serious adverse drug reactions.",Number of major (including nocturnal) hypoglycaemic events,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
1333,NCT00832182,Number of hypoglycemic episodes and adverse events,9-point blood glucose profile,1999-12-22,COMPLETED,INTERVENTIONAL,['PHASE3'],
1334,NCT02107326,Effect of Webdia Software use on HbA1C,Effect of Webdia Software use on the incidence of hypoglycaemic events,2014-05,COMPLETED,INTERVENTIONAL,['NA'],
1335,NCT05742230,Change From Baseline in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) at Week 12,"Change From Baseline in blood pressure at Week 4, 12",2023-04-15,RECRUITING,INTERVENTIONAL,['NA'],Occurrence of major renal events
1336,NCT02252224,The number and incidence rate of adverse events and serious adverse event including unexpected adverse drug reactions,Changes in 2-hr PPG before and after administration of Forxiga,2014-09-23,COMPLETED,OBSERVATIONAL,['NA'],
1337,NCT05179668,Δ Left ventricular mass indexed to body surface area,Δ Body weight [kg],2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
1338,NCT00785005,,,2008-05,COMPLETED,OBSERVATIONAL,['NA'],
1339,NCT03107208,Rate of Rebound Hyperglycemia,Evaluation of CGM and POC Glucose Monitoring During DKA Treatment in Children.,2017-07-21,COMPLETED,INTERVENTIONAL,['PHASE4'],
1340,NCT00953914,autonomic modulation assessed by heart rate variability,,2005-03,COMPLETED,INTERVENTIONAL,['NA'],
1341,NCT04653454,CGM accuracy - mean absolute relative difference (MARD),Readmission rate at 30 days,2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1342,NCT00424762,Peak Oxygen Uptake (VO2),Percentage of Patients Developing New or Worsening Peripheral Edema,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
1343,NCT01060670,Incidence of Complete Wound Closure,Change in Short Form Health Survey (SF-36) Quality of Life Metrics,2010-04,COMPLETED,INTERVENTIONAL,['NA'],
1344,NCT00006162,,,1994-10,COMPLETED,INTERVENTIONAL,['NA'],
1345,NCT03304626,Number of Participants With Acute Cellular Rejection Between Study and Control Groups,Number of Participants With Adverse Events,2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE2'],
1346,NCT00159731,Adverse events,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1347,NCT02366351,The number of volunteers with adverse events as a measure of safety and tolerability,Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1348,NCT02292290,Composite,HbA1c only,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
1349,NCT03528031,Visceral adiposity,24-hour diet recall,2018-06-19,COMPLETED,INTERVENTIONAL,['NA'],
1350,NCT04999189,Change in blood pressure,,2021-09-01,UNKNOWN,INTERVENTIONAL,['NA'],
1351,NCT03570138,Prevalence of cardiac arrythmic events during a 14 days Continuous ECG Monitoring,Prevalence of ventricular extrasystoles,2018-06-29,UNKNOWN,INTERVENTIONAL,['NA'],
1352,NCT00620282,Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF),Number of Hypoglycaemic Episodes,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
1353,NCT02624583,Changes in platelet reactivity between the three time points,Changes in the lipid profile between the three time points,2010-06,COMPLETED,OBSERVATIONAL,['NA'],
1354,NCT00791453,Hgb A1C and BMI measurements will improve,,2008-04,COMPLETED,OBSERVATIONAL,['NA'],
1355,NCT01947855,Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
1356,NCT05348122,Changes in glycosylated hemoglobin (HbA1c) from baseline to week 17,The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (Nab).,2022-06-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1357,NCT00486291,Change From Baseline in HbA1c at Week 28.,Absolute Weight Change (kg) From Baseline to Week 28,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
1358,NCT01594281,Change From Baseline in Area of Neovascularizations (NVs) at End of Core Study (EOCS),Number of PRP Laser Spots Until EOCS,2012-12-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
1359,NCT02986984,Rapid progression of kidney function loss,Serious Adverse Events,2016-12,RECRUITING,OBSERVATIONAL,['NA'],
1360,NCT05561855,The change of HbA1c from baseline,The change in depression severity from baseline,2022-10-07,COMPLETED,INTERVENTIONAL,['NA'],
1361,NCT02773095,Price of Novartis Access medicines and equivalents at alternative for-profit drug sellers,,2016-06,COMPLETED,INTERVENTIONAL,['NA'],
1362,NCT04292509,blood ketones > 0.6mmol/l.,severe hypoglycemic episodes,2020-02-15,COMPLETED,INTERVENTIONAL,['NA'],
1363,NCT02634216,Effect of Capros on Blood Glycemic Index,,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
1364,NCT00567112,Half Life (t½) for OCT (Fasted) and DFC (Fasted),t1/2 for OCT (Fasted) and OCT (After Meal),2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1365,NCT05632029,Malondialdehyde,Glutathione,2022-10-20,RECRUITING,INTERVENTIONAL,['NA'],
1366,NCT02000024,Changes in weight,Changes in HDL-cholesterol,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
1367,NCT02961595,Appearance of type 1 diabetes associated auto-antibodies in serum,Presence of enterovirus RNA in stools,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
1368,NCT03670641,Change in Baseline A1C and A1C Measured at 3 Month Intervals up to 12 Months,Number of Participants Achieving Euglycemic Glucose Targets Within a 4 Week Period,2019-03-26,COMPLETED,INTERVENTIONAL,['PHASE4'],
1369,NCT05966727,Measurement of serum persistent organic pollutants (POPs) concentrations by mass spectrometry.,Measurement of serum POPs concentrations by mass spectrometry after bariatric surgery,2024-03-31,RECRUITING,INTERVENTIONAL,['NA'],
1370,NCT02768818,Glucose metabolism changes,Admission to Neonatal Intensive Care Unit (NICU),2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1371,NCT03376789,Change in HbA1c,Change in 8-point SMBG,2017-11-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
1372,NCT01356849,Change from baseline to Week 12 in Urinary Albumin to Creatinine Ratio (UACR),Differences in change from baseline to each post baseline measure for each of the Kidney Disease Quality of Life (KDQOL) Kidney Disease Targeted Scales,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1373,NCT01314222,The primary endpoint of this study is the average pain score for BMS-954561 vs. placebo.,"Evaluate the tolerability and safety of BMS-954561 in patients with DPNP as measured by the frequency and severity of adverse events, frequency of severe adverse events, and discontinuations due to adverse events.",2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
1374,NCT02246582,Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD),Retrospective Analysis (MARD for the GSR With Minimum and 1 Additional Calibration),2014-09,COMPLETED,INTERVENTIONAL,['NA'],
1375,NCT00504673,Body weight loss,Incidence of hypoglycaemia,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
1376,NCT05756712,The Change of Blood Glucose Level in mmol/L based on OGTT (Oral Glucose Tolerance Test) after Intervention,The Change of Fast Blood Glucose Level in mmol/L based on OGTT (Oral Glucose Tolerance Test) after Intervention,2023-03-06,COMPLETED,INTERVENTIONAL,['NA'],
1377,NCT05733455,Fasting serum C-peptide,Fasting serum low-density lipoprotein (LDL) cholesterol levels,2023-05-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
1378,NCT03970889,Change in the number of missed meal boluses,Positive predictive value of a Klue meal alert,2018-10-12,COMPLETED,INTERVENTIONAL,['NA'],
1379,NCT03226990,pressure areas,denture retention,2017-06-01,COMPLETED,INTERVENTIONAL,['NA'],
1380,NCT04784130,Clinical Outcomes-A1c,Behavioral outcome - medication adherence; questions,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],
1381,NCT01729078,Changes in liver fat content after 12 weeks of intervention,Change in glucose metabolism after 12 weeks of intervention,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
1382,NCT01873066,The proportion of time spent in the target glucose range from 3.9 to 10.0 mmol/l based on CGM,"The proportion of time with glucose levels in significant hyperglycaemia, as based on CGM (glucose levels > 16.7 mmol/l)",2014-08-28,COMPLETED,INTERVENTIONAL,['NA'],Utility evaluation
1383,NCT04950634,To assess the role of sex on the progression of subclinical atherosclerosis in patients with T1D.,To identify novel circulating markers of subclinical atherosclerosis,2018-09-01,RECRUITING,OBSERVATIONAL,['NA'],
1384,NCT03686657,Change from baseline in acute insulin response to glucose (AIRg) for treatment naive patients,Change from baseline in Adiponectin,2023-10-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1385,NCT00542009,Body weight,"Change in following parameters: Post-prandial and fasting glucose, and insulin",2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
1386,NCT05747118,Adherence,Change in triglycerides,2022-08-15,COMPLETED,OBSERVATIONAL,['NA'],
1387,NCT01814748,Percentage of Participants Who Discontinued Study Drug Due to an AE,Percentage of Participants Who Required Glycemic Rescue by Week 24,2013-05-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
1388,NCT01868542,Change in Glycosylated Haemoglobin A1c (HbA1c) From Baseline.,Incidence of Adverse Events,2013-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
1389,NCT03820752,"Proportion of adult chronically ill patients correctly vaccinated diphtheria, tetanus, pneumococci, hepatitis B and influenza according to Belgian recommended vaccination schedule","Proportion of adult patients with antibodies against diphtheria, tetanus and pertussis.",2014-10,COMPLETED,OBSERVATIONAL,['NA'],
1390,NCT04613076,Depression change,Proportion of participants with change in glycosylated hemoglobin,2019-09-03,COMPLETED,INTERVENTIONAL,['NA'],Utilization of health care services
1391,NCT02261194,Change in depressive symptoms,Change in life space,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
1392,NCT00843232,"Distinctive curves of glucose, C peptide, insulin, glucagon, GLP-1, GIP and ghrelin during a standardized mixed meal tolerance test, in T2DM subjects after sixty-five years old in comparison with middle-age T2DM subjects",Distinctive DPP-IV activity as measured by spectrophotometer in T2DM subjects after sixty-five years old in comparison with middle-age T2DM subjects.,2009-07,COMPLETED,OBSERVATIONAL,['NA'],
1393,NCT01105923,Intervention acceptance,Quality improvement based on problem list accuracy/completion,2010-05,UNKNOWN,INTERVENTIONAL,['NA'],
1394,NCT05318183,Change in fasting plasma glucose,Intestinal whole wheat phytochemical: phenolic compounds,2022-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Gut microbiota relative abundance
1395,NCT05971940,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Domain Scores,2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE3'],
1396,NCT00494988,Remission rate,HbA1c,2004-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
1397,NCT03512184,Determine if Liver Fat via Fibroscan Controlled Attentuation Pattern score has decreased as a result of YMCA program,"Measuring the effectiveness of the YMCA Program, as per metabolic blood work that's analyzed",2018-01-03,COMPLETED,INTERVENTIONAL,['NA'],
1398,NCT04643873,Muscle mass amounts in the trunk and extremities,6 minutes walk test,2020-01-06,UNKNOWN,INTERVENTIONAL,['NA'],
1399,NCT05788341,Positive Islet Autoantibodies,,2023-05-30,RECRUITING,OBSERVATIONAL,['NA'],
1400,NCT03965013,Number of treatment-emergent adverse events,Maximum observed serum NNC0268-0965 concentration after a single dose,2019-06-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
1401,NCT02713841,Bioavailability,,2013-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1402,NCT04763525,Glycosylated haemoglobin,Intracellular water,2018-10-04,COMPLETED,INTERVENTIONAL,['NA'],
1403,NCT06124547,Area under the plasma concentration versus time curve (AUC) 0-inf (Metformin only),Number of participants with adverse events (AEs),2023-01-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
1404,NCT05076955,Healing Rate,Wound Closure,2021-03-31,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
1405,NCT01117350,Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Comparative Period,Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Extension Period,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
1406,NCT01788930,Response to antiplatelet therapy,Effects of CPAP treatment for severe obstructive sleep apnea on aspirin efficacity in type-2 diabetic patients,2013-02,TERMINATED,INTERVENTIONAL,['NA'],
1407,NCT00634842,Percentage of Participants Achieving Glycosylated Haemoglobin A1c (HbA1c) Less Than 7%,"Incidence of Hypoglycaemic Episodes (All, Major, Minor and Symptoms Only)",2008-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
1408,NCT01051011,Glycemic control assessed by HbA1c,"Meal tolerance test (in a subset of patients): Glucose, insulin, C-peptide, glucagon values",2010-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
1409,NCT00972283,Rate of Treatment Emergent Adverse Events (AEs),Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,2009-09-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1410,NCT01983215,number of patients with infections,infection rates,2013-04,UNKNOWN,INTERVENTIONAL,['NA'],
1411,NCT05335629,Effect on ST2 (suppression of tumerogenicity 2) level in the acute phase after myocardial infarction,Echocardiographic changes due to intervention,2022-06-01,COMPLETED,INTERVENTIONAL,['NA'],
1412,NCT00502515,Rate of epidermal nerve fiber regeneration,"Safety: physical examination, clinical laboratories, adverse event reporting",2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
1413,NCT03155867,Area under the blood glucose curve (AUC 0-240),AUC (0-30min) for insulin,2017-04-05,COMPLETED,INTERVENTIONAL,['NA'],
1414,NCT06169982,Pharmacokinetics (PK): Area under the concentration curve during one dosing interval at steady state (AUCss) of LY3209590,"PK: Total amount of glucose infused during one dosing interval at steady state (Gtot,SS) of LY3209590",2023-12-07,RECRUITING,INTERVENTIONAL,['PHASE1'],
1415,NCT02530866,Change in baseline maternal glycemia at 32-36 weeks gestation,Lipid profile measurements,2015-11,COMPLETED,INTERVENTIONAL,['NA'],
1416,NCT00089557,,,na,TERMINATED,INTERVENTIONAL,['PHASE2'],
1417,NCT01057693,Change From Single-Blind Baseline in Mean Pain Score at Week 19 During Double-Blind Phase,Patient Global Evaluation of Study Medication (GESM) (Double-Blind Phase),2010-03-31,COMPLETED,INTERVENTIONAL,['PHASE3'],
1418,NCT03443180,Change in the plasma-induced transcriptional assay,Leukocyte analyses,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],
1419,NCT05791942,MyChart letter opened,Completion rate of one screening/test,2023-03-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
1420,NCT01173926,Area under the glucose infusion rate curve,Area under the serum insulin aspart concentration-time curve,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
1421,NCT00215735,,,2004-06,TERMINATED,INTERVENTIONAL,['NA'],
1422,NCT00490893,Hormone response to hypoglycemia (glucagon) Symptom response to hypoglycemia,"Hormone response (epinephrine, growth hormone, cortisol) to hypoglycemia",2006-03,TERMINATED,INTERVENTIONAL,['PHASE4'],
1423,NCT05893927,"""Self-Efficacy for Diabetes Scale""",Blood pressure,2024-02-15,RECRUITING,INTERVENTIONAL,['NA'],
1424,NCT03620357,HbA1c,,2018-09-05,COMPLETED,INTERVENTIONAL,['NA'],
1425,NCT06079008,The proportion of cardiac valve calcification between survival group and mortality group,,2016-06-01,COMPLETED,OBSERVATIONAL,['NA'],
1426,NCT03530579,Change in hip-to-waist ratio measurements,,2014-02-13,COMPLETED,INTERVENTIONAL,['NA'],
1427,NCT04323462,Wound Healing,time to ulcer healing,2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],amputation
1428,NCT01588743,AUC75-120 of Glucose Infusion Rate (GIR),AUC0-10 of Acute Insulin Response (AIR) during IVGTT,2008-10,UNKNOWN,INTERVENTIONAL,['NA'],
1429,NCT02278939,Count of Participants Who Completed the Study,Change in Body Mass Index (BMI),2014-11,COMPLETED,INTERVENTIONAL,['NA'],
1430,NCT05023798,Exploratory Usability Objective,,2021-09-15,UNKNOWN,OBSERVATIONAL,['NA'],
1431,NCT01970241,Mean POC Glucose Level Between Groups,Episodes of Hypoglycemia Between NPH and Control Groups,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4'],Correlation of C-peptide With Length of Stay
1432,NCT03804970,Proportion of scheduled eye care visits attended over 1 year,Visual acuity in the better seeing eye.,2019-08-15,COMPLETED,INTERVENTIONAL,['NA'],
1433,NCT01394510,Fasting Urine F2 Alpha Isoprostane Levels,Oral Disposition Index,2011-06,COMPLETED,INTERVENTIONAL,['NA'],
1434,NCT04117022,Full-field flicker ERG (ffERG) Measurements: magnitude (microvolts) and the phase (milliseconds) and the area ratio for magnitude and the area ratio for Phase,Optical coherence tomography angiography (OCTA): radial macular and optic nerve capillary density (number/square millimeter),2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],
1435,NCT03719911,Change in Hemoglobin A1c,,2018-08-05,COMPLETED,INTERVENTIONAL,['NA'],
1436,NCT03495349,"Occurrence of adverse effects in patients treated by antibiotherapy for diabetic foot infection, assessed by clinical or biological methods",,2018-06-05,COMPLETED,OBSERVATIONAL,['NA'],
1437,NCT02256332,Post prandial blood glucose positive incremental area under the curve,Post prandial insulin area under the curve,2015-01,COMPLETED,INTERVENTIONAL,['NA'],Intestinal discomfort
1438,NCT03445702,Lactate to pyruvate ratio,Genomic testing,2018-10-15,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
1439,NCT06200532,Ease of use scores,,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1440,NCT00442884,change of glucose measurements after stress test in the fasting and fed state,,2006-02,COMPLETED,INTERVENTIONAL,['NA'],
1441,NCT03739034,high density lipoprotein cholesterol,full plate,2018-06-28,COMPLETED,INTERVENTIONAL,['NA'],
1442,NCT01117831,Lipids goal achievement,Achievement of National Clinical Practice Recommendations among Puerto Rican Population with Diabetes Mellitus,2010-03,COMPLETED,OBSERVATIONAL,['NA'],Achievement of National Clinical Practice Recommendations among Puerto Rican Population with Diabetes Mellitus
1443,NCT01455142,Maximum observed serum insulin aspart concentration,Maximum glucose infusion rate,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
1444,NCT00633997,"Skin concentration of vildagliptin and its two metabolites, LAY151 and LAF237-O-Glucuronide, compared to the plasma concentration on Day 10","10 day's treatment with vildagliptin 50 mg orally twice daily on hematology, blood chemistry and physical exams in healthy volunteers and patients with type 2 diabetes",2008-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1445,NCT01482247,Functional transcranial doppler measures,Finger Blood Flow - Plethysmography (PAT),2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1446,NCT02931773,Sympathetic hyperactivity in recently diagnosed DM2 patients,,2016-08,UNKNOWN,OBSERVATIONAL,['NA'],
1447,NCT04269668,Percentage of time of glucose sensor readings below 54 mg/dl,incidence of DKA,2020-07-19,COMPLETED,INTERVENTIONAL,['NA'],INSPIRE questionnaire measures
1448,NCT04529889,Change of obesity status during childhood and adolescence,Change of type 2 diabetes during childhood and adolescence,2012-02-01,RECRUITING,OBSERVATIONAL,['NA'],
1449,NCT05271045,serum HbA1c (mg/dL),TAC (mg/dL),2021-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
1450,NCT06152536,Physiopathology of glucose after two different meals,Physiopathology of insulin after two different meals,2022-06-09,RECRUITING,INTERVENTIONAL,['NA'],
1451,NCT04391088,number of diabetic patients up to date with their mandatory and recommended vaccinations,number of patients vaccinated during hospitalization,2019-05-01,COMPLETED,OBSERVATIONAL,['NA'],
1452,NCT06334133,Change in incidence of Level 2 or Level 3 hypoglycemia,To assess the incidence of adverse events,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],11-item/Short Form Hypoglycemia Fear Scale
1453,NCT05407831,HOMA Index and Beta cell function,MODY probability >25%,2022-03-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
1454,NCT01358981,Number of Participants With Clinically Significant Adverse Effects,C-Peptide Area Under the Effective Concentration Curve (AUEC),2011-05-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
1455,NCT05338567,Validation of the accuracy of the predicted length of the small intestine,Building prediction formulas through machine deep learning,2019-10-02,RECRUITING,OBSERVATIONAL,['NA'],
1456,NCT05019508,We will assess the predictive ability of fetal Cardiac Function Parameter for diagnosis of Gestational Diabetes Mellitus by oral glucose tolerance tests,Secondary neonatal outcomes,2021-08-13,UNKNOWN,OBSERVATIONAL,['NA'],
1457,NCT01236365,Hs-CRP Levels Assessed at Randomization and 6 Months,Descending Aortic Strain,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1458,NCT03622359,Lower extremity perfusion,Limb salvage,2017-02-17,RECRUITING,INTERVENTIONAL,['NA'],
1459,NCT00286494,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Body Weight (Week 26).,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
1460,NCT06322212,Assess anxiety in T2DM adults with thiamine treatment.,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1461,NCT05543720,Death and/or all-cause unplanned readmission,Days alive and out-of-hospital,2022-10-17,RECRUITING,INTERVENTIONAL,['NA'],
1462,NCT05873049,Artificial dermis (AD) or split-thickness skin graft (STSG) take rate,Vancouver scar score on 180 days,2022-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1463,NCT03830216,CGM time in range,Change in patient reported outcomes - HCS,2019-05-30,TERMINATED,INTERVENTIONAL,['NA'],Number of insulin dose administrations
1464,NCT04789993,Type of additional autoimmune diseases at type 1 diabetes diagnosis,Occurence of specific treatment onset in patients followed for type 1 diabetes with thyroid dysfunction due to Hashimoto,2021-03-15,UNKNOWN,OBSERVATIONAL,['NA'],
1465,NCT03279627,"Patient understanding of discharge instructions for home diabetes therapy according to presence or absence of hypoglycemia (defined as BG < 70 mg/dl), hyperglycemia (defined as BG > 250 mg/dl), or BG 70-250 mg/dl at time of hospital discharge",Association between patient understanding of home diabetes therapy and frequency of ER visits and hospital readmissions at 30- and 90-day following the index hospitalization,2017-08-28,COMPLETED,OBSERVATIONAL,['NA'],
1466,NCT00705861,"Erectile Function domain score (sum of Question 1,2,3,4,5 and 15) of the International Index of Erectile Function (IIEF) Questionnaire","the score from : 1) IIEF Q3 & Q4, 2) other domains of IIEF, 3) Sexual Encounter Profile(SEP)Q2 and Q3, 4) Life Satisfaction Checklist, 5) Global Efficacy Assessment Question(GEAQ)",2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
1467,NCT02752412,Change from baseline in HbA1c,Measurement of anti-insulin antibodies from baseline,2016-05-17,COMPLETED,INTERVENTIONAL,['PHASE3'],
1468,NCT01867970,Physical activity,Physical activity in daily life,2013-04,COMPLETED,INTERVENTIONAL,['NA'],Health status
1469,NCT05602532,TyG index in type 2diaberes Mellitus,,2022-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1470,NCT00433823,,,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1471,NCT01538485,Increase of regulatory FOXP3+ T cells,serum calcium level,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1472,NCT05639478,Change From Baseline of the Foot and Ankle range of motion at 12-week,Implementation at 12 weeks,2023-03-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
1473,NCT03761251,Hemoglobin A1c,,2018-10-31,COMPLETED,INTERVENTIONAL,['NA'],
1474,NCT04738591,Glycated Hemoglobin (HbA1C),Retention rate,2020-12-30,COMPLETED,INTERVENTIONAL,['NA'],International Physical Activity Questionnaire (IPAQ)
1475,NCT01664676,Glomerular Filtration Rate (51Cr-EDTA plasma clearance),Plasma concentrations of various hormones,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
1476,NCT02064348,"QTcI, (Individual heart rate corrected QT (Interval in the ECG: from the start of the QRS complex to the end) interval) based on ECG recordings obtained at 11 time points","QTcI, based on ECG (electrocardiogram) recordings obtained at 2 out of 8 time points",2014-02-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
1477,NCT01557296,Metabolic Control - HbA1c,"gastrointestinal symptoms - Questionnaire: Patient Assessment of upper Gastrointestinal Disorders Symptoms, Gastrointestinal Symptom Rating Scale",2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1478,NCT00285909,PPAR-gamma activated gene expression,Postprandial changes of HPA-axis activity,2006-03,COMPLETED,INTERVENTIONAL,['NA'],
1479,NCT00534105,Cholesterol,LDL,2007-09,COMPLETED,OBSERVATIONAL,['NA'],
1480,NCT05129735,Improvement of quality of life score from baseline to 12-weeks,Improvement in LDL cholesterol levels from baseline to 12-weeks,2022-09-15,UNKNOWN,INTERVENTIONAL,['NA'],
1481,NCT00322621,Change From Baseline (Week 8) in Brief Pain Inventory (BPI) 24-hour Average Pain Item Score at Week 34 Endpoint,Change From Baseline (Week 0) in Vital Signs: Weight at Week 34 Endpoint,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
1482,NCT04509362,TIR (70-180 mg/dl,Diabetic Ketoacidosis,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],
1483,NCT01787396,HbA1c,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
1484,NCT00478595,Relative change from baseline in in body weight,Safety: overview of adverse events,2007-04,TERMINATED,INTERVENTIONAL,['PHASE3'],
1485,NCT03034798,Blood glucose concentrations,Participants estimated blood glucose concentration,2015-01-14,COMPLETED,OBSERVATIONAL,['NA'],
1486,NCT02841553,Changes in C-peptide levels in participants,Changes in best-corrected visual acuity in participants measured by Snellen optotype,2011-07,RECRUITING,OBSERVATIONAL,['NA'],
1487,NCT00969007,5% weight loss,,2008-11,COMPLETED,INTERVENTIONAL,['NA'],
1488,NCT03211195,Assessment of PK parameter: AUC,Treatment emergent adverse events (TEAE),2017-06-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
1489,NCT05431140,Diabetes Treatment Satisfaction Questionnaire (DTSQc),Time spent by the HCP,2022-06-20,RECRUITING,OBSERVATIONAL,['NA'],
1490,NCT03278587,Cataract surgical rate,Number of cases of ocular disease detected,2018-05-31,COMPLETED,INTERVENTIONAL,['NA'],
1491,NCT01432938,Pharmacokinetics: Time to Maximum Concentration (Tmax) of R-warfarin and S-warfarin,Pharmacodynamics: Maximum Observed International Normalized Ratio (INRmax) of Warfarin,2011-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
1492,NCT03678896,Change from baseline in hemoglobin A1c levels at 6 months,Change from baseline in self-reported health,2017-01-05,COMPLETED,INTERVENTIONAL,['NA'],
1493,NCT03467503,Maternal inflammation,Maternal dietary intakes,2018-05-01,COMPLETED,INTERVENTIONAL,['NA'],Maternal metabolomics
1494,NCT06336239,The prevalence of albuminuria,Evaluate the management of patients with type 2 diabetes mellitus and cardiovascular disease across different levels of cardiology departments in hospitals.,2023-12-21,RECRUITING,OBSERVATIONAL,['NA'],Exploratory Objective
1495,NCT02556918,Number of Patients With Persistent Hyperglycemia,Number of Subjects Returning to the ER Within 30 Days,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1496,NCT00202618,A 50% reduction in UAE from the baseline,A change in high sensitivity C-reactive protein (hsCRP) from the baseline to the end of the intervention period,2003-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1497,NCT00615368,Cognitive function,Hypoglycemic hormonal response,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
1498,NCT00797615,The primary outcome measure will be the between-group differences in BMI and body fat.,Secondary outcomes will include dietary intake and physical activity.,2008-11,COMPLETED,INTERVENTIONAL,['NA'],
1499,NCT05576298,Area under the glucose infusion rate curve from administration to end of clamp from time zero to 24 hours,Maximum glucose infusion rate,2021-10-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1500,NCT00592332,Catecholamine levels,,2005-06,COMPLETED,INTERVENTIONAL,['NA'],
1501,NCT06165159,The primary outcome corresponds to the score obtained after completing the study questionnaire. The questionnaire is completed at the participation agreement.,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1502,NCT06085703,Change of olfactory brain activation by fMRI,Change of metabolism,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],
1503,NCT01690208,Glycemic control as measured by HbA1c compared to baseline,Control of BMI and other obesity indices compared to baseline,2012-05,UNKNOWN,INTERVENTIONAL,['NA'],
1504,NCT04306289,Changes in Pain severity,Changes in Neuropathic Pain Symptom,2020-06-01,UNKNOWN,INTERVENTIONAL,['NA'],
1505,NCT06203002,Change from Baseline to Week 8 in Average Daily Pain Score (ADPS),Change from Baseline to Week 8 in Total Neuropathic Pain Symptom Inventory (NPSI) Score,2023-11-29,RECRUITING,INTERVENTIONAL,['PHASE2'],
1506,NCT02709915,Insulin Dose,Clock Gene mRNA expression,2016-11,COMPLETED,INTERVENTIONAL,['NA'],Body Weight
1507,NCT03821675,Change in Wound Size in Response to Electrical Stimulation Therapy,Change in Tissue Oxygen Saturation in Response to Electrical Stimulation,2019-02-28,COMPLETED,INTERVENTIONAL,['NA'],Change From Baseline in Skin Perfusion in Response to Electrical Stimulation
1508,NCT05992974,Number of participants with gestational diabetes,,2023-08-31,RECRUITING,OBSERVATIONAL,['NA'],
1509,NCT03755752,Endothelial cell density,Mean corneal thickness,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],
1510,NCT02515461,Changes in glomerulus basal lamina assessed using transmission electron microscopy.,Protein concentration in urine,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],
1511,NCT01535495,Area of retinal neovascularization on fundus photography,Early Treatment Diabetic Retinopathy Study visual acuity in study and fellow eye,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1512,NCT03169413,Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive potassium channel gene in diabetic patients diagnosed under the age of one year.,dentification of possible demographic and environmental risk factors associated with increased risk of diabetes in diabetic patient under the age of one year.,2018-01,UNKNOWN,OBSERVATIONAL,['NA'],
1513,NCT00947726,Decrease transepidermal water loss and foot dryness in study subjects.,,2009-07,COMPLETED,INTERVENTIONAL,['NA'],
1514,NCT02465411,HbA1c in venous sample,Number of self-reported severe hypoglycaemic events per year,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
1515,NCT05683392,Number of other serious device-related adverse events,Number of interventions for study meal challenges,2023-02-01,COMPLETED,INTERVENTIONAL,['NA'],
1516,NCT04144374,Omadacycline Tissue Penetration.,Omadacycline Area Under the Curve (AUC) in Tissue,2020-02-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
1517,NCT01951729,Insulin secretion rates during each treatment.,Plasma pancreatic polypeptide levels during each treatment.,2013-03-13,COMPLETED,INTERVENTIONAL,['PHASE1'],Plasma xenin-25 levels during each treatment.
1518,NCT01268813,Development of Diabetes or complication,,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],
1519,NCT04654676,"Changes in mean amplitude of glycemic excursions in mmol/L, Standard deviation of the mean glucose levels in mmol/L, M value in mmol/L, Mean absolute glucose in mmol/L, Continuous overlapping net glycemic action in mmol/L, Lability index in mmol/L","Area under curve above 10.0mmol/day, area under curve below 3.9mmol/day",2018-09-15,COMPLETED,INTERVENTIONAL,['PHASE4'],
1520,NCT03039933,Decrease in scores on the Hypoglycemia Fear Survey,,2016-08,COMPLETED,INTERVENTIONAL,['NA'],
1521,NCT03508739,Intact glucagon like peptide-1 (GLP-1) levels after the mixed meal,"Neprilysin enzyme (drug) activity at baseline, during sacubitril/valsartan, and during valsartan",2018-06-01,SUSPENDED,INTERVENTIONAL,['PHASE3'],
1522,NCT06230276,Difference in an area under the curve of a glucose concentration change 4 hours after a meal (30 g and 50 g of carbohydrates) with a missed premeal bolus between individual HCL systems.,Difference in CGM parameters after a meal (30 g and 50 g of carbohydrates) with a missed premeal bolus between individual HCL systems using insulin aspart.,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],
1523,NCT00925080,"IVBG System accuracy will primarily be assessed relative to ISO 15197 criteria (i.e., within ±15 mg/dL at YSI glucose levels < 75 mg/dL, and within ±20% at YSI glucose levels >75 mg/dL).",,2009-06,COMPLETED,OBSERVATIONAL,['NA'],
1524,NCT05072353,Healing,amount of adipose stem cells used for grafting,2021-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1525,NCT02444910,Change from baseline of the 2 hour oral glucose tolerance test (OGTT) at day 28.,Change in Insulin Sensitivity Based on Euglycemic Clamp Study,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1526,NCT02998944,Obesty,,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
1527,NCT06105931,Change in triglycerides from baseline to 1 year,,2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE1'],
1528,NCT01634464,"Long-term evidence of early human programming of obesity measured biochemical perinatal biomarkers, and the offspring growth and development.",,2007-03,UNKNOWN,OBSERVATIONAL,['NA'],
1529,NCT01725815,Health Related Quality of Life (HRQOL),Medication Adherence,2011-06,COMPLETED,INTERVENTIONAL,['NA'],
1530,NCT05002933,Mean change in HbA1c from baseline to week 24,Mean change in body weight from baseline to Week 12 and Week 24,2021-05-20,COMPLETED,INTERVENTIONAL,['PHASE4'],
1531,NCT03323294,Fatty Acid Oxidation in Type 2 Diabetes with metformin,,2017-10-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1532,NCT01454284,Hemoglobin A1c (HbA1c),Rapid Assessment of Physical Activity (RAPA),2012-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1533,NCT00145925,Composite of new or substantially worsening nephropathy or microvascular eye disease.,"Includes cerebrovascular disease, coronary heart disease, heart failure, peripheral vascular disease, cardiovascular and all-cause mortality, microalbuminuria, visual deterioration, new or worsening nephropathy, cognitive function, and dementia.",2001-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1534,NCT00732511,"Effect of Coreg CR compared to Toprol XL on endothelial function, vascular compliance, and parameters of oxidative stress from time of randomization to study drug termination",,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1535,NCT05087225,measurement of blood glucose one month after first or second shot of mRNA based covid-19 vaccines,enhancements of hypoglycemic effects of metformin and insulin by PEG,2021-11-11,UNKNOWN,OBSERVATIONAL,['NA'],
1536,NCT06248775,Acceptability of the VITAAAL intervention,Morning void urine,2023-11-16,RECRUITING,INTERVENTIONAL,['NA'],
1537,NCT03815487,Reduction of Sensor Glucose,,2018-11-19,COMPLETED,INTERVENTIONAL,['NA'],
1538,NCT05893797,Difference in the Average Number of Missed Bolus Doses (MBDs),Change from Baseline (Run in Week 0) in Health Care Provider (HCP) Questionnaires,2023-10-05,RECRUITING,INTERVENTIONAL,['NA'],
1539,NCT05081011,Attitudes Toward Medication Adherence,Glycemic Improvement,2021-03-24,COMPLETED,INTERVENTIONAL,['NA'],
1540,NCT01149421,Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP),Measurement of LY2189265 Drug Concentration for Pharmacokinetics - Area Under the Concentration Time Curve (AUC),2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
1541,NCT01752803,Hb A1c,inflammatory markers,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],Lipoproteins
1542,NCT01392560,Change in Glomerular Filtration Rate (GFR) After 8 Weeks of Treatment With Empagliflozin Under Controlled Conditions of Euglycaemia and Hyperglycaemia,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
1543,NCT03387826,Platelet reactivity measured in P2Y12 reaction units (PRU) at the end of the 2 study periods,"VerifyNow P2Y12 assay % inhibition, using the TRAP-induced response at the end of the 2 study periods",2018-01-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
1544,NCT02061488,"Assessment of time spent in target range (glycemia between 70 and 145 mg/dl) and in hypoglycemia (glycemia <70 mg/dl), during the night (11 PM to 8 AM)",Assessment of glucose values during the night (glycemia and interstitial glucose values),2014-03,COMPLETED,INTERVENTIONAL,['NA'],
1545,NCT01803828,Change from Baseline in Left Ventricular torsion (°) at 5 months,Effects of PDE5i on Body composition,2014-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
1546,NCT01811849,Time to 1/2 maximal insulin concentration,AUC 0-30 and AUC 0-60,2012-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1547,NCT00736515,"Decreasing value of FPG and HbA1c, dosage of insulin and control rate of FPG",Weight change,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
1548,NCT01909687,Analysis of system accuracy,,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
1549,NCT03560271,Change in Glycosylated Hemoglobin (HbA1c) from Baseline at Week 24,Proportion of subjects with decrease in HbA1c of ≥ 1.0% from Baseline at Week 24,2018-06-18,COMPLETED,INTERVENTIONAL,['PHASE2'],
1550,NCT03761134,Change in hemoglobin A1c (HbA1c),Adverse events,2018-11-30,TERMINATED,INTERVENTIONAL,['PHASE3'],
1551,NCT03851848,Talocrural joint dorsiflexion ROM will be measured using a universal goniometer,Foot plantar pressure distribution (FPP) will be measured using Platform Pedography system,2019-03-03,UNKNOWN,INTERVENTIONAL,['NA'],
1552,NCT03654313,Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability of MEDI6570,Immunogenicity rate,2018-09-28,COMPLETED,INTERVENTIONAL,['PHASE1'],
1553,NCT05882071,"Proportion of patients with a history of cardio-vascular events including heart failure hospitalizations and lower limb amputation, renal events, ketoacidosis, Fournier's gangrene over the two years before the index date (initiation of SGLT2i)",Time from drug initiation to death all cause,2023-11-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1554,NCT02587780,Blood glucose response,Body fat percentage,2015-11,UNKNOWN,OBSERVATIONAL,['NA'],
1555,NCT00960882,DMMET-01 Plasmatic concentration,glycated hemoglobin,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
1556,NCT02549495,Systolic blood pressure,Disease control,2013-03,COMPLETED,OBSERVATIONAL,['NA'],
1557,NCT01334229,Measurement of Apolipoprotein B48 and Apolipoprotein B100 Production Rates With Stable Isotope During Postprandial Period,Measurement of Apolipoprotein B48 and Apolipoprotein B100 Fractional Catabolic Rates With Stable Isotope During Postprandial Period,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
1558,NCT00476931,"Total Neuropathy Score (TNS),Evoked nerve conduction velocity (NCV), Quantitative Sensory Testing (QST), %of subjects with conversion of unmeasurable to measurable NCV and NIS-LL",Safety,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
1559,NCT00693511,Insulin sensitivity,Change in visceral abdominal adipose tissue,2007-10,COMPLETED,INTERVENTIONAL,['NA'],
1560,NCT04257877,"Targeted proteomic analysis in children with DT1 (levels of certain plasma proteomics such as sorbitol, fructose, myo-inositol, scyllo-inositol, serine, lysine, tertadecanoic, palmitic, stearic, eicosanoic fatty acids)",Electrophysiological study,2018-11-20,RECRUITING,OBSERVATIONAL,['NA'],
1561,NCT05762653,Degree of impairment of exocrine pancreatic function,Factors associated with pancreatic fibrosis,2022-02-03,RECRUITING,OBSERVATIONAL,['NA'],
1562,NCT03730610,Effects of exercise training - brain inflammation,Effects of exercise training - ectopic fat,2019-01-30,COMPLETED,INTERVENTIONAL,['NA'],
1563,NCT00976937,Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% and at Least 5% Weight Loss From Baseline at Week 24,Percentage of Patients Requiring Rescue Therapy During 24-Week Period,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia
1564,NCT05878444,Presence of our bacteria in feces,Adverse effect,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
1565,NCT04641312,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3457263,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
1566,NCT05053828,"Calculate MedWise Risk Score (TM) of <10, 11-14, 15-19, 20-30, >30 for T2D patients to examine patient risk for adverse drug events.",,2021-09-20,COMPLETED,OBSERVATIONAL,['NA'],
1567,NCT00782366,"Assess accessibility and feasibility, including positive and negative aspects of integrating predictive genomics at the clinic focusing on patients' and physicians' attitudes",Assess effects of predictive genomics on self-reported health behavior and on physician-patient interaction,2008-03,COMPLETED,OBSERVATIONAL,['NA'],
1568,NCT04691219,Effect on glycated hemoglobin (A1C) (efficacy),Self-reported adverse events (safety),2019-05-26,COMPLETED,INTERVENTIONAL,['NA'],
1569,NCT06120881,Feasibility of Higher Metformin Dose measured with the Feasibility of Intervention Measure (FIM),Co-efficient of variation of glucose,2024-04-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
1570,NCT02716519,Target Ulcer Complications,"During the post-acute phase, weekly surgical procedures for target ulcer treatment",2016-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
1571,NCT04291391,Differences between groups in circulating C-reactive protein (CRP) at Week 4,Change from Baseline in Phospholipids Classes Quantifications in Red Blood Cells at Week 4 and Differences Between Groups at Baseline and Week 4.,2019-09-01,COMPLETED,INTERVENTIONAL,['NA'],
1572,NCT00989079,Apparent volume of distribution (Vz/F),Urinary recovery of Ertugliflozin,2009-10-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
1573,NCT01095653,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]),2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1574,NCT03970031,"Change in the weighted average of standardized AST, CK-18, and HbA1c values (standard deviations) from baseline to Week 26","Time to first event of death or adjudicated non-fatal MI or USA hospitalization, adjudicated hospital admission for HF, adjudicated nonfatal ischemic stroke, or liver event in all randomized subjects.",2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
1575,NCT00414999,"Part B: Safety & tolerability of 2 concentrations of TG100801 (ophthalmic examinations, ocular comfort ratings, ocular/systemic adverse events, lab tests) when administered twice a day for 14 days, assessed up to 7-14 days following dosing.",Systemic pharmacokinetics (Part B only),2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1576,NCT01472432,Capillary Density,iNOS,2011-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
1577,NCT02613897,Change in Endogenous Glucose Production (EGP),Change in Free Fatty Acids (FFA),2016-01,COMPLETED,INTERVENTIONAL,['NA'],
1578,NCT04634500,Change from baseline in HbA1c,,2020-11-18,COMPLETED,INTERVENTIONAL,['PHASE3'],
1579,NCT06254014,HbA1c,blood pressure,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
1580,NCT01887431,Change in Glycosylated Hemoglobin (Hba1c),Patients' satisfaction,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
1581,NCT01408888,Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Sitagliptin,Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of LY2189265,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1582,NCT03312439,Non-communicable disease assessed by the Swedish national patient register,,2012-06-01,UNKNOWN,INTERVENTIONAL,['NA'],
1583,NCT03029351,change from baseline in albuminuria levels,Change in Nrf-2/keap-1,2017-01-10,TERMINATED,INTERVENTIONAL,['PHASE4'],
1584,NCT05057065,Efficacy of NAs therapy,Incidence of liver fibrosis and cirrhosis,2021-09-15,UNKNOWN,OBSERVATIONAL,['NA'],
1585,NCT01439672,Insulin Sensitivity,,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
1586,NCT02523222,Treatment failure of at-risk infants,,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
1587,NCT02589639,Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 16 Weeks of Treatment.,Percentage of Patients With Investigator Defined Drug-Related Adverse Events (AEs),2015-10-28,COMPLETED,INTERVENTIONAL,['PHASE4'],
1588,NCT03485092,left ventricular global longitudinal strain (GLS),Intensification of diuretic therapy,2018-03-16,COMPLETED,INTERVENTIONAL,['PHASE4'],DNA and epigenetics
1589,NCT04053712,Number of carbohydrate interventions to treat hypoglycemia,Mean Borg scale level during exercise (RANGE:0-10),2019-07-16,COMPLETED,INTERVENTIONAL,['PHASE4'],
1590,NCT00823940,"Pharmacokinetic parameters: AUC, Cmax, Tmax, t1/2, tlag, Cl/F, and V/F","Pharmacodynamic parameters may include change from baseline in glucose, insulin, C-peptide and AUC following administration of IV glucagon in a standardized GC test with and without prior administration of GSK1362885",2009-01-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
1591,NCT02942069,Blood glucose response measured with CGM,,2016-12,COMPLETED,OBSERVATIONAL,['NA'],
1592,NCT05546138,Progression and regression of neuropathy,Correlation between central and peripheral measurements,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],fMRI as a marker for progression of neuropathy
1593,NCT00740519,Incidence of serious adverse drug reactions including major hypoglycaemic events,HCP time used on titration training,2008-09,COMPLETED,OBSERVATIONAL,['NA'],
1594,NCT00308386,"% of patients at goal for all three parameters (HbA1C <7, BP <130/80, LDL <100)",Physician satisfaction - survey filled out by physician,2006-08-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1595,NCT05516966,Incidence of Adverse Events (Safety and Tolerability),Immunogenicity: anti-HRS9531 antibody,2022-10-12,RECRUITING,INTERVENTIONAL,['PHASE1'],
1596,NCT00306436,composite criteria reflecting a good glycemic and arterial pressure status. Success defined by all measurements of HbA1c < 6.5% and of systolic (diastolic) pressure <=135 (85) mmHg if proteinuria is < 1g/24h or <= 125 (75) if proteinuria is => 1g/24h,,2006-05,UNKNOWN,INTERVENTIONAL,['NA'],
1597,NCT04831697,Change in Glycemic Control from Baseline to 6 months,Change in Health Related Quality of Life from Baseline to 6 months,2021-12-14,RECRUITING,INTERVENTIONAL,['NA'],
1598,NCT01888796,Change in left ventricular diastolic function,Change in serum NT-pro BNP levels,2013-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
1599,NCT01427699,Safety and Tolerability,Preliminary Efficacy,2011-06-30,COMPLETED,INTERVENTIONAL,['PHASE2'],
1600,NCT05443334,Change in HbA1c,"DTSQs, change in absolute treatment satisfaction",2020-11-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1601,NCT02500186,Change in blood glucose level using CGM,Adverse events,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
1602,NCT04556760,Change in glucose AUC(0-4) versus baseline compared to prednisolone following a standardised MMTT,Safety and tolerability of AZD9567 by assessing the number of participants with adverse events,2020-11-26,COMPLETED,INTERVENTIONAL,['PHASE2'],
1603,NCT03350191,Glucagon receptor occupancy,Change lipid biomarkers,2017-12-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
1604,NCT00784966,The functional capability of the islet allograft to normalize glucose metabolism in the absence of insulin therapy.,Reduction in insulin requirements in those patients who do not achieve insulin independence with improved metabolic control.,2011-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1605,NCT04055480,Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on subcutaneous glucose monitoring (CGM).,"Total, basal and bolus insulin dose",2019-08-10,COMPLETED,INTERVENTIONAL,['NA'],Utility evaluation is the frequency and duration of use of the closed-loop system at home.
1606,NCT02302599,The efficacy of umbilical cord mesenchymal stem cells in Chinese adults with T2D,safety parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
1607,NCT02298556,Absolute change in systolic blood pressure,Blood pressure variability (daily or hourly) in home blood pressure measurement,2014-10,COMPLETED,OBSERVATIONAL,['NA'],
1608,NCT01403831,Hemoglobin A1C at 6 months,Diabetes knowledge,2011-07,COMPLETED,INTERVENTIONAL,['NA'],
1609,NCT02745613,Insulin sensitivity,Myokine concentrations,2016-04,COMPLETED,INTERVENTIONAL,['NA'],
1610,NCT01326598,The primary objective is to compare change of average glycemic control as measured by A1C from baseline to the end of V-Go use for the whole cohort as well as each of the five categories of baseline treatment.,To describe changes in participants' weight from the beginning to the end of the study.,2012-01,COMPLETED,OBSERVATIONAL,['NA'],
1611,NCT01115205,Change in haemoglobin A1c (HbA1c) levels,Compliance with walking sessions,2006-03,COMPLETED,INTERVENTIONAL,['NA'],
1612,NCT03294915,Insulin sensitivity,Glycemic control,2018-10,UNKNOWN,INTERVENTIONAL,['NA'],
1613,NCT02801448,Delta-HbA1c,Delta-fasting blood glucose,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
1614,NCT03213093,the rate of incidence of diabetic foot ulcer,Neurovascular response to pressure,2017-12-01,RECRUITING,INTERVENTIONAL,['NA'],
1615,NCT03848533,Nuclear anomalies frequency,Serum Lactate,2019-08-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],Treatment attachment
1616,NCT01959984,The c-peptide level.,"The plasma glucose, insulin, c-peptide and relevant incretin hormones level during ""75g Oral Glucose Tolerance Test"", ""100g Standard Noodles Tolerance Test"" and ""100g Steamed Bread Tolerance Test"".",2013-01,UNKNOWN,INTERVENTIONAL,['NA'],Safety
1617,NCT00576277,Pharmacodynamic profile,Correlation between plasma concentrations of AV411 and pain intensity assessments,2006-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1618,NCT05654805,change in insulin resistance (Matsuda),change in IGF-1 and its binding proteins,2022-12-15,RECRUITING,INTERVENTIONAL,['NA'],change in faecal excretion of BCAA metabolites
1619,NCT02510664,Acceptability: Number of Participants That Felt the Intervention Was Well-Received,"Provider-family Relationship, Provider-report",2014-07,COMPLETED,INTERVENTIONAL,['NA'],
1620,NCT01289587,Aerobic fitness,Adherence/Attendance: Number of physical activity sessions attended,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
1621,NCT03603990,Visual acuity,,2018-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],
1622,NCT00933998,Epidermal Nerve Density Count,,2006-06,COMPLETED,INTERVENTIONAL,['NA'],
1623,NCT01374854,c-peptide area under the curve during OGTT,insulin area under the curve during OGTT,2009-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1624,NCT04428606,Blood glucose effects of dietary supplement: Metabolic Rheostat vs. Butyrate Ultra,Impact of Metabolic Rheostat and Butyrate Ultra on food addiction and cravings,2021-04-01,COMPLETED,INTERVENTIONAL,['NA'],
1625,NCT01271517,HbA1c,IGF-I,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1626,NCT02314533,urinary albumin to creatinine ratio (mg/g),,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1627,NCT06084468,Incidence of heart failure,Number of Participants with admission with stroke,2023-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1628,NCT01165190,,,2008-05,UNKNOWN,OBSERVATIONAL,['NA'],
1629,NCT00643110,Completion of 6 subjects.,,2008-04,WITHDRAWN,INTERVENTIONAL,['NA'],
1630,NCT02029924,Area under the curve (AUC),"Safety and Tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters",2013-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
1631,NCT04285983,Percentage of Participants who had One or More Adverse Reactions,,2020-03-01,COMPLETED,OBSERVATIONAL,['NA'],
1632,NCT05448105,User Experience - Acceptance,Change in Diabetes Readiness for Change,2022-12-22,COMPLETED,INTERVENTIONAL,['NA'],
1633,NCT02195856,Hepatic perfusion,Plasma incretin concentration,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
1634,NCT02926079,Metabolic flexibility - Mother,Oxygen consumption rates in umbilical cord mesenchymal stem cells,2017-05-23,COMPLETED,OBSERVATIONAL,['NA'],
1635,NCT03742440,Number of Participants With Complete Closure of the Index Ulcer,Total Adverse Events,2018-11-20,COMPLETED,INTERVENTIONAL,['PHASE4'],
1636,NCT02466217,Immune cells phenotyping expressed as the each cell type % within total PBMCs,Characterization specific and common variations in immune cells frequencies between patients - between Disease cohorts,2015-07-29,COMPLETED,OBSERVATIONAL,['NA'],
1637,NCT02252965,Overall Gastrointestinal (GI) Tolerability Assessed as Percentage of Subjects With Gastrointestinal Adverse Events During Treatment Period,Percentage of Subjects Who Are Compliant to Treatment,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
1638,NCT02621489,The degree of non-covered stent struts by Bydureon add on to Insulin over that of Insulin as analyzed by optical coherence tomography (OCT).,"Gene expression (Affymetrix) e.g., transcription factors of sirtuins (SIRT) and nitric oxide synthase (NOS)",2015-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
1639,NCT06277258,Number of Participants with adequate glycaemic control,Maternal satisfaction,2023-01-31,RECRUITING,INTERVENTIONAL,['NA'],
1640,NCT01604213,Reduction in serum levels of Interleukin 6 (IL-6),Improvement in other markers of athero-thrombosis and inflammation:,2012-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
1641,NCT06069518,Average glucose concentration detected in 24-hour periods.,Magnitude and duration of periods1s of hiccups (<70 mg/dl) and hyperglycemia (>180 mg/dl) recorded in 24-hour periods.,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1642,NCT01856790,Peak Post-prandial Venous Glucose Levels,the Incremental Meal-related Glucose Area Under Curve (AUC),2013-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Mean Nocturnal Glucose Levels
1643,NCT06132204,PK parameters of HRS-7535: AUC0-inf,Adverse events,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
1644,NCT00945711,define general characteristics of the diabetes and eating disorder population,,2010-03,COMPLETED,OBSERVATIONAL,['NA'],
1645,NCT01294436,Mean Change in Seated Systolic Blood Pressure,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Mean Change in Body Weight
1646,NCT03607604,Urinary C-peptide Creatinine Ratio (UCPCR),Prevalence of MODY,2015-04-01,UNKNOWN,OBSERVATIONAL,['NA'],
1647,NCT04932928,Change in HbA1c,Change in the Korean Version of Revised Summary of Diabetes Self-Care Activities Questionnaire (SDSCA-K) survey score,2021-03-23,RECRUITING,INTERVENTIONAL,['NA'],Change in CGM glucose variability
1648,NCT05620576,Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS),Change from Baseline on the EuroQol-5D 5 Level Questionnaire (EQ-5D-5L),2022-11-14,COMPLETED,INTERVENTIONAL,['PHASE2'],
1649,NCT02358096,Mean change of log transformed urinary albumin to creatinine ratio (UACR) from baseline to end of treatment,Proportion of subjects with either >30% or >40% or >50% reduction in AER from baseline to end of treatment,2015-03-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
1650,NCT00787605,Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP),Evaluate the Safety and Tolerability,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
1651,NCT02188186,Change of HbA1c,Lipid profile,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4'],Body composition
1652,NCT00145288,,,2003-10,UNKNOWN,OBSERVATIONAL,['NA'],
1653,NCT02573662,Change in insulin sensitivity,Change in insulin sensitivity,2015-04,UNKNOWN,OBSERVATIONAL,['NA'],
1654,NCT03135015,Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours,ISSI-2 Index of Beta-cell Function,2017-04-26,COMPLETED,INTERVENTIONAL,['PHASE1'],Effect of Capsules vs. Tablets
1655,NCT03726008,Changes of biological indicator,Basic information of maternal,2018-01-22,TERMINATED,INTERVENTIONAL,['NA'],
1656,NCT00767741,Insulin blood level with and with out the intervention,,2010-11,COMPLETED,INTERVENTIONAL,['NA'],
1657,NCT00844194,Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 12,Change of Pulse Rate From Baseline at Week 12,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
1658,NCT00376181,Change from Baseline in Glycosylated Hemoglobin.,Change from Baseline in Systolic Blood Pressure,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
1659,NCT01671345,Patients Active Participatory Communication Behaviors,Hemoglobin A1c,2013-11-27,COMPLETED,INTERVENTIONAL,['NA'],
1660,NCT02179281,Significant between-group difference in number of hypoglycemic events,,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
1661,NCT06199440,Primary Outcome,Secondary Outcome,2022-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1662,NCT02917928,Change in Oral Glucose Tolerance Test,Change in general cognitive function,2016-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in body composition
1663,NCT02650726,anti-inflammatory ability of HDL,endothelium-dependent flow-mediated dilatation (FMD),2014-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
1664,NCT03525769,Death,Hepatocellular carcinom,2018-05-05,RECRUITING,OBSERVATIONAL,['NA'],Chronic kidney disease
1665,NCT02040025,Change from baseline in TCOM (Transcutaneous oximetry measurement) values,Change from baseline in hemoglobin A1C laboratory values,2014-04,TERMINATED,OBSERVATIONAL,['NA'],
1666,NCT04932356,HbA1c Result,patient motivation,2021-05-10,RECRUITING,INTERVENTIONAL,['NA'],
1667,NCT01270061,HIV testing rate,Linkage to care,2012-04,WITHDRAWN,INTERVENTIONAL,['NA'],
1668,NCT00951119,The effect of the breathing device on SBP is the main study parameter,Secondary endpoints include diastolic blood pressure (DBP) and quality of life.,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
1669,NCT00911482,Spillover of free fatty acids from chylomicrons,,2008-06,COMPLETED,OBSERVATIONAL,['NA'],
1670,NCT00749190,Change From Baseline in HbA1c After 12 Weeks of Treatment,Trough Concentrations of Empagliflozin in Plasma,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
1671,NCT05354518,Simulation Design Scale,Semi-Structured Focus Group Training Activity Evaluation Form,2022-04-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1672,NCT03217409,Low density lipoprotein cholesterol (LDL-C) (%),Fibroblast Growth Factor 21,2017-08-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
1673,NCT02924064,The Changes in HbA1c at Week 24,The Changes in Fasting Plasma Glucose (FPG) at Week 24,2016-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
1674,NCT02134132,ABI,Quality of life,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1675,NCT02435693,Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded: Fasting blood glucose measurements recorded (mg/dl).Postprandial bloodglucoseRecorded,Quality of Life score,2012-07,COMPLETED,INTERVENTIONAL,['NA'],
1676,NCT00694070,Number of Participants That Could Answer at Least 85% of the Comprehension Questions Correctly (Comprehension of the Program Reports),,2008-07,COMPLETED,OBSERVATIONAL,['NA'],
1677,NCT00198913,weight,psychometrics,2002-06,COMPLETED,INTERVENTIONAL,['NA'],
1678,NCT04514523,Acceptability - Clinicians,Feasibility 3,2020-04-28,COMPLETED,INTERVENTIONAL,['NA'],
1679,NCT01675271,VO2max,mental health,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
1680,NCT02131948,Endogenous glucose production,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1681,NCT00001963,,,1999-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
1682,NCT01869933,Ocular Safety and Tolerability,Systemic Safety and Tolerability,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
1683,NCT01004757,myocardial diastolic function,"triglycerides, insulin resistance",2008-02,UNKNOWN,INTERVENTIONAL,['NA'],
1684,NCT01244971,Glycemic control,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1685,NCT00660998,Sexual Encounter Profile Question 3,Safety and Tolerability,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
1686,NCT01088165,The influence of adalimumab treatment in comparison to treatment with fumaric acid esters on the functional integrity of the endothelium will be monitored by flow mediated dilatation (FMD),Influence of adalimumab in comparison to fumaric acid esters on biochemical cardiovascular and metabolic risk factors,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1687,NCT00338104,Percentage of Blood Glucose Values Between 80 - 140,Percentage of Glucose Levels > 180 mg/dL,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
1688,NCT01156974,change in number of care goals met,Kinds of patients who benefit from working with a care guide,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
1689,NCT00979394,Evaluate characteristics or co morbidities being existent for patient with T2D at GP,,2009-10,TERMINATED,OBSERVATIONAL,['NA'],
1690,NCT04581421,Liverfat,Insulin clearance determined during steady state insulin infusion,2020-12-03,COMPLETED,INTERVENTIONAL,['NA'],
1691,NCT05396079,Assessment of Flow-Mediated Dilatation,,2023-03-28,COMPLETED,INTERVENTIONAL,['NA'],
1692,NCT00841919,Pre and post- prandial glucose levels,High excursions of blood sugars (>300 mg/dl).,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
1693,NCT02355145,Change in the frequency of usage by physicians of the main criteria for selecting the add-on therapy in patients with inadequately metformin-controlled type 2 diabetes,Number of years until starting the add-on therapies after diagnosis,2015-04-02,COMPLETED,OBSERVATIONAL,['NA'],
1694,NCT03993145,Adherence,Changes in HbA1c,2020-02-07,COMPLETED,INTERVENTIONAL,['NA'],Participant satisfaction
1695,NCT04253613,IL-10 level in GCF,,2013-01-15,COMPLETED,OBSERVATIONAL,['NA'],
1696,NCT05526157,Descriptive summary of patient comedications,Descriptive summary of temporal changes in the baseline characteristics of medication-specific cohorts,2022-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1697,NCT03960255,Proportion (%) of patients with complete wound healing at 24 weeks,Proportion of patients who Die,2021-02-20,RECRUITING,OBSERVATIONAL,['NA'],
1698,NCT00102388,Change from baseline in HbA1c at 104 weeks,Patients with reduction in HbA1x >/= 0.5% after 104 weeks,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1699,NCT00707668,The incidence of diabetes,Insulin sensitivity and resistance of Korean subjects,2007-05,UNKNOWN,OBSERVATIONAL,['NA'],
1700,NCT04847219,TIme in range,calorie intake,2019-10-09,COMPLETED,INTERVENTIONAL,['NA'],
1701,NCT02304718,the risk of gestational diabetes mellitus,pregnancy outcome,2014-12,COMPLETED,INTERVENTIONAL,['NA'],
1702,NCT02457858,"Islet yield using BMX-010, compared to current standard islet isolation data",AE/SAE morbidity within 1 month post-transplant,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1703,NCT01715818,"Time to first occurrence of any component of the composite event (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke) as adjudicated by the Clinical Events Committee (CEC)","Time to first occurrence of a composite with components as adjudicated by the CEC: all-cause mortality, non-fatal MI and non-fatal stroke (in each of the subgroups with or without evidence of T2D at baseline)",2012-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
1704,NCT05887895,Area under the Glucose Infusion Rate (GIR) - time curve (Only for HR20014 and INS062）,Incidence and severity of adverse events (AEs),2023-05-23,COMPLETED,INTERVENTIONAL,['PHASE1'],
1705,NCT03187145,Number of patients with full stomach,the mean gastric emptying time of clear liquid and light meal,2017-06-15,UNKNOWN,OBSERVATIONAL,['NA'],Correlation of diabetes mellitus complications with delayed stomach empty
1706,NCT01269034,The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.,"Postprandial Glucose Excursions, Glucagon Concentrations and Gastric Emptying in Normal Healthy Controls.",2010-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
1707,NCT05975528,Changes of Cellular senescence markers,Changes of body composition using Inbody (cm2),2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
1708,NCT04949568,Glucose Variability data from continuous glucose monitor (CGM) will be downloaded directly from participants provided (blinded) FreeStyle Libre Pro,"Diabetes Distress Scale (DDS) (17-item), using Numerical Rating Scale: 0-6",2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1709,NCT04534894,fluorescence characteristics of NAD(P)H in venous blood by FLIM can assist early diagnosis of diabetic cardiomyopathy,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],
1710,NCT02638246,Percentage of days conducted at least 4 tests per day.,Feasibility,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
1711,NCT02546401,Area Under Curve (AUC) of glycemia,Area Under Curve (AUC) during 4H after a high-fat meal,2015-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
1712,NCT04266171,Change in HbA1c from baseline,Compliance/Satisfaction Questionnaire,2020-01-16,UNKNOWN,INTERVENTIONAL,['NA'],
1713,NCT00634608,health information experiences of the patient,clinician feedback on the health information prescription process,2008-02,COMPLETED,INTERVENTIONAL,['NA'],
1714,NCT04853810,Percentage of skin intolerance to adhesives in diabetic patients,Evolution of lesions,2021-05-17,COMPLETED,OBSERVATIONAL,['NA'],
1715,NCT05058690,Number of participants identified with pre-diabetes/type 2 diabetes mellitus when fasting blood sample test results are compared against FatHealth algorithm results,Number of participants identified with pre-diabetes/type 2 diabetes mellitus when oral glucose tolerance test results are compared against FatHealth algorithm results,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1716,NCT05762120,Weight Loss,,2023-02-03,RECRUITING,INTERVENTIONAL,['NA'],
1717,NCT05624762,pain score,Neuropathy Deficit Score (NDS),2022-07-07,RECRUITING,INTERVENTIONAL,['NA'],The sensory nerve conduction velocity (SNCS)
1718,NCT03604419,The change from baseline value of HbA1c will be compared between treatments,"The change from baseline value of Fasting Plasma Glucose at Weeks 2, 4, 8, and 12",2018-06-13,COMPLETED,INTERVENTIONAL,['PHASE2'],
1719,NCT05000762,Platelet aggregation,,2021-06-01,WITHDRAWN,OBSERVATIONAL,['NA'],
1720,NCT04475380,Target lesion failure (TLF) at 2-year follow up in all-comers,Clinically indicated target lesion revascularization,2018-09-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1721,NCT04765631,"The main outcome is the comparison of total volumetric bone mineral density (vBMD) at the tibia and distal radius, in type 2 diabetics compared to non-diabetic subjects.",,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],
1722,NCT00877890,Change in HbA1c From Baseline to Week 24,Assessment on Event Rate of Treatment-emergent Minor Hypoglycemic Events,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
1723,NCT02589626,Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment,Change From Baseline in HbA1c After 52 Weeks of Treatment,2015-10-29,COMPLETED,INTERVENTIONAL,['PHASE4'],
1724,NCT06011512,"Proportion of participants developing diabetes mellitus during the study period, measured in changes of HbA1c.",Duration and cumulative glucocorticoid dosage,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],
1725,NCT00121355,,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
1726,NCT02603510,Frequency of infusion set occlusions,Number of adverse events,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1727,NCT02307110,prevalence (percentages) of the stages of diabetic retinopathy (DR),mean NEI-VFQ 25 score,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
1728,NCT04617405,"Association between the level, content and bioactivity of exosomes in serum and plasma Versus Insulin sensitivity at five times during pregnancy.",Association between the body weight Versus Insulin sensitivity at five times during pregnancy.,2021-01-11,RECRUITING,OBSERVATIONAL,['NA'],
1729,NCT02275091,small LDL particles,,2014-10,UNKNOWN,OBSERVATIONAL,['NA'],
1730,NCT02360774,Change in Body Weight,Change in Glycemic Control,2015-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
1731,NCT01474772,DPN Pain on Walking Based on a 11-point NRS of Each Treatment Period (Week 6 of Each Treatment Period),Euro QoL-5 Dimensions (EQ-5D) - Health State Profile Utility Scores at the End of Each Treatment Period (Week 6 of Each Treatment Period),2011-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1732,NCT00082407,Change in Glcosylated Hemoglobin (HbA1c),Change in Rate of Hypoglycemic Events,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
1733,NCT00955903,Change in Abdominal Fat Mass,Weight Change/Maintenance,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1734,NCT03362554,Change in insulin sensitivity,Body mass,2018-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1735,NCT05813652,"Medications (appropriateness, comprehensiveness)",,2022-10-05,RECRUITING,OBSERVATIONAL,['NA'],
1736,NCT04952948,Change in blood pressure in type-2 diabetes,,2016-08-23,COMPLETED,INTERVENTIONAL,['NA'],
1737,NCT02312843,Change in cognitive performance from baseline following 6 month of high or low intensity exercise regimen,Change from baseline in blood sugar concentration and cerebrospinal fluid glucose measures during an oral glucose tolerance test following 6 months of high or low intensity exercise,2013-03,COMPLETED,INTERVENTIONAL,['NA'],Change from baseline in brain network connectivity using brain imaging
1738,NCT00417729,Oxidative stress,Adiponectin,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1739,NCT04232995,Berg Balance Scale,,2019-03-12,COMPLETED,INTERVENTIONAL,['NA'],
1740,NCT03390179,glucose concentration,glucose concentraion,2017-09-04,COMPLETED,OBSERVATIONAL,['NA'],
1741,NCT00548197,Best Corrected Visual Acuity,Anatomic Status of the Retina,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1742,NCT05369065,Device success,Change of anti-hypertensive medications,2022-01-27,RECRUITING,INTERVENTIONAL,['PHASE1'],
1743,NCT01341795,differences of sitagliptin and metformin trough concentration according to genetic variations of transporters,differences of HbA1c change according to genetic variations of transporters,2011-07,UNKNOWN,OBSERVATIONAL,['NA'],
1744,NCT01022762,Change in Glycosylated Haemoglobin (HbA1c),Change in Body Weight,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
1745,NCT03232294,The relationship between fetal abdominal wall thickness and macrosomia,,2016-04-01,COMPLETED,OBSERVATIONAL,['NA'],
1746,NCT05404178,Diabetic Foot Self-Care Questionnaire,Foot Care Behavior Scale,2022-06-10,COMPLETED,OBSERVATIONAL,['NA'],
1747,NCT00539409,"Monitor and assess whether Pulsatile Intravenous Insulin Therapy can effect Metabolic Integrity in patients with Diabetes Mellitus. Monitor results of QOL questionnaires, Hgb A1C levels, medications to see if patients complications improve",,2006-11,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1748,NCT01443143,Percent of time in euglycemic range,Percent of time in hyperglycemic range,2010-12,UNKNOWN,INTERVENTIONAL,['NA'],
1749,NCT03638102,Sleep duration,Depressive symptoms,2019-02-01,COMPLETED,INTERVENTIONAL,['NA'],
1750,NCT03147677,Changes in 24h urinary protein quantity by comparing visits at week 20 with the baseline,Changes in urinary albumin / creatinine (UACR) of morning urine by comparing visits at week 20 with the baseline,2016-07-28,COMPLETED,INTERVENTIONAL,['PHASE4'],Incidence of all adverse events (AEs) and serious adverse events (SAEs)
1751,NCT00754689,Change from baseline in A1C,Percent change from baseline in HDL-C,2008-09,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
1752,NCT03374462,Improvement in A1C Levels,Acceptability of home-based telemedicine,2017-11-27,COMPLETED,INTERVENTIONAL,['NA'],
1753,NCT01319357,effect of saxagliptin compared to placebo on endothelial and vascular function of the retinal circulation,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1754,NCT01581736,insulin sensitivity,acetylation of mitochondrial adenine nucleotide translocase,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1'],
1755,NCT01151293,,,2009-07,COMPLETED,OBSERVATIONAL,['NA'],
1756,NCT05752929,Number of paticipants with Glicemic control,Number of participants with hypoglycemia,2016-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1757,NCT00469339,"Examine whether a family-centered feedback approach, as compared to an individual-focused approach, encourages communications regarding family risk and the development of strategies to adopt health promoting behaviors within the household.",,2007-04-27,COMPLETED,OBSERVATIONAL,['NA'],
1758,NCT05608265,Successful performance of the real-time eye tracking function by post-image processing,Image Quality as assessed by user assessment of image quality parameters,2022-08-31,COMPLETED,INTERVENTIONAL,['NA'],
1759,NCT00872846,Evaluation of the of device and/or procedure related adverse events,Significant decrease in the HbA1c values from baseline,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
1760,NCT00567489,Change From the Baseline Value in HbA1c at Month 3 and 6,Change From Baseline of Left Ventricular (LV) Ejection Fraction as Determined by MRI at Month 6,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1761,NCT02628301,Microvascular Insulin Sensitivity,Whole Body Insulin Sensitivity,2015-04,COMPLETED,INTERVENTIONAL,['NA'],
1762,NCT04184947,3 point major adverse cardiovascular events (4P-MACE),Revascularization,2014-03-01,COMPLETED,OBSERVATIONAL,['NA'],Occurrence of adverse events
1763,NCT01517568,"Total recovery of tritium, [3H]-liraglutide and metabolites in urine and faeces",Adverse events,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1764,NCT00964587,HbA1C,Barriers to Self-Management,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
1765,NCT00606112,"Safety and Tolerance of a single intravenous dose of trodusquemine (MSI-1436) in obese, type 2 diabetics",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
1766,NCT03709966,Physical activity measurements,Motivation and auto-regulation of physical activity,2017-12-07,COMPLETED,INTERVENTIONAL,['NA'],Cardiometabolic measurement: Low-density lipoprotein cholesterol (LDL)
1767,NCT04591925,Days of successful insulin delivery through the SteadiSet™ insulin infusion device versus a commercially available insulin infusion set,,2021-02-05,TERMINATED,INTERVENTIONAL,['NA'],
1768,NCT01360567,Percent change of HOMA insulin resistance and TG,Percent change of HbA1C and Cholesterol,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
1769,NCT02180646,Plasma Glucose Level Post-meal (AUC [0-4]),Post-meal Level of Glucose-dependent Insulinotropic Peptide (GIP) (AUC),2011-12,COMPLETED,INTERVENTIONAL,['NA'],Post-meal Glucagon-like Peptide-1 (GLP-1) Level (AUC )
1770,NCT00741585,"To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk assessment.","To evaluate the impact of changes in ambulatory BP in vascular, metabolic, and renal risk assessment.",2008-09-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1771,NCT02942914,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics: Average Glucose from 8-Point Glucose Profiles in Participants with T2DM treated with Placebo or LY3209590,2016-12-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
1772,NCT04016012,Change in Blood glucose levels,Change of Body Mass Index (BMI),2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1773,NCT01954472,Feasibility measured by recruitment and retention rates,Exercise history,na,WITHDRAWN,INTERVENTIONAL,['NA'],
1774,NCT02461394,Acceptance criteria defined by ISO 15197:2013 (see description),,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
1775,NCT04622371,SF-36,,2020-01-10,COMPLETED,INTERVENTIONAL,['NA'],
1776,NCT03230266,"Collection of catheters for intra-peritoneal insulin infusion from implanted pumps presenting obstructions or not : collection of biological and device samples (blood, catheters, insulin)",Associated conditions related to the patient and to infused insulin,2017-06-02,TERMINATED,INTERVENTIONAL,['NA'],
1777,NCT00662857,Relative Bioavailability of 30 U of TI (TI Inhalation Powder B) Versus 10 U of sc Insulin Lispro,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1778,NCT00349427,glycemic control at treatment 24-week measured by HbA1c (Glycosylated hemoglobin),"glycemic control at treatment 24-week measured by fasting plasma glucose and daily insulin dose, proportion of subjects who reduce total daily insulin dose after treatment of 8, 16, and 24 weeks",2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1779,NCT05022615,"Number of Ungradable ETDRS Images within the 7 standard fields of Clarus, Optos, and Standard 7 Field imaging",Reason Image Quality is compromised per image grader,2021-09-29,COMPLETED,OBSERVATIONAL,['NA'],
1780,NCT04964713,major adverse cardiovascular events,,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1781,NCT04784975,High-resolution peripheral quantitative computed tomography (HRpQCT) strength of cortical and trabecular bone.,Glycemia,2021-04-23,COMPLETED,OBSERVATIONAL,['NA'],
1782,NCT03804879,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),Change From Baseline in Waist-to-hip Ratio,2018-12-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
1783,NCT03914404,Changes of Total Symptom Score(TSS),Changes of EuroQol-5 Dimensions(EQ 5D),2016-01-26,COMPLETED,INTERVENTIONAL,['PHASE4'],
1784,NCT05472441,Change in Hemoglobin A1c,Change in food security assessed using the 18-item U.S. Household Food Security Survey Module,2023-02-06,RECRUITING,INTERVENTIONAL,['NA'],
1785,NCT02290600,"Accuracy of continuous glucose sensor output by individualizing sensor bias in subjects with type 1 diabetes, assessed by quantifying the improvement in CGM accuracy as measured by MARD (mean absolute relative difference).",Continuous Glucose Monitor sensor failure,2015-01,COMPLETED,OBSERVATIONAL,['NA'],
1786,NCT02516657,Mean weekly blood glucose,Total Daily insulin dose,2012-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Amylase level
1787,NCT04943926,Diabetes remission,Changes in quality of life,2022-01-04,RECRUITING,INTERVENTIONAL,['NA'],Changes in appetite/satiety and ketones from baseline
1788,NCT03644199,Glucose levels,Evaluation of gastric emptying,2011-03-30,WITHDRAWN,INTERVENTIONAL,['NA'],
1789,NCT03086330,Change in HbA1c,Change in Fundoscopy,2017-03-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
1790,NCT03929679,Change in Glycated Haemoglobin A1c (HbA1c),Patient completed the study under treatment with semaglutide (yes/no),2019-05-28,COMPLETED,OBSERVATIONAL,['NA'],
1791,NCT00913367,Mean change in HbA1c from baseline to the last visit,Adverse events,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
1792,NCT05651490,Change in HbA1c over 18 months,Cost-effectiveness of PST-D,2020-03-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1793,NCT01240252,Proportion of insulin resistant patients with elevated serine/threonine phosphorylation of IRS-1 in muscle.,Quantitative assay of the ability of insulin to clear glucose from the blood in insulin resistant patients.,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
1794,NCT01658579,Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL]),Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline Up to Week 16,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
1795,NCT05291351,Change in postprandial glycemic response,Treatment palatability,2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],
1796,NCT01394887,presence of inflammation,presence of type 2 diabetes,2002-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1797,NCT02049814,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Change From Baseline in Body Weight Over Time,2014-05-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
1798,NCT04692415,Changes from baseline in arterial stiffness after treatment,Changes from baseline in CRP,2018-12-15,COMPLETED,INTERVENTIONAL,['PHASE4'],
1799,NCT01407289,Mean blood glucose,Number of glucose measurements in hyperglycaemic ranges,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
1800,NCT06151964,Drug accumulation ratio for Cmax of AZD9550 following repeat weekly SC doses,Effect of AZD9550 on amino acid levels in blood versus placebo,2023-09-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1801,NCT02520921,"first main vascular event occurring within the 18 months after randomization among the following: Death (any), Myocardial infarction, Stroke, Urgent coronary revascularization and/or stent thrombosis, Acute arterial thrombotic event","Death, myocardial infarction, stroke, urgent revascularization, stent thrombosis, acute arterial thrombotic event and major bleeding analyzed specifically and separately",2016-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
1802,NCT01740817,Muscle Insulin Sensitivity-M Value,Extracellular Signal-regulated Kinase (ERK) Phosphorylation in Muscle,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
1803,NCT00598793,HbA1c,Insulin dose,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
1804,NCT01213940,Change in Late Outgrowth Endothelial Progenitor Cells,,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
1805,NCT06169033,Area under curve (AUC) of the T2DM remission prediction model after 1 year,Area under curve (AUC) of the T2DM relapse model,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],
1806,NCT01824043,Gain in visual acuity and transparence of vitreous in treated eyes.,,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],Serum glucose levels will be compared with the visual outcomes
1807,NCT06096506,Change in Hemoglobin A1c (HbA1c),Change in Diabetes Management by the Nourishing the Community Through Culinary Medicine survey (NCCM),2023-11-08,RECRUITING,INTERVENTIONAL,['NA'],
1808,NCT03260673,Comparison of the corneal endothelial cell density before-after cataract surgery,Comparison of the central corneal thickness(CCT) before-after cataract surgery,2015-09-01,COMPLETED,OBSERVATIONAL,['NA'],
1809,NCT02985502,Quality of Life Questionnaire,,2016-12,UNKNOWN,OBSERVATIONAL,['NA'],
1810,NCT05018026,Sugar Levels,Overall Diet Quality,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],
1811,NCT00930956,Blood glucose,,2006-05,COMPLETED,INTERVENTIONAL,['NA'],
1812,NCT04616066,The effect of phytoestrogens on HbA1C and fasting blood glucose in patients with type 2 diabetes,Determine whether date phytoestrogens affect insulin resistance,2021-10-10,COMPLETED,INTERVENTIONAL,['NA'],
1813,NCT00604396,HbA1c,Insulin antibodies,2003-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
1814,NCT02173457,Change in HbA1c from baseline after 24 weeks of treatment,Percentage of patients who discontinue the trial due to hyperglycemia,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
1815,NCT02722499,HbA1c,Resource Utilization and Cost,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
1816,NCT06074965,Event rate of lipohypertrophy (LH),Cohort analysis by duration of diabetes,2022-10-05,COMPLETED,INTERVENTIONAL,['NA'],
1817,NCT04219800,Sitting time,Musculoskeletal problems,2020-12-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],General self-efficacy
1818,NCT01219400,Glucagon response to hypoglycemia,Catecholamine response to hypoglycemia,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
1819,NCT04134650,Change from basal fasting and 2 hours glucose levels during the oral glucose tolerance test at 12 months,Change from basal insulin sensitivity at 12 months,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1820,NCT05081817,Difference in glucose measurement,,2019-08-01,COMPLETED,OBSERVATIONAL,['NA'],
1821,NCT01794364,Apparent Volume of Distribution (Vz/F),,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
1822,NCT03599401,Change in Glycosylated Hemoglobin levels,Change in Clinical attachment level,2016-10-15,COMPLETED,INTERVENTIONAL,['NA'],
1823,NCT02098447,change in local blood perfusion index (BPI) related to physiological state (diabetics/healthy),Adverse effects of stimulation,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
1824,NCT02129946,Fasting and postprandial insulin,Satiety-producing effect,2014-01,COMPLETED,INTERVENTIONAL,['NA'],3-Day food records
1825,NCT06151821,Diabetes distress scale,Number of hypoglycemic and hyperglycemic episodes,2023-08-01,COMPLETED,INTERVENTIONAL,['NA'],
1826,NCT00006160,,,na,COMPLETED,INTERVENTIONAL,['NA'],
1827,NCT02912728,Time in glucose range 70-180,Satisfaction Questionnaire,2017-01-30,COMPLETED,INTERVENTIONAL,['NA'],
1828,NCT01956305,determine glycemic response,To assess the effects of repeated doses of DS-7309 on glucagon levels in T2DM subjects,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
1829,NCT03506711,Change in coronary cross sectional area (mm2),,2016-02-01,COMPLETED,INTERVENTIONAL,['NA'],
1830,NCT01574365,Adverse event collection and assessment,Profile of Pharmacokinetics,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2'],
1831,NCT01819272,Change in Fasting Plasma Glucose (mg/dL) at 4 Weeks,Change in HbA1c (%) at 12 Weeks,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
1832,NCT06257966,HbA1c,blood pressure,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
1833,NCT03243058,C-peptide response,C-peptide response,2023-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",HbA1c level
1834,NCT00991380,Physical Activity,,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
1835,NCT02486341,Intraday glycemic variability measured by the average of MAGE index (Mean amplitude of glycemic excursions) everyday of exploitable recording by the participant.,Fragility level (Rockwood criteria),2016-03-31,COMPLETED,INTERVENTIONAL,['NA'],
1836,NCT01765946,Longevity gene expression,Monocyte polarization status,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
1837,NCT05258630,Retention in assessments,Diabetes medication adherence,2022-02-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
1838,NCT03583268,Percent time spent </= 3.9 mmol/L as measured by continuous glucose monitor,Continuous overall net glycemic action (CONGA-mmol/L) as measured by continuous glucose monitor,2013-05,COMPLETED,INTERVENTIONAL,['NA'],Muscle mass as assessed by DEXA
1839,NCT05768945,Time to dementia onset,Time to Alzheimer's disease onset,2022-11-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1840,NCT02333864,Accuracy Verification of the POGO® BGMS: Minimum outcome of 95% of results within 20% of reference measurement.,,2014-12,COMPLETED,OBSERVATIONAL,['NA'],
1841,NCT00653510,Metabolic changes,Left ventricular function,2008-03,COMPLETED,INTERVENTIONAL,['NA'],
1842,NCT01824862,foveal sensitivity,Retinal thickness,2013-01,COMPLETED,OBSERVATIONAL,['NA'],
1843,NCT00228891,Measure the stabilization or reduction of the decline of diabetic neuropathy by pt questionnaires and diagnostic tests,,2004-02,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1844,NCT01781533,the percentage of glucose values obtained every 15 min in predefined glucose ranges,Accuracy of the glucose monitoring unit,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
1845,NCT02779556,Hemoglobin A1C (HbA1C),Diabetes Knowledge (0-13),2016-11-07,COMPLETED,INTERVENTIONAL,['NA'],
1846,NCT00546325,"Change in physical examinations, vital signs, laboratory parameters, adverse events","Change in adiponectin, fasting insulin, Blood Pressure, concomitant medications, health resource use, CRP (C Reactive Protein), ALT (Alanine Aminotransferase), albumin/creatinine ratio",2007-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1847,NCT01991548,User Acceptance of the New MiniMed 640G Insulin Pump and Guardian Link Transmitter,,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
1848,NCT03283566,Quotient of Stimulated C-peptide/Glucose Level Normalized for IEQ/Kg Infused in Response to MMTT,Ratio of C-peptide AUC to Glucose AUC in Response to MMTT Adjusted for Infused Islet Cell Mass,2017-10-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
1849,NCT05352022,Glycemic control (HbA1c),Quality of life as measured by the Short Form Health Survey (SF-12),2022-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1850,NCT01295385,"To quantify the myocardial blood flow at rest and after ""cold pressor test"" in a population of healthy volunteers",To estimate the metabolic and structural abnormalities in this population,2011-02,UNKNOWN,INTERVENTIONAL,['NA'],
1851,NCT05375695,"Participants' experiences, needs and barriers",Sexual functioning,2022-04-01,COMPLETED,INTERVENTIONAL,['NA'],
1852,NCT05408416,central retinal thickness,reoperation,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],
1853,NCT02729246,Change from Baseline of beta cell function,Change from Baseline of beta cell function,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
1854,NCT01052272,Peak Early Filling Rate Normalized to EDV,,2005-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1855,NCT01159184,,,2010-01,COMPLETED,OBSERVATIONAL,['NA'],
1856,NCT02928939,Patients with diabetes mellitus and systemic corticosteroids,,2016-10,COMPLETED,OBSERVATIONAL,['NA'],
1857,NCT04076384,Patient Activation Measure (PAM-13),The Finnish Diabetes Risc Calculator (FINDRISC),2019-08-19,COMPLETED,INTERVENTIONAL,['NA'],
1858,NCT00703599,Lowering of insulin-dependence and anti-hyperglycemic medication dosages,"No detrimental change seen in kidney function tests, liver function tests and other haematological parameters.",2007-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1859,NCT06205030,HOMA-estimated insulin resistance,Inflammatory biomarkers,2024-06-14,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],lipid profile
1860,NCT00101764,,,2005-01-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
1861,NCT06229236,Percent of participants whose Diabetes Technology Utilization Score (DTUS) increases (based on review of last 14 days of CGM and insulin pump data),HbA1c change,2024-02-13,RECRUITING,INTERVENTIONAL,['NA'],Provider reported Feasibility of Intervention Measure (FIM)
1862,NCT01939782,"Metabolic Clock Gene Expression in Peripheral Blood Cells(PBC),",Serum Cortisol,2015-02,UNKNOWN,INTERVENTIONAL,['NA'],
1863,NCT04795271,Change in the maximum plantar pressure (kPa),,2020-11-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
1864,NCT02747108,Weight Change From Baseline to 12 Months,Change in Mental Health,2015-12-02,COMPLETED,INTERVENTIONAL,['NA'],
1865,NCT03582956,Peripheral Sensitivity to High Dose Insulin,,2019-01-01,TERMINATED,INTERVENTIONAL,['NA'],
1866,NCT00491465,fructosamine,3 days CGMS & SBGM profile,2007-07,UNKNOWN,INTERVENTIONAL,['NA'],
1867,NCT05268705,The primary endpoint is the difference between study arms in difference from start to end plasma glucose concentration during 45 min fasted cycling (assessed by YSI (Yellow Spring Instruments 2900 STAT Plus)).,Change in plasma glucose from injection of glucagon to peak plasma glucose assessed by YSI during observation phase 3,2022-02-03,COMPLETED,INTERVENTIONAL,['NA'],
1868,NCT01288898,"Safety and Tolerability assessed by the incidence of adverse events, vital signs, physical examinations, 12-lead ECG and lab-tests",Pharmacodynamics assessed by the ASP1941 glucose concentration changes in blood and urine,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
1869,NCT02748330,P2Y12 reaction unit (PRU),Non-coronary artery bypass graft (CABG) related major or minor or minimal bleeding,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
1870,NCT04273412,incidence of gestational diabetes mellitus,feto-maternal,2018-10-13,COMPLETED,INTERVENTIONAL,['NA'],
1871,NCT04028427,Change in Diabetes Self-Management Questionnaire,Change in HbA1c level,2019-10-14,COMPLETED,INTERVENTIONAL,['NA'],
1872,NCT04053504,Monthly Intervention Calls Completed by Parent Leaders,Change in Degree of Impact of diabetes on the family system,2019-05-04,COMPLETED,INTERVENTIONAL,['NA'],
1873,NCT00000542,,,1993-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
1874,NCT04648618,Cytokines,,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
1875,NCT03569501,neonatal leptin,maternal fasting plasma glucose concentration,2017-08-01,UNKNOWN,INTERVENTIONAL,['NA'],
1876,NCT02126605,Percent agreement between DAD alerts and glucose readings,"Psychosocial variables (quality of life, fear of hypo-/hyperglycemia, diabetes distress, self-efficacy, and DAD experiences)",2014-07,UNKNOWN,OBSERVATIONAL,['NA'],
1877,NCT05483140,Program Effectiveness,Medication Usage use,2022-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Quality of Life (QOL) SF-12
1878,NCT04569721,Number of Procedure Related Complications,Change in Fasting C-peptide Levels,2021-02-19,WITHDRAWN,INTERVENTIONAL,['NA'],
1879,NCT02795052,Change in Neurologic Function,,2016-06,RECRUITING,INTERVENTIONAL,['NA'],
1880,NCT02532088,Blood Glucose Level,Beta Cell Function,2020-05,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1881,NCT04217161,Blood glucose measurement,Hypoglycemia events,2020-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1882,NCT00561132,Changes on insulin sensitivity assessed with a euglycemic-hyperinsulinemic clamp technique,Changes on anthropometrical measures,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
1883,NCT02162550,Change in carotid plaque volume,Change in carotid plaque composition,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1884,NCT03369899,System Related adverse device effects,,2017-12-11,COMPLETED,OBSERVATIONAL,['NA'],
1885,NCT00998335,Hepatic Steatosis,Percent Change From Baseline in Vascular Inflammatory Markers,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
1886,NCT01841073,Glycaemic Control,Food Intake in Gram at 9 Weeks,2011-03,COMPLETED,INTERVENTIONAL,['NA'],Percentage Change in Body Weight
1887,NCT02229487,GLP-1 Levels in Response to Oral Glucose Tolerance Test,,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
1888,NCT00497536,CV SSPIasp,"• Δ SSPIAsp (S.C. /I.V.) • AUC IAsp • Tmax IAsp • Cmax IAsp - Bioequivalence of Iasp under SS (GIR, S-FFA, S-glycerol)",2007-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
1889,NCT00816608,The development of diabetes,DM complication,2006-08,COMPLETED,OBSERVATIONAL,['NA'],
1890,NCT03027219,Flow change,,2017-01-31,COMPLETED,OBSERVATIONAL,['NA'],
1891,NCT04865809,Change in BOP - Bleeding on Probing (percentage),,2021-05-12,COMPLETED,INTERVENTIONAL,['NA'],
1892,NCT01145534,blood glucose,Salivary glucose level,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1893,NCT01021826,Occurrence (and severity) of hyperglycemia following primary hip or knee replacement,Prevalence of glucose metabolism disorders and metabolic syndrome,2009-12,COMPLETED,OBSERVATIONAL,['NA'],
1894,NCT05824572,Patient Activation Measure-Short Form,Patient Satisfaction Questionnaire-18,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],
1895,NCT02344641,The change in plasma NT-proBNP level after using exenatide for 4 weeks,,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],
1896,NCT05260814,changes in HbA1c,cytokine changes,2022-03,UNKNOWN,INTERVENTIONAL,['NA'],
1897,NCT02760017,fasting glucose levels,Plasma endothelin-1 levels,2016-04,COMPLETED,INTERVENTIONAL,['NA'],
1898,NCT05553145,Prevalence of autoimmune antibodies in patients with Type 2 Diabetes,Prevalence of autoimmune antibodies in patients with T2D managed by primary care,2022-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
1899,NCT00641550,"Maternal outcome: preterm labor, weight gain, preeclampsia, gestational diabetes Perinatal outcome: birthweight, Apgar scores, body composition, admission at neonatal intensive care unit","Doppler flow velocimetry indexes: pulsatility, resistance and A/B relation (uterine arteries, fetal middle cerebral artery and umbilical arteries)",2008-04,UNKNOWN,INTERVENTIONAL,['NA'],
1900,NCT03818711,Glycemic control (A1C),Quality of Parental Involvement,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],
1901,NCT00156897,Absolute weight loss compared to baseline,Changes in other safety parameters,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
1902,NCT01935349,The proportion of HT/ DM patients who have achieved the target blood pressure.,"GOPC consultation, SOPC, A&E and hospital attendance rates in the past 12 months.",2010-09,COMPLETED,OBSERVATIONAL,['NA'],
1903,NCT04723550,Glucose control (HbA1c levels),Change in biological parameter: e-GFR,2021-01-05,UNKNOWN,INTERVENTIONAL,['NA'],Cost effectiveness
1904,NCT02933164,CGM Relative Difference to Laboratory Reference reported as MARD,,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],
1905,NCT03235362,"YHR1705, YHR1706 Css, max",,2017-08-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
1906,NCT00365781,"Evaluate and examine the effect of treatment on laboratory results, vital signs, and adverse events.",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
1907,NCT04194450,Plasma Glucose,Monocyte Histone Acetylation,2020-01-15,COMPLETED,INTERVENTIONAL,['NA'],
1908,NCT02769728,Changes in insulin sensitivity,Changes in beta-cell function,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
1909,NCT01500005,arterial stiffness,blood pressure holter,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
1910,NCT00813995,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,2008-12-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
1911,NCT04935671,Depression,Tryptophan,2020-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1912,NCT01901757,"Metformin, rosuvastatin Cmax, AUClast","Metformin, rosuvastatin Vd/F",2013-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
1913,NCT00578604,diffuse near infrared spectroscopy measurements,,2007-09,COMPLETED,OBSERVATIONAL,['NA'],
1914,NCT02561078,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline in Body Weight,2015-10-20,COMPLETED,INTERVENTIONAL,['PHASE3'],
1915,NCT01346046,Continuing validation of SCOUT DS algorithm,,2011-05,COMPLETED,OBSERVATIONAL,['NA'],
1916,NCT04348565,Self-efficacy level in diabetes management,Quality of life Measurement,2019-11-01,UNKNOWN,INTERVENTIONAL,['NA'],
1917,NCT00908271,Absolute oral bioavailability,Electrocardiograms (ECGs),2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
1918,NCT04170998,Change from baseline in HbA1c (%) After 24 weeks,Change from baseline in 7-point SMBG After 24 weeks,2020-01-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
1919,NCT00339313,,,2000-01-12,COMPLETED,OBSERVATIONAL,['NA'],
1920,NCT01099618,Length of Remission,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
1921,NCT03209258,Shift ('improvement') in functional recovery (death or disability) defined by the modified Rankin Scale (mRS),Residence,2017-12-12,COMPLETED,INTERVENTIONAL,['NA'],
1922,NCT00419497,area under the curve for insulin (AUC Insulin0-120) at the oral glucose tolerance test,120-min plasma insulin,2003-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1923,NCT02366598,Blood pressure,Energy/fatigue,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
1924,NCT05480657,Efficacy - Insulin independence,Efficacy - Durability of insulin independence - long term,2022-09-30,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
1925,NCT04170543,Urine albumin:creatinine ratio (UACR),Safety and tolerability by clinical laboratory evaluations,2019-11-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety and tolerability by assessment of vital signs
1926,NCT05696964,Changes in perceptions of the patient-clinician relationship by patients of participating residents.,"Changes in the ""spirit of motivational interviewing"" rating given to the resident by the facilitator in role plays in motivational interviewing practice.",2024-02-01,WITHDRAWN,INTERVENTIONAL,['NA'],
1927,NCT05951621,2-h postprandial plasma glucose,"Self-Rating Anxiety Scale, SAS",2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Maternal and infant complications during childbirth
1928,NCT00791661,Number of Participants Who Discontinued Treatment Due to an Adverse Event,24-hour Weighted Mean Glucose (WMG) Concentration,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
1929,NCT02954692,Mean change from baseline in HbA1c,Mean change from baseline in Diabetes Treatment Satisfaction Questionnaire (DTSO) scores,2016-11-30,COMPLETED,INTERVENTIONAL,['PHASE4'],
1930,NCT01512108,Incidence of Treatment Emergent Adverse Events (AEs),Change in FPG From Baseline to Week 52,2012-01-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
1931,NCT01115257,,,2001-10,COMPLETED,INTERVENTIONAL,['NA'],
1932,NCT04040426,Percentage of index ulcers healed at 12 weeks,"Changes in peripheral neuropathy using Semmes Weinstein Monofilament ""10""point",2019-08-06,COMPLETED,INTERVENTIONAL,['NA'],
1933,NCT04256486,"Glycemic Control, Measured by Change in Adjusted Mean HbA1c(%) From Baseline at various time points",,2022-04-21,RECRUITING,INTERVENTIONAL,['NA'],
1934,NCT05770687,Major adverse cardiac and cerebrovascular events,Changes in echocardiograhic parameters,2020-08-01,RECRUITING,OBSERVATIONAL,['NA'],
1935,NCT03567408,activated clotting time(ACT),30-day bleeding events,2018-09-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],
1936,NCT01137058,Target goal of HbA1c (< 7.0%) without hypoglycemia,Body mass index (BMI) changes,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
1937,NCT01144338,Primary Safety Outcome MACE Events,Secondary Efficacy Outcome Hospitalization for HF,2010-06-18,COMPLETED,INTERVENTIONAL,['PHASE3'],
1938,NCT04345120,GIP concentration changes before and after meal.,"Stable Valley concentration (ctrough, SS).",2020-06-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
1939,NCT04711083,correlation between nocturnal oxygen desaturation and glycemic control,,2020-04-20,COMPLETED,OBSERVATIONAL,['NA'],
1940,NCT02344433,Accuracy of family members identified (defined as the agreement of first and second degree relatives identified by both the tool (VICKY or MFHP) and the genetic counselor),Family and provider communication (Communication of family health history with family members and health care providers),2016-11,COMPLETED,INTERVENTIONAL,['NA'],
1941,NCT01767441,change in glucose response (pAUC) to mixed meal test between baseline and 1 month after undergoing bariatric surgery or being put on low calorie diet,changes in active GLP1 systemic bioavailability during a mixed meal test between baseline and 1 or 12 months after undergoing bariatric surgery or being put on low calorie diet.,2013-02,COMPLETED,OBSERVATIONAL,['NA'],change in HbA1c between baseline and 1 or 12 months after undergoing bariatric surgery or being put on low calorie diet.
1942,NCT02236793,Incidence of complete wound closure.,Treatment emergent adverse events.,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
1943,NCT00157508,Cardiac and renal hemodynamics after 4 weeks of treatment,,2003-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
1944,NCT03805633,Change in glucose during oral glucose tolerance test (oGTT),Hemoglobin A1c (HbA1c),2018-02-02,WITHDRAWN,OBSERVATIONAL,['NA'],
1945,NCT01741103,change from baseline in mean glucose concentrations,Change in NFkappaB following meal challenge.,2011-06,WITHDRAWN,INTERVENTIONAL,['NA'],
1946,NCT05115188,Glucose values in the oral glucose tolerance test,Participant preference - qualitative measurement,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
1947,NCT05229718,"Change in diabetes-related distress, measured by Problem Areas in Diabetes (PAID)","Change in alcohol use, measured by Alcohol Use Disorders Identification Test Consumption (AUDIT-C)",2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1948,NCT02852980,Glycemia realized after childbirth,Percentage of women who have pursued the dietary and hygiene rules,2015-07,COMPLETED,OBSERVATIONAL,['NA'],
1949,NCT06155539,Differential metabolites,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
1950,NCT05185518,glucose sensing accuracy,user satisfaction,2025-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
1951,NCT04459936,Responders (Dichotomised: responder/non-responder),Serum Urate,2020-11-24,WITHDRAWN,INTERVENTIONAL,['NA'],Hospitalisation
1952,NCT00965302,Diabetes remission,c-reactive protein,2009-08,TERMINATED,INTERVENTIONAL,['NA'],
1953,NCT01114763,,,2003-06,COMPLETED,OBSERVATIONAL,['NA'],
1954,NCT01846767,Peak Delta over baseline in 13CO2 breath enrichment,Per cent dose recovered,2012-04,COMPLETED,INTERVENTIONAL,['NA'],Diabetes classifications and measures of insulin resistance
1955,NCT00205335,Hemoglobin A1C,Satisfaction with care,2004-01,COMPLETED,INTERVENTIONAL,['NA'],
1956,NCT00971659,the unadjusted 6-hour postprandial blood glucose excursion (AUCBG0-6h) following ingestion of a standardized breakfast,"mean daily blood glucose (BG) from 7-point 24h BG profiles, fasting BG, self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid profiles, HOMA-IR index, hypoglycemic episodes",2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
1957,NCT01267448,"The proportion of responders in each arm. Responder: FBG 70-300 and/or PPBG <400 mg/dl (week1-6), FBG 70-250 and/or PPBG <300 mg/dl (week 7-12) and without metabolic exclusion criteria, repeat ED visits, hospitalization or significant hypoglycemia.",The number of fold increase in beta cell function in the 2 arms.,2014-09-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
1958,NCT01771250,VLDL-TG Clearance Rate,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
1959,NCT01809327,Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26,Number of Participants With Treatment Emergent Adverse Events (AEs),2013-06-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
1960,NCT02758483,Compare the intraday and interday glucose variability effect of sucrose-free with a sucrose-free diet for patients with type 1 diabetes.,"Compare the interday glycemic variability effect of sucrose-free diet and sucrose-added diet, through MODD index, in patients with type 1 diabetes",2017-03-23,COMPLETED,INTERVENTIONAL,['NA'],
1961,NCT01486771,Establish efficacy of intravitreal pegaptanib sodium injections in causing regression of high risk proliferative diabetic retinopathy as compared to panretinal photocoagulation,Establish the efficacy of intravitreal pegaptanib injections in preventing the loss of best corrected visual acuity,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1962,NCT00087516,Change From Baseline in A1C at Week 24,Change From Baseline in 2-hr PMG at Week 104,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
1963,NCT01977495,Enrollment and participation rates,Uptake of Device Usage,2013-12,COMPLETED,INTERVENTIONAL,['NA'],Change in Hemoglobin A1c
1964,NCT00141232,Prop of pats. who achieve measured triglycerides <1.5 mmol/L (<200 mg/dl),Prop of pats who achieve triglycerides <1.5 mmol/L (<200 mg/dl) at 52 weeks.,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
1965,NCT04424238,glycemic qualification rate,pregnancy outcome,2016-03-15,UNKNOWN,INTERVENTIONAL,['NA'],
1966,NCT03420040,Change in fasting blood glucose between baseline to week 4,,2017-11-27,UNKNOWN,INTERVENTIONAL,['NA'],
1967,NCT05967260,Probability of overnight hypoglycemia,Change in weight,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],
1968,NCT03908762,Change in A1C,Rate of Hypoglycemia,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
1969,NCT01621178,Change From Baseline in Hemoglobin A1c (HbA1c),Participants With Events of Allergic/Hypersensitivity Reactions,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
1970,NCT03078764,Diabetes related distress,Fasting blood glucose,2017-06-09,COMPLETED,INTERVENTIONAL,['NA'],Self-efficacy (for nurse)
1971,NCT03681691,Change in Uptake of Glucose and Ketone Bodies in Whole Brain and Alzheimer's Disease-related Regions of Interest.,Change in Short-term Memory and Executive Function Composite Scores.,2019-05-13,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Microbleeds
1972,NCT05349591,Adverse Events,Stimulated C-peptide level,2022-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
1973,NCT01731080,calcification score,site of calcification,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],
1974,NCT04082390,Change in Fasting Blood Glucose (FBG) at approximately 4 weeks of the GFL System Diet with Release supplement versus GFL System Diet with placebo supplement,Change from baseline in Heart Rate between the 2 groups,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],
1975,NCT01984827,ECG Analysis,Proportion of Participants with Adverse Events,2019-02-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
1976,NCT00941369,"Health Assessment, Patient treatment satisfaction and Quality-of-Life",Hypoglycemia assessment,2009-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
1977,NCT04120077,glycosylated hemoglobin (HbA1c) percentage,Color Contrast Threshold Sensitivity (minimal percentage contrast detection for each pre-specified wavelength),2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Macular pigment optical density (MPOD) in relative density units
1978,NCT04055428,Change in energy expenditure after natriuretic peptide augmentation,Impact of Natriuretic Peptide Genotype on Study Endpoints,2020-08-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in Metabolomic Profile
1979,NCT00810420,,,2007-02,COMPLETED,OBSERVATIONAL,['NA'],
1980,NCT00521937,Complete wound closure at week 12,Time to complete wound healing,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
1981,NCT03847116,Light-to-moderate alcohol consumption (LMAC) and risk of prevalent type 2 diabetes mellitus (T2DM),LMAC and incident risk of T2DM,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],
1982,NCT03462420,Change of shoulder performance from baseline to 6 weeks after physiotherapy,Physical activity level,2018-09-03,UNKNOWN,INTERVENTIONAL,['NA'],
1983,NCT03804411,Body mass index,Molecular-genetic markers of endothelial damage,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
1984,NCT03989908,Change in insulin response,Change in satiety rating,2019-01-13,COMPLETED,INTERVENTIONAL,['NA'],
1985,NCT01613716,Visual Acuity,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
1986,NCT03203811,AUC,Insulin,2017-02-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
1987,NCT04496154,Fasting WAT IL-1β secretion,Insulin sensitivity and secretion,2013-09-05,COMPLETED,INTERVENTIONAL,['NA'],Post-hoc analysis of WAT receptors for apoB-lipoproteins and fatty acids
1988,NCT00627445,Change in Glycosylated Haemoglobin A1c (HbA1c),Number of Nocturnal Hypoglycaemic Episodes,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
1989,NCT04664205,Change in Fat Metabolism,Change in Continuous Glucose (Area Under the Curve),2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],
1990,NCT00600262,,,2005-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
1991,NCT05285449,High-sensitivity C-reactive protein,,2022-02-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
1992,NCT05790317,"Presence of post-operative nausea, vomiting and retching",,2022-02-14,COMPLETED,INTERVENTIONAL,['NA'],
1993,NCT00449930,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Vomiting,2007-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
1994,NCT05073068,Nocturnal respiratory exchange ratio,Blood glucose levels following the exercise intervention measured continuously using a continuous glucose monitor device,2022-01-25,RECRUITING,INTERVENTIONAL,['NA'],Feet sensitivity based on a clinical foot assessment
1995,NCT05248776,Efficacy in lowering plasma glucose during the Oral Glucose Tolerance Test (OGTT) after 2 weeks of CPL207280 treatment,CPL207280 concentration immediately prior to dosing (Ctrough),2022-01-21,RECRUITING,INTERVENTIONAL,['PHASE2'],
1996,NCT01846377,Change in fasting insulin from baseline to immediate post intervention (approximately 3 months post baseline assessment) and 2-months post intervention (approximately 5 months post baseline assessment),Change in Fruit and Vegetable Intake,2014-04,COMPLETED,INTERVENTIONAL,['NA'],Change in Moderate to Vigorous Physical Activity
1997,NCT01122316,Health-Related Quality of Life (HRQoL),Creatinine Level as a Measure of Renal Function,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
1998,NCT01984762,Rate of resolution of type 2 diabetes,postoperative complications,2012-09,RECRUITING,INTERVENTIONAL,['NA'],Glycemic control mechanisms
1999,NCT00148538,HbA1c at the end of the 6-month exercise period,quality of life,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
2000,NCT01611883,Change in Glycated Hemoglobin (HbA1c) From Baseline,Percent Change in Non-HDL-cholesterol From Baseline,2012-07-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
2001,NCT01975935,Difference in Hemoglobin A1c Values,Change in Weight,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2002,NCT04281069,glycaemia,Hemoglobin A1c,2019-03-01,COMPLETED,OBSERVATIONAL,['NA'],systolic and diastolic blood pressure
2003,NCT01063868,Number of Subjects With Treatment-emergent Adverse Events (TEAE),,2010-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
2004,NCT05823337,five-day second hour postprandial glucose average,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2005,NCT01883037,Does HemoCue Glucose 201 RT provide lab-quality results in the analysis of glucose values during oral glucose tolerance tests?,Is HemoCue Glucose 201 RT method cost saving relative to the traditional laboratory method for analysing glucose values taken during oral glucose tolerance tests?,2013-06,COMPLETED,OBSERVATIONAL,['NA'],2. To see if the HemoCue Glucose 201 RT offers sufficient advantages to make it a viable alternative to conventional testing
2006,NCT05031429,"Safety, as indicated by hypoglycemia","Impact on activities of daily living, as indicated by Munich Chronotype Questionnaire (MCTQ)",2022-01-01,COMPLETED,INTERVENTIONAL,['NA'],
2007,NCT05497960,Program satisfaction,Perceived Stress Scale Center for Epidemiologic Studies Depression Scale (CES-D),2022-09-01,COMPLETED,INTERVENTIONAL,['NA'],
2008,NCT02795559,Serum acetate response,Post-lunch ghrelin response,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
2009,NCT00738153,"The incidence of serious adverse drug reactions, including major hypoglycaemic events",Sub -group analysis of hypo risk,2008-06,COMPLETED,OBSERVATIONAL,['NA'],
2010,NCT00786136,An absolute increase in SCr >=0.5mg/dL（>=44.2μmmol/L）or a >= 25% increase in SCr from baseline to 72h after the procedure,"The composite of hospitalization for aggravated renal function, acute renal failure, dialysis or hemofiltration, aggravated at least 1 class of heart function, acute left ventricular failure or death from all causes.",2008-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
2011,NCT02104466,Change from baseline in average weekly pain on the 11-point Pain Intensity Numerical Rating Scale (PI-NRS) at week 12,Patient satisfaction,2015-03,COMPLETED,INTERVENTIONAL,['NA'],Use of medications at baseline and throughout 12-week intervention period
2012,NCT05808699,Sensitivity and Specificity Corrected for Enrichment,"Observed Sensitivity and Specificity, Level II",2023-03-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Precision substudy
2013,NCT01864239,Self-reported medication adherence,Serum Cholesterol Levels,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
2014,NCT01792986,Difference in Mean Glucose Level Between Baseline and the End of the Sixth Week.,Difference in Red Blood Cell Count Between Baseline and the End of the Sixth Week.,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
2015,NCT03664583,Mental Health Using the Short-Form 12 Health Survey Version 2 (SF-12v2) - Mental Component Summary score.,Collaboration Using the Partnership Self-Assessment Tool (PSAT),2019-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2016,NCT05632055,miRNA profile,FGF21 profile,2000-08-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
2017,NCT05747664,AUClast of DWP16001,,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
2018,NCT05765292,C-peptide,cytokines levels,2021-03-01,COMPLETED,INTERVENTIONAL,['NA'],
2019,NCT04968171,Partial clinical remission time,Albumine to creatynine ratio ACR [mg/g],2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],
2020,NCT01409408,Renin activity and concentration,Correlation of drug effects and left ventricular mass and function (systolic and diastolic),2011-04,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
2021,NCT00901992,A1c values,weight (Body mass index),2009-05,COMPLETED,INTERVENTIONAL,['NA'],
2022,NCT02879422,Proliferative retinopathy diabetic,,2013-10-16,COMPLETED,INTERVENTIONAL,['NA'],
2023,NCT00556465,Proteinuria,"blood pressure,serum creatinine,GFR,c-reactive protein,",2007-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2024,NCT01979471,The difference in change in estimated cardiovascular risk between advanced care and usual care groups,"Achievement of individual and the ""triple target""",2014-01,COMPLETED,INTERVENTIONAL,['NA'],
2025,NCT00225849,"Composite event of cerebro/cardiovascular (CV) death, nonfatal cerebral stroke (of any cause) and nonfatal myocardial infarction (MI)",Severe side-effects that lead to interruption of the study medication.,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2026,NCT05287737,Pancreatic islet function,Histological examination pancreas,2022-06-21,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
2027,NCT01588639,Occurrence rate of serious adverse drug reactions including severe hypoglycaemic events,Number and ratio of missed injections,2012-08,COMPLETED,OBSERVATIONAL,['NA'],
2028,NCT02445170,Health-related quality of life measured by the HRQoL score,The 15D health-related quality of life instrument,2015-07,WITHDRAWN,OBSERVATIONAL,['NA'],
2029,NCT01940770,Adverse event incidence,Mean change of lipid metabolism,2013-10-18,COMPLETED,OBSERVATIONAL,['NA'],
2030,NCT04091516,Weight loss,Body Composition,2019-08-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2031,NCT02315287,Change of HbA1c,microalbumin to creatinine ratio,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],Body weight
2032,NCT02218099,"Part 2: Safety and tolerability of ASP8232 measured by nature, frequency and severity of AEs, vital signs, safety laboratory tests, routine ECG",Part 2: 24-hour urinary albumin excretion rate (UAER),2013-09-16,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2033,NCT03835923,Change in HbA1c,"Number of the combined endpoint ""4P-MACE""",2019-02-12,COMPLETED,INTERVENTIONAL,['NA'],
2034,NCT02150824,The percentage of patients with drug- related adverse events,Change from baseline in fasting plasma glucose (FPG) after 28 days of treatment,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
2035,NCT00390520,Glucagon counterregulatory response to hypoglycemia of the last 30 min of the 2.5 mM hypoglycemic clamp after 4 weeks treatment,"Safety based primarily on frequency of adverse events, number of notable abnormal laboratory values, and frequency and severity of hypoglycemic events",2006-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
2036,NCT05019274,Hemoglobin A1c,Food security score,2021-08-09,COMPLETED,INTERVENTIONAL,['NA'],
2037,NCT04182646,Change in NAFLD activity Score,Changes in Glycemic control,2020-01-08,UNKNOWN,INTERVENTIONAL,['NA'],
2038,NCT01629199,"At 12 weeks, wound closure rate of diabetic foot ulcers",average size reduction of diabetic ulcer,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
2039,NCT01877200,Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,2013-06,COMPLETED,OBSERVATIONAL,['NA'],
2040,NCT00708604,Percent of subjects who have achieved insulin sufficiency post transplant.,HgAlc</= 6.5%,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
2041,NCT00871936,Reduction in HbA1c,Adverse Events,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
2042,NCT01789788,Safety: Incidence of adverse events,Pharmacodynamics of RO681135: Blood analysis,2013-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
2043,NCT03646916,Post-operative blood sugar,,2020-09-15,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
2044,NCT03744975,Plasma cGMP Response,Renal response,2018-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
2045,NCT03743285,Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL,,2018-11-14,COMPLETED,INTERVENTIONAL,['NA'],
2046,NCT02240680,Change From Baseline in Hemoglobin A1c (HbA1c) After 24 Weeks of Treatment.,Change From Baseline in Fasting Plasma Glucose (FPG),2014-09-23,COMPLETED,INTERVENTIONAL,['PHASE4'],
2047,NCT03121196,Epices score distribution,Adverse perinatal outcomes,2017-05,UNKNOWN,OBSERVATIONAL,['NA'],
2048,NCT03847194,Diabetes Distress,Adherence,2020-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2049,NCT00404599,Reduction in oxLDL levels,Reduction in plasma endothelial function parameters such as soluble Vascular Adhesion Molecule (sVCAM) and von Willebrand factor,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2050,NCT06139913,Estradiol blood test,,2023-03-15,COMPLETED,INTERVENTIONAL,['NA'],
2051,NCT01379729,Primary outcome measurement is a parameter of functional beta cell mass at 6 months PT. Functional beta-cell mass will be calculated using the AUC/min between 150 and 160 min during hyperglycemic clamp at 180 mg/dl.,Changes from Baseline,2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2052,NCT02670928,Number of Patients With Clinically Significant Weight Reduction (>5%) Compared to Baseline at Month 12,Percentage Hange From Baseline in Body Mass Index (BMI) at Month 12,2015-07-20,COMPLETED,INTERVENTIONAL,['PHASE4'],
2053,NCT06283797,Glycated hemoglobin (HbA1c) level,Number of needed interventions by the parents/guardians or care providers,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],"Severity of treatment-emergent SUSARs, SAEs, ARs and AEs"
2054,NCT03410277,Neurochemical response to HG before and after induction of IAH,Antecedent physical activity,2018-05-24,RECRUITING,INTERVENTIONAL,['NA'],
2055,NCT04854083,HbA1c,"Change in the oxygen uptake and perfusion in subcutaneous and intra-abdominal adipose tissue, brown adipose tissue, skeletal muscle, gut and liver",2022-02-17,RECRUITING,INTERVENTIONAL,['PHASE4'],
2056,NCT01440517,Evidence of Active Myocardial Angiogenesis/Remodeling,Uptake of 99mTc-maraciclatide Agent in Diabetic Subjects With Heart Failure With Preserved Left Ventricular Fraction and Subjects With Diabetes Mellitus and Asymptomatic Diastolic Dysfunction,2011-08,TERMINATED,INTERVENTIONAL,['PHASE2'],
2057,NCT03314272,Percentage of patients who had hypoglycemic events,,2018-05-16,COMPLETED,INTERVENTIONAL,['NA'],
2058,NCT00237640,"- Primary outcomes include HbA1c, glucose, total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides levels.",,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
2059,NCT04411277,Primary outcome is time in range (TIR),-Glucose Variability,2020-08-05,COMPLETED,OBSERVATIONAL,['NA'],
2060,NCT04689971,Improvement in Brief Pain inventory at week 8,,2020-11-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2061,NCT01029795,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 12 Weeks,Mean Total Daily Dose of LY2599506 During the 12-week Treatment Period,2010-02,TERMINATED,INTERVENTIONAL,['PHASE2'],
2062,NCT01754792,To assess hidrocarbonated metabolism parameters before and after pinitol/placebo administration,To evaluate oxidative stress on mitochondrial function before and after pinitol/placebo administration,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
2063,NCT01295073,Change in retinal thickness measurements by Optical Coherence Tomography (OCT) from screening to Day 28 between subjects undergoing surgery with and without Trientine use.,Secondary analyses will involve evaluations of the change in visual acuity and fundus photography results from screening to Day 28.,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
2064,NCT02982330,Incremental area under the glucose curve (continuous glucose monitor),Mean Blod Glucose (continuous glucose monitor),2016-11,COMPLETED,INTERVENTIONAL,['NA'],Satiety VAS 100
2065,NCT00382239,Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 12,"Changes in body weight, waist size and waist/hip ratio from Baseline to Week 12",2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
2066,NCT01531933,Change in 15-minute post prandial insulin level,Adverse events,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
2067,NCT05088993,Change from baseline postural stability at 3 months,Change from baseline functional capacity at 3 months,2021-02-15,COMPLETED,INTERVENTIONAL,['NA'],
2068,NCT02957838,Changes in Mitochondrial Function,diabetic late complications,2016-11,COMPLETED,INTERVENTIONAL,['NA'],
2069,NCT00260156,Change from baseline in hyperglycemia and arginine-stimulated first phase insulin secretion at 52 weeks,Beta-cell function parameter derived from standard meal challenge,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
2070,NCT05177107,Percent area reduction of study ulcer through Week 13,Microbiological eradication of the target pathogen,2021-11-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-emergent AEs due to phage therapy
2071,NCT02906930,Change in HbA1c,PGI-C Item: Scores of the Two Individual Items (Used for Validation of the IWQOL Questionnaire),2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE3'],
2072,NCT02159014,Activity adherence rates,10 year risk of developing diabetes mellitus,2014-08,COMPLETED,INTERVENTIONAL,['NA'],Life quality
2073,NCT00318214,"Changes in electrocardiograms (ECGs), vital signs, and clinical laboratory values.",Time to closure and percent reduction in surface area of the target ulcer.,2006-06,TERMINATED,INTERVENTIONAL,['PHASE2'],
2074,NCT00562952,Reduction in cardiac events,Reduction in NT-proBNP,2007-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2075,NCT01964833,Change in the clinical attachment level at 180 days.,Cytokines in the crevicular fluid,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
2076,NCT04232293,eLift and FibroMeter sensitivity for the diagnosis of advanced hepatic fibrosis,Complication of diabetes,2021-06-25,RECRUITING,INTERVENTIONAL,['NA'],
2077,NCT01990092,Change in plasma methylmalonic acid (MMA) levels,Change in neuropathic symptoms as measured by the Neuropathy Total Symptom Score-6 questionnaire (NTSS-6),2013-11,UNKNOWN,INTERVENTIONAL,['NA'],
2078,NCT00315627,Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia,Restoration of Hypoglycemia Awareness 1 Year After Transplantation,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
2079,NCT01849289,Change From Baseline in HbA1c (%) (Analysed by Central Laboratory),Number of Treatment Emergent AEs (Adverse Events),2013-06-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
2080,NCT05791201,Part B and Part C: Change in Peak C-peptide during Mixed-Meal Tolerance Test (MMTT),Part C: Change in HbA1c values,2023-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2081,NCT00703482,Evolution of the E'/E septal ratio,Evolution of the PV doppler parameters,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2082,NCT04721145,Change in Personal CGM Use,Using Personal CGM,2021-01-25,COMPLETED,INTERVENTIONAL,['NA'],
2083,NCT03562208,C Peptide,A1C,2018-01-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2084,NCT04446754,Diet intake,Lean mass,2019-04-10,COMPLETED,OBSERVATIONAL,['NA'],
2085,NCT02338193,Change in Body Weight,First Phase Insulin Secretion (IGI/HOMA-IR),2015-09-22,COMPLETED,INTERVENTIONAL,['PHASE3'],
2086,NCT00387452,Time and frequency domain measures of heart rate variability,Linear transfer-function analysis of cerebral autoregulation during upright tilt,2006-02,COMPLETED,INTERVENTIONAL,['NA'],
2087,NCT02200965,Assessment of change in completion of nine key care processes in diabetes,Assessment of change in surrogate markers that define hard outcomes in diabetes,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
2088,NCT05628597,Glycated hemoglobin,Compliance,2021-11-23,COMPLETED,INTERVENTIONAL,['NA'],
2089,NCT03750695,Percent Change in Endothelial Function,,2018-11-20,COMPLETED,INTERVENTIONAL,['NA'],
2090,NCT03603704,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose,2018-08-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
2091,NCT00232362,annular tissue Doppler velocity,,2007-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
2092,NCT04579016,Weight loss,"Questionnaire data pertaining to physical activity, General Health and Well Being, Motivation to change and Risk Perception Survey for Developing Diabetes",2020-01-13,UNKNOWN,INTERVENTIONAL,['NA'],
2093,NCT04334213,"AUCtau,ss of CKD-501, D745, D150","Fluctuation of CKD-501, D745, D150",2020-05-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
2094,NCT05653518,Glucose Time-in-Range,Insulin sensitivity,2023-09-09,RECRUITING,INTERVENTIONAL,['NA'],Human CD14+CD16- monocytes
2095,NCT02835014,Number of patients with a positive depression screening,Improvement in Diabetes Control defined by HbA1C equal or lower than 8.5%,2017-04-26,COMPLETED,OBSERVATIONAL,['NA'],
2096,NCT03310944,Assessment of PK Parameter: Maximum plasma concentration (Cmax),Adverse Events,2017-10-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
2097,NCT05754424,Area under the glucose infusion rate-time curve of insulin aspart,,2023-02-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
2098,NCT06112418,The primary objective is to compare Cleerly stage-based care with risk factor-based care on the risk of CV events.,The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.,2024-03-06,RECRUITING,INTERVENTIONAL,['NA'],The safety objective is to assess harm with the 2 prevention strategies
2099,NCT00190970,The objectives of this study is to evaluate the effect of ruboxistaurin on subjects with diabetic peripheral polyneuropathy,Ruboxistaurin will improve quantitative sensory testing and increase nerve fiber density in subjects with diabetic peripheral polyneuropathy.,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2100,NCT03714451,Change in glycemic variability,Change in glucose levels,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],Eating behavior
2101,NCT01969747,"Change From Baseline in 24 h UGE (g/24 h) After Seven Days of Treatment With Empagliflozin 2.5 mg, 10 mg, or 25 mg, or Placebo",,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
2102,NCT06301191,Comparison of liver stiffness difference among treatment groups,,2022-03-01,RECRUITING,OBSERVATIONAL,['NA'],
2103,NCT04499638,How is the influence of T2DM on complications related to peripheral vascular catheters in hospitalized patients,,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
2104,NCT04201912,Toll like receptor 2 activity,Toll like receptor 4 activity,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],
2105,NCT03692208,Documentation of Diabetes Goal,Patient Ability to Reach Personalized Goals,2018-10-29,COMPLETED,INTERVENTIONAL,['NA'],Health Care Utilization
2106,NCT00362518,The goal is to determine the effects of the vitamin C and vitamin E on surrogate markers of atherosclerosis following an atherogenic meal in type 2 diabetes,To determine changes in surrogate markers of atherosclerosis in type 2 diabetes,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
2107,NCT03731637,Determine sensitivity and specificity of serum CA 19-9 in pre-symptomatic pancreatic ductal adenocarcinoma in subjects with new-onset hyperglycemia and diabetes,,2018-10-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
2108,NCT03055169,value of the odds ratio associated with the relationship between a polymorphism TCF7L2 gene and the occurrence of hyperglycemia,Insulin Resistance (HOMA),2012-04,COMPLETED,OBSERVATIONAL,['NA'],Number of patients with genotype TCF7L2 by PCR
2109,NCT05814107,Incidence of Treatment-Emergent Adverse Events in CT-996 participants,Effect of a High-Fat Meal on Plasma Concentration of CT-996,2023-05-09,RECRUITING,INTERVENTIONAL,['PHASE1'],
2110,NCT01633710,Presence or absence of peripheral arterial disease,,2009-05,TERMINATED,OBSERVATIONAL,['NA'],
2111,NCT00943059,lipid accumulation in ectopic tissue (cardiac and skeletal muscle),oxidative stress markers,2010-03,COMPLETED,INTERVENTIONAL,['NA'],
2112,NCT05249062,Participants' engagement with the SHAPES app during the pilot,Exploration of user engagement behaviors,2023-02-09,COMPLETED,INTERVENTIONAL,['NA'],Economic impact of the intervention
2113,NCT01509755,HbA1c (glycosylated haemoglobin),Adverse events,2000-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2114,NCT05081037,Body fat mass at the end of the 6 month intervention period,"Change in fasting lipid profile from baseline, 6 months, 12 months, 24 months and 36 months",2021-09-06,RECRUITING,INTERVENTIONAL,['NA'],Change in quality of life from baseline at 36 months (34-38 months)
2115,NCT02892604,Percent time of active insulin closed-loop delivery,Percent time with blood glucose in target range,2015-11-24,TERMINATED,INTERVENTIONAL,['NA'],
2116,NCT03156478,Change in body weight,Usage of the Internet intervention,2017-04-10,RECRUITING,INTERVENTIONAL,['NA'],
2117,NCT01178476,The frequency of severe hypoglycaemia event,"The frequency of clinical hypoglycaemia (sensation of hypoglycaemia and BG<3.5mmol/l), biochemical hypoglycaemia (BG<3.5mmol/l), and nocturnal hypoglycaemia (waking up with a sensation of hypoglycaemia and BG<3.5mmol/l)",2009-11,WITHDRAWN,INTERVENTIONAL,['NA'],
2118,NCT01074762,Stroke,Amputation,1989-03,COMPLETED,INTERVENTIONAL,['NA'],
2119,NCT04686552,insulin,lipids,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],
2120,NCT02807155,Number of Routine Diabetes Clinic Visits,Arizona Integrative Outcomes Scale,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
2121,NCT02815748,The area under the plasma concentration-time curve (AUC) of SP2086 acid,The number of volunteers with adverse events as a measure of safety and tolerability,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
2122,NCT01342614,Blood pressure measurement,,2006-05,COMPLETED,INTERVENTIONAL,['NA'],
2123,NCT04237493,Hyperglycemia,Hyperosmolar hyperglycemic state,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE4'],
2124,NCT02287506,Time to optimum treatment following diagnosis.,Mean glycaemic control,2015-08-28,TERMINATED,INTERVENTIONAL,['NA'],
2125,NCT00935766,Change in Pulse Wave Velocity in Active vs. Placebo-treated Patients.,Change in hsCRP,2009-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
2126,NCT03867851,Other AEs/SAEs after islet transplantation,Change in C-peptide / (glucose x creatinine) ratio (CPGCR),2021-02-08,RECRUITING,INTERVENTIONAL,['PHASE2'],
2127,NCT05017571,Change in Homeostatic model assessment of insulin resistance (HOMA-IR),Change in Matsuda Index,2021-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],
2128,NCT02612675,Area under the blood glucose curve (AUC 0-240),,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
2129,NCT05088265,System Usability Scale,,2021-10-26,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
2130,NCT04560998,Change in maximum walking distance on a constant load treadmill test,Change in Short Form 36 (SF-36) physical functioning domain,2020-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
2131,NCT02585427,Triglycerides response of different treatments,Gastric inhibitory polypeptide response of different treatments,2014-11,COMPLETED,INTERVENTIONAL,['NA'],
2132,NCT03094819,Qualified eye examination rate,Participant perceptions,2016-03-17,UNKNOWN,INTERVENTIONAL,['NA'],
2133,NCT03957603,Change in Fasting insulin concentration from Baseline at 2 months,The incidence of macrosomia infants,2019-05-16,COMPLETED,INTERVENTIONAL,['NA'],
2134,NCT05535478,Change in proportion of long term care facility (LTCF) residents with Alzheimer's disease adn related dementias (ADRD) and diabetes with high risk medications (HRM) use,Feasibility of the STRIDE Educational Program,2023-01-31,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
2135,NCT02520050,Absolute and relative change in HbA1c,Absolute and relative change in energy intake,2015-04,COMPLETED,INTERVENTIONAL,['NA'],
2136,NCT02738086,Study-Related Adverse Events,"Late Life Function and Disability Scale, Limitation",2016-07-01,COMPLETED,INTERVENTIONAL,['NA'],
2137,NCT03696810,LOR ratios,Retinal Thickness,2018-10-30,COMPLETED,INTERVENTIONAL,['NA'],
2138,NCT04141891,Decisional Conflict Scale (DCS) Scores at Day 0 (Post-intervention),Occurrence of self-reported crashes,2019-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2139,NCT05628584,Differences in postprandial glycemia,Gastrointestinal symptoms,2022-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2140,NCT05461560,Changes in maximal incremental capillary blood glucose level (iCmax) between baseline and endpoint within the intervention group vs. control.,Changes in area under the curve of incremental capillary blood glucose levels (iAUC) in the intervention group vs. control,2021-12-05,RECRUITING,INTERVENTIONAL,['NA'],
2141,NCT02363907,Point Accuracy of CGM ISF Readings to Blood Glucose Measured by a Reference Device,,2012-09,COMPLETED,OBSERVATIONAL,['NA'],
2142,NCT03235219,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Change From Baseline in Insulin Sensitivity as Assessed by Homeostasis Model Assessment for Insulin Sensitivity (HOMA-%S),2017-08-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
2143,NCT03602989,Sensitivity and specificity,,2018-07-05,UNKNOWN,OBSERVATIONAL,['NA'],
2144,NCT02829268,Number of Participants With Treatment-related Adverse Events as Assessed by Liver Function Tests,Changes in Neurological Functions in Participants Assessed by the Wolfram Unified Rating Scale (WURS),2017-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2145,NCT01440530,Diabetes Knowledge,Diabetes Self Care,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
2146,NCT03934970,Comparison of diagnostic accuracy of Diffusion tensor imaging of peripheral nerves in comparison to Diabetic Neuropathy Examination in diabetic patients.,Identifying cut-off value for abnormal diffusion tensor apparent diffusion coefficient in diabetic neuropathy.,2015-04-30,COMPLETED,OBSERVATIONAL,['NA'],
2147,NCT04820348,Adherence to wearing continuous glucose monitoring (CGM) devices to measure glucose levels.,Feasibility of assessing the comorbidity of depressive/anxiety symptoms and type 2 diabetes and the impact of depression and anxiety on diet-medication adherence and lifestyle choices.,2021-04-09,COMPLETED,OBSERVATIONAL,['NA'],
2148,NCT01175928,Nerve Conduction Studies,Quality of life questionnaires,2010-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2149,NCT03259984,DNA methylation of genes in insulin resistance,mRNA expression of genes,2016-11,COMPLETED,OBSERVATIONAL,['NA'],
2150,NCT02835287,Incidence of composite major cardiovascular disease events,Cost-effectiveness,2016-10-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2151,NCT00856011,"Nerve morphology (Fascicular area, myelinated nerve fiber density, endoneurial capillary density and subperineurial space",,2003-12,COMPLETED,OBSERVATIONAL,['NA'],
2152,NCT05504226,Changes from baseline HbA1c at week 24,Changes from baseline in BMI at week 24,2022-10,RECRUITING,INTERVENTIONAL,['PHASE3'],
2153,NCT05913193,Nutritional status risk by MUST,Global Leadership Initiative on Malnutrition (GLIM) Diagnosis of Malnutrition,2023-12-15,RECRUITING,OBSERVATIONAL,['NA'],Calf Circumference
2154,NCT01256892,,,na,COMPLETED,INTERVENTIONAL,['NA'],
2155,NCT03551535,Adherence rate,Neonatal hypoglycemia rates,2018-11-01,WITHDRAWN,INTERVENTIONAL,['NA'],
2156,NCT00797212,Number of AST Results Within +/- 15mg/dL or +/- 20% of Fingerstick (FS)Blood Glucose Results,Percentage of Participant Ratings for Overall Testing Experience With This Meter,2008-11,COMPLETED,INTERVENTIONAL,['NA'],
2157,NCT00656422,To describe changes in hepatic fat content between groups.,To evaluate safety between groups.,2007-11,TERMINATED,INTERVENTIONAL,['PHASE3'],
2158,NCT03794934,Percentage of time in target range 70-180 mg/dL,Percentage of time in target range 70-180 mg/dL,2019-02-26,UNKNOWN,INTERVENTIONAL,['NA'],
2159,NCT04007133,Compliance rate with statin measured by the Girerd test,Compliance rate with statin according to risk factors,2018-01-31,TERMINATED,OBSERVATIONAL,['NA'],
2160,NCT00321542,Death or acute myocardial infarction,"Composite of the primary outcome and the onset of new symptoms of coronary artery disease with proven myocardial ischemia (supported by treadmill, nuclear scan or stress echo findings) or the need for a revascularization procedure.",2006-09,UNKNOWN,OBSERVATIONAL,['NA'],
2161,NCT03270436,Change in Mean Body Weight (kg),Change in Proportion of Participants Engaging in Sufficient Levels of Physical Activity,2018-01-08,COMPLETED,INTERVENTIONAL,['NA'],Change in Perceived Family Support for Exercise and Dietary Habits
2162,NCT02294175,"Total Bacteria Colony Forming Units (CFUs; Natural-log Transformed),With Phenylethyl Alcohol (PEA) Plating","Satisfaction: Wound Pain, Day 8",2015-01,COMPLETED,INTERVENTIONAL,['NA'],
2163,NCT02282475,Assess visceral adipose fat and intrahepatic lipid stores change during pregnancy,Compare glucose tolerance in pregnant women with gestational diabetes to those with normal glucose tolerance,2014-11-30,COMPLETED,OBSERVATIONAL,['NA'],
2164,NCT00021580,,,na,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2165,NCT00042601,Change in food intake of participants on Pramlintide,Effect of pramlintide on postprandial metabolic and hormonal responses,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
2166,NCT04883086,The extent of root dental caries,Measuring the vitamin D levels,2020-12-15,COMPLETED,OBSERVATIONAL,['NA'],
2167,NCT00699179,Change in HbA1c from baseline,Number of adverse drug reactions (ADR),2008-06,COMPLETED,OBSERVATIONAL,['NA'],
2168,NCT00437606,AUCo-inf and Cmax of plasma and urine GK Activator (2) and M4. AUC0-6 of plasma glucose.,"AEs, laboratory parameters.",2007-03,TERMINATED,INTERVENTIONAL,['PHASE1'],
2169,NCT04066959,Hemoglobin A1c,Blood glucose testing,2020-11-16,RECRUITING,INTERVENTIONAL,['NA'],
2170,NCT03457168,New-onset CKD,Cardiac events,2019-02-01,RECRUITING,INTERVENTIONAL,['NA'],
2171,NCT06315725,"Mean plasma glucose, basal and bolus insulin changes in individuals with T1D on AP following beverage consumption.",Resting Energy Expenditure (REE) and nutrient partitioning changes in individuals with T1D on AP following beverage consumption,2024-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2172,NCT00755547,Insulin sensitivity measured from Bergman's frequently sampled intravenous glucose tolerance test,1H-Magnetic resonance spectroscopy-derived measure of lipid content in liver and muscle tissue,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
2173,NCT00713830,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia
2174,NCT03449784,number with dyslipidemia,number of patient not achieving LDL-C target according to cardiovascular risk,2012-05-01,RECRUITING,OBSERVATIONAL,['NA'],
2175,NCT00132288,"Change in physical activity of those allocated to the intervention group compared to ""wait-listed"" controls as measured by the Seattle-Rapid Assessment of Physical Activity questionnaire",Determinants of choice in favor of study participation,2005-05,COMPLETED,INTERVENTIONAL,['NA'],
2176,NCT01511900,Frequency and severity of adverse events,Changes from baseline in vital signs,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
2177,NCT01525784,to examine prospectively frequency of hypoglycemia,To examine prosectively the effect of rt-cgms on glycemic control,2012-02,UNKNOWN,OBSERVATIONAL,['NA'],
2178,NCT01662999,AUC(INF) of Saxagliptin From a Single Dose of 5 mg Saxagliptin Versus AUC(INF) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population,Number of Participants With Change From Baseline in ECG Interval - Safety Population,2012-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
2179,NCT03764280,Percentage of time of sensor glucose levels spent in target range (defined to be between 3.9 mmol/L and 10.0 mmol/L).,Number of participants experiencing hypoglycemia requiring oral treatment during,2018-07-02,COMPLETED,INTERVENTIONAL,['NA'],
2180,NCT00999856,demonstrate correlation between the fluorescence reading of the insert and capillary blood glucose measurement,duty of care,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2'],
2181,NCT02754817,Change in HbA1c (Hemoglobin A1c),Percentage of responders for HbA1c below 7 percent (53 mmol/mol) with no hypoglycaemic episodes,2016-04-26,COMPLETED,OBSERVATIONAL,['NA'],
2182,NCT02056431,Change in Patient Quality of Life at Baseline and 8 Months,Number of Participants With Minimally Effective Dose in 12 Months,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
2183,NCT01512654,Percentage of total time spent by patients in safe range (70-180mg/dL),Score of patient survey regarding the acceptability of DIAdvisor-2 system,2008-09,COMPLETED,INTERVENTIONAL,['NA'],
2184,NCT01852136,Overall Pen Needle Preference,Pen user group subset comparisons,2012-09,COMPLETED,OBSERVATIONAL,['NA'],
2185,NCT05268237,"Incidence, nature and severity of adverse events",Serum concentration of liraglutide,2023-04-25,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2186,NCT00907114,center subfield mean thickness using Stratus OCT measured in microns,"macular volume using Stratus OCT, measured in cubic millimeters",2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2187,NCT02496221,Maximum Change From Baseline in Common Bile Duct Diameter During CCK Infusion,Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick,2015-06-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
2188,NCT03007329,change in hepatic lipid content measured with magnetic resonance spectroscopy in %,change in glomerular filtration rate,2017-03-08,COMPLETED,INTERVENTIONAL,['PHASE4'],change in cholesterol
2189,NCT05887180,"Rate of adverse cardiovascular and cerebrovascular events (MACCE ""Plus"" events)",Incremental cost-utility relation (societal perspective),2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2190,NCT01230034,Size of the reduction of urinary albumin in 24 hours to the various controls,"1. Size of the reduction of mean 24-hour average daytime and nighttime average. 2. Size of the reduction of central blood pressure. 3. Magnitude of changes in plasma concentrations of angiotensin II, bradykinin and BNP after 24 weeks of treatment.",2010-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2191,NCT04504968,Difference in physical function,Health-related quality of life,2022-02-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2192,NCT05322304,neuropsychological function,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],
2193,NCT04131049,Postprandial glucose response by continous glucose monitoring,,2019-06-24,COMPLETED,INTERVENTIONAL,['NA'],
2194,NCT00169832,Change in plaque volume in one SVG (by IVUS),14 Fluid retention,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
2195,NCT04208620,Clinical laboratory evaluations,Proportion of subjects achieving > 5% body weight loss,2020-01-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
2196,NCT01614782,Number of participants who discontinued from study drug due to an adverse event,Apparent terminal half-life (apparent t1/2) following once daily administration of MK-5823,2012-06,TERMINATED,INTERVENTIONAL,['PHASE1'],
2197,NCT02058641,Macrophage cell count and surface expression of markers of M1 and M2 polarization in blister fluid,Time to healing of cantharidin-induced blisters,2014-02-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
2198,NCT05719675,Health-related quality of life,,2023-03-01,COMPLETED,INTERVENTIONAL,['NA'],
2199,NCT06158503,Bone remodeling improvement,HbA1c change,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2200,NCT03078231,Number of subjects whose EyeArt results match the reading center grading for identifying referable diabetic eye disease (moderate NPDR or higher on the ICDR scale or surrogate markers for CSME).,,2017-02-17,COMPLETED,OBSERVATIONAL,['NA'],
2201,NCT01498367,HbA1c levels,Economic Evaluation (Cost-Effective Analysis- Cost Utility Analysis),2011-03,COMPLETED,INTERVENTIONAL,['NA'],
2202,NCT04537624,Change in Glycated haemoglobin (HbA1c ),HbA1c reduction >=1%-points and body weight reduction of >=3% (Yes/No),2020-08-24,COMPLETED,OBSERVATIONAL,['NA'],
2203,NCT04092023,Glycemic control,QOL: Audit of Diabetes Dependent Quality of Life (ADDQoL-19),2018-10-02,COMPLETED,INTERVENTIONAL,['NA'],
2204,NCT01292018,Proportion of type 2 diabetic dyslipidemia patients achieving the target LDL goal according to ADA 2010. These patients should be on stable dose of Lipid Lowering Drugs(LDL) for at least 3 months,Control of dyslipidemia by all commercial available brands hypolipidemics drugs,2011-02,COMPLETED,OBSERVATIONAL,['NA'],
2205,NCT04624516,The time of plantar foot diabetic ulcer recurrence incidence,callus,2019-09-04,COMPLETED,INTERVENTIONAL,['NA'],
2206,NCT03677609,Patient adherence: Vaccine and screening recommendations,Physician mindset: Mindset Beliefs Survey,2018-01-04,COMPLETED,INTERVENTIONAL,['NA'],
2207,NCT05985135,Protein synthesis,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2208,NCT00285194,"-Immune activity and pharmacokinetic assessments included hOKT3γ1 (Ala-Ala) level and half-life, monoclonal antibody coating and modulation of CD3 on peripheral blood T cells, and anti-hOKT3γ1 (Ala-Ala) antibody responses.","-Proportion of subjects with slet graft loss will be defined as a return to insulin therapy for >30 days, absence of basal and arginine-stimulated C-peptide, re-transplantation, or patient death;",2000-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2209,NCT01022177,retinal perfusion by HRF/OBF/RVA,,2009-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2210,NCT04849845,Post-prandial Glucose Excursion,"Change in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Between Two Points, Baseline and 120 Minutes Post-Afrezza Dose",2021-04-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
2211,NCT04364087,the prevalence of diabetes and prediabetes in infertile women with PCOS,Factors associated with diabetes and prediabetes,2020-06-01,COMPLETED,OBSERVATIONAL,['NA'],
2212,NCT00701831,Time to dose titration,Physician Satisfaction Questionnaire,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
2213,NCT02431234,Serum RANKL concentrations,,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],
2214,NCT00820573,Average of Plasma Glucose During Mixed Meal Tolerance Test (MTT) Compared to Baseline Plasma Glucose to Post Therapy (6-weeks).,Changes in Plasma Glucose Post-MTT After Each Six Weeks of Therapy Compared to Baseline,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
2215,NCT00631488,Change From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels,Change From BL to Week 4 in the 2-Hour Active GLP-1 Total AUC,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2216,NCT02400515,Glucose levels,Low Density Level (LDL) Cholesterol levels,2007-08,COMPLETED,INTERVENTIONAL,['NA'],Hospital Anxiety and Depression scale (HADS)
2217,NCT05026424,Post-prandial glycemic markers,Insulinogenic index,2021-08-02,COMPLETED,INTERVENTIONAL,['NA'],
2218,NCT01228032,Quality of healthcare services received,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
2219,NCT00700830,Assessment the incidence of the Serious Adverse Events including the major Hypoglycaemia.,Weight,2008-01,COMPLETED,OBSERVATIONAL,['NA'],
2220,NCT00417131,,,2006-10,COMPLETED,OBSERVATIONAL,['NA'],
2221,NCT02958956,Number of 10 Most Common Cancers Associated Cases,Number of 10 Most Common Cancer Cases By Dose of Pioglitazone,1997-01-01,COMPLETED,OBSERVATIONAL,['NA'],
2222,NCT00286637,Number of Participants who Show Evidence of Glaucoma Progression,,1995-01,COMPLETED,OBSERVATIONAL,['NA'],
2223,NCT04028960,Percentage of Time With Dangerous Hypoglycemia,Glucose Management Indicator (GMI),2019-10-23,TERMINATED,INTERVENTIONAL,['PHASE2'],
2224,NCT04817228,Change from baseline in wound biofilm presence before and after treatment,,2021-04-21,COMPLETED,INTERVENTIONAL,['PHASE2'],
2225,NCT00873561,To assess the effect of repeated administrations of NBI-6024 on endogenous insulin production as measured by C-peptide levels in adult and adolescent patients with new onset type 1 diabetes mellitus,"To examine the effects of repeated administrations of NBI-6024 on insulin usage, glycemic control, and immune function (immunodynamics and pharmacodynamics) To examine the safety and tolerability of repeated administrations of NBI-6024",2001-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
2226,NCT00454623,,,2006-03,UNKNOWN,INTERVENTIONAL,['NA'],
2227,NCT05046015,Change from Baseline in Overall Dry Skin Score,Skin barrier,2016-09,COMPLETED,INTERVENTIONAL,['NA'],Cracks/ Fissures
2228,NCT03462017,Change in Flow Mediated Dilation (FMD),Assessment of PK parameter: AUC0-24,2018-03-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
2229,NCT01585506,Frequency and level of difficulty in introducing changes in compliance with the guidelines for biphasic insulin analogue use in subjects previously treated with biphasic human insulins,"Correlations between the difficulty in introducing changes in compliance with the guidelines for biphasic insulin analogue use in subjects previously treated with biphasic human insulins, and psychosocial factors",2010-09-20,COMPLETED,OBSERVATIONAL,['NA'],
2230,NCT02325206,reduction of intravenous insulin dose,urinary glucose excretion,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
2231,NCT01774149,Change in the Frequency of Hyper- and Hypo-glycemic Events From Baseline to Week 8-12.,Change in HbA1c,2013-03,COMPLETED,INTERVENTIONAL,['NA'],Empowerment
2232,NCT04132739,Changes in strength,,2019-03-01,TERMINATED,INTERVENTIONAL,['NA'],
2233,NCT00984737,To determine the prevalence of newly diagnosed hyperglycemia in coronary ICU.,"To search for the cases with stress hyperglycemia and inquire its relationship with disease severity and functional outcomes, such as longevity of ICU stay.",2007-05,COMPLETED,INTERVENTIONAL,['NA'],
2234,NCT03257449,Body fat percentage change,,2016-03,UNKNOWN,OBSERVATIONAL,['NA'],
2235,NCT01990638,left ventricular diastolic function,exercise capacity,2004-11,COMPLETED,OBSERVATIONAL,['NA'],
2236,NCT01071785,"Changes on the components of metabolic syndrome (according to IDF and WHO criteria): blood pressure, waist, body mass index (BMI), triglycerides, high-density lipoprotein (HDL) cholesterol, glucose values (HBA1c) and urinary albumin excretion.",changes on serum fatty acids and serum cholesterol,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
2237,NCT02327754,Change from baseline in urine albumin creatinine ratio,"sUA, eGFR, L-FABP, HbA1c, SBP, DBP, TC",na,COMPLETED,INTERVENTIONAL,['PHASE2'],
2238,NCT02820558,Stage A Safety: Side effects reported for entire cohort,C-Peptide Levels (large cohort),2016-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],sP Longevity
2239,NCT03205904,glycemic improvement after nutritional orientation in patients with cystic fibrosis in the pre-diabetic phase,To evaluate anthropometric data of the patients before and after the intervention.,2016-12-12,COMPLETED,INTERVENTIONAL,['NA'],
2240,NCT02589314,Evidence of alteration on pro and anti-inflammatory cytokines by CBA,,2015-11,TERMINATED,OBSERVATIONAL,['NA'],
2241,NCT03437694,Hypertension,,2018-08-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2242,NCT00069784,"Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure (HF)",Incidence of Development of Type 2 Diabetes Mellitus in Participants With IGT and/or IFG,2003-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Patients With First Occurrence of Any Type of Cancer
2243,NCT03015480,Change in 24-hour urine sodium,Change in Net Endogenous Acid Production (NEAP),2017-02-13,COMPLETED,INTERVENTIONAL,['NA'],
2244,NCT00396357,Change from baseline in hemoglobin A 1 c (HbA1c) after 24 weeks of treatment,Change from baseline in fasting plasma glucose after 24 weeks,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
2245,NCT01798238,Glycosylated hemoglobin,Glycosylated hemoglobin <6.5% subject percent,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
2246,NCT00277732,The difference between the study groups in the change of blood glucose and HbA1c,Frequency of eye and foot examination,2006-01,COMPLETED,INTERVENTIONAL,['NA'],
2247,NCT01056315,Average Pain Intensity,Assessment of Rescue Medication Usage During the 4-week Titration.,2009-11,TERMINATED,INTERVENTIONAL,['PHASE2'],
2248,NCT06290349,Change from the baseline in HbA1c (%) after 24 weeks,Change from the baseline in weight after 24 weeks,2024-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
2249,NCT05610865,Interview and visual inspection of ulcers recovery rate,Percentages (%) of wound closure rate (with respect to time) will be assessed.,2020-11-20,RECRUITING,INTERVENTIONAL,['PHASE1'],
2250,NCT02506452,Wound closure observed at up to 12 weeks following baseline visit defined as 100% re-epithelialization without drainage confirmed at 2 weeks following initial observation of closure.,,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],
2251,NCT03169205,Maternal outcome,fetal outcome,2017-05-01,UNKNOWN,OBSERVATIONAL,['NA'],
2252,NCT02535715,Hepatic Glucose Production (Co-primary Outcome),Plasma Free Fatty Acid Concentrations,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2253,NCT05985291,Average change from baseline to 3 months in treatment responder rates,Average change from baseline to 6 months in treatment responder rates assessed by Visual Analog Scale (0-10 cm),2023-07-03,RECRUITING,OBSERVATIONAL,['NA'],Assessment of subject outcomes satisfaction as measured through Patient Global Impression of Change (PGIC) (1-7 where higher scores mean better outcome) at 3 months and 6 months.
2254,NCT00604656,Insulin aspart antibodies,HbA1c,2003-05-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
2255,NCT05281562,Effect of supplemental immunonutrition on wound healing in patients with diabetic foot ulcers as assessed by the Pressure Ulcer Scale for Healing (PUSH) Tool 3.0.,"Long term effect of supplemental immunonutrition on wound healing in patients with diabetic foot ulcers on rates of ulcer recurrence, infection, surgical intervention, and amputation.",2022-07-01,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2256,NCT01045707,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2257,NCT02208921,The proportion of T2DM patients with Chronic Kidney Disease (CKD),Frequency of patients with HbA1C less than 7% in T2DM patients with and without CKD,2014-09,COMPLETED,OBSERVATIONAL,['NA'],
2258,NCT00563433,Reduction in clinical signs and symptoms of infection,Wound depth.,1994-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
2259,NCT02548273,CHANGE FROM BASELINE IN CENTRAL CORNEAL THICKNESS AT 3 MONTHS,,2013-01,COMPLETED,OBSERVATIONAL,['NA'],
2260,NCT05078255,Mean glucose levels (assessed by blinded continuous glucose monitoring (CGM)),,2022-01-27,RECRUITING,INTERVENTIONAL,['NA'],
2261,NCT04503564,Rate of Infusion Set Survival at End of Day 7,,2019-11-13,COMPLETED,INTERVENTIONAL,['NA'],
2262,NCT01577719,Effectiveness of a 6 month culturally-specific multi-media intervention on Heart Health Risk,Change in the MI risk score and clinical events,2009-06,UNKNOWN,INTERVENTIONAL,['NA'],
2263,NCT00607737,laser doppler blood flow,insulin detemir specific antibodies,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2264,NCT00074633,,,2000-01,COMPLETED,INTERVENTIONAL,['NA'],
2265,NCT00934336,"Assay of isoprostane-F2, an indicator of lipid peroxidase derivative production, in the 24 hour urine",,2008-11,COMPLETED,INTERVENTIONAL,['NA'],
2266,NCT04907708,Mean morphometric diffusion capacity for oxygen (MMDC) in placental tissues,Percentage of immuno-antigens present in placental tissue,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],
2267,NCT04657016,Percentage of Participants with ≥5% Body Weight Reduction,Change from Baseline in Waist Circumference,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
2268,NCT03674281,Percentage of Time of Blood Glucose in Range 70-180 mg/dL,Sleep Patterns,2018-09-24,COMPLETED,INTERVENTIONAL,['NA'],
2269,NCT03569735,Cognitive disorder (occurrence of cognitive disorder),Usual gait speed,2018-05-26,RECRUITING,OBSERVATIONAL,['NA'],
2270,NCT00778804,Framingham 10-year risk index,"Blood pressure, cholesterol, 6 minute walk test, glucose and A1c, CVD knowledge and risk perception",2004-07,COMPLETED,INTERVENTIONAL,['NA'],
2271,NCT04828785,Hemoglobin A1c at Month 6,Frequency of self-reported severe hypoglycemia at Month 12,2021-07-02,RECRUITING,INTERVENTIONAL,['NA'],Stress Score at 12 months
2272,NCT00403481,Change From Baseline to Week 12 in Systolic BP (SBP) as Measured by 24-hour ABPM.,Change in Ambulatory BP (Diastolic) From Baseline to Week 12 During the Last (Week 12 ) 4 and 6 Hours of the Last 24-hour Dosing Period.,2006-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
2273,NCT02844907,AIM3: To determine the fasting GLP-1 effect.,,2018-07-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2274,NCT00516464,"To evaluate the effect of ranibizumab on vitrectomy complications such as recurrent vitreous hemorrhage, postoperative retinal detachment rates, and development of intraoperative retinal breaks.",,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2275,NCT02035891,The incidence of overt nephropathy,Death from any cause,2013-12,UNKNOWN,INTERVENTIONAL,['NA'],
2276,NCT01951547,Effect of periodontal intervention on probing attachment levels of diabetics with periodontal disease,Effect Of periodontal intervention on hs-CRP levels in diabetics with periodontal disease,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
2277,NCT03829800,Change from baseline Subjective appetite at 180 minutes,HbA1c,2016-09-01,COMPLETED,INTERVENTIONAL,['NA'],
2278,NCT02372253,Functional Beta Cell Mass,Hypoglycemic Events,2015-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Beta Cell Markers
2279,NCT02695706,Skin acceptability through the self perception of patients.,Instrumental Performance Measures,2016-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
2280,NCT00921570,Flow mediated dilatation,"TWEAK, PTX-3, Systolic Blood Pressure and Diastolic Blood Pressure",2008-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
2281,NCT02386020,Change in Clinical attachment level,Change in Probing depth,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2282,NCT05505994,Change from baseline in HbA1c,,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
2283,NCT05703386,Progression of cerebral small vessel disease,,2022-11-08,RECRUITING,OBSERVATIONAL,['NA'],
2284,NCT03785951,Change in fasting and day long insulin levels,Change in body composition,2018-12,UNKNOWN,INTERVENTIONAL,['NA'],Metabonomics
2285,NCT02818192,Change in albumin excretion over time.,Change in estimated glomerular filtration rate (eGFR) over time.,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],
2286,NCT00806585,Change From Baseline in Sitting Systolic Blood Pressure (SiSBP) at Week 12,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,2008-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
2287,NCT02355717,Bone strength-strain index,Serum C-terminal telopeptide of type 1 collagen (CTX),2014-12,UNKNOWN,OBSERVATIONAL,['NA'],
2288,NCT05529108,Change in bile acid concentration,Change in dietary,2022-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2289,NCT02306681,The percentage of patients who experience at least 1 hypoglycaemic episode,DSQOLS (Diabetes-Specific Quality-of-Life Scale) scores,2014-10-30,COMPLETED,OBSERVATIONAL,['NA'],
2290,NCT02994277,System connectivity,Meal composition's effect in the efficacy of the system to control glycaemia,2016-11,COMPLETED,INTERVENTIONAL,['NA'],
2291,NCT00210847,Change in the average of daily pain score recorded in the IVR system from baseline to the patient's final week of treatment with study medication.,"Efficacy measured by Brief Pain Inventory, Visual Analogue Scale, Short-Form McGill Pain Questionnaire, Profile of Mood States, SF-36 Health Survey, Physician and Subject Global Impression of Change, average daily sleep interference",2003-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
2292,NCT04265261,Percentage of Participants with Adverse Events (AEs),Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye,2020-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2293,NCT04155060,The primary outcome was 28-day mortality,,2017-04-01,COMPLETED,OBSERVATIONAL,['NA'],
2294,NCT00700154,Plasma glucose levels,laboratories for inflammation and oxidative stress,2011-11,TERMINATED,INTERVENTIONAL,['NA'],
2295,NCT01914302,Blood Volumes measured in microliters,Pain rating measure on a 0-20 Gracely Scale,2013-07,COMPLETED,OBSERVATIONAL,['NA'],
2296,NCT01455441,HbA1c,Myocardial echocardiography,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
2297,NCT03848767,Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL,,2019-02-20,COMPLETED,INTERVENTIONAL,['NA'],
2298,NCT06216340,Weight change,Incident diabetes,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Changes of C-reactive protein
2299,NCT03795662,Number of participants who develop diabetes,Number of participants who are readmitted,2019-01-07,RECRUITING,OBSERVATIONAL,['NA'],HbA1c to assess the average blood glucose levels 3 months before admission
2300,NCT00698126,Number of major hypoglycaemic events reported as serious adverse drug reactions,Quality of Life (QoL),2007-10,COMPLETED,OBSERVATIONAL,['NA'],
2301,NCT06236672,change in HbA1c (%),,2023-02-15,COMPLETED,OBSERVATIONAL,['NA'],
2302,NCT02366572,Subjective Appetite,Energy/fatigue,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
2303,NCT02375828,Acceptability of an oral solution of glibenclamide (Hedonic visual scale),No alteration in metabolic control of the disease,2015-03-20,COMPLETED,INTERVENTIONAL,['PHASE3'],
2304,NCT02705430,HbA1c < 7%,Lipid membrane fatty acid composition analysis,2018-06-20,UNKNOWN,INTERVENTIONAL,['NA'],
2305,NCT01418716,Quality of the cardiovascular preventive care,Use of public programs,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
2306,NCT03741153,the percentage of diabetic patients with pseudo-exfoliation syndrome,,2019-01,UNKNOWN,OBSERVATIONAL,['NA'],
2307,NCT01487811,Maximum drug concentration of the two formulations (Cmax),Frequency of adverse events,2005-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
2308,NCT03325569,The main outcome was difference in fasting and after load GLP1 levels between two groups,"The secondary outcome was to evaluate the between group difference in beta cell function, and visceral adipose tissue.",2017-02-13,COMPLETED,INTERVENTIONAL,['NA'],
2309,NCT04021251,Validation of predictive algorithms for determining blood glucose levels,,2018-12-20,UNKNOWN,INTERVENTIONAL,['NA'],
2310,NCT05945576,The morphometric characteristics of IDs in pediatric and adult's patients.,Analyse of (epi)genetic mutations transmission in proband and relatives.,2017-03-10,RECRUITING,OBSERVATIONAL,['NA'],"Description of different scientific rational for transferring a therapeutic approach (clinical guidelines) from an ID to another (identification of common phenotype, i.e. metabolic profile)."
2311,NCT05544435,Summary of diabetes self-care activities scale (SDSCA),Metabolic variable values,2019-09-25,COMPLETED,INTERVENTIONAL,['NA'],
2312,NCT00698230,Change from Baseline to Week 12 in hemoglobin A1c (HbA1c),Change from Baseline to Week 12 in fasting plasma glucose (FPG).,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2313,NCT05658991,Retinal function amplitude,Retinal function latency.,2022-12-11,RECRUITING,INTERVENTIONAL,['NA'],
2314,NCT01377935,Hospital admission for acute kidney injury,Hospitalizations for acute kidney injury and/or death due to acute kidney injury,2009-08,COMPLETED,OBSERVATIONAL,['NA'],
2315,NCT05744856,The acceptability of the self-care intervention,Self-care of GDM,2023-01-16,RECRUITING,INTERVENTIONAL,['NA'],Costs
2316,NCT00711217,Wound healing,Clinical outcome data,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
2317,NCT03748433,Time Spent in Hypoglycaemia,,2019-01-03,TERMINATED,INTERVENTIONAL,['NA'],
2318,NCT01495013,Non inferiority of glimepiride/atorvastatin compared with glimepiride + atorvastatin taken as separate tablets in reducing LDL levels,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
2319,NCT01475552,"Peak cardiac enzyme level (CK-MB,troponin-I)",The rate of periprocedural myocardial infarction,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
2320,NCT05266742,Patient Identification Form,,2019-12-15,COMPLETED,INTERVENTIONAL,['NA'],
2321,NCT00185159,Time to the first occurrence of microalbuminuria defined as excretion of greater than 35 mg albumin/g urine creatinine for women and greater than 25 mg albumin/g urine creatinine for men in morning spot urine,Safety and tolerability,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
2322,NCT00411333,Change in retinal vascular density from baseline on fluorescein angiography,Safety,2006-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
2323,NCT00283218,"• Cmaxglu: Peak plasma glucose following test meal (breakfast). A comparison will be made between BIAsp 50 vs BIAsp 70, BIAsp 30 vs BIAsp 70, BIAsp 30 vs BIAsp 50 and IAsp vs BIAsp 30, 50 and 70.","AUCins: The area under insulin aspart concentration (0-12, 0-6, 6-12, 0-4, 4-8, 8-12 hours after test meal) after a single injection of one of the four insulin aspart preparation: IAsp (NovoRapid®), Biphasic insulin aspart 30, 50 and 70.",2006-01,COMPLETED,INTERVENTIONAL,['NA'],
2324,NCT05580978,Change in percentage of CGM glucose readings > 120 mg/dL,Motivation and Attitudes Toward Changing Health,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],
2325,NCT05588258,Assessment of the skin quality of participants' feet before and after the cream application intervention using a validated questionnaire.,,2021-11-02,COMPLETED,INTERVENTIONAL,['NA'],
2326,NCT03987802,Adverse Events (AEs),Change in HbA1c,2021-01-20,COMPLETED,OBSERVATIONAL,['NA'],
2327,NCT00228878,Researchers will assess whether pulsatile IV insulin therapy can successfully reverse the abnormal underlying metabolism in diabetic patients to the point of improving their quality of life.,,2003-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2328,NCT01614379,,,2012-06,WITHDRAWN,OBSERVATIONAL,['NA'],
2329,NCT00824616,Number of Participants Who Experienced One or More Episodes of Hypoglycemia (Symptomatic or Asymptomatic),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2330,NCT04971317,Health Perceptions of SSBs Post-Intervention or Post-Control,,2018-09-05,COMPLETED,INTERVENTIONAL,['NA'],
2331,NCT00413348,Change in inflammatory response to E. coli endotoxin injection,,2006-11,UNKNOWN,INTERVENTIONAL,['NA'],
2332,NCT01372852,"plasma adiponectin concentration, isoform distribution and activity.",,2010-05,UNKNOWN,OBSERVATIONAL,['NA'],
2333,NCT01831336,Target Lesion Failure (TLF),Target Lesion Failure (TLF),2013-02,COMPLETED,OBSERVATIONAL,['NA'],
2334,NCT04109508,"AUC0-24h,sema,SS; area under the semaglutide plasma concentration-time curve during a dosing interval at steady state","t½,sema,SS; terminal half-life of semaglutide at steady state",2019-10-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
2335,NCT05615740,Vascular density in central and peripheral retina - healthy subjects,Vascular density in central and peripheral retina - diabetic patients,2022-05-02,RECRUITING,INTERVENTIONAL,['NA'],
2336,NCT05591664,eicosapentaenoic acid,,2022-10-17,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2337,NCT05984459,Diabetes remission,Decreases in poglycemic drug treatments,2023-01-30,COMPLETED,OBSERVATIONAL,['NA'],
2338,NCT04802044,Correlation of HbA1c with Clinical Disease Severity,Proportion of Long COVID Syndrome,2020-12-08,UNKNOWN,OBSERVATIONAL,['NA'],
2339,NCT06044532,Change of skin hydration on the dorsum of the forearm after two and a half hours of wearing the sham device.,Change of skin blood flux induced by oral glycemia tolerance test,2023-03-01,COMPLETED,INTERVENTIONAL,['NA'],
2340,NCT00746460,Feasibility of using health care providers other than physicians within a GMF to conduct a CV risk assessment and intervention on primary prevention patients,Satisfaction of the patient,2008-06,COMPLETED,INTERVENTIONAL,['NA'],
2341,NCT01180712,Oral Glucose Tolerance Test,Fasting blood glucose/insulin,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
2342,NCT00037297,,,2001-07,COMPLETED,OBSERVATIONAL,['NA'],
2343,NCT02568384,"Percent of Responses From Persons Who Performed Each ""Software Operations"" Task and Rated Each Statement as Strongly Agree, Agree, or Neither Agree Nor Disagree.",Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neither Agree Nor Disagree' With Questionnaire Statements Regarding Clarity and Utility of User Instructions For Onyx Glucose Meter and App System,2015-10,COMPLETED,INTERVENTIONAL,['NA'],Average Change in Total Daily Insulin Dose From Study Start to End of Study
2344,NCT03001323,Reduction in frequency of diabetic ketoacidosis,Basal insulin requirements,2017-01,TERMINATED,INTERVENTIONAL,['NA'],
2345,NCT03672656,Pain assessed by NRS,Satisfaction assessed by the VAS,2008-01-01,COMPLETED,INTERVENTIONAL,['NA'],
2346,NCT00309465,Primary: Preoperative Fasting Blood Sugar Upon Arrival at the Hospital Prior to Surgery,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
2347,NCT01607931,Incretin effect,,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
2348,NCT04618458,Parent BMI,Child stress,2020-12-01,COMPLETED,INTERVENTIONAL,['NA'],Child tanner stage
2349,NCT01848795,Glycated hemoglobin,,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2350,NCT00663884,Change of HbA1c before and after administration of test drug,"Change of CRP, 8-OHdG and Nitrotyrosine before and after administration of test drug",2008-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
2351,NCT04897113,Dynamics summary for improvement of aging biomarkers' values assessed by a patient's biochemical blood count,"scales of the ""Health-Promoting Lifestyle Profile""",2021-05-12,UNKNOWN,INTERVENTIONAL,['NA'],
2352,NCT04847999,Blood glucose incremental area under the curve,Blood glucose total area under the curve,2020-11-20,COMPLETED,INTERVENTIONAL,['NA'],Taste Questionnaire
2353,NCT05160272,Circulating C-peptide by iAUC of C-peptide during an IVGTT,Ctrough-ss (Day 28) and the change from baseline to Day 28,2022-01-07,RECRUITING,INTERVENTIONAL,['PHASE2'],
2354,NCT04791787,Hepatic Fat Content,Fructosamine level,2020-11-25,COMPLETED,INTERVENTIONAL,['NA'],
2355,NCT03144050,Clinical risk category,Ulcer incidence,2017-04-14,UNKNOWN,OBSERVATIONAL,['NA'],
2356,NCT02501538,Tissue Perfusion as Measured by TCPO2,Percent Wound Area Reduction,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
2357,NCT01975428,Participant Perceptions of Utility of Monitoring,Total Health Care Utilization and Costs.,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
2358,NCT02638805,Number (percentage) and severity of treatment-emergent adverse events (TEAEs) of nausea and/or vomiting,Change in body weight,2015-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Change from baseline in cholesterol
2359,NCT04043260,Percentage of readings below 54 mg/dl,Change in HbA1C post study treatment,2019-11-27,COMPLETED,INTERVENTIONAL,['NA'],
2360,NCT05620251,humoral immune response after second vaccine dose,Adverse events,2021-09-03,COMPLETED,OBSERVATIONAL,['NA'],
2361,NCT03902925,Pain score,Surgical complications,2019-01-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Anesthetic medications
2362,NCT00650897,Depressive symptoms,Diabetes self-care,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2363,NCT02578498,Peak glucose value,Plasma glucose variation,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
2364,NCT04427488,Circadian Rhythm Evaluation with Morningness Eveningness Questionnaire,Ferrans&Powers Quality of Life,2020-06-15,COMPLETED,INTERVENTIONAL,['NA'],
2365,NCT02532855,Percentage of Participants Who Discontinued Study Drug Due to an AE,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,2015-10-20,COMPLETED,INTERVENTIONAL,['PHASE3'],
2366,NCT01186952,Total fat mass,visceral fat thickness,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
2367,NCT04198948,Gliclazide AUC,Insulin,2019-03-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
2368,NCT05351879,"Number of Clinically Significant Abnormal Results From Laboratory measurements (hematology, clinical chemistry) and Urine analysis.",Change in time in hyperglycemic range > 10 mmol/L,2022-05-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2369,NCT02728687,BPI pain interference improvement 3 months,incidence of side effects,2017-03-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2370,NCT06296251,Body fat mass,AST,2024-03-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2371,NCT03189407,Change in estimated glomerular filtration rate,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA'],
2372,NCT04555421,Fat percentage,Blood tests changes - glycemic control,2020-10,UNKNOWN,INTERVENTIONAL,['NA'],
2373,NCT01564797,Effect of the intervention on physical activity levels in diabetics and pre-diabetic participants,Effect of the intervention on changes in knowledge and attitudes about diabetes,2008-07,COMPLETED,INTERVENTIONAL,['NA'],
2374,NCT02916680,Absence of ophthalmic complications,Change in total number of hypoglycemic events,2016-03,RECRUITING,INTERVENTIONAL,['NA'],
2375,NCT03297294,Change in Weekly Mean 24-hour Average Pain Score Using the 11 Point Numerical Rating Scale (NRS) From Baseline to Week 12,Treatment Emergent Adverse Events During Urgent Safety Measure (USM) Follow-Up,2018-03-14,TERMINATED,INTERVENTIONAL,['PHASE2'],
2376,NCT03025451,Weight,Fasting Glucose,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
2377,NCT05662189,pancreatic beta cell function (BCF),,2022-03-15,RECRUITING,INTERVENTIONAL,['NA'],
2378,NCT01593059,Target Lesion Failure (TLF),Clinical Procedural Success,2012-08,TERMINATED,OBSERVATIONAL,['NA'],
2379,NCT01302756,Gestational diabetes,Gestational hypertension,2012-04,WITHDRAWN,INTERVENTIONAL,['NA'],
2380,NCT01828970,Mean plasma glucose level measured 3 times just before the first hemodialysis session,Deaths and major cardiovascular events,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2381,NCT01098253,Hemoglobin A1C,Nine Item Patient Health Questionnaire (PHQ-9),2009-01,COMPLETED,INTERVENTIONAL,['NA'],
2382,NCT01223456,Clinical Response determined by cure rate,,2010-10,TERMINATED,OBSERVATIONAL,['NA'],
2383,NCT02800044,accuracy,acceptability,2017-03-14,TERMINATED,INTERVENTIONAL,['NA'],
2384,NCT03032354,"Area under the curve (AUC) during fasting and at 30,60,90,120 min following the start of the meal",Fasting c- peptide concentrations in ng/ml,2017-07-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2385,NCT00849563,Percentage of weight loss,Change in HOmeostasis Model Assessment of Insulin Resistance (HOMA-IR),2009-04,COMPLETED,INTERVENTIONAL,['NA'],
2386,NCT01331343,Difference in Change in A1c (%) between continuous use of CGM and control,Difference in change in A1c (%) between biweekly use of CGM and continuous use of CGM,2004-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
2387,NCT03680079,HbA1c,Depression screening,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],
2388,NCT01575080,Number of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (<100mg/dL) or Within +/- 15% (>=100mg/dL) of Laboratory Glucose Method,Number of Subject Responses That 'Agree' or 'Strongly Agree' With Questionnaire Statements,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
2389,NCT05412264,Increased pedometer steps,Waist circumference,2014-01,TERMINATED,INTERVENTIONAL,['NA'],Questionnaire
2390,NCT00005140,,,1977-09,COMPLETED,OBSERVATIONAL,['NA'],
2391,NCT02593032,Percent of Participants With Adherence at Month 6,,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
2392,NCT00270608,,,2007-03,UNKNOWN,OBSERVATIONAL,['NA'],
2393,NCT06028139,HbA1c,Healthcare cost as measured by WPAI,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2394,NCT01781884,C-peptide value,HbA1C level,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],Daily dosage of insulin (units/kg).
2395,NCT01764373,Change in aerobic fitness,Change in pain experienced,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
2396,NCT03821753,Macular capillary density in the external deep capillary network,Oxidative stress markers,2019-01-07,UNKNOWN,OBSERVATIONAL,['NA'],
2397,NCT02130505,Postprandial change in leukocyte activation,Correlation between acute glycemia and leukocyte activation,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
2398,NCT00803777,Number of Duplicate Subject BGM Results Within +/- 15mg/dL or +/- 20% of Healthcare Professional Capillary Results,Average Within Replicate Coefficient of Variation CV (Precision),2008-12,COMPLETED,INTERVENTIONAL,['NA'],
2399,NCT01642355,Reduction of Non-HDL cholesterol,Cardiovascular events,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
2400,NCT04325126,serum RBP4 level,,2020-04-01,RECRUITING,OBSERVATIONAL,['NA'],
2401,NCT06190405,Large-for-gestational age,Rate of hypertensive disorders of pregnancy,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2402,NCT00506272,average blood glucose,,2007-12,UNKNOWN,INTERVENTIONAL,['NA'],
2403,NCT00903500,Dexa scan,"Questionnaires on psycho-social determinants of physical activity, on environmental determinants of physical activity and a motivational questionnaire",2007-07,COMPLETED,INTERVENTIONAL,['NA'],
2404,NCT03437109,The prevalence of hypogonadism in patients with T2DM,,2017-12-06,COMPLETED,OBSERVATIONAL,['NA'],
2405,NCT02411032,Medication refills,LDL cholesterol,2015-04,COMPLETED,INTERVENTIONAL,['NA'],
2406,NCT01987674,HbA1c,Postprandial glycemia,2014-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Homeostasis model assessment of insulin resistance (HOMA-IR)
2407,NCT00964184,HbA1C,insulin,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
2408,NCT00997763,Angiographic in-segment late loss at angiography,Angiographic pattern of restenosis,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
2409,NCT04484480,Medial-Lateral Stability Index,,2020-01-01,COMPLETED,INTERVENTIONAL,['NA'],
2410,NCT03331432,Glucose tolerance,,2015-10-28,COMPLETED,INTERVENTIONAL,['NA'],
2411,NCT02136758,Body Mass Index,Blood Lipids,2009-04,TERMINATED,INTERVENTIONAL,['NA'],Exercise Capacity
2412,NCT02684565,Change in glucose tolerance and body composition that Are Related to Low protein BCAA Treatment,Change in glucose tolerance and body composition that Are Related to High Protein BCAA treament,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
2413,NCT00306696,Changes in Haematocrit following 7 days diuretic adminstration.,"Total body fluid & extracellular fluid, body weight, haematocrit & haemoglobin.",2002-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
2414,NCT00703209,"To determine if nerve decompression of lower extremities in patients suffering from painful symptomatic diabetic neuropathy with chronic nerve compression, has a significant impact on alleviation of pain, and improvement in quality of life.","To measure changes in quality of life. This includes medication changes, pain relief, restoration of sensation, etc.",2008-01,COMPLETED,INTERVENTIONAL,['NA'],
2415,NCT01684709,12-month glycemic control,Secondary effects upon adjustment to diabetes,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
2416,NCT03809793,Insulin Sensitivity,Change in intramuscular DAGs,2020-01-06,COMPLETED,INTERVENTIONAL,['NA'],
2417,NCT06031389,Detection of intestinal flora difference between intervention group and control group with diabetic nephropathy by bacterial 16srDNA sequencing,Statistical analysis of the degree of proteinuria relief in intervention group and control group.,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2418,NCT01588470,Myocardial Glucose Uptake,Change in Hemoglobin A1c,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
2419,NCT03588104,Change in glycemic control,Patient Assessment of Chronic Illness Care (PACIC),2018-12-03,COMPLETED,INTERVENTIONAL,['NA'],
2420,NCT01155284,2 Hour C-peptide AUC in Response to MMTT,2 Hour C-peptide AUC in Response to MMTT,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
2421,NCT03654521,Fetal interventricular septum thickness,,2018-08-01,UNKNOWN,INTERVENTIONAL,['NA'],
2422,NCT02266030,Coronary artery stenosis,Lipid metabolism,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Heart rate
2423,NCT02399657,The ratio of eyes showing reduced hard exudates in macula (1500 micrometer from foveal center),Number of eyes having increased intraocular pressure,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2424,NCT01042769,"Effect on cardiovascular death, non-fatal myocardial infarction and non-fatal stroke",Tolerability and long-term safety profile,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
2425,NCT00701454,"prevalence of diabetes, hypertension and hyperlipidemia",,2005-09,COMPLETED,OBSERVATIONAL,['NA'],
2426,NCT01415115,SCOUT Comparison,Hypertension,2007-03,COMPLETED,OBSERVATIONAL,['NA'],
2427,NCT01241448,Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c),The 30-Day Adjusted Rate of Hypoglycemic Episodes,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2428,NCT02768480,Glycemic Control,Death,2015-06,COMPLETED,INTERVENTIONAL,['NA'],Blood Pressure
2429,NCT04011683,"Incidence of cardiac arrhythmias during hypoglycaemia, euglycaemia, hyperglycaemia.",Mean amplitude of glycaemic excursions (MAGE) and cardiac arrhythmia.,2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],
2430,NCT01506895,Change from baseline in Spectral Domain Optical Coherance Tomography,Plasma concentration versus time curve (AUC) of study drug,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2431,NCT01562561,HbA1c (glycosylated haemoglobin),Adverse events,2001-06-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2432,NCT01667900,Pharmacokinetics: Half-life of Dulaglutide,Part B - Pharmacodynamics: Area Under the Plasma Glucose Time Curve From Time Zero to 4 Hours Postmeal (gAUC[0-4]),2012-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
2433,NCT00114998,,,2005-06,COMPLETED,OBSERVATIONAL,['NA'],
2434,NCT04954313,Association between changes in oral health and changes in systemic health (Flow-mediated dilation),Impact of treatment on triglycerides,2021-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
2435,NCT03179280,post-prandial euglycaemia (PPG),,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
2436,NCT01999374,Duration of sustained islet allograft function,,2013-03,RECRUITING,OBSERVATIONAL,['NA'],
2437,NCT01040962,,,2008-08,COMPLETED,OBSERVATIONAL,['NA'],
2438,NCT05379686,Percentage of time in target glucose range (PG: 3.9 - 10.0 mmol/l) during and for 1-hour after dynamic physical exercise,Coefficient of variation in PG concentrations,2022-09-21,RECRUITING,INTERVENTIONAL,['NA'],
2439,NCT03368586,FGM accuracy,Sensor related-issues,2016-07-02,COMPLETED,OBSERVATIONAL,['NA'],
2440,NCT06118671,Change of HbA1c,Change of LDL-c,2023-11-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2441,NCT00446810,Endothelial function (flow mediated dilatation - ultrasound- and reactive hyperemia- laser doppler-),Parameters of autonomic neuropathy,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2442,NCT02564913,nailfold videocapillaroscopy,,2011-12,COMPLETED,OBSERVATIONAL,['NA'],
2443,NCT04888780,Quality Criteria for Consumer Health Information (DISCERN) Website Evaluation Scale,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],
2444,NCT01400659,CGM-Glucose Area Under the Curve,frequency of adverse events (incl. SAE),2009-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
2445,NCT04547244,CRTd responders rate,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],
2446,NCT01306110,,,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
2447,NCT02010242,Albuminuria,Glucose metabolism,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Neuropathic pain
2448,NCT05199454,Brachial artery flow-mediated dilation (percent vasodilation) in 60 obese diabetic subjects,Glycosphingolipid content (ng/ml) in adiposomes from 60 obese diabetic subjects,2022-05-16,RECRUITING,INTERVENTIONAL,['NA'],
2449,NCT06018324,DTSQc,Treatment costs,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2450,NCT04754919,"The rates of diabetes related hospital episodes, including Diabetic Ketoacidosis, between the 2 study groups before and after transition",To compare the proportion of young people in the study groups who fail to attend at least one out-patient adult diabetes appointment during the first year after transition,2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
2451,NCT00261352,The change in HDL-C from baseline to the end of the randomized treatment period.,"Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",2005-03,TERMINATED,INTERVENTIONAL,['PHASE3'],
2452,NCT01633021,Social &amp; relational factors from family network data,Cognitive network utility evaluation,2012-07-05,COMPLETED,OBSERVATIONAL,['NA'],
2453,NCT02879409,Determination of the variability of HbA1c (by measurement of standard deviation of HbA1c) between the 2 diabetes treatment thresholds,Comparison of HbA1c (percent) for each subject at baseline and following sample storage of 2 years to assess HbA1c measurement stability.,2016-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2454,NCT02445079,Baseline prevalence and incident change in carotid intima media thickness,Baseline prevalence and incident change in chronic obstructive pulmonary disease,2013-12,COMPLETED,OBSERVATIONAL,['NA'],
2455,NCT05315908,Timeliness of Testing,Number of Household Members Referred for Testing,2020-11-01,TERMINATED,INTERVENTIONAL,['NA'],
2456,NCT00288977,independence from insulin injections with adequate control of blood glucose in subjects with Type 1 diabetes at one year post final transplant,,2000-09,COMPLETED,INTERVENTIONAL,['NA'],
2457,NCT05336019,Retention rate,Glycated Hemoglobin A1c (HbA1c),2022-10-01,COMPLETED,INTERVENTIONAL,['NA'],
2458,NCT00305604,Change From Baseline in HbA1c (Hemoglobin A1c) at Week 24,Rapidity of Onset of Action as Determined by Home Glucose Monitoring After 1 Week,2006-03-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
2459,NCT04634591,Changes in GI hormones concentrations during the mixed meal tolerance test (MMTT),Adipose tissue methylome,2015-09-10,RECRUITING,OBSERVATIONAL,['NA'],
2460,NCT04216849,UACR,eGFR,2020-07-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2461,NCT03919877,Classification of metabolic subphenotype,Change in area under the curve (AUC) of blood glucose level,2018-05-24,RECRUITING,INTERVENTIONAL,['NA'],
2462,NCT04569630,Accuracy of the HEADWIND-model: Diagnostic accuracy of the hypoglycemia warning system (HEADWIND) in detecting hypoglycemia (blood glucose < 3.9 and < 3.0 mmol/l) quantified as the area under the receiver operator characteristics curve (AUC ROC).,Perceived working alliance with IVA,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],
2463,NCT04976426,multidimensional network biomarkers,,2022-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2464,NCT02945332,Miles walked,Waist circumference change,2016-10,COMPLETED,INTERVENTIONAL,['NA'],Food consumption change
2465,NCT06062069,Compare the effect of CT-868 versus placebo on change in HbA1c (%) from baseline,Change in insulin doses from baseline when comparing CT-868 to placebo.,2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Time in hyperglycemia as per CGM metrics.
2466,NCT01521520,,,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],
2467,NCT04049149,Incidence of any diabetes-related micro/macrovascular endpoints (Part 3 of study),Changes in patient's Depression Anxiety Stress (Part 3 of study),2020-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2468,NCT00878891,Percent of time in normoglycemia (0.8 - 1.10 g/L),Adverse events due to the device,2009-04,TERMINATED,INTERVENTIONAL,['NA'],
2469,NCT01461330,Change from Baseline in Blood Pressure at 4 weeks,Change from Baseline in glucose control at 4 weeks,2011-02,TERMINATED,INTERVENTIONAL,['NA'],
2470,NCT01037842,the change in HbA1c from randomization to endpoint,the proportion of subjects with HbA1c <7% after 16 weeks of treatment and the change in FPG and 2-hr postprandial glucose (PPG) from baseline,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
2471,NCT03349684,Absolute change in the levels of glycosylated hemoglobin (HbA1c),Number of participants with adverse events,2018-03-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
2472,NCT03802487,Pharmacokinetic (PK) parameter: Absolute Bioavailability (F),Safety: Adverse events,2019-01-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
2473,NCT05409391,mean daily blood glucose concentration,glycemic variability,2022-06-15,COMPLETED,INTERVENTIONAL,['NA'],
2474,NCT04697485,Change in NT-proBNP,Compliance,2021-01-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
2475,NCT03765359,Changes in the insulin need during pregnancy,Inflammatory markers,2019-08-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
2476,NCT04677127,Glycemic Control Change,Self-Efficacy Questionnaire,2019-06-17,COMPLETED,INTERVENTIONAL,['NA'],
2477,NCT05954819,Change of Diabetes Self-Management,,2023-07-28,COMPLETED,INTERVENTIONAL,['NA'],
2478,NCT04597957,Change in weight (pounds) in intervention and control group.,Number of visits to Clinic based farmers market (the mercardo) per participant in Fresh Rx program.,2018-07-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
2479,NCT03486223,Insulin Sensitivity,Renal Plasma Flow (RPF),2018-05-17,COMPLETED,INTERVENTIONAL,['PHASE2'],Soluble Epoxide Hydrolase Activity in Tissue
2480,NCT03982238,total testosterone levels,free testosterone,2019-06-15,COMPLETED,INTERVENTIONAL,['PHASE4'],
2481,NCT04606576,Mean change from baseline in A1C,Mean change in fasting glucose,2020-12-15,TERMINATED,INTERVENTIONAL,['PHASE3'],
2482,NCT01240070,Cardiovascular events,cardiovascular risk factors changes,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2483,NCT03208751,Change in VO2peak in ml/kg/min,Change in max. Watts/kg bodyweight,2011-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
2484,NCT02977598,"Atherogenic index of plasma (AIP) values compared with glucose metabolism parameters like HbA1c, Fasting Plasma Glucose and 2-hour plasma glucose levels.",,2014-02,COMPLETED,OBSERVATIONAL,['NA'],
2485,NCT01223651,Accuracy of continuous glucose monitoring system (CGMS).,The effect of altitude on the recognition of hypoglycaemic symptoms.,2012-01,TERMINATED,INTERVENTIONAL,['NA'],
2486,NCT04417218,Change in Plasma 2-AAA Concentration From Baseline,,2020-08-17,COMPLETED,INTERVENTIONAL,['NA'],
2487,NCT01066130,"Psychosocial well-being as measured by interview with a medical social worker, Hospital Anxiety and Depression Scale, General Coping Questionnaire, Social Situation Questionnaire, and self-reported satisfaction with psychosocial treatment","Medical parameters that show whether the patient has reached treatment goals for his or her disease; for example, glycated hemoglobin (HbA1c) for diabetes and the Disease Activity Score (DAS) for rheumatoid arthritis",2001-01,COMPLETED,INTERVENTIONAL,['NA'],
2488,NCT03636243,Reactive Hyperemia Index (RHI),study of the peri-aortic and peri-brachial adipose tissue (TAPV),2019-10-15,RECRUITING,INTERVENTIONAL,['NA'],
2489,NCT05559515,A1C,return to normoglycemia,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],
2490,NCT02790957,Wound healing rate,Incidence of adverse events and reactions,2016-06,TERMINATED,INTERVENTIONAL,['PHASE2'],
2491,NCT03694145,Proportion of patients accurately diagnosed with retinopathy,,2018-10-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
2492,NCT02176278,Attainment of at least 3 treatment targets,Incidence of all-diabetes related endpoints,2014-06,COMPLETED,INTERVENTIONAL,['NA'],Changes in albuminuria
2493,NCT00622271,"Enroll patients and their families into either a treatment group or a wait list control (WLC) group to determine the impact of a peer and family-based group intervention on improving adjustment, coping, and functioning among adolescents with diabetes.",Diabetes-related medical improvements from baseline to post-treatment and maintained at 4 months and 6 months post-treatment.,2008-02,COMPLETED,INTERVENTIONAL,['NA'],
2494,NCT01111955,Lowering of fasting plasma glucose (FPG) throughout the study to see if there is a decrease from baseline,"Pharmacodynamics (measuring daily glucose, glucose AUC, HbA1c, lipid profiles, HPA markers, free testosterone, and SHBG)",2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
2495,NCT02173067,varition in blood glucose levels during oral surgery with local anaesthesia (lidocaina and lidocaine with epinephrine),Hemodynamic effects during the surgery with local anesthetia (lidocaine and lidocaine with epinephrine),2009-09,COMPLETED,OBSERVATIONAL,['NA'],Anxiety levels during the oral surgery with local anesthesia (lidocaine and lidocaine and epinephrine)
2496,NCT00277277,Body weight at 8 weeks; Body Mass Index at 8 weeks; Diabetes outcomes at 8 weeks,Hip/waist circumference at 8 weeks; Energy and nutrient intake at 8 weeks; Physical activity at 8 weeks,2004-08,COMPLETED,INTERVENTIONAL,['NA'],
2497,NCT02339311,Patient Activation,Diabetes associated health indicators,2012-06,TERMINATED,OBSERVATIONAL,['NA'],
2498,NCT02799563,Test 1 scores,Scores on Standardized exams,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
2499,NCT02257190,Glycemic control,Insulin sensitivity,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
2500,NCT00551954,forearm blood flow assessed by forearm occlusion plethysmography after a mixed meal,"forearm blood flow assessed by forearm occlusion plethysmography in the fasting state, plasma glucose excursion in response to the mixed meal, insulin levels in response to the mixed meal, triglyceride levels in response to the mixed meal",2006-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
2501,NCT03670602,Change From Baseline in Glycemic Control,Changes in Working Memory,2019-01-17,COMPLETED,INTERVENTIONAL,['NA'],Changes in Relative Reinforcing Efficacy of Unhealthy Food
2502,NCT05081921,Change in the International Knee Documentation Committee (IKDC 2000),Change in ultrasonographic findings in knee joint,2022-01-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2503,NCT02111226,Blood Pressure,Blood Pressure,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],
2504,NCT01908348,Endothelial function,,2013-07-18,COMPLETED,INTERVENTIONAL,['NA'],
2505,NCT00363987,changes in urine protein and GFR,plasma lipids,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
2506,NCT03785275,Beta cell mass,Beta cell mass vs. beta cell function,2017-12-06,TERMINATED,OBSERVATIONAL,['NA'],
2507,NCT06222775,Glycated hemoglobin,Changes in Medication cholesterol,2023-12-04,RECRUITING,INTERVENTIONAL,['NA'],
2508,NCT06041399,the presence of diabetic peripheral neuropathy,,2012-02-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
2509,NCT00629304,Comparison of HbA1c mean between the 3 groups,"Effective number of patients carrying on the use of the system in routine care, at their own expense and in agreement with their physician",2007-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
2510,NCT01038648,1. Rate of conversion of IGT to diabetes. 2. Relative reduction of incidence of diabetes by Sitagliptin among people with IGT compared to Placebo. 3. Increase in reversal of IGT to NGT,1. Beneficial effects in beta cell function. 2. Changes in insulin resistance 3. Improvement in cardiovascular risk factors by Sitagliptin.,2011-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
2511,NCT05972954,Number of Treatment Emergent Adverse Events (TEAE),Pharmacokinetics: Cmax [ng/ml],2023-05-22,RECRUITING,INTERVENTIONAL,['PHASE2'],
2512,NCT04104243,Comparison of Engagement and Retention of Men vs Standard Diabetes Prevention Program,Compare change in hemoglobin A1c over 6 months,2021-08-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2513,NCT03826381,Prevalence of NAFLD and actual estimate of liver signal measured by MR spectroscopy,"NAFLD, as measured by MR spectroscopy, and its association with glucose profiles in relation to impaired renal function",2019-05-06,COMPLETED,OBSERVATIONAL,['NA'],
2514,NCT06334302,Delta postprandial glucose level,Labeled Magnitude Scale (gLMS),2024-03-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2515,NCT01077570,Number of serious adverse drug reactions (SADRs) including major hypoglycaemic (low blood sugar) events,Change in postprandial blood glucose (PBG),2010-03,COMPLETED,OBSERVATIONAL,['NA'],
2516,NCT01552603,Mean Percent of Time in Target Blood Glucose Range,Mean Deviation From Target Blood Glucose,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
2517,NCT03490942,Plasma Epinephrine,,2018-03-15,TERMINATED,INTERVENTIONAL,['PHASE2'],
2518,NCT00842972,,,na,COMPLETED,OBSERVATIONAL,['NA'],
2519,NCT01217476,"Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Origin After a Maximum of 12 Weeks Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition to Best Local Cares",Relative Wound Area Regression of 40% or More at 6 Week,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
2520,NCT01354015,Change in HbA1c,Change in HbA1c Over 3 Months,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
2521,NCT01101568,AUC(0-inf) and Cmax of simvastatin/simvastatin acid alone and in the presence of GSK1292263,"PK parameter values: AUC(0-24h), Cmax, tmax and t1/2 for GSK1292263 and assessment of steady-state",2010-04-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
2522,NCT00353600,,,1994-08-19,COMPLETED,OBSERVATIONAL,['NA'],
2523,NCT01996995,complete cure of the target nail,Change surface healthy target nail / all clinically infected toes patients free of hyperkeratosis,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
2524,NCT01122979,Proportion of patients that reach the target of HbA1c ≤7% without confirmed nocturnal hypoglycaemia in each treatment group and the respective CI 90%.,Creatinine clearance variation,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
2525,NCT04100278,LDL-c change,DASS-C21scale score change,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Diabetes complications
2526,NCT03528707,liver stiffness (LS),cytokines levels,2015-04-14,COMPLETED,INTERVENTIONAL,['NA'],
2527,NCT02812238,Mean IL-1 Beta Release From Peripheral Blood Mononuclear Cells During Refeeding After 24 Hour Fast,,2016-06-23,COMPLETED,INTERVENTIONAL,['NA'],
2528,NCT00067678,,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2529,NCT00732524,The primary outcome was the patients' ability to avoid repeat ED visits or hospitalization in either of the discharge regimens.,The secondary outcomes included the number of subjects who reached a fasting or pre-meal BG goal of 80 to 130 mg/dl and assessment of the beta cell function at the beginning and end of the study as measured by C-peptide levels during OGTT testing.,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
2530,NCT02467478,Urinary Function Marker in CKD,Resting Metabolic Rate (RMR),2015-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
2531,NCT01809288,"Determine if there are differences in African, African-American and white women in the relationship between triglyceride levels, (a frequently used screening test for diabetes and heart disease) glucose tolerance status and insulin resistance.",Determine if there are race or ethnic differences in the pancreatic secretion of insulin relative to the degree of insulin resistance.,2013-09-26,COMPLETED,OBSERVATIONAL,['NA'],
2532,NCT01147718,The pharmacokinetic parameters of digoxin with and without albiglutide,Safety of digoxin with and without albiglutide,2010-06-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
2533,NCT00486629,Excessive weight gain during pregnancy,"macrosomia, requirement of delivery procedures",2004-07,RECRUITING,INTERVENTIONAL,['NA'],
2534,NCT03104933,Levels o Copeptin as predictor of vasopressor requirements (measured by index inotropic and vasopressor dependency ratio) and fluid requirement,Levels of proADM and Copeptin as predictors of lactate clearance,2016-07-01,COMPLETED,OBSERVATIONAL,['NA'],
2535,NCT06002997,Number of pregnant women with Periodontal disease,Percantage of HbA1C (Glycosylated haemoglobin),2012-05-03,COMPLETED,OBSERVATIONAL,['NA'],
2536,NCT03002116,Mean foot tissue temperature,,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
2537,NCT01754662,"Insulin resistance, lipid profile",Endothelial function,2011-10,COMPLETED,INTERVENTIONAL,['NA'],
2538,NCT04880291,Safety and tolerability following single ascending doses of GFB-024,Characterize the incidence and persistence of immunogenicity of GFB-024 following repeated doses,2021-05-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
2539,NCT02480465,The mean percent change of HbA1c,"Safety evaluation - physical examination, vital sign, laboratory, adverse event",2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2540,NCT00529815,This study will determine if a real-time continuous glucose monitoring system is a more effective method of improving glycemic control in patients with type 2 diabetes than is episodic self blood glucose monitoring in the both the short- and long-term.,"The results of this study could also provide information on the impact of the two methods of glycemic monitoring on number of hypoglycemic and hyperglycemic events, and quality of life.",2007-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2541,NCT00690638,To demonstrate changes in HbA1c,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
2542,NCT05219812,Change in weekly mean 24-hour average pain intensity score using the 11-point Numeric Rating Scale (NRS) from baseline to the end of intervention,Number of participants with treatment emergent adverse events (TEAE),2022-02-16,COMPLETED,INTERVENTIONAL,['PHASE2'],
2543,NCT02081014,Serious Adverse Events,Glucose Tmax (Post-insulin),2014-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
2544,NCT00214786,Achievement of Insulin Independence at 12-month Post Transplant,The Quality of Life of the Recipients Measured With the RAND 36-item Short Form Health Survey,2005-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
2545,NCT01137812,Change in HbA1c From Baseline to Week 52,Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
2546,NCT00044148,,,2002-07-16,COMPLETED,INTERVENTIONAL,['PHASE2'],
2547,NCT00468117,Proportion of patients w/HbA1c </= to 6.5% and an absence of severe hypoglycemic events or a reduction in HbA1c of at least 1 point and an absence of severe hypoglycemic events,"Reduction in insulin requirements, HbA1c, MAGE, LI, HYPO score, fasting glucose, beta score, serum creatinine, c-peptide levels, MMTT, Clarke Survey, FSIGT, CGMS, number of hypoglycemic events, renal impact, cardiovascular impact, and quality of life",2007-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2548,NCT02808182,whole-body organ-specific DFA partitioning,Lipoprotein lipase activity,2017-01-17,COMPLETED,INTERVENTIONAL,['NA'],
2549,NCT05210504,Change in level of 2-AAA in urine,,2022-03-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
2550,NCT03689374,Change From Baseline in Glycated Haemoglobin (HbA1c),Change From Baseline to Week 52 in Diabetes Quality of Life Clinical Trial Questionnaire (DQLCTQ-R): Scores From the 8 Domains,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2551,NCT04159922,Score of the Bortner self-questionnaire,,2019-12-03,COMPLETED,OBSERVATIONAL,['NA'],
2552,NCT04233138,Users' satisfaction of the SUPPORT platform,Knowledge about diabetes self-management,2020-02-05,UNKNOWN,INTERVENTIONAL,['NA'],
2553,NCT06134986,Change in percent body weight,Change in ketones,2023-11-20,RECRUITING,INTERVENTIONAL,['NA'],
2554,NCT04335565,Postprandial glucose levels,Subjective feelings of satiety,2020-03-03,WITHDRAWN,INTERVENTIONAL,['NA'],
2555,NCT01364298,Change From Baseline in Average Numeric Pain Intensity Scale (NPIS) Score at Day 84,Number of Participants With Adverse Events (AEs),2011-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
2556,NCT03169530,Cardiovascular Disease or Death,Diabetes,2018-02-05,TERMINATED,INTERVENTIONAL,['NA'],Pre-Diabetes
2557,NCT00427986,"Retinal thickness estimated by the fast protocol of the StratusOCT (0, 2, 4, 8, 10, 15, 20, 30, 60, 90, 120 and 180 min).","Side effects during the three-hour examination period, to evaluate if caused by galactose per se or by an increase in intracapillary osmotic pressure.",2007-01,TERMINATED,INTERVENTIONAL,['NA'],
2558,NCT01751360,Blood Glucose,,2013-04-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2559,NCT04460092,Pain when insulin injection,,2020-05-25,UNKNOWN,INTERVENTIONAL,['NA'],
2560,NCT01232946,Myocardial Fatty Acid Esterification Rate,,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
2561,NCT01094418,Nerve conduction parameters,Clinical neuropathic scoring system,2009-06,COMPLETED,OBSERVATIONAL,['NA'],
2562,NCT04023539,Glycated hemoglobin,Blood pressure,2019-09-04,COMPLETED,INTERVENTIONAL,['NA'],
2563,NCT00668954,Percent change of oxidant stress and lipid oxidation,High Sensitivity C-reactive protein HsCRP,2008-04,COMPLETED,INTERVENTIONAL,['NA'],
2564,NCT04297592,Periprosthetic joint infections,Wound complication,2020-06-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4'],
2565,NCT02695082,Incidence of Acute Kidney injury (AKI),,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],
2566,NCT03550963,between-group difference in glucose control,between-group difference in undesirable clinical outcome,2018-06-23,UNKNOWN,INTERVENTIONAL,['NA'],
2567,NCT04983979,Proportion of patients on Maximum dose (300mg) Irbesartan therapy at 12 weeks compared to placebo,Change in GFR at the end of study from baseline,2022-06-17,TERMINATED,INTERVENTIONAL,['PHASE2'],
2568,NCT01294423,Adjusted Mean Change in HbA1c Levels,Adjusted Mean Change in Body Weight,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
2569,NCT05610046,Glycaemic response (Matsuda index),Gutt insulin sensitivity index,2023-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2570,NCT02169570,Change in chest X-ray,Change in Random Blood Sugar (RBS),2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2571,NCT06106035,HbA1c,Food Cost,2024-02-13,RECRUITING,INTERVENTIONAL,['NA'],
2572,NCT06252038,Weight change across 12 months,CDC-NDPP Physical Activity Goal,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2573,NCT03522870,Glycosylated Hemoglobin A1c,EQ-5D-5L,2018-05-01,COMPLETED,INTERVENTIONAL,['NA'],
2574,NCT00881543,"secretion of glucose, insulin, glucagon, C-peptide and lipid profile after isocaloric diets",Washout of dipeptidyl peptidase IV inhibitors after one month without the drug,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
2575,NCT00875459,The frequency of occurrence of hypoglycemia measured quarterly over one year.,"Changes in total daily:prandial insulin dose, insulin dose, body weight, insulin antibody titers, the effects of insulin antibodies on glycemic control, individual and group mean %HbA1c measured quarterly and over one year.",2007-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
2576,NCT00603499,Reduction in the systolic and diastolic blood pressures,Average increase of serum magnesium levels Changes in lipid profile,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
2577,NCT02256293,Acceptability,Diabetes self-management,2015-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2578,NCT03985306,Qualitative assessment of the inforatio technique,,2019-03-20,COMPLETED,INTERVENTIONAL,['NA'],
2579,NCT01982565,Measure the efficacy of the NOx generating dressing,Measure the rate of repeat ulcers and breakdown in healing.,2013-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2580,NCT05256875,Measurement of the agreement between the prevalence rates of non-adherence obtained by LC-MS/MS and the prevalence as diagnosed by (Medication Possession Ratio) MPR ≤0.80,Determination of significant predictors of non-adherence as diagnosed by urine LC-MS/MS,2022-08-30,RECRUITING,OBSERVATIONAL,['NA'],
2581,NCT06265181,Type 2 Diabetes Self-Management Scale,Introductory Features Form,2024-03-27,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2582,NCT05581043,Blood glucose following the OGTT,"Plasma concentrations of 3-OHB, insulin, C-peptide, glucagon like peptide-1 (GLP-1), cholecystokinin (CCK), acetaminophen, free fatty acids along others.",2023-01-12,COMPLETED,INTERVENTIONAL,['NA'],
2583,NCT06232421,Number of patients with trophic ulcers cured,percentage reduction in the non-epithelialized area of the wound surface in relation to the initial one,2024-02-08,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2584,NCT02730949,efficacy of DCI oral supplementation on metabolic control,Insulin Requirement (I.R.) IU/kg,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
2585,NCT00381134,Change in 24 hour urine albumin to creatinine ratio after 12 months of treatment,plasma aldosterone level,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
2586,NCT01756196,episodes of systemic reactions after spinal steroid injection,,2011-10,COMPLETED,OBSERVATIONAL,['NA'],
2587,NCT06117358,Prevalence of Pre-Diabetes in Overweight and Obese children and adolescents in Assiut governorate,,2023-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2588,NCT04537520,Wound area,,2020-07-02,COMPLETED,INTERVENTIONAL,['NA'],
2589,NCT00747383,Comparison of GLP-1 response at baseline and after 3 months treatment of both groups.,,2008-09,COMPLETED,INTERVENTIONAL,['NA'],
2590,NCT04089462,Percentage of time spent in the hypoglycemic range (CGM <3.9 mmol/l),Question about patient preference regarding the two study arms,2019-09-30,COMPLETED,INTERVENTIONAL,['NA'],
2591,NCT06218992,MMP-9,Thermal imaging: Ocular surface temperature (OST),2023-12-30,RECRUITING,OBSERVATIONAL,['NA'],
2592,NCT04176276,Urine expression of miR-25,,2018-03-01,COMPLETED,OBSERVATIONAL,['NA'],
2593,NCT02057861,reversal of diabetic patients,hemodynamic changes,2013-01,COMPLETED,OBSERVATIONAL,['NA'],
2594,NCT03721874,Change in nightly substrate oxidation measured as respiration quotient (RQ) during the sleeping period,Change in systolic and diastolic blood pressure,2019-04-30,COMPLETED,INTERVENTIONAL,['PHASE4'],
2595,NCT04945070,HbA1C,Treatment Satisfaction,2021-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],hsCRP
2596,NCT04810676,Cmax of CKD-383,CL/F of CKD-383,2021-04-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
2597,NCT00442845,Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks.,Change from baseline in apolipoprotein-B (Apo-B) and change from baseline in glycosylated hemoglobin (HbA1c) was assessed at 12 weeks.,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2598,NCT02007577,Quantification of Insulin Action With the Insulin Suppression Test (IST),Quantification of Insulin Clearance With the Graded Glucose Infusion Test (GGIT),2010-07,COMPLETED,INTERVENTIONAL,['NA'],
2599,NCT01148238,T-reg,"HLA, anti-GAD, anti-IA2, white blood count, CRP, fasting C-peptide, HbA1c",2012-08,WITHDRAWN,OBSERVATIONAL,['NA'],
2600,NCT00000112,,,na,UNKNOWN,OBSERVATIONAL,['NA'],
2601,NCT05950282,"Assessment of Fasting Insulin levels and HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) scores among different groups stratified by age, sex, race/ethnicity, BMI, and PCOS (Polycystic Ovary Syndrome) diagnosis.","Identify any significant interactions or relationships between the primary outcomes (Fasting Insulin and HOMA-IR) and the demographic and clinical factors, including age, sex, race/ethnicity, BMI, and PCOS diagnosis.",2023-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2602,NCT02481596,Adherence to Diet - Problem Eating Behavior,Diabetes Self-efficacy,2016-05-23,COMPLETED,INTERVENTIONAL,['NA'],
2603,NCT04228484,Change in [plasma C-peptide] / [plasma glucose] after near-normalisation of plasma glucose,,2020-01-07,COMPLETED,INTERVENTIONAL,['NA'],
2604,NCT00414986,HEDIS-like measures of acute phase management of depression,Patient report (by survey) of their primary care experience,2005-09,COMPLETED,INTERVENTIONAL,['NA'],
2605,NCT01850810,Hunger,Prospective Consumption,2013-05,COMPLETED,INTERVENTIONAL,['NA'],
2606,NCT01617031,Intensity of platelet agregation following exposure to 0.5 mg/ml arachidonic acid,Closure time after exposure of total blood to Collagen-epinephrine,2010-09,COMPLETED,OBSERVATIONAL,['NA'],
2607,NCT00888836,"To assess the efficacy of bariatric surgery in inducing partial or total remission of type 2 diabetes mellitus, as compared to standard medical anti-diabetic care (STC).","Secondary endpoints include percentage change of fasting plasma glucose levels, glycated hemoglobin, weight, waist circumference, blood pressure, cholesterol, HDL-cholesterol and triglycerides, hard cardiovascular risk and quality of life.",2009-04,COMPLETED,INTERVENTIONAL,['NA'],
2608,NCT06137469,Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.：(AUC0-300min),Immunogenicity indicators: anti-Noiiglutide antibodies,2023-12-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
2609,NCT03254368,"Safety and tolerability as assessed by change in medication use, vital signs, physical examination findings, mental well-being questionnaires, laboratory evaluations, and electrocardiogram results",Change in patient reported outcomes measures,2017-09-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
2610,NCT00380445,To explore whether vildagliptin augments insulin mediated inhibition of adipose tissue lipid mobilization following a mixed meal in patients with type 2 diabetes,To measure the effects of vildagliptin on tissue carbohydrate metabolism (skeletal muscle),2006-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2611,NCT03640221,Muscle sympathetic nerve activity (bursts/minute),Arterial baroreflex gain.,2018-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
2612,NCT00104182,HbA1C,Blood glucose,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
2613,NCT01980524,MYCL,Ejection Fraction,2013-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Stroke Volume
2614,NCT04673656,Changes in HOMA-IR,Changes in fasting insulin,2021-04-18,COMPLETED,INTERVENTIONAL,['NA'],
2615,NCT05334173,Excess Weight Loss (%EWL),Remission or improvement of Obstructive Sleep Apnea Syndrome,2019-01-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Quality of life after surgery
2616,NCT05257460,Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on continuous glucose monitoring (CGM),Total bolus insulin dose (units/day),2022-01-25,COMPLETED,INTERVENTIONAL,['NA'],Utility evaluation is the frequency and duration of use of the closed-loop system at home
2617,NCT03631108,Iris Vessel Geometric Characteristics,,2018-10,UNKNOWN,OBSERVATIONAL,['NA'],
2618,NCT06310148,The cost-effectiveness for delivering the CDCC Pilot Scheme on the incremental cost-effectiveness ratio,Amount of direct medical costs between two groups,2024-01-18,RECRUITING,INTERVENTIONAL,['NA'],
2619,NCT00287404,,,2005-10,COMPLETED,OBSERVATIONAL,['NA'],
2620,NCT05594706,"Correlation of 1,5-anhydroglucitol levels in patients with longstanding disease with indirect markers of beta-cell function and mass",,2023-01-27,RECRUITING,OBSERVATIONAL,['NA'],
2621,NCT01102959,Number the answers correct or incorrect on carbohydrate counting in portions of real food,,2010-03,UNKNOWN,INTERVENTIONAL,['NA'],
2622,NCT01425866,Mean change in glycated haemoglobin (GlyHb),Change in blood pressure,2011-10,COMPLETED,INTERVENTIONAL,['NA'],
2623,NCT01665352,Change from baseline in HbA1c (%) as compared to placebo,Subject achievement of body weight loss ≥ 2%,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
2624,NCT00387101,To determine the efficacy and safety of Dermal-LSR plus Standard of Care (SOC) for the treatment of chronic diabetic foot ulcers in comparison to treatment with SOC alone.,,2006-02,TERMINATED,INTERVENTIONAL,['PHASE3'],
2625,NCT05944549,Percent weight loss,Change in food security as assessed by the National Health Interview Survey(NHIS) Food Insecurity Screener,2023-05-12,RECRUITING,INTERVENTIONAL,['NA'],
2626,NCT01083108,The primary outcome of the study is the change in total body insulin sensitivity due to RYGBP alone using the euglycemic hyperinsulinemic clamp technique.,"The secondary outcomes are changes in insulin sensitivity, insulin secretion, and gut hormones due to caloric restriction alone, caloric restriction plus RYGBP, and RYGBP alone.",2011-03-31,TERMINATED,INTERVENTIONAL,['PHASE2'],
2627,NCT02012972,NCDs and NCD risk factors in the study population by time on ART,Changes in NCD risks or prevalence,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
2628,NCT02715791,Diabetes self-efficacy,Physical Activity,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
2629,NCT00424411,Primary outcome is 24 week change in baseline in HbA1c.,Patient satisfaction and preference.,1999-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
2630,NCT00309231,Efficacy,,na,WITHDRAWN,OBSERVATIONAL,['NA'],
2631,NCT00157729,"Determine the efficacy of MC-1 and of the combination of MC-1/ACE inhibitor on metabolic function as measured by insulinemia, fasting serum glucose, glycated hemoglobin, and triglycerides.",mean changes in creatinine,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
2632,NCT01473147,Mean amplitude of glycaemic excursions (MAGE),homeostasis model assessment(HOMA),2011-10,COMPLETED,INTERVENTIONAL,['NA'],
2633,NCT05810545,Maternal health - Gestational diabetes mellus,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],
2634,NCT01741181,Endothelial function as assessed by the reactive hyperemia index and endothelial progenitor cells,No. of circulating endothelial cells and endothelial microparticles,2012-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
2635,NCT03078491,Change in duration of hypoglycemia,Barriers and facilitators of CGM use,2017-03-30,COMPLETED,INTERVENTIONAL,['NA'],
2636,NCT00717158,Health Care utilization and costs using claims data,Change in quality of life,2001-05,COMPLETED,INTERVENTIONAL,['NA'],
2637,NCT05333393,Blood Glucose Levels,Regulating the Nutrition of Children according to their blood sugar level,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],
2638,NCT01643967,Evaluate the efficacy and safety of ozone released by the device Philozon Medplus in the treatment of patients with diabetic foot.,Evaluate the release of ozone in the environment by equipment MEdplus after insufflation rectal in patients with diabetic foot.,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],
2639,NCT01005069,Reduction of venous Fasting Plasma Glucose from baseline,Change in lipid profile from baseline,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2640,NCT00207233,Change in expression of selected adipocyte metabolic genes,,2004-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2641,NCT04237129,GIRmax,Safety and local tolerability,2019-08-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
2642,NCT02672748,Adult BMI change,child BMI z-score change,2015-11,COMPLETED,INTERVENTIONAL,['NA'],
2643,NCT02181842,Blood Glucose-Related Laboratory Parameters (HbA1c Values) at Each Time Point,Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs),2009-01-26,COMPLETED,OBSERVATIONAL,['NA'],
2644,NCT04926298,Time spent in hyper and hypoglycemia during Marathon,Time spent in hyper and hypoglycemia during PR1 and PR2,2020-08-15,UNKNOWN,OBSERVATIONAL,['NA'],
2645,NCT03562767,Percentage of Participants That Are Enrolled and Attend the Study the Study Sessions Compared to Enrolled,Change in Diabetes Health Belief Scale,2018-12-05,TERMINATED,INTERVENTIONAL,['NA'],
2646,NCT04005287,"Incidence and Treatment-Emergent Adverse Events as assessed by a dermal assessment (Draize score (scale 0.0 - 4.0) score of skin erythema, edema, pruritus and dryness score) of the dosing area",Norfolk Quality of Life Measure (QOL) Patient Questionnaire,2019-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Patients' Global Impression of Change
2647,NCT01106677,Change in HbA1c From Baseline to Week 26,Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
2648,NCT06251895,SII,readmission,2021-08-01,COMPLETED,OBSERVATIONAL,['NA'],
2649,NCT02322268,Glycemic control,Lipid profile,2014-08,COMPLETED,INTERVENTIONAL,['NA'],
2650,NCT05038137,Assess feasibility and adherence to time period of eating recommendations in both study groups.,Continuous Glucose Monitor (CGM) derived metrics,2022-05-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2651,NCT01449019,The incretin effect,Plasma concentrations of Glucose-dependent insulinotropic polpypeptide (GIP),2006-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
2652,NCT01923389,Number of Participants With Positive Anti-PF-05231023 Antibodies and Neutralizing Antibodies.,Observed Accumulation Ratio (Rac) for Cmax and AUCtau of PF-05231023 (C-terminus and N-terminus PF-05231023 and Total CVX-2000 Antibody Scaffold),2013-09,TERMINATED,INTERVENTIONAL,['PHASE1'],
2653,NCT04768673,AUClast,CL/F,2021-03-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
2654,NCT03528720,The earliest and most frequently occurring fundus quadrant of diabetic retinopathy in fundus fluorescein angiography.,,2017-06-13,COMPLETED,OBSERVATIONAL,['NA'],
2655,NCT02308800,"Compare clinical outcomes (time to wound healing, number of surgeries) with Negative Pressure Wound Therapy with irrigation and Negative Pressure Wound Therapy without irrigation.",Compare quantitative cultures (bacterial load as measured by qPCR) and number of clinical infections in patients treated with NPWT with irrigation compared to conventional NPWT.,2015-01,WITHDRAWN,INTERVENTIONAL,['NA'],Compare responses to the HR-QOL questionnaires of patients treated with NPWT with irrigation compared to conventional NPWT.
2656,NCT02325622,Association between mean plasma glucose concentration and glycated hemoglobin in cirrhosis,,2013-12,UNKNOWN,OBSERVATIONAL,['NA'],
2657,NCT02614170,Measure C-peptide and Insulin in Healthy Individuals,,2015-03,COMPLETED,OBSERVATIONAL,['NA'],
2658,NCT03185741,Medication Adherence: Pill Count,Treatment Knowledge,2018-01-05,COMPLETED,INTERVENTIONAL,['NA'],
2659,NCT00845156,Insulin Resistance,,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
2660,NCT00521820,Progression of Congestive Heart Failure.,All cause mortality.,2000-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
2661,NCT05847075,Plasma HSP72,Inflammatory/anti-inflammatory markers,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2662,NCT05050266,Engagement in virtual care for preventive services,Participation and engagement: ROSE,2021-10-21,RECRUITING,INTERVENTIONAL,['NA'],
2663,NCT00466362,,,2007-04,UNKNOWN,OBSERVATIONAL,['NA'],
2664,NCT06190808,Mean Absolute Relative Difference (MARD).,Adverse event nature and frequency,2024-01-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2665,NCT02150889,Differences in insulin sensitivity between groups,Differences in fitness level between groups,2014-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Differences in body composition between groups
2666,NCT02727608,Increased survival of ICC´s transplanted as measured by peak c-peptide,Bleeding,2016-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Effect of eculizumab on IBMIR
2667,NCT01518166,Area under the curve of digoxin,Adverse events,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
2668,NCT00713011,Change in Proteinuria,Change in index of glycemia (HbA1c),2008-11,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
2669,NCT01509001,glucose control,haemodynamic improvement,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2670,NCT02463500,Adverse Events,,2015-01,COMPLETED,OBSERVATIONAL,['NA'],
2671,NCT06272565,Untargeted metabolomics for metabolic profile using UHPLC/MS,Central subfield thickness,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2672,NCT05413746,Changes in wound size,Time to removal of non-viable tissue from wound bed,2018-02-05,COMPLETED,INTERVENTIONAL,['NA'],
2673,NCT05961163,"Composite index of nausea, vomiting, tiredness/fatigue, vertigo, circulation problems/syncopes, muscle cramps, headache, extrasystoles, palpitations, edemas, shortness of breath, depressive mood, anxiety, mental confusion","Reasons for drop out (eg, bad health condition, hospital admission, death)",2023-07-24,TERMINATED,OBSERVATIONAL,['NA'],
2674,NCT01130558,Mean blood Glucose,rate of use of sliding scale insulin,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
2675,NCT00731432,The primary endpoint of the study will be the comparison between THPP and PP in reducing the gingival index (GI) at the site of patch placement,Beta-glucuronidase enzyme found in gingival crevicular fluid (GCF) of the tested sites. The GCF will be collected from the second most posterior tooth in all four quadrants.,2008-08,SUSPENDED,INTERVENTIONAL,['PHASE2'],
2676,NCT04542148,Time In Range,Umbilical cord blood surfactant protein D (SP-D),2022-02-10,RECRUITING,INTERVENTIONAL,['PHASE2'],
2677,NCT00373269,FVIIa,TF-PCA,2001-10,COMPLETED,OBSERVATIONAL,['NA'],
2678,NCT01962701,Fetal plasma copeptin concentration,,2013-01,COMPLETED,OBSERVATIONAL,['NA'],
2679,NCT02212665,Changes in insulin sensitivity,Patient-reported outcome measure,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
2680,NCT02556554,Change(s) in Behavior and/or Concerns of Diabetics.,Evaluation of Maternal and Fetal Outcomes.,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
2681,NCT00295555,Normalization of high blood pressure,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2682,NCT03436693,The proportion of subjects with a decline in estimated glomerular filtration rate (eGFR) from baseline at Week 104,Change from baseline in urine albumin-to-creatinine ratio (UACR) at each assessment time point,2018-02-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
2683,NCT05631054,Best corrected visual acuity at the last follow-up,The occurrence of vitrectomy for the fellow eye,2022-11-10,RECRUITING,OBSERVATIONAL,['NA'],
2684,NCT00325962,To compare oral 6R-BH4 to placebo with respect to change from baseline in arterial systolic blood pressure after 8 weeks of treatment in subjects with poorly controlled hypertension.,To assess the safety of oral dosing of 6R-BH4 in subjects with poorly controlled hypertension,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2685,NCT01789021,Differences in accuracy between blood glucose monitoring systems across the overall tested glucose range by comparing the mean absolute value of relative (percent) difference (MARD) between the meter value and the reference value,,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
2686,NCT03928340,2 hours post prandial blood sugar measurement.,neonatal Intensive care admission,2019-04-29,COMPLETED,INTERVENTIONAL,['PHASE4'],
2687,NCT04186377,Change of ulcer surface area,Incidence of amputations,2020-05-15,TERMINATED,INTERVENTIONAL,['PHASE2'],
2688,NCT05398783,Mean difference and limits of agreement between measured and predicted BSA,,2022-10-25,RECRUITING,OBSERVATIONAL,['NA'],
2689,NCT03654989,"Comparison of wound closure between the 3 groups: iontophoresis of treprostinil, iontophoresis of placebo, and standard of care, over12 weeks.",Evaluation of safety via the appearance of the wound,2020-01-28,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2690,NCT01463449,Low grade inflammation in adipose tissue after weight loss induced by gastric bypass,Quantity of fat in the liver,2011-11,COMPLETED,OBSERVATIONAL,['NA'],
2691,NCT01610219,Change in Dietary Intake,Change in Parent BMI,2008-08,COMPLETED,INTERVENTIONAL,['NA'],
2692,NCT05441267,Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE+),Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE),2023-03-13,RECRUITING,INTERVENTIONAL,['PHASE4'],
2693,NCT02207777,Changes in hepatic insulin sensitivity,Changes in fat free mass,2014-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2694,NCT00517465,Glucose AUC,Pharmacokinetic parameters,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
2695,NCT02977442,Effects of exercise on mitochondrial dynamics,Insulin sensitivity,2016-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2696,NCT01852968,alterations in hippocampal glucose transport kinetics,alterations in hippocampal neurochemistry,2013-05,COMPLETED,OBSERVATIONAL,['NA'],
2697,NCT05147324,Change in percent time in range,Change in hemoglobin A1c percentage,2021-12-13,COMPLETED,INTERVENTIONAL,['NA'],
2698,NCT03992248,Hepatic glycogen,Insulin sensitivity,2019-01-31,COMPLETED,INTERVENTIONAL,['NA'],
2699,NCT05481944,Left ventricular myocardial longitudinal strain measured by MRI (%),Epicardial fat volume measured from ECG gated Dixon MRI images,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2700,NCT01580917,Latency time after occlusive loading,Response time to Maximum Flow,2007-11,COMPLETED,OBSERVATIONAL,['NA'],
2701,NCT01074801,The primary outcome measure is time spent with plasma glucose concentration in the target range (3.9-10.0 mmol/L) between 24:00 on Day 1 to 08:00 on Day 3.,Secondary outcomes will include: (i) Total and basal insulin delivery between 24:00 on Day 1 and 08:00 on Day 3 (36 hours) (ii) CGM glucose levels between 24:00 on Day 1 and 08:00 on Day 3 (36 hours),2010-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
2702,NCT00636766,Ultrasound and immunohistochemical parameters of plaque stability; novel cardiovascular risk factors,Long-term cardiovascular outcomes,2005-09,COMPLETED,INTERVENTIONAL,['NA'],
2703,NCT01398423,Safety,Efficacy,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2704,NCT05126251,The scores of short form health survey (SF-36),,2021-12-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2705,NCT01650324,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Change of Dipeptidyl Peptidase 4 (DPP4) Activities Between 48 Hrs Post Dose and 0 hr Predose,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
2706,NCT00485056,The primary endpoint will be the TDI E' ratio which is the relatively preload independent measure of ventricular diastolic function.,E/E' measured by TDI (a non-invasive measure of preload).,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
2707,NCT00837759,Change in C-peptide,Change in ZnT8 Autoantibody Titer,2009-02,TERMINATED,INTERVENTIONAL,['PHASE2'],
2708,NCT02108353,Efficacy (AUC),Efficacy AUC insulin 12 weeks,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2709,NCT01228240,,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
2710,NCT01086150,Pain Scores From Composite Visual Analog Scale,"Keratinocyte Immunoreactivity of Nav1.6, Nav1.7, CGRP",2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2711,NCT01556529,"HbA1c, incidence of typical diabetes complications",quantitative diabetes typical complication risk profile,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
2712,NCT00398853,Insulin Sensitivity as assessed with hyperinsulinemic-euglycemic clamps,"body weight and fat distribution, myocellular and intrahepatic lipid content as assessed with MRS scans",2003-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
2713,NCT06027151,PERIODONTAL POCKET DEPTH (PPD),RECESIION OF GINGIVAL MARGIN:,2022-10-06,COMPLETED,INTERVENTIONAL,['NA'],
2714,NCT03887416,Changes in nighttime blood pressure,Changes in HBA1C,2019-04-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2715,NCT06217887,Change of olfactory brain activation by fMRI,Change of metabolism,2020-05-10,RECRUITING,INTERVENTIONAL,['NA'],
2716,NCT05924516,Use of coping strategies,Usability,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Energy level
2717,NCT04438018,HbA1c,Marker of inflammation #4: interleukin-1 receptor antagonist (IL-1Ra),2020-07-01,COMPLETED,OBSERVATIONAL,['NA'],Fear of diabetes complications
2718,NCT00280085,Pancreatic perfusion,,2005-12,TERMINATED,INTERVENTIONAL,['NA'],
2719,NCT01874431,Ratio of UACR at Day 90 to UACR at Baseline,Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale),2013-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
2720,NCT04800536,QTc interval,Plasma glucose decline rate and symptomatic response,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2721,NCT02612844,The number of treatment emergent adverse events,The maximum glucose infusion rate,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
2722,NCT01953224,Change in Physical Activity From Baseline to 12 Weeks,Change in Motivation From Baseline to 12 Weeks,2014-09,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants With Adverse Events
2723,NCT00479791,"Insulin, and glucose",Triglycerides,1997-04,COMPLETED,INTERVENTIONAL,['NA'],
2724,NCT05198895,Accuracy of the Glyconics-SX System in detection of DM status based on dichotomised outcomes as per the chemometric model (HbA1c measurements as internal control),"Analysis of safety outcomes (AEs, SAEs), including any safety outcomes listed in the comments, such as potential, suspected de novo diabetes diagnosis cases based on HbA1c readings",2022-08-01,COMPLETED,INTERVENTIONAL,['NA'],
2725,NCT00973492,"MAGE, ADRR, Lability Index and LBGI computed with the blood glucose measurement or CGMS",anti-insulin antibodies by ELISA,2007-09,UNKNOWN,OBSERVATIONAL,['NA'],
2726,NCT03542240,Change in intestinal barrier function,,2018-09-19,COMPLETED,INTERVENTIONAL,['NA'],
2727,NCT05662826,Satisfaction,System usability,2023-01-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2728,NCT01610934,Fasting Plasma Glucose,Plasma concentrations of incretin hormones,2012-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2729,NCT02956655,The remission rate of diabetes,Uric acid (mmol/l),2016-07,UNKNOWN,INTERVENTIONAL,['NA'],
2730,NCT02621476,Percent of Participants Using Mail Order Pharmacy (MOP) After Intervention,,2017-02-01,COMPLETED,INTERVENTIONAL,['NA'],
2731,NCT00566813,Number of Participants With HbA1c Less Than or Equal to 6.5 & Free of Severe Hypoglycemic Events,,2004-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2732,NCT01855243,Mean BG After First Day of Hospitalization,Mortality Rate,2010-03,COMPLETED,INTERVENTIONAL,['NA'],
2733,NCT05979077,Participant Tool and Workflow Survey,To evaluate the impact of a patient-facing EHR-enabled questionnaire on glycemic control and visit efficiency.,2023-04-03,RECRUITING,INTERVENTIONAL,['NA'],
2734,NCT02791490,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event,Percentage of Participants Receiving Glycemic Rescue Therapy,2016-06-16,COMPLETED,INTERVENTIONAL,['PHASE3'],
2735,NCT02402504,Subjective Appetite,Physical Comfort,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
2736,NCT01052597,to determine the effectiveness of curcumin on reduction of atherosclerotic events and risks in Type 2 diabetic patients,"To examine the effectiveness of curcumin on the reduction of blood sugar, glycosylated hemoglobin (HBA1c), lipid profile, and insulin resistance",2009-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2737,NCT03466177,Retinal biomarkers for AD: receiver operating characteristic (ROC),Retinal biomarkers for AD: disease progression by measuring the change from baseline at 2 years and more,2018-03-01,RECRUITING,OBSERVATIONAL,['NA'],
2738,NCT04562467,Change in the frequency of ALDHhiSSClowCD133+ cells in individuals treated with IPE compared to SOC for 3 months,,2020-09-24,COMPLETED,INTERVENTIONAL,['PHASE4'],Changes in the concentration of serum inflammatory markers from baseline to the 3-month visit in individuals treated with IPE compared to SOC
2739,NCT00922389,Adverse events and laboratory parameters,Trans Cutaneous partial pressure of Oxygen: TCpO2,2009-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2740,NCT03345004,Change in Stimulated C-peptide During a MMTT,Change in Body Mass Index (BMI),2017-12-20,COMPLETED,INTERVENTIONAL,['PHASE2'],
2741,NCT03437720,Resolution of Non-alcoholic steatohepatitis (NASH),Assessment of PK parameter: Ctrough,2019-05-23,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
2742,NCT01487109,To assess the change in urinary albumin to creatinine ratio,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2743,NCT03935919,Sensor accuracy in the perioperative period,Standard deviation of sensor glucose levels in the postoperative period,2019-08-13,COMPLETED,OBSERVATIONAL,['NA'],
2744,NCT05333822,blood glucose improvement in type 2 diabetic patients by continuous glucose monitoring.,insulin C-peptide gastric emptying,2021-03-01,COMPLETED,INTERVENTIONAL,['NA'],
2745,NCT05881616,Content of serum metabolomics,,2023-07-18,RECRUITING,OBSERVATIONAL,['NA'],
2746,NCT01444443,Number of hypoglycemic events,Time spent in euglycemia (3.9-8.0 mmol/l); mean blood glucose level; LBGI,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
2747,NCT02222909,Change in Emergency Department Visits + Hospital Days,,2014-04,COMPLETED,INTERVENTIONAL,['NA'],
2748,NCT05423938,Postprandial glycemic response,Postprandial insulin response,2019-11-04,COMPLETED,INTERVENTIONAL,['NA'],
2749,NCT01346072,Body Weight,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
2750,NCT03250403,pain,Conduction velocity,2017-04-01,COMPLETED,INTERVENTIONAL,['NA'],
2751,NCT04634214,Severity of COVID 19 among people with and without diabetes,Length of hospital stay,2020-11-16,UNKNOWN,OBSERVATIONAL,['NA'],
2752,NCT06202079,Change in HbA1c,Change in ADA and Nab of GZR4,2023-08-29,RECRUITING,INTERVENTIONAL,['PHASE2'],
2753,NCT01276288,Urinary Sodium Excretion Over 24-hour run-in Periods,"Number of Subjects With Clinical Relevant Abnormalities in Vital Signs, Clinical Laboratory Tests, 12-lead Resting Electrocardiogram (ECG), Physical Examination and Assessment of Tolerability by the Investigator",2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
2754,NCT00678990,Safety,,2019-01,UNKNOWN,INTERVENTIONAL,['NA'],
2755,NCT03639545,Arterial function,Glycemic control,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2756,NCT01486914,Area under the Curve (AUC) (insulin aspart),Adverse events,2003-01-19,COMPLETED,INTERVENTIONAL,['PHASE1'],
2757,NCT00013741,,,na,COMPLETED,INTERVENTIONAL,['NA'],
2758,NCT06144554,Glucose Outcomes during the 4-hour post-bolus period using the SmartBolus Calculator: o Percentage of time < 54 mg/dL o Percentage of time in range 70-180 mg/dL,,2023-09-25,RECRUITING,OBSERVATIONAL,['NA'],
2759,NCT00412126,Volume of intimal hyperplasia in the stented segment by IVUS at 6 months following PCI,"Late loss in minimal luminal diameter of stented site in coronary vessel evaluated by QCA at 6 months post-PCIb) Rate of clinical events at one year (hospital admission for unstable angina, CHF, MI, stroke, revascularization, and death)",2002-07,COMPLETED,INTERVENTIONAL,['NA'],
2760,NCT00642538,AUC 0-240 min post-prandial serum glucose,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
2761,NCT04401904,AGE-RAGE Measurement in Plasma,6 Minute Walking Distance,2020-06-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2762,NCT00258115,glycemia,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
2763,NCT01183013,Change From Baseline in HbA1c After 30 Weeks of Treatment.,Incidence of Rescue Therapy During the First 30 Weeks of Treatment,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
2764,NCT00993070,"Pain relief from pain score reduction, using visual analog scale (VAS)","Overall clinical improvement, measured by Clinician Global Impression of Change(CGIC)",2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2765,NCT06198725,The 2h C-peptide level of the MMTT test,Triglyceride,2024-01-08,RECRUITING,INTERVENTIONAL,['NA'],
2766,NCT04413357,Area under the blood glucose curve,Insulinogenic index,2020-05-18,COMPLETED,INTERVENTIONAL,['NA'],
2767,NCT00546702,Change of HbA1c.,"Blood glucose parameters, hypoglycaemic episodes and dosage of the mealtime and basal insulins.",2004-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
2768,NCT02984813,Flavoprotein fluorescence index,Humphrey visual field testing (24-2),2016-04-15,TERMINATED,INTERVENTIONAL,['PHASE1'],
2769,NCT00099866,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA B at 52 weeks,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2770,NCT03193125,Liver mitochondrial fatty acid processing,,2017-05-15,COMPLETED,INTERVENTIONAL,['NA'],
2771,NCT05881837,Percentage change in body weight,Change from baseline in glycosylated haemoglobin (HbA1c) after 32 weeks of treatment,2023-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
2772,NCT05933161,Estimated average glucose (eAG) values based on fructosamine lab values,Number of hypoglycemic unawareness episodes,2023-11-10,RECRUITING,OBSERVATIONAL,['NA'],
2773,NCT00131287,Percent reduction of glycated hemoglobin (HAb1C) and insulin resistance(HOMA-IR),"Glucose, cholesterol, triglyceride, leptin, adiponectin comparisons",2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
2774,NCT01538576,HbA1c (glycosylated haemoglobin),Adverse Events,2003-12,COMPLETED,OBSERVATIONAL,['NA'],
2775,NCT02426099,Efficacy (Blood pressure reduction),Creatinine (Change in serum creatinine),2011-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
2776,NCT02676648,HbA1c,Body Weight Percent Lost,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
2777,NCT00732121,Change from baseline in the integrated response to the mixed meal test of markers of bone turnover following 8 weeks of treatment with sitagliptin vs. placebo.,Change in insulin secretion during the mixed meal test.,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2778,NCT01043770,The proportion of people in the intervention and control groups with prevalent metabolic syndrome according to the IDF criteria.,Changes in general self-efficacy as measured by GSE,2009-08,COMPLETED,INTERVENTIONAL,['NA'],
2779,NCT03551925,Change in Adherence to Refills and Medication Scale (Seven-item) (ARMS-7) Score,Change in Blood pressure,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],
2780,NCT04501991,Lipid profile,,2020-03-11,COMPLETED,OBSERVATIONAL,['NA'],
2781,NCT00790348,,,2008-07,UNKNOWN,OBSERVATIONAL,['NA'],
2782,NCT04141475,change of LVEF between before and after 12 weeks of treatment,,2020-11-24,TERMINATED,INTERVENTIONAL,['NA'],
2783,NCT05407662,Baseline all-cause healthcare costs by place of service,"sMRA continuing user questions - Treatment Satisfaction Questionnaire for Medication version 1.4 (TSQM v1.4) - validated PROM the evaluates patients' perception of sMRA treatment effectiveness, convenience, and overall satisfaction",2022-11-02,COMPLETED,OBSERVATIONAL,['NA'],
2784,NCT00908921,Change in glycosylated hemoglobin (HbA1c) rate,Percentage of patients achieving HbA1c <7.0,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
2785,NCT04791358,Referrals,,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA'],
2786,NCT04874922,metabolic control variables evaluation form (fourth),Pregnancy Outcomes Evaluation Form for Mother and Baby,2021-05-15,COMPLETED,INTERVENTIONAL,['NA'],
2787,NCT02551640,Differences in the change in physical activity levels between control and intervention groups as measured by daily physical activity measured by the Gear Fit device provided to participants in both groups,Differences in the change in C-reactive protein between control and intervention groups,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
2788,NCT05695170,Study protocol feasibility,Partner support.,2022-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2789,NCT02590094,Visual Acuity,Time,2015-10,COMPLETED,INTERVENTIONAL,['NA'],
2790,NCT03726983,Newborn baby weight,Change of Health Promotion Scale,2017-01-05,COMPLETED,INTERVENTIONAL,['NA'],
2791,NCT05164523,BDNF concentrations,,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],
2792,NCT06146699,prevalence of diabetic retinopathy,,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2793,NCT00143520,Change in HbA1c,"FPG, Lipids, hsCRP, Adiponectin",2004-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2794,NCT04509856,Diabetes knowledge level (DKL),Blood pressure,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],
2795,NCT01345734,Incidence of serious adverse drug reactions (SADRs),"Change in HbA1c (glycosylated haemoglobin)""",2011-09-01,COMPLETED,OBSERVATIONAL,['NA'],
2796,NCT05948969,New prescription of a SGLT2i and/or GLP-1RA,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],
2797,NCT02107976,Whether acute changes in glycemia and/or red blood cell ascorbate (vitamin C) modify RBC deformability.,Whether RBC vitamin C concentrations can be increased by vitamin Csupplementation over several weeks in diabetic subjects.,2019-06-14,RECRUITING,INTERVENTIONAL,['PHASE1'],
2798,NCT01903044,"Wound healing (wound size, wound stage) - monitoring the healing of trophic lesions",Survival without amputation,2014-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2799,NCT00764244,Percentage of patients with visual gain ≥ 3 ETDRS lines at 2 years,Evolution of visual field in each group,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
2800,NCT04302974,"Incremental cost-effectiveness ratio per DM/HT-related complication or all-cause death avoided, and per QALY gained by RAMP or PSCC",,2019-08-01,RECRUITING,OBSERVATIONAL,['NA'],
2801,NCT01000922,To compare the maximal post prandial blood glucose concentration and the time to maximal post prandial glucose concentration between the different treatments,"To compare the ppGlucmax for all treatments, the ppTGluc-max, the AUCGluc 0-180 and the AUCGluc 0-360, CGluc-baseline for all treatments.",2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
2802,NCT03228706,"Change of medication adherence at baseline, and at 3, 6 and 12 months after intervention.","Change of intention to adhere at baseline, and at 3, 6 and 12 months after intervention.",2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],Sustainability of the Program
2803,NCT02765347,HbA1c,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
2804,NCT03623607,Patient acceptance of diabetes self-management education delivered via an e-learning platform.,To conduct iterative rapid-cycle usability testing of the enhanced Diabetes To Go program content and processes and establish a Diabetes To Go program toolkit for widespread implementation,2016-04-01,COMPLETED,OBSERVATIONAL,['NA'],Implementation effectiveness evaluation
2805,NCT01137903,Number of healing patients,Quality of life,2010-04,UNKNOWN,INTERVENTIONAL,['NA'],
2806,NCT00441129,Difference in HbA1C From Baseline and 6 Months,Change From Baseline in Total Daily Dose (TDD),2006-06,COMPLETED,INTERVENTIONAL,['NA'],
2807,NCT01298154,Food Intake,Blood Glucose,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
2808,NCT02816099,Comparaison of linear correlation coefficients between plasma concentrations of apoC1 and CETP activity,,2014-11-20,COMPLETED,INTERVENTIONAL,['NA'],
2809,NCT01002547,"Liver Histology (Kleiner's et al Criteria, Hepatology 2005)",LDL-cholesterol,2010-06-24,COMPLETED,INTERVENTIONAL,['PHASE4'],
2810,NCT05876273,Percent of Time-in-Range (TIR) on NAP versus UMPC.,Participant Feedback,2023-05-30,COMPLETED,INTERVENTIONAL,['NA'],
2811,NCT05355090,Change in HbA1c,Change in body weight,2022-04-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2812,NCT00308646,,,2004-10,TERMINATED,OBSERVATIONAL,['NA'],
2813,NCT02627534,Probing Depth,Clinical Attachment Level,2014-04,COMPLETED,INTERVENTIONAL,['NA'],Gingival Recession
2814,NCT03421262,Large for gestational age,Medical cost,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],
2815,NCT01688986,,,2012-08-25,COMPLETED,OBSERVATIONAL,['NA'],
2816,NCT01956851,correlation of kisspeptin levels with GLP 1,,2013-09,COMPLETED,OBSERVATIONAL,['NA'],
2817,NCT01511042,Frequency of Intermediate Phenotypes in Subjects with Diabetes Mellitus versus Hypertension,Frequency of salt sensitive subtype in Diabetics versus hypertensives,1999-12,TERMINATED,OBSERVATIONAL,['NA'],
2818,NCT00630617,Body Mass Index,Knowledge and attitudes,2004-07,COMPLETED,INTERVENTIONAL,['NA'],
2819,NCT01505426,Change in HbA1c from baseline to end of treatment,"Safety assessed by the incidence of adverse events, vital signs safety labo-tests and 12-lead ECG",2011-11-28,COMPLETED,INTERVENTIONAL,['PHASE3'],
2820,NCT03101930,Change in Plasminogen Activator Inhibitor-1,Fasting Insulin,2017-05-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Change in Weight
2821,NCT01858506,Change in lifestyle knowledge,Weight and waist circumference,2014-08,COMPLETED,INTERVENTIONAL,['NA'],Medical regimen for diabetes management
2822,NCT02681497,change in HbA1c value,Evidence of urinary tract infection (UTI) documented,2016-03,COMPLETED,OBSERVATIONAL,['NA'],
2823,NCT05066516,AUC,Vd,2020-06-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
2824,NCT05044130,VLDL-triglyceride uptake in adipose tissue - Measurement of fatty acid concentration and specific activity in adipose tissue biopsies,Insulin sensitivity,2021-09-14,COMPLETED,INTERVENTIONAL,['NA'],
2825,NCT00759889,To analyze and image wounds using microscopy and molecular techniques,,2007-03,COMPLETED,OBSERVATIONAL,['NA'],
2826,NCT03774069,Percentage of readings below 54 mg/dl (3.3 mmol/l),Number of physician override Advisor recommendation,2020-12-01,WITHDRAWN,INTERVENTIONAL,['NA'],
2827,NCT02842359,Change from baseline in flow mediated dilatation,Rate of change from baseline in T-cell induced inflammatory factors,2016-08-23,COMPLETED,INTERVENTIONAL,['PHASE4'],
2828,NCT06319703,Change in Hemoglobin A1C (HbA1c) Test Scores,International Physical Activity Questionnaire (IPAQ) Short-Version Score,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2829,NCT02974504,HbA1c,HbA1c response rate,2016-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
2830,NCT04984226,FACIT-F Fatigue (PRO),PROMIS Fatigue (PRO),2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Inflammatory cytokines. TNF-alpha and IL-6
2831,NCT06331338,glycemic control (HbA1c),Diabetes Self-Care Behavior Scale,2024-02-14,RECRUITING,INTERVENTIONAL,['NA'],
2832,NCT05209061,Evaluation of metabolic profile,Appendix biofilm,2023-02-01,RECRUITING,OBSERVATIONAL,['NA'],
2833,NCT01421355,Change in Brachial Artery Diameter,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
2834,NCT06092515,Red blood cell membrane fatty acids concentrations,Anemia,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],
2835,NCT02148523,Statin Adherence,Morisky Medication Adherence Scale (MMAS),2014-01,COMPLETED,INTERVENTIONAL,['NA'],
2836,NCT06231225,Post-COVID-19 Functional Status scale,Dyspnoea-12 (D-12) scale,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2837,NCT00298428,Primary biological end-point: To compare SIPA levels in DM vs. MS vs. no DM/MS patients,,2006-05,COMPLETED,INTERVENTIONAL,['NA'],
2838,NCT04938843,Glycemic control,Liver fat function test GGT,2021-08-16,UNKNOWN,INTERVENTIONAL,['NA'],
2839,NCT02147522,Response Rate - 50 Percent or Greater Reduction in Patient Health Survey-9 (PHQ-9) Score Since Baseline,Change From Baseline in MOS Short-Form Health Survey Physical Component Summary (PCS),2013-10,COMPLETED,INTERVENTIONAL,['NA'],Change From Baseline in Self-Efficacy for Managing Chronic Disease (SEMCD) Score
2840,NCT02316665,change in mean nocturnal glycemia,Change in mean heart rate after intervention,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
2841,NCT00874809,What are the mean number of changes in the basal infusion rate(change is defined as any alternation in the basal rate >0.1 U/hr) and what are the mean differences and mean duration (hrs) of these changes.,What mathematical formulas describe the relationship between the dosing factors and do they significantly differ from those previously established by King and Armstrong,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
2842,NCT02416765,Mean glucose levels as measured by the glucose sensor.,Total carbohydrate intake,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2843,NCT05928260,HbA1c,Quality of Life,2023-08-10,RECRUITING,INTERVENTIONAL,['NA'],
2844,NCT06032325,biomarkers,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
2845,NCT00254800,Assessment of Pharmacokinetics profile of exenatide measured by AUC and Cmax,"Safety and Tolerability assessment by Adverse events, clinical laboratory evaluations, vital signs, ECG blood glucose, body weight, physical examination and exenatide antibodies.",2005-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
2846,NCT01579981,Beta cell glucose sensitivity,Ad libitum food intake,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
2847,NCT03862690,Change in glycosylated haemoglobin A1c (HbA1c),Change in health-related quality of life (EQ-5D),2020-05-28,WITHDRAWN,OBSERVATIONAL,['NA'],
2848,NCT00117793,Limb Pistoning,Frustration (PEQ Scale),2005-08,COMPLETED,INTERVENTIONAL,['NA'],
2849,NCT02477761,Plasma glucose concentration,Plasma glucose-dependent insulinotropic polypeptide concentration,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],
2850,NCT04846673,visual analogue scale (VAS),"3 level version of Euro-Qol-5 dimensions, EQ-5D-3L",2021-05-14,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2851,NCT02258698,Number of adverse outcomes in relation to Insulin resistance measured as HOMA (homeostasis model assessment),Number of adverse outcomes in relation to Insulin resistance measured as irisin,2013-05,COMPLETED,OBSERVATIONAL,['NA'],
2852,NCT06186102,"Change in Physical performance, peak oxygen consumption (VO2max)",Days alive and out of hospital,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Skeletal muscle satellite cell (MuSC) proliferation assays
2853,NCT03496597,surface of the central retinal avascular zone,,2018-02-23,UNKNOWN,OBSERVATIONAL,['NA'],
2854,NCT01264497,Change from baseline in relative insulin response,Number of subjects with a change in the control of diabetes,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
2855,NCT03481335,HbA1c,Cost-utility,2018-06-01,COMPLETED,INTERVENTIONAL,['NA'],
2856,NCT05143827,60-min glucose,AUC glucose 180 min,2021-11-20,RECRUITING,INTERVENTIONAL,['NA'],
2857,NCT02609815,gut microbiota composition change from baseline,HbA1c change,2015-11-01,COMPLETED,INTERVENTIONAL,['NA'],PYY
2858,NCT00569426,Overall needle preference,Handling and acceptance of needles,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
2859,NCT04744714,Neonatal outcomes,annual follow-up results,2021-02-01,RECRUITING,OBSERVATIONAL,['NA'],
2860,NCT01330251,Changes in fecal microbiota,,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
2861,NCT01458210,Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Ortho-Cyclen - Ethinyl Estradiol (EE),,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
2862,NCT02464033,Number of Patients With an Infection Reported as Adverse Event Related to Study Treatment,GAD65-induced MCP-1 Secretion,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
2863,NCT00971503,Significant increase in C-peptide levels after transplant in 70% of the patient.,Normalization of the hemoglobin A1C after transplant in 70% of the patients. Normalization of blood glucose levels.,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
2864,NCT02302443,Incidence and severity of treatment emergent adverse events,Area under the concentration-time curve (AUC) of HM12470 following a single dose,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
2865,NCT01212120,Presence/absence of the same S. aureus genetic profile in the nose and on the foot lesion.,,2010-09,COMPLETED,OBSERVATIONAL,['NA'],
2866,NCT01053195,Incidence of type 2 diabetes,Cost-effectiveness of the lifestyle intervention,2005-12,COMPLETED,INTERVENTIONAL,['NA'],
2867,NCT03862716,Proportion of participants achieving drug-free diabetes remission,Proportion of participants achieving drug-free diabetes regression,2019-04-23,COMPLETED,INTERVENTIONAL,['PHASE3'],"the change in time range over 2 weeks (defined as 4-8 mmol/l), based on up to 2 weeks of Abbott Freestyle Libre ProTM sensor wear"
2868,NCT01806727,Predicted Cardiovascular Risk,Predicted Cardiovascular Risk,2013-04,COMPLETED,INTERVENTIONAL,['NA'],Health Costs
2869,NCT00300911,"Plasma Brain Natriuretic Peptide levels, echocardiographic measurements were made before the treatment and repeated after three months and six months of the treatment",,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
2870,NCT05079399,Epigenetic changes in circulating angiogenic cells with different severities of diabetic retinopathy,Change in retinal thickness in optical coherence tomography angiography (OCT-A),2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],
2871,NCT01588587,Frequency of cancers,Receptor for AGE concentration,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],
2872,NCT04530292,Measurement of HbA1c (%) one year after the discovery of diabetes.,Percentage of time spent wearing the sensor for patients with Freestyle sensor,2020-09-28,COMPLETED,INTERVENTIONAL,['NA'],
2873,NCT03508934,Decrease in hypoglycemia during the hospitalization,,2018-07-01,RECRUITING,INTERVENTIONAL,['NA'],
2874,NCT03447275,The difference in serum vitamin B6 concentrations between cases and controls,The difference in serum and urine vitamin B6 vitamers between patients with advanced global vascular risk versus those with a low vascular risk,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
2875,NCT01824355,Percent of Self Test Fingerstick Blood Glucose Results Within ±15 mg/dL (< 75 mg/dL) and Within ±20% (≥ 75 mg/dL) of the Laboratory Glucose Method,Number of Subject Responses That 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
2876,NCT01908530,Difference to the Venous Blood Glucose MARD,Acceptability Questionnaire,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
2877,NCT01277913,Mean isometric hand grip force,"% patients with vitamin D hypervitaminosis (>200 ng/ml (500 nmol/L) and or hypercalcemia (>2.7 mmol/l) assessed at summer,spring, autumn, and winter",2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2878,NCT06170515,HbA1c Performance,Type of errors as displayed,2023-04-03,RECRUITING,INTERVENTIONAL,['NA'],
2879,NCT01505673,Glycemic Control Measured by HbA1c,Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2880,NCT01145742,Blood pressure,LDL Cholesterol,2006-11,COMPLETED,INTERVENTIONAL,['NA'],
2881,NCT02746861,Average reduction in HbA1c from baseline,,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],
2882,NCT00166036,Change in Plasma Thiobarbituric Acid Reactive Substance (TBARS) Levels,Change in Flow-mediated Dilatation (FMD),2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
2883,NCT05344690,Association of EPO gene polymorphism and the risk of confirmed diabetic retinopathy diagnosis,The association of confounding factors on the incidence of diabetic retinopathy,2022-05-20,COMPLETED,OBSERVATIONAL,['NA'],
2884,NCT03902288,Cortisol hormone measurement,Serum total antioxidant activity measurement,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
2885,NCT00940173,"To establish preliminary evidence of the efficacy of DIABECELL(R), as measured by a reduction in serial HbA1C levels",To determine whether DIABECELL(R) causes an improvement in quality-of-life,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2886,NCT05768191,To compare improvements from baseline in patient HbA1c when aggressively treated with insulin human isophane plus rapid acting human insulin vs treatment with Premix human insulin,"correlation between patient QoL and glucose variability as measured by CGMS (baseline, week 16 and week 32)",2023-06-15,RECRUITING,INTERVENTIONAL,['PHASE4'],
2887,NCT03104829,HbA1C,Diabetic self-care behavior score,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],
2888,NCT03175120,Change in HbA1c,Occurrence of Neutralising Liraglutide Antibodies Cross Reacting Native GLP-1,2017-05-26,COMPLETED,INTERVENTIONAL,['PHASE3'],
2889,NCT01537705,VAS,Routine Blood Panel,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
2890,NCT01194830,Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks,Change From Baseline in 2-hour Post-prandial Glucose (PPG) After 24 Weeks,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
2891,NCT03876015,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),2019-05-01,COMPLETED,OBSERVATIONAL,['NA'],
2892,NCT03921242,Heterogeneity of Treatment Effect Via Pre-specified Sub-Group Analyses,Difference in Laboratory-Measured eGFR (mL/min),2019-08-01,COMPLETED,OBSERVATIONAL,['NA'],
2893,NCT02895672,A1C,,2016-08,COMPLETED,OBSERVATIONAL,['NA'],
2894,NCT01371266,"Area under the curve glucose, response for OGTT. Glucose-120 min OGTT-AUC",Serum Lipids,2011-06,COMPLETED,INTERVENTIONAL,['NA'],
2895,NCT00315614,A Reduction or Absence of Rejection Episodes,Number of Subjects With Reduction of Severe Hypoglycemia and Improvement in Hypoglycemia Awareness,2000-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
2896,NCT00001870,,,1999-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
2897,NCT00381719,Reduction in Daily Pain Score,Quality of Life questionnaires,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2898,NCT03154073,Insulin Sensitivity Index (μmol·kg^-1·min^-1·pM^-1),Change in 24-hour Glycemic Control (glucose AUC),2017-07-20,COMPLETED,INTERVENTIONAL,['NA'],
2899,NCT02934737,Markers of progression of diabetes,,2016-10,COMPLETED,OBSERVATIONAL,['NA'],
2900,NCT02404896,,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],
2901,NCT03138746,insulin sensitivity,change in inflammatory cytokines,2018-08-13,COMPLETED,OBSERVATIONAL,['NA'],
2902,NCT03864991,Changes in HbA1c,Episodes of acute complications,2018-10-29,UNKNOWN,INTERVENTIONAL,['NA'],
2903,NCT06281899,Time to the First Occurrence of Any of the Components of the Composite: ≥30% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death,Changes in the quality of life,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],Compliance to carbohydrate intake
2904,NCT00946972,"Adverse events, laboratory values, vital signs, ECGs",Incretin levels,2009-07,TERMINATED,INTERVENTIONAL,['PHASE1'],
2905,NCT00703417,,,2006-05,COMPLETED,OBSERVATIONAL,['NA'],
2906,NCT02053051,Post-prandial hypoglycaemia,Number achieving target HbA1c ( ≤ 53 mmol/mol ),2013-11-12,COMPLETED,INTERVENTIONAL,['NA'],Acceptability questionnaire (non-validated)
2907,NCT06310980,Time in range,DIDS,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2908,NCT05577728,Long-term glycemic control defined as proportion of patients who will achieve an HbA1c of less than 7.0% (53.0 mmol/mol),Number of hypoglycemic episodes leading to an inpatient admission or emergency room encounter.,2021-07-01,COMPLETED,OBSERVATIONAL,['NA'],
2909,NCT03252080,ADDQoL score at endpoint,HbA1c at endpoint,2017-08,UNKNOWN,INTERVENTIONAL,['NA'],
2910,NCT01995539,Change From Baseline in A1C at 3 Months,Number of Serious Adverse Device Effects (SADE).,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
2911,NCT01627977,Visibility of the membrane after injection of the dye,Usefulness of the dye,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
2912,NCT03834610,"Improvement in Penile Doppler parameters after treatment including peak systolic velocity in (cm/sec), end diastolic volume in (cm/sec) and resistive index (RI) that = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity.",,2017-10-01,COMPLETED,INTERVENTIONAL,['NA'],
2913,NCT03878745,BD Nano™ PRO Pen Needle Compared to Terumo Nanopass® (Injection Pain),BD Nano™ PRO vs Terumo Nanopass® (Leakage),2019-02-11,COMPLETED,INTERVENTIONAL,['NA'],Compare BD Nano™ PRO vs Terumo Nanopass® (Needle Breaking)
2914,NCT00729079,The primary outcome measure is weight loss with a goal of 7% of initial weight.,;Fat intake less than 25% and saturated fat less than 10% Fiber intake of at least 25 grams per day;Fasting blood sugar < 100 mg/dL; Absence of tobacco use,2008-12,COMPLETED,INTERVENTIONAL,['NA'],
2915,NCT03372824,Glycated albumin reference interval in pregnancy,Admission to neonatal intensive care unit,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],
2916,NCT00377858,Hemoglobin A1c (HbA1c) at 36 Week Endpoint,Change From Baseline in Absolute Body Weight at 36 Week Endpoint,2006-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
2917,NCT05124405,To evaluate the feasibility of the ( PA) Physical Activity intervention.,,2018-05-24,SUSPENDED,INTERVENTIONAL,['NA'],
2918,NCT02580591,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD)),Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26,2015-12-22,COMPLETED,INTERVENTIONAL,['PHASE3'],
2919,NCT02212522,Genetic and environmental risk factors of T1D predisposition,"Undertake a prospective research of G and E risk factors of ""death in bed"" syndrome in diabetic adolescents",2004-11,UNKNOWN,OBSERVATIONAL,['NA'],
2920,NCT02690467,Fructosamine levels,Number of episodes of insulin leakage at injection site,2016-09-06,UNKNOWN,INTERVENTIONAL,['NA'],
2921,NCT04225455,To compare the data generated from the continuous glucose monitoring system (CGMS) Dexcom G6® with their routine self-glucose monitoring in pilots with class 1 and class 2 certificates,Previous 6 months logged data,2019-12-05,RECRUITING,OBSERVATIONAL,['NA'],
2922,NCT00034788,Time to complete ulcer healing.,Incidence of complete ulcer healing and reduction in total ulcer area at end of study. Incidence of adverse events throughout study.,2000-12,TERMINATED,INTERVENTIONAL,['PHASE3'],
2923,NCT02355288,"Successfully enrolled, eligible and consenting patients within the first year of enrollment.",Quality of Life (QOL),2018-10-01,WITHDRAWN,INTERVENTIONAL,['NA'],
2924,NCT00579228,Carotid intima media measurement change,,2007-04-25,COMPLETED,OBSERVATIONAL,['NA'],
2925,NCT04920279,Validity of the Turkish Version of Activities-specific Balance Confidence Scale in Patients With Diagnosis of the Diabetes Mellitus Before.,,2018-06-11,COMPLETED,OBSERVATIONAL,['NA'],
2926,NCT01095068,,,2010-03,TERMINATED,INTERVENTIONAL,['NA'],
2927,NCT02098395,Change From Baseline in Glycosylated Haemoglobin (HbA1c),Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
2928,NCT01993511,Change in beta-cell function after RYGB.,Change in insulin sensitivity after RYGB.,2010-06,UNKNOWN,OBSERVATIONAL,['NA'],Change in insulin clearance after RYGB.
2929,NCT00913497,Difference in the Two Hour and Four Hour Post Prandial Blood Glucose Levels Following Administration of Insulin Glulisine Versus Insulin Aspart at the End of the Twenty Study Days,Occurrence of Hypoglycemia;,2009-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
2930,NCT05444842,healing rate,,2022-07-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2931,NCT01035879,Evaluate the effect of MBX-2982 on the absolute and percent change from baseline and placebo in mean weighted average of 14-point blood glucose levels associated with a standardized breakfast and lunch,Evaluate the effect of MBX-2982 on additional glycemic parameters.,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
2932,NCT06292962,Neuropathic pain scores,Quality of life score,2023-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2933,NCT03199261,Bioequivalency between the 2 formulations of rE-4,,2016-12-23,COMPLETED,INTERVENTIONAL,['PHASE1'],
2934,NCT03011177,HbA1c,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
2935,NCT02411825,Number of adverse events,Change from baseline in HbA1c,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
2936,NCT03660631,Effect of physician/pharmacist collaboration on implementation fidelity,Development of payment contracts,2018-09-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2937,NCT05261906,Change in HbA1c from Baseline,Change in rapid insulin use from Baseline,2022-09-26,RECRUITING,INTERVENTIONAL,['NA'],Participant Feedback
2938,NCT00571935,HbA1c,Quality of Life (QoL),2003-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
2939,NCT01972113,Change in beta-cell function,"Effects of sex, race, bone age, and pubertal stage on changes in glucosemetabolism (insulin sensitivity and beta-cell function)",2013-09,UNKNOWN,INTERVENTIONAL,['NA'],
2940,NCT01393808,Changes in urinary albumin excretion from baseline at 4 month.,Ambulatory and 24-hour blood pressure profile.,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
2941,NCT00911404,Need of insulin treatment for GDM,Fetal morbidity,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
2942,NCT01030978,"2-hour plasma glucose, category of glucose tolerance (IGT, NGT, T2DM)",Family assessment device (FAD) score,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
2943,NCT03899402,Change in HbA1c following dapagliflozin,Diabetic ketoacidosis assessment,2019-05-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
2944,NCT00819455,Progression to diabetes,Acceptability of text messaging as tool to prevent diabetes.,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
2945,NCT00593424,Paired t-test or Wilcoxon signed rank test will be used to evaluate the change in fasting triglycerides with the diets.,Post-prandial lipids will be evaluated by t-test or Wilcoxon signed rank test for AUC of triglyceride and remnant lipoprotein measured by immunoseparation.,2002-08,COMPLETED,INTERVENTIONAL,['NA'],
2946,NCT04311853,Implementation of new evidence-based nutrition practice guidelines,Improved health outcomes,2010-02,COMPLETED,OBSERVATIONAL,['NA'],
2947,NCT05968222,Five times Sit To Stand (5STS),,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
2948,NCT03313297,Skin 11β-HSD1 activity,Skin RNA-seq gene expression profiling,2018-04-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2949,NCT01346033,Validation of SCOUT DS algorithm for detecting known type 2 diabetes,,2010-10,COMPLETED,OBSERVATIONAL,['NA'],
2950,NCT00013299,,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
2951,NCT00465881,,,2006-01,COMPLETED,OBSERVATIONAL,['NA'],
2952,NCT03755934,Change in the weekly average of the average daily pain scores,To characterise the dose-response relationship of MEDI7352 on chronic pain in subjects with PDN,2018-11-19,COMPLETED,INTERVENTIONAL,['PHASE2'],
2953,NCT05996380,Safety endpoints: Number of Adverse Events,,2023-06-09,RECRUITING,INTERVENTIONAL,['PHASE1'],
2954,NCT01140932,ERG,Retinal Vessel Caliber,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
2955,NCT03134170,Hemoglobin A1C,Preventative care,2015-08-01,UNKNOWN,INTERVENTIONAL,['NA'],
2956,NCT04132908,blood samples,,2016-10-01,COMPLETED,INTERVENTIONAL,['NA'],
2957,NCT02671656,Uricemia,"Haematocrit, glucose and lipid levels, medications",2016-03,WITHDRAWN,OBSERVATIONAL,['NA'],
2958,NCT00320970,Urinary carboxymethyllysine,,2002-08,COMPLETED,INTERVENTIONAL,['NA'],
2959,NCT01315756,"Improved glycemic control, HbA1c","Lipids, self-care, lifestyle changes, complications, quality of life.",2011-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
2960,NCT00167284,Lipids,Patient and physician barriers to diabetes care,2001-10,COMPLETED,INTERVENTIONAL,['NA'],
2961,NCT05176795,Gut microbiota composition,Fecal contamination with nanoparticles,2022-03-16,RECRUITING,OBSERVATIONAL,['NA'],
2962,NCT05415644,The PK parameters of retagliptin and metformin in the blood plasma on fasting and after meals area under the drug-time curve (AUC0-∞),Adverse events,2022-07-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
2963,NCT05888688,Volumetric quadriceps skeletal muscle mass (cm^3),Sarcopenia assessment,2023-12-06,RECRUITING,OBSERVATIONAL,['NA'],quadriceps musculoskeletal Biopsy Analysis
2964,NCT06322940,Change in whole-body insulin sensitivity,Change in lipid profile,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Change in total energy intake
2965,NCT01932944,Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System compared to venous and capillary glucose,,2013-08,COMPLETED,OBSERVATIONAL,['NA'],
2966,NCT01352663,Change in HbAlc from baseline till the end of treatment period.,Percentage change in immunogenic response.,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
2967,NCT02806739,Number of Participants With Adverse Events That Are Related to Treatment,Effects of Soy Intake on C-reactive Protein (CRP),2013-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
2968,NCT03216564,Urinary albumin creatinine ratio (ACR) measured biochemically,Blood pressure,2017-05-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],Patient Reported Outcome: Quality of life
2969,NCT01589835,HbA1c Progression to diabetes,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
2970,NCT00297583,serum insulin concentrations,Adverse events and hypoglycemic episodes collection,2004-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
2971,NCT02831361,changes from baseline HbA1c at week 25,Changes of HOMA-β at week 25,2016-10-17,COMPLETED,INTERVENTIONAL,['PHASE3'],Changes of Triglyceride at week 25
2972,NCT02435329,Impaired endothelial function in patients with type 2 DM with/ without diabetic neuropathy and Charcot foot compared to their healthy counterparts as measured by:,Impaired bone metabolism in patients with type 2 DM with/ without diabetic neuropathy and Charcot foot compared to their healthy counterparts as assessed by:,2015-06,COMPLETED,OBSERVATIONAL,['NA'],
2973,NCT00021944,,,2001-04,COMPLETED,OBSERVATIONAL,['NA'],
2974,NCT04882332,Correlation between Metformin Usage Index and Vitamin B12 status among Egyptian patients with type 2 diabetes,,2021-05-05,UNKNOWN,OBSERVATIONAL,['NA'],
2975,NCT04284943,The success rate of biochemical improvement of diabetes as measured by HbA1c < 6.5%,The success rate of biochemical improvement of diabetes as measured by HbA1c < 6.5%,2020-12-01,RECRUITING,INTERVENTIONAL,['NA'],
2976,NCT05114018,Insulin sensitivity by Matsuda Index,Adverse events,2020-06-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
2977,NCT00135070,Glucose control,Length of stay,2005-07,TERMINATED,INTERVENTIONAL,['PHASE4'],
2978,NCT06120556,"Difference in HbA1c change from baseline (%) among SIDD, SIRD, MARD, MOD subtypes","Difference in percentage of patients reaching HbA1c below 7% among SIDD, SIRD, MARD, MOD subtypes",2023-06-10,COMPLETED,OBSERVATIONAL,['NA'],
2979,NCT00820703,To evaluate the safety and clinical effect of Nexagon® administered topically to diabetic foot ulcers.,To pilot the collection of data that may be considered useful in planning future studies of Nexagon® administered topically to diabetic foot ulcers.,2009-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2980,NCT01333592,Incidences of Adverse Events,Change From Baseline in HbA1c at 52 Weeks,na,COMPLETED,INTERVENTIONAL,['PHASE3'],
2981,NCT02439879,Total Symptoms Score,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
2982,NCT03951168,Diabetes Specific Quality of Life,HDL-C,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],
2983,NCT03919656,Metabolomics changes in urine,Changes in albuminuria,2019-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],
2984,NCT02467790,Pharmacokinetic index,Incidence of adverse events and serious adverse events,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],
2985,NCT05849428,Time-matched CGM-derived blood glucose differences between left arm and right arm in patients with Type 1 or Type 2 Diabetes below target range (<70 mg/dL).,Time-matched CGM-derived blood glucose differences between left arm and right arm in patients above target range (>180 mg/dL).,2023-05,RECRUITING,INTERVENTIONAL,['NA'],
2986,NCT00955201,Peroneal Nerve Conduction Velocity,Short Form-36V: Mental Component Score,2010-01-14,COMPLETED,INTERVENTIONAL,['NA'],Age
2987,NCT00402194,Insulin-stimulated Leg Glucose Uptake,,2005-06,COMPLETED,INTERVENTIONAL,['NA'],
2988,NCT05090488,Change from baseline HbA1C at 3 months and 6 months,Change from baseline quality of life,2020-12-14,UNKNOWN,INTERVENTIONAL,['NA'],
2989,NCT02843724,Clinically meaningful reduction of HbA1c above and beyond that of control arm,Adverse Events,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
2990,NCT03690180,Decrease in serum magnesium,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],
2991,NCT00548639,Morisky medication adherence scale,,2007-08,COMPLETED,INTERVENTIONAL,['NA'],
2992,NCT01512680,Difference between HbA1c at Month 12 and Month 0 > 0.5%,"Better score at surveys of quality of life (SF-6D, DQOL) and auto-management",2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
2993,NCT05422053,Other serious adverse events,Glucose < 70 mg/dL,2022-06-29,COMPLETED,INTERVENTIONAL,['NA'],CGM Metrics by Time of Day
2994,NCT04491253,Self-management: diabetes,Social support,2021-09-13,COMPLETED,INTERVENTIONAL,['NA'],
2995,NCT01222078,Proportion of Anti-otelixizumab Neutralizing Antibodies,Terminal Phase Half-life (Thalf) of Otelixizumab,2010-11-22,TERMINATED,INTERVENTIONAL,['PHASE2'],
2996,NCT00388986,AUC0-tau of glyburide,"AEs, laboratory parameters.",2006-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
2997,NCT03207269,Fasting Plasma glucose,Fasting continuous glucose monitoring glucose,2017-07-20,COMPLETED,INTERVENTIONAL,['NA'],
2998,NCT02152371,Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c),Rate of Hypoglycemic Events up to 28 Weeks,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
2999,NCT03033433,Stage 2: Number of Participants with Adverse events and Serious adverse events that are related to treatment,Stage2: Change from baseline in biomarker( serum fructosamine) testing results.,2016-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
3000,NCT05992350,Minutes of Sleep per Day,Change in how parents feel about episodes of hypoglycemia in their children,2024-01-16,RECRUITING,OBSERVATIONAL,['NA'],
3001,NCT04572009,percentage of time in glycemic target,changes in activity over time,2021-01-12,COMPLETED,INTERVENTIONAL,['NA'],
3002,NCT06107153,Change in hemoglobin A1c,Hypoglycemia,2023-11-01,RECRUITING,INTERVENTIONAL,['NA'],
3003,NCT01113515,Safety outcome,Efficacy outcome,2014-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacokinetics
3004,NCT01713465,Frequency of participants with increase in treatment adherence scores,Frequency of participants with increase in Satisfaction to Medical Care,2012-03,UNKNOWN,INTERVENTIONAL,['NA'],
3005,NCT05636007,nocturnal hypoglycemia,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],
3006,NCT03481283,Blood vessel wall amylin deposition vs severity of peripheral neuropathy,Heat thermode test vs RBC amylin and blood vessel wall amylin deposition,2018-02-05,RECRUITING,OBSERVATIONAL,['NA'],
3007,NCT06295900,Patient Introduction Form,Patient Follow-up Form,2024-01-05,RECRUITING,INTERVENTIONAL,['NA'],Visual Comparison Sleep Scale
3008,NCT02505893,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs),72-hour Continuous Glucose Monitoring,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
3009,NCT02227875,Change in HbA1c From Baseline to 24 Weeks,Change in Cross-Reactive Insulin Antibody Percent Binding for Lantus Assay Over Time,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
3010,NCT05549570,Area under the plasma concentration versus time curve (AUC) 0-t,"Number of participants with adverse events (AEs), abnormal clinical laboratory test results, physical examination findings and glycemia.",2017-10-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
3011,NCT00888732,"Cmaxglu: Peak plasma glucose following test meal (breakfast). A comparison will be made between fast-acting human insulin vs. IAsp, BIAsp 50 and BIAsp 70, IAsp vs BIAsp 50 and BIAsp 70, BIAsp 50 vs. BIAsp 70.","Serum GH, total IGF-I, IGF-I bioactivity, IGFBP-1, IGFBP-2, binary complex of IGF-I, IGFBP-3 and the acid-labile subunit (ALS)",2009-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
3012,NCT04260100,Dietary Behaviour,Fasting Blood Glucose,2020-02-17,COMPLETED,INTERVENTIONAL,['NA'],
3013,NCT02010541,Glycaemic control,knowledge on diet and diabetes management,2013-12,UNKNOWN,OBSERVATIONAL,['NA'],Quality of Life measures
3014,NCT01726413,Mean 24-hour average pain intensity (API) score.,Clinician Global Impression of Change,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
3015,NCT00337298,Vessel diameter changes in arbitrary units as measured with the Retinal Vessel Analyzer,24 hour ambulatory blood pressure (mmHg),2006-07,COMPLETED,INTERVENTIONAL,['NA'],
3016,NCT02368600,Proportion of subjects developed GDM,Proportion of neonates born with macrosomia,2015-04-21,COMPLETED,INTERVENTIONAL,['NA'],
3017,NCT05203042,Timed Get Up and Go Test-Motor and Cognitive Task:,Biochemical Analysis,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA'],
3018,NCT06172166,Continuity of care,Diabetic Ketoacidosis,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3019,NCT01813799,Difference in average 24-h pain intensity (Likert scale) between before and after IP administration,Average daily dose of acetaminophen,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
3020,NCT02373059,Patient Involvement Questionnaire,Patient Medication Adherence Questionnaire,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
3021,NCT02204527,Ambulatory Blood pressure monitoring,,2015-10,TERMINATED,INTERVENTIONAL,['NA'],
3022,NCT05175677,Impact on diabetes control in the study population,Lifestyle modification for diabetic patients,2022-03-10,COMPLETED,OBSERVATIONAL,['NA'],
3023,NCT00069628,HbA1c value obtained 6 months after randomization,Diabetes Self Management Profile at 6 months,2003-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
3024,NCT04369703,Assess relative change,,2020-01-28,COMPLETED,OBSERVATIONAL,['NA'],
3025,NCT01630512,change in severity of depressive symptoms,intersession changes in mood,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
3026,NCT02030600,Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period,FPG (Fasting Plasma Glucose),2014-01-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
3027,NCT00155922,,,2003-11,UNKNOWN,OBSERVATIONAL,['NA'],
3028,NCT02175121,Number of Participants With Electrocardiogram (ECG) Data Meeting Criteria of Potential Clinical Concern,Apparent Clearance (CL/F),2014-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
3029,NCT01821846,The incidence of SADRs (Serious Adverse Drug Reactions),Number of SAEs/ ADRs (Serious Adverse Events/Adverse Drug Reactions),2013-11-20,COMPLETED,OBSERVATIONAL,['NA'],
3030,NCT00331448,,,2000-06,UNKNOWN,OBSERVATIONAL,['NA'],
3031,NCT05723445,Change in percent time in target range 70-180 mg/dL,Change in intestinal fatty acid binding protein (I-FABP),2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],
3032,NCT02683902,Weight loss,"Weight, waist circumference and total body fat loss after 3 and 6 month of end of intervention",2016-03,UNKNOWN,INTERVENTIONAL,['NA'],
3033,NCT02521675,percentage of time spent over 24 hours in hyperglycemia (> 180 mg / dL) (> 10 mmol / L),"Comparison between number of hypoglycemic events predicted by the prediction function ""DIABRASPORT"" and number of hypoglycemic events actually occurred.",2016-01,COMPLETED,INTERVENTIONAL,['NA'],
3034,NCT05824286,Change in measured HbA1c from baseline to 24 weeks,The rate of severe hypoglycemic events and confirmed hypoglycemic events during the 24 weeks of the study,2023-01-04,RECRUITING,INTERVENTIONAL,['NA'],
3035,NCT05838222,Feasibility measure,Hypertension,2023-05-08,COMPLETED,INTERVENTIONAL,['NA'],
3036,NCT03717909,Visual acuity (VA),Pancreatic beta cell reserve - glycated haemoglobin or equivalent,2018-12-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],PMBC - Biomarker 2
3037,NCT02649465,The improvement in histologic features of NAFLD,Epigenomic changes from baseline in genes of the liver and blood cells,2015-11-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
3038,NCT01303900,Cardiovascular disease risk factors,Association between clotting factor concentrate administration and cardiovascular events,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],
3039,NCT02264951,plasma GIP,plasma CCK,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
3040,NCT01968265,The effect of ISIS-GCCRRx on serum fructosamine,The tolerability of ISIS-GCCRRx,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
3041,NCT02967211,Change in HbA1c (percentage %),Change in fasting plasma glucose,2015-12-21,COMPLETED,INTERVENTIONAL,['PHASE4'],
3042,NCT01041144,HbA1c,PP2hr Lipid profile,na,COMPLETED,INTERVENTIONAL,['NA'],
3043,NCT05347030,The change in the value of 2-hour blood glucose from baseline at the end of the 12-week treatment,The change from baseline of blood pressure,2022-10-06,RECRUITING,INTERVENTIONAL,['NA'],Incidence of Adverse Events
3044,NCT00108927,,,2003-12,COMPLETED,OBSERVATIONAL,['NA'],
3045,NCT03147274,Change from baseline self-care adherence at 12 months,Change from baseline hemoglobin A1c at 12 months,2017-05-03,COMPLETED,INTERVENTIONAL,['NA'],
3046,NCT01099137,The change of HbA1c,HbA1c < 7.0% without hypoglycemia,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
3047,NCT00660907,Adjusted Mean Change in HbA1c Levels,Proportion of Participants With Body Weight Reduction of at Least 5%,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
3048,NCT02661906,Improvement in quality of life,Improvement in lipid profile,2016-08,COMPLETED,INTERVENTIONAL,['NA'],
3049,NCT02152891,Change in rate of EMS Calls,,2015-11-01,COMPLETED,INTERVENTIONAL,['NA'],
3050,NCT03161652,Vasoinhibin vitreous levels,Blood pressure,2017-05-24,RECRUITING,INTERVENTIONAL,['PHASE2'],
3051,NCT02290925,Glycosylated Haemoglobin,Renal Adverse Effects - 2,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
3052,NCT03663322,Fasting glucose,A1C,2018-11-15,UNKNOWN,INTERVENTIONAL,['NA'],
3053,NCT01107171,Hemoglobin A1c (HbA1c),"The rate of adverse events,the blood and urine and stool routine examination, electrocardiogram (ECG)and liver and kidney function tests",2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
3054,NCT01686945,Number of treatment emergent adverse events (TEAEs) recorded,Change from baseline in glycosylated haemoglobin type A1c (HbA1c),2012-09-19,COMPLETED,INTERVENTIONAL,['PHASE1'],
3055,NCT01189422,Dose regimen,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE1'],
3056,NCT02060357,Endothelial stent coverage,MACE,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
3057,NCT01697657,Incidence of total self-recorded hypoglycaemic episodes,Incidence of adverse events,2001-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
3058,NCT00655603,Glucose turn-over,"The inhibitory effect of GLP-1 on glucagon, and the role of this in its anti-diabetic potential, measured by looking at glucose turn-over.",2008-03,UNKNOWN,INTERVENTIONAL,['NA'],
3059,NCT01739205,Weight loss,Inflammation,2008-01,COMPLETED,INTERVENTIONAL,['NA'],Other outcomes
3060,NCT05316662,Change in HbA1c,"DTSQs, change in absolute treatment satisfaction",2022-04-06,RECRUITING,OBSERVATIONAL,['NA'],
3061,NCT05394727,Change from baseline in Plasma insulin concentrations to week 4,,2021-04-01,RECRUITING,INTERVENTIONAL,['NA'],
3062,NCT03851666,Effect of the treatment on reduction of the HbA1c level (%),Effect of the treatment on evolution of the subject weight,2018-08-09,COMPLETED,INTERVENTIONAL,['NA'],
3063,NCT03440203,Activities of daily living,,2017-05-11,COMPLETED,OBSERVATIONAL,['NA'],
3064,NCT05924724,Treatment Satisfaction,Activity in the last 7 days,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],
3065,NCT01961401,insulin sensitivity,,2013-01,TERMINATED,INTERVENTIONAL,['NA'],
3066,NCT02011178,Glomerular filtration rate,Lipids,2014-03,WITHDRAWN,INTERVENTIONAL,['NA'],Quality of life score
3067,NCT01467141,Change in HbA1c (glycosylated haemoglobin A1c),Incidence of Adverse Events (AEs),2002-06-19,COMPLETED,INTERVENTIONAL,['PHASE4'],
3068,NCT04240574,Subjects Feedback,,2020-01-24,TERMINATED,INTERVENTIONAL,['NA'],
3069,NCT05596760,EHR documentation of Goals of Care discussions,Anxiety and depression (HADS),2023-09-11,RECRUITING,INTERVENTIONAL,['NA'],
3070,NCT01807377,HDL cholesterol,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
3071,NCT04825795,Prevalence of obstructive coronary disease,Change in coronary calcium score,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],
3072,NCT01924312,Brain T2 hyperintensity volume on MRI,Total brain volume,2013-05,COMPLETED,INTERVENTIONAL,['NA'],
3073,NCT03774394,Platelet Reactivity Index (PRI) Assessed by VASP. The Cutoff for High Platelet Reactivity is >50%,Clopidogrel Active Metabolite Concentration,2019-08-22,COMPLETED,INTERVENTIONAL,['PHASE4'],Platelet Reactivity Index (PRI) Assessed by VASP. The Cutoff for High Platelet Reactivity is >50%
3074,NCT01582308,Percent Inhibition of Dipeptidyl Peptidase IV (DPP-4) Activity at Trough,Pharmacokinetic Analysis: Time to the Peak Plasma Drug Concentration (Tmax),2012-06-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
3075,NCT01964950,Number of Participants Reporting One or More Serious Adverse Drug Reaction,Change From Baseline in Fasting Insulin Level,2011-07,COMPLETED,OBSERVATIONAL,['NA'],
3076,NCT00031213,,,2001-09,COMPLETED,OBSERVATIONAL,['NA'],
3077,NCT01582282,Triglyceride Change From Baseline,,1988-05,TERMINATED,INTERVENTIONAL,['PHASE4'],
3078,NCT02312427,Serum BNP level with and without DPP-4 inhibitor use.,"Other neurohormonal factors (Changes in plasma renin, aldosterone, serum stromal cell-derived factor 1 alpha, serum active glucagon-like peptide-1, serum active glucose-dependent insulinotropic polypeptid)",2015-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
3079,NCT00591227,Hospital Length of Stay,Frequency of Hypoglycemia During Emergency Room Therapy With Insulin,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
3080,NCT01609088,Brachial artery flow mediated dilation,C-reactive protein,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
3081,NCT00990184,Acute Insulin Response (AIRg) to Intravenous Glucose,Glucose Disappearance Rate,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
3082,NCT04799925,Effect of treatment of hyperuricemia on estimated Glomerular Filtration Rate by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.,,2021-04-15,UNKNOWN,OBSERVATIONAL,['NA'],
3083,NCT00488930,"Measure changes in dendritic cells at baseline, 6 months and 1 year following weight loss",,2007-06,TERMINATED,OBSERVATIONAL,['NA'],
3084,NCT03999853,Insulin sensitivity,Glucose Variability and Triglycerides,2022-07-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3085,NCT04975464,COVID 19 survey,,2011-11-15,UNKNOWN,OBSERVATIONAL,['NA'],
3086,NCT01222429,"indices of renal function (serum creatinine, microalbumin)",,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
3087,NCT05579977,"Placebo-adjusted, percent change from baseline in body weight at Week 32 in Obesity",Assessment of mental health as determined by Columbia-Suicide Severity Rating Scale (C-SSRS) in Obesity,2022-10-27,TERMINATED,INTERVENTIONAL,['PHASE2'],
3088,NCT04757285,determine stress hormones in serum cortisol and copeptin,correlation of psychological stress with stress hormone copeptin,2020-05-10,COMPLETED,OBSERVATIONAL,['NA'],
3089,NCT05661799,Change in amount of physical activity assessed by the French Version of GPAQ,Progressive medical data assessed by a specific form for the study,2021-09-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3090,NCT00873925,C-Peptide following the 1 year mixed meal tolerance test,Peripheral Blood T-cell assays,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
3091,NCT03623139,Change in mean amplitude of glycaemic excursions (MAGE),Change in intake of dietary fibre,2018-09-28,COMPLETED,INTERVENTIONAL,['NA'],Change in urinary biomarkers of carbohydrate intake
3092,NCT01633086,Neuopathic Pain Scale,the likelihood of reusing the nitric oxide gel recorded,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
3093,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Cholesterol,Change in FPG From Baseline to Week 78,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
3094,NCT01563887,The change in the number of hypoglycemia-related driving mishaps,,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
3095,NCT01698385,Change from Baseline in oral glucose tolerance test at variable time frames,Change from Baseline in weight at variable time frames,2008-02,COMPLETED,INTERVENTIONAL,['NA'],
3096,NCT00523042,"Changes in lung function, chest X-rays, or asthma exacerbation frequency",Preprandial insulin doses,2007-08-30,TERMINATED,INTERVENTIONAL,['PHASE3'],
3097,NCT06036004,Change in EmBody/EmFace to assess recognition of facial and body expressions,Change in Beck's Depression Inventory II (BDI-II) to assess depression,2024-01-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in Close third-person assessment
3098,NCT04664036,Association of NAFLD with microvascular and macrovascular complications in type 1 diabetes mellitus: odds ratio to develop in NAFLD and diabetes compared to diabetes without NAFLD in subjects with no prior complications,Natural history of NAFLD in type 1 diabetes,2018-09-17,RECRUITING,OBSERVATIONAL,['NA'],
3099,NCT01002352,Improvement of comorbidities,"Mortality, weight loss, surgical complications",2007-06,UNKNOWN,OBSERVATIONAL,['NA'],
3100,NCT01240980,"Safety and Tolerability of the investigational drug, as assessed by adverse event monitoring, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments",The single-dose pharmacokinetics parameter apparent clearance from plasma after extra-vascular administration (CLT/F) of BMS-903452 will be derived from the plasma concentration versus time data,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
3101,NCT04275141,In vivo kinetics of lactate,DNA Banking,2022-01-17,RECRUITING,INTERVENTIONAL,['NA'],
3102,NCT04016155,Difference in time in hypoglycaemia,Fear of hypoglycaemia,2019-07-17,UNKNOWN,INTERVENTIONAL,['NA'],
3103,NCT03066284,Impact of IPT on QoL of children and adolescents from their perspective and their parents' perspective,,2016-03-14,UNKNOWN,OBSERVATIONAL,['NA'],
3104,NCT05286892,Perceived Competence Scale,,2023-04-30,RECRUITING,INTERVENTIONAL,['NA'],
3105,NCT01759953,Knowledge on insulin therapy for diabetes,Attitudes regarding diabetes/insulin,2014-07,COMPLETED,INTERVENTIONAL,['NA'],Reasons for not finishing the game
3106,NCT03562078,Hemoglobin,high frequency (HF),2017-05-22,UNKNOWN,INTERVENTIONAL,['NA'],
3107,NCT02837094,To examine the risk of C19A3 GNP administration in terms of general safety and induction of hypersensitivity.,To study the immune responses to C19A3 GNP generated in the draining (axillary) lymph node.,2016-09-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
3108,NCT04090242,Change in Attitude Toward Diabetes - Diabetes Empowerment Scale (DES) From Baseline to End of Study,Patient Satisfaction at Study End,2019-09-06,TERMINATED,INTERVENTIONAL,['NA'],Number of Hours of Patient Engagement With App
3109,NCT05266404,Volume of distribution (apparent) following extravascular administration (based on terminal phase) (Vz/F),Number of subjects with adverse events (AEs),2022-03-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
3110,NCT03207711,frequency of eating in response to cravings (primary mechanistic outcome),Perceived Stress (secondary mechanistic outcome),2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],
3111,NCT02691247,Change From Baseline in 4-hour Mixed Meal Tolerance Test (MMTT)-Stimulated C-peptide Area Under the Curve (AUC) at Week 52,Change From Baseline in Mean Daily Dose of Insulin,2016-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
3112,NCT02107469,Improvement of NTSS-6 SCORE in per cent from baseline,Assessment of compliance regarding medication and dietary recommendations (score).,2014-06,COMPLETED,INTERVENTIONAL,['NA'],Patient Diary
3113,NCT02684929,Change in glucose disposal,Change in gene expression in adipose tissue,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
3114,NCT02249910,Area under the digoxin plasma concentration-time curve,Number of hypoglycaemic episodes,2014-09-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
3115,NCT06150209,Time Closure in Diabetic foot ulcers Managed with Vendaje,Reduction of wound volume in diabetic foot ulcers treated with Vendaje,2024-01-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3116,NCT00682903,"The HbA1c, the witness of the quality of the metabolic balance, in 6 and 12 months. We shall compare the deltae of HbA1c between the period of inclusion and 6 and 12 months following the training course in the ""fonctional"" insulin therapy",,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
3117,NCT05607576,Post radiation Dexcom G6 transmitter functional duration,,2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3118,NCT04407234,PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen,PK: Cmax of Acetaminophen at Steady State For T2DM,2020-09-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
3119,NCT04061200,Albuminuria,Inflammatory and endothelial biomarkers,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3120,NCT03566810,Maximum Observed Plasma Concentration (Cmax) of Metformin,Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings,2018-10-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
3121,NCT00000620,First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.,First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.,1999-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
3122,NCT03515421,Marketing Claims Evaluation questionnaire.,,2018-04-09,COMPLETED,INTERVENTIONAL,['NA'],
3123,NCT01293773,Target lesion failure,Effect of dual antiplatelet therapy on outcome,2010-10,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
3124,NCT02848547,Incidence of type 2 diabetes among participants enrolled in the diabetes prevention programme.,Long-term impact of healthy lifestyle through mobile phone based text messaging,2016-01,COMPLETED,OBSERVATIONAL,['NA'],
3125,NCT01536626,HbA1c (glycosylated haemoglobin),Quality of Life (QoL) using the World Health Organization Wellbeing Index (WHO-5),2006-06-09,COMPLETED,OBSERVATIONAL,['NA'],
3126,NCT02456051,Pancreatic cancer diagnosis,Mortality,2015-04,TERMINATED,OBSERVATIONAL,['NA'],
3127,NCT04306939,Common disease mechanisms and repurposing of medications.,Patient Reported Global Health Assessment,2014-11-01,SUSPENDED,OBSERVATIONAL,['NA'],
3128,NCT04440319,Statistical analyses for HbA1c and Fasting blood glucose,Statistical analyses for Waist Circumference,2020-07-01,COMPLETED,INTERVENTIONAL,['NA'],
3129,NCT03102892,Salivary glucose - collection of stimulated saliva in 10 minutes and measured with a colorimetric kit,Capillary glycemia measured by a glucometer,2017-04-24,TERMINATED,INTERVENTIONAL,['NA'],
3130,NCT00134277,Primary patency after 6 months,Proving the superiority or non-superiority of one treatment procedure to another treatment procedure,2004-09,COMPLETED,INTERVENTIONAL,['NA'],
3131,NCT05696366,Change in HbA1c,Change in subject self reported ambulatory insulin dosing,2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3132,NCT05368454,Change in HbA1c,Change in diabetes distress,2022-05-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3133,NCT04388059,glycemic control in morbid obese diabetic adolescents.,weight loss in morbid obese diabetic adolescents.,2014-12,COMPLETED,OBSERVATIONAL,['NA'],
3134,NCT01756105,Efficacy of metformin in treatment of gestational diabetes based on capillary glycaemia with an objective of less than 6 measures out of range,,2012-06,TERMINATED,INTERVENTIONAL,['PHASE2'],
3135,NCT00063232,Change in the Histological NASH Activity Index at 48 Weeks Compared With Baseline (Number of Participants in Each Change Category),"Change in Insulin Sensitivity (Glucose Tolerance, Homeostatic Model Assessment of Insulin Resistence (HOMA-IR)) From Baseline",2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3136,NCT01405261,Overview of Treatment Emergent Adverse Events (AEs),The time to maximum concentration (tmax) of NNC 0113-0987 in plasma,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
3137,NCT04696640,Change in hemoglobin A1c (HbA1c),Remote patient monitoring survey,2021-06-03,COMPLETED,INTERVENTIONAL,['NA'],
3138,NCT01571817,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
3139,NCT02817217,The area under the plasma concentration-time curve (AUC) of Valsartan,The number of volunteers with adverse events as a measure of safety and tolerability,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3140,NCT03758430,Change from Baseline to Week 16 in Hemoglobin A1c (HbA1c),Change from Baseline to Week 16 in Post-Prandial Glucose Concentrations Following Commonly Eaten Meals,2019-02-06,COMPLETED,OBSERVATIONAL,['NA'],
3141,NCT01873859,Change of Baseline Creatinine 48 hr After Recieving Contrast Media in the Presence or Absence of Metformin Use.,,2013-05,COMPLETED,INTERVENTIONAL,['NA'],
3142,NCT05477628,zBMI,Dietary Quality,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3143,NCT01857973,Percentage of Time in Euglycemic Range - Phase 3 (Closed-loop Using the NGP Pump Platform),Percentage of Time in Euglycemic Range - Phase 7,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
3144,NCT04739215,"Main Structural Objective: Changes in serum levels of procollagen type I C-terminal propertied (PICP, ng/mL)",Changes in high sensitivity troponin T (pg/mL),2021-01-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3145,NCT02626832,AVP response to plasma osmolality as measured by slopes between the two variables,,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
3146,NCT01656915,Cytokines,,2012-06,COMPLETED,OBSERVATIONAL,['NA'],
3147,NCT02987738,Time in Range 70-180%,Reduction of Insulin dose,2017-02-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
3148,NCT03278158,"Safety and tolerability of single ascending oral doses of XEN-D0501, (1, 2, 4 and 8 mg) versus placebo in type 2 diabetic patients in treatment with metformin (Incidence of adverse events in type 2 diabetic patients)",,2017-09-18,COMPLETED,INTERVENTIONAL,['PHASE2'],
3149,NCT00689377,"Prevalence of lower extremities peripheral arterial disease (PAD), in subjects with a moderate CVD risk, with no overt cardiovascular diseases nor diabetes mellitus","Determinants (i.e., subject and physician characteristics) for PAD underdiagnosis in the selected population",2007-05,COMPLETED,OBSERVATIONAL,['NA'],
3150,NCT03965000,Changes in the gene expression,,2019-01-24,UNKNOWN,OBSERVATIONAL,['NA'],
3151,NCT01727349,Measure of risk of developing type 2 diabetes in at-risk families,,2011-12-14,COMPLETED,INTERVENTIONAL,['NA'],
3152,NCT04563598,Total earnings from employment and/or self-employment by study year (all study participants),Ever received Supplemental Security Income (SSI) benefits at age 65 since randomization (all study participants),2016-12-19,COMPLETED,OBSERVATIONAL,['NA'],Ever retired during first 10 years after randomization (all study participants)
3153,NCT02639988,Time to the addition of a new treatment for type 2 diabetes in months,Proportion of patients with increased HOMA-IR between 2 visits in %,2016-04-13,SUSPENDED,OBSERVATIONAL,['NA'],
3154,NCT00797134,Retinal thickness.,Choroidal Thickness,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
3155,NCT02740283,Rate of GDM diagnosed in 18-20 gestational week.,,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],
3156,NCT04521634,Stroke Primary outcome - MRS,,2020-09-30,COMPLETED,OBSERVATIONAL,['NA'],
3157,NCT03023293,postpartum glucose metabolism,,2017-03-10,UNKNOWN,OBSERVATIONAL,['NA'],
3158,NCT04002557,Young people's beliefs about good health as assessed by interview with open questions,,2019-05-31,COMPLETED,OBSERVATIONAL,['NA'],
3159,NCT04909580,Decisional Conflict,Genetic Counselling Satisfaction Scale (modified version),2013-09-05,COMPLETED,INTERVENTIONAL,['NA'],
3160,NCT04253431,Volume (uL) of blood in the capillary tube,The intensity of pain perceived by the patient assessed with the use of the VAS (Visual Analog Scale).,2013-08,COMPLETED,INTERVENTIONAL,['NA'],
3161,NCT06323538,Incidence of diabetes type 2,Intake of medication,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Microbiome
3162,NCT01344928,,,na,UNKNOWN,INTERVENTIONAL,['NA'],
3163,NCT02470637,Assessment of PD parameter: Area under the glucose infusion rate curve within 24 hours after administration of the investigational medicinal product or until administration of rescue insulin (GIR-AUC0-end),Number of patients with adverse events,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
3164,NCT00966368,Maximum observed Insulin Degludec concentration after single dose,Terminal half-life for Insulin Degludec,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
3165,NCT00791479,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Collection and Evaluation of Plasma Levels (Pharmacokinetics [PK]) of LY2189265,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
3166,NCT04112069,Percentage of Time With CGM Glucose Values <54 mg/dl,,2018-07-09,COMPLETED,INTERVENTIONAL,['NA'],Number of Episodes of Diabetic Ketoacidosis (DKA)
3167,NCT05349955,Primary Outcome of Phase 2: Composite of 3P MACE and hospitalization for heart failure.,Secondary Outcome of Phase 2: All-cause death,2022-11-21,RECRUITING,INTERVENTIONAL,['NA'],The time rate of glycemic target range
3168,NCT05422352,Nerve Growth Factor,,2021-01-14,COMPLETED,INTERVENTIONAL,['NA'],
3169,NCT05755321,Characterization of neural progenitors cells,,2020-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3170,NCT00810173,,,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
3171,NCT01481116,Change From Baseline in HbA1c at Weeks 78 and 104,"Change From Baseline in Fasting Plasma Glucose at Weeks 26, 52, 78 and 104",2012-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
3172,NCT01521598,Relief of diabetic neuropathy pain,Average daily pain score,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
3173,NCT02177786,Change in eGFR From Baseline at Week 48,Percentage of Participants Achieving at Least a 30% Reduction From Baseline in Albuminuria (As Measured by Urine Albumin to Creatinine Ratio) at Week 48,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3174,NCT05015946,Health related quality of life (HRQoL),Aerobic intensity and movement patterns,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],
3175,NCT02224365,Blood Pressure,Body Composition,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
3176,NCT03193944,Achieving 25 (OH) D upper than insufficient serum 25(OH) D level >30 ng/l.,Improved blood pressure,2017-02-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
3177,NCT04573920,Change in proteinuria for FSGS patients at 1.5 mg dose,,2021-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
3178,NCT05829239,Change in insulin sensitivity,Change in intrahepatic triglyceride content,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in the transcriptome in adipose tissue
3179,NCT03952728,Medicare Part D Prescription Drug Fill Count,Medicare Skilled Nursing Facility payments,2016-12-19,COMPLETED,OBSERVATIONAL,['NA'],Medicare Imaging + Test payments
3180,NCT05368142,Wound healing rate up to 30 days,Pathogenic bacteria positive rate,2022-05-20,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3181,NCT02748980,The coronary microcirculation dysfunction is measured by index of microcirculatory resistance,,2016-03,UNKNOWN,OBSERVATIONAL,['NA'],
3182,NCT00238836,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3183,NCT05758545,Complete wound healing,Quality of life survey,2023-06-19,RECRUITING,INTERVENTIONAL,['NA'],
3184,NCT05315973,Accuracy: glucose readings in mg/dL,"Acceptability: questionnaire ratings on a scale of 1-5, with 5 being the highest",2022-06-01,WITHDRAWN,INTERVENTIONAL,['NA'],
3185,NCT00957060,Fasting and postprandial glucose,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
3186,NCT00700362,Plasma glucose level.,laboratories for inflammation and oxidative stress.,2011-12,WITHDRAWN,OBSERVATIONAL,['NA'],
3187,NCT03660293,"The cardiac changes induced by Simvastatin, captopril and L-Carnitine in type 1 diabetic children and adolescents.",Identification of risk factors for developing diabetic cardiac insult.,2017-04-01,COMPLETED,INTERVENTIONAL,['NA'],
3188,NCT00104572,Effect of Testosterone Gel vs. Anastrozole on Bone Mineral Density,Effect of Testosterone Gel vs. Anastrozole on Prostate Volume/Prostate Specific Antigen Levels/Urinary Function,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3189,NCT04833569,Crestal bone loss,Interleukin-6,2020-09-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
3190,NCT00763074,,,2006-04,COMPLETED,INTERVENTIONAL,['NA'],
3191,NCT00781950,"Number of Participants With All-cause Mortality, Cardiovascular Mortality, Stroke, and Myocardial Infarctions","Effects on Exercise Performance, Blood Pressure and Circulating Lipid Levels.",2008-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3192,NCT03625648,Time to ESRD or death,Rate of change in eGFR per year during the study period,2019-11-18,RECRUITING,INTERVENTIONAL,['PHASE4'],
3193,NCT04894916,User Experience,Change in Medication Adherence,2021-06-12,COMPLETED,INTERVENTIONAL,['NA'],
3194,NCT01760356,Change in the Percentage of expression of IL-2 in CD4 and CD8 subsets of T lymphocytes.,Post transplant surgical complications,2011-05-01,TERMINATED,OBSERVATIONAL,['NA'],
3195,NCT03023228,Assessment of change in Diabetes knowledge as measured by an 11-item diabetes knowledge survey,Medication adherence (Modified Morisky Medication Adherence Scale 4-item),2010-05,COMPLETED,INTERVENTIONAL,['NA'],
3196,NCT04558775,Proportion of participants who have DFU wound recurrence by 16 weeks after complete wound healing,Clinician assessment of DFU wound recurrence,2020-06-17,COMPLETED,OBSERVATIONAL,['NA'],
3197,NCT03407196,Change in HbA1c(%),Discontinuation rates of dapagliflozin in the first 6 months of treatment,2017-05-24,COMPLETED,OBSERVATIONAL,['NA'],
3198,NCT05158244,"Number of participants with clinically significant, abnormal 12-lead ECG parameters",Plasma Decay Half-Life (t1/2) of PF-07081532,2021-12-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
3199,NCT03426085,Sudomotor Function,Inflammatory Markers Tumor Necrosis factor α (TNF α),2016-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3200,NCT04621656,Assessment of percent of total time monitored that blood glucose is in range 70-180 mg/dL,Assessment of change in sleep quality and pattern as measured by heart rate monitor coupled to participant logs.,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA'],
3201,NCT01467063,Insulin Sensitivity,Glucagon-like Peptide 1 (GLP-1),2011-10,COMPLETED,INTERVENTIONAL,['NA'],
3202,NCT06253429,Changes in urinary albumin excretion rate,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
3203,NCT04431947,Duration of Sleep,Impact of Sleep on Glycemic Variability,2020-03-13,COMPLETED,OBSERVATIONAL,['NA'],
3204,NCT01989988,Remission of diabetes,weight loss and improvement in quality of life,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],
3205,NCT01277900,Gastric Bypass in the Treatment of Type 2 Diabetes in Patients with a BMI of 25 to 35 kg/m2,,2011-01,UNKNOWN,OBSERVATIONAL,['NA'],
3206,NCT04573335,All-cause mortality,COVID-19 illness,2020-06-01,COMPLETED,OBSERVATIONAL,['NA'],
3207,NCT04219124,Plasma concentration of 3-hydroxybutyrate,Plasma acylcarnitines measured by targeted metabolomics,2018-09-20,COMPLETED,INTERVENTIONAL,['PHASE4'],
3208,NCT04076007,24 hour Ambulatory Blood Pressure monitoring after 2 weeks placebo juice,Insulin sensitivity,2009-12,COMPLETED,INTERVENTIONAL,['NA'],
3209,NCT01498731,Rate of major adverse cardiac events (MACE) within 30 days Copeptin vs. Control arm.,Length of hospital stay,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
3210,NCT01973413,Percent Time Near Normoglycemia,Glycemic Events,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
3211,NCT02671331,Excess weight loss (EWL),Protein malnutrition,2016-01,TERMINATED,OBSERVATIONAL,['NA'],
3212,NCT00653341,Percentage of subjects reaching target HbA1c = or < 7% at endpoint and not experiencing symptomatic nocturnal hypoglycemia,"Safety data (Adverse events, vital signs, laboratory values, etc.)",2000-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
3213,NCT00309712,percent of patients achieving study goal oftriglycerides <200 mg/dL,"Percent of patients achieving all study goals: LDL-C < 100 mg/dL, HDL-C:40 mg/dL, Triglycerides <200 mg/dL and the Percent of patients achieving non-HDL cholesterol <130 mg/dL",2002-08,COMPLETED,INTERVENTIONAL,['NA'],
3214,NCT02553382,Change in HbA1c,Change in 24h ambulatory systolic blood pressure,2015-11,COMPLETED,INTERVENTIONAL,['NA'],Change in Hs-CRP
3215,NCT00362011,Hemoglobin A1c,"compliance (plasma fatty-acids, returned supplements, diet records, body weight).",2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3216,NCT04402710,"Acceptability as assessed by semi-structured exit interviews with participants which will include questions related to their thoughts and feelings about the study and whether they believed the study was acceptable (e.g. content, timing).",Change in Cognitive Emotion Regulation strategies from baseline to 6 weeks (intervention end),2020-09-01,COMPLETED,INTERVENTIONAL,['NA'],
3217,NCT01168765,Biomarkers,Quality adjusted life years,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
3218,NCT01047735,Feasibility of performing a randomized trial comparing two major types of bariatric surgery versus a lifestyle weight loss intervention (LWLI) induced by diet and increased physical activity in moderately obese patients with T2DM.,Preliminary information regarding the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss with diet and increased physical activity.,2009-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3219,NCT04648137,area under the concentration time curve in oxytocin level,Level of general physical & mental health using the short form health survey (SF-36),2021-02-05,COMPLETED,INTERVENTIONAL,['NA'],
3220,NCT03630445,"Appetite ratings (Visual Analog Scale, VAS)",Breath hydrogen (fermentability),2015-06-02,COMPLETED,INTERVENTIONAL,['NA'],
3221,NCT03666065,maximum insulin concentration,Time to GIR Max,2020-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
3222,NCT05623189,Primary Endpoint,Endpoint 28,2022-12-27,RECRUITING,INTERVENTIONAL,['PHASE2'],
3223,NCT02755064,Relationship between gastric emptying and glycemia,Number of subjects with delayed gastric emptying,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
3224,NCT01728883,Test efficacy of the test algorithm improvements,Assess patient satisfaction with the test,2013-04,COMPLETED,OBSERVATIONAL,['NA'],
3225,NCT01236794,Insulin Sensitivity,QOL,2010-05,COMPLETED,INTERVENTIONAL,['NA'],
3226,NCT03463564,Change in glucose variability,Diabetes treatment satisfaction,2016-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
3227,NCT05961878,Handgrip test,Dietary lifestyle,2023-07-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],health-related quality of life
3228,NCT02680457,Glycemic Variability: Mean Amplitude of Glucose Excursion (MAGE),Glycemic Variability: Area Under the Curve of Glucose,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
3229,NCT00720317,"We aim to screen African-American diabetic patients with retinopathy to ascertain whether sickle trait is present, and if so whether there is increased severity of diabetic retinopathy in the group with sickle trait.",,2008-05,COMPLETED,OBSERVATIONAL,['NA'],
3230,NCT00770926,Body weight,diet,2006-09,COMPLETED,INTERVENTIONAL,['NA'],
3231,NCT01769378,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks,Change From Baseline in Amylase,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
3232,NCT05454891,Glucose Area Under Curve [AUC],Percentage of time between 70-140 mg/dL,2022-07-15,RECRUITING,INTERVENTIONAL,['PHASE4'],
3233,NCT01946997,Normative retinal thickness data for comparison,,2006-07,COMPLETED,OBSERVATIONAL,['NA'],
3234,NCT01982435,Number of Participants With Severe Non-ocular Adverse Event,Number of Participants With Nonperfusion,2014-06-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3235,NCT05089942,Efficacy of Recombinant Human Insulin Patch ZJSRM2021,Pain assessment of Recombinant Human Insulin Patch ZJSRM2021,2021-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3236,NCT04342624,Mircobiome effects of cinnamon through stool sample collection,,2021-04-14,COMPLETED,INTERVENTIONAL,['NA'],
3237,NCT05072587,Serum 7-Ketocholesterol (7-KC),World Health Organization (WHO-5) Index of Well Being,2021-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
3238,NCT01790945,% change in Diabetic Retinopahy/Diabetic Macular Edema diagnosis with pre-screening system compared to post-screening system,Change in HgA1C from Primary Care Physician referral to post retinal specialist visit,2013-02,UNKNOWN,OBSERVATIONAL,['NA'],Time from PCP referral for patient to see an ophthalmologist and appointment with retinal specialist
3239,NCT03522311,Visual acuity measurement,Presence of postoperative vitreous hemorrhage,2013-01,COMPLETED,OBSERVATIONAL,['NA'],Presence of postoperative retinal detachment
3240,NCT01589718,Tractional Retinal Detachment Repair,Visual Acuity,2012-04,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
3241,NCT04992312,Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacokinetics (PK): AUC of Nasal Glucagon,2022-03-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
3242,NCT01282567,Dosage of plasma insulin concentration and blood glucose every 20 minutes during 6 hours and 40 minutes,,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
3243,NCT01375270,Insulin Secretion,"Plasma Cytokines (IL-6, TNF, IL-1beta, IL-1ra)",2011-04,COMPLETED,INTERVENTIONAL,['NA'],
3244,NCT02956642,Change in HbA1c Levels,Change in fasting lipid panel.,2018-11-14,COMPLETED,INTERVENTIONAL,['NA'],
3245,NCT00770952,Change from Baseline in Homeostatic Model Assessment - Beta cell.,Change from Baseline in Total Cholesterol,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
3246,NCT06203106,Biobank,,2022-11-10,RECRUITING,OBSERVATIONAL,['NA'],
3247,NCT01451398,Change From Baseline to Week 24 in HbA1c,Change in Body Weight From Baseline to Week 24,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3248,NCT04558827,Effectiveness of Intervention: Changes in Insulin Dosage,Feasibility: Percent of day compliant with Carbohydrate target,2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],
3249,NCT00467285,Changes in BMD 0.33 Radius,Changes in CTx at Follow up,2006-10,COMPLETED,OBSERVATIONAL,['NA'],
3250,NCT01546844,"Change in Hemoglobin A1c - In control, over time.",Disease Management,2012-03,UNKNOWN,INTERVENTIONAL,['NA'],
3251,NCT01794650,24 hour blood glucose area under the curve,Ketogenesis,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
3252,NCT02389335,"Roles of interferon gamma, interleukin-2, tumor necrotizan factor alpha in the pathogenesis of type 1 diabetes",,2013-04,COMPLETED,OBSERVATIONAL,['NA'],
3253,NCT01241253,Net blood glucose changes over time,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
3254,NCT00958997,PET-determined pancreatic islet beta-cell mass,Insulin secretion response following an acute arginine-stimulus test,2009-08,COMPLETED,OBSERVATIONAL,['NA'],
3255,NCT01967849,Glucose Tolerance,Insulin resistance,1999-09,RECRUITING,INTERVENTIONAL,['NA'],Gene Expression
3256,NCT02962492,Change in Beta-hydroxybutyrate Levels in Blood,Change in Total Insulin Dose,2016-11-01,COMPLETED,INTERVENTIONAL,['NA'],
3257,NCT00613782,Insulin Resistance,Bone microarchitecture,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3258,NCT04620967,Time in range,Ketoacidosis,2021-02-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3259,NCT04958356,"Number of participants with confirmed positivity for at least one diabetes-associated autoantibody (insulin autoantibodies and antibodies to GAD65, islet antigen 2 and zinc transporter 8) or confirmed positivity for tissue transglutaminase antibodies",,2018-11-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3260,NCT04642755,"Prevalence of malnutrition, DM and helminth infections in LTBI individuals and their effects on biosignatures",,2021-04-19,RECRUITING,OBSERVATIONAL,['NA'],
3261,NCT00499824,Change in HbA1c from baseline in subjects with baseline HbA1c >/=6.5%,"HbA1c, FPG, BP, lipids; hypoglycemic events; health care use; number of GP HbA1c measurements; number of treatment escalations; adverse events; barriers to guideline implementation; determine if study patients are representative of GP's diabetic practice",2007-01,COMPLETED,INTERVENTIONAL,['NA'],
3262,NCT00916513,"Diabetes-related QoL and treatment satisfaction questionnaires: DTSQ, ADDQoL, HFSws and EQ5D","Health-economic variables: Use of healthcare resources Days off work (for either hypoglycaemias, acute or chronic complications)",2009-05,COMPLETED,OBSERVATIONAL,['NA'],
3263,NCT02321904,The utility of corneal confocal microscopy to assess diabetic neuropathy in children.,Corneal nerve branching density (CBD) by CCM,2008-06,COMPLETED,OBSERVATIONAL,['NA'],
3264,NCT00603590,Systolic Blood Pressure,LDL Cholesterol,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
3265,NCT03679273,PEDIS score,,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA'],
3266,NCT04038528,glycated hemoglobin (GlyH) level,Hyperglycemic events,2018-03-01,UNKNOWN,OBSERVATIONAL,['NA'],
3267,NCT03332472,HbA1c,Standard deviation,2013-12,COMPLETED,INTERVENTIONAL,['NA'],
3268,NCT01965665,Change in Sepsis Rate,,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
3269,NCT05330247,Change in glycated hemoglobin (HbA1c) after 12 months on the CRHP diet compared with the CD diet,Change in hepatic fat content after 12 months on the CRHP diet compared with the CD diet,2022-09-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in Health Literacy after follow-up at 24 months on the CRHP diet compared with the CD diet
3270,NCT04304430,Combined categorized endpoint,Proportion of patients attaining blood pressure target,2018-10-18,COMPLETED,OBSERVATIONAL,['NA'],
3271,NCT04970810,A1c,Diabetes Self-Efficacy,2021-07-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3272,NCT03429088,Feasibility of identifying and recruiting sufficient number of participants into a telephone-based physical activity intervention.,Physical Activity Self-Regulation,2015-06-01,COMPLETED,INTERVENTIONAL,['NA'],
3273,NCT03272074,"Fasting blood glucose, insulin resistance, and insulin sensitivity",Lipid panel,2015-09-11,COMPLETED,INTERVENTIONAL,['NA'],ABCA1 Protein
3274,NCT06117436,Wound Healing size,Treatment-related side effects.,2023-10-19,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3275,NCT02445833,Changes in blood pressure levels at 6 and 12 months,Satisfaction with treatment,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
3276,NCT04838405,Incidence of Treatment-Emergent Adverse Events as assessed by self-report,Change in mean insulin levels,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE1'],
3277,NCT00515801,plasma glucagon concentrations during insulin induced hypoglycemia with and without glibenclamide pretreatment,cognitive function during insulin induced hypoglycemia with and without glibenclamide pretreatment,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3278,NCT02994316,Interest of copeptin dosage as a severity marker in children under the age of 16 with diabatic ketoacidosis,Correlation between plasma copeptin levels and other markers used in management of diabatic ketoacidosis in the first 36 hours after diagnosis- Plasma copeptin levels at diagnosis of diabate mellitus type 1 without ketoacidosis in children,2016-10-03,COMPLETED,INTERVENTIONAL,['NA'],
3279,NCT00458029,Fasting insulin (mU/mL),"Decisions, policies, and activities at the school, local, state, or federal level that influence the school environment for nutrition and physical activity",2006-08,COMPLETED,INTERVENTIONAL,['NA'],
3280,NCT03352674,Incidence of immune response,Adverse events,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3281,NCT00608101,catecholamines,,2010-09,WITHDRAWN,INTERVENTIONAL,['NA'],
3282,NCT05606913,HbA1c change from baseline at week 28,To assess changes in PD parameters fasting C-peptide at different time points before and after administration.,2023-01-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
3283,NCT05930561,Annualized number of aflibercept injections in the study eye,Percentage of subjects with a ≥2 and ≥3-Step Diabetic Retinopathy Severity (DRS) improvement from baseline on the ETDRS-DRSS,2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE2'],"Incidence and severity of treatment-emergent adverse events and serious adverse events, including clinically significant changes in safety parameters"
3284,NCT05607979,Primary Endpoint,Change in Pain Scores over time (60 days),2022-12-15,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3285,NCT01811485,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 14 Weeks Between Treatment Groups,"Number of Patients With Adverse Events (Including Hypoglycemia), Serious Adverse Events and Death",2013-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
3286,NCT05301413,DPP Class Attendance,Office/clinic visits,2022-07-20,RECRUITING,INTERVENTIONAL,['PHASE2'],
3287,NCT02261831,rDNA comparison between cases and controls,,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
3288,NCT02742662,Change in body weight in kg,Change in plasma triglycerides,2016-04,COMPLETED,INTERVENTIONAL,['NA'],
3289,NCT00374361,,,2003-07,COMPLETED,OBSERVATIONAL,['NA'],
3290,NCT02949037,Patient Activation Measure (PAM),Summary of Diabetes Self-Care Activities (SDSCA),2017-07-01,COMPLETED,INTERVENTIONAL,['NA'],
3291,NCT05576025,24-hour area under the curve (AUC) for glucose,,2022-11-23,RECRUITING,INTERVENTIONAL,['NA'],Sedentary time
3292,NCT00313742,The difference between plasma glucose concentrations immediately pre-exercise and the minimum plasma glucose concentrations (nadir) in the period 0-150 min following exercise,Incidence of adverse events during the trial,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
3293,NCT00134147,Glycosylated hemoglobin,Safety based on adverse events reported and laboratory tests,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
3294,NCT01219582,Change in Hemoglobin A1c (HbA1c) levels,Percentage of patients with satisfaction of treatment,2010-10,COMPLETED,OBSERVATIONAL,['NA'],
3295,NCT00516204,Cholesterol levels,,2007-07,COMPLETED,OBSERVATIONAL,['NA'],
3296,NCT01152957,Glycemic Control,Cholesterol,2010-07,COMPLETED,INTERVENTIONAL,['NA'],
3297,NCT03531905,Percent Change From Baseline to Week 12/End of Study (EOS) in Low-density Lipoprotein Cholesterol (LDL-C),Percent Change From Baseline to Week 12 in HbA1c,2018-05-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
3298,NCT01678469,link between plasma concentrations and dietary intakes of lipophilic micronutrients and risk of developing a Gestational diabetes mellitus,,2011-11-28,COMPLETED,INTERVENTIONAL,['NA'],
3299,NCT05799976,Care gap order rate,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Care gap completion rate
3300,NCT02122666,Sarcoplasmic Reticulum Composition,Lean and Fat Body Mass,2014-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3301,NCT01937598,Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC),AUC Active GIP,2013-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
3302,NCT05366868,Time from study drug initiation (Week 0) to detection of two consecutive HbA1c levels of 7.0% or higher by laboratory tests after Week 16.,Time from Week 0 to detection of two consecutive HbA1c levels of 7.0% or higher by laboratory tests after Week 16 by patient characteristics,2022-05-26,RECRUITING,INTERVENTIONAL,['PHASE4'],
3303,NCT00286598,Change in weight-bearing physical activity (steps/day),Foot-related self-care,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3304,NCT05933174,Proportion of patients who had a conversation with their primary care provider about SU use and alternatives for their diabetes management,Diabetes Distress Scale,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],
3305,NCT00481117,"Safety labs, ECGs, vital signs, adverse events.",Pharmacodynamics (lab samples) and Pharmacokinetics (lab samples),2008-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
3306,NCT00156078,Mean pain score,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
3307,NCT03380416,Liver fat content,Biochemical parameters,2017-04-04,COMPLETED,INTERVENTIONAL,['NA'],
3308,NCT00782496,Average Number of Weekly Post-Prandial Blood Glucose Tests Performed by Subjects Using Either Basic or Advanced Meter Features,Percent of Level 2 Participants Who Rated Helpfulness of Advanced Meter Features as 1 or 2,2008-11,COMPLETED,INTERVENTIONAL,['NA'],
3309,NCT03387657,Assessment of PK parameter: AUCtau,Assessment of PK parameter: tmax,2018-01-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
3310,NCT00005474,,,1996-09,COMPLETED,OBSERVATIONAL,['NA'],
3311,NCT01724502,Protein Concentration of Mitochondria,,2012-09,COMPLETED,INTERVENTIONAL,['NA'],
3312,NCT04991142,Feasibility of measuring meal quantity and composition using CGMs,Feasibility of measuring impact of gut microbiota on estimations of meal composition using CGMs,2021-09-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3313,NCT01593371,Serum concentrations of leptin,,2011-07,COMPLETED,INTERVENTIONAL,['NA'],
3314,NCT02617160,Percentage of glucose readings within range of 70-180 mg/dl,Percentage of glucose readings below 50 mg/dl,2016-05,TERMINATED,INTERVENTIONAL,['NA'],Device Satisfaction
3315,NCT04405895,Change in Clock Genes mRNA,Change in Overall Glycemia,2020-05-31,UNKNOWN,INTERVENTIONAL,['NA'],
3316,NCT02192255,120 day medication adherence,"Composite Control Level of Blood pressure, A1c and/or LDL",2012-01,COMPLETED,INTERVENTIONAL,['NA'],
3317,NCT04385888,Glycemic Variability,Inflammatory cytokines (e.g. IL-6),2020-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3318,NCT02201199,Area under the serum insulin glargine (INS) concentration curve over the first 12 hours after dosing,"Safety and tolerability (Number of patients with adverse events, clinically significant changes in vital signs, laboratory parameters)",2014-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
3319,NCT06268743,Gut microbiome diversity through 16S ribosomal RNA genes,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3320,NCT02597309,Reduction in insulin recuirement,,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
3321,NCT04762251,HbA1c,Adherence,2021-02-17,RECRUITING,INTERVENTIONAL,['NA'],
3322,NCT03356340,End-stage Renal Disease,,1993-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3323,NCT01480804,change in hemoglobin A1c,"Change in clinical, functional and psycho social tests and questionnaires",2006-11,COMPLETED,INTERVENTIONAL,['NA'],
3324,NCT04668651,Antral content,Perioperative respiratory complications,2021-01-12,COMPLETED,OBSERVATIONAL,['NA'],
3325,NCT04886388,The difference in the mean change from baseline in HbA1c at Day 90 between Intervention and Standard of Care groups,The difference in the mean change from baseline in HbA1c at Day 180 between Intervention and Standard of Care groups,2021-04-22,COMPLETED,INTERVENTIONAL,['PHASE3'],
3326,NCT02334241,Favourable healing outcome (FHO),Number of local cares requiring instrumental debridement (surgical or sharp debridement).,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
3327,NCT01774565,Time spent in target glucose range (5.6-10.0mmol/l),"Pre-breakfast, pre-lunch, pre-dinner, and evening capillary glucose values",2016-08,COMPLETED,INTERVENTIONAL,['NA'],Total and endogenous insulin exposure within 1 hour postprandial period (Phase 4 only)
3328,NCT03597412,Change from baseline to week 24 in LDL-C level,Occurrence of MACCE (Major Adverse Cardiovascular and Cerebrovascular Event),2018-10-17,COMPLETED,INTERVENTIONAL,['PHASE4'],
3329,NCT00287807,"Glycemic control; HbA1c at baseline, 3 months, 6 months, 9 months and 1 year (endpoint)",bodyweight; Bodymass index at baseline and endpoint,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
3330,NCT05468632,Change in glycated haemoglobin (HbA1c),Having at least 1 severe hypoglycaemic episode,2022-07-05,COMPLETED,OBSERVATIONAL,['NA'],
3331,NCT00677664,Retinal function,Nerve fiber layer thickness,2006-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3332,NCT02123628,Primary outcome measure was the proportion of patients of each group with remission of diabetic foot osteomyelitis at the end of follow-up.,tolerance to treatment in each group of patients,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
3333,NCT01169818,Change (decrease) in mean hemoglobin glycosylated (HbA1c) level,PROMs (patient reported outcome measures) scores from the DTSQs/c (diabetes treatment satisfaction questionnaire status) and EQ-5D (European quality of life - 5 dimensions),2010-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
3334,NCT00765063,Number of Trivial Hemorrhages,36-Item Short-Form Health Survey (SF-36) Score,2008-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3335,NCT02105792,Response to diabetes therapy,Collection of samples for analysis of potential biomarkers,2013-03,COMPLETED,OBSERVATIONAL,['NA'],
3336,NCT02117063,Change in mean score for the PACES scale after 6-months of intervention,Changes in anthropometric and biochemical indices of metabolism and possible PCOS,2012-04,RECRUITING,INTERVENTIONAL,['NA'],
3337,NCT02103595,Perception of pain during infusion set insertion assessed by means of a visual analogue scale (VAS),Insulin set replacement pattern,2013-11-01,COMPLETED,INTERVENTIONAL,['NA'],
3338,NCT02572856,Feasibility of Instrument: Count of CGM Instrument Issues,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA'],
3339,NCT01932476,Change in Markers of Autoimmunity,Gastrointestinal Symptoms,2013-08,COMPLETED,INTERVENTIONAL,['NA'],
3340,NCT06071975,"Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)","Number of patients with rescue medication over the course of the clinical trial and within periods: until treatment week ≤5, ≤11, ≤14, ≤18, ≤22, ≤26, ≤30, ≤34, ≤43, ≤47, ≤52",2023-11-02,RECRUITING,INTERVENTIONAL,['PHASE3'],Number and severity of adverse events (AE)
3341,NCT05524792,Other Diabetes mellitus,Taste disorders,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],
3342,NCT02439684,The specificity of the use of HbA1c,DM risk,2013-05,COMPLETED,OBSERVATIONAL,['NA'],
3343,NCT02528396,AUClispro 0-30min (timepoint 0 = time of dosing),Local tolerability injection site reactions,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
3344,NCT01832077,cost-effectiveness,Cost-effectiveness of van,2015-01,COMPLETED,OBSERVATIONAL,['NA'],
3345,NCT03021811,Rate of complete wound closure,Impact of treatment on Health-related Quality of Life (CWIS questionnaire),2015-10,COMPLETED,INTERVENTIONAL,['NA'],
3346,NCT02509858,area under the glucose uptake versus time curve-AUC,Number of participants with adverse events,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
3347,NCT03426956,Difference in GLP-1 secretion (evaluated by iAUC).,Difference in bile acid responses (evaluated by iAUC) between the two test days.,2018-02-08,UNKNOWN,INTERVENTIONAL,['NA'],
3348,NCT05622981,Change from baseline body mass index (BMI) percentile at 24 weeks,Adherence to follow-up scheduling,2023-03-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3349,NCT01529541,The Change in HbA1c from baseline to week24.,change from baseline to week 24 in HOMA-IR,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
3350,NCT04060693,Measurement accuracy of IMD,Safety evaluation: paucity of adverse events,2019-12-10,WITHDRAWN,INTERVENTIONAL,['NA'],
3351,NCT03027960,urine sodium concentrations via ion selective electrodes,blood volume,2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
3352,NCT01350284,The effect of 3grams cinnamon on gastric emptying half time,Food intake,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
3353,NCT05039957,Complication rate,,2021-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3354,NCT04758884,"To compare changes in HbA1c at 6 months in a group of patients with T1D in the reference area of the ""Hospital Comarcal de l´Alt Penedès"" followed by telemedicine versus to the usual management in consultation.",Differences in terms of number of unplanned contacts with the specialist in a group of patients with T1D followed by telemedicine versus to the usual management in consultation.,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
3355,NCT02105324,Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 5,Percentage of Participants Using Pramlintide During the Usual Care Period,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
3356,NCT03267758,change in baseline flow mediated dilation (FMD) at 6 weeks,,2018-05-15,RECRUITING,INTERVENTIONAL,['NA'],
3357,NCT01999452,Change of HbA1c,,2015-10,WITHDRAWN,INTERVENTIONAL,['NA'],
3358,NCT03115099,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacokinetics: Maximum Concentration (Cmax) of LY3325656,2017-05-31,COMPLETED,INTERVENTIONAL,['PHASE1'],
3359,NCT04427982,DES Score,,2020-09-03,COMPLETED,INTERVENTIONAL,['NA'],Glycated Hemoglobin (A1c)
3360,NCT00690326,incremental physical activity,glycosylated hemoglobin,2006-05,COMPLETED,INTERVENTIONAL,['NA'],
3361,NCT05725889,"Finger tap, visual and auditory reaction test data within 10 seconds",,2021-07-15,COMPLETED,OBSERVATIONAL,['NA'],
3362,NCT05324189,Specificity of identification of referable and non-referable Diabetic,The accuracy of identification of referable and non-referable DR for early diagnosis of DR,2022-04-18,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3363,NCT00230464,Rate of appearance of endogenous glucose,Rate of appearance of oral glucose,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3364,NCT00254254,Number of adverse events,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
3365,NCT03984058,Recruitment Yield as assessed by number of participants enrolled from electronic medical records (EMR),Adherence to Pap Therapy as assessed by the ResMed AirView Remote Monitoring system,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],
3366,NCT01441518,Perinatal mortality and morbidity rates,Costs,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
3367,NCT01487629,Central subfield macular thickness (CSFT) change,Best-corrected visual acuity change,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3368,NCT02601729,Evolution over time of HbA1c,Quality of life measured by the Diabetes Quality of Life for Youth for children,2014-09,COMPLETED,OBSERVATIONAL,['NA'],
3369,NCT01653119,A composite of cardiovascular mortality or a clinical diagnosis of a non-fatal ACS,A composite of cardiovascular mortality or a clinical diagnosis of a non-fatal ACS,2012-04,UNKNOWN,INTERVENTIONAL,['NA'],The proportion of any AST or ALT >3 x ULN or CK >5 x ULN
3370,NCT00105352,"Co-efficient of reproducibility of the MMTT, and the GST, provided from the duplicate tests within the same individuals",,2004-11,COMPLETED,INTERVENTIONAL,['NA'],
3371,NCT00018486,,,1999-04,COMPLETED,OBSERVATIONAL,['NA'],
3372,NCT05088616,Change in A1c (from baseline to 90 days and 180 days),Change in identity and level of cultural connectedness (using part of Multigroup Ethnic Identity Measure survey questions) (from baseline to 90 days and 180 days),2021-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3373,NCT05795439,HbA1C,Diet Acceptability,2023-07-11,RECRUITING,INTERVENTIONAL,['NA'],
3374,NCT03254381,Number of exercise classes attended at trial completion (6 months),Change in blood glucose levels as measured by finger prick glucose test,2017-11-02,COMPLETED,INTERVENTIONAL,['NA'],
3375,NCT05589155,Long term change in diabetes via fasting blood glucose,Quality of Life after using mHealth apps assessed by World Health Organization Quality of Life BREF questionnaire,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],
3376,NCT00032734,serum sodium concentration,safety assessment,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3377,NCT01798030,Vitamin D,,2009-11,UNKNOWN,OBSERVATIONAL,['NA'],PTH
3378,NCT02312596,Percent of wounds healed,Quality of Life score,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
3379,NCT01011387,Mean Change in Wound Area.,,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
3380,NCT01307995,,,2007-04,COMPLETED,OBSERVATIONAL,['NA'],
3381,NCT03064906,Percentage of time in hyperglycemic range(defined as ≥ 250 mg/dL),Effect of changing setpoints,2017-03-18,COMPLETED,INTERVENTIONAL,['NA'],
3382,NCT05038020,To Investigate the Efficacy of AKST4290 Assessed by the Improvement in the DRSS Score From Baseline.,To Evaluate the Changes From Baseline in the Workplace Productivity and Activity Impairment General Health (WPAI-GH) Questionnaire.,2021-08-17,TERMINATED,INTERVENTIONAL,['PHASE2'],
3383,NCT05829642,Number of Participants with hospital readmission,Number of hypertension patients (all risk levels) with drug prescription appropriate,2020-11-24,COMPLETED,OBSERVATIONAL,['NA'],
3384,NCT05409235,Proportion of participants who have improved by ≥ 2 steps from baseline in Diabetic Retinopathy Severity Scale (DRSS) scores,Time to administration of rescue therapy,2022-07-29,COMPLETED,INTERVENTIONAL,['PHASE2'],
3385,NCT03180710,Cmax_total,Number of hypoglycaemic events in each treatment arm,2017-06-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
3386,NCT03794752,Response Speed to Visual-motor Skills to Identify Shapes and Objects With the Head-mounted Electronic Visual Enhancement Device,,2015-02,TERMINATED,INTERVENTIONAL,['NA'],
3387,NCT04135365,"Cognitive Function: Behavior Rating Inventory of Executive Function, Second Edition",Imaging,2021-01-18,COMPLETED,OBSERVATIONAL,['NA'],
3388,NCT01930097,The positive incremental area under the curve of postprandial glucose excursions,Incremental area under the curve of the 4-hr postprandial glucose excursions but the reference glucose is set to 5.0 mmol/L if premeal glucose is less than 5.0 mmol/L.,2013-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
3389,NCT04421053,The incidence rate of infant outcomes,the value of gestational weight gain during third trimester,2020-03-24,UNKNOWN,OBSERVATIONAL,['NA'],
3390,NCT03498001,Change from Baseline Concentration of intramyocardial triglycerides at 6 months,,2018-04-16,COMPLETED,INTERVENTIONAL,['NA'],
3391,NCT03278236,Change in glycaemia,Change in food intake,2017-09-21,TERMINATED,INTERVENTIONAL,['NA'],
3392,NCT05733962,Percentage of time spent in 70 - 180 mg/dL glycemic range,Scoring of Diabetes Treatment Satisfaction (DTSQs) Questionnaire,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3393,NCT02106104,"Changes from baseline following 8-week treatment with linagliptin vs glimepiride on fasting and postprandial renal hemodynamics, measured as GFR / ERPF (determined by inulin/para-aminohippuric-acid clearance)",Blood Pressure and Heart Rate,2014-03,COMPLETED,INTERVENTIONAL,['PHASE4'],DPP4- and ACE activity
3394,NCT00550095,Change in Albumin Creatinine Ratio (ACR) from baseline over a period of 24 weeks.,Percent reduction of (BP) at 24 weeks compared to baseline level. Percent of patients whose BP is controlled at 24 weeks (< 130/80),2007-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
3395,NCT01940003,Glycemic control,Birth injury,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
3396,NCT01073020,Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up.,Cardiovascular Risk,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
3397,NCT05822232,Efficacy endpoint,,2022-08-17,RECRUITING,INTERVENTIONAL,['NA'],
3398,NCT01531855,24 hour blood glucose area under the curve,Ketogenesis,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
3399,NCT03545841,Maximal aerobic capacity,Vascular stiffness,2015-03-09,COMPLETED,INTERVENTIONAL,['NA'],
3400,NCT03951805,Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose Monitoring),"Number of Hypoglycaemic Alert Episodes (Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by Blood Glucose (BG) Meter)",2019-05-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3401,NCT00217061,Adherence to the decision to use or not to use statins,Trust in clinician,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
3402,NCT05322213,Change in Vascular Endothelial Function,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
3403,NCT03903042,Image Quality of Aurora camera,Outcome of artificial intelligence algorithm,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],
3404,NCT03861039,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Number of Participants With Anti-Tirzepatide Antibodies,2019-03-30,COMPLETED,INTERVENTIONAL,['PHASE3'],
3405,NCT03407833,Ability to establish organoid cultures,,2018-02-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
3406,NCT00234871,Changes in urinary albumin:creatinine ratio,"Changes in blood pressure (BP), BP control, ABPM, proteinuria, GFR lipid parameters, glycemic control, quality of life, CRP, oxidative stress markers, clinical safety labs and adverse events.",2004-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
3407,NCT00566865,pharmacodynamics of mitiglinide,safety and tolerance of mitiglinide when co-administered with 600 mg gemfibrozil,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
3408,NCT00883038,Insulin resistance,Visceral to subcutaneous fatty tissue ratio,2008-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
3409,NCT03978884,Proportion of Subjects achieving Target Blood Pressure,,2019-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
3410,NCT00368095,,,2006-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3411,NCT01779089,Change in 24 hour urine protein/creatinine ratio (average of 2 values) baseline compared to 6-months in placebo vs minocycline,Change in urine and blood biomarkers in minocycline vs placebo treated patients at baseline vs 6 mos,2009-02,UNKNOWN,INTERVENTIONAL,['NA'],Safety
3412,NCT00606138,Number of Participants With Occurrence of Adverse Events,"Occurrence Rate of Proliferative Diabetic Complications Including Vitreous Hemorrhage, Iris Neovascularization, and Tractional Retinal Detachment",2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3413,NCT04482283,Proportion of patients diagnosed with symptomatic HF,,2020-07-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3414,NCT01329016,Study drug dosage in pregnancy,Determine GLY and MET PK parameters,2011-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3415,NCT02183350,Assessment of tolerability by investigator on a 4-point scale,Change in plasma glucose levels,2005-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
3416,NCT02087293,Discontinuation of mediation,Adverse drug reaction awareness,2013-06,UNKNOWN,INTERVENTIONAL,['NA'],Call metrics
3417,NCT05535985,Incidence of postoperative delirium,Expression of peroxisome proliferators-activated receptor-γcoactivator-1α (PGC-1α),2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Mini-mental state examination (MMSE) score
3418,NCT02610036,presence of microangiopathy,,2012-03,COMPLETED,OBSERVATIONAL,['NA'],
3419,NCT04208295,Autonomic adrenergic measure,,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA'],
3420,NCT00558909,Global tolerability - number of patients by category,PTF (peak trough fluctuation).,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
3421,NCT05404295,The efficacy of UCB-PL in ulcer healing by assessing the change in ulcer size.,,2019-06-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
3422,NCT02668250,Incidence of a composite of mortality or major postoperative morbidity.,,2017-02-03,COMPLETED,INTERVENTIONAL,['NA'],
3423,NCT02751398,subclinical diastolic dysfunction assessed by supine bicycle diastolic stress echocardiography,the impact of dapagliflozin on resting diastolic function,2016-08-18,COMPLETED,INTERVENTIONAL,['PHASE4'],
3424,NCT03255902,Effect of Intervention on Evening Glucose Control.,Difference Between Child's Pre-intervention and 3 Month Hemoglobin A1c Value,2016-05-24,COMPLETED,INTERVENTIONAL,['NA'],
3425,NCT01645891,Complete (100%) wound closure defined as complete re-epithelialization without drainage,Total Bates-Jensen Wound Assessment Tool Score,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
3426,NCT02672059,Diagnosis of neuropathy,Synovium tissue collection for RNA,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],
3427,NCT05146869,Change from baseline in active glucagon-like peptide1 concentration,Clinically significant changes from baseline in routine urine test will be recorded as AEs at each visit time point.,2021-12-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
3428,NCT01945840,Weight loss,Glycaemia,2013-10,RECRUITING,INTERVENTIONAL,['NA'],
3429,NCT05296759,Pittsburgh sleep quality index,,2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
3430,NCT00993603,To estimate the correlation between weight loss over 8 months achieved through a programme of intensive lifestyle management and changes in GLP-1 production over the same period in obese without presence of diabetes but with family history of diabetes.,"The secondary aim is to examine the changes in weight, cardiovascular risk factors and hormonal regulators of food intake and blood glucose metabolism.",2010-09,COMPLETED,INTERVENTIONAL,['NA'],
3431,NCT00541697,Determine the additional LDL-C lowering achieved by switching to MK0653A as compared to Atorvastatin after 6 weeks of treatment,Determine the effect of MK0653A versus Atorvastatin on total cholesterol after 6 weeks of treatment,2005-01-19,COMPLETED,INTERVENTIONAL,['PHASE3'],
3432,NCT03906383,Diameter change of retinal vessels,,2017-11-21,COMPLETED,INTERVENTIONAL,['NA'],
3433,NCT03239366,Change in HbA1c levels from baseline,Evaluation of the safety profile of 2 capsules of Bio-K+50B® (dosage of 100 billions bacterias),2017-09-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3434,NCT00704314,insulin sensitivity,ectopic lipid deposition in liver and muscle,2002-10,COMPLETED,INTERVENTIONAL,['NA'],
3435,NCT04314427,Glucose control,Changes in glycemic control,2012-09,COMPLETED,OBSERVATIONAL,['NA'],
3436,NCT02459496,change in blood glucose profile in the mixed-meal tolerance test (MMTT) - combined parameter,"change in parameters of autonomic neuropathy - measures of cardio-autonomic neuropathy (SANN, MSDD)",2013-09,UNKNOWN,INTERVENTIONAL,['NA'],
3437,NCT01800734,1. Composite plasma glucose and hormone responses to a mixed meal 2. Glucose control coefficients,Composite plasma free fatty and amino acid responses to a mixed meal,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3438,NCT04533646,Time in Target,Hypoglycemia duration,2021-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
3439,NCT05809843,The measurements of retinal and choriocapillary vessel density in type 1 diabetic patients undergoing artificial pancreas device,,2023-01-30,COMPLETED,OBSERVATIONAL,['NA'],
3440,NCT06148649,Change from baseline of HbA1c at week 12,Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs),2023-12-10,RECRUITING,INTERVENTIONAL,['PHASE2'],
3441,NCT06222476,renal magnetic resonance imaging(MRI),HOMA2-IS,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3442,NCT02783066,Gait Speed Difference Between Pulseflow Offflaoding and Standard Offloading,Peak Forefoot Pressure,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
3443,NCT01230749,Change From Baseline (Day -1) to Day 28 in Twenty-Four-Hour Weighted Average Glucose (24-Hour WAG),Change From Baseline to Day 29 in Body Weight,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
3444,NCT02352480,Time to heal,W-QOL (Quality of life with chronic wounds) score,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],
3445,NCT05338125,Electrophysiological properties,Endocrine deficiencies,2020-12-10,TERMINATED,INTERVENTIONAL,['NA'],
3446,NCT06219590,Numerical rating pain scale,,2023-10-28,RECRUITING,INTERVENTIONAL,['NA'],
3447,NCT05234944,Acceptability,Glycemic Outcome - Time in Range,2022-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3448,NCT02510612,sedation level,noradrenaline measured by Biochemical test,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3449,NCT00929539,Change in glycosylated hemoglobin (HbA1c) levels,Safety and tolerability data,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3450,NCT02312375,Insulinogenic index,"Urinary albumin creatinine ratio, urinary protein creatinine ratio",2015-03,COMPLETED,INTERVENTIONAL,['NA'],
3451,NCT03557151,Glycosylated Hemoglobin (HbA1c),Diabetes Self Management Profile - Parent Proxy Report,2018-07-13,COMPLETED,INTERVENTIONAL,['NA'],Type 1 Diabetes and Life (T1DAL) Scale - Caregiver Report
3452,NCT06052371,Performance evaluation: blood glucose monitoring system accuracy: BGMS vs reference instrument,,2023-10-16,TERMINATED,OBSERVATIONAL,['NA'],
3453,NCT01787916,Assessment of Changes in Glycemic Control by HbA1c.,Assessment of Changes on Adipose Tissue,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
3454,NCT04593693,"Goal of therapy: The wound bed is progressing acceptably towards a transition to another treatment modality such as Moist Wound Healing (MWH), surgical closure, or a flap or graft",Evaluate overall satisfaction from clinicians,2020-12-10,COMPLETED,INTERVENTIONAL,['NA'],Determine performance satisfaction of dressing components on periwound
3455,NCT02159378,Serum fructosamine rate,,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
3456,NCT00044694,Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28,Change in serum fructosamine from Baseline (Day 1) to Day 14 and to Day 28,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
3457,NCT01591525,,,2012-06,UNKNOWN,OBSERVATIONAL,['NA'],
3458,NCT02077686,Change from baseline in diabetes-specific empowerment on the adapted Diabetes Empowerment Scale at the 2-week and 6-month follow-up,Change from baseline in depressive symptoms on the CES-D at the 2-week and 6-month follow-up,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
3459,NCT01375738,Blood sugar stabilization after gastrectomy,,2011-07,UNKNOWN,INTERVENTIONAL,['NA'],
3460,NCT02110979,Knowledge score,Decisional conflict,2014-04,COMPLETED,INTERVENTIONAL,['NA'],
3461,NCT02671864,Prevalence of Severe DR at V1 (inclusion),Concentrations of blood circulating EPCs and PBMCs,2016-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3462,NCT00000462,,,1987-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
3463,NCT04239521,Study 4: The incidence of a composite of viral infections in adult patients with Alopecia Areata,Study 4: The incidence of herpes simplex infection in adult patients with Alopecia Areata,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],
3464,NCT05044442,Severe hypoglycaemia (using continuous glucose monitoring),area under the curve of episodes of hypoglycaemia and hyperglycaemia,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],
3465,NCT06064786,GCF levels of fetuin A and hsCRP evaluation in all groups,,2023-08-01,COMPLETED,OBSERVATIONAL,['NA'],
3466,NCT01239550,Low dose basal insulin detemir will potentiate weight loss in obese patients with type 2 diabetes mellitus undergoing a hypocaloric diet intervention by improving dopamine signaling,Neuropsychiatric functions,2011-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3467,NCT04790175,Safety Information (Non-serious Adverse Events),,2021-03-29,RECRUITING,OBSERVATIONAL,['NA'],
3468,NCT05990517,C-peptide change,Quality of life score,2023-02-22,RECRUITING,INTERVENTIONAL,['PHASE2'],
3469,NCT00464854,Achievement of a fasting blood glucose of 130 mg/dl and a mean daily glucose level of 180 mg/dl during hospitalization,Hypoglycemia of < 60 mg% (symptomatic and asymptomatic),2005-07,TERMINATED,INTERVENTIONAL,['NA'],
3470,NCT04774822,To determine the sensitivity and specificity of RETINA-AI Galaxy to detect vision-threatening diabetic retinopathy in the primary care setting,,2021-03-25,COMPLETED,OBSERVATIONAL,['NA'],
3471,NCT05922033,Fasting glycemic control,Diabetes Distress Screening (DDS) Scale,2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE4'],
3472,NCT01556152,Mean 24-hour average pain intensity (API) score,"Pharmacokinetics: Cmax, Tmax, AUC 0-tau, AUC0-24",na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
3473,NCT00313547,Heart rate variability,Impact of selected pharmacogenetic polymorphisms,2006-04,TERMINATED,INTERVENTIONAL,['PHASE4'],
3474,NCT04766450,Concentration of Glutathione peroxidase,,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE4'],Toronto clinical scoring system
3475,NCT01939834,Time in range overnight,Time within target range,2013-12,TERMINATED,INTERVENTIONAL,['NA'],
3476,NCT04414579,Time to stabilization of rising blood sugar by CGM after correction bolus,Treatment related impact measures between arms,2019-03-27,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3477,NCT01499472,healed ulcer,,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],
3478,NCT04524949,Change in stimulated C-peptide response during the first two hours of a mixed meal tolerance test (MMTT) from baseline to 48 weeks between IMCY-0098 and placebo groups,To evaluate the safety features of IMCY-0098 on lymphocytes ratio,2020-12-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
3479,NCT05509881,Percent (%) of time in target glucose range (70-180 mg/dl),Hypoglycemia Fear,2023-12-12,RECRUITING,INTERVENTIONAL,['NA'],Participant feedback on continuous glucose monitoring training sessions
3480,NCT03841591,Rate of maternal weight gain per week,Incidence of macrosomia,2018-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
3481,NCT00790556,Mean Change From Baseline in Hepatic Glucose Production (HGP) at Day 14,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Hepatic Glucose Production (HGP) at Baseline
3482,NCT02688075,Change From Baseline in Mean Glycosylated Hemoglobin (HbA1c) at 6 and 12 Months,Number of Participants with Adverse Events (AEs) and Serious AEs,2015-11-13,COMPLETED,OBSERVATIONAL,['NA'],
3483,NCT01728714,"Number of people with type 2 diabetes treated with oral antidiabetics assessed as compliant with treatment after 1 year educational programme on diabetes, compared with normal clinical practice.","Measure level of satisfaction of the patient with treatment and medical care following 1 year educational programme on diabetes, compared with normal clinical practice.",2014-05-19,COMPLETED,OBSERVATIONAL,['NA'],
3484,NCT01173991,Glycated haemoglobin (HbA1c),Hypoglycemia (capillary glucose<50 mg/dl),2008-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
3485,NCT00652288,Maximum Glucose Infusion Rate (GIR) to maintain euglycemia,Time to Maximum Glucose Infusion Rate,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
3486,NCT02798393,Decrease in Pain (MPI Pain Scale),Improvement in Sensation,2016-06,TERMINATED,INTERVENTIONAL,['NA'],Safety Assessment (incidence of treatment related AEs at each follow up visit)
3487,NCT00256867,Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy,Number of of Participants With Laboratory Evaluations of Potential Clinical Concern at Any Time Post-baseline,2005-08-18,COMPLETED,INTERVENTIONAL,['PHASE3'],
3488,NCT01411865,Death or non-fatal myocardial infarction,Prescription for nitrate,2011-08,COMPLETED,INTERVENTIONAL,['NA'],
3489,NCT02891382,Change in Glycated Hemoglobin,Change in Weight,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
3490,NCT02931656,Change from Glycemic level,Change from Fetal heart rate,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
3491,NCT01265017,stimulated C-peptide response,Insulin requirement,2012-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
3492,NCT00885352,Change From Baseline in Hemoglobin A1c (A1C) at Week 26,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26,2009-04-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
3493,NCT05541458,Body Weight - 12 month,,2022-09-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3494,NCT02193984,Changes in HbA1c levels.,Changes in distress.,2009-02,UNKNOWN,INTERVENTIONAL,['NA'],
3495,NCT03865394,Changes in wound size,Record of adverse events,2019-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3496,NCT05666843,Cardiometabolic risk profile (DIAL risk score),Skeletal muscle fat infiltration,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],
3497,NCT00145379,HbA1c after the two intervention periods,"Insulin need, hypoglycaemia frequence, body weight, lipid profile, blood pressure after the two intervention periods",2003-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
3498,NCT03226210,The primary endpoint was the between-group difference of MAGE,,2015-02-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
3499,NCT01097551,Evaluation of the presence of a retinal endothelial dysfunction in patients with type 1 diabetes mellitus with Dynamic vessel analyser(assessment study visit),"Serum concentration of: CRP, ICAM-1, VCAM-1, VEGF, angiopoietin 2 and endostatin.",2011-01,COMPLETED,OBSERVATIONAL,['NA'],
3500,NCT06043245,Type 2 Diabetes (T2D) remission.,Epicardial fat,2023-06-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
3501,NCT00976391,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 26,"Change From Baseline in Body Weight at Weeks 36, 48 and 52",2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
3502,NCT05219942,Total crystalline insulin consumption,,2020-12-01,RECRUITING,INTERVENTIONAL,['NA'],
3503,NCT06078683,Changes in maximal exercise performance,Change in Cardiac function after acute ingestion of KE or placebo,2023-06-06,RECRUITING,INTERVENTIONAL,['NA'],Change in stiffness
3504,NCT00885118,Change From Baseline in 8-point Glucose,"CLR,ss",2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
3505,NCT02451137,Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe Hypoglycemia,"Percentage of Participants With at Least One Treatment-Emergent Hypoglycemia Event (Any Time of the Day, Nocturnal) Per Type of Hypoglycaemia During the Month 6 and Month 12 on Treatment Period",2015-06-16,COMPLETED,INTERVENTIONAL,['PHASE4'],
3506,NCT02475109,Number of Patients with Adverse Events,Time to first rescue treatment,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
3507,NCT04702477,Intervention Attendance,Program satisfaction and barriers for attending sessions,2018-08-01,COMPLETED,INTERVENTIONAL,['NA'],
3508,NCT04618354,Bone mineral density,LH,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],
3509,NCT03557658,Urinary Glucose Excretion 0-48 Hours,,2018-07-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
3510,NCT02734667,Time Spent in Hypoglycemia (< 70 mg/dL),C-peptide,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
3511,NCT00580710,Brain response to blood glucose levels,,2001-08,COMPLETED,OBSERVATIONAL,['NA'],
3512,NCT06040567,Inflammatory Neuropathy Cause and Treatment (INCAT),Physical Activity Scale (PAS2),2023-09-23,RECRUITING,OBSERVATIONAL,['NA'],
3513,NCT00823225,Major amputation free survival,"Total survival, major amputation rate, rate of complete ulcer healing, rate of adverse events",2008-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
3514,NCT05856877,"Comparison of the blood-brain-barrier permeability in different age, weight, sex and metabolic risk groups",,2023-05-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3515,NCT04303611,Weight Loss,,2018-08-13,COMPLETED,OBSERVATIONAL,['NA'],
3516,NCT00400231,triglyceride levels,"HDL-C, Resistin, insulin resistance",2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
3517,NCT00917449,To evaluate the efficacy of long term (18 months) L-Arginine therapy in preventing or delaying clinical onset of type 2 diabetes mellitus in subjects with impaired glucose tolerance (IGT) and Metabolic Syndrome.,Define if the treatment with L-arginine can ameliorate insulin sensitivity and endothelial dysfunction and find new risk profiles and candidate genes able to characterize the sub-group of patients at higher risk to develop type 2 diabetes mellitus.,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
3518,NCT00175266,,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],
3519,NCT00173641,,,2005-09,UNKNOWN,OBSERVATIONAL,['NA'],
3520,NCT02182830,Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks,Change From Baseline in Trough Seated DBP (mmHg) at Week 24,2014-07-25,COMPLETED,INTERVENTIONAL,['PHASE3'],
3521,NCT03191227,Metabolic syndrome,Anxiety,2010-04,COMPLETED,OBSERVATIONAL,['NA'],
3522,NCT02692040,Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability],Body Weight (Percentage Change From Baseline),2015-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3523,NCT05294822,Changes in HbA1c values,Changes in glucagon,2019-09-30,UNKNOWN,INTERVENTIONAL,['NA'],
3524,NCT02963441,Sufficient vs. Insufficient Image Quality Output From IDx-DR,,2017-01,COMPLETED,OBSERVATIONAL,['NA'],
3525,NCT00980187,"Better metabolic effects of indapamide SR 1.5 mg+quinapril by comparison with hydrochlorothiazide 25 mg+quinapril, in patients with hypertension and type 2 diabetes mellitus.","Better safety of indapamide SR 1.5 mg+quinapril by comparison with hydrochlorothiazide 25 mg+quinapril, in patients with hypertension and type 2 diabetes mellitus",2008-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
3526,NCT01592539,,,2012-05,COMPLETED,OBSERVATIONAL,['NA'],
3527,NCT01046422,Fasting Plasma Glucose Improvement,Lipid profiles,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
3528,NCT05688332,Change in mean Glycated Hemoglobin (HbA1c) levels,Drug related AEs,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
3529,NCT01648244,Change in A1c,Demographic variables,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
3530,NCT02330276,Change From Baseline in Circulating Urinary Concentrations of Intact Epicatechin and Epi Metabolites,Change From Baseline in Circulating C-Peptide Concentrations (ng/mL*24hr),2014-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
3531,NCT05145998,Change in baseline blood glucose over 3 hours (glycemic response),Change in satiety sensation,2018-05-23,COMPLETED,INTERVENTIONAL,['NA'],
3532,NCT00201292,,,2005-03,UNKNOWN,OBSERVATIONAL,['NA'],
3533,NCT06126354,Relative change in serum C-peptide,Plasma glucose kinetics: endogenous glucose production,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Serum cortisol level
3534,NCT05363761,Device success,Hypertension Control:,2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],
3535,NCT00964574,Mean change in Glycosylated haemoglobin (HbA1c),Mean change of Fasting Blood Glucose and Post Prandial Glycemia,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
3536,NCT02776722,Chronic glycemic outcome - fasting insulin,,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],
3537,NCT01689090,Diameter changes of retinal vessels,,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
3538,NCT05446337,Facilitators and Barriers,Value-Based Healthcare,2022-07-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3539,NCT03928249,Fasting glycemia,Rate of change in anthropometric parameters,2019-12-01,COMPLETED,INTERVENTIONAL,['NA'],
3540,NCT01390636,Variation in Glycemic Profiles of ED-DMT1 and ED/only,Impact of Dietary Intake on Glucose Profiles of ED-DMT1 and ED/only,2011-07,TERMINATED,OBSERVATIONAL,['NA'],
3541,NCT06094920,Treatment adherence,(Additive) treatment effects finerenone on fasting plasma glucose,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
3542,NCT00738114,assess impact of hyperglycemia and diabetes during the periop period on clinical outcome(mortality and morbidity)in patients undergoing general and non-cardiac surgery.,determine the scope of clinical inertia in patients with diabetes and untreated hyperglycemia in patients undergoing non-cardiac surgery,2008-08,COMPLETED,OBSERVATIONAL,['NA'],
3543,NCT04269655,Percentage time in severe hyperglycemia of interstitial glucose values,Hospital readmission rate,2020-02-25,TERMINATED,INTERVENTIONAL,['NA'],CGM Satisfaction
3544,NCT04892771,Number of wound,Adequate footwear,2021-05-20,COMPLETED,OBSERVATIONAL,['NA'],
3545,NCT01980914,Number of Participants With Hypoglycemia (Blood Sugar Level <70 mg/dl,Alteration in Cardiac Rhythm,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
3546,NCT00949091,TAK-875 M-I renal clearance CLr,Absolute change from baseline to Day 14 in insulinogenic index,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3547,NCT04042441,Change in local laboratory measured glycosylated haemoglobin (HbA1c),Time period from initiation to discontinuation of treatment with Ryzodeg®,2019-07-29,COMPLETED,OBSERVATIONAL,['NA'],
3548,NCT01413542,"The Effect of Enalaprilat (ACE Inhibition), Sitagliptin (DPP4 Inhibition), or the Combination on the Vasodilator Response (Forearm Blood Flow) to Substance P (SP) and Bradykinin (Group 1) or Glucagon Like Peptide-1 and Brain Naturetic Peptide (Group 2).",Effect of Treatment (DPP4 Inhibition vs. Placebo) on Venous GLP-1 Levels in Response to Arterial GLP-1 Infusion,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
3549,NCT03646799,AUClast of Metformin,CL/F of Metformin,2018-08-30,UNKNOWN,INTERVENTIONAL,['PHASE1'],
3550,NCT01134107,Mean of Last Six 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Insulin Aspart 6D Pump Reservoir In-use,Number of Participants Who Achieve or Maintain a Glycated Hemoglobin A1c (HbA1c) Less Than or Equal to 6.5% and Less Than 7%,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Change From Baseline to 12 Weeks Endpoint for Each Treatment in Blood Pressure
3551,NCT01729130,Change in body fat distribution,,2009-09,COMPLETED,OBSERVATIONAL,['NA'],
3552,NCT04298970,iAUC,,2020-03-03,COMPLETED,INTERVENTIONAL,['NA'],
3553,NCT00791895,Percentage of subjects achieving HbA1c below 6.5%,,2003-06-26,COMPLETED,INTERVENTIONAL,['PHASE4'],
3554,NCT00493727,This research will test the possibility the Mucomyst given by mouth for a month will decrease oxidative stress and slow the disease.,Reduction of proteinuria,2006-09,COMPLETED,INTERVENTIONAL,['NA'],
3555,NCT05141968,"Percent of HbA1c in children with T1DM for both intervention, and control groups.","Concentration of Vitamin D for both intervention, and control groups",2017-10-01,COMPLETED,INTERVENTIONAL,['NA'],
3556,NCT02147314,Accuracy of the Yofimeter as compared to the YSI 2300 Stat Plus Glucose Analyzer,Evaluate the usability of instructional materials.,2014-06,COMPLETED,OBSERVATIONAL,['NA'],
3557,NCT01699763,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) Across the Overall Tested Glucose Range,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) in the High Glucose Range (>180 mg/dL),2012-10,COMPLETED,INTERVENTIONAL,['NA'],
3558,NCT03888872,Measuring Nerve Conduction Velocity,,2019-03-12,COMPLETED,INTERVENTIONAL,['NA'],
3559,NCT00940472,"Metabolic Control (Fasting glucose, postprandial glucose, HbA1C)",Adverse Events,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3560,NCT00233142,hemoglobin A1C (indicator of blood glucose),quality of life,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3561,NCT04330079,Percent change in global myocardial perfusion reserve (MPR) index,"Change in blood pressure(systolic, diastolic both )",2020-05-21,TERMINATED,INTERVENTIONAL,['PHASE4'],
3562,NCT00753896,Assessment of Event Rate of Treatment-Emergent Hypoglycemic Events,Change in Blood Pressure From Baseline to Week 52,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
3563,NCT00289497,Intervention of device use decreases foot ulcers.,Comparison of foot ulceration from enhanced device group as opposed to control group.,2000-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3564,NCT04966754,Rate of mortality,Quality of life,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
3565,NCT01432405,Hepatic Fat,Plasma Adipocytokines,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
3566,NCT04254653,Evaluate diabetes nutrition education program impact on self efficacy for healthful eating,,2020-02-20,UNKNOWN,INTERVENTIONAL,['NA'],
3567,NCT02765204,Change in plasma glucagon levels from baseline to 7 hours after single-dose administration of drug.,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
3568,NCT02099929,ODILE minimal model analysis,Glucose metabolism,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
3569,NCT04392284,Treatment credibility,Changes in lipids,2021-04-19,COMPLETED,INTERVENTIONAL,['NA'],
3570,NCT05481034,Percentage of time with sensor glucose measurements between 3.9 and 10.0 mmol/L,Proportion of participants with sensor glucose in the target range (3.9 - 10.0 mmol/L for >70% of the time.,2023-01-11,COMPLETED,INTERVENTIONAL,['NA'],Nature and severity of adverse events
3571,NCT00249314,,,2005-11,UNKNOWN,OBSERVATIONAL,['NA'],
3572,NCT01546558,"Area under the plasma concentration vs time curve over the dosing interval, at steady state (AUCtau) of metformin","Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of ranolazine and metabolites",2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
3573,NCT02980276,Insulin Initiation/Fasting Glucose,Gestational weight gain,2017-06-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Cost effectiveness and budget impact of metformin treatment in addition to standard care
3574,NCT00815828,To compare the frequency of women who use insulin in the group who participate in the exercise program with the group that don't do the exercises,To verify the impact of the exercise program on the adequacy of capillary glycemic control of the pregnant women,2006-10,COMPLETED,INTERVENTIONAL,['NA'],
3575,NCT04050553,Change in Mean Glucagon Concentration During Induced Hypoglycemia from Target Plasma Glucose (PG) Concentration of 100 Milligrams per Deciliter (mg/dL) to a Nadir Target of 45 mg/dL,Mean Change in Heart Rate from Induced Hypoglycemia Target PG Concentration of 100 mg/dL to a Nadir Target of 45 mg/dL,2020-02-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
3576,NCT02240381,Expression of Helios or glycoprotein A repetitions predominant in alpha4beta7+Foxp3+ Tregs versus alpha4beta7+Foxp3- conventional T cells,Post-HCT donor derived Th1 and Treg subsets,2014-11-20,TERMINATED,INTERVENTIONAL,['NA'],
3577,NCT04530617,Rate of hospitalizations and oxygen use,,2020-10-05,TERMINATED,INTERVENTIONAL,['PHASE2'],
3578,NCT00681278,Attainment rate to the target blood pressure.,Change in DBP/SBP value during the follow-up period will be addressed. Change in the DBP/SBP value will be investigated according to the risk factors and concurrent disease.,2008-04,COMPLETED,OBSERVATIONAL,['NA'],
3579,NCT02886884,Number of Treatment Emergent Serious Adverse Events (TE-SAEs),Tumor Necrosis Factor (TNF) Alpha Levels,2017-10-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3580,NCT01398826,,,2011-05,UNKNOWN,OBSERVATIONAL,['NA'],
3581,NCT04754334,Mean change in A1C,The mean change in fasting plasma glucose,2021-03-16,TERMINATED,INTERVENTIONAL,['PHASE3'],
3582,NCT01718925,Fatigue,,2012-10,COMPLETED,OBSERVATIONAL,['NA'],
3583,NCT01460459,HbA1c,quality of life,2011-05,UNKNOWN,INTERVENTIONAL,['NA'],
3584,NCT03830879,Fetal outcomes.,Neurodevelopment.,2018-03-06,RECRUITING,OBSERVATIONAL,['NA'],
3585,NCT01379170,Thyroid hormone-induced change in whole body insulin sensitivity (change in insulin-stimulated glucose disposal) and muscle mitochondrial function,Thyroid hormone-induced change of lipid content in skeletal muscle and liver and brown adipose tissue activity,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3586,NCT00830076,Incremental Post-prandial 4-hour Weighted Mean Active Glucagon-like Peptide-1 (GLP-1) Plasma Concentrations,Incremental Post-prandial 4-hour Weighted Mean Plasma Glucose Concentrations,2008-12-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
3587,NCT02588950,Part B: Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax) of U-500R,Part B: Pharmacodynamics: Time to Rmax (tRmax) of U-500R,2016-01-12,TERMINATED,INTERVENTIONAL,['PHASE1'],
3588,NCT01488734,25OH Vitamin D level,Markers of inflammation and metabolic control,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
3589,NCT01074268,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),Extension Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
3590,NCT03981627,ΔAUCPG(0-4h),Safety and tolerability (Adverse Events recording),2019-06-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3591,NCT02874963,Biochemical parameter: high sensitive C-Reactive Protein - hs-CRP (mean value in mg/L),"Mean probing depth (PD) (mean in mm, as a measure of periodontal parameter)",2015-11,UNKNOWN,INTERVENTIONAL,['NA'],
3592,NCT00633425,Change in interstitial glucose levels between the observation and maintenance phases.,HbA1c and fasting blood glucose levels.,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
3593,NCT06154135,Time in range,Reasons to stop using the DBLG-1 device,2022-12-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Patients who stop using the DBLG-1 system
3594,NCT00666458,Hemoglobin A1c (HbA1c) Change From Baseline to Week 18,Fasting Plasma Glucose Change From Baseline to Week 18 (mmol/L),2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
3595,NCT03463941,Health Educators' Perceptions of Feasibility as Measured by Semi-structured Interviews,Goal Attainment as Measured by Days Per Week That Participants Exercised for 30 Minutes or More,2019-01-05,COMPLETED,INTERVENTIONAL,['NA'],
3596,NCT00814008,retinal blood flow after 1 hour of insulin clamp,"Mean blood velocities in ophthalmic artery, posterior ciliary arteries and central retinal artery after 1 hour of insulin clamp",1999-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3597,NCT00608049,"Systolic blood pressure (SBP), Low Density Lipoproteins (LDL) cholesterol, High Density Lipoproteins (HDL) cholesterol, triglycerides, and insulin sensitivity",Overall CVD risk using risk equations,2008-02,COMPLETED,INTERVENTIONAL,['NA'],
3598,NCT02009527,Change in endothelial function,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
3599,NCT01343589,fatty acid composition in plasma,phytanic acid,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
3600,NCT02845791,The primary endpoint is to detect a change in objectively measured MVPA of 10 minutes per day within the intervention group at 6 months.,Blood Pressure (Parent(s)/guardian(s)),2016-07,COMPLETED,INTERVENTIONAL,['NA'],
3601,NCT03264976,exosomal miRNAs in serum samples,,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA'],
3602,NCT02788903,Number of Participants Diagnosed With COVID-19 Who Were Hospitalized,"Number of Patients With a COVID-19 Diagnosis and ICU Use, Ventilator Use, or Death",2016-03,COMPLETED,OBSERVATIONAL,['NA'],
3603,NCT01918865,Change in plasma HbA1c levels at Week 27 compared to Baseline as a measure of efficacy,"Change in FPG, weekly average SMPG, seven-point glucose profile, lipid profile, body weight, & BMI at Week 27 compared to Baseline as a measure of efficacy",2013-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
3604,NCT01760746,The primary outcome will be the change in global levels of intraocular inflammatory cytokines in the aqueous humour of patients with Proliferative Diabetic Retinopathy.,Secondary outcome measure considers intraoperative complications during vitrectomy.,2012-07,COMPLETED,OBSERVATIONAL,['NA'],
3605,NCT06035874,The change in liver fat content,Change between groups in HDL levels,2023-10-15,RECRUITING,INTERVENTIONAL,['NA'],
3606,NCT02925559,Glycemic Variability,Hypoglycemia,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
3607,NCT01316367,HbA1c level,Body Mass Index (BMI),2003-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
3608,NCT05597293,Number of participants with a change in HbA1c of 5.5 mmol/mol or more,Change in the Diabetes Quality of Life (DQOL) score,2023-02-27,RECRUITING,INTERVENTIONAL,['NA'],
3609,NCT00958269,"Safety and tolerability of dutogliptin as assessed by analysis of AEs/SAEs, laboratory data, vital signs, and ECGs",Per cent ex vivo DPP4 inhibition after drug dosing,2009-08,TERMINATED,INTERVENTIONAL,['PHASE3'],
3610,NCT01928199,2-hour Oral Glucose Tolerance Test-derived Blood Sugar,6 Month OGTT Result (Completion of Washout From Study Drug),2013-09,COMPLETED,INTERVENTIONAL,['PHASE4'],"Hemoglobin A1c, 6 Month"
3611,NCT01488877,Number of Participants With Confirmed and Severe Hyperkalemia,Change From Baseline in Sitting Pulse Rate at Day 15,2012-01,TERMINATED,INTERVENTIONAL,['PHASE1'],
3612,NCT03244800,Cohort 1: Percent Change From Baseline in Body Weight to Day 50,Cohort 1 and Cohort 2: Number of Participants With Positive Anti-drug Antibodies (ADA) to MEDI0382,2017-09-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
3613,NCT00507494,proteinuria,"efficacy: filtration fraction, renal nitric oxide bioavailability, insulin resistance, platelet function safety: tolerability, plasma glucose, body weight, edema",2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
3614,NCT04409587,Percent time in euglycemia (BG 70 to 180 mg/dl) by CGM,Total daily insulin dosage,2018-04-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
3615,NCT02811172,Collection of samples: mother's milk,Bioactive peptides,2017-01,COMPLETED,OBSERVATIONAL,['NA'],
3616,NCT00839774,Postprandial dietary fatty acid oxidation,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
3617,NCT01713530,Change From Baseline in HbA1c (%),Incidence of Treatment Emergent Adverse Events (TEAE),2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
3618,NCT02912455,Change at Six Months Versus Baseline in Hemoglobin A1c Value (%),Change in Leg Bone Mineral Density,2017-01-05,TERMINATED,INTERVENTIONAL,['PHASE4'],
3619,NCT02920385,Area under the semaglutide plasma concentration-time curve during a dosing interval (0-24 hours) at steady state,Maximum observed SNAC plasma concentration during a dosing interval (0-24 hours) at steady state,2016-10-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
3620,NCT01924637,Mean change in plasma glucose concentration,Area under the serum insulin aspart concentration-time curve,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
3621,NCT00273286,treatment adherence,quality of life,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
3622,NCT04783376,Capillary blood glucose levels six hours after the test meals.,assessment of serum triglyceride level three hours after the test meal following each intervention,2021-04-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
3623,NCT04283201,New type 2 diabetes cases,,2020-02-20,COMPLETED,INTERVENTIONAL,['PHASE2'],
3624,NCT02168816,Number of Participants With Bone Infection,Number of Participants With Ulcer Resolution,2014-03-19,TERMINATED,INTERVENTIONAL,['PHASE2'],
3625,NCT03575988,"pulmonary function parameters(diffusing capacity for carbon monoxide of lung/unit volume,DLCO/VA,%)","Vascular endothelial function(endothelin-1,ET-1,μmol /L)",2018-07-03,UNKNOWN,OBSERVATIONAL,['NA'],"Serum lipid(Triglycerides,TG(mg/dl))"
3626,NCT03235050,Percent Change in Body Weight,Immunogenicity Endpoint: Median Titer of the Anti-Drug Antibodies (ADA) to MEDI0382 in the Positive Participants,2017-08-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
3627,NCT00044460,Change in HbA1c from baseline to Week 24.,Change in FPG (fasting plasma glucose) from baseline to Week 24; characterize the effects of rosiglitazone on the albumin-creatinine ratio at Week 24.,2002-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
3628,NCT05149625,Hemoglobin A1c (HbA1c),"Fasting, postprandial plasma glucose",2022-11-27,RECRUITING,INTERVENTIONAL,['NA'],
3629,NCT00566475,hemoglobin A1c,"glucose levels, hypoglycemia, quality of life, satisfaction",2007-01,COMPLETED,INTERVENTIONAL,['NA'],
3630,NCT02457975,Visual Acuity as assessed by the Early Treatment of Diabetic Retinopathy Study (EDTRS) Classification,Spectral Density-Optical Coherence Tomography (SD-OCT),2015-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
3631,NCT03840343,Adverse Events,Kidney Function,2019-10-23,TERMINATED,INTERVENTIONAL,['PHASE1'],
3632,NCT02844660,Study Safety Measurement,Cost effectiveness of treatment,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
3633,NCT04769167,Maternal Immune Response,,2021-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3634,NCT01851694,Second-phase insulin response during GPA test,Change in insulin secretion among CF groups,2013-05,RECRUITING,INTERVENTIONAL,['NA'],
3635,NCT00713440,"Incretin effect before and after dysregulation of glucose homeostasis using high calorie diet, physical inactivity and administration of adrenocortical steroids.",GLP-1 and GIP response curves,2008-07,COMPLETED,INTERVENTIONAL,['NA'],
3636,NCT01100892,"Change in lung function (FEV1, FVC)","Change in effort-dependent lung function: MIP, MEP, SnIP",2010-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
3637,NCT04207541,Proportion of insulin initiation,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],
3638,NCT00950898,plasma glucose levels,plasma insulin,2006-11,COMPLETED,INTERVENTIONAL,['NA'],
3639,NCT05228340,Ulcer recurrence,Incremental cost-effectiveness in QALY's of flexor tenotomy after 2 years,2022-03-15,RECRUITING,INTERVENTIONAL,['NA'],
3640,NCT01241370,"Comparison of retinal microvascular endothelial function in obese insulin sensitive, insulin-resistant and type 2 diabetic subjects with retinal microvascular endothelial function in lean healthy control subjects.",Comparison of the Oral Glucose Tolerance Test (OGTT) in the different subject groups with skin and retinal endothelial function.,2009-05,COMPLETED,OBSERVATIONAL,['NA'],
3641,NCT04193566,Change in Renal oxygenation,Change in baroreflex sensitivity,2020-02-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
3642,NCT02201550,Change in number of specific immune cells in blood detected by flow cytometry,,2013-02,COMPLETED,OBSERVATIONAL,['NA'],
3643,NCT01640834,Pharmacodynamics: Change From Baseline to Day 2 in 24-hour Insulin Dose,Pharmacodynamics: Area Under the Glucose Concentration Curve After a Single Dose of Glucagon on Day 3,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
3644,NCT00596297,Intra- and postoperative intra-ocular bleeding,Visual acuity,2007-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3645,NCT02017171,iGFR at the End of the Wash-out Period,Fatal or Non-fatal Cardiovascular Events,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
3646,NCT02553408,Patient and Care provider satisfaction structured interview guide,,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
3647,NCT01084850,Corneal endothelium cell number,Corneal endothelium morphology,2009-06,UNKNOWN,OBSERVATIONAL,['NA'],
3648,NCT03885869,The Evaluation of Dual Task Performance,,2019-03-25,COMPLETED,OBSERVATIONAL,['NA'],
3649,NCT03560505,Common fibular nerve fascicle properties,,2018-05-16,COMPLETED,OBSERVATIONAL,['NA'],
3650,NCT04978974,Effects of stress management program as assessed using Coping Strategies Questionnaire,Effects of stress management program as assessed using Baseline,2019-05-03,COMPLETED,INTERVENTIONAL,['NA'],
3651,NCT01275235,Risk of type 2 diabetes mellitus (T2DM),,2012-12,TERMINATED,OBSERVATIONAL,['NA'],
3652,NCT01054300,Time Taken to Reach the Maximum Observed Plasma Concentration (Tmax) of Ertugliflozin,,2010-02-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
3653,NCT02610738,Participant feedback on teaching,Change in perceived stress - parent participants,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
3654,NCT00320853,"OGIS Index, Total Insulin Secretion",ApoB,2006-04,COMPLETED,INTERVENTIONAL,['NA'],
3655,NCT03094767,Change from baseline of Glycated Hemoglobin at 3 months,Change from baseline of the distance traveled at 3 months.,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],
3656,NCT02255266,Frequency of patients achieving HbA1c reduction of at least 1%-point,Changes in blood pressure and lipid profile,2015-03-26,COMPLETED,OBSERVATIONAL,['NA'],
3657,NCT00775736,"The number of serious adverse drug reactions, including major hypoglycaemic episodes, reported during the study period.",Weight changes,2008-10,COMPLETED,OBSERVATIONAL,['NA'],
3658,NCT03159299,Change in Hemoglobin A1C From Baseline,Change in Diabetes Self-Efficacy From Baseline,2017-05-08,COMPLETED,INTERVENTIONAL,['NA'],Fidelity of Yo Puedo Sessions
3659,NCT01512797,Change in Area Under the Curve (AUC) Glucose Levels After Mixed Meal Test,Active GLP-1,2012-07,COMPLETED,INTERVENTIONAL,['NA'],
3660,NCT01919385,Evaluate the performance of the System while the subject is under close medical supervision in the Clinical Research Center (CRC) setting,Capturing the number of Adverse Events as a measure of assessing subject safety,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
3661,NCT03401697,Number of Type 2 Diabetes patients that initiate HCV treatment,HCV cure rate,2018-01-23,COMPLETED,OBSERVATIONAL,['NA'],
3662,NCT02384447,ultrasonographic appearance,,2014-06,WITHDRAWN,OBSERVATIONAL,['NA'],
3663,NCT04052815,Change from Baseline Glycated hemoglobin at 12 months,Dietary assessment of fat consumption,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Rosenberg self-esteem
3664,NCT05493345,Feasibility and fidelity,Loneliness,2022-08-05,RECRUITING,OBSERVATIONAL,['NA'],
3665,NCT00596323,,,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
3666,NCT02945540,Measuring patient satisfaction at childbirth by a questionnaire on satisfaction of hospital care,Neonatal blood glucose measurement,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],
3667,NCT01520428,HbA1C,HbA1c,2010-06,UNKNOWN,INTERVENTIONAL,['NA'],
3668,NCT03406585,Efficacy; comparison of the intervention versus placebo at day 372 versus start of treatment,"Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372",2017-11-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3669,NCT01140438,insulin secretion,glycemic control,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
3670,NCT00389350,HbA1c,,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3671,NCT01705210,Functional and structural connectivity relationships of multiple brain regions and biomarkers of brain alterations,Cardiovascular risk factors,2012-05,COMPLETED,OBSERVATIONAL,['NA'],
3672,NCT05087758,Wound Healing,Incidence of Treatment Emergent Adverse Events,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],
3673,NCT02798757,Composite outcome measure. % change to the concentrations of specific metabolites.,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
3674,NCT00451321,Number of Participants With Positive Epstein Barr Virus (EBV) Viral Load,Change From Baseline in Percent Glycosylated Hemoglobin (HbA1c),2006-07-31,TERMINATED,INTERVENTIONAL,['PHASE2'],
3675,NCT05994755,"association between hypoglycemia, glycemic variability and cardiac arrhythmias","association between hypoglycemia, glycemic variability and heart failure",2023-10-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3676,NCT02045199,Complete healing of target fissure on the heel,,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
3677,NCT01677611,Skeletal muscle sirtuin 1 (SIRT1) expression,Liver function,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
3678,NCT04917471,Percentage recovery of left ventricular function,,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],
3679,NCT06269120,Glycated haemoglobin (HbA1c ) reduction greater than or equal to (≥) 0.5%-point and body weight reduction ≥ 5%,Change in high sensitive C-reactive protein (hsCRP),2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3680,NCT05895552,Count of reported adverse events,,2023-08-21,RECRUITING,INTERVENTIONAL,['PHASE2'],
3681,NCT04062773,HbA1c,Inflammatory markers,2019-07-10,UNKNOWN,INTERVENTIONAL,['NA'],
3682,NCT03437330,Change in skeletal muscle H202 concentration between baseline and end of treatment (EoT),Change in plasma FFA levels,2021-10-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
3683,NCT02508844,Change in glucose levels (Oral glucose tolerance test),Change in HbA1c,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
3684,NCT02156336,Fifty percent or greater reduction in the mean Numeric Rating Scale (11-point NRS 0-10) recorded in the subjects' diaries from ranolazine compared to placebo.,Occurrence of Serious Adverse Events after randomization,2014-05,TERMINATED,INTERVENTIONAL,['PHASE4'],
3685,NCT04306770,Diabetic control,Incidence of vascular complications,2020-01-20,UNKNOWN,INTERVENTIONAL,['NA'],
3686,NCT01106157,Change in Metabolic Function Baseline to 12 Months.,Change in White Blood Count (WBC) From Baseline to 12 Months,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3687,NCT05820477,Change in Self-Management (Person with Diabetes),Diabetes Distress (Person with Diabetes),2023-04-25,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Change in emotional support (support person)
3688,NCT01225653,The diameter of retinal arterioles,The severity of diabetic retinopathy,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
3689,NCT01144078,Feasibility of these exercise interventions in people with type 2 diabetes,Exercise Self-efficacy,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
3690,NCT04063930,Urinary albumin creatinine ratio (UACR),Urinary potassium,2019-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],Safety outcome - Electrocardiogram
3691,NCT05965869,Evaluate the integration of the intervention,Provide acceptability data of the intervention,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],
3692,NCT00515632,"HbA1c, fasting plasma glucose and 7-point plasma glucose profiles, weight gain, lower leg oedema and safety parameters.","Waist and hip circumferences, plasmaNT-proBNP, ECG, body composition as measured by DXA, blood lipid profiles, plasma insulin",2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
3693,NCT03988764,Proportion of patients carrying mutations in previously unstudied genes that meet statistical criteria of pathogenicity for monogenic diabetes.,Risk-prediction score for monogenic diabetes mutation in antibody negative T1D patients,2019-09-24,RECRUITING,OBSERVATIONAL,['NA'],
3694,NCT05197101,vaginal birth rate,,2022-01-17,UNKNOWN,INTERVENTIONAL,['NA'],
3695,NCT01498185,Mean Change From Baseline in 7-Point Glucose Monitoring (7-PGM) at Day 7,Pharmacokinetic Parameters on Day 7 - Ratio of Metabolite (RM) to Parent AUC[TAU],2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
3696,NCT00486681,compare glycemic control of patients hospitalized in 3 departments,mean of % of glycemia for patients in warning phase with or without diabetologist intervention,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
3697,NCT04706481,"To discover the pathological mechanism of different acute and chronic diseases such as cancer, stroke, heart disease, dementia & diabetes",,2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],
3698,NCT01850615,Change From Baseline in HbA1c,Number of Adverse Events,2013-09-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
3699,NCT00460018,Postpartum weight retention,breastfeeding duration,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3700,NCT01653392,Infant Outcomes,,2012-07,COMPLETED,OBSERVATIONAL,['NA'],
3701,NCT02605889,Improvement of blood postprandial glucose levels,Improvement of Nursing Diagnoses,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],
3702,NCT05358080,Proportion of subjects maintained or improved in DRSS level,Proportion of subjects with CSME,2022-05-27,RECRUITING,INTERVENTIONAL,['PHASE4'],
3703,NCT04804774,HbA1c,,2021-03-23,COMPLETED,INTERVENTIONAL,['NA'],
3704,NCT04724330,Total gestational weight gain,Proportion of low birth weight infants,2021-03-15,RECRUITING,INTERVENTIONAL,['NA'],
3705,NCT02031341,"Fore-arm insulin uptake measured as ([A]-[V]) x F in pmol/min where A = arterial insulin concentrations, V= venous insulin concentrations, F = fore arm plasma flow;",,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
3706,NCT04143412,Urinary albumin/creatinin ratio (UACR),Serum K,2019-02-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3707,NCT02981966,Endogenous Glucose Production Measurement,Renal Glucose Production Measurement of Change,2019-05-23,COMPLETED,INTERVENTIONAL,['PHASE4'],
3708,NCT01435616,Change From Baseline to 52 Week Endpoint in Hemoglobin A1c (HbA1c),Percentage of Participants With Equal or Above 2- and 3-fold ULN for Alanine Transaminase/Serum Glutamic Pyruvic Transaminase (ALT/SGPT) and Aspartate Transaminase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT),2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3709,NCT00651105,GLP-1 and non GLP-1 effects of LAF237 on glucagon secretion in patients with Type-2 diabetes and matching healthy subjects,"Effects of LAF237 on prandial glucose profiles, prandial insulin, and gastric-emptying in patients with Type-2 diabetes and in matching healthy subjects.",2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
3710,NCT00780650,Change in level of catecholamines in blood from baseline,,2009-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
3711,NCT04092569,"Change from Baseline Blood Glycosylated haemoglobin, HbA1c at 9 months",The Chinese version of the Diabetes Empowerment Scale Questionnaire - Short Form,2019-09-10,UNKNOWN,INTERVENTIONAL,['NA'],
3712,NCT01702298,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C),2012-12-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
3713,NCT05368402,"The proportion of responders at week 27/28 (visit 4), with responders defined as ""patients with an HbA1c reduction from baseline of ≥0.50% (absolute difference) without episodes of severe hypoglycemia",Incidence of Treatment Emergent Adverse Events (TEAEs) recorded from the beginning of study treatment to up to the end of study participation,2022-07-27,TERMINATED,INTERVENTIONAL,['PHASE2'],
3714,NCT06291129,Bleeding on probing,,2022-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3715,NCT03223389,Within group difference in cholecystokinin (CCK) secretion (evaluated by AUC above basal).,Between group comparison of differences in CCK secretion (evaluated by AUC above basal).,2017-08-07,UNKNOWN,INTERVENTIONAL,['NA'],
3716,NCT00495469,Mean Change From Baseline in Hemoglobin A1c (Glycosylated Hemoglobin) (HbA1c) at Week 12,Number of Participants With Abnormal Hematology Value of PCI at Any Time on Therapy,2007-08-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
3717,NCT04550520,Maximal increase in copeptin level,Maximal Change in oxytocin,2020-09-28,COMPLETED,INTERVENTIONAL,['NA'],
3718,NCT02529982,Change in pancreatic B-cell function,Waist circumference,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
3719,NCT04489966,Abdominal fat Abdominal fat,The 10-year risk assessment table for Ischemic cardiovascular disease,2018-12-01,COMPLETED,INTERVENTIONAL,['NA'],
3720,NCT00524875,early post-vitrectomy vitreous hemorrhage,Visual improvement,2007-01,UNKNOWN,INTERVENTIONAL,['NA'],
3721,NCT00543751,,,2003-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
3722,NCT01337362,EEG,Cognitive function,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
3723,NCT03819335,Empowerment,Satisfaction with the app,2019-04-09,COMPLETED,INTERVENTIONAL,['NA'],
3724,NCT03938324,Change in Patient activation as measured by the Patient Activation Measure (PAM-13),Change in Emotional Health as measured by the Brief Symptom Inventory (BSI 18),2019-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3725,NCT02447172,Percent of Patients With a Clinical Outcome of Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection),Percent of Subjects That Had an Amputation Associated With the Target Ulcer,2015-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
3726,NCT01199783,Clinical Response of the Infection at Test-of-cure (TOC) at Day 14 Post Therapy,Rate of Amputations Due to Infection,2011-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
3727,NCT02898766,Area under the blood glucose curve (AUC 0-240),AUC (0-30min) for insulin,2016-08,COMPLETED,INTERVENTIONAL,['NA'],
3728,NCT02916576,System accuracy criteria (see description),,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
3729,NCT00727220,Change in HgBA1c,,1999-11,COMPLETED,OBSERVATIONAL,['NA'],
3730,NCT02246959,Change in LDL cholesterol from baseline to 12 months,Statin Adherence,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
3731,NCT01625598,Sensitivity of detecting moderate non proliferative diabetic retinopathy or more severe DR and/or significant macular edema on a person-specific basis.,Specificity on an eye-specific basis [Clinical examination only],2012-04,COMPLETED,OBSERVATIONAL,['NA'],
3732,NCT06246799,Number of subjects failing to achieving HbA1c <6.5% Long-term,Change in body weight,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
3733,NCT05948592,3. Percentage of patients that achieve a 50% reduction in wound surface area by week 4,4. Percentage of patients with target strain not-susceptible to TP-102 for TP-102 versus Placebo at EOT;,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],
3734,NCT03369821,"Measure beta cell function in EET1D compared to T1D, NDM and non-diabetic controls.",Association of maternal and paternal non-inherited HLA alleles with EET1D,2017-09-01,RECRUITING,OBSERVATIONAL,['NA'],
3735,NCT04603508,Percent change from baseline of LDL-c levels.,Incidence and severity of adverse events recorded during the study.,2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
3736,NCT01756703,Frequency and nature of treatment-emergent adverse events and serious adverse events.,Plasma concentrations of MT-3995 and its major metabolite,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
3737,NCT01030861,Rate of New Diabetes Per Year,Number of Participants With Adverse Events,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
3738,NCT05211479,Evaluation of the anxiety level of adolescents with type 1 diabetes,,2021-12-20,COMPLETED,INTERVENTIONAL,['NA'],
3739,NCT04915066,Permanent discontinuation of insulin pump use.,type of diabete,2021-06-29,COMPLETED,OBSERVATIONAL,['NA'],
3740,NCT02839226,"comparison of the formation of new granulation tissue according to a Granulation Score, between the AR/101 treated group and the placebo group, during the treatment phases",Mean time to response (equal or more then 75% of granulation tissue) during two weeks of treatment phase 2,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3741,NCT00762671,Endothelium-dependent and endothelium-independent vasodilation of peripheral resistance and conduit vessels will be studied in diabetic (type 1 and 2) and healthy subjects two weeks following randomization to the ebselen or placebo.,,1999-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3742,NCT02450500,Participants acceptability of intervention by focus group,"Health status, well being, food intake and exercise levels by questionnaires",2015-03,COMPLETED,INTERVENTIONAL,['NA'],
3743,NCT04454827,Fear of Hypoglycemia,HbA1c,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],
3744,NCT01158131,Postpartum weight loss,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
3745,NCT05855863,Cognitive function testing,Attention assessment,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Concentration of irisin
3746,NCT04195243,Flow Mediated Dilation,Blood pressure,2019-12-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3747,NCT04712916,Change in value of blood pressure readings,,2017-06-10,COMPLETED,INTERVENTIONAL,['NA'],
3748,NCT01418456,Time to healing of foot ulceration in each group,• Percentage of patients in each group that are healed at 20 weeks.,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3749,NCT00432809,Success Rate of Biochemical Resolution of Diabetes at 12 Months as Measured by HbA1c ≤ 6% With no Diabetes Medications,Cardiovascular Medications - Anticoagulants,2007-02,COMPLETED,INTERVENTIONAL,['NA'],
3750,NCT01123239,Hemoglobin A1c,Health-related quality of life,2006-01,COMPLETED,INTERVENTIONAL,['NA'],
3751,NCT06246578,Difference between paired Dexcom and Libre glucose values,,2024-01-19,RECRUITING,INTERVENTIONAL,['NA'],
3752,NCT04279444,Insulin resistance (HOMA-IR),"Triglyceride, glucose, and insulin AUCs",2020-06-16,COMPLETED,INTERVENTIONAL,['NA'],
3753,NCT04186702,central subfield thickness (CST),patient compliant-complications,2014-09-10,COMPLETED,INTERVENTIONAL,['NA'],
3754,NCT03514238,Insulin Sensitivity,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],
3755,NCT06003751,Systemic Adverse events,,2023-08-05,RECRUITING,INTERVENTIONAL,['PHASE2'],
3756,NCT01722240,HbA1c (%),Body Weight,2012-11-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
3757,NCT05279911,Osteoprotegrin (OPG) level,,2021-03-03,COMPLETED,INTERVENTIONAL,['NA'],
3758,NCT02681874,Increase in Healthy Food Dietary Patterns,Improvement in Parental Feeding Behaviors,2015-12,COMPLETED,INTERVENTIONAL,['NA'],
3759,NCT02134860,Insulin resistance,,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
3760,NCT03324971,Change in Hemoglobin A1c,,2017-06-02,COMPLETED,INTERVENTIONAL,['NA'],
3761,NCT01682902,Mean change in plasma glucose concentration,Number of episodes of infusion set occlusions,2012-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
3762,NCT01136096,Exercise behavior,Exercise behavior,2004-01,COMPLETED,INTERVENTIONAL,['NA'],
3763,NCT06048510,Incidence of GDM diagnosed during pregnancy.,Neonatal morbidity 4,2023-12-18,RECRUITING,INTERVENTIONAL,['NA'],
3764,NCT03192228,Success rate of the therapeutic education program,Long term success rate of the therapeutic education program,2011-07,COMPLETED,OBSERVATIONAL,['NA'],
3765,NCT01519102,Incremental area under the curve of plasma glucose concentration as compared to pre-meal glucose value of the postprandial glucose excursions,Percentage of postprandial time of plasma glucose concentrations spent in the low range (below 4.0mmol/l),2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
3766,NCT02750267,Percent of Sensor Glucose Readings Between 70-180 mg/dL,End of Night Blood Glucose,2016-05,COMPLETED,INTERVENTIONAL,['NA'],
3767,NCT02561377,glycemic control,Incidence rate of diabetes,2015-09,UNKNOWN,INTERVENTIONAL,['NA'],
3768,NCT00600730,fMRi scans,,na,WITHDRAWN,INTERVENTIONAL,['NA'],
3769,NCT04369833,Number of Participants With Insulin Resistance,,2020-05-11,COMPLETED,OBSERVATIONAL,['NA'],
3770,NCT02600338,Mean arterial pressure,,2014-09,UNKNOWN,OBSERVATIONAL,['NA'],
3771,NCT02985866,Time Above 180 mg/dL,Coefficient of Variation,2017-10-27,COMPLETED,INTERVENTIONAL,['NA'],
3772,NCT01297387,,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],
3773,NCT03816293,Surgical Site Infection Rate per 100 surgeries,Dehiscence incidence and rate per 100 surgeries,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],
3774,NCT04540536,Change in hemoglobin A1c after three-month follow-up visit after remote continuous glucose monitoring monitoring and secure text messaging.,,2021-11-01,RECRUITING,INTERVENTIONAL,['NA'],Average time spent by medical provider per participant per day.
3775,NCT02981069,Change in Endogenous Glucose Production (EGP) After 16 Weeks of Treatment With Each Study Drug.,Change in Plasma Insulin Concentration,2017-12-15,COMPLETED,INTERVENTIONAL,['PHASE4'],
3776,NCT06336512,Estimation of Gestational DM,,2023-01-15,COMPLETED,INTERVENTIONAL,['NA'],
3777,NCT05409027,Pharmacokinetics (Cmax),Urinary HSD-1 Ratio,2021-08-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
3778,NCT02933424,Change in body composition,Meal challenge,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
3779,NCT00835861,Blood Glucose Measurements,Number of Babies With Adverse Neonatal Outcomes,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
3780,NCT02333851,Differences in mean daily blood glucose concentration,Total daily Insulin use in International Units per Kg of weight,2013-06,TERMINATED,INTERVENTIONAL,['PHASE4'],
3781,NCT03281616,Body weight reduction,Blood HbA1c,2014-06-01,COMPLETED,INTERVENTIONAL,['NA'],
3782,NCT04127448,Change in Verbal fluency test (VFT) from baseline to 6th week,Change in Random Blood sugar (RBS) from baseline to 6th week,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],Change in respiratory rate in breaths/min from baseline to 6th week.
3783,NCT03199053,Change from baseline in HbA1c at Week 26,"Percentage of subjects with baseline HbA1c ≥ 7%, who achieve an HbA1c level < 7.0% at Week 26",2017-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Percentage of subjects with baseline HbA1c ≥ 7% who achieve an HbA1c level < 7.0% at Week 52
3784,NCT03102476,"Onset of action, time from trial product administration until the blood glucose concentration has decreased at least 0.3 mmol/L (5 mg/dL) from the baseline",Time to maximum glucose infusion rate curve,2016-06,COMPLETED,INTERVENTIONAL,['NA'],
3785,NCT00773279,HbA1c (Glycosylated Haemoglobin) for Participants Treated With PDS290 and FlexPen®,"Hypoglycaemic Episodes, Number of Events Per Subject Day",2008-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
3786,NCT06173934,Characteristics of gastric emptying(the gastric half-emptying time ) in patients with type 1 diabetes.,The blood glucose,2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],
3787,NCT01646047,Changes in visual function,Changes in retinal structure,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
3788,NCT05669547,Time in Range (TIR) at 12 months (measured with an independent FSL Pro IQ sensor),Percentage of time glucose control algorithm active DHFCL outcomes,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Reasons for discontinuation of the DHFCL treatment.
3789,NCT03061266,Glycated hemoglobin (HbA1c),quality of life using questionnaire,2016-03-09,UNKNOWN,INTERVENTIONAL,['NA'],
3790,NCT01282957,Rate of use of the three home-based technologies,"Usability and functionality of the study's online web portal, Way to Health, and wifi-enabled home health monitoring devices",2011-02,COMPLETED,INTERVENTIONAL,['NA'],
3791,NCT06059404,Mini Nutritional Assessment-Short Form,Falls efficacy scale,2023-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
3792,NCT05284344,Gastric-half emptying time of the 75 g glucose drink,Heart rate,2021-01-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3793,NCT06223204,Change of the electrical impedance tomography (EIT) signal of the thoracic region across the glycemic trajectory.,"Performance of the machine learning model to predict glucose values from the above-mentioned signals (EIT, symptoms, voice, physiological signals) using the Clarke Error Grid.",2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3794,NCT01272583,Glucagon Response to Acute Hypoglycaemia,Symptomatic Hormone Responses to Acute Hypoglycaemia.,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
3795,NCT01607450,Myocardial Glucose Uptake.,GLP-1 Concentrations,2010-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3796,NCT01201928,"Comparison of change from baseline to final treatment visit in pulmonary function (FEV1 FVC, TLC and DLco) between treatment Groups (TI vs comparator arms) using ANCOVA models.",,2010-10,TERMINATED,OBSERVATIONAL,['NA'],
3797,NCT03396146,Measurement of pancreatic polypeptide for calculating the area under the curve,Measurement of fecal elastase level,2018-06-14,COMPLETED,INTERVENTIONAL,['NA'],
3798,NCT00738660,Reduction in albumin excretion rate,"24 hr ambulatory BP reduction,nocturnal BP reduction, proportion of dippers",2007-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
3799,NCT02895750,Efficacy of once daily Metformin XR on 24-h blood glucose control,Tolerability of Metformin XR in mild to moderate (CKD) 2,2017-08-30,COMPLETED,INTERVENTIONAL,['PHASE2'],
3800,NCT02074683,Durability of Relief and reduction of foot pressure,Assessment of pain and skin lesions,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
3801,NCT01695629,changes between control and diabetic patients,,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
3802,NCT03342274,Weight loss,Triglycerides,2018-02-16,COMPLETED,INTERVENTIONAL,['NA'],
3803,NCT05548218,Change in A1C level,,2022-08-15,RECRUITING,INTERVENTIONAL,['NA'],
3804,NCT02491814,Subjective Appetite,Food Intake,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3805,NCT02027103,Serum concentrations of osteoprotegrin,,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
3806,NCT05560386,Body Mass Index (BMI),Emotional Eating Score,2020-08-01,COMPLETED,INTERVENTIONAL,['NA'],
3807,NCT04665102,Validation of Image classification by transfer learning algorithm,,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA'],
3808,NCT00771901,Body Composition,VLDL-triglyceride (TG) Concentration,2008-02,COMPLETED,INTERVENTIONAL,['NA'],
3809,NCT05694741,"Adverse Events (AEs), and Serious Adverse Events (SAEs)",Maximum observed concentration (Cmax),2022-12-20,TERMINATED,INTERVENTIONAL,['PHASE1'],
3810,NCT02891954,Urinary glucose excretion (during the time interval 24-48 hours after first administration of canagliflozin),Serum uric acid,2016-09,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1'],
3811,NCT01511198,Body weight,Adverse events,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
3812,NCT01517919,"Changes in clinical, self-care and diabetes-related quality of life from baseline","Changes in clinical, self-care and diabetes-related quality of life from baseline",2010-01,COMPLETED,INTERVENTIONAL,['NA'],
3813,NCT01026194,Change From Baseline in HbA1c at Week 12,Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
3814,NCT01493388,Percentage of adolescents between 13 and 15 years with HbA1c less than 7.5%,Type and dose of insulin treatment,2012-03,COMPLETED,OBSERVATIONAL,['NA'],
3815,NCT00918151,"Percentage of diabetic patients having dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications, respectively","Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, nephropathy and retinopathy)",2009-05,COMPLETED,OBSERVATIONAL,['NA'],
3816,NCT02168491,Change in HbA1c From Baseline to End,Change in Body Weight From Baseline to End of Study,2014-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
3817,NCT04564911,Change from baseline HbA1c at week 24,Number of individuals requiring medication up-titration from baseline to week 24,2020-12-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3818,NCT06146036,Incremental Area Under the Curve (AUC),Blood pressure,2024-01-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3819,NCT04172337,Change in average calories per serving purchased per shopping trip,Calories per dollar spent per shopping trip,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],
3820,NCT01235039,Serum insulin concentration,Glucose infusion rate,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3821,NCT01483781,Change in hematology laboratory analytes,Change in percent Hemoglobin A1c (HbA1c),2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
3822,NCT00357370,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 12 (Last Observation Carried Forward [LOCF]) - Cohort 2,"Adjusted Mean Total Daily Dose of Insulin (TDDI) Change From Baseline at Week 12 (LOCF), Including Data After Up-titration of Insulin) - Cohort 2",2006-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3823,NCT00912002,Mean Percent of Dose Recovered in Urine and Feces Following a Single Oral Dose of [^14C]MK-0941 (160 µCi).,Number of Participants Who Discontinued the Study Due to An Adverse Event,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
3824,NCT02523001,uAQP2,Cholesterolemia,2013-10,COMPLETED,OBSERVATIONAL,['NA'],
3825,NCT01092663,Postprandial Glucose (AUC),Postprandial Glucagon (AUC),2010-03,COMPLETED,INTERVENTIONAL,['NA'],
3826,NCT02932514,Usability of the Eversense CGM System over 180 days will be evaluated through Study Questionnaires.,,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],
3827,NCT00789295,Postprandial response triglyceride of chylomicrons and large VLDL,Lipolytic activities,2004-03,COMPLETED,INTERVENTIONAL,['NA'],
3828,NCT04702672,Postprandial glycemic response,Visual analogue scale (VAS),2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3829,NCT02059005,Change in Substance Use Rates From Baseline,Number of Hospitalizations and Use of Emergency Services,2014-11-18,COMPLETED,INTERVENTIONAL,['NA'],
3830,NCT01193218,Change From Baseline in HbA1c After 12 Weeks of Treatment.,Change From Baseline in FPG,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Confirmed Hypoglycaemic Adverse Events
3831,NCT03164538,Number of PP-MI Sessions Completed by Participants,Change in Diabetes Self-Care,2017-07-25,COMPLETED,INTERVENTIONAL,['NA'],Change in Hemoglobin A1c
3832,NCT04100551,relationship between renal function and podological grade,factors associated with the occurrence of complications and comorbidities,2019-10-01,COMPLETED,OBSERVATIONAL,['NA'],
3833,NCT03398577,Percent reduction in interleukin (IL)-1β levels,Percent change in Adiponectin levels,2018-02-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3834,NCT02384226,Engagement with the Application,Acceptability of the Application,2015-09,COMPLETED,OBSERVATIONAL,['NA'],
3835,NCT03596983,Protocol adherence rates measured by the percentage of participants completing greater than or equal to 4 daily sleep diary entries per week for 80% or more of the intervention period.,,2019-04-10,COMPLETED,INTERVENTIONAL,['NA'],
3836,NCT04663282,Change in HbA1c,Serum INS068 concentration,2021-02-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
3837,NCT06177691,C-peptide,Hospitalizations,2021-05-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3838,NCT05023538,Global longitudinal strain (%),"Calf muscle oxygen saturation (haemoglobin variables: ΔHHb, ΔtHb, ΔHbO2 and ΔTSI%)",2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],
3839,NCT00577148,Mean change per year in Non-Alcoholic Fatty Liver Disease [NAFLD] Activity Score (NAS),Change from baseline in serum hyaluronate and hepatic transaminases (AST/ALT),2008-02,TERMINATED,INTERVENTIONAL,['PHASE3'],
3840,NCT01476345,Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2963016 and Lantus,Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
3841,NCT01709305,Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2),Percentage of Participants With a GI AE of Abdominal Pain (Phase 2),2012-11-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
3842,NCT06115616,g of glucose,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3843,NCT02068027,Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score,Mean Daily Worst Pain Intensity Numeric Pain Rating Scale Scores,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3844,NCT02222623,Mean daily blood glucose,Hospital mortality,2015-04,WITHDRAWN,INTERVENTIONAL,['NA'],Length of hospital stay
3845,NCT02916706,Change in HbA1c From Baseline to Week 24,The Changes in Fasting Plasma Glucose (FPG) at Week 24,2016-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
3846,NCT00707616,Disposition Index,,2006-03,COMPLETED,OBSERVATIONAL,['NA'],
3847,NCT05955339,Quality of Life - Physical functioning,Visit communication style and shared decision-making,2024-01-24,RECRUITING,INTERVENTIONAL,['NA'],Caregiver engagement in clinic visit [Caregiver outcome]
3848,NCT00224224,"To identify the differences between primary care and traditional medicine residents in clinical performance, continuity of care and utilization of resources.",,1995-01,COMPLETED,OBSERVATIONAL,['NA'],
3849,NCT02227485,Modified Gingival Index,Satisfaction of Patients,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
3850,NCT00932048,Vascular inflammation analyzed by PET: Define attenuation of plaque inflammation (plaque SUV or TBR) at 12 weeks,Change in carotid plaque thickness by ultrasound,2011-08,WITHDRAWN,INTERVENTIONAL,['NA'],
3851,NCT00988182,"Blood glucose, Insulin, Subjective appetite",Physical comfort,na,COMPLETED,INTERVENTIONAL,['NA'],
3852,NCT03335930,exercise-induced glucose response,trend of post-exercise blood glucose,2009-03-01,COMPLETED,INTERVENTIONAL,['NA'],
3853,NCT02171351,Sympathetic nerve reactivity in response to a single session of neuromuscular electrostimulation,sympathetic nerve reactivity in response to a single session of voluntary muscular contractions,2020-08-01,WITHDRAWN,INTERVENTIONAL,['NA'],comparison of sympathetic nerve reactivity between the different groups and procedures
3854,NCT01565096,Postprandial increase in intact proinsulin levels in patient treated with Vildagliptin and Metformin compared to intact proinsulin levels in patients treated with Glimepiride and Metformin (Area under the curve 0-300 min),Drug related adverse events,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
3855,NCT02276144,Compare prevalence of obstetric complications between non-alcoholic fatty liver and normal pregnant women,,2014-11,UNKNOWN,OBSERVATIONAL,['NA'],
3856,NCT04816890,Body weight change from baseline to week 16 of treatment,Hypoglycaemic episodes,2021-03-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
3857,NCT02204397,Safety and tolerability,Composite C-Peptide efficacy according to specific parameters,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
3858,NCT00793884,Social and Demographic Characteristics,Change in Diastolic Blood Pressure,2008-10,SUSPENDED,OBSERVATIONAL,['NA'],
3859,NCT00628212,Change From Baseline in HbA1c at Week 12,Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
3860,NCT01578096,Hemoglobin A1c,Diabetes specific distress,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
3861,NCT05492630,AUC0-∞,,2021-05-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
3862,NCT05514925,Intraoperative bleeding,Visual acuity,2017-11-21,RECRUITING,INTERVENTIONAL,['PHASE4'],
3863,NCT02084004,Change in HbA1c from baseline to week 12,Adverse effects,2015-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3864,NCT03889977,Changes in blood triglycerides,Changes in substances that react with thiobarbituric acid (TBARS),2019-02-11,COMPLETED,INTERVENTIONAL,['NA'],
3865,NCT01989975,Subject Experience After Using the Carelink Connect Device,Number of Participants With Investigational Device Deficiencies,2013-05,COMPLETED,OBSERVATIONAL,['NA'],
3866,NCT00347698,Score on a patient satisfaction scale at six months and one year,Complications associated to each treatment,2006-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3867,NCT00533442,Event-Specific Survival Comparisons,"Overall Pancreas Transplant Function at 12, 36, and 60 Months Post-transplant.",2000-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3868,NCT06070103,"Depression ,Anxiety and stress disorders among diabetic patients in Assuit University Hospitals.",,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
3869,NCT04455867,Neuropsychological function,Cognitive Status,2017-12-21,RECRUITING,OBSERVATIONAL,['NA'],
3870,NCT06301022,serum potassium,,2022-12-15,RECRUITING,OBSERVATIONAL,['NA'],
3871,NCT00800410,Hemoglobin A1c,Diabetes specific emotional distress,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3872,NCT02893891,SF-36 Questionnaire evaluation,Effectiveness evaluation,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
3873,NCT01943045,Fasting Plasma Glucose,Lipids,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
3874,NCT02372578,Change from Baseline in mean 24-hour average pain intensity as reported on the NPRS,Clinical Global Impression of Change (CGIC),2015-05-27,TERMINATED,INTERVENTIONAL,['PHASE2'],
3875,NCT00685594,development of diabetes type 2,change in telomer length,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Oral glucose tolerance response to vitamin D supplementation in relation to polymorphisms in the vitamin D system
3876,NCT03728647,nursing hours,insulin performance rate,2013-08-16,COMPLETED,INTERVENTIONAL,['NA'],
3877,NCT03675269,Change in wound size,,2018-09-05,WITHDRAWN,INTERVENTIONAL,['NA'],
3878,NCT00330733,Change in Systemic Glucose Disposal- Glucose Infusion Rates,Plasma Adiponectin,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
3879,NCT03280524,Quality of Life Questionnaire SF-36,,2016-01,COMPLETED,INTERVENTIONAL,['NA'],Stanford Health Assessment Questionnaire
3880,NCT03720197,Number of non-severe hypoglycemic episodes,Number of steps,2019-02-20,RECRUITING,OBSERVATIONAL,['NA'],
3881,NCT00371007,"HbA1c, safety and tolerability",Plasma glucose,2004-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
3882,NCT05604352,Assessing the safety of the DiaSole insole,acceptability of DiaSole to health care professionals (HCPs),2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3883,NCT04083820,Change in Glycated Haemoglobin A1c (HbA1c),Patient completed the study under treatment with semaglutide (yes/no),2019-09-16,COMPLETED,OBSERVATIONAL,['NA'],
3884,NCT01884363,Change in reactive hyperemia index occurring between baseline and 12 weeks (end of intervention),Change in blood levels of hormones produced by fat cells between baseline and 12 weeks (end of intervention),2013-06,COMPLETED,INTERVENTIONAL,['NA'],Change in heart rate variability between baseline and 12 weeks post-intervention
3885,NCT02346344,"Repeatability of the meal tolerance test and the arginine stimulation test, as indicated by the ICC (intraclass correlation coefficient)",,2014-04,COMPLETED,OBSERVATIONAL,['NA'],
3886,NCT02749942,Peripheral tissue oxygen oxygenation of dorsal part of foot,Cardiovascular Autonomic neuropathy; Heart rate variability,2016-05-11,COMPLETED,INTERVENTIONAL,['NA'],"Assessment of quality of life and empowerment, 4"
3887,NCT02022111,Percentage of Combined Improvement of Depressive Symptoms and CVD Risk Factors,Cost Utility in the Treatment Arm and Usual Care Arms,2014-03,COMPLETED,INTERVENTIONAL,['NA'],
3888,NCT05769868,Ejection Intraventricular Pressure Difference (EIVPD) measure,Matrix metalloproteinase-1 (MMP-1),2023-04-18,RECRUITING,INTERVENTIONAL,['PHASE3'],
3889,NCT05048719,Change From Baseline in HbA1c in LY3502970 as Compared to Placebo,Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970,2021-09-15,COMPLETED,INTERVENTIONAL,['PHASE2'],
3890,NCT05869734,Sleep efficiency,Self-management of urologic health,2023-05-30,RECRUITING,INTERVENTIONAL,['NA'],
3891,NCT03800901,Change in the percentage of evidence-based diagnostic and treatment decisions made in the simulations.,Impact of available CME and ABIM MOC on retention rate,2019-01-11,COMPLETED,INTERVENTIONAL,['NA'],
3892,NCT03119584,Improvement in frequency of bowel movements,,2015-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
3893,NCT00944060,body weight,"dietary fat intake, fruit and vegetable intake, physical activity, stress, affects",na,COMPLETED,INTERVENTIONAL,['PHASE3'],
3894,NCT05918484,Specificity,Percentage of iCGM in MODY patients,2023-07-01,RECRUITING,OBSERVATIONAL,['NA'],
3895,NCT00689546,Duration of icteric hepatitis.,Mortality,2007-02,UNKNOWN,OBSERVATIONAL,['NA'],
3896,NCT01447121,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15mg/dL (<75 mg/dL) or Within +/- 20% (>=75 mg/dL) of Laboratory Glucose Method,Number of Study Staff Results Within +/- 15mg/dL (<75 mg/dL) or Within +/- 20% (>=75 mg/dL) of Laboratory Glucose Method When Testing Subject Blood Glucose (BG),2011-09,COMPLETED,INTERVENTIONAL,['NA'],
3897,NCT05773209,Changes in subfoveal choroidal thickness,Changes in DR grading,2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3898,NCT01935466,Bladder cancer rate,,2013-07,COMPLETED,OBSERVATIONAL,['NA'],
3899,NCT00865033,Bioequivalence according to US FDA guidelines,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
3900,NCT01998269,Measure of Medication Self-Management (MeDS),,2013-11,COMPLETED,OBSERVATIONAL,['NA'],
3901,NCT01810822,Albumin to Creatinine Ratio,,1994-05,COMPLETED,OBSERVATIONAL,['NA'],
3902,NCT00588380,Insulin Secretion at 150-180 Minutes.,Insulin Secretion at 210-240 Minutes,2007-11,COMPLETED,INTERVENTIONAL,['NA'],
3903,NCT01804803,Changes in HbA1c from baseline value,"Subgroup analyses of changes in HbA1c from baseline according to patients' age (<45 yrs, >45yrs), type of diabetes (type 1, type 2), and diabetes duration (<5 yrs, >5 yrs)",2013-09-09,COMPLETED,INTERVENTIONAL,['NA'],
3904,NCT00655798,inflammation parameters,glucose and fat response,2006-12,COMPLETED,INTERVENTIONAL,['NA'],
3905,NCT05630508,User friendliness,physical performance assessments - endurance,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],
3906,NCT02608853,Incidence of all malignant neoplasms,Incidence of acute pancreatitis,2015-01,COMPLETED,OBSERVATIONAL,['NA'],
3907,NCT02691429,ocular inflammation,complications of the posterior segment,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
3908,NCT01769404,Concentration of Epinephrine,Concentration of Norepinephrine,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
3909,NCT04031417,Hypoxia and low humidity on the endothelial function in healthy volunteers and patients with type 2 diabetes using Wilcoxon signed rank test,,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
3910,NCT01114061,show no increase in hypoglycemia events when the InsuPatch device is used compared to the number of hypoglycemia events when the InsuPatch device is not used.,,na,SUSPENDED,INTERVENTIONAL,['NA'],
3911,NCT00251953,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),"Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",2004-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
3912,NCT02287883,PHQ-4,,2015-04,COMPLETED,OBSERVATIONAL,['NA'],
3913,NCT06063109,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Pharmacokinetics - PTF,2023-10-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
3914,NCT02664207,Post-operative complications,,2016-01-26,RECRUITING,INTERVENTIONAL,['NA'],
3915,NCT01927562,Changed in Mixed Meal Tolerance From Baseline to 3 Months,,2013-07-13,COMPLETED,INTERVENTIONAL,['NA'],
3916,NCT00407381,Mean Change in Best Corrected Visual Acuity (BCVA) at Month 6,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
3917,NCT00132418,"Incidence of medically important infections, defined as infections that result in hospitalization or treatment with intravenous antibiotics","Infections associated with antimicrobial use; physical examination, vital signs, clinical laboratory assessments; symptom assessment, withdrawals, deaths, and serious adverse events",2000-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
3918,NCT00005479,,,1996-09,COMPLETED,OBSERVATIONAL,['NA'],
3919,NCT00491543,Pharmacokinetics,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3920,NCT03380403,Infection control,Osteomyelitis evaluation,2010-01-01,COMPLETED,INTERVENTIONAL,['NA'],
3921,NCT05394844,A1C,Self-Efficacy for Diabetes,2022-11-11,RECRUITING,INTERVENTIONAL,['NA'],
3922,NCT05144737,Change in body mass index over a 6-month period,Change in resting metabolism over a 12-month period,2021-11-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in pain severity over the 12-month period
3923,NCT00690768,amount of intraoperative intra-ocular bleeding,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
3924,NCT05353114,The primary outcome measure was the requirement of Therapeutic Footwear change after prescription because ill fitting.,Number of participants with an ulcer occurrence event,2022-06-15,COMPLETED,INTERVENTIONAL,['NA'],
3925,NCT03751813,lower blood stress markers via venous draw,,2019-03-21,TERMINATED,INTERVENTIONAL,['NA'],
3926,NCT04885712,Changes in HbA1c,,2021-05-28,COMPLETED,INTERVENTIONAL,['PHASE3'],
3927,NCT00570102,Positivity for two or more diabetes-associated autoantibodies and/or clinical type 1 diabetes,,1995-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
3928,NCT00865124,Change in Coronary Flow Reserve From Baseline to 6 Months,Change in Renal Plasma Flow,2008-09,COMPLETED,INTERVENTIONAL,['NA'],
3929,NCT00494884,Change from baseline in HbA1c,Change in systolic and diastolic blood pressure,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
3930,NCT04161131,Hemoglobin A1c (HbA1c),Frequency of Blood Glucose Monitoring,2019-12-09,COMPLETED,INTERVENTIONAL,['NA'],
3931,NCT01023906,Sensory/hedonic rating,Genetic Variation,2008-07,COMPLETED,OBSERVATIONAL,['NA'],
3932,NCT05286853,Primary Composite Endpoint,Second Secondary Endpoint: Time to End Stage Renal Disease,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
3933,NCT01179945,Blood glucose area under the curve (AUC),Metabolite Profiles,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
3934,NCT01076075,Number of Participants Discontinuing Study Drug Due to An Adverse Event,Change From Baseline in Fasting Plasma Glucose at Week 24,2010-06-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
3935,NCT05472883,Correlation between plasma levels of 9 target molecules and diabetes remission,The expression level of genes encoding 9 biomarkers in the adipocyte and the muscle cell,2023-02-27,RECRUITING,INTERVENTIONAL,['NA'],
3936,NCT03085524,Restenosis,,2017-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
3937,NCT05929196,Blood sample relative permittivity,Mathematical model of blood glucose dependence on blood dielectric parameters,2023-07-12,COMPLETED,INTERVENTIONAL,['NA'],
3938,NCT03192605,Glucose (mmol/L),,2017-05-15,COMPLETED,INTERVENTIONAL,['NA'],
3939,NCT03567824,Change in Serum Magnesium Concentration,Change in HbA1c,2026-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
3940,NCT04518813,Safety evaluation of the Investigational Medical Device by reporting of adverse events,Device function,2020-09-24,COMPLETED,INTERVENTIONAL,['NA'],
3941,NCT00892372,,,2009-04,COMPLETED,OBSERVATIONAL,['NA'],
3942,NCT02579837,Proportion of participants with Actionable Eye Disease (AED),Proportion of participants with Diabetic Maculopathy (DME),2016-03,COMPLETED,INTERVENTIONAL,['NA'],
3943,NCT01594333,Number of Subjects With Major Adverse Cardiovascular Event or Hospitalization for Unstable Angina That Led to Urgent Coronary Revascularization,Number of Subjects With New Onset Type 2 Diabetes,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Subjects With Atrial Fibrillation
3944,NCT05290506,change from baseline in insulin sensitivity/resistance index after 12-week treatment,change from baseline in beta-cell function after 12-week treatment,2020-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
3945,NCT05444595,Body weight,Program acceptability from community health workers and study participants,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3946,NCT01832181,Adiposity in the offspring,adipocytokine profile in the offspring,2013-04,COMPLETED,OBSERVATIONAL,['NA'],
3947,NCT00668590,Hemoglobin A1c,Diabetes self-care behaviors,2008-08,COMPLETED,INTERVENTIONAL,['NA'],
3948,NCT00661063,pain evaluation by visual analogue scale,pain evaluation by amount of rescue medication required,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],
3949,NCT06251466,Admission to the neonatal intensive care (NIC) in pregnancies with gestational diabetes mellitus in which telemonitoring was added to the standard care of gestational diabetes mellitus compared to the standard care without telemonitoring.,Reaction time from measuring abnormal glucose values to performing an intervention in pregnancies in which telemonitoring was added to the standard care of gestational diabetes mellitus compared to the standard care alone.,2023-12-18,RECRUITING,INTERVENTIONAL,['NA'],Satisfaction and usability of the modified care process through the administration of patient and staff questionnaires compared to the conventional follow-up approach.
3950,NCT03390231,Changes of inflammation-related markers in diabetic patients after Stem Cell Educator therapy,Metabolic control in fasting C-peptide levels,2017-11-27,UNKNOWN,INTERVENTIONAL,['PHASE2'],
3951,NCT03201406,Mortality,,2017-06-20,UNKNOWN,OBSERVATIONAL,['NA'],
3952,NCT03920085,Clinical Evaluation of Blood Glucose result (mg/dl) from LifeScan Blood Glucose Monitoring Systems by comparison of a blood glucose result (mg/dl) obtained from a reference instrument (YSI2900) to demonstrate accuracy (%).,,2019-01-08,COMPLETED,INTERVENTIONAL,['NA'],
3953,NCT01648218,Blood glucose - inpatient,Mortality,2012-08,TERMINATED,INTERVENTIONAL,['PHASE4'],
3954,NCT05380596,Adherence to treatment - Brief Medication Questionnaire (BMQ),Quality of life measured by DQOL-Brazil;,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
3955,NCT00790153,Pharmacodynamic variables,"Safety Variables (AEs, BP, pulse, electrocardiogram (ECG), hypoglycaemic symptoms and laboratory variables)",2008-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
3956,NCT06203860,"Time to first occurrence of major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke, and hospitalisation for heart failure (HF).",Cost-effectiveness ratio of implementing a Cardio-Metabolic Clinic,2023-11-01,RECRUITING,INTERVENTIONAL,['NA'],
3957,NCT02498054,Success rate to categorize blood glucose values into accepted ranges.,Actual time taken to categorize blood glucose values into accepted ranges on the questionnaire provided.,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
3958,NCT04187443,Treatment-emergent adverse events,Average mean change in best corrected visual acuity,2020-06-02,RECRUITING,INTERVENTIONAL,['PHASE1'],
3959,NCT02796534,"Prevalence of obstructive sleep apnea syndrome by oxymetry, confirmed by polysomnography",Incidence of new cardiovascular events and changes in microangiopathic complications of diabetes patients depending on the presence of sleep apnea syndrome and to the adherence to CPAP treatment in case of sleep apnea syndrome treated,2016-07-28,COMPLETED,OBSERVATIONAL,['NA'],
3960,NCT03798054,Change in HbA1c,Immunogenicity (antibody variables),2019-02-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
3961,NCT00005116,,,na,COMPLETED,INTERVENTIONAL,['NA'],
3962,NCT01536600,Change in HbA1c (glycosylated haemoglobin),Adverse drug reactions (ADR),2004-09,COMPLETED,OBSERVATIONAL,['NA'],
3963,NCT05709847,Verbal memory,Processing Speed,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],
3964,NCT00921960,Prevalence and severity of LVD,,2005-01,COMPLETED,INTERVENTIONAL,['NA'],
3965,NCT02841969,Rate of complete wound healing,,2017-02-28,SUSPENDED,INTERVENTIONAL,['NA'],
3966,NCT03417466,Mean Percentage of Enlite Sensor Values That Are Within 20% Agreement of Gold Standard (Yellow Springs Instrument (YSI) YSI Plasma Glucose Values),Consensus Error Grid Analysis of Paired Sensor and YSI Plasma Glucose Values,2018-06-28,COMPLETED,INTERVENTIONAL,['NA'],
3967,NCT04621929,New kidney stone formation (mm2) as determined by non-contrast CT scan,Change in urinary uric acid parameters,2021-03-31,RECRUITING,INTERVENTIONAL,['PHASE3'],
3968,NCT03021837,The length of time that maternal glucose levels remain elevated after steroid administration.,,2012-08-24,COMPLETED,OBSERVATIONAL,['NA'],
3969,NCT00561158,"Fat intake (measured by Food Frequency Questionnaire) including: percent calories from fat, percent calories from saturated fat.",Cultural relevancy,1994-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
3970,NCT06188234,Change in HbA1c at 6 months of prescribing Tenero Tablet/Tenero Emextended Release Tablet compared to baseline,,2022-12-27,RECRUITING,OBSERVATIONAL,['NA'],
3971,NCT01904383,Percentage of Participants With Drug Related Adverse Events,The Mean Change From Baseline to Last Observation of the Treatment Period in Haemoglobin A1c (HbA1c),2013-07-01,COMPLETED,OBSERVATIONAL,['NA'],
3972,NCT00732147,Endogenous glucose production,Endogenous VLDL-Triglyceride production,2009-04,WITHDRAWN,INTERVENTIONAL,['NA'],
3973,NCT00312156,HbA1c,Hypoglycaemia,2002-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
3974,NCT03016832,ACR,High sensitivity C,2017-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
3975,NCT01631084,Incidence of all diabetes-related clinical endpoints,Proportions of patients with improved control of risk factors,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
3976,NCT00907374,Microalbuminuria Reported as Urinary Albumin:Creatinine Ratio,Endothelial Dysfunction,2005-07,COMPLETED,INTERVENTIONAL,['NA'],
3977,NCT00496405,Retinal thickness,Best corrected visual acuity,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
3978,NCT00541879,Diabetes knowledge and prevention behaviors in elementary school children,"Parental diabetes knowledge, self-reported physical activity",2001-08,COMPLETED,INTERVENTIONAL,['NA'],
3979,NCT01820169,Improvement in HbA1c in 6 months,5. Doctor's opinion for Accu-Chek 360° View.,2013-04,TERMINATED,INTERVENTIONAL,['NA'],
3980,NCT02427464,Number of Participants With Treatment-emergent Adverse Events.,Participants With at Least a 50 Percent Reduction in Average 24-hour Pain Score From Baseline to Day 180,2016-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
3981,NCT04004273,Change in liver saturated lipid index (%) determined by proton magnetic resonance spectroscopy (1H-MRS) using a 3T MRI scanner,Change in macronutrient intake,2018-10-30,COMPLETED,INTERVENTIONAL,['NA'],
3982,NCT01303042,pre- and postprandial glucose levels in SMBG,Total score of Questionnaire on QOL,2011-02,UNKNOWN,INTERVENTIONAL,['NA'],
3983,NCT00360815,,,1983-08,COMPLETED,INTERVENTIONAL,['NA'],
3984,NCT05777330,Progression to persistent dysglycemia and stage 3 type 1 diabetes,,2023-08-09,RECRUITING,INTERVENTIONAL,['NA'],
3985,NCT00306072,The primary variable to be measured was positive AUC (0-180 minutes) for plasma glucose.,· Positive AUC 0-180 (0 to 120) minutes for serum insulin,2005-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
3986,NCT01062048,Mean change in 2hr-postprandial glucose (PPG),,2008-10,COMPLETED,OBSERVATIONAL,['NA'],
3987,NCT05566912,Completing the surveys,,2021-10-15,COMPLETED,OBSERVATIONAL,['NA'],
3988,NCT01929863,Mean Change From Baseline in Overall Gastrointestinal Symptom Rating Scale (GSRS) Scores,Median Time to Observed Peak Plasma Concentration (Tmax) When Co-dosed With GSK2330672 or Placebo on Day 7,2013-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
3989,NCT00675220,Safety profile of Insulin Aspart among Filipino patients,,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
3990,NCT05999110,Change in Respiratory Compensation Point (RCP - VO2),Change medical appointments number related with Knee Osteoarthritis,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],
3991,NCT02041377,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15 mg/dL (<100 mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory Glucose Method,Number of Subject Responses That Strongly Agree or Agree or Are Neutral With Questionnaire Statements,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
3992,NCT02060266,"Concentration of the major metabolites of [3H]-semaglutide in plasma, urine, and faeces",Maximum observed semaglutide plasma concentration,2014-02-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
3993,NCT00977808,Occurrence of Hypoglycemic Episodes,,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
3994,NCT05609747,high sensitivity C- reactive protein- hsCRP.,Clinical and Radiographic success,2021-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
3995,NCT03552523,Average Time Spent With CGMG Less Than 54 mg/dl,,2017-07-28,COMPLETED,INTERVENTIONAL,['NA'],
3996,NCT05963152,Chronic change in Colour Trails Test score,12 week acute change in Colour Trails Test score,2023-07-20,RECRUITING,INTERVENTIONAL,['NA'],
3997,NCT04203147,LDL-Cholesterol,Self-Care Behaviors,2020-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Resource Utilization and Cost
3998,NCT02959762,Change in beta-cell function,Change in endothelial function (flow-mediated dilation),2016-10,UNKNOWN,INTERVENTIONAL,['NA'],
3999,NCT04476472,Time in Range 70-180 mg/dL,Body Mass Index (BMI) (kg/m^2),2020-09-08,COMPLETED,INTERVENTIONAL,['NA'],
4000,NCT02649010,Enlite 3 Sensor inserted at Arm accuracy using a real time device: (640G pump) with the minimum calibration requirements (every 12 hours after the second calibration) will be evaluated.,,2016-01,WITHDRAWN,INTERVENTIONAL,['NA'],
4001,NCT01107431,Fasting Blood Glucose,Fasting Blood Insulin Levels,2008-12,COMPLETED,INTERVENTIONAL,['NA'],
4002,NCT01008163,"Change from baseline in the fasting plasma glucose and postprandial glucose [after 2 hours, oral glucose tolerance test (OGTT) (75 g)] and HbA1c",Lipid profile,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
4003,NCT03766724,"Cmax,ss",,2018-11-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
4004,NCT00649909,The outcome measure is the laboratory Aspirin Resistance.,"To determine the incidence of laboratory aspirin resistance in type 2 DM in stable out-patients in the diabetic clinic, and possibly related factors.",2008-11,COMPLETED,OBSERVATIONAL,['NA'],
4005,NCT04759495,Changes in glycated haemoglobin (HbA1c),"Incidence of skin reaction, infection or hematoma at the site of insertion of the sensor",2019-06-01,UNKNOWN,INTERVENTIONAL,['NA'],
4006,NCT05737654,Change in quality of life,,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],
4007,NCT01444248,compliance of patients treated with once-daily or twice-daily,other adverse events,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
4008,NCT05467345,Number of results from the Contour Next and Contour Plus Elite BGMSs reference values within ±20% of reference values,,2022-08-24,COMPLETED,OBSERVATIONAL,['NA'],
4009,NCT01508065,Accuracy of the Glucometer CGM-305 blood glucose readings as evaluated by Clark error grid with measurements of venous blood as the comparing value,The safety of the Glucometer CGM-305 in evaluating blood glucose levels,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],
4010,NCT00141986,change in 25(OH)D from baseline,changes in urine calcium:creatinine ratio,2003-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
4011,NCT06032429,the self-management level assessed by the self-developed scale,the self-care level assessed by the self-developed scale,2019-02-01,COMPLETED,INTERVENTIONAL,['NA'],
4012,NCT01552499,The proportion of completely healed ulcers in patients treated with amniotic membrane vs. standard of care,Mean time to complete healing,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
4013,NCT01412905,,,2007-02,COMPLETED,OBSERVATIONAL,['NA'],
4014,NCT05439226,HbA1C,Metabolomics,2022-07-05,RECRUITING,INTERVENTIONAL,['NA'],
4015,NCT01664624,Change From Baseline in Postprandial Area Under the Curve From Time 0 to 8 Hours (AUC[0-8]) for Active Glucagon-like Peptide-1,Change From Baseline to Day 11 in 24-hour Average Plasma Glucose,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
4016,NCT00525577,Change from baseline in HbA1c to the 6-month time point is identical in the study groups (placebo and AGI-1067 treatment groups),• Change of HbA1c from baseline throughout the study • Change of FPG from baseline throughout the study•,2007-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4017,NCT05322746,Short Form McGill Pain Questionnaire,,2022-04-28,COMPLETED,INTERVENTIONAL,['NA'],
4018,NCT02821117,Change in Time in Range,,2016-06-30,COMPLETED,INTERVENTIONAL,['NA'],
4019,NCT00727857,Percent Change From Baseline in Glycosylated Hemoglobin,Change From Baseline in Small Very Low Density Lipoprotein (V1+V2) Concentration,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
4020,NCT00824499,HBA1C,Influenza Vaccination Prescriptions,2004-02,UNKNOWN,INTERVENTIONAL,['NA'],
4021,NCT04129190,Oral Glucose Tolerance,,2019-10-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],
4022,NCT02305355,The mean percent change of Triglyceride(TG),The mean percent change of apolipoprotein B,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
4023,NCT00521027,"Reduction in the average skin-to-skin time of the first surgical debridement with VERSAJET™, compared to conventional debridement techniques.","Difference in outcomes of the procedure, according to the debridement technique in terms of; time to wound closure, number of subsequent debridements, number of serious adverse events",2006-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
4024,NCT01856595,Changes From Baseline for Mean Daily Glucose (mg/dL) on Day 28 (AUC Approach),Percent Change From Baseline in Lipid Parameters (mg/dL) by Treatment Group on Days 14 and 28 - Part B,2013-05-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
4025,NCT05340868,Body composition - change in body weight (kg),Body composition - change in lean body mass content (kg),2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],
4026,NCT01527747,Change in fasting and postprandial triglyceride concentrations,Changes in glycemia,2012-01,SUSPENDED,INTERVENTIONAL,['PHASE4'],
4027,NCT04998032,HbA1c,salvage treatment,2021-10-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4028,NCT00198471,Vitreous detachment,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
4029,NCT05881447,Incidence of cardiovascular- and non-classic risk factors of CKD:,Assessment of Hypertension incidence,2023-06-21,RECRUITING,OBSERVATIONAL,['NA'],
4030,NCT02995629,Perceived patient pain assessment,Time of treatment,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
4031,NCT00394875,lipid profile,health care consumption and costs,2002-03,COMPLETED,INTERVENTIONAL,['NA'],
4032,NCT06324669,Rate of endogenous glucose production,Energy expenditure,2024-03-16,RECRUITING,INTERVENTIONAL,['NA'],
4033,NCT00230087,(2) HOMA model- determined by the OGTT method,"Change in serum levels of proinflammatory cytokines (ie IL-6, TnF-αR2)",2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
4034,NCT05761743,Assess glycemic control after parathyroidectomy in patients with primary hyperparathyroidism and concomitant type 2 diabetes mellitus,Assess the changes in skeletal profile after parathyroidectomy in patients with primary hyperparathyroidism and concomitant type 2 diabetes mellitus,2023-02-27,RECRUITING,OBSERVATIONAL,['NA'],
4035,NCT02706119,Hypoglycemia symptoms,Blood glucose coefficient of variation (CV),2016-07-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Adverse events
4036,NCT01107886,"Participants With Any Event From the Composite of Cardiovascular Death (CV Death), Non-fatal Myocardial Infarction (MI), or Non-fatal Ischaemic Stroke",Participants With Event of Death,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
4037,NCT01508949,Change in weight,Adverse events,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
4038,NCT05838287,Change in Diastolic function,PCr:ATP ratio,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE4'],
4039,NCT01301521,Water-soluble Cinnamon,,2013-06-11,COMPLETED,INTERVENTIONAL,['NA'],
4040,NCT00462631,Late lumen loss at 9 months,Target vessel failure,2007-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4041,NCT02834689,Mean 24 hour glucose levels (mmol/l),Time spent above 10 mmol/l glucose,2016-07-01,COMPLETED,INTERVENTIONAL,['NA'],
4042,NCT04959799,Retrospective description of the setting of dalbavancin treatment in diabetic patients.,Incidence of Adverse Events,2022-01-02,COMPLETED,OBSERVATIONAL,['NA'],
4043,NCT01165944,HgA1c,Continuous glucose monitoring,2009-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4044,NCT00523393,Change of number of circulating EPC 4 weeks after start of therapy compared to baseline as detected by FACS analysis,Markers of inflammation and vascular risk in diabetes,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
4045,NCT01093833,Blood Glucose,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
4046,NCT03872089,Correlation with podologic grade,,2019-04-08,TERMINATED,INTERVENTIONAL,['NA'],
4047,NCT03534921,Healthcare interventions - referrals,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],
4048,NCT00807976,Prevalence of orthostatic hypotension,"Adverse events, Score risk profile questionnaire, Heart rate, Gender, Body mass index, Medication, Smoking, History of cardiovascular disease, Family history of cardiovascular disease, Duration of diabetes mellitus, Glycosylated haemoglobin, Insulin use",2009-01,COMPLETED,OBSERVATIONAL,['NA'],
4049,NCT03626623,Number of Wounds With Wound Closure,Indirect Diabetic Foot Ulcer (DFU) Product(s) Costs,2019-05-21,TERMINATED,INTERVENTIONAL,['NA'],
4050,NCT05426096,Hyperglycemia (glucose >180 mmol/dL),Glucose at first PACU measurement,2022-10-05,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Incidence of surgical site infection
4051,NCT01521910,Rate of decline of GFR,,1995-04,COMPLETED,INTERVENTIONAL,['NA'],
4052,NCT03665974,Pre-pregnancy BMI,,2013-01-05,COMPLETED,OBSERVATIONAL,['NA'],
4053,NCT01849965,The proportion of subjects with a target ulcer which achieves complete wound closure by 10 weeks (confirmed 2 weeks later) after initiation of treatment.,The proportion of subjects with a target ulcer which achieves complete wound closure by 10 weeks (confirmed two weeks later) after initiation of treatment.,2013-04,TERMINATED,INTERVENTIONAL,['PHASE3'],Incidence of and time to target ulcer recurrence after confirmed complete wound closure has been established.
4054,NCT02861157,STARx Transition Readiness Questionnaire,Quality of Life,2015-07-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
4055,NCT05886088,Glycated hemoglobin (HbA1c),Blood pressure,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
4056,NCT04754464,BFM,HOMA-IR,2020-05-13,COMPLETED,INTERVENTIONAL,['NA'],WHtR
4057,NCT01127659,Insulin Sensitivity,Body Composition,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
4058,NCT05065879,Neutralizing antibody level,Adverse events following vaccination,2021-10-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
4059,NCT03441919,"Arterial wall inflammation, measured by 18F-FDG-PET/CT","Arterial wall inflammation, measured by 18F-FDG-PET/CT",2018-01-18,COMPLETED,OBSERVATIONAL,['NA'],
4060,NCT03189225,"Venous blood collected for impact assessment of Biochemistry parameters on 3 LifeScan Blood Glucose Monitoring Systems (OneTouch Ultra 2, OneTouch Verio, OneTouch SelectPlus).",,2016-08-01,COMPLETED,INTERVENTIONAL,['NA'],
4061,NCT05811078,Implementation of trainings containing peer interactive group support to adolescents and application of scales,Evaluation of Data,2023-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
4062,NCT06333132,Number of participants with incretin effect's restoration after achieving weightloss-induced diabetes remission,Rate of sustained weightloss-induced diabetes remission assessed by 2 consecutive HbA1c <48mmol/mol within 6 months,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
4063,NCT03565458,"Peak Plasma Concentration (Cmax) of gemigliptin, dapagliflozin, empagliflozin",metabolic ratio of gemigliptin,2018-04-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],
4064,NCT00728156,To compare the effect of Clopidogrel in reduction of thrombogenicity in patients with T2DM and CAD with placebo,To characterise features in T2DM patients responsible for increased thrombogenicity,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
4065,NCT05135195,Average time it takes to understand how to interact with the system and run the simulation of the bus ride,,2021-10-24,COMPLETED,INTERVENTIONAL,['NA'],
4066,NCT03550066,Acceptance of Health Message,Diabetes Prevention Behavior: Intention,2018-06-01,COMPLETED,INTERVENTIONAL,['NA'],
4067,NCT01142297,Implant Stability Quotient (ISQ),Clinical Success of Implants,2008-07,COMPLETED,INTERVENTIONAL,['NA'],
4068,NCT00771680,Serious adverse drug reactions including major hypoglycaemic events,Quality of Life (QoL) as assessed by patient questionnaire,2008-10,COMPLETED,OBSERVATIONAL,['NA'],
4069,NCT05337098,24-hour glycemic control,Monocyte chemoattractant protein-1,2023-01-16,RECRUITING,INTERVENTIONAL,['NA'],
4070,NCT05735873,Change from Baseline to 12 weeks in Numeric Pain Rating Scale,Change from Baseline to 12 weeks in diastolic blood pressure,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
4071,NCT02887898,Change in HbA1c,Change in treatment satisfaction,2016-09,COMPLETED,INTERVENTIONAL,['NA'],Adherences to bolus calculator use
4072,NCT00772356,Comparison of glucose infusion rate necessary to keep blood glucose constant,Serum insulin and free fatty acid levels,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
4073,NCT01908894,Speed of absorption (TINS-50%-early) of BIOD-123 and BIOD-125 versus Humalog.,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
4074,NCT06099067,3-point MACE,,2020-05-15,COMPLETED,OBSERVATIONAL,['NA'],
4075,NCT02436369,Change from baseline in values of HbA1c at 8 week,"Change from baseline in values of Lipid profile (Total cholesterol, triglyceride, LDL-C, HDL-C) at 8 week",2014-09,COMPLETED,INTERVENTIONAL,['NA'],
4076,NCT01627899,Change in A1C From Baseline to Week 24,Change in 30 Day Mean Glucose Comparing First Month to Last Month After 24 Weeks,2012-10-01,TERMINATED,INTERVENTIONAL,['NA'],
4077,NCT00326326,HDL-C Safety and Efficacy,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
4078,NCT00468351,"Central Macular Thickness, Best Corrected Visual Acuity",Intraocular pressure; lens status,2006-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],
4079,NCT01103609,To evaluate the pharmacokinetics of warfarin after a single dose when administered alone and in combination with AZD1656 at steady state by assessment of AUC and Cmax of both enantiomers of warfarin (S- and R-warfarin).,"To describe the pharmacokinetics of AZD1656 and its metabolite during concomitant warfarin administration by assessment of AUC0-24, Cmax, Ctrough, tmax, t1/2 and CL/F (AZD1656 only).",2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
4080,NCT03962296,The change(Improvement)in the hard exduates,The change of total macular volum(TMV),2012-11-21,COMPLETED,INTERVENTIONAL,['PHASE4'],
4081,NCT04084171,Primary Outcome,CGM Consensus Goal,2019-09-26,COMPLETED,INTERVENTIONAL,['NA'],
4082,NCT02546063,Average of the postprandial area under the glucose curve (AUC) measured over three hours after each meal's start using Continuous Glucose Monitoring,User satisfaction,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
4083,NCT04051359,The rate of treatment failure defined as patients needing additional hypoglycemic therapy by long-insulin acting analogue detemir evaluated by capillary glucose levels,,2019-08-15,UNKNOWN,INTERVENTIONAL,['NA'],
4084,NCT02666924,Glycemic control,Albuminuria screen,2017-10-31,COMPLETED,INTERVENTIONAL,['NA'],Diabetes self knowledge assessment
4085,NCT02482662,proportion of OGTTs falsely negative,preference of participants regarding the two tests (OGTT vs. SMBG),2014-11,COMPLETED,OBSERVATIONAL,['NA'],
4086,NCT01352390,Number of Participants that schedule an appointment for receipt of a Pap smear.,Number of Participants that schedule an appointment for receipt of a Fasting plasma glucose test,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
4087,NCT02994095,PACIC score,,2014-03,COMPLETED,INTERVENTIONAL,['NA'],
4088,NCT04932213,Change from baseline in pupillary diameter,Change from baseline in central corneal thickness (CCT),2021-07-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
4089,NCT01217463,"Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition",Relative Wound Area Regression of 40% or More at 6 Week,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
4090,NCT00566566,,,2008-01,UNKNOWN,OBSERVATIONAL,['NA'],
4091,NCT05661474,the proportion of patients complete responders,,2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
4092,NCT03530930,Change From Baseline in Visual Analogue Scale for Pain,Patient global assessment of osteoarthritis,2018-06-29,COMPLETED,INTERVENTIONAL,['PHASE4'],
4093,NCT03863054,Percentage change in ulcer size,Pain at wound site,2018-08-17,COMPLETED,OBSERVATIONAL,['NA'],
4094,NCT06003400,Change in wound size between V1 and the last treatment,,2023-03-29,RECRUITING,INTERVENTIONAL,['NA'],
4095,NCT05263232,average 24h blood glucose levels,Culturing human primary myotubes to assess circadian reporter characteristics,2022-03-16,COMPLETED,INTERVENTIONAL,['NA'],mRNA in peripheral blood mononuclear cells (PBMC) of markers involved in the molecular clock
4096,NCT00790517,Cholesterol levels,Health/functional status,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
4097,NCT05407207,Change in fear of falling,Change in depression,2018-06-01,UNKNOWN,INTERVENTIONAL,['NA'],
4098,NCT02117154,Area Under The Curve for Glucose excursion,"Measurement of HbA1c, fructosamine, Glycated albumin levels",2013-06,COMPLETED,OBSERVATIONAL,['NA'],
4099,NCT00548522,The documentation of Cpeptide in women with type 1 diabetes who are pregnant,,2007-08,TERMINATED,OBSERVATIONAL,['NA'],
4100,NCT04582448,"AUCIco,0-inf,SD, Area under the serum insulin icodec concentration-time curve after a single dose","tmax,Ico,SD, Time to maximum observed serum insulin icodec concentration after a single dose",2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
4101,NCT00968786,"blood pressure, blood glucose, body weight and visceral fat levels.",albuminuria,2008-08,UNKNOWN,INTERVENTIONAL,['NA'],
4102,NCT02829177,Improved Albuminuria,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
4103,NCT04190368,Number of Standard Care cohort participants completing appointments,PROMIS - Informational Support,2021-09-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Provider/Facilitator Session Feedback Form:
4104,NCT04150315,Major adverse coronary or cerebral event,,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA'],
4105,NCT05736484,Change in mean daily step count from baseline to the end of the 26 week intervention period.,Participants' acute care utilization throughout the entire study (Baseline to end of study [52 weeks]).,2023-09-19,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
4106,NCT06218147,Percent of glucose time in range assessed by using continuous glucose monitor,Amount of fasting blood glucose,2024-01-31,RECRUITING,INTERVENTIONAL,['NA'],
4107,NCT00464061,Efficacy (sub-study): change from baseline for glycemic measure HbA1c,Safety: adverse events and laboratory abnormalities,2007-04,TERMINATED,INTERVENTIONAL,['PHASE3'],
4108,NCT02819011,Center of Mass (COM) Sway Change Baseline to 6 Months,Stride Length,2016-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
4109,NCT01498913,Body weight,Adverse events,2001-08-30,COMPLETED,OBSERVATIONAL,['NA'],
4110,NCT01421225,Nocturnal Glycemic Control,Pre-lunch Blood Glucose Level,2011-08,COMPLETED,INTERVENTIONAL,['NA'],
4111,NCT01500798,Measured GFR assessed by plasma clearance of Tc99m-DTPA,Circulating endothelial cell assessments,2012-01-31,TERMINATED,INTERVENTIONAL,['PHASE1'],
4112,NCT03882970,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 (Millimole/Liter (mmol/L))] or Severe Hypoglycemia,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
4113,NCT02135952,Changes in number of sites with probing depth (PD) ≥5 mm post-treatment,Occurrence of adverse events,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
4114,NCT05492916,Percentage Change in Body Weight,Change in San Francisco Chinese Food Security Module Score,2023-06-27,RECRUITING,INTERVENTIONAL,['NA'],
4115,NCT04454957,Healthcare expenditures,Patient Health Questionnaire,2020-08-24,RECRUITING,INTERVENTIONAL,['NA'],
4116,NCT03486535,Sensory block duration,Rescue analgesic consumption,2018-02-20,COMPLETED,OBSERVATIONAL,['NA'],
4117,NCT01709123,Blood Glucose Levels,Blood Levels of Cytokines/Inflammatory Biomarkers,2007-08,COMPLETED,INTERVENTIONAL,['NA'],
4118,NCT01654172,Change in Fasting Brain Blood Flow,Change in diabetes control,2006-09,COMPLETED,INTERVENTIONAL,['NA'],
4119,NCT05222373,Change from Baseline HbA1c to 6 months,Change from Baseline Quality of Life to 6 months,2023-12-07,RECRUITING,INTERVENTIONAL,['NA'],Intervention Implementation Adaptability
4120,NCT02293135,Peripheral microcirculation measured using Laser Doppler flowmetry,Reactive Hyperemia Index (RHI),2014-11,UNKNOWN,INTERVENTIONAL,['NA'],
4121,NCT01316107,change from baseline in hemoglobin A1c (HbA1c),"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",2011-01-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
4122,NCT02365129,Change from Baseline in BAT mass and activity evaluated with Positron emission tomography/computed tomography (PET/CT),Change from Baseline in Basal Heart Rate Variability: with a heart rate monitor,2015-02,UNKNOWN,INTERVENTIONAL,['NA'],
4123,NCT01018602,development of type 2 diabetes mellitus by criteria of ADA 1997,,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
4124,NCT01715012,Safety,Scarring of skin graft donor site,2012-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
4125,NCT01919489,Glycemic Control at Hospital Discharge and 6 Months Follow up,Self-measured Blood Glucose (SMBG) 7-point Profiles at 26 Weeks Follow up,2014-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
4126,NCT03067662,Change in fasting plasma glucose levels (mg/dL),Length (cm) of child 3 months after delivery,2012-09-27,UNKNOWN,INTERVENTIONAL,['NA'],
4127,NCT05616273,A description of the strength and reproducibility of the relationship of post-Mixed Meal and Arginine stimulated glucagon with hypoglycaemia.,Home finger prick blood spot C-peptide measurement is a practical alternative to MMTT,2023-03-23,RECRUITING,OBSERVATIONAL,['NA'],
4128,NCT00998699,Change in beta-cell function as measured by change in C-peptide level during thd MMTT (Mixed meal tolerance test) at Day 112 compared to baseline (Day 0 pre-dose),Measurement of serum concentrations of XOMA 052,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
4129,NCT01744132,All Aims: DFE follow-up adherence rate,Aim 3: Rates of ocular disease,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
4130,NCT02949193,HbA1c,HbA1c response rate,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
4131,NCT01917669,Are peak (nM) calcium responses to bradykinin enhanced along the continuum of disease in skin fibroblasts from the 4 patient groups?,Are glucose utilization rates (a.u./min) measured in skin fibroblasts from the 4 patient groups different with disease progression?,2013-10,WITHDRAWN,OBSERVATIONAL,['NA'],"What component of peripheral metabolic dysregulation (HbA1c (%), adiponectin (ug/mL), cholesterol (mg/dL)) is associated with changes in calcium responses (nM) in skin fibroblasts?"
4132,NCT03650088,Change in Weight,Change in Diabetes-related Quality of Life: The Diabetes Obstacles Questionnaire (DOQ-30),2019-10-20,COMPLETED,INTERVENTIONAL,['NA'],
4133,NCT01494935,Insulin Sensitivity,ceramides and diacylglycerol,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
4134,NCT00603031,phase insulin response and phase insulin response measured as incremental area under the curve from 0-10 minutes and incremental area under the curve from 10-45 minutes respectively after iv glucose,maximal insulin response defined as mean insulin at time 47 and 49 minutes (2 and 4 minutes after infusion of L-Arginine),2008-01,COMPLETED,INTERVENTIONAL,['NA'],
4135,NCT05850611,Wound Size,Neutrophils count at baseline and after the intervention,2023-04-30,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
4136,NCT06099509,Completion of 75-gram oral glucose tolerance test,,2023-11-02,RECRUITING,INTERVENTIONAL,['NA'],Patient satisfaction
4137,NCT00704223,number of major and minor hypoglycaemic events and adverse events,FBG,2008-05,COMPLETED,OBSERVATIONAL,['NA'],
4138,NCT00824148,Level of HbA1c concentration,Number of hypoglycemic events,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
4139,NCT02244814,Neonatal adiposity,Placental fatty acid transporter protein-2 expression,2015-07,COMPLETED,INTERVENTIONAL,['NA'],Infant Adiposity
4140,NCT00116922,Development of diabetes based on 1 positive OGTT or 2 fasting glucose levels,"Lipids, CBC, CRP, homocysteine, adiponectin, insulin, proinsulin, and routine biochemistry will be done annually",2004-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
4141,NCT01922791,Prevalence of allergy in child,Physical activity by questionnaires and activity monitor,2013-10,COMPLETED,INTERVENTIONAL,['NA'],"Body composition, growth, development and metabolic markers of the child"
4142,NCT03922750,Percentage of Time in Target Range 3.9-10.0 mmol/L (70-180 Milligrams Per Deciliter (mg/dL)) Measured Using CGM (Continuous Glucose Monitoring),"Number of Hypoglycaemic Alert Episodes(Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by BG Meter)",2019-05-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
4143,NCT05457933,Noninferiority in mean differences between groups in their daily blood glucose concentrations,Diuretics Use,2022-07-29,COMPLETED,INTERVENTIONAL,['PHASE4'],
4144,NCT01829256,Change in kidney function as measured by estimated glomerular filtration rate based on cystatin C(eGFRcys),"Change in blood pressure, glucose/HbA1c and urine albumin",2014-05,COMPLETED,INTERVENTIONAL,['NA'],
4145,NCT05165628,"Incidence of changes from baseline in haematology, biochemistry, and urinalysis parameters.",Duration of clinic/home care visits across groups,2022-01-04,RECRUITING,INTERVENTIONAL,['PHASE1'],
4146,NCT01718522,Number (n) of Excursions <70 mg/dl Per Sensor Day at Baseline and 3 Months,Interstitial Sensor Glucose Excursions After Meals (Amplitude of Excursions) at Baseline and 3 Months,2012-02,COMPLETED,OBSERVATIONAL,['NA'],
4147,NCT03416270,Proximal sodium reabsorption (FENa),Urinary adenosine,2018-06-28,COMPLETED,INTERVENTIONAL,['PHASE2'],
4148,NCT02784236,To analyze the metabolic impact measured through HbA1c of a telemedicine program by MenaDiab® online platform in the care of patients with DM1.,,2014-04,COMPLETED,INTERVENTIONAL,['NA'],
4149,NCT02287285,Beta Cell Sensitivity (BCS),Maximal Beta Cell Function,2014-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
4150,NCT01202266,Pharmacokinetic Endpoints: single dose and steady state pharmacokinetics of PF-05161704 and its metabolite PF-05200145. Urinary recovery will also be assessed for PF-05161704 and PF-05200145,Exploratory Parameters: absolute value and change from Day 0 baseline in concentrations of fasting serum lipids and body weight,2010-08,TERMINATED,INTERVENTIONAL,['PHASE1'],
4151,NCT02969863,Percentage of Time Spent With Dexcom CGMG < 60 mg/dl,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA'],
4152,NCT04088461,Pancreatic beta cell function,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
4153,NCT01429506,weight loss,glycemic control,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
4154,NCT00722631,Effect of treatment on the nominal change in FDG uptake of atherosclerotic plaque from baseline after 4 months of treatment as measured by FDG-PET/CT imaging.,All cardiovascular events and all cause death for 5 years,2007-05,COMPLETED,INTERVENTIONAL,['NA'],
4155,NCT04866264,Subjective effectiveness questionnaire of eNutrition Optimizer,systolic and diastolic blood pressure,2021-11-11,RECRUITING,INTERVENTIONAL,['NA'],
4156,NCT03999268,Change from baseline in psychological insulin resistance at 6 months,Provider Satisfaction,2019-11-25,COMPLETED,INTERVENTIONAL,['NA'],Provider usability
4157,NCT04436900,Angiography with fluorescein,,2018-04-10,COMPLETED,INTERVENTIONAL,['NA'],
4158,NCT00563225,"To evaluate safety & efficacy of Insulin glargine ( injection at bedtime, once a day) on the changes of HbA1c.","To evaluate the efficacy of Insulin glargine (injection at bedtime, once a day) on the changes of FPG.",2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
4159,NCT01868555,Adverse events (AEs),Area under the serum insulin aspart concentration curve,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
4160,NCT05491005,HbA1c,Diabetes complications follow-up,2022-08-31,RECRUITING,INTERVENTIONAL,['NA'],proBNP
4161,NCT01837121,Not-attended rate,Satisfaction with care,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
4162,NCT05762107,Incidence of nocturnal hypoglycemia,Incidence of hypoglycemia,2023-07-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Mean glucose concentration
4163,NCT02952352,Weight,Stages of Change for weight loss,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],
4164,NCT00162305,To assess the safety and tolerability of multiple oral doses of BMS-512148 administered alone or concomitantly with metformin in diabetic subjects,To identify potential biomarkers in both urine and blood,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
4165,NCT00489879,"HbA1c, fasting blood glucose level, Weight change, Blood pressure level in the morning, lipid profiles","exercise time during one week, self reported change in dietary habit, fat consumption ratio",2007-07,COMPLETED,INTERVENTIONAL,['NA'],
4166,NCT00177398,Time to mean 24 hour plasma glucose < 180 mg/dl,Outpatient glycemic control and self management practices,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
4167,NCT05577286,balance,,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
4168,NCT00434616,"Major amputation of the index limb or persisting, unchanged critical limb ischemia",survival without amputation,2007-04,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4169,NCT06287645,Finding inter-rater agreement among the graders,,2022-05-12,RECRUITING,OBSERVATIONAL,['NA'],
4170,NCT04589689,Adolescent quality of life,Hemoglobin A1c (HbA1c),2020-12-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4171,NCT05144802,Assess accuracy of interstitial glucose values measured respectively by FreeStyle® Libre and Dexcom® G6 compared to blood glucose values in standardized hypoxemia conditions in patients with diabetes and in healthy volunteers.,Tolerability of acute hypoxia,2022-05-16,RECRUITING,INTERVENTIONAL,['NA'],
4172,NCT02489968,Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment,,2015-05-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
4173,NCT02068872,Safety of Sleeve Gastrectomy,Weight Loss,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
4174,NCT03440502,the incidence of complete failure of spinal block.,determine the effect of DM on the other spinal block criteria,2018-04-01,UNKNOWN,OBSERVATIONAL,['NA'],
4175,NCT01249677,Improvements in first and second phase insulin secretion,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
4176,NCT00308308,Compare the Mean Change From Baseline to Week 52 in HbA1c,Severe Hypoglycemia Event Rate,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
4177,NCT00182286,,,1999-09,COMPLETED,OBSERVATIONAL,['NA'],
4178,NCT03308773,Time to development of type 2 diabetes,,2009-01-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
4179,NCT02051959,Reduced phantom limb pain,Effects of treatment on the electrical activity of the brain,2015-05,SUSPENDED,INTERVENTIONAL,['NA'],
4180,NCT01242826,Area under the serum insulin aspart concentration-time curve from 0 to 24hours,Number of hypoglycaemic events,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
4181,NCT02597049,Change From Baseline in the HbA1c at 24 Weeks (Efficacy Estimand),Number of Participants With Adjudicated Cardiovascular (CV) Events,2015-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
4182,NCT05624853,Change from baseline to week 8 in Visual Analogue Scale(VAS),Number and proportion of subjects with adverse event,2020-05-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
4183,NCT01043029,Renal function: estimated glomerular filtration rate,Effect on blood hemoglobin,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
4184,NCT02920918,Change From Baseline Ventilatory Efficiency at 12 Weeks,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
4185,NCT05915884,Change in triglyceride index,,2023-06-10,RECRUITING,OBSERVATIONAL,['NA'],
4186,NCT03222180,Glycated hemoglobin (Hemoglobin A1c),Website utilization,2018-02-15,COMPLETED,INTERVENTIONAL,['NA'],
4187,NCT06188572,Ferrans&Powers Quality of Life Index Diabetes Version,,2023-05-01,COMPLETED,OBSERVATIONAL,['NA'],
4188,NCT05751720,Change in Liver fat quantification,Glycaemic control,2023-10-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4189,NCT00423215,Measure of Glycolysated Haemoglobin (HbA1c) level reduction,Patient's satisfaction,2006-03,COMPLETED,OBSERVATIONAL,['NA'],
4190,NCT03965975,Accuracy to compared device,,2019-06-10,UNKNOWN,INTERVENTIONAL,['NA'],
4191,NCT03221127,Death,Infectious disease,1984-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
4192,NCT02695433,Changes in insulin sensitivity as measured by the Matsuda composite index of insulin sensitivity (MISI) in 12-week intervention of active treatment vs control treatment.,Changes in plasma HDL cholesterol in 12-week intervention of active treatment vs control treatment.,2016-03-01,COMPLETED,INTERVENTIONAL,['NA'],Changes in blood MCP-1 in 12-week intervention of active treatment vs control treatment.
4193,NCT01894568,Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c),Percentage of Participants With Total and Nocturnal Hypoglycemic Events (HE),2013-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
4194,NCT02544347,omentin levels,clinical attachment level,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
4195,NCT02924207,change in hemoglobin A1c from baseline,actual cost and change in frequency of drug side effects,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
4196,NCT03018938,Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c),Change From Baseline to Week 48 in Self-Efficacy About Insulin Therapy Questionnaire (SEITQ) Score,2017-02-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
4197,NCT05904743,Change in HbA1c,CGM-measured hypoglycemia events (both a safety and efficacy endpoint),2023-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Patient-reported outcome (PRO) questionnaires
4198,NCT00355537,"The effect of testosterone replacement on arterial stiffness measured by ultrasound derived index B of the femoral artery in men with a combination of DM, PVD and hypogonadism.","The effect of testosterone on markers of vascular risk; blood pressure, serum-lipid levels, weight, waist circumference, body fat percentage, urinary micro-albumin concentration and C reactive protein levels.",2006-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
4199,NCT04992299,Recruitment Feasibility: Percentage of Eligible Adolescents who Enroll,Assessment Feasibility: Percentage Accuracy of Protocols,2022-05-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4200,NCT01902316,measurement of the amount of plasma peptides,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],
4201,NCT01480791,The primary endpoint is baseline-adjusted change in media/lumen ratio in patients who were randomized to aliskiren (group 1) comparatively to those randomized to hydrochlorothiazide (group 2),Flow-mediated dilation in hypertensive diabetic patients randomized to aliskiren vs. hydrochlorothiazide,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
4202,NCT03638778,"AUC0-24h,sema,day10, area under the semaglutide plasma concentration time curve from 0 to 24 hours after the 10th dosing",Number of treatment emergent adverse events,2018-08-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
4203,NCT00858273,Glutathione Concentration,Plasma Protein Bound 3-nitrotyrosine,2008-03,COMPLETED,INTERVENTIONAL,['NA'],
4204,NCT04051229,Blood collection_insulin follow up 2,VO2 peak,2019-10-29,TERMINATED,INTERVENTIONAL,['NA'],
4205,NCT03869281,Fracture incidence,,2019-12-07,COMPLETED,OBSERVATIONAL,['NA'],
4206,NCT04031222,Inflammatory markers,,2017-05-19,COMPLETED,OBSERVATIONAL,['NA'],
4207,NCT05498974,PAID,Metabolomics,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],
4208,NCT01960231,fasting and post glucose load glucose level,fasting and post glucose load c-peptide,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],glucose metabolism measured by CGMS
4209,NCT02228642,Prevalence of Hypoglycemia Associated Autonomic Failure in the inpatient setting as assessed by hypoglycemia symptom scores,Measures of cognitive function following a hypoglycemic event,2014-08,COMPLETED,OBSERVATIONAL,['NA'],Measure of cognitive function
4210,NCT03753568,Adherence to the medication,Variation of daily pill taking times,2019-03-20,UNKNOWN,INTERVENTIONAL,['NA'],
4211,NCT02464462,Serum calcidiol,Glycated Hemoglobin,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
4212,NCT05222477,"Sleep quality (0 is best, 3 is worst)",Abdominal and pelvic floor muscle electrical activity,2021-11-15,COMPLETED,INTERVENTIONAL,['NA'],
4213,NCT00818077,Glycemic Response to the Fixed Meal,,2008-01,COMPLETED,OBSERVATIONAL,['NA'],
4214,NCT05492305,subjective effect of GLP1 receptor agonist on mental health,mean change in eating disorder examination questionnaire (EDE-Q) score with GLP1 receptor agonist over 12-16 weeks,2022-09,RECRUITING,OBSERVATIONAL,['NA'],
4215,NCT03427931,Percentage Time in Range 70-180 mg/dL by CGM,Percentage Time in Range <70 mg/dL by CGM,2018-02-01,COMPLETED,INTERVENTIONAL,['NA'],
4216,NCT05091736,Analysis of system accuracy based on DIN EN ISO 15197,,2021-10-18,COMPLETED,INTERVENTIONAL,['NA'],
4217,NCT00935467,Evidence of steady-state pharmacokinetics (PK) of 2.5 mg saxagliptin administered twice daily with meals to healthy subjects,To assess the safety and tolerability of 2.5 mg saxagliptin administered twice daily with meals to healthy subjects,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
4218,NCT05154045,Glucose positive area under the curve (AUC),Glucose Concentrations,2022-04-09,COMPLETED,INTERVENTIONAL,['NA'],Sensory Questionnaire
4219,NCT04429737,Assessment of the change in Albumin (g/L) relative to baseline,,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],
4220,NCT05684341,Change from baseline in HbA1c at Week 24,Number of participants with adverse events during the 24-week study period,2023-02-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4221,NCT02560090,Change of Self-management Success Measured by Diabetes Self-Management Assessment Survey Tool from Baseline to Study Completion,Change of Diet Measured By a 24-item Introduction to the Lifestyle Survey from Baseline to Study Completion,2015-06-01,COMPLETED,INTERVENTIONAL,['NA'],
4222,NCT05571306,Changes in Diabetes Distress levels,Changes in Blood lipds,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],Changes in Resilience measured using the Conner-Davidson Resilience Scale
4223,NCT04217291,Changes in Glycosylated Hemoglobin A1c (HbA1c),Changes in abdominal weight relative to baseline at 8 and 16 weeks.,2019-12-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
4224,NCT01726621,User Acceptance of the New MiniMed 620G and 640G Insulin Pumps and Guardian Link Transmitter,,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
4225,NCT02194517,HbA1c (glycated hemoglobin),Glucose Area Under the Curve (AUC),2013-04,COMPLETED,INTERVENTIONAL,['NA'],Treatment satisfaction
4226,NCT02208115,Acute subjective appetite responses,,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
4227,NCT01588366,Change From Baseline to Day 28 in Hepatic Glycogen Content,Change From Baseline to Day 29 in Insulin Response to an Arginine Stimulation Test (AST) (Part A),2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
4228,NCT02723539,Proportion of participants who are clinically cured,Proportion of participants who are microbiologically cured,2017-03-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
4229,NCT04263675,Study the mechanisms linked to the effect of breastfeeding on the growth of children in women who have had GDM.,"Associate level of hormones related to satiety and energy metabolism (i.e. endocannabinoids, ghrelin, leptin) in the human milk of women with or without GDM and the growth of the child.",2020-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
4230,NCT05130593,Palatability of Bar,Measurement of Blood Levels of Serum Insulin Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.,2021-10-25,COMPLETED,OBSERVATIONAL,['NA'],
4231,NCT06297980,Glucose standard deviation,Glucose standard deviation,2024-03-15,RECRUITING,INTERVENTIONAL,['NA'],
4232,NCT05523375,Body weight (Percent Change),Perceived Stress Scale-4 Questionnaire,2022-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4233,NCT05214209,Acceptability of mobile app assessed by a semi-structured interview,Change in waist-to-hip ratio,2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4234,NCT02718638,Changes in cytokines plasma levels,,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
4235,NCT01161043,Glucose Sensor Accuracy When Compared to SMBG: Proportion of Glucose Sensor Readings That Met Accuracy Criteria [Time Frame: Days One Through Six of Sensor Use],Device Related Moderate or Device Related Severe Adverse Events,2010-07,COMPLETED,INTERVENTIONAL,['NA'],
4236,NCT03945968,incidence of postoperative complications,mortality after abdominal surgery,2019-07-01,RECRUITING,OBSERVATIONAL,['NA'],
4237,NCT00399997,Patient-reported health related quality of life at 4 and 10 months,Patient-reported compliance with national guidelines for physical activity at 4 and 10 months,2005-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4238,NCT03430284,Control rate of diabetes and diabetic vascular complications,Stage of diabetic retinopathy evaluated by fundus photograph,2018-04-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
4239,NCT00021801,,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
4240,NCT03404895,Number of days to ulcer healing,Total number of subjects with minor and major amputations,2018-04-13,RECRUITING,INTERVENTIONAL,['NA'],
4241,NCT01051245,"Combined outcome assessing adequate control of hypertension, LDL-cholesterol and glycated hemoglobin",Quality of care process measures,2010-03,COMPLETED,INTERVENTIONAL,['NA'],
4242,NCT05330208,Incidence of reaction of the injection sites,Immunogenicity,2022-04-30,UNKNOWN,INTERVENTIONAL,['PHASE1'],
4243,NCT03479788,REM OSA,,2018-06-04,COMPLETED,OBSERVATIONAL,['NA'],
4244,NCT01536639,HbA1c (glycosylated haemoglobin),Adverse events,2006-01,COMPLETED,OBSERVATIONAL,['NA'],
4245,NCT02662842,Comparative Infusion Set Wear Comfort,Overall Infusion Set Preference,2016-01,COMPLETED,OBSERVATIONAL,['NA'],
4246,NCT04660006,Change from baseline of retinal thickness up to 3 months post-cataract surgery.,Development of new cystoid macular edema,2019-05-27,UNKNOWN,OBSERVATIONAL,['NA'],
4247,NCT02480244,Change in BMI,Change in blood pressure,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
4248,NCT02647346,Occurrence of Plantar Diabetic Foot Ulcer,Device-related Injuries,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
4249,NCT02460783,Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) P-pan-Tyrosine-IRS-1 (pY-IRS-1),Mean Change in Total Sedentary Bouts,2015-06-22,COMPLETED,INTERVENTIONAL,['NA'],
4250,NCT00944619,Percentage of plasma glucose values in target (3.9-8.0 mmol/L),Percentage of plasma glucose and CGM values below 3.0 mmol/L,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
4251,NCT05944718,Impact of continuous and intermittent CGM use on blood glucose levels in comparison to standard of care in people living with type 1 diabetes,5. Cost of continuous and intermittent CGM use from a user and provider perspective,2023-09-11,RECRUITING,INTERVENTIONAL,['NA'],
4252,NCT05716308,Criteria for visual acuity changes,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA'],
4253,NCT01620125,HOMA index,Changes in diabetes medication and hypoglycemia events,2012-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
4254,NCT00975533,"composite quantitative score calculate from the results of glycemic control, weight response and degree of hypoglycemia",differences in insulin requirement,2009-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
4255,NCT01260857,Report of Adverse Events occurence (Safety),% of patients reaching BP goal of <140/90 mmHg and <130/80 mmHg for DM and proteinuric patients,2013-03,WITHDRAWN,OBSERVATIONAL,['NA'],
4256,NCT01941719,Patient Interpretation of Neuropathy (PIN) Questionnaire,Foot Complications,2008-05-02,COMPLETED,INTERVENTIONAL,['NA'],
4257,NCT01391585,response rate to home monitoring prompts,response to barrier questions for non-adherence,2011-06,COMPLETED,INTERVENTIONAL,['NA'],
4258,NCT02805543,The correlation between the bilateral retrobulbar RI and bilateral kidney RI in 34 patients,,2016-02,COMPLETED,OBSERVATIONAL,['NA'],
4259,NCT04528212,Sirtuin1 (SIRT1) (ng/ml),Triglyceride (mg/dl),2020-11-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
4260,NCT00891683,To evaluate the potential efficacy of AEG33773 in reducing chronic pain due to DPN,To explore AEG33773-dependent pharmacodynamic (PD) effects in blood of patients,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
4261,NCT04047537,Hemoglobin A1c,Change from baseline in Laboratory Complete Blood count Values,2019-08-06,TERMINATED,INTERVENTIONAL,['NA'],
4262,NCT03751501,Change in Visual Acuity (Letters),Number of AEs/SAEs,2018-11-22,UNKNOWN,INTERVENTIONAL,['NA'],
4263,NCT00654381,Examination of Long-term Safety of Linagliptin (52-week Treatment),Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
4264,NCT00527397,Self-Monitoring Blood Glucose Levels: Change From Baseline,Insulin Antibody Levels : Change From Baseline,2007-08,TERMINATED,INTERVENTIONAL,['PHASE3'],
4265,NCT03060980,Reduction in weight,,2017-03-03,TERMINATED,INTERVENTIONAL,['PHASE3'],
4266,NCT01189890,Number of Participants Discontinuing Study Treatment Due to An AE,LS Mean Change From Baseline in Participant Body Weight at Week 30,2010-08-16,COMPLETED,INTERVENTIONAL,['PHASE3'],
4267,NCT00549133,"Evaluation of the effect of irbesartan on nitric oxide (NO), which has key role in the endothelial dysfunction and the development of pressure vasomotor response, compared to standard therapy (atenolol)","Evaluation of the effect of irbesartan on chronic inflammatory process and tendency for procoagulation, associated with endothelial dysfunction, compared to atenolol.",2003-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
4268,NCT02080377,Number of women willing to be randomised,Clinical Outcome,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
4269,NCT02418091,Change in Blood Pressure,Change in taking medicine as prescribed,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
4270,NCT05038046,Change from Baseline in Nerve Conduction Velocity at 3 months,heart rate variability,2016-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
4271,NCT02950181,Observing Cerebral oximetry readings when patients present to the pediatric emergency department,,2014-07-29,TERMINATED,INTERVENTIONAL,['NA'],
4272,NCT06132126,Part B: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters,Part A and Part B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC),2023-11-17,RECRUITING,INTERVENTIONAL,['PHASE1'],
4273,NCT00469833,Insulin Concentration in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia.,HbA1c Before and After 2 Months of Insulin Treatment to Improve Average Glycemia.,2008-04,COMPLETED,INTERVENTIONAL,['NA'],
4274,NCT03160196,Proportions of participants with normal Hb1Ac,,2018-01,UNKNOWN,INTERVENTIONAL,['NA'],
4275,NCT01512979,Change From Baseline in HbA1c After 24 Weeks,Change From Baseline in FPG by Visit Over Time,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
4276,NCT05919927,Sum score of the Z-scores of the performed standardized neuropsychological tests,,2018-06-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
4277,NCT01698697,Area under the glucose infusion rate curve,GIRmax: The maximal GIR (glucose infusion rate),2002-09-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
4278,NCT02501850,Change in blood levels of Lipoprotein (a) (Lp(a)),,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
4279,NCT00521690,"Incidence of serious adverse events, including major hypoglycaemic events",Incidence of hypoglycaemic episodes,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
4280,NCT01388361,Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin),Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
4281,NCT02214641,Glycated hemoglobin (HbA1C),Summary of Diabetes Self-Care Activities (SDSCA),2014-10,COMPLETED,INTERVENTIONAL,['NA'],
4282,NCT05407961,Part B: Change from Baseline in Total Clamp Disposition Index (cDI),Part A & B: Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT,2022-06-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
4283,NCT05452993,diabetic retinopathy screening rate,consistance between artificial intelligence and ophthalmologist re-read for doubtful images,2022-09,UNKNOWN,INTERVENTIONAL,['NA'],
4284,NCT06072287,Illness-related distress,Cognitive and Behavioural Responses to Symptoms,2023-06-28,RECRUITING,OBSERVATIONAL,['NA'],
4285,NCT01396837,Number of Participants Experiencing Adverse Events,Percent of Reduction in Wound Size Over 12 Weeks (ITT Population),2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
4286,NCT02202161,Number of Participants With Fecal Occult Blood Monitoring for Symptomatic or Visible Gastrointestinal Bleeding or Asymptomatic Occult Bleeding,Sitagliptin Steady State PK Parameters When Co-dosed With Metformin-AUC(0-10),2014-08-27,COMPLETED,INTERVENTIONAL,['PHASE2'],
4287,NCT05109520,"Time in range (TIR, 70-180 mg/dL)","Treatment satisfaction measured by the Diabetes Treatment Satisfaction Questionnaire, status (DTSQs)",2021-09-08,COMPLETED,OBSERVATIONAL,['NA'],Hospitalization
4288,NCT02537704,Change in body weight,Change in liver enzymes [AST and ALT],2015-09,UNKNOWN,INTERVENTIONAL,['NA'],
4289,NCT02961517,Effect of sociodemographic characteristics,Preference for online,2016-12,UNKNOWN,OBSERVATIONAL,['NA'],
4290,NCT01516242,Patient satisfaction with NovoPen® 4 insulin delivery system,Hypoglycaemia,2006-10,COMPLETED,OBSERVATIONAL,['NA'],
4291,NCT05057806,ATPmax production,Patient-Reported Outcomes Measure Information System (PROMIS),2021-01-13,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
4292,NCT02771821,Glycated Hemoglobin,Waist Circumference,2014-08,COMPLETED,INTERVENTIONAL,['NA'],
4293,NCT03814512,Change in Total Sleep Time,,2019-03-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4294,NCT00682097,"AUC0-24h, Cmax",Parameters of glucose metabolism,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
4295,NCT02911311,The primary outcome is mean visual acuity change(BCVA),change of central retinal thickness,2019-10-12,UNKNOWN,INTERVENTIONAL,['NA'],
4296,NCT04361097,Creatinine Clearance,Lactate,2018-08-07,COMPLETED,INTERVENTIONAL,['NA'],
4297,NCT02823600,Usability of the RetinaVue Hand-Held 100 Camera,Pre-and Post-eye Exam Rates in the Diabetic Dialysis Population,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
4298,NCT02274207,Days to patient discharge,Rate of adverse event,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
4299,NCT02475421,Metabolic clearance rate of glucagon,The volume of distribution of glucagon,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
4300,NCT05760768,gestation weight gain（GWG）,diastasis recti abdominis（RDA）,2021-12-01,COMPLETED,INTERVENTIONAL,['NA'],
4301,NCT02934893,Hemoglobin A1C,Patient satisfaction questionnaire,2015-04,UNKNOWN,INTERVENTIONAL,['NA'],
4302,NCT03710928,Hemoglobin A1C change,Highly Processed Food Withdrawal Scale (ProWS),2020-01-03,RECRUITING,INTERVENTIONAL,['NA'],
4303,NCT01270763,High density lipoprotein cholesterol,Physical activity/fitness,2009-07,COMPLETED,OBSERVATIONAL,['NA'],
4304,NCT00485758,Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo,Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Triglycerides in Patients With Type 2 Diabetes When Compared to Placebo,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
4305,NCT01940965,"Safety over 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data",Absolute change in body weight,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
4306,NCT02478853,"Implementation of the new care framework assessed with interviews, chart audit and questionnaires",Fidelity of care to framework measure with chart audit,2015-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
4307,NCT01720446,"Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke",Change From Baseline to Last Assessment in the Trial in Other Treatment Outcomes: Vital Signs (Pulse Rate),2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
4308,NCT03066830,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,Percentage of Participants With HbA1c <7.0% at Week 26,2017-02-24,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Hypoglycemic Events
4309,NCT04965051,HbA1c,Insulin dose,2021-08,UNKNOWN,INTERVENTIONAL,['NA'],
4310,NCT02119689,The ACE/ACE2 ratio within EPC's,The balance of the RAS (renin-angiotensin system) within EPCs,2011-10-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Fluorescein angiogram findings
4311,NCT05071287,Gut Metabolomics,Glycemic Control,2021-06-03,COMPLETED,INTERVENTIONAL,['NA'],Fecal Metabolomics
4312,NCT01819844,"Average Blood Glucose Over the Closed-loop Control Period, as Determined From GlucoScout Measurements.",Accuracy of the CGM Device Using the GlucoScout Measurements as the Standard.,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
4313,NCT01278160,Change in Glycosylated Haemoglobin A1c (HbA1c) From Baseline,Number of Treatment Emergent Hypoglycaemic Episodes,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
4314,NCT01893125,Pain Intensity Numerical Rating Scale,Neuropathic Pain Symptom Inventory,2013-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
4315,NCT04270942,Safety and tolerability of teplizumab treatment,Change in T-cell Subpopulations,2020-03-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
4316,NCT05963022,Change from Baseline in Hemoglobin A1c (HbA1c),Percentage of Participants Who Achieved Weight loss of ≥15%,2023-08-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
4317,NCT04620876,Visualization and image analysis of a structure of interest,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA'],
4318,NCT05671250,Wound area regression rate,rate of partial wound closure of ≥ 50%,2021-07-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse effects
4319,NCT04087941,Change in 24-hour Morphine Milligram Equivalents (MME),Efficacy- Change in Average Pain Intensity,2019-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],
4320,NCT01264809,Change in daily physical activity measured by SenseWear Pro3 Armband®. Participants were instructed to wear the monitor for seven days during all waking hours except bathing.,Benefits obtained after the physical activity counseling,2011-03,UNKNOWN,INTERVENTIONAL,['NA'],
4321,NCT05174507,Number of symptomatic hypoglycemia,Change in RNA sequencing (RNAseq) in peripheral PBMC,2022-06-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
4322,NCT03767790,Time in target glucose range,Unanticipated adverse device effects (UADE),2019-01-03,COMPLETED,INTERVENTIONAL,['NA'],Device Issues
4323,NCT00516074,Change in Mean 24-hour Heart Rate From Baseline to Endpoint,Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
4324,NCT03384758,rHb,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA'],
4325,NCT03078725,Failure rate,incidence of medication side effects,2017-06-20,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
4326,NCT02692716,"Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke",Change in Triglycerides - Ratio to Baseline,2017-01-17,COMPLETED,INTERVENTIONAL,['PHASE3'],
4327,NCT01997281,Area Under the Curve (AUC) of Plasma Total GLP-1 Levels After Intake of the Study Meal,AUC of Plasma Total GLP-1 Levels After Lunch,2013-12,COMPLETED,INTERVENTIONAL,['NA'],
4328,NCT00392028,"blood,tissue and bone drug levels",,2006-11,WITHDRAWN,INTERVENTIONAL,['NA'],
4329,NCT03394352,Continuous Glucose Monitor metrics,,2018-01-17,COMPLETED,INTERVENTIONAL,['NA'],
4330,NCT00496145,"Hemoglobin A1c, Health Distress, Symptoms of Hypoglycemia, Symptoms of Hyperglycemia","Amount of exercise,self-efficacy, communication with physician,fatigue, activity limitation,physician visits",2002-08,COMPLETED,INTERVENTIONAL,['NA'],
4331,NCT04876274,HbA1C,Score of Simplified True / False Version of Diabetes Knowledge Scale,2020-07-14,COMPLETED,INTERVENTIONAL,['NA'],Score of Newest Vital Sign
4332,NCT00269061,Changes in interstitial fluid volume in the lower extremities as measured by MRI.,"Assessments of other indicators of fluid volume changes, including labwork evaluation, fluid compartment volume measurement, direct measurement of the calf.",2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
4333,NCT04217759,Change in diabetes risk score from week 0 to week 13,Facilitation (PA) score,2017-10-01,COMPLETED,INTERVENTIONAL,['NA'],
4334,NCT00960453,"To evaluate the pharmacodynamics (activity of Dipeptidyl peptidase-IV enzyme) after repeated administrations of sitagliptin 25, 50 and 100 mg",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
4335,NCT00445627,evaluate phenotype of T2DM,,2007-06-18,COMPLETED,OBSERVATIONAL,['NA'],
4336,NCT05550480,Time spent with glucose value <3.0 mmol/l (level 2 hypoglycemia),Hypoglycemia awareness,2022-09-08,RECRUITING,INTERVENTIONAL,['NA'],
4337,NCT01462227,Glucose Infusion Rate (mg/kg.Min),Norepinephrine (pg/mL),2011-08,COMPLETED,INTERVENTIONAL,['NA'],
4338,NCT01615081,Acute 3-h changes from baseline in the postprandial concentration of glucose,ad libitum energy intake (EI),2012-05,COMPLETED,INTERVENTIONAL,['NA'],
4339,NCT04380077,postoperative vitreous hemorrhage rate,visual acuity,2020-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4340,NCT00925977,Treatment satisfaction,Hypoglycemic events,2009-07,TERMINATED,INTERVENTIONAL,['NA'],
4341,NCT01207934,Post-treatment Glucose Disposal. I.e. Glucose Disposal After Treatment With Leptin or Placebo.,Post-treatment Plasma Leptin Levels,1998-08,COMPLETED,INTERVENTIONAL,['NA'],
4342,NCT02463487,Number of Participants Who Achieved Complete Healing or Coverage of the Study Wound,Number of Participants With Wound Dehiscence After Hospital Discharge,2015-06-02,COMPLETED,INTERVENTIONAL,['NA'],
4343,NCT03597568,Vascular endothelial function,Oxidative stress,2019-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4344,NCT01703208,Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event in a Sub-Study of Participants Taking Insulin Excluding Data After Background AHA Change,Percentage of Participants Achieving a Target A1C <7.0 % (53 mmol/Mol) at Week 18 in a Sub-Study of Participants Taking Insulin,2012-10-05,TERMINATED,INTERVENTIONAL,['PHASE3'],Number of Participants With an Event Per 100 Person-years of the Event of the First Hospitalization for Heart Failure (Exploratory)
4345,NCT04660305,Area under the glucose infusion-rate curve of insulin aspart,,2020-12-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
4346,NCT00012688,,,na,COMPLETED,INTERVENTIONAL,['NA'],
4347,NCT04280016,Wound measurement size,Waist circumference,2021-05-14,UNKNOWN,INTERVENTIONAL,['NA'],
4348,NCT06080802,HRQOL using Minnesota Living with Heart Failure Questionnaire for quality-of-life evaluation (MLFHQ),Change in body weight,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4349,NCT01340664,Change in HbA1c From Baseline to Week 18,Percentage of Patients With HbA1c <7% at Week 18,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
4350,NCT01726764,Change in Area Under Curve (AUC) 0-24h of metformin,Change in messenger RiboNucleic Acid (mRNA),2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Hypericin/hyperforin
4351,NCT03859401,Number of hypoglycemic occurrences in relation to exercise activity,CGM-based High Blood Glucose Index,2019-04-12,COMPLETED,INTERVENTIONAL,['NA'],Total Amount of Rescue Carbohydrates
4352,NCT03014908,Metabolic phenotype of type 1 diabetes mellitus,,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
4353,NCT03135964,The reduction rate of pressure ulcer size,The reduction rate of diabetic foot ulcer size,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
4354,NCT06246435,Assessment of body mass index ( BMI in kg/m^2)as anthropometric measurements,estimation of lipid profile,2014-02-20,COMPLETED,OBSERVATIONAL,['NA'],
4355,NCT05188625,Attendance rate,Foetal outcome 2,2021-01-13,COMPLETED,INTERVENTIONAL,['NA'],
4356,NCT00501709,lnsulin independence,,2007-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4357,NCT03281512,Diabetes,Overweight,1989-01-01,COMPLETED,OBSERVATIONAL,['NA'],
4358,NCT05444153,Participants acheiving body weight reduction greater than or equal to (>=) 5% (Yes/No),Change in Control of Eating Questionnaire (CoEQ) score - Craving for Savory domaina,2022-10-06,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
4359,NCT00543621,"HbA1c, Fasting blood glucose,blood pressure, weight loss",,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
4360,NCT06057662,Problem Areas in Diabetes (PAID),,2023-08-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
4361,NCT00997711,"The composite of death, nonfatal myocardial infarction (MI), or Target- Vessel Revascularization (TVR) at 12 months post procedure.",Stent thrombosis (ARC criteria),2009-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
4362,NCT00776854,Decrease of Bioburden Effect In diabetic Foot Ulcer,,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],
4363,NCT00853801,Providers improve their ability to diagnose and treat metabolic syndrome/pre-diabetes.,Assess changes in insulin resistance using the HOMA-IR index and in vascular inflammation status using C-Reactive protein in the intervention and control groups.,2006-02,COMPLETED,INTERVENTIONAL,['NA'],
4364,NCT01595594,Clinical Attachment Level,Microbial Load,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
4365,NCT03152084,Change in 24-hour Sodium Excretion From Baseline to Start of Treatment,Number of Patients With AEs and SAEs,2017-07-12,TERMINATED,INTERVENTIONAL,['PHASE4'],
4366,NCT01402232,contrast-induced nephropathy,Follow-up major adverse cardiovascular and clinical events,2013-01,UNKNOWN,OBSERVATIONAL,['NA'],
4367,NCT01517412,Change in HbA1c From Baseline to Week 24,Change in Diabetes Treatment Satisfaction Questionnaire Score (DTSQs) From Baseline to Week 24,2012-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
4368,NCT02294474,Change in HbA1c From Baseline to Week 26,Percentage of Participants With Treatment-Emergent Anti-insulin Antibodies (AIAs),2015-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Change in Daily Insulin Dose From Baseline to Week 26
4369,NCT01370837,Induration Size as a Response to Intracutaneous Candida Albicans.,,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
4370,NCT03400501,Lower beta hydroxybutyrate levels,Measure of beta hydroxybutyrate levels between the 2 groups.,2017-10-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
4371,NCT01228526,Percent of study ulcers healed,,2010-08,COMPLETED,OBSERVATIONAL,['NA'],
4372,NCT03083899,Patient reported outcome,Diabetes Dependent quality of Life,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],
4373,NCT00501488,,,2006-03,COMPLETED,OBSERVATIONAL,['NA'],
4374,NCT01748552,Number of Participants With 1 or More Serious Adverse Event(s) (SAEs),Change From Baseline in C-Peptide Area Under the Effective Concentration Curve From Time 0 to 6 h Postdose [AUEC(0-6)],2012-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
4375,NCT03174821,The change of 8-hydroxy-deoxyguanosine (8-OHdG),The change of superoxide dismutase (SOD),2010-10-20,COMPLETED,INTERVENTIONAL,['NA'],
4376,NCT00306176,Cardiovascular risk factors alterations,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
4377,NCT05840796,interleukin (IL)-6,lipid profile,2014-04-01,COMPLETED,INTERVENTIONAL,['NA'],
4378,NCT03686917,CHAT-P Score,Multicultural Quality of Life Index,2018-10-01,COMPLETED,OBSERVATIONAL,['NA'],
4379,NCT00843388,"albuminuria, expected decrease","plasma renin, angiotensin, aldosteron",2009-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
4380,NCT00264394,Reduction in total cholesterol in the entire SHCS population,"The reduction in total cholesterol, systolic and diastolic blood pressure, and Framingham 10-year CHD risk score in individuals with a greater than or equal to 10% 10 year risk of CHD (according to the Framingham risk profile)",2006-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
4381,NCT06007157,24-hour Blood Pressure,Hydration state,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],
4382,NCT02313428,Wound Closure,Quality of Life for subjects- SF-36,2020-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4383,NCT00041405,,,2001-07,COMPLETED,OBSERVATIONAL,['NA'],
4384,NCT03997331,Change in HbA1c,Median Adherence to Metformin,2020-05,UNKNOWN,INTERVENTIONAL,['NA'],
4385,NCT01930188,Change in HbA1c (Glycosylated Haemoglobin) From Baseline,Subjects Who Achieved HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target (Yes/no),2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
4386,NCT01053078,Cerebral Blood Flow,Hypoglycemia Symptom Score,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4387,NCT01726829,The percentage of nights mean overnight sensor glucose levels was within90-140 mg/dl,Artificial Pancreas Satisfaction Questionnaire,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
4388,NCT00791128,% of Excess Weight Loss (EWL),HbA1c Values at 12 Months,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
4389,NCT00570739,Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) in Pre-Diabetic Subjects From Baseline to 16 Weeks,Percent of Subjects Meeting Type 2 Diabetes Criteria (Fasting Plasma Glucose >or= to 126 mg/dL or Plasma Glucose >or= to 200 mg/dL Post 2 Hr Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
4390,NCT02768220,Change in AGE levels,Change in weight,2017-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
4391,NCT04035993,Accuracy of the HEADWIND-model: Diagnostic accuracy of the hypoglycaemia warning system (HEADWIND) to detect hypoglycaemia (blood glucose <3.9mmol/l and <3.0mmol/l) quantified as the area under the receiver operator characteristics curve (AUC ROC).,Cognitive and emotional trust in the recommendations of the EWS,2019-10-07,COMPLETED,INTERVENTIONAL,['NA'],
4392,NCT05594563,Number of participants with treatment-related adverse events as assessed by CTCAE v5,"Biomarkers of β cell stress at 3, 6, 9, and 12 months after treatment.",2023-03-14,RECRUITING,INTERVENTIONAL,['PHASE2'],
4393,NCT04522882,Glucose level modification,Medication intake,2020-09-09,COMPLETED,INTERVENTIONAL,['NA'],
4394,NCT03144505,"Changes from baseline HbA1c at 3, 6, 9 and 12 months",Changes from baseline quality of Life at 12 months,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
4395,NCT04448262,inflammatory cells,perceived Health state,2019-07-10,TERMINATED,OBSERVATIONAL,['NA'],
4396,NCT04011228,Specifying the microRNAs in saliva in diabetic patients,Correlation of the percentage of the content of fat in the skeletal muscle with miRNA´s in diabetic patients.,2016-02-29,UNKNOWN,OBSERVATIONAL,['NA'],
4397,NCT02293577,Time with blood glucose >300 mg/dL,Physical Activity,2014-11,COMPLETED,OBSERVATIONAL,['NA'],
4398,NCT03379792,Energy Expenditure,,2018-03-08,COMPLETED,OBSERVATIONAL,['NA'],
4399,NCT05111301,CGM Time Above 180 mg/dL,Coefficient of Variation (CV),2021-11-30,COMPLETED,INTERVENTIONAL,['NA'],Unanticipated Adverse Device Effects
4400,NCT04245267,Glycemic control after the program,"Health-related Quality of Life perception assessed by EQ-5D Indexed score (0-1, higher score means better Quality of life perception)",2017-01-07,UNKNOWN,INTERVENTIONAL,['NA'],Blood pressure of the patients who attended the program compared with patients attended in primary care units (wait-list)
4401,NCT04600622,Average Feasibility Score,Change in Family and Friend Involvement in Diabetes score,2021-06-17,COMPLETED,INTERVENTIONAL,['NA'],
4402,NCT03664921,Numeric Pain Scale,Adverse Events,2018-11-15,COMPLETED,INTERVENTIONAL,['PHASE2'],
4403,NCT06206525,Clinical significant hypoglycemia,Clinical significant hyperglycemia,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
4404,NCT00982371,"1 Tesla peripheral MRI assessment at non dominant distal radius: Trabecular bone micro-architecture parameters Tb.Th, Tb.Sp, Tb.N, BV/TV, bone CSA, marrow space","Calcium, vitamin D and vitamin K dietary intakes; TUG (sec); grip strength; DXA assessment of hip, lumbar spine, total body; physical activity",2008-09,COMPLETED,OBSERVATIONAL,['NA'],
4405,NCT00815178,Maximum inspiratory pressure,autonomic modulation assessed by heart rate variability,2006-09,COMPLETED,INTERVENTIONAL,['NA'],
4406,NCT05353790,Changes in Kidney function markers,Changes in Cognitive Function-6,2021-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4407,NCT01307410,Incidence of CVD events,Annual incidence of microvascular complications,2011-03,UNKNOWN,OBSERVATIONAL,['NA'],
4408,NCT05022875,Change in Hypoglycemic Events,Change in Diabetes Knowledge Questionnaire score over time,2021-04-23,UNKNOWN,INTERVENTIONAL,['NA'],
4409,NCT04697758,Safety as Assessed by Incidence of Adverse Events (AEs),,2020-12-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4410,NCT04549415,Number of participants with newly diagnosed diabetes mellitus,Lipid profile markers,2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
4411,NCT00412230,,,2006-10,COMPLETED,OBSERVATIONAL,['NA'],
4412,NCT05068895,Metabolic profiles of lower extremity artery disease,Pathway analysis of differential metabolites,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],
4413,NCT00005665,,,na,UNKNOWN,INTERVENTIONAL,['PHASE2'],
4414,NCT00579436,Adipocyte Size After Fish Oil Treatment,Insulin Resistance After Fish Oil Regiment,2007-01,COMPLETED,INTERVENTIONAL,['NA'],
4415,NCT06231771,Proportion of patients with complete healing/closure of the target ulcer at any time during the 6-weeks period.,The proportion of patients with at least 50% closure of target ulcer during the 6-weeks period,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4416,NCT01269996,To evaluate the treatment efficacy,proportion of patients with HbA1c <6.5% in 1 year,2011-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
4417,NCT00536549,"HbA1c, fasting blood glucose level, weight change, blood pressure in the morning, lipid profiles",three day diary meals and seven day physical activity diary,2007-02,COMPLETED,INTERVENTIONAL,['NA'],
4418,NCT04115592,Postprandial glucose,Postprandial insulin,2019-02-20,COMPLETED,INTERVENTIONAL,['NA'],
4419,NCT01596244,Weight (kg),Body Mass Index (kg/m2),2008-04,COMPLETED,INTERVENTIONAL,['NA'],
4420,NCT01195090,The Percentages of Patient Achieving an A1C <7%,Baseline High-density Lipoprotein Cholesterol (HDL-C),2009-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
4421,NCT00327912,Gastro-intestinal side effects,Eating pattern,2006-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
4422,NCT05295706,Change in HbA1C,Change in the Behavioral Strategies - Engagement and Intentions score,2022-06-01,UNKNOWN,INTERVENTIONAL,['NA'],
4423,NCT02236962,brown adipose tissue activity,,2012-04,UNKNOWN,INTERVENTIONAL,['NA'],
4424,NCT01983917,Change of diabetic retinopathy risk factors,Motivation for adhering to treatment recommendations and follow-up,2012-09,WITHDRAWN,INTERVENTIONAL,['NA'],
4425,NCT00964262,To evaluate the safety and pharmacokinetics of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection,To examine the effect on glucose control and pharmacodynamic parameters of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
4426,NCT04872647,Change of HOMA2-IR,EVS,2020-12-18,UNKNOWN,INTERVENTIONAL,['NA'],
4427,NCT06275971,Time within the target range of 100-180 mg/dL,Mortality within 30 days of surgery,2022-11-24,RECRUITING,INTERVENTIONAL,['NA'],
4428,NCT05822609,Change in kidney cortical relaxation rates (R2*),Change in total daily insulin dose,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
4429,NCT01099956,Increase of Interleukine 6 in group DTI versus control group,"Increase of others cytokines (IL1-beta, l'IL-4, l'IL-10 and TNF alpha) and increase of High sensitivity CRP in group DTI versus control group",2010-04,COMPLETED,OBSERVATIONAL,['NA'],
4430,NCT03763474,Change from 6 months glycosylated hemoglobin at 12 months in the 2 groups,Diabetes Treatment Satisfaction Questionnaire (DTSQ) score in the 2 groups,2017-04-01,COMPLETED,INTERVENTIONAL,['NA'],
4431,NCT05070741,Change in intraepidermal nerve fibers (IENF),Utah Early Neuropathy Scale (UENS),2020-07-27,TERMINATED,INTERVENTIONAL,['NA'],
4432,NCT01778049,Change From Baseline of HbA1c After 24 Weeks of Treatment.,Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
4433,NCT04769115,Predicting diabetic foot complications,,2021-02-24,COMPLETED,INTERVENTIONAL,['NA'],
4434,NCT05042505,Changes from baseline to month 12 in liver and pancreatic fat content.,"Safety assessment at months 3, 6, 9 and 12",2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],
4435,NCT01285934,C-peptide,Stimulated C-peptide levels during mixed meal tolerance test,2009-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4436,NCT03563313,Time in Target Range,BMI,2018-06-28,COMPLETED,INTERVENTIONAL,['NA'],Any Adverse Event Rate Per 100 Person-years
4437,NCT01426685,sudden cardiac death,non-fatal cardiovascular event,2007-08,UNKNOWN,OBSERVATIONAL,['NA'],
4438,NCT05975242,Spanish-language Diabetes Self-Efficacy Scale (DSES-S),Weight,2023-04-04,RECRUITING,INTERVENTIONAL,['NA'],Mobile Device Proficiency Questionnaire (MDPQ)
4439,NCT00942188,Change From Baseline in the Glycosylated Hemoglobin (HbA1c) at 12 Weeks,Pharmacokinetics Measured by Serum Concentration at End of Dosing (12 Weeks),2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
4440,NCT03572699,Sensitivity and specificity of the AI in detecting any grade of diabetic retinopathy,Sensitivity and specificity of the AI in detecting sight threatening diabetic retinopathy (referable retinopathy defined as severe non proliferative retinopathy or greater),2018-07-11,UNKNOWN,OBSERVATIONAL,['NA'],
4441,NCT04474808,Feet Care Feelings,,2020-08-01,COMPLETED,INTERVENTIONAL,['NA'],
4442,NCT01121835,Percentage of patients with Glycosylated Haemoglobin (HbA1c) <7% with no documented symptomatic hypoglycemia (confirmed by a Plasma Glucose (PG) ≤ 56 mg/dL [3.1 mmol/L],Biochemistry and lipid profile,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
4443,NCT00515099,2-Hour C-peptide Area Under the Curve (AUC) Result in Response to Standardized Mixed Meal Tolerance Test (MMTT),Hemoglobin A1c,2007-08,TERMINATED,INTERVENTIONAL,['PHASE2'],
4444,NCT03868813,Users' Expectation from a Health Coaching System,,2019-07-01,COMPLETED,OBSERVATIONAL,['NA'],
4445,NCT01460446,Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 24,The Diabetes Treatment Satisfaction Questionnaire at Baseline (DTSQs) Score and the Diabetes Treatment Satisfaction Questionnaire for Change From Baseline (DTSQc) Score,2011-10,COMPLETED,INTERVENTIONAL,['NA'],
4446,NCT01496430,Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure,Change From Baseline to Week 6 and Week 24 in AUC for Glucagon During OGTT,2012-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
4447,NCT05814406,HbA1C (24 Weeks) lowering effect,HbA1c lowering effect,2023-01-12,RECRUITING,INTERVENTIONAL,['PHASE3'],
4448,NCT01109043,Changes in systolic and diastolic BP,Assessment of quality of life (SQ-8 Short Form Health Survey),2009-06,COMPLETED,OBSERVATIONAL,['NA'],
4449,NCT00907075,"Average percent deviations from the assigned eating system score for full days, meals, and snacks for each group during each evaluation period throughout the intervention (days 23-28 and days 51-56).",Change in dietary macronutrient composition from baseline to end of treatment.,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
4450,NCT02713477,Measurement of plasma glucose concentrations,Measurement of anti-insulin antibodies,2016-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
4451,NCT03837262,Recruitment and retention,WPAI questionnaire,2019-03-25,COMPLETED,INTERVENTIONAL,['NA'],
4452,NCT01929512,"metformin, rosuvastatin AUClast","Metformin, rosuvastatin Vd/F",2013-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
4453,NCT02273180,Change in HbA1c From Baseline to Week 26,Percentage of Participants With Treatment Emergent Anti-insulin Antibodies (AIAs),2014-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Change in Daily Insulin Dose From Baseline to Week 26 and Week 52
4454,NCT02289612,Satiety-producing effect for each pudding and control product,3-Day food records,2014-11,COMPLETED,INTERVENTIONAL,['NA'],Heart rate and blood pressure
4455,NCT01138488,Area under the serum insulin aspart concentration-time curve,Maximum observed insulin aspart concentration of NN5401 (insulin degludec/insulin aspart) observed,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
4456,NCT04692220,Variables associated with the presence of an Adverse Drug Events or Drug-Related Problems,Number and type of Adverse Drug Events and Drug-Related Problems,2011-11-01,COMPLETED,OBSERVATIONAL,['NA'],
4457,NCT05561517,Plasma glucose,,2023-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4458,NCT05236335,Cardiac Output (L/min),Exercise capacity (METs),2022-02-01,COMPLETED,INTERVENTIONAL,['NA'],
4459,NCT01487798,Frequency of hypoglycaemic episodes,Diabetes Treatment Satisfaction Questionaire,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
4460,NCT01527643,"Cmax, maximum insulin aspart concentration",Incidence of hypoglycaemic events,2003-11-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
4461,NCT02548000,Quadriceps Muscle Quality measure by echo intensity,Quadriceps muscle power capacity measure by rate of torque development.,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
4462,NCT03466398,Hemoglobin A1c,DKA Admission Rates,2018-04-11,WITHDRAWN,INTERVENTIONAL,['NA'],
4463,NCT02250677,Differences in physical performance between two groups of statin treated patients,,2014-04,COMPLETED,OBSERVATIONAL,['NA'],
4464,NCT00639457,Insulin-stimulated Glucose Disposal Rate,Myocardial Contractility-DBP,2005-01,COMPLETED,INTERVENTIONAL,['NA'],
4465,NCT06292624,Muscle oxygenation,Functional mobility,2023-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4466,NCT02945449,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaire,2017-01-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
4467,NCT01370616,Percentage of Participants With Favorable Clinical Response Assessments at Discontinuation of Intravenous (IV) Study Therapy (DCIV),Percentage of Participants Who Discontinued Treatment Due to an AE,2011-09-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
4468,NCT06202950,Glycemic control form,,2023-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4469,NCT03651466,"Incidence, nature and severity of Adverse events",Pharmacokinetics(PK) variables,2017-08-31,COMPLETED,INTERVENTIONAL,['PHASE1'],
4470,NCT02234973,mean HbA1C of patients with diabetes (A1C ≥ 8.0% at baseline),,2014-09,COMPLETED,OBSERVATIONAL,['NA'],
4471,NCT00993096,Area (AUC) under the glucose infusion rate curve,Area (AUC) under the insulin aspart concentration time curve,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
4472,NCT00780715,HbA1c Change,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
4473,NCT01486940,HbA1c (glycosylated haemoglobin),Incidence of adverse events,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
4474,NCT02953249,Wound healing change after tooth extraction through epithelialization,Radiographic analysis of bone repair,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],
4475,NCT03274089,Hemoglobin A1c,Health-related quality of life questionnaire,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA'],
4476,NCT02890836,Early preterm delivery (Danish),Chronic hypertension,2016-02,COMPLETED,OBSERVATIONAL,['NA'],Body mass index (BMI)
4477,NCT01871831,Influence of the blood sample's partial pressure on blood glucose measurement results,,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
4478,NCT03956797,Incidence of Anesthesia-Related Adverse Events,Pain of Intravitreal Injection (Follow-Up): VAS,2019-04-15,COMPLETED,INTERVENTIONAL,['NA'],
4479,NCT04544527,all-cause mortality,chronic complications of diabetes,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],
4480,NCT00063674,,,2003-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4481,NCT02065674,,,2014-02,AVAILABLE,EXPANDED_ACCESS,['NA'],
4482,NCT02666521,Frequency of mild hypoglycaemic episodes,Frequency of severe hypoglycaemic episodes,2012-07-20,COMPLETED,OBSERVATIONAL,['NA'],Incidence and severity of hypoglycaemic episodes
4483,NCT00729326,Change in Time-averaged Glucose During a 24 Hour Period,Episodes of Hypoglycemia (Overall),2008-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
4484,NCT02868320,change in HbA1c,Rate of hospital/ER admissions,2014-04,COMPLETED,INTERVENTIONAL,['NA'],
4485,NCT03422965,Perifoveal vessel density,Foveal Avascular Zone,2017-05-08,UNKNOWN,INTERVENTIONAL,['NA'],
4486,NCT05491252,Change in Glycemic Control (HbA1c),Self Care Behaviors,2022-04-21,COMPLETED,INTERVENTIONAL,['NA'],
4487,NCT04952766,Protective humoral response after vaccination,Clinical protection after vaccination,2021-03-26,COMPLETED,INTERVENTIONAL,['PHASE4'],
4488,NCT05407376,Change in HbA1c between baseline and 6 months,Analyze the difference in difference of patient-reported nutritional security between the intervention and control group.,2021-11-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4489,NCT04840368,"Changes in Peak Oxygen Consumption (VO2peak), expressed in mL/Kg/min","Change in Executive function, assessed by the Trail making test",2021-05-03,UNKNOWN,INTERVENTIONAL,['NA'],
4490,NCT00871312,Wound closure,The level of wound pain,2007-05,TERMINATED,INTERVENTIONAL,['NA'],
4491,NCT05953532,Measure of Engagement in Personal Healthcare,Glycemic control,2023-11-01,RECRUITING,INTERVENTIONAL,['NA'],
4492,NCT06083675,Change in glycated haemoglobin (HbA1c),Change in AHA Life's Simple 7 summary score,2024-01-26,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
4493,NCT01591902,Difference in percentages of subjects with a 3-step or greater progression (from both eyes) on the Early Treatment Diabetic Retinopathy Study (ETDRS) PERSON scale.,Change from baseline in HbA1c by intensification of concomitant diabetic treatment,2012-06,TERMINATED,INTERVENTIONAL,['PHASE4'],
4494,NCT04009642,The difference in myocardial FA extraction fraction (%) between T2D patients and non-diabetic controls at rest.,,2018-03-05,COMPLETED,OBSERVATIONAL,['NA'],
4495,NCT01120444,Blood Glucose,Insulin levels,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4496,NCT01176656,prevalence of hypoglycemia and impact of hypoglycemia,"Treatment adherence and modification related to hypoglycemia, including health status, glycemic control and healthcare utilization",2010-09,COMPLETED,OBSERVATIONAL,['NA'],
4497,NCT00670683,Incidence of adverse events,Clinical laboratory abnormality,2007-07,COMPLETED,OBSERVATIONAL,['NA'],
4498,NCT01575301,Change in HbA1c between baseline and 6 months,,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
4499,NCT00993720,insulin-dose,"weight change from baseline, change in fructosamine from baseline",2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4500,NCT01482455,Blood flow,Interstitial insulin concentration,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
4501,NCT00494559,Comparison of pioglitazone and placebo on 8 months follow-up neointima volume by intravascular ultrasound (IVUS).,"Comparison of pioglitazone and placebo on the changes in the levels of inflammatory markers (hsCRP, IL-6, TNF-α, adiponectin).",2007-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
4502,NCT00768651,Weight Change From Baseline After 6 Months of Therapy,Blood Glucose Laboratory Value Before Mixed Meal Tolerance Test (MMTT) After the 3 Month Washout Period,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
4503,NCT00740922,The primary objective of this study is to retrospectively evaluate the safety of sterile becaplermin gel vs. sterile placebo gel treatment 12 months or more after the last dose was administered.,The secondary objective of the trial was to evaluate recurrence of the Target Ulcer if it had healed in the previous trial.,1999-07,COMPLETED,OBSERVATIONAL,['NA'],
4504,NCT01192711,Blood levels of glycosylated hemoglobin,Frequency and times of hypoglycemic events with regard to occurrence during the day (24 hours) and total treatment duration (24 weeks),2009-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],
4505,NCT03730727,Postprandial blood glucose concentrations.,Postprandial blood glucose control.,2017-10-09,COMPLETED,INTERVENTIONAL,['NA'],
4506,NCT00508430,Pain severity rating,Clinical's global impression of change,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2'],
4507,NCT05291975,Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS),Neuropathic Pain Symptom Inventory (NPSI),2022-02-17,RECRUITING,INTERVENTIONAL,['NA'],
4508,NCT01524770,Pharmacokinetics: Maximum Concentration (Cmax) for Dulaglutide,Pharmacokinetics: Time to Maximum Concentration (Tmax) for Dulaglutide,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
4509,NCT05074147,Percentage of treated patients achieving remission from the diabetic foot osteomyelitis at the end of follow-up,Rates of major amputation in each group of patients.,2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
4510,NCT06023810,Wagner's ulcer classification scale,Watson Patient Satisfaction Assessment Form According to Healing Processes,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
4511,NCT02426606,Postprandial blood insulin,,2014-11,COMPLETED,INTERVENTIONAL,['NA'],
4512,NCT00728377,Gestational diabetes diagnosis assessed through glucose tolerance test.,Adoption and maintenance of exercise during pregnancy,2007-07,COMPLETED,INTERVENTIONAL,['NA'],
4513,NCT04676906,The apparent elimination half-life of each of the 3 study compounds and their active metabolite after a single iv dose of each of the 3 study compounds,,2020-11-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
4514,NCT00656682,% Change in Body Weight,% Change in Body Weight,2008-04,COMPLETED,INTERVENTIONAL,['NA'],
4515,NCT05795582,Comparison of the values of upstroke time (TMS) obtained by a new method of measurement by PPG (photoplethysmographic) technique and IPSo,,2023-06-14,RECRUITING,INTERVENTIONAL,['NA'],
4516,NCT00529048,Progress in Incretin effect in patients with T2DM compared with healthy subjects,GIP and GLP-1 responscurvs,2007-10,COMPLETED,OBSERVATIONAL,['NA'],
4517,NCT05937984,Change in PROMIS-29 v2.0 Profile,Change in nerve conduction assessments,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
4518,NCT01323088,"Abdominal obesity, visceral fat","insulin sensitivity by a 3-hour hyperinsulinemic-euglycemic clamp, oral glucose tolerance test, liver fat and intramyocellular lipid by 1H-magnetic resonance spectroscopy.",2010-08,COMPLETED,INTERVENTIONAL,['NA'],
4519,NCT05933616,Correlation between blood glucose and patterns,"Association between the onset of change in glucose, vital signs and VOC spectra",2023-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4520,NCT01478776,postprandial ASP,gene expression of C5L2,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
4521,NCT01960179,"Safety over 24 and 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data.",Absolute change in body weight,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
4522,NCT02449213,Insulin resistance,glycated hemoglobin (HbA1c),2016-03-11,COMPLETED,OBSERVATIONAL,['NA'],
4523,NCT04712409,Change in GIP dynamic profile,Metabolic syndrome remission rates,2020-08-16,RECRUITING,INTERVENTIONAL,['NA'],Late morbidity
4524,NCT00592072,Telephone Search,,2005-07,COMPLETED,INTERVENTIONAL,['NA'],
4525,NCT01186354,Accurate understanding of genetic risk information,Impact on behavior change,2010-07,COMPLETED,INTERVENTIONAL,['NA'],
4526,NCT03556605,"Change in A1c from baseline at 12 weeks in intervention group compared to control group. At this point, control group subjects will cross-over to the same treatment as the intervention group for an additional 12 weeks.",,2018-07-30,UNKNOWN,INTERVENTIONAL,['NA'],
4527,NCT03136822,Recovery of the wound 100%,Recovery of the wound 80%,2017-04-26,COMPLETED,INTERVENTIONAL,['NA'],
4528,NCT00634868,The wound healing process,,2008-08,TERMINATED,INTERVENTIONAL,['NA'],
4529,NCT00530023,Change in A1C From Baseline to Week 15,Hypoglycemia Fear Scale (HFS) Assessed at Baseline and Week 15,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
4530,NCT04887077,Change in daily physical activity from baseline to 3 months,Change in weight bias internalisation from baseline to 9 months,2021-06-10,UNKNOWN,INTERVENTIONAL,['NA'],Perceived exertion during the APA sessions
4531,NCT01951287,plasma glucose levels,Plasma Insulin Levels,2013-08,COMPLETED,INTERVENTIONAL,['NA'],
4532,NCT00797888,HbA1c,diabetes self-care activities,2008-09,COMPLETED,INTERVENTIONAL,['NA'],
4533,NCT04311021,The main study parameter will be the current prevalence of IAH and exposure to SH in the past 12 months.,Answers to questionnaire,2020-01-23,UNKNOWN,OBSERVATIONAL,['NA'],
4534,NCT00311298,Weight gain,Mortality,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
4535,NCT03885362,MARD between Libre and YSI,Missing glucose data,2019-12-11,COMPLETED,INTERVENTIONAL,['NA'],
4536,NCT02639130,total AUC Glucose over 4 hour following the meal,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
4537,NCT00266240,"HbA1c mean change from baseline, compared to placebo.",Pharmacokinetic and exposure-response relationship,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
4538,NCT04815772,The advantages of including the effect of diabetes and smoking on periodontal disease in the 2018 classification compared to the 1999 classification,,2020-11-01,COMPLETED,OBSERVATIONAL,['NA'],
4539,NCT04235621,% of Patients with Change in Treatment,,2019-12-20,TERMINATED,OBSERVATIONAL,['NA'],
4540,NCT01005498,Laboratory findings and body composition,,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4541,NCT01981031,End of action of 0.8 U/kg BioChaperone® Combo (time from administration until blood glucose concentration is consistently above 8.3 mmol/L during the glucose clamp procedure),Number of Adverse Events,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
4542,NCT05411640,Australian type 2 diabetes risk assessment tool (AUSDRISK),Borg rating of perceived exertion (RPE),2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
4543,NCT01257412,change in glycosylated haemoglobin A1c (HbA1c).,mean change from baseline in fasting plasma glucose (FPG),2012-01,SUSPENDED,INTERVENTIONAL,['PHASE3'],
4544,NCT02432547,Number of intravitreal aflibercept injections over 24 months,Mean change in treatment interval over time,2017-06-15,COMPLETED,INTERVENTIONAL,['PHASE4'],Development of new proliferative diabetic retinopathy on wide-field fluorescein angiography
4545,NCT00687284,Change in glycaemic control as measured by HbA1c.,Change in waist and hip perimeter,2008-02,COMPLETED,OBSERVATIONAL,['NA'],
4546,NCT03588000,absolute change in % HbA1c from baseline to 12 months,change in blood glucose from baseline to 24 month,2018-11-23,COMPLETED,INTERVENTIONAL,['NA'],change in health economics indexes from baseline to 24 months
4547,NCT01835964,Change Between Pre and Post Challenge Glucose Variability,,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
4548,NCT03669770,Changes in Glycaemic control between baseline and follow-up,,2017-09-22,COMPLETED,OBSERVATIONAL,['NA'],Health-related quality of life
4549,NCT03597815,Apnea-Hypopnea Index,CPAP compliance,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
4550,NCT04403945,the comparison of the density of total length of the small perfusd vessels(PDV) in the acquisition window between the 3 groups,Correlation comparison: The correlation between SDF vascular parameters and the clinical data of the subjects was compared,2019-06-01,COMPLETED,OBSERVATIONAL,['NA'],
4551,NCT03449433,Pharmacokinetics (PK): Insulin Lispro or Insulin Aspart Area Under the Concentration Curve From Zero to Seven Hours (AUC 0-7h) Following Administration of Each Study Arm,Pharmacodynamics (PD): Change From Baseline Area Under the Concentration Curve of Glucose Relative to a Mixed Meal Tolerance Test (MMTT),2018-03-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
4552,NCT04383990,Hypoglycemia incidence,Acute diabetes complications,2020-02-28,COMPLETED,INTERVENTIONAL,['NA'],
4553,NCT00325364,To assess the change in baseline to endpoint in HbA1c in Type II diabetic patients comparing inhaled human insulin to injectable insulin,To assess the pharmacokinetics on inhaled human insulin in a subgroup of patients,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
4554,NCT03875755,Rate of patients requiring insulin therapy during pregnancy,Conservation of serum and plasma; cord fluid. The samples may be used for further analyses ancillary studies and which could be beneficial for GDM care based on evolution in scientific knowledge. This biolgical collection is optional,2020-03-04,RECRUITING,INTERVENTIONAL,['NA'],
4555,NCT01353469,Change in HbA1c from baseline to the end of treatment,Change in fasting plasma glucose from baseline to the end of treatment,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
4556,NCT01767389,"For treatment utilization patterns: treatment modification (discontinuation of the index ADA, switching of the index and concomitant ADA, and add-on therapy) will be assessed.",,2012-09,COMPLETED,OBSERVATIONAL,['NA'],
4557,NCT02566317,Mean Change in Sitting Time at Work From Baseline to 12 Months,Clustered Metabolic Risk Score From Baseline to 12 Months,2016-01-15,COMPLETED,INTERVENTIONAL,['NA'],Dynamic Glucose Control
4558,NCT00739180,"Abdominal obesity, visceral fat","Insulin sensitivity and secretion, glucose tolerance",2007-11,COMPLETED,INTERVENTIONAL,['NA'],
4559,NCT05266963,Patient-reported change in pancreatic exocrine insufficiency (PEI) symptoms,,2022-09-02,ENROLLING_BY_INVITATION,INTERVENTIONAL,['EARLY_PHASE1'],
4560,NCT01744236,"Changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on pancreatic exocrine function, measured as fecal Elastase-1.",Changes from baseline following infusion of GLP-1RA (acute effects*) and changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following gastrointestinal parameters:,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
4561,NCT02660827,Age 2-13 Years Old Subjects Change in A1C,Age 7-13 Years Old Subjects PLGM Performance - Event Rate Without Hypoglycemia at YSI-FST <=65 mg/dL,2016-04-18,COMPLETED,INTERVENTIONAL,['NA'],
4562,NCT02962921,Left ventricle ejection fraction (%),Time needed to exert insulin effect on myocardial function (hour),2003-02,COMPLETED,INTERVENTIONAL,['PHASE4'],A' (centimeters)
4563,NCT04832984,Change in body weight,Change in anthropometry measures,2022-03-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4564,NCT04153929,Absolute Change in HbA1c From Baseline to 16 Weeks,Percentage of Patients With 10% or Greater Body Weight Loss From Baseline to 16 Weeks,2020-04-30,COMPLETED,INTERVENTIONAL,['PHASE2'],
4565,NCT03826472,Fasting Glucose Measured Using Continuous Glucose Monitoring,Inhibitory Control Task (Percent Correct),2019-03-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
4566,NCT00194259,Effects of OSA on weight,,2001-08,UNKNOWN,OBSERVATIONAL,['NA'],
4567,NCT03870997,Number of Participants With Self-reported Influenza Vaccination in People With Diabetes,,2018-09-12,COMPLETED,INTERVENTIONAL,['NA'],
4568,NCT02847390,Hyperglycemia,,2015-08,COMPLETED,OBSERVATIONAL,['NA'],
4569,NCT02711059,quality of life - self estimation protocol,cognition,2015-10,WITHDRAWN,INTERVENTIONAL,['NA'],
4570,NCT00461630,Major Vascular Event,Mortality,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
4571,NCT01817959,"Area Under the Curve (AUC) for the Serum C-peptide Level During the First 2 Hours of an MMTT (Mixed Meal Tolerance Test), Normalized by the Number of Islet Equivalent (IEQ)/kg",β-cell Function as Assessed by Transplant Estimated Function (TEF) in Efficacy Population 1,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Frequency of Patients Positive/Negative for Autoantibodies Against Class II Human Leucocyte Antigen (HLA) in Efficacy Population 1
4572,NCT03284996,Early detection of diabetic nephropathy in patients with type 2 diabetes mellitus by measuring changes in renal resistive index using Doppler ultrasonography,,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],
4573,NCT02326337,Wound closure within 12 weeks with the use of Topical Wound Oxygen Therapy (TWO2),Economic Analysis,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],
4574,NCT03205150,Change From Baseline in Alanine Aminotransferase (ALT) at Week 12,Change From Baseline in Aspartate Aminotransferase (AST) at Week 12,2017-10-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
4575,NCT06201611,The mean nerve action potential amplitude (sural and tibial nerves) between Arm 1 and Arm 3 at 24 weeks follow-up.,The proportion of patients who progress to develop severe neuropathy,2024-01-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4576,NCT02373592,Foot ulceration,Glycosilated hemoglobin control targets,2015-09,COMPLETED,INTERVENTIONAL,['NA'],"Sub-group analyses, intervention group only"
4577,NCT01238484,Range of Motion,Pain,2010-08,TERMINATED,INTERVENTIONAL,['NA'],
4578,NCT01880476,Changes from baseline in the Summary of Diabetes Self-Care Activities questionnaire,Changes from baseline in number of hypoglycemic events per week (blood glucose <4.0 mmol/L),2013-06,COMPLETED,INTERVENTIONAL,['NA'],Partnership and collaboration questionnaire
4579,NCT05903482,Gastric volume in pediatric patients on GLP-1 RA,,2023-06-06,RECRUITING,OBSERVATIONAL,['NA'],
4580,NCT02890693,Self-reported symptoms of depression (mother) measured by Edinburgh Postnatal Depression Scale,Laboratory (mother): miRNA,2016-09,COMPLETED,INTERVENTIONAL,['NA'],"Self-reported life events (mother, partner) measured by Life Events Questionnaire"
4581,NCT02250066,Incidence of Diabetes in 322 Subjects with Prediabetes,,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
4582,NCT02288585,Change in LDL-C,Change in blood lipids,2014-10,COMPLETED,INTERVENTIONAL,['NA'],Change in Advanced Glycation End products (AGEs)
4583,NCT01170442,Area under the curve of HA1C.,incidence of hypercalciuria,2011-12,TERMINATED,INTERVENTIONAL,['PHASE3'],
4584,NCT02422420,Weight Change,,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
4585,NCT04651816,Subject Retention,Opinions about PSH DPP program,2021-05-25,COMPLETED,INTERVENTIONAL,['NA'],
4586,NCT02227849,Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events),Change in Blood Pressure,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
4587,NCT04633941,Weight,Physical Activity Level,2020-06-01,COMPLETED,OBSERVATIONAL,['NA'],
4588,NCT02836574,Change in Renal Function,Treatment emergent adverse events,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
4589,NCT01302145,"Safety assessed by incidence of adverse events, vital signs, 12-lead ECG and glucose monitoring",Pharmacokinetics assessed by metformin plasma concentration change,2009-02-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
4590,NCT02872922,Percentage of the endothelium-dependent vasodilation (%FMD),Percentage of the endothelium-independent vasodilation (%NMD),2016-12-10,COMPLETED,INTERVENTIONAL,['NA'],
4591,NCT04146155,Initial and absolute claudication distance,Changes from baseline in HbA1c,2020-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
4592,NCT04430582,Assessment of working memory,Assessment of psychomotor speed,2020-08-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
4593,NCT00456963,new hypertension or initiation of any antihypertensive treatment during the treatment period of the trial.,variations of fasting blood glucose.,2007-09,TERMINATED,INTERVENTIONAL,['PHASE4'],
4594,NCT02499107,Food Intake,subjective appetite,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
4595,NCT04952324,carriers of the MTHFR gene mutation have higher serum homocysteine concentrations in the blood,,2020-09-01,COMPLETED,OBSERVATIONAL,['NA'],
4596,NCT04672031,Difference in birth weight,IUFD or stillbirth,2021-07-08,RECRUITING,INTERVENTIONAL,['NA'],
4597,NCT00645840,Effect of Anakinra Treatment on PBMC Gene Expression for Patients,C-peptide Secretory Capacity,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4598,NCT00747149,Percentage of Subjects Achieving Canadian Low Density Lipoprotein Cholesterol (LDL-C) Target Goals (i.e. LDL-C ≤ 2.0 mmol/L) After 12 Weeks of Rosuvastatin Therapy,Incidence of Adverse Events and Abnormal Laboratory Values After 12 Weeks of Therapy,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
4599,NCT05066230,Proportion of eyes improving ≥2 steps on the ETDRS Diabetic Retinopathy Severity Scale (DRSS),Safety and Tolerability of KSI-301 5 mg compared to sham treatment,2021-08-30,TERMINATED,INTERVENTIONAL,['PHASE3'],
4600,NCT02451917,Number of Hypoglycemic Events,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4'],Estimated Glomerular Filtration Rate (eGFR) Calculated by CKD-EPI
4601,NCT02026232,Effect of HCQ on Fasting Blood Glucose,Effect of HCQ on Fasting Low Density Lipoprotein,2012-03,TERMINATED,INTERVENTIONAL,['NA'],
4602,NCT05014789,Serious Adverse Events,CGM Metrics by time of day,2021-08-19,COMPLETED,INTERVENTIONAL,['NA'],
4603,NCT00319189,Insuline release,Plasma endothelin-1,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
4604,NCT06309654,Superoxide dismutases (SOD),,2021-09-13,COMPLETED,INTERVENTIONAL,['NA'],
4605,NCT01754142,"Effectiveness of Kombiglyze XR as assessed by change from baseline in Hemoglobin A1c (HbA1c), Fasting plasma glucose (FPG), and 2-hour post-prandial glucose (2-hr PPG)","Safety information related to overdose, drug-to-drug interaction and laboratory abnormalities based on incidence rates of AEs",2012-11-24,COMPLETED,OBSERVATIONAL,['NA'],
4606,NCT04283162,The rate of the progression of diabetic retinopathy,Changes in metabolic biomarkers such as HbA1c,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
4607,NCT02388100,HbA1c obtained from venous versus capillary measurements at one point in time for each participant.,,2015-03,COMPLETED,OBSERVATIONAL,['NA'],
4608,NCT03092882,Change from Baseline in A1c at 6 months,,2017-03-03,COMPLETED,INTERVENTIONAL,['NA'],
4609,NCT03939442,diabetes remission,,2019-02-10,COMPLETED,OBSERVATIONAL,['NA'],
4610,NCT03636529,serum uric acid,Serum triglycerides,2010-06-01,COMPLETED,INTERVENTIONAL,['NA'],
4611,NCT00622089,The following parameters will be evaluated at Week 12 and Week 24: • Proportion of subjects who reach the lipid goal as defined in the protocol from baseline • Proportion of subjects who meet the HbA1c goal as defined in the protocol from baseline,,2008-01,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4612,NCT03466567,"Cmax,SNAC,SD, maximum observed SNAC plasma concentration on the concentration-time curve after a single dose of oral semaglutide","Cmax,E1247,SD, maximum observed SNAC metabolite E1247 plasma concentration on the concentration-time curve after a single dose of oral semaglutide",2018-03-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
4613,NCT05040971,Change to normoglycemia (Normoglycemia is defined as having both HbA1c below 6.0% (below 42 mmol/mol) and FPG below 5.5 mmol/L (below 99 mg/dL),Change in lipids - Very low density lipoprotein (VLDL) cholesterol,2021-09-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
4614,NCT01890629,Mean Amplitude Glycemic Excursion,Glucose Standard Deviation in CGMS data,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
4615,NCT00904202,"Average daily pain intensity (BPI Questions 3,4,5, and 6)","Safety assessments include adverse events; dermal assessments/sensory testing, clinical laboratory tests, vital sign measurements and physical/neurological examination",2003-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
4616,NCT04304963,LIG optimum detection of hypoglycemia,Secondary outcome 10,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],
4617,NCT02007278,Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE),"Number of Patients With Any Adverse Events, Serious Adverse Events and Death",2014-01-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
4618,NCT05925920,Safety and Tolerability of ENT-03,effect on insulin and insulin sensitivity,2023-06-13,RECRUITING,INTERVENTIONAL,['PHASE1'],
4619,NCT05577169,Acceptability of intervention in the study population.,"Hemoglobin A1c (HbA1c, %)",2022-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Child and Adolescent Social Support Scale (CASSS) questionnaire
4620,NCT02553213,Change of blood glucose,,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],Changes of body composition
4621,NCT05751525,IQ score,"Hyperactivity, emotional problems, conduct problems, peer relationships, prosocial behaviour.",2016-07-01,RECRUITING,OBSERVATIONAL,['NA'],
4622,NCT02843139,It is expected that the identification of circulating miRNAs as potential biomarkers may facilitate to the diagnosis of obese preschoolers at high risk for developing diabetes.,,2014-04,COMPLETED,OBSERVATIONAL,['NA'],
4623,NCT00348374,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at End of Treatment,Change From Baseline in Standard Deviation of 24-hour Glucose Values Measured by Continuous Glucose Monitoring System (CGMS),2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
4624,NCT05794789,Change from baseline in children's moderate to vigorous physical activity to 6 months,Social Identity,2023-08-10,RECRUITING,INTERVENTIONAL,['NA'],
4625,NCT04088552,Change in abdominal circumference,Change in knowledge regarding hypertension,2020-03-07,COMPLETED,INTERVENTIONAL,['NA'],
4626,NCT04139369,"Overall mean methylation percentage (%) of CpGs cytosine-guanosine islands within the promoter regions of INS, PTPN-22,HLA-G genes between T1DM and healthy children and adolescents",,2012-05,COMPLETED,OBSERVATIONAL,['NA'],
4627,NCT02065752,Plasma concentration of metformin following the single dose of drug administration,Percentage of participants with adverse events as a measure of safety and tolerability,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
4628,NCT00260234,"Safety - will be evaluated by the incidence, grade, and type of adverse events, changes in laboratory parameters, evaluation of the implant site and physical exams.",Functional duration - will be determined by stimulated C-peptide from OGTT.,2005-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4629,NCT04167410,Rates of hypoglycaemia development,,2017-09-15,COMPLETED,INTERVENTIONAL,['NA'],
4630,NCT01305434,change in 2 hour post prandial blood glucose,"number of subjects with adverse changes in creatinine, AST, ALT, and blood pressure due to intervention",2011-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4631,NCT03453970,"Change from baseline diastolic blood pressure (DBP) at 6 months, change from baseline diastolic blood pressure at 12 months and change from baseline diastolic blood pressure at 18 months.","Change from the baseline level of adherence to the diet at 6 months, change from the baseline level of adherence to the diet at 12 months and change from the baseline level of adherence to the diet at 18 months.",2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],Participation in the program
4632,NCT05552859,Difference in the mean change from baseline to Week 24 in HbA1c level (Gla-300 vs IDeg-100),"Number of participants with adverse events (AEs)) and serious adverse events (SAEs), including adverse events of special interest (AESIs)",2022-12-05,TERMINATED,INTERVENTIONAL,['PHASE4'],
4633,NCT05752591,Genetic predisposition,,2018-05-25,COMPLETED,OBSERVATIONAL,['NA'],
4634,NCT01387737,"Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events",Change in Blood Pressure,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
4635,NCT01729403,Change in whole-body insulin sensitivity as assessed by M-value (Insulin-stimulated glucose disposal rate),Safety: Incidence of adverse events,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
4636,NCT02897219,Change from baseline in HbA1c,Safety assessed by laboratory tests: Urinalysis,2016-08-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
4637,NCT00996437,"Safety (Injected-related, Ocular Drug-related and Systemic Drug-related)",Very Severe Visual Acuity Loss (Defined as <20/800),2010-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4638,NCT04759469,Exercise enjoyment and acceptability,Adherence rates,2018-12-01,COMPLETED,INTERVENTIONAL,['NA'],
4639,NCT06141967,patients real positive for each screening technique,Nurse's satisfaction with the use of Withings Sleep Analyzer,2023-11-30,RECRUITING,INTERVENTIONAL,['NA'],
4640,NCT05370781,Change in Regimen Adherence,Change in Adherence to gender norms,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],
4641,NCT04446767,Wound assessment,,2020-06-30,COMPLETED,INTERVENTIONAL,['NA'],
4642,NCT05629403,HOMA-IR,,2021-09-01,COMPLETED,OBSERVATIONAL,['NA'],
4643,NCT01958671,Percentage of Participants Discontinuing Study Treatment Due to an AE,Change From Baseline in DBP at Week 26,2013-10-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
4644,NCT02386982,24-hour glucose change,"Composite measure of adverse events monitoring, physical examinations,12 lead ECGs, vital sign,and safety laboratory measurement",2015-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
4645,NCT02478762,Foetal glycated hemoglobin,Treatment satisfaction,2015-03,TERMINATED,INTERVENTIONAL,['PHASE3'],
4646,NCT01983007,Arterial dilation,,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
4647,NCT02517866,Percentage of Participants With Blood Pressure (BP) <140/85 mmHg (Systolic BP <140 mmHg and Diastolic BP <85 mmHg) by Clinic-Measured Sitting BP at Week 12,"Change From Baseline in DBP at Week 12 in ""Treatment-Naïve"" Participants",2015-07-13,COMPLETED,INTERVENTIONAL,['PHASE4'],
4648,NCT00004360,,,1995-09,COMPLETED,OBSERVATIONAL,['NA'],
4649,NCT02386540,Number of emergency department visits,"Qualitative analysis of action plans (Health coach documentation notes will be analyzed, data will be coded to identify themes such as type of goals, barriers to care, and resources identified in the action plan)",2015-02-06,COMPLETED,INTERVENTIONAL,['NA'],
4650,NCT00211471,tyo investigate the use of anecortave acetate in rubeosis iridis,mean change in VA(ETDRS) from baseline to 24 months,2002-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
4651,NCT00039026,Change in HbA1c from Baseline to Week 30,Change in body weight from Baseline to each intermediate visit and Week 30,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
4652,NCT02203240,Change in insulin sensitivity,Change in gut permeability,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
4653,NCT01517555,Area under the curve of post prandial plasma glucose,Adverse events,2006-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
4654,NCT05446415,Changes mRNA expression levels of active L cells,,2020-02-05,RECRUITING,INTERVENTIONAL,['NA'],
4655,NCT02138006,Cardiovascular Mortality,Morbidity of Cardiovascular Complications,1982-09,COMPLETED,INTERVENTIONAL,['NA'],
4656,NCT03705260,Hemoglobin A1C,Change in rate of symptomatic hypoglycemia requiring medical intervention,2018-11-26,COMPLETED,INTERVENTIONAL,['NA'],
4657,NCT03656341,Manchester Foot Pain and Disability INdex,Foot Health Score,2018-09-27,COMPLETED,INTERVENTIONAL,['NA'],
4658,NCT04063046,early prognosis (Delirium),intraoperative vasopressor use,2019-11-12,UNKNOWN,INTERVENTIONAL,['NA'],
4659,NCT00138567,Change from baseline in HbA1c at 104 weeks,Change in HOMA B between 52 weeks and 104 weeks,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
4660,NCT04233580,Number of Participants Who Healed,Tissue Oxygenation (StO2) of the Dorsal Foot,2020-07-09,COMPLETED,INTERVENTIONAL,['NA'],
4661,NCT01953393,Beta-cell function,,2006-04,COMPLETED,INTERVENTIONAL,['NA'],
4662,NCT00998686,"To demonstrate safety and tolerability of dutogliptin as assessed by vital signs, adverse event reporting, routine clinical laboratory assessments, and ECG",To demonstrate maintenance or lowering of HbA1c and fasting plasma glucose,2009-11,TERMINATED,INTERVENTIONAL,['PHASE3'],
4663,NCT01208558,Change of waist circumference,Change of quantity and dosage of blood sugar-lowering drugs,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4664,NCT04091373,Area under the plasma concentration time curve,"Incidence of treatment-emergent adverse events, including those related to changes in vital signs (including body temperature, heart rate, blood pressure) and safety laboratory evaluations (including hematology, chemistry, plasma glucose, urinalysis).",2019-09-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
4665,NCT05761886,Proportion of items self-reported by pharmacist - Fidelity,Change in barriers to medication adherence,2023-05-16,RECRUITING,INTERVENTIONAL,['NA'],
4666,NCT05310526,food intake of 400g of vegetables per day,Professionals' perception regarding the incorporation of MAC guidelines into practice (implementation component),2022-11-01,COMPLETED,INTERVENTIONAL,['NA'],
4667,NCT02681185,HbA1c,Survey of Quality of Life,2018-03-01,TERMINATED,INTERVENTIONAL,['NA'],
4668,NCT02821104,C4 Copy Number,Insulin Sensitivity,2016-06,COMPLETED,OBSERVATIONAL,['NA'],
4669,NCT05004948,Change in Glycated hemoglobin% (HbA1c%),The maximum oxygen uptake (VO2max),2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],
4670,NCT04910997,Peak aerobic capacity (fitness),Depression questionnaire,2021-06-01,WITHDRAWN,INTERVENTIONAL,['NA'],
4671,NCT02413060,HbA1c,,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],
4672,NCT03752840,Pinhole visual acuity (logMAR) in people aged 60 years and older,Cost-effectiveness of the screening intervention,2019-04-21,RECRUITING,INTERVENTIONAL,['NA'],"Bilateral presenting blindness in people aged 60 years and older, defined as presenting visual acuity worse than Snellen 20/400 (Metric Snellen worse than 6/120; logMAR worse than 1.3) in the better-seeing eye"
4673,NCT00404963,"Safety will be monitored by assessing adverse reactions,changes in laboratory values (hematology, clinical chemistry, urinalysis),changes in vital signs (oral body temperature,60 second respiratory rate, blood pressure and heart rate), and ECG changes.","Blood levels of GSK376501 Effects of GSK376501 on the body, by measuring changes in insulin, glucose, and other markers",2006-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
4674,NCT03792399,Change of score for self efficacy,Change in exercise amount (time spent in sedentary behavior),2016-03-07,COMPLETED,INTERVENTIONAL,['NA'],
4675,NCT05863793,Peroneal Motor Nerve Conduction Velocity,Sural Sensory Nerve Conduction Velocity,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],
4676,NCT06037252,Percent Change From Baseline in Body Weight,Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC),2023-09-21,RECRUITING,INTERVENTIONAL,['PHASE2'],
4677,NCT03242343,Occurrence of safety events,,2017-11-29,COMPLETED,INTERVENTIONAL,['NA'],
4678,NCT02681094,Change From Baseline in HbA1c at Week 24,Change in Total Body Weight at 24 Weeks,2016-02-26,COMPLETED,INTERVENTIONAL,['PHASE3'],
4679,NCT03983551,Change in urinary albumin-to-creatinine ratio,Change in systolic blood pressure,2016-03-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
4680,NCT02697201,Effects of lipid infusion on mitochondrial fission,Insulin sensitivity,2016-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
4681,NCT00737126,Change in albumin excretion rate,"Change in serum homocysteine, thrombomodulin and von Willebrand factor.",2004-01,COMPLETED,INTERVENTIONAL,['NA'],
4682,NCT01076023,"Incidence of cardiovascular events, including fatal and non-fatal acute coronary syndromes (acute myocardial infarction [AMI] or unstable angina), fatal or non-fatal stroke, and other cardiovascular death.",Outcomes of current anti-diabetic treatment,2010-02,UNKNOWN,OBSERVATIONAL,['NA'],
4683,NCT05806723,change in testosterone level after atorvastatin treatment,change in DHEAS levels after atorvastatin treatment,2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE4'],change in vitamin D level after atorvastatin treatment
4684,NCT04071626,"Peak VO2, ml/kg/Min, as Measured by Metabolic Gas Exchange",Serum Ketone Bodies (Betahydroxybutyrate),2020-03-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
4685,NCT01770561,Performance longevity,Physical duration,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
4686,NCT04640064,Hb A1C pre and post Confinement in Latin American children with Type 1 Diabetes,,2020-11-22,UNKNOWN,OBSERVATIONAL,['NA'],
4687,NCT00106366,HbA1c,Glucose profiles,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
4688,NCT04975230,Continuous Glucose Monitor (CGM) data downloaded directly from each participant's existing or provided blinded Dexcom G6 [trademark],Diabetes Symptom Checklist Revised (34-item),2022-04-29,COMPLETED,INTERVENTIONAL,['NA'],
4689,NCT00204282,Nurse practitioner run group visits will improve compliance with established American Diabetes Association guidelines for screening and preventive care,Compliance with established American Diabetes Association guidelines for screening and preventive care will lower cardiovascular risk,2003-08,COMPLETED,INTERVENTIONAL,['NA'],
4690,NCT01833988,Percentage of Time With a Low Plasma Glucose Reading (Less Than 70mg/dl) in the Bionic Pancreas Arm as Compared to Insulin Pump Arm,Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Number of Carbohydrate Interventions for Hypoglycemia at Night,2013-04,COMPLETED,INTERVENTIONAL,['NA'],Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Mean Insulin Total Daily Dose
4691,NCT03734445,Change in Homeostatic Model Assesment for Insulin Resistance (HOMA-IR) from baseline to 12 and 24 weeks,Changes in Intestinal microbiota patterns from baseline to 12 and 24 weeks,2020-01-09,UNKNOWN,INTERVENTIONAL,['NA'],Changes in plasma zinc from baseline to 12 and 24 weeks
4692,NCT02750098,Aqueous humor glucose concentration,Hemoglobin A1c,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],
4693,NCT01191268,Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c),"Number of Participants With Treatment Emergent Adverse Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose",2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
4694,NCT03329651,Difference in postprandial glycemic control as assessed by mean blood glucose concentration during a 4 hour mixed-meal tolerance test,Difference in peripheral glucose uptake as assessed by rate of glucose disappearance from blood,2017-11-10,COMPLETED,INTERVENTIONAL,['NA'],
4695,NCT02974699,Plasma Amino Acid Levels,Change in Plasma Amino Acid Levels,2017-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
4696,NCT00770575,Change in the intima-media thickness of the common carotid artery.,Change from Baseline in Pulse wave velocity.,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
4697,NCT01263496,Number of Participants With Adverse Events.,Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit).,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
4698,NCT02691312,Number of participants diagnosed with retinopathy,,2016-07,COMPLETED,OBSERVATIONAL,['NA'],
4699,NCT02643797,Systolic blood pressure (SBP); mmHg units,Morisky Medication Adherence Scale (MMAS) - patient-reported outcome,2016-03-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Cost-effectiveness using the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model
4700,NCT04449120,Change in fasting insulin level,Change in culinary habits measured by Culinary Habits Frequency Questionnaire (CHFC),2020-06-01,COMPLETED,INTERVENTIONAL,['NA'],
4701,NCT05401708,Correlation between blood and urinary tests and complications in patients with type 1 and 2 diabetes mellitus and prediabetes (cross-sectional),,2022-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
4702,NCT01044602,"Resolution of obesity co-morbidities including hypertension, OSA, and hyperlipidemia",Identify predictors of success with regard to improved co-morbidities and velocity of weight loss,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
4703,NCT04614623,Hemoglobin A1c (HbA1c) Change From Baseline to 6 months (End of study),Mean blood glucose (MBG) Change From Baseline to 6 months (End of study),2020-11-01,UNKNOWN,INTERVENTIONAL,['NA'],PedsQL-Diabetes Module Change from Baseline to 6 months (study end)
4704,NCT00487981,Pain Rating at 6 Months Post Activation Compared to Baseline,,2007-02,TERMINATED,INTERVENTIONAL,['PHASE4'],
4705,NCT02703350,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) (Part B),Pharmacodynamics (PD): Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT) (Part B),2016-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
4706,NCT00325624,A1c,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
4707,NCT03560375,Change in body weight,Change in frailty syndrome,2018-05-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
4708,NCT03578991,Change of score obtained in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).,The Resource Utilization in Dementia (RUD).,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],
4709,NCT01253278,Number of Participants with Clinically Significant Effects,Change from baseline to day 14 in C-peptide,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
4710,NCT04384471,Self-reported acute diabetes complication,"Impact on stress, anxiety and depression for children and adolescents",2020-04-29,COMPLETED,OBSERVATIONAL,['NA'],
4711,NCT04296825,"Changes in lipid profiles (total cholesterol, total triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol in millimole per liter)","Changes in gut hormones (amylin, ghrelin, GLP-1, PP and PYY in petagram per milliliter)",2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
4712,NCT00340639,,,2003-01-28,COMPLETED,OBSERVATIONAL,['NA'],
4713,NCT04410718,Plasma glucose levels and left ventricular ejection fraction,Diabetes status and change high-sensitivity troponins,2020-04-20,COMPLETED,OBSERVATIONAL,['NA'],
4714,NCT05647226,HbA1C <6.5% (48mmol/mol),HbA1C <6.5% (48mmol/mol),2022-01-09,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
4715,NCT01823406,Difference in the levels of TCA cycle metabolites between groups during euglycemia and hyperglycemia,,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
4716,NCT01781754,Levels of gene expression for UCP2 (RQ),Improved metabolic state,2013-01,UNKNOWN,OBSERVATIONAL,['NA'],
4717,NCT05364190,The cumulative mean of daily diuresis,The progression of heart failure severity,2022-06-04,RECRUITING,INTERVENTIONAL,['PHASE3'],
4718,NCT00689026,The Percentage of Patients That Received a Quality of Colonoscopy Preparation Rating of <=2 on a 5 Point Likert Scale.,,2008-05,TERMINATED,INTERVENTIONAL,['NA'],
4719,NCT05770154,Peak torque,Dynamic balance,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
4720,NCT00797823,Effectiveness of Closed Loop Diabetes Control,Percent of Time Venous Blood Glucose <70 mg/dl,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
4721,NCT05621551,Hs-Troponin-I,Hs-Troponin-I,2022-11-11,RECRUITING,INTERVENTIONAL,['PHASE4'],Length of in-hospital time
4722,NCT02273050,Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue,Patients Rescued for Failing to Achieve Pre-specified Glycemic Targets or Discontinuation for Lack of Efficacy During the 24-week Double-blind Treatment Phase,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
4723,NCT05210530,Incidence of adverse events with causality related to VCTX210A units and/or the surgical procedures required to implant and explant the VCTX210A units.,The percentage of graft cells per unit that have differentiated into endocrine/beta cells as determined by immunohistochemical staining.,2022-01-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
4724,NCT04833660,Quality of life after intervention to be assessed with Short Form 36-Item Health Survey,,2021-04-30,UNKNOWN,INTERVENTIONAL,['NA'],
4725,NCT03146208,Role of endothelial bio markers in patients with coronary artery disease,,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA'],
4726,NCT00994266,Difference of glucose concentrations (fasting and post-prandial) at week 24 and at the beginning of the study considering the adjusted insulin doses during treatment,Difference of triglycerides and cholesterol concentrations at week 24 and at the beginning of the study,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
4727,NCT02361606,Youth satisfaction of the program. (Questionnaire regarding the degree that the session was helpful.),"Change in glycemic control. (HbaA1c levels, obtained from medical records)",2009-03,COMPLETED,INTERVENTIONAL,['NA'],Youth expectations of the program. (Questionnaire regarding the expectations of the possible benefits of the program.)
4728,NCT03049228,Cellular respiration ex vivo,Basal energy metabolism,2017-03-21,COMPLETED,OBSERVATIONAL,['NA'],
4729,NCT03712501,Triacylglycerol,Superoxide dismutase 3,2017-10-01,COMPLETED,INTERVENTIONAL,['NA'],
4730,NCT03246997,Overall satisfaction score,Self Efficacy for Eating/Cooking Fruit and Vegetables by Condrasky,2017-06-21,COMPLETED,INTERVENTIONAL,['NA'],
4731,NCT02773381,Area under the serum glucose concentration-time curve,Area under the paracetamol plasma concentration-time curve,2016-06-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
4732,NCT01919788,"Insulin and growth hormone signalling, expressed as CHANGE in phosphorylation of intracellular target proteins and mRNA expression of target genes in muscle- and fat-tissue.",Metabolism,2013-08,COMPLETED,INTERVENTIONAL,['NA'],
4733,NCT01898026,Postprandial Glycemia,Satiety Score,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],Safety
4734,NCT01238276,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],
4735,NCT05418179,Inflammatory parameters,Total Body lean mass Percentage (%),2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],
4736,NCT04135248,Rate of self-reported hypoglycaemia,Number of days needed to break the fast,2019-04-18,UNKNOWN,OBSERVATIONAL,['NA'],
4737,NCT01221545,"Primary Objective to assess the safety and tolerability of AZD1656, following oral administration of single ascending supratherapeutic doses of AZD1656 to patients with type 2 diabetes mellitus in a fasted state.",Secondary objective to evaluate glucose levels and insulin secretion in type 2 diabetes mellitus patients following oral administration of single ascending supratherapeutic doses of AZD1656,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
4738,NCT03927859,Number of bookings made through the TOP program,Number of self-reported booking made outside of TOP,2018-07-05,UNKNOWN,INTERVENTIONAL,['NA'],
4739,NCT02700048,Within Person Difference in Peak Epinephrine During Hypoglycemia,Naloxone Pharmacokinetics,2016-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4740,NCT01556880,incidence rate of DM,incidence of DM,2009-05,COMPLETED,INTERVENTIONAL,['NA'],
4741,NCT00081328,Treatment Failure (Loss of Glycemic Control),Comorbidity -- Triglycerides Dyslipidemia,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
4742,NCT00770302,Pharmacokinetic variables for saxagliptin after single and multiple oral doses of 5 mg saxagliptin,"Safety variables (adverse events reported, vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests after single and multiple oral doses of 5 mg saxagliptin",2008-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
4743,NCT03461510,fMRI performance in relation to dysglycemia,,2017-12-05,COMPLETED,INTERVENTIONAL,['NA'],
4744,NCT02631265,Percentage of time of capillary blood glucose levels spent below 4 mmol/L,Relative difference between capillary blood glucose levels and sensor glucose levels,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
4745,NCT00999635,Reduction in peak pressure,Comparison of cost,2006-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4746,NCT05228522,Glucose Tolerance,Dietary behaviors,2021-12-12,RECRUITING,INTERVENTIONAL,['NA'],
4747,NCT03773185,Amyloid load,,2018-12-15,WITHDRAWN,OBSERVATIONAL,['NA'],
4748,NCT03793101,Visual acuity,Corneal Incision thickness,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
4749,NCT05133765,"Comparison of TIR in blood glucose values during, and 1-hour after, dynamic physical exercise",To compare the influence of carbohydrate feeding before versus during exercise on the physiological responses to dynamic physical exercise,2021-09-14,COMPLETED,INTERVENTIONAL,['NA'],Comparison of the maximum iG concentration
4750,NCT05852132,Incidence of proliferative diabetic retinopathy (PDR),,2024-05-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
4751,NCT05404711,Feasibility of CGM use to determine Type 2 Diabetes Risk,Acceptability of CGM use for at-home T2D risk evaluation in youth,2022-10-11,COMPLETED,INTERVENTIONAL,['NA'],
4752,NCT02537470,Glycosylated haemoglobin A1c (HbA1c) at Week 12,"Safety endpoints include AEs, incidence of urinary tract infections, incidence of genital fungal infections, vital signs, ECGs and standard laboratory tests",2015-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
4753,NCT00000154,,,1976-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
4754,NCT03362983,Quality-of-care outcome measures (n=131),Interdisciplinary learning (n=20),2016-01-01,COMPLETED,INTERVENTIONAL,['NA'],
4755,NCT00106808,Change in HBA1c from baseline to Week 24,To assess safety and tolerability of both Muraglitazar regimens relative to pioglitazone regimen when administered for up to 24 weeks,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
4756,NCT02161250,resistant starch effects,,2014-04,COMPLETED,INTERVENTIONAL,['NA'],
4757,NCT06129448,Effect of Tumor necrosis factor- α (TNF-α) on cardiac functions,,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
4758,NCT03944616,HbA1c,Dietary Practices,2019-06-06,COMPLETED,INTERVENTIONAL,['NA'],
4759,NCT01002053,Interval worsening of the severity of neuropathy,New functional neuropathy defined as any new sensory or motor deficit compared to preoperatively.,2012-02,COMPLETED,OBSERVATIONAL,['NA'],
4760,NCT04081883,Comparison between biosensor to CGMS responses,,2023-01-27,COMPLETED,INTERVENTIONAL,['NA'],
4761,NCT03117998,Change in Average Daily Total Insulin Use,Continuous Glucose Monitoring (CGM) - Change in Percent Time Spent in Hypoglycemia (Blood Glucose Range <55 mg/dL) at Week 12,2017-09-19,COMPLETED,INTERVENTIONAL,['PHASE2'],
4762,NCT03880760,Change in concentration of blood glucose (AC),Change in concentration of TGF-β1,2018-08-01,COMPLETED,INTERVENTIONAL,['NA'],
4763,NCT04043065,Beta-cell secretion,"Appetite, satiety, and general well-being",2019-01-28,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
4764,NCT05266885,High incidence of HTN in Diabetics,,2019-11-01,COMPLETED,OBSERVATIONAL,['NA'],
4765,NCT02871180,Hypoglycemia,Blood glucose profile,2003-03,COMPLETED,INTERVENTIONAL,['NA'],
4766,NCT05025540,AUC,mPA,2021-06-01,COMPLETED,OBSERVATIONAL,['NA'],
4767,NCT05793645,Assessment of adherence,Description of Adverse events,2023-05-15,RECRUITING,INTERVENTIONAL,['NA'],
4768,NCT00046462,To determine the difference in glycemic control as measured by HbA1C between substituting the TZD with insulin glargine and adding a third oral agent in patients who fail a TZD/sulfonylurea or TZD/metformin combination therapy,Change in serum lipid profile,2001-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
4769,NCT03272269,Incidence of all adverse events reported for subjects,Assessment of residual beta cell function and markers of metabolic control,2017-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],Assessment of T lymphocyte immune response to IMCY-0098
4770,NCT00021918,,,2001-04,COMPLETED,OBSERVATIONAL,['NA'],
4771,NCT05214573,3-point MACE,Severe genitourinary tract infection,2021-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
4772,NCT05211869,Technology Use,Technology Use,2022-11-07,RECRUITING,INTERVENTIONAL,['NA'],Cost
4773,NCT03161964,Ratio of Self-reported Hypoglycemic Episodes to Total Hypoglycemic Episodes Determined by Continuous Glucose Monitoring (CGM),Mean Blood Glucose,2017-10-19,TERMINATED,INTERVENTIONAL,['PHASE2'],
4774,NCT05519163,New-onset diabetic foot,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],
4775,NCT02948777,LDL Pool Size of ApoB100 Before and After Evolocumab,Mean ApoB48 iAUC Before and After Evolocumab,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
4776,NCT00450710,Evaluate safety and efficacy of the ileal interposition associated with a sleeve gastrectomy and the ileal interposition associated with a diverted sleeve gastrectomy.,Hormonal effect and effect of the operations on diabetes related and total mortality.,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
4777,NCT05395377,Patient-Centered Outcomes,,2017-12-18,COMPLETED,INTERVENTIONAL,['NA'],
4778,NCT04722900,Body height,Magnetic resonance imaging,2021-01-15,RECRUITING,OBSERVATIONAL,['NA'],
4779,NCT01394341,Plasma liraglutide concentration (pmol/L),Cardiovascular risk factors (lipids and blood pressure),2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
4780,NCT00359801,Time to Persistent Decline in FEV1 Exceeding 20% From Baseline,Change in Glycosylated Hemoglobin (HbA1c) From Baseline,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
4781,NCT02914886,Relative thickness as assessed by MRI,Side effects,2016-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
4782,NCT01972542,Changes of Triglyceride,Changes of incretin,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
4783,NCT01798264,Number of Subjects With Study Drug-Related Adverse Events,Change in Weight From Baseline to 4 Weeks,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
4784,NCT05491421,To assess safety and tolerability of multiple escalation doses of ZT002 in healthy participants with a BMI range of 26 kg/m2 to 40 kg/m2 and a body weight of ≥80 kg through incidence severity of serious adverse events in MAD Cohorts.,The anti-drug antibody (ADA) response through testing serum or plasma of the participant post dosing in SAD and MAD cohorts.,2022-09-02,RECRUITING,INTERVENTIONAL,['PHASE1'],
4785,NCT03089463,Perfusion measurement,Ulceration incident,2017-11-27,SUSPENDED,OBSERVATIONAL,['NA'],
4786,NCT03419624,Change in HbA1c from baseline (week 0) to week 28,Proportion of patients achieving HbA1c of ≤ 7% at week 28 compared to baseline,2018-02-19,TERMINATED,INTERVENTIONAL,['PHASE3'],
4787,NCT04234217,Plasma norepinephrine levels,,2019-11-26,RECRUITING,INTERVENTIONAL,['NA'],
4788,NCT04835350,The safety of the prototype device Pancreas4ALL,Quality of life of patient living on closed loop system Pancreas4ALL,2021-02-19,UNKNOWN,INTERVENTIONAL,['NA'],
4789,NCT00574912,Maximum Glucose Infusion Rate,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
4790,NCT03002246,Comparison Between 5D Limb Vol and 2D Birth weight Prediction,Birth weight Predictions in Suspected Growth Abnormalities,2017-01-06,COMPLETED,OBSERVATIONAL,['NA'],
4791,NCT03249259,Cognitive function,Glucose metabolism,2016-03-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Hypoglycemia
4792,NCT01059825,Change From Baseline in HbA1c at Week 12,Number of Participants Who Discontinued Study Medication Due to an AE,2010-02-24,COMPLETED,INTERVENTIONAL,['PHASE2'],
4793,NCT01684722,Change in Estimated Glomerular Filtration Rate,Change in NT-proBNP,2010-07,COMPLETED,INTERVENTIONAL,['NA'],
4794,NCT00708578,HbA1c values,Fasting Blood Glucose level,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
4795,NCT06000813,IMB barrier sum score,Diabetes self-efficacy,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
4796,NCT02672176,Diabetes Self-Efficacy Measured Using the Diabetes Empowerment Scale Short Form (DES-SF)- Scores at 9-months,Perceived Stress Measured by PSS,2016-02,COMPLETED,INTERVENTIONAL,['NA'],PROMIS Physical Function
4797,NCT06300047,Lost to Followup,Clinical Outcome 6,2024-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
4798,NCT02493309,Blood glucose Area Under the Curve (AUC),Blood Pressure,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
4799,NCT00551876,Percent change in fasting LDL-C from baseline to the average of the Week 6/Week 12 measurements,Well tolerated in patients in Diabetic patients,2001-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
4800,NCT02517320,Change form baseline in UACR,Adverse events,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
4801,NCT05048264,Change in blood glucose measures,,2023-05-04,RECRUITING,OBSERVATIONAL,['NA'],
4802,NCT00593489,Insulin Prescription Rate - the Number of Insulin-eligible Patients Per 12 Months Who Are Prescribed Insulin in Each Family Physician (FP) Practice,Physician Score for Self-efficacy of Insulin Initiation & Titration,2006-07,COMPLETED,INTERVENTIONAL,['NA'],
4803,NCT00187785,retention of medical information,patient satisfaction,2005-09,TERMINATED,INTERVENTIONAL,['NA'],
4804,NCT05933356,The Positive and Negative Syndrome Scale (PANSS),,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],
4805,NCT02159144,browning of subcutaneous white adipose,,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
4806,NCT04093856,"Volumetric bone mineral density (vBMD) at the spine, hip, radius and tibia",Health-related quality of life,2020-01-14,COMPLETED,OBSERVATIONAL,['NA'],
4807,NCT00788840,Weight change,Glycaemic control,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
4808,NCT03959423,Change in Percentage of Euglycemia,Change in Percent of Time in Hypoglycemic Range (<70 mg/dL),2019-07-24,COMPLETED,INTERVENTIONAL,['NA'],
4809,NCT02434315,Change from Baseline - time in glucose range - for penultimate sensor wear,,2015-04,COMPLETED,INTERVENTIONAL,['NA'],
4810,NCT01041599,Correlation between albuminuria and arterial stiffness,,2009-10,COMPLETED,OBSERVATIONAL,['NA'],
4811,NCT05528770,Difference in Daytime Time-in-range,Difference in Overall Time-below-range,2022-10-20,COMPLETED,INTERVENTIONAL,['NA'],
4812,NCT04608136,Change from baseline Insulin at 180 minutes,Changes in fat intake following dietary intervention,2020-09-21,COMPLETED,INTERVENTIONAL,['NA'],
4813,NCT00031239,,,2001-09,COMPLETED,OBSERVATIONAL,['NA'],
4814,NCT00547872,Death and myocardial infarction,Symptomatic heart failure,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
4815,NCT00233311,,,2004-03,COMPLETED,OBSERVATIONAL,['NA'],
4816,NCT04287439,Change in pain severity,Change in Quality of life status,2018-06-08,COMPLETED,INTERVENTIONAL,['NA'],
4817,NCT01094899,"evaluate the MicroScanner, alterations quantitative and qualitative bone in the foot in patients with type 1 diabetes 2 with or without neuropathy",correlation involving bone and extension of neuropathy Assessment criteria associated with biological abnormalities qualitative and quantitative bone in diabetic subjects,2010-03-10,COMPLETED,INTERVENTIONAL,['NA'],
4818,NCT03126513,Efficacy of G-POEM in gastroparesis in percentage of scintigraphic improvement at 4hrs,security of G-POEM in gastroparesis,2017-04-01,COMPLETED,INTERVENTIONAL,['NA'],
4819,NCT01721811,Retinal oximetry during hyperglycemia,,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],
4820,NCT02691481,Glucose area under the curve 0-240 minutes,,2014-05,COMPLETED,INTERVENTIONAL,['NA'],
4821,NCT00995345,Change in HbA1c From Baseline (Week 0) to Week 24,Percentage of Patients Requiring Rescue Therapy for Elevated Glucose,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
4822,NCT01572753,AUC 0-24h; Area under the semaglutide concentration curve from time 0-24 hours after the 10th dosing,t1/2; the terminal half-life of semaglutide,2012-04-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
4823,NCT05324462,Change in local laboratory measured Glycated Haemoglobin A1c (HbA1c),Comparison between the daily dose of basal insulin and IDegLira,2022-03-22,COMPLETED,OBSERVATIONAL,['NA'],
4824,NCT00291590,Reduction in glycated hemoglobin levels,Improvement in health status and diabetes self-care practices,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
4825,NCT05902156,The Metabolic Parameter Monitoring Form,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
4826,NCT05377320,Imaging surveillance,,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
4827,NCT00514618,The Primary Outcome Measure Will be the Time Interval From Start of Induction to Delivery.,"Other Outcome Measures Will be Number of Doses of Medication Required, Oxytocin Requirements, and Route of Delivery.",2006-03,TERMINATED,INTERVENTIONAL,['NA'],
4828,NCT05392452,The proportion of time spent in the target glucose range from 5.6 to 10.0 mmol/L,"Peri- and postoperative costs (perspectives: hospital, statutory health insurance system)",2022-08-09,COMPLETED,INTERVENTIONAL,['NA'],Number of clinically significant hyperglycaemic events (>20.0 mmol/L) with ketonaemia (beta-hydroxybutyrate >1.0 mmol/L)
4829,NCT01630928,Change in blood pressure,Effect of RDN on subclinical organ injury: Impedance cardiography,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
4830,NCT01795144,Incretin Effect,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
4831,NCT02434744,"Number of Subjects Experiencing Adverse Events as a Measure of Safety, Tolerability, and Efficacy",Changes in Serum Levels of Non-Esterified Free Fatty Acids,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
4832,NCT01394055,Pharmacodynamic (PD) effects of RM-131 on gastric emptying,Pharmacokinetics (PK) of RM-131,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
4833,NCT02882477,C-Peptide levels in blood in response to Glucose Challenge - Oral Glucose tolerance test ( OGTT ) and Intra venous glucose tolerance test IVGTT,,2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4834,NCT04924400,Percentage of patients who complete the study,Total cost of care over 6 months.,2022-03,UNKNOWN,INTERVENTIONAL,['NA'],
4835,NCT03936049,"Relative hazard of composite outcome of Stroke, MI, and Mortality",,2017-09-22,COMPLETED,OBSERVATIONAL,['NA'],
4836,NCT05499702,Rate of leucine oxidation in response to rising glucagon concentrations,,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],
4837,NCT05336214,Change in practice-reported prescriptions of Continuous Glucose Monitors,Implementation and Maintenance,2022-06-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4838,NCT00084110,,,1993-08,TERMINATED,OBSERVATIONAL,['NA'],
4839,NCT00508599,Insulin resistance and orthostatic response,"Change in glucose, insulin, and orthostatic impairment.",2003-01,COMPLETED,INTERVENTIONAL,['NA'],
4840,NCT05924932,glycated hemoglobin,mean sensor glucose value,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],Safety and Tolerability
4841,NCT03371303,exit orders after hospitalization,,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA'],
4842,NCT03331289,Change in EGP From Baseline to Post-oral Glucose Load.,,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE4'],
4843,NCT01879917,Beta-cell function,Postprandial glucagon,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Hypoglycemia
4844,NCT00037258,,,2001-09,COMPLETED,OBSERVATIONAL,['NA'],
4845,NCT01382121,Psychological: Self-Efficacy,Changes in variability (standard deviation),2010-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
4846,NCT01904032,Change in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline (Month 0) to Month 6 for the High Dose Cohort Versus Low Dose Cohort,Change in Diastolic Blood Pressure From Baseline (Month 0) to Month 6 for the High Dose Cohort Versus Low Dose Cohort,2013-11-21,COMPLETED,INTERVENTIONAL,['PHASE2'],
4847,NCT06305351,Proportion of participants who discontinued study medication due to an AE,t1/2 of plasma K-833,2023-12-07,RECRUITING,INTERVENTIONAL,['PHASE1'],
4848,NCT01689129,Change from baseline in HbA1c,Number of Patients with various types of Hypoglycemia Events,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
4849,NCT06279234,Number of Participants With Change From Baseline in Physical Examination,Renal Clearance (CLr),2024-02-20,RECRUITING,INTERVENTIONAL,['PHASE1'],
4850,NCT05611684,blood lipid changes,Inflammation factors,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
4851,NCT04249778,"Number of Participants With Hospital Admissions, Emergency Department Visits, Urgent Clinic Visits for Heart Failure (HF) and Death After Admission With Acute Decompensated Heart Failure (ADHF)",Number of Participants With Acute Kidney Injury,2020-07-29,COMPLETED,INTERVENTIONAL,['PHASE4'],
4852,NCT01919476,Change in markers for glucose intolerance.,Change in metabolic markers,2011-09,COMPLETED,INTERVENTIONAL,['NA'],Change in satiety markers
4853,NCT03597035,Left Ventricular Mass,,2018-07-17,TERMINATED,INTERVENTIONAL,['PHASE4'],
4854,NCT02791295,Weight change,Retention of weight change,2016-10-04,COMPLETED,INTERVENTIONAL,['NA'],
4855,NCT02584582,Glucagon concentration (postprandial),triacylglycerol (TAG),2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4856,NCT02509429,Time spent with blood glucose <70 mg/dl,Score of the Hypo Fear Survey,2015-06-16,COMPLETED,INTERVENTIONAL,['PHASE2'],
4857,NCT01475565,Change from Gestation Week 12-14 in Insulin Sensitivity at Gestation Week 32-34,Change from Gestation Week 12-14 in Physical Activity at Gestation Week 32-34,2013-05,TERMINATED,OBSERVATIONAL,['NA'],
4858,NCT04484259,P2Y12 reaction units (PRU),,2021-03-31,RECRUITING,INTERVENTIONAL,['PHASE4'],
4859,NCT03127696,Proportion of subjects with at least 20% lean-associated microbiota in recipients after FMT compared with subjects receiving lifestyle intervention alone up to week 24,Changes in liver stiffness to assess improvement of other metabolic disease weeks 24 compared with baseline,2017-04-26,COMPLETED,INTERVENTIONAL,['NA'],
4860,NCT00292890,"HbA1c levels, insulin doses and the number of experienced hypoglycaemic events",blood glucose measurements and the experiences of the patients,2004-01,COMPLETED,INTERVENTIONAL,['NA'],
4861,NCT01664247,Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%),Change From Baseline in Patient Reported Health-related Quality of Life Using the Short-Form 36 Health Survey Version 2 (SF-36®v2),2012-10-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
4862,NCT00961662,Change From Baseline HbA1c After Six Months of Treatment in Patients With Type 2 Diabetes Mellitus,Body Weight Loss (Compared to Baseline),2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
4863,NCT01190436,Percentage of Participants With Decrease in Heart Rate by at Least 10 Bpm at Week 12,Number of Participants With Adverse Events (AEs),2009-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
4864,NCT02315495,Blood glucose concentrations at pre-defined intervals,half-emptying time (T50),2015-04-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
4865,NCT03925064,ultrasonographic myocardial performance index values,,2018-08-01,COMPLETED,OBSERVATIONAL,['NA'],
4866,NCT00539435,"Monitor and assess whether Pulsatile Intravenous Insulin Therapy can effect progression of cardiac disease in diabetic patients. Monitor results of Cardiac tests,carotid ultrasounds and echocardiograms,cardiac QOL, labs, meds to analyze progress.",,2007-09,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
4867,NCT01408277,Mean Percent Change in Wound Area,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
4868,NCT00014911,Percent of Participants That Achieved Insulin Independence With Adequate Control of Blood Glucose Levels at One Year Post Final Islet Transplantation.,Percent of Participants With Detectable Fasting Basal C-Peptide Levels,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
4869,NCT00308256,Patient's acceptance of the disease evaluated by an analogical visual scale rating,Episodes number of severe hypoglycaemia having required an intervention of a third party or a hospitalization.,2006-03,COMPLETED,INTERVENTIONAL,['NA'],
4870,NCT02532101,Blood glucose level,Beta Cell Function,2014-12,TERMINATED,INTERVENTIONAL,['NA'],
4871,NCT04800679,Extent of neovascular tissues in disc-diameter measured by investigator according to the wide-field FAG,Central retinal thickness according to macular OCT,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
4872,NCT04335331,A1c order,Weight,2020-02-27,COMPLETED,OBSERVATIONAL,['NA'],
4873,NCT04582357,Physical activity program attendance,Security,2020-12,WITHDRAWN,INTERVENTIONAL,['NA'],
4874,NCT02772783,Nucleus Accumbens Blood Flow,"Functional Connectivity of Nucleus Accumbens, Hypothalamus and Other Brain Areas Involved in Intake Regulation",2016-07,COMPLETED,INTERVENTIONAL,['NA'],Metabolomics
4875,NCT00945204,"The percentage of participants reaching target control of HbA1c (7.0), and blood pressure (<140/80) and cholesterol (<4 mmol/l),",Control of risk factors in all patients with type 2 diabetes in participating practices using anonymised routine data,2007-05,COMPLETED,INTERVENTIONAL,['NA'],
4876,NCT02901860,cardio-metabolic risk,Obesity,2012-01,COMPLETED,OBSERVATIONAL,['NA'],
4877,NCT03791125,PK profile of Salvianolic acid A following administration of multiple doses assessed by time of occurrence of Cmax [tmax],,2018-11-20,UNKNOWN,INTERVENTIONAL,['PHASE1'],
4878,NCT00879203,,,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
4879,NCT05352815,Change in glycated haemoglobin (HbA1c),"Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3)",2022-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
4880,NCT04032561,Sleep Duration,HbA1c,2019-01-08,COMPLETED,OBSERVATIONAL,['NA'],
4881,NCT01722227,Mean weekly blood glucose concentrations.,HbA1c,2012-11,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
4882,NCT04210024,Change in Health Literacy,,2019-05-03,COMPLETED,INTERVENTIONAL,['NA'],
4883,NCT00231634,Percent change in body weight and change in Hemoglobin A1c (HbA1c) from baseline to Week 52.,"Change from baseline to Week 52 in BMI, FPG; safety evaluations (adverse events, hypoglycemic events) throughout study.",2001-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
4884,NCT04256447,Urinary sodium concentrations,,2018-05-02,COMPLETED,OBSERVATIONAL,['NA'],
4885,NCT01144728,Evolution of Fasting Plasma Glucose (FPG),Change in Weight,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
4886,NCT03928132,"Change from immediate clinical behavioural intention at 3 months, as measured by CPD-REACTION questionnaire",Acceptability Questionnaire,2017-04-01,COMPLETED,INTERVENTIONAL,['NA'],
4887,NCT01694758,Percentage of patients in the benchmarking group achieving pre-set targets for HbA1c1,The LDL cholesterol parameter of the primary and secondary objectives according to ATP III guidelines,2012-11,COMPLETED,OBSERVATIONAL,['NA'],
4888,NCT01486238,Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity(BCVA) Score in the Study Eye Compared With Baseline.,Proportion of Subjects Requiring Macular Laser Treatment at Week 12 and Week 24.,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
4889,NCT01767831,Ability of Behavioral Intervention to Improve Glycemic Outcome,Relationships Between Physiology and Behavior Transferred to In Silico Environment,2013-03,TERMINATED,OBSERVATIONAL,['NA'],
4890,NCT02057497,Association of defined G protein- and FTO-related genotypes with the presence of T2DM or T1DM from a blood sample; also other genes of potential relevance for the evolution of obesity and/or diabetes.,Association of defined G protein- and FTO-related genotypes with the T2DM risk of healthy volunteers from a blood sample.,2017-10-09,WITHDRAWN,OBSERVATIONAL,['NA'],
4891,NCT01445899,Efficacy (Stratum II),Anatomical changes in retina and retinal nerve fiber layer morphology (Stratum II),2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
4892,NCT02082756,Change in 2-hour postprandial blood glucose between baseline to week 12,Adverse effects,2015-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4893,NCT06150690,Glycated hemoglobin,Islet area,2012-08-21,RECRUITING,OBSERVATIONAL,['NA'],
4894,NCT01618552,Physician use of self-efficacy enhancing interviewing techniques,Healthcare Climate Questionnaire,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
4895,NCT04335513,Continuous glucose monitor (CGM) % time >140 mg/dL,Diabetes attitude survey change over time,2020-04-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Change in Diabetes Knowledge from 6 month to 12 months follow-up.
4896,NCT04298684,Percentage of patients in each group who had at least a 20% decrease in one or more nodules of more than 2 cm at 2 years.,Percentage of adiponectin receptor expression in thyroid tissues after TN surgery,2021-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
4897,NCT00837096,Number of Participants With 100% Wound Closure,,2007-06,TERMINATED,INTERVENTIONAL,['NA'],
4898,NCT02336217,Number of hypoglycemic episodes,ADDQOL score,2014-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
4899,NCT01607944,Glucose turnover,Palmitate turnover and oxidation,2012-04,COMPLETED,OBSERVATIONAL,['NA'],
4900,NCT01253304,Pharmacokinetics: Apparent Volume of Distribution (Vz/F),,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
4901,NCT02689778,Effect of oral pirfenidone (1800 mg) in glomerular filtration rate,Number of patients with treatment related adverse events,2016-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
4902,NCT01926041,Number of Participants With New-onset Type 2 Diabetes Mellitus (DM),HbA1c Change Between Baseline and 6 Months,2013-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],10-year Probability of Regression to Normoglycemia
4903,NCT06035536,Percentage of index ulcers healed at 12 weeks,Change in pain levels during the clinical investigation,2023-06-08,RECRUITING,INTERVENTIONAL,['NA'],"Cost to closure (both treatment groups; all wounds, and only closed wounds)"
4904,NCT01467401,HbA1c (glycolated haemoglobin),Number and severity of hypoglycaemic episodes,2002-08-19,COMPLETED,INTERVENTIONAL,['PHASE4'],
4905,NCT01859598,the Change of Hypoglycemia During Follow-up.,Overall Weight Gain From Visit 1 to Visit 3,2011-12,COMPLETED,OBSERVATIONAL,['NA'],
4906,NCT05217290,The Effect of Health Education Given to Prediabetes Patients by Video Conferencing on Self-Management and Exercise Status,,2022-01,UNKNOWN,INTERVENTIONAL,['NA'],
4907,NCT03366337,Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 12,,2017-12-26,COMPLETED,INTERVENTIONAL,['PHASE2'],
4908,NCT04450407,Change From Baseline in Hemoglobin A1c (HbA1c),Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3209590,2020-07-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
4909,NCT00803608,The first occurrence of a plantar ulcer or pre-ulcer in subjects who have had one previously healed plantar ulcer,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
4910,NCT01529528,The Change in HbA1c from baseline to week24,change from baseline to week 24 in HOMA-IR,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
4911,NCT02580513,Insulin Sensitivity,Heart rate,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
4912,NCT00241423,Time-averaged serum glucose during a 24-hour period,To compare the effects of exenatide and placebo on serum glucose,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
4913,NCT02639507,average (mean) improvement in Best Corrected Visual Acuity (BCVA) as measured with Snellen visual acuity,,2015-06,COMPLETED,OBSERVATIONAL,['NA'],
4914,NCT01960205,oral glucose tolerance test,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
4915,NCT03814395,Numbers of participants with adverse pregnancy outcomes,Fetal Humerus Length,2018-06-28,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
4916,NCT00012753,,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],
4917,NCT06319287,Primary endpoints,Secondary Endpoint,2024-02-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Tertiary Endpoints
4918,NCT04730882,Myocardial Microvascular Perfusion (measured by contrast-enhanced ultrasound),E-selectin,2021-04-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
4919,NCT01878045,End-Stage Renal Disease,Death,2013-11-07,SUSPENDED,OBSERVATIONAL,['NA'],
4920,NCT01364584,Peak Oxygen Consumption (VO2 Peak),Echocardiographic Measures - Lateral E:E',2010-10,COMPLETED,INTERVENTIONAL,['NA'],
4921,NCT02488057,Beta Cell Function,Presence of genetic polymorphisms,2016-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
4922,NCT00949221,"Comparison of the effect of 2 strategies of real time continuous glucose monitoring vs conventional SMBG on glycated haemoglobin = HbA1c measured at inclusion, 3, 6, 9, 12 months",Medico-economic evaluation,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4923,NCT01128985,The concentration of canagliflozin and major metabolites (M5 and M7) in blood will be measured by protocol-specified pharmacokinetic parameters.,"The safety and tolerability of canagliflozin will be determined by monitoring adverse events and findings from laboratory evaluations, vital signs measurements, and ECG measurements reported.",2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
4924,NCT04721847,Self-completed Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS),Diabetic peripheral neuropathic pain impact measure,2020-08-13,COMPLETED,INTERVENTIONAL,['NA'],
4925,NCT05804890,Comparing Activated Carbon Cloth Dressing and Silver-Based Dressing in a Diabetic Foot Ulcer Population.,,2022-08-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
4926,NCT05497674,rongliflozin:Cmax ratios of geometric means of rongliflozin+probenecid relative to rongliflozin alone.,the number of participants with adverse events (AE) in Cohort B,2022-02-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
4927,NCT05138029,Review the patient's vision before surgery,Review the patient's vision for 6 months after surgery,2021-11-15,RECRUITING,INTERVENTIONAL,['PHASE3'],
4928,NCT04282005,Assessment of liver inflammation and fibrosis,"Assessment of bile acids in fasting and postprandial phase in response to a mixed meal test (MMT) in a subset of patients (total no.=18; 6 RYGB, 6 SG, 6 lifestyle intervention)",2020-02-13,UNKNOWN,INTERVENTIONAL,['NA'],
4929,NCT02849080,Participants Who Achieve HbA1c <7.0% (53 mmol/Mol) ADA Target (Yes/no),Change in DTSQ- Sustainability,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE3'],
4930,NCT04355832,Change in the level of catecholamines in plasma,,2020-06-24,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
4931,NCT01467375,Frequency of hypoglycaemic episodes,HbA1c (glycosylated haemoglobin),2001-01-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
4932,NCT05719181,Effect of Recombinant Human Bone Morphogenetic The Primary outcome will be measuring the effect of rhBMP- 2/ACS in improving the secondary stability of dental implant by using RFA in comparison to control group.,,2021-12-06,RECRUITING,INTERVENTIONAL,['PHASE1'],
4933,NCT03698708,Center for Epidemiologic Studies - Depression Scale Revised (CESD-R),Hemoglobin A1c (HbA1c),2019-01-20,COMPLETED,INTERVENTIONAL,['NA'],Treatment Satisfaction Survey
4934,NCT01596920,"Complete closure of the index wound, defined as 100% re-epithelialization as determined by the Investigator, anytime up to the Day 84 Visit",percent of wounds achieving complete closure,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
4935,NCT01472666,Postprandial triglyceride response,"Postprandial apolipoprotein-48 (apoB-48), 6 hour",2011-10,COMPLETED,INTERVENTIONAL,['NA'],
4936,NCT04857346,Clinical attachment level,Interleukin-6,2020-06-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4937,NCT00549757,Percentage of Participants With All Cause Mortality (Extension Phase),Percentage of Participants With Occurrence of Secondary Renal Composite Endpoint (Extension Phase),2007-10,TERMINATED,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Angioedema/Angioedema-like Events or Colorectal Events (Extension Phase)
4938,NCT01525693,"The primary endpoint of this study is the overall proportion of patients whose HbA1c is less than 6.5%, measured at the end of one year follow up.",The clinical effectiveness of each regimen measured by the proportion of patients reaching the target glycemic control,2012-04,UNKNOWN,OBSERVATIONAL,['NA'],
4939,NCT04910178,"fatty liver staging (0, I, II, and III)",Changes in total protein and albumin,2020-12-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
4940,NCT05881213,Cmax of CKD-378,,2023-06-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
4941,NCT03064841,"Percentage of Patients Attained Blood Glucose Control Target Defined as Glycated Haemoglobin A1c (HbA1c)<7%, According to 2015 American Diabetes Association (ADA) and 2013 Chinese Diabetes Society (CDS) Guidelines.",Follow up Duration of Type 2 Diabetes Related Risk Factors in Clinical Practice,2017-03-09,COMPLETED,OBSERVATIONAL,['NA'],
4942,NCT03705195,Difference in insulin secretion and incretin effect between two matched clamps (presence and absence of low dose gliclazide),"Insulin secretory response analysed by KCNJ11 Genotype (E23K, E23E, K23K)",2018-08-03,COMPLETED,INTERVENTIONAL,['NA'],
4943,NCT03994536,Level of empowerment,Clinic attendance 2,2019-08-15,RECRUITING,INTERVENTIONAL,['NA'],
4944,NCT00239148,To evaluate the safety and tolerability of repeated subcutaneous doses of E1 in combination with G1 in patients with type 1 diabetes,To evaluate the pharmacokinetic (PK) profile and clinical effects of repeated subcutaneous doses of E1 in combination with G1 in patients with type 1 diabetes,2005-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
4945,NCT01631643,Change in A1C from baseline to week 24,Change in 30 day mean glucose comparing first month to last month after 24 weeks,2012-12,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
4946,NCT00904176,Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs,"To assess the safety and tolerability of the combination of dapagliflozin with warfarin, and the combination of dapagliflozin with digoxin in healthy subjects",2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
4947,NCT04532385,Change from baseline in TNF-α at week 12,Change from baseline in body water at week 12,2018-06-12,COMPLETED,INTERVENTIONAL,['NA'],
4948,NCT00202670,,,2004-01,TERMINATED,OBSERVATIONAL,['NA'],
4949,NCT05112146,Post-prandial glucose,T max glucose,2018-08-20,COMPLETED,INTERVENTIONAL,['NA'],
4950,NCT01766778,Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 12,"Number of Patients With Adverse Events, Serious Adverse Events and Death as an Assessment of Overall Safety and Tolerability",2013-05-13,COMPLETED,INTERVENTIONAL,['PHASE4'],
4951,NCT01648647,,,2012-05,COMPLETED,OBSERVATIONAL,['NA'],
4952,NCT02805361,The mean change in HbAlc from mean baseline and at Month 12.,Changes from baseline in Diastolic Blood Pressures,2016-08-21,COMPLETED,OBSERVATIONAL,['NA'],Capture influence of the combined effect of fasting and hot climate on the level of total ketone bodies levels in T2DM subjects treated with Dapagliflozin
4953,NCT00789191,HbA1c (Glycosylated Haemoglobin A1c),Self-measured 9-point Plasma Glucose Profile,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
4954,NCT02799121,Complete Wound Closure,Neuro-QoL,2016-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
4955,NCT06140537,Albuminuria,safety and tolerability,2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
4956,NCT00403091,Lipids,Smoking cessation advice,2005-04,COMPLETED,INTERVENTIONAL,['NA'],
4957,NCT03121755,Total cellular cholesterol on leukocytes collected from the subjects,,2015-01-21,COMPLETED,OBSERVATIONAL,['NA'],
4958,NCT02505516,Number of diabetic patients on metformin therapy,,2013-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
4959,NCT01747356,12-month TVF occurrence,Patient related adverse events,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
4960,NCT02531776,Area under curve (AUC) of skin blood perfusion increase,"Skin reactions (bleeding, bruising, redness, swelling) on a scale from 0 to 4.",2014-12,COMPLETED,INTERVENTIONAL,['NA'],
4961,NCT00354939,Frequency of subjects with conventionally detected hypoglycemia,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
4962,NCT02306005,Factors influencing relationship between insulin treatment and lipoproteins,Development of Diabetic kidney disease,2014-11,UNKNOWN,OBSERVATIONAL,['NA'],
4963,NCT02026817,"metformin, rosuvastatin AUClast","Metformin, rosuvastatin AUCinf",2013-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
4964,NCT04286464,Swabs during respiratory infection,Sputum,2003-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
4965,NCT00931034,Change in body weight from baseline to week 24,"Analyze circumference measurements & body composition; blood glucose, HbA1c, insulin, lipid profile, blood pressure & questionnaire responses on food cravings and quality of life",2007-03,COMPLETED,INTERVENTIONAL,['NA'],
4966,NCT06280053,Wound Healing,Incidence of Safety Events,2016-03-02,COMPLETED,INTERVENTIONAL,['NA'],
4967,NCT00825253,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
4968,NCT03095651,Maximal Glucose Infusion Rate,Apparent Terminal Half-life,2017-04-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
4969,NCT00239707,"GIP, glucose, insulin measured frequently during infusions","GLP-1, ghrelin measured frequently during infusions",2003-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
4970,NCT03842683,Optimal Time Shift of Continuous Glucose Monitoring Measurements,Area Under the Receiver Operating Characteristics Curve of the Hypoglycemia Prediction,2016-06-06,COMPLETED,OBSERVATIONAL,['NA'],
4971,NCT04028076,Change in Hemoglobin A1c,Adherence to Refills and Medications Scale for Diabetes (ARMS-D),2019-07-10,COMPLETED,INTERVENTIONAL,['NA'],
4972,NCT00639080,,,2008-03,COMPLETED,OBSERVATIONAL,['NA'],
4973,NCT00291356,"Safety and tolerability: side effects and relevant changes in blood pressure, heart rate and ECG measurements, blood and urine measurements, the amount of fluid taken in and excreted, and kidney function will be monitored over course of study.",Amount and percentage of glucose excreted in urine by kidneys. Effect of compounds on lipid metabolism analysed.,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
4974,NCT02776696,Percentage of glucose sensor readings within 70 to 180 mg/dl,Closed-loop acceptance questionnaire,2016-06,COMPLETED,INTERVENTIONAL,['NA'],
4975,NCT01375166,Retinal blood flow velocities,,2013-03-06,TERMINATED,OBSERVATIONAL,['NA'],
4976,NCT03359837,Change in hemoglobin A1c (HbA1c),Subgroup analysis,2018-01-20,COMPLETED,INTERVENTIONAL,['PHASE4'],
4977,NCT00734474,Glycosylated Hemoglobin (HbA1c) Change From Baseline,Antibodies to LY2189265,2008-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Number of Participants With Adjudicated Cardiovascular Events at 104 Weeks
4978,NCT01478672,SF-36,EQ-5D,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
4979,NCT05487755,change in 2- Hours Postprandial blood glucose,Change in serum malondialdehyde (MDA) .,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
4980,NCT04543630,Implant survival,Effect of implant placement and graft material on hematological and inflammatory parameters,2020-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
4981,NCT04240964,Composition of the DFO Metagenome,,2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],
4982,NCT05605704,rate of fasting glycemia level reduction,,2023-01-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",rate of H1B1C balance variation
4983,NCT05250999,Toronto Clinical Neuropathy scoring system,,2021-07-15,COMPLETED,INTERVENTIONAL,['NA'],
4984,NCT03586830,Number of Participants With Treatment Emergent Adverse Events (TEAEs),Number of Participants With Greater Than or Equal to (>=) 5 Percent (%) Weight Loss at Week 12,2018-06-26,COMPLETED,INTERVENTIONAL,['PHASE2'],
4985,NCT01214356,Change in Urinary Albumin:Creatinine Ratio (ACR),Decrease in Estimated Glomerular Filtration Rate (eGFR),2010-08,COMPLETED,INTERVENTIONAL,['NA'],
4986,NCT02120755,Reduction in Wound Size,,na,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
4987,NCT01856881,Subject incidence of anti-AMG 876 antibodies,Pharmacodynamic parameters,2013-03,TERMINATED,INTERVENTIONAL,['PHASE1'],
4988,NCT04038931,Evaluating autoimmune response to AIPs,,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA'],
4989,NCT00686816,weight loss,Weight maintained,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
4990,NCT01147276,Glucagon response to hypoglycemia,Catecholamine response to hypoglycemic,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
4991,NCT03436992,Change in Flow-Mediated Dilation (FMD),,2018-04-17,COMPLETED,INTERVENTIONAL,['NA'],
4992,NCT01833403,Insulin Sensitivity,,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
4993,NCT00790699,"The Primary Outcome Will be Measured by HbA1c Values Taken at Screening, Baseline and After Three Months.","The Secondary Outcome Will Measure Patient Satisfaction, Opinions and Attitudes Toward Using the Multiple Injection Port for Insulin and Symlin Administration Compared to Standard Symlin Injections (Measured Through Using Questionnaires).",2009-08,TERMINATED,INTERVENTIONAL,['NA'],
4994,NCT05995756,overall mean absolute relative difference (MARD),,2021-12-20,COMPLETED,OBSERVATIONAL,['NA'],
4995,NCT00228865,"Using repetitive respiratory quotients, we will assess the success of the reversal of the abnormal underlying metabolism in diabetic patients from primarily fat metabolism to carbohydrate metabolism.",,2003-06,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
4996,NCT00519623,Pharmacodynamics of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients (GIRmax),Skin Response to the Application of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
4997,NCT01868230,Child Length,,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
4998,NCT01496443,AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose Pharmacokinetic Parameter for TAK-875,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
4999,NCT05462756,Change from Baseline in HbA1c,Treatment Experience for Diabetes Injection Device at Week 26 - Experience Questionnaire (DID-EQ),2022-08-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
5000,NCT02655666,Change in Glycosylated Hemoglobin (A1C),Percentage of Time in the Hyperglycemic Range,2015-04,TERMINATED,OBSERVATIONAL,['NA'],
5001,NCT02764905,change in A1C,change in indices will be collected before initiation of intervention and will be measured again after 3 months and 12 months,2016-11,COMPLETED,OBSERVATIONAL,['NA'],
5002,NCT03222765,Sudomotor Index,depressive symptoms,2015-03-15,UNKNOWN,INTERVENTIONAL,['NA'],
5003,NCT05411458,Heart rates,Health Related Quality of Life,2021-05-01,COMPLETED,INTERVENTIONAL,['NA'],
5004,NCT05325892,IDH,,2022-03-01,UNKNOWN,OBSERVATIONAL,['NA'],
5005,NCT03215914,Endogenous Glucose Production,Endogenous Glucose Production,2017-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
5006,NCT04558645,General Quality of life,Dyspnea,2020-09-18,COMPLETED,OBSERVATIONAL,['NA'],
5007,NCT04372316,changes of inferior whorl length （IWL）from baseline at 8 weeks,changes of corneal nerve fibre tortuosity （CNFT) from baseline at 8 weeks,2017-12-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],
5008,NCT05110365,sphygmomanometer,(EuroQoL five-dimensional instrument ),2021-06-26,COMPLETED,INTERVENTIONAL,['NA'],
5009,NCT00306098,a1c less than 6.5 without severe hypoglycemia,assessment of EXN to improve islet survival at time of islet transplantation - number of subjects achieving insulin independence with a single infusion,2000-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
5010,NCT00289848,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18,Change From Baseline in 2-hr Post-Meal Glucose (PMG) at Week 18,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
5011,NCT00567775,Area under the serum insulin curve,Time to maximum serum insulin concentration,2002-10-21,COMPLETED,INTERVENTIONAL,['PHASE2'],
5012,NCT05395000,Success rate of glucagon administration,Preferences in relation to the teaching method of administering the two forms of glucagon,2021-03-19,COMPLETED,INTERVENTIONAL,['NA'],
5013,NCT04145154,Changing the dimensions of the ulcer area,Change in pain intensity,2018-06-05,COMPLETED,INTERVENTIONAL,['NA'],
5014,NCT00568074,HbA1c,adverse events,2003-12-16,COMPLETED,INTERVENTIONAL,['PHASE4'],
5015,NCT03455257,Change in per capita food expeditures,Change in Grip Strength,2017-04-25,UNKNOWN,INTERVENTIONAL,['NA'],
5016,NCT02371876,Percent of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15mg/dL (<100mg/dL) and Within +/- 15% (>=100mg/dL) of Laboratory Glucose Method,Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements Regarding Views/Behaviors Related to Self-Monitoring Blood Glucose,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
5017,NCT03037593,incidence of gestational diabetes,Shoulder Dystocia,2017-06-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5018,NCT04075032,Change (1 log units) of Bacteroidetes per gram of feces,"Evaluation of genotype frequencies for 60 single nucleotide polymorphisms (SNPs) related to the incidence of obesity, metabolism, diabetes and cardiovascular diseases",2018-06-10,COMPLETED,INTERVENTIONAL,['NA'],
5019,NCT03495089,Presence of diabetic neuropathy diagnosed by EMG,Utah Early Neuropathy Scale,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
5020,NCT05351476,Change from baseline whole-body lipolysis at 12 weeks,Change in adipogenesis,2022-05-20,RECRUITING,INTERVENTIONAL,['NA'],
5021,NCT03450200,"Change in signs of DPN after intervention, at follow-up",Change in walking speed,2017-06-17,COMPLETED,INTERVENTIONAL,['NA'],
5022,NCT04014192,Change from baseline to post-treatment in islet alpha cell secretory function.,"Change from baseline to post-treatment in urinary output of uric acid, sodium, calcium, and phosphorus.",2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
5023,NCT01795248,Change in glucose tolerance,Deterioration in glycaemic status,2012-07,COMPLETED,INTERVENTIONAL,['PHASE4'],Changes in bonemarkers
5024,NCT01213901,"Anatomic site, abdomen versus deltoid, that offers the most consistent(superior) absorption of insulin",Injection technique which allows the most comfortable method of inserting the needle subcutaneously,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
5025,NCT02577536,Number of women delivering at each gestational week,Number of live births,2017-09-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
5026,NCT02958072,Healing of malleoli ulcer (YES/NO),"Z scores of combined plasma concentration of growth factors, cytokines and inflammatory markers",2016-11,COMPLETED,INTERVENTIONAL,['NA'],
5027,NCT01703637,Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 12,The side effect of each drug.,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],change from baseline in content of NOS
5028,NCT02165228,Metabolic Syndrome Extent,Mindfulness,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
5029,NCT01215435,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 11,Number of Treatment Emergent Hypoglycaemic Episodes,2011-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
5030,NCT01343446,Coping style of Patients with Diabetes suffer from Sleep Disorder,,2011-02,COMPLETED,OBSERVATIONAL,['NA'],
5031,NCT00998595,the fraction of each group that participates in postpartum follow up and glucose tolerance testing 4-12 weeks post partum.,the fraction of women in each group that attends a referral visit,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
5032,NCT02630277,Assess ocular and non-ocular adverse events,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
5033,NCT02418637,Feasibility (Likert scale),,2015-04,COMPLETED,INTERVENTIONAL,['NA'],
5034,NCT01459133,Efficacy of Inhaled Insulin versus Subcutaneous Insulin in a patient who receives inadequate response from subcutaneous alone.,,2013-05,WITHDRAWN,INTERVENTIONAL,['NA'],
5035,NCT03565666,Percentage of Time Where Glucose is Less Than 54 mg/dL,,2018-07-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Mean Absolute Relative Difference Between Senseonics Eversense CGM and Contour Next One Glucose Meter
5036,NCT02623608,"Area under the curve (AUC) of postprandial triglyceridemia (0-4h) after each intervention, compared to the reference meal","Area under the curve of postprandial glycemia (0-4h) after each intervention, compared to the reference meal",2015-08,COMPLETED,INTERVENTIONAL,['NA'],
5037,NCT00846391,Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Week 4,,2008-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
5038,NCT04589351,Urinary albumin creatinine ratio (UACR),Magnetic resonans estimate of kidney parenchymal triglyceride fraction,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Urine extracellular vesicles
5039,NCT03511885,"Proportions of hospital coronary patients and high risk individuals in primary care achieving European lifestyle, risk factors and therapeutic targets for cardiovascular disease prevention",,2016-08-23,COMPLETED,OBSERVATIONAL,['NA'],
5040,NCT00396227,Change from baseline in HemoglobinA1c (HbA1c),Incidence of prespecified adverse events while on treatment with study drug,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
5041,NCT06129526,Number of participants who suffer from bleeding events as defined by the Bleeding Academic Research Consortium (BARC) criteria during the entire follow-up period.,"Number of participants who suffer from the secondary safety end points which are Atrial fibrillation, Palpitations, Arrhythmias, Heart failure, Pneumonia, Peripheral edema, Diarrhea.",2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
5042,NCT01091025,To identify if using the selective approach to screen for CFRD is as accurate as screening all patients with OGTT at annual review.,Which is the more cost effective way of screening all patients with OGTT?,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
5043,NCT05977309,Comparison of the effects of topical ozone therapy and placebo on the healing of diabetic foot ulcers.,Comparison of topical ozone therapy and placebo groups for diabetic foot ulcer infection,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
5044,NCT02056366,Primary Efficacy of α-lipoic Acid in patients with cardiac autonomic neuropathy,Secondary Efficacy of α-lipoic Acid in patients with cardiac autonomic neuropathy,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of Patients with Adverse events as a Measure of Safety
5045,NCT02588859,Medication usage in enrolled subjects,Reduction in HbA1C,2015-10-30,COMPLETED,OBSERVATIONAL,['NA'],
5046,NCT02548741,Plasma methylglyoxal (MG) concentration (μM),The urine imidazolinone (IMZ) concentration (nM),2015-09,UNKNOWN,INTERVENTIONAL,['NA'],
5047,NCT00709150,Reduction in symptoms of major depression,Quality of life,2005-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
5048,NCT03436628,Change in Hemoglobin A1c (HbA1c),Change in Parental Monitoring,2018-03-01,COMPLETED,INTERVENTIONAL,['NA'],
5049,NCT05468411,Overall liking for meals,,2019-11-01,COMPLETED,INTERVENTIONAL,['NA'],
5050,NCT01728467,Change in plasma glucose following treatment with RVX000222 compared to placebo,Change in insulin secretion and insulin sensitivity following treatment with RVX000222 compared to placebo,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
5051,NCT00448903,total healing with intact skin or a significant improvement defined as a reduction of ulcer area > or = 50% or one degree reduction on Wagner Classification.,incidence of major bleeding and the incidence of adverse events.,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
5052,NCT00540709,Primary efficacy data was HbA1c.,Secondary efficacy data included HbA1c.,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
5053,NCT01447251,Number of participants with a change in their seven serum biomarker panel results,Number of participants with increased Continuous Positive Airway Pressure (CPAP)Compliance,2011-09,COMPLETED,INTERVENTIONAL,['NA'],
5054,NCT00865592,To demonstrate safety and tolerability of dutogliptin,To demonstrate maintenance or lowering of fasting blood glucose,2009-03,TERMINATED,INTERVENTIONAL,['PHASE3'],
5055,NCT04930276,the glycemic qualification rate,pregnancy outcome,2021-03-05,UNKNOWN,INTERVENTIONAL,['NA'],
5056,NCT01883622,"Glucose variability indexes during first, second and third trimester of pregnancy","Association between HbA1c and glucose variability indicators in the three trimesters pf pregnancy, in the three groups of women",2004-01,COMPLETED,OBSERVATIONAL,['NA'],
5057,NCT01400191,Endogenous glucose production,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
5058,NCT02861781,comparison of miRNA,changes in miRNA in plasma level,2016-02-02,RECRUITING,OBSERVATIONAL,['NA'],
5059,NCT02745821,"Prevalence of number of vessels fulfilling each of 4 permutations of fractional flow reserve (FFR) and coronary flow reserve (CFR) ie FFR ≤0.80 CFR ≥2.0, FFR ≤0.80 CFR <2.0, FFR >0.80 CFR ≥2.0 and FFR >0.80 CFR <2.0.",Change in index of microvascular resistance (IMR) in target vessel,2016-06,TERMINATED,INTERVENTIONAL,['NA'],
5060,NCT02193113,Number of participants with Adverse Events as a measure of safety and tolerability,Best Corrected Visual Acuity as measured by ETDRS EVA,2014-07-18,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in retinal thickness from baseline
5061,NCT05998525,changes in cardiac epicardial fat volume quantified in cm3 and evaluated by simple cardiac tomography.,Mortality due to cardiovascular causes,2021-06-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
5062,NCT03680482,glycemic response in blood,Insulin response in blood,2016-01-11,COMPLETED,INTERVENTIONAL,['NA'],Through food provided ad libitum (objective appetite)
5063,NCT03167411,AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity),Urinary Glucose Excretion (UGE),2017-05-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
5064,NCT02214329,Gait,Functional Performance,2014-02,UNKNOWN,INTERVENTIONAL,['NA'],
5065,NCT00172536,Diastolic heart function,Blood test,2004-10,COMPLETED,INTERVENTIONAL,['NA'],
5066,NCT00576862,Evolution of efficacy parameters between first study visit (V1) and last study visit (V5),,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
5067,NCT01422421,important secondary composite endpoint,new onset or deterioration of heart failure,2011-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
5068,NCT00659646,Number of Participants With a Clinical Cure at Visit 3 (Day 7),Lipsky Wound Score,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
5069,NCT03884647,DELPHI's reliability,,2020-04-01,COMPLETED,OBSERVATIONAL,['NA'],
5070,NCT05123196,Change from baseline in the weekly mean 24-hour average NRS score at Week 12 in treatment period,Proportion of CGIC responder at each assessment point,2021-11-16,COMPLETED,INTERVENTIONAL,['PHASE2'],
5071,NCT04841837,Time in range,Body composition (fat and muscle mass),2021-04-15,RECRUITING,INTERVENTIONAL,['NA'],
5072,NCT02690766,Change in Body Weight,,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
5073,NCT00661921,Change from baseline in HbA1c at week 14 (end of treatment),,2008-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
5074,NCT00184665,HbA1c,Hypoglycaemia,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
5075,NCT03891056,Number of participans with normal glycosylated hemoglobin levels,Comparison postoperative pain in sleeve and bypass with analogue assessment scale of postoperative pain.,2019-01-15,UNKNOWN,INTERVENTIONAL,['NA'],
5076,NCT05661149,Percentage time spent in the euglycaemic range specific for pregnancy (63-140 mg/dL),,2023-05-11,COMPLETED,OBSERVATIONAL,['NA'],
5077,NCT00441363,Change in Baseline to End of Study in HbA1c,Number of Serious Adverse Events Experienced by the Subjects,2005-02,TERMINATED,INTERVENTIONAL,['PHASE3'],
5078,NCT01094769,Urine albumin/creatinine ratio (UACR),muscle sympathetic nerve activity (MSNA),2011-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
5079,NCT04959552,Characterize the safety of the FreeStyle Libre 2 Flash Glucose Monitoring System when used to manage diabetes in pediatric and young adult patient populations,,2021-06-01,RECRUITING,OBSERVATIONAL,['NA'],
5080,NCT05373004,estimated glomerular filtration rate,the change in Urine Albumin Creatinine Ratio (UACR),2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']","the rates of clinical events (myocardial infarction, ESRD, congestive heart failure, and stroke)"
5081,NCT05723185,Analyse and compare the function of the two outpatient clinic models,,2023-02-13,RECRUITING,OBSERVATIONAL,['NA'],
5082,NCT03435198,Absolute and relative change in concentration of measured volatile organic compounds in human breath in subjects with type 1 diabetes during hypoglycemia compared to euglycemia measured by proton-transfer-reaction time-of-flight mass spectrometry.,Identify differences in patterns of exhaled VOCs in people who have hypoglycemia unawareness,2018-03-01,COMPLETED,OBSERVATIONAL,['NA'],
5083,NCT05892861,The change of cognitive function from baseline at 3 and 6 months,The change of dietary control belief from baseline at 3 and 6 months,2021-06-03,COMPLETED,INTERVENTIONAL,['NA'],The change of health behavior frequency per week from baseline at 3 and 6 months
5084,NCT00882882,Bioequivalence based on AUC and Cmax,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
5085,NCT04583813,Maintenance of sinus rhythm after the blanking period,Safety endpoint: Incidence of adverse events,2021-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],Changes in patient's functional capacity
5086,NCT05790785,Change in biomarkers of vascular health during the first 24 months of type 1 diabetes diagnosis,Smoking and substance use,2023-12-01,RECRUITING,OBSERVATIONAL,['NA'],
5087,NCT00254501,Change in Hemoglobin A-1C From Baseline,Change in Diabetes Knowledge and Empowerment (Patient Self-efficacy) From Baseline to 12 Months,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
5088,NCT04086043,Changes in glycosylated hemoglobin from baseline to 6 months,Changes in blood urea nitrogen (BUN) up to 2 years,2019-09-10,UNKNOWN,INTERVENTIONAL,['NA'],
5089,NCT02233179,Daily Physical Activities,,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
5090,NCT01831102,total adiponectin concentration,Insulin sensitivity,2011-03,COMPLETED,OBSERVATIONAL,['NA'],
5091,NCT00710008,"ATP-Synthesis, liver lipid content, skeletal muscle lipid content",,2006-02,COMPLETED,INTERVENTIONAL,['NA'],
5092,NCT04006028,Non-diabetic renal disease,Patient survival,2019-06-06,COMPLETED,OBSERVATIONAL,['NA'],
5093,NCT01547104,fasting oxidatively modified nucleosides 8-oxodG and 8-oxoGuo,Body Weight,2012-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
5094,NCT04154579,Change in Pulse Oximetry from Week 1 to Week 16,Weekly Post-Session Survey,2019-07-01,TERMINATED,INTERVENTIONAL,['NA'],HeRe We Ed Week 16 Survey
5095,NCT04219709,Glycemic threshold for hypothalamic activation,Blood glucose level at which participant reports symptoms of hypoglycemia.,2020-01-03,RECRUITING,INTERVENTIONAL,['NA'],
5096,NCT00715663,Patient and doctor's convenience,Patient satisfaction on devices,2007-02,COMPLETED,OBSERVATIONAL,['NA'],
5097,NCT00579150,Primary Outcome,Secondary Outcome Measure,2009-01,TERMINATED,OBSERVATIONAL,['NA'],
5098,NCT05542147,Endothelial Function,Platelet aggregation induced by arachidonic acid,2022-07-03,RECRUITING,INTERVENTIONAL,['NA'],Haematopoietic stem/progenitor cells (HSPCs)
5099,NCT02345291,• Change from the baseline week to Week 3 in the weekly average daily pain intensity as measured on an 11-point numerical pain scale (NPS),Incidence of treatment-emergent AEs (TEAEs),2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
5100,NCT04082702,Waist circumference: Number of participants above the recommended level,Cortisol (ng/mL),2013-02-22,COMPLETED,INTERVENTIONAL,['NA'],
5101,NCT00943371,15-Hour weighted mean plasma glucose (WMG) concentration,4-Hour weighted mean plasma glucose (WMG) concentration,2007-08,TERMINATED,INTERVENTIONAL,['PHASE1'],
5102,NCT00542178,"Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of Proliferative Diabetic Retinopathy Necessitating Photocoagulation Therapy or Vitrectomy",Development or Progression of Macular Edema,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
5103,NCT01601236,Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12,"Percent Change From Baseline of Serum Total Cholesterol, Triglycerides, LDL, HDL, Lp(a), Albumin, and Cortisol",2012-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Mean HbA1c
5104,NCT01515553,"Cmax, maximum concentration",Adverse events,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
5105,NCT01070238,Lower postprandial glucose and insulin responses after isomaltulose ingestion than after sucrose,,na,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5106,NCT02488616,Percentage of time of glucose levels spent between 3.9 and 10.0 mmol/L,Number of days with hypoglycemic events less than 3.1 mmol/L,2018-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
5107,NCT03716401,Cross-sectional (multi-centre collaboration),Longitudinal (multi-centre collaboration),2018-09-01,RECRUITING,OBSERVATIONAL,['NA'],Exeter Microvasculature Assessment Cohort - Thickness of the sublingual glycocalyx
5108,NCT00314717,Self-blood-glucose-monitoring results,perceptions of diet treatments,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
5109,NCT05463874,Diabetes Distress as measured by the Problem Areas in Diabetes - Teen Version (PAID-T),Diabetes distress as measured by the Problem Areas in Diabetes - Teen version (PAID-T),2022-10-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Time in Range
5110,NCT06316115,Introductory Information Form,Meggit-Wagner classification of diabetic foot,2023-12-12,RECRUITING,INTERVENTIONAL,['NA'],State Anxiety scale (STAI)
5111,NCT05596656,positive skin prick test,,2018-02-01,COMPLETED,OBSERVATIONAL,['NA'],
5112,NCT02598986,AUC of serum glucose,,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
5113,NCT01215097,HbA1c Change From Baseline at Week 24,Number With HbA1c at Least Lowering 0.5%,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
5114,NCT02338921,Glycemic target goal achievement rate,Glycemic target goal achievement rate,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4'],body weight change
5115,NCT01274715,Change in Hemoglobin A1C,,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
5116,NCT04051008,Change in Nutritional Quality of Purchases,Nutritional Quality of Foods Consumed,2019-10-14,COMPLETED,INTERVENTIONAL,['NA'],
5117,NCT01192373,Exercise capacity and oxygen consumption,metabolic and hormonal profile,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
5118,NCT04058730,Glycosylated Haemoglobin less than 6.5 mg/dl,,2015-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
5119,NCT04976361,Measurement of retinal thickness,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA'],
5120,NCT05787990,Presence of Diabetes Nephropathy,Severity of diabetes peripheral neuropathy,2021-10-14,RECRUITING,OBSERVATIONAL,['NA'],
5121,NCT01219465,C peptide release test,Immunologic reconstitution parameters,2010-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5122,NCT04255238,Chages from baseline HbA1c at Week24,,2020-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],
5123,NCT04497805,Proportions of subjects who achieved complete wound closure.,Durability of complete wound closure for the additional 24 weeks.,2020-09-08,RECRUITING,INTERVENTIONAL,['PHASE2'],
5124,NCT02366273,Evaluation of correlation between diabetes and psoriasis,,2015-02-01,COMPLETED,OBSERVATIONAL,['NA'],
5125,NCT02887677,Ambulatory systolic aortic pressure,HbA1c,2016-10,TERMINATED,INTERVENTIONAL,['PHASE4'],
5126,NCT03356457,• Measurement of hormone changes during hypoglycemia,cognitive function,2017-11-30,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
5127,NCT02577003,Percentage of Participants Who Discontinued Study Drug Due to an AE,Change From Baseline in Body Weight at Week 24,2015-11-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
5128,NCT05682495,Pharmacokinetics parameters of Metformin in the fed state: AUC0-inf (if applicable),The incidence and severity of adverse events/serious adverse events,2023-01-31,COMPLETED,INTERVENTIONAL,['PHASE1'],
5129,NCT01650259,Percentage of Participants With Adverse Drug Reactions (ADRs),Change From Baseline in HbA1c at the Last Observation During the Observation Period.,2012-07-23,COMPLETED,OBSERVATIONAL,['NA'],
5130,NCT05686421,Comfort Level Rating of Device C on 0-5 Scale,Time Duration to Adjust for Number of Motion Artifacts Present with Device C Imaging,2023-03-30,COMPLETED,INTERVENTIONAL,['NA'],
5131,NCT01973920,Adverse events and serious adverse events occurence,To assess the pharmacodynamic effect of multiple doses of Oshadi Icp as measured by the area under the glucose concentration-time curve,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluating the total daily injected insulin dose during administration of Oshadi Icp vs routine use
5132,NCT02804750,Percentage of Participants With One or More Severe (≥Grade 3) Adverse Events,Percentage of Participants With IGT / T2DM Who Experienced a ≥25% Reduction in AUCglucose Following Treatment With CORT125134,2016-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
5133,NCT02586545,"Change from baseline Hemoglobin A, Glycosylated (HbA1c) at 12, 24 and 36 months",The proportion of patients who meet national standard indicators reflecting quality of care,2015-08,COMPLETED,INTERVENTIONAL,['NA'],"Change from baseline diabetes symptoms at 12, 24 and 36 months"
5134,NCT00065663,,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
5135,NCT00415688,Hemoglobin A1c,Serum lipoproteins,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
5136,NCT05888909,change in estimated glomerular filtration rate (eGFR) from baseline,,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],
5137,NCT00658463,"Fractional Catabolic Rates (FCR)of VLDL1-apoB, VLDL2-apoB, IDL-apoB, LDL-apoB and HDL-apoA-I","Production Rates (PR) of VLDL1-apoB, VLDL2-apoB, IDL-apoB, LDL-apoB and HDL-apoA-I",2006-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
5138,NCT03388229,association between frequency of food group/item consumption and HbA1c among T2D patients,"To measure the percentage of frequency of consumption of food groups among T2D patients ,",2017-08-08,COMPLETED,OBSERVATIONAL,['NA'],
5139,NCT01806194,Change in Hemoglobin A1c,Change in Weight,2012-01,COMPLETED,INTERVENTIONAL,['NA'],Blood Pressure
5140,NCT05561595,Internalized Health-Related Stigma Scale,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
5141,NCT00174642,Insulin doses,Adverse events,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
5142,NCT04008745,Change from Baseline of the Fuzzy classification of the diabetic neuropathy severity at 8-weeks,Change from Baseline Functional balance at 8-weeks,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],
5143,NCT05104593,Change in healthcare appointments,Change in number of participants with advanced directives,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
5144,NCT01433406,Adverse events,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
5145,NCT03849339,AUClast of Metformin,Vd/F of Metformin,2019-01-28,UNKNOWN,INTERVENTIONAL,['PHASE1'],
5146,NCT04284722,Incidence of Perioperative Hyperglycemia,Mortality,2020-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
5147,NCT05904847,Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes,Blood Glucose Level,2023-06-16,COMPLETED,INTERVENTIONAL,['NA'],
5148,NCT06256549,"Compared with Semaglutide, the changes of HbA1c compared with baseline after continuous administration of GZR18 injection for 24 weeks",The overall incidence of adverse events and the incidence of serious adverse events,2023-08-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
5149,NCT03950973,Change in HbA1c as measured by an HbA1c machine,Change in Unmet Social Risk Factors as measured by participant questionnaire,2019-06-26,COMPLETED,INTERVENTIONAL,['NA'],
5150,NCT02395315,Differences in alveolar bone vascularity among well-controlled and not well-controlled diabetic patients.,RANK-L to OPG ratio,2015-12,COMPLETED,OBSERVATIONAL,['NA'],Implant surgery-related complications
5151,NCT03614780,temperature,fasting glucose,2017-07-11,COMPLETED,INTERVENTIONAL,['NA'],
5152,NCT05061459,Expression levels of circANKRD36 in the development and progression of DN.,Correlation between expression levels of circANKRD36 and pro-inflammatory cytokine (TNF-α and IL-6) in the development and progression of DN.,2021-10,UNKNOWN,OBSERVATIONAL,['NA'],
5153,NCT04631653,diagnostic accuracy,Referral rate of diabetic retinopathy,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
5154,NCT01945099,"Peak post-prandial venous glucose levels obtained after breakfast, lunch, and dinner between CL alone and CL+PH20preRx and CL+INS-PH20",Peak post-prandial insulin levels following meals,2013-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Area Under Curve meal-related insulin excursion following meals
5155,NCT00950079,Incidence of contrast-induced nephropathy,myocardial infarction,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
5156,NCT01998113,insulin treatment,Neonatal Intensive Care Unit (NICU) admittance,2013-03,COMPLETED,OBSERVATIONAL,['NA'],
5157,NCT02059161,Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Through Week 24,Bolus Insulin Dose Per kg of Body Weight at Week 24,2013-10-17,COMPLETED,INTERVENTIONAL,['PHASE3'],
5158,NCT01220557,Changes in Glycemic Control Measured by A1c,Evaluation of the Diabetes Education Course,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
5159,NCT04888598,Vessel density,Vessel density,2021-06-01,RECRUITING,OBSERVATIONAL,['NA'],
5160,NCT00790309,Determine to what extent improvements in glycemic control can be attributed to caloric restriction after weight loss surgery,Determine changes in inflammatory markers after weight loss surgery,2008-12,COMPLETED,OBSERVATIONAL,['NA'],
5161,NCT02598791,food intake,procollagen type 1 N-terminal propeptide (P1NP),2015-10-01,COMPLETED,INTERVENTIONAL,['NA'],
5162,NCT00057317,,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
5163,NCT04698330,Change in HbA1c,Hypoglycemic events,2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
5164,NCT00903851,Mean change from baseline to Week 3 in average pain intensity as measured from patient diaries using Brief Pain Inventory Question 5.,"Assessment of safety was based on AEs, skin assessment, physical examination, vital signs, clinical laboratory data, and plasma lidocaine levels",2002-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
5165,NCT03459573,Hemoglobin A1c,Self-Monitoring of Blood Glucose,2018-02-23,UNKNOWN,INTERVENTIONAL,['NA'],Life Satisfaction
5166,NCT00350064,Change in Abdominal Visceral Fat,Endothelial Function,2004-04,UNKNOWN,INTERVENTIONAL,['NA'],
5167,NCT01991769,endothelial function,,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
5168,NCT02944110,PPG excursions measured as incremental area under curve (iAUC),Gastric inhibitory peptide (GIP) and Glucagon like peptide-1 (GLP-1) pmol/l,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],
5169,NCT02565368,Cmax of Lobeglitazon and metformin,Vd/F of Lobeglitazon and metformin,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
5170,NCT00744237,Change From Baseline in Mean Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in Insulin Resistance Based on Homeostasis Model Assessment of Insulin Resistance (HOMA-IR),2008-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
5171,NCT00167570,Durability during household and community mobility.,"User perceptions of comfort, fit, and function.",2003-04,COMPLETED,OBSERVATIONAL,['NA'],
5172,NCT05862311,Evaluation of bone metabolism biomarkers in different periodontal conditions,Plaque index,2020-03-12,COMPLETED,INTERVENTIONAL,['NA'],
5173,NCT00569907,,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
5174,NCT03609996,Clinical regression of neovascularization not requiring further treatment beyond RBZ,,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA'],
5175,NCT01129960,Change From Baseline to Endpoint in Mean Pain,,2010-11,TERMINATED,INTERVENTIONAL,['PHASE3'],
5176,NCT01393873,rapid changes in the level of retinopathy,,2011-07,TERMINATED,OBSERVATIONAL,['NA'],
5177,NCT01956929,Change in Glucagon-induced endogenous glucose production.,Change in glucagon-induced alterations in whole body protein metabolism and resting energy expenditure.,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
5178,NCT01817595,Time required to teach meter/internet platform,,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
5179,NCT05491954,Changes in glycemic control over late gestation as measured by A1c,The number of neonatal hypoglycemic episodes,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],
5180,NCT04159766,Change in plasma glucagon,,2019-10-16,COMPLETED,INTERVENTIONAL,['PHASE2'],
5181,NCT02142309,"The primary outcome is maintenance of metabolic control (glycemic durability), defined as time to primary failure with a HbA1c value >7% on maximally tolerated doses of the assigned drug.",Continuous glucose monitoring for 72 consecutive hours at least once each year of follow-up,2005-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],Changes of triglyceride level from baseline each year of follow up
5182,NCT03767543,Change in glycated hemoglobin (HbA1c)%,Annualized rate of hypoglycemia (<3.0 mmol/L) over 26 weeks,2019-03-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
5183,NCT02586831,Proportion of regulatory T cells,Incidence of immune response adverse events,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5184,NCT00551564,Insulin resistance,Body composition,2007-07-31,COMPLETED,INTERVENTIONAL,['PHASE1'],
5185,NCT00337610,Change From Baseline in A1C at Week 18,Change From Baseline in A1C at Week 30,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
5186,NCT05928013,Vibration Perception Threshold (volts) as measured by person with diabetes,,2023-04-19,RECRUITING,INTERVENTIONAL,['NA'],
5187,NCT01740778,Blood Glucose Reading,Pain Scale Rating,2009-08,COMPLETED,OBSERVATIONAL,['NA'],
5188,NCT06085378,The proportion of patients with modified rankin scale (mRS) 0-2 scores at 90±7 days,Changes of Montreal cognitive assessment (MoCA) from baseline to 90±7 days,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],"Incidence, severity, and causality of adverse events (AE) and serious adverse events (SAE) during the intervention"
5189,NCT03739580,Salvage limb rate (for CLI patients),Major Adverse Events at 12-month Post Procedure,2016-10-01,UNKNOWN,INTERVENTIONAL,['NA'],
5190,NCT05646147,Reliability of standard bedside tests and the maximal systolic acceleration (ACCmax),Wound healing and ACCmax,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
5191,NCT03951298,Change in regional brain volumes over time,Change in disease severity score,2018-08-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
5192,NCT04260438,"Cmax of CKD-501, D759, D150, CKD-393",,2020-04-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
5193,NCT06328010,Data collection of 5000 patients,Different types of wounds/injuries heal rate,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
5194,NCT01247363,Number of Participants With Clinically Significant Adverse Effects,Number of Hypoglycemic Events,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
5195,NCT02685774,Cmax of Metformin,Vd/F of Metformin,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
5196,NCT00511030,,,2007-07,COMPLETED,OBSERVATIONAL,['NA'],
5197,NCT03560323,Cardiac Function,Myocardial energetics,2019-01-07,RECRUITING,INTERVENTIONAL,['PHASE1'],
5198,NCT01356381,"Measure: effect of treatment on insulin sensitivity, assessed as glucose Rd (rate of glucose disposal).",,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
5199,NCT03823664,Cardiorespiratory fitness,Pulmonary functions,2018-11-01,COMPLETED,OBSERVATIONAL,['NA'],
5200,NCT02888769,Change in systolic blood pressure obtained in office during each interview,Change in proportion of non-smokers,2016-08,COMPLETED,INTERVENTIONAL,['NA'],
5201,NCT00917553,The Mean Change in the Foveal Sensitivity of Matrix Frequency Doubling Perimetry (FDP) From Baseline in the Treated Group Compared to the Placebo Group,Number of Participants Who Developed Vitreous or Preretinal Hemorrhage,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
5202,NCT06294704,time spent within glycemic target 70-180 mg/dL,Time spent in level 2 hypoglycemia (< 50 mg/gdl),2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
5203,NCT01876992,% Cyclic Amine Mono Phosphate (cAMP) Response Element Binding Protein (CBP) White Blood Cell (WBC) Phosphorylation (Metformin Treated vs no Treatment),Fasting Blood Glucose.,2012-01,TERMINATED,INTERVENTIONAL,['NA'],Effect of Dose Escalation
5204,NCT03271580,macrophage phenotyping,,2020-02-01,TERMINATED,OBSERVATIONAL,['NA'],
5205,NCT01058772,C-section rate,Indication for Cesarean Section,2010-03,COMPLETED,INTERVENTIONAL,['NA'],
5206,NCT05370612,Percentage of Time Where Blood Glucose is between 70-140 milligrams per deciliter (mg/dL),Qualitative Outcome: Interviews to understand Participant Sense of Control around Glucose Monitoring,2022-08-08,RECRUITING,INTERVENTIONAL,['NA'],
5207,NCT03713437,Levels of differentially methylated insulin DNA from infancy to early adulthood in people with cystic fibrosis,Correlation between level of differentially methylated insulin DNA and use of CFTR modulator therapy.,2019-04-04,COMPLETED,OBSERVATIONAL,['NA'],
5208,NCT02232503,The prevalence of diabetic retinopathy as the proportion of patients with DR (any stage) in a given subgroup according to DM duration,Evaluate the impact of risk factors on the prevalence of Diabetic Retinopathy and Diabetic Macular Edema,2015-02,COMPLETED,OBSERVATIONAL,['NA'],Identification of patients with extreme phenotypes and family history of DM with eye complications
5209,NCT06089070,Feasibility of CGM use measured with Feasibility of Intervention Measure.,Problem Areas in Diabetes,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],
5210,NCT05777317,Lower limb pain responder rate,Average change in body weight,2023-04-24,RECRUITING,INTERVENTIONAL,['NA'],
5211,NCT01352767,efficacy,Satisfaction,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
5212,NCT05159089,Metabolic participants outcomes,Socioeconomic participant status,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],Medication patients intake
5213,NCT00229437,Change from Baseline in composite measure of maximal nerve conduction velocity (Nerve Conduction Studies).,Change from Baseline in quality of life index (SF-36 Health Survey).,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
5214,NCT05575609,height anthropometric measurement,,2022-11-01,COMPLETED,OBSERVATIONAL,['NA'],
5215,NCT00134329,Relation of erectile dysfunction with sex steroids,"Optimalisation of the healthcare for diabetic patients, so that the quality of life for male diabetic patients can be improved",2005-05,COMPLETED,OBSERVATIONAL,['NA'],
5216,NCT04858321,Insulin sensitivity,Cardiac output,2021-05-24,COMPLETED,INTERVENTIONAL,['NA'],
5217,NCT03939624,Cardiovascular death,Heart failure,2018-10-01,COMPLETED,OBSERVATIONAL,['NA'],
5218,NCT03725657,Measure of sleep expenditure through wrist accelerometer,Measure of insulin dosage,2018-10-29,COMPLETED,OBSERVATIONAL,['NA'],
5219,NCT02569684,Changes in plasma GLP-1 in response to standardized test meal before and after six weeks of ingestion of prebiotic fibers or placebo,,2015-10,COMPLETED,INTERVENTIONAL,['NA'],
5220,NCT01645332,Reduction of A1c level,Adverse events,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
5221,NCT06095492,Spot urine protein-creatinine ratio,Changes in HbA1c,2023-10-30,RECRUITING,INTERVENTIONAL,['NA'],
5222,NCT00351650,,,2006-07-09,COMPLETED,OBSERVATIONAL,['NA'],
5223,NCT04093635,Management of diabetic foot ulcers.,,2019-11,UNKNOWN,OBSERVATIONAL,['NA'],
5224,NCT04324736,Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19,describe the care management of hospitalized subjects with diabetes and COVID-19,2020-03-10,COMPLETED,OBSERVATIONAL,['NA'],
5225,NCT01897532,"Time to the First Occurrence of Any of the Following Adjudication-confirmed Components of the Primary Composite Endpoint 3-point Major Adverse Cardiovascular (CV) Events (3-point MACE): CV Death, Non-fatal Myocardial Infarction (MI) or Non-fatal Stroke.","Time to the First Occurrence of Any of the Following Adjudication-confirmed Components: Renal Death, Sustained End Stage Renal Disease (ESRD), or Sustained Decrease of 40% or More in Estimated Glomerular Filtration Rate (eGFR).",2013-07-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
5226,NCT04511468,Change the Risk of T2DM Progression,The assessment on the Safety of the ZCC Supplementation for the respondents,2021-06-23,UNKNOWN,INTERVENTIONAL,['NA'],Change in Vitamin C Level (optional)
5227,NCT05662332,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Treatment Experience in Diabetes Injection Device Experience Questionnaire (DID-EQ) in Device Characteristics,2023-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
5228,NCT00401115,"Safety and tolerability as assessed by visual acuity, intraocular pressure, slit lamp and indirect ophthalmoscope",Visual Acuity,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
5229,NCT05521737,Nerve Conduction Velocity,Genetic expression,2021-11-01,RECRUITING,INTERVENTIONAL,['NA'],
5230,NCT01468116,,,2011-03,UNKNOWN,OBSERVATIONAL,['NA'],
5231,NCT01680926,insulin demand per day,body weight,2009-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
5232,NCT00551538,Combined morning and evening mean 2 hour postprandial plasma glucose during each 24 hour inpatient period.,Insulin dose and body weight,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
5233,NCT01325987,HbA1C,AUC for c-peptide and glucose after MMTT,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
5234,NCT05613400,The change in the TH BMD after 18 months of simvastatin compared with ezetimibe,The changes in TBS after 18 months of simvastatin compared with ezetimibe,2022-04-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4'],
5235,NCT00745433,HbA1c,Variability in FPG (Fasting Plasma Glucose),2008-01,COMPLETED,OBSERVATIONAL,['NA'],
5236,NCT04931030,Change from baseline urine microalbuminuria at 12 weeks,Change from baseline Interleukin-6 (IL-6) at 12 weeks,2019-03-15,COMPLETED,INTERVENTIONAL,['NA'],
5237,NCT06227221,The primary endpoint of the study is the change from baseline of serum C-peptide area under the curve (AUC) over 2 hours following a mixed meal,"Drug safety: gastrointestinal symptoms, rashes, fatigue, bleeding, anemia, infections, cardiovascular events, etc.",2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
5238,NCT00936234,Endothelial Function,Number and Function of Progenitor Cells,2009-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
5239,NCT02009514,Glucose below 4.0 mmol/l,Glucose below 4.0 mmol/l during specified time intervals,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Standard deviation of glucose during specified time intervals
5240,NCT04183257,Homeostatic Model Assessment of Insulin Resistance,Glycated Hemoglobin (HbA1C),2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE4'],
5241,NCT02687152,Change in cutaneous microvascular endothelial function,,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5242,NCT05180591,Change in HbA1c values,Change in adjusted HbA1c,2022-03-22,RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory: Change in overall inflammation
5243,NCT03462069,Assessment of PD parameters in blood,Assessment of pharmacokinetic (PK) parameters: tmax,2018-03-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
5244,NCT02486484,vision before and after ziv-aflibercept,central macular thickness before and after ziv-aflibercept,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
5245,NCT00867386,Patient and graft survival.,Reversal or halting of diabetic complications,2006-12,COMPLETED,OBSERVATIONAL,['NA'],
5246,NCT00421733,Change From Baseline to the Last On-treatment Measurement in Urine Albumin to Creatinine Ratio (UACR) Levels Determined From the First Morning Void (FMV) Urine Collections Comparing Placebo to the Combined Paricalcitol Treatment Groups (1 Mcg and 2 Mcg).,Change From Baseline to the Last On-treatment Observation in Intact Parathyroid Hormone (iPTH) Levels.,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
5247,NCT03821220,Physical activity level assessed through average weekly steps,Vitamin C intake 0<mg/day<2500,2019-02-15,UNKNOWN,INTERVENTIONAL,['NA'],
5248,NCT05199350,Determination of autonomic dysfunction by subject,Establish the absence of any relationship of autonomic dysfunction (AD) to any other vital signs parameters.,2021-11-17,COMPLETED,OBSERVATIONAL,['NA'],
5249,NCT03236558,"Variability of the diversity of antigen-receptors' repertoires, expressed by regulatory T cells from type I diabetes patients and healthy controls.",Ratio between TCR diversities expressed by Treg cells vs. conventional T cells.,2018-03,WITHDRAWN,INTERVENTIONAL,['NA'],
5250,NCT03895229,Time to Maximum drug concentration in plasma (tmax),Half life( t½) of drug in plasma,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
5251,NCT00325650,Time of progression to type 2 diabetes,Change from baseline in HDL-Cholesterol and triglycerides (TG),2006-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
5252,NCT02860611,Difference in T helper cytokines between groups,,2013-02,COMPLETED,OBSERVATIONAL,['NA'],
5253,NCT00342927,Diabetes and diabetic kidney disease.,Blood pressure and serum lipids.,2001-03-07,RECRUITING,OBSERVATIONAL,['NA'],
5254,NCT04302168,Birthweight,Gene expression of glucose transporters,2020-04-01,RECRUITING,INTERVENTIONAL,['NA'],
5255,NCT00999050,Hemoglobin A1C changes,improvement in glycemic control,2009-10,UNKNOWN,INTERVENTIONAL,['NA'],
5256,NCT01564485,Systolic BP Pressure,,2008-07,COMPLETED,INTERVENTIONAL,['NA'],Change in Treatment by PCP
5257,NCT05035368,The mean difference in glucose infusion rate (GIR) from baseline,Change in average (previous 3 days) daily insulin requirements,2021-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
5258,NCT03338439,Diastolic Blood Pressure,Vascular event,2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],
5259,NCT05378620,Change in Baseline Self-Efficacy for Diabetes Scale at 6 months,Change in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 6 months; % Units,2022-10-17,RECRUITING,INTERVENTIONAL,['NA'],Participant Satisfaction
5260,NCT04843592,the patient's compliance after using SOKARY mobile app,,2019-08-30,COMPLETED,OBSERVATIONAL,['NA'],
5261,NCT02461589,Change in HbA1c (Glycosylated Haemoglobin),Change in Systolic and Diastolic Blood Pressure,2015-09-21,COMPLETED,INTERVENTIONAL,['PHASE2'],
5262,NCT02154100,Arterial Stiffness,Body Composition,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
5263,NCT00121966,HbA1c following two years of treatment,urine albumin/creatinine ratio,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
5264,NCT02026843,Aqueous secretory angiogenic and anti-angiogenic protein concentration,,2012-04,UNKNOWN,OBSERVATIONAL,['NA'],
5265,NCT03366532,Mortality,,1980-08,COMPLETED,OBSERVATIONAL,['NA'],
5266,NCT00566189,Improvement or reversal of type 2 diabetes mellitus,Retardation of progression or regression of albuminuria as detected by microalbuminuria assay in 24-h urine collection,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
5267,NCT04041739,detect magnitude of fungal infection as an etiology causing persistent non healed diabetic foot osteomyelitis,detect response of healing of resistant infected osteomyelitis to antifungal therapy,2020-01,UNKNOWN,OBSERVATIONAL,['NA'],
5268,NCT05537233,Proportion of adults with T1D achieving composite outcome (CGM-measured time in range (TIR)>70% with time below range (TBR) of <4% and reduction in body weight by 5%) at 26 weeks in the semaglutide group compared to placebo group,Change in NAFLD biomarkers,2023-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in ectopic fat volumes in the abdomen and around the heart
5269,NCT03558581,Glycemic control - HbA1< 7%,Improve Knowledge assessed by questionaries DKNA,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],Improve attitude and coping of Diabetes assessed by questionaries ATT-19
5270,NCT03934281,Epidermization rate at 6 months.,Epidermization rate at 2 months,2018-06-27,COMPLETED,INTERVENTIONAL,['NA'],
5271,NCT00212901,reducing proteinuria,"side-effects of hypotension, postural symptom",2004-08,COMPLETED,INTERVENTIONAL,['NA'],
5272,NCT01238289,mean percent change Hemoglobin A1c (HbA1c),"Body mass index, blood pressure and lipid changes",2006-09,COMPLETED,INTERVENTIONAL,['NA'],
5273,NCT02065050,Hemoglobin A1c,BMI,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
5274,NCT01548248,Change in HbA1c (glycosylated haemoglobin),Number of adverse events,2006-01,COMPLETED,OBSERVATIONAL,['NA'],
5275,NCT03793673,Social Determinants of Health Tool,Cost to Payor as as assessed using the Team Costs- YA,2019-01-20,COMPLETED,INTERVENTIONAL,['NA'],Standard Care - Tools Questions
5276,NCT03660371,BCVA,,2018-09-04,COMPLETED,INTERVENTIONAL,['NA'],
5277,NCT00374595,Carotid Intima Media Thickness (CIMT),,2006-04,COMPLETED,OBSERVATIONAL,['NA'],
5278,NCT02909894,Blood glucose Area Under the Curve (AUC),Cognitive function - Part 4 - Rapid Visual Information Processing Test,2016-05-26,COMPLETED,INTERVENTIONAL,['NA'],
5279,NCT05535842,"Changes in diabetes knowledge among patients and carers in the intervention group using GLOW Quiz at baseline, interim (3 months) and end-of-trial (6 months).",GLOW App usability perception among patients and carers in the intervention group will be measured at the end-of-trial (6 months).,2022-11-28,RECRUITING,INTERVENTIONAL,['NA'],
5280,NCT00692237,"Left Ventricular Torsion Defined as Change in Ventricular Mid-wall Rotation (°) Measured by Cine-Cardiac Magnetic Resonance (CMR) Imaging With Tagging, Before and After Three Months of Treatment With Sildenafil and Placebo (100 mg/Day).",Ejection Fraction (EF) Defined as the Volume of Blood Ejected With Each Beat Was Measured on Cine-Cardiac Magnetic Resonance (CMR) Images Before and After Three Months Treatment With Sildenafil and Placebo (100 mg/Day).,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
5281,NCT04941794,Chronic Heart Failure,6 minutes walk test,2021-07-01,RECRUITING,OBSERVATIONAL,['NA'],HOMA-IR
5282,NCT05268081,Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes and cholesterol,Questionnaire for the assessment of practice staffs' confidence in managing type-2 diabetes and cholesterol at 12 and 24 month,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
5283,NCT00795262,Comparison of relative change of systolic BP/diastolic BP and urinary albumin excretion from baseline in diabetic patients treated with quinapril plus lipoic acid versus quinapril and placebo.,"Comparison of patients treated with quinapril plus lipoic acid versus quinapril plus placebo in the following areas: a) Changes from baseline in high sensitivity C-reactive protein, adiponectin, and leptin",2008-07,COMPLETED,INTERVENTIONAL,['NA'],
5284,NCT02611232,FPIR (first phase insulin response),Serum C-peptide AUC,2015-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],
5285,NCT03880162,Change from baseline in intrahepatic triglyceride content,Change from baseline in insulin sensitivity,2019-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Length of hospital stay
5286,NCT01771185,Hb A1a,Lipidic control,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],
5287,NCT03823092,polarization sensitivity,,2017-11-09,UNKNOWN,OBSERVATIONAL,['NA'],
5288,NCT00712478,Evaluate improvement of diabetes control with fasting glycemia and after diner glycemia measurements,Evaluate improvement of diabetes control with fasting glycemia and after diner glycemia measurements,2007-09,COMPLETED,OBSERVATIONAL,['NA'],
5289,NCT03341026,Accuracy,Reliability,2020-06,UNKNOWN,INTERVENTIONAL,['NA'],
5290,NCT02776007,Libre-user evaluation questionnaire,Glycemic control measured by HbA1c,2016-07,COMPLETED,INTERVENTIONAL,['NA'],Average fasting blood glucose level
5291,NCT00592527,HbA1c,Incidence of adverse events,2004-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
5292,NCT05019807,Follow-up rate in patients with diabetic macular edema receiving education materials about diabetes and its complications.,,2020-12-18,COMPLETED,INTERVENTIONAL,['NA'],
5293,NCT06147232,Change in dynamic R2*-weighted signal (BOLD) as an indirect measure of renal blood oxygenation,Difference in Kidney Function after 12 weeks treatment with sotagliflozin vs placebo,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Ethnicity
5294,NCT00262548,"All participants will receive an intervention on diet and physical activity counseling, which will be carefully monitored.","Other variables will be: proinflammatory cytokines - tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6), IL-12, Th2/Th3 cytokines -IL-4, IL-10 and transforming growth factor beta (TGF-beta)",2005-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
5295,NCT00443521,Vitreous haemorrhage,Safety and Tolerance of the treatment,2005-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
5296,NCT05336071,Area under the plasma concentration versus time curve (AUC0-inf ) of INS068 injection,Number of subjects with adverse events and the severity of adverse events,2022-05-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
5297,NCT00255645,,,2005-09,TERMINATED,OBSERVATIONAL,['NA'],
5298,NCT00317954,Changes in blood pressure,Changes in glomerular filtration rate,2003-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
5299,NCT05806957,Specificity of the Ophthal-360 Software to detect diabetic retinopathy in fundus images,,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
5300,NCT01387165,The achievement of the planned completed number of questionnaires.,Assessment of fasting blood glucose,2004-10,COMPLETED,OBSERVATIONAL,['NA'],
5301,NCT03710850,Glucose disposal,Suppression of lipolysis,2018-05-01,COMPLETED,INTERVENTIONAL,['NA'],
5302,NCT00007098,,,1995-05,COMPLETED,OBSERVATIONAL,['NA'],
5303,NCT04879511,Glycemic control(HbA1c%),circulating neuregulin-4 level,2018-02-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
5304,NCT01557972,Death,Macrovascular complications,1999-11,UNKNOWN,OBSERVATIONAL,['NA'],
5305,NCT00094770,Change From Baseline in HbA1c at Week 52,Number of Participants With Drug-related LAEs at Week 104,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
5306,NCT04601740,Change in Glycated haemoglobin (HbA1c ),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",2020-11-17,COMPLETED,OBSERVATIONAL,['NA'],
5307,NCT01833559,The incidence of GDM at the second gestational trimester,Gestational outcomes,2012-06,UNKNOWN,INTERVENTIONAL,['NA'],Child growth measures
5308,NCT03089528,intubation difficulty,adverse outcomes related to tracheal intubation.,2017-04-01,COMPLETED,INTERVENTIONAL,['NA'],
5309,NCT04755946,Absolute change in Estimated glomerular filtration rate (eGFR),Change in serum irisin level,2021-03-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
5310,NCT02440282,Heart rate,,2012-01,COMPLETED,OBSERVATIONAL,['NA'],
5311,NCT03809299,Insulin sensitivity,Autophagy level,2019-06-20,COMPLETED,INTERVENTIONAL,['NA'],
5312,NCT04732208,Sensitivity and Specificity of the AI in detecting any grade of diabetic retinopathy in those with established diabetes mellitus (DM),To compare the diagnostic ability of the AI in mydriatic and non-mydriatic eyes,2022-04-20,COMPLETED,OBSERVATIONAL,['NA'],
5313,NCT00099905,Change from baseline in HbA1c at 24 weeks,Change from baseline in fasting lipids at 24 weeks,2004-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
5314,NCT05999656,Rate of wound area change,Change in Wagner scale,2023-05-28,RECRUITING,INTERVENTIONAL,['NA'],
5315,NCT04192292,Difference in incretin effect between mixed meal tests,Variation in blood glucose during intervention blocks analysed by continuous glucose monitoring,2019-10-08,COMPLETED,INTERVENTIONAL,['NA'],
5316,NCT00571220,Change in incretin,,2005-09,COMPLETED,OBSERVATIONAL,['NA'],
5317,NCT02455076,Change in HbA1c Concentration Inpatient,Change in Diastolic Blood Pressure,2015-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
5318,NCT02971228,"Safety and Tolerability as Measured by Adverse Events, Local Tolerability of Infusion Site Reactions, and Clinical Laboratory Parameters",Bionic Pancreas User Opinion Survey,2016-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
5319,NCT04262661,Part 2: Number of treatment emergent adverse events,Maximum observed serum NNC0472-0147 concentration at steady state,2020-03-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
5320,NCT01109212,Urinary Albumin Excretion (µg/min) levels in the overnight urine specimen.,Albuminuria remission rates,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
5321,NCT06187129,cross sectional area of peripheral nerves using nerve ultrasound,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
5322,NCT01392027,Validation of glycoprotein panel as a pancreatic cancer biomarker,,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
5323,NCT01029886,Change in HbA1c From Baseline to Week 26,Assessment of Event Rate of Treatment-emergent Hypoglycemic Events,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
5324,NCT02651480,Blood pressure,Quality of Life and Mood,2016-02,SUSPENDED,INTERVENTIONAL,['NA'],
5325,NCT03717233,Forefoot plantar pressure,Measures of fall risk,2018-10-18,COMPLETED,INTERVENTIONAL,['NA'],
5326,NCT00262704,lipid control,,2001-12,COMPLETED,INTERVENTIONAL,['NA'],
5327,NCT01336322,Beta-cell function,Glucose control,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
5328,NCT00574834,Changes in Insulin Sensitivity,,2007-03,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],
5329,NCT02622672,Fasting glucose,high sensitivity interleukin (hs-IL-6),2016-01-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
5330,NCT02586519,Rate of Wound Resolution,Complication Rates,2016-06,TERMINATED,INTERVENTIONAL,['NA'],
5331,NCT00972452,"The overall aim of the project is to determine whether or not acute exercise training influences postprandial metabolic, vascular or autonomic nervous system responses in individuals with insulin resistance or T2D.",,2009-08,COMPLETED,INTERVENTIONAL,['NA'],
5332,NCT00976261,"Part B: Safety, tolerability parameters: adverse events, gastro-intestinal side effects, subject reported outcomes, clinical laboratory results, ECGs and vital signs",Part B: 3-O-Methyl-Glucose Kinetics,2009-10-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
5333,NCT01892280,Change in glycemic control from baseline to 1 year,Psychosocial factors (self-report surveys),2013-11,COMPLETED,INTERVENTIONAL,['NA'],
5334,NCT00935129,Treatment satisfaction,continuous glucose measurements,2009-08,COMPLETED,INTERVENTIONAL,['NA'],
5335,NCT03444064,Adverse Events,Stimulated C-peptide level,2018-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
5336,NCT02500706,Change From Baseline in HbA1c 26 Weeks After Randomisation,Change From Baseline in Body Mass Index 26 Weeks After Randomisation,2016-05-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
5337,NCT01666028,Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on subcutaneous glucose monitoring (CGM) adjusted for sensor error.,"Number of episodes of hypoglycaemia, severe hypoglycaemia as well as nature and severity of any other adverse events.",2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of use of the closed-loop system at home.
5338,NCT05700513,Fasting blood glucose,High-sensitivity C-reactive protein level,2023-07-28,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5339,NCT01235429,hemoglobin A1c,Quality of life,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
5340,NCT03655535,2 hr PPG,Change in oral hypoglycemic medication,2018-09-19,COMPLETED,INTERVENTIONAL,['PHASE2'],
5341,NCT06098417,soluble biomarkers of liver fibrosis,Biobank,2015-09-22,RECRUITING,OBSERVATIONAL,['NA'],
5342,NCT02075307,DNA damage in peripheral blood mononuclear cells,Insulin resistance,2014-01,COMPLETED,INTERVENTIONAL,['NA'],Thiol/Redox changes
5343,NCT02796378,Physical performance measured by VO2-max,Difference in mitochondrial function measured by respirometry,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],
5344,NCT01545791,"Number of serious adverse drug reactions (SADRs), including major hypoglycaemic events",Quality of Life as assessed by a treatment satisfaction questionnaire,2006-05,COMPLETED,OBSERVATIONAL,['NA'],
5345,NCT03655223,Incidence Rates: Number of newborns who screen positive comparative to the whole sample,Impact of Screening: Semi-structured parent interviews.,2018-10-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
5346,NCT05145374,Measurement of Glucose Concentration,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],
5347,NCT05411952,Change in mean of HbA1c from baseline to 6 months,Change in mean of Mediterranean Diet Quality Index Scale (KIDMED) from baseline to 6 Months,2020-08-13,COMPLETED,INTERVENTIONAL,['NA'],
5348,NCT05836350,fasting plasma glucose levels,cardiac function: tricuspid regurgitation systolic jet velocity,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
5349,NCT00424437,Primary outcome is 24 week change in baseline in HbA1c,Patient satisfaction and preference.,1999-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
5350,NCT05681286,C-reactive protein to serum albumin ratio in type 2diabetic patients with diabetic nephropathy,,2023-08-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
5351,NCT01621516,Change in the stimulated serum C-peptide leveS (mean area under the curve [AUC] after hypercemic clamp test,,2012-06,COMPLETED,OBSERVATIONAL,['NA'],
5352,NCT00854035,Safety and Tolerability,Fasting plasma glucose,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
5353,NCT02657083,"to evaluate the safety and efficacy of blood glucose control using the DreaMed MD-AID in children and adolescents with T1D during and after planned physical activity, in a controlled in-hospital environment.",to evaluate the physiologic responses and risk of hypoglycemia among children and adolescents with T1D after afternoon exercise during closed-loop control in a controlled in-hospital environment,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
5354,NCT02847091,Percent change from baseline in insulin dose,Safety assessed by biochemistry,2016-07-29,COMPLETED,INTERVENTIONAL,['PHASE4'],
5355,NCT03879642,Hypoglycemia Fear Survey,Child Hemoglobin A1c,2015-10-01,COMPLETED,INTERVENTIONAL,['NA'],
5356,NCT06242808,Adherence,Self-efficacy and knowledge around food procurement and healthy eating,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
5357,NCT05628662,Percentage of CGM time in glucose range 70-180 mg/dl during the study.,Number of acute metabolic events during the study,2021-10-22,COMPLETED,INTERVENTIONAL,['NA'],
5358,NCT00897390,Metformin PK Parameter Tmax,"Electrocardiogram (ECG), Vital Sign, and Physical Finding Abnormalities",2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
5359,NCT06155487,"Part B (MAD): Heat pain tolerance (The Maximum temperature that the subject can tolerate, ℃)",Part B (MAD): Number of participants with SAE,2023-11-27,RECRUITING,INTERVENTIONAL,['PHASE1'],
5360,NCT01211847,Triglyceride-lowering efficacy of DCCR,Improvement in other lipid profiles with DCCR,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
5361,NCT05563987,Change in Diabetes Distress Scale,Psychological flexibility,2021-10-01,COMPLETED,INTERVENTIONAL,['NA'],
5362,NCT01536652,HbA1c (glycosylated haemoglobin),Incidence of hypoglycaemic episodes,2006-01,COMPLETED,OBSERVATIONAL,['NA'],
5363,NCT04404699,Correlation of stimulation TcPO2 parameters with the type of peripheral arterial flow,Correlation of stimulation TcPO2 parameters with macrocirculation parameters,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],
5364,NCT05238012,HbA1c levels,non HDL-C levels,2022-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
5365,NCT06048653,Executive function,,2022-08-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
5366,NCT02248454,"Predictors of fat ""sensitivity""",,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
5367,NCT03061227,Brain activity,Change in hormone levels,2017-02-10,COMPLETED,INTERVENTIONAL,['NA'],
5368,NCT02109835,Greater than 20% increase in plaque volume,Greater than 20% increase in coronary artery calcium score,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],"Incidence of major adverse cardiovascular events (MACE) during the 18-month follow-up period. MACE is defined as incidence of cardiac death, non-fatal myocardial infarction, STEMI and NSTEMI, unstable angina, late revascularization and onset of angina"
5369,NCT04732611,Blood Glycose,Endothelial function,2021-03,UNKNOWN,INTERVENTIONAL,['NA'],
5370,NCT03561987,Evaluate the association of the cardiovascular benefit of the obese patient after bariatric surgery with the basic mechanisms of adipose tissue (metabolic profile),Determine the association of the cardiovascular prognosis modification (risk subgroups) with the basal metabolic profile.,2013-11-06,UNKNOWN,OBSERVATIONAL,['NA'],
5371,NCT04083339,Peak VO2 during cardio-pulmonary exercise test (CPET);,Changes in the modified Kansas City Cardiomyopathy Questionnaire (KCCQ) score,2019-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Changes in echocardiographic parameters
5372,NCT06330987,Fetal Autonomic Nervous sysTem Evaluation (FANTE),Obstetric Complications and mode of Delivery,2019-08-13,RECRUITING,OBSERVATIONAL,['NA'],
5373,NCT00351234,To see if the number of hypoglycemic events decreases with treatment of carnitine on type I diabetic patients. The measurements will be taken after the second 72-hour continuous glucose monitoring.,,2004-10,COMPLETED,OBSERVATIONAL,['NA'],
5374,NCT01322321,Measure: Change from baseline of stimulated C-peptide after a mixed meal tolerance test at 13 months,Measure: anti-ACZ885 antibodies,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
5375,NCT01725412,Microabluminuria,Serum Thiamine Level,2012-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],Inflammatory Markers
5376,NCT06080542,Interstitial glucose,Lactate,2023-02-01,COMPLETED,INTERVENTIONAL,['NA'],PHYSICAL ACTIVITY
5377,NCT01518101,Proportion of patients preferring each treatment regimen,Investigator preference and subjective reasons of preference to each treatment,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
5378,NCT00223613,Development of clinical type 1 diabetes,Changes in serum metabolite patterns (metabolomics),1997-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],
5379,NCT05184868,Area under Curve for Glucose Infusion Rate,,2022-01-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
5380,NCT05421780,Change in blood amino acid concentration,Change in blood pressure,2022-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
5381,NCT03042936,Change From Baseline Hemoglobin A1c,Change From Baseline Shuttle Run Speed,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
5382,NCT05336929,HbA1c values,Diabetes Knowledge Level,2016-06-01,COMPLETED,INTERVENTIONAL,['NA'],Roy Adaptation Model Interview results
5383,NCT00939250,Glycosylated Hemoglobin,Quick Inventory of Depressive Symptoms - Self Report,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
5384,NCT01961024,VLDL-TG storage in adipose tissue,18F-THA fractional storage,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
5385,NCT02133729,Metabolic index value,Prevalence of abnormal glucose tolerance in women with GDM,2011-06,COMPLETED,INTERVENTIONAL,['NA'],Adiponectin level
5386,NCT02687256,Time to an infusion set failure due to an occlusion,signs of infection at insulin infusion site,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
5387,NCT00906529,Length of Hospitalization Stay,Time to becoming medically stable for discharge,2009-05,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
5388,NCT04375449,Glucose-iAUC(0-180min),GLP-1-iAUC(0-120min),2020-05-04,COMPLETED,INTERVENTIONAL,['NA'],
5389,NCT00886366,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables and ECG)","Pharmacodynamic variables (P-Glucose, S-Insulin and C-peptide)",2009-04,TERMINATED,INTERVENTIONAL,['PHASE1'],
5390,NCT01202461,Best-corrected visual acuity,Central subfield macular thickness,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
5391,NCT02681887,change in beta-islet cell function,change in TNF-alpha,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],
5392,NCT01425255,sleep quality,Glycemic control,2011-08,WITHDRAWN,OBSERVATIONAL,['NA'],
5393,NCT02236754,Mean BPND (non-displaceable binding potential),,2013-07,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],
5394,NCT05115682,Exercise-induced Changes in 24 Hour Interstitial Glucose Concentration,Metabolic Response to Exercise,2021-11-10,UNKNOWN,INTERVENTIONAL,['NA'],
5395,NCT04129268,Lowering of blood glucose values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities,Lowering of serum insulin values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],
5396,NCT05232071,Assessment of the effect of lanifibranor alone compared to placebo and the effect of lanifibranor in combination with empagliflozin compared to placebo on absolute change in HbA1c from baseline (Week 0) to Week 24,,2022-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
5397,NCT00838903,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104,Change From Baseline in Body Weight at Week 156,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
5398,NCT03371082,Immunogenicity,Efficacy - The number and percentage of subjects who achieve a HbA1c of < 7.0%,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE3'],
5399,NCT03502031,Combination Therapy - RAAS inhibition and Spironolactone to lower UP/Cr,Combination Therapy - RAAS inhibition and Spironolactone that develop hyperkalemia,2018-10-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
5400,NCT02241993,Difference between very large sensor accuracy errors (≥50% from reference glucose) with the simultaneous use of four sensors vs one sensor.,Difference between mean absolute relative difference with the simultaneous use of four sensors vs one sensor.,2010-07,COMPLETED,OBSERVATIONAL,['NA'],
5401,NCT03197324,AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity),,2017-07-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
5402,NCT02411682,Postprandial Glucose,Postprandial Free Fatty Acids,2014-05,UNKNOWN,INTERVENTIONAL,['NA'],
5403,NCT01007266,To evaluate the effect of a minimally invasive intervention (the buddy system) on hemoglobin A1c levels in adolescents with T2DM.,"To assess changes between groups in body weight, number of home glucose monitor checks, compliance with medications, adherence to visit schedule, and psychological well-being.",2009-10-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
5404,NCT02689362,Absolute variation of the values obtained in the baseline for the HbA1c,"Absolute variation of the values obtained in the baseline for the parameter, body weight.",2017-08-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
5405,NCT01375491,MMP Activity,CRP,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
5406,NCT01868646,Changes in the Mean Value of HbA1c,Satisfaction of Diabetes Treatment Based on Diabetes Treatment Satisfaction Questionnaire Data,2013-05-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
5407,NCT00131846,New onset type 2 diabetes (WHO criteria 1998),Gout (American College of Rheumatology 1997 criteria C),2004-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
5408,NCT02405767,Change in impedance,Impedance of different wound tissues,2015-04,COMPLETED,INTERVENTIONAL,['NA'],
5409,NCT00222846,Dietary adherence,Waist circumference,2004-05,COMPLETED,INTERVENTIONAL,['NA'],
5410,NCT05161897,"Change in glucose tolerance [Time Frame: baseline, 10 days, 20 days, and 30 days]","Change in dietary intake [Time Frame: baseline, 10 days, 20 days, and 30 days]",2022-04,UNKNOWN,INTERVENTIONAL,['NA'],
5411,NCT01035281,To evaluate the efficacy of nabilone compared to placebo in the treatment of diabetic neuropathy-associated peripheral neuropathic pain (DPN).,To evaluate safety and tolerability of nabilone for the treatment of neuropathic pain in subjects with diabetic peripheral neuropathy.,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
5412,NCT00116207,Global [11C]HED Retention Index (RI),Inflammation,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
5413,NCT06110143,Prevalence of gestational diabetes,,2021-11-13,RECRUITING,INTERVENTIONAL,['NA'],
5414,NCT03926598,Participant Task Completion Rate for Usability Testing Session,,2019-06-05,COMPLETED,OBSERVATIONAL,['NA'],
5415,NCT05199077,percentage change,Changes of ECG examination results,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
5416,NCT02487680,Area under the curve for Glucose after ingestion of a test meal,Area under the curve for insulin after ingestion of a test meal,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
5417,NCT01158417,NF-Kb,GLP-1,2008-12,TERMINATED,INTERVENTIONAL,['NA'],
5418,NCT00736632,"Hypertension (24h Blood Pressure, Central Blood Pressure, and Office BP)",Urine Calcium to Creatinine Ratio.,2006-05,COMPLETED,INTERVENTIONAL,['NA'],
5419,NCT05182359,The relation of prescription rates of cardioprotective medications (SGLT2i or GLP1 RA) to CVD-T2D test risk assessment in the Informed group vs. Uninformed group.,"Survey of healthcare providers on the impact of SomaLogic's CVD-T2D calculator on patient care, medication prescription, and risk perception.",2022-01-26,COMPLETED,INTERVENTIONAL,['NA'],The change in prescription rates of cardioprotective medications (SGLT2i or GLP1 RA) after revealing the Metabolic Factors test results at the end of the study in the Informed group.
5420,NCT04363710,Weight in kilogram and height in meters will be combined to report BMI in Kg/m^2,,2017-05-31,COMPLETED,INTERVENTIONAL,['NA'],
5421,NCT01456195,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Meal Tolerance Test (MTT),2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
5422,NCT04271631,Change from Baseline Hb1A1c at 3 months,Self-Monitoring Blood Glucose,2019-06-12,UNKNOWN,INTERVENTIONAL,['NA'],
5423,NCT02388958,Postpartum weight change measured in kilograms,Change in dietary choices during versus after pregnancy measured with the Personal Diabetes Questionnaire,2014-06,COMPLETED,OBSERVATIONAL,['NA'],
5424,NCT01594567,Blood Pressure (BP) Analysis,,2012-03,UNKNOWN,OBSERVATIONAL,['NA'],
5425,NCT00552903,For patients with diabetes: blood HbA1c at target level (7% or less),"Improvement in body mass index, health-related quality of life (15D instrument), amount of exercise, diet, smoking cessation; for patients with heart failure also use of emergency services and NYHA class",2007-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],
5426,NCT05254496,Changes in HgbA1c,Changes in blood pressure,2022-04-04,RECRUITING,INTERVENTIONAL,['NA'],
5427,NCT03527667,Proportion of CO readings completed,Cigarettes per day,2018-06-22,COMPLETED,INTERVENTIONAL,['NA'],
5428,NCT01039116,2 year change in insulin resistance via HOMA-IR,"Change in dietary intakes of energy, fat, carbohydrate and selected essential nutrients. Change in minutes/day spend in moderate- and high-intensity physical activity. Improvement or stabilization of self-esteem.",2005-03,COMPLETED,INTERVENTIONAL,['NA'],
5429,NCT02490085,Percentage of time of plasma glucose concentrations spent in the target range,Number of patients experiencing at least one hypoglycemic event requiring treatment,2015-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
5430,NCT03814434,Radiographic Bone height Gain,Periimplant Pocket probing depth,2018-05-28,UNKNOWN,INTERVENTIONAL,['NA'],
5431,NCT03224234,Number of Participants Experiencing Insulclock Device Malfunctions,Change in Diabetes Quality of Life Clinical Trial Questionnaire-Revised (DQLCTQ-R) Score,2017-11-29,COMPLETED,INTERVENTIONAL,['NA'],
5432,NCT02768506,Weight loss,Diabetes remission,2009-09,COMPLETED,OBSERVATIONAL,['NA'],
5433,NCT01196728,Safety measurements,PK samples for CM3.1-AC100,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
5434,NCT03609697,Percent weight change,Carotid artery intima-media thickness (cIMT),2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
5435,NCT00449553,Change from baseline in glycosylated hemoglobin.,"Change from baseline in fasting lipoproteins (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein-cholesterol and triglycerides).",2001-06,COMPLETED,OBSERVATIONAL,['NA'],
5436,NCT03091920,Change From Study Baseline Over Time in Estimated Glomerular Filtration Rate (eGFR),,2017-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],
5437,NCT04064437,Vertebral fracture detected with VFA,Osteocalcin,2019-07-29,COMPLETED,OBSERVATIONAL,['NA'],Microalbuminuria
5438,NCT02709707,Accuracy of blood glucose measurements as performed by lay users,Assessment by lay users of the ease of use of the iGlucose Blood Glucose Monitoring System,2016-03,COMPLETED,OBSERVATIONAL,['NA'],
5439,NCT05001815,Time in range (TIR) at 34 weeks of gestation,"Questionnaires (Self-rated Depression Scale, SDS)",2021-12-15,UNKNOWN,INTERVENTIONAL,['NA'],
5440,NCT02764021,Changes in glycated hemoglobin (HbA1c) at the end of 6 weeks of isoenergetic low carbohydrate diet compared to 6 weeks of the recommended antidiabetic control diet.,Changes in insulin-like growth factor-binding protein 3 (IGFBP-3) at baseline to week 6 will be compared to changes from week 6 to 12. Changes in IGFBP-3 will be assessed from week 12 to 36.,2016-04,COMPLETED,INTERVENTIONAL,['NA'],
5441,NCT05797285,Wound Closure,Change in Quality of Life,2023-02-28,COMPLETED,INTERVENTIONAL,['NA'],Number of Adverse Events Observed
5442,NCT02481141,Change From Baseline in Fasting Blood Glucose,Change From Baseline in Triglycerides (Component of Lipid Profile),2014-07,COMPLETED,INTERVENTIONAL,['NA'],
5443,NCT00660309,Change From Single Dose Peak to Steady State Peak in Renal Plasma Flow (RPF) After Aliskiren or Irbesartan,Change From Baseline in Retinal Blood Flow After Aliskiren or Irbesartan,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
5444,NCT02113163,"AUC following single and repeat single oral administration of metformin eicosapentaenoate, metformin hydrochloride and Vascepa",,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
5445,NCT02420054,Change of insulin secretion,Insulin signalling cascade proteins,2015-04,UNKNOWN,INTERVENTIONAL,['NA'],
5446,NCT05603793,Stunting,Bone age,2022-09-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Household Dietary Diversity Scale (HDDS)
5447,NCT01724554,Mean Change in Capillary Non-Perfusion,,2012-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5448,NCT01377844,Change From Baseline in Hemoglobin A1c at 24 Weeks,Percentage of Subjects Achieving HbA1c <7%,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
5449,NCT00714441,"Distress. Patient distress will be assessed across several measures including: the 20-item CES-D, the 17-item DDS, the PHQ8, and screening items from the SCID to rule out psychosis.",Lipids,2008-07,COMPLETED,INTERVENTIONAL,['NA'],
5450,NCT00418522,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population,"Change From Baseline in Diabetes Treatment Satisfaction Questionnaire-Status, Diabetes Treatment Satisfaction Questionnaire-Change, Diabetes-39, Mental Health Inventory-17, and SF-36 Vitality Domain Questionnaire",2007-03,COMPLETED,INTERVENTIONAL,['PHASE4'],Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the FAS
5451,NCT04456166,Incidence of gastric ultrasonography score as low risk (grade 0 or 1),The incidence of nausea and vomiting,2020-06-22,COMPLETED,OBSERVATIONAL,['NA'],
5452,NCT00820807,Mean changes in blood HbA1c values from baseline to end of study,"Mean changes in total body fat, lean tissue and abdominal fat as determined by DEXA [distribution or absolute changes]",2009-01,TERMINATED,INTERVENTIONAL,['NA'],
5453,NCT01179672,Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score,Mean Change From Baseline at 12 Week Endpoint in the SDS Total Score,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
5454,NCT04817514,Supraspinatus tendon thickness measurement,,2021-11-01,UNKNOWN,INTERVENTIONAL,['NA'],
5455,NCT02248311,Subclinical Cardiovascular Diseases,Ischemic events,2014-09,UNKNOWN,OBSERVATIONAL,['NA'],
5456,NCT00231725,To collect complaint data on the Pre-filled Pen B when used by persons with type 2 diabetes to self-administer insulin in take-home situations for 2 months.,To assess overall patient perception of the device's performance through a patient questionnaire.,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
5457,NCT02309138,Large for Gestational Age (LGA) Infant,Neonatal Composite Morbidity,2015-08-11,COMPLETED,INTERVENTIONAL,['NA'],
5458,NCT02467998,Healing,Side effects and adverse Events During Therapy,2005-01,UNKNOWN,OBSERVATIONAL,['NA'],
5459,NCT04101383,AUC(0-t),,2017-10-16,COMPLETED,INTERVENTIONAL,['NA'],
5460,NCT00442767,"Assess the Mean Area Under the Curve (AUC) for Blood Glucose Concentration in Subjects Treated With Pramlintide + Insulin, Compared to Insulin Alone","Measure of Glucagon Concentration in Subjects Treated With Pramlintide + Insulin, Compared to Insulin Alone.",2007-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
5461,NCT06098625,Change in spot urine protein-creatinine ratio,Changes in HbA1c,2023-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
5462,NCT04410419,Mean difference of preoperative glucose between the two groups,Rate of peri-operative insulin use,2018-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
5463,NCT03845179,C-peptide,Lipids,2019-05-29,COMPLETED,INTERVENTIONAL,['NA'],heart rate
5464,NCT02643277,Comparison of the glycaemic outcome measured as improvement in HbA1c (≤ 7.0% (53mmol/mol)) in the intervention group in comparison with the conventional care.,Adherence to the prescription,2014-12,COMPLETED,INTERVENTIONAL,['NA'],
5465,NCT02292810,Glucose level,Autonomic control,2014-11,UNKNOWN,INTERVENTIONAL,['NA'],
5466,NCT03188835,BAT triglyceride content,hormonal responses,2017-05-23,COMPLETED,INTERVENTIONAL,['NA'],
5467,NCT06074458,Change in percentage of participants who remain on AID as measured by medical record review,Episodes of severe hypoglycemia as measured by chart review,2024-01-29,RECRUITING,INTERVENTIONAL,['NA'],
5468,NCT03433573,Point Accuracy Determined as % within Consensus Error Grid Zone A,,2018-02-16,COMPLETED,INTERVENTIONAL,['NA'],
5469,NCT00510952,Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c),Total Daily Insulin Dose Per Body Weight (Units/Kilograms) at Endpoint,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
5470,NCT03189732,Change in adipose tissue lipolysis in response to exercise,Change in lactate production in response to exercise,2015-10-01,COMPLETED,INTERVENTIONAL,['NA'],
5471,NCT04006392,Participants With a 30% or Greater Change in Visual Analog Scale (VAS) Pain Scores,,2019-02-15,TERMINATED,INTERVENTIONAL,['NA'],
5472,NCT06335225,HbA1c,Waist hip ratio,2024-03-13,RECRUITING,INTERVENTIONAL,['NA'],
5473,NCT00911833,,,2009-05-19,COMPLETED,OBSERVATIONAL,['NA'],
5474,NCT02115412,Adherence determinants,Medication usage,2014-07,COMPLETED,OBSERVATIONAL,['NA'],Adverse Events
5475,NCT02008942,Time to 99% Inhibition of Serum Thromboxane,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
5476,NCT00730275,Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity Following a Single Dose of Sitagliptin,Plasma Dipeptidyl Peptidase-4 (DPP-4) Activity Following a Single Dose of Sitagliptin or Placebo,2008-07-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
5477,NCT02087124,Dose-response of whey protein as pre-meal on apolipoprotein B48 after a high-fat meal in subjects with the metabolic syndrome measured as incremental Area Under the Curve (iAUC -15 - 360 min),Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the Curve (AUC -15 - 360 min),2014-03,COMPLETED,INTERVENTIONAL,['NA'],Responses of satiety visual analog scale (VAS) measured as incremental Area Under the Curve (AUC -15 - 360 min)
5478,NCT05854251,Change in insulinogenic index (IGI) concentration following a standardized mixed-meal test,,2023-06-15,RECRUITING,INTERVENTIONAL,['PHASE2'],
5479,NCT01747083,Cmax,AUClast,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
5480,NCT03034759,overall time in target (70-180mg/dl),corrective bolus after meal during intervention phase,2019-10-01,WITHDRAWN,INTERVENTIONAL,['NA'],
5481,NCT02662010,Change in Advanced Glycation Endproducts (AGE) Levels,Change in HbA1C Levels,2016-03,COMPLETED,OBSERVATIONAL,['NA'],
5482,NCT04132128,HbA1c,HbA1C for measuring glucose control,2015-11-25,COMPLETED,INTERVENTIONAL,['NA'],
5483,NCT04465721,Adherence,Lipid profile,2021-06-14,RECRUITING,INTERVENTIONAL,['NA'],
5484,NCT01499511,Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack),Number of Participants Who Have Experienced a Transient Ischaemic Attack (TIA) Since the End of the ASCOT Trial,2012-01,COMPLETED,OBSERVATIONAL,['NA'],
5485,NCT01479075,Insulin sensitivity,Energy metabolism,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
5486,NCT03956173,QTc prolongation.,Oxidative stress markers (8-oxoGuo),2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],
5487,NCT03009864,changes of albumin-to-creatinine ration,the rate of doubling the baseline with serum creatinine value,2017-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
5488,NCT00135096,"Compare change in weight from baseline to study week 52 in the per-protocol population of premeal Apidra vs postmeal Apidra, in patients receiving Lantus as basal insulin",,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
5489,NCT03258723,Change in Hemoglobin A1c (HbA1c),Change in Sugar-sweetened Beverage Intake (Teaspoons Per Day),2018-07-30,TERMINATED,INTERVENTIONAL,['PHASE4'],
5490,NCT01066715,Mean change from baseline (Day 0 pre-dose) in HbA1c at Day 182,Serum levels of XOMA 052 (select sites only),2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
5491,NCT05483816,Changes in brain activity and connectivity through functional Magnetic Resonance Imaging (fMRI) between somatotopic and non somatotopic stimulation at feet,changes in speed and cadence in the 10 meter and 6 min walk test,2022-06-30,RECRUITING,INTERVENTIONAL,['NA'],Changes in reflex
5492,NCT00573261,Assessing the Change of Parameters of Autonomic Nerve Function Such as Heart Rate Variability by Means of the LifeShirt System Upon Treatment of Pregabalin vs. Placebo in Patients With Diabetes and Peripheral Neuropathy.,To Assess the Change in Disability Scale Upon Treatment of Pregabalin in Comparison to Placebo.,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
5493,NCT04414280,Time in range,The Parent's fear of hypoglycemia scale - modified version of the Hypoglycemia Fear Survey for use with parents,2020-03-12,RECRUITING,OBSERVATIONAL,['NA'],"Correlation between 'duration of type 1 diabetes of the patient (years)' and 'quality of life in partners of T1D patients using hybrid closed-loop therapy', the latter being measured by the DIDP-FM questionnaire. Note: only in case of substudy"
5494,NCT04875780,Percent weight change,User feedback as assessed by an online exit questionnaire,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],Diabetes incidence
5495,NCT01043354,medication adherence,exercise adherence,2008-09,COMPLETED,INTERVENTIONAL,['NA'],
5496,NCT03767478,"Primary outcome measure: sural nerve conductivity measured using a nerve conduction study at 6 months. This includes conduction velocity (m/s), calculated using distance and latency (ms), and sensory nerve action potential (SNAP) amplitude (μV).",Secondary outcome measure: device credibility and expectancy measured using modified credibility and expectancy questionnaire.,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
5497,NCT01596504,Change From Baseline to Day 56 in Plasma Glucose Corrected Area Under The Plasma Concentration-Time Curve (AUC) From Time 0.5 Hours to 4.5 Hours,Change From Baseline to Day 56 in the Cumulative Score Mean on the Appetite Perception Using a Visual Analogue Scale After Standardized Solid Breakfast,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
5498,NCT01711385,Occurrence of follow-up visit to physician regarding screening result,Improved periodontal measures,2009-04,COMPLETED,INTERVENTIONAL,['NA'],
5499,NCT00035750,,,2001-09,COMPLETED,OBSERVATIONAL,['NA'],
5500,NCT03015519,Time to reach half of the maximum plasma concentration (t1/2) of albiglutide: Part A,Change from Baseline in Children's Depression Inventory 2 Self Report Short Version [CDI 2: SR(S)],2017-08-14,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
5501,NCT01023113,"Comparison of the two methods in relation to visual field loss in terms of MD,CPSD and each quadrants loss of fields",Effect on macular edema in terms of OCT thickness,2009-09,UNKNOWN,INTERVENTIONAL,['NA'],
5502,NCT02070835,healing rate,recurrent rate,2014-04,COMPLETED,INTERVENTIONAL,['NA'],complication rate
5503,NCT01520753,Fasting serum glucose,Incidence of adverse events,1999-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
5504,NCT00385671,"Mean Change From Baseline to 12 Weeks in Weekly Mean of Daily 24 Hour Average Pain Score, Pregabalin Compared With Duloxetine",Number of Patients With Treatment-Emergent Elevated Laboratory Analytes,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
5505,NCT04590833,Processing speed,BMI,2021-06-01,UNKNOWN,INTERVENTIONAL,['NA'],
5506,NCT04817215,Mean change from baseline (Visit 1) in A1C at 26 weeks,Safety of repeat administration of ORMD-0801 in inadequately controlled T2DM subjects,2021-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],Means and mean changes from baseline over time for C-peptide
5507,NCT05195333,World Health Organization Quality of life Short Form for measurement of quality of life,Body mass index (BMI) measurement,2022-02-01,COMPLETED,INTERVENTIONAL,['NA'],
5508,NCT01122446,Adverse Events,First-phase Insulin Response From IvGTT Over Time,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
5509,NCT05786703,CHANGE IN BLOOD PRESSURE LEVEL,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],
5510,NCT01501201,overall mortality,"cost, cost-effectiveness and cost utility",2011-08-08,RECRUITING,INTERVENTIONAL,['PHASE4'],
5511,NCT02310932,cholesterol,medication adherence,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
5512,NCT06033508,inflammatory markers,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
5513,NCT00417950,Postprandial hyperglycemia,Postprandial oxidative stress,2007-01,UNKNOWN,INTERVENTIONAL,['NA'],
5514,NCT01793350,Efficacy of BC-DN-01,Safety of BC-DN-01,2013-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5515,NCT04295889,Cost-effectiveness of the screening.,Usability scores of the two screening methods.,2019-11-14,UNKNOWN,INTERVENTIONAL,['NA'],Role of health literacy in albuminuria screening.
5516,NCT03349944,HbA1c,Oral glucose tolerance test,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],
5517,NCT02325271,Placental growth factor,Blood pressure,2015-02,COMPLETED,OBSERVATIONAL,['NA'],
5518,NCT03374774,Proportion of patients who are using BIAsp 30 as their primary insulin,Diabetes Pen Experience Measure (DPEM) Scores (frequency of each item),2017-11-13,COMPLETED,OBSERVATIONAL,['NA'],
5519,NCT01217112,The Change From Baseline in Mean Serum High Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment,The Change From Baseline in Mean Beck Depression Inventory-II (BDI-II) Score at the End of 91 Days (13 Weeks) of Treatment,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
5520,NCT01303315,Decrees in HbA1c of at least 0.5 points and Weight loss of at least 3% of total body weight after 6 month of treatment,Glycemic and metabolic parameters,2011-01,TERMINATED,INTERVENTIONAL,['NA'],
5521,NCT00967642,"Reintervention, Myocardial Infarction, Cardiovascular Death",,2006-08,TERMINATED,INTERVENTIONAL,['NA'],
5522,NCT02650596,left ventricular ejection fraction measured by 3D echocardiography,differences in the incidences of treatment-emergent adverse events,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],
5523,NCT02762695,Systolic and Diastolic Blood Pressure,Medication adherence,2016-05-04,UNKNOWN,INTERVENTIONAL,['NA'],
5524,NCT01533142,weight loss,remission of diabetes mellitus type 2,2012-02,UNKNOWN,OBSERVATIONAL,['NA'],
5525,NCT02343354,Change in post 75 gram glucose load 2-hour glucose value in mothers and fathers,Change in diastolic blood pressure in mothers and fathers,2014-11,COMPLETED,INTERVENTIONAL,['NA'],
5526,NCT03972215,Differences of serum C-peptide levels between BBR and placebo treatment groups during the 2-hour hyperglycemic clamp study.,Differences of blood glucose levels between BBR and placebo treatment groups during the 2-hour hyperglycemic clamp study.,2019-10-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Heart rate and QT-interval duration using electrocardiogram before and after drug treatment.
5527,NCT02655627,HbA1c,Euro Quality of Life-5 Dimension,2015-04,COMPLETED,INTERVENTIONAL,['NA'],cholesterol levels
5528,NCT01643382,Incidence of Poor Graft Function After Kidney Transplant,,2012-08,COMPLETED,INTERVENTIONAL,['NA'],
5529,NCT03238963,Percentage of Participants With Any Ocular Adverse Events Over the On-treatment Period,Percentage of Participants With Adverse Events Other Than Ocular Adverse Events Over On-treatment Period,2017-09-19,COMPLETED,INTERVENTIONAL,['PHASE2'],
5530,NCT02871817,Amsler Grid,Assess repeatability of mobile application testing,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],
5531,NCT06007508,Does early administration of insulin glargine result in a change in ICU length of stay when compared to usual care for the treatment of diabetic ketoacidosis?,The change in duration of elevated anion gap when compared to usual care,2022-05-31,TERMINATED,INTERVENTIONAL,['PHASE2'],
5532,NCT00576667,Mean change per year in Non-Alcoholic Fatty Liver Disease [NAFLD] Activity Score (NAS),Change from baseline in hepatic transaminases (AST/ALT),2008-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
5533,NCT02471040,Cognitive Function,,2013-05-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
5534,NCT04474535,Macrovascular complications,Association between c-peptide and complications,2020-03-03,UNKNOWN,OBSERVATIONAL,['NA'],
5535,NCT05543083,Insulin Resistance,Adiposity,2023-06-02,RECRUITING,INTERVENTIONAL,['NA'],Intervention Acceptability
5536,NCT01868594,Changes in the Mean Value of HbA1c,Satisfaction of Diabetes Treatment Based on Diabetes Treatment Satisfaction Questionnaire Data,2013-05-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
5537,NCT01339637,Validation of the SCOUT DS algorithm comparing it to Oral Glucose Tolerance Test in dark skinned individuals,Compare SCOUT DS and FPG to HbA1c,2011-04,COMPLETED,OBSERVATIONAL,['NA'],
5538,NCT05164263,SAFETY and TOLERABILITY Outcomes,Efficacy outcomes,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
5539,NCT01710527,Apparent First-order Elimination or Terminal Rate Constant,Assessment of Subject Well-being Questionnaire,2012-05-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
5540,NCT04199676,Accuracy of immediate glucose tolerance testing,Transition to primary care,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],
5541,NCT00316667,,,2006-06,COMPLETED,OBSERVATIONAL,['NA'],
5542,NCT02849899,Diabetes event,The cost-effectiveness ratio,2018-10-26,RECRUITING,INTERVENTIONAL,['PHASE3'],
5543,NCT03313856,Modification in HbA1c in patients with type 2 diabetes after of administration of combination with Guazuma ulmifolia and Tecoma stans,"Renal safety of administration of guazuma, tecoma through the determination of serum creatinine",2010-01-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
5544,NCT01185574,Metabolic control,depressive symptoms,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
5545,NCT01496820,Postprandial blood glucose(PPG),HDL-cholesterol,2011-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
5546,NCT05801432,The change in coronary atherosclerosis detected by initial and follow-up CCTA,,2021-08-24,RECRUITING,OBSERVATIONAL,['NA'],
5547,NCT01142895,,,2010-05,COMPLETED,OBSERVATIONAL,['NA'],
5548,NCT00222768,Method development of dose-responsive measurement of insulin-stimulated glucose uptake of adipose tissue using 18-FDG and Positron Emission Tomography,To assess regional variation in insulin-stimulated glucose uptake in adipose tissue.,2005-04,COMPLETED,OBSERVATIONAL,['NA'],
5549,NCT06178094,Waist circumference value,,2022-02-21,COMPLETED,INTERVENTIONAL,['NA'],
5550,NCT06191094,Rates of post-operative vitreous hemorrhage,Number of patients with intra-operative bleeding,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
5551,NCT02420262,Change in HbA1c (Glycosylated Haemoglobin),Responder for HbA1c Below or Equal to 6.5 %,2015-07-26,COMPLETED,INTERVENTIONAL,['PHASE3'],
5552,NCT06037486,Analysis of system accuracy based on DIN EN ISO 15197,,2022-10-17,COMPLETED,INTERVENTIONAL,['NA'],
5553,NCT05392231,Early prediction of gestational diabetes,,2022-02-10,COMPLETED,OBSERVATIONAL,['NA'],
5554,NCT05851820,overall length of hospital stay,,2020-09-25,COMPLETED,OBSERVATIONAL,['NA'],
5555,NCT02714660,Mean Score on Burden of Treatment Questionnaire,,2016-02,COMPLETED,OBSERVATIONAL,['NA'],
5556,NCT02371694,Glycaemic excursion,Number of hypoglycaemic events in the 24h post-test meal,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
5557,NCT04556851,HbA1c change from baseline at week 24,Percentage of Patients Required Use of Rescue Therapy or Dropout due to Hyperglycemia,2020-09-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
5558,NCT01456806,HbA1c,Quality of Care Indicators,2006-12,COMPLETED,INTERVENTIONAL,['NA'],
5559,NCT05243160,PANSS-6 (positive and negative syndrome scale),Adverse interactions,2022-02-11,UNKNOWN,INTERVENTIONAL,['NA'],
5560,NCT05230615,Change in HbA1c (Glycated haemoglobin),"DTSQs (Diabetes Treatment Satisfaction Questionnaire, status), change in absolute treatment satisfaction From baseline (week 0) to",2021-11-21,COMPLETED,OBSERVATIONAL,['NA'],
5561,NCT04267770,Change in Basal Insulin Rate,,2018-04-10,COMPLETED,INTERVENTIONAL,['NA'],
5562,NCT05565924,The functional balance,Fasting blood glucose level,2022-01-02,COMPLETED,INTERVENTIONAL,['NA'],
5563,NCT03161327,Positive Predictive Value of Digital ABI in Diagnosing PAD,,2017-07-15,COMPLETED,INTERVENTIONAL,['NA'],
5564,NCT03123237,Renal Counts,,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],
5565,NCT00767208,Apparition of exogenous glucose in plasma in the postprandial phase and its effect on carbohydrate and lipid metabolism,Carbohydrate and lipid oxidation,2005-01,COMPLETED,INTERVENTIONAL,['NA'],
5566,NCT01342484,Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 12 Weeks of Treatment,Change From Baseline in Fasting Plasma Glucose (FPG) After 12 Weeks of Treatment,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
5567,NCT01573949,Health-Related Quality of Life (HRQoL),Creatinine Level as a Measure of Renal Function,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
5568,NCT00926068,Complete ulcer closure,Incidence of improved ulcers,2010-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],
5569,NCT04631913,Beta-cell function,,2020-08-14,UNKNOWN,OBSERVATIONAL,['NA'],
5570,NCT02631512,Performance of Woulgan Gel as primary dressing in diabetic foot ulcer in terms of reduced wound size in sqcm.,Useability of Woulgan as primary dressing in diabetic foot ulcer measured as degree of pain (100 mm VAS).,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
5571,NCT02131246,Mean plasma glucose concentration,Area under the serum insulin aspart concentration-time curve,2014-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
5572,NCT06297850,Agreement between glucose,Agreement between glucose readings when at high glucose levels,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Mortality
5573,NCT03864432,Cmax of Gemigliptin,,2019-07-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
5574,NCT03359590,The Frequency of Hypoglycaemic Episodes With Sitagliptin vs Placebo Treatment.,,2018-03-21,COMPLETED,INTERVENTIONAL,['PHASE2'],
5575,NCT01038089,Brachial artery flow-mediated dilation,"Blood markers of inflammation, oxidative stress, insulin resistance",2010-01,COMPLETED,INTERVENTIONAL,['NA'],
5576,NCT03145649,Infant head circumference at day 90,,2010-01-12,COMPLETED,OBSERVATIONAL,['NA'],
5577,NCT03215043,Glucose,alanine aminotransferase,2017-07-02,COMPLETED,INTERVENTIONAL,['NA'],visceral fat area
5578,NCT04114903,Change in Plasma Insulin,Stanford Leisure-Time Activity Categorical Item (L-Cat),2019-11-08,RECRUITING,OBSERVATIONAL,['NA'],"Daily online survey of cannabis use, alcohol use, exercise and diet"
5579,NCT04161170,Change of HbA1c (glycated hemoglobin) at 6months from baseline,time in range of >250 mg/dL by CGMS in interventional group C,2019-11-20,UNKNOWN,INTERVENTIONAL,['NA'],
5580,NCT03870724,Type 2 diabetes,,2019-08-27,COMPLETED,OBSERVATIONAL,['NA'],
5581,NCT01105429,"Safety and Tolerability of the investigational drug, as assessed by adverse event monitoring, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments",Excretion of the investigational drug and metabolites from the body,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
5582,NCT05174078,Change in participants' body weight,Nutrition Education: Self-Efficacy for Managing Chronic Diseases Scale,2022-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
5583,NCT02645448,Concentration of glucose and hyperglycemia prevalence,Correlation between heart rate variability and glucose 24 hours,2014-11,COMPLETED,INTERVENTIONAL,['NA'],
5584,NCT03782155,Wound healing:Number of cells per clauster in tissue sample of wound.,,2021-06-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Incidence of treatment- adverse events
5585,NCT02710617,System accuracy criteria (see description),,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
5586,NCT00205725,Effects of olanzapine/ziprasidone/haloperidol on glucose regulation,Explore treatment-related effects on glucose effectiveness,2000-11,COMPLETED,INTERVENTIONAL,['NA'],
5587,NCT00783744,Frequency of subjects with HbA1c ≤ 7.0 % and > 7.0 %,"Frequency of subjects with FBG ≤ 100 mg/dl (5.5 mmol/l), 100 mg/dl < FBG ≤ 120 mg/dl (5.5 mmol/l < FBG ≤ 6.6 mmol/l), 120 mg/dl < FBG ≤ 150 mg/dl (6.6 mmol/l < FBG ≤ 8.3 mmol/l) and > 150 mg/dl (> 8.3 mmol/l)",2001-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
5588,NCT02426294,Evidence of efficacy of glycemic control indicated by the mean changes of HbA1c (%) at week 26 from baseline,Evidence of efficacy of glycemic control indicated by the mean changes of HbA1c (%) at week 12 from baseline,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
5589,NCT03840928,RAPID-3 (MD-HAQ with visual analogue scale for pain and patient global measure for overall health),,2015-04-01,RECRUITING,OBSERVATIONAL,['NA'],
5590,NCT04585776,Percentage of Time With Sensor Glucose Values Between 70 and 180 Milligrams Per Deciliter (mg/dL) With Continuous Glucose Monitoring (CGM),Product of Insulin to Carbohydrate Ratio and Total Daily Dose (ICR×TDD),2020-10-30,COMPLETED,INTERVENTIONAL,['PHASE2'],
5591,NCT04734015,Change in Adult Participant Fasting HbA1c,Change in Depression and Depressive symptoms - Adult and Youth participants,2021-06-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in Diabetes Empowerment - Adult participants
5592,NCT00145392,,,2002-09,COMPLETED,OBSERVATIONAL,['NA'],
5593,NCT02079376,improvement of HbA1c,Relationship between blood TG level and the GCM efficacy,2013-11,UNKNOWN,INTERVENTIONAL,['NA'],
5594,NCT01649466,Rate of confirmed hypoglycemic events,Change from baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9) at 24 week,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
5595,NCT04156685,Part B : AUClast under fed condition,Part B : t1/2 under fed condition,2019-08-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
5596,NCT06258148,Changes in glycosylated hemoglobin (HbA1c) from baseline at 24 weeks of treatment,The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (NAb),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
5597,NCT02724566,Delta between Glucose Infusion Rate,Clinic sign of apelin toxicity,2016-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
5598,NCT01967030,Incident Type 2 Diabetes,Maternal waist circumference,2008-05,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Metabolite profiles
5599,NCT02326259,Progression of diabetic retinopathy,,2015-03,COMPLETED,OBSERVATIONAL,['NA'],
5600,NCT03474393,Change in HbA1c,DTSQ,2018-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
5601,NCT03237767,Glycaemic control (measured using arm-mounted Freestyle Libre continuous glucose monitor),Physical activity,2018-05-01,TERMINATED,INTERVENTIONAL,['NA'],
5602,NCT04170790,Heart Rate,,2019-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
5603,NCT05880654,Effect of SRP on GCF levels of IL-39 & IL35,,2023-01-01,COMPLETED,INTERVENTIONAL,['NA'],
5604,NCT00005487,CVD,,1999-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
5605,NCT04973644,HbA1c concentration,Diabetes Treatment Satisfaction Questionnaire,2021-08-21,UNKNOWN,INTERVENTIONAL,['NA'],
5606,NCT05099770,Primary Composite Endpoint,Secondary Composite Endpoint,2022-01-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
5607,NCT01515930,Diabetes Management Scale,Blood Glucose Testing Frequency,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
5608,NCT01969357,the change from baseline in HbA1c at 12 week,"Change From Baseline in Body Weight at Week 4,8,12",2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
5609,NCT02623478,Pharmacokinetics (PK): Area under the Concentration Curve (AUC) of Insulin Lispro,Pharmacodynamics (PD): AUC of Glucose Following a Meal,2018-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
5610,NCT01055652,To evaluate the pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with type 2 diabetes by assessment of AUC and Cmax of dapagliflozin,"To evaluate the pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with type 2 diabetes by assessmentof AUC0-t, tmax, t1/2, CL/F.",2010-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
5611,NCT04272840,Transfer/KM Level 3: Change in average dietary GI,"Maternal Weight, during pregnancy",2019-10-24,UNKNOWN,INTERVENTIONAL,['NA'],
5612,NCT03014479,Change From Baseline in Total Score for All Question Items in the Diabetes Therapy Related -QOL (DTR-QOL) Questionnaire at the End of Study,Number of Participants With Hospitalization for Type 2 Diabetes (Excluding Educational Hospitalization Without Worsening of Diabetes),2017-02-18,COMPLETED,INTERVENTIONAL,['PHASE4'],
5613,NCT01401790,Patients' health (reported number of hypoglycemias and nocturnal hypoglycemias),Family satisfaction with the software application,2008-02,COMPLETED,INTERVENTIONAL,['NA'],
5614,NCT04829045,Homeostasis model assessment- insulin resistance (HOMA-IR),Incident of treatment adverse events in terms of intensity (grades 1 - 5),2021-05-27,COMPLETED,INTERVENTIONAL,['NA'],
5615,NCT00198757,at 52 weeks of maintenance,changes in medication costs and health related quality of life.,2002-07,COMPLETED,INTERVENTIONAL,['NA'],
5616,NCT02957513,Diabetes Self-Care Activities,Average Blood Sugar (A1c),2016-11-01,UNKNOWN,INTERVENTIONAL,['NA'],
5617,NCT05516797,Difference in change in 14-day CGM-derived TIR,Difference in Change in HbA1c,2022-09-22,COMPLETED,INTERVENTIONAL,['NA'],"Difference in change in the CGM-derived metric, Mean amplitude of glucose excursion, from Baseline to 3-month Post-Dietary Change period"
5618,NCT02971865,Consumer Assessment of Healthcare Providers and Systems (CAHPS),Patient Health Questionnaire-9 (PHQ-9,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
5619,NCT06260254,Matsuda insulin sensitivity index in the morning after exposure to high vibration,Evening neurobehavioural accuracy,2024-02-05,RECRUITING,INTERVENTIONAL,['NA'],
5620,NCT00926744,Objectively measured amount of physical activity,Incidence of musculoskeletal and joint pain,2006-04,UNKNOWN,INTERVENTIONAL,['NA'],
5621,NCT01002768,Baseline-adjusted hypoglycaemic symptoms score at nadir plasma glucose concentration,Hypoglycaemic symptoms score during recovery from hypoglycaemia,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
5622,NCT00597233,Prandial blood glucose lowering profile,Serious adverse events,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
5623,NCT00726778,"To test phenotype-genotype associations between each one of the AIMs and measures of FI, SI and AIRg after adjusting for body composition in a sample of AA, HA and EA prepubertal children.",,2004-05,COMPLETED,OBSERVATIONAL,['NA'],
5624,NCT03727035,Expression of CD163 gene,Quantify the levels of CD163,2018-02-10,UNKNOWN,OBSERVATIONAL,['NA'],
5625,NCT02381119,change in fasting insulin levels,20 nutrition-related SNPs (single nucleotide polymorphisms),2015-05,COMPLETED,INTERVENTIONAL,['NA'],
5626,NCT04344301,Acceptability of Intervention Measure (AIM),,2020-08-31,COMPLETED,INTERVENTIONAL,['NA'],Stigma Scale for Chronic Illness (SSCI-8)
5627,NCT01023698,Stabilization of proliferative diabetic retinopathy,,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
5628,NCT03468894,Change in Workplace sitting time,Change in perceived vigor,2018-03-22,WITHDRAWN,INTERVENTIONAL,['NA'],
5629,NCT04485871,Fasting white adipose tissue NLRP3 inflammasome activation,Physical activity,2019-12-19,RECRUITING,INTERVENTIONAL,['NA'],
5630,NCT05863884,Blood Glucose Level,Diabetes Self-Management Score,2022-02-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],COVID-19 Vaccination Confidence and Uptake
5631,NCT00766909,Insulin Sensitivity,plasma glucagon,2008-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
5632,NCT00110864,Effect on change in average daily insulin dose,Effect on lipid levels,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
5633,NCT01561508,change in stimulated c-peptide,change in total daily insulin dose per kilogram,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
5634,NCT04257565,Wound Healing,Physical Function,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],
5635,NCT05663931,Mean glucose levels,Infection,2023-01-10,RECRUITING,INTERVENTIONAL,['NA'],
5636,NCT05329415,Rifampicin/Isoniazid/Pyrazinamide Cmax 2 hours post-dose,Mean daily subcutaneous glucose measurement,2022-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
5637,NCT02001532,Agatston Score (CT),,2014-05,COMPLETED,OBSERVATIONAL,['NA'],
5638,NCT03298542,Number of Participants With Treatment Related AEs and SAEs Reported From Week 52 to Week 78,Incidence of Antibodies to Golimumab,2017-10-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
5639,NCT02903615,Glucose control,Follow-up of glycemic control and insulin secretion,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
5640,NCT00770835,Increase from Baseline in the number of Endothelial Progenitor Cells (CD34+KDR+).,Urinary albumin excretion.,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
5641,NCT04919954,Tebipenem Pivoxil Hydrobromide Tissue Penetration,Tebipenem Pivoxil Hydrobromide Area Under the Curve (AUC) in Tissue,2021-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
5642,NCT05120388,number of participants with insulin requirement,number of participants with diabetes at postpartum,2022-01-11,RECRUITING,INTERVENTIONAL,['NA'],
5643,NCT03651622,Change in Time in Clinical Hypoglycemia - Randomization 3,Change in Time in Target Glucose Range - Randomization 3,2018-11-12,COMPLETED,INTERVENTIONAL,['NA'],
5644,NCT04212325,patient satisfaction: survey,,2019-12-10,COMPLETED,INTERVENTIONAL,['NA'],
5645,NCT05163054,Incidence of hypoglycemia,Life quality.,2022-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
5646,NCT06252051,Immunogenicity,Inflammatory interleukin measurements,2021-01-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
5647,NCT00430755,"Detection of Medical Problems (by Number of Problems Reported by Computer Assisted History, That Were Not Reported by Physician Taken History)",,2005-08,COMPLETED,INTERVENTIONAL,['NA'],
5648,NCT02295085,Incident cancer during the period of cohort follow-up,Incident renal disease during the period of cohort follow-up,1990-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Other incident conditions during the period of cohort followup
5649,NCT05282680,Cardiovascular complications in diabetes,Diabetes progression,2014-02-01,RECRUITING,OBSERVATIONAL,['NA'],
5650,NCT03867773,Change from baseline to week 8 in body weight,"Change from baseline to week 8 in sex steroid levels (estrogen, androgens, sex hormone binding globulin)",2019-02-01,COMPLETED,INTERVENTIONAL,['NA'],
5651,NCT00468364,,,2003-07,COMPLETED,OBSERVATIONAL,['NA'],
5652,NCT01248481,Change in HbA1c,Postprandial Blood Glucose,2010-09,COMPLETED,OBSERVATIONAL,['NA'],
5653,NCT00995540,Injection tolerability,C-peptide,2009-11,TERMINATED,INTERVENTIONAL,['PHASE2'],
5654,NCT02545062,The differences between the MoCa test score in diabetics and in a control group of non diabetics,"The relation between the MoCa test score and the presence of macrovascular complication, ischemic heart disease, non-fatal myocardial infarct, stable and unstable angina, heart failure, non-fatal stroke, peripheral vascular disease",2014-05,UNKNOWN,INTERVENTIONAL,['NA'],
5655,NCT00364377,Lowering of Fasting Glucose,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
5656,NCT02982798,Cmax of Metformin and rosuvastatin,,2017-07-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
5657,NCT00455598,Change and % change from baseline Adiponectin,concomitant medications,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
5658,NCT00971516,Healing profile of cytokines,,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
5659,NCT00018616,,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
5660,NCT01600937,Physical Activity Behavior,Musculo-skeletal disturbances,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
5661,NCT02104804,Change in HbA1c From Baseline to Week 24,Analysis of Change in Mean Total Daily Dose of Insulin From Baseline to Week 24,2014-05-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
5662,NCT04506151,Glycemic control,Mood,2021-01-19,RECRUITING,INTERVENTIONAL,['NA'],
5663,NCT04424537,Change in fasting blood glucose level,Change in Muscle function as measured by relative power of jump,2024-01,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],
5664,NCT01517321,"Incidences of adverse experiences and change in vital sign, safety lab etc. as parameters of safety and tolerability",Fasting plasma glucose,na,COMPLETED,INTERVENTIONAL,['PHASE3'],
5665,NCT00657319,HbA1C,"General conditions (reason of switch, BMI, selected laboratory parameters, quality of care)",2007-10,COMPLETED,OBSERVATIONAL,['NA'],
5666,NCT03343782,Adverse events,Hemoglobin A1c (HbA1c) level,2017-11-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5667,NCT02403427,postprandial glucose,Glucose variability parameters,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],Patients' acceptances to use VoiceDiab system
5668,NCT01215955,Change From Baseline to 24 Week Endpoint in Glycated Hemoglobin (HbA1c),Percentage of Participants With Severe Hypoglycemic Episodes,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
5669,NCT01834378,HOMA IR,,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
5670,NCT00461331,Number of Participants With Glycemic Control (Glucose Levels Between 180-300 mg/dL) 24 to 100 Hours After Line Change,"Oxidative Stress Marker 48, 72 and 96 Hours After Keeping the Same Pump Infusion Line in Place",2004-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
5671,NCT00801892,"Physical Activity, Steps Walked",Fatigue/Inertia,2009-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
5672,NCT01477112,Changes in oxidative status,Serum and erythrocyte folates.,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
5673,NCT04709887,Healing rate of wound surface,Recurrence rate of foot ulcer,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
5674,NCT05074667,Proportion of Participants with sustained CGM use,Mean change in BMI from baseline,2021-12-01,COMPLETED,INTERVENTIONAL,['NA'],
5675,NCT02586155,Incidence of First Occurrence of Adjudication-confirmed Narrowly Defined MACE,Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline Over Time Within and Between Treatment Groups for Subjects With Impaired Renal Function at Baseline (eGFR <60 mL/Min/1.7m2),2015-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
5676,NCT03969719,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 16,Change From Baseline in HbA1c at All Timepoints Other Than Week 16,2019-07-18,COMPLETED,INTERVENTIONAL,['PHASE2'],
5677,NCT00128336,Weight,Change in mood state,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
5678,NCT03622957,Glomerular Filtration Rate [ml/min/1.73m2],CV Events (Yes/No),2018-08-10,UNKNOWN,OBSERVATIONAL,['NA'],
5679,NCT01351675,Time-to-first event of the composite endpoint,"Frequency, intensity, and relationship to study drug of adverse events and serious adverse events, as well as clinical and laboratory test abnormalities.",2011-06-30,TERMINATED,INTERVENTIONAL,['PHASE3'],
5680,NCT05039034,Prevalence rate of dyslipidemia,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],
5681,NCT03358121,Asprosin dynamics,,2017-07-11,COMPLETED,OBSERVATIONAL,['NA'],
5682,NCT02827266,Percentage of Participants With Hemoglobin Greater Than (>) 11 Grams per Deciliter (g/dL) After 8-Week Correction Phase,Number of Participants per Type of Diabetes,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
5683,NCT01077323,"Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis (During ""Past Use"" Period) - Time on Drug Analysis","Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis Among Initiators of Exenatide, Diabetics Initiating Other Antidiabetic Drugs, and the Non-diabetes Cohort - Intent to Treat Analysis",2004-09,COMPLETED,OBSERVATIONAL,['NA'],
5684,NCT00551356,Change from baseline to endpoint in 2h postprandial blood glucose excursion after breakfast,Total Insulin Doses,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
5685,NCT00351884,Change from baseline in HbA1c at 24 weeks,Change from baseline in body weight at 24 weeks,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
5686,NCT05354297,Changes in A1c from screening to 3 and 6 months in each of the OneTouch Solutions programs,Change from baseline in medication adherence as assessed by a medication adherence survey after 3 and 6 months,2022-07-26,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Quantify the number of medical insurance claims made by subjects within each of the OneTouch Solutions programs using data harvested from a large medical insurance dataset
5687,NCT04623697,Stimulated insulin secretion,Fasting blood glucose,2020-11-01,RECRUITING,OBSERVATIONAL,['NA'],
5688,NCT01103648,C reactive protein,Tumor necrosis factor alpha,2005-06,COMPLETED,INTERVENTIONAL,['NA'],
5689,NCT01254552,Prevalence of Occult Myocardial Scar on Delayed-enhanced MRI in Asymptomatic Patients With Type 2 Diabetes Mellitus,Number of Patients With and Without Occult Myocardial Scar on Cardiac MRI According to the Degree of Stenosis,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
5690,NCT00418366,Determination of the pharmacokinetics of MK0431 (sitagliptin phosphate) in patients with renal insufficiency compared to healthy volunteers,Safety and tolerability in patients with renal insufficiency,2003-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
5691,NCT02677454,Mean Absolute Relative Difference (MARD),questionnaire,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
5692,NCT04383314,Change in Self-reported physical function of participants after intervention,Number of participants with Osteoarthritis,2021-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
5693,NCT02898506,FPIR (1+3min serum insulin level after iv glucose infusion),Serum C-peptide AUC,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
5694,NCT05686694,State Anxiety Scale,,2023-11-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
5695,NCT00913562,Flicker induced vasodilatation,,2009-06,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
5696,NCT05998460,GGE adherence,Changes in the soluble receptor for advanced glycation end-products (sRAGE),2024-01-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
5697,NCT00854594,Provider Abilities Scale - Subscale From the Midwest (MW) Clinicians' Network,Attitudes Toward Healthcare Teams Scale and Subscales,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
5698,NCT06185491,Coefficient of variation of individual HGI distribution,"Glycation gap, determined from comparison between HbA1C measured and HbA1C derived from glycated albumin",2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
5699,NCT04927871,Change of weight in kilograms,Percentage of Completion of the program.,2020-11-16,COMPLETED,INTERVENTIONAL,['NA'],
5700,NCT01991795,"Composite of Cardiovascular (CV) Death, MI or Stroke",All-cause Death,2014-02-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Permanent Discontinuation of Study Medication Due to Any Bleeding Event
5701,NCT00326573,"HbA1C at 6 months, end of intervention and one year follow up",quality of life at baseline and end of one year intervention,2001-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5702,NCT00572650,Pharmacokinetic measures,Safety and tolerability measures,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
5703,NCT04702490,Safety and tolerability of MET409 with or without empagliflozin (incidence of adverse events),Pharmacodynamic profile of MET409 alone or in combination with empagliflozin,2020-12-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],
5704,NCT05692518,Creation of a patent anastomosis,,2022-12-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
5705,NCT00501657,Gastric emptying rate,"Intragastric distribution, gastrointestinal hormone release (GLP-1, GIP), glycemia, insulinemia, appetite",2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
5706,NCT00309192,Macular edema reduction or stabilization 6 months after treatment.,Tolerance of the treatment.,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
5707,NCT01297738,Cerebral binding of [123I]FP-CIT to serotonin- and dopamine transporters and correlation with changes in in vivo and ex vivo insulin sensitivity,Insulin signalling pathways,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
5708,NCT00869128,Sleep Efficiency,,1995-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
5709,NCT05709938,Mid night blood glucose level,,2019-11-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
5710,NCT03268005,Change in Glycosylated Haemoglobin (HbA1c),Change From Baseline in Body Mass Index (BMI),2017-09-19,COMPLETED,INTERVENTIONAL,['PHASE3'],
5711,NCT05110625,Change from Baseline Glycated Hemoglobin (HbA1C) at 6 months,Quantification of alcohol consumption - FISTERRA,2021-12-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Follow-up rate
5712,NCT02287532,"Efficacy data: change in HbA1c, measured at 1 year minus the value baseline",,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
5713,NCT00815399,Circulating Endothelial microparticles,"Glucose profile, lipid profile, hemoglobin A1c, carotid intima-media thickness",2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
5714,NCT02716870,Inflammation,,2015-06,UNKNOWN,OBSERVATIONAL,['NA'],
5715,NCT02205996,To examine the effect of hypoglycaemia on platelet surface expression of platelet activation markers P-selectin and fibrinogen binding.,To measure changes in markers of inflammation (high sensitivity C-reactive protein) and endothelial function using EndoPat 2000,2011-11,COMPLETED,INTERVENTIONAL,['NA'],To assess the effects of hypoglycaemia on participants scores on cognitive function tests
5716,NCT04733612,Change from Baseline Quality of Life Assessed by SF-36v2 at 6 months,Change from Baseline Energy Intake at 6 months,2016-06-30,COMPLETED,INTERVENTIONAL,['NA'],
5717,NCT05896319,Change in residual socket volume,Change in pain assessment,2022-09-07,COMPLETED,INTERVENTIONAL,['NA'],
5718,NCT06042517,Glucose metabolic clearance rate,High blood glucose index (HBGI),2023-09-30,RECRUITING,INTERVENTIONAL,['NA'],
5719,NCT02557620,Area under the semaglutide concentration-time curves,Area under the the single dose concentration-time curve,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
5720,NCT02218619,C-peptide measurement as reflection of insulin secretion,liver function tests,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
5721,NCT01159249,"Measure AEs, vital signs, laboratory evaluations",HOMA-B,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
5722,NCT02009670,"Fat oxidation, energy expenditure",Breath sampling 13CO2,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
5723,NCT01248143,Assess the effects of green tea and FPP on the levels of C-reactive proteins,Assess the effect of green tea and fermented papaya preparation on development of atheroma and drug therapy outcomes,2010-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
5724,NCT05717387,Change in percent of time in range (glucose between 3.9-7.8mmol/L) over 6 months measured with continuous glucose monitoring.,Change in quality of life,2023-04-11,RECRUITING,INTERVENTIONAL,['NA'],
5725,NCT05169034,System Performance,,2021-12-14,TERMINATED,OBSERVATIONAL,['NA'],
5726,NCT02068508,Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs),Number of Participants Who Received Specific Daily Dose of Insulin Product at Each Time Points,2009-07-30,COMPLETED,OBSERVATIONAL,['NA'],
5727,NCT03282981,Measurement of timolol serum during the treatment phase,The time to wound closure between the two groups,2018-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
5728,NCT02839044,"Absolute change in ongoing calcium deposition quantified as volumetric bone metabolic rate (CSUVMEAN x cm3) in the femoral artery between baseline and 6 months after baseline, as determined by 18F-NaF PET/CT imaging.",,2016-06,COMPLETED,INTERVENTIONAL,['NA'],
5729,NCT01845064,Determine the pharmacokinetic of DM199 after single and multiple doses,Determine changes in immune cell populations by FACS analysis.,2013-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5730,NCT00282685,Improvement of neurological score: modified NIS(LL)+7,Heart rate variability,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
5731,NCT03364387,"Composites of Myocardial Infarction, Hospitalization, Revascularization, Death",Heart failure,2018-03-05,COMPLETED,OBSERVATIONAL,['NA'],
5732,NCT00455520,Change From Baseline (at Randomization) in Average Pain Intensity on an 11-point Numerical Rating Scale (NRS) Over the Last Week of the Double-blind Maintenance Period at Week 12,Change From Baseline in Brief Pain Inventory (BPI) Total Pain Score Over the Last Week of the Maintenance Period at Week 12.,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
5733,NCT01185236,change of ApoB/ApoA1,safety,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
5734,NCT00692562,kidney function,autoantibodies,2005-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5735,NCT05713266,All cause higher level of care utilization,Highly likely+somewhat likely COVID-19 related healthcare utilization,2022-10-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
5736,NCT02002091,Number of Patients With Erectile Dysfunction,Number of Patients That Died From Cardio Vascular Cause,2009-01,COMPLETED,OBSERVATIONAL,['NA'],
5737,NCT03324776,Percentage change from baseline HbA1c,Percent of time that Blood glucose (BG) is under 70 mg/dL on CGMS,2017-10-16,COMPLETED,INTERVENTIONAL,['PHASE3'],
5738,NCT02505334,Change in Glycosylated Haemoglobin (HbA1c) (Week 26),Change in Calcitonin,2015-07-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
5739,NCT00279045,Time from randomization to the primary action point (monotherapy failure).,"Comparison of effects of long-term treatment with Rosiglitazone, Metformin, Glyburide: - maintenance/restoration of beta-cell function: HOMA IS, progression of microalbuminuria, fibrinolytic markers (PAI-1,fibrinogen, CRP).",2000-01-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
5740,NCT02978807,Prevalence of Gestational Diabetes via venous 75 gm oral glucose tolerance test,"Specificity, Sensitivity, positive predictive value, and negative predictive value of alternative point of care screening strategies",2012-07,COMPLETED,OBSERVATIONAL,['NA'],
5741,NCT03905863,Percentage Reduction in Ulcer Area (cm^2).,Number of Adverse Events,2019-06-04,COMPLETED,INTERVENTIONAL,['NA'],
5742,NCT03004664,Patients will improve their capacity for diabetes self-management: Measured through change in Patient Activation,Patients will successfully self-manage their diabetes as measured though change (reduction) in chronic stress levels,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],
5743,NCT00166673,Navigator Accuracy,Exploratory assessment of impact of Navigator on HbA1c,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
5744,NCT03240432,Time spent with glucose level <70 mg/dL,Time spent with glucose level <54 mg/dL,2017-09-26,COMPLETED,INTERVENTIONAL,['NA'],Glycemic variability (coefficient of variation)
5745,NCT03422263,Maximum oxygen uptake,Body constitution (Muscle mass predicted II),2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],Echocardiographic parameters (E/e' avg)
5746,NCT02983812,Hospital readmission within 30 days of discharge,Total health care cost utilization in 6 months after discharge,2017-01-23,COMPLETED,OBSERVATIONAL,['NA'],
5747,NCT03787511,Proportion of patients with small fiber neuropathy,values of the DN4 questionnaire in diabetic patients,2019-03-05,RECRUITING,INTERVENTIONAL,['NA'],
5748,NCT00658957,The percentage of patients who remain free of signs and symptoms of infection until the end of the study,Treatment emergent Adverse Events,2008-04,TERMINATED,INTERVENTIONAL,['PHASE2'],
5749,NCT06164535,serum amyloid-β,HOMA-IR,2023-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
5750,NCT04261361,Glycemic control,DM-specific distress,2018-12-12,COMPLETED,INTERVENTIONAL,['NA'],
5751,NCT01200394,Change From Baseline in Urinary Albumin Creatinine Ratio (UACR) at Week 12,Plasma Concentration Versus Time Summary of PF-00489791,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
5752,NCT00913393,Measure: change from baseline in 24-hour urinary ACR for each arm compared with placebo,Measure: Change from baseline in serum creatinine for each FG-3019 arm compared with placebo,2009-02,TERMINATED,INTERVENTIONAL,['PHASE2'],
5753,NCT01476449,Mean Change in Early Treatment for Diabetic Retinopathy Study (ETDRS) Eye Chart Vision.,"Percentage of Patients Anatomically ""Dry.""",2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
5754,NCT00062764,Number of Patients With Improvement in Liver Histology,Mean BMI Change,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
5755,NCT00971997,Percentage of Participants Achieving Hemoglobin A1c (HbA1c) Below 6.5% at Week 48 Endpoint,Number of Hypoglycemia Episodes Participants Experienced at Any Time From Baseline Through Week 48,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
5756,NCT00858013,The Durability of Nateglinide in Comparison With Those of Glimepiride Based on the Withdrawal Rate,HOMA-IR,2009-04-24,COMPLETED,INTERVENTIONAL,['PHASE4'],
5757,NCT00555490,mortality or using dialysis,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
5758,NCT05030844,The change in diabetes self managament of individuals with Type 2 diabetes at 3rd month and 6 rd month with the Diabetes Self-Management Scale,Metabolic control variables,2021-07-14,COMPLETED,INTERVENTIONAL,['NA'],
5759,NCT01120119,C peptide,Glycometabolic control,na,COMPLETED,INTERVENTIONAL,['PHASE2'],
5760,NCT05362968,Lipid control,Diabetes risk hormones,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE1'],
5761,NCT01895387,Plasma Lp-PLA2 activity,PBMC Lp-PLA2 activity,2012-01,COMPLETED,INTERVENTIONAL,['NA'],LDL particle size
5762,NCT04289818,Change from Baseline HbA1c at 6 months,Change of Body mass index at 6 months,2018-02-01,COMPLETED,INTERVENTIONAL,['NA'],
5763,NCT02985099,Defect depth reduction (%),plaque index,2015-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
5764,NCT00977262,PBMC gene expression profiles,Endothelial function,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
5765,NCT03506750,Changes of intraocular VEGF and PLGF of patients with proliferative diabetic retinopathy post-IVC (intravitreous injection of Conbercept).,Effect of IVC on postoperative complications,2017-06-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
5766,NCT06247748,Baseline-corrected difference of Corrected QT interval after multiple subcutaneous injections of JY09 injection,Immunogenicity,2023-10-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Relative abundance
5767,NCT06022601,HbA1c,Systolic and Diastolic Blood pressure,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],
5768,NCT01370005,Mean 24-hour Systolic Blood Pressure Change From Baseline,Orthostatic Blood Pressure,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Confirmed Hypoglycaemic Adverse Events
5769,NCT01910051,anthropometric measures and metabolic biomarkers indicative of prediabetes,intra-subject and inter-subject variability of analyzed biomarkers,2013-09-25,COMPLETED,OBSERVATIONAL,['NA'],"the correlation between anthropometric data, medical history, and biomarkers with regard to metabolic risk"
5770,NCT00925717,Investigate LDL-C goal achievement rate according to ADA recommendation,Investigate reduction of 10-year risk for CHD by using UKPDS risk engine,2009-05,COMPLETED,OBSERVATIONAL,['NA'],
5771,NCT05094401,Mean change in HbA1c,Change in Medications,2021-10-04,TERMINATED,INTERVENTIONAL,['PHASE3'],
5772,NCT01099397,"Number of Participants Diagnosed With Prediabetes or Normal Glucose, by 2 Measurements (Fasting Glucose Measurement and Glucose Measurement After a 2-hour Oral Glucose Tolerance Test [OGTT]), at Three Timepoints During Antihypertensive Treatment",,2009-05,COMPLETED,OBSERVATIONAL,['NA'],
5773,NCT02825251,Change in Glycosylated Haemoglobin (HbA1c),Number of Subjects With at Least One Non-routine Change-of-infusion-sets Categorised by Reasons for Change-of-infusion-sets,2016-07-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
5774,NCT02071498,adherence,safety medication use,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
5775,NCT03455543,Change in Pain Intensity,Changes in Nerve Conduction Studies of Amplitude Between Baseline and End of Treatment at 4 Months.,2018-03-26,COMPLETED,INTERVENTIONAL,['NA'],Exploratory Endpoint: Changes in Intraepidermal Nerve Fiber Density (IENFD) at the Distal Thigh and Distal Leg - Part B
5776,NCT04383197,Insulin secretion,Body composition,2019-12-10,UNKNOWN,INTERVENTIONAL,['NA'],
5777,NCT03810378,Hemoglobin A1c (HbA1c),Blood pressure,2019-06-05,COMPLETED,INTERVENTIONAL,['NA'],Adherence to diet protocols
5778,NCT05818995,albuminuria,,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
5779,NCT03254979,Implementation of the recommended clinical intervention by health care porfessionals,Lifestyle change at patient level,2017-03-15,COMPLETED,INTERVENTIONAL,['NA'],
5780,NCT01808690,Change in Insulin Sensitivity,Change in Aortic Wall Sheer Stress (WSS),2013-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Change in Brachial Artery Distensibility
5781,NCT03264352,Composite of Major Adverse Cardiovascular and Cerebrovascular Events,Cancer,2018-02-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
5782,NCT04955834,Change value of glycosylated hemoglobin (HbA1c),Abnormal findings,2021-07-27,RECRUITING,INTERVENTIONAL,['PHASE3'],
5783,NCT02144909,Change from Baseline diabetes management functioning as measured by the Problem Areas in Diabetes questionnaire at 3 months and 6 months,Change from Baseline weight in kg at 3 months and 6 months,2013-11,COMPLETED,INTERVENTIONAL,['NA'],Change from Baseline dietary patterns as a questionnaire at 3 months and 6 months
5784,NCT00300105,"Adverse events, laboratory variables, physical examination, cardiac evaluation, hypoglycemic events, electrocardiogram, vital signs (blood pressure and pulse), body weight","Central obesity (waist circumference, hip circumference and waist/hip ratio)",2005-10,TERMINATED,INTERVENTIONAL,['PHASE3'],
5785,NCT02024399,Improved body compositon (decrease in % fat; increase in % lean tissue) using DEXA,"Improved levels of fitness using ACSM guidelines / assessments to measure such constructs of fitness as flexibility, muscle strength, cardiovascular endurance and agility.",2004-08,COMPLETED,INTERVENTIONAL,['NA'],Quality of life as perceived by the children and the parents.
5786,NCT01984567,Plasma oxyphytosterol concentrations,Markers reflecting antioxidant capacity,2013-04,UNKNOWN,INTERVENTIONAL,['NA'],
5787,NCT00436176,Rate of HbA1c control (<7%),Rate of blood pressure control (< 140/90 mmHg),2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
5788,NCT01187069,HbA1c,Problem Areas In Diabetes scale (PAID),2009-08,COMPLETED,INTERVENTIONAL,['NA'],
5789,NCT01000688,Forearm vasodilator response to intra-arterial infusion of acetylcholine (endothelium-dependent) following treatment with vildagliptin and following active control with acarbose,Effect of vildagliptin on ex vivo mononuclear cell responses to various stimuli,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
5790,NCT00695526,the change of total to HDL cholesterol ratio,the change of UAE,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
5791,NCT01450592,Percentage of complex carbohydrate intake from total carbohydrate by Indian diabetic population,Percentage of diabetic population with glycaemic control,2012-05,COMPLETED,OBSERVATIONAL,['NA'],
5792,NCT00437918,7 point SMBG (self monitoring of blood glucose),HOMA-beta for predicting the effectiveness of each agents,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
5793,NCT00395746,Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment,Hypoglycaemic Episodes,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
5794,NCT00894868,To evaluate the effect of vildagliptin on left ventricular function in patients with T2DM and CHF (NYHA class I-III) by showing that vildagliptin is at least not inferior to placebo with respect to change in left ventricular ejection fraction (LVEF).,To evaluate the efficacy of vildagliptin in patients with T2DM and CHF (NYHA class I-III) by assessing the HbA1c reduction with vildagliptin compared to placebo after 16 weeks of treatment.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
5795,NCT00563004,Reduction in fasting plasma glucose of more than 20% in the treatment group compared to placebo,Reduction by half in the daily dose of oral hypoglycemic agents compared to baseline,2008-08,COMPLETED,INTERVENTIONAL,['NA'],
5796,NCT04760444,Self-Care Activities,Diabetes Distress,2021-05-15,COMPLETED,INTERVENTIONAL,['NA'],
5797,NCT05374343,Plasma concentrations of rongliflozin,Change from baseline in 24-hour urine glucose excretion in varying degrees of kidney function,2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE1'],
5798,NCT01887964,Changes in metabolic syndrome risk components,Changes in blood glucose indices,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
5799,NCT00663000,To evaluate a correlation between IGF-I and glucose tolerance in patients with acromegaly.To evaluate changes of impaired glucose tolerance by different treatment options for acromegaly.,"Evaluate a correlation between body weight/BMI, age, family history of diabetes,duration of acromegaly and current medical treatment for acromegaly and glucose tolerance / insulin resistance",2008-04,COMPLETED,OBSERVATIONAL,['NA'],
5800,NCT05944029,Weight,,2023-02-20,RECRUITING,INTERVENTIONAL,['NA'],
5801,NCT05417425,Incidence in wound closure by week 12 of treatment,Increase in physical function and ambulation,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],
5802,NCT01710371,Optimal PET-determined mean pancreatic Volume of Distribution (VT) of 18F-AV-133,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
5803,NCT00867022,Serum Noradrenalin level,"Heart rate variability: LF, VLF, HF",2004-08,COMPLETED,OBSERVATIONAL,['NA'],
5804,NCT03932084,Glucose fluctuation,Blood lipids,2017-02-01,UNKNOWN,INTERVENTIONAL,['NA'],
5805,NCT02059187,Percentage of Participants With Confirmed Anti-Insulin Antibodies (AIA) up to Week 24,Percentage of Participants With Hemoglobin A1C <6.5% at Week 24,2014-02-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
5806,NCT05713448,Prevalence of patients with type 1 diabetes and obesity,,2021-02-24,RECRUITING,OBSERVATIONAL,['NA'],
5807,NCT02838147,Neonatal hypoglycemia,Macrosomia,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],
5808,NCT03392441,Change in Structural MRI,,2017-11-30,COMPLETED,INTERVENTIONAL,['NA'],
5809,NCT04910763,Changes in Hormonal Response to Feeding,Changes in Ad libitum Energy Intake - Free Living,2019-06-12,TERMINATED,INTERVENTIONAL,['NA'],
5810,NCT01899872,Circulating endothelial progenitor cells,Forearm vascular reactivity,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],
5811,NCT04298229,"Cumulative Change in Weight (Kilograms) Per 40mg of IV Furosemide Equivalents, Adjusted for Baseline Weight",Hospital Readmission,2020-04-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
5812,NCT00363948,tolerability,Plasma glucose,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
5813,NCT03974139,cerebrospinal fluid /plasma leptin ratio,Score of the Dutch Eating Behaviour Questionnaire (DEBQ),2020-07-03,RECRUITING,INTERVENTIONAL,['PHASE2'],
5814,NCT01020123,HbA1c: Change From Baseline to 4 Month,EC50 to Characterise the PD Properties of AZD1656.,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
5815,NCT05802927,Postprandial blood glucose,Appetite,2023-07-05,COMPLETED,INTERVENTIONAL,['NA'],
5816,NCT05181917,TIme in range,Prediction capacity of the model of postprandial glucose values,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Actions carried out by participants
5817,NCT05670600,Change in pain level at 4th and 8th weeks compared to baseline.,Effect of neuropathic pain on quality of life at 4 and 8 weeks change from initial state,2021-07-19,COMPLETED,INTERVENTIONAL,['NA'],
5818,NCT01939496,Change From Baseline in the Mean 24-Hour Systolic Blood Pressure (SBP) to Week 6,"Change From Baseline in the Difference in Seated Heart Rate (HR) and Standing HR to Day 2, to Week 3, and to Week 6",2013-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
5819,NCT06289387,"Role of the PNPLA3, TM6SF2, GCKR, MBOAT7 and HSD17B13 genetic variants in the development and progression of MASLD.",Correlation between serum creatinine levels (eGFR) and the genetic variants,2024-01-20,RECRUITING,OBSERVATIONAL,['NA'],
5820,NCT04298515,Nefratin-1 in insulin resistance,,2020-03-02,UNKNOWN,INTERVENTIONAL,['NA'],
5821,NCT00839878,Percentage of diabetic patients having diabetic nephropathy,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, nephropathy and retinopathy)",2009-03,COMPLETED,OBSERVATIONAL,['NA'],
5822,NCT01043965,"myocardial blood flow velocity, myocardial blood flow reserve",,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5823,NCT06143215,Recurrence rate,Minor amputation rate,2023-12-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
5824,NCT02709057,Incident diabetes,The change in insulin sensitivity during a 3 year follow-up,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],Incident cardiovascular disease
5825,NCT02746627,Glycemic Control (HbA1c),Coping,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
5826,NCT01409889,Participant Weight,Minutes of Physical Activity,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
5827,NCT03537131,"Time to hypoglycaemia during the exercise challenge, before and after dapagliflozin treatment.","Concentration of plasma potassium, sodium, calcium and pH at each 10min interval during exercise challenge",2018-06-02,TERMINATED,INTERVENTIONAL,['PHASE2'],
5828,NCT01129232,Prevalence of virus infected islets in pancreatic biopsies,Glycosylated hemoglobin A1 (HbA1c),2011-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
5829,NCT05728411,Rate of foot ulceration,Mean or median self-efficacy for diabetes,2023-10-02,RECRUITING,INTERVENTIONAL,['NA'],"Utilization (outpatient visits, emergency room visits, hospitalizations) - any vs. none and number"
5830,NCT00385528,"Psychological distress, quality of life",health care utilization,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
5831,NCT03908021,profile the oral bacteria related to caries and periodontal disease of children with type 1 diabetes mellitus,,2019-08-01,COMPLETED,OBSERVATIONAL,['NA'],
5832,NCT01932775,"Mean percentage of blood glucose measurements in the target range 70 to 140 mg/dl, as calculated by all premeal and bedtime glucose values measured ≥ 24 hours after start of therapy",Mean daily blood glucose as calculated by premeal and bedtime blood glucose values: Overall and per treatment day,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
5833,NCT04854603,Insulin,Food pleasantness,2021-09-02,COMPLETED,INTERVENTIONAL,['NA'],
5834,NCT02348294,Increase in erythema index,,2015-02,UNKNOWN,INTERVENTIONAL,['NA'],
5835,NCT05619406,Primary Outcome,Secondary Outcome,2022-08-20,RECRUITING,INTERVENTIONAL,['NA'],
5836,NCT05870358,Biochemical Findings: RANKL/OPG,,2021-02-18,COMPLETED,INTERVENTIONAL,['PHASE4'],
5837,NCT02581098,Wound macrophage isolation to determine miR-21,,2019-08-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
5838,NCT00005168,,,1984-08,COMPLETED,OBSERVATIONAL,['NA'],
5839,NCT03178019,Intergroup analysis of the associations between DPP4 activity and markers of inflammation,"Intergroup analysis of the associations between DPP4 activity and insulin resistance indexes, heart rate and blood pressure variability, and measures of adiposity",2014-02-01,COMPLETED,OBSERVATIONAL,['NA'],
5840,NCT03987308,The percentage of patients with at least a 0.7% change in the absolute value of glycated hemoglobin,The percentages of subjects with greater than 3% weight loss,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
5841,NCT01186003,Reduction in Rebound Hyperglycemia (Blood Glucose Levels Over 180 mg/dl),Reduction in Time to Get Back to Control of Glycemia (140-180 mg/dl) if Rebound Hyperglycemia Occurs,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
5842,NCT03316261,greater than 10% risk for multiple beta-cell autoantibodies/type 1 diabetes,,2017-10-19,RECRUITING,OBSERVATIONAL,['NA'],
5843,NCT04930224,oestradiol,,2019-07-01,COMPLETED,OBSERVATIONAL,['NA'],
5844,NCT01416649,Sleep duration and sleep efficiency,,2011-02-01,COMPLETED,OBSERVATIONAL,['NA'],
5845,NCT05135039,The rate of progression from prediabetes to diabetes one year after the intervention in both groups of subjects.,Changes in the number of CD4 T cells after one year intervention in the two groups.,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],
5846,NCT02722655,Intelligence quotient evaluation,Hypertension,2008-03,RECRUITING,OBSERVATIONAL,['NA'],
5847,NCT00789737,Percent Change in Hemoglobin A1c,"Change in Postprandial Plasma Glucose, 2 Hours After a Meal Tolerance Test",2009-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
5848,NCT00612950,2.phase insulin response measured as incremental area under the curve from 10-120 minutes,"2.phase insulin response measured as incremental area under the curve from 10-120 minutes, after 4 weeks of insulin treatment",2006-10,COMPLETED,INTERVENTIONAL,['NA'],
5849,NCT01794091,"All cause mortality, cardiovascular death, myocardial infarction or stroke",,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],
5850,NCT04262700,A1c change from baseline after 12 weeks,,2020-02-07,UNKNOWN,INTERVENTIONAL,['NA'],
5851,NCT00969592,fractional and total glucose infusion rates,fractional and total insulin areas under the curve (AUC),2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
5852,NCT00252837,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),Audit of Diabetes Dependent Quality of Life (ADDQoL). ADDQoL will only be applied in Poland.,2005-04,TERMINATED,INTERVENTIONAL,['PHASE3'],
5853,NCT01197898,Change From Baseline in Extent of Presence/Absence of Epithelial Tongue.,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
5854,NCT00740051,HbA1c Change From Baseline at Week 18 (Final Analysis),The Change in FPG From Baseline by Visit Over Time,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
5855,NCT00542334,Frequency and magnitude of nocturnal hypoglycemia,Patient satisfaction with continuous glucose sensing,2008-09,COMPLETED,OBSERVATIONAL,['NA'],
5856,NCT06215352,Gestational weight gain,,2024-01-09,RECRUITING,OBSERVATIONAL,['NA'],
5857,NCT02660242,Glycemic Response During Exercise and Early Recovery,CGM Metrics During Late Recovery - Time > 250 mg/dL,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
5858,NCT01113216,Identification of Genes or other factors that influence the development of CFRD,,2008-04,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
5859,NCT02028975,Plasma levels of biological markers of orosensorielle perception fatty acids,Measure the detection threshold for linoleic acid,na,UNKNOWN,INTERVENTIONAL,['NA'],
5860,NCT02058147,Change in HbA1c From Baseline to Week 30,Percentage of Participants With Severe Symptomatic Hypoglycemia,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
5861,NCT04787978,"Change in cardiovascular health (a composite measure of blood pressure, cholesterol, glucose, physical activity, smoking status, and body mass index).",Change in Patient Activation,2020-02-29,COMPLETED,INTERVENTIONAL,['NA'],
5862,NCT01794143,"Time to HbA1c>=7%, while receiving metformin and the randomly assigned study medication","Time to HbA1c>7.5%, while receiving metformin and the randomly assigned study medication.",2013-05,COMPLETED,INTERVENTIONAL,['PHASE3'],"Time to HbA1c>7.5%, while receiving study medications and basal insulin"
5863,NCT00495014,"Adverse reactions and changes in laboratory values, vital signs, and/or ECGs following each dose",Body weight following 14 days of repeat dosing with GSK376501.,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
5864,NCT06108388,Hematopoietic colony formation in ALDHhiSSClow regenerative cell subsets,Frequency and absolute number of circulating ALDHhiSSClowCD133+ progenitor cells,2023-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
5865,NCT00476918,"Visual acuity, no of treatments, duration of efficacy","intraocular pressure, retinal thickness",2006-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],
5866,NCT01123187,Composite criteria: insulin independence and Glycosylated Hemoglobin (HbA1c) under 8% at one year after the transplantation,Evaluation of kidney function,2003-03,COMPLETED,INTERVENTIONAL,['NA'],
5867,NCT04295031,metformin daily dose in diabetic outpatients type 2,renal filtration rate,2019-10-09,UNKNOWN,OBSERVATIONAL,['NA'],
5868,NCT04940962,Kinetics of the appearance of endocannabinoids produced by visceral adipose tissue explants in culture medium estimated by the area under the curve in obese subjects and in controls.,,2021-09-29,RECRUITING,INTERVENTIONAL,['NA'],
5869,NCT05431660,Plantar pressure senses,Vibration sense,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Individuals' information about diabetic foot
5870,NCT02410005,24h urine 24hr urine albuminuria,,2014-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Estimated glomuerula filtration rate (eGFR)
5871,NCT01328821,To assess safety and tolerability of CTP-499,"To assess Pharmacokinetics, Pharmacodynamics and relative bioavailability",2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
5872,NCT02893072,intravenous glucose,,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],
5873,NCT03028220,"% Time Spent in Hypoglycaemia (<3.3mmol/L, 60mg/dL)",Glucose Variability Measured by CONGA,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
5874,NCT05507697,Change of nerve conduction velocities in the lower extremity,Change of glycosylated hemoglobin (HbA1c),2022-05-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5875,NCT01056198,Bates-Jensen Wound Assessment Score - Modified (BWAT-m),Percent of Wound Area Change From Baseline at the End of 12 Week Follow-up,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
5876,NCT03047200,Restoration of sustained euglycemia without exogenous insulin or with reduced insulin dosage in patients who underwent pancreatic islet cell after kidney transplantation,To assess total islet mass needed to achieve sustained euglycemia with or without exogenous insulin.,2008-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
5877,NCT01882907,Non-inferiority of HbA1C Change From Baseline in Vildagliptin + Metformin Group Compared With Pioglitazone + Metformin Group,"the Mean Changes of Insulin, C-peptide, HOMA-IR, HOMA-beta From Baseline Between Vildagliptin + Metformin and Pioglitazone + Metformin Groups",2009-12,COMPLETED,INTERVENTIONAL,['PHASE4'],the Numbers of Participants With Adverse Events Between Vildagliptin + Metformin and Pioglitazone + Metformin Groups
5878,NCT00709683,Incidence of major hypoglycaemic events reported as serious adverse drug reactions,"Average post-breakfast (90-120 mins), post-lunch (90-120 mins), post-dinner (90-120 mins) plasma glucose level",2008-05,COMPLETED,OBSERVATIONAL,['NA'],
5879,NCT05305326,Telocytes,,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA'],
5880,NCT01989754,Progression of Albuminuria,Cardiovascular (CV) Death,2014-01-16,COMPLETED,INTERVENTIONAL,['PHASE4'],
5881,NCT04819178,Diabetic ketoacidosis,Hypoglyceamia,2021-06-01,WITHDRAWN,OBSERVATIONAL,['NA'],
5882,NCT03256747,Glucose levels,Oxygenation tissue,2017-09-15,COMPLETED,INTERVENTIONAL,['NA'],
5883,NCT02285231,2-h oral glucose tolerance tests (OGTTs,,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
5884,NCT00348231,daily profile of blood glucose,QOL,2004-11,UNKNOWN,INTERVENTIONAL,['NA'],
5885,NCT05107544,Time change in range,Change in mood of adolescents,2021-09-04,COMPLETED,INTERVENTIONAL,['NA'],
5886,NCT00973271,The effect of DCCR on triglycerides in subjects without diabetes mellitus who have very high triglycerides over a period of 84 days,The effects of DCCR on Apo B and non-HDL in subjects without diabetes mellitus who have very high triglycerides over a period of 84 days,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
5887,NCT02776098,Compare change in mean lean body mass (LBM) from baseline to end of study,Compare Intramyocellular lipid (IMCL) accumulation from baseline to end of study,2016-05,COMPLETED,OBSERVATIONAL,['NA'],
5888,NCT02129231,Total antioxidant capacity,nerve conduction studies,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],alanine aminotransferase
5889,NCT03006471,Number of Participants With a Dipper Reverse Circadian Blood Pattern at Week 12,Number of Participants With Prediabetes Plus Prehypertension at Week 12,2016-03-30,COMPLETED,INTERVENTIONAL,['PHASE4'],
5890,NCT05021705,renal biopsy,,2016-01,COMPLETED,OBSERVATIONAL,['NA'],
5891,NCT05654285,"Glucose, insulin, glucagon, glucagon-like peptide-1 (GLP-1), peptide tyrosine tyrosine (PYY), glucose-dependent insulinotropic polypeptide (GIP), pancreatic polypeptide (PP), leptin, and ghrelin",,2016-02-08,COMPLETED,INTERVENTIONAL,['NA'],
5892,NCT05647824,Fingerstick Test: Obtain TV4 BGMS performance data in the hands of lay users with diabetes using fingerstick capillary blood obtained with Microlet NEXT® lancing device.,Subject Questionnaire on the Usability of TV4 BGMS,2020-02-05,COMPLETED,OBSERVATIONAL,['NA'],
5893,NCT05786521,6 minute walking distance,,2023-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
5894,NCT04769037,Persistent confirmed multiple beta-cell autoantibodies,Measurement of Safety parameters,2021-04-22,RECRUITING,INTERVENTIONAL,['NA'],Stool calprotectin
5895,NCT03290768,Program Completion Rate (%),Coaching Participation Rate,2017-09-13,COMPLETED,INTERVENTIONAL,['NA'],
5896,NCT01776528,Safety and tolerability,Pharmacodynamics,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
5897,NCT04828304,Efficacy PLASOMA - wound surface area reduction,Patient acceptability,2021-05-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
5898,NCT05380544,Patient and clinician acceptability of the trial process and ESWT,"Validity, reliability and responsiveness of virtual follow-up for wound healing in research",2022-04-13,RECRUITING,INTERVENTIONAL,['NA'],
5899,NCT00556751,"Development of resting ECG abnormalities, specifically isolated non-specific ST-segment and T-wave abnormalities",,1985-01,COMPLETED,OBSERVATIONAL,['NA'],
5900,NCT00231621,Percent change in body weight and the percent change in fasting serum triglycerides from baseline (Week 0) to Week 60.,"Absolute change in body weight, body mass index, triglycerides, and absolute and percentage changes in cholesterol measures from baseline to Week 60. Safety evaluations throughout study.",2001-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
5901,NCT01342263,Healthcare utilization,Health outcomes,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
5902,NCT01102452,The daily blood glucose level will be monitored by the CGMS (continuous glucose monitoring system)device,,2010-04,COMPLETED,INTERVENTIONAL,['NA'],
5903,NCT06173232,Primary Objective,,2023-11-20,RECRUITING,OBSERVATIONAL,['NA'],Exploratory Endpoint
5904,NCT01324921,Positive AUC for plasma glucose concentration,Positive AUC for serum insulin concentration,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
5905,NCT03136289,Adolescent prediabetes and diabetes.,,2013-12,COMPLETED,OBSERVATIONAL,['NA'],
5906,NCT04380064,Postoperative ERM Development,Visual Acuity,2020-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
5907,NCT04417452,Maturation of the gonadal regulation,,2019-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
5908,NCT00836030,Percentage of diabetic patients having diabetic eye complications,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)",2009-01,COMPLETED,OBSERVATIONAL,['NA'],
5909,NCT00351000,Change From Baseline on Fasting Insulin,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
5910,NCT05706155,Change in Glycated Hemoglobin,Adherence to a plant-based diet,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],
5911,NCT00800683,HbA1c Change From Baseline at Week 12,"Clinically Relevant Drug-related Abnormalities for Blood Chemistry, Pulse Rate, Laboratory Parameters and ECG",2008-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
5912,NCT01322035,Measure erythrocyte G6PD levels in diabetic vs. non-diabetic morbidly obese patients undergoing laparoscopic Gastric Bypass.,Measure hepatocyte G6PD levels in diabetic vs. non-diabetic morbidly obese patients undergoing laparoscopic gastric bypass.,2009-12,COMPLETED,OBSERVATIONAL,['NA'],
5913,NCT06173245,Change of subfoveal choroidal thickness (SFCT),Change of visual acuity (VA),2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],
5914,NCT00841087,Rate of Nocturnal Major and Minor Hypoglycaemic Episodes,Systolic Blood Pressure (BP),2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
5915,NCT00979368,Exposure to the investigational drug will be measured to assess safety and tolerability,To assess the single dose Pharmacokinetics of BMS-816336,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
5916,NCT01718015,"Concentrations of IGF-I and II, sCD-163, VEGF, NGF and BDNF in cerebrospinal fluid and blood.","Nerve conduction studies: Nerve velocity, Amplitude, F-waves, Motor Unit Number Estimate (dominating arm and non-dominating leg)",2012-11,UNKNOWN,OBSERVATIONAL,['NA'],Protein profile of the cerebrospinal fluid using mass spectrometry.
5917,NCT04863755,Change from Baseline Blood Pressure at 4 months,Change from Baseline HDL cholesterol at 4 months,2017-05-09,COMPLETED,INTERVENTIONAL,['NA'],
5918,NCT05210972,Coronary artery disease severity,Correlation of HbA1c to CAD severity,2021-07-01,COMPLETED,OBSERVATIONAL,['NA'],
5919,NCT04848480,Change in Glycosylated Haemoglobin (HbA1c) at Week 26,Change in Body Weight,2021-04-30,COMPLETED,INTERVENTIONAL,['PHASE3'],
5920,NCT00708175,Percent Change From Baseline to Month 12 in Bone Mineral Density in the Total Proximal Femur by Dual-Energy-Ray Absorptiometry (DXA),Percent Change From Month 12 to Month 18 in Bone Mineral Density in the Total Proximal Femur by DXA,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of Participants With Fracture
5921,NCT00570687,EGP AOC0-480 - Meal Challenge,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
5922,NCT03320031,glucose variability,hypoglycemia,2017-06-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
5923,NCT05843929,Diabetic foot exam: dermatologic examination,Diabetes Self-Care,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
5924,NCT01376323,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12,Number of Participants With HbA1c < 7.0% and < 6.5%,2011-07-13,COMPLETED,INTERVENTIONAL,['PHASE2'],
5925,NCT04820556,"Significant (p<0,05) correlation (r>0,5) between abundance of Faecalibacterium genus and concentration of lipopolysaccharide",,2021-04-12,COMPLETED,OBSERVATIONAL,['NA'],
5926,NCT00714844,,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
5927,NCT05544643,Percentage of sets that failed due to unexplained hyperglycemia,,2022-08-04,COMPLETED,INTERVENTIONAL,['NA'],
5928,NCT04855292,Safety and tolerability assessed by incidence and severity of adverse events,The occurrence of TG103 anti-drug antibodies (ADA),2021-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
5929,NCT05943626,Insulin sensitivity change from baseline,Average (per week) daytime alertness change from baseline,2023-06-13,RECRUITING,INTERVENTIONAL,['NA'],
5930,NCT00810290,HgbA1c,Change in quality of life.,2004-07,COMPLETED,INTERVENTIONAL,['NA'],
5931,NCT04127994,Impact of 3 stroke diet in glycemic variability compared to a 6 stroke diet,Impact of 3 stroke diet in weight loss compared to a 6 stroke diet,2018-08-17,RECRUITING,INTERVENTIONAL,['NA'],
5932,NCT03895697,Time to plasma glucose recovery,Immunogenicity - Occurrence of anti-drug antibodies,2019-03-26,COMPLETED,INTERVENTIONAL,['PHASE3'],
5933,NCT01281228,Differences in neuronal activity in CNS reward and satiety circuits,Self-reported hunger,2011-09,COMPLETED,INTERVENTIONAL,['NA'],
5934,NCT03238547,Diagnostic Sensitivity and Specificity,,2017-08-01,COMPLETED,OBSERVATIONAL,['NA'],
5935,NCT01001611,Change from baseline in Glycosylated Hemoglobin (HbA1c),"Change from baseline in glycemic parameters (Fasting Plasma Glucose, C-peptide, Homeostasis Model Assessment of Insulin Resistance(HOMA-IR), Homeostasis Model Assessment of β-cell function(HOMA-β), Quantitative Insulin Check Index(QUICKI))",2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
5936,NCT01717183,Percentage of complete wound closure,Change in wound surface area,2013-04,UNKNOWN,INTERVENTIONAL,['NA'],
5937,NCT02872402,Weight retention,Time physically active,2016-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
5938,NCT00896610,Blood glucose level,,2009-05-13,TERMINATED,OBSERVATIONAL,['NA'],
5939,NCT03889210,Rate of change in plasma glucose concentration,Correlation with physical activity,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],
5940,NCT00914524,The change in the urinary protein/creatinine ratio from baseline to the end of treatment.,The change of creatinine clearance,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
5941,NCT04484987,Adipose tissue gene expression,Peripheral diurnal rhythmicity in in peripheral mononuclear blood cells,2020-11-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
5942,NCT03769948,Diabetic retinopathy indicator (yes/no),,2022-02,UNKNOWN,OBSERVATIONAL,['NA'],
5943,NCT02748122,Change in score on Quality of Life questionnaire,,2015-10,TERMINATED,INTERVENTIONAL,['NA'],
5944,NCT05971082,remission of fatty liver disease,,2023-08-24,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
5945,NCT02081118,Change in baseline in glycosylated haemoglobin (HbA1c) at 16 weeks,Glycated albumin,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants with Immunogenicity by HM11260C
5946,NCT06045221,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Short Form 36 Version 2 (SF-36-v2) Acute Form Domain Summary Scores,2023-09-22,RECRUITING,INTERVENTIONAL,['PHASE3'],
5947,NCT04741568,"Change in Diabetes Eating Problem Survey Revised (Markowitz et al., 2010)",Change in Children's Eating Behaviour Questionnaire (Wardle et al. 2001),2021-06-07,COMPLETED,INTERVENTIONAL,['NA'],Feasibility Outcomes: Usability of Online Content (Google Analytics)
5948,NCT03003806,Percentage of glucose readings below 54 mg/dl (3.3 mmol/l),Diabetes treatment satisfaction questionnaire,2017-10-02,COMPLETED,INTERVENTIONAL,['NA'],
5949,NCT01332071,Cmax of Metformin Hydrochloride,,2009-11-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
5950,NCT05538819,Hospitalizations and emergency visits for heart failure,Hospitalizations for acute myocardial infarction or stroke,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],
5951,NCT02555631,Change in Weight in Pounds,Number of Participants That Participated in Each Session,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
5952,NCT04859348,APGAR Score,,2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],
5953,NCT01444534,Quality of Life,Self-monitoring of blood glucose (SMBG),2011-09,COMPLETED,INTERVENTIONAL,['NA'],
5954,NCT05714761,Percentage of participants with at least 72 hours of CGM data downloaded.,Negative predictive value (NPV),2023-02-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
5955,NCT01096667,Change From Baseline on 24-hour Average SBP at Week 4,Number of Participants Who Discontinued Study Drug Due to an AE,2010-05-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
5956,NCT00065793,apoB concentration of LDL with apoC-III,,2003-07,COMPLETED,OBSERVATIONAL,['NA'],
5957,NCT01680133,Change from baseline in insulin sensitivity of adipose tissue and skeletal muscle lipolysis,Baseline skeletal muscle lipid accumulation,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
5958,NCT00789308,Level of stimulated c-peptide at 90-minute derived from the mixed-meal tolerance test (MMTT),Incidence of immune sensitization defined by detecting anti-HLA antibodies not present prior to transplantation,2008-07-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
5959,NCT00135330,Change in ASIiAUC During a Hyperglycemic Clamp Test.,Pedal Edema Score,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
5960,NCT04865770,"Change in kidney inflammation (medulla), T1 mapping (MRI)",Change in kidney function (creatinine clearance) (urinalysis,2021-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
5961,NCT01686828,Insulin Sensitivity Quantified by Matsuda Index,Changes in Adipose Tissue Gene Expression,2013-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5962,NCT04133922,change in insulin sensitivity between baseline and 2 hour insulin clamp,change in pulse wave velocity between baseline and 2 hour insulin clamp,2019-10-14,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],
5963,NCT03514108,Met-HeFT combined endpoint: Death or hospitalization with worsening heart failure or acute myocardial infarction or stroke or urgent heart failure visit,Met-HeFT secondary endpoint: Hospitalization or death caused by lactate acidosis.,2018-03-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
5964,NCT04332354,glycemic profile after bariatric surgery,identification of predictive factors for diabetes remission 1 year after surgery,2016-03-30,COMPLETED,OBSERVATIONAL,['NA'],
5965,NCT00746642,"Mellitor technology feasibility will be established by comparing Mellitor glucose measurements results to ""gold standard, Yellow Springs"" glucose analyzer, or a comparable. Interdevice variability should be within 10%.",,2009-10,UNKNOWN,INTERVENTIONAL,['NA'],
5966,NCT05098327,HOMA-IR,TLR-4,2021-08-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
5967,NCT05208424,Short-term outcome,,2020-02-27,COMPLETED,OBSERVATIONAL,['NA'],
5968,NCT02963922,Participants Losing at Least 5% of Baseline Body Weight,Change in Laboratory Parameters (Biochemistry) - Thyroid Stimulating Hormone,2017-02-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
5969,NCT03788642,Ulcer Healing Rate,Clinical Success - Complications,2019-01-15,COMPLETED,INTERVENTIONAL,['NA'],
5970,NCT02803489,Sensitivity and specificity of the tele-notifications,"Clinical events including medical consultations, hospitalizations and adverse events",2016-04-08,TERMINATED,INTERVENTIONAL,['NA'],
5971,NCT01790308,the percentage of the patients who maintain glucose control 1 year after short intensive therapy,the remission rate differ from interventions in newly-diagnosed type 2 diabetic patients,2013-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
5972,NCT02268916,Social Participation,,2015-06-01,COMPLETED,INTERVENTIONAL,['NA'],Physical Function
5973,NCT00627380,The primary efficacy outcome is a metabolic parameter: insulin integrated area under the curve (AUC) during the oral glucose tolerance test.,Safety: CD4 count and plasma HIV RNA,2005-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
5974,NCT01840358,Frequency of hypoglycemias,Frequency of hyperglycemias,2013-04,UNKNOWN,INTERVENTIONAL,['NA'],
5975,NCT03803072,Weekly adherence rates for time restricted eating (TRE),Change between baseline and post-intervention visceral fat area,2019-01-18,COMPLETED,INTERVENTIONAL,['NA'],
5976,NCT05358444,Survey Administration Feasibility as assessed by mean time for administration of surveys to participants,Change in caregiver attitudes regarding child health behaviors,2022-07-08,COMPLETED,INTERVENTIONAL,['NA'],
5977,NCT00771693,"Co- primary platelet response variables: U46619 stimulated platelet P- selectin activation, platelet-leukocyte aggregation, platelet-platelet aggregates and platelet-monocyte aggregates.",To elucidate if short-term lowering of blood glucose by insulin infusion (pretreatment standardization of blood glucose) reduces platelet activity in patients with T2DM.,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
5978,NCT05370560,Type 2 diabetes mellitus,,2010-12-01,COMPLETED,OBSERVATIONAL,['NA'],
5979,NCT00109720,Blood glucose level,Diabetes Related Quality of life,2002-08,COMPLETED,INTERVENTIONAL,['NA'],
5980,NCT05193929,Percentage of index ulcers healed,Changes in wound quality of life from screening visit to end of study ( per W-QoL),2021-12-15,RECRUITING,INTERVENTIONAL,['NA'],Cost to Closure
5981,NCT01201460,,,2009-04,COMPLETED,OBSERVATIONAL,['NA'],
5982,NCT00212914,The proportion of patients screened in each group,,2002-05,COMPLETED,INTERVENTIONAL,['NA'],
5983,NCT05009602,Diagnostic accuracy,Inter- and intra-rater reliability,2022-03-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
5984,NCT04662164,AEs,fasting plasma glucose,2025-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
5985,NCT02301806,"Change in endothelial function during the OGTT evaluated by flow-mediated vasodilatation (FMD). The change is defined as below, assuming the peak value and changes of FMD will be observed at t=60 min.",Change in endothelial function during OGTT* evaluated by endo-PAT. Change in endothelial function after 12-week treatment at the fasting state evaluated by endo-PAT and FMD.,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Change in the number of EPCs after 12-week treatment
5986,NCT00370942,Efficacy variables Dose response (change from baseline in HbA1c) at stipulated date in each treatment group,Long term safety variables,2006-04-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
5987,NCT01024790,Depression,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
5988,NCT00971243,Change in HbA1c From Baseline to Week 24,"Adverse Events, Laboratory Tests, Vital Signs, Etc.",2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
5989,NCT01796418,Brachial ankle pulse wave velocity (PWV),Blood pressure,2013-03,UNKNOWN,INTERVENTIONAL,['NA'],
5990,NCT03464812,Program completion,Patient and referring provider satisfaction,2017-08-04,COMPLETED,INTERVENTIONAL,['NA'],
5991,NCT03052400,Hemoglobin A1c,Basal Insulin Dose,2017-02-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
5992,NCT01667783,Change in HbA1c from baseline to final data collection,Change in insulin secretion,2012-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
5993,NCT05771090,Characteristics of volatile organic compound (VOC) signals measured by the Sokru device,Oxygen saturation,2023-04-01,COMPLETED,INTERVENTIONAL,['NA'],
5994,NCT00082251,,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],
5995,NCT05024032,Percentage of Participants Who Achieve ≥5% Body Weight Reduction,Mean Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 10 mg and 15 mg),2021-09-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
5996,NCT00797563,Number of Capillary and Venous Results Within +/- 15mg/dL or +/- 20% of Laboratory Glucose Method,Number of Partipants Who Gave These Ratings for Overall Testing Experience With This Meter,2008-11,COMPLETED,INTERVENTIONAL,['NA'],
5997,NCT02016846,Glucose levels 2 hours after 75 gr OGTT,,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
5998,NCT04254029,Variation of mitral E' velocity,Variation of blood pressure.,2016-11-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
5999,NCT04956094,Proportion of patients diagnosed with gestational diabetes mellitus,,2021-06-21,RECRUITING,OBSERVATIONAL,['NA'],
6000,NCT01713023,Compare the effects of fructose and glucose and TAS1R2 in postprandial metabolism of individuals with type 1 diabetes,Effect of fructose or glucose on leptin levels,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
6001,NCT01526941,"Steady state area under the glucose infusion rate profile, 6-12 hours",Adverse events,2001-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
6002,NCT02738996,Postprandial glucose excursions measured with Area under curve,"Qualitative exploration of the knowledge, beliefs and experiences of those with type 2 diabetes on the use of technology to decrease sedentary behaviour and improve glycaemic control",2016-05,UNKNOWN,INTERVENTIONAL,['NA'],
6003,NCT05757258,"Association between incidence of MALE and IL-1, IL-6, TNF-alpha, C reactive protein, HMGB-1, osteoprotegerin, sortilin and omentin-1 serum levels","Association between incidence of cardiovascular death and IL-1, IL-6, TNF-alpha, C reactive protein, HMGB-1, osteoprotegerin, sortilin and omentin-1 serum levels",2019-10-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
6004,NCT01857167,insulin resistance,,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
6005,NCT03257501,System Related adverse device effects,,2017-08-22,COMPLETED,OBSERVATIONAL,['NA'],
6006,NCT00838916,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,Albiglutide Plasma Concentrations at Week 8 and Week 24,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
6007,NCT04626323,Mean differenceGlomerular filtration rate (GFR),Costs of care and health care utilization,2021-05-25,RECRUITING,INTERVENTIONAL,['PHASE2'],
6008,NCT00477191,Change in CRP Levels From Baseline to 6 Months of Treatment in Subjects With Psoriasis and Metabolic Syndrome,Change in the Safety and Tolerability of Etanercept in Patients With Psoriasis and Metabolic Syndrome Over a 6-month Period.,2007-05,TERMINATED,INTERVENTIONAL,['NA'],
6009,NCT01279317,Postprandial Glycemic Incremental Area Under the Curve,,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
6010,NCT05443802,Metabolic complications,Episode of severe hypoglycaemia in patients suffering from first ketoacidosis episode,2022-08-16,RECRUITING,INTERVENTIONAL,['NA'],
6011,NCT05037526,Composite adverse pregnancy and neonatal outcome,Respiratory distress syndrome,2021-09-24,RECRUITING,INTERVENTIONAL,['NA'],
6012,NCT02927951,Decrease in fall risk associated with walking assessed with the Physiological Profile Assesment,Patient Global Impression of Change (PGIC),2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
6013,NCT02469558,insulin sensitivity,,2015-09,COMPLETED,INTERVENTIONAL,['NA'],Quality of Life
6014,NCT04877366,Post-prandial glycemic excursion (ARMs A and B),Matsuda Index (ARMs A and B),2021-07-21,COMPLETED,INTERVENTIONAL,['NA'],Plasma IL-6 iAUC (ARMs A and B)
6015,NCT04365400,Change in HbA1c From Baseline to Week 26,"Change in HbA1c From Baseline to Weeks 4, 8, 12, 16 and 20",2020-10-13,TERMINATED,INTERVENTIONAL,['PHASE2'],
6016,NCT00722371,Change From Baseline in A1C at Week 54,Change From Baseline in 2-Hour PMG at Week 54,2008-09-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
6017,NCT06249399,Bladder Sensation,Patient Information Form,2023-05-03,COMPLETED,INTERVENTIONAL,['NA'],
6018,NCT00507936,"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP",Clinician Global Impression: Severity (CGI-S) and Patient Global Impression: Change (PGI-C),2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
6019,NCT04461041,Left Ventricular (LV) mass,Hematocrit,2021-04-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
6020,NCT00330330,To evaluate the pharmacologic activity of ISIS 113715,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
6021,NCT00747006,Lunch Plasma Glucose Excursion - Amendment 1 (Humalog Treated Type 2 Subjects),Lunch Plasma Glucose AOC(0-240) - Amendment 1 (Humalog Treated Type 2 Subjects),2008-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
6022,NCT02366416,Change of bloodglucose,Change of musculoskeletal pain,2015-04,COMPLETED,INTERVENTIONAL,['NA'],
6023,NCT00559884,Urine:,lab tests:,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
6024,NCT05926947,Post prandial insulemia,Short Form 12 (SF-12) questionnaire,2023-07-05,RECRUITING,INTERVENTIONAL,['NA'],
6025,NCT03144869,Acceptability,Parental fear of hypoglycaemia,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],
6026,NCT05792072,Changes in brain plasticity,influence on nerve conduction,2023-05-02,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
6027,NCT02660736,Peak plasma concentration (Cmax) for albiglutide in session 1 and 2,Composite of urinalysis parameters as a measure of safety,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
6028,NCT06055582,Glycemic indices as per Continuous glucose monitoring system (CGMS) & HbA1c (%),,2022-02-11,COMPLETED,INTERVENTIONAL,['NA'],
6029,NCT00758082,Comparison of HbA1c means,Number of hypoglycemias (moderate and severe) during the 3-month period,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
6030,NCT02271776,systemic insulin sensitivity,skeletal muscle and adipose tissue gen and protein expression,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
6031,NCT03618628,Peak Plantar Pressure,,2016-05-24,COMPLETED,INTERVENTIONAL,['NA'],
6032,NCT00951912,Percentage Change in Low Density Lipoprotein Cholesterol,Total Energy Intake at Follow-up,2009-08,COMPLETED,INTERVENTIONAL,['NA'],
6033,NCT03243253,"association between densities of fast food (FFR) and full service restaurants (FSR) with mortality from CVD and stroke, and the prevalence of type 2 diabetes (T2D).",,2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],
6034,NCT00756613,The Long Term Effect of Intensive Glycemic Control in Type 2 Diabetes on Major Cardiovascular Complication.,Patients Reported Health Related Quality of Life,2008-02-01,COMPLETED,OBSERVATIONAL,['NA'],
6035,NCT04426708,The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUCinf;,The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of fu;,2019-02-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
6036,NCT06147466,Time in target range,Perceived social support,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],
6037,NCT02963753,To determine serum glucose levels in both groups during 75 gram oral glucose tolerance test screening,,2016-01,COMPLETED,OBSERVATIONAL,['NA'],
6038,NCT02639637,Forearm Blood Flow,Heart Rate,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
6039,NCT04237883,Aggregate Focus Quality Measure order rates at the first visit,Number of Open Tests,2019-11-01,COMPLETED,INTERVENTIONAL,['NA'],
6040,NCT00095654,death,Renal Events,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
6041,NCT02475499,Incident pancreatic cancer,,2014-03,COMPLETED,OBSERVATIONAL,['NA'],
6042,NCT00941447,Blood Glucose,Quality of Life,2009-04,COMPLETED,INTERVENTIONAL,['NA'],
6043,NCT06241638,HbA1c in the two groups,,2022-07-01,COMPLETED,INTERVENTIONAL,['NA'],
6044,NCT01684748,Insulin Sensitivity by Intravenous Glucose Tolerance Testing (Change Over Time),,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4'],Collagen Gene Expression in Skeletal Muscle (Change Over Time)
6045,NCT04319003,Change in sugary beverage (coffee/tea) consumption using beverage frequency questionnaires,,2018-08-03,COMPLETED,INTERVENTIONAL,['NA'],
6046,NCT00147251,Changing LDL Cholesterol,Changing Blood Pressure,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
6047,NCT00007800,,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
6048,NCT03738865,Severe Hypoglycemia Rescue,Hypoglycemia Resolution,2018-09-27,COMPLETED,INTERVENTIONAL,['PHASE3'],
6049,NCT02280174,"Measurement of the Area Under the Curve of Plasma apoB-48 Levels During Postprandial Period (Time 0,2,4,6,8 Hours)",,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
6050,NCT04861324,Maternal Lipids,Maternal serum carotenoids,2021-04-28,COMPLETED,INTERVENTIONAL,['NA'],
6051,NCT05029804,Pedometer,,2021-09-30,UNKNOWN,INTERVENTIONAL,['NA'],
6052,NCT02970838,Change in HbA1c value,Change in diet history,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
6053,NCT02989688,Blood glucose response curve,Flavour acceptability scale for ONS product,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
6054,NCT02255682,Difference in myalgia,Difference in mitochondrial function,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
6055,NCT05681884,Primary Objective,Mean change in CST,2023-05-16,RECRUITING,INTERVENTIONAL,['PHASE2'],
6056,NCT03823027,Tolerability measured as evaluation of Adverse Events,Performance measured as changes in body fat %,2019-01-28,COMPLETED,INTERVENTIONAL,['NA'],Explorative Endpoint on changes in microbiome diversity (species not defined)
6057,NCT01542476,Change in Patient-Reported Outcomes (PRO) using World Health Organization 5 (WHO-5) item Well-being Index: Insulin Treatment Appraisal Scale (ITAS),Adverse events,2006-08,COMPLETED,OBSERVATIONAL,['NA'],
6058,NCT01865279,Area under the glucose infusion rate curve (trial part 2 only),Area under the serum insulin concentration curve,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
6059,NCT06206317,Static Two-Point Discrimination Test,,2024-02-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
6060,NCT04529278,Weight Loss at Week 26,Therapeutic monitoring,2021-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
6061,NCT04013594,Glycemic variability,hand grip strength,2019-08-20,COMPLETED,INTERVENTIONAL,['NA'],
6062,NCT02166294,Number of participants with adverse events,Time to Initial Wound Closure,2014-06,TERMINATED,INTERVENTIONAL,['NA'],
6063,NCT02955238,Change in Carotid Intimal Medial Thickness (CIMT) Measurement,Medication Adherence,2009-08,COMPLETED,INTERVENTIONAL,['NA'],
6064,NCT00829062,The aim of this project is to present evidence based practice to Missouri Medicaid to expand coverage of continuous subcutaneous insulin infusion (CSII) in pediatric patients with diabetes. - Hemoglobin A1C,Glycemic variability as shown by continuous glucose recording,2009-01,WITHDRAWN,INTERVENTIONAL,['NA'],
6065,NCT02416193,Trail Making Test Part B,Semantic Fluency Test,2015-09-23,TERMINATED,INTERVENTIONAL,['PHASE2'],
6066,NCT03353818,Physical activity,Estimated VO2max,2017-05-01,UNKNOWN,INTERVENTIONAL,['NA'],
6067,NCT00846638,Drinking outcome,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
6068,NCT04799327,Change from baseline in body weight,Concentration of SHR20004 in plasma at steady state,2021-03-29,UNKNOWN,INTERVENTIONAL,['PHASE2'],
6069,NCT01580098,HbA1c,Number of Hospitalisations,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
6070,NCT01782105,Weight change during pregnancy,Optimize the intervention before measuring its impact on the prevention of gestational diabetes mellitus on a larger scale.,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
6071,NCT05346614,Rate of diabetes remission,Compliance,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
6072,NCT01546597,"Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of metformin","Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of ranolazine and metabolites",2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
6073,NCT02433262,To measure the prevalence of GDM diagnosed using WHO versus IADPSG criteria,To measure the incidence of adverse neonatal outcomes in women diagnosed with GDM using either of the criteria (WHO or IADPSG),2015-04,UNKNOWN,INTERVENTIONAL,['NA'],
6074,NCT01172743,,,2009-06,TERMINATED,OBSERVATIONAL,['NA'],
6075,NCT04989634,Incidence of gestational diabetes mellitus,Incidence of premature birth,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
6076,NCT00694122,Blood Glucose,Growth Hormone,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
6077,NCT00473330,Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24,Mean Change From Month 36 in Central Foveal Thickness in the Study Eye at Month 48,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
6078,NCT04133493,Wound Healing,Pain reduction: visual analogue scale (VAS),2019-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Histology assessment from biopsies
6079,NCT00131144,time to progression of diabetic retinopathy,time to moderate vision loss,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
6080,NCT02934113,Change in Weight,,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
6081,NCT02042664,intracardiac triglyceride,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
6082,NCT03202979,Change of item 5 score in Brief Pain Inventory Short Form (BPI-SF) scale,Frequency of treatment-related adverse events,2017-05-16,COMPLETED,INTERVENTIONAL,['PHASE2'],
6083,NCT02196350,percentage of participants that reach normoglycemia,change in indices for hepatic insulin resistance,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
6084,NCT06059833,magnesium perecentage,,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
6085,NCT02397421,Change in LV end systolic volume (absolute value and indexed for BSA) or LV end diastolic volume (absolute value and indexed for BSA),"The safety of dapagliflozin use in diabetic, heart failure patients with regard to worsening HF, hospitalization and death will be evaluated",2015-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
6086,NCT04222231,Change in insulin sensitivity by blood-flow restriction or classical resistance training,Changes in skeletal muscle mass by blood-flow restriction or classical resistance training,2019-10-28,RECRUITING,INTERVENTIONAL,['NA'],Changes in skeletal muscle strength by blood-flow restriction or classical resistance training
6087,NCT03520660,Phase I - SVR 12,Phase II: Change in Ishak fibrosis score,2018-10-19,RECRUITING,INTERVENTIONAL,['PHASE4'],
6088,NCT00136188,Change in renal endothelial function,,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
6089,NCT03936634,Arm B - Auto-antibody positive first degree family members,Arm B - Auto-antibody positive first degree family members - Framework,2016-11-14,UNKNOWN,OBSERVATIONAL,['NA'],
6090,NCT00328848,Quality of medical management,Opportunity costs of caregiver time,2005-10,COMPLETED,INTERVENTIONAL,['NA'],
6091,NCT05342545,Frequency of UACR testing order for CKD in patients with T2DM who have not had such testing within the past year,Frequency of new clinical diagnosis of CKD in patients with T2DM who have not had UACR assessment within the past year,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],Frequency of referral to a nephrologist
6092,NCT01472328,Skeletal muscle insulin sensitivity,,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
6093,NCT02050984,Reduction of hypertension medication prescription,Reduction of hypertension medication prescription,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],Adverse events
6094,NCT05551858,Adverse events,Change in Pain Measurements numeric score from baseline to end of treatment with proglumide compared to Placebo,2022-11-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6095,NCT02274272,Change in blood fat,Change in the DM marker,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
6096,NCT03405415,Assessment of glucose concentrations,,2018-01-27,COMPLETED,INTERVENTIONAL,['NA'],
6097,NCT01590758,Number of Participants With Clinical Response,Number of Participants With Treatment-emergent Adverse Events (TEAE),2014-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
6098,NCT06117449,HbA1C level,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
6099,NCT02154347,Change From Baseline in HbA1c,,na,COMPLETED,INTERVENTIONAL,['PHASE4'],
6100,NCT01779596,exercise induced blood flow,exercise induced Flow Mediated Dilation,2011-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
6101,NCT02226003,Percentage of Participants Who Discontinued Study Medication Due to an AE - All Participants as Treated Excluding Rescue Approach,Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 - Full Analysis Set Excluding Rescue Approach,2014-09-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
6102,NCT00225225,modification of the diet prevents weight gain.,develop specific dietary recommendations,2002-10,TERMINATED,INTERVENTIONAL,['NA'],
6103,NCT03942471,Change in HbA1c Measurements after Mindfulness Training,,2015-10-14,COMPLETED,INTERVENTIONAL,['NA'],
6104,NCT02569151,Death,"new, worsened, or improved microvascular and macrovascular events",2016-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
6105,NCT00819741,Change in Glycosylated Haemoglobin A1c (HbA1c),Haematology: Haemoglobin,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
6106,NCT03556033,Symptom score in response to insulin-induced hypoglycaemia,Glucose variability as measured by glucose sensor monitoring,2018-11-23,COMPLETED,INTERVENTIONAL,['PHASE2'],Inflammatory/atherogenic phenotype of circulating monocytes from the participating patients
6107,NCT01663220,,,2012-05,COMPLETED,OBSERVATIONAL,['NA'],
6108,NCT04058626,Diagnostic Accuracy,,2019-03-04,COMPLETED,OBSERVATIONAL,['NA'],
6109,NCT00675740,between-group difference in flow-mediated dilation of the brachial artery,relative effects of treatment on parameters of - glucose metabolism - inflammatory plasma markers - markers of endothelial function - cellular markers in muscle and fat biopsies,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
6110,NCT04120259,Measurement of Fasting Blood Sugar,,2019-04-22,COMPLETED,INTERVENTIONAL,['NA'],
6111,NCT01824407,Complete closure,Rate of amputation and other adverse events,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],
6112,NCT05252728,Differences of β diversity of gut microbiota between diabetic groups and healthy control.,,2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],
6113,NCT05176132,Prevalence of unrecognized obesity-related diseases,SDOI attitude to physical activity questionnaire,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],
6114,NCT06327711,Fasted Insulin,Conicity Index,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Urine biomarkers - inflammation
6115,NCT01068197,Change in BMI z-score between the two dietary groups,"Differences in subjective, hormonal, and metabolic between the two dietary arms",2003-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
6116,NCT02759107,Number of Participants With One or More Serious Adverse Event(s) (SAEs),Pharmacodynamics (PD): Ratio of AUC of Glucose on Day 23 to Baseline (Part C),2016-05-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
6117,NCT01129557,Cumulative Incidence of Aldosterone Breakthrough in Subjects Who Completed the 9-month Study Protocol.,Pre- and Post-treatment Serum Aldosterone in Subjects With and Without Aldosterone Breakthrough.,2009-09,TERMINATED,INTERVENTIONAL,['PHASE4'],
6118,NCT03168633,HbA1C values of patients after 6 months,percentage of messages opened and read,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
6119,NCT01586442,PIIINP,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
6120,NCT04905680,"Behaviour, self-efficacy and attitudes",Systolic and Diastolic Blood pressure,2021-05-04,UNKNOWN,INTERVENTIONAL,['NA'],
6121,NCT04867707,Change in glycocalyx integrity,Change in Vascular function,2021-07-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
6122,NCT00996658,Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks,Change From Baseline in Fasting Plasma Glucose (FPG) After 18 Weeks,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
6123,NCT02517242,Glycated Hemoglobin,Presence of asyntomatic hypoglycemias,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],
6124,NCT01749345,Quality of life,Low density lipoprotein (LDL) Cholesterol,2012-07,COMPLETED,OBSERVATIONAL,['NA'],
6125,NCT02191111,Change in Service Counts From Baseline to End of Intervention Period,,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
6126,NCT01137695,Glucose control,adverse effects,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],
6127,NCT02014740,Echocardiographic Epicardial Fat Thickness,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
6128,NCT00110448,"Aortic and peripheral vascular events, which needs internal medicine and/or surgical medical treatment",,2002-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
6129,NCT03059719,Incidence of treatment-emergent AE (safety and tolerability),PB-119 blood concentration,2015-04-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
6130,NCT04708145,DRSS Level Achievement in the VOYAGE study,Incidence of Adverse Events,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
6131,NCT05322200,"Compare the regression of vulnerable coronary plaque (necrotic core) assessed using histologically validated ""Plaque Maps"" derived from CT Coronary angiography in patients with raised HbA1c admitted with ACS and treated with oral Semaglutide or placebo.",Evaluate the effect of oral Semaglutide on levels of biomarkers of oxidative stress.,2022-08-31,RECRUITING,INTERVENTIONAL,['PHASE4'],
6132,NCT06222086,Physical activity level assessment with multi-sensor activity tracking,Upper extremity functional exercise capacity (percentage of the expected value (%)),2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
6133,NCT03195855,Change in maximum ankle range of dorsiflexion in stance phase when both feet are in contact with the ground (double support phase).,Change in functional reach test,2018-05-11,COMPLETED,INTERVENTIONAL,['NA'],To investigate the compliance/adherence rates of the home exercise programme
6134,NCT03811587,Dosage of antidiabetic medication used,,2018-11-05,COMPLETED,INTERVENTIONAL,['NA'],
6135,NCT04145804,The achievable percentage of time in range (TIR) 70 - 180 mg/dL for the whole study population after 3 months.,Percentage of time spend in Auto Mode,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
6136,NCT02217306,Contrast Sensitivity,,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
6137,NCT03369145,Leukocyte cell-derived chemotaxin 2 (LECT2),Body fat percentage,2017-12-11,COMPLETED,INTERVENTIONAL,['NA'],
6138,NCT05134662,Changes from baseline in fasting serum glucose and insulin as measured by Homeostasis Model Assessment for Insulin Resistance 2 (HOMA-IR2),Change from baseline in hemoglobin A1c (HbA1c),2022-02-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Change from baseline metformin concentrations
6139,NCT01279928,,,2010-03,COMPLETED,OBSERVATIONAL,['NA'],
6140,NCT04737499,Change of Concentration of HbA1c,Change of Score of Quality of life,2016-07-05,COMPLETED,INTERVENTIONAL,['NA'],
6141,NCT01471509,Change in blood glucose concentration,Change in serum insulin concentration,1982-08,SUSPENDED,INTERVENTIONAL,['NA'],
6142,NCT02552355,Glucose Tolerance,Glucose Profiles From Real-Time Continuous Glucose Monitoring,2015-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
6143,NCT00511732,Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline),"Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations",2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
6144,NCT01223339,Urinary Glucose Excretion over 24 hours for the Multiple Dose Cohort,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
6145,NCT00841867,To determine differences in glucose metabolism between subjects who have had partial pancreatectomy due to a benign lesion and those who have not had such a surgery.,,2008-12,COMPLETED,OBSERVATIONAL,['NA'],
6146,NCT02851849,Change from baseline in HbA1c,Change from baseline in body weight,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],"Exploratory Objective - Change from baseline from an Oral Glucose Tolerance Test (area under the curve for glucose, glucagon, insulin, C-peptide, and total and active GLP-1)"
6147,NCT01527539,HbA1c,Occurence of hypoglycaemic episodes,2001-11-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
6148,NCT06144788,Changes in HbA1c at the 12 week from the baseline,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
6149,NCT03631186,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),2018-09-12,COMPLETED,OBSERVATIONAL,['NA'],
6150,NCT04128150,Evolution of retina diseases,,2018-01-17,UNKNOWN,OBSERVATIONAL,['NA'],
6151,NCT02244879,C reactive protein (CRP),Metabolic and oxidative markers,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3'],body composition and bone mineral density
6152,NCT05849753,Percent sensor glucose time-in-range,Technology Attitudes,2023-07-26,RECRUITING,OBSERVATIONAL,['NA'],
6153,NCT01023243,Completion of foot exam,Patient report in validation of Natural Language Processing,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
6154,NCT03704103,Number of participants meeting HgbA1c <7%,Hypoglycemia,2018-08-28,COMPLETED,INTERVENTIONAL,['NA'],iSage Product Satisfaction Survey (iSage group only)
6155,NCT02313805,The total number of educational points addressed for the safe and effective use of insulin (of the possible 21 specified),"The number of educational points addressed under each of the four educational domains: insulin side effects, recognition and treatment of hypoglycemia, administration of insulin, and drawing up insulin using the syringe method.",2014-07,UNKNOWN,INTERVENTIONAL,['NA'],
6156,NCT00473525,Evaluation of Dose Response in HbA1c (%),Incidence of Adverse Events,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
6157,NCT03559621,weight-loss goal,Sence of Coherence,2019-04-14,COMPLETED,INTERVENTIONAL,['NA'],
6158,NCT06136793,Participant Cardiometabolic Disease Markers: Waist circumference,Household Supports for cardiometabolic disease reduction measures: Family Collective-Efficacy,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
6159,NCT05836194,The International Clinical Diabetic Retinopathy Disease Severity Scale within the 2-fields fundus photography and Ultra-Wide field scanning laser ophthalmoscopy (Optomap) imaging and statistical comparison,Number of predominantly peripheral lession(PPL) with Optomap imaging,2023-02-01,RECRUITING,OBSERVATIONAL,['NA'],
6160,NCT00555854,HbA1c,"Lipids profile ,blood pressure, waist, BMI and medication Questionnaire: PAID PCD HCCQ TSRQ Health Care Behavioural a",2005-12,COMPLETED,INTERVENTIONAL,['NA'],
6161,NCT02475070,Glucagon Response to Meal,Incretin Hormones,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
6162,NCT06050642,Change in the 7-question Type-1 Diabetes Distress Score (T1-DDS-7) [Comparison: Enhanced Care vs Standard Care],E.2 Number and relevance of impact that can have an impact on diabetes [Comparison: Enhanced Care vs Standard Care],2023-09-04,RECRUITING,INTERVENTIONAL,['NA'],
6163,NCT00444483,The primary outcome measure regarding patients metabolic control was the improvement of quality of life six months after DTTP.,A secondary objective of the study was the comparison of QoL- subscale in patients already on insulin therapy with those newly on insulin therapy.,na,COMPLETED,INTERVENTIONAL,['NA'],
6164,NCT03139864,Comparison of substrate utilization between infants with type 1 diabetes and infants without type 1 diabetes during exercise,Comparison between infants during 10 days before and 4 days after exercise of blood glucose modification,2017-04-04,UNKNOWN,INTERVENTIONAL,['NA'],
6165,NCT04216875,Change in score result before and after the introduction of the diabetes score criteria for treatment of diabetes patients in the primary care setting,Evaluation of practice tool used for the documentation and evaluation of the diabetes score,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],
6166,NCT01816906,Postural Sway During Shod Standing,Ankle Strength Right 2,2012-04,COMPLETED,INTERVENTIONAL,['NA'],Vibration Perception Threshold
6167,NCT01010035,to identify the removal of the free and esterified cholesterol in type 2 diabetes patients,,2006-09,COMPLETED,OBSERVATIONAL,['NA'],
6168,NCT00817973,Triglyceride levels,Incretin levels,na,COMPLETED,INTERVENTIONAL,['NA'],
6169,NCT04561609,Change in Monofilament test,Change in skin temperature,2020-05-02,UNKNOWN,INTERVENTIONAL,['NA'],
6170,NCT01607684,Frequency of gastric peristalsis,Influence of age on parameters of diabetic polyneuropathy measurable by magnetic marker imaging,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
6171,NCT05625321,Dietary Intake,Perceived Quality of Life,2023-03-27,RECRUITING,INTERVENTIONAL,['NA'],
6172,NCT04710940,Completion of diabetes self-management training (Aim 3),Hemoglobin A1C (HbA1C) (Aim 3),2021-01-13,COMPLETED,INTERVENTIONAL,['NA'],Predictors of guideline-concordant diabetes care (Clinical utilization) (Aim 1)
6173,NCT03455868,"Change in areal bone mineral density at lumbar spine, hip and radius",Change in cutaneous Advanced glycation end products (AGEs),2018-03-15,RECRUITING,OBSERVATIONAL,['NA'],Prevalence and incidence of non-vertebral fractures
6174,NCT01259206,Increased Calcaneal Spur Incidence in Patients With Obesity and Type 2 Diabetes Mellitus,,2009-02,COMPLETED,OBSERVATIONAL,['NA'],
6175,NCT00742547,HbA1c,incidence of diabetes-related complications,2008-10,COMPLETED,INTERVENTIONAL,['NA'],
6176,NCT05789251,standardized breakfast test resuslt compare to oral induced hyperglycemia test,,2023-06-19,RECRUITING,INTERVENTIONAL,['NA'],
6177,NCT03961659,Change of olfactory brain activation by fMRI,Olfactory threshold test,2019-05,UNKNOWN,INTERVENTIONAL,['NA'],
6178,NCT01948479,ulcer recurrence rates,peak pressure reduction with the addition of the intervention,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],
6179,NCT01941199,"Cmax,ss of DA-1229 and metformin",,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
6180,NCT01104142,,,2009-04,COMPLETED,OBSERVATIONAL,['NA'],
6181,NCT04907721,Differences in the calculated GLUSENTIC index between individuals with or without MASLD without diabetes,"Simple linear regression between the variables, pancreatic steatosis and amino acid stimulated glucagon or insulin levels in individuals without diabetes.",2021-05-27,COMPLETED,INTERVENTIONAL,['NA'],Differences in fetuin-B
6182,NCT01693133,Percentage of subjects with complete closure of the study ulcer,Cost effectiveness of treatment,2012-07,COMPLETED,INTERVENTIONAL,['NA'],Safety
6183,NCT00859638,Physical Functioning Inventory (PFI),Eight Foot Walk Test,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
6184,NCT03438162,Medication adherence assessment method,Adverse events questionnaire,2018-04-01,COMPLETED,INTERVENTIONAL,['NA'],
6185,NCT01375322,To compare the change from baseline in blood pressures (DBP/SBP) to 16-week regimen between Amtrel® and Co-Diovan®,To compare the response rate (defined as SBP < 130 mmHg and DBP < 80 mmHg) at the end of study,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
6186,NCT05296044,Changes in HbA1c,,2022-04-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],
6187,NCT01762657,Insulin Requirements Among Patients Treated with Oral Cyclosporine and Oral Lansoprazole,Glucagon C-peptide (under the curve) and Hemoglobin A1C levels among patients with existing type 1 diabetes treated with Cyclosporine and Lansoprazole,2014-09,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
6188,NCT04371653,Number of Participants With an Increase in Flora Diversity in Fecal Samples,Monitor subjects' health information,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
6189,NCT05724888,Retention for follow-up measurements,BREQ2 (Behavioral Regulation in Exercise Questionnaire-2) change,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
6190,NCT01263483,Change From Baseline in Glycosylated Hemoglobin (Week 12).,Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)).,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
6191,NCT02339909,Number of Patients Attending Screening Appointment,Number of Patients Requiring Intervention After Sight Outcome From Diabetic Retinopathy Screening.,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
6192,NCT05686655,sleep problems as frequent awakening during the night,,2023-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
6193,NCT00256607,1) Determine the cross-sectional relationship between baseline levels of novel CVRF and the,,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
6194,NCT05591391,Time in range,Treatment satisfaction questionnaire,2022-09-28,RECRUITING,INTERVENTIONAL,['NA'],
6195,NCT03257566,Screening the incidence of hypothyroidism in patients with type 1 diabetes,,2017-11,UNKNOWN,OBSERVATIONAL,['NA'],
6196,NCT04390295,Adjusted Mean Change in HbA1c Levels,The number of volunteers with adverse events as a measurement of safety,2017-11-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],
6197,NCT05073978,maternal outcomes,,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],
6198,NCT05479591,Change in Glycated Haemoglobin A1c (HbA1c),Change in body weight,2022-07-30,WITHDRAWN,OBSERVATIONAL,['NA'],
6199,NCT01086189,Postprandial glucose and insulin,Postprandial satiety,2009-12,COMPLETED,OBSERVATIONAL,['NA'],
6200,NCT01023581,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in Fasting Plasma Glucose Over Time,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
6201,NCT04058639,wound healing time in weeks,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA'],
6202,NCT00240175,Quantitative measures of plantar pressure,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
6203,NCT03010319,"Percentage of Subjects With Complete Wound Closure, as Assessed by the Investigator, at or Before Week 12 of the Treatment Phase","Rate of Wound Closure, as Assessed by Computerized Planimetry.",2017-01,COMPLETED,INTERVENTIONAL,['NA'],
6204,NCT01113099,Statin prescription at hospital discharge,,2006-06,COMPLETED,INTERVENTIONAL,['NA'],
6205,NCT01147731,The pharmacokinetic parameters (AUC and Cmax) of R and S-warfarin isomers with and without albiglutide,The effect of albiglutide on the pharmacodynamics of warfarin as determined by the International Normalisation Ratio (INR).,2010-06-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
6206,NCT02434094,Human factors feedback,,2015-04,COMPLETED,OBSERVATIONAL,['NA'],
6207,NCT01234155,Glycemic Control,Body Composition,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
6208,NCT05348551,Assessment of the proportion of pediatric patients with access to remote monitoring,Evaluation of patients' (and parents') perception of telemonitoring using a scale,2022-05-20,UNKNOWN,OBSERVATIONAL,['NA'],
6209,NCT01754467,Acceptability of NEAT!,Changes in Total Sedentary Time,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
6210,NCT01416324,Adverse events relative to placebo,Measurement of the apparent volume of distribution (V/F) of the study drug,2011-06-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
6211,NCT04889053,The prevalence and incidence rate of CAC in T2DM,The effect of statins on the occurrence and development of CAC in patients with T2DM,2021-06-01,RECRUITING,OBSERVATIONAL,['NA'],
6212,NCT05051436,Oral glucose tolerance test,Hemoglobin A1C,2021-12-13,RECRUITING,INTERVENTIONAL,['PHASE4'],Muscle biopsy
6213,NCT00696982,"arterial stiffness, defined as change in augmentation index measured by means of a non-invasive technique using the commercially available SphygmoCor System, and the results of the 24 hour blood pressure monitoring","The secondary end results would be oxidative stress parameters, as evaluated by oxidized LDL and Isoprostanes, and markers of inflammatory status, including measurements of pro-inflammatory interleukins and performance of highly sensitive CRP test.",2008-06,UNKNOWN,INTERVENTIONAL,['NA'],
6214,NCT01192139,Metformin Cmax,"Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and Electrocardiogram (ECG) Abnormalities",2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
6215,NCT04120623,the effect of dapagliflozin combined with CSII on glucose profile,"the effects of dapagliflozin combined with CSII on lipid metabolism(total cholesterol in mmol/l, total glyceride in mmol/l)",2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
6216,NCT00604383,Percentage of Participants Who Had Sustained Moderate Visual Loss (SMVL) as Defined as a Visual Acuity Loss of ≥15 Letters Measured Twice During a 6-month Period,Change From Baseline up to 36 Months in Mental and Physical Components of the Medical Outcomes Study 36-Item Short Form (SF-36) Health Status Questionnaire,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
6217,NCT02389010,Number of closed skin ulcers within 4 weeks of treatment with cord blood platelet gel (CBPG) vs standard local medications,Cost of treatment,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
6218,NCT05327595,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,PD: Change from Baseline to Day 28 in Oral Glucose Tolerance (OGTT) 2 Hour Glucose,2022-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
6219,NCT04381429,Change of time in range of blood glucose variation (70-180 mg/dl) versus baseline at the end of each treatment period of 3 months (the last 2 weeks of the period of 3 months) is assessed.,Other CGM parameters: Time in range of blood glucose 70-140 mg/dl,2020-08-17,RECRUITING,INTERVENTIONAL,['PHASE4'],
6220,NCT04339530,HOMA-IR (Homeostasis modelling assessment-Insulin resistance),Augmentation index,2019-07-01,SUSPENDED,OBSERVATIONAL,['NA'],
6221,NCT03960814,Age at death of cardiovascular disease,,2019-05-21,COMPLETED,OBSERVATIONAL,['NA'],
6222,NCT03901898,Number of patients who have attended screening,,2019-07-16,COMPLETED,INTERVENTIONAL,['NA'],
6223,NCT03399825,Evaluation of the sensitivity and specificity of OCTA,,2018-01,WITHDRAWN,OBSERVATIONAL,['NA'],
6224,NCT00348855,"Number of patients who reach all the therapeutic goals defined by the guidelines in the total study population, in the sub-group of patients with hypertension, but free of type-2 diabetes (T2D), and in the sub-group with hypertension and T2D.","Levels of blood pressure, LDL-Cholesterol, tobacco consumption in the whole population plus levels of HbA1c and aspirin use in the TD2 population",2006-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
6225,NCT06028386,Days to complete wound closure,Changes in quality of life,2023-08-15,RECRUITING,INTERVENTIONAL,['NA'],
6226,NCT01947790,The changes of LVM,The changes of endothelial function,2013-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
6227,NCT03414736,Frequency of GI AEs,Adverse events (AEs),2018-01-19,COMPLETED,INTERVENTIONAL,['PHASE1'],
6228,NCT04243746,Serum high density lipoprotein (HDL) (mmol/L),Incidence of treatment-emergent adverse events [Safety ],2020-03-03,COMPLETED,INTERVENTIONAL,['NA'],
6229,NCT00554281,Decrease in HYPO score,Number of patients who decide to continue using the device,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
6230,NCT01937702,injection pain,variability of injection pain,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
6231,NCT03017352,Change in HbA1c,hsCRP (High-Sensitivity C-Reactive Protein),2016-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
6232,NCT00329225,HbA1c at each visit,FPG at each visit C-peptide at each visit lipids at each visit BNP at each visit CRP at each visit PAI-1 at each visit MMP-9 at each visit,2002-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
6233,NCT01613937,HbA1c,hours of physical activity per week at all time points,2009-12,COMPLETED,INTERVENTIONAL,['NA'],
6234,NCT05984979,VOC Patterns over time as boxplots,Correlation between VOCs and subgroups,2023-08-07,RECRUITING,OBSERVATIONAL,['NA'],
6235,NCT00327418,or unstable angina or resuscitated cardiac arrest or stroke.,baseline in various lipid and lipoprotein parameters.,1997-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
6236,NCT01917760,pharmacokinetic characteristics of γ-aminobutyric acid (GABA),serological characteristics,2013-07,COMPLETED,OBSERVATIONAL,['NA'],Exploratory measures
6237,NCT01465152,Change of % HbA1c (glycosylated haemoglobin) in blood,Treatment compliance,2002-03-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
6238,NCT02200991,Change from baseline in postprandial plasma glucose at Day 29 after a standardized breakfast,Proportion of patients with adverse events,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
6239,NCT02277509,Percent Change in BMI,Sustained changes in HbA1c,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
6240,NCT01113801,Change in Log Transformed (In) Serum Creatinine From Baseline to 12 Month Endpoint,Estimated Glomerular Filtration Rate (eGFR) Slope of Change From Baseline Through 12 Months,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2'],
6241,NCT00000153,,,1984-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
6242,NCT05040009,Screening for diabetic foot and diabetic complication in patients attending at Diabetic center,,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
6243,NCT00940797,Insulin sensitivity,"Creatinine, Total Cholesterol, HDL, Triglycerides, Uric acid, AST, ALT, FA, DHL",2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
6244,NCT05281614,Adverse events of vedolizumab treatment as a measure of safety and tolerability,Change in T1D antibody titers,2022-09-21,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
6245,NCT03202875,Assessment of PD parameters: Area under the body weight standardized glucose infusion rate (GIR),Number of adverse events (AEs),2012-11-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
6246,NCT01263509,Number of Participants With Adverse Events.,Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit).,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
6247,NCT03051243,Percentage of patient with mean blood glucose levels,TTD (total daily dose) of insulin,2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
6248,NCT05216796,Decrease in cerebral gluatamate,,2022-05-18,RECRUITING,INTERVENTIONAL,['NA'],
6249,NCT03059550,Percentage of OGTT performed after an acute coronary syndrome,Profile of the patients according to their glucose abnormalities,2013-03-01,UNKNOWN,OBSERVATIONAL,['NA'],
6250,NCT02012465,Incidence of hyperglycemia,Remission of primary oncologic diagnosis at one year,2013-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
6251,NCT04903756,Analysis of audio-recorded consultations between surgeons and patients.,Analysis of healthcare professional interviews,2020-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
6252,NCT02938026,Change of weight,,2016-05-01,COMPLETED,INTERVENTIONAL,['NA'],
6253,NCT01363609,food-stimuli related neuronal activity in reward and satiety circuits as represented by BOLD fMRI signal change from baseline (%),GLP-1 analog treatment related changes in obese patients with type 2 diabetes in brain arterial blood flow.,2011-10,COMPLETED,INTERVENTIONAL,['NA'],
6254,NCT03982381,"Time to first occurence of a confirmed composite endpoint of death, myocardial infarction, stroke, heart failure, diabetic nephropathy, retinopathy or foot ulcer.",Health-related quality of life with respect to diabetes treatment satisfaction.,2019-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
6255,NCT01686620,Change in HbA1C,Daily blood glucose measures,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
6256,NCT03700502,resting-state functional Magnetic Resonance Imaging,,2016-06-05,UNKNOWN,OBSERVATIONAL,['NA'],
6257,NCT01710748,Neointimal hyperplasia volume obstruction,Target vessel failure,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
6258,NCT03638349,Scaled preference questionnaires on new blood glucose monitoring digital tool.,Preference questionnaires on new blood glucose monitoring digital tool based on insulin or non-insulin using subjects,2018-07-17,COMPLETED,OBSERVATIONAL,['NA'],
6259,NCT00901043,Brachial artery flow mediated dilation (FMD),"Change in weight, waist circumference, blood pressure, fasting lipids, fasting insulin, HBA1c and glucose levels",2007-10,COMPLETED,INTERVENTIONAL,['NA'],
6260,NCT02899572,Measurement of HbA1c according to the randomisation group,,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],
6261,NCT00279305,Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4-hour Mixed Meal Tolerance Test (MMTT) Administered at 1 Year,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
6262,NCT05234281,Changes in level of patient activation,Changes in level of functioning,2021-05-01,RECRUITING,INTERVENTIONAL,['NA'],
6263,NCT04468243,Point of Care HbA1c Test,,2021-04-01,TERMINATED,INTERVENTIONAL,['NA'],
6264,NCT03360981,Major adverse cardiac events (MACE),stem cells isolated in epicardial fat.,2017-09-20,UNKNOWN,INTERVENTIONAL,['PHASE4'],
6265,NCT01898572,Carotid Intima Media Thickness (CIMT),CIMT,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],Diet intake
6266,NCT02145611,Change from baseline in the central blood pressure after 12 weeks of vildagliptin x glibenclamide treatment,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
6267,NCT01536028,Area under the GIR (glucose infusion rate)-curves in the first two hours post-dosing,Hypoglycaemic episodes,2006-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
6268,NCT04092140,Electromyogram,,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA'],
6269,NCT03829046,Number of Adverse Events,Alpha5/Beta3 Activation Levels,2019-06-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
6270,NCT02106585,fe(total) (fraction of systemically available drug excreted into the urine over entire collection interval),,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
6271,NCT04892069,Change in Glycated Haemoglobin (HbA1c),Change in the occurrence of severe hypoglycaemic events before and after initiation of treatment,2021-05-27,COMPLETED,OBSERVATIONAL,['NA'],
6272,NCT05574335,Acceptable T cell phenotype signature by the change from baseline in the CD4 Treg/Tem ratio,Insulin use (U/kg/day),2023-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6273,NCT00350701,Effect of Androgel Treatment on Relative Nuclear Factor kB Activity Compared to Placebo,Change in Inflammatory Mediator C-Reactive Protein (CRP) Following Treatment With Testosterone,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
6274,NCT01864564,Number of Participants With a Composite Perinatal Outcome,Large for Gestational Age,2013-06-18,COMPLETED,INTERVENTIONAL,['NA'],
6275,NCT01906970,"Measurement accuracy, glucose control quality, safety, handling and functionality of ClampArt®",,2013-06-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
6276,NCT04195477,Change in BMI,Change in Physical Activity,2020-10-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
6277,NCT00948116,Development of contrast induced nephropathy (CIN) which will be defined as an increase in Cr of ≥ 44 μmol/l within 72 hours post-procedure.,,2009-07,UNKNOWN,OBSERVATIONAL,['NA'],
6278,NCT04961931,urine phosphorus concetration,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
6279,NCT06149793,"Feasibility, safety, tolerability",,2023-12-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
6280,NCT01611168,"Lipids (LDLc, HDLc, cholesterol, and triglyceride)",,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
6281,NCT05481801,Vaccination adherence,Death,2022-09-01,COMPLETED,OBSERVATIONAL,['NA'],
6282,NCT00001346,,,1992-11,COMPLETED,OBSERVATIONAL,['NA'],
6283,NCT03071692,"Number of patients with first occurrence of nonfatal MI, nonfatal ischemic stroke, coronary revascularization, or CV death.",Nonfasting Remnant Cholesterol Endpoint,2017-03-23,TERMINATED,INTERVENTIONAL,['PHASE3'],
6284,NCT05786534,Weight will be measured before and after the trial,,2022-12-09,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
6285,NCT04315545,fasting and postprandial insulin,fasting and postprandial stable glucose isotopes,2020-02-06,RECRUITING,OBSERVATIONAL,['NA'],MP
6286,NCT01208701,Fractional excretion of sodium,Augmentations index,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
6287,NCT01209416,Effects of ghrelin during basal and hyperinsulinemic conditions,,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
6288,NCT04278742,Wound healing,Behaviour score assessed by questionnaire,2018-12-03,UNKNOWN,INTERVENTIONAL,['NA'],
6289,NCT01787669,Proportion of eyes that have central macular thickness <300 microns 6 months after switching,Mean change in central macular thickness (CMT) as measured by OCT.,2013-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Mean change in BCVA (best corrected visual acuity)
6290,NCT01731431,"Composite criterion of neonatal complications associated with gestational diabetes: macrosomia or birth weight ≥ 90th percentile for gestational age, neonatal hypoglycemia and neonatal hyperbilirubinemia","Rates of caesarean section, preterm delivery rate, neonatal mortality rate, number of neonatal and maternal trauma related to delivery, number of respiratory distress, number of prenatal visits, number of days of hospitalization",2012-05-18,COMPLETED,INTERVENTIONAL,['PHASE3'],
6291,NCT03100383,Gestational Weight Gain (GWG).,Eating behavior,2013-11-01,COMPLETED,OBSERVATIONAL,['NA'],
6292,NCT02479399,Incidence of malignant tumor,Safety developed by adverse events and laboratory tests,2014-07-17,COMPLETED,OBSERVATIONAL,['NA'],
6293,NCT03877003,"Plasma lipids (total cholesterol, HDL cholesterol and triglycerides) in mg/dL",Analysis of microbiota diversity (expressed as concentrations of different microorganisms.,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],
6294,NCT00228605,Safety and tolerability when used over a 12-month period for the management of breakthrough pain in opioid tolerant patients,Assess the patients' overall medication performance,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
6295,NCT02400450,LDL-Cholesterol,Food Consumption Patterns,2016-09,WITHDRAWN,INTERVENTIONAL,['NA'],
6296,NCT06232746,Anastomosis Patency,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
6297,NCT01189461,Mean Total Number of Injections,Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Week 48 (End of Treatment),2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
6298,NCT00509262,Percentage of Participants With Hypoglycemic Events,Change From Baseline in Body Weight at Week 54,2007-10-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
6299,NCT01334151,Speed of absorption,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
6300,NCT02863276,Postoperative protein balance (leucine) (umol/kg/h),Postoperative glucose metabolism: Glucose clearance (ml/kg/min),2009-12,COMPLETED,INTERVENTIONAL,['NA'],
6301,NCT03652389,reduction in the levels of HbA1c,,2018-12-18,COMPLETED,INTERVENTIONAL,['NA'],
6302,NCT04028089,Glycaemic excursion during an oral glucose tolerance test,Time of delivery,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA'],Epigenetic modification
6303,NCT00057304,,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
6304,NCT02072096,Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia,Change From Baseline of Estimated Glomerular Filtration Rate (eGFR),2014-02,TERMINATED,INTERVENTIONAL,['PHASE4'],Change From Baseline in Mini-mental State Examination (MMSE) Score
6305,NCT00001203,,,1985-04-22,COMPLETED,OBSERVATIONAL,['NA'],
6306,NCT05119179,Previously unidentified cis-eQTLs associated with change in gene expression due to GLP-1 challenge,Polygenic prediction model for GLP-1 therapy-associated outcomes,2021-11-22,RECRUITING,INTERVENTIONAL,['PHASE4'],
6307,NCT01447979,estimation of the failure rates of system components,percent time of active CTR,2012-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
6308,NCT05873920,atrial fibrillation recurrence,,2023-05-09,RECRUITING,OBSERVATIONAL,['NA'],
6309,NCT00812539,Subject and provider satisfaction with the intervention.,Subject knowledge of diabetes and motivation,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
6310,NCT00748072,The Primary Outcome Measure Was the Incidence of Post-biopsy Bleeding Complications.,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
6311,NCT02129595,"insulin sensitivity: overall, muscle- and liver specific",brown adipose tissue activity,2014-04,COMPLETED,INTERVENTIONAL,['NA'],Blood pressure
6312,NCT01763346,Steady State Beta Cell Compensation,,2013-06,COMPLETED,INTERVENTIONAL,['NA'],Glycemia
6313,NCT01183455,Mixed-Meal Tolerance Test (MMTT)-Stimulated 2-hour C-peptide Area Under the Curve (AUC),Pharmacokinetic Parameters of Aralast NP,2010-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
6314,NCT00543959,Body fluid gain from baseline after 12 weeks,Fasting plasma glucose after 12 weeks,2006-06,TERMINATED,INTERVENTIONAL,['PHASE2'],
6315,NCT06283992,Proportion of Participants Who Login to the Portal,Proportion of participants that are re-admitted,2024-03-31,RECRUITING,INTERVENTIONAL,['NA'],
6316,NCT04171648,Change from Baseline Blood Glucose Response (Glycemic Response),waist to hip ratio,2020-03-02,TERMINATED,INTERVENTIONAL,['NA'],
6317,NCT02650206,Macrophage polarization: % M2 macrophages in adipose tissue and peripheral blood according to positivity for cell surface markers (measured by flow cytometry).,Macrophage polarization: M1 to M2 ratio in adipose tissue and peripheral blood according to cell surface markers (measured by flow cytometry),2015-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
6318,NCT03964987,ARNm expression,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],
6319,NCT00196989,Percentage change from Baseline (Day 1) in glycated hemoglobin (HbA1c) levels at Week 16 as a measure of improvement in glucose control,Change from Baseline (Day 1) in QUICKI at Week 16,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
6320,NCT01124617,Change From Baseline in Average Numerical Rating Scale (NRS) Score at Week 12,Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Scores at Week 12,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
6321,NCT00518115,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16,Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
6322,NCT05478070,Maternal outcomes,,2022-05-15,RECRUITING,INTERVENTIONAL,['NA'],
6323,NCT00529204,Reduction in Serum ALT From Baseline to 24 Weeks of Exenatide Therapy,Safety of Exenatide in Patients With NAFLD and Type 2 Diabetes,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
6324,NCT01398995,Comparison of glucose excursion (change in blood glucose) between baseline and the end of exercise between the four conditions.,Ratio of respiratory quotient (RQ) at the beginning of exercise to RQ at the end of exercise compared between the four conditions.,2011-05,TERMINATED,INTERVENTIONAL,['NA'],
6325,NCT03794739,Altered TMEM219 expression in pancreatic islets/beta cells in diabetes.,Altered TMEM219-peripheral regulating factors in diabetes.,2020-08-08,RECRUITING,OBSERVATIONAL,['NA'],
6326,NCT05231031,Serum cortisol level,The perceived stress score (PSS),2021-01-01,COMPLETED,INTERVENTIONAL,['NA'],
6327,NCT01497600,Area under the glucose infusion rate curve,Adverse events,2004-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
6328,NCT01498900,HbA1c (glycosylated haemoglobin),Adverse drug reactions (ADR),2004-08,COMPLETED,OBSERVATIONAL,['NA'],
6329,NCT01885260,The effect of ISIS-GCGRRx on serum fructosamine,The tolerability of ISIS-GCGRRx,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
6330,NCT00116831,Model Adjusted Change From Baseline in Percent Atheroma Volume (PAV) to Month 18,Number of Other Cardiovascular Events,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
6331,NCT03760991,Change in glycated hemoglobin (HbA1c),Number of participants with health care utilization,2018-12-18,COMPLETED,INTERVENTIONAL,['PHASE4'],
6332,NCT01772251,Adverse events and serious adverse events occurence,• To assess the pharmacodynamic effect of multiple doses of Oshadi Icp as measured by the area under the glucose concentration-time curve,2013-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",• Evaluating the total daily injected insulin dose during administration of Oshadi Icp vs. placebo
6333,NCT04512885,success rate,satisfaction measured by auto-questionnaire,2020-07-16,COMPLETED,OBSERVATIONAL,['NA'],
6334,NCT03657537,Cognitive composite score (global score),Symbol Digit Modalities Test (SDMT),2018-09-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
6335,NCT01431807,Adverse events,,2011-09-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
6336,NCT00344903,,,2007-09,COMPLETED,OBSERVATIONAL,['NA'],
6337,NCT04747639,iAUC insulin 250,gastro-intestinal symptoms,2015-10-28,COMPLETED,INTERVENTIONAL,['NA'],
6338,NCT01776099,metabolic improvement of type 2 diabetes,,2012-11,UNKNOWN,INTERVENTIONAL,['NA'],
6339,NCT03459079,Change in intrahepatic triglycerides (IHTG) quantified by proton magnetic resonance and spectroscopy (¹H-MRS),Change in plasma biomarkers of liver fibrosis.,2018-08-14,COMPLETED,INTERVENTIONAL,['PHASE2'],
6340,NCT04822740,Glycemic variability by the coefficient of variation of blood glucose in percent,Patient satisfaction,2022-12-07,TERMINATED,INTERVENTIONAL,['NA'],
6341,NCT00720889,Total body insulin sensitivity,Glycerol turnover and free fatty acid concentration,2008-07,COMPLETED,OBSERVATIONAL,['NA'],
6342,NCT02660047,Left ventricular filling pressure (= early peak filling rate / peak mitral annulus longitudinal motion),Brown adipose tissue,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4'],Hypoglycaemic episodes
6343,NCT01973361,Change in wound surface area,Number of wounds healed,2013-12,COMPLETED,INTERVENTIONAL,['NA'],
6344,NCT06230705,Cardiovascular Risk Factor Knowledge,,2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
6345,NCT03192410,Major cardiovascular events,Cognitive function,2002-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Circulating fatty acids
6346,NCT03645109,Changes in the parameters that make up the glycemic profile,"Changes in calcium, phosphorus and vitamin D3",2020-02-28,COMPLETED,INTERVENTIONAL,['NA'],
6347,NCT03683888,Epicardial fat thickness (EAT),Hemoglobin A1c (HbA1c) percentage (%),2018-06-01,COMPLETED,INTERVENTIONAL,['NA'],
6348,NCT00713921,Develop and quantify methods for evaluating bladder dysfunction in diabetes and stroke. Develop pilot data of medical therapy (Toviaz) in diabetic and stroke bladder dysfunction.,,2009-09-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],
6349,NCT02373150,Safety and tolerability of imeglimin: laboratory assessments,,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
6350,NCT01113671,Reverse Cholesterol transport of the HDL,Serum inflammatory markers,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
6351,NCT01374568,Bone Turnover in Subjects Treated With Sitagliptin When Compared to Those Treated With Placebo,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE4'],
6352,NCT05926414,HbA1c (%) changes,,2023-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
6353,NCT03181737,Diabetes Self-Management Questionnaire (DSMQ-R),Subjective usefulness of the program,2017-08-03,TERMINATED,INTERVENTIONAL,['NA'],
6354,NCT04665570,Mean change in HbA1c,Descriptive analysis of adverse events (AEs),2020-12-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
6355,NCT03794336,Overall Gastrointestinal tolerability,Medication possession ratio (MPR),2019-06-29,COMPLETED,INTERVENTIONAL,['PHASE4'],
6356,NCT03544684,24 hour glycaemic profile,,2015-03-09,COMPLETED,INTERVENTIONAL,['NA'],
6357,NCT01559025,Beta cell function,Glycemic variability,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],
6358,NCT02050074,Change in the gut hormone glucagon-like peptide 1 (GLP-1),,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
6359,NCT04550585,Low-literacy based education on diabetes knowledge,,2017-04-01,COMPLETED,OBSERVATIONAL,['NA'],
6360,NCT04916132,Prevalence,Death,2021-08-10,RECRUITING,OBSERVATIONAL,['NA'],
6361,NCT02587975,Serum concentration of C-terminal telopeptide after treatment in comparison with the baseline,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],
6362,NCT00449891,,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
6363,NCT02097277,Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12,Percentage of Participants With ANTI-BMS-986036 Antibody Response,2014-04-15,COMPLETED,INTERVENTIONAL,['PHASE2'],
6364,NCT00872326,Angiographic evaluation of angiogenesis and vasculogenesis at target limb,Ankle-Brachial pressure index,2007-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6365,NCT00788879,Fruit and Vegetable Intake,Confirmed Awareness: Confirmation of recognition of messages,2003-02,COMPLETED,INTERVENTIONAL,['NA'],
6366,NCT03512236,AUCPram_0-8h,Safety and tolerability (Adverse Events recording),2018-04-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
6367,NCT01364428,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
6368,NCT02582840,24-hour Urinary Glucose (g/24h) Mean Change From Baseline on Day 7 - Pharmacodynamic (PD) Set,Seated Systolic Blood Pressure (mmHG) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
6369,NCT00585936,,,2007-09,COMPLETED,OBSERVATIONAL,['NA'],
6370,NCT00518882,Change in Glycosylated A1c (HbA1c) at Week 26,"Hypoglyceamic Episodes, Weeks 26-78",2007-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
6371,NCT02219269,Contraceptive method continuation and satisfaction,If Contraception is Accessed in post-partum or post-abortion setting,2014-06,COMPLETED,OBSERVATIONAL,['NA'],
6372,NCT05823948,Change in glycated haemoglobin (HbA1c),,2023-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
6373,NCT00118963,Glycemic control (HbA1c).,"Markers of endothelial dysfunction, inflammation and fibrinolysis including Small-dense-LDL, Lp(a) and Apo B100, von Willebrand-factor, ICAM, VCAM, selectin, endothelin, Amadori-protein, CRP, fibrinogen, IL-6, TNF-alfa, ADMA, PAI- and t-PA-activity",2003-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
6374,NCT03874715,Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm),Pharmacokinetics: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm),2019-03-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
6375,NCT03388762,GlycoMark,Adverse events,2017-12-05,COMPLETED,INTERVENTIONAL,['NA'],
6376,NCT06156124,Clinical problems,Sociodemographic data,2023-06-13,RECRUITING,OBSERVATIONAL,['NA'],
6377,NCT04860336,Large for gestational age (LGA),Nutrition Substudy: large for gestational age birthweight,2021-04-01,RECRUITING,OBSERVATIONAL,['NA'],Nutrition Substudy: Maternal fasting free fatty acids
6378,NCT03767608,Comparison between groups,,2016-01,COMPLETED,OBSERVATIONAL,['NA'],
6379,NCT03162237,Blood glucose,Cytokine detection,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
6380,NCT04683211,Iodine supplementation,,2021-01-05,COMPLETED,OBSERVATIONAL,['NA'],
6381,NCT02367690,Presence of Local Skin Reactions (LSR),Ulcer Closure,2015-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6382,NCT00804986,Change in Hemoglobin A1C (HbA1c) From Baseline to Week 12 Endpoint,Percent of Participants Domain Scores Indicating No Problems on European Quality of Life (EuroQol) at Baseline and Week 12 Endpoint,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
6383,NCT05094037,Number of foot ulcers,,2023-12-04,RECRUITING,INTERVENTIONAL,['NA'],
6384,NCT04070794,"AUC0-∞ of gemigliptin, LC 15-0636 and metformin",,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
6385,NCT05702931,Mean sensor glucose (mmol/L),Incidence of self-reported hypoglycaemic episodes,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
6386,NCT00608348,Muscle sympathetic nerve activity,,2002-04,COMPLETED,INTERVENTIONAL,['NA'],
6387,NCT05934409,"Change in cardiac non-esterified fatty acid (NEFA) uptake, oxidation and esterification",Change in glycerol turnover,2023-11-01,RECRUITING,INTERVENTIONAL,['NA'],
6388,NCT02027259,Change in 10-year UKPDS coronary event risk and PHQ-9 depression scores.,,2012-01-19,COMPLETED,INTERVENTIONAL,['NA'],
6389,NCT04883424,Diabetes Attitude Scale,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA'],
6390,NCT02002975,Changes From Baseline in Metabolic Syndrome Parameters (Diastolic Blood Pressure) at Final Assessment Point,"Association Between Patient Baseline Characteristics, Including Any Metabolic Syndrome-related Risk Factors, and Onset of New Cerebral and Cardiovascular Events",2007-10-16,COMPLETED,OBSERVATIONAL,['NA'],
6391,NCT01109316,Mean of Last Five 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Day 2 for Insulin Lispro 2D and Day 6 for Insulin Aspart 6D Pump Reservoir In-use,Change From Baseline to 8 Weeks Endpoint for Each Treatment in Blood Pressure,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
6392,NCT01372163,Number of participants with Adverse Events as a measure of safety and tolerability.,"Urinary recovery and renal clearance of PF-05190457 will be estimated via comparison of the plasma AUC and urinary excretion to provide AE0-τ, AE0-τ%, and CLR as the data permit.",2011-07,TERMINATED,INTERVENTIONAL,['PHASE1'],
6393,NCT01832441,Abolition or reduction of insulin by >50 percentage,Improvement in HbA1C levels,2014-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6394,NCT01316835,,,2010-12,UNKNOWN,OBSERVATIONAL,['NA'],
6395,NCT04216654,association between microalbuminuria and infection by H. pylori in type 2 diabetic patients.,,2019-07-01,COMPLETED,OBSERVATIONAL,['NA'],
6396,NCT04387448,Percentage change in Urine Albumin-to-Creatinine Ratio (UACR),Plasma PK parameters: area under the plasma concentration-time curve (AUC),2020-07-28,TERMINATED,INTERVENTIONAL,['PHASE2'],
6397,NCT02758275,Changes of mean score adherence to treatment from baseline at 6 and 12 months,Changes of mean systolic blood pressure from baseline at 6 and 12 months,2016-04-28,COMPLETED,INTERVENTIONAL,['NA'],
6398,NCT00532506,,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],
6399,NCT04515992,Change from baseline of HbA1c,,2018-03-01,COMPLETED,INTERVENTIONAL,['NA'],
6400,NCT05147961,"Development of type 2 diabetes, diagnosed by fasting or post-challenge plasma glucose concentrations meeting the American Diabetes Association criteria.",Bioinformatics and systems biology methodologies,2022-05-25,RECRUITING,INTERVENTIONAL,['NA'],
6401,NCT03159052,The number of volunteers with adverse events as a measure of safety,Adjusted Mean Change in Fasting Plasma Glucose,2017-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],
6402,NCT00326222,PAM - Patient activation measure,Triglyceride,2006-05,COMPLETED,INTERVENTIONAL,['NA'],
6403,NCT04976517,readmission,,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
6404,NCT04926415,Change in Adiponectin Plasma Concentration induced by sham taVNS,Changes in Autonomic Function induced by sham taVNS,2021-06-14,COMPLETED,INTERVENTIONAL,['NA'],
6405,NCT01901861,Release of incretins hormones,,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
6406,NCT03789695,Difference in annual eGFR decline (slopes) between dabigatran and warfarin patients,,2018-11-14,UNKNOWN,INTERVENTIONAL,['PHASE4'],
6407,NCT02683135,"Difference in glycemic control assessed by continuous glucose monitoring in low-carbohydrate, low-carbohydrate plus post-meal walking, and high-carbohydrate low-fat arm.",Change from baseline in flow mediated dilation of brachial artery after 4 days of intervention.,2015-11,COMPLETED,INTERVENTIONAL,['NA'],Change from baseline in body weight after a single meal and 4 days of intervention.
6408,NCT05181826,Independent performance measure of sensitivity and specificity of a multi-analyte blood test,Ascertain Sample Stability,2019-05-21,RECRUITING,OBSERVATIONAL,['NA'],
6409,NCT01448174,normalization of serum LDL cholesterol,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
6410,NCT03578094,Assessment of the anthropometric measurements of the infant according to the breastfeeding patterns,,2015-12-01,COMPLETED,OBSERVATIONAL,['NA'],
6411,NCT01514305,Absolute Relative Difference (%) to Reference Standard,,2011-11,COMPLETED,OBSERVATIONAL,['NA'],
6412,NCT02673138,Differences in BHB (Beta-hydroxybutyrate) Levels Following Interruption of Basal,Differences in Glucagon Levels Following the Interruption of the Basal Subcutaneous Insulin Infusion,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
6413,NCT02911948,Change in Glycosylated Haemoglobin (HbA1c),Change From Baseline in Patient Reported Outcomes (PROs) of Treatment: EuroQol-5D (EQ-5D-5L) Questionnaire,2016-09-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
6414,NCT00859079,time to reach a plasma glucose below 115 mg/dl,number of hypoglycaemic episodes,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
6415,NCT00097500,Beta-cell Function After 52 Weeks of Therapy,"M-value at Baseline, Week 52 and Week 56",2004-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
6416,NCT04767880,Concentration differences in blood glucose following an OGTT,Continuous glucose measurements (CGM),2021-04-26,COMPLETED,INTERVENTIONAL,['NA'],
6417,NCT00130481,Low density lipoprotein,Glycated hemoglobin (HbA1c),2005-04,COMPLETED,INTERVENTIONAL,['NA'],
6418,NCT05990595,Glycosylated hemoglobin (HbA1C),Small-dense LDL-cholesterol,2023-07-07,RECRUITING,INTERVENTIONAL,['NA'],"Center for Epidemiologic Studies Depression Scale (CES-D), NIMH"
6419,NCT01091896,Recurrent vitreous hemorrhage incidence after vitrectomy,Visual outcome,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
6420,NCT00723307,Difference in progression of carotid intima-media thickness (measured in millimetres) between groups treated with metformin and placebo,Difference in progression of carotid total plaque volume (measured in cubic millimetres) between groups treated with metformin and placebo,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
6421,NCT06130917,Numeric pain rating scale,,2023-11-05,RECRUITING,INTERVENTIONAL,['NA'],
6422,NCT05847400,predictors of CKD among T2DM patients attending Assiut University Hospitals. To classify our patients into stages according to KDIGO guidelines,the possible risk factors contributing to progessing CKD in T2DM patients.,2024-03-01,RECRUITING,OBSERVATIONAL,['NA'],
6423,NCT03519529,sex hormone-binding globulin,SD,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],
6424,NCT02587936,"All Cause Hospitalizations for Patients With a Triad of Chronic Kidney Disease, Diabetes and Hypertension",30-day All Cause Readmissions (for Those Patients Who Have an Index Hospitalization),2016-07-18,COMPLETED,INTERVENTIONAL,['NA'],
6425,NCT02421055,Number of Participants With Complete Diabetes Remission at 3 Months,BMI Reduction,2015-06,COMPLETED,OBSERVATIONAL,['NA'],
6426,NCT05596812,Feasibility of the novel risk stratification screening tool,Health service outcomes - Short-form Patient Satisfaction Questionnaire (PSQ-18),2022-08-23,RECRUITING,INTERVENTIONAL,['NA'],
6427,NCT00411411,Restoration of the Insulinotropic Effect of GIP,"Examination of GLP-2, Somatostatin, Glucagon, Peptide-YY and Two Glycaemic Control Parameters (HbA1c and Fasting Plasma Glucose)",2007-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
6428,NCT03519841,Generation and validation of predictive models by ISUP and MARD measures,Safety evaluation: paucity of adverse events,2018-04-13,COMPLETED,INTERVENTIONAL,['NA'],
6429,NCT00937326,Apparent Volume of Distribution After Oral Administration (Vd/F) at Day 1 and Day 28,Change From Baseline in HOMA-percentage of Beta Cell Function at Day 28,2009-08-19,COMPLETED,INTERVENTIONAL,['PHASE2'],
6430,NCT00979459,Maximum Plasma Concentration (Cmax) for MK-1006,Number of Participants Who Discontinued Study Medication Due to an Adverse Event,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
6431,NCT01828125,Incremental area under the curve of plasma glucose concentrations,Time for 75% of glucagon appearance,2013-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
6432,NCT04559191,the normalized absolute change in total atheroma volume on serial intravascular ultrasound imaging.,the frequency of hypoglycemia,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
6433,NCT00763087,daily step count,skin breakdown,2008-09,COMPLETED,INTERVENTIONAL,['NA'],
6434,NCT00160017,HbA1c,"These intermediate outcomes will be measured as well, in both the intervention and the control group.",2005-01,COMPLETED,OBSERVATIONAL,['NA'],
6435,NCT02673554,Insulin secretory response after GIP bolus or infusion.,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
6436,NCT00737074,Final opening or closure of macular hole,Post-operation best corrected visual acuity,2002-01,COMPLETED,OBSERVATIONAL,['NA'],
6437,NCT02041286,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15 mg/dL (<100 mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory Glucose Method,Number of Subject Responses That Strongly Agree or Agree or Are Neutral With Questionnaire Statements,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
6438,NCT02311075,Change from Baseline in EET concentration during endothelial stimulation,Change from Baseline in ROS concentration during endothelial stimulation,2014-12,COMPLETED,INTERVENTIONAL,['NA'],
6439,NCT03324438,Pediatric Diabetes Quality of Life Scale - Change from baseline and every 12 weeks up to 72 weeks (18 mo),Biological Markers of T1D Complications - Change from baseline and every 24 weeks up to 72 weeks (18 mo),2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],
6440,NCT05454059,HbA1c levels,Clinical attachment level (CAL),2020-10-22,COMPLETED,INTERVENTIONAL,['NA'],
6441,NCT04437641,Smoking prevalence,Parental smoking evolution,2019-10-22,UNKNOWN,OBSERVATIONAL,['NA'],
6442,NCT01192659,"To identify risk factors for lymphopenia, defined as an absolute lymphocyte count < 500 cells/μl, or investigator reported lymphopenia, in the SAVOR study population.",To evaluate whether risk factors for low lymphocyte counts or decreasing lymphocyte count differ between saxagliptin users and non-users.,2010-05,COMPLETED,OBSERVATIONAL,['NA'],
6443,NCT02285205,changes from baseline in controlled attenuation parameters (CAP),,2014-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
6444,NCT06319560,To compare the shearwave elastography of the placenta between the two groups,Hospital admission,2024-01-02,RECRUITING,INTERVENTIONAL,['NA'],
6445,NCT02023489,change in myocardial glycogen content,change in myocardial lipid composition,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],differences in hepatic energy metabolism/ATP synthesis
6446,NCT03497260,Time (in minutes) to hypoglycaemia (plasma glucose <3.9mmol/l),Carbon dioxide production during exercise,2019-01-04,COMPLETED,INTERVENTIONAL,['NA'],
6447,NCT05581225,"Changes in geometric perfusion deficits (GPD) on the superficial and deep retinal vascular layers on SS-OCTA, considering macular region and midperiphery.","Changes in mean luminous sensitivity in dB, evaluated by Microperimetry.",2022-12-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
6448,NCT01043510,Area under the glucose infusion rate curve during one dosing interval at steady state,Area under the Insulin Degludec concentration-time curve during one dosing interval at steady state,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
6449,NCT05238142,Primary Effectiveness Endpoint - Percent of time in range (TIR 70-180 mg/dL),Secondary Effectiveness Endpoint - Percent of time in range (TIR 70-180 mg/dL),2022-02-25,RECRUITING,INTERVENTIONAL,['NA'],
6450,NCT00227383,Solid-phase gastric emptying time and score on Gastroparesis Cardinal Symptom Index(GCSI) at 2 weeks,,na,UNKNOWN,INTERVENTIONAL,['PHASE3'],
6451,NCT02251301,Change from baseline in glycemic control assessed by continuous glucose monitoring at end of week 12 of intervention,Change from baseline in peak oxygen uptake as a measure of aerobic fitness at end of week 12 of intervention.,2015-01,COMPLETED,INTERVENTIONAL,['NA'],Change from baseline in task switching capabilities at end of week 12 of intervention.
6452,NCT00272402,Clinical inertia,Direct Medical Costs,2006-02,COMPLETED,INTERVENTIONAL,['NA'],
6453,NCT01755273,Resolution of diabetes,,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],
6454,NCT02464878,The Proportion of GLASSIA Versus Control CIT06 Subjects Achieving Insulin Independence After First Infusion of Single Donor Islets.,"Cardiovascular Events [Death, Cerebrovascular Accident (CVA), Myocardial Infarction (MI)] and Changes in Atherogenic Profile for GLASSIA Treated Versus Control Subjects",2017-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
6455,NCT03100084,Rate of acute cesarean section (due to suspected fetal distress),Abnormal intrapartum CTG patterns,2016-09-15,UNKNOWN,OBSERVATIONAL,['NA'],
6456,NCT04039763,Change in glycated haeomglobin (HbA1c),,2020-09-03,RECRUITING,INTERVENTIONAL,['NA'],
6457,NCT01415271,HbA1c,unplanned hospitalizations,2011-10,TERMINATED,INTERVENTIONAL,['NA'],
6458,NCT03723486,Change in HOMA-IR,Gut Hormone,2015-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
6459,NCT03406377,Change in HbA1c in Subjects With Type 2 DM,Change From Baseline of Fasting Plasma Glucose (FPG).,2018-04-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
6460,NCT01829061,The objective is to conduct reproducibility testing using duplicates of each of 3 levels of HbA1C,Obtain CLIA Waiver Status for the Quo-Test,2013-04,TERMINATED,OBSERVATIONAL,['NA'],
6461,NCT02378259,Body Mass Index (kg/m2),Attention,2014-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Cancer or precancerous lesions
6462,NCT04523155,Change in Glucose Metabolism,Change in Triglycerides,2020-08-24,COMPLETED,INTERVENTIONAL,['NA'],
6463,NCT00614783,Produced SCOUT DS measurement algorithm.,Intra- and inter-day Scout test reproducibility.,2007-05,COMPLETED,OBSERVATIONAL,['NA'],
6464,NCT00455403,Change in Carotid Intima-media Thickness From Baseline to Year 1,,2006-04,COMPLETED,INTERVENTIONAL,['NA'],
6465,NCT01162993,Pain intensity measured on a weighted NRS according to Jensen and a PGIC for pain measured on a 7-point Likert scale.,"Effect SCS on health related quality of life, quality of sleep, mood, blood glucose control, large/small nerve fibre functions, predictive factors success of SCS treatment, small fibre loss/regeneration, cost-utility and cost-effectiveness",2010-04,UNKNOWN,INTERVENTIONAL,['NA'],
6466,NCT01083433,Glycemic Control,Diabetes Knowledge,2010-05,COMPLETED,INTERVENTIONAL,['NA'],
6467,NCT00972244,Adjusted Mean Change in HbA1c Levels,Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
6468,NCT00373178,Novel cardiovascular risk factors modification,Lipid and glucose regulation,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
6469,NCT01402388,"Lifestyle impact on GLP-1, HbA1c and fasting glycaemia.",,2007-10,COMPLETED,INTERVENTIONAL,['NA'],
6470,NCT02592616,Ad-libitum meal energy intake,Satiety,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],
6471,NCT04587414,Change in total mean daily step count,"Changes in the mean daily number of moderate-to-vigorous PA bouts lasting at least 1, 5 and 10 minutes.",2019-03-06,UNKNOWN,INTERVENTIONAL,['NA'],
6472,NCT05009433,Childhood outcomes: changes in diastolic blood pressure,Covid-19 disease,2021-06-24,RECRUITING,INTERVENTIONAL,['NA'],The serotonin transporter (5-HTTLPR) polymorphism
6473,NCT05472142,Change in DSMES Referrals,Change in A1c Levels,2023-05-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
6474,NCT03234101,All-cause mortality,,2016-06,UNKNOWN,OBSERVATIONAL,['NA'],
6475,NCT01965509,To assess HbA1C levels after treatment,To assess Fasting blood glucose levels,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2'],To assess number of participants with Adverse Events as a Measure of Safety and Tolerability
6476,NCT04796428,Primary Objective,Secondary Objectives - biomarkers,2021-06-30,UNKNOWN,INTERVENTIONAL,['PHASE4'],Safety Objectives
6477,NCT00652509,"Program satisfaction, behavioral and emotional outcomes.","Blood sugar level, blood pressure, lipids, cost, comorbidities.",2008-05-01,COMPLETED,INTERVENTIONAL,['NA'],
6478,NCT00905073,insulin dose,renal function,1990-02,COMPLETED,INTERVENTIONAL,['NA'],
6479,NCT02975297,Cue-induced Craving for Cigarettes Following Virtual Reality Exposure as Assessed by the Questionnaire of Smoking Urges,Post-quit Craving as Assessed by the Questionnaire of Smoking Urges,2016-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6480,NCT00032474,,,2001-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6481,NCT01846312,Fluctuation in islet autoantibodies titers,Fluctuation in T-cell specificity profiling (mainly for CD8 (cluster of differentiation 8) T-cells),2013-05,COMPLETED,OBSERVATIONAL,['NA'],
6482,NCT03367377,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Average Glucose from 7-Point Glucose Profiles,2018-01-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
6483,NCT01869621,Heritability,Single nucleotide polymorphisms (SNPs),2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
6484,NCT06250192,Birthweight standard deviation score,Continuous glucose monitoring metrics 1 months post delivery,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],
6485,NCT03566524,Change in Arginine production,Change in Insulin secretion,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],
6486,NCT04707469,Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52),Change From Baseline in Pulse (Week 68),2021-01-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
6487,NCT01728116,Primary Safety Endpoint: Early Device Removal Due to Device-Related SAE,Percentage of Subjects Who Achieve % Total Body Weight Loss Greater Than or Equal to 5% at 12 Months,2012-12,TERMINATED,INTERVENTIONAL,['NA'],
6488,NCT04054843,Maternal plasma afamin levels In first trimester GDM prediction,,2019-09-01,COMPLETED,OBSERVATIONAL,['NA'],
6489,NCT01173315,Evidence of clinically neuropathy confirmed by nerve conduction velocities,nephropathy indices were determined by 3 times urine microalbumin concentration using Enzyme Immuno Assay commercial kit,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
6490,NCT06229847,"mindful eating, its subgroups and diabetes control in patients with type 2 diabetes","mindful eating, its subgroups and the presence of obesity in patients with type 2 diabetes",2019-07-01,COMPLETED,OBSERVATIONAL,['NA'],
6491,NCT00766298,"Effects of physical activity and weight loss, alone or in combination, on intramyocellular lipid, intermuscular adipose tissue and abdominal AT, oxidative capacity and insulin resistance.",Assess the mechanisms by which these interventions may prevent the development of diabetes,2004-06,COMPLETED,INTERVENTIONAL,['NA'],
6492,NCT03215498,"Continuous subcutaneous infusion related area under the insulin aspart curve, baseline corrected and based on concentrations from 0 to 30 min",Number of hypoglycaemic episodes,2017-07-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
6493,NCT05975827,2-week reduction rate of wound area,2-week wound healing rate,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
6494,NCT05422235,Changes passive ankle stiffness compared with baseline and last measurement and Follow-up,Changes vibration test compared with baseline and last measurement and Follow-up,2022-11-12,RECRUITING,INTERVENTIONAL,['NA'],
6495,NCT05911659,Platelet Reactivity Index and maximum platelet aggregation,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],
6496,NCT02351323,Weight gain,Change in A1C,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
6497,NCT04021199,Genetic diagnosis of atypical diabetes: More comprehensive genetic tests,,2018-10-22,COMPLETED,INTERVENTIONAL,['NA'],
6498,NCT02881060,Increase in plasma glucose,Difference in glucose sensor data between the study period with and without alcohol - Number of hypoglycaemia episodes (glucose sensor value < 4.0 mmol/l),2016-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
6499,NCT02035566,Re-hospitalization,Compliance with recommended (by discharging physician/primary health professional) drug therapy use for heart failure,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
6500,NCT00408824,,,2006-09,UNKNOWN,OBSERVATIONAL,['NA'],
6501,NCT00395512,Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Mean HDL Particle Size,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
6502,NCT00648284,,,2004-03,COMPLETED,OBSERVATIONAL,['NA'],
6503,NCT04056208,Fasting plasma glucose concentration,Change in the composition of the gut microbiome,2019-09-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
6504,NCT02719756,Dynamics (delta from the baseline) of blood glucose variability - integral index of glycemia (LBGI-HBGI) after 3 months of therapy,Percentage of diabetes mellitus patients achieved individual target HbA1c,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
6505,NCT04979312,Prevention of gestational diabetes mellitus and preeclampsia,Examine role of sleep as a potential mechanism in changing blood pressure in pregnancy,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
6506,NCT01516255,Maximum time-matched mean difference between the baseline subtracted QTci intervals,Serial electrocardiography,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
6507,NCT01492062,Test the feasibility of using MMPPC controller for closed loop insulin delivery in a monitored inpatient clinical research environment.,Efficacy,2011-02,WITHDRAWN,INTERVENTIONAL,['NA'],
6508,NCT02016911,Area under the semaglutide plasma concentration curve,Maximum observed SNAC plasma concentration,2013-12-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
6509,NCT01898286,Hypoglycemic Events,Change From Baseline in Glucagon-stimulated C-peptide AUC at Early Termination Visit,2013-10,TERMINATED,INTERVENTIONAL,['PHASE3'],Glycemic Control (Change From Baseline in % HbA1c)
6510,NCT00488527,Number of severe hypoglycemia,- Change in body weight initial visit vs. final visit,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
6511,NCT02589873,Body weight lost,Stress and well-being,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
6512,NCT04756102,diagnosis of gestational diabetes,,2018-01-30,COMPLETED,OBSERVATIONAL,['NA'],
6513,NCT03708029,Complete Wound Closure,Percent(%) Healed,2018-11-13,UNKNOWN,INTERVENTIONAL,['NA'],
6514,NCT01017718,"How many children and adolescents suffering from diabetes mellitus type 1 (duration of disease > 1 year, age 8 to 18a, insulin requirement > 0.5 IU/kg/d) show pathological nerve conduction velocity?",Is there a correlation between nerve conduction velocity in our study patients and the Young Score?,2009-05,COMPLETED,OBSERVATIONAL,['NA'],
6515,NCT01666223,Change in GLP-1,Change in bile acid composition,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
6516,NCT05599633,Change of high density lipoprotein cholesterol (HDL-C) level,Change of heart rate from baseline,2022-01-10,RECRUITING,INTERVENTIONAL,['NA'],
6517,NCT01135992,HbA1c (Glycosylated Haemoglobin),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
6518,NCT01570140,Health Related Quality of Life,Clinical parameters,2012-05,COMPLETED,OBSERVATIONAL,['NA'],
6519,NCT05296447,To evaluate the long-term safety of RGX-314,Proportion of participants with any sight-threatening ocular diabetic complications,2022-04-04,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
6520,NCT01926522,Change from Baseline of 10-metres walk test,Followup change from Baseline of the Glycated Hemoglobin (HbA1c),2013-09,COMPLETED,INTERVENTIONAL,['NA'],
6521,NCT00489229,Measuring arterial stiffness (pulse wave velocity and augmentation index),"Measuring fasting blood sugar and 2 hours post prandial sugars, fasting insulin level, HbA1c, and total cholesterol level.",2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
6522,NCT02937441,Optic Nerve Sheath diameters will be measured from 3 mm back of globe.,,2016-08,COMPLETED,OBSERVATIONAL,['NA'],
6523,NCT01420016,Predicted Annual Rate of Change in 10-year Risk of Fatal or Nonfatal Heart Attack or Stroke,,2012-08-20,COMPLETED,INTERVENTIONAL,['NA'],
6524,NCT00005365,,,1993-02,COMPLETED,OBSERVATIONAL,['NA'],
6525,NCT00777712,Determine molecular mechanisms underlying impaired wound healing in diabetes,Characterize mechanisms responsible for dysregulated wound inflammatory cell function in patients with diabetes,2008-09-01,RECRUITING,OBSERVATIONAL,['NA'],
6526,NCT04328363,Glucosa level,Reversion to normal glucose,2020-10,UNKNOWN,INTERVENTIONAL,['NA'],
6527,NCT06113341,Participant downloaded and actively used the app (Yes/No),Change in laboratory measured FPG,2024-05-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
6528,NCT00710424,Number of Responders at the 30% Improvement Level at the End of Treatment,Change From Baseline in Mean Intoxication 0-10 Numerical Rating Scale Score at the End of Treatment,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
6529,NCT00761176,The Incidence of Wounds Reaching Complete Closure,,2008-07,TERMINATED,INTERVENTIONAL,['NA'],
6530,NCT05329376,"Screening for depression, anxiety and common mental health disorders in elderly",Perception of stress:,2023-06-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
6531,NCT02694575,EPC,Renal function,2015-03-01,COMPLETED,OBSERVATIONAL,['NA'],
6532,NCT05749874,Time to first occurrence of composite endpoint of new-onset diabetes and major cardiovascular events.,Time to newly diagnosed cancer,2023-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Subgroup analysis 10 for primary outcome measure
6533,NCT04670094,Mortality up to 3 months from admission,Correlation between admission to ICU and in-hospital mortality,2020-12-30,COMPLETED,OBSERVATIONAL,['NA'],
6534,NCT03762096,Change in endothelial function,Effects of resveratrol on molecular signaling,2018-03-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
6535,NCT02373332,inhibition of platelet activation,,2013-08,COMPLETED,OBSERVATIONAL,['NA'],
6536,NCT05166785,Changes in HbA1c in participants in DPP-TOAT is similar to those in In-Person DPP,Adherence to the DPP-TOAT is greater than the in-person DPP,2022-10-05,RECRUITING,INTERVENTIONAL,['NA'],
6537,NCT04350879,Risk of unplanned pregnancy,,2020-03-12,COMPLETED,OBSERVATIONAL,['NA'],
6538,NCT01409330,whole body insulin sensitivity,pancreatic fat,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
6539,NCT04232774,Incidence of Serious Device- and Procedure-Related Complications,Procedure Success,2019-11-04,COMPLETED,INTERVENTIONAL,['NA'],
6540,NCT01945645,Modelled cardiovascular disease risk,Smoking,2006-09,COMPLETED,INTERVENTIONAL,['NA'],
6541,NCT01147692,The effect of albiglutide on the pharmacokinetics of simvastatin,The pertinent plasma pharmacokinetic parameters of simvastatin with and without albiglutide,2010-05-19,COMPLETED,INTERVENTIONAL,['PHASE1'],
6542,NCT03258086,Assessment of vitamin D level (ng/ml),,2016-11-01,COMPLETED,INTERVENTIONAL,['NA'],
6543,NCT00924937,"Combined apparition of hard cardiovascular events (myocardial infarction, revascularization, ischemic stroke, documented peripheral artery disease or cardiovascular death) after a median follow-up of 7 years.",Subgroup analysis,2009-11,COMPLETED,INTERVENTIONAL,['NA'],Further Studies
6544,NCT05681468,Effect of diets on LDL-cholesterol levels by comparing groups at 6 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 6 months).,Effect of diets on inflammatory markers (C-reactive protein (CRP)) by comparing groups at 6 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 6 months).,2023-09-18,RECRUITING,INTERVENTIONAL,['NA'],Change in fatty acid composition to confirm adherence to the diets at 6 months
6545,NCT00655902,Change in Insulin sensitivity (ISI composite) from 3h OGTT,Changes in Metabolomic profile in blood and urine,2008-04,COMPLETED,INTERVENTIONAL,['NA'],
6546,NCT04545411,Change in Vascular Endothelial Function,,2021-02-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6547,NCT00994682,"Liver Histology (Using Kleiner et al Criteria, Hepatology 2005)",Bone Mineral Density,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
6548,NCT01455064,Clarke Error Grid Analysis,,2011-10,COMPLETED,OBSERVATIONAL,['NA'],
6549,NCT04692688,Percent of Subjects with an improvement in Diabetic Retinopathy Severity Score (DRSS),Mean Change in Central Subfield Thickness (CST),2021-04-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
6550,NCT05788731,The proportion of patients integrating the common law system,Proportion of patients resorting to one or more consultations with a general practitioner.,2023-01-18,COMPLETED,OBSERVATIONAL,['NA'],
6551,NCT02020629,Glucagon response to hypoglycemia,Catecholamines,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4'],HbA1c
6552,NCT01433393,HbA1c,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],
6553,NCT01237509,Hypoglycaemia associated EEG changes during sleep,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],
6554,NCT01068951,The concentration of stimulated c-peptide at 90 minutes after the start of a mixed meal tolerance test at 365+/-10 days following the infusion or not with mesenchymal stem cells,,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
6555,NCT02624830,Metabolic control,Insulin secretory response to a glucagon test,2019-02-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],
6556,NCT05306028,Blood glucose control rate,HbA1C control rate,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],Overall survival，OS
6557,NCT05591235,Insulin resistance,,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
6558,NCT00983021,"Number and severity of adverse events, number and severity of local tolerability issues at the injection site, number and severity of hypoglycaemic episodes",The area under the NN1250 concentration-time curve after single-dose,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
6559,NCT04963777,Change in frequency of hypoglycemia,Change in serum metabolite concentration,2022-03-29,RECRUITING,INTERVENTIONAL,['NA'],
6560,NCT05968131,Change in Quality of Life,,2021-10-27,COMPLETED,INTERVENTIONAL,['NA'],
6561,NCT03921216,Interstitial fluid-to-serum ratio for LDL cholesterol,,2019-04-17,SUSPENDED,OBSERVATIONAL,['NA'],
6562,NCT01075997,The primary endpoint will be improvement of glycemic control as measured by glycosylated hemoglobin (A1c).,"To compare mean blood glucose levels,the number of hypo- and hyperglycemic events,the duration of time spent in target blood glucose range,the perceived level of diabetes-related stress and the perceived effect of diabetes on quality of life.",2007-11,UNKNOWN,INTERVENTIONAL,['NA'],
6563,NCT04177303,Change in GLP-1 (glucagon like peptide) and GIP (gastric inhibitory peptide) postprandial secretion,Change in gut microbiome analysis,2019-11-29,UNKNOWN,INTERVENTIONAL,['PHASE3'],
6564,NCT02099110,Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach,Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach,2014-04-22,COMPLETED,INTERVENTIONAL,['PHASE3'],
6565,NCT00889486,change from baseline in gastric half-emptying time,change from baseline in gastroparesis symptoms and health-related quality of life,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
6566,NCT00266253,HbA1c mean change from baseline compared with placebo.,Pharmacokinetic and exposure-response relationship,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
6567,NCT03662217,Evaluation of the total daily time of plasma glucose levels,Change in Fructosamin parameter,2018-10-28,UNKNOWN,INTERVENTIONAL,['NA'],Patients Diet compliance evaluation
6568,NCT02229227,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Parameters,2014-11-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
6569,NCT00806572,4-hour C-peptide AUC,Insulin usage,2002-05,TERMINATED,INTERVENTIONAL,['PHASE2'],
6570,NCT00696722,Acetylcholine induced vasodilation,assessment of vascular inflammation by determination of adhesion molecule levels,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
6571,NCT04774224,The primary endpoint of the study is the change from baseline of plasma C-peptide area under the curve (AUC) over 2 hours following a mixed meal.,"The composite outcome assessing both the frequency, and when relevant, the severity of all adverse events.",2020-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
6572,NCT01754415,International Physical Activity Questionnaire (IPAQ),The physical fitness assessment,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
6573,NCT03592355,Days until third available appointment,Revenue from virtual or in-person visit,2018-04-13,TERMINATED,INTERVENTIONAL,['NA'],
6574,NCT00994513,Endothelial function,Pulse wave velocity,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
6575,NCT00006331,,,na,UNKNOWN,OBSERVATIONAL,['NA'],
6576,NCT05061602,Biomechanical and Viscoelastic Properties,Lower Limb Function,2021-09-20,COMPLETED,OBSERVATIONAL,['NA'],
6577,NCT00337142,,,2006-06,COMPLETED,OBSERVATIONAL,['NA'],
6578,NCT05513729,The activity of CEPT in pmol/mL/min,The activity of CEPT in pmol/mL/min,2022-08-18,RECRUITING,OBSERVATIONAL,['NA'],
6579,NCT03717194,Global Longitudinal Strain (GLS),Body Fat Mass,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
6580,NCT00324792,changes in urinary LTE4 excretion and HbA1c after 3-month intensive insulin therapy versus baseline,sICAM-1 plasma levels,2006-05,COMPLETED,INTERVENTIONAL,['NA'],
6581,NCT01497522,Change from baseline in glycosylated hemoglobin (HbA1c) at 12 weeks between treatment groups,"Number of patients with adverse events (including hypoglycemia), serious adverse events and death",2011-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
6582,NCT02775253,The changes of UCP-1 expression in subcutaneous white adipose before and after cold acclimation program,,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],
6583,NCT01903070,ΔAUCGLP-1-OGTT(0-240),,2013-07-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
6584,NCT03806920,hepatic insulin extraction,additional endocrine parameters,2016-11-05,COMPLETED,INTERVENTIONAL,['NA'],
6585,NCT01909908,Incidence of adverse events,,2013-02,TERMINATED,INTERVENTIONAL,['NA'],
6586,NCT04907214,Change in Liver Steatosis at 3 Months,Change in the Plasma Inflammatory Cytokine IL-6 After 3 Months,2021-07-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6587,NCT02336945,"Glucose variability as measured by AGP Interquartile Range, (IQR) obtained via System-Pro Sensor.",Assessment of ambulatory glucose profiles (AGPs) generated by the Software,2015-01,COMPLETED,OBSERVATIONAL,['NA'],
6588,NCT04841096,Mean difference change between groups in HbA1c concentration,Incidence of adverse events and reactions,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE3'],
6589,NCT06180109,Time of the maximum measured plasma concentration (Tmax),,2023-07-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
6590,NCT01915550,Proper Glycemic Control,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
6591,NCT04320069,Percentage of Time >180 mg/dL,Coefficient of Variation,2020-06-09,COMPLETED,INTERVENTIONAL,['NA'],
6592,NCT02537834,Change from Baseline in HbA1c at 52 weeks,Change in Free Fatty Acid,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
6593,NCT01232608,Atherosclerosis,Visceral obesity,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
6594,NCT05265741,Number of Participants with Gestational Diabetes Mellitus (GDM) Week 8 to post-delivery throughout their entire pregnancy,Gestational age at Delivery,2021-11-09,RECRUITING,OBSERVATIONAL,['NA'],
6595,NCT00575874,Change in HbA1c from baseline for rivoglitazone HCl compared to that for placebo,Change in Fasting Plasma Glucose from baseline for rivoglitazone HCl compared to that for placebo. Change in HbA1c from baseline compared to that for pioglitazone HCl,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
6596,NCT04129424,The preprandial insulin dose of insulin pump at the end of the 6-day follow-up,The frequency of errors in patency of needle fixation,2019-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
6597,NCT05284071,"Diabetes Treatment Satisfaction Questionnaire (change, DTSQc), at 3 months","Summary of adherence in the population, from baseline to 3 months, from 3 months to end of investigation and from baseline to end of investigation.",2022-03-14,COMPLETED,INTERVENTIONAL,['NA'],
6598,NCT01228981,Phenotypes of Diabetic Retinopathy progression.,,2010-03,COMPLETED,OBSERVATIONAL,['NA'],
6599,NCT02459106,Levels of miRNA will be measured as well as the adipose tissue specific miRNA.,,2015-05-27,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
6600,NCT02315300,Glucose Levels < 65 mg/dl,Association anf temporal coincidence of glycemic variability as assessed by changes in glucose excursion as well as mean amplitude of glycemic excursion (MAGE),2014-11,COMPLETED,INTERVENTIONAL,['NA'],
6601,NCT03624062,Immunologic Analysis,Insulin Use,2020-08-31,RECRUITING,INTERVENTIONAL,['PHASE1'],
6602,NCT00974051,Blood Glucose Nadir,Percent of Nighttime Glucose Levels >250 mg/dl,2008-03,COMPLETED,INTERVENTIONAL,['NA'],
6603,NCT01434407,Urine AGE,Urine isoprostanes,2011-08,COMPLETED,INTERVENTIONAL,['NA'],
6604,NCT03140865,Change in performance on cognitive measures.,Change in brain volumes on magnetic resonance imaging (MRI).,2014-01,RECRUITING,OBSERVATIONAL,['NA'],
6605,NCT03241706,Glucose Infusion Rate,Peripheral Glucose Uptake,2018-08-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
6606,NCT05951283,1. Change in Corneal nerve fibre density (CNFD),Quality of life questionnaire,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
6607,NCT06186843,Weekly one day food recall,Triglycerides,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],"Urine electrolytes (Na, K, Cl, Ca, Phosphorous)"
6608,NCT01194258,Change From Baseline in Glycosylated Hemoglobin A1C (HbA1C) at the End of Each Treatment Period,Mean Daily PPG Excursions,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
6609,NCT00253786,"Composite endpoint of time to first occurrence of (1) Doubling of serum creatinine, (2) Need for chronic dialysis or renal transplantation, or (3) Death in Protocol B",Urinary protein/creatinine ratio in Protocol B,2005-11-11,COMPLETED,INTERVENTIONAL,['NA'],
6610,NCT00516048,Incidence of Potentially Immune-related Treatment-emergent Adverse Events,Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
6611,NCT03089632,Changes in upper gastrointestinal symptoms assessed by the Gastroparesis Cardinal Symptoms Index (GCSI),Changes in glycemic control assessed by continuous glucose monitoring,2017-12-15,UNKNOWN,INTERVENTIONAL,['NA'],
6612,NCT00170742,regression of neovascularization.,Determine tolerability and safety,2003-12,TERMINATED,INTERVENTIONAL,['PHASE3'],
6613,NCT03176056,The reduction of medication effect score (MES),The improvement of carotid intima-media thickness (IMT),2016-02-02,COMPLETED,INTERVENTIONAL,['NA'],
6614,NCT05441982,24-hour glycemic control,Monocyte chemoattractant protein-1,2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],
6615,NCT04810260,Diabetes quality of life measured by the Diabetes Quality of Life instrument,Patient Health Questionnaire-9 for depression,2021-03-01,COMPLETED,INTERVENTIONAL,['NA'],
6616,NCT04632849,Total Treatment Effect (TTE),Treatment Optimization Scale,2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],
6617,NCT02000687,determine the rate of allosensitization in patients after failed islet transplantation,,2008-12,RECRUITING,OBSERVATIONAL,['NA'],
6618,NCT00448344,The Impact of a Family-supported Intervention on Rates of Abstinence From Cigarettes Compared to a Standard Intervention,The Impact of a Family-supported Intervention on Abstinence at 12-month Follow-up,2008-02,COMPLETED,INTERVENTIONAL,['NA'],
6619,NCT05689424,Percentage of suppression of endogenous glucose production,,2024-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
6620,NCT02637154,Change in glycaemic variability,Influence of changes in marker of bone turnover: aminoterminal telopeptide of type I collagen (INTP - ng/ml),2015-10-15,UNKNOWN,INTERVENTIONAL,['NA'],
6621,NCT01564498,Blood cholesterol,circulating biomarkers of cardiovascular disease and type II diabetes risk,2012-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],
6622,NCT04892680,Change in HbA1c at 6 months from baseline,Change in medication adherence at 6 months from baseline,2021-03-04,TERMINATED,INTERVENTIONAL,['NA'],Health care utilization at 6 and 12 months from baseline
6623,NCT02326129,"Compare 11β-HSD1 activity and 5α-reductase activity among obese adolescents with T2D, obese adolescents without T2D and normal weight controls",Metabolic signatures correlate with parameters of glucose tolerance,2015-02,COMPLETED,OBSERVATIONAL,['NA'],
6624,NCT01466075,Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (<75mg/dL) or Within +/- 20% (>=75mg/dL) of Laboratory Glucose Method,Number of Subjects Able to Perform Given Tasks Using Product Labeling for Instruction,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
6625,NCT04251156,Subjects who achieve body weight reduction equal to or above 5% (yes/no),Change in calcitonin,2020-12-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
6626,NCT02205528,Change in HbA1c,Change in percent HbA1c,2014-08-18,COMPLETED,INTERVENTIONAL,['PHASE2'],
6627,NCT01562678,Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
6628,NCT01798225,Periodontal Pocket Probing Depth (PD),,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
6629,NCT00688701,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Percentage of Patients Requiring Rescue Therapy During the Double-Blind Treatment Period,2008-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia
6630,NCT05377502,Serum glucose levels,,2021-12-15,RECRUITING,OBSERVATIONAL,['NA'],
6631,NCT02908555,Glycemic control,Executive functioning,2016-01,COMPLETED,OBSERVATIONAL,['NA'],
6632,NCT01237314,4-hour glycemic response at 3 time points,,2010-11,COMPLETED,OBSERVATIONAL,['NA'],
6633,NCT05292495,Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf,ADA：anti-drug antibody,2022-03-31,UNKNOWN,INTERVENTIONAL,['PHASE1'],
6634,NCT05923632,Quality of Life Scale for Children with Type 1 Diabetes (PedsQL 3.0),Diabetes Management Self-Efficacy Scale in Adolescents with Type 1 Diabetes,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
6635,NCT04881799,Change in body mass index,,2022-07-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
6636,NCT00503152,Development of persistent microalbuminuria (i.e. urinary albumin excretion rate >20 µg/min in at least 2 of 3 consecutive overnight urine collections confirmed in two consecutive visits). Whenever a patient will be found to have 2 of 3 collections in the,Regression to low-normal albuminuria (i.e. urinary albumin excretion rate <7 µg/min in at least 2 of 3 consecutive overnight urine collections confirmed in two consecutive visits); Albuminuria (considered as a continuous variable); Serum creatinine (v,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
6637,NCT00310297,"Time to GLUmax (Tmax, min)","Time to maximum concentration (Tmax, min)",2004-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
6638,NCT05574062,Continuation Phase Primary Endpoint: mean in HbA1c,Continuation Phase Secondary Endpoint 3- Time spent in target range (70 to 180 mg/dL [3.9-10.0 mmol/L]),2023-03-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
6639,NCT02874313,Change from baseline in of retinal microaneurysm or hard exudates,Change from baseline of intraocular pressure,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
6640,NCT00763802,CSME needing Photocoagulation,Vision Loss,2007-09,COMPLETED,OBSERVATIONAL,['NA'],
6641,NCT03510624,Area under the curve (AUC) blood glucose concentrations during an OGTT,"Concentration(t) (C(t))rebaudioside A, steviol and steviol glucuronide",2018-11-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
6642,NCT06247514,Disordered Eating Behaviors (DEBs) - Change in Participant-Reported Outcomes (PROs),Change in participant's HbA1c,2024-01-05,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
6643,NCT01862939,incremental area under the curve (IAUC) blood glucose,determine blood concentrations of DS-7309,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
6644,NCT04859205,To compare the level of confidence in treating individuals with type 1 diabetes measured at 3 months to the level of confidence measured at baseline.,Satisfaction of the platform.,2021-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
6645,NCT05151705,Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf,Pharmacodynamic：Serum c-peptide,2021-12-20,UNKNOWN,INTERVENTIONAL,['PHASE1'],
6646,NCT05642793,rate of postvitrectomy complication,postvitrectomy BCVA,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
6647,NCT01478607,Percentage change in health related quality of life (HRQOL) total score as assessed by the disease specific Norfolk scale,Treatment satisfaction using the Self-Assessment of Treatment (SAT) questionnaire at week 12/End Of Study visit,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
6648,NCT01692938,Repeatability of Microperimetry Tests in Normal and With Pathology Participants Based on 3 Microperimetry Tests Taken for Each Participant for a Given Operator-device Combination.,,2012-10,COMPLETED,OBSERVATIONAL,['NA'],
6649,NCT01359904,Hemoglobin A1c Levels,the Number of Infections Related to Vascular Access in Dialysis Among Those Who Receive a Higher Glucose Concentration in the Dialysate and Those Who Receive the Standard Concentration,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
6650,NCT02146651,Pharmacokinetic endpoint: Cmax(Lisp),"Safety and Tolerability: adverse events, local tolerability, vital signs variations, ECG, laboratory safety parameters.",2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
6651,NCT00469092,Glycosylated Haemoglobin A1c (HbA1c),Number of Subjects Reporting Treatment Emergent Adverse Events,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
6652,NCT03426423,Continuous smoking abstinence,Continuous smoking abstinence,2018-03-01,TERMINATED,INTERVENTIONAL,['NA'],Exploratory microbiota outcome
6653,NCT04660630,change of triglyceride,Compliance rate of low density lipoprotein cholesterol,2020-01-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Health self assessment
6654,NCT04423302,Fasting plasma glucose concentration at V3 with a 3 times a day regimen,Proportion of subjects having an improvement or a deterioration of their glycemic status from V1,2020-07-08,COMPLETED,INTERVENTIONAL,['NA'],
6655,NCT05446948,the efficiency of stripping membrane,best corrected visual acuity (BCVA),2022-07-11,COMPLETED,INTERVENTIONAL,['NA'],Post-operative complications
6656,NCT02261441,Cardiovascular risk factors,,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],
6657,NCT00286468,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Body Weight (Week 26).,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
6658,NCT05822674,Stress hyperglycemia Ratio,Inflammatory markers,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],
6659,NCT00935220,"DPP-4 Inhibition: E_24,ss",DPP-4 Inhibition: E_24,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
6660,NCT01102946,Fluorescein leakage area (mm2),Rod pathway integrity and oscillatory potential amplitudes,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
6661,NCT01183104,Number of Participants With Hypoglycaemia,Change From Baseline in Body Weight at 52 W,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
6662,NCT05840497,Gestational diabetes,Maternal and fetal pregnancy outcomes,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],
6663,NCT04058015,in-hospital mortality,,2019-06-03,COMPLETED,OBSERVATIONAL,['NA'],
6664,NCT01075698,The effects of ARB therapy and that of standard therapy except ARB on the biomarker levels (UACR and BNP),"The effect of the two treatments on the incidence of events, and the relationship between the incidence of events and the biomarker levels (UACR, BNP, urine 8-hydroxy-2-deoxyguanosine, serum adiponectin, serum high-molecule adiponectin, eGFR)",2009-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
6665,NCT04694053,Fournier's gangrene evolution after treatment,,2020-11-04,COMPLETED,OBSERVATIONAL,['NA'],
6666,NCT03181165,Proportion of participants not on glucose-lowering medications,Diastolic Blood Pressure,2017-07-05,COMPLETED,INTERVENTIONAL,['NA'],Intervention Satisfaction
6667,NCT01853072,Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0),Percentage of Participants With With a > 10-letter Loss in BCVA From Day 7 to Any Visit,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
6668,NCT02628106,the Change of Tissue Content of Deoxyhemoglobin Assessed by BOLD-MRI,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
6669,NCT01130480,Successful rate of blood glucose control (the proportion of patients with HbA1c <7%),To evaluate the change of quality of life in the 6 months by the health questionnaire SF-36,2010-05-31,COMPLETED,INTERVENTIONAL,['NA'],
6670,NCT02916667,Offspring of participants with GDM with higher Chrono Biological score will be reported with higher birth weight (+100 gr) compared to offspring of participants with GDM with lower Chrono Biological score.,Offspring of participants with GDM with higher Chrono Biological score will be reported with higher birth weight above the 90 percentile compared to offspring of participants with GDM with lower Chrono Biological score.,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],
6671,NCT00777621,Glucoregulatory function,,2008-04,COMPLETED,INTERVENTIONAL,['NA'],
6672,NCT02790645,Assessment of clinical and metabolic parameters (glycosylated hemoglobin-HbA1c- and glycemic variability-SD-).,Assessment of cost-effectiveness with a structured interview designed by our research group of direct and indirect costs.,2012-09,COMPLETED,INTERVENTIONAL,['NA'],
6673,NCT03781024,Patients' perspective through a patient led Survey of Health and quality of life via patient reported outcome measures using Visual analogue scale given at Baseline and follow up. Measuring effectiveness and quality of life from 0 to 10,Visual Analogue scales,2018-12-01,UNKNOWN,OBSERVATIONAL,['NA'],
6674,NCT02730962,Insulin Sensitivity,Adverse Event Rates,2016-06,TERMINATED,INTERVENTIONAL,['PHASE2'],
6675,NCT02408705,"Area under the curve of the endogenous glucose production from (=EGP) from begin of the hypoglycaemic clamp 5.5 mmol/L period until the end of recovery period (4.0 mmol/L), calculated from stable isotope labelled plasma glucose",Change in fasting plasma glucose during each period detected by blood at the begin of the visits and measured by a laboratory (tube: lithium heparin plasma),2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of self-reported hypoglycaemic episodes during each period
6676,NCT02137720,HbA1c,Cholesterol,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
6677,NCT02408120,Mean Daily BG Levels,Mean Daily Dose of Insulin,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
6678,NCT04198857,Neonatal hypoglycemia,Glucose readings over glycemic target,2021-10-18,RECRUITING,INTERVENTIONAL,['NA'],
6679,NCT02212925,Assessment of tolerability by investigator on a 4-point scale,Area under the curve of plasma glucose,2006-11,TERMINATED,INTERVENTIONAL,['PHASE1'],
6680,NCT05300022,Intervention Retention,Child Perceived CGM Benefits and Burdens,2022-11-10,RECRUITING,INTERVENTIONAL,['NA'],Child BMI Z-score
6681,NCT03489031,basal/total ratio,hypoglycemia,2016-04-11,COMPLETED,OBSERVATIONAL,['NA'],
6682,NCT02481479,The change in LVEF from baseline to 6 months,Change in log-scale in NT-pro BNP,2015-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
6683,NCT03503552,Bone mineral density,Urine Markers,2015-02-13,COMPLETED,OBSERVATIONAL,['NA'],
6684,NCT05564039,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite CT) - Physical Functioning Score,2022-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
6685,NCT05369793,Change in HbA1c,Changes of Douleur Neuropathique-4 (DN4) questionnaire (DN4),2022-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Major adverse cardiovascular events (MACE)
6686,NCT00985101,endothelial damage,,2010-04,UNKNOWN,OBSERVATIONAL,['NA'],
6687,NCT01077401,Deaths Due to Myocardial Infarction,Mean Change in Retinal Thickness at Month 6,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
6688,NCT06119035,Glucose levels will be analyzed,Serum samples,2023-11-06,COMPLETED,INTERVENTIONAL,['NA'],
6689,NCT02086955,Effectiveness of nurse-led intervention for high risk patients with diabetic foot ulceration/amputation,,2013-02,UNKNOWN,INTERVENTIONAL,['NA'],
6690,NCT03117829,Change in brain blood flow from baseline to 12 weeks,Change in brain blood flow from 12 weeks to 6 month post intervention,2017-03-15,COMPLETED,INTERVENTIONAL,['NA'],
6691,NCT02379299,Number of CHO interventions to treat hypoglycemia,,na,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
6692,NCT05043467,Incidence of major adverse events (AEs) and any AEs that occurred during the administration period of lobeglitazone,"Changes in glycated hemoglobin (HbA1c) and glucose, lipid parameters",2019-01-02,COMPLETED,OBSERVATIONAL,['NA'],
6693,NCT02961192,Change in mean daily steps,Change in LDL-C levels,2017-02-13,COMPLETED,INTERVENTIONAL,['NA'],
6694,NCT01342042,To compare treatment arms in terms of change from baseline to endpoint in HbA1c,To compare treatment arms in terms of change from baseline to endpoint in body weight,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
6695,NCT01446705,Health Care Quality: Affect of HIE on LDL Levels of Participants.,Health Care Quality: Care Sensitive Admissions,2012-12,COMPLETED,OBSERVATIONAL,['NA'],
6696,NCT00372086,HbA1c,adiponectin,2003-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
6697,NCT01793909,Change in Muscle Oxygen Saturation,,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
6698,NCT06038669,DBS kit assay performance,Interviews,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
6699,NCT05887791,Glucose iAUC,Satiety assessment,2023-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Amino acids
6700,NCT02224118,Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs),Number of Participants Exhibiting Anti-Drug Antibodies for CNTO 3649 at any Visit,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
6701,NCT04696159,Change from Baseline in Glucose Levels measured by Continuous Glucose Monitor,Change from Baseline on Gastroparesis Cardinal Symptom Index,2023-01-04,RECRUITING,INTERVENTIONAL,['NA'],
6702,NCT03644004,Performing oral glucose tolerance test in order to detect type 2 diabetes,,2018-10-30,COMPLETED,OBSERVATIONAL,['NA'],
6703,NCT01318083,Change From Baseline in Glycosylated Hemoglobin (Week 12).,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).,2008-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
6704,NCT04649203,TSS (Total Symptom Score),,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE3'],
6705,NCT05562492,Time spent in the target glucose range between 3.9 and 10.0 mmol/L based on CGM glucose levels,Percentage of time of CGM availability,2023-04-12,RECRUITING,INTERVENTIONAL,['NA'],Human Factors Evaluation - Questionnaires
6706,NCT06025110,Change from baseline in beta-cell function as compared to placebo at week 52.,Assess the incidence and severity of adverse,2023-01-23,RECRUITING,INTERVENTIONAL,['PHASE2'],
6707,NCT03088475,Self-efficacy: change is being assessed,Unplanned medical consultation,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
6708,NCT00060931,Change from baseline in HbA1c at 5 months,"Blood pressure at 3 and 5 months Body weight at 3 and 5 months Lab levels (glucose, insulin, triglycerides, cholesterol, and albumin:creatinine ratio) at 3 and 5 months.",2001-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
6709,NCT03714594,Glucose Metabolism,,2018-07-24,COMPLETED,INTERVENTIONAL,['PHASE2'],
6710,NCT05622123,Correlation between residual beta cell mass and function,Correlation with other parameters,2023-02-23,RECRUITING,INTERVENTIONAL,['PHASE2'],
6711,NCT03832907,Number of Severe Hyperglycemia (>240 mg/dl) Events by POC Reading Compared to CGM Reading,"Percentage of Dexcom G6 CGM Sensor Values Within 15/15%for Values > 180 mg/dl, Compared to the Standard-of-care POC BG",2019-02-21,COMPLETED,INTERVENTIONAL,['NA'],
6712,NCT02787551,Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 52: Single Arm Extension Period,Number of Documented Symptomatic Hypoglycemia Events Per Participant-Year: Single Arm Extension Period,2016-07-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
6713,NCT04000867,Overall Pain reduction,Improved Activities of daily living,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA'],
6714,NCT02026830,Causative microorganisms and their antibiotic sensitivity patterns in diabetic patients with a foot infection in Turkey.,,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
6715,NCT05677685,CFU (Colony Forming Units),Adverse Events,2023-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
6716,NCT03483155,the incidence of Cardiovascular disease,,2018-04-15,UNKNOWN,OBSERVATIONAL,['NA'],
6717,NCT03549104,Fear of Hypoglycemia,Glycemic Variability,2019-01-14,COMPLETED,INTERVENTIONAL,['NA'],
6718,NCT00808535,,,2009-02,UNKNOWN,OBSERVATIONAL,['NA'],
6719,NCT00741702,systolic blood pressure,"Change in diastolic blood pressure, change in urine albumin status and incidence of adverse events",2001-09,COMPLETED,INTERVENTIONAL,['NA'],
6720,NCT01618409,Patient Understanding of their Medication Regimen,Self-reported Adherence,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
6721,NCT05037591,"Blood Glucose ""change"" is being assessed",waist-to-hip ratio (WHR),2021-08-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
6722,NCT04812171,Influence of diabetes mellitus on apical periodontitis healing after non-surgical endodontic treatment,Association of glycated hemoglobin level (HbA1C) with apical periodontitis healing,2021-04-01,COMPLETED,OBSERVATIONAL,['NA'],
6723,NCT01488474,Minimal current threshold for distal motor response at needle tip nerve contact,,2012-01,COMPLETED,OBSERVATIONAL,['NA'],
6724,NCT05413928,Core body temperature response to meal consumption,Heart rate response to meal consumption,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
6725,NCT02548650,Maximal Platelet Aggregation in DM,Maximal Platelet Aggregation in Non-DM,2016-03-25,COMPLETED,INTERVENTIONAL,['PHASE4'],
6726,NCT01041690,Intra- and post-operative bleedings were recorded.,Best Corrected Visual Acuity,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
6727,NCT00812253,Hospital Length of Stay,Cardiac Output,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
6728,NCT02098746,Frequency of Serious Adverse Drug Reactions,Change From Baseline in Fasting Insulin Level,2011-06,COMPLETED,OBSERVATIONAL,['NA'],
6729,NCT05743387,Mean HbA1c (in percent),Occurrence of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs),2023-05-13,RECRUITING,INTERVENTIONAL,['NA'],Change in dosage of lipid-lowering medications prescribed by CC-VHWs or healthcare professionals
6730,NCT00309751,Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C),Number of Patients Attaining National Cholesterol Education Program (NCEP) LDL-C Target,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
6731,NCT02558452,Development of donor specific antibodies (DSA),Quality of life measures,2016-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
6732,NCT00025883,"Triglycerides at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin",,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
6733,NCT02789800,Evaluation of Intervention Effectiveness - Change in Self-Management outcomes,Evaluation of Intervention Effectiveness - Change in Patient-Centredness,2016-04-22,COMPLETED,INTERVENTIONAL,['NA'],
6734,NCT00005152,Coronary heart disease (CHD),,1980-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
6735,NCT01612741,Data collection on pre treatment concomitant diseases,Safety variables will be summarized using descriptive statistics based on adverse events collection,2008-04,COMPLETED,OBSERVATIONAL,['NA'],
6736,NCT05925556,change in Self-Care Inventory from baseline to 6 weeks; higher score = better self-care; range 1-5; also change over ecological momentary assessment period,change in Quality of Marriage Index and intimacy subscale from Personal Assessment of Intimacy in Relationships from baseline to 6 weeks; higher numbers = better; range = 1 to 7; also change over ecological momentary assessment period,2023-08-02,RECRUITING,INTERVENTIONAL,['NA'],change in self-efficacy subscale from Multidimensional Diabetes Questionnaire from baseline to 6 weeks; higher numbers = greater efficacy; range = 0 to 100%; also change over ecological momentary assessment period
6737,NCT03531177,Waist circumference,Physical activity,2018-04-26,COMPLETED,INTERVENTIONAL,['NA'],
6738,NCT02114476,Diabetes mellitus,metabolic syndrome,2014-03,UNKNOWN,INTERVENTIONAL,['NA'],
6739,NCT00793143,Excessive weight loss,QOL (15D and BAROS),2008-04,COMPLETED,OBSERVATIONAL,['NA'],
6740,NCT02375932,Glycemic Control (HbA1c control (% patients < 7.0% and mean HbA1c levels),Patient assessment of visit communication (measures of communication quality using validated instruments),2015-03,COMPLETED,INTERVENTIONAL,['NA'],
6741,NCT04761094,HbA1C,Hospital admission,2021-09-01,COMPLETED,OBSERVATIONAL,['NA'],
6742,NCT00108004,Understand management issues in subjects with type 1 and type 2 diabetes mellitus,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
6743,NCT02127216,Improvement in hemoglobin A1c,Adherence to diabetes care plan,2014-06,UNKNOWN,INTERVENTIONAL,['NA'],
6744,NCT01413126,Change from baseline in glucose homeostasis at eight hours,Change from baseline in appetitive sensations at twelve hours,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
6745,NCT03767556,EVALUATION OF LUNG VOLUMES AND CAPACITIES,EVALUATION OF INSPIRATORY MUSCLE STRENGTH,2018-12-15,COMPLETED,INTERVENTIONAL,['NA'],
6746,NCT04185844,Slope of the GFR,Slope of change in proteinuria over time,2020-08-31,RECRUITING,OBSERVATIONAL,['NA'],
6747,NCT00958061,Determine the prevalence of lifetime and current psychiatric conditions including PTSD among women who served during the Vietnam Era.,Characterize the level of current disability in women who served during the Vietnam Era.,2010-03-01,COMPLETED,OBSERVATIONAL,['NA'],
6748,NCT01681693,Plasma glucose,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
6749,NCT01663519,In shoe plantar pressure measurement,Gait analysis,2008-01,COMPLETED,INTERVENTIONAL,['NA'],Cost and cost analysis
6750,NCT02845466,Level of Applied Growth Factors in Chronic Wound Fluid,Levels of Healing Biomarkers in Chronic Wound Fluid,2018-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],
6751,NCT00745498,Recurrent VH Incidence (Early and Late),Postoperative Resolution of Neovascularization,2008-06,COMPLETED,INTERVENTIONAL,['NA'],
6752,NCT03254849,Blood Pressure reduction,,2017-12-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
6753,NCT02634515,"PD: GIRmax, maximum glucose infusion rate",Assessment of local tolerability at the injection site,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
6754,NCT03355092,Mean reduction in HbA1c,,2018-02-23,WITHDRAWN,INTERVENTIONAL,['NA'],
6755,NCT04834089,Proportion of patients with change in COVID-19 disease progression profile after administration of anti-SARS-CoV-2 serum,Deaths,2021-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Proportion of patients with change in COVID-19 disease progression
6756,NCT02409329,Change in Glycemic Control as Indicated by Hemoglobin A1c (HbA1c),Change in Self-reported Medication Adherence,2016-05-23,COMPLETED,INTERVENTIONAL,['NA'],Change in Glycemic Control - REACH Only vs. Control & REACH+FAMS vs. Control
6757,NCT00453934,,Number and type of adverse events.,2007-05,TERMINATED,INTERVENTIONAL,['PHASE4'],
6758,NCT01117584,Change from baseline in HbA1c at Week 12,Achievement of target goal (HbA1c <6.5%) at Week 12,2010-04-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
6759,NCT00351507,Effect on gastric emptying,"Effect on endogenous glucose appearance, glucose appearance and glucose disposal",2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
6760,NCT03989232,Change in HbA1c,Change in Pulse Rate,2019-06-19,COMPLETED,INTERVENTIONAL,['PHASE3'],
6761,NCT01477476,Frequency of Adverse Events,,2012-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
6762,NCT05443568,Change in HbA1c (Glycated haemoglobin),"DTSQs (Diabetes Treatment Satisfaction Questionnaire, status), change in absolute treatment satisfaction",2023-03-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
6763,NCT03682640,Stimulated C-peptide during an MMTT,Change in stimulated C-peptide,2018-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],
6764,NCT01934842,Non Inferiority of Analyte Levels,,2013-09,WITHDRAWN,INTERVENTIONAL,['NA'],
6765,NCT01373450,Change From Baseline in Beta Cell Sensitivity to Glucose (Φ) After a Single Dose of OXM,"Change From Baseline in Insulinotrophic Effect (ISR/G) After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM",2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
6766,NCT00162799,Increase of insulin sensitivity in apparently healthy men and woman evaluate by means of i.v. glucose tolerance test (PTEVGMR).,Reduction antropometric measures associated with insulin resistance and arterial hypertension.,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
6767,NCT01456026,Postprandial Change from Baseline in Flow Mediated Dilatation,Postprandial Change from Baseline in Microcirculation (Laser-Doppler measurements of reactive hyperemia at the hand),2009-06,COMPLETED,INTERVENTIONAL,['NA'],
6768,NCT00508287,Safety: incidence of adverse events,"PD Measures: Fasting and postprandial serum glucose (AUC), serum insulin, and plasma glucagon concentrations. Acetaminophen plasma concentrations will be measured after a single dose of acetaminophen",2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
6769,NCT01994811,Prevalence of non-communicable diseases,,2013-04,COMPLETED,OBSERVATIONAL,['NA'],
6770,NCT04874116,Change in Medication Adherence,Change in CollaboRATE,2021-05-26,RECRUITING,INTERVENTIONAL,['NA'],
6771,NCT01131676,"Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke.",Percentage of Participants With the Composite Microvascular Outcome,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
6772,NCT02136602,To study interventricular septal thickness in fetus of diabetic mother and correlate it with good glycemic control.,,2012-01,COMPLETED,OBSERVATIONAL,['NA'],
6773,NCT00267839,"Bone parameters after 6, 12 and 18 months",Quality of live after 12 and 18 months,2006-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
6774,NCT02940418,Safety of using allogenic ASC assessed by any adverse events,,2017-02-19,UNKNOWN,INTERVENTIONAL,['PHASE1'],
6775,NCT05920096,Acceptability - nurses' (intervention providers) satisfaction with the intervention,Preliminary evidence of effectiveness - point prevalence smoking abstinence at follow-up,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],
6776,NCT00661908,,,2004-03,COMPLETED,OBSERVATIONAL,['NA'],
6777,NCT05641090,Trail Making Test-B and Stroop test,Nitric oxide,2021-12-16,RECRUITING,INTERVENTIONAL,['NA'],
6778,NCT01098461,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16,Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
6779,NCT00213070,,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],
6780,NCT00456898,the biotransformation of codeine to morphine and the safety and tolerability of DVS SR,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
6781,NCT00696657,HbA1c,Percentage of Subjects Developing Anti-semaglutide Antibodies,2008-06-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
6782,NCT04074603,The glucose fluctuation,Assessment of safety and tolerance,2019-09-01,COMPLETED,INTERVENTIONAL,['NA'],
6783,NCT02411929,Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUC Last) (Dose Normalized to 1 mg) and Absolute Oral Bioavailability (F) (Period 1),Number of Participants Discontinuing Study Drug Due to Adverse Events (Periods 1 and 2),2014-10-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
6784,NCT00320112,Change in Glycemic Control (HbA1c),Number of Participants With Insulin Starts at 6 Months,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
6785,NCT00259896,Pharmacodynamic measurements during 7 days of dosing.,Pharmacokinetic measurements during 7 days of dosing.,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
6786,NCT00303134,Insulin independence 12 months after final islet infusion,Mixed meal test,2003-08-01,TERMINATED,INTERVENTIONAL,['PHASE1'],
6787,NCT02460978,Adjusted Mean Change From Baseline in HbA1c at Week 24,Percentage of Subjects With HbA1c Reduction From Baseline to Week 24 Last Observation Carried Forward (LOCF) >= 0.5% and Without Severe Hypoglycemia Events at Week 24,2015-07-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
6788,NCT01951235,Change in HbA1c,"Safety will be assessed by the incidence of adverse events (AEs), physical examination, relevant changes on laboratory tests, vital signs, and 12-lead electrocardiograms (ECG)",2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
6789,NCT04897815,Changes of cerebral blood flow on fasting and 1 hour postprandial.,The relationship between the fluctuation of blood glucose and the change of cerebral blood flow.,2021-07-01,UNKNOWN,OBSERVATIONAL,['NA'],
6790,NCT05666128,Change in HbA1c(%),,2022-06-17,RECRUITING,INTERVENTIONAL,['PHASE2'],
6791,NCT05729516,change in glycemic control,changes in perceived diabetes self-efficacy,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
6792,NCT00858897,Glutathione Concentration,,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
6793,NCT04562454,fluctuation of blood glucose after eating different food,,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
6794,NCT06148259,Change in prostate symptoms,,2021-03-12,COMPLETED,INTERVENTIONAL,['NA'],
6795,NCT05029297,"To demonstrate the efficacy and the non-inferiority of a new formulation of the capsaicin topical solution in ""roll-on"" compared to capsaicin in cream.",Grade of compliance/complacency of treatment.,2010-11-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
6796,NCT05329844,AUC0-t of Vildagliptin for the test and the reference products,Number of treatment-related adverse events (AE) for the test and the reference products as assessed by guidance predefined in the protocol,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
6797,NCT04684836,Continuity of care as assessed by attendance at follow-up appointment,Ease of use and access to telemedicine based on Telehealth Usability Questionnaire (TUQ),2021-03-15,COMPLETED,OBSERVATIONAL,['NA'],
6798,NCT04240171,HbA1c %,IL-34 (pg./ml),2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],
6799,NCT02976012,• Ocular and systemic safety evaluation for adverse events at any time point through 52 weeks:,Proportion of enrolled eyes requiring intraoperative endolaser in a PRP pattern at the time of initial vitrectomy,2016-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6800,NCT04543032,Measurement of stride length,Assessment of Quality of life,2021-01-05,COMPLETED,INTERVENTIONAL,['NA'],
6801,NCT05073835,Weight loss,GLP-1 levels,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
6802,NCT02999841,Change of the visceral fat area in square centimeter assessed by abdominal CT scans from baseline to 24 weeks.,Change of brain natriuretic peptide in nanograms per milliliter from baseline to 24 weeks.,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
6803,NCT05320510,Change of HbA1c concentration,Change of TC concentration,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
6804,NCT03138356,PK assessment: Cmax (Maximum observed plasma concentration),"Laboratory assessments (hematology, clinical chemistry and urinalysis)",2017-05-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
6805,NCT01255293,Retinal redetachment rate,Silicone oil emulsification rate,2010-11,COMPLETED,INTERVENTIONAL,['NA'],
6806,NCT05321368,Blood Pressure Control as assessed by percentage of participants with controlled Blood Pressure,Change in Health-Related Quality of Life as assessed by the PROMIS 29,2023-10-16,RECRUITING,INTERVENTIONAL,['NA'],
6807,NCT01493934,Change of glycemia,insulin resistance,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6808,NCT03246828,Change in plasma glucagon from baseline (0min),Continuous glucose monitor recordings,2017-07-03,COMPLETED,INTERVENTIONAL,['NA'],
6809,NCT02187913,resistant starch effects,,2014-07,UNKNOWN,INTERVENTIONAL,['NA'],
6810,NCT01907113,Cmax (Maximum Concentration of the Analyte in Plasma),Assessment of Tolerability by Investigator,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
6811,NCT02377583,Depression (CDI) score,Hippocampal volume and mean diffusion,2012-08,UNKNOWN,OBSERVATIONAL,['NA'],
6812,NCT01697618,Area under the serum insulin curve,Serum glucose excursions (EXC),1997-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
6813,NCT06046833,Metrics of Glucose Variability,Hypoglycemia episodes,2024-01-08,RECRUITING,INTERVENTIONAL,['NA'],GIQLI questionnaire
6814,NCT04104451,SAE,Change in A1c,2019-11-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
6815,NCT05409131,Percent of time in range 70-180 mg/dL,Change in Diabetes Quality of Life (DQL)-brief total score,2022-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
6816,NCT00695565,Change From Baseline to Week 12 in the Average Daily Pain NPRS (Numeric Pain Rating Scale) Score; mLOCF Imputation,Change in Blood Pressure From Baseline to Week 12,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
6817,NCT00889785,Lipids,self-care behaviors,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
6818,NCT00569465,arterial blood pressure decrease,oxidative parameters decrease,2005-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
6819,NCT06313164,Reduced glutathione (GSH) levels in erythrocyte hemolysate change in patients with type 2 diabetes mellitus,Postprandial Insulin (PPI) Levels Change in Patients with Type 2 Diabetes Mellitus,2023-06-20,COMPLETED,INTERVENTIONAL,['NA'],
6820,NCT04064203,p-glucagon,growth hormone,2017-07-05,COMPLETED,INTERVENTIONAL,['NA'],
6821,NCT00813930,Six-month United Kingdom Prospective Diabetes Study (UKPDS) risk engine score. The UKPDS risk engine is a validated scoring system that uses multiple clinical characteristics to predict new coronary heart disease risks in patients with type 2 diabetes.,"Six-month: HbA1c, seated systolic blood pressure, serum Total Cholesterol concentration, serum HDL-C concentration, Total/HDL-C ratio value, LDL-C concentration, self-reported smoking status, adherence to medications and lifestyle measures.",2008-11,UNKNOWN,INTERVENTIONAL,['NA'],
6822,NCT04524832,"Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state (AUC0-24h,sema,SS)",Change in blood pressure,2020-09-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
6823,NCT01381900,Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 18,Percentage of Patients With Glycosylated Hemoglobin (HbA1c) <6.5% at Week 18,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
6824,NCT03988140,Change from baseline Peri-implant Probing Depth (PPD) at 24 months.,Markers on peri-implant crevicular fluid,2014-11-01,COMPLETED,INTERVENTIONAL,['NA'],
6825,NCT02750007,Number of Treatment Emergent Adverse Events(TEAEs),The minimum dose of HS-20004 that could keep plasma glucose under 6.1 mmol/L in Type 2 Diabetic Patients,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],
6826,NCT03073551,Glucose levels,Maternal weight gain,2010-07-27,UNKNOWN,INTERVENTIONAL,['NA'],
6827,NCT05925829,Safety of SVF and aaPRP in Type 2 Diabetes Patients,,2017-01-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
6828,NCT00505375,Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 2 Year Visit,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
6829,NCT01043445,"The effect of this newly discovered GPR 119 agonist on gut hormone responses, in particular GLP-1 in response of the different meals administered to the subjects","Glucose homeostasis, gall bladder contraction in response of the different meals administered to the subjects",2009-09,COMPLETED,INTERVENTIONAL,['NA'],
6830,NCT00044421,Reduction in the progression of DPN measured by composite score,"Vibration sensation;Electrophysiology of tibial, peroneal and sural nerves;Neurological signs;Neuropathic symptoms;Clinical global impression of change;Health outcome measures",2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
6831,NCT02815787,The area under the plasma concentration-time curve (AUC) of Glyburide,The number of volunteers with adverse events as a measure of safety and tolerability,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
6832,NCT00888628,Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant.,Reduction of Insulin Requriements,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6833,NCT05610124,Food Intake,Change in Fatigue Level,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],
6834,NCT04293367,Change in Post-absorptive Lipid Oxidation,Glucose Disposal Rate (GDR) during the Hyperinsulinemic-Euglycemic Clamp,2009-06-01,COMPLETED,INTERVENTIONAL,['NA'],
6835,NCT06268990,Insulin sensitivity,Tolerability of repeated FMT,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],
6836,NCT05294861,Gut Microbiome,Overall Glycemia,2022-04-28,UNKNOWN,INTERVENTIONAL,['NA'],
6837,NCT00642681,To measure Serum FDKP AUC,,2007-12,COMPLETED,OBSERVATIONAL,['NA'],
6838,NCT00654121,body weight gain.,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
6839,NCT04247620,Glycemic Control (HbA1c),Social Vulnerability (CDC/ATSDR Social Vulnerability Index),2020-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
6840,NCT00959725,Best-corrected visual acuity,Macular thickness,2009-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6841,NCT02128581,Calories consumed during buffet meal test,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
6842,NCT03180281,"Fasting blood glucose,glycosylated hemoglobin(GHbA1c)",Incidence of hypoglycemia,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
6843,NCT01280695,Change From Baseline in Fasting Plasma Glucose,Change From Baseline in High Molecular Weight Adiponectin,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
6844,NCT01655186,Mean change in body weight as measured by Dual Energy X-ray Absorptiometry (DXA),"Frequency, intensity and relationship of study drug to adverse events and serious adverse events, as well as clinical, and laboratory test result abnormalities",2012-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
6845,NCT01818310,Amputation-free survival,Quality of life outcome,2012-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Blood glucose and pancreatic function response
6846,NCT01235819,change in insulin requirement,C peptide response,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
6847,NCT03220919,Doses,Hypoglycemia,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],Adverse effects
6848,NCT03736083,Change in Diabetes Treatment Satisfaction Questionnaire- Parent version,Change in Glycemic control measured by A1c,2019-09,WITHDRAWN,INTERVENTIONAL,['NA'],Percentage of glucose sensor readings above 180 mg/dl
6849,NCT05685927,Changes in parameters defining sarcopenia in relation to weight-loss or glycemic improvement,"Correlation analyses of primary measures with metabolic parameters including insulin resistance, HbA1c, metabolic economy, bioenergetics, and low-grade systemic inflammation (hs-CRP)",2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],EMG assessment of myopathic changes
6850,NCT00101751,HbA1c and Incidence of hypoglycemia,Postprandial glucose from 8-point SMBG spontaneously reported adverse events; any changes from baseline,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
6851,NCT01624116,Change in body weight and fructosamine levels during Ramadan fasting.,Change in renal profile from baseline to end of Ramadan,2011-08,COMPLETED,INTERVENTIONAL,['NA'],
6852,NCT00910767,Percentage of plasma glucose values in target (3.9 - 8.0 mmol/L),Percentage of plasma glucose and CGM values below 3.0 mmol/L,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
6853,NCT00478322,"Assessment of ECGs, physical examinations and laboratory values for adverse events",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
6854,NCT00500331,Change From Baseline (Week 0) in Glycosylated Hemoglobin (HbA1c) (%) at Week 12,Number of Participants With Change From Baseline in Standard Laboratory Parameters of Potential Clinical Concern,2007-01-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
6855,NCT03987919,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Percentage of Participants Achieving an HbA1c Target Value of <5.7%,2019-07-30,COMPLETED,INTERVENTIONAL,['PHASE3'],
6856,NCT01447992,estimation of the failure rates of system components,percent time of active CTR,2011-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
6857,NCT01739829,To establish the safety and efficacy of xenotransplantation of DIABECELL,,2011-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6858,NCT04033042,Risk/benefit analysis,Number of encountered Device Deficiencies,2019-09-18,COMPLETED,INTERVENTIONAL,['NA'],
6859,NCT04503408,Time of activities of daily living test,,2019-09-13,COMPLETED,OBSERVATIONAL,['NA'],
6860,NCT00925119,Change in Free Fatty Acid Kinetics,Change in Insulin,2009-12,TERMINATED,INTERVENTIONAL,['PHASE4'],
6861,NCT05161793,CGM - Tele-monitoring effects on HbA1c,CGM-Tele-monitoring effects on protocol driven enhancement of therapy with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) and sodium-glucose cotransporter -2 (SGLT-2) inhibitors,2022-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
6862,NCT05610111,CGM-measured percent time in range 70-180 mg/dL,CGM-measured coefficient of variation during the day,2023-01-18,RECRUITING,INTERVENTIONAL,['NA'],
6863,NCT00962065,Change From Baseline at Day 28 in 24-hour Urinary Glucose Excretion,Change From Baseline at Day 28 in Triglycerides,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
6864,NCT03179254,Postoperative blood glucose level,,2010-03-22,COMPLETED,INTERVENTIONAL,['PHASE4'],
6865,NCT06329544,Degree of fibrosis,,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
6866,NCT01082445,Tissue oxygenation improvement,Oxidation status reduction,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
6867,NCT01455883,Change in HbA1c,,2013-02,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
6868,NCT03325322,Effect on Mesenchymal stem cell function including cell migration,Number of participants with treatment-related adverse events including hospitalization,2018-01-02,SUSPENDED,INTERVENTIONAL,['PHASE2'],
6869,NCT02282397,Phase 2 (T1DM),Phase 2 (T1DM) - Insulin Use Outcomes,2014-09,COMPLETED,INTERVENTIONAL,['NA'],Phase 1 (T2DM) - Post-Hoc A1C Outcome
6870,NCT01858545,Number of Participants With Complete Wound Closure,,2013-05,TERMINATED,INTERVENTIONAL,['NA'],
6871,NCT00664183,Ultrasound,"Ultrasound, OCT, Safety",2008-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
6872,NCT04510506,Combined Triple Label Surveillance and Randomized substudies: Change in insulin sensitivity (Si) over time,Both substudies: Change in percent time <70 mg/dL,2020-11-19,RECRUITING,INTERVENTIONAL,['NA'],
6873,NCT03321279,"Change in mean daily step count from the baseline period to the intervention period, using a wearable pedometer (Nokia Steel) to measure step count.","Functional decline from admission to 3 months post-discharge, measured using validated survey assessments.",2018-01-11,COMPLETED,INTERVENTIONAL,['NA'],
6874,NCT05230342,Evaluation of the total daily interstitial glucose over 140 mg/dl,16s ribosomal gene analysis,2022-08-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
6875,NCT04501406,The proportion of pioglitazone-treated patients relative to placebo achieving an improvement of ≥2 points in non-alcoholic fatty liver disease activity score (NAS) without an increase in fibrosis stage.,Mean change in liver fibrosis,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Glycemic control
6876,NCT00572052,HbA1c,Quality of Life,2002-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
6877,NCT03174340,Prescription of insulin during the follow-up,Compliance with the exercise (in the exercise group only),2008-02-21,COMPLETED,INTERVENTIONAL,['NA'],Dosage of short-acting insulin
6878,NCT01709851,Point Accuracy of the microdialysis signal,Rate accuracy of the microdialysis signal,2012-11,COMPLETED,OBSERVATIONAL,['NA'],
6879,NCT04054934,"Affects of reversal circadian clock on sleep quality among both healthy and T1DM adolescents (mainly T1DM), controlled for BMI-SDS, and mean HbA1c in T1D patients.",Metabolic parameters according to night/day sleep cycle among healthy and among T1D patients,2022-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
6880,NCT02809963,Liver fat content,potassium,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
6881,NCT01973972,Hemoglobin A1c,Estimated Costs of Intervention Strategies,2014-12-12,COMPLETED,INTERVENTIONAL,['NA'],
6882,NCT00101530,,,2004-09,COMPLETED,OBSERVATIONAL,['NA'],
6883,NCT00639665,Hemodynamic Measurements,Blood Pressure,2008-01,COMPLETED,OBSERVATIONAL,['NA'],
6884,NCT02370537,Part B: Baseline Corrected Cmax for Total EPA+DHA Following Administration of EPANOVA® and OMACOR®.,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
6885,NCT00815217,"wound measurements, healing of wounds, pictures of wounds",,2009-02,UNKNOWN,INTERVENTIONAL,['NA'],
6886,NCT00948324,beta cell function;fast blood glucose;,,2008-06,SUSPENDED,INTERVENTIONAL,['PHASE4'],
6887,NCT04113694,Novolog Subjects - Rate of Infusion Set Failure at the End of Day 6,Novolog Subjects - Rate of Infusion Set Failure at the End of Day 7.,2019-10-14,COMPLETED,INTERVENTIONAL,['NA'],
6888,NCT00646724,Glucose and C-peptide levels,Complete Blood Count,2008-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6889,NCT05362578,Change in American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptoms Index-Daily Diary (ANMS GCSI-DD),Electrocardiogram (ECG),2022-09-08,RECRUITING,INTERVENTIONAL,['NA'],36-Item Short Form Survey Instrument (SF-36) to measure quality of life (QOL)
6890,NCT03249610,Number of subjects with reduced Body Mass Index,Number of subjects with reduced Fasting Blood Glucose,2014-03-11,COMPLETED,INTERVENTIONAL,['NA'],
6891,NCT04033705,"The time spent within, above and below the target glucose range (4-10mmol/L) in the post operative period",Post operative infections,2019-06-11,COMPLETED,OBSERVATIONAL,['NA'],
6892,NCT00802269,Pain (NRS-11 scale),,2008-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
6893,NCT00324584,frequency of hypoglycemic episodes (<70 mg/dl),,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
6894,NCT06118931,Average 24-hour glucose total area under the curve (AUC) over 7 days,TRE fasting window adherence,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Safety and Adverse Events
6895,NCT06176703,Glycemic control,Quality of life,2023-11-22,RECRUITING,INTERVENTIONAL,['NA'],
6896,NCT04037098,Decreased of gestational diabetes incidence,,2022-07-31,WITHDRAWN,INTERVENTIONAL,['NA'],
6897,NCT05174975,Change in Glycosylated hemoglobin(HbA1c) levels,Change in Diabetic Positive Characteristics,2021-10-20,COMPLETED,INTERVENTIONAL,['NA'],
6898,NCT00716170,Plasma glucagon responses,,2008-07,COMPLETED,OBSERVATIONAL,['NA'],
6899,NCT04656210,Atrophy difference based on two cerebral MRI volumetries,changes in amyloid biomarkers in blood at 4 years of inclusion,2021-10-14,RECRUITING,OBSERVATIONAL,['NA'],
6900,NCT01915849,Area Under the Postprandial Curve (AUC) for Rate of Appearance (Ra) of Exogenous Glucose,,2013-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
6901,NCT02797314,Trabecular Bone Score,,2017-03-28,RECRUITING,INTERVENTIONAL,['NA'],
6902,NCT03702465,Difference in glucose regulation between the control and intervention arm,Number of participant withdrawals in the trial,2018-11-26,COMPLETED,INTERVENTIONAL,['NA'],
6903,NCT01530048,"Cmax, maximum concentration",Adverse events,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
6904,NCT02506582,Blood glucose level by 2-h oral glucose tolerance tests (OGTTs),,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
6905,NCT01874080,Point estimates and 90% CIs for the ratio of geometric means for AUC(INF) for Saxagliptin and Metformin in the 5/500 mg FDC XR (Mt. Vernon/Humacao) and 5/500 mg FDC XR (Mt. Vernon),"Safety assessments based on adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests",2013-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
6906,NCT01208948,occurrence of clinically significant macular edema (CSME) within a follow-up period of 2 years,The time to CSME development,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
6907,NCT03536910,Changes in copeptin levels after general or spinal anesthesia,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA'],
6908,NCT00818935,Glycated Haemoglobin,"body weight, homocysteine, C-reactive protein, plasma lipids and lipoproteins, fasting body glucose, insulin, insulin resistance, serum urea, creatinine, C-peptide",2004-06,COMPLETED,INTERVENTIONAL,['NA'],
6909,NCT04940572,Preservation of auditory function.,Quality of sleep assessment on adult population - Qualitative questionnaire (no scale),2021-11-26,RECRUITING,INTERVENTIONAL,['PHASE2'],
6910,NCT03799185,Prevalence of dyslipidemia,Prevalence of cardiovascular associated risk factors,2016-01-04,COMPLETED,OBSERVATIONAL,['NA'],Dietary assessment
6911,NCT06025422,During the procedure difference in the mean in-shoe PPP by ROI associated with each toe gap standard,During the procedure PTSR associated with habitual footwear,2023-03-13,RECRUITING,OBSERVATIONAL,['NA'],
6912,NCT05795972,glycemic control,akkermania levels,2020-06-01,RECRUITING,INTERVENTIONAL,['NA'],
6913,NCT01826162,"Fat oxidation, energy expenditure",Appetite VAS scoring,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
6914,NCT03029390,Insulin sensitivity,Creatinine levels,2016-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
6915,NCT03851978,Change in vaccination rates,Barriers to receiving vaccination,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],
6916,NCT01893242,Time to the first occurrence of either component of the composite endpoint: end stage renal disease or cardiovascular death,Time to the first occurrence of any component of composite outcome of end-stage renal disease and all-cause mortality,2013-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
6917,NCT03393338,Number of emergency room visits and hospitalizations over 12 months,Physician Trust,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],
6918,NCT02739217,Description and number of abnormal laboratory values and adverse events that are related to treatment.,Change from baseline of antidiabetic treatment,2016-02-22,COMPLETED,INTERVENTIONAL,['PHASE2'],Change from baseline in hyperinsulinaemic-euglycaemic clamp measurements.
6919,NCT01961674,Temperature at supraclavicular region,Glycaemic response,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
6920,NCT01260246,To demonstrate improvement in liver disease (based on liver biopsy)with sitagliptin.,In individuals with NASH and DM2: To determine the correlation between changes in histology with changes in hepatic fat demonstrated by MRI and changes in fibrosis by Fibroscan.,2010-12,TERMINATED,INTERVENTIONAL,['NA'],
6921,NCT04553380,Incidence of hypoglycemia,Daily doses of insulin at the study end point.,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
6922,NCT04354740,Major adverse cardiac events (MACEs),In hospital mortality,2020-07,UNKNOWN,OBSERVATIONAL,['NA'],
6923,NCT06283849,sedentary time,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
6924,NCT00504816,blood hormone levels,vital signs,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
6925,NCT04259489,Glycemic achieving rate,The days of Hospitalization due to hypoglycemia,2020-01-31,UNKNOWN,INTERVENTIONAL,['NA'],
6926,NCT03658317,renal resistive index,stage of diabetic nephropathy,2018-09,UNKNOWN,INTERVENTIONAL,['NA'],
6927,NCT03347968,Maximum international normalized ratio (INRmax),Clinical laboratory assessment (urinalysis),2017-11-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
6928,NCT01480362,Time until wound closure within the maximum study treatment time,Adverse Events,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
6929,NCT00919347,"The primary outcome will be to quantify, using the ANSR ANX 3.0 technology, the prevalence of cardiac autonomic neuropathy (CAN), diabetic autonomic neuropathy (DAN),referred to as advanced autonomic nervous system dysfunction in non-diabetic patients.",The strength of various comorbidities as predictors of autonomic dysfunction in both diabetics and non-diabetics will be evaluated. The differential effect of these various comorbidities in Type I versus Type II diabetes on ANS dysfunction and neuropathy,2009-06,COMPLETED,OBSERVATIONAL,['NA'],
6930,NCT02449187,AUC(last),Vd/F,2017-08-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
6931,NCT03883230,GLYWD test result,Clinician's wound characterization,2017-07-27,COMPLETED,OBSERVATIONAL,['NA'],
6932,NCT06032988,Effects of probiotics supplementation on glycemic control (HbA1c),Effects of probiotics supplementation on changes in gut microbiota diversity (alpha- and beta-diversity),2023-08-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
6933,NCT04771403,Percent of Time With Sensed Glucose <70 mg/dl,Mean Amount of Insulin Delivered Per Day (in Units/Day),2021-02-23,COMPLETED,INTERVENTIONAL,['NA'],
6934,NCT00300976,"The occurrence of myocardial infarction, coronary bypass surgery, percutaneous transluminal coronary angioplasty, stroke, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, carotid artery stenting, or death",All-cause mortality (deaths due to any cause),2006-05,UNKNOWN,INTERVENTIONAL,['NA'],Changes in QOL (EQ-5D)
6935,NCT04223895,"Cmax of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337","Cmax of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D326, D337",2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
6936,NCT01334645,Copeptin value,"Troponin, Myoglobin and Creatin Kinase values. Clinicals and paraclinicals events .",2011-03,COMPLETED,INTERVENTIONAL,['NA'],
6937,NCT03933696,Cognition,Melatonin Levels,2019-01-02,RECRUITING,INTERVENTIONAL,['NA'],
6938,NCT05222490,Estimate of a difference in temperature between two feet per subject,To evaluate the usability of FeeSee device by patient and healthcare providers,2021-07-13,UNKNOWN,INTERVENTIONAL,['NA'],
6939,NCT02587286,Change in HbA1c,Change in HbA1c,2015-03,COMPLETED,INTERVENTIONAL,['NA'],mHealth intervention satisfaction
6940,NCT01537497,Modulation of carbohydrate and lipid metabolism,Area under the curve (AUC) of PF-05175157 after single oral doses,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
6941,NCT00947427,C-peptide Response to Mixed Meal Glucose Tolerance Test (MMTT) at One Year for Subjects Given Canakinumab Compared to Placebo,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
6942,NCT03037099,Dietary glycemic index,Systolic blood pressure,2017-01,COMPLETED,INTERVENTIONAL,['NA'],
6943,NCT01199692,,,2010-08,COMPLETED,OBSERVATIONAL,['NA'],
6944,NCT05838209,clinical attachment level,clinical attachment levels,2023-04-05,RECRUITING,INTERVENTIONAL,['NA'],
6945,NCT04336800,To build a registry of diabetic volunteers by inviting them to get a LiverMultiScanand collecting their contact information to seek interest in participating in future studies.,To use multi-parametric MRI (LiverMultiScan) of the liver to assess liver health,2020-04-01,COMPLETED,OBSERVATIONAL,['NA'],
6946,NCT04474496,Workplace Preventative Actions to Decrease Risk of COVID-19 Exposure,Sources of Stress During COVID-19,2020-07-27,COMPLETED,OBSERVATIONAL,['NA'],
6947,NCT01966978,Mean Change From Randomization in A1c at Week 26,Change in Short Form-36 (SF-36) Questionnaire Score,2014-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
6948,NCT03912480,glucose-c peptide release test,Continuous dynamic blood glucose,2019-01-05,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
6949,NCT00272064,Changes of glycosilated haemoglobin (HbA1c),Hypoglycemic episodes,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
6950,NCT02243176,Absolute Change From Baseline in HbA1c at Week 24 (DAO),Change From Baseline in Body Weight,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
6951,NCT01885546,User's ability to obtain the enhanced meter feature,,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
6952,NCT01154348,Safety and pharmacokinetics of multiple-dose oral co-administration of S-707106 and metformin in fed state in patients with type 2 diabetes mellitus,The effect of multiple doses of metformin on pharmacokinetics of S-707106,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
6953,NCT06278935,Participant satisfaction,DFU-related outcomes,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
6954,NCT01288300,Changes in glycosylated hemoglobin (Hba1c)from baseline at 3 and 6 months,Changes in diabetes self-empowerment from baseline to 3 and 6 months,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
6955,NCT04498156,Preferences regarding chronic kidney disease in T2D,Time point of communicated CKD diagnosis,2020-09-16,COMPLETED,OBSERVATIONAL,['NA'],
6956,NCT02094911,Change in fasting insulin,Process indicators,2011-10,UNKNOWN,INTERVENTIONAL,['NA'],
6957,NCT06264271,difference in HbA1c,differences in coefficient of variation,2022-02-01,COMPLETED,OBSERVATIONAL,['NA'],
6958,NCT02174146,leptin levels in gingival tissue,clinical attachment level,2013-09,COMPLETED,INTERVENTIONAL,['NA'],
6959,NCT00853944,Islet function as measured by hyperglycemic clamp,Change in insulin requirement (absolute and % decrease from pre-transplant dose),2009-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
6960,NCT00224276,,,na,COMPLETED,OBSERVATIONAL,['NA'],
6961,NCT04164966,Characterization of circulating β cell-specific exosomes in children with T1D and healthy normal controls using baseline samples,,2019-11-27,RECRUITING,OBSERVATIONAL,['NA'],
6962,NCT01280682,Change of 3-hour Mean Area Under the Curve (AUC) of C-peptide,HbA1c Levels,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
6963,NCT00899470,Metformin T-half and T-max,Number of Participant With Clinically Relevant Physical Examination Abnormalities,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
6964,NCT01880827,Splanchnic blood flow,GIP and GLP-1 blood concetrations,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
6965,NCT00949442,HbA1c,Need of additional prandial insulin,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
6966,NCT01333774,Change in HbA1c value between initial and final visit,Number of participants with adverse events in both study groups. The influence of different approaches to dietary advising on the appearance of adverse events.,2008-05,COMPLETED,OBSERVATIONAL,['NA'],
6967,NCT01865292,Area under the glucose infusion rate curve,Area under the insulin degludec/insulin glargine curve,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
6968,NCT03165877,Objective satiety,Adherence to treatment,2016-05-31,COMPLETED,INTERVENTIONAL,['NA'],
6969,NCT03312595,Percentage of Participants With Wound Closed,Time to Wound Closure,2017-09-14,COMPLETED,INTERVENTIONAL,['NA'],
6970,NCT05256303,"Total cost, hospitalization",Percent of day lying down,2022-02-16,COMPLETED,INTERVENTIONAL,['NA'],Qualitative interviews
6971,NCT05394571,ratio of patients who reached the HbA1c target of equal to or below 7%,The effect of the level of physical activity on the HbA1c changes,2021-08-15,COMPLETED,OBSERVATIONAL,['NA'],
6972,NCT01588106,Reduction in HbA1c,,2012-06,COMPLETED,OBSERVATIONAL,['NA'],
6973,NCT04907019,AUC0-∞,CLz/F,2021-07-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
6974,NCT03380988,Postprandial glucose response,,2015-11,COMPLETED,INTERVENTIONAL,['NA'],
6975,NCT01549964,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Fasting Plasma Glucose (FPG),2012-04,TERMINATED,INTERVENTIONAL,['PHASE3'],
6976,NCT04612595,increasing by 50% of the serum creatinine level from baseline,,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
6977,NCT02989649,Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level at Month 6,Time to Alogliptin or Alogliptin FDCs Dose Escalation or Dose Reduction,2016-12-22,TERMINATED,OBSERVATIONAL,['NA'],
6978,NCT01698008,Evidence for Improved Diabetic Care With Mobile Phone Application Use,,2012-01-28,COMPLETED,INTERVENTIONAL,['NA'],
6979,NCT01553266,Change from 12 months prior to intervention in HbA1c up to 12 months during the intervention,MDET educators' quarterly debriefing session group discussions regarding intervention issues,2012-03-01,COMPLETED,OBSERVATIONAL,['NA'],
6980,NCT01490879,Incidence of Reference Diabetic Foot Ulcer (RDFU) complete closure determined by Investigator Assessment,Incidence of adverse events,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
6981,NCT01528059,Glycemic control,Nutritional status assessment,2012-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
6982,NCT03889600,Feasibility - Implementation fidelity: percentage of indicated referrals that are made,Limited Efficacy - 30-Day readmission rate,2021-03-02,WITHDRAWN,INTERVENTIONAL,['NA'],Process Outcome- Referral Completion: percentage of patients who receive services post-referral
6983,NCT01081938,Glycaemic parameters assessment,"Incidence of symptomatic, nocturnal and severe hypoglycemias",2010-02,TERMINATED,INTERVENTIONAL,['PHASE4'],
6984,NCT00986700,fasting glucose level,,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
6985,NCT02626156,Time Spent in Minutes Engaging in Physical Activities,Knowledge Questionnaire of Study Instructions,2015-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
6986,NCT05878431,Neuropathic Pain Impact on Quality of Life Questionnaire (NePIQOL),,2022-01-01,COMPLETED,INTERVENTIONAL,['NA'],
6987,NCT03240289,Patient satisfaction and feedback,Diabetes self-efficacy (Measured using the Perceived Diabetes Self-Management Scale),2013-12,COMPLETED,INTERVENTIONAL,['NA'],
6988,NCT02577016,Percentage of Participants Who Discontinued Study Drug Due to an AE,Change From Baseline in FPG at Week 24,2015-11-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
6989,NCT04372355,HbA1c change at Week 8 in comparison to Baseline,HbA1c change at Week 12 in comparison to Baseline,2019-06-19,COMPLETED,INTERVENTIONAL,['PHASE2'],
6990,NCT04934228,Adipose Tissue Sample: Efficacy of 4-week supply of Clonidine Compared VS 4-week supply of control condition using hydrochlorothiazide (HCTZ) and a separate placebo treatment,,2021-07-01,RECRUITING,INTERVENTIONAL,['PHASE1'],
6991,NCT04066400,Effect of ATI-free Nutrition on hepatic inflammation,Quality of Life using the chronic liver disease questionnaire (CLDQ),2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],
6992,NCT01961622,Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on subcutaneous glucose monitoring,Continuous subcutaneous glucose monitoring (CGM) based outcome during day period between 08:00 to 23:00,2014-04,COMPLETED,INTERVENTIONAL,['NA'],Effect of study intervention based on pre-study glycaemic control
6993,NCT05360537,Change from Baseline Reactive Hyperemia Index at 3 and 9 months,Change of intra and extra-hospital mortality,2021-04-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
6994,NCT03078478,Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks),Change in Body Weight From Baseline to End of Treatment (up to 88 Weeks),2017-03-13,COMPLETED,INTERVENTIONAL,['PHASE3'],
6995,NCT00659711,"Change in Reactive Oxygen Species (ROS) Generation by MNC, Protein and mRNA Expression of p47phox Subunit of NADPH Oxidase, in MNC's of Obese Type 2 Diabetic Patients",Change in Oxidative Stress From Baseline to 12 Weeks,2008-03,COMPLETED,INTERVENTIONAL,['NA'],
6996,NCT04885153,Changes from Baseline Vascular Cell Adhesion Molecule-1 (VCAM -1) at 3 Months,,2016-11-01,COMPLETED,INTERVENTIONAL,['NA'],
6997,NCT05037058,Proportion of patients receiving guidance on individualized physical activity,,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA'],
6998,NCT04705558,change in glycated hemoglobin,change in Body composition,2020-07-20,UNKNOWN,INTERVENTIONAL,['NA'],
6999,NCT01697631,HbA1c (glycosylated haemoglobin),"Hypoglycaemic episodes (minor, major or nocturnal)",2002-07-22,COMPLETED,INTERVENTIONAL,['PHASE4'],
7000,NCT01388192,Change of glucose metabolism after pancreaticoduodenectomy,,2011-11,UNKNOWN,OBSERVATIONAL,['NA'],
7001,NCT01264796,quality of life,,2009-11,COMPLETED,INTERVENTIONAL,['NA'],
7002,NCT01078103,,,2005-07,COMPLETED,OBSERVATIONAL,['NA'],
7003,NCT05145452,Muscle endurance,Physical performance,2021-01-14,SUSPENDED,INTERVENTIONAL,['NA'],
7004,NCT02488213,Glicemic control,Adherence to nutritional counseling,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],
7005,NCT04127084,changes of 8-OH-dG,Change in angiotensin,2019-10-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],
7006,NCT01076842,The primary endpoint is the improvement in A1C goal measured in mean reduction in A1c levels over 24 weeks.,Hypoglycemia weight waist-hip ratio frequency of hypoglycemia weight FBGL lipid levels CBC CMP biometric parameters of activity heat flux galvanic skin response heart rate level of physical activity and energy expenditure,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
7007,NCT01318135,Number of Participants With Adverse Events.,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Final Visit).,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
7008,NCT02057172,Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks,Number of subjects attaining goal glycosylated haemoglobin (HbA1c) <7%,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Assess the immunogenicity of HM11260C
7009,NCT04583462,Change between below-knee arterial calcification score evaluated by CT-scan at T0 and T2years in type 1 diabetic patients treated or not with metformin.,Change between below- knee arterial calcification score progression between T0 and T2years with initial below-knee arterial calcification score ≤ and >400 (subgroup analysis),2021-06-02,RECRUITING,INTERVENTIONAL,['PHASE3'],
7010,NCT01422876,Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Treatment Naive Patients,Occurrence of Treat to Target Efficacy Response for Treatment Naive Patients,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
7011,NCT01659294,diabetes distress (DDS),Depressive Symptoms Severity,2012-08,COMPLETED,INTERVENTIONAL,['NA'],
7012,NCT04655131,Number of positive events for each protein amount.,,2018-06-18,COMPLETED,INTERVENTIONAL,['NA'],
7013,NCT02938832,Diabetes incidence,Quality of Life,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
7014,NCT03460899,Changes in Platelet Activation Marker Adenosin Diphosphate (%),Changes in Coagulation Marker Fibrinogen (g/L),2018-02-12,COMPLETED,INTERVENTIONAL,['NA'],
7015,NCT03712046,Diagnostic accuracy of 18F-FDG PET-CT for the diagnosis of diabetic foot osteomyelitis,,2019-01-15,TERMINATED,INTERVENTIONAL,['NA'],
7016,NCT03804905,Lacking medication insurance,Time from allocation to use of Trillium Health Partners outpatient pharmacy,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Health care costs
7017,NCT02157350,Proliferative diabetic retinopathy progression/regression.,"Retinal vessel geometry (caliber, fractals and tortuosity)",2014-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Retinal areas of non-perfusion.
7018,NCT03755479,Achieving glucose values more than 67% in Time in Range (70-180 mg/dl),Time spend in Auto Mode,2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],
7019,NCT05741437,2. Cmax of CKD-378: Maximum plasma concentration of the drug,,2023-04-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
7020,NCT00611988,Maximal treadmill walking distance,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
7021,NCT03985566,Change in insulin response,Change in glucose trajectories over 14 days of continous glucose monitoring,2018-07-03,COMPLETED,INTERVENTIONAL,['NA'],
7022,NCT03948347,Percentage of patients with the 90-day new stroke events (ischemic or hemorrhagic),Percentage of patients with the 90-day Modified Rankin Scale (mRS) ≤ 2,2019-06-25,RECRUITING,INTERVENTIONAL,['NA'],
7023,NCT03143816,Change in Time in Range (%) (70-180 mg/dl) With TI on CGM,Hypoglycemia Frequency (%) (Below the Target <70mg/dl) on CGM,2017-09-30,COMPLETED,INTERVENTIONAL,['PHASE4'],
7024,NCT00364988,Renal function,,2005-01,COMPLETED,INTERVENTIONAL,['NA'],
7025,NCT04143802,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change from Baseline in Mean Daily Plasma Glucose (PG),2019-12-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
7026,NCT00159536,pre-eclampsia,Snoring and sleep quality,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
7027,NCT01991054,Change in Hba1c (%) in study groups,serum albumin,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
7028,NCT04085926,Percentage of participants with healed foot ulcers at 12 weeks,"Sick-leave from work (number of days per participant) during treatment period (average 12 weeks) and during the period after treatment end up to 12 months later, assessed with study-specific questionnaire and Swedish Social Insurance Agency's system data",2019-08-02,RECRUITING,INTERVENTIONAL,['NA'],
7029,NCT01307137,Compare changes in weight and hemoglobin A1c between participants receiving peer-led care (with or without TAP intervention) and those receiving UC over 12 months.,"Compare changes in health care utilization (physician visits, emergency visits, and days in hospital) among treatment groups (UC, PC, and TAP).",2011-06,UNKNOWN,INTERVENTIONAL,['NA'],
7030,NCT04246814,Change in complete ulcer healing,Short Form-36 Health Survey questionnaire,2019-08-27,COMPLETED,INTERVENTIONAL,['NA'],
7031,NCT05958264,Determination of DeBacker Score of sublingual microcirculation of children,Differences of DeBacker Score of sublingual microcirculation with parameters of healthy children in the same age categories,2023-02-01,RECRUITING,OBSERVATIONAL,['NA'],
7032,NCT04371042,Registry creation,,2019-09-01,RECRUITING,OBSERVATIONAL,['NA'],
7033,NCT04400344,Current state of diabetic foot care education and knowledge base among diabetic educators,,2020-06-13,UNKNOWN,OBSERVATIONAL,['NA'],
7034,NCT00525889,Incidence and severity of adverse events and laboratory anomalies,HbA1c levels,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
7035,NCT04226378,Glycated hemoglobin (A1C),Annual incidence of severe hypoglycemia,2020-01-20,COMPLETED,OBSERVATIONAL,['NA'],A1C stratified by age cohort
7036,NCT01433380,Changes in carbohydrate and lipid metabolism,"Pharmacokinetics: 0.5, 1, 1.5, 2.5, 6.5, 10.5, 24 hrs after dosing, parameters: Cmax, Tmax and Area under the Curve (AUC)",2011-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
7037,NCT04511715,Percentage of patients with equal or more than 2 stages of progression in diabetic retinopathy staging,Number of visits,2020-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
7038,NCT05687643,Peak plantar strain,Regional Peak Plantar pressure,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
7039,NCT00334919,Cytokines,Lipids,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
7040,NCT01817127,Human milk glycans,Human Milk Transcriptomics,2009-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Alkaline phosphatase levels
7041,NCT05894252,Quality of life Short Form 36 Health Survey Questionnaire (SF-36) t2,Health Locus Control (Multidimensional Health Locus of Control form C- MHLC) t2,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
7042,NCT05427916,Number of Participants With Healing Complication,Patient Satisfaction,2022-07-12,TERMINATED,INTERVENTIONAL,['NA'],
7043,NCT01497301,Change in Hemoglobin A1C,Change in LDL cholesterol,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
7044,NCT00379548,Insulin resistance assessed by HOMA,,2005-11,COMPLETED,INTERVENTIONAL,['NA'],
7045,NCT02212067,Area under the serum insulin concentration time curve from 10-120 minutes after a 25 g glucose bolus i.v. infusion (IVGTT).,Slope of the ISR vs. glucose curve (dose-response relationship),2014-08-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
7046,NCT03655067,Center for Epidemiological Studies - Depression Scale (CES-D),Problem Areas in Diabetes - Teen version,2020-12-15,COMPLETED,INTERVENTIONAL,['NA'],
7047,NCT02676401,Adverse events,Change from baseline in Urine Albumin to Creatinine Ratio (UACR),2016-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
7048,NCT00954343,Percentage decrease of ulcer size twelve weeks after treatment begin (i.e. first shock wave treatment) compared to the baseline (ulcer size at first treatment),Tissue oxygen concentration after shock wave treatment,2009-08,WITHDRAWN,INTERVENTIONAL,['NA'],
7049,NCT01000363,"Patients who participate in the diabetes group visits should achieve improvement in Clinical outcomes - better A1C levels, reduced blood pressure, reduced cholesterol levels",behavioral outcomes,2009-11,COMPLETED,OBSERVATIONAL,['NA'],
7050,NCT01366287,"Safety: Safety labs, vital signs, ECGs, physical examinations and adverse event monitoring.",,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
7051,NCT05505721,Body mass index (kg/m2),,2021-03-16,COMPLETED,OBSERVATIONAL,['NA'],
7052,NCT00018239,,,1999-10,COMPLETED,INTERVENTIONAL,['NA'],
7053,NCT01839071,Fat tissue biopsy,Blood collection,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
7054,NCT00001987,Diabetes control,,1976-02-01,RECRUITING,OBSERVATIONAL,['NA'],
7055,NCT00202748,Change in self-reported activity,Quality of life,2004-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],
7056,NCT00247455,Plasma GLP-1 concentration,C-peptide/insulin ratio as marker of hepatic insulin extraction,2002-03,COMPLETED,INTERVENTIONAL,['NA'],
7057,NCT00175253,,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
7058,NCT01946451,Gene expression in patients with idiopathic and secondary epiretinal membranes in proliferative diabetic retinopathy.,,2012-06,UNKNOWN,OBSERVATIONAL,['NA'],
7059,NCT01243424,The First 3-point Major Adverse Cardiovascular Events (3P-MACE),CGM Sub-study : Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Millimoles/ Litre) to End of Study,2010-11-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
7060,NCT02155361,Pain Scores on the Neuropathic Pain Scale (NPS),Motor amplitude (microvolt) of tibial nerve,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
7061,NCT03516422,Wound healing,Reduction in bacterial colonization,2018-11,UNKNOWN,INTERVENTIONAL,['NA'],
7062,NCT01087502,HbA1c Change From Baseline to Week 12,Plasma Concentration of Linagliptin at Trough,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
7063,NCT04473274,Adverse events attributable,A1c,2020-05-21,COMPLETED,INTERVENTIONAL,['PHASE4'],
7064,NCT05887635,Tolerability Endpoint:,Change in ALT and AST from baseline to 24 weeks post procedure.,2023-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
7065,NCT02856516,Area under the blood glucose curve (AUC 0-240),AUC (0-30min) for insulin,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
7066,NCT06148688,International Physical Activity Questionnaire,Blood Sugar Monitoring Form,2023-03-27,RECRUITING,INTERVENTIONAL,['NA'],
7067,NCT00845468,,,2006-01,COMPLETED,OBSERVATIONAL,['NA'],
7068,NCT01003184,Percentage of Patients Achieving Glycosylated Hemoglobin (HbA1c) Concentration ≤7.0% With Weight Loss (≥1.0 kg) at Endpoint (Week 26),Hypoglycemia Rate Per Year,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
7069,NCT00082381,Change in Glycosylated Hemoglobin (HbA1c),Change in Rate of Hypoglycemic Events,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
7070,NCT03292185,Area under the plasma liraglutide concentration time curve,Local tolerability at the injection site,2017-09-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
7071,NCT01593215,Insulin Secretion,Glucose,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
7072,NCT02956811,Change in left ventricular (LV) Mass by Cardiac MRI at 52 weeks,Change in diastolic function and global longitudinal strain,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE4'],
7073,NCT05459987,Feasibility of an intensive multidisciplinary program based on lifestyle changes in coronary heart disease patients recently diagnosed with prediabetes that are referred to the Centre EPIC.,"Evolution of the HOMA-IR between the start of the program, the end of intervention (3 months) and the follow-up visit (6 months).",2022-03-15,COMPLETED,INTERVENTIONAL,['NA'],
7074,NCT04106050,Change in Nerve Excitability from Baseline (Day 1) to Last Treatment Visit (Day 8) as Determined by Compound Muscle Action Potential Threshold Tracking (CMAP-TT) in the Median Nerve of Healthy Participants,Time to Reach Maximum Observed Concentration (Tmax),2020-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
7075,NCT02276859,Postprandial glycemia,Mean amplitude of glycemic excursion,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
7076,NCT02512523,Mean amplitude of glucose excursion (MAGE),"Safety (All AE including SAE, hypoglycemia, laboratory tests, vital sign, and physical examination)",2015-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
7077,NCT01527630,"Cmax, maximum insulin aspart concentration","t½, terminal half-life",2002-11-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
7078,NCT01313156,"Metabolic Syndrome, Type 2 Diabetes",,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
7079,NCT02160717,Beta-Cell Function measured as Disposition Index,,2014-05,COMPLETED,OBSERVATIONAL,['NA'],
7080,NCT04642378,Time in target glucose range,Daily insulin dose,2021-10-01,UNKNOWN,INTERVENTIONAL,['NA'],
7081,NCT00923962,Coronary metabolite uptake,,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
7082,NCT03380832,Vestibular threshold,,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
7083,NCT00399347,,,2005-01,COMPLETED,OBSERVATIONAL,['NA'],
7084,NCT02045758,Non-Inferiority of Analyte Levels,,2014-12,UNKNOWN,INTERVENTIONAL,['NA'],
7085,NCT02620787,Tedizolid Tissue Penetration,Tedizolid AUC in Plasma,2016-02-23,COMPLETED,INTERVENTIONAL,['PHASE1'],
7086,NCT01301287,HbA1c,Insulin concentration during oral glucose tolerance test,2010-01,UNKNOWN,INTERVENTIONAL,['NA'],
7087,NCT04259775,Percent of patients at target range from baseline to 26 weeks,Problem Areas in Diabetes Scale (PAID),2022-09,WITHDRAWN,INTERVENTIONAL,['NA'],
7088,NCT05141565,Mortality,,2021-05-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
7089,NCT01351922,"Percentage of patients having complications (dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications)",,2011-04,COMPLETED,OBSERVATIONAL,['NA'],
7090,NCT01341717,Reduction in HbA1c from baseline,Change in lipid profile from baseline,2012-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
7091,NCT02140983,OGTT,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
7092,NCT01410357,SF-36 Health Survey at 60 Weeks; Physical Health Component,Comparison of ISMI (Stigma Resistance) Score Between TTIM and TAU at 60 Weeks,2011-07,COMPLETED,INTERVENTIONAL,['NA'],Comparison of PMHSMS (Perceived Mental Health Self-Management Scale) Score Between TTIM and TAU at 60 Weeks
7093,NCT00732160,Insulin Secretion,Insulin Sensitivity,2008-09,COMPLETED,INTERVENTIONAL,['NA'],
7094,NCT04201938,insulin sensitivity (%S),cytokines levels,2018-02-01,COMPLETED,INTERVENTIONAL,['NA'],
7095,NCT00535925,"""Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)""","""Number of Participants Who Achieved of BP, HbA1c and Total, HDL and LDL Cholesterol Goals at the End of Intervention Phase""",2005-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
7096,NCT05794152,Adverse birth outcomes,Number of participants developing type 2 diabetes,2023-03-21,RECRUITING,INTERVENTIONAL,['NA'],
7097,NCT06067451,To determine the impact of SMART Goal setting on BMI z-scores To determine the impact of SMART Goal setting on BMI z-scores,Temporal changes in Lipids,2023-12-10,RECRUITING,INTERVENTIONAL,['NA'],
7098,NCT02148250,Duration (in Hours) of 20 % Dextrose Infusion Requirement,Total Glucose Required to Maintain Euglycaemia,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
7099,NCT02324010,Gastric emptying,Appetite,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
7100,NCT01282970,"Safety and tolerability of BI 135585 will be assessed in a descriptive way using physical examinations (occurence of findings), vital signs, electrocardiograms, laboratory tests, and incidence and severity of adverse events.",Exploratory evaluation of the pharmacodynamics of BI 135585 by measuring of cortisol and cortisone and their metabolites in urine,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
7101,NCT02702440,Body weight,,2015-05,UNKNOWN,OBSERVATIONAL,['NA'],
7102,NCT03002155,Chair Stand Test (5x Sit-to-Stand) at 12-week Session,Adverse Events,2017-01,COMPLETED,INTERVENTIONAL,['NA'],Recruitment
7103,NCT01325064,subclinical organ damage,,2010-06,COMPLETED,OBSERVATIONAL,['NA'],
7104,NCT01010594,Change in Hba1c,change in fruit intake,2009-11,TERMINATED,INTERVENTIONAL,['NA'],
7105,NCT04444375,Manchester Foot Pain and Disability Index,,2017-12-01,COMPLETED,OBSERVATIONAL,['NA'],
7106,NCT01030926,Area under the NN1250 concentration-time curve after single dose,Time to maximum observed NN1250 concentration after single dose,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
7107,NCT04688671,Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale (PI-NRS),Change in the Daily Amount of Acetaminophen Use From Baseline to Week 4,2020-11-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
7108,NCT00364767,"enzymes involved in fatty acid oxidation, oxidative phosphorylation and glycolysis in skeletal muscle","insulin sensitivity (oral glucose tolerance test) and related factors (adiponectin, HbA1c)",2004-10,COMPLETED,INTERVENTIONAL,['NA'],
7109,NCT00426413,,,2007-05,COMPLETED,OBSERVATIONAL,['NA'],
7110,NCT05586542,Adverse events,Cost,2022-10-03,RECRUITING,INTERVENTIONAL,['PHASE1'],
7111,NCT05276778,Patients' acceptance of diabetic retinopathy screenings in general practice,,2022-02-28,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
7112,NCT02736253,The cases applied amputation(minor or major) and The cases applied major amputation,To Decide Independent Risk factors for AMPUTATION and - for MAJOR AMPUTATION.,2012-06,COMPLETED,OBSERVATIONAL,['NA'],
7113,NCT01154374,The incidence of complete healing of the target ulcer.,Absolute and percentage change in ulcer surface area from baseline to endpoint.,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
7114,NCT05086549,Rate of change in albuminuria (urine ACR),Rate of change in proteinuria (urine PCR),2021-09-29,COMPLETED,OBSERVATIONAL,['NA'],
7115,NCT05101135,Changes in HbA1c,,2021-11-17,UNKNOWN,INTERVENTIONAL,['PHASE3'],
7116,NCT03993990,Foot infection and recurrence of foot ulcer,Self-efficacy regarding diabetes-related foot ulcer self-management,2019-08-01,WITHDRAWN,INTERVENTIONAL,['NA'],
7117,NCT02674828,number of consecutive weeks step goal met,Habitual Total Weekday Activity Score,2016-02-01,COMPLETED,INTERVENTIONAL,['NA'],
7118,NCT01216618,Safety,Pharmacodynamic,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
7119,NCT00457938,"Project specific: improvement in serum triglycerides, insulin resistance, liver triglyceride content, liver volume, Hgb A1c,",,2006-04,COMPLETED,INTERVENTIONAL,['NA'],
7120,NCT00314379,Endothelial function by a non-invasive method of FMD,"Predefined in the protocol submitted to the EC approved prior to study beginning and the Inform Consent Form signed by all study participants prior to study related procedures, serum was preserved for the analysis of oxidative and inflammatory markers.",2006-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
7121,NCT01647438,Change in Saturated Fat (% of Daily Kilo-calories From Fat) Intake,,2012-08,COMPLETED,INTERVENTIONAL,['NA'],
7122,NCT05928637,Cmax,,2023-07-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
7123,NCT05870462,Changes in the mean frequency (%) of circulating ALDHhiSSClow primitive progenitor cells in individuals treated with semaglutide versus usual care for 6 months,Changes in the frequency (%) of circulating ALDHhiSSChi pro-inflammatory granulocyte precursors in individuals treated with semaglutide versus usual care for 6 months,2023-04-29,RECRUITING,INTERVENTIONAL,['PHASE4'],
7124,NCT05489536,Incidence of GDM,Physical Activity,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
7125,NCT03589092,GDM Identification,Clinical outcomes determination,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
7126,NCT01619059,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24,Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]),2012-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
7127,NCT03798717,Mean AUC (Area Under the Curve) Plasma [Glucose],Change in Inflammatory Status,2019-02-20,COMPLETED,INTERVENTIONAL,['NA'],
7128,NCT05593874,Clinical failure,Time-to-additional-intervention,2022-10-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
7129,NCT05188573,Clinical performance of test: Specificity,Stage Shift,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
7130,NCT00534014,To determine the optimal oral dose of vitamin C and E to reduce surrogate markers of atherosclerosis (blockages in blood vessels) following the consumption of an atherogenic high fat lunch in type 2 diabetic individuals.,"To study the effects of vitamin C on fibrinogen, insulin, glucose, PAI-1, adiponectin, free MDA, Oxy LDL,CRP, cholesterol, and FFA.",2006-01,COMPLETED,INTERVENTIONAL,['NA'],
7131,NCT04057339,Change in glycemic parameters,Change in hs-CRP,2019-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in mitochondrial structure and gene expression in skeletal muscle
7132,NCT03627455,MACE,,2003-01-01,COMPLETED,OBSERVATIONAL,['NA'],
7133,NCT04997460,Correlation of glycated hemoglobin and glycemic variability,Correlation of hypoglycemia and glycemic variability,2021-01-11,UNKNOWN,OBSERVATIONAL,['NA'],C-peptide concentration in different pregnancy trimesters
7134,NCT00036192,,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
7135,NCT01816672,Compare time to heal in Wagner 1 and 2 diabetic foot ulcers at 12 weeks treated with AutoloGel versus usual and customary care,Number of patients with adverse events as a measure of tolerability,2013-04,TERMINATED,INTERVENTIONAL,['NA'],
7136,NCT03451201,Endothelial Dependent Mediated Vascular Dilation,Endothelial independent vascular dilation,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
7137,NCT04705506,Markers of vascular calcification,,2017-02-05,COMPLETED,INTERVENTIONAL,['NA'],
7138,NCT03615755,Serum creatinine,,2016-12-27,COMPLETED,INTERVENTIONAL,['NA'],
7139,NCT00985842,Oxygen in tissue,,2009-11-01,COMPLETED,INTERVENTIONAL,['NA'],
7140,NCT03571217,choroidal thickness (CT),,2014-10-01,RECRUITING,OBSERVATIONAL,['NA'],
7141,NCT02820298,T1/2 (Apparent Terminal Elimination Half-life),,2016-06-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
7142,NCT02330939,postprandial incremental glucose AUC,,2014-06,UNKNOWN,INTERVENTIONAL,['NA'],
7143,NCT00106236,hemoglobin A1c,health-related QOL (Quality of Life),2003-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
7144,NCT01501877,Point prevalence abstinence from smoking,,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
7145,NCT03332836,Number of participants with adverse events,AUC of HM12460A,2017-10-25,TERMINATED,INTERVENTIONAL,['PHASE1'],
7146,NCT05555095,"Patient satisfaction, 1-item researcher generated question",,2022-09-26,RECRUITING,OBSERVATIONAL,['NA'],
7147,NCT06017544,MACE,,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],
7148,NCT03607799,Glucose area-under-the-curve (glucose AUC),Gestational diabetes mellitus,2020-11-26,RECRUITING,INTERVENTIONAL,['NA'],Maternal pregnancy complications
7149,NCT06035523,Percentage of index ulcers (the ulcers being treated in the study) healed at 12 weeks,Change in subjects reported pain levels (NPRS),2021-12-29,RECRUITING,INTERVENTIONAL,['NA'],Cost to closure
7150,NCT00494312,"Incidence of liver inflammation or injury greater than 3 times the upper limit of normal, as monitored by serum alanine aminotransaminase elevation.","Change from Baseline or greater than 1.5 times the upper limit of normal (whichever is greater) in the level of alanine aminotransferase, aspartate aminotransferase, total or direct bilirubin, alkaline phosphatase or gamma-glutamyl transpeptidase.",2000-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
7151,NCT00752180,Mean AUCins.0-12h and Cins.max,"PK endpoints: AUC0-4h, AUC0-6h, AUC6-12h,tmax, t½ and elimination rate constant.PD endpoints: AUCGIR0-4h, AUCGIR0-6h, AUCGIR6-12h, AUCGIR0-12h, GIRmax and tGIRmax .Safety endpoints: AEs, hematology, biochemistry, urinalyses, physical exam",2008-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
7152,NCT03855449,Task Analysis Wireframe Development part 2,,2019-06-05,RECRUITING,INTERVENTIONAL,['NA'],
7153,NCT02470039,Change in fasting plasma glucose (FPG),area under the serum insulin concentration-time curve,2015-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
7154,NCT05631119,collect biospecimen samples,,2022-12-15,COMPLETED,OBSERVATIONAL,['NA'],
7155,NCT02055014,Glycated haemoglobin (HbA1c),Weight,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],
7156,NCT02648204,Change in HbA1c,Change in Pulse Rate,2016-01-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
7157,NCT05768958,Ad libitum energy intake (KJ) after exercise compared with rest,Borg RPE,2023-03-22,RECRUITING,INTERVENTIONAL,['NA'],
7158,NCT03794232,Incidence of blood sugar reversal to normal after intervention,Body weight,2016-05-30,COMPLETED,INTERVENTIONAL,['NA'],
7159,NCT04755647,To measure the methemoglobin percent level during NORS compared to hypotonic saline administration in participants withe DFU,To measure the efficacy of NORS compared to placebo on the change in wound area in participants with DFU,2021-02-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
7160,NCT01529918,Patient's uptake and preferences,"The comparison of yield of actual diabetes detected from those who have high risk at self risk-assessment, compared to the usual diabetes detection rate in a random sample from the practice within a one year period.",2009-11,UNKNOWN,INTERVENTIONAL,['NA'],
7161,NCT00438698,Change in Fasting Glucose,Urinary C-peptide,2004-09,COMPLETED,INTERVENTIONAL,['NA'],
7162,NCT00802152,Hemoglobin A1c (HbA1c) or Systolic blood pressure (SBP),Patient-entered device data,2009-05,COMPLETED,INTERVENTIONAL,['NA'],
7163,NCT01182493,Between Group Difference in HbA1c When Comparing CSII to MDI,Safety - Diabetic Ketoacidosis Incidence,2010-12,COMPLETED,INTERVENTIONAL,['NA'],
7164,NCT06228898,changes in hematologic inflammatory markers with glycemic control,,2022-01-15,COMPLETED,OBSERVATIONAL,['NA'],
7165,NCT03595384,Participant Satisfaction With Overall Program,Waist Circumference,2018-04-29,COMPLETED,INTERVENTIONAL,['NA'],
7166,NCT01115088,"Effects of stevia, aspartame, and sucrose on food intake, satiety, and postprandial glucose and insulin levels.",Satiating effects by examining food consumption,2006-01,COMPLETED,INTERVENTIONAL,['NA'],
7167,NCT02712255,Physical activity,Physical activity,2016-03,WITHDRAWN,INTERVENTIONAL,['NA'],Habitual sedentary behavior
7168,NCT00757588,Adjusted Mean Change From Baseline in A1C Levels (Last Observation Carried Forward [LOCF]),Change From Baseline in Mean Total Daily Dose of Insulin (MTDDI) (LOCF),2008-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Reported and Confirmed Hypoglycemia
7169,NCT02413567,Device or procedure related Serious Adverse Events (SAEs) and Unanticipated Adverse Device Effects (UADEs),,2015-03-23,COMPLETED,INTERVENTIONAL,['NA'],
7170,NCT05579119,Change of the mean daily blood glucose levels during hospital,Mean length of stay in days in the hospital among different groups,2022-07-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
7171,NCT01177332,Intrahepatic lipid content (IHL) and hepatic ATP and PI concentrations,"Substrate oxidation and blood plasma levels of FFA, triglycerides, glucose and catecholamines",2010-04,COMPLETED,INTERVENTIONAL,['NA'],
7172,NCT04824586,Intraoperative level of glucose,Insulin quantities,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
7173,NCT03506776,change from baseline foot assessment as evidenced by a diabetic foot ulcer,change from baseline foot assessment evidenced by presence or absence of redness,2017-08-21,COMPLETED,INTERVENTIONAL,['NA'],
7174,NCT00879697,Total Walking Distance,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
7175,NCT04662398,Erectile dysfunction,,2020-12-05,COMPLETED,INTERVENTIONAL,['NA'],
7176,NCT02360527,"Retinal neurodegeneration among three groups of type 2 diabetic patients patients with AD, patients with MCI and patients without AD or MCI.",,2014-09,COMPLETED,OBSERVATIONAL,['NA'],
7177,NCT04029480,Number of Participants Who Discontinue Study Treatment Due to an AE over 54 weeks,Change from Baseline in FPG at 54 Weeks,2019-10-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
7178,NCT00150423,Safety Efficacy,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
7179,NCT01503892,Increased intraepidermal nerve fiber density,Subjective improvement,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],
7180,NCT02289235,Change in score of fatty liver in fibroscan,Number of patients with adverse events,2019-05-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
7181,NCT00263393,The proportion of individuals with correct knowledge about the effects of behavioural determinants of the risk of cardiovascular disease,The risk factor levels of the population identified as high risk.,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
7182,NCT00194909,"Our primary outcome will be a reduction in the weekly average 11 point Likert pain scale (0 - no pain, 10 - worst possible pain) at 8 weeks.","Secondary outcomes will include the Rand-36 quality of life scale, McGill visual analogue scale (VAS) and a sleep interference scale.",2004-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
7183,NCT04891315,Correlation of sVAP-1 levels with Fetal outcomes: Miscarriage,Correlation of sVAP-1 levels with patient characteristics: Medications at time of booking,2021-07-25,TERMINATED,OBSERVATIONAL,['NA'],
7184,NCT03170752,Proportion of patients who are comprehensively screened to the number of eligible patients seen in the intervention group compared to the control group as assessed by the completeness of CV Screening Checklist data collection form.,The patient and NP factors that influence participation in the CASP as assessed by content analysis of patient and NP feedback questionnaires.,2017-09-28,COMPLETED,INTERVENTIONAL,['NA'],
7185,NCT02023411,SUV Max on PET/CT Scan at 12 Months,Clinical Events,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
7186,NCT02535169,Changes in the oral disposition index measured by oral glucose tolerance test,,2014-05,COMPLETED,INTERVENTIONAL,['NA'],
7187,NCT00829660,A composite cardiovascular outcome defined as the time after randomisation to the first occurrence of any one of the following: -Cardiovascular death -Non-fatal MI -Non-fatal stroke -Hospitalisation for Unstable Angina -Hospitalisation for Heart Failure,"Resource use, costs and cost effectiveness",2009-02-17,COMPLETED,INTERVENTIONAL,['PHASE4'],
7188,NCT04237311,Semen quality assessment,Semen quality assessment,2020-05-01,UNKNOWN,OBSERVATIONAL,['NA'],
7189,NCT03170089,Patient awareness,Oral hygiene,2017-06-30,UNKNOWN,INTERVENTIONAL,['NA'],
7190,NCT01881919,Risk of getting hyperuricemia assessed by the measure of plasma uric acid.,Metabolomic and metabonomic profiling of blood plasma,2013-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Primary health assessment
7191,NCT00455325,Insulin Sensitivity,Triglycerides,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
7192,NCT00712439,The primary study objective is to assess the relative efficacy of G-ER versus placebo in reducing the mean daily pain score from the baseline week to end of efficacy treatment period (Treatment Week 4) in patients with DPN.,"Secondary efficacy measures will include changes from baseline in average daily sleep interference scores, SF-MPQ, BPI,NPS, PGIC, and CGIC.",2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
7193,NCT05365152,Time required for blood sugar to reach target,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],
7194,NCT00434772,glucose,hospitalisation days,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
7195,NCT02155023,difference between calibrated measurements and reference,evaluate necessary run-in procedures by assessment of error over time,2014-01,COMPLETED,INTERVENTIONAL,['NA'],Malfunction of the systems
7196,NCT03196024,Change in tobacco use,Support for healthy behaviors,2017-10-05,COMPLETED,INTERVENTIONAL,['NA'],
7197,NCT00005135,,,1991-09,COMPLETED,OBSERVATIONAL,['NA'],
7198,NCT00286624,• The proportion of recipients who develop alloantibodies directed at islet donor alloantigens during the first year after the first and any subsequent islet transplants.,• The impact of islet transplantation on the quality of life of transplant recipients.,2003-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
7199,NCT01306981,Best corrected visual acuity,Extent of retinal neovascularisation,2011-03-30,COMPLETED,INTERVENTIONAL,['PHASE4'],
7200,NCT06045598,Lumbal proprioception,Dynamic Balance,2023-09-10,RECRUITING,OBSERVATIONAL,['NA'],
7201,NCT03936023,"Relative hazard of composite outcome of Stroke, MI, and Mortality",,2017-09-22,COMPLETED,OBSERVATIONAL,['NA'],
7202,NCT02579395,Objective Physical Activity via accelerometer,Physical Activity Partner Investment Scale,2015-10,COMPLETED,INTERVENTIONAL,['NA'],
7203,NCT01535677,Maximum concentration (Cmax),Safety profile description in term of Safety Labs,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
7204,NCT01087086,Glucose Profile,Fatty Liver biomarkers / Non invasive liver scoring system.,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
7205,NCT05203471,Proportion of patients receiving guideline-concordant vascular and infectious disease care processes,Proportion of patients undergoing amputation,2023-02-16,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Patient retention rate
7206,NCT02435199,"The efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN), as assessed by the difference in the weekly mean of the 24 hour average pain score, using an 11-point Numeric Rating Scale (NRS).",The safety and tolerability of EMA401 in patients with PDN as measured by number and severity of adverse events.,2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
7207,NCT02089126,HbA1c Changes,,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],
7208,NCT01427257,Pharmacokinetics,Safety/Tolerability,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
7209,NCT01032629,"Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke",Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) to High-Density Lipoprotein-Cholesterol (HDL-C) Ratio at End-of-Treatment,2009-12-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
7210,NCT02042339,ICG (indocyanine green) video angiography,High performance 3D LifeViz™ system,2019-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],Endothelial progenitor cells
7211,NCT00882726,Safety and tolerability of a single IV or SC administration of CNTO 3649 in healthy participants; Safety and tolerability of multiple SC injections of CNTO 3649 in Type 2 Diabetic Patients,"Pharmacokinetics, pharmacodynamics and immunogenicity of CNTO 3649 following single and multiple administrations.",2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
7212,NCT01726777,"Change in plasma glucose concentration 2 hours after consuming 75g oral glucose (2 hour PC glucose, or 2hrPC glucose)",Correlation between changes in serum 25-hydroxy-vitamin D concentration (25(OH)D) and changes in 2 hour PC glucose,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Urinary calcium:creatinine ratio
7213,NCT06156137,The composite adverse outcomes,,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],
7214,NCT04441658,The changes in HbA1C level,The changes in blood glucose level,2020-04-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
7215,NCT00701155,Incidence of serious ADRs incl. major hypoglycemias,Variability in fasting Blood Sugar and average plasma glucose levels,2007-07,COMPLETED,OBSERVATIONAL,['NA'],
7216,NCT02305381,Change in HbA1c (Glycosylated Haemoglobin),HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target,2014-12-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
7217,NCT00796744,The Primary Efficacy Parameter Will be the Proportion of Ulcers Healed by 12 Weeks as Defined as 100 % Epithelialized With no Drainage.,The Time to Re-epithelialization of the Ulcer Site.,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
7218,NCT01181440,Proportion of patients with complete wound closure,Recurrence of the ulcer,1994-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
7219,NCT04938869,Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) survey score,Incidence of adverse events,2021-10-05,COMPLETED,INTERVENTIONAL,['NA'],
7220,NCT05874635,App engagement,,2023-05-11,RECRUITING,INTERVENTIONAL,['NA'],
7221,NCT02607345,the difference in glycemic index between 25gr. Zusto® and 25gr. Glucomedics®,,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
7222,NCT03847779,Changes in average spectral amplitude of the entire frequency range between baseline and after stimulus,,2019-02-04,COMPLETED,INTERVENTIONAL,['NA'],
7223,NCT01977560,Skeletal muscle insulin sensitivity,Skeletal muscle mitochondrial metabolites,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
7224,NCT04495881,HbA1c change,Glycated Albumin（GSA）change,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
7225,NCT05795309,Percentage time spent in glucose target (3.9-10mmol/L),Percentage time spent in hyperglycaemia (>10mmol/L),2023-08-16,RECRUITING,INTERVENTIONAL,['NA'],
7226,NCT00173940,,,na,UNKNOWN,OBSERVATIONAL,['NA'],
7227,NCT01441921,Changes from baseline in circulating levels of glucose and insulin according to the intervention arm,Changes from baseline in telomeric length of leukocytes (LTL),2011-09,COMPLETED,INTERVENTIONAL,['NA'],
7228,NCT05243238,MNSI score for neuropathy,,2020-03-01,COMPLETED,INTERVENTIONAL,['NA'],
7229,NCT05870670,"AUC0-24h,0130, SS: Area Under the NNC0519-0130 Plasma Concentration-Time Curve After the Last Dose in Each Treatment Period",Number of Treatment Emergent Adverse Events (TEAEs),2023-05-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
7230,NCT03544411,Change of malondialdehyde,Change of Glutahione,2018-07-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
7231,NCT00470418,Safety Assessments: Number of Participants With Adverse Events,Changes From Baseline in Clinical Measures of Cognition at Terminal Visit,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
7232,NCT05266261,Bone mineral density,Bone turnover markers,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],
7233,NCT00747968,steady glucose metabolism in the heart and brain during hyperglycemia with GLP-1-analogue infusion compared to placebo.,,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
7234,NCT01494298,ApoB Levels in African American Men With Diabetes and Those Without.,Lipoprotein a [Lp(a)] in African Americans With Diabetes and Without.,2011-12,COMPLETED,OBSERVATIONAL,['NA'],
7235,NCT00322257,HbA1c,Fasting plasma glucose,2006-05-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
7236,NCT03961347,Adverse Event and/or Serious Adverse Event,,2020-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
7237,NCT06188013,differential proteins of exosomes,,2024-01-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
7238,NCT04143321,Seattle angina questionnaire 1,Seattle angina questionnaire 5,2018-09-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Exercise tolerance test 3
7239,NCT00552734,Decrease in A1c of at least 0.4% in the insulin guidance software group as compared to the control group at 6 months and/or 1 year.,"Hypoglycemic episodes, weight gain, insulin dose, frequency of self monitoring of glucose",2005-07,COMPLETED,OBSERVATIONAL,['NA'],
7240,NCT03660189,Time to anion gap closure in hours,Total volume of intravenous fluids administered,2018-09-17,COMPLETED,INTERVENTIONAL,['NA'],
7241,NCT01257451,To evaluate the proportion of vildagliptin treated patients achieving HbA1c reduction and/or proportion reaching investigator defined target HbA1c relative to placebo,To assess the responder rates of patients treated with vildagliptin as compared to placebo,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
7242,NCT05726409,Satisfaction with the mobile application,Change in nutrition knowledge,2023-09,WITHDRAWN,INTERVENTIONAL,['NA'],
7243,NCT01002807,Blood samples to measure the pharmacokinetic parameters Cmax and AUC for the combination products versus each investigational product alone,"Safety and tolerability measures (adverse events, physical exams, vital signs, ECGs, and clinical laboratory assessments)",2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
7244,NCT02713555,Change from baseline diabetes status at 12 months after surgery,Assessment of changes in Glucagon levels from baseline,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
7245,NCT00102466,Change from baseline in HbA1c at 52 weeks,Patients with reduction in HbA1c >/= 0.5% after 52 weeks,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
7246,NCT02667327,Incidence of complete wound closure at Week 12 based on investigator assessment,Time in days to first complete wound closure of the target ulcer based on investigator assessment over the 12 week treatment period,2018-11-21,TERMINATED,INTERVENTIONAL,['PHASE3'],
7247,NCT04079660,fasting capillary blood glucose level,LOS,2021-02-01,COMPLETED,OBSERVATIONAL,['NA'],
7248,NCT00212290,Beta-amyloid in spinal fluid (sub-study),"Blood levels of insulin, insulin degrading enzyme, cortisol and inflammatory markers",2002-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
7249,NCT00755846,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 85.,Mean Percent Incidence of Marked Hyperglycemia (Fasting Plasma Glucose ≥ 200 mg/dL).,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
7250,NCT03067480,Time Spent in Target Range,,2017-06-06,TERMINATED,INTERVENTIONAL,['NA'],
7251,NCT05399134,Postprandial glycemic response of novel staple foods in Type 2 diabetics,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA'],
7252,NCT00711490,Change in Visual Acuity From Baseline to 6 Months,"Change in Fluid Leakage in the Macula of the Study Eye From Baseline to 12 Months, as Measured on Fluorescein Angiography (FA)",2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
7253,NCT01108120,The recurrence rate of diabetic foot ulcers,cardiovascular events during the follow up period,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
7254,NCT04665999,Insulin sensitivity computed using a Kalman filter-base algorithm embedding a model of glucose-insulin dynamics.,,2021-01-15,COMPLETED,OBSERVATIONAL,['NA'],
7255,NCT03601910,Cmax of CKD-380 and D308,,2018-07-16,UNKNOWN,INTERVENTIONAL,['PHASE1'],
7256,NCT05315037,Assess glucose response to different resistance training methods,To assess for correlation between lactate and glucose using different resistance training methods,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
7257,NCT04264793,Change in HbA1c,Change in Diabetes Treatment Satisfaction Score,2011-11-20,COMPLETED,INTERVENTIONAL,['NA'],
7258,NCT04537676,Quality of Life Score (ulcer-specific),,2020-09-15,UNKNOWN,OBSERVATIONAL,['NA'],
7259,NCT01635361,Operation of the NMS,Professional relationships,2012-08,COMPLETED,INTERVENTIONAL,['NA'],
7260,NCT03298295,Area of inflammation (mm2),Macrophage marker gene expression (fold change),2018-02-01,RECRUITING,INTERVENTIONAL,['NA'],
7261,NCT03464045,occurence of renal cancer,occurence of other urinary tract cancers,2016-11-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
7262,NCT00131664,Mean Change From Baseline in A1C at Month 6,Mean Change From Baseline in Adiponectin at Month 12,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
7263,NCT05772507,relative wound area reduction (RWAR),Nature and incidence of Treatment Adverse Effects as assessed in percentage for each dressing,2023-08-22,RECRUITING,INTERVENTIONAL,['NA'],
7264,NCT03204240,Change in beta cell function,Change in muscle fatigue,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],
7265,NCT02582242,Change in Glycosylated Haemoglobin (HbA1c),Change From Baseline in Patient-reported Treatment Satisfaction as Assessed by the Diabetes Treatment Satisfaction Questionnaire (Status) (DTSQs),2015-10-19,COMPLETED,INTERVENTIONAL,['PHASE4'],
7266,NCT00604669,Mortality,,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
7267,NCT03113448,Visual analog scale (0-100 mm.),Neuropathic Pain Scale (NPS),2017-01-19,COMPLETED,INTERVENTIONAL,['PHASE3'],
7268,NCT01680341,Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%),Number of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes,2012-08-31,COMPLETED,INTERVENTIONAL,['PHASE3'],
7269,NCT00001395,,,1994-03,COMPLETED,OBSERVATIONAL,['NA'],
7270,NCT04185558,Incidence of complete wound closure by 12 weeks,Number of patients showing a consistence wound closure post healing determination,2019-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
7271,NCT03144271,Number of Adverse Events,Morning fasting glucagon,2007-06-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
7272,NCT03280914,Control rate of hypertension,Medical cost,2017-08-01,COMPLETED,OBSERVATIONAL,['NA'],
7273,NCT04537884,Ocular and systemic safety and tolerability of a single intravitreal injection of UBX1325 evaluated by the incidence of dose limiting toxicities (DLTs) and treatment emergent adverse events (TEAEs),Plasma concentration of UBX1325 following a single intravitreal injection,2020-10-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
7274,NCT06327633,Change of olfactory brain activation by fMRI,Change of metabolism,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],
7275,NCT00585494,Prevalence of Hyperglycemia in the Elective Orthopedic Population,Prevalence of Adverse Outcomes in the Hyperglycemic Elective Orthopedic Population.,2007-12,COMPLETED,OBSERVATIONAL,['NA'],
7276,NCT05177172,Glucose tolerance,Subjective appetite variables,2021-12-01,COMPLETED,INTERVENTIONAL,['NA'],
7277,NCT05806190,Time spent in hypoglycaemia,Hospital Anxiety and Depression (HADS) Score,2023-04-17,COMPLETED,OBSERVATIONAL,['NA'],
7278,NCT05451147,OBJECTIVE PARAMETERS,SUBJECTIVE PARAMETERS,2018-09-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
7279,NCT01492959,Change in HbA1c (glycosylated haemoglobin),Adverse events: Serious and non-serious,2004-03-23,COMPLETED,OBSERVATIONAL,['NA'],
7280,NCT04082585,Correlation of Global Health Scores to Social Determinants of Health,Change from Baseline - HDL Cholesterol Ratio,2019-09-04,COMPLETED,OBSERVATIONAL,['NA'],
7281,NCT01924767,Assessment of Tolerability by Investigator,Serum Insulin,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
7282,NCT05736263,Comparison of CGM-derived percentage time in range (TIR) when temporary target is enabled or disabled during exercise,CGM-derived percentage time below range (TBR < 54 mg/dl) during and after exercise trials,2023-03-31,RECRUITING,INTERVENTIONAL,['NA'],Associations between sleep quality and glycemic variations
7283,NCT00727896,"Behavioural changes resulting in diet, better adherence to treatment.","Reduction in HbA1c, other glycemic measures and improvement in blood lipid parameters",2008-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
7284,NCT01178723,blood glucose balance,lipid profile,na,UNKNOWN,INTERVENTIONAL,['NA'],
7285,NCT00397631,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24,Change From Baseline in 2-hour PPG (Post-prandial Glucose) at Week 24,2006-12-19,COMPLETED,INTERVENTIONAL,['PHASE3'],
7286,NCT00906919,A1C,Cholesterol levels,2004-04,COMPLETED,INTERVENTIONAL,['NA'],
7287,NCT03155568,failure rate,Duration of motor blockade,2017-06-15,UNKNOWN,INTERVENTIONAL,['NA'],
7288,NCT00867594,To determine the safety and tolerability of multi-doses of Oramed oral insulin in people with type 1 diabetes,To determine if oral insulin is likely to improve glycemic stability assessed by the reduction of the frequency and severity of hypoglycemic episodes in people with unstable type 1 diabetes,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
7289,NCT03983499,HbA1c Blood Value,Generalized Anxiety Disorder 7-item (GAD-7),2015-07-16,COMPLETED,INTERVENTIONAL,['NA'],
7290,NCT03847701,MAGE comparison following 3 months of intake of a diet either high or low in SDS,Characterisation of the percent of compliance to H-SDS diet in free living conditions,2019-06-25,UNKNOWN,INTERVENTIONAL,['NA'],
7291,NCT00854113,VZ/F,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
7292,NCT01285245,insulin sensitivity as determined by euglycemic hyperinsulinemic clamp,insulin sensitivity as determined by euglycemic hyperinsulinemic clamp,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],
7293,NCT04564872,HbA1c Change From Baseline at Week 24,Percentage of Patients Required Use of Rescue Therapy or Dropout due to Hyperglycemia and Week 52,2020-11-13,COMPLETED,INTERVENTIONAL,['PHASE3'],
7294,NCT04322032,Cmax,,2020-04-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],
7295,NCT01221519,"Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of tmax of AZD1656.","pharmacodynamics of AZD1656 following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of AUC(0-4) for insulin",2010-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
7296,NCT02768987,Change from baseline in daily physical activity energy expenditure over 24 weeks,Change from baseline in push-up test over 24 weeks,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
7297,NCT01008345,level of oxidized LDL cholesterol at end of study,small dense LDL level,2008-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
7298,NCT05263401,Postprandial P-glucose,Differences in circulating concentrations of gastrin,2022-01-01,COMPLETED,INTERVENTIONAL,['NA'],
7299,NCT03940209,HbA1c,Health-related Quality of Life,2019-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
7300,NCT00335413,Changes in glomerular filtration rate,Changes in fractional albumin clearance,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
7301,NCT00296400,Urinary Protein/Creatinine Ratio at Week 52 [LOCF],Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
7302,NCT04515849,To assess the effects of cotadutide at different dose levels compared to placebo on UACR after 14 weeks,To evaluate the safety and tolerability of cotadutide compared to placebo by assessment of changes in ECG,2020-08-31,COMPLETED,INTERVENTIONAL,['PHASE2'],To assess the effects of cotadutide at different dose levels compared to placebo and semaglutide on rate pressure product
7303,NCT00684658,Pediatric Quality of Life Inventory (PedsQL),Diabetes Conflict,2008-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
7304,NCT01052714,Beck Anxiety Inventory (BAI) Mean Total Score Change Per Week From Baseline to Termination,,2010-09-01,COMPLETED,INTERVENTIONAL,['NA'],
7305,NCT03607448,System Performance,System Related Adverse Device Effects,2018-07-23,COMPLETED,OBSERVATIONAL,['NA'],
7306,NCT00361608,,,2008-07,WITHDRAWN,OBSERVATIONAL,['NA'],
7307,NCT04303468,Postprandial glycaemic response during a 2 hour oral glucose tolerance test (OGTT),Plasma glutamate concentration,2020-09-29,COMPLETED,INTERVENTIONAL,['NA'],
7308,NCT00468039,glycosylated hemoglobin (HbA1c)at Baseline and week 24,"Safety assessed by monitoring and recording all adverse events, serious adverse events.",2007-03-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
7309,NCT04853615,SGLT2i proves protective effect,SGLT2i is non inferior to allopurinol,2021-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
7310,NCT01826409,Glucose profiles during meal tolerance test,Change in lipid profiles,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
7311,NCT00728598,"Vitreous levels and serum levels of Fractalkine, VEGF, other growth factor.",,1998-01,COMPLETED,OBSERVATIONAL,['NA'],
7312,NCT00141076,Insulin sensitivity as measured by FS-IVGTT,Thermic effect of food,2003-10,COMPLETED,INTERVENTIONAL,['NA'],
7313,NCT03968380,Glucose Tolerance,Waist circumference,2020-10-13,UNKNOWN,OBSERVATIONAL,['NA'],
7314,NCT02859818,Self-efficacy evaluated with the 10 items-SEDM,"Outcome expectations, socio-structural factors and personal goals",2016-12,UNKNOWN,INTERVENTIONAL,['NA'],
7315,NCT02304497,PRF levels of insulin like growth factor -1 (IGF-1),,2013-03,COMPLETED,OBSERVATIONAL,['NA'],
7316,NCT01080976,Search Engine Preference,,2010-03,COMPLETED,OBSERVATIONAL,['NA'],
7317,NCT04379726,TASK 4: incidence of post-transplant diabetes in subjects without CFRD,TASK 3: variations of other respiratory and muscle-performance parameters,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA'],
7318,NCT04764786,the between-group difference in postprandial glycemia changes after the dietary interventions,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],
7319,NCT02898155,Rate of potentially avoidable admissions,Standardized Rate of potentially avoidable admissions,2016-06,COMPLETED,OBSERVATIONAL,['NA'],
7320,NCT00427154,Change in HbA1c,Change in body weight,2007-01-10,TERMINATED,INTERVENTIONAL,['PHASE3'],
7321,NCT04267601,Change of HbA1C,,2017-07-06,UNKNOWN,OBSERVATIONAL,['NA'],
7322,NCT00728351,HbA1c reduction after 24 weeks of treatment in patients with T2DM inadequately controlled with metformin monotherapy,Changes in the fasting lipid profile,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
7323,NCT04735042,Change from Baseline of total bacterial load,Triglycerides,2020-10-07,UNKNOWN,OBSERVATIONAL,['NA'],
7324,NCT03283657,Intent to treat questionnaire: Participant initiation of treatment to intensive lifestyle (ILI) or Metformin,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],
7325,NCT05074732,Reduction in violence,Improving overall functioning level,2019-12-01,RECRUITING,OBSERVATIONAL,['NA'],
7326,NCT00501878,Pupil diameters were measured.,blood pressure and heart rate were measured,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
7327,NCT03753087,Change in 6-minute walking distance (6MWD),Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) score,2019-01-16,COMPLETED,INTERVENTIONAL,['PHASE4'],
7328,NCT00690755,Alterations in PKC-zeta mRNA in Vastus Lateralis Skeletal Muscles,,2000-05,COMPLETED,OBSERVATIONAL,['NA'],
7329,NCT06203067,HbA1c,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
7330,NCT00340938,,,2004-11-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
7331,NCT02702011,Change From Baseline in 24 Hour UGE on Day 7,,2016-03-20,COMPLETED,INTERVENTIONAL,['PHASE2'],
7332,NCT06069583,Self-efficacy for diabetes management,Cost effectiveness (HbA1c),2024-01-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],"Experience with Support platform (Barriers, facilitators, satisfaction, fidelity) - Health Care Provider"
7333,NCT02814838,Area Under the Curve (AUC)(0-2 h) of C-peptide Response to the Mixed Meal Tolerance Test (MMTT) at Week 13,Proportion of Patients With HbA1c <7% and Absence of Episodes of Severe Hypoglycaemia From the Previous Visit in Patients With Screening C-peptide < Median Value,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
7334,NCT01858532,Time to the First Occurrence of a Component of the Composite Renal Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized),Time to the Cardiovascular Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized),2013-05-17,TERMINATED,INTERVENTIONAL,['PHASE3'],
7335,NCT06320756,Therapist Satisfaction feedback collected through 3 quantitative questions and 1 free text qualitative question on the app,Change in mental health distress as measured by the Diabetes Distress Scale (DDS-17),2024-02-23,RECRUITING,INTERVENTIONAL,['NA'],
7336,NCT02180152,Weight gain after postprandial walks in obese pregnant women.,,2015-03,WITHDRAWN,INTERVENTIONAL,['NA'],
7337,NCT02706977,Change in Visual Acuity assessed by the Standard Snellen Static Chart,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
7338,NCT00678145,Change in the counterregulatory responses to hypoglycemia compared to controls,Symptom scores,2008-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
7339,NCT00592241,Validate safety while using the ADI Insulin Pump by intended users. This objective will be assessed by independently and successfully carrying out a list of tasks.,Evaluate user's satisfaction.,2007-11,COMPLETED,INTERVENTIONAL,['NA'],
7340,NCT02356848,Ulceration,step count,2015-09-03,COMPLETED,INTERVENTIONAL,['NA'],
7341,NCT05169359,Change from pre-visit diabetes distress score at 1 week post visit,Promis,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],
7342,NCT04430660,Change in percent 13C enrichment of bicarbonate measured via carbon-13 magnetic resonance spectroscopy (13C-MRS),,2020-08-19,COMPLETED,INTERVENTIONAL,['NA'],
7343,NCT02459691,Change in weight from baseline,Clinically significant weight loss,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
7344,NCT06189638,Clinical response,Wound infection Score and Total Wound Score,2024-01-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
7345,NCT01777893,Incidence of type 2 diabetes,In a sub-group: Insulin Growth factor 2 (IGF-II) and IGF-II receptor (IGF2R),2013-06,COMPLETED,INTERVENTIONAL,['NA'],Direct and indirect costs.
7346,NCT02536768,HIV viral supression using lab data,,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
7347,NCT00511719,"Intra-patient and inter-patient comparison of CV % between treatments was based on a t-test.for bioavailability (ie, SI AUC0-540 min) & bioeffect (ie, GIR AUC0-540 min)","Safety variables included adverse events (AEs), clinical laboratory tests, HbA1c, pulmonary function tests, electrocardiograms, vital signs, physical examinations, and diabetes-specific signs",2004-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
7348,NCT04107935,Change From Baseline in Glycemic Control,Change From Baseline in Medication Adherence Across 3 Month Intervals for 12 Months,2020-02-04,TERMINATED,INTERVENTIONAL,['NA'],
7349,NCT00470860,Knowledge related to blood pressure and lipid management for diabetes patients,,2004-12,COMPLETED,INTERVENTIONAL,['NA'],
7350,NCT02423434,Comparison of Manual versus Automated Image analysis,Determination of the Factors associated with CCM Parameters and their Longitudinal Change,2014-09,COMPLETED,OBSERVATIONAL,['NA'],
7351,NCT04282395,Change from baseline in depressive symptoms at 24 months,Change from baseline in social support at 12 months,2020-01-25,RECRUITING,INTERVENTIONAL,['NA'],
7352,NCT00467649,The Percentage of Patients Achieving HbA1c <=7% at Week 24 With no Gain in Body Weight From Baseline and no Incidence of Severe Hypoglycemia,Phase 2: Change in Body Weight at Week 36,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4'],Hypoglycemia Adverse Events
7353,NCT06279637,Glycemic Control (Hemoglobin A1C [HbA1C]),,2024-03-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
7354,NCT05029583,Prevalence of presumed advanced NASH based on biochemical and FibroScan results,Health-related quality of life by study arm,2021-08-11,RECRUITING,INTERVENTIONAL,['NA'],
7355,NCT02985853,Capillary Blood Glucose,,2008-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
7356,NCT00574405,"Change in Mixed-meal-stimulated Peak C-peptide Value (Via Mixed-meal Tolerance Test) After 12 Months of Insulin Pump Therapy, Compared With MDI.",Patient Satisfaction With Mode of Therapy and Patient Compliance With Treatment Recommendations.,2005-04,COMPLETED,INTERVENTIONAL,['NA'],
7357,NCT01749020,Determine if the consumption of DC rich in polyphenols can induce a change in insulin sensitivity,Determine if the consumption of DC rich in polyphenols can induce a change in high sensitivity CRP,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
7358,NCT00996645,Primary Disease-Related Outcomes: mean BP and mean LDL level.,Efficacy of intervention,2010-07,COMPLETED,INTERVENTIONAL,['NA'],
7359,NCT01135446,Total 24-hour Urinary Glucose Excretion as a Measure of Pharmacodynamic Effect,Dapagliflozin and Dapagliflozin 3-O-glucuronide (Metabolite of Dapagliflozin) Concentrations to Characterize Dapagliflozin Pharmacokinetics,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
7360,NCT06112691,The accuracy,The percent of false positive detection of DR,2022-02-01,RECRUITING,OBSERVATIONAL,['NA'],
7361,NCT02757937,Change in Diabetes Self-Efficacy Scale Score from Baseline to 4 Months,Change in glycated haemoglobin (HbA1c) from Baseline to 6 Months,2016-05,COMPLETED,INTERVENTIONAL,['NA'],
7362,NCT03406923,Change in diabetes control,Experiences and perceptions of the intervention processes and outcomes,2018-12-04,COMPLETED,INTERVENTIONAL,['NA'],
7363,NCT04035395,Rate of Change in Hemoglobin A1c,Rate of Change in Self-efficacy: Diabetes Self-Efficacy Scale,2016-09-29,COMPLETED,INTERVENTIONAL,['NA'],
7364,NCT01605773,Triglyceride levels post standardised fat tolerance test,Change in FPG (fasting plasma glucose),2001-11-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
7365,NCT00905528,Change in eGFR after 1 year,,2002-01,COMPLETED,OBSERVATIONAL,['NA'],
7366,NCT04540016,"Area under the concentration-time curve (AUC0-t, AUC0-∞)",,2020-11-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
7367,NCT03374020,The level of agreement between NOTAL-OCT and commercial OCT in detecting fluid in the 10 central degrees of the macula.,,2017-01-17,COMPLETED,OBSERVATIONAL,['NA'],
7368,NCT02204280,"The urine UbA52 levels in 30 patients with type 2 diabetic mellitus,30 patients with diabetic nephropathy，30 patients with proteinuria due to nondiabetic renal disease and 30 healthy persons",,2014-08,COMPLETED,OBSERVATIONAL,['NA'],
7369,NCT00700648,Incidence of SAEs (serious adverse event),Other safety & efficacy measures,2008-03,COMPLETED,OBSERVATIONAL,['NA'],
7370,NCT03338023,Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus®),Rate of Documented Symptomatic Hypoglycemia,2018-03-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
7371,NCT06305286,Number of Participants who are insulin-independent post- first and final transplant,Number of Participants with glycosylated hemoglobin (HbA1c) <7.0%,2024-03-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in variability after final islet cell transplant and years after discontinuation of AT-1501
7372,NCT01597531,Type 2 diabetes remission,First Phase Insulin secretion,2012-06,TERMINATED,INTERVENTIONAL,['PHASE4'],
7373,NCT00989976,diabetes risk as assessed by disposition index,,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
7374,NCT03445377,Sensor Glucose readings within target range,Total daily insulin dose,2018-07-16,COMPLETED,INTERVENTIONAL,['NA'],
7375,NCT05585697,Plasma concentration of Osteocalcin,trabecular separation distance,2022-10-07,COMPLETED,OBSERVATIONAL,['NA'],
7376,NCT04945161,"Primary endpoint:Q-RT-PCR, for the inflammation stage and the remodeling stage",Secondary endpoint (5): wound reduction rate of each target gene in each group,2021-02-23,COMPLETED,INTERVENTIONAL,['NA'],Safety endpoint(3):Change from baseline in laboratory tests
7377,NCT01445951,Change From Baseline to Week 24 in HbA1c,Proportion of Responders Achieving HbA1c <= 7.0%,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Severe Hypoglycemia Event Rate
7378,NCT06290544,Prevalence of cardiovascular disease in type 1 diabetes patients,Stratify type 1 patient by glucose control using HbA1c and Ambulatory Glucose Profile metrics.,2021-11-29,RECRUITING,INTERVENTIONAL,['NA'],
7379,NCT00525304,Medical service use patterns,Quantitative and qualitative survey ratings,2007-09,COMPLETED,INTERVENTIONAL,['NA'],
7380,NCT01370707,Change from baseline in HbA1c at week 24,Glycemic variability,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
7381,NCT04263376,Changes in human gut microbiota,,2019-04-24,COMPLETED,OBSERVATIONAL,['NA'],
7382,NCT05335863,Areas under the glucose metabolism curve for the determination of the glycemic index,,2021-11-03,COMPLETED,INTERVENTIONAL,['NA'],
7383,NCT01977391,"All-cause and cardiovascular mortality in elderly Korean men and women according to BMI, waist circumference, and presence of diabetes",Survival probability among study populations,1999-08,COMPLETED,OBSERVATIONAL,['NA'],
7384,NCT04450563,Percentage of time of plasma glucose levels spent in target range (placebo vs empagliflozin 5 mg),Rise in ketone level between interventions,2020-11-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
7385,NCT01657318,,,2012-09-01,TERMINATED,OBSERVATIONAL,['NA'],
7386,NCT00806897,Change in HbA1c from baseline,Change in body weight,2009-01,COMPLETED,OBSERVATIONAL,['NA'],
7387,NCT03862547,intracavernous p75NTR,"clinical staging of ED and NGF,TrKa,p75NTR",2019-01-30,UNKNOWN,INTERVENTIONAL,['NA'],
7388,NCT01289990,Changes From Baseline in HbA1c (%) After 76 Weeks of Treatment,Fasting Plasma Glucose Change From Baseline After 76 Weeks of Treatment,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
7389,NCT04337723,ABI/WIFI adoption,ABI/WIFI sustainability,2020-03-10,COMPLETED,INTERVENTIONAL,['NA'],
7390,NCT02306122,Duration of Nonadherence Event,Probability of Pharmacist Action Triggered,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
7391,NCT00577590,Percent Change in Plasma Triglycerides,,2003-10,COMPLETED,INTERVENTIONAL,['NA'],
7392,NCT04988594,Changes from baseline in parameters associated with glucose homeostasis,Changes in oxidative stress parameters,2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],
7393,NCT02501161,Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification,Change in TRIM-D,2016-01-31,COMPLETED,INTERVENTIONAL,['PHASE3'],
7394,NCT02045290,Change in insulin resistance (IR) from baseline to 13 weeks,Change in Adipose IR from baseline to 13 weeks,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
7395,NCT00869102,Insulin secretion,,2009-05,WITHDRAWN,INTERVENTIONAL,['NA'],
7396,NCT04944316,24-hour Carbohydrate to Insulin Ratio,Interleukin (IL) - 1 (IL-1) and interleukin-6 (IL-6),2022-01-19,COMPLETED,INTERVENTIONAL,['NA'],Diet Acceptability
7397,NCT03979768,Number of Participants with undiagnosed type 2 diabetes,Explore if there was any difference in the number of participants with a high risk of developing type 2 diabetes in the risk test only (RTO)- group and the group that also offered a HbA1c-measurement (HbA1c-group),2016-09-15,COMPLETED,INTERVENTIONAL,['NA'],
7398,NCT04631159,Change from baseline HbA1c through a mobile app.,The number of participants who have related every day steps as assessed by Mi Smart Band 4.,2020-05-01,UNKNOWN,INTERVENTIONAL,['NA'],
7399,NCT04888390,Oxygen consumption (VO2),MEP (maximal exspiratory pressure),2021-04-20,RECRUITING,INTERVENTIONAL,['NA'],
7400,NCT01680211,Change in Blood Sugar and lipid profiles,Clinical laboratory evaluations,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
7401,NCT01535105,Frequency of Impaired Glucose Homeostasis among obese adolescents in high risk diabetes prone population,Description of the metabolic profile in obese adolescents,2012-08,UNKNOWN,OBSERVATIONAL,['NA'],
7402,NCT01945216,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Fasting Blood Glucose,2010-07-08,COMPLETED,OBSERVATIONAL,['NA'],
7403,NCT03563794,blood glucose,hypoglycemia,2018-06-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
7404,NCT04869800,Cmax of CKD-398,Vd/F of CKD-398,2021-05-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
7405,NCT03600116,Identification of Volatile Organic Chemical Indicators of Hypoglycemia,,2018-05-24,COMPLETED,OBSERVATIONAL,['NA'],
7406,NCT01785771,Change in HbA1c between Week 39 and Day 0,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
7407,NCT02305199,Postoperative glucose level,Postoperative Stress hormone level,2015-01-01,WITHDRAWN,INTERVENTIONAL,['NA'],
7408,NCT05302050,Change in HbA1c,Significant change in HbA1c,2022-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
7409,NCT01475435,Evaluate level change of oxidative stress biomarkers in crevicular gingival fluid and whole saliva on diabetes type 2 individuals,,2011-08,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
7410,NCT01552811,Difference in pancreatic uptake of % injected dose (ID) [11]5-hydroxy tryptophan between healthy volunteers and patients with long-standing type 1 diabetes,,2012-03,COMPLETED,OBSERVATIONAL,['NA'],
7411,NCT00694278,,,2008-06,UNKNOWN,OBSERVATIONAL,['NA'],
7412,NCT01490658,NN4440 (2/500) Cmax (maximum plasma concentration) combination tablet,Vital signs,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
7413,NCT00194896,Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months.,Patients Positive for T Cell Responses to Islet Proteins at 36 Months.,2000-02,COMPLETED,INTERVENTIONAL,['NA'],
7414,NCT02583919,Change in HbA1C,"Safety and Tolerability will be assessed by determining the incidence, severity, dose-relationship adverse-effects, and changes in laboratory evaluations within each dose cohort",2015-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
7415,NCT05658744,Behavior change,,2019-12-25,COMPLETED,INTERVENTIONAL,['NA'],
7416,NCT03007186,Blood glucose measurements,Insulin level,2016-10,COMPLETED,OBSERVATIONAL,['NA'],Result of oral glucose tolerance test
7417,NCT01042301,Identification and characterization of new CD8+ T lymphocytes related to type 1 diabetes and its evolution (2009-2012),Identification and characterization of new profiles of humoral and cellular markers (including T cell reactivity and miRNA) related to type 1 diabetes (2010-2014).,2007-09,COMPLETED,INTERVENTIONAL,['NA'],
7418,NCT00865683,Insulin sensitivity,Interleukin-6 (IL-6),2009-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],
7419,NCT00732602,plasma-glucagon Area Under Curve at 0-90 min. and 90-180 min.,,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
7420,NCT02686281,Number of Participants with Serious and Non-Serious Adverse Events,Area Under the Concentration-Time Curve,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1'],
7421,NCT03215069,Baseline-adjusted ISSI-2 at 48-weeks,Glucose tolerance status at 48-weeks,2018-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of life at 48 weeks
7422,NCT05521061,HbA1C levels,Total daily dose of insulin,2022-05-28,RECRUITING,INTERVENTIONAL,['NA'],
7423,NCT01339390,Change in Weight (From Baseline),,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
7424,NCT04903496,"The proportion of non-diabetic patients with established cardiovascular disease, or chronic kidney disease, or at high cardiovascular risk among all non-diabetic patients","Serum creatine concentration (μmol/L) at the latest visit for all patients, as well as the trends for inpatients over time (2015, 2017, and 2019 respectively)",2021-09-06,COMPLETED,OBSERVATIONAL,['NA'],
7425,NCT03323281,Measuring memory,Measuring memory,2019-12-07,RECRUITING,OBSERVATIONAL,['NA'],Measurement of cognition by the Mini Mental State Examination (MMSE)
7426,NCT02212158,Change in Baseline HA1c at 12 months post baseline,Change from baseline in Children's Hope Scale at 60 weeks,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],
7427,NCT04669912,Changes in percentage of time spent in range 70-180 mg/dL during second month of lockdown compared to before lockdown,Evolution of glucose sensor use compared to before lockdown.,2021-01-15,COMPLETED,OBSERVATIONAL,['NA'],
7428,NCT00562172,Glucose Homeostasis and glycemic control status,"Insulin resistance parameter, Hypoglycemic episode, symptomatic, Weight change, Lipid profile, Inflammatory markers (CRP, Adiponectin, etcs), Patient satisfaction with diabetes treatment, Urine analysis, Creatinine",2007-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
7429,NCT03334370,Change of the proportion of patients who have achieved a HbA1c <7.5%.,"Service utilization outcomes measured by hospital attendance rates at baseline and 12, 24, 36 and 48 months after enrollment.",2010-09,COMPLETED,OBSERVATIONAL,['NA'],
7430,NCT02057848,Plasma glucose,,2011-07,COMPLETED,INTERVENTIONAL,['NA'],
7431,NCT03332849,Number of participants with adverse events,AUC of HM12470,2015-07-28,UNKNOWN,INTERVENTIONAL,['PHASE1'],
7432,NCT03787836,Exercise responders following additional exercise program,Body mass index,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],
7433,NCT01217892,Adjusted Mean Change in HbA1c Levels,"Proportion of Participants With HbA1c<7.0% at Week 16, in Participants Who Had HbA1c ≥7.0% at Baseline.",2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
7434,NCT06037551,Analysis of system accuracy based on DIN EN ISO 15197,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
7435,NCT02235584,The potentiating effects of GLP-1 on second phase insulin response when clamped at at bloodsugar of 7 mmol/l,Second phase insulin response to GIP infusion at 7mmol/l,2009-07,COMPLETED,INTERVENTIONAL,['NA'],Total insulin response to arginine infusion
7436,NCT04589533,Variation in fasting glycemia between the two groups of Centres during phase 3 of the study,Description of characteristics of patients with T2DM hospitalized in Internal Medicine,2019-09-19,UNKNOWN,OBSERVATIONAL,['NA'],
7437,NCT00875290,Reduce blood glucose variability among 0-3 year old children with type I diabetes.,Number of adverse events,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],
7438,NCT03704818,Digit Symbol Substitution Performance Response to Hypoglycemia,,2018-10-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
7439,NCT00326196,The Hypothesis Being Tested is That a Strategy of Initial Surgical Revascularization is Superior to Percutaneous Intervention in Preventing Death or Myocardial Infarction in Diabetics With Severe Ischemic Heart Disease Assessed up to 4 Years.,,2006-07,TERMINATED,INTERVENTIONAL,['PHASE4'],
7440,NCT06199505,Change in HbA1c,Change from baseline in ADA and Nab,2023-11-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],Change from Baseline in Body Weight
7441,NCT05259644,Change in Body Weight,Change in fasting blood glucose,2022-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Change in the IWQOL (The Impact of Weight on Quality of Life) questionnaire
7442,NCT03141710,Change of oral glucose tolerance test (OGTT),Change of fermentation markers,2017-05-10,UNKNOWN,INTERVENTIONAL,['NA'],
7443,NCT03130894,type 2 diabetes,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],
7444,NCT01142050,ITT; insulin dosage; Hemoglobin A1c; Fast blood glucose (FBG) and Postmeal blood glucose (PBG); C-peptide levels; Serum Insulin levels;,Serious adverse event frequency and severity,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],
7445,NCT03973827,Delta-change of C-peptide AreaUnder the Curve (AUC) (0-120 min) for Mixed Meal Tolerance Test (MMTT) at day 372 following WJMSC infusion when compared to test performed before start of treatment.,"Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372.",2019-05-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
7446,NCT03769883,Pancreatic beta-cell function (Per protocol),Satiety,2018-12-12,UNKNOWN,INTERVENTIONAL,['NA'],Fat tissue metabolic function
7447,NCT04233034,C-peptide,DKA,2020-07-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
7448,NCT02711839,HbA1c After Intervention,Triglyceride After Intervention,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
7449,NCT02810613,"A collection of samples for the purpose of (bio)medical laboratory assays including immunological, metabolic, transcriptional or biological analyses.",,2016-05-31,WITHDRAWN,OBSERVATIONAL,['NA'],
7450,NCT01620333,Area under the insulin aspart curve in the interval from 0 to 24 hours (BIAsp 70),Adverse events,2000-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
7451,NCT01892020,2-hour PPG (Postprandial Plasma Glucose) Increment Following a Standard Meal Test,Incidence of AEs (Adverse Event),2013-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
7452,NCT05676034,To assess the safety and tolerability of AMX0035in adult participants with Wolfram syndrome,To evaluate the effect of AMX0035 on HbA1c levels,2023-03-03,RECRUITING,INTERVENTIONAL,['PHASE2'],
7453,NCT03617757,Incidence of DM,Capacity of the studied population to join intensive lifestyle intervention,2017-10-01,COMPLETED,INTERVENTIONAL,['NA'],
7454,NCT01758380,Percentage of patients experiencing at least one Hypoglycaemic Event (HE) during the Ramadan fasting period to test superiority,"Number of patients with treatment emergent adverse events (AEs), serious AEs, discontinuation due to AEs, deaths or laboratory abnormalities as assessment of safety and tolerability",2013-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
7455,NCT02691897,HbA1c,Number of patients with adverse events,2019-07,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
7456,NCT06190938,"The Demographic characteristics were classified into four groups: Gender, Financial status, Educational level, and Profession.",,2022-06-23,COMPLETED,OBSERVATIONAL,['NA'],
7457,NCT00604344,HbA1c,Insulin antibodies,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
7458,NCT04836221,Feasibility of an active management strategy for comorbidities,Provider perspectives on acceptability of active management of comorbidities,2021-05-05,COMPLETED,INTERVENTIONAL,['NA'],Preliminary changes in social support
7459,NCT00487162,Wound Infection,Hemodynamic Instability,2007-06,TERMINATED,INTERVENTIONAL,['NA'],
7460,NCT02229396,Change in HbA1c From Baseline to Week 28,Change in Systolic Blood Pressure From Baseline to Week 28,2014-09-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
7461,NCT04984200,Overall agreement between the results from multiple EyeArt operations,,2021-07-13,COMPLETED,OBSERVATIONAL,['NA'],
7462,NCT01324505,Area under the levonorgestrel concentration-time curve,Percentage of subjects experiencing adverse events,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
7463,NCT02091336,fetal growth,insulin requirements to achieve glucose targets,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],need of c section
7464,NCT02131701,improvement in physical fitness,changes in body composition,2006-10,COMPLETED,INTERVENTIONAL,['NA'],changes in muscle strength
7465,NCT00797524,Retinal leakage and retinal thickness.,,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
7466,NCT03755960,Visual analogue Scale (VAS) general complaints and pain,neurophysiological assessment of Nervus Suralis height of amplitude of action potential,2019-03-02,COMPLETED,INTERVENTIONAL,['NA'],
7467,NCT03068078,"Glycemic control, dyslipidemia and metabolic markers",Gut dysbiosis,2016-11,COMPLETED,INTERVENTIONAL,['NA'],
7468,NCT01148680,ß score evaluation 6 months after first infusion (group 1 'immediate registration on infusion waiting list') or 6 months after inclusion (group 2: 'delayed registration on infusion waiting list'),Evaluation of side effects and iatrogenic effects,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
7469,NCT01511835,OGTT,Number of newborn infants requiring Neonatal Intensive Care (NIC),na,UNKNOWN,INTERVENTIONAL,['PHASE4'],
7470,NCT01678820,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Percentage of Participants With A1C Level <7% at Week 16,2012-10-10,TERMINATED,INTERVENTIONAL,['PHASE3'],
7471,NCT05546281,"Forced food categorization task according to the categories ""healthy / unhealthy""",Type 1 Diabetes Distress Scale (T1-DDS),2022-10-01,RECRUITING,OBSERVATIONAL,['NA'],
7472,NCT02875782,Self-reported 7-day point-prevalence smoking abstinence,Self-reported quit attempt numbers over the past 12 months.,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
7473,NCT01816633,Time to heal,Number of patients with adverse events as a measure of tolerability,2013-10,TERMINATED,INTERVENTIONAL,['NA'],
7474,NCT02214017,Glycemia,Lipids,2011-10,COMPLETED,INTERVENTIONAL,['NA'],Blood Pressure
7475,NCT00340678,Number of Participants With Decline in GFR,Glomerular Volume,1995-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
7476,NCT00372814,Metabolic Control: Hemoglobin A1c (HbA1c),"Regimen Adherence: Diabetes Management Scale (DMS), Twenty-Four Hour Recall Interview, Glucose Meter Downloads",2007-03,COMPLETED,INTERVENTIONAL,['NA'],
7477,NCT01643031,"Rate of elevation of troponin or CK-MB (above the upper limit of normal, and above 3 times the upper limit of normal) measured 20-24 hours after the PCI.","Rate of major adverse cardiovascular endpoints including death, myocardial infarction or urgent target vessel revascularization at 30 days",2012-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
7478,NCT04082884,Percentage of Time in Target Range of 70-180 mg/dL.,Average Sensor Glucose Level,2020-06-25,COMPLETED,INTERVENTIONAL,['NA'],
7479,NCT01968668,Change of urinary albumin-to creatinine ratio,Change in serum potassium concentration,2013-10-28,COMPLETED,INTERVENTIONAL,['PHASE2'],
7480,NCT00220207,Hemoglobin A1c,,2003-09,COMPLETED,INTERVENTIONAL,['NA'],
7481,NCT00949351,Assess short-term safety of the combination of aliskiren 300 mg/valsartan 160 mg /enalapril 20 mg in patients with diabetic nephropathy,Change of Urinary TGFb1 compare to baseline,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
7482,NCT03645421,Number of Patients Who Experienced Adverse Events (AEs),Number of Patients With Antidrug Antibody (ADA) Response to MEDI0382,2018-08-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
7483,NCT05692934,Pharmacokinetics parameters of Metformin in the fast and fed state: AUC0-inf (if applicable),The incidence and severity of adverse events/serious adverse events,2023-01-31,COMPLETED,INTERVENTIONAL,['PHASE1'],
7484,NCT00236379,Change in the Disposition Index derived from the Frequently Sampled Intravenous Glucose Tolerance Test (which shows how the body regulates glucose),Changes in measurements of metabolism and glucose regulation; changes in results of tests and questionnaires evaluating the effectiveness and safety (including laboratory tests and anthropomatic measurements) of medications used to treat schizophrenia,na,COMPLETED,INTERVENTIONAL,['PHASE4'],
7485,NCT05156736,Burden of atherosclerotic plaque assessed via coronary computed tomography angiography,Incidence of hypertension in mm Hg measured by Omron digital BP apprataus,2023-03-15,RECRUITING,OBSERVATIONAL,['NA'],
7486,NCT03413215,Composite primary endpoint,Composite secondary endpoint,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],
7487,NCT00427271,glomerular filtration rate,,2003-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
7488,NCT00296374,Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.,Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
7489,NCT02800252,Periodontal pockets with mean probing depth (PD) ≥5mm,Plaque index (%),2016-06,UNKNOWN,INTERVENTIONAL,['NA'],Glycated hemoglobin
7490,NCT04496921,Change in serum vitamin K levels from baseline at 6 months,Glycemic marker levels,2020-08-10,WITHDRAWN,INTERVENTIONAL,['NA'],
7491,NCT01439178,"intraocular VEGF levels (pg/ml) in both groups (measured in aqueous humor), using multiplex beads immunoassay",,2011-08,UNKNOWN,INTERVENTIONAL,['NA'],
7492,NCT01916265,AUCGlucose of different glucagon dosages given s.c.,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
7493,NCT03371108,Treatment-induced Anti-Insulin Antibody (TI-AIA) is the Primary Endpoint,Efficacy - HbA1c Control,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE3'],
7494,NCT00073268,,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
7495,NCT01855321,Percentage of improvement in Glycemic control after Vitamin D therapy.,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
7496,NCT04256460,Change of BMI from baseline at 12 months,Change of Low density lipoprotein cholesterol from baseline at 12 months,2019-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change of C-reaction protein from baseline at 12 months
7497,NCT00602914,Blood samples for PK and PD will be collected,"Feedback from study participants and staff on their overall impression with the MicronJet device, using questionnaires",2008-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
7498,NCT01098994,Demonstrate the presence of HDL dysfunction among individuals with the Haptoglobin 2/1 and 2/2 compared to those with the Hp 1/1 phenotype and improvement in HDL dysfunction with natural d-α-tocopherol supplementation,Assessment of adherence to the clinical trial study protocol in a random sample of individuals with type 1 diabetes recruited from the ACR and CHP/EDC Diabetes Registries,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
7499,NCT02640118,PPG excursions measured as incremental area under curve (iAUC),"glucagon, gastrin, cholecystokinin, GIP, GLP-1, oxyntomodulin",2015-08,COMPLETED,INTERVENTIONAL,['NA'],
7500,NCT02864212,Invasive blood pressure,,2014-09,UNKNOWN,OBSERVATIONAL,['NA'],
7501,NCT00655330,urinary albumin excretion or proteinuria at week 48,,2008-05,UNKNOWN,INTERVENTIONAL,['NA'],
7502,NCT00768040,"Change From Baseline in Central Retinal Thickness in Patients With Type 1 or Type 2 Diabetes, After 12 Weeks of Treatment",,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
7503,NCT03921593,Quantification of Quality of Life,Estimate cost-effectiveness of pancreas transplantation,2018-11-04,UNKNOWN,OBSERVATIONAL,['NA'],
7504,NCT02915250,Delta AUC BG 0-2h (area under the blood glucose concentration-time curve),Hypoglycaemic events,2016-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
7505,NCT00748137,24 hours BGL > 8.3mmol/l (CGMS),HbA1c,2008-03,UNKNOWN,INTERVENTIONAL,['NA'],
7506,NCT01435707,fasting blood glucose,visual analogue scale of subjective pain,2011-09,COMPLETED,INTERVENTIONAL,['NA'],
7507,NCT02587104,"The proportion of product related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events",Cost effectiveness of treatment of dHACM,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
7508,NCT01798420,Hemoglobin A1C LEVEL,Glucose levels,2012-04,COMPLETED,OBSERVATIONAL,['NA'],Weight
7509,NCT00656864,Change in incretin-mediated insulin secretion and receptor regulation of glucose-dependent insulinotropic peptide (GIP) in patients with type 2 diabetes.,Change in adipocyte GIP receptor mRNA expression levels.,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
7510,NCT05369052,Vital signs - heart rate,Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators,2022-05-03,RECRUITING,INTERVENTIONAL,['PHASE3'],
7511,NCT04457531,Mean maximal nerve conduction velocity,low density lipid Protein cholesterol (LDL-C).,2020-10-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],"Amino acids, lipid metabolites, vitamins, neurotransmitters and other metabolites"
7512,NCT00366132,Time to Complete Wound Healing,"o Durability of wound closure (i.e., status of wound at one week following determination of ""healed"")",2006-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
7513,NCT00994253,"The primary objective is to assess the effect of a multimodal drug therapy regimen including the renin inhibitor Tekturna (aliskiren), an ACE inhibitor, and a calcium channel blocker on coronary flow reserve (CFR) in hypertensive Type II diabetics.","Secondary measures include evaluation of serum and urine biomarkers related to endothelial function, the renin-angiotensin system, oxidative stress, and inflammation.",2009-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
7514,NCT04677699,Diagnosis of Celiac Disease,Severity of disease at diagnosis,2020-12,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
7515,NCT06065852,Facilitate translational and epidemiological research,,2009-11-06,RECRUITING,OBSERVATIONAL,['NA'],
7516,NCT03792646,Postural Balance (sway velocity) change from baseline,Inflammatory biomarkers - plasma concentration change from baseline (Tumor necrosis factor-alpha),2018-05-01,UNKNOWN,INTERVENTIONAL,['NA'],
7517,NCT00001313,,,1992-05-10,COMPLETED,OBSERVATIONAL,['NA'],
7518,NCT00920582,Mean Change From Baseline in HbA1c Between Teplizumab and Placebo,Number of Participants With Serious Adverse Events,2009-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
7519,NCT00751842,Meal Stimulated C-peptide (area under the curve),Insulin Dose,2008-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
7520,NCT02895867,Change in Hemoglobin A1C (A1C),Change in c-reactive protein level,2016-05,COMPLETED,INTERVENTIONAL,['NA'],
7521,NCT00667732,The Percentage of Intent to Treat Participants Randomized and Treated in Each Arm Who Had Lab-measured A1c <6.5% at 24 Weeks of Treatment,The Percentage of Per Protocol Participants Randomized and Treated in Each Arm Who Had Lab-measured A1c <6.5% at 24 Weeks of Treatment,2007-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
7522,NCT01861392,Postural balance training diabetic type 2,Quality of life of diabetics type 2,2013-05,UNKNOWN,INTERVENTIONAL,['NA'],
7523,NCT01184768,Number of subjects with new diagnosis of type 2 diabetes,Effect of vitamin D status on glucose tolerance,2008-01,COMPLETED,OBSERVATIONAL,['NA'],
7524,NCT06259318,Optimism,,2023-06-21,COMPLETED,INTERVENTIONAL,['NA'],
7525,NCT02140424,Rate of bone mineral accrual,Change bone microarchitectural parameters in patients with diabetes vs. controls,2013-08,RECRUITING,OBSERVATIONAL,['NA'],Association of bone mineral accrual with moderate-to-vigorous physical activity
7526,NCT00824694,Principal endpoints will be measured 48 weeks after group assignment and include the number of medication changes and HbA1c. Interim analysis will include HbA1c measurement at 3 mont intervals.,"Secondary endpoints include changes in patient attitudes toward SMBG, daily carbohydrate consumption, physical activity level, BMI, and medication compliance (for subjects on OHA).",2009-03,COMPLETED,INTERVENTIONAL,['NA'],
7527,NCT05943899,Association between SGLT2i intake and hepatic fibrosis,,2020-02-01,COMPLETED,OBSERVATIONAL,['NA'],
7528,NCT01067924,Change in physical activity as measured by the GODIN physical activity questionnaire,"Change in Hemoglobin A1C, BMI, six minute walk-test, QoL, and self-efficacy.",2009-09,COMPLETED,INTERVENTIONAL,['NA'],
7529,NCT02317835,Detection of hot spots on a foot thermal map image,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
7530,NCT01046318,Clinical laboratory tests,Changes in fasting blood glucose (FBG) from baseline to each visit (OC) and Week 52 (LOCF),2009-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
7531,NCT06057077,change in HA1c and mounts of insulin of basal and bolus which will be taken daily is the same or decreased after one year of follow up,the change in weight after follow up of one year,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
7532,NCT01410773,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/-15mg/dL(<75 mg/dL) or Within +/- 20% (>=75 mg/dL) of Laboratory Glucose Method,Number of Alternative Site (AST) Palm Blood Glucose (BG) Results Within +/- 15mg/dL (<75mg/dL) or Within +/- 20% (>=75mg/dL) of Laboratory Glucose Method,2011-07,COMPLETED,INTERVENTIONAL,['NA'],
7533,NCT05674981,Change from baseline in Cys-C (Cystatin C) level at 6 months,Change from baseline in gut microbiota at 6 months,2023-04-24,RECRUITING,INTERVENTIONAL,['NA'],
7534,NCT00812578,Insulin secretion and insulin resistance,"Glycemic control, lipid status, inflammatory markers, BMD",2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
7535,NCT01058733,physicians' labour time and frequency of contact with the online communication system required for reviewing the patients' information and sending recommendations,,2006-10,COMPLETED,INTERVENTIONAL,['NA'],
7536,NCT06256172,"5 readings of Respiratory Data (FEV1, FVC, FEV1/FVC ratio) in L using the Respiratory unit in Medlink is acquired and the average value is reported.",,2023-06-16,COMPLETED,INTERVENTIONAL,['NA'],
7537,NCT05654142,"Assess changes in weight at baseline 0, 6, 12,24 and 52",,2023-04-17,RECRUITING,INTERVENTIONAL,['NA'],
7538,NCT00308373,,,2004-07,COMPLETED,INTERVENTIONAL,['NA'],
7539,NCT01443741,Variation in HbA1c,Severe hypoglycemia over 6 months and quality of life,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
7540,NCT02685345,change in 24 hour weighted mean glucose,change in derived glucagon AUC,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
7541,NCT04490941,Glycated haemoglobin (HbA1c),triglyceride concentration,2020-07-22,RECRUITING,INTERVENTIONAL,['NA'],
7542,NCT02121483,t1/2,Change From Baseline in 8-point Plasma Glucose Profile Over 24 h After Study Drug Intake,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
7543,NCT05422807,Change in Body Mass Index (Weight Status) at 6 months and at 12 months,Waist circumference (weight status),2011-04,COMPLETED,INTERVENTIONAL,['NA'],Teen Quality of Life
7544,NCT02623998,Number of Participants With Severe Hypoglycemic Episodes,Change in Waist Circumference,2016-07-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
7545,NCT02815722,The area under the plasma concentration-time curve (AUC) of Simvastatin,The number of volunteers with adverse events as a measure of safety and tolerability,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
7546,NCT00837577,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12,2009-02-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
7547,NCT01863914,Primary patent rate of AV fistula,Composite outcome measurement of the overall shunt-related complication rate,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Composite outcome measurement of systemic pro-inflammatory response
7548,NCT01814267,Assess the incremental cost-effectiveness ratio from the french health system perspective,Assess acceptability of telemedicine care (compliance and satisfaction) for patients and nurses.,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
7549,NCT04271709,Proportion of Subjects with Visual Acuity Worse than 20/40,,2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
7550,NCT02222506,Safety and tolerability of the KLOX BioPhotonic System in patients with diabetic foot ulcers.,Wound volume reduction over time.,2013-04,COMPLETED,INTERVENTIONAL,['NA'],Impact of treatment on Health-related quality of life.
7551,NCT01304225,Incidence of severe visual loss after 1 year,Retinal sensitivity,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],
7552,NCT03121027,Anemia,,2011-05-11,COMPLETED,OBSERVATIONAL,['NA'],
7553,NCT01009138,Depressive Symptoms (CES-D Score),Health-care Costs: Medication Intake,2009-11,COMPLETED,INTERVENTIONAL,['NA'],
7554,NCT00865345,Glucose Sensor Accuracy When Compared to Laboratory Standard (YSI-Yellow Springs Instruments),Device Related Moderate or Device Related Severe Adverse Events,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
7555,NCT00683020,Changes in the Mental Component Summary of the SF-12 Health Survey,Changes in Diastolic Blood Pressure (DBP),2009-04,COMPLETED,INTERVENTIONAL,['NA'],
7556,NCT01862263,Percentage of patients with hyperglycemic events evaluated with CGM,"Number of patients with adverse events, serious adverse events and death as evaluation of safety and tolerability of coadministration of vildagliptin with insulin",2013-05,TERMINATED,INTERVENTIONAL,['PHASE4'],
7557,NCT02813161,Death,Patient Reported Outcome,2015-02,RECRUITING,OBSERVATIONAL,['NA'],
7558,NCT00741390,"Difference in Lancing Pain for Device Pair at Visit 2. (For Subjects Assigned to Arms A, B, C Only)",Reported Device Preference Within Lancing Pair at Visit 2,2008-08,COMPLETED,INTERVENTIONAL,['NA'],
7559,NCT03509454,The microvascular function by estimating the glycocalyx thickness,peripheral neuropathy,2016-04-01,COMPLETED,OBSERVATIONAL,['NA'],
7560,NCT02405260,Change in HbA1c (Glycosylated haemoglobin),Pulse,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
7561,NCT00537719,Change from baseline of the time to 50% gastric emptying (gastric emptying t½) of the solid and liquid components of a meal at 72 hours after dosing in healthy volunteers.,Exploratory correlation of % contents remaining in stomach after a meal.GSK716155 concentration before meal & at the time gastric emptying is complete. Safety and tolerability parameters each visit.,2007-12-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
7562,NCT00928005,Cardiovascular structure and function,Body composition,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
7563,NCT04949152,MACE,,2016-06-01,RECRUITING,OBSERVATIONAL,['NA'],
7564,NCT00564395,Assess the Mean Area Under the Curve (AUC) for Blood Glucose Concentration in Subjects Treated With Either Insulin Detemir Mixed With Rapid Acting Insulin (RAI) or Insulin Detemir and RAI as Separate Subcutaneous Injections,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
7565,NCT05670379,Adverse events,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
7566,NCT01915264,Incidence of severe hypoglycemia or documented symptomatic or asymptomatic hypoglycemic events reported as adverse events,Number of patient with adverse event (Tolerability),2015-08,WITHDRAWN,OBSERVATIONAL,['NA'],
7567,NCT04633642,Change From Baseline Myofibroblasts Formation (Myofibroblasts Content) at 6 Weeks,Wound Size,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],
7568,NCT05814965,hs-CRP,,2023-04-05,RECRUITING,INTERVENTIONAL,['NA'],
7569,NCT02203084,Albumin/creatinine ratio,,2014-09-01,COMPLETED,OBSERVATIONAL,['NA'],
7570,NCT00008801,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
7571,NCT04665284,Number of participants reported adverse events,Frequency of participants achieved FBS level within normal range,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Mean score of diabetes mellitus quality of life
7572,NCT01692028,HOMA-IR,Blood pressure,2012-02,COMPLETED,OBSERVATIONAL,['NA'],
7573,NCT03411460,Satisfaction of patient-determined hospital care at discharge in the two groups,Number of hypoglycmic events with the corresponding glucose level,2017-04-19,TERMINATED,INTERVENTIONAL,['NA'],
7574,NCT00553280,Summary of Adverse Events,Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
7575,NCT01890876,Glucose tolerance,Cardiovascular fitness,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
7576,NCT06315127,Donor milk supplementation and exclusive breastfeeding rate at 4 months,Exploring donor milk supplementation and head circumference measurements,2023-11-28,RECRUITING,INTERVENTIONAL,['NA'],Exploratory outcome: exploring donor milk supplementation and maternal cortisol concentrations
7577,NCT02437084,Insulin Secretion Rate Area Under the Curve (ISR-AUC),OGTT Insulin AUC,2015-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
7578,NCT00167115,Fasting plasma HDL cholesterol,Episodes of hypoglycemia,2004-12,COMPLETED,INTERVENTIONAL,['NA'],
7579,NCT00519727,safety and tolerability,Pharmacokinetic profile all doses and Pharmacodynamics for multi-dose groups.,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
7580,NCT02648685,the proportion of basal/post-prandial blood glucose contributed to the overall glycaemia(HbA1c),,2015-11-30,COMPLETED,OBSERVATIONAL,['NA'],
7581,NCT00569998,Evaluation of overall pen preference,Adverse events,2003-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
7582,NCT00160485,Newborn birth weight,Incidence of neonatal metabolic derangement,2004-06,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
7583,NCT01537445,Kidney function,Kidney hemodynamics and oxygenation,2012-02,UNKNOWN,OBSERVATIONAL,['NA'],
7584,NCT01778348,"Time spent overnight in the target glucose range (3.9 to 8.0 mmol/l), as assessed by adjusted continuous subcutaneous glucose monitoring (CGM)",Episodes of symptomatic hypoglycaemia,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Utility Evaluation
7585,NCT00699426,insulin secretion,blood pressure,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
7586,NCT01967589,Number of treatment emergent adverse events (TEAEs) recorded,Change in body weight,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
7587,NCT02573519,Difference in total gastrointestinal transit time between diabetic patients and healthy subjects,Difference in regional transit times in diabetic patients´s 3D-transit before and after Malone antegrade continence enema,2015-10,TERMINATED,INTERVENTIONAL,['NA'],
7588,NCT04608058,Change in Self-management behavior,Change in Glycated hemoglobin A1c,2019-07-30,COMPLETED,INTERVENTIONAL,['NA'],
7589,NCT05144984,Change in HbA1c,Number of treatment-emergent adverse events (TEAEs),2021-11-29,COMPLETED,INTERVENTIONAL,['PHASE2'],
7590,NCT03890588,Number of Patients With Referral to Nephrology,,2019-04-17,COMPLETED,INTERVENTIONAL,['NA'],
7591,NCT02450097,Change from baseline in fasting serum insulin in 6 months.,,2013-12,COMPLETED,INTERVENTIONAL,['NA'],
7592,NCT04782934,Incidence of sensor failure,Post explantation follow-up,2021-02-25,COMPLETED,INTERVENTIONAL,['NA'],"Assessment of influence of interference substances (i.e. ethanol, lactate, ketones, paracetamol, acetylsalicylic acid, sorbitol, fructose, aspartame, ibuprofen, caffeine and ascorbic acid [Vitamin C])"
7593,NCT01747967,Correlation between residual insulin secretion and T-cell responses against beta-cell antigens.,Correlation between residual insulin and glucagon secretion.,2011-11-15,COMPLETED,INTERVENTIONAL,['NA'],
7594,NCT02044718,The number of participants with preventable adverse events,Quality of the chart review,2011-11,COMPLETED,OBSERVATIONAL,['NA'],
7595,NCT02072551,Mean insulin secretion output,glucago secretion output,2012-12,UNKNOWN,OBSERVATIONAL,['NA'],
7596,NCT03249506,Incidence Rate of the Composite of All-cause Mortality (ACM) or Hospitalization for Heart Failure (HF),Percentage of Participants With Below Knee Lower Extremity (BKLE) Amputation,2016-05-12,COMPLETED,OBSERVATIONAL,['NA'],
7597,NCT05292066,Toronto clinical neuropathy score,,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
7598,NCT05764629,Hemoglobin A1c (HbA1c),Adverse events,2021-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
7599,NCT01827280,Change from Baseline in microcirculation function at 30 days,Change from Baseline in endothelial function at 30 days,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4'],Change from Baseline in incretins and inflammation markers at 30 days
7600,NCT03738982,"Change in the percentage of time spent in hypoglycaemia (glucose level below 3, 9 mmol/L or 70 mg/dl)",Evaluation of usability and the treatment satisfaction of PEPPER system by using non-validated questionnaires.,2018-01-09,COMPLETED,INTERVENTIONAL,['NA'],
7601,NCT02500628,Heart Rate Variability (Frequency Domain),Number of Patients Reporting Side Effects From the Medication,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
7602,NCT04570735,Correlation between morphometric and functional and metabolic biomarker data obtained by magnetic resonance spectroscopy (MRS) in 3 different patient groups,Correlation between metabolic MRS biomarkers and urine and plasma metabolites quantification.,2020-10-07,UNKNOWN,OBSERVATIONAL,['NA'],
7603,NCT04477928,"Demonstrated feasibility of large-scale population screening, as evidenced by:",Assessment of costs associated with implementation of study compared to potential impacts on cost and quality of life.,2020-07-17,RECRUITING,OBSERVATIONAL,['NA'],
7604,NCT01312207,visual acuity change after surgery,Optical coherence tomography findings,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],
7605,NCT02811874,HbA1c,Weight,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
7606,NCT00461136,To evaluate the time-course of the antiproteinuric effect of renin inhibition with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established nephropathy.,To investigate whether there is a change on biomarkers of inflammation and cardiovascular risk.,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
7607,NCT04662879,Earlier detection of pancreatic ductal adenocarcinoma (PDAC),Depression and Anxiety as early indicators,2021-10-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
7608,NCT01273558,RTG values using the MMTT and the stepwise hyperglycemic clamp methods,Rate of Urinary glucose excretion (UGE) during the MMTT and the hyperglycemic clamp procedure,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
7609,NCT01093794,Cmax for Sitagliptin and Metformin,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
7610,NCT03301792,Effect of Diabetes Group Care on postpartum weight retention,Psychosocial Stress and Depression,2017-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
7611,NCT01053793,Glycemic response,Bioavailability of polyphenols from potatoes,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
7612,NCT05368623,To determine the sensitivity and specificity of RETINA-AI Galaxy v2.0 for diabetic retinopathy screening in the primary care setting.,,2022-11-03,COMPLETED,OBSERVATIONAL,['NA'],
7613,NCT03970772,Changes in glucose values from baseline to 30 minute,"Coefficient of Variation, by CGM",2019-04-15,COMPLETED,INTERVENTIONAL,['NA'],
7614,NCT06191328,HbA1c,Serum lipid profile,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
7615,NCT00221455,"Clinical Outcome Measures: HbA1c, LDL,and the presence or absence of clinically significant proteinuria.",Technology Adoption will be measured by tracking the patient usage of the various portal features,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
7616,NCT00659828,Weight,Bone Mineral Density,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
7617,NCT00690235,Weight Loss With Pramlintide in Persons With Schizophrenia Who Have Gained Weight Taking Olanzapine or Clozapine,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
7618,NCT02579655,"Composite rate of all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, need for coronary revascularization, hospitalizations for chronic disease-related ambulatory care sensitive conditions",Overall health care costs,2015-11,COMPLETED,INTERVENTIONAL,['NA'],
7619,NCT00494663,"1. The primary efficacy endpoint will be change from baseline to the end of treatment (Study Visit 6, Week 16) in HbA1c","1. Change from baseline to Week 8 in total and LDL-cholesterol (LDL-C) 2. Change from baseline to the end of treatment (Week 16) in the following : Seated blood pressure (systolic, diastolic and mean arterial pressure) Fasting blood glucose",2007-07,TERMINATED,INTERVENTIONAL,['PHASE2'],
7620,NCT02097342,To study the effect of Linagliptin on insulin sensitivity by performing euglycemic hyperinsulinemic clamp in patients with type 2 diabetes mellitus.,To study the effects of Linagliptin on glycemic control and beta cell function in patients with type 2 diabetes mellitus 6 months,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],To study the effect of voglibose on glucagon like peptide1 (GLP1) secretion and insulin resistance in patients with type 2 diabetes mellitus 6 months
7621,NCT02628392,change in HbA1c,change in triglyceride,2015-11,COMPLETED,INTERVENTIONAL,['NA'],
7622,NCT03001583,Weight loss,Weight loss,2019-10-30,WITHDRAWN,INTERVENTIONAL,['NA'],
7623,NCT04879758,"Changes in Calories Burn between baseline and 4-week post-intervention, and between baseline and 6-month follow-up","Changes in Self-reported Psychological Status between baseline and Immediate post-intervention, between baseline and 4-week post-intervention, and between baseline and 6-month follow-up",2021-07-07,RECRUITING,INTERVENTIONAL,['NA'],
7624,NCT03552757,Participants Who Achieve (Yes/no): Body Weight Reduction ≥5% - Semaglutide 2.4 mg Versus Placebo,Change in Calcitonin - Semaglutide 2.4 mg Versus Placebo,2018-06-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
7625,NCT00607347,Correlation of area under curve (AUC) up to 24 hour time point of atenolol plasma drug concentrations and glucose/insulin values obtained from OGTT and triglycerides,"HDL-cholesterol, fatty acids, total cholesterol",2008-02,COMPLETED,INTERVENTIONAL,['NA'],
7626,NCT04124211,Safety of FMT,Blood chemistry panel,2019-08-25,UNKNOWN,INTERVENTIONAL,['NA'],
7627,NCT03538743,Number of Participants With Abnormal Electrocardiogram (ECG) Interval,Renal Clearance (CLr) of PF-06882961 on Day 28,2018-06-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
7628,NCT00339885,"T2D status, quantitative traits measurements",,1996-06-01,COMPLETED,OBSERVATIONAL,['NA'],
7629,NCT00445354,hemoglobin A1c,diabetes medications,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
7630,NCT05294536,Area under the plasma concentration-time curve from time zero to time t (AUC0-t),"Adverse Event, Serious Adverse Event",2020-06-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
7631,NCT05872711,Change of time in range (TIR) 70-180 mg/dl after following a LCD or a MD in adolescents with T1DM.,Change in LDL cholesterol,2023-04-19,RECRUITING,INTERVENTIONAL,['NA'],
7632,NCT01144975,"Safety assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, daily fasting blood glucose measured by the subject using a glucose monitor, and treatment-emergent adverse events.","Anti-diabetic activity measured by HbA1c, FPG, OGTT, C-peptide, and insulin collected at time points specified in the protocol.",2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
7633,NCT06305208,Change in the number and dose of anti-diabetic medications,Changes in health-related quality of life scores (EuroQol-5D-5L),2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],
7634,NCT04864327,HbA1c,BP(systolic and diastolic blood pressure),2011-05-05,COMPLETED,INTERVENTIONAL,['NA'],
7635,NCT01065337,"The patient is alive, the patient has not undergone any major amputation, complete primary wound healing has been achieved, no ipsilateral relapse has occurred",Rate major amputations Rate of patients with complete ulcer healing Rate of treatment related complications Improvement of ankle brachial index (ABI) Improvement of transcutaneous oxygen partial pressure (TcPO2) Improvement of local perfusion,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
7636,NCT01475461,Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12,Number of Participants With Abnormal Laboratory Values,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
7637,NCT01285232,"To determine the effect of anakinra on insulin secretion, as derived from hyperglycemic clamps .",Effects of anakinra on fat cell morphology and gene expression,2011-01,UNKNOWN,INTERVENTIONAL,['NA'],
7638,NCT03309007,Change in Leucocyte LC3 Score,,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
7639,NCT02101229,Time spent in blood glucose range [70-180 mg/dl],time spent below 70 mg/dl and above 180 mg/dl,2014-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
7640,NCT05267925,Homeostatic Model Assessment of Insulin Resistance,Blood urea nitrogen (BUN),2022-01-08,TERMINATED,INTERVENTIONAL,['NA'],PROMIS-29 Health-related Quality of Life
7641,NCT03042442,Rate of patients with loss of > 5% body weight,"Assessing the survival rate by phone-calls follow-up every 6 months, up to 2 years",2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],
7642,NCT01792206,The change in brachial artery Flow Mediated Dilataion with paracalcitol (1mcg/day)compared with placebo for 3 months.,Biomarker Measurement,2009-09,UNKNOWN,INTERVENTIONAL,['NA'],
7643,NCT05789550,The prevelance of H PYLORI Infection in type 2 DM,,2023-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
7644,NCT01397942,Insulin sensitivity,Urine and blood samples,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
7645,NCT02147860,DiAs time within target,,2014-05,COMPLETED,INTERVENTIONAL,['NA'],
7646,NCT03311516,The ratio of normoglycemia values to total glucose values,Usability of the insulin pump,2019-10-10,UNKNOWN,INTERVENTIONAL,['NA'],
7647,NCT03010683,"Differences in Endothelial Glycocalyx Thickness at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.",Endothelial Glycocalyx and Coronary Flow Reserve.,2015-11,COMPLETED,INTERVENTIONAL,['NA'],
7648,NCT05343884,Diagnostic Failure,Secondary end-points,2022-03-15,RECRUITING,INTERVENTIONAL,['NA'],
7649,NCT02868606,Transfer to intensive care unit (y/n),In-hospital death (y/n),2015-07,COMPLETED,OBSERVATIONAL,['NA'],
7650,NCT00703235,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
7651,NCT03688919,Change From Baseline in Youth Future Orientation (Objective Measure) at 8 Weeks (Z-score),Change From Baseline in Self-Care Inventory Revised at 8 Weeks (Z-score),2019-05-13,COMPLETED,INTERVENTIONAL,['NA'],
7652,NCT01819922,Cardiopulmonary Exercise Test: Oxygen Uptake Efficiency Slope (OUES): 1 Hour 40 Minute Post-dose,Plasma Metabolomic Profiles Before and Immediately Following Steady State and Incremental Exercise,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
7653,NCT04226027,Change in HbA1c value,PAID Score,2020-01-17,UNKNOWN,INTERVENTIONAL,['NA'],
7654,NCT01171703,Occlusion of the stent or bypass,Restenosis measured by Duplex Ultrasound or CTA,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
7655,NCT04256005,Area Under the Curve following second Carbohydrate load measured by continuous glucose monitoring,Mean Heart Rate (HR) during the exercise trials,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],
7656,NCT03407599,"AUC(IAsp),0-12h, area under the serum insulin aspart concentration-time curve from 0 to 12 hours",Number of hypoglycaemic episodes,2018-01-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
7657,NCT04930679,Fasting blood glucose,,2018-11-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
7658,NCT05508490,prevalence of acute kidney injury in diabetic ketoacidosis,,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
7659,NCT05745090,Composite endpoint based on first occurrence of all-cause death or cardiovascular events,All-cause hospitalization,2022-11-10,RECRUITING,OBSERVATIONAL,['NA'],Proportion of study subjects with reduced left ventricular diastolic function
7660,NCT01567254,Blood glucose values before and after listening to the recording.,"The delta of HA1C between before and after three months of periodic listening to auditory guided imagery, compared to listening to music.",2012-04,COMPLETED,INTERVENTIONAL,['NA'],
7661,NCT01619592,Quality of Life (QoL),,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
7662,NCT00238498,Change from baseline in HbA1c at 12 weeks,Change from baseline in HOMA IR at 12 weeks,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
7663,NCT01782547,Change in Hemoglobin A1c,Change in Diabetes Knowledge,2013-06,COMPLETED,INTERVENTIONAL,['NA'],Telehealth intervention satisfaction
7664,NCT05253768,Percentage of change in weight compared with baseline.,Safety of FMT,2024-03,RECRUITING,INTERVENTIONAL,['PHASE2'],
7665,NCT00876980,HbA1C,Fasting glucose & fructosamine microalbuminuria blood pressure lipids endothelial function,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
7666,NCT01127308,Number of Participants Experiencing an Adverse Event (AE),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
7667,NCT01484262,Diabetes-related quality of life assessed by ADDQoL (Audit of Diabetes-Dependent Quality of Life),Total cost of patient education,2011-11-14,COMPLETED,OBSERVATIONAL,['NA'],
7668,NCT00681460,newborn weight,"parameters of metabolic control in mother and newborn, insulin resistance, inflammatory reaction, oxidative stress, fetal growth,",2008-05,COMPLETED,INTERVENTIONAL,['NA'],
7669,NCT00978796,The primary objective of this pilot study is to compare 24-hour blood glucose values (overnight and pre- and post- prandial glucoses) in adult subjects with type 1 diabetes receiving either sitagliptin or placebo,Time spent in hypoglycemic and hyperglycemic excursions recorded on the DexCom STS continuous glucose monitor (CGM) at 3 time periods throughout the study,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
7670,NCT00155454,Recurrent vitreous hemorrhage rate,,2004-09,COMPLETED,INTERVENTIONAL,['NA'],
7671,NCT03838783,Time in range within 6 hours,Change in TRIM-D Score,2018-05-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],
7672,NCT06286566,Number of complication,Valuation of patient satisfaction,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
7673,NCT01923688,Incidence of Severe Hypoglycemia,,2011-08,COMPLETED,INTERVENTIONAL,['NA'],
7674,NCT04755660,Physical activity,Hemoglobin A1c,2021-03-15,COMPLETED,INTERVENTIONAL,['NA'],
7675,NCT01327209,,,2010-12,COMPLETED,OBSERVATIONAL,['NA'],
7676,NCT00939276,Percentage of patients who develop macular edema within 90 days following cataract surgery,Mean change in best-corrected visual acuity (BCVA) from baseline to Day 90,2009-08,TERMINATED,INTERVENTIONAL,['PHASE3'],
7677,NCT05054712,To describe the prevalence of metabolic liver diseases (NAFLD and GH) by different diagnostic approaches in the population of patients with T1D.,To study the relationship between metabolic liver diseases in patients with T1D and the presence of microvascular and macrovascular complications.,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA'],
7678,NCT00632008,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
7679,NCT05694520,The incidences of adverse maternofetal outcomes,Change from baseline the inflammatory factors at 2 months,2023-06-10,RECRUITING,INTERVENTIONAL,['NA'],
7680,NCT04494139,Healthy food intake,Systolic Blood pressure,2020-11-01,UNKNOWN,INTERVENTIONAL,['NA'],
7681,NCT01387633,blood pressure,Self-monitoring of blood glucose,2011-06,UNKNOWN,INTERVENTIONAL,['NA'],
7682,NCT06048757,Change in daily insulin dose requirement,App usability,2023-08-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
7683,NCT00491023,,,2007-02,COMPLETED,OBSERVATIONAL,['NA'],
7684,NCT02126423,Kirby Bauer disc diffusion antimicrobial susceptibility,,2014-05,COMPLETED,OBSERVATIONAL,['NA'],
7685,NCT06040164,Change in 2-oleoyl-glycerol (2-OG) levels in saliva and plasma,Oral health impact profile,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
7686,NCT00994812,Miscarriage rates,Effects of metformin versus placebo on the rates of gestational diabetes during pregnancy,2002-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
7687,NCT04589325,Residual insulin secretion,HbA1c,2022-11-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in International Physical Activity Questionnaire (IPAQ) scores from baseline and week 52.
7688,NCT05331586,Excessive gestational weight gain,Pelvic Floor and sexual disorders during pregnancy,2022-07,UNKNOWN,INTERVENTIONAL,['NA'],
7689,NCT00673621,AUCF 0-360 min of serum insulin,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
7690,NCT01541956,Change from baseline in hemoglobin A1c(HbA1C) after 24 weeks of treatment with vildagliptin,"Number of patients with adverse events, serious adverse events and death",2012-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
7691,NCT04536480,Change in total body fat mass (kg),Change in BMI in excess of the 95th percentile (%BMIp95),2023-04-15,RECRUITING,INTERVENTIONAL,['NA'],Adult eating behavior Questionnaire
7692,NCT05353686,Primary endpoint,,2019-02-25,COMPLETED,INTERVENTIONAL,['PHASE2'],
7693,NCT04639726,Post-prandial glycemic excursion.,Beta-cell function II,2020-09-28,COMPLETED,INTERVENTIONAL,['NA'],Plasma peptide
7694,NCT02551900,Change from baseline in cutaneous blood flow,Change from baseline in Peripheral arterial stiffness,2014-09-01,COMPLETED,INTERVENTIONAL,['NA'],
7695,NCT05942079,Change in adherence to treatment,,2022-09-15,RECRUITING,OBSERVATIONAL,['NA'],
7696,NCT01101204,Antiinflammatory effects of combined antidiabetic and hypolipemic treatment,Coagulation parameters,2012-07,UNKNOWN,INTERVENTIONAL,['NA'],
7697,NCT03362151,Delta glucose (maximum rise from baseline glucose) mg/dL,percent time glucose <70 mg/dL,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],
7698,NCT03004612,Change from basal fasting and post2h OGTT glucose levels at 12 and 24 months,Incidence of type 2 diabetes,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
7699,NCT04682626,A1c,25OHD,2020-12-25,COMPLETED,INTERVENTIONAL,['NA'],
7700,NCT06068114,Pyloric distensibility,Autonomic function testing,2022-10-05,RECRUITING,OBSERVATIONAL,['NA'],
7701,NCT01045954,Determine the mean value for the slop between the variables of total daily dose versus total basal dose.,"Determine the slope between the other variables: weight, total daily dose, total basal dose, insulin correction carbohydrate rate, correction factor",2010-01,UNKNOWN,INTERVENTIONAL,['NA'],
7702,NCT04549324,The association between sleep apnea and systolic function in patients with diabetic nephropathy.,Association between 2D atrial global strain as determined during echocardiography and sleep apnea in patients with diabetic nephropathy.,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],
7703,NCT00133952,Percentage of Participants With Sustained Moderate Visual Loss (SMVL) Any Time Baseline Through Month 48,Number of Participants Requiring Repeat Focal Photocoagulation at Any Time From Baseline Though Month 24,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
7704,NCT01193179,"Adverse events, clinical laboratory tests",Secondary Outcome HbA1c,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
7705,NCT05442840,Change in Baseline Hemoglobin A1C (HbA1C) at 10 months,Modifiable Risk Factor - Blood Pressure,2022-07-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
7706,NCT00734253,Change in serum creatinine from baseline to end of study.,"SCr slope, change in PCR, Cystatin C slope and change from baseline.",2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
7707,NCT00639600,"Rate of insulin-independence at 6 and 12 months after transplantation, duration of insulin-independence, survival curves","Tolerance (Measurement of portal pressure during islet injection) Quality of life (Questionnaires SF-36 and DQOL at inclusion time, then every 6 months during their waiting period and then 6 months and 12 months after transplantation) Costs",2008-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
7708,NCT01395303,,,2011-04,COMPLETED,OBSERVATIONAL,['NA'],
7709,NCT04595396,Weight Loss,Early complications,2012-09-01,COMPLETED,OBSERVATIONAL,['NA'],
7710,NCT00069537,Accuracy of the GlucoWatch G2 Biographer and CGMS,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
7711,NCT01991470,"Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With the Guardian Mobile System","Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With GST3C Transmitter, Using One Additional Calibration During FST",2015-03,COMPLETED,INTERVENTIONAL,['NA'],
7712,NCT02790060,Fear of hypoglycemia score,Standard Deviation (SD) of recorded Home Monitoring of Blood Glucose (HMPG),2015-06,COMPLETED,OBSERVATIONAL,['NA'],
7713,NCT05308095,Diagnostic accuracy of the hypoglycaemia warning system using in-vehicle data to detect hypoglycaemia quantified as the area under the receiver operating characteristics curve (AUROC).,Technology acceptance of the hypoglycaemia warning system,2022-04-13,COMPLETED,INTERVENTIONAL,['NA'],
7714,NCT00005205,,,1987-08,COMPLETED,OBSERVATIONAL,['NA'],
7715,NCT04749693,time in 70 - 180 mg/dL glycemic range,incidence of the system on the necessary healthcare professional charge,2021-05-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
7716,NCT01195662,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) for 12 Week Double-Blind Treatment Period - Randomized Participants,"Proportion of Participants With Orthostatic Hypotension at Baseline and Week 12, Including Data After Rescue",2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
7717,NCT02518581,Activity-induced energy expenditure,,2015-08-12,COMPLETED,INTERVENTIONAL,['NA'],
7718,NCT05096858,Insulin use,,2020-06-01,RECRUITING,OBSERVATIONAL,['NA'],
7719,NCT04521712,Pancreatic beta cell function,Maternal diabetes mellitus,2021-09-17,RECRUITING,INTERVENTIONAL,['NA'],
7720,NCT06327815,Change in HbA1c from baseline,To evaluate the difference in adherence of FDC versus co-administered dual therapy by Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire in Chinese patients with T2DM.,2024-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],SDBG (Standard Deviation of Blood Glucose)
7721,NCT00004992,Development of diabetes,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
7722,NCT03008824,Differences in B12 levels between GDM and Controls,Predictors of abnormal post-natal OGTT in the first trimester,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],Validation of newborn adiposity measured by skin-fold thickness and objective measurement by PEAPOD
7723,NCT04192019,Time to hypoglycaemia,Any adverse events,2023-04,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],
7724,NCT02969798,Glucose tolerance status,,2014-01-01,RECRUITING,INTERVENTIONAL,['NA'],
7725,NCT00056290,Safety,,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
7726,NCT03382873,Weight loss,Decreased Glycemia,2018-02-08,UNKNOWN,INTERVENTIONAL,['NA'],
7727,NCT01340768,Percentage of Participants With at Least One Symptomatic Hypoglycemic Event,Percentage of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event,2010-06-22,COMPLETED,INTERVENTIONAL,['PHASE3'],
7728,NCT01071772,Exercise capacity,Regional left ventricular function before and after maximum exercise(regional 2D tissue velocity and strain),2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
7729,NCT00739336,Body Weight,Questionnaires,2008-07,COMPLETED,INTERVENTIONAL,['NA'],
7730,NCT01146886,Assessment of tolerability by the investigator,Total urinary corticosteroids (5α-THF + 5β-THF + THE + UFF + UFE) as an indicator of the activation of the HPA axis,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
7731,NCT01945918,Change in body mass index (BMI) from baseline to 18 months,Evidence of documented self-management support for patients through medical record review,2013-10,COMPLETED,INTERVENTIONAL,['NA'],Change in patient-reported diabetes self-care rating from baseline to 18 months
7732,NCT01460251,DiaPep277-specific antibodies,Daily insulin dose adjusted to body weight at study end,2012-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
7733,NCT04451980,Adipose tissue T cell surface marker phenotype and antigen receptor sequence,Circulating T cell surface marker phenotype,2017-08-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
7734,NCT05249881,Change in glycemic Index in Diabetes mellitus type-2 Patients,Weight Changes in Obese People,2022-03-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
7735,NCT00486941,Self-reported physical activity,Glucose tolerance (OGTT),2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
7736,NCT01971125,Prevalence of Left Ventricular Dysfunction in patients with type II diabetes,,2006-07,COMPLETED,OBSERVATIONAL,['NA'],
7737,NCT04939766,Change in burden of diabetes following activation of closed loop,Glycemic variability,2021-06,UNKNOWN,INTERVENTIONAL,['NA'],
7738,NCT05633784,Change in tolerance capacity,Assessment of physical activity.,2022-08-18,RECRUITING,INTERVENTIONAL,['NA'],
7739,NCT00677313,"To provide metreleptin, an investigational medication, under a treatment protocol to subjects with lipodystrophy that is associated with diabetes mellitus and/or hypertriglyceridemia","Information on the efficacy of metreleptin as assessed by its effects on fasting triglyceride concentrations, HbA1c, and fasting glucose concentrations in subjects with lipodystrophy that is associated with diabetes mellitus and/or hypertriglyceridemia",2009-03,COMPLETED,INTERVENTIONAL,['NA'],
7740,NCT03930004,Left atrial dysfunction,,2018-07-06,COMPLETED,OBSERVATIONAL,['NA'],
7741,NCT02223793,Change in ad Hoc Risk Score (Measure on a Scale From Min 4 to Max 14),8-week Change in Total Cholesterol,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],Effect of Heart Age and Tailord CVD Advice After 1 Year
7742,NCT03682445,Change in HbA1c level.,,2019-11-04,COMPLETED,INTERVENTIONAL,['NA'],
7743,NCT04410055,Oxygen consumption,Attention levels,2012-01-08,UNKNOWN,INTERVENTIONAL,['NA'],
7744,NCT03829514,Number of Individual Plasma Proteins That Changed From Baseline to End-point Based on Limma T-Test of Protein Abundance as Determined by Proteomic Analysis Via Liquid Chromatography-mass Spectrometry,,2019-02-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
7745,NCT03024788,prevalence of retinopathy,incidence of retinopathy,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],
7746,NCT04023734,Medication adherence,Patients' willingness to maintain the intervention,2019-08-16,COMPLETED,INTERVENTIONAL,['NA'],
7747,NCT03165812,Type 2 Diabetes Mellitus (T2DM) patients in SADJB-SG group achieving glycated hemoglobin (HbA1c) level of less than 7% (with or without diabetes medications) in 2 years as compare to patients in IMT group.,Identification of genetic biomarkers.,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
7748,NCT06299098,Percent change in total fat mass,Severity of TEAEs,2024-03-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
7749,NCT00851773,Adverse events,Antibody development against N9535,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
7750,NCT05784220,Fasting blood glucose at final visit < 7 mmol/L measured by lab test,Change in blood pressure,2019-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Objective scoring of program coach audits
7751,NCT05953818,Brain magnetic resonance high-resolution structural imaging was performed to observe the changes of brain structure,The cognitive function of the two groups was evaluated and analyzed by the Chinese version of Montreal Cognitive Assessment Scale (MoCA),2023-05-30,RECRUITING,OBSERVATIONAL,['NA'],
7752,NCT00225628,4) Compliance to guidelines regarding the screening and management of osteoporosis,2) Physician satisfaction regarding follow-up of abnormal test results,2000-09,COMPLETED,INTERVENTIONAL,['NA'],
7753,NCT04027530,Renal oxygenation measured by BOLD-MRI (R2*),Total insulin extraction,2020-12-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
7754,NCT04307511,changes of Maximum Amplitude (MA) detected by TEG,,2020-04-20,RECRUITING,INTERVENTIONAL,['PHASE4'],
7755,NCT01690962,Mood,Quality of life,2012-11,COMPLETED,INTERVENTIONAL,['NA'],Acceptability of vegan diet
7756,NCT02679287,Hemoglobin A1c,Hemoglobin A1c by Study Session,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
7757,NCT00922402,Average time to glycemic target (90-130 mg/dL),Evaluation of organizational impact,2009-06,WITHDRAWN,INTERVENTIONAL,['NA'],
7758,NCT06007430,Body Mass Index (BMI),Rate Pressure Product,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
7759,NCT00907881,Correlation Between HbA1c Values at Week 12 and Hypoglycemia Scores,Correlation Between HbA1c Values at Baseline and Hypoglycemia Scores at Week 12,2009-08,COMPLETED,OBSERVATIONAL,['NA'],
7760,NCT03970161,GCL+ thickness in the macular region obtained using the 3D Macula (v) mode,,2019-05-29,UNKNOWN,INTERVENTIONAL,['NA'],
7761,NCT02863354,Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0,"Change in Area of Total Retinal Capillary Non-perfusion, as Assessed by the Central Reading Center",2016-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
7762,NCT02066350,Endothelial function,Oral glucose tolerance test,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
7763,NCT01455870,Change in HbA1c between Week 52 and Day 0,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
7764,NCT00413465,"Renal plasma flow, Glomerular filtration rate, Plasma cytokine content, Endotoxemia score, Plasma angiotensin II and renin content, Plasma thromboxane B2 content, Plasma PAI-1 content","Mean arterial pressure, Heart rate, Oxygen saturation, Body temperature,",2006-11,UNKNOWN,INTERVENTIONAL,['NA'],
7765,NCT01974778,BAT activity,,2014-03,TERMINATED,INTERVENTIONAL,['NA'],
7766,NCT01684813,Number of patients who achieve inhibition of platelet aggregation greater that 50%,Number of participants who are non-responsiveness to antiaggregation therapy as a measure of efficacy,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
7767,NCT02707380,Paired T-test to compare test-retest Perceived dyspnea,,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
7768,NCT05542901,Joint Position Sense,Functional Capacity,2022-09-13,COMPLETED,INTERVENTIONAL,['NA'],
7769,NCT05436041,Variance and Within-Provider Covariance of Patient Change in Diet Quality (measured via Healthy Eating Index),Impact of Nutri on Patient Diet Quality (measured via Healthy Eating Index),2022-06-14,COMPLETED,INTERVENTIONAL,['NA'],Impact of Nutri on PCP Diet Counseling Competency
7770,NCT02549924,Mean amplitude of glucose excursions (MAGE),Body and visceral fat %,2016-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
7771,NCT04770532,Change in HbA1c (glycated haemoglobin),Change in body weight,2021-03-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
7772,NCT01049737,"Left ventricular mass index by cardiac ultrasonography, Intima media thickness by carotid ultrasonographic investigation and tonometry for measurements of the carotid, femoral and radial pulse pressure wave form and pulse wave velocity",Cardiovascular morbidity and mortality,2005-05,COMPLETED,OBSERVATIONAL,['NA'],
7773,NCT02803905,A1c </= 6.5% and no severe hypoglycemia,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2016-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
7774,NCT05928572,Phase 1 CGM-derived time in range (TIR),Total healthy eating index (HEI) score,2023-07-25,RECRUITING,INTERVENTIONAL,['NA'],Phase 2 CGM-derived time in range (TIR)
7775,NCT01744392,Medication Possession Ratio at 6 Months,Pulse at 6 Months,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
7776,NCT02129985,remission rate of type 2 diabetes at a year.,the beta cell function change,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],number of hypoglycemia and severe hypoglycemia during the study
7777,NCT06066515,Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76,Relative change from baseline to Week 76 in liver fat content (%),2023-11-15,RECRUITING,INTERVENTIONAL,['PHASE3'],
7778,NCT01746017,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change From Baseline in C-Peptide Area Under the Effective Concentration Curve From Time Zero to 6 Hours [AUEC(0-6)],2012-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
7779,NCT03458286,Total wound healing,Diabetic foot ulcer reoccurrence rates,2018-04,UNKNOWN,INTERVENTIONAL,['NA'],
7780,NCT04223973,Estimation of A1C based on average blood glucose measured by continuous glucose sensor,Compare pump tolerance for the active group (Medtrum Pump) vs Control Group Patients (comparator device) in order to assess non inferiority,2020-01-29,COMPLETED,INTERVENTIONAL,['NA'],
7781,NCT04513704,"Area under the semaglutide plasma concentration - time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,day10)","Time to maximum observed semaglutide plasma concentration after the 10th dosing (tmax,0-24h,sema,day10)",2020-08-28,COMPLETED,INTERVENTIONAL,['PHASE1'],
7782,NCT00310752,,,2006-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
7783,NCT04246190,"AUClast of CKD-501, D759 and CKD-396",,2020-02-24,UNKNOWN,INTERVENTIONAL,['PHASE1'],
7784,NCT00109369,Glycemic control,Functional status,2003-06,COMPLETED,INTERVENTIONAL,['NA'],
7785,NCT02208206,Analysis of gene expression,,2014-07,COMPLETED,OBSERVATIONAL,['NA'],
7786,NCT00225342,Angina status at 3 months,Biochemical markers of inflammation at 3 months,na,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
7787,NCT05385211,Exocrine pancreatic insufficiency,,2022-04-30,COMPLETED,OBSERVATIONAL,['NA'],
7788,NCT00157222,,,2005-05,UNKNOWN,OBSERVATIONAL,['NA'],
7789,NCT00317915,Development of overt nephropathy,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],
7790,NCT04061473,glucagon excursions measured as incremental area under the curve (iAUC),food intake,2019-04-02,COMPLETED,INTERVENTIONAL,['NA'],
7791,NCT00861042,Subject withdrawal due to adverse events,Quality of life assessments during specific site visits,2002-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
7792,NCT06194240,12-Item Short Form Health Survey,Generic Adherence Profile for Chronic Diseases,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],
7793,NCT02691273,10 percentage improvement in the quality of life questionnaire,,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
7794,NCT05896644,Change in number of ED Visits,Change in blood pressure,2023-06-20,RECRUITING,INTERVENTIONAL,['NA'],
7795,NCT00435019,Glycosylated Haemoglobin A1c (HbA1c),Observed Insulin Antibody Values,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
7796,NCT03090464,Change from baseline to end of study (Month 6) in HbA1c levels,Proportion of patients in both cohorts who intensify antihyperglycemic treatment from Visit 1,2017-05-08,COMPLETED,OBSERVATIONAL,['NA'],Change in baseline to Month 6 in Morisky Medication Adherence Scale (8-item) (adherence)
7797,NCT01729156,Whole Body Glucose Rd,VLDL-TG Oxidation,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
7798,NCT05565534,"Number of in-person, virtual or phone contacts with the NP",Number of participants with Chemotherapy Dose Reductions,2023-02-28,RECRUITING,INTERVENTIONAL,['NA'],
7799,NCT00659932,Hemoglobin A1C (HbA1C),Diabetes Quality of Life (ADDQoL),2002-05,COMPLETED,INTERVENTIONAL,['NA'],
7800,NCT02331420,Cardiac autonomic function (heart rate variability measurements on 24-hour Holter ECG recordings),,2015-02,UNKNOWN,INTERVENTIONAL,['NA'],
7801,NCT04123054,Change in HbA1c levels,Mean sensor glucose level during:,2020-03-05,RECRUITING,INTERVENTIONAL,['NA'],Recurrent themes from semi-structured interviews
7802,NCT02393872,Body mass index (BMI),,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],
7803,NCT03825926,Edinburgh postpartum depression scale (EPDS) follow up GDM or non-GDM,Expenditure on GDM after the diagnosis,2019-06-01,RECRUITING,OBSERVATIONAL,['NA'],
7804,NCT05975541,Fecal calprotectin levels identification,assessment of the circadian rhythm trough MEQ questionnaire,2023-10-01,RECRUITING,OBSERVATIONAL,['NA'],
7805,NCT02675257,Improvement of glycaemic control as measured by the HbA1c,Improvement of quality of life as measured with the Short Form-36 Health Survey (SF-36),2015-07-01,COMPLETED,INTERVENTIONAL,['NA'],Inflammatory Marker: Adiponectin
7806,NCT00109434,Hypoglycemia defined as <=70 mg/dL.,Changes in epinephrine and glucagon levels.,2004-06,COMPLETED,OBSERVATIONAL,['NA'],
7807,NCT01301196,Sedentary behaviour,Psychosocial indicators,2010-10,UNKNOWN,INTERVENTIONAL,['NA'],
7808,NCT03613857,Ischemic or hemorrhagic stroke,,2017-04-15,COMPLETED,OBSERVATIONAL,['NA'],
7809,NCT05319990,Insulin Sensitivity,Effective Renal Plasma Flow (ERPF),2022-03-09,RECRUITING,OBSERVATIONAL,['NA'],
7810,NCT00133692,First occurrence of death or nonfatal myocardial infarction (MI) or nonfatal stroke,Compliance,1997-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
7811,NCT03542487,Patient A1c,Flowsheet Entry Values (descriptive),2018-05-01,COMPLETED,INTERVENTIONAL,['NA'],
7812,NCT02086539,Enrollment into the Habit Formation study,,2014-04,COMPLETED,INTERVENTIONAL,['NA'],
7813,NCT04601753,Change in Glycated haemoglobin (HbA1c ),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",2020-11-12,COMPLETED,OBSERVATIONAL,['NA'],
7814,NCT04451915,The occurrence of materno-fetal complications,Number of complications in each subgroup of the late GDM management group,2020-11-30,RECRUITING,INTERVENTIONAL,['NA'],
7815,NCT00791076,Total Amount of Insulin Administered While on Placebo/PP.,Frequency of Hypoglycemia Defined as < 60 mg/dl.,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
7816,NCT03299790,ECG (Electrocardiogram),Maximal oxygen uptake (ml/O2/kg/min),2017-10-06,COMPLETED,INTERVENTIONAL,['NA'],
7817,NCT00407641,"the composite event rate in death (any cause), myocardial infarction and stroke",Lipid profile,2009-03,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
7818,NCT05353699,"Implementation change: Change from Baseline Implementation at 3, 6,9 months",Qualitative assessment-maintenance:,2022-05-01,UNKNOWN,INTERVENTIONAL,['NA'],
7819,NCT05413369,Change in HbA1c from baseline to Week 24,Change in fasting C-peptide,2022-07-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
7820,NCT03174288,Augmentation Index-Change from baseline,Microvascular Blood Volume-Change from baseline,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
7821,NCT00833716,AUC of NN9535,"Laboratory safety, adverse events",2009-02-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
7822,NCT03508323,HbA1c,,2018-04-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
7823,NCT01109797,"Measure and compare change in self-efficacy and change in diabetes knowledge, diabetes quality of life, family conflict, and treatment satisfaction for and between the two groups.",Make exploratory baseline comparisons between the two groups of HgbA1c,2010-04,COMPLETED,INTERVENTIONAL,['NA'],
7824,NCT02725502,Effect of Linagliptin on insulin requirement in T1DM patients,Effect of linagliptin on glucagon level during mixed meal test in T1DM patients,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],
7825,NCT04711226,Efficacy- Insulin independence,Efficacy- HbA1c,2021-02-19,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Exploratory- Pharmacokinetic Parameters- (t1/2)
7826,NCT02361489,A1C,Hypoglycemia,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
7827,NCT05581264,Difference in Glycated hemoglobin (HbA1c) level between experimental group and control group across time,Difference in health related quality of life HRQOL scale scores between experimental group and control group across time,2021-09-28,COMPLETED,INTERVENTIONAL,['NA'],
7828,NCT01023646,"Glucose, Insulin, Free Fatty Acids.","Fasting and non-fasting plasma lipids and lipoproteins, C reactive protein (CRP), HbAIc.",2007-12,COMPLETED,INTERVENTIONAL,['NA'],
7829,NCT00850798,"The primary study outcomes are a composite of macrovascular events and a composite of microvascular events, considered both jointly and separately.","The secondary outcomes are death from any cause, disability from any cause, total coronary events, total cerebrovascular events, heart failure, peripheral vascular events, all cardiovascular events, and hospitalization for 24 hours or more.",2009-02,UNKNOWN,INTERVENTIONAL,['NA'],
7830,NCT04207099,Rate of change in wound area of diabetic foot ulcers in ARM 2 vs ARM 1,Wound Healing Rate,2020-02-14,UNKNOWN,OBSERVATIONAL,['NA'],
7831,NCT04916314,HbA1c,Diabetes related quality of life and distresses; EQ5D score,2021-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Participants' experience of using the app-based support
7832,NCT01419652,periprocedural glucose,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
7833,NCT05852639,To evaluate the efficacy (sensitivity & specificity) of fetal cerebroplacental ratio at term in prediction of adverse neonatal outcome in pregnancies complicated by gestational diabetes,To evaluate the incidence of adverse neonatal outcome in both groups,2022-11-30,RECRUITING,OBSERVATIONAL,['NA'],
7834,NCT02733991,Mean Number of Sensor Glucose Hypoglycaemic Events Below or Equal to 55 mg/dL Per Patient/Week.,Mean Time Spent of Sensor Glucose Values Within Range and Including 70-180 mg/dL.,2016-12,COMPLETED,INTERVENTIONAL,['NA'],
7835,NCT03167866,HbA1c levels at 6 months from beginning of messages,Diabetes Quality of Life questionnaire,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],
7836,NCT06317142,Postprandial hepatic and muscle glucose uptake determined by Fluorodeoxyglucose-Positron emission tomography ([18F]-FDG-PET) combined with oral glucose tolerance test (OGTT),Whole body gluconeogenesis after acipimox treatment determined by deuterated water,2024-04-01,RECRUITING,OBSERVATIONAL,['NA'],Body composition determined by Bodpod
7837,NCT00687453,Hemoglobin A1c Change From Baseline,Any Adverse Event Other Than Hypoglycemia,2003-02,TERMINATED,INTERVENTIONAL,['PHASE4'],
7838,NCT01170468,The incidence of DM,time to develop DM,2011-12,TERMINATED,INTERVENTIONAL,['PHASE3'],
7839,NCT01504620,Accuracy of the blood glucose meter in comparison to a standard reference,Hematocrit Interference (Helios),2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
7840,NCT04522921,Change in fat mass/fat free mass,Inflammatory markers,2020-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
7841,NCT02347787,Short Form Health Survey (SF-12) Physical Component Score (PCS),Hospital Admission - Mean Length of Stay (Among Participants With Hospitalization),2015-01-28,COMPLETED,INTERVENTIONAL,['NA'],
7842,NCT03182582,Bacterial Load Pre- and Post-Sharp Debridement,Percent Change in Wound Size - 1 Week Post-debridement,2017-01-05,COMPLETED,INTERVENTIONAL,['NA'],
7843,NCT01508897,"Cmax, maximum concentration",Adverse events,2004-05-28,COMPLETED,INTERVENTIONAL,['PHASE1'],
7844,NCT00286572,Death and/or major adverse cardiac events,,2004-01,COMPLETED,OBSERVATIONAL,['NA'],
7845,NCT01877590,Alpha-lipoic acid regress the left ventricular mass,The change of endothelial dysfunction before and after alpha-lipoic acid intervention.,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
7846,NCT01309022,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],
7847,NCT00184574,HbA1c,Other glycemic variables,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
7848,NCT02077309,Effect of linagliptin on vascular inflammation of the carotic artery,Effect of linagliptin on biomarkers of vascular inflammation,2014-08,TERMINATED,INTERVENTIONAL,['PHASE3'],
7849,NCT05330390,Blood drug concentration,,2022-04-04,UNKNOWN,OBSERVATIONAL,['NA'],
7850,NCT02402374,Proportion of patients with complete wound closure,,2018-04-12,UNKNOWN,INTERVENTIONAL,['NA'],
7851,NCT02547337,Intestinal blood flow acquired with PET and DWI (ml ml-1 min-1),,2015-09-10,COMPLETED,OBSERVATIONAL,['NA'],
7852,NCT02225951,3-hr postprandial glucose response,,2014-07,TERMINATED,INTERVENTIONAL,['NA'],
7853,NCT03266133,Self-reported sleep duration,Preeclampsia,2017-11-27,COMPLETED,INTERVENTIONAL,['NA'],
7854,NCT02444325,effect of group prenatal care on maternal diabetes self-care activities as measured Diabetes Self-Care Activities Measure,Contraception,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
7855,NCT05304325,"Adipose tissue fibrosis using qRT-PCR, immunoblotting, histochemistry and immunohistochemistry","Inflammation in adipose tissue using qRT-PCR, immunoblotting and immunohistochemistry",2012-04-25,UNKNOWN,OBSERVATIONAL,['NA'],
7856,NCT00505960,HbA1c,BP control,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
7857,NCT02154997,Post prandial blood glucose levels,,2014-11,UNKNOWN,OBSERVATIONAL,['NA'],
7858,NCT06138821,Change in Liver Fibrosis measurement at 12 months compared to baseline,Change in eating behaviors compared to baseline,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
7859,NCT01704417,"BGpre-exe - BGminimum,exe, difference between blood glucose concentration before exercise and the minimum blood glucose concentration observed during exercise","BGminimum,30-180min,post-exe, minimum blood glucose concentration",2012-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
7860,NCT02911792,GFR (Glomerular Filtration Rate) Change After Treatment,,2016-12-20,COMPLETED,INTERVENTIONAL,['PHASE4'],
7861,NCT02136654,Change in A1C or blood pressure (systolic or diastolic blood pressure),change in health status,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],Procedure related outcomes
7862,NCT05558878,Effect of Ambroxol on Superoxide dismutase,Effect of Ambroxol on clinical outcome : Pain assessment using the Numeric rating scale NRS,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
7863,NCT02053714,Changes in knowledge of diabetes self-management from baseline to six months as evidenced by scores on the Stanford Diabetes Self-Management Questionnaire.,Changes in diastolic and systolic blood pressure from baseline to six months.,2013-12,COMPLETED,INTERVENTIONAL,['NA'],
7864,NCT01077505,AUC0-24 of norethindrone and ethinyl estradiol after OC alone in Period 1 and after OC with albiglutide in Period 2.,Predose serum levels of progesterone after OC alone and after OC with albiglutide.,2010-03-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
7865,NCT04006938,Fasting blood sugar level,,2019-07,UNKNOWN,INTERVENTIONAL,['NA'],
7866,NCT05899023,Percent of Patients who Complete at least One In-Person Follow-up Outpatient Visit,Percent of Patients who Start on Diabetes Medications within 6 Months of Diagnosis,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
7867,NCT01028846,Endogenous Glucose Production (EGP),,2011-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
7868,NCT00202033,HbA1c,blood glucose testing frequency,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
7869,NCT01158625,"Blood pressure, nighttime blood pressure and 24 h blood pressure",Urine albumin excretion,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
7870,NCT00353691,Change in HbA1c from baseline to Week 24 or last evaluable ontreatment value.,Mean change in body mass index (BMI) from baseline to Wk 12 and Wk 24 or last evaluable on-treatment value,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
7871,NCT00732862,HbA1c,Catecholamines,1998-02,COMPLETED,INTERVENTIONAL,['NA'],
7872,NCT00978835,Blood Pressure,Hemoglobin A1c,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
7873,NCT00162175,Compare change from baseline in HbA1c after 24 weeks of treatment with muraglitazar + glyburide vs placebo + glyburide,"Change in FPG from basline to W24, proportion of subjects receiving therapeutic response at W24, percent change of fasting lipid levels from baseline to W11/12, change in hs-CRP from baseline to W24",2003-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
7874,NCT05247034,Rate-dependent depression on the frequency of stimulation of the H reflex,Diabetes 39 Instrument,2021-06-04,RECRUITING,INTERVENTIONAL,['NA'],
7875,NCT04499768,VD at 3 months postoperatively,BCVA at 3 months postoperatively,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA'],
7876,NCT03179085,The Patient Activation Measure (PAM),Nutritional Measures,2017-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
7877,NCT03489967,Change in glucose levels 15 minutes after hypoglycemic treatment,Number of patients requiring a second treatment 15 minutes after the first hypoglycemic treatment,2018-04-18,COMPLETED,INTERVENTIONAL,['NA'],
7878,NCT06330480,Effectiveness of the albuminuria screening,Cost-effectiveness of screening strategies compared to standard of care: treatment effectiveness based on actual observed event rates,2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],"Overall effectiveness of broader population-based screening strategies applied to screening on heart failure, coronary artery disease, and type 2 diabetes."
7879,NCT00073281,,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
7880,NCT03195868,"total nerve fiber density,",NTSS- Nueropathy Total Symptom Score,2019-09-30,COMPLETED,INTERVENTIONAL,['NA'],
7881,NCT02056210,CD34+ stem cell mobilization in diabetic vs non diabetic subjects,EPC (endothelial progenitor cell) mobilization within diabetic patients,2014-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
7882,NCT05071820,Percent weight lost at 12 months from baseline weight,change in hemoglobin A1c,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],
7883,NCT03421379,Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia,PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM,2018-02-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
7884,NCT03903016,Assessment of PK parameter :INS-AUClast -,Adverse Events,2019-03-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
7885,NCT02830048,Decrease in fasting plasma glucagon concentration,Pre-dose plasma concentration of glibenclamide,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
7886,NCT00849056,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,Change From Baseline in Body Weight at Week 156,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
7887,NCT00803660,The percentage of patients achieving the BP<130/80 mmHg,The number and percentage of patients with positive proteinuria by treatment groups,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
7888,NCT00745342,"Glycemic control, assessed by hemoglobin A1c","Parent involvement in diabetes management tasks, measured using the Diabetes Family Responsibility Questionnaire (youth and parent versions)",1999-03,COMPLETED,INTERVENTIONAL,['NA'],
7889,NCT00886574,Maximal and mean intima media thickness (IMT) of both common carotid artery of the cilostazol group in comparison with the aspirin group,Events of hemorrhagic vascular complication,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
7890,NCT05979246,marginal bone loss,Survival rate,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
7891,NCT02502071,Change in Number of Participants With Urine Uric Acid Precipitation by Polarized Microscopy,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
7892,NCT00800085,The systematic and simultaneous determination of markers of functional beta cell mass and immune status allows stratification according to the stage of the pathogenic process rather than according to a late metabolic consequence of this process,,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
7893,NCT02001805,Body Composition,Activity level and diet,2010-12,UNKNOWN,OBSERVATIONAL,['NA'],
7894,NCT00472095,Hemoglobin A1c,,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
7895,NCT01318122,Number of Participants With Adverse Events.,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Final Visit).,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
7896,NCT02915198,"Time in days to death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina, or symptom-driven coronary revascularization",Time in days to Diabetes Outcome,2023-04-03,RECRUITING,INTERVENTIONAL,['PHASE4'],
7897,NCT05269589,Hemoglobin A1C (HbA1C),Blood pressure,2022-02-18,RECRUITING,INTERVENTIONAL,['NA'],
7898,NCT03285230,Health outcomes,,1990-06-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
7899,NCT01950806,Change in biomarkers of insulin resistance compared with control diet,Change in plasma lipid profile compared with control diet,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
7900,NCT00618007,HbA1c,Fasting Insulin,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
7901,NCT01085773,Glycated hemoglobin (HbA1c).,"Adherence, Anthropometry,Blood pressure, Lipid profile, VO2max and quality of life.",2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
7902,NCT00616811,Safety and tolerability in patients with T2DM and severe renal insufficiency over 24 weeks of treatment,Efficacy of vildagliptin versus sitagliptin in patients with T2DM and severe renal insufficiency by assessing the hemoglobin A1c (HbA1c ) and fasting plasma glucose (FPG) reduction from baseline,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
7903,NCT06171230,Pain intensity measured with the Numeric Rating Scale (NRS),Pain Disability Index (PDI) Limitations in daily activities,2024-03-01,RECRUITING,INTERVENTIONAL,['NA'],
7904,NCT03479671,Insulin Sensitivity,,2020-01-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
7905,NCT02518334,Oral glucose tolerance test,,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
7906,NCT01710774,healing time for leg ulcer and/or diabetes related foot ulcer,"A new foot ulcer appears, the incidence of amputation and survival.",2012-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
7907,NCT00646542,To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 24 weeks of treatment,To explore the efficacy of vildagliptin (50 mg qd) versus placebo in patients with T2DM and moderate or severe renal insufficiency.,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
7908,NCT03263728,Prevalence of myocardial ischaemia,Major adverse cardiovascular events,2017-08-10,COMPLETED,INTERVENTIONAL,['NA'],
7909,NCT03511521,Glycemic Control,Percentage of Glucose Values Within the Hypoglycemic Range,2018-03-27,TERMINATED,INTERVENTIONAL,['PHASE4'],
7910,NCT01469312,Change in Blood Glucose,,2010-04,COMPLETED,INTERVENTIONAL,['NA'],
7911,NCT02863419,Change in HbA1c (Week 26),Change in DTSQs: Individual Items and Total Treatment Satisfaction Score (6 of the 8 Items Summed),2016-08-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
7912,NCT05819138,Change in Carotid and Radial Artery Pulse Wave Velocity (CR-PWV),Change in Renal Vascular Resistance (RVR),2023-06-21,RECRUITING,INTERVENTIONAL,['PHASE3'],
7913,NCT05475587,Body constitution of body constitution questionnaire (BCQ),,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],
7914,NCT01879800,Mean Change in Participants World Health Organization Quality of Life Measure- Physical Score: Change From Baseline to 3 and 6 Month Follow-up.,Mean Change in Hamilton Anxiety Rating Scale (HAM-A) From Baseline to 3 and 6 Month Follow-up,2012-08,COMPLETED,INTERVENTIONAL,['NA'],
7915,NCT01151072,Area under the serum Insulin Degludec concentration-time curve (only for subcutaneous administration),Back-extrapolated initial serum Insulin Degludec concentration after single-dose (only for intravenous administration),2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
7916,NCT02124590,Change in Acylcarnitine/Carnitine ratio,Change in Mitochondrial Function,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
7917,NCT03980236,Change in A1c,,2019-05-06,TERMINATED,INTERVENTIONAL,['NA'],
7918,NCT00550329,,,2007-10,COMPLETED,OBSERVATIONAL,['NA'],
7919,NCT05860842,Change in peak power output (PPO),,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
7920,NCT05925933,Metabolomics profile,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
7921,NCT00568854,Kinetics of Mycobacterial-specific Immune Response After BCG Vaccination,,2007-04,TERMINATED,INTERVENTIONAL,['NA'],
7922,NCT05472272,Percent of participants achieving significant weight loss and diabetes remission,Metabolomic profiling performed by liquid chromatography mass spectrometry,2022-08-03,RECRUITING,INTERVENTIONAL,['NA'],
7923,NCT00513630,"Composite of cardiovascular events which were defined as death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke or arterial revascularization",new peripheral vascular events,2004-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
7924,NCT01773707,Change from Normal Glucose Tolerance to Abnormal Glucose Tolerance,Change in C-peptide response to Oral Glucose Tolerance Test (OGTT),2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
7925,NCT01225081,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",2010-09-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
7926,NCT05163964,The change of baseline continuous glucose monitoring (CGM) profile among prediabetes adults at 6 months.,The change of chronotype among prediabetes adults at 6 months.,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],
7927,NCT03159832,The maximum plasma concentration (Cmax) of SHR3824,The number of volunteers with adverse events as a measure of safety and tolerability,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],
7928,NCT03460769,"Protocol and Regulatory Compliance Monitoring of Regulatory Documents for Consortium Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",,2017-11-01,RECRUITING,OBSERVATIONAL,['NA'],
7929,NCT00585897,Hemoglobin A1c,Fasting glucose,2007-01,COMPLETED,INTERVENTIONAL,['NA'],
7930,NCT05697484,diabetes control,Usability and satisfaction,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
7931,NCT03020485,Change in post prandial Blood glucose for 180 minutes period,,2014-12,COMPLETED,INTERVENTIONAL,['NA'],
7932,NCT00917267,Change in HbA1c From Baseline to Week 26.,Assessment of Event Rate of Treatment-emergent Hypoglycemic Events,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
7933,NCT01421147,Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c),Rate Per 30 Days of Hypoglycemic Events,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
7934,NCT03673969,Excess weight loss,Diarrhoea,2019-02-01,WITHDRAWN,INTERVENTIONAL,['NA'],
7935,NCT05160974,• Incidence (%) of SAEs in patients who are treated with Qtern,• Clinically significant results from urinalysis,2021-12-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
7936,NCT00549874,Myocardial blood flow regulation,biomarkers of oxidative/nitrosative stress,2002-02,COMPLETED,INTERVENTIONAL,['NA'],
7937,NCT02972528,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection,Assess the efficacy of allogenic Platelet Lysate injection by clinical examination,2018-02-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
7938,NCT03995498,Percentage of time of interstitial glucose concentrations spent between 4.0-10.0 mmol/L,Total number of confirmed hypoglycemia episodes requiring treatment,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],
7939,NCT03314467,Presence of obstructive sleep apnea in diabetic patients is a predictive factor for diabetic retinopathy occurence,Correlation between severity of obstructive sleep apnea and presence of diabetic retinopathy,2017-10-06,COMPLETED,OBSERVATIONAL,['NA'],
7940,NCT03365349,Change from baseline IPQR (Illness Perception Questionnaire) score at 3 months,comparison of the two groups concerning answers to qualitative interviews at T 3 months after the intervention,2012-02-01,COMPLETED,INTERVENTIONAL,['NA'],
7941,NCT00949663,"The effects of GIP, xenin-25, or a combination of GIP plus xenin-25 on insulin secretion and blood glucose levels",We will develop an assay to measure the normal fasting and postprandial concentrations of endogenous xenin-25 and determine whether they are altered in T2DM.,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
7942,NCT03664089,Weight loss,Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Lipid Panel,2018-09-10,COMPLETED,INTERVENTIONAL,['NA'],
7943,NCT06029517,Change in SSB intake for men affiliated with Native American athletic communities,Change in body weight,2022-07-20,RECRUITING,INTERVENTIONAL,['NA'],
7944,NCT01210664,Number of Participants Experiencing Severe or Life Threatening Laboratory Abnormalities,Hemoglobin A1c,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
7945,NCT02542631,Change in A1C From Baseline to the Completion of 24 Weeks of Basal and Bolus Insulin Therapy,Number of Participants With Severe Hypoglycemic Event,2015-08-01,COMPLETED,INTERVENTIONAL,['NA'],Change in Quality of Life From Baseline to Week 24
7946,NCT05615558,Insulin sensitivity,Diabetes treatment satisfaction measured by the diabetes treatment satisfaction questionnaire,2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],
7947,NCT00540488,Adjusted area under the curve (adj-AUC) of glucose response,Adjusted peak for glucose and insulin response;peak time for glucose and insulin response; Adj-AUC for insulin response; change in glucose and insulin; subjective gastrointestinal tolerance,2002-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
7948,NCT05033899,Quality of recovery after surgery (QoR40),serum markers of stress response: interleukin 6 ( IL-6),2021-05-01,COMPLETED,INTERVENTIONAL,['NA'],
7949,NCT02106039,Better diabetes control in diabetes patients with tuberculosis under treatment,Association between glycemic control and clinical-microbiological response to TB treatment,2014-04-28,COMPLETED,INTERVENTIONAL,['NA'],
7950,NCT03202680,Change in insulin sensitivity index (Si),Apo A1 measurements.,2017-07-06,COMPLETED,INTERVENTIONAL,['NA'],
7951,NCT00669630,Diet History Questionnaire; 7 - Day Physical Activity Recall,"Blood pressure; Total cholesterol, HDL, LDL, Triglycerides; Glucose level; Hemoglobin A1C (Diabetics only)",2008-09,COMPLETED,INTERVENTIONAL,['NA'],
7952,NCT04382521,Participant's mean ratings of message utility to measure acceptability of the text-message intervention,Change in physical function measured by 6-minute test,2020-09-22,COMPLETED,INTERVENTIONAL,['NA'],
7953,NCT00745914,Change in carotid plaque volume,"Change in inflammatory markers include C-reactive protein, interleukin-6, adiponectin, metalloproteinases",2008-09,COMPLETED,INTERVENTIONAL,['NA'],
7954,NCT01060605,"Evidence of insulin independence with adequate control of blood glucose (<140 mg/mL fasting; < 180 mg/mL post prandial, after the final infusion","renal and liver function, white blood cells count, total lymphocytes and lymphocytes subpopulations (CD24, CD19), hemoglobin, fibrinogen (FG), cross-linked fibrin degradation products, C-reactive protein (CRP)",2001-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
7955,NCT01151891,Pedal puncture wounds,Infection in pedal puncture wounds,2010-06,COMPLETED,OBSERVATIONAL,['NA'],
7956,NCT03547635,"The Number of Participants Meeting Criteria of Complete Wound Closure, as Assessed by the Investigator at or Before Week 12 of the Treatment Phase, Which is Confirmed Closed Two Weeks Later.",,2018-05-03,COMPLETED,INTERVENTIONAL,['NA'],
7957,NCT05908448,Accuracy,,2024-02-07,RECRUITING,OBSERVATIONAL,['NA'],
7958,NCT05527847,Change in blood glucose (hemoglobin A1C),Adherence to Refills and Medicines Scale for Diabetes (ARMS-D) Score,2023-02-13,COMPLETED,INTERVENTIONAL,['NA'],
7959,NCT01403025,The incidence of SADRs (Serious Adverse Drug Reactions),The incidence rate and type of ADRs (Adverse Drug Reactions),2011-07-19,COMPLETED,OBSERVATIONAL,['NA'],
7960,NCT04881123,A change of urine albumin-to-creatinine ratio (UACR) of > 30% from Baseline to Day 168,PK trough SER150 concentrations (pre-dose),2021-08-18,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
7961,NCT00497666,,,2007-08,UNKNOWN,OBSERVATIONAL,['NA'],
7962,NCT03612037,Glycemic control,Blood lipids,2016-09-01,COMPLETED,INTERVENTIONAL,['NA'],
7963,NCT02563457,Hemoglobin A1c blood level,,2009-02,COMPLETED,INTERVENTIONAL,['NA'],Quality of life
7964,NCT02826044,Cumulative excretion of SP2086,The number of volunteers with adverse events as a measure of safety and tolerability,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],
7965,NCT00276367,,,2006-10,WITHDRAWN,OBSERVATIONAL,['NA'],
7966,NCT06270836,Proportion of eyes improving ≥2 steps on the ETDRS Diabetic Retinopathy Severity Scale (DRSS),Safety and Tolerability of KSI-301 5 mg compared to sham treatment,2024-03-29,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
7967,NCT02146404,Brain lactate concentration,Hormone response,2014-08,COMPLETED,INTERVENTIONAL,['NA'],
7968,NCT03378908,Glycemic profile below pregnancy target capillary blood glucose concentration,Point-of-care glycated hemoglobin (HbA1c),2018-02-01,COMPLETED,INTERVENTIONAL,['NA'],
7969,NCT01717313,"Percentage of Participants Who Discontinued From the Study Drug Due to an Adverse Event (Phase A + Phase B, Excluding Data After Glycemic Rescue, Safety Population)","Change From Baseline in FPG at Week 54 (Phase A + Phase B, FAS Population)",2012-12-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
7970,NCT05165368,Pain Intensity Level,Pain Quality Assessment,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],
7971,NCT02388113,glycosylated hemoglobin (HbA1c),,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
7972,NCT05078658,Change in continuous glucose monitoring time in target range (3.9-10.0 mmol/l) during the LCD period compared to the RCD period,Differences in urine metabolome between the LCD and RCD periods,2021-09-22,RECRUITING,INTERVENTIONAL,['NA'],
7973,NCT03675074,Change in HbA1c,Change in weight,2018-09-12,WITHDRAWN,INTERVENTIONAL,['NA'],Improvement in metabolic comorbidities
7974,NCT02230618,Incidence of Adverse Events (AEs),The reason for initiating or intensifying treatment with Ryzodeg™,2015-11-24,COMPLETED,OBSERVATIONAL,['NA'],
7975,NCT05112445,OCTA metrics and predict progression to PDR and/ or CI- DME,,2022-05-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
7976,NCT02185482,change in depression using SCL-90 depression scale,Glycemic control measured using glycosylated hemoglobin levels,2014-08,COMPLETED,INTERVENTIONAL,['NA'],Global assessment of improvement using Patient Global Impression
7977,NCT04315519,Cardiorespiratory Fitness,The Strength of Hamstring Muscle,2020-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
7978,NCT00320008,Years of life years gained,Diabetic neuropathy,1992-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
7979,NCT03249896,Percentage of patients who have excessive gestational weight gain (EGWG),Neonatal intensive care unit admission,2017-09-05,UNKNOWN,INTERVENTIONAL,['NA'],
7980,NCT00598871,Number of Participants With Treatment Emergent Adverse Events (TEAEs) After Treatment With Thymosin Beta 4 in the Target Eye of Diabetic Patients During Vitrectomy,Number of Participants With Corneal Epithelial Wound Healing at Day 14 (End of Treatment),2007-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
7981,NCT01052025,To examine the efficacy of curcumin on the delay of degenerative beta-cells in pancrease for protection of Type 2 Diabetes in patients with impaired glucose tolerance (Pre-diabetes),"To examine the efficacy of curcumin on the reduction of blood sugar level, lipid profile, insulin resistance status and oxidative stress status in Pre-diabetes patients",2009-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
7982,NCT05960604,"Difference of mean CCE, dP/dt, SVI, CPI, Ea at the 30th second of passive leg raising by hypertension and diabetes mellitus",Predictive factors of hypotension,2023-12-25,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Days out of hospital 30
7983,NCT02305784,Blood concentration of YKL-40 (ng/ml),Change of Blood concentration of YKL-40 (ng/ml) during an exacerbation,2015-05,COMPLETED,OBSERVATIONAL,['NA'],
7984,NCT00704236,Glucose Disposal Rate,"Fasting Plasma Glucose,Postprandial Plasma Glucose,HbA1c,triglyceride,cholesterol,HDL-c and LDL-c,lipid levels ,body weight, blood pressure",2006-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
7985,NCT01238978,Percent of patients in each of the two treatment groups presenting no hypoglycemia (confirmed events with SMBG and severe episodes) after 24 wk of randomized therapy added to their ongoing metformin background therapy.,"Glycemic control assessed by A1C, and the mean of 6 Points self-monitoring of blood glucose (SMBG) at baseline and after 24 weeks.",2010-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
7986,NCT00119938,"Composite measure of diabetes self-care activities, developed from the Summary of Diabetes Self-Care Measure","Biological markers of diabetes care (hemoglobin A1c, blood pressure, LDL cholesterol)",2004-09,COMPLETED,INTERVENTIONAL,['NA'],
7987,NCT01156597,Increased HDL-Cholesterol and Decreased Triglycerides,Cholesterol Efflux Capacity of HDL,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
7988,NCT02384148,Difference of period length,Difference of amplitude,2011-06,UNKNOWN,OBSERVATIONAL,['NA'],
7989,NCT05177250,Bisphenol A and paraben detection in urine samples of diabetic (n=50) and non diabetic persons (n=50),,2022-02-20,RECRUITING,INTERVENTIONAL,['NA'],
7990,NCT05631535,Changes in body weight,Changes in perception of health-related quality of life,2023-01-04,RECRUITING,INTERVENTIONAL,['NA'],
7991,NCT01895569,Glycemic variability,Glyco-metabolic control,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],Insulin-resistance parameters
7992,NCT00521742,Change in the walking distance during a standardized 6-minute walk test.,Change in Body Weight,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
7993,NCT00395343,Change From Baseline in A1C at Week 24,Percent of Patients With A1C < 6.5% at Week 24,2006-12-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Change From Baseline in A1C at Week 24
7994,NCT02535299,physiological parameter:glycosylated hemoglobin A1c,physiological parameter:TNF-α,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],
7995,NCT03723707,Percent of Patients Who Reach Consensus Target HBA1c,,2018-12-03,COMPLETED,INTERVENTIONAL,['NA'],
7996,NCT04928248,Change in hemoglobin A1c (HbA1c) levels,Change in body mass index (BMI) levels,2021-09-23,COMPLETED,INTERVENTIONAL,['NA'],Rate of use of the Disease Manager's diabetes module
7997,NCT05179954,Apolipoprotein C turnover rate,Apolipoprotein B-100 concentration,2022-05-09,RECRUITING,INTERVENTIONAL,['NA'],
7998,NCT01714232,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) Across the Overall Tested Glucose Range,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) in the High Glucose Range (>180 mg/dL),2012-10,COMPLETED,INTERVENTIONAL,['NA'],
7999,NCT00673543,Time point at which glucose elevation occurs after glucocorticoid administration (greater than 50% increase in the patient's baseline blood) glucose level.,Pre-corticosteroid insulin amount,2008-05,COMPLETED,OBSERVATIONAL,['NA'],
8000,NCT01678183,Improvement in hemoglobin A1c,Improvement in blood pressure.,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Lipid levels
8001,NCT00615264,Change From Baseline in Glucagon-stimulated C-peptide AUC at 24 Months,Change From Baseline in Mixed-meal Stimulated C-peptide AUC at 24 Months,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
8002,NCT03061851,The proportion of patients with HbA1c <7% after 48 weeks of maltose software intervention,The total score of Kessler's psychological distress scale after 48 weeks of intervention was higher than baseline.,2017-01-25,UNKNOWN,INTERVENTIONAL,['NA'],
8003,NCT03819153,"Time to first occurrence of a composite primary outcome event defined as persistent eGFR decline of greater than or equal to 50 percentage from trial start, reaching ESRD, death from kidney disease or death from cardiovascular disease",Number of severe hypoglycaemic episodes,2019-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
8004,NCT02483949,Change from baseline to 6 months of moderate and vigorous physical activity (walking).,Change from baseline to 6 months in Low Glycemic Index foods.,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
8005,NCT01931644,Biospecimen & Clinical Data Collection,,2013-07,RECRUITING,OBSERVATIONAL,['NA'],
8006,NCT00596063,The primary objective is to test for bioequivalence based on AUC0-12h and Cmax between Wockhardt's Insulin Human Regular for injection and Novolin® R,"PK endpoints: AUC, tmax and t½ PD endpoints: AUC-GIR, GIRmax and tGIRmax Safety endpoints: AEs, haematology, biochemistry, urinalyses, physical examination, vital signs, ECGs, blood glucose and local tolerability.",2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
8007,NCT01441986,Area under the blood glucose (BG) concentration-time profile,Adverse events,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
8008,NCT02137174,HBA1C,Hypoglycemia rate,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
8009,NCT02927639,Change in Self-Care Inventory (SCI) Score From Baseline to 6 Months,Change in Hemoglobin A1c (HbA1c) From Baseline to 6 Months,2018-07-31,COMPLETED,INTERVENTIONAL,['NA'],
8010,NCT04927858,Prevalence of a History of CVD Among Swedish Patients With T2DM Who Started Empagliflozin Treatment Between 1st of January 2015 and 31st of December 2017,,2018-04-02,COMPLETED,OBSERVATIONAL,['NA'],
8011,NCT00846248,insulin resistance,,2006-01,COMPLETED,INTERVENTIONAL,['NA'],
8012,NCT01774942,Glycosylated hemoglobin (HbA1a),high-sensitivity C-reactive protein (hsCRP),2008-06-01,COMPLETED,INTERVENTIONAL,['NA'],Retention of implants
8013,NCT03056456,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC [0-5 h]) of Following Administration of Each Study Arm With a Standard Dual-wave Bolus,Glucodynamics (GD): Change From Baseline Area Under the Concentration Curve From Time Zero to 5 Hours (AUC [0-5 h]) of Glucose Relative to MMTT Following Administration of Each Study Arm With a Standard Dual-wave Bolus,2017-02-23,COMPLETED,INTERVENTIONAL,['PHASE1'],
8014,NCT01889810,Change in Insulin Resistance,Health Status,2013-08,COMPLETED,INTERVENTIONAL,['NA'],
8015,NCT02443753,Safety and Tolerability will be evaluated as the incidence of AEs and SAEs/UADEs.,Efficacy as measured by Change in HbA1c (%),2015-05,TERMINATED,INTERVENTIONAL,['NA'],
8016,NCT03815552,time in range,time of hypoglycemia,2018-10-08,COMPLETED,INTERVENTIONAL,['NA'],
8017,NCT03903965,OCT Angiography parameters,aqueous humor cytokines levels,2018-09-01,COMPLETED,OBSERVATIONAL,['NA'],
8018,NCT04800861,glycemic control,average per patient,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],
8019,NCT05951140,Improve eating behavior towards healthier choices,Calculation of the Polygenic Risk Score,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],
8020,NCT01227473,"insulin resistance, as measured by the homeostatic model assessment-insulin resistance (HOMA-IR)",Insulin resistance as measured by the HOMA-IR,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8021,NCT02222350,change in 24-hour weighted mean blood glucose,change in postprandial plasma glucose level,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
8022,NCT02914691,Change in Urinary Peptide Patterns (Proteomics),,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
8023,NCT00960791,"Total recovery of radioactive dose, rate and routes of excretion of total radioactivity, metabolic pattern and metabolic profile, and PK variables of AZD1656 (AUC, Cmax, tmax, t1/2, Total Ae, CL/F and CLR)",Plasma Glucose,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
8024,NCT00064714,Change in basal C-peptide level,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
8025,NCT05391659,AUC,false positives and false negatives,2021-06-17,RECRUITING,INTERVENTIONAL,['NA'],
8026,NCT00264901,Comparison of the change from baseline to end of treatment,Within-subject variation of before-breakfast SMPG values at Visit 2 and Visit 3,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
8027,NCT03739125,Change from baseline in Glycosylated Hemoglobin (HbA1c),Evaluate safety of CKD-501 from number of participants with adverse events,2017-11-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
8028,NCT04476693,Total trial area under the curve (AUC) for insulin.,Total trial area under the curve (AUC) for triaclyglycerol,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],
8029,NCT04383041,Summary of Diabetes Self-Care Activities for Diabetes and Kidney Disease (SDSCA) Score,DTSQ Participation rate,2020-07-02,COMPLETED,OBSERVATIONAL,['NA'],
8030,NCT01590836,Area under the glucose infusion rate curve during one dosing interval,Maximum observed serum insulin aspart concentration,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
8031,NCT06131411,Glycated haemoglobin (HbA1c),Adherence to Mediterranean Diet,2023-11-07,RECRUITING,INTERVENTIONAL,['NA'],
8032,NCT05571800,Effect of mango consumption on glycemic control evaluated by HOMA-β,Effect of mango consumption on anthropometric measure WC/HC ratio,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],
8033,NCT01691365,Oxidative damage,Antioxidant status,2008-09,COMPLETED,INTERVENTIONAL,['PHASE4'],Infections
8034,NCT03206294,Measurement of biological test glycosylated haemoglobin evolution between the entrance and discharge,,2017-03-08,COMPLETED,INTERVENTIONAL,['NA'],
8035,NCT05059860,Time Control IQ system not in use,Hospital Anxiety and Depression questionnaire,2023-06-09,RECRUITING,OBSERVATIONAL,['NA'],Gold Hypoglycaemia questionnaire
8036,NCT01067950,"The primary end-point is the 5-year evaluation of efficacy/failure rate, a composite end-point including: (i) patient mortality and (ii) renal function impairment",Secondary objectives are to evaluate and to compare the safety and the efficacy of the two treatments (IPT versus IIT).,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],
8037,NCT03801824,Post meal blood glucose level,Maternal weight gain,2014-04,COMPLETED,INTERVENTIONAL,['NA'],Level of post-meal blood glucose
8038,NCT01741480,ICU Transfer,Mortality,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
8039,NCT02949739,>7% reduction in weight,Reduction of ≥5 cm waist circumference,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
8040,NCT05733195,GDM（Pregnancies with gestational diabetes mellitus and no gestational diabetes）,,2022-05-04,RECRUITING,OBSERVATIONAL,['NA'],
8041,NCT01734785,HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment,Body Weight Change From Baseline After 24 Weeks of Double-blind Treatment,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
8042,NCT05479214,Maternal Blood glucose readings,Neonatal outcomes,2022-07-29,COMPLETED,INTERVENTIONAL,['PHASE4'],
8043,NCT02855307,Percentage of time of plasma glucose levels spent below 3.9 mmol/L,Mean time (minutes) to the first hypoglycemic event,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
8044,NCT05259033,Change in glycated haemoglobin (HbA1c),Number of severe hypoglycaemic episodes (level 3),2022-04-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
8045,NCT06006468,Number of multi-islet autoantibody positive participants,Number of participants developing Coeliac disease,2023-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
8046,NCT04327622,Prevalence of diabetes foot complications: neuropathy risk,Association between foot risk variables and the presence of a foot ulcer,2020-03-03,COMPLETED,OBSERVATIONAL,['NA'],
8047,NCT01232673,Major limb amputation,Tissue perfusion measurements,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
8048,NCT02550548,Beta cell sensitivity,,2016-04-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
8049,NCT01969084,Phosphocreatine (PCR) Recovery Time After Exhaustive or up to 6 Minutes of Leg Exercise.,Changes in Circulating Endothelial Progenitor Cell Phenotypes,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
8050,NCT03702660,Glucagon,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],
8051,NCT02402361,Risk factors and determinants for neuropathic pain,,2016-04-01,COMPLETED,OBSERVATIONAL,['NA'],
8052,NCT00013052,,,na,COMPLETED,INTERVENTIONAL,['NA'],
8053,NCT02236481,Glycated Hemoglobin,Plasma levels of glucose,2013-07,TERMINATED,INTERVENTIONAL,['PHASE4'],
8054,NCT06287736,Change in PROMIS quality of life in relation to pain level,change in neuropathic symptoms using Michigan Neuropathy Screening instrument,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
8055,NCT04578964,Determining the effect of cardiovascular risk factors on the mean age of the first acute coronary syndrome,Model for calculating the acute coronary syndrome age,2014-01-02,RECRUITING,OBSERVATIONAL,['NA'],
8056,NCT03241212,Change in knowledge about type 1 diabetes,Percent of text messages responded to in the study.,2017-09-12,COMPLETED,INTERVENTIONAL,['NA'],
8057,NCT04497532,Amniotic fluid index (AFI) after 2 weeks,,2021-03-20,UNKNOWN,INTERVENTIONAL,['NA'],
8058,NCT01556594,Number of Participants With at Least One Adverse Event,Area Under the Curve (AUC0-last) of Baseline Adjusted Glucagon,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
8059,NCT01677013,C-peptide,adverse event,2011-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8060,NCT00400283,To determine the safety and the tolerability of ascending multiple oral doses of NNC 55 0414 in patients with type 2 diabetes.,,2001-01-19,COMPLETED,INTERVENTIONAL,['PHASE1'],
8061,NCT01068171,decrease in size of wound,non-healing wound,2010-05,WITHDRAWN,INTERVENTIONAL,['NA'],
8062,NCT04577976,Safety of the SMBG devices. The safety of self-monitoring of blood glucose (SMBG) when used to manage diabetes in a pediatric patient population will be characterized: Serious Adverse events,,2020-09-23,TERMINATED,OBSERVATIONAL,['NA'],
8063,NCT05857943,Sensitivity and Specificity,,2023-03-29,COMPLETED,INTERVENTIONAL,['NA'],
8064,NCT04090840,Weight loss,Hemoglobin a1c,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA'],
8065,NCT03908242,Plasma concentrations of salvianolic acid A,,2019-04-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],
8066,NCT01724385,The percentage of eyes that vitreous hemorrhage has been completely resolved,The change in best corrected visual acuity (BCVA) from baseline,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4'],Numbers of injection
8067,NCT05659537,Percentage of Participants with AEs and SAEs,Mean Change from Baseline in Hemoglobin A1c (HbA1c),2022-12-29,COMPLETED,INTERVENTIONAL,['PHASE4'],
8068,NCT01041768,Proportion of patients achieving diabetes complete remission (HbA1c 6% or below) or diabetes control (HbA1c between 7% and 6.1%) on free diet and with no antidiabetic medical therapy.,Stable reduction of preoperative HbA1c; BMI; mortality/morbidity; Major components of the metabolic syndrome; Diabetes complications; Improvement of beta-cell function; insulin resistance reduction ; Overall and CV disease mortality.,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],
8069,NCT02474381,Infrapopliteal arterial patency of the affected extremity,Amputation rate of the affected extremity,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],
8070,NCT00884819,Hepatic adiposity as assessed using MRI,"Reproductive parameters (androgens, hirsutism)",2008-12,TERMINATED,INTERVENTIONAL,['NA'],
8071,NCT03615807,Number of Participants Experiencing Clinical Failure,Number of Participants Experiencing Adverse Events Related to the Antibiotic Therapy,2017-02-16,COMPLETED,INTERVENTIONAL,['NA'],
8072,NCT04875858,Serotype-specific immunogenicity assessed by opsonophagocytic killing assay.,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2021-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8073,NCT00826904,Change in maternal postprandial lipemia,Correlation of neonatal adiposity and fetal growth,2007-10,COMPLETED,OBSERVATIONAL,['NA'],
8074,NCT03383146,Number of Participants With Anti-relamorelin Antibody Testing Results by Visit,,2018-02-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
8075,NCT01284608,Diabetes,Fracture Risk Assessment Tool (FRAx) assessment,2011-03,COMPLETED,OBSERVATIONAL,['NA'],
8076,NCT01589029,Regression of retinal neovascularizations (NVE and NVD) in FA.,Change in HbA1c and inflammatory markers,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1'],
8077,NCT02827383,Continuous Glucose Monitor,Heart Rate,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
8078,NCT00871416,"Location of the injected sterile, atmospheric air",Cutis/subcutis thickness on 14 recommended injection sites,1997-04-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
8079,NCT05307237,Infection Rate,Electronic Medical Record (EMR) - Derived Outcome: fasting POC blood glucose,2022-04-19,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Process Indicators (Maintenance): Stakeholder and advisory board feedback
8080,NCT01023945,Change in plasma glucose levels,Change in serum insulin levels,2009-11-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
8081,NCT03068286,Anxiety (as measured by the 7 item Generalised Anxiety Disorder inventory),Patient Experience (As measured by the Patient Experience Questionnaire),2017-01-01,TERMINATED,INTERVENTIONAL,['NA'],
8082,NCT03002545,questionnaire SF-36,,2016-12,COMPLETED,INTERVENTIONAL,['NA'],
8083,NCT00915954,Percentage With Growth Hormone (GH) Suppression to < 0.4 ng/ml,"Median Bioactive IGF-1 Area Under the Curve in Response to Placebo, OGTT, and rhIGF1 Testing",2008-12,COMPLETED,INTERVENTIONAL,['NA'],
8084,NCT01697150,Percent time of active CTR,Frequency analysis of lost data caused by system components,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
8085,NCT01828242,HbA1C,Fasting Blood Glucose,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Iron status
8086,NCT00082238,,,2003-03,COMPLETED,INTERVENTIONAL,['NA'],
8087,NCT03995238,Step Length Symmetry,World Health Organization Disability Assessment Scale 2.0,2019-10-09,RECRUITING,INTERVENTIONAL,['NA'],Socket Comfort Score
8088,NCT04624321,Change of long-term blood glucose concentration measured as glycated hemoglobin at one year,Insulin secretion,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],"Change of long-term blood glucose concentration measured as glycated hemoglobin in participants with and without Mild Obesity-related Diabetes, respectively."
8089,NCT02230891,Change in Cardiac Global Longitudinal Strain,Change in Troponin T Measured Using a High Sensitivity Assay,2014-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
8090,NCT06227819,Establish equivalence of BVA-200 to BVA-100,Usability,2023-05-23,COMPLETED,OBSERVATIONAL,['NA'],
8091,NCT01953757,Pain,Quality of life,2013-09,COMPLETED,INTERVENTIONAL,['NA'],Acceptability of vegan diet
8092,NCT02634879,Physician performance,Patient satisfaction,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
8093,NCT00312364,"Incidence of complete healing of target ulcer at endpoint or 90 days, whichever is earlier.","Incidence, intensity, and seriousness of adverse events. Changes in irritation scores.",2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
8094,NCT05464043,Retrospective study: characterization of hyperglycemia and diabetes after liver or kidney transplantation,Prospective: analysis of impaired glucose tolerance (prediabetes) and diabetes after liver or kidney transplantation,2019-06-20,COMPLETED,INTERVENTIONAL,['NA'],
8095,NCT03517527,Exercise Decisional Balance Scale,,2015-10-25,COMPLETED,INTERVENTIONAL,['NA'],
8096,NCT00548808,Change From Baseline to 48 Week Endpoint in Hemoglobin A1c (HbA1c),Safety: Number of Participants With Serious and Non-Serious Adverse Events,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
8097,NCT05451914,Change in Blood Glucose Control,Satisfaction/Usability of My Diabetes Care (for Intervention Group),2023-07-06,RECRUITING,INTERVENTIONAL,['NA'],
8098,NCT00367978,Time from baseline to the achievement of first treatment success (defined as achieving a blood pressure (BP) <130/80 mm Hg). The proportion and cumulative proportion of patients who achieved first treatment success were also determined.,change from baseline in estimated glomerular filtration rate (EGFR) at Week 24,2001-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
8099,NCT03505268,The impact of telehealthcare intervention on the change of the glycemic control in children with type 1 diabetes,,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA'],
8100,NCT03824379,Change of Human Serum Osteocalcin level,Quality of Life (QoL) Assessment: D-39 Questionnaire,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
8101,NCT00681850,"HbA1c, LDL-cholesterol, Systolic Blood Pressure","Glycaemia, Triglycerides, Total and HDL-Cholesterol, Diastolic Blood Pressure, Waist circumference, Smoking habits, Microalbuminuria, Body Mass Index, Physical activity (Rating scale and step counter), Degree of ophthalmic control and dietary advice",2008-03,COMPLETED,OBSERVATIONAL,['NA'],
8102,NCT04839575,Symptom Severity Reduction,,2021-04-06,TERMINATED,INTERVENTIONAL,['PHASE2'],
8103,NCT01450943,Wound Closure by Week 15,Cost Effectiveness,2011-10-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
8104,NCT05478967,Incidence of VH,Changes of BCVA,2019-08-08,COMPLETED,INTERVENTIONAL,['NA'],
8105,NCT01830998,MMSE Olfactory function dementia,,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],
8106,NCT03394313,Mortality,,2017-09-15,RECRUITING,OBSERVATIONAL,['NA'],
8107,NCT02921425,Systolic and Diastolic Blood Pressure,Change in Patient Activation,2014-07-01,COMPLETED,INTERVENTIONAL,['NA'],
8108,NCT04371978,Time to clinical change,"Time to virologic response, defined as no detection of SARS-CoV-2 in a PCR test.",2020-10-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
8109,NCT02761018,Reduction in hemoglobin a1c,,2017-08-08,COMPLETED,INTERVENTIONAL,['NA'],
8110,NCT06289933,Cmax,,2024-03,RECRUITING,INTERVENTIONAL,['PHASE1'],
8111,NCT00642798,Pharmacokinetics of sitagliptin after administration of single and multiple 100-mg doses of sitagliptin to healthy chinese adult subjects.,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
8112,NCT04864860,postprandial blood insulin concentration,side effect of ecklonia cava,2021-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8113,NCT05276128,glucose tolerance,Appetite sensations,2022-03-20,COMPLETED,INTERVENTIONAL,['NA'],Cognitive test variable
8114,NCT02738151,Change From Baseline in HbA1c to Week 24,"Hypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal ) Event Rate Per Participant Year During Study Period",2016-05-19,COMPLETED,INTERVENTIONAL,['PHASE4'],Change From Baseline in Total Diabetes Treatment Satisfaction Questionnaire (DTSQ) Status at Week 12 and Week 24
8115,NCT05626413,The risk of cardiovascular disease and events among patients with diabetes,,2015-01-01,RECRUITING,OBSERVATIONAL,['NA'],
8116,NCT00135915,,,2005-08,COMPLETED,OBSERVATIONAL,['NA'],
8117,NCT03098654,Retention in HIV care,Cost-effectiveness of integrating NCD screening and care with HIV screening and care,2018-02-05,COMPLETED,INTERVENTIONAL,['NA'],
8118,NCT00153088,Non-transition to overt nephropathy,Change in renal parameters Composite endpoint,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
8119,NCT05377333,Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,PK: Area Under the Concentration Versus Time Curve (AUC) of LY3457263,2022-06-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
8120,NCT00619697,HbA1c,Safety profile,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
8121,NCT04847856,"To compare the mean differences in the: Blood glucose level, BMI, Waist circumference between intervention and control groups","To compare the mean differences in the: HbA1C, Serum cholestrol, and blood pressure between intervention and control groups",2020-03-30,COMPLETED,INTERVENTIONAL,['NA'],To explore the knowlege and skills gained by nurse staff as a result of their participation in the trial intervention.
8122,NCT00251940,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),"• Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",2004-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
8123,NCT01366794,Release of gut hormones,Insulin secretion,2011-09,COMPLETED,INTERVENTIONAL,['NA'],
8124,NCT00914706,Change in monitoring frequency,,2009-06,COMPLETED,OBSERVATIONAL,['NA'],
8125,NCT02461914,Composite measure the plasma concentrations of warfarin,Incidence of adverse events and serious adverse events,2015-08-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
8126,NCT04274660,Change in diabetes self-management as assessed by the Diabetes Self-Care Activities Measure,Cost effectiveness,2017-09-08,COMPLETED,INTERVENTIONAL,['NA'],
8127,NCT03066089,Change in Postprandial sugar,"SGPT,SGOT,ALP,Creatinine,TLC,DLC & Hb",2015-12-14,COMPLETED,INTERVENTIONAL,['PHASE4'],
8128,NCT04418427,Time to worsening of DME disease activity in the study eye.,"Incidence of clinically significant findings via physical examinations, ocular examinations, imaging, and laboratory evaluation",2020-05-28,COMPLETED,INTERVENTIONAL,['PHASE2'],
8129,NCT04255264,Inflammatory status,,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
8130,NCT00506298,The primary efficacy endpoint will measure change in fasting plasma glucose from Baseline to Day 90,"The exploratory efficacy endpoints will measure change in the following parameters: HOMA Index, HgbA1C, fructosamine, LDL, HDL, OGTT, triglycerides and total cholesterol from Baseline to Day 90",2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
8131,NCT01742741,Effect size of Control-to-Range (CTR) vs. Continuous Glucose Monitor (CGM)-augmented insulin pump treatment in an outpatient setting.,Time spent in target range,2013-05,COMPLETED,INTERVENTIONAL,['NA'],Reliability of inter-device connections between DiAs and the CGM and between DiAs and the insulin pump.
8132,NCT03421301,intestinal microbiota,inflammatory profile,2014-08-07,COMPLETED,INTERVENTIONAL,['NA'],
8133,NCT00842192,HbA1c,Number of adverse drug reactions (ADR),2009-04,COMPLETED,OBSERVATIONAL,['NA'],
8134,NCT01106885,Participant cardiovascular risk index,Resource use,2005-05,COMPLETED,INTERVENTIONAL,['NA'],
8135,NCT03141892,System related adverse device effects and serious adverse effects,,2017-04-13,COMPLETED,OBSERVATIONAL,['NA'],
8136,NCT01701557,time to normalization of bicarbonate and pH,the length of treatment,2007-11,COMPLETED,INTERVENTIONAL,['NA'],
8137,NCT01067118,The primary endpoint for this third phase is daytime (6 am to midnight) average glucose values.is percent of CGMS glucose values in range (70-180 mg/dL) for the third week fo sensor data in each group.,,2010-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
8138,NCT01388153,Difference of postprandial Area under curve from 0 to 4 hours (AUC(0-4)) of blood glucose following sucrose load without (Day 1) and with Glucobay (Day 2),Tmax of serum insulin following sucrose load without (Day 1) and with Glucobay (Day 2),2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
8139,NCT01268644,HbA1c,Change in HbA1c From Baseline to Week 20 on Leptin Therapy,2010-09,TERMINATED,INTERVENTIONAL,['PHASE1'],
8140,NCT06313008,Troponin (ng/ml),FBG (mg/dl),2023-08-10,RECRUITING,INTERVENTIONAL,['NA'],
8141,NCT05050019,the incidence of disruptions to insulin pump therapy or continuous glucose monitoring in patients with diabetes mellitus as a result of hospitalization or medical test,,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA'],
8142,NCT01355536,The prevalence of Diabetes Mellitus,Serum levels of insulin,2006-10,COMPLETED,OBSERVATIONAL,['NA'],
8143,NCT03652649,Type 2 diabetes remission,Hunger scale scores,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],
8144,NCT05052918,Carotid ultrasound,,2021-09-08,RECRUITING,INTERVENTIONAL,['NA'],
8145,NCT01629277,Primary efficacy outcome measure,Secondary efficacy outcome measure,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
8146,NCT03372005,Blood pressure,,2017-09-12,UNKNOWN,INTERVENTIONAL,['NA'],
8147,NCT04451109,Rate of overall vaginal delivery,Rate of caesarean sections,2020-12-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
8148,NCT03407118,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to 10 Hours (AUC 0-10h) Following Administration of Each Treatment Arm,Glucodynamics (GD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp Following Administration of Each Treatment Arm,2018-02-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
8149,NCT05040087,β-CELL FUNCTION - PRIMARY OUTCOME #2c.,COST EFFECTIVENESS - to be explored only if additional (ancillary) funding can be obtained,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],
8150,NCT00168519,glucose metabolism,,2002-10,COMPLETED,INTERVENTIONAL,['NA'],
8151,NCT05856149,Percent weight change three months post intervention,Program Evaluation - Program Satisfaction,2023-04-19,RECRUITING,INTERVENTIONAL,['NA'],
8152,NCT01002339,Primary Outcome Measure (Glucose Intolerance),Percentage of Patients Using Acetylsalicylic Acid (ASA),2010-02,TERMINATED,INTERVENTIONAL,['PHASE4'],
8153,NCT04356742,Change from the baseline in HbA1c (%) after 24 weeks,Change from the baseline in weight after 24 weeks,2020-05-26,COMPLETED,INTERVENTIONAL,['PHASE3'],
8154,NCT04159558,Satisfaction with the mobile application assessed by an ad hoc questionnaire,Treatment adherence assessed by Morisky Medication Adherence Scale (MMAS),2018-04-24,UNKNOWN,INTERVENTIONAL,['NA'],Health goals compliance assessed by an ad hoc questionnaire
8155,NCT05556954,The percent change in foot ulcer surface area (cm2) after 12 weeks of observation for either infected or non-infected diabetic foot ulcers,Proportion of participants that reach a 50% reduction in surface area of the DFU for both cohorts,2022-10-13,RECRUITING,OBSERVATIONAL,['NA'],
8156,NCT03936036,"Relative hazard of composite outcome of Stroke, MI, and Mortality",,2017-09-22,COMPLETED,OBSERVATIONAL,['NA'],
8157,NCT01068860,"Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-2 Hours, From Baseline to 4 Weeks.","Number of Participants Reporting Death, Serious Adverse Events (SAEs) and Adverse Events (AEs) Above 5% Frequency, From Baseline to 4 Weeks",2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
8158,NCT01159847,The effects of sitagliptin on β cell function and insulin sensitivity of LADA patients,The possible immunomodulatory effects of sitagliptin on LADA patients,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8159,NCT06000371,"Dimensions of diabetic foot ulcer (manual measurement of length, width and depth of the ulcer by metal ruler).",,2020-04-25,COMPLETED,OBSERVATIONAL,['NA'],
8160,NCT03751657,Change in HbA1c [Millimoles/Mole (mmol/Mol)],Change in Anti-insulin 287 Antibody Level,2018-11-29,COMPLETED,INTERVENTIONAL,['PHASE2'],
8161,NCT01986855,Percentage of Participants Who Discontinued Study Treatment Due to an AE,Percentage of Participants With A1C <7.0% (<53 mmol/Mol) at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
8162,NCT04176731,Percentage of Time in Range 70-180 mg/dL During Overall (Days 1-14) and Standard Therapy Period (14 Days),"Total Daily Bolus Insulin (Units, Units/kg)",2019-12-15,COMPLETED,INTERVENTIONAL,['NA'],
8163,NCT00523835,,,2002-04,COMPLETED,OBSERVATIONAL,['NA'],
8164,NCT00980941,Appetite,Palatability of treatments,2007-12,COMPLETED,INTERVENTIONAL,['NA'],
8165,NCT03105011,Absolute change in laboratory-measured HgbA1C,,2017-03-13,COMPLETED,INTERVENTIONAL,['NA'],
8166,NCT03721991,insulin production,metabolic parameters quality of life,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA'],
8167,NCT02356757,Ulcerative and non-ulcerative Foot lesions,Cost-effectiveness,2015-08-24,COMPLETED,INTERVENTIONAL,['NA'],
8168,NCT05734313,Depressive symptom severity,Hemoglobin A1c (HbA1c),2023-10-31,RECRUITING,INTERVENTIONAL,['NA'],Anxiety symptom severity
8169,NCT01108276,Overall decrease in wound size,,2010-05,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
8170,NCT00167778,Local Dynamic Stability (Ankle During Turning With the Prosthesis on the Outside of the Turn),How Bothersome Was Your Pain?,2005-01,COMPLETED,INTERVENTIONAL,['NA'],
8171,NCT03970122,Urine PK parameters: CLR,,2019-05-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
8172,NCT00790491,"Validate the AUGMENT dietary and physical activity assessments using dietary recalls and accelerometer data,",Survey participating providers and patients to assess acceptability of AUGMENT within a clinical setting.,2007-10,COMPLETED,INTERVENTIONAL,['NA'],
8173,NCT05095610,HbA1c difference,Insulin dose,2021-11-01,COMPLETED,OBSERVATIONAL,['NA'],
8174,NCT03033407,glycated hemoglobin levels,change in blood pressure within each group,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
8175,NCT04756011,Evaluation of health-related quality of life (HRQL),,2020-03-15,COMPLETED,OBSERVATIONAL,['NA'],
8176,NCT01328639,Change in Patient Health Questionnaire-9 items (PHQ-9) score,Change in Satisfaction with care,2010-11,COMPLETED,INTERVENTIONAL,['NA'],
8177,NCT02320110,Correlation of irisin leves with risk factors for metabolic syndrome in Hispanic children,"Irisin plasma levels and adiponectin, leptin, insulin and resistin.",2014-09,COMPLETED,OBSERVATIONAL,['NA'],
8178,NCT00231894,2 Hour Glucose From Glucose Tolerance Test US Sample,Change From Baseline in Serum HDL at 3 Months (3 Months-baseline) China Site,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
8179,NCT01415037,Change in detection of posterior vitreous detachment: 20MHz annular array versus 10MHz single element,,2011-10,COMPLETED,OBSERVATIONAL,['NA'],
8180,NCT02066766,Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,2015-04-22,COMPLETED,OBSERVATIONAL,['NA'],
8181,NCT00790257,Inflammatory/immunological reaction and insulin production,- Encapsulated human islets function and biocompatibility,2008-11,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
8182,NCT03977116,ventricular arrhythmias recurrence,hospitalization for heart failure worsening,2017-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
8183,NCT01417845,Exercise Capacity,,2011-09,COMPLETED,INTERVENTIONAL,['NA'],
8184,NCT03687827,"Percentage of Time Spent in Glycaemic Target Range 70-180 mg/dL (3.9-10.0 mmol/L) Both Inclusive, Using Flash Glucose Monitoring (FGM)",Mean Glucose Levels Using Flash Glucose Monitoring (FGM),2018-10-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
8185,NCT04181996,6 month change in FDG uptake TBR (Tissue to Blood Ratio) in the MDS (Maximum Disease Segment),Levels of Interleukin-6 (IL-6) (pg/ml) and its change.,2020-08-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Exploratory outcomes - the effect on quality of life outcomes
8186,NCT05268393,Interventionist adherence to session manuals,Glycemic control,2022-03-31,COMPLETED,INTERVENTIONAL,['NA'],
8187,NCT06246279,Reynolds Adjustment Screening Inventory for Adolescents,Glycemic Control - Hemoglobin A1C,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],
8188,NCT01898702,Glycosylated hemoglobin A,Health services utilization,2013-05,UNKNOWN,INTERVENTIONAL,['NA'],
8189,NCT00880139,Arteriolar to venous ratio,"Systolic/diastolic arterial blood pressure, pulse rate",2009-06,TERMINATED,OBSERVATIONAL,['NA'],
8190,NCT05965336,Biomechanical modulation of ankle stiffness,Changes induced by biofeedback in biomechanics during gait,2024-05,RECRUITING,INTERVENTIONAL,['NA'],
8191,NCT03103854,HbA1C at 12 months,HbA1C at 3 months,2014-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
8192,NCT00005530,,,1994-05,COMPLETED,OBSERVATIONAL,['NA'],
8193,NCT04249102,To evaluate the change in baseline hypoglycemia after 8-week Continuous Glucose Monitoring system use,To evaluate the change in the quality of life of patients with and without impaired hypoglycemia awareness using Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system.,2020-03-12,UNKNOWN,INTERVENTIONAL,['NA'],
8194,NCT02283411,Safety of the Abbott Sensor Based Glucose Monitoring Systems Was Characterized by Adverse Device Effects and Serious Adverse Device Effects Experienced by Study Participants.,The Point Accuracy of the Device Performance Was Evaluated in Reference to Capillary Blood Glucose (BG).,2014-11,COMPLETED,INTERVENTIONAL,['NA'],
8195,NCT01005121,24 hr urine protein collection,,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
8196,NCT03566472,SDBG,,2018-06-12,UNKNOWN,OBSERVATIONAL,['NA'],
8197,NCT02352246,loss of abdominal fat mass (g),Change from baseline in food behavior after training (visual analog scale from Flint et al. 2000),2015-02,UNKNOWN,INTERVENTIONAL,['NA'],
8198,NCT01934712,Area under the serum insulin aspart concentration-time curve,Area under the glucose infusion rate (GIR) curve,2013-08-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
8199,NCT05275231,Acceptability: Changes in Satisfaction questionnaire,Changes in weight of participant's social contact,2022-04-04,COMPLETED,INTERVENTIONAL,['NA'],
8200,NCT01417897,Nitrotyrosine,intact Proinsulin,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8201,NCT00005266,,,1990-09,COMPLETED,OBSERVATIONAL,['NA'],
8202,NCT00798785,Evidence of clinically relevant beta cell graft function,,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8203,NCT00231387,"The effect of 52 wks oral treatment with rosiglitazone in comparison to placebo on change from baseline of the plaque total wall volume in the carotid artery, in patients with type 2 dm and vascular disease/hypertension, using cardiac mri.","These include magnetic resonance endpoints related to plaque lipid content, volume, plaque size and fibrous cap thickness. Colour duplex measurements, laboratory assays for glycaemia and lipids.",2002-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
8204,NCT00301392,Cumulative incidence of diabetes based on 1 positive OGTT or fasting glucose levels,Number of adverse events,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
8205,NCT02574195,Percentage of patients with diabetes mellitus type 1 and type 2diabetes mellitus complications,"Structure of antidiabetic therapy (% insulin, % OAD mono, % OAD dual, % OAD triple)",2015-08,COMPLETED,OBSERVATIONAL,['NA'],
8206,NCT01123122,Islet cell function,,2011-09,WITHDRAWN,INTERVENTIONAL,['NA'],
8207,NCT04959487,Change in food insecurity severity from baseline to six months by study arm,Change in diabetes self-efficacy from baseline to six months by study arm,2021-08-23,RECRUITING,INTERVENTIONAL,['NA'],Durability in scores of food security from six to twelve months in the intervention arm.
8208,NCT04826159,Change in cardiac PCr/ATP ratio with dobutamine stress (Stage 1 only) measured by 31P-MRS at baseline and at EOT with 200 mg BID of IMB-1018972,"Safety and tolerability of IMB-1018972 as measured by incidence and severity of treatment emergent AEs (including AEs leading to study drug discontinuation and AEs leading to death), as well as incidence of treatment emergent SAEs",2021-04-21,RECRUITING,INTERVENTIONAL,['PHASE2'],
8209,NCT01013792,Percent Diabetic Foot Ulcer Area Reduction From Baseline to Last Treatment Visit,,2009-11,TERMINATED,INTERVENTIONAL,['NA'],
8210,NCT01297946,Percentage of time of plasma glucose concentrations spent in target range (4.0-10.0 mmol/l from 4:00p.m.-11:00p.m. and 4.0-8.0 mmol/l from 11:00p.m.-7:00a.m.),Number of subjects with at least one exercise-induced plasma glucose measurement below 3.0 mmol/l.,na,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8211,NCT00276497,Reduction in conversion of IGT to diabetes,benefits of the drug on anthropometric variables and biochemical parameters,2003-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
8212,NCT01819129,Change From Baseline in HbA1c,Change From Baseline in Body Weight,2013-09-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
8213,NCT00145093,To determine the effect of Baker's yeast treatment on glycemicic control and insulin resistance when given in combination with oral blood glucose lowering therapy to patients with type 2 diabetes mellitus,"To determine the effect of Baker's yeast treatment on serum lipids, blood pressure, body fat percentage and BMI when given in combination with oral blood glucose lowering therapy to patients with type 2 diabetes mellitus",2004-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
8214,NCT04373967,glycated hemoglobin (HbA1c),Percentage of participants with clinically significant change from baseline in laboratory parameters.,2020-04-29,UNKNOWN,INTERVENTIONAL,['PHASE3'],
8215,NCT05719740,"to test and evaluate the role of bone-derived factor (osteocrin) in glucose metabolism,in diabetic patients with risk of micro and macrovascular complications .","to identify bone-derived factor (osteocrin) may provide as new perspectives on the prediction, prevention, and treatment of diabetes mellitus",2023-02,RECRUITING,OBSERVATIONAL,['NA'],
8216,NCT05453344,Change in HbA1c,rtCGM measurements,2022-08-10,RECRUITING,INTERVENTIONAL,['NA'],
8217,NCT06117631,Determine how parent support coaching and other predictors relate to infant and toddler growth in Latino children in first 2 years of life.,,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],
8218,NCT01264263,"Measurement of intima media thickness, visit 2","hs-C-Reactive Protein, visit 2",2011-01,COMPLETED,OBSERVATIONAL,['NA'],
8219,NCT04125329,Incidence of Treatment-Emergent and Treatment-Chronic Adverse Events of human umbilical cord mesenchymal stem cells for diabetic nephropathy patient,Changes in eGFR before and after treatment; Changes in 24h urine protein quantification before and after treatment,2020-04-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
8220,NCT03641352,Change from baseline in Glycosylated Hemoglobin,Change from baseline in Apo-AⅠ,2018-05-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],
8221,NCT04419779,Demonstrate superiority of Revita DMR to sham in improving glycemic control,Demonstrate superiority of Revita DMR to sham in elimination of insulin use at 24 weeks,2021-03-08,RECRUITING,INTERVENTIONAL,['NA'],
8222,NCT04962399,rs1800796,,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
8223,NCT04322071,Thematic Analysis,,2020-02-26,UNKNOWN,OBSERVATIONAL,['NA'],
8224,NCT01964521,Changes in Signs and Symptoms of Local Infection,Levels of Pain in Connection to Dressing Changes.,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
8225,NCT06055036,Cardiovascular Health,"Identify the organizational context and resources necessary to align, coordinate, and sustain academic-community-government partnerships focused on advancing cardiovascular health equity.",2023-08-24,RECRUITING,INTERVENTIONAL,['NA'],
8226,NCT03207893,Medication changes,change in psychological functioning (attitude towards glucose monitoring questionnaire),2018-07-19,COMPLETED,INTERVENTIONAL,['NA'],
8227,NCT06020846,Blood glucose level,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],
8228,NCT02703337,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) (Part B),Pharmacodynamics (PD): Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT) (Part B),2016-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
8229,NCT05908968,Reduction in wound area,Complete wound closure,2017-09-19,COMPLETED,INTERVENTIONAL,['NA'],
8230,NCT04203563,Change from Baseline in American Heart Association's Life's Simple 7 score at 12 Weeks,Change from Baseline Stress at 12 Weeks,2019-08-20,COMPLETED,INTERVENTIONAL,['NA'],
8231,NCT03646292,liver fat change measured by MRI-PDFF in co-localized regions of interest within each of nine liver segments,The changes in inflammation status,2018-12-19,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8232,NCT00626249,Differences in exposure to fumaryl diketopiperazine (FDKP),Additional safety parameters,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
8233,NCT03920397,Glycemic control after an adipose tissue-derived stem/stromal cells,Oral cholecalciferol 2000UI/day supplementation,2015-03-01,COMPLETED,INTERVENTIONAL,['NA'],
8234,NCT04048642,Change in total daily insulin requirements,Change in urinary catecholamines,2020-12-01,COMPLETED,INTERVENTIONAL,['NA'],
8235,NCT02371343,Birth size,Insulin like growth factor DNA methylation,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],
8236,NCT02726100,"The proportion of patients achieving at least two ""ABC"" goals",Mean change in the Summary of Diabetes Self-Care Activities (SDSCA) from baseline to 24 month,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],Mean change in estimated glomerular filtration rate (GFR)
8237,NCT00443755,Change From Baseline in Insulin Sensitivity as Measured by Glucose Infusion Rate (GIR),Change From Baseline in the Inflammatory Biomarker Adiponectin,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline in Fat-Free Mass (FFM)
8238,NCT01809730,Transfusion within 48 hours post-op,,2012-05,WITHDRAWN,OBSERVATIONAL,['NA'],
8239,NCT03976271,Inflammatory responses of hypoglycaemia by measuring the cytokine production of isolated monocytes using ELISA,Oxidative stress responses using oxidative stress marker,2019-08-12,COMPLETED,INTERVENTIONAL,['NA'],
8240,NCT01462266,Change From Baseline in Daily Insulin Dose at Week 24,Time to Achieve the Fasting Glucose Target,2012-01-13,COMPLETED,INTERVENTIONAL,['PHASE3'],
8241,NCT01298076,Visual acuity gain,Safety,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
8242,NCT05357534,average running speed,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
8243,NCT04453605,Incidence of microvascular complication,Change of HbA1c through study completion (an average of 5 year),2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],
8244,NCT00390975,Proportion of patients treated with tegaserod that improve gastric emptying at Week 2 as compared with baseline via a solid phase technetium gastric emptying time (GET),The safety and tolerability of tegaserod,2007-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
8245,NCT06015685,Change in feasibility of intervention measure (FIM) scores,Change in urine microalbumin,2023-10-20,RECRUITING,INTERVENTIONAL,['NA'],
8246,NCT00388388,Effect of 6 months of losartan or hydrochlorothiazide on media/lumen ratio of gluteal subcutaneous resistance arteries in otherwise normal subjects who fulfill criteria for pre-hypertension and pre-diabetes,"Safety and tolerability of 6 month therapy with losartan or hydrochlorothiazide, and effect on media thickness, lumen diameter and vascular function of gluteal subcutaneous resistance arteries, and serum and tissue inflammatory markers in same subjects",2007-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
8247,NCT00398619,"Assessment of ECGs, laboratory results and physical exams for adverse events",,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
8248,NCT01450787,Conjunctival Staining Score,Tear Film Osmolarity,2012-01,TERMINATED,OBSERVATIONAL,['NA'],Corneal Staining
8249,NCT02460354,Change in mean urine osmolality,Change in mean urine volume,2015-09,TERMINATED,INTERVENTIONAL,['PHASE1'],
8250,NCT00456352,Treatment success based on patients' glycemic control.,"Physiologic measurements, Comorbidity improvement, Improvement in QOL.",2007-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
8251,NCT02871882,Change in Postprandial Glucose,,2016-09-15,COMPLETED,INTERVENTIONAL,['PHASE2'],
8252,NCT02263352,Change in Serum MDA,Change in Clinical attachment level (CAL),2013-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
8253,NCT05743244,The area under the stimulated C-peptide curve (Y_AUC),,2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE2'],
8254,NCT05821322,Change in plasma glucose during exercise,Carbohydrate needed (g),2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],
8255,NCT01413204,Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value),"Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events, Laboratory Tests, 12-lead ECG and Vital Signs",2011-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
8256,NCT03598855,Changes in vascular function,Change cerebrovascular function,2017-06-01,COMPLETED,INTERVENTIONAL,['NA'],Change in insulin sensitivity
8257,NCT01050166,Evidence of safety and efficacy of MRI imaging of transplanted human labeled islets,,2008-08-15,COMPLETED,OBSERVATIONAL,['NA'],
8258,NCT02933788,platelet reactivity testing,"Observation of Clinical laboratory data(total cholesterol, HDL, LDL and triglyceride",2016-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8259,NCT02231658,Change from baseline (week -1) in the number of reflux episodes,Change from baseline (week -1) in the time of pH < 4.0 in the lower third of the oesophagus,2015-07-16,TERMINATED,INTERVENTIONAL,['PHASE1'],
8260,NCT01359241,Percent of plasma glucose values within target range 3.9-8.0 mmol/l,Frequency of hyperglycaemia,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
8261,NCT03504605,Self-compassion items,,2018-08-15,COMPLETED,INTERVENTIONAL,['NA'],Pediatric Inventory for Parents
8262,NCT00656435,The severity of intraoperative bleeding and vitreous clear-up time.,Percentage of prolonged vitreous clear-up (≥ 3 weeks) and recurrent hemorrhage rate.,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
8263,NCT00838799,Change in mean daily pain rating,50% reduction in pain,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
8264,NCT02377531,Composite Perinatal morbidity,Maternal weight gain,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],
8265,NCT05331469,Hba1c reduction,Weight changes after intervention,2021-07-19,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8266,NCT02559128,Exercise capacity,Endothelial function,2013-12,UNKNOWN,OBSERVATIONAL,['NA'],
8267,NCT00681161,"blood glucose level, composite autonomic system score (CASS), homeostasis assessment model (HOMA), insulin sensitivity index (ISI)",,2006-03,COMPLETED,INTERVENTIONAL,['NA'],
8268,NCT02563522,Proportion of Subjects With a Target Wound Closure by the 4-month Follow-up Visit,,2017-06-27,TERMINATED,INTERVENTIONAL,['PHASE3'],
8269,NCT06069076,Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease.,correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on urinary Albumin- Creatinine Ratio.,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
8270,NCT00973401,"Changes in amplitude/implicit times, retinal vessel diameter, dark adaptation and OCT",,2009-09,UNKNOWN,OBSERVATIONAL,['NA'],
8271,NCT03765164,Diagnosis-Treatment,Workup Costs,2018-11-05,COMPLETED,INTERVENTIONAL,['NA'],
8272,NCT03183726,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Wound size and depth measurement,2016-01-11,COMPLETED,OBSERVATIONAL,['NA'],
8273,NCT06033664,Number of participants with a percentage change in Hemoglobin A1C (HbgA1C),Change in food insecurity,2023-11-06,RECRUITING,INTERVENTIONAL,['NA'],
8274,NCT01843881,"Change in Total Disposition Index from Study 1 (Exendin 9,39) to Study 2 (saline)",,2012-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
8275,NCT01777282,Number of Participants With Any Hypoglycemic Event,Time to Study Withdrawal Due to Hyperglycemia,2013-02-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
8276,NCT01492283,The Incretin effect,Plasma glucagon response,2011-12,COMPLETED,OBSERVATIONAL,['NA'],
8277,NCT02836808,Diabetes control after 4 visits in a structured multidisciplinary program for patients with diabetes,Quality of life after 4 visits in a structured multidisciplinary program for patients with diabetes,2013-10-31,RECRUITING,INTERVENTIONAL,['NA'],Social-economic impact of living and eating expenses of a multidisciplinary intervention for patients with diabetes
8278,NCT05431686,"Perceived benefit of the SMA intervention content, as measured by user satisfaction surveys summary statistics (mean and standard deviation as well as percent answering a specific Likert level)",CGM Benefits and Burdens scale,2022-02-16,RECRUITING,INTERVENTIONAL,['NA'],
8279,NCT06290947,Improvement in Aerobic Capacity,Change in Body Mass Index (BMI),2022-03-06,COMPLETED,INTERVENTIONAL,['NA'],
8280,NCT03037255,Number of patients who died from any cause by the end of the study censoring period,Number of patients who received guideline recommended therapy during the study period,2003-01,COMPLETED,OBSERVATIONAL,['NA'],
8281,NCT00704197,To assess sex differences in adipose tissue gene expression in different fat depots,To assess sex differences in other characteristics of adipose tissue structure and function in different fat depots across sex including: preadipocyte kinetics; lipolysis and lipogenesis; macrophage content; and tissue oxygenation,2007-08,TERMINATED,OBSERVATIONAL,['NA'],
8282,NCT01785108,"Change in C-peptide (90 minute value and AUC mean 0-120 min) during a Mixed Meal Tolerance Test from baseline to month 6, 15 and 30","Fasting C-peptide, change between baseline and month 6, 15 and 30",2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
8283,NCT04498819,Feasibility: Adherence,Participant Attitudes: Diabetes Emotional Distress,2020-11-09,COMPLETED,INTERVENTIONAL,['NA'],
8284,NCT00157482,"LDL-cholesterol, at 16 weeks of treatment. LDL-cholesterol is measured at -4, 0, 8, 12 and 16 weeks.","Urinary albumin excretion, at -4, 0, 8 and 16 weeks",2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
8285,NCT00625833,Change from baseline in weekly average pain score,Modified Brief Pain Inventory-Short Form,2007-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
8286,NCT00737776,HbA1c change,Diabetes Fear of Self-Injection Questionnaire (D-FISQ),2008-05,COMPLETED,OBSERVATIONAL,['NA'],
8287,NCT02839031,Glycated hemoglobin (HbA1c) level,,2015-03-11,TERMINATED,INTERVENTIONAL,['NA'],
8288,NCT05383404,measured degree of dehydration,,2022-06-25,RECRUITING,OBSERVATIONAL,['NA'],
8289,NCT00588172,Change in glucose area under the curve after a mixed meal in response to metformin,Change in glucose disappearance and suppression of endogenous glucose production in response to metformin,2010-06,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
8290,NCT03388723,Epigenetic signatures in the cord blood of the offspring of GDM mothers.,Qualitative and quantitative comparison of epigenetic signatures in the offspring of GDM mothers [Indian and Danish cohort].,2014-09-02,COMPLETED,OBSERVATIONAL,['NA'],
8291,NCT00448526,time to the doubling of sCr,% change of urinary albumin and protein excretion from baseline,1997-12,TERMINATED,INTERVENTIONAL,['NA'],
8292,NCT02417935,Change From Baseline to 12 Weeks in the Weekly Mean of the 24-Hour Average Pain Score on the 11-Point Numeric Rating Scale (NRS),Number of Participants With a 30% and 50% Reduction in the Weekly Mean of the 24-Hour Average Pain Score on the 11-Point NRS at 12 Weeks,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
8293,NCT00592904,Mean Change From Baseline in SF-MPQ Current Pain Intensity (CPI): From Baseline to Week 48,Mean Change From Baseline in Short Form 36 Item (SF-36) Health Survey: Physical and Mental Component Scores From Baseline to Week 48/EOT,2008-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
8294,NCT03428295,Percentage of time in severe hyperglycemic range,,2017-06-22,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8295,NCT01182480,Patient Engagement,Glycemic Control,2010-05,COMPLETED,INTERVENTIONAL,['NA'],
8296,NCT03059277,Change in Central Subfield Thickness (CST),Number of Intravitreal Injections,2018-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
8297,NCT00031226,,,2004-09,COMPLETED,OBSERVATIONAL,['NA'],
8298,NCT05367063,Change in myocardial micro-perfusion,Change in resting mocardial blood flow,2022-01-05,RECRUITING,INTERVENTIONAL,['PHASE4'],
8299,NCT05337644,Positive Intraoperative Indocyanine green test,,2022-01-21,COMPLETED,OBSERVATIONAL,['NA'],
8300,NCT01550809,The Area Under the Curve (AUC) of the Glucose Infusion Rate (GIR) During the 5-hour Postprandial Period (AUC-GIR0-5h).,The Area Under the Curve (AUC) of Plasma Glucose (PG) Above the Threshold of 140 mg/dl (AUC-PG>140).,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
8301,NCT05418569,Self/Parent-reported questionnaires on hypoglycemia frequency,Self-reported smartphone application usage satisfaction,2021-07-01,RECRUITING,INTERVENTIONAL,['NA'],
8302,NCT00147719,To assess the additional lowering of HbA1C achieved by addition of colesevelam hydrochloride to current antidiabetic therapy,To assess the safety and tolerability of colesevelam hydrochloride when added on to current therapy,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
8303,NCT02988427,Diabetes Self-efficacy,Clinical Outcomes,2016-12,WITHDRAWN,OBSERVATIONAL,['NA'],
8304,NCT04013919,Glucose levels,,2019-09-20,UNKNOWN,OBSERVATIONAL,['NA'],
8305,NCT01126580,Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c),Measurement of LY2189265 Drug Concentration for Pharmacokinetics: Area Under the Concentration Curve (AUC),2010-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
8306,NCT00676208,Change in Confidence in Ability to Perform Teamwork,Change in Professionals' Attitudes About Diabetes,2008-04,COMPLETED,INTERVENTIONAL,['NA'],
8307,NCT03090451,Non-insulin mediated glucose uptake (NIMGU),Time spent in hyperglycemia,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],
8308,NCT03602963,Accuracy of the Dexcom G5 mobile continuous glucose monitoring (CGM) system by comparison of sensor glucose measurements with capillary blood glucose determinations,Patients' and parents' satisfaction with the Dexcom G5 mobile CGM system will be evaluated by a standardized questionnaire,2018-07-09,COMPLETED,OBSERVATIONAL,['NA'],
8309,NCT01630369,Decrease of Hb A1c ≥ 1%,Assessment of efficacy of education courses in Diabetes Schools,2012-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
8310,NCT02214719,Glucose control - A1c,Long term use,2014-08,COMPLETED,INTERVENTIONAL,['NA'],
8311,NCT01881009,Target Sensor Glucose 70-150 mg/dl,Target Sensor Glucose 70-180 mg/dl,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
8312,NCT02530450,The Primary Outcome Measure Was Change in HgbA1c,"% Time Spent in Hypoglycemia, Hyperglycemia, and Euglycemia",2011-05,COMPLETED,OBSERVATIONAL,['NA'],
8313,NCT06314048,Diabetes distress measured at baseline and 12 months post-diagnosis.,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
8314,NCT02266576,Change From Baseline in the Quality of Life Short Form Survey (SF-12),Change in From Baseline in Empowerment,2015-06,COMPLETED,INTERVENTIONAL,['NA'],Lipid Bioassays
8315,NCT00233259,Hemoglobin A1c,Social support,2006-03,COMPLETED,INTERVENTIONAL,['NA'],
8316,NCT03415295,Gestational diabetes mellitus,,2012-08-01,COMPLETED,OBSERVATIONAL,['NA'],
8317,NCT05291013,Muscular insulin sensitivity,Metabolomics,2022-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
8318,NCT03426345,Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period,Number of Participants With Anti-relamorelin Antibody Testing Results by Visit,2018-02-16,TERMINATED,INTERVENTIONAL,['PHASE3'],
8319,NCT05307042,Decline renal concentration ability,Decline in kidney-function,2022-05,UNKNOWN,OBSERVATIONAL,['NA'],
8320,NCT01546766,Pupillary response,Pupillary response.,2007-02,COMPLETED,OBSERVATIONAL,['NA'],
8321,NCT01067963,"Primary outcomes utilized in this study will be disease burden (measured as diabetes-related distress), quality of life (measured as health related QOL), and glycemic health (measured as hemoglobin A1C).",Secondary exploratory outcomes for quality of life include measures of health-related quality of life for diabetes and overall quality of life.,2009-12,TERMINATED,INTERVENTIONAL,['NA'],
8322,NCT02159417,The feasibility of the application of the action ETP in the MAPLS,The satisfaction of the staffs as for the implementation and the realization of the experiment,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
8323,NCT05758467,Cardiovascular health and oral health,,2019-07-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
8324,NCT00451113,Safety and efficacy of Sitagliptin in an elderly population with type 2 diabetes,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
8325,NCT00730561,Change in nerve conduction velocity,,2006-03,COMPLETED,INTERVENTIONAL,['NA'],
8326,NCT02245399,change in HbA1c,urinary analyses,2014-10,COMPLETED,INTERVENTIONAL,['NA'],Estradiol level
8327,NCT03252964,Program Completion Rate (%),Coaching Participation Rate,2017-07-28,COMPLETED,INTERVENTIONAL,['NA'],
8328,NCT04447859,Gastrointestinal adverse events (GI-AEs),,2020-02-23,UNKNOWN,INTERVENTIONAL,['PHASE3'],
8329,NCT02704494,Serum creatinin,Number of patients with adverse events,2016-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
8330,NCT01422057,Major cardiovascular event,Total mortality,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],
8331,NCT01834144,"Time Spent in Hypoglycaemia in the 12-hour Period Following Exercise, Defined as an Interstitial Glucose Reading <4.0mmol/L and Measured by Continuous Glucose Monitor.","Glycaemic Variability, Measured by the Mean Amplitude of Glycaemic Excursions (MAGE), in the 12-hour Period Following Exercise. This is Calculated From the Same Continuous Glucose Monitor Data as the Primary Outcome.",2013-05,TERMINATED,INTERVENTIONAL,['NA'],
8332,NCT00663260,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF],Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF]),2008-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
8333,NCT06035406,PK parameters：AUC0-∞；,Incidence and severity of adverse events (AEs),2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
8334,NCT02927678,"Rate of remission of osteomyelitis at one year after the cessation of antibiotic treatment, evaluated by white blood cell SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography).",Negative predictive value of White Blood Cell SPECT/CT performed at the end of antibiotic treatment to predict the remission of osteomyelitis at one year.,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],
8335,NCT00229684,Endogenous creatinine clearance,"The safety and tolerability of tesaglitazar in type 2 diabetics by assessments of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, body weight, and physical examination.",2004-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
8336,NCT00539890,Mean change in HbA1c from baseline to treatment week 24,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
8337,NCT02197299,Skeletal muscle total carnitine content,,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
8338,NCT00808431,"Growth trajectories (using BMI, waist circumference), body composition","Physical activity accelerometry change over time, parental self-efficacy, child feeding questionnaire (parental food habits), identification of medical home",2008-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
8339,NCT01940302,Metabolic Control,,2013-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
8340,NCT06011356,Step count,Patient Activation Measure (PAM),2023-08-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
8341,NCT01983046,fat oxidation,Hormones that influence energy metabolism - Circulating metabolites - Inflammatory markers - plasma SCFA content; - Indirect markers of insulin sensitivity - Appetite (VAS-scoring).,2013-09,COMPLETED,INTERVENTIONAL,['NA'],
8342,NCT02545049,"The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure.","The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death",2015-09-17,COMPLETED,INTERVENTIONAL,['PHASE3'],
8343,NCT02100475,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Number of Treatment-emergent Confirmed Hypoglycaemic Episodes,2014-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
8344,NCT01455415,Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period),PGIC Score at the End of Period 1 (Week 6) - Categorized Scores,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
8345,NCT04325347,Change in number of awakenings during the night between experimental and control intervention.,"Nature, severity and impact of insomnia",2021-01-27,UNKNOWN,INTERVENTIONAL,['NA'],
8346,NCT02665689,Difference of Best Corrected Visual Acuity Measured in ETDRS Letters Score Between Month 12 Baseline Visit,Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment,2016-01-18,TERMINATED,INTERVENTIONAL,['PHASE4'],
8347,NCT01527656,"Cmax, maximum insulin aspart concentration",Incidence of hypoglycaemic events,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
8348,NCT00360061,HBA1c,Modified Health Care Climate Questionnaire (at baseline only).,2001-09,COMPLETED,INTERVENTIONAL,['NA'],
8349,NCT06066944,Measure the intensity of neuropathy induced pain,,2024-02-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
8350,NCT03336528,Mean Daily Blood Glucose Concentration in Discharged Patients.,Number of Episodes of Severe Hyperglycemia in Discharged Patients,2018-01-02,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of Participants Experiencing Acute Kidney Injury in Discharged Patients
8351,NCT03651908,Radiographic parameters - Change in bone level,clinical parameters - Changes in relative clinical attachment level,2017-09-05,COMPLETED,INTERVENTIONAL,['NA'],
8352,NCT01067209,"Primary outcome measure: cardiac function, myocardial fat deposition","Plasma lipidomics, liver fat deposition",2010-01,COMPLETED,OBSERVATIONAL,['NA'],
8353,NCT01215903,Plasma and serum inflammatory markers,Fatty acids of phospholipids in skeletal muscle,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
8354,NCT04931537,Urinary Albumin Creatinine Ratio，UACR,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA'],
8355,NCT00141401,Safety Efficacy,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
8356,NCT05062460,Rate of adherence,Number of patients with brachial plexus palsy,2021-07-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
8357,NCT02441504,Change in Cutaneous Capillary Density in twelve weeks of aerobic physical activity,,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
8358,NCT02545738,Change in albuminuria,24h heart rate,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
8359,NCT03914183,The percentage of participants in the mCPN group who demonstrate an improvement (vs baseline performance) in the recommended site rotation techniques relative to the proportion of that in the control group.,the percentage of participating patients who decide to continue using mCPN upon study completion,2018-10-15,COMPLETED,INTERVENTIONAL,['NA'],
8360,NCT06159543,8-iso-PGF2 alpha,Lean body mass,2024-03-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
8361,NCT01264523,Fat-free mass,Satiety assessment,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
8362,NCT01165268,The reduction in TmG after 7 days of oral administration of 10 mg of dapagliflozin,"Pharmacokinetics (Cmin, Cmax, Tmax, and AUC (TAU)) of dapagliflozin",2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
8363,NCT05829811,Detection of neurological disorders,Analysing of potential precipitating factors for DFU,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
8364,NCT00624767,To evaluate the effect on postprandial glycemic control of intranasal insulin compared to NovoLog,To evaluate the pharmacokinetics of intranasal insulin compared to NovoLog,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
8365,NCT02360878,Change in postprandial glucagon-like peptide-1 (GLP-1) secretion from baseline 3 weeks after explantation,Change in postprandial glucosedependent insulinotropic peptide (GIP) from baseline 3 weeks after explantation,2013-02,COMPLETED,OBSERVATIONAL,['NA'],Change in caloric intake as measured by ad libitum meal test 3 weeks after explantation
8366,NCT02686996,Change in insulin sensitivity measured by euglycaemic glucose clamp,Change in Resting systolic and diastolic blood pressure,2017-02-13,UNKNOWN,INTERVENTIONAL,['NA'],Change in Other Tissue Analyses
8367,NCT00446277,central corneal thickness,intraocular pressure,2007-01,SUSPENDED,OBSERVATIONAL,['NA'],
8368,NCT02661581,Glycemic Control measured by HbA1c,"Weight measured on a high quality, calibrated digital scale, with the participant wearing clothes, but no shoes",2013-11,UNKNOWN,INTERVENTIONAL,['NA'],
8369,NCT05491850,Effect of moderate physical activity on early symptoms of peripheral diabetic neuropathy in type-II diabetes,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA'],
8370,NCT01626469,Change in ophthalmic artery blood flow from baseline,Change in renal plasma flow (RPF) from baseline,2012-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8371,NCT01518205,Proportion of subjects obtaining the ulcer healing (Class 0A according to TEXAS classification) after 12 month from the study starts.,proportion of subjects with major amputation (these are usually below the knee or above the knee)- in agreement with the approved amendment,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
8372,NCT00840541,CSME,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],
8373,NCT02973321,Change From Baseline in HbA1c to Week 26,Change From Baseline in Pharmacodynamic Biomarkers to Week 26 - Waist and Hip Circumferences,2016-12-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
8374,NCT00536250,hepatic fat content and abdominal fat ratio,,2001-09,COMPLETED,OBSERVATIONAL,['NA'],
8375,NCT00969566,The change of HbA1c,Homeostatic model assessment of insulin resistance (HOMA-IR),2009-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
8376,NCT04686201,Percentage of uncontrolled Diabetes Mellitus patients who have good control diabetes after using Diabetes Mobile Application,,2019-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
8377,NCT00044668,"Change in concentrations of fasting plasma glucose and lipids from Baseline Visit 2 (Day 1) to Week 24, to Week 52, and to each intermediate visit",,2002-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
8378,NCT01724645,HbA1C :Glycated Hemoglobin,Heart rate,2010-09,COMPLETED,INTERVENTIONAL,['NA'],Lipid modifying (oral medication)
8379,NCT03414892,the mean change in glucose area under curve (AUC) from baseline.,the mean changes of post-prandial blood glucose from baseline,2018-01-03,COMPLETED,INTERVENTIONAL,['PHASE1'],the changes of GA (Glycated albumin) from baseline
8380,NCT04492566,Time in Target Glucose Range,Mean CGM Glucose Level,2020-07-27,COMPLETED,INTERVENTIONAL,['NA'],Fetal Outcomes: Neonatal Intensive Care Unit Admission
8381,NCT03045250,Normative values for corneal confocal microscopy (CCM),Serum biomarkers - fibrinogen,2018-08-01,WITHDRAWN,INTERVENTIONAL,['NA'],
8382,NCT01281605,To compare the change in HbA1c between two study groups at Week 24.,To evaluate the incidence of adverse events.,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
8383,NCT01006291,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
8384,NCT00272090,severe nocturnal hypoglycemias will be measured throughout the study period.,severe hypoglycemias and nocturnal hypoglycemias will be measured throughout the study period.,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
8385,NCT02175459,"Change from baseline in metabolic status (normal glucose tolerance, impaired glucose tolerance, diabetes)","islet cell areas (beta, Alpha and delta cell positive area)",2010-08,RECRUITING,OBSERVATIONAL,['NA'],change in gene expression analysis among different groups of baseline metabolic status
8386,NCT02606747,Foot sole tactile threshold,,2015-03,UNKNOWN,OBSERVATIONAL,['NA'],
8387,NCT00182494,3. Impact on incidence of diabetes,3. Sustained changes in eating & activity patterns,2005-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8388,NCT01863667,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline in Body Weight at Week 54,2013-07-08,TERMINATED,INTERVENTIONAL,['PHASE3'],
8389,NCT05939349,Glycemic control,Nutrition knowledge,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Provider satisfaction survey
8390,NCT04612868,"Sensitivity and Specificity, Based on Two Macula-centered Images (One Image From Each Eye of the Patient)","Imageability, Based on Four Images (One Macula Centered Image and One Optic Disc Centered Image Per Eye)",2020-10-16,COMPLETED,INTERVENTIONAL,['NA'],
8391,NCT02798250,Percentage of time below 4.0 mmol/L,Total glucagon delivery,2016-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
8392,NCT05565651,Outcome percentage Phyla,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],
8393,NCT02875821,changes in visceral fat area,Changes in liver fat,2016-04-26,COMPLETED,INTERVENTIONAL,['PHASE4'],
8394,NCT02763267,Insulin secretory response,Change in insulin secretory response,2016-02,COMPLETED,OBSERVATIONAL,['NA'],
8395,NCT01616563,Number of Participants That Have Reversal of Metabolic Syndrome,Changes in Continuous Metabolic Syndrome Risk Score,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
8396,NCT05525117,HbA1c,Proportion of patients achieving a reduction in HbA1c,2023-07-04,RECRUITING,INTERVENTIONAL,['NA'],systolic blood pressure
8397,NCT04190251,Medication adherence (longitudinal data),Patients' satisfaction,2016-04-14,COMPLETED,INTERVENTIONAL,['NA'],
8398,NCT05695651,Investigate the association between TyG index and HOMA IR with the risk of macrovascular and microvascular complications of type 2 diabetes,Percentage of diabetic patients who developed vascular complications.,2023-02-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
8399,NCT01879137,Discriminative value of copeptin after arginine infusion in the differential diagnosis of polyuria-polydipsia syndrome.,,2013-06,COMPLETED,OBSERVATIONAL,['NA'],
8400,NCT04328181,quality of the images,Statistical comparison between SPCCT and DECT,2021-01-29,RECRUITING,INTERVENTIONAL,['NA'],
8401,NCT06283394,Percentage of food purchasing expenditures spent on eligible healthy foods,Qualitative results,2024-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
8402,NCT01736059,Incidence and severity of ocular adverse events,The number of stem cells isolated and injected into the study eye,2012-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence and severity of systemic adverse events
8403,NCT02796170,Change in Blood Pressure From Baseline to 6 Weeks Measured by ABPM,Change in Urinary AGT Levels From Baseline to 6 Weeks,2016-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
8404,NCT02025673,"Serum levels of betatrophin in type 2 diabetes patients, gestational diabetes patients and pregnant women",Correlation of betatrophin concentration with other variables,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],
8405,NCT06273761,Medication adherence,Beliefs in medicines,2024-02-06,RECRUITING,INTERVENTIONAL,['NA'],
8406,NCT01911104,Change in ATPmax,Change in in vivo and in vitro mitochondrial function,2013-10-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Promoter methylation
8407,NCT00781001,Spontaneous Pain Score,Adverse events,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8408,NCT03566693,Phase 2: Change in CGM time in target range,Phase 2: Change in CGM time-hypoglycemic,2018-07-30,COMPLETED,INTERVENTIONAL,['NA'],Phase 1 and Phase 2: Safety Events - Other adverse events
8409,NCT01382303,Percentage Change in Proteinuia,Mean Change of TNF-a,2010-10-25,COMPLETED,INTERVENTIONAL,['PHASE4'],
8410,NCT00624013,HbA1C (%),Quality of Life,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
8411,NCT02701894,HbA1c,HOMA- IR,2012-12,UNKNOWN,OBSERVATIONAL,['NA'],
8412,NCT03827434,Change in mortality among participants who are managed with Continuous Glucose Monitoring Devices and Clarity versus participants who are managed with Point of Care glucose testing (standard of care),,2018-12-01,WITHDRAWN,INTERVENTIONAL,['NA'],
8413,NCT03297931,Food intake,,2017-07-19,UNKNOWN,INTERVENTIONAL,['NA'],
8414,NCT05483972,Change in Adult and Offspring Waist Measurements,,2022-10-04,COMPLETED,INTERVENTIONAL,['NA'],
8415,NCT04856670,Aqueous humor concentrations of inflammatory mediators at the onset of manual cataract surgery and following femtosecond laser treatment,Prevalence and severity of postoperative flare,2021-05-25,UNKNOWN,OBSERVATIONAL,['NA'],
8416,NCT03511898,Incidence of dose-limiting toxicities up to the Day 14 visit,Occurrence of laboratory abnormalities up to the end of the study,2018-05-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
8417,NCT05867797,prognosis risk factors and outcomes of AKI in patients with DKA,,2023-05-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
8418,NCT01878682,"The accuracy of the VibraTip® device, as measured by a comparison with the Gold Standard, the 10g Semmes Weinstein Monofilament (MF) Test by a Diabetologist.",,2014-02-06,COMPLETED,OBSERVATIONAL,['NA'],
8419,NCT05195138,Feasibility: overall study retention,Type 2 diabetes stigma,2023-05-31,RECRUITING,INTERVENTIONAL,['NA'],
8420,NCT05025852,Body Mass Index (BMI) z-score,Neurocognitive development,2022-05-11,RECRUITING,OBSERVATIONAL,['NA'],
8421,NCT03972982,remission rate,,2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8422,NCT01944904,The Effects of Xyloologosarcharide (XOS) on colonic flora in volunteers with abnormal glucose levels,The Effects of Xyloologosarcharide (XOS) on glucose and insulin,2013-09,COMPLETED,INTERVENTIONAL,['NA'],The effects of Xylooligosaccharide (XOS) on body weight and body composition
8423,NCT00209170,"Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week 24",,2004-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
8424,NCT00330954,,,2006-06,COMPLETED,OBSERVATIONAL,['NA'],
8425,NCT01712061,Percent Reduction From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12,"Summary of Plasma PF-04634817 Pharmacokinetic (PK) Concentrations at Day 1 and Weeks 1, 4, 8 and 12",2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Increased Fasting Blood Glucose
8426,NCT00479466,Change From Baseline to Week 12 in Fasting Plasma Glucose (FPG),Change From Baseline to Week 12 in 2-Hour Post Prandial Glucose (PPG),2007-07,TERMINATED,INTERVENTIONAL,['PHASE2'],
8427,NCT00539175,pain intensity,"Semmes-Weinstein sensation, proprioception, quality of life",2004-10,COMPLETED,INTERVENTIONAL,['NA'],
8428,NCT01427920,Change in HbA1c (Glycosylated Haemoglobin) - PP,Patient Reported Outcomes Evaluated: Treatment-Related Impact Measures for Diabetes (TRIM-D) - Total Score,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
8429,NCT04464694,Early postoperative vitreous haemorrhage,Mean Best-corrected visual acuity (BCVA) at Month 6,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8430,NCT00945165,Hyperglycemia,Mean Blood Glucose,2009-07,COMPLETED,INTERVENTIONAL,['NA'],
8431,NCT05707481,Change in Health related Quality of Life,"Change in Patients health related Knowledge, Attitude and Practice",2023-08-22,RECRUITING,INTERVENTIONAL,['NA'],
8432,NCT05169060,Change from baseline of omega-3 index at 16 and 24 weeks,Change from baseline in urine microalbuminuria levels after 16 and 24 weeks.,2023-06-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8433,NCT02006836,AUCs With/Without Pomelo,,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
8434,NCT00253240,,,2004-09,COMPLETED,OBSERVATIONAL,['NA'],
8435,NCT05917249,Change of the perfusion index at the end of the first session compared to baseline readings.,The total remission rate,2023-06-07,COMPLETED,INTERVENTIONAL,['NA'],
8436,NCT01724190,IDAA1c,,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
8437,NCT03184337,Change in body mass index,Change in self-assessed general health,2017-04-24,COMPLETED,INTERVENTIONAL,['NA'],
8438,NCT01343056,"Hemoglobin A1C (HbA1C, %)",Systolic Blood Pressure,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
8439,NCT04102202,To evaluate the effect of BOL-DP-o-05 on preservation of beta-cell function,To assess the percent of subjects who require a daily insulin dose < 0.5 IU/kg body weight,2020-11-15,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8440,NCT03444363,Laboratory findings,Clinical findings,2013-09-20,COMPLETED,INTERVENTIONAL,['NA'],
8441,NCT03118050,Amino acid transporter expression,Muscle protein synthesis,2017-05-28,COMPLETED,INTERVENTIONAL,['NA'],
8442,NCT01504412,Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy,Mean Change in Short Form-McGill Pain Questionnaire From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
8443,NCT00398892,HbA1c change for lipoic acid vs placebo,Urine ACR change for lipoic acid vs placebo,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
8444,NCT04666987,Change in Glycated Haemoglobin (HbA1c),Treatment simplification (decrease in insulin dose or number of concomitant OADs) (yes/no),2020-10-21,COMPLETED,OBSERVATIONAL,['NA'],
8445,NCT00027456,,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
8446,NCT01406496,Post-prandial blood glucose excursions following three different meals and three different timings of insulin bolus.,,2011-08,UNKNOWN,INTERVENTIONAL,['NA'],
8447,NCT02635243,Time to reach a smoothed blood glucose of 70 mg/dL after initial administration of investigational medicinal product,Time to reach a smoothed blood glucose of 90 mg/dL after initial administration of investigational medicinal product,2016-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
8448,NCT04889183,Change from baseline to week 24 in urinary albumin:creatinine ratio (UACR),high sensitivity C-reactive protein (CRP),2022-03-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],
8449,NCT02241889,Percent of Time With Sensed Glucose Between 70-180 mg/dl,Percent of Time of CBG>180 mg/dl,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
8450,NCT00697450,Weight effect,Improvement in HbA1c levels,2008-07,COMPLETED,OBSERVATIONAL,['NA'],
8451,NCT04198935,Adherence to the the program,,2020-05,UNKNOWN,INTERVENTIONAL,['NA'],
8452,NCT02046395,Change in Urine Microalbumin Creatinine Ratio,Change in the Level of Urinary Free Light Chains,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
8453,NCT00268645,"For efficacy: FBG (Fasting Blood Glucose), HbA1c",For safety: ICA (Insulin Cell Antibody),2004-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
8454,NCT00973726,"Changes in amplitude/implicit times, changes in dark adaptation, changes in vessel caliber, changes in Optical coherence tomography (OCT)",,2009-09,UNKNOWN,INTERVENTIONAL,['NA'],
8455,NCT00264589,cardiac function at rest and during exercise,substrate utilization during exercise,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
8456,NCT02085681,Proportion of patients with confirmed Diabetic Retinopathy (DR) diagnosed at the eye hospital,Proportion of patients eligible for referral who had DR and who did not attend,2014-05,COMPLETED,INTERVENTIONAL,['NA'],Drivers of acceptance
8457,NCT03766620,Body Weight Change,Albumin Levels,2018-11-29,COMPLETED,OBSERVATIONAL,['NA'],Physician Product Satisfaction
8458,NCT02590016,Neonatal hypoglycemia,Proportion of participants needing insulin-glucose-infusion in the observational arm,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8459,NCT02266823,Primary outcome: Lipoproteins. We will evaluate the impact of the intervention on serum lipids obtained after a 12-hour fast,,2015-10,COMPLETED,INTERVENTIONAL,['NA'],
8460,NCT00810992,Body mass index,Intima media thickness HbA1C Lipid status Platelet activation markers as prognostic biomarkers,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
8461,NCT03138447,Basal Insulin Dose,Office Contacts,2017-03-30,COMPLETED,INTERVENTIONAL,['NA'],
8462,NCT06144593,24-hour average sensor glucose,Fasting plasma concentrations of triacylglycerols,2024-01,RECRUITING,INTERVENTIONAL,['NA'],Explorative outcomes - Qualitative evaluation to assess feasibility of the dietary strategy
8463,NCT03853941,Change in healthcare professionals' communication style,Fidelity of delivery,2019-03-21,COMPLETED,INTERVENTIONAL,['NA'],
8464,NCT05407467,HbA1c,Blood Pressure,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8465,NCT01880736,Change From Baseline in HbA1c (%) Glycosylated Haemoglobin),Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes in the Maintenance Period,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
8466,NCT03770052,HbA1c at 24 week,total bilirubin,2018-10-24,COMPLETED,INTERVENTIONAL,['PHASE4'],
8467,NCT03729323,Blood pressure,,2018-04-11,COMPLETED,INTERVENTIONAL,['NA'],
8468,NCT03693521,Change in physical activity level,Physical Activity on Prescription,2019-10-07,COMPLETED,INTERVENTIONAL,['NA'],
8469,NCT05496907,Effectiveness of Intervention using HbA1c levels,Mental Health Outcome,2022-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
8470,NCT04422145,All cause mortality at study endpoint with each participant having a minimum follow up of 12 months and the final analysis of data being done 58 months after the first participant was recruited (this is study endpoint.),Assessment of differences in mortality rate between type 1 and type 2 diabetes participants,2013-02-01,COMPLETED,INTERVENTIONAL,['NA'],
8471,NCT00302874,Mean blood glucose during hospitalization,"Disposition at discharge (home, nursing home)",2003-02,COMPLETED,INTERVENTIONAL,['NA'],
8472,NCT02292511,Global Cognitive Functioning,Antisaccade direction errors,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
8473,NCT00445913,The trial is designed to assure that the toxicity rate is acceptably low to warrant further study of the cell vaccine in efficacy trials.,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
8474,NCT04285450,Homeostasis model assessment of insulin resistance (HOMA-IR),,2019-10-27,COMPLETED,INTERVENTIONAL,['NA'],
8475,NCT03648138,Hypothetical beverage choice,Negative reactions to the label,2020-01-17,COMPLETED,INTERVENTIONAL,['NA'],
8476,NCT05102149,Change in HbA1c,,2021-09-30,RECRUITING,INTERVENTIONAL,['PHASE3'],
8477,NCT00602472,HbA1c Change From Baseline to Week 24,Percentage of Patients Who Have a HbA1c Lowering by 0.5% at Week 24,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
8478,NCT00802022,Pain intensity measured on a weighted NRS according to Jensen and a PGIC for pain measured on a 7-point Likert scale.,"The practical- and technical feasibility of the procedures, predicting successful pain relief by SCS by classifying patients according to the MDNS. Define possible other predictors for successful pain relief.",2009-01,COMPLETED,INTERVENTIONAL,['NA'],
8479,NCT01554566,serum lipids,C-peptide,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
8480,NCT03998046,Number of Participants Who Achieved 5% Weight Loss Goal at 6 Months,Number of Participants Who Achieved 5% Weight Loss Goal in 12 Months,2019-12-16,COMPLETED,INTERVENTIONAL,['NA'],
8481,NCT04016584,"Success (evaluated by a Yes/No format) recruiting and completing a new targeted diabetes and insulin education program, Diabetes Pueblo, for Latino adults with type 2 diabetes.",Participant evaluation of Diabetes Pueblo evaluated by questionnaire,2019-05-10,COMPLETED,INTERVENTIONAL,['NA'],"Menopausal status, pregnancy status, and gestational diabetes history for women determined by questionnaire"
8482,NCT02730078,Diabetes-related distress,LDL-cholesterol,2016-04,COMPLETED,INTERVENTIONAL,['NA'],Adverse event
8483,NCT02280564,Change from Baseline in HbA1c at 4 months,Change from Baseline in Quality of Life measures at 4 months,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
8484,NCT04157738,Caregiver Treatment Adherence at 1 Month and 4 Months Post-intervention,Glycemic Variability (GV) at 1 Month and 4 Months Post-intervention,2019-11-27,COMPLETED,INTERVENTIONAL,['PHASE4'],
8485,NCT05337826,The co-primary implementation outcomes,Diabetes health related quality of life measures,2022-04-20,RECRUITING,INTERVENTIONAL,['NA'],
8486,NCT06303453,PainDETECT Tool,,2024-02-25,RECRUITING,INTERVENTIONAL,['NA'],
8487,NCT04270578,Glucose tolerance during 75 g oral glucose tolerance test,blood sample,2012-05-23,RECRUITING,OBSERVATIONAL,['NA'],
8488,NCT04117269,Percentage of diabetic foot ulcers healed,Time to healing,2019-11-15,RECRUITING,INTERVENTIONAL,['NA'],
8489,NCT02060279,"β-carotene, FABP4 and C16:1n7 palmitolate levels",Macrophage expression of genes involved in lipid and lipoprotein metabolism and adipose deposition,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
8490,NCT05833958,Change in glycosylated haemoglobin (HbA1c),Medication tolerability,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
8491,NCT03334175,Palatability of Supplement,Change in Low Density Lipoprotein Levels,2018-05-21,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants Who Had Plasma Metabolomics Performed
8492,NCT01068678,Change in Glycosylated Haemoglobin (HbA1c),Change in Body Weight,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
8493,NCT01823458,Attendance at exercise classes,LDL cholesterol,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
8494,NCT00231608,The mean change from baseline to Month 6 in abdominal visceral fat as assessed by computed tomography; the safety of Topiramate for up to 12 months of continued treatment in male subjects with abdominal obesity.,"Mean change and percent change in body weight, and mean change in total abdominal fat, subcutaneous abdominal fat, body composition, and body mass index from baseline to Month 6.",1998-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
8495,NCT00285233,"Monitor the incidence, timing, and severity of adverse events as well as their relationship to the islet transplant procedure and additional protocol-regulated treatment products during the first year after islet transplantation.","Assess, in a selected group of islet allotransplant recipients, the autoimmune and alloimmune responses to transplanted islets at intervals during the first year posttransplant.",2000-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8496,NCT01828229,Insulin sensitivity,visceral adiposity,2009-01,COMPLETED,INTERVENTIONAL,['NA'],aerobic fitness
8497,NCT01488279,Insulin Sensitivity,Change in Insulin Secretion (AIRg or Acute Insulinogenic Response to Glucose),2012-09,COMPLETED,INTERVENTIONAL,['NA'],
8498,NCT00737815,Fasting insulin,Gene Expression,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
8499,NCT03414216,Any recurrence of any ulcer at same location,,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA'],
8500,NCT02998970,Left Ventricular (LV) mass Changes,Plasma catecholamine levels,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8501,NCT01699737,Change in glycosylated hemoglobin (HbA1c) after administration of JTT-851,Pharmacokinetics of JTT-851 and its metabolites,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Relationship between dose and response of JTT-851
8502,NCT04114682,Magnetic Resonance Imaging metrics for liver fibro-inflammation in patients with type 2 diabetes,longer term evaluation of clinical outcomes,2020-01-27,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
8503,NCT04403841,Disease awareness,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],
8504,NCT02763423,Changes from baseline exogenous insulin dose at different time points post treatment,titres of islet antigen antibodies,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
8505,NCT05343624,Time in Range,Hypoglycemia,2020-06-18,COMPLETED,INTERVENTIONAL,['NA'],
8506,NCT01322789,Safety,Immunologic reconstitution parameters,2008-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8507,NCT01987206,time spent in safe blood glucose range,glucose level extremes and need for outside intervention,2014-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
8508,NCT01022658,"Vago-sympathetic activity, arterial stiffness, endothelial function",,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
8509,NCT00683657,Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4,Change From Baseline in 2-Day Average Fasting Plasma Glucose (FPG) at Week 4,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
8510,NCT04076995,Area Under the Curve for Plasma osmolality,Mood assessment with a questionnaire,2019-09-18,COMPLETED,INTERVENTIONAL,['NA'],
8511,NCT00546351,Number of Participants Experiencing the Occurrence of at Least One Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).,Average Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS) at Last Visit.,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
8512,NCT02344602,The Change in Effective Renal Plasma Flow (ERPF) After an 8 week Treatment with Febuxostat,The Change in Skin Biopsy Measures of Neurohormonal Activation After an 8 week Treatment with Febuxostat,2012-12-18,COMPLETED,INTERVENTIONAL,['PHASE4'],
8513,NCT06001801,Change in weight,Change in reported diet quality,2023-09-18,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
8514,NCT02948673,Insulin sensitivity,Mitochondrial reactive oxygen species production,2016-05,COMPLETED,INTERVENTIONAL,['NA'],
8515,NCT03949582,Blood insulin,Energy intake 72 hours post study visit,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA'],
8516,NCT02504762,Assessing conventional CABG vs HCR in diabetic patients with multivessel CAD,Number of patients we can enroll in 1 year,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
8517,NCT01736865,Disposition Index,Number of Participants With Change in Glycemia,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Effect of Vitamin D Supplementation on Plasma Concentrations of Surrogate Biomarkers of Cholesterol Absorption (Campesterol and β-sitosterol) and Endogenous Synthesis (Lathosterol and Desmosterol)
8518,NCT01065298,Reduction of insulin requirement by ≥ 50% by the end of 6 months of ABMSCT and Improvement in Glucagon stimulated C - peptide levels .,Any reduction in requirement of insulin dosage and any improvement of HbA1c levels as compared to controls.,2009-11,COMPLETED,OBSERVATIONAL,['NA'],
8519,NCT01402037,evaluate the hyperglycemic clamp to measure the functional beta cell mass test,evaluate the continuous glucose monitoring to measure within- and between-day glycemic variability,2011-07,UNKNOWN,INTERVENTIONAL,['NA'],
8520,NCT03025984,compliant diabetes care,,2016-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
8521,NCT01005420,Insulin Sensitivity,Cognitive Performance,2007-02,WITHDRAWN,INTERVENTIONAL,['NA'],
8522,NCT06047262,Change in HbA1c in blood of patients for dapansutrile compared to placebo,Change in fasting plasma glucose for dapansutrile compared to placebo,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
8523,NCT02854748,"Cmax,ss of Lobeglitazone",AUCinf of Lobeglitazone,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],
8524,NCT01055223,Number of Low Impact Fractures in Males and Females After 12 Months of Exposure to TZD,Number of Hip Fractures Combined in Males and Females After 12 Months of Exposure to TZD,2009-05,COMPLETED,OBSERVATIONAL,['NA'],
8525,NCT03573856,Change from 0 to 12 months in fasting insulin,Change from 0 to 12 months in fasting glucose,2018-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Potential for sustained delivery
8526,NCT03789578,"AUCSema,0-tz, area under the plasma semaglutide concentration-time curve from 0 hours to last quantifiable observation after a single dose",Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide neutralising antibodies cross reacting with endogenous GLP-1,2019-01-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
8527,NCT01195532,"AUC0-t, AUC0-∞, Cmax, Tmax, T1/2, and MRT in plasma will be determined with gliclazide concentrations by non-compartment methods.",,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],
8528,NCT01058577,"plasma ion concentrations (sodium, potassium, chloride, calcium, magnesium) and osmolarity",blood glucose concentration,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
8529,NCT04907006,Cmax,CLz/F,2021-08-31,COMPLETED,INTERVENTIONAL,['PHASE1'],
8530,NCT03558867,"Mean change in glycated haemoglobin (HbA1C, %) from baseline",Liver fat,2018-06-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Gut microbiome (exploratory)
8531,NCT04025853,Evaluate the effectiveness of biomarkers to differentiate osteomyelitis from deep soft tissue infections in patients with diabetic foot ulcers.,,2015-06,COMPLETED,OBSERVATIONAL,['NA'],
8532,NCT01298245,The differences in the distribution of candidate genotypes and alleles between the study groups,the frequencies of haplotypes of different single nucleotide polymorphisms,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],
8533,NCT05938712,Proximal tubular natriuresis with monotherapy,Safety: The number of allergic reaction events.,2023-10-24,RECRUITING,INTERVENTIONAL,['PHASE2'],
8534,NCT00965458,2-Hour C-peptide Area Under the Curve (AUC) Result in Response to Standardized Mixed Meal Tolerance Test (MMTT),Hemoglobin A1c,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
8535,NCT05747352,Glucose time,Glucose time,2023-06-05,COMPLETED,OBSERVATIONAL,['NA'],
8536,NCT01513590,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Number of Treatment Emergent AEs (Adverse Events),2012-01-16,COMPLETED,INTERVENTIONAL,['PHASE3'],
8537,NCT04743856,Change from baseline in Step counts at 12 months,Triglycerides over all timepoints for 12 months,2022-03-29,RECRUITING,INTERVENTIONAL,['NA'],
8538,NCT03206827,Changes in the intake of nutrients and nutritional status of participants as a measure of diet modification,Genotoxicity testing of human fecal water in 2D and 3D cell cultures,2016-11-29,COMPLETED,INTERVENTIONAL,['NA'],
8539,NCT01324739,glucose,"insulin, c-peptide",2010-05,COMPLETED,INTERVENTIONAL,['NA'],
8540,NCT01927315,Circulating progenitor cells,Triglycerides,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
8541,NCT04380844,Diabetes Knowledge Questionnaire,,2021-02-01,UNKNOWN,INTERVENTIONAL,['NA'],
8542,NCT01530347,correlation between the acetone values generated by study device and oxygen,Clarke Error Grid (segment 1 only),2012-03,TERMINATED,INTERVENTIONAL,['PHASE1'],
8543,NCT03907202,Safety laboratory parameter - urinalysis.,Fridericia's corrected QT interval (QTcF).,2018-04-17,TERMINATED,INTERVENTIONAL,['PHASE1'],
8544,NCT03939143,Maximum plasmaconcentration of drug in plasma(Cmax),Terminal elimination half-life(t1/2),2019-02-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
8545,NCT03313960,Hemoglobin A1c,Health-related Quality of Life,2017-10-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8546,NCT02214056,Percentage of eligible patients who actually received the mobile team exam,GP and patient acceptability of the mobile team exam,2015-02,COMPLETED,OBSERVATIONAL,['NA'],
8547,NCT02328599,Change in HbA1c,HbA1c < 6.5%,2018-04-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],change in albuminuria
8548,NCT01978925,Medication Adherence,Quality of Life,2013-11,COMPLETED,INTERVENTIONAL,['NA'],Fasting plasma glucose for diabetic patients
8549,NCT01939366,Change in Average Pain Intensity.,,2013-09-27,COMPLETED,INTERVENTIONAL,['PHASE2'],
8550,NCT00830791,Plasma AUC (0-infinity) After Administration of a Single Oral Dose of 5 mg of MK-0941 Among Participants With Severe Renal Insufficiency vs Matched Controls,Plasma Glucose Concentration After Administration of a Single Oral Dose of 5 mg of MK-0941 to Participants With Severe Renal Insufficiency Versus Matched Controls,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1'],
8551,NCT01567033,Body Mass Index,Survey,2012-04-26,COMPLETED,INTERVENTIONAL,['NA'],
8552,NCT02206919,Popliteal FMD MRI technique correlates with albuminuria in those with early diabetic disease,Dietary risk factors related to chronic disease,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],
8553,NCT03906786,Adherence to self-care behaviors. The Diabetes Self-Care Inventory-Revised,,2019-03-07,UNKNOWN,INTERVENTIONAL,['NA'],
8554,NCT00423501,Absolute change from baseline in HbAlc,"AEs, laboratory parameters, primary pharmacokinetic parameters",2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
8555,NCT05135676,Co-primary Outcome: CGM-measured percent time <54 mg/dL (non-inferiority),CGM Metrics by nighttime only (00:00 AM to 06:00 AM),2022-05-10,COMPLETED,INTERVENTIONAL,['NA'],Glucose Variability
8556,NCT05473286,Change in Glycated haemoglobin (HbA1c ),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",2022-09-30,WITHDRAWN,OBSERVATIONAL,['NA'],
8557,NCT04141878,Change in DDPP Neuropsychological Test Battery,Change in Glycated Hemoglobin (Hemoglobin A1C),2021-05-26,RECRUITING,INTERVENTIONAL,['NA'],
8558,NCT00787839,"Ability of Different Screening Tests Which Can be Performed Opportunistically (During Outpatient Visits -- at Any Time of Day, Regardless of Meal Status) to Predict Findings With the Oral Glucose Tolerance Test (in the Morning, After an Overnight Fast)",Cost to Identify a Single Case of High-risk Dysglycemia or Previously Unrecognized Diabetes,2009-06,COMPLETED,OBSERVATIONAL,['NA'],
8559,NCT00379379,"Hypoglycemic activity, plasma insulin level, HOMA index","Triglyceride, cholesterol, free fatty acid",2005-01,COMPLETED,INTERVENTIONAL,['NA'],
8560,NCT00440375,"metabolic bone markers before and after the intervention,",association between the changes in bone turnover parameters and plasma cytokine levels,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
8561,NCT02659748,Insulin sensitivity,Bacterial microbiota,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],
8562,NCT03412006,Change in urinary albumin to creatinine ratio (UACR),Number of patients with serious adverse events,2018-02-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
8563,NCT06132477,Effect of GLP1-RA on Glycemic control,,2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
8564,NCT03934944,Change in foot care behaviour as measured by the SDSCA,Proportion of participants who developed a new diabetic foot ulcer,2019-02-10,UNKNOWN,INTERVENTIONAL,['NA'],
8565,NCT02692547,Descriptive endpoints,Descriptive endpoints,2016-02,WITHDRAWN,INTERVENTIONAL,['NA'],
8566,NCT04910321,Incidence of type 2 diabetes diagnosed as fasting blood glucose larger than 7.0 mmol/L,Change of body mass index,2020-12-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
8567,NCT04266379,Difference in percent of time spent with blood glucose level below 70 mg/dL,Weight and Body Mass Index (BMI),2020-05-13,UNKNOWN,INTERVENTIONAL,['NA'],
8568,NCT05198284,Referrals,,2021-11-01,RECRUITING,OBSERVATIONAL,['NA'],
8569,NCT02299479,Change From Baseline in Supplemental Carbohydrate Interventions up to 3 Months From Baseline.,Change From Baseline in Supplemental Carbohydrate Interventions up to 3 Months From Baseline in Subjects With Activity Effect.,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
8570,NCT00935051,"MMP-1/TIMP-1 ratio at Week 0 assessed by ELISA and percent change in wound area of diabetic foot ulcer between week 0, week 4 and week 12","Correlation between MMP9, MMP13, MMP9/TIMP1 and MMP13/ TIMP1 ratios and wound healing expressed by the percent change in wound area between week 0, week 4 and week 12.",2009-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
8571,NCT00564551,Weight loss,Inflammatory Markers,2007-10,COMPLETED,INTERVENTIONAL,['NA'],
8572,NCT05854797,Body Mass Index,,2022-10-28,COMPLETED,INTERVENTIONAL,['NA'],
8573,NCT03832933,Change in body weight by weight scale,Change in % FFM,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],
8574,NCT02053272,Change from baseline to the end of treatment in mean glycosylated haemoglobin A1c (HbA1c) level.,Change from baseline to the end of study in mean Cannabis Withdrawal Scale (CWS) total score.,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
8575,NCT00797186,change in microvascular perfusion,,2008-11,UNKNOWN,INTERVENTIONAL,['NA'],
8576,NCT03174548,Area under curve (AUC) of sotagliflozin,Number (%) of subjects with treatment emergent adverse events,2017-06-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
8577,NCT02027753,Response rate (percentage of patients who meet the target HbA1c ≤7%) at week 24 (6 months) after adding insulin therapy,Number of Patients with Adverse Events,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
8578,NCT04837989,Social Comparison Scale,Brief Illness Perception Questionnaire,2021-02-01,TERMINATED,INTERVENTIONAL,['NA'],
8579,NCT03403686,Assessing CD34+ cells function,,2018-01-11,RECRUITING,OBSERVATIONAL,['NA'],
8580,NCT03866005,Required number of anti-VEGF injections,Need for adjunctive laser photocoagulation and/or use of intravitreal steroids,2019-11-01,UNKNOWN,INTERVENTIONAL,['NA'],
8581,NCT00093015,Time to All-cause Mortality or End Stage Renal Disease (ESRD),Time to Hospitalization Due to Acute Myocardial Ischemia,2004-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
8582,NCT00312130,Change from baseline in acute insulin response to an iv glucose load at 6 weeks,Change from baseline in acute insulin response to an iv glucose load at 8 weeks,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
8583,NCT05148390,"Exudate accumulation in the wound by IMD ( 'no', 'minimal amount', 'medium amount', 'high amount')",Incidence of device disintegration (removability in one piece),2022-04-24,COMPLETED,OBSERVATIONAL,['NA'],
8584,NCT02235935,OCT results,Visual Acuity,2014-09,UNKNOWN,OBSERVATIONAL,['NA'],
8585,NCT02131896,lipid profile,Endothelial function,2014-12-01,TERMINATED,INTERVENTIONAL,['NA'],
8586,NCT01751932,Mean Absolute Relative Difference (MARD),Accuracy of sensors per glycemic range and trial phase,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
8587,NCT02164266,Incidence of adverse events (AEs),Fasting serum insulin (Part 2 only),2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
8588,NCT01733758,"Mean HbA1c at Baseline, Week 24, and Change From Baseline at Week 24",Time to Study Withdrawal for Any Reason,2013-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
8589,NCT04699734,Indication of pain relieved extremity,Distribution of evoked pain,2020-09-08,RECRUITING,INTERVENTIONAL,['NA'],
8590,NCT03811548,Change in HbA1c From Baseline to Week 24,Percentage of Patients Who Have Received Rescue Therapy at Week 24 (Core period) and Week 52 (Extension period),2019-05-23,UNKNOWN,INTERVENTIONAL,['PHASE3'],Population pharmacokinetics assessment
8591,NCT00428961,,,2002-07,COMPLETED,OBSERVATIONAL,['NA'],
8592,NCT02804165,Identification of gene-enterovirus interaction effect on T1D onset,"""Precipitating"" effect of enterovirus infection on T1D.",2017-01,WITHDRAWN,INTERVENTIONAL,['NA'],
8593,NCT01523405,Diabetic Quality of Life using Modified 15 item DQoL (MDQoL) questionnaire,Disease modifying variables Body Mass Index (BMI) and Blood Pressure (BP),2012-03,COMPLETED,OBSERVATIONAL,['NA'],
8594,NCT05032001,Change from baseline in visceral fat measured by bioimpedance in kg at weet twelve,,2021-08-01,UNKNOWN,INTERVENTIONAL,['NA'],Change from baseline in A1c level at week twelve
8595,NCT01387984,,,2010-04,COMPLETED,OBSERVATIONAL,['NA'],
8596,NCT00694057,To evaluate the safety and tolerance of HE3286 10 mg per day (5 mg BID) compared to placebo from baseline to week 12.,To evaluate the effect of HE3286 on insulin sensitivity over time.,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
8597,NCT01768403,"Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force (TJETF) guidelines.","The association between achievement of LDL-C goals, according to the Third Joint European Task Force / NCEP ATP III / 2004 updated NCEP ATP III guidelines, and patient and physician variables, assessed by multivariate logistic regression models",2010-09,COMPLETED,OBSERVATIONAL,['NA'],
8598,NCT00789750,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR),2009-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
8599,NCT02703324,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]),Pharmacodynamics (PD): Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT),2016-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
8600,NCT00762190,Left ventricular mass index by body surface area measured by echocardiogram.,"Change from Baseline in apolipoproteins (AI, B).",2003-11,TERMINATED,INTERVENTIONAL,['PHASE3'],
8601,NCT01099865,,,2009-12,COMPLETED,OBSERVATIONAL,['NA'],
8602,NCT02010528,parental diabetes-related distress,psychosocial characteristics,2013-12,COMPLETED,OBSERVATIONAL,['NA'],objective measures
8603,NCT01044537,Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf),Change From Baseline in Ratio of Insulin Area Under Curve (Insulin AUC) to Glucose Area Under Curve (Glucose AUC) After a Mixed Meal Tolerance Test (MMTT) on Day 1,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
8604,NCT04831606,Percentage of healed lesions on the total lesions treated for each arm,Healing time,2021-07-31,RECRUITING,INTERVENTIONAL,['NA'],Evaluation of cost-effectiveness of using EmoLED for the treatment of ulcers
8605,NCT02438943,Proportion of persons attending health centers in the Southeast Health region with normal lipid values,Proportion of persons attending health centers in the Southeast Health region with normal blood pressure values,2014-02,UNKNOWN,INTERVENTIONAL,['NA'],
8606,NCT02440555,Sensitivity of detection of type 2 diabetes,To evaluate the numbers of patients screened by self-administered questionnaire and diagnosed as diabetics using fasting glucose.,2014-11,COMPLETED,OBSERVATIONAL,['NA'],
8607,NCT00422058,Mean Change From Baseline in Body Weight at Week 20,Change From Baseline in Blood Pressure at Week 104,2007-01-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
8608,NCT05717205,mucosal nerve length density (MNLD),Immunohistochemical differences,2023-02-16,RECRUITING,INTERVENTIONAL,['NA'],
8609,NCT00993824,Hypoglycemia Percentage of Time <70 mg/dL Average by Group,,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
8610,NCT02128932,Change in HbA1c From Baseline,"Subjects Who Achieve HbA1c ≤6.5% (48 mmol/Mol), American Association of Clinical Endocrinologists (AACE)",2014-08-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
8611,NCT05752279,Hospital free days (HFD) up to day-28 after study enrolment,Cumulative potassium replacement,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Cost-effectiveness
8612,NCT04736225,HbA1C,self-care behavior,2010-06-01,COMPLETED,INTERVENTIONAL,['NA'],
8613,NCT04534439,Mean change in urine albumin to creatinine ratio (UACR) in APX-115 group compared to placebo group,,2020-08-24,COMPLETED,INTERVENTIONAL,['PHASE2'],
8614,NCT04585204,the difference of GDM detection rate of 50 gr- 100 gr OGTT and 75 gr OGTT,,2020-10-01,UNKNOWN,INTERVENTIONAL,['NA'],
8615,NCT02199028,Duration of Insulin Infusion Set Wear as a Measure of the Effect of Hyaluronidase Treatment,Pain Tolerability of Hyaluronidase Injections,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
8616,NCT01065402,The daily blood glucose level will be monitored by the continuous glucose monitoring system (CGMS) device Medtronic MiniMed.,,2010-02,UNKNOWN,INTERVENTIONAL,['NA'],
8617,NCT06127251,Retention Rate in each group,Changes in T2D risk score,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Change in the Outcome Expectations for Exercise Scale questionnaires.
8618,NCT04215523,"Composite outcome of Stroke, MI, and Mortality",,2019-07-08,COMPLETED,OBSERVATIONAL,['NA'],
8619,NCT02752880,The Percentage Change in HbA1c Level From Baseline to 12 Weeks,The Percentage Change in 2hPG From Baseline to Week 12,2016-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
8620,NCT05324930,Change in DFU size,Complete wound healing,2021-12-02,COMPLETED,INTERVENTIONAL,['NA'],
8621,NCT05278143,Severe hyperglycaemic events detection,Time in severe hyperglycaemia,2021-04-12,UNKNOWN,OBSERVATIONAL,['NA'],
8622,NCT04040634,"Time to cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failure",Time to All-Cause Probable Dementia,2019-08-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
8623,NCT00955669,Magnetic resonance angiography,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
8624,NCT06268808,HbA1c,Frequency of hypoglycaemia events,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
8625,NCT03736785,Change From Baseline in HbA1c,Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3209590,2018-11-15,COMPLETED,INTERVENTIONAL,['PHASE2'],
8626,NCT00741429,Change in FEV1 (L) from Baseline Visit in Parent Trial to Visit 2 of MKC-TI-126,Change in Hemoglobin Corrected DLco (mL/min/mmHg) from Final Assessment of Treatment Phase in Parent Trial to Visit 2 of MKC-TI-126,2007-05,COMPLETED,OBSERVATIONAL,['NA'],
8627,NCT02682563,Effective Renal Plasma Flow (ERPF) in ml/Min,Kidney Injury Molecule-1 (KIM-1) in ng/mmol,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4'],Systolic Blood Pressure
8628,NCT05789706,Change from pre-intervention baseline in hemoblobin A1c,Change in Medication Adherence Score from baseline,2021-03-24,COMPLETED,INTERVENTIONAL,['NA'],
8629,NCT00511667,Participants Discontinued Because of Any Clinical Adverse Experience,Concentration of MK-0941 at 24 Hours (C24hr) After Multiple Doses of MK-0941,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
8630,NCT03047486,Glucose Time below range (hypoglycemia < 70 mg/dl) from CGM recording,HbA1c,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],Medical time at each consultation
8631,NCT05717491,Fasting glucose value according to the level of precariousness,Risk (odds Ratio) of (pre) diabetes and accelerated aging for assessed exposures,2021-12-14,RECRUITING,OBSERVATIONAL,['NA'],
8632,NCT03986073,Glycosylated hemoglobin (HbA1c),GLP-1 (glucagon-like peptide-1),2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
8633,NCT03234491,PostPrandial Blood Glucose,Venous Glucose Levels,2017-11-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
8634,NCT03423355,Change in blood EPO levels,Change of diastolic function parameters,2021-09,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
8635,NCT00605449,drug plasma levels of GSK376501:,"GSK376501 Day 7 AUC(0-24), Cmax, tmax and t1/2.",2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
8636,NCT01270542,"The Effect of an Anti-VEGF (Vascular Endothelial Growth Factor) Agent, Bevacizumab, on Levels of Vitreous and Aqueous Growth Factor Levels (pg/mL) in Eyes With Traction Retinal Detachment Due to PDR",Improvement of Visual Outcomes in Patients Given Pre-operative Adjunctive Bevacizumab in Eyes Undergoing PDR Surgery.,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
8637,NCT01945996,Acceptability 2: Would Patients Recommend the Program to Family or Friends?,Change in Summary of Diabetes Self-care Activities - Carb Spacing Sub Score,2013-09,COMPLETED,INTERVENTIONAL,['NA'],
8638,NCT02468037,Improvement in glucose area under the curve.,Improvement in insulin secretory capacity,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
8639,NCT05145465,Waist size (cm),,2021-09-01,UNKNOWN,INTERVENTIONAL,['NA'],
8640,NCT03312478,Odds of Type 1 Diabetes Mellitus child having a diabetic parent,Characterization of diabetes education,2017-10-13,COMPLETED,INTERVENTIONAL,['PHASE4'],
8641,NCT03666923,Incidence of dose-limiting toxicities up to the Day 14 visit,Occurrence of laboratory abnormalities up to the end of the study,2018-09-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
8642,NCT03723759,"AUCIAsp,0h-t - Area under the serum insulin aspart concentration-time curve from 0 to t hours after investigational medicinal product (IMP) administration, where t is end of exposure",Number of hypoglycaemic episodes in the treatment emergent period,2018-10-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
8643,NCT02745808,Safety and Tolerability assessed by Adverse Events,Improvement in penile colour Doppler ultrasonography,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],
8644,NCT05979584,4-week wound healing rate,Infection evaluation,2023-11-15,RECRUITING,INTERVENTIONAL,['NA'],
8645,NCT00976326,Area under the NN1250 concentration-time curve after single-dose,Number of adverse events,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
8646,NCT03983187,the standard deviation of blood glucose,time in range,2019-06-15,UNKNOWN,INTERVENTIONAL,['NA'],
8647,NCT00407849,Safety of intravitreal triamcinolone acetonide after 12 months of treatment.,,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8648,NCT01743963,Delay Interval (Days From Randomization Until the Provider Signs the Order for a hgbA1C Level).,Feasibility/Reach/Adoption,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
8649,NCT01087242,glycosylated hemoglobin,"fasting blood glucose,2-hour postprandial blood glucose,true insulin,TG,TG、LCL-C、HDL-C、BMI,waistline, hipline,TCM syndrome and sign",2009-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],
8650,NCT04862923,Change in glycated haemoglobin (HbA1c),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",2021-05-12,COMPLETED,OBSERVATIONAL,['NA'],
8651,NCT06025513,Standard pharmacokinetics/pharmacodynamics (PK/PD) endpoints as applicable after injection of a rapid-acting mealtime insulin,,2024-02-16,RECRUITING,INTERVENTIONAL,['NA'],
8652,NCT01703286,Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28,Number of Patients With Adverse Events,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
8653,NCT03740581,Number of participants with complete wound closure (epithelialisation) at 12 weeks in both intensive and conventional treatment groups.,Incidence of any amputation.,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],
8654,NCT05835037,Zinc-dependent effect on HbA1c at 1 year,Zinc-dependent effect on HbA1c at 6 months,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
8655,NCT00576784,The proportion of patients with an increase in HbA1c by 0.5 % after 6 months of treatment compared to baseline HbA1c value,Absolute change of HbA1c Insulin resistance according to minimal model and HOMA-S analysis change of insulin resistance according to minimal model and HOMA-S analysis to baseline first phase insulin response,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
8656,NCT05715307,Glycated haemoglobin (HbA1c) control rate,Number of participants with abnormal Renal function,2023-02-09,RECRUITING,INTERVENTIONAL,['NA'],
8657,NCT02059174,M1 Glargine Metabolite PK: Maximum Plasma Concentration (Cmax),M1 Glargine Metabolite PK: Area Under the Plasma Concentration Versus Time Curve Over the Second 12 Hours After Dosing (AUC12-24),2014-02-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
8658,NCT03242018,Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus Placebo,Percentage of Participants With Treatment-emergent Adverse Events (TEAEs),2017-08-16,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Hypoglycemic Events
8659,NCT04684420,Maximum Observed Plasma Concentration (Cmax) of Metformin,Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metformin,2020-12-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
8660,NCT04577183,Number of Participants With Reduction in Wound Size,,2018-07-11,COMPLETED,INTERVENTIONAL,['NA'],
8661,NCT04827615,Body weight,,2019-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
8662,NCT01772914,Changes in copeptin levels after intake of a oral glucose tolerance test- and a mixed meal tolerance test liquid,,2013-02,COMPLETED,OBSERVATIONAL,['NA'],
8663,NCT01272804,Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14,Change From Baseline in Lactate Level at Day 6 and 14,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
8664,NCT00926133,The prevalence of abnormal glucose regulation defined by an oral glucose tolerance test (OGTT).,Study the relationship between abnormal glucose regulation and prognosis after STEMI.,2005-11,UNKNOWN,OBSERVATIONAL,['NA'],
8665,NCT05142020,Significantly different proteins at 32-34 gestational weeks,,2022-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
8666,NCT02754219,Pharmacokinetic(Cmax of Evogliptin),,2016-09-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
8667,NCT04998461,Comparison of gene expression in USC (Urinary Stem Cells),,2021-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
8668,NCT01474083,Pharmacokinetic parameters of GK1-399 from plasma concentrations,Pharmacodynamic parameters of plasma glucose,2011-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8669,NCT00545870,To investigate the change in macular edema and the absolute change in visual acuity. To investigate the change of neovascularisation.,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
8670,NCT03458715,Glycated hemoglobin (HbA1c),Hypoglycemia event,2017-09-21,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8671,NCT05501483,Changes in fat cell lipolysis after 6 months of treatment,Changes in fat cell heterogeneity after 6 months of treatment,2023-02-08,RECRUITING,INTERVENTIONAL,['NA'],Changes in tissue cellularity after 6 months of treatment (explorative outcome)
8672,NCT01128621,Number of Participants With Relationship Between GSK1292263 Drug Exposures and Pharmacodynamic Parameters (Part B),,2009-11-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
8673,NCT05810311,Change in kidney oxygenation levels,Change in urinary reactive oxygen species (ROS),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
8674,NCT00739323,,,2006-12,COMPLETED,OBSERVATIONAL,['NA'],
8675,NCT04972955,New diagnosis of maternal diabetes or prediabetes based on 75g OGTT,Cost component analysis of CGM vs. 75g OGTT,2023-07-04,RECRUITING,OBSERVATIONAL,['NA'],
8676,NCT03504592,Completeness and accuracy of blood glucose record,Unscheduled health care access episodes,2018-05-01,COMPLETED,INTERVENTIONAL,['NA'],
8677,NCT01821079,Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf),Plasma Decay Half-Life (t1/2),2013-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
8678,NCT04385758,Diabetes Distress (using DDS),Self-Reported Hypoglycemia and Hyperglycemia,2020-07-13,COMPLETED,INTERVENTIONAL,['NA'],
8679,NCT05742243,Beta-cell function at 48 weeks,Adverse events,2023-02-13,RECRUITING,INTERVENTIONAL,['PHASE2'],
8680,NCT00600626,HbA1c,changes in body weight and vital signs,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
8681,NCT01464099,Maximum plasma concentration (Cmax) of insulin aspart,AUC (area under the curve) of insulin aspart,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
8682,NCT03261362,Clamp test,Mixed Meal Test,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
8683,NCT04235504,HbA1c 6 Months Change Between AHCL and MDI,Hypoglycemic Events,2020-07-13,COMPLETED,INTERVENTIONAL,['NA'],HbA1c 12 Months Change Between Groups
8684,NCT01236846,serum 25-hydroxyvitamin D,Blood pressure,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
8685,NCT02705053,"Change in Hemoglobin A1c (HbA1c) (%) from baseline (week 2) to end of week 15 (end of study), with A1c measured at weeks 7 and 11 as well for repeated measures.","Time with glucose ≤ 70 mg/dL, overall",2016-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
8686,NCT02324569,Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs) That Occurred Before Start of Treatment Period II,Change From Baseline in Self-Monitoring of Blood Glucose Before Breakfast,2014-12-27,COMPLETED,INTERVENTIONAL,['PHASE3'],
8687,NCT05293340,"Time in range (TIR) between 140 and 180 mg/dL [TIR (140-180)]- Change from Prior to Intervention, to Final Two Weeks of Intervention",Regression analysis between average composite acceptability score on the weekly Avocado Acceptability Questionnaire and motives underlying the selection of food assessed by the Food Choice Questionnaire (FCQ),2022-03-31,TERMINATED,INTERVENTIONAL,['NA'],
8688,NCT02229110,The number of participants with change in allocation of care after intervention,Number of participants who meet their treatment goals,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
8689,NCT02151188,Glucose response of different treatments,Gastric emptying rate,2014-03,COMPLETED,INTERVENTIONAL,['NA'],
8690,NCT00073034,,,2004-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
8691,NCT01614327,Sensitivity and specificity of retinal screening for risk stratification of DR using digital fundus photographs with and without the assistance of the RiskAnalyzer.,Sensitivity and specificity of retinal screening for risk stratification of DR using digital fundus photographs and the RiskAnalyzer,2012-08,COMPLETED,OBSERVATIONAL,['NA'],
8692,NCT00850824,glycosolated hemoglobin (HbA1c) levels,keeping specialty referral for medical exams,2007-10,COMPLETED,INTERVENTIONAL,['NA'],
8693,NCT02647320,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12,Count of Participants With HbA1c Less Than 7.0% at Week 12,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
8694,NCT03037528,Glycemic Control,Depressive Symptoms,2017-01-27,COMPLETED,INTERVENTIONAL,['NA'],
8695,NCT02379078,Decisional Conflict in Patients With Diabetes,Intention to Engage in Shared Decision-making in Health Care Providers,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
8696,NCT00835757,The difference in means between DTI parameters (FA and MD) measured in the sural nerve between subjects with DPN and healthy control subjects.,The association between DTI parameters and clinical and electrophysiological measures of DPN,2008-09,COMPLETED,OBSERVATIONAL,['NA'],
8697,NCT00316082,Change From Baseline in Hemoglobin A1 (A1C) at Week 24,Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
8698,NCT05884775,Change in Hemoglobin A1C (HbA1c),Total Number of Reports Viewed by Patients via PRO Interactive Dashboard,2025-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
8699,NCT02964247,Change in HbA1c,Subjects Who Achieve Weight Loss by 3% or More,2017-03-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
8700,NCT00537303,Glycosylated Haemoglobin A1c (HbA1c),Cardiovascular Risk Marker: High-sensitivity C-reactive Peptide,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
8701,NCT04756141,Mean Absolute Relative Difference (MARD),Continuous Glucose Monitor (CGM) Calibrations,2021-03-03,COMPLETED,INTERVENTIONAL,['NA'],
8702,NCT02915029,Patient Activation Measure (PAM) Level Greater Than 2,8-Item Morisky Score,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
8703,NCT01870297,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Change From Baseline to Day 28 in Fasting Glucose,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
8704,NCT01205308,non-cholesterol sterols,,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
8705,NCT01426802,Evaluate the safety and tolerability of vildagliptin 50 mg bid,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
8706,NCT04956263,Concentration-time curve in plasma glucose (AUC(0-120min) ),Objectives for Insulin Requirements,2021-06-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
8707,NCT02541838,Change in protective stepping as determined by the number of steps it take to recover from a balance perturbation from baseline to 3 months and baseline to 6 months,Change in mobility as measured by the modified physical performance test,2016-05,TERMINATED,INTERVENTIONAL,['NA'],
8708,NCT05867017,Measure of free plasma glucose (FPG),Body Weight,2023-07-10,RECRUITING,OBSERVATIONAL,['NA'],
8709,NCT03061461,Wound size,Satisfaction,2017-02-23,UNKNOWN,INTERVENTIONAL,['NA'],
8710,NCT00437112,"Compare, in insulin-naive patients with type 2 diabetes on one or more oral antihyperglycemic medications, a regimen adding mealtime HIIP versus a regimen adding insulin glargine with respect to change in HbA1c from baseline to endpoint.",Patient reported outcome of Experience with Insulin Therapy Questionnaire,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
8711,NCT04620590,Change in 24-hr sodium excretion,,2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8712,NCT00159211,Abdominal adipose tissue (on scan) variation at 6 month,inflammation gene expression in sub-cutaneous fat,2005-05,TERMINATED,INTERVENTIONAL,['NA'],
8713,NCT00990444,Identification of the lowest dose of oral insulin in dextran matrix that produces a significant lowering of post-prandial blood glucose.,To establish the dose(s) when administered in a multi-dose fashion that lowers plasma glucose levels versus placebo in patients with Type 2 diabetes,2009-09,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8714,NCT05050500,The rate of heart failure occurrence,,2023-05-08,RECRUITING,INTERVENTIONAL,['PHASE4'],
8715,NCT02239458,Oral Disposition Index,,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],
8716,NCT00817505,"Pharmacokinetic variables ( Area under the plasma concentration vs. time curve (AUC), maximum plasma concentration (Cmax), time to reach maximum plasma concentration (tmax), terminal elimination half-life (t½) and apparent oral clearance (CL/F)","Safety Variables (AEs, BP, pulse, electrocardiogram (ECG), hypoglycaemic symptoms and laboratory variables)",2008-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
8717,NCT00558935,measurements of dyslipidemia,lipid functionality,2007-10,TERMINATED,INTERVENTIONAL,['NA'],
8718,NCT00248157,long-term safety and tolerability,monitor long-term efficacy,2005-11,TERMINATED,INTERVENTIONAL,['PHASE3'],
8719,NCT01551667,Humoral immune response,Presence / absence of clonal complexes of the S. aureus strains,2012-11,COMPLETED,OBSERVATIONAL,['NA'],
8720,NCT05089890,Bacterial and fungal species irreversibly bound to the dressing after 2 days (+ 1 day).,Wound fluid inflammatory biomarker levels at 14 days (±1 days) compared to baseline,2021-10,UNKNOWN,INTERVENTIONAL,['NA'],
8721,NCT06272695,Change in Time to glucagon treatment success at Week 6.,Change from baseline in hemoglobin A1c (HbA1c) at Week 6.,2024-02-29,RECRUITING,INTERVENTIONAL,['PHASE1'],
8722,NCT00304603,Percent change in weight,Number of patients with adverse events,2004-04,COMPLETED,OBSERVATIONAL,['NA'],
8723,NCT01226043,Patient Overall Preference,Percentage of Patients Who Discontinued Investigational Product During the Observational Phase,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of Patients With Hypoglycemic Events
8724,NCT00842894,Incidence of serious adverse drug reactions (SADRs),Change in body weight,2009-05,COMPLETED,OBSERVATIONAL,['NA'],
8725,NCT03410173,Changes of cognitive function assessed by cognitive function scale after 12 weeks.,Fasting serum insulin.,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],
8726,NCT02953977,Change from baseline weight,Changes in Stages of Change for healthy eating and physical activity,2018-06-15,COMPLETED,INTERVENTIONAL,['NA'],
8727,NCT00196235,,,1995-01,COMPLETED,OBSERVATIONAL,['NA'],
8728,NCT04221360,AUClast of D390 and CKD-375,CL/F of D390 and CKD-375,2020-01-29,UNKNOWN,INTERVENTIONAL,['PHASE1'],
8729,NCT02685475,Sensory block duration,Rescue analgesic consumption,2015-02,COMPLETED,OBSERVATIONAL,['NA'],
8730,NCT03314246,Change in HbA1c,Change in diabetes treatment satisfaction,2017-04-03,COMPLETED,INTERVENTIONAL,['NA'],
8731,NCT06211556,Difference in change in FGF21 incremental area-under-the-curve,Difference in change in fasting plasma alanine aminotransferase,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Difference in change in lipid parameters
8732,NCT00446472,Completely healed wounds,,2007-04,UNKNOWN,INTERVENTIONAL,['NA'],
8733,NCT01823341,"Comparison of the Time Spent in Hypoglycemia (<70 mg/dl, 3.9 mmol/L) Overnight on Intervention Nights Versus Control Nights, Normalized to an 8-hour Period.",Percent of Mornings With Urine Ketones >/= 15 mg/dl,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
8734,NCT05498116,Change in Albuminuria,Change in Large Elastic Artery Stiffness,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE4'],
8735,NCT00463502,,,na,COMPLETED,INTERVENTIONAL,['PHASE4'],
8736,NCT01201109,Patient self-reported outcome questionnaire,Nerve conduction study and vibrotactile sense,2010-11,UNKNOWN,OBSERVATIONAL,['NA'],
8737,NCT00676923,,,2008-03,COMPLETED,OBSERVATIONAL,['NA'],
8738,NCT04738032,Diabetes self-management behaviors,,2020-08-26,COMPLETED,OBSERVATIONAL,['NA'],
8739,NCT05786612,Percentage wound area reduction during the investigational test period of four weeks,Total treatment costs during the investigational test period based on the number of dressings used during the investigation and the unit price of the products,2023-01-30,COMPLETED,INTERVENTIONAL,['NA'],
8740,NCT04007809,Evaluation and follow-up of quality of life: DisabKids Questionnaires,Production of prediction model of β-cell mass evolution,2019-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
8741,NCT05583045,HbA1c,Creatinine,2022-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
8742,NCT01341392,Amlodipine AUC,Amlodipine Tmax,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
8743,NCT03259724,HbA1c,HOMA-IR,2017-01-30,UNKNOWN,OBSERVATIONAL,['NA'],
8744,NCT04300205,Altered pain experience associated with chronic wounds,,2020-02-25,COMPLETED,INTERVENTIONAL,['NA'],
8745,NCT05449821,Asprosin Levels,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],
8746,NCT01301833,Number of Participants With Adverse Events,Change From Baseline in Fasting Immuno Reactive Insulin (IRI) at Week 52,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
8747,NCT04382794,Death,Clinical parameter of acute lung disease,2020-05-14,COMPLETED,OBSERVATIONAL,['NA'],
8748,NCT05158478,repeatability precision,,2022-02-22,COMPLETED,INTERVENTIONAL,['NA'],
8749,NCT05439473,Effect of treatment with Curalin on the change in plasma HbA1c,Safety of Curalin as assessed by adverse events,2021-08-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
8750,NCT02372149,Change in Overall Neuropathy Limitations Score (ONLS) after 3 months,Adverse Events,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8751,NCT00071409,"assess efficacy and safety based on arginine stimulated C peptide, fasting C peptide, average daily insulin dose, fasting glucose, glycosylated hemoglobin (Hb A1c), and AEs",,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
8752,NCT01533428,Percent Change in the Average Daily Pain Score From Baseline to Between Weeks 2 and 8,"Safety Assessed Through Adverse Events (AE) and Serious Adverse Events (SAE), Vital Signs, and Laboratory Analyses From Baseline to Week 12",2012-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
8753,NCT00908778,"Ultrasound, OCT, and clinical exam","Ultrasound ,OCT ,Safety, and Clinical Exam",2008-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
8754,NCT00735501,"Incidence of serious adverse drug reactions, including major hypoglycaemic events",Weight changes,2008-03,COMPLETED,OBSERVATIONAL,['NA'],
8755,NCT01804881,The Change in EEQ (Emotional Eater Questionnaire) Score is the Primary Outcome Measure in This Study.,Change in Weight,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
8756,NCT00641407,Change in hemoglobin A1c (HbA1c) level from baseline to end point for each treatment group.,"Percentage of subjects achieving HbA1c ≤7%, incidence of self-reported hypoglycaemic episodes, comparison of SMPG values from 8-point profiles, insulin doses, and body weight.",2007-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
8757,NCT05856318,QRISK3,Diabetes Risk,2023-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
8758,NCT02620553,Evaluation of Blood Glucose Levels,T-cell responses related to potential immune response to Insulin,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8759,NCT03403231,Engagement in Recommended Behaviors to Prevent Type 2 Diabetes,Physical Activity,2018-02-01,COMPLETED,INTERVENTIONAL,['NA'],
8760,NCT02367534,hemorrhage,C-peptide,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8761,NCT04689425,Wound area reduction rate,Amputation rate at 8 weeks,2021-03-30,RECRUITING,INTERVENTIONAL,['PHASE3'],
8762,NCT00957762,"To compare different methods of body composition analyses with the gold standard 4-compartment monitoring to determine accuracy and validity of those alternative, but less labor-intensive techniques.",To cross-validate the derived regression equations against the gold standard 4-compartment model in an independent group of persons with SCI.,2009-08,UNKNOWN,OBSERVATIONAL,['NA'],
8763,NCT00520182,"Triglyceride level, glycated hemoglobin level, fasting plasma glucose","Weight, BMI, waist hip circumference, insulin resistance using HOMA (fasting glucose to fasting insulin ration), HDL-Cholesterol level.",2004-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],
8764,NCT00328172,Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 12,Percentage of Patients With Absolute Efficacy Response (HbA1c <= 7.0%) at 12 Weeks,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
8765,NCT00419718,Area under the plasma insulin profile in the interval,Maximum plasma insulin concentration,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
8766,NCT05783115,visual analogue scale,skin temperature,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],
8767,NCT02671968,"Change in the total number of low glucose events (<55 mg/dl), between baseline and outcome phase (week 22-26) in CGM group and control group (change = subtracting number of follow up events from number of baseline events",,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
8768,NCT04323189,Dipeptidyl peptidase 4 (DPP4),Mean heart rate,2020-08-26,RECRUITING,INTERVENTIONAL,['PHASE4'],
8769,NCT04449198,Skeletal Muscle Mitochondrial Function,Change in Post Occlusive Reactive Hyperemia (PORH),2020-10-14,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
8770,NCT02353975,The accumulative excretion rate of SHR3824 and its metabolites in urine and feces,The number of volunteers with adverse events as a measure of safety and tolerability.,2014-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
8771,NCT00797069,To compare the postprandial glycemic response of patients with type 2 diabetes consuming single servings of a standard liquid nutrition product and two diabetes-specific liquid nutrition products.,To compare the postprandial insulinemic response of patients with type 2 diabetes consuming single servings of a standard liquid nutrition product and two diabetes-specific liquid nutrition products.,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
8772,NCT02116426,Final diagnosis of ACS non ST + (yes/no),Number of patients taken in charge that day by ambulance staff.,2015-07-29,COMPLETED,OBSERVATIONAL,['NA'],
8773,NCT02315274,Glucose variability,Changes is severe hypoglycemia,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
8774,NCT02034695,The proportion of patients who have achieved a HbA1c level <7%.,"Service utilization outcomes measured by GOPC consultation, SOPC consultation, A&E and hospital attendance rates in the past 12 months.",2010-09,COMPLETED,OBSERVATIONAL,['NA'],
8775,NCT02104739,Monocyte NfkB Levels as Detected by Western Blotting,Peak Forearm Blood Flow,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
8776,NCT04332003,Time to complete wound closure.,Change in oxygenation at the wound site,2021-01-01,WITHDRAWN,INTERVENTIONAL,['NA'],
8777,NCT05885906,Change in unstimulated Salivary flow rate,,2023-07-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
8778,NCT04616053,HbA1c,Lipids - triglycerides,2021-09,UNKNOWN,INTERVENTIONAL,['NA'],
8779,NCT01251211,Average pain intensity on numerical scales in a self diary by the patient,Predictors of the response,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Evaluate pain relief at 24 weeks
8780,NCT06335771,Macrophage isolation in skeletal muscle tissue,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
8781,NCT00063583,The primary endpoint will be the change in renal function from baseline to the end of the study period (12 months).,• Determine the relationship between % change in TGF-b1 levels and the change in GFR,2003-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8782,NCT00881530,"Clinical Relevant Abnormalities for Physical Examination, Vital Signs, ECG and Laboratory Measurements",Change From Baseline in Fasting Plasma Glucose (FPG) Over Time,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
8783,NCT01303055,beta cell function evaluated from 75 g OGTT,"1,5-AG level",2011-02,UNKNOWN,INTERVENTIONAL,['NA'],
8784,NCT02139943,Percentage of Participants With Adverse Events,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
8785,NCT01926925,Plasma levels of markers of endothelial activation and vascular inflammation,,2001-05,COMPLETED,OBSERVATIONAL,['NA'],
8786,NCT04893135,RANKL/OPG level,Sudoscan measurement,2021-10-11,COMPLETED,INTERVENTIONAL,['NA'],
8787,NCT05351359,step count,body mass index,2022-04-25,RECRUITING,INTERVENTIONAL,['NA'],
8788,NCT00137046,Annual Rate of Change in Carbon Monoxide Diffusion Capacity (DLco),Insulin Antibodies,2002-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
8789,NCT05794581,To assess area under the curve (AUC) in glucose metabolism during MMTT,Area under the acetaminophen concentration-time (AUC),2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE1'],
8790,NCT00481598,"glycogen metabolism, gluconeogenesis, after 3 months of treatment;",,2006-01,COMPLETED,INTERVENTIONAL,['NA'],
8791,NCT02024477,CD 34+ Cell Function,Arterial Stiffness,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
8792,NCT05486065,Change in Glycosylated Haemoglobin (HbA1c),Number of Treatment-emergent Severe Hypoglycaemic Episodes,2022-08-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
8793,NCT02999945,Fat Free Mass,macronutrients in breastmilk-protein,2019-03,WITHDRAWN,INTERVENTIONAL,['NA'],
8794,NCT02082704,HbA1c levels,Patient's perceptions of the optimal parameters for the SE game intervention.,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
8795,NCT05816941,HbA1c test,Sulcus bleeding index (SBI),2016-01-03,COMPLETED,INTERVENTIONAL,['NA'],
8796,NCT03050827,Ocular Nerve Fiber Density,Autonomic Function Tests - Root Mean Square of the Successive Differences,2014-05-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
8797,NCT05806554,Accuracy,,2023-07-19,RECRUITING,OBSERVATIONAL,['NA'],
8798,NCT01386645,Disposition Index,Glycemic Variability,2011-07,COMPLETED,INTERVENTIONAL,['NA'],
8799,NCT02716623,Participant compliance with study specific CR diet,Presence of Tumor M2-PK,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
8800,NCT01844037,Change in office systolic blood pressure (SBP) from baseline to 6 months,Change in office SBP,2014-07,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
8801,NCT06214520,HbA1c,Usability of the Empower+ app and Motivational Interviewing module,2024-01-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
8802,NCT02383940,Change From Baseline in Hemoglobin A1C (A1C) at Week 12,Change From Baseline in Number of Hypoglycemic Events/Day (<=70 mg/dL) by Self-Monitored Blood Glucose (SMBG) at Week 12,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
8803,NCT00506961,The percentage of patients achieving the combined treatment goal of LDL-C < 100mg/dl and non-HDL-C < 130 mg/dl at week 12 with rosuvastatin treatment compared with simvastatin treatment,Percentage of patients achieving the LDL-C goal of <70 mg/dL at Week;The mean percent change from baseline in lipid profile at week 4 and week 12;,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
8804,NCT02147431,Change in mean glucagon concentration during hypoglycaemia (change from target level 5.5 mmol/L to nadir (target 2.5 mmol/L)),Time from termination of insulin infusion at nadir to reach plasma glucose level 4.0 mmol/L,2014-05-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
8805,NCT04575389,the association of serum uric acid (SUA) level with metabolic risk factors in patients with type 2 diabetes,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],
8806,NCT00967837,To measure progress of wound healing in subjects that have failed conventional wound care healing treatments for 60 days,,2006-01,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
8807,NCT04564586,Inactivity,Hemoglobin A1c,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
8808,NCT02762370,Change From Baseline for Average Blood Glucose (mg/dL),Area Under the Effect (AUE) Curves for Average Blood Glucose - FX006 Versus TCA IR,2016-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Average Blood Glucose From Baseline (Hour -48 to Hour -1) to Hour 1 to Hour 48 for FX006 32 mg Relative to TCA IR 40 mg.
8809,NCT02073058,Clinical point accuracy as assessed by the Consensus Error Grid,"Composite measure: Clinical point accuracy (Clarke Error Grid), trend accuracy (R-deviation, Rate Error Grid and Continuous Glucose Error Grid) and lag time, performance of notifications (sensitivity and false notifications) and questionnaire responses.",2014-02,COMPLETED,OBSERVATIONAL,['NA'],
8810,NCT05282264,Acceptability of hybrid closed-loop systems,Hypoglycemia Fear,2022-04-01,COMPLETED,OBSERVATIONAL,['NA'],
8811,NCT00519935,Metabolic Control: Hemoglobin A1c (HbA1c),Quality of life,2001-07,COMPLETED,INTERVENTIONAL,['NA'],
8812,NCT05033054,Change in serum klotho levels at 12 week,Change in serum magnesium levels at 12 weeks,2022-11-20,RECRUITING,OBSERVATIONAL,['NA'],
8813,NCT04807959,Reduction of Visceral Adiposity,Increase of Intracellular Fluid,2016-10-27,COMPLETED,OBSERVATIONAL,['NA'],
8814,NCT01147861,Weighted mean AUC for glucose,"Weighted mean AUC for NEFA, glycerol, triglycerides, insulin, and C-peptide",2010-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
8815,NCT02488252,Change in spot urine albumin-to-creatinine ratio,Rate of CKD stage transition,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
8816,NCT06318429,blood sugar,,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
8817,NCT04313920,Plasma Glucose Concentration,Gastric Emptying,2020-04-07,COMPLETED,INTERVENTIONAL,['NA'],
8818,NCT02504658,Total Self-Efficacy Score on the Physical Activity and Healthy Food Efficacy Scale for Children,"Number of text message responses to Goal Setting Question, as a measure of Adherence",2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
8819,NCT05092399,Effects of VLCD,Effects of VLCD and bariatric surgery,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],
8820,NCT00574340,Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2,,2007-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
8821,NCT05232812,Radiation exposure of 3-[11C]-OHB,,2022-06-01,COMPLETED,INTERVENTIONAL,['NA'],
8822,NCT02399826,Proportion of ulcers completely healed by amniotic memrane versus standard care,Proportion of ulcers healed by amniotic membrane versus standard care,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],
8823,NCT04930588,The receptor ErbB4 in saliva,Body Mass Index (BMI),2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],
8824,NCT05752851,Fecal 16S rRNA gene sequencing,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA'],
8825,NCT01745549,hematic fructosamine levels,patient's satisfaction,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
8826,NCT00253760,a global metabolic spectrum detectable by H-NMR,,2004-02,COMPLETED,INTERVENTIONAL,['NA'],
8827,NCT00336323,Percentage of Participants With <250 Microns or ≥ 50% Reduction in Retinal Thickening From Baseline Over All Study Visits,Distribution of Change in Visual Acuity Over All Study Visits,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Central Subfield Thickness From 3 to 6 Weeks Among Eyes That Received 2.5mg Bevacizumab at 6 Weeks and Had Within >11% Increase in Change of Central Subfield Thickness From 6 Weeks to 9 Weeks
8828,NCT00988377,Blood glucose subjective appetite Food intake at 30 min,physical comfort palatability,2007-05,COMPLETED,INTERVENTIONAL,['NA'],
8829,NCT00643760,Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at End of Maintenance Treatment (EOMT) Using Last Observation Carried Forward (LOCF) Data,Change From Baseline in Emotional Functioning as Assessed by the Profile of Mood States-Brief Form (POMS-B) at EOMT Using LOCF Data,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
8830,NCT04745702,Oral Glucose Tolerance Test,TNF (Tumor Necrosis Factor - alpha),2020-11-02,UNKNOWN,INTERVENTIONAL,['NA'],
8831,NCT02176681,Mean glucose value of CGM [M] to be averaged from day 2 and day 3 of CGM,Mean HbA1C and Glycated albumin,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
8832,NCT00729365,"Development of Microalbuminuria (High Urine Albumin). Hypertension, Urine and Blood Markers Will Also be Evaluated for Assessment of Kidney Disease State.",We Will Assess Changes in the Relative Stiffness of Your Arteries (Endothelial Dysfunction) in Persons With Type 1 Diabetes Over the 5year Study.,2008-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
8833,NCT00665093,HbA1c,"FPG, PG profile, weight, % of subjects on target",2007-05,COMPLETED,OBSERVATIONAL,['NA'],
8834,NCT00815789,"Change in the outcome (SBP, Hb A1c, or LDL) from baseline to the 12 month evaluation.","Changes in CVD related health behaviors (e.g., aspirin use, medication adherence, exercise, and diet) as well as changes in stroke and CHD risk as assessed by the UPKDS risk engine",2008-12,COMPLETED,INTERVENTIONAL,['NA'],
8835,NCT02093221,Change From Baseline in Mixed Meal Tolerance Test (MMTMT) Stimulated C-peptide 2 Hour Area Under the Concentration-time Curve (AUC),Change From Baseline for Mean Daily Glucose Levels Prior to Meals and Bedtime,2014-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
8836,NCT02862730,Percent of Time With Sensed Glucose Between 3.9-10 mmol/L,Mean Amount of Glucagon Delivered,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
8837,NCT00119535,� Optimal timing of photocoagulation (prior to intervention and 12 months after interventions,� Meeting retinopathy screening and surveillance guidelines � Patient satisfaction with care � Resource utilization (during study and previous 12 months) � Intervention Costs (conclusion of study),2004-08,COMPLETED,INTERVENTIONAL,['NA'],
8838,NCT01154881,Area under the glucose infusion rate curve from 0-24 hours at steady state,Area under the insulin degludec concentration-time curve from 0-24 hours at steady state,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
8839,NCT00068887,,,1999-09,WITHDRAWN,OBSERVATIONAL,['NA'],
8840,NCT02082028,Change in HbA1c levels from baseline,Participants satisfaction with SMBG meter assessed by Visual Analog Scale (VAS),2012-06-27,COMPLETED,INTERVENTIONAL,['NA'],
8841,NCT03414723,Assessment of PK parameter: AUCtau,Adverse events,2018-01-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
8842,NCT05417152,Scanning session completion status,,2022-06-29,COMPLETED,OBSERVATIONAL,['NA'],
8843,NCT02524782,Part B: Change in LDL-C from baseline to Day 36,"Part B: Pharmacokinetics of MEDI4166, time to maximum observed plasma drug concentration (Tmax)",2015-10-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
8844,NCT05890690,Difference in maximal increase in copeptin levels in plasma (pmol/l),,2023-06-02,RECRUITING,INTERVENTIONAL,['NA'],
8845,NCT01136746,Percentage of Capillary Plasma Glucose Measurements Within the Range of 71 to 179 mg/dL Throughout the Hospital Study Period,Number of Participants With Major Adverse Cardiovascular Events (MACE),2011-03,TERMINATED,INTERVENTIONAL,['PHASE3'],
8846,NCT03125694,Change from baseline in mean glycated hemoglobin (A1C) levels by sitagliptin vs. pioglitazone,,2015-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
8847,NCT06125873,It controls blood Glycated hemoglobin level in type 2 diabetic patients.,Moringa leaf powder effect on body weight of patients,2023-03-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],
8848,NCT02476409,Change in Body Weight at 48 Hours Stratified by Copeptin,Change in Body Weight at Day 8,2015-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
8849,NCT04330911,Digital Spirometer,,2019-02-01,COMPLETED,INTERVENTIONAL,['NA'],
8850,NCT00522210,Hemoglobin A1C,Diabetes Quality of Life Questionaire-youth version,2008-03,COMPLETED,INTERVENTIONAL,['NA'],
8851,NCT04210128,severe hyperglycemia,,2019-12-20,COMPLETED,OBSERVATIONAL,['NA'],
8852,NCT02082184,HbA1c at 6 Months,Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc) Scores From Day 1 to Day 194.,2014-03,COMPLETED,INTERVENTIONAL,['NA'],
8853,NCT01878370,Proportion of patients with perfect composite high risk score,cholesterol (LDL),2013-06,COMPLETED,INTERVENTIONAL,['NA'],Each metric within the composite scores
8854,NCT00479609,"Insulin sensitivity,","Glucose tolerance, HbA1c levels, Abdominal obesity, prostate safety, Sexual function, Sleepiness, Urinary symptoms, Hypogonadal symptoms score",2007-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],
8855,NCT05833100,Hematocrit Measurement,β-Ketone Testing of Subject Plasma Samples,2022-08-15,TERMINATED,INTERVENTIONAL,['NA'],
8856,NCT01069926,"Change-from-baseline variables will be calculated for the safety variables listed below, as the post-treatment value minus the value at baseline",To evaluate the safety of AZD1656 in T2DM patients with various degrees of renal impairment. To describe the pharmacodynamics of AZD1656 in T2DM patients with various degrees of renal impairment by assessment of 24-hours glucose profile,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
8857,NCT01683331,The Incidence of New Onset of Diabetes After Transplant (NODAT) 12 Months After Kidney Transplantation,The Incidence of New Onset of Diabetes After Transplant (NODAT) 24 Months After Kidney Transplantation,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4'],"Incidence of Impaired Fasting Glycemia and Impaired Glucose Tolerance 6, 12 and 24 Months After Transplantation."
8858,NCT04977011,Anxiety Visual Analog Scale.,Richards-Campbell Sleep Scale,2019-01-02,COMPLETED,INTERVENTIONAL,['NA'],
8859,NCT05591339,F-glucose,Time to Type-2 diabetes development,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
8860,NCT00212303,Blood pressure at 6 months,Systemic inflammation at 6 months,2004-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
8861,NCT02836873,Change From Baseline in HbA1c at 24 Weeks,Change From Baseline in HbA1c in Subjects With Stage 3b CKD (eGFR 30 to 44 mL/Min/1.73 m2) at Week 24,2016-09-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
8862,NCT05095389,DFU Closure Rate,Percent Reduction of Wound Area,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
8863,NCT03491436,blood glucose 2 hours after meal 3,,2017-05-01,WITHDRAWN,INTERVENTIONAL,['NA'],
8864,NCT00916357,Postprandial Glucose (PPG) Excursion Following a Liquid Meal,Time to Percentage of Insulin Exposure (as Measured by Area Under the Curve [AUC]),2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
8865,NCT01258075,Percent Change in Hemoglobin A1c (HbA1c) From Baseline to Month 6,Number of Participants Requiring Rescue Medication Who Initially Met Rescue Criteria,2011-02-24,COMPLETED,INTERVENTIONAL,['PHASE4'],
8866,NCT02256189,Glucagon Counterregulation to Hypoglycemia,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
8867,NCT00505882,The change in weight (kg) will be compared between as well as within the placebo and the pramlintide treatment group from baseline to the end of the study.,mixed meal tolerance test-the C-peptide area under the curve The HOMA R and McAuley's index HbA1c The event rate of severe hypoglycemia Waist circumference Cardio C-reactive protein level DQOL Safety parameter,2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
8868,NCT00544518,The change of HbA1c from baseline to the end of treatment,the changes of fasting and after standard meal glucose and insulin level and plasma lipid level,2007-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
8869,NCT05643768,Change from baseline insulin sensitivity after 6 weeks of IMST,Change from baseline Nitric Oxide-mediated Endothelial Dependent Dilation (EDD),2023-06-30,RECRUITING,INTERVENTIONAL,['NA'],Change from baseline proteomic analysis
8870,NCT05939895,To diagnose missed cases of prediabetes.,,2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],
8871,NCT00433628,,,2007-02-07,COMPLETED,OBSERVATIONAL,['NA'],
8872,NCT05697991,Prevalence of hepatic steatosis in T2DM,Pathogenesis of progressive disease,2015-03-23,RECRUITING,OBSERVATIONAL,['NA'],
8873,NCT05267990,rate of major coronary heart disease,medical expenditure,2022-03-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
8874,NCT02554877,Change From Baseline in Glycosylated Hemoglobin (HbA1c) (%) at Week 12 as Compared to Placebo,"Changes From Baseline in Body Weight at Weeks 2, 4, 8, and 12.",2015-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
8875,NCT00005481,,,1996-09,COMPLETED,OBSERVATIONAL,['NA'],
8876,NCT01702012,Change in HbA1c (%),Change in fasting blood glucose (mg/dl),2013-01,COMPLETED,INTERVENTIONAL,['NA'],
8877,NCT00016835,,,2001-10-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
8878,NCT00711152,Change in glycated hemoglobin level,Hospitalizations with total length of stay,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
8879,NCT00845793,Changes in the results of the nutrition quality questionnaire,Changes in anthropometric measures Changes in physical activity levels,2009-04,UNKNOWN,INTERVENTIONAL,['NA'],
8880,NCT01552408,Incidence and Severity of Ocular and Non-ocular Adverse Events (AE's) Through Month 36.,Mean Change in Peripheral Visual Field as Measured by Goldmann Visual Field at Screen and Month and 36.,2012-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8881,NCT03338829,Frequency of glucose monitoring,,2016-05-05,UNKNOWN,INTERVENTIONAL,['NA'],
8882,NCT03764410,blood test for glycated hemoglobin,,2016-12-20,COMPLETED,INTERVENTIONAL,['NA'],
8883,NCT02241317,Hypoglycaemia,,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],
8884,NCT02467920,the absolute change in HbA1c from baseline to 24-week endpoint of basal insulin glargine combination with exenatide bid vs. switching to aspart30 in type 2 diabetic patients inadequately controlled on premixed human insulin and metformin.,The incidence and rate of hypoglycaemic events during the study,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
8885,NCT00006426,,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
8886,NCT00213122,,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],
8887,NCT04153981,Number or Participants With Hypoglycemic Events,Change From Week 4 in Insulin Treatment Satisfaction Questionnaire (ITSQ),2019-12-16,COMPLETED,INTERVENTIONAL,['PHASE4'],
8888,NCT03736486,"Success (evaluated by Yes/No format) recruiting and establishing a pilot cohort of 100 Latino adults with Type 2 Diabetes and creating data collection methods to describe genetics, biology, behavior, psychology, & environment in Type 2 Diabetes",Trust in physician measured by the Trust in Physician (TPS) questionnaire,2017-08-24,COMPLETED,OBSERVATIONAL,['NA'],"Success measured by the number of health care workers trained, upskilled, and employed to be community health care workers (Especialistas) and the number of participant encounters with a trained health care worker"
8889,NCT00868790,Number of Participants Who Discontinued Study Treatment Due to an AE,Percentage Change From Baseline (BL) After 4-Week Treatment in Low-Density Lipoprotein C (LDL-C) Levels,2009-03-24,TERMINATED,INTERVENTIONAL,['PHASE2'],
8890,NCT04661917,Change from baseline in urine albumin-to-creatinine ratio (UACR) to the end of treatment (Visit 6),Frequency of treatment-emergent adverse events (TEAEs),2021-05-31,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
8891,NCT02036554,"Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months",Prevalence of NODAT at 12 month(V6),2013-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8892,NCT06273215,Pharmacokinetics of study drug,Genotype of OATP and BCRP,2023-03-05,RECRUITING,INTERVENTIONAL,['PHASE4'],
8893,NCT02137057,"Change of Heart rate variability during spinal anesthesia : total power, power of LF and HF, and LF/HF ratio",,2014-05,COMPLETED,OBSERVATIONAL,['NA'],
8894,NCT01660789,BMI,,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
8895,NCT02651181,"Time in range of sensor glucose data between 70 mg/dL to 180 mg/dL,during day time (6am-12am)",Incidence of Severe Hypoglycemia,2016-06,COMPLETED,INTERVENTIONAL,['NA'],Total insulin dose
8896,NCT00245882,HbA1c,Factors influencing adherence to diabetes regimen,2005-10,COMPLETED,INTERVENTIONAL,['NA'],
8897,NCT04003259,Change in systolic and diastolic blood pressure (mmHg),Fitness index,2009-01-01,COMPLETED,INTERVENTIONAL,['NA'],
8898,NCT06219850,Assessed changes from cardiorespiratory fitness,Assessed changes in Circadian Rhythms,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
8899,NCT03866343,Insulin sensitivity,Microvascular function,2018-09-07,COMPLETED,INTERVENTIONAL,['NA'],
8900,NCT05912218,Lower limb atheroma plaque inflammation,Lower limb atheroma plaque progression,2023-06-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
8901,NCT03380546,Composite endpoint: birth weight ≥ 90th percentile for gestational age (large for gestational age: LGA) and/or neonatal hypoglycemia and/or shoulder dystocia and/or birth injury.,Conservation of serum and plasma; cord fluid. The samples may be used for further analyses ancillary studies and which could be beneficial for GDM care based on evolution in scientific knowledge.,2018-07-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
8902,NCT02360254,Change in HbA1c,Glucose variability,2015-01,COMPLETED,OBSERVATIONAL,['NA'],
8903,NCT01559896,"The change (baseline vs 2 hours, and baseline vs 2 days) in arterial stiffness measured as carotid-femoral pulse wave velocity","Changes in glucose and insulin concentrations and calculated HOMA-index, incretins, lipids, characteristics of the microcirculation, and non-invasively assessed upper-arm blood pressure and central aortic systolic blood pressure and heart rate changes",2011-09,COMPLETED,INTERVENTIONAL,['NA'],
8904,NCT03286751,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Versus Time Curve (AUC),Glucodynamics: Total Amount of Glucose Infused (Gtot),2017-10-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
8905,NCT04529239,"Glucose biomarker data from the continuous glucose monitoring device, which will be analyzed as a function of different homeostasis responses from the 3 different cohorts of individuals (i.e., i) low to moderate risk; ii) high risk, iii) very high risk).",,2020-08-31,COMPLETED,OBSERVATIONAL,['NA'],
8906,NCT02033499,Mean Difference in Health-related Quality of Life Scores From Baseline to 52 Weeks,Number of Participants on Specified Diabetes Medications at Baseline and Follow-up,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
8907,NCT00768105,"Safety variables (AE, BP, pulse, weight, plasma glucose, laboratory variables and ECG)",Pharmacodynamic variables,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
8908,NCT00140647,"The change of the mean maximum carotid intimal medial thickness (IMT)evaluated across 12 segments involving the left and right common carotid, bifurcation and internal carotid arteries.",The change over time in the mean IMT across the common carotid far wall IMT of the right and the left carotid arteries.,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
8909,NCT00975169,we plan to conduct a case-control study to test the association between single nucleotide polymorphisms (SNPs) in certain candidate genes and TZDs related peripheral edema,,2009-02,UNKNOWN,OBSERVATIONAL,['NA'],
8910,NCT05926388,Insulin Administration Observation Form 2,,2022-01-10,COMPLETED,INTERVENTIONAL,['NA'],
8911,NCT02459938,Percentage of subjects achieving normoglycemia,Area under the plasma concentration versus time curve (AUC),2015-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
8912,NCT01571232,The Change in Central Foveal Thickness (Microns on High Resolution OCT).,The Change in Mean Central Amplitude on Multi-focal ERG From Baseline.,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
8913,NCT05640180,"Time to first occurrence of the composite endpoint of Cardiovascular (CV) death or non-fatal CV event (i.e. myocardial infarction, stroke, or hospitalization for heart failure)","Time to first occurrence of the following composite endpoint: onset of kidney failure, a sustained decrease in eGFR of ≥ 57% from baseline over at least 4 weeks or renal death",2022-11-23,COMPLETED,OBSERVATIONAL,['NA'],
8914,NCT05476276,Daily 0-10 pain NRS,Opioid Use Questionnaire (OUQ),2022-09-21,RECRUITING,INTERVENTIONAL,['PHASE2'],Neuropathy Examination
8915,NCT02307695,Change of Mean amplitude of glycemic excursions (MAGE) from baseline in patients with type 1 diabetes treated with saxagliptin plus insulin or insulin alone by continuous glucose monitoring system (CGMS),Change of insulin dosage (U/kg/d) from baseline in patients with type 1 diabetes treated with saxagliptin plus insulin or insulin alone,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8916,NCT03782259,Global Myocardial Strain,T2 Relaxation Time,2019-02-26,COMPLETED,INTERVENTIONAL,['PHASE4'],hsCRP
8917,NCT00941954,Change in ambulatory activity (walking),Change in ambulatory activity (walking),2009-09,COMPLETED,INTERVENTIONAL,['NA'],
8918,NCT02521506,number of hypoglycemic events,,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
8919,NCT01487408,HbA1c (glycosylated haemoglobin),Adverse events,2002-04,COMPLETED,OBSERVATIONAL,['NA'],
8920,NCT01935804,"Change in mean percentage change in BMD at various sites by Dual energy X-ray absorptiometry(DXA) from baseline and at 6, 12 months in PIO versus MET treatment group.",Bone turnover Markers and other Biomarkers,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory and safety outcomes
8921,NCT03527641,Homeostasis model assessment of insulin resistance (HOMA-IR),Everyday Discrimination Scale,2018-05-01,COMPLETED,INTERVENTIONAL,['NA'],
8922,NCT02320344,Problem Areas in Diabetes,Triglycerides,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
8923,NCT01621776,The Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Lunch.,Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Breakfast,2011-06,COMPLETED,INTERVENTIONAL,['NA'],
8924,NCT03480945,Endothelial function,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],
8925,NCT06050577,Procollagen type 1 N-terminal propeptide (P1NP),Body mass index (BMI),2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Osteogenic potential
8926,NCT00696111,Sleep recording/polysomnography,24-hour hormonal profiles,2007-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
8927,NCT06009055,Heart rate variability（HRV）,,2023-09-17,RECRUITING,INTERVENTIONAL,['NA'],
8928,NCT00289614,Increase in serum creatinine (SCr) at 48-72 hours post dose,Decrease in estimated glomerular filtration rate (eGFR) at 48-72 hours post dose; occurrence of adverse events,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
8929,NCT04270656,"Variation of hepatic steatosis, between the insulin pump therapy (CSII) vs Multi injection treatement (MDI) groups.","Calculation negative predictive values of the FLI for the detection of fatty liver in this population, by using the quantification of hepatic MRI as Gold Standard.",2021-02-05,UNKNOWN,INTERVENTIONAL,['NA'],
8930,NCT06235762,Heart Rate (HR) beats per minute (bpm),"Physical activity level (sedentary, moderate, advanced)",2020-08-16,COMPLETED,INTERVENTIONAL,['NA'],
8931,NCT01295177,% of Wound healing closing measured each week,Complete wound healing,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8932,NCT02503865,Systolic/ Diastolic Blood Pressures (mm Hg),Immunoassay Cortisole in Blood,2003-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8933,NCT05835596,General Practitioner attendance 1 year postpartum,Clinical cardiovascular follow-up at recruitment hospital: serum biomarkers associated to cardiovascular risk,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
8934,NCT02346838,Change in insulin sensitivity.,Change in arterial stiffness.,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
8935,NCT03026218,Reduction in the number of individuals requiring pharmacotherapy for treatment of gestational diabetes,Reduction in the number of infants with neonatal hypoglycemia.,2017-04-15,COMPLETED,INTERVENTIONAL,['NA'],
8936,NCT00151190,"HbA1c, Triglycerides, Cholesterol, Urine Microalbumin, Blood Pressure,","Patients' attitudes and knowledge about diabetes self-management, American Diabetes Association standards of care.",2005-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
8937,NCT01144520,Ex vivo leukocyte function by measuring ROS production,Ex vivo NADPH oxidase gene and protein expression,2010-03,TERMINATED,OBSERVATIONAL,['NA'],
8938,NCT05184049,The change of resting-state functional Magnetic Resonance Imaging,Mean change of Montreal Cognitive Assessment,2022-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8939,NCT02015130,"Composite endpoint: All cause mortality, non-fatal myocardial infarction, coronary revascularization, cardiac arrest with resuscitation, heart failure, non-fatal stroke, progression of nephropathy or retinopathy, severe hypoglycaemia and cancer",Quality of life,2013-10,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],All cause hospitalization
8940,NCT03271879,"The primary endpoint is the burden of premature ventricular complexes, defined as the PVCs percentage of all beats in a pre-specified period captured on ICD or CRTD/P device",Left ventricular ejection fraction (EF),2018-02-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8941,NCT04596631,Change from baseline in glycosylated haemoglobin (HbA1c),SNAC plasma concentrations,2020-11-02,RECRUITING,INTERVENTIONAL,['PHASE3'],
8942,NCT05151276,The Turkish Multidimensional Diabetes Questionnaire,triglyceride,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],
8943,NCT03692884,The number of patients whoes Diabetic Kidney disease (DKD) is worsen,The number of patients who develop Diabetic foot,2018-07-01,RECRUITING,OBSERVATIONAL,['NA'],
8944,NCT01637324,,,2011-05,COMPLETED,OBSERVATIONAL,['NA'],
8945,NCT00570141,Percent Wounds Closed,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
8946,NCT06066021,Change in the Diabetes Knowledge Questionnaire (DKQ - Portuguese version),Measure the change in BMI,2023-10-13,RECRUITING,INTERVENTIONAL,['NA'],
8947,NCT01821508,The primary endpoint will be the proportion of patients that present normalization of the albumin/creatinine ratio in isolated urine samples (normal value considered as an albumin/creatinine ratio of less than 30 μg/mg ).,Changes in hepatic fibrosis,2013-04-18,COMPLETED,INTERVENTIONAL,['NA'],
8948,NCT00764361,Number of Participants Without Adverse Events,Analyze the Molecular Changes in Pro-inflammatory Cytokine Levels That Occur in Diabetic Foot Ulcers as a Function of Healing Rate in the Presence /Absence of NanoDOX Hydrogel (1% Doxycycline Monohydrate Gel),2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
8949,NCT01191983,Percentage of Participants Maintaining Hb Concentration Within the Target Range (10-12 g/dL) During EEP,Short Form-36 Health Survey (SF-36) score,2010-08-13,COMPLETED,INTERVENTIONAL,['PHASE4'],
8950,NCT04276207,Time to Recovery From Hyperglycemia Following Administration of LY900014 and Insulin Lispro (Humalog) After Pump Suspension,Pharmacokinetics (PK): Time to Maximum Observed Insulin Lispro Concentration (Tmax) Following Administration of LY900014 and Insulin Lispro (Humalog),2020-02-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
8951,NCT05144672,The relation between different stages of diabetic nephropathy and irisin level.,,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
8952,NCT00498147,Rates of cardiovascular events and other complications of diabetes compared to provincial and national rates,"The secondary outcomes will be total mortality, CV- related events, and other selected complications of diabetes.",2007-07,UNKNOWN,OBSERVATIONAL,['NA'],
8953,NCT01966380,Absorption of Wound Exudates.,,2013-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
8954,NCT04726319,Changes in risk-appropriate screening based on family history,Attitudes towards the FHAMe intervention,2021-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
8955,NCT00741026,Plasma Free Fatty Acid,Diastolic Blood Pressure,2008-08,COMPLETED,INTERVENTIONAL,['NA'],
8956,NCT01729286,Complete wound closure,Nonserious and serious adverse events,2012-09,TERMINATED,INTERVENTIONAL,['NA'],
8957,NCT02489942,Number of Patients With Adverse Drug Reactions (ADRs),Change From Baseline in Fasting Plasma Glucose (FPG) at the Last- Observation During Observation Period,2015-06-12,COMPLETED,OBSERVATIONAL,['NA'],
8958,NCT05797051,Microhyperspectral image of urine specimen,,2023-05-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
8959,NCT03912909,Reduction in muscle sympathetic nerve activity,Change in glycemic control,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
8960,NCT02442921,Change of urinary protein excretion ( mg/24hrs) from baseline to 18 months.,,2016-02-22,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
8961,NCT04509193,Any major or clinically-relevant nonmajor bleed resulting in hospitalization,New-onset vascular dementia,2020-08-21,COMPLETED,OBSERVATIONAL,['NA'],
8962,NCT01691989,Change from baseline in hemoglobin HbA1c,Safety: incidence of adverse events,2012-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
8963,NCT05316298,Postoperative wound healing,Foot Function Index (FFI) scores,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],
8964,NCT02414958,Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD) ),Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26,2015-06-30,COMPLETED,INTERVENTIONAL,['PHASE3'],
8965,NCT03859245,Hard Drusen in the Mid-periphery pathology,Triglycerides/HDL ratio,2019-02-23,UNKNOWN,INTERVENTIONAL,['NA'],
8966,NCT03617770,Sleep Regularity,Diabetes Distress,2019-01-09,COMPLETED,INTERVENTIONAL,['NA'],
8967,NCT03467659,Appetitive behavior,,2017-02-16,COMPLETED,INTERVENTIONAL,['NA'],
8968,NCT01211717,"Measuring Pain, using the short form McGill pain questionnaire",Measuring Muscle strength of the studied muscle,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
8969,NCT00422357,Blood pressure every two weeks.,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
8970,NCT00754741,LDL-cholesterol Levels,Cardiovascular Morbidity and Mortality (Exploratory),2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
8971,NCT03527537,Composite Neonatal Outcome,Preeclampsia,2021-05-04,RECRUITING,INTERVENTIONAL,['PHASE4'],
8972,NCT01542554,Change in blood HbA1c,Change in blood pressure,2012-03,UNKNOWN,INTERVENTIONAL,['NA'],
8973,NCT00613951,Change in Glycosylated Haemoglobin (HbA1c),Physical Examination,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
8974,NCT04876079,Time spent of glucose levels < 4.0 mmol/L,Percentage of participants experiencing a rebound hyperglycemia (≥ 10.0 mmol/L) within the first hour following the first carbobydrates consumption,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],
8975,NCT02551874,Mean Change From Baseline in HbA1c at Week 24,Change From Baseline in the Mean Value of 24-hour Glucose at Week 2,2015-10-20,COMPLETED,INTERVENTIONAL,['PHASE3'],
8976,NCT04488887,coefficient of variation (CV),,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
8977,NCT06080451,Proportion of patient participants with subsequent follow-up visit within 3 months,Sustainability,2023-10-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
8978,NCT00432029,Forearm Blood Flow,,2006-12,COMPLETED,INTERVENTIONAL,['NA'],
8979,NCT02366468,Mean Average Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye From Month 1 to Study Treatment Completion (Month 12),Number of Participants With Change in Diabetic Retinopathy Study (DRS) Retinopathy Scale,2015-02-23,COMPLETED,INTERVENTIONAL,['PHASE4'],
8980,NCT00280865,Absolute change from baseline to end of randomized treatment period in fasting plasma glucose (FPG),"To evaluate diabetes-specific instruments, Audit of Diabetes Dependent Quality of Life (ADDQoL) and The Diabetes Treatment Satisfaction Questionnaire (DTSQ) (s and c) in the study population and estimate the effect size of the instruments in patients r",2002-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
8981,NCT02232698,Time Spent <70 mg/dL,Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc) Scores From Day 1 to Day 208,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
8982,NCT03804125,"the number and type of suspected adverse drug reactions, including serious and non-serious cases",,2021-09-01,WITHDRAWN,OBSERVATIONAL,['NA'],
8983,NCT02064881,Change in postprandial lipemia at 4 months,Number of Participants with Serious and Non-Serious Adverse Events,2015-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
8984,NCT02133118,"The course of weight (Kg) after starting individual SU's, pioglitazone or insulin as add-on therapy.","The course of the glycaemic control (HbA1c %) , up to five years after starting individual SU's, pioglitazone or insulin as add-on therapy.",1998-01,COMPLETED,OBSERVATIONAL,['NA'],
8985,NCT02928666,Number of conflicting recommendations detected out of total number of conflicts,,2018-10,UNKNOWN,INTERVENTIONAL,['NA'],
8986,NCT02769377,HbA1c,Hypoglycemia,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
8987,NCT02572414,Adherence to Department of Health and Human Services physical activity guideline,Adherence to 5-a-Day diet guideline,2015-01-08,COMPLETED,INTERVENTIONAL,['NA'],
8988,NCT00101426,Efficacy,Safety,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
8989,NCT03937934,Change in number of days a week and minutes per day participants participate in physical activity and sedentary activity,Change in Systolic and/or Diastolic Hypertension mmHg,2019-05-20,COMPLETED,INTERVENTIONAL,['NA'],
8990,NCT05369871,Glycemic control evaluation for the 12-week main study,System satisfaction questionnaire evaluation,2022-08-29,COMPLETED,INTERVENTIONAL,['NA'],
8991,NCT04653805,Number of visits with the primary care team in the previous 12 months,,2017-01,COMPLETED,OBSERVATIONAL,['NA'],
8992,NCT05168605,Change in Blood pressure,,2022-07-27,RECRUITING,INTERVENTIONAL,['NA'],
8993,NCT03763669,Insulin resistance,Fetal sonographic parameters,2018-11-14,COMPLETED,INTERVENTIONAL,['NA'],
8994,NCT03082859,Mean 24-hour blood glucose concentrations (mmol/L),Glycaemic Variability (Glucose levels),2016-07,UNKNOWN,INTERVENTIONAL,['NA'],Mood measured using the Brunel Scale of Mood States (BRUMS)
8995,NCT04255004,probability of healing at 24 months,rest pain,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
8996,NCT00533494,"HbA1c, LDL, systolic blood pressure",,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
8997,NCT00860392,Effects of increase in serum free fatty acid levels on ketogenesis as measured using a isotopic tracer and serum ketone body concentration in healthy lean subjects,Effects of increase in serum free fatty acid levels on ketogenesis as measured using a isotopic tracer and serum ketone body concentration in obese subjects,2009-03-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
8998,NCT05969015,Glycemic control,Diabetes Attitude Questionnaire (ATT-19),2022-01-15,RECRUITING,INTERVENTIONAL,['NA'],Adverse Events
8999,NCT02470455,Change in Glycosylated Hemoglobin (HbA1c) from baseline,Lipid profile,2011-07,COMPLETED,OBSERVATIONAL,['NA'],
9000,NCT03663738,HbA1c,Quality of life related to health,2018-02-05,COMPLETED,INTERVENTIONAL,['NA'],
9001,NCT00374426,,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
9002,NCT00571519,Change in A1c From Baseline Through Week 20 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus,Number of Participants With Treatment-Emergent Adverse Events by System Organ Class and Preferred Term Following Rivoglitazone or Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus,2007-11-14,TERMINATED,INTERVENTIONAL,['PHASE3'],
9003,NCT04881994,"Maximum observed drug concentration of unbound finerenone (Cmax,u) in plasma",Number of participants with adverse events,2014-03-25,COMPLETED,INTERVENTIONAL,['PHASE1'],Half-life associated with the terminal slope (t1/2) of finerenone
9004,NCT00861952,Numeric pain scale (0-10) for immediate relief,Adverse event reports,2010-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
9005,NCT00344240,Physical activity,,2005-08,COMPLETED,INTERVENTIONAL,['NA'],
9006,NCT01427998,Serum glucose,Plasma insulin,1999-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
9007,NCT05668819,Change in PPG,Change in WHR,2023-02-09,RECRUITING,INTERVENTIONAL,['NA'],
9008,NCT04663295,Change in Time in Target Range (% of Sensor Glucose (SG)): 70 mg/dL (3.9 mmol/L) ≤ SG ≤ 180 mg/dL (10 mmol/L),"Time in Specific Range Stratified by Baseline HbA1c Ranges (< 7%, 7 - < 7.5%, 7.5 - 8%, > 8%)",2020-10-31,COMPLETED,INTERVENTIONAL,['NA'],
9009,NCT02310009,Beta-cell function,Glucose disposition,2014-12,WITHDRAWN,INTERVENTIONAL,['NA'],
9010,NCT05989867,steamed bun meal test result 3,glycemic control,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],
9011,NCT01775813,Insulin Sensitivity,High Density Lipoprotein,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
9012,NCT00961857,The area under the plasma concentration vs. time curve (AUC) after administration of sitagliptin/metformin (50/500 and 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets,Peak plasma concentration (Cmax) of sitagliptin and metformin after administration of sitagliptin/metformin (50/500 and 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets,2005-12-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
9013,NCT04477707,Progression of non-proliferative diabetic retinopathy (NPDR),Change in severity of diabetic retinopathy (DR),2020-07-23,COMPLETED,OBSERVATIONAL,['NA'],
9014,NCT01224548,weight,hip circumference,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
9015,NCT02699736,"Incidence of long-term virological, immunological and morbidity and mortality outcomes across different regions in Europe; and demographic, clinical, therapeutic and viral factors associated with these outcomes",Incidence of toxicities related to direct acting antivirals by regions,1994-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
9016,NCT02946632,"Proportion of patients who met HbA1c < 6.5% without hypoglycaemia, weight gain, or discontinuation due to adverse events at 104 weeks",Changes in fat and lean mass from baseline to at 104 weeks,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],AEs/SAEs
9017,NCT04201171,HRQOL,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],
9018,NCT01616472,"New diagnoses of diabetes, hypertension, cataracts, osteoporosis, or avascular necrosis",,2012-04,COMPLETED,OBSERVATIONAL,['NA'],
9019,NCT00478335,24h Urine Volume,,2007-05,COMPLETED,INTERVENTIONAL,['NA'],
9020,NCT01857375,Insulin Dosing Accuracy (in units),Patient satisfaction with method of insulin administration measured by questionnaire.,2009-10,COMPLETED,OBSERVATIONAL,['NA'],
9021,NCT03337412,Chronological evolution of the physical activity score of patients benefiting from the education program with intervention of the adapted physical activity educator,musculoskeletal disorders,2017-11-13,COMPLETED,INTERVENTIONAL,['NA'],
9022,NCT02685449,Postprandial glycemia,The difference between the maximum and baseline glucose level,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
9023,NCT06051318,Postprandial subcutaneous interstitial fluid glucose measured by continuous glucose monitor (CGM),Participant's gut microbiome species richness,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
9024,NCT05370339,Assessment of facilitators and barriers to good sleep quality and duration,Identification of common causes of sleep disruptors in adolescents with type 1 diabetes,2022-06-15,COMPLETED,OBSERVATIONAL,['NA'],
9025,NCT03818568,glomerular filtration,Mortality,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],
9026,NCT03191331,gestational weight gain (GWG),Eating habits,2017-06-06,COMPLETED,INTERVENTIONAL,['NA'],
9027,NCT00424333,Primary outcome is 24 week change in baseline in HbA1c.,Patient satisfaction and preference.,1999-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
9028,NCT02100319,Changes From Baseline in Home Blood Pressure on Final Assessment Point (up to Week 24),Percentage of Participants Who Had One or More Adverse Events,2014-03-03,COMPLETED,OBSERVATIONAL,['NA'],
9029,NCT05389254,The CCU occupancy rate,Major adverse cardiovascular events after 3 months,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
9030,NCT02943486,Wound size change,Presence of Exudate,2017-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9031,NCT02835989,Change in number of repeat EMS calls,Change in number of hospital admissions,2018-10-25,COMPLETED,INTERVENTIONAL,['NA'],
9032,NCT01835730,Incidence and severity of adverse events including hypoglycemia,Pharmacodynamic Response,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
9033,NCT02325466,Mean Change in High Shear Blood Viscosity,Mean Change in Microvascular Blood Flow Composite Score,2015-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
9034,NCT03669887,Proportion achieving body weight goal,% of achieving dietary intervention goal,2018-09-12,COMPLETED,INTERVENTIONAL,['NA'],
9035,NCT03243136,Type 2 diabetes,,2004-01-01,COMPLETED,OBSERVATIONAL,['NA'],
9036,NCT03863561,Validity of the SCPI with HbA1c,Responsiveness of the total SCPI score to an intervention,2017-10-11,COMPLETED,OBSERVATIONAL,['NA'],
9037,NCT00758680,Number of Participants Who Discontinued Treatment Due to an AE,Least Squares Mean Change From Baseline in 24-Hour Weighted Mean Glucose (WMG),2008-08,TERMINATED,INTERVENTIONAL,['PHASE1'],
9038,NCT04135287,HbA1c,Fasting Plasma Glucagon,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
9039,NCT02109029,Part B: Pharmacokinetics: ISF-to-Serum Concentrations,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
9040,NCT00625781,Perinatal morbidity and intrauterine growth,Children´s future health,2008-02,COMPLETED,INTERVENTIONAL,['NA'],
9041,NCT03069729,Pattern of thermal recovery,Correlation of DPN severity levels and DR severity levels,2017-03-08,COMPLETED,OBSERVATIONAL,['NA'],
9042,NCT01503164,Insulin Sensitivity (SI),Area Under the Curve Assessed by Oral Glucose Tolerance Test (OGTT),2011-09,COMPLETED,INTERVENTIONAL,['NA'],
9043,NCT04884633,Achieving good metabolic control of diabetes,The rate of significat glomerula filtration rate reduction,2019-08-15,UNKNOWN,INTERVENTIONAL,['NA'],
9044,NCT06061510,Diastolic blood pressure,Rate of smoking among participants,2019-06-08,COMPLETED,INTERVENTIONAL,['NA'],
9045,NCT05456984,Empower up,Diabetes treatment,2022-05-03,COMPLETED,OBSERVATIONAL,['NA'],
9046,NCT03987841,Hemoglobin A1c (A1C),Feasibility: Percentage of Sessions Attended,2021-10-01,COMPLETED,INTERVENTIONAL,['NA'],
9047,NCT06163248,Change in insulin resistance (M value),Change in lipid profile (mg/dl),2024-01-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Hunger and satiety (score)
9048,NCT03587948,Diabetic eye diseases,,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],
9049,NCT00461058,"Incidence of cardiovascular death, hospitalization or clinic visit for heart failure with i.v. administration of diuretics during 26 week treatment period.","Efficacy: Change from baseline to week 26 in Hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), fasting plasma insulin (FPI) and lipid profile.",2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
9050,NCT01752842,Change in Cardiac Systolic Function as Measured by Fractional Shortening Percent,Change in C24:0/C16:0 Ceramide Ratio,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
9051,NCT02308735,Phosphatidylethanol Level,,2014-03,TERMINATED,OBSERVATIONAL,['NA'],
9052,NCT04154020,Mean time to healing of ulcers(s) in treated limb,Incidence of new ulcers on feet,2019-11-30,COMPLETED,INTERVENTIONAL,['NA'],
9053,NCT03242109,Diabetes,,2005-03-01,COMPLETED,OBSERVATIONAL,['NA'],
9054,NCT00221156,Cardiovascular event free survival time,Change in lipid profile,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
9055,NCT01577095,plasma glucose,plasma insulin,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
9056,NCT04018105,Area under the curve of D-Xylose,Area under the curve of GLP-1,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
9057,NCT01874483,Occurrence of adverse events,"Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t)",2013-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
9058,NCT05614089,Time-in-range (TIR),Quality of Life (e.g. PedsQL Pediatric Quality of Life Inventory),2023-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
9059,NCT06083909,To explore the correlation of sarcopenia and obesity on insulin resistance,To explore the correlation of sarcopenic obesity and glucometabolic and cardiovascular risk.,2022-04-06,COMPLETED,OBSERVATIONAL,['NA'],
9060,NCT00763815,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia
9061,NCT05672433,Area under the curve for glucose during mixed meal test (mmol/L*min),Food consumption in kilocalories (kcal),2022-06-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Fasting Homeostatic Model Assessment for Insulin Resistance by C-peptide (arbitrary unit).
9062,NCT03173391,Change from baseline in HbA1c,Incidence of Treatment-Emergent Adverse Events over time,2017-07-18,COMPLETED,INTERVENTIONAL,['PHASE3'],
9063,NCT04233203,MAGE,TIR-TAR-TUR,2020-01-31,COMPLETED,OBSERVATIONAL,['NA'],Severe adverse effects
9064,NCT05223569,Changes in visual acuity,Changes in visual acuity after 48 weeks,2022-03-03,RECRUITING,INTERVENTIONAL,['NA'],
9065,NCT06059326,Number of Participants With Treatment-Emergent Adverse Events (TEAEs),Change from baseline of HbA1c,2019-01-22,COMPLETED,INTERVENTIONAL,['PHASE2'],
9066,NCT05799781,Percent of time with sensed glucose between 70-180 mg/dl,Mean amount of insulin delivered per day,2023-03-13,RECRUITING,INTERVENTIONAL,['NA'],
9067,NCT06260605,Education,,2023-12-19,COMPLETED,INTERVENTIONAL,['NA'],
9068,NCT05071950,Postprandial glucose (mg/dl),side-effects of D-allulose,2021-03-10,COMPLETED,INTERVENTIONAL,['NA'],
9069,NCT02903264,Gestational diabetes mellitus diagnosed by an endocrinologist,Leukocytosis as an indicator of inflammation,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
9070,NCT00761852,To test the hypothesis that activation of protein kinase Cß (PKCß) impairs vascular reactivity in patients with diabetes mellitus,,1999-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
9071,NCT00298844,,,2006-01,UNKNOWN,OBSERVATIONAL,['NA'],
9072,NCT02075281,Change from baseline in body weight at 20 weeks,"Change from baseline in blood lipid profile (e.g., cholesterol, and LDL-C level) at 20 week",2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Change from baseline in β-cell function at 20 week
9073,NCT00839683,Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs,"To assess the effect of dapagliflozin on the PK of simvastatin acid (active metabolite of simvastatin), when coadministered in healthy subjects",2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
9074,NCT00437775,,,2007-01,UNKNOWN,OBSERVATIONAL,['NA'],
9075,NCT00255541,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),"Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",2004-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
9076,NCT00664534,Baseline Adjusted Glycosylated Hemoglobin (HbA1c) at Endpoint,Number of Participants With Adverse Events,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
9077,NCT02582814,Vital Signs (Blood Pressure),Adjusted Change From Baseline in SBP in Subjects With Baseline SBP/DBP >= 140/90 mmHg,2015-10-26,COMPLETED,INTERVENTIONAL,['PHASE3'],
9078,NCT03544320,Change in hemoglobin A1c,Change in low-density lipoprotein (LDL) levels,2018-07-09,COMPLETED,INTERVENTIONAL,['NA'],Hospitalization
9079,NCT00333671,"Retinal thickness by fast retinal thickness mapping by optical coherence tomography at times 0, 2, 4, 8, 10, 15, 20, 30, 60, 90, 120 and 180 minutes after the last swallow of glycerol.",dose dependent differences in the same time spectrum.,2004-12,COMPLETED,INTERVENTIONAL,['NA'],
9080,NCT00072904,The primary objective of this research is to determine whether treatment with either insulin or an oral diabetes agent that increases endogenous insulin secretion will improve BMI and pulmonary function in cystic fibrosis patients who have diabetes,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
9081,NCT06239506,alternative FRs,levels of FPG,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],
9082,NCT01930448,Change in Incretin Effect,Change in Body Composition,2008-09,WITHDRAWN,OBSERVATIONAL,['NA'],
9083,NCT01068756,AUC (area under the concentration-time curve) Single dose pharmacokinetic parameter will be derived from plasma concentration versus time data,Tmax (time of maximum observed concentration) Single dose pharmacokinetic parameter will be derived from plasma concentration versus time data,2010-03,TERMINATED,INTERVENTIONAL,['PHASE1'],
9084,NCT04550468,Change from Baseline Hemoglobin A1c at 12 weeks,Continuous glucose monitoring,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],
9085,NCT04950283,Insulin sensitivity,,2021-07-07,RECRUITING,OBSERVATIONAL,['NA'],
9086,NCT01956357,Glycated hemoglobin,Global Histone Deacetylases activity,2012-08,COMPLETED,INTERVENTIONAL,['NA'],Sleep quality.
9087,NCT01283425,frequency of mild hypoglycemia events (Blood Glucose<60mg/dl) with InsuPatch and without.,Adverse events (AE's) count with InsuPatch and without.,2011-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
9088,NCT03811288,Participants with a history of established cardiovascular disease (CVD),Participants with high risk of CVD according to the risk engine from the United Kingdom Prospective Diabetes Study (UKPDS),2018-12-10,COMPLETED,OBSERVATIONAL,['NA'],
9089,NCT01546181,photoreceptor density,,2010-10,COMPLETED,OBSERVATIONAL,['NA'],
9090,NCT03711656,Sensitivity (SE) and specificity (SP) to predict Level 1 hypoglycemia,Number of Level 3: severe hypoglycemia,2018-10-10,COMPLETED,INTERVENTIONAL,['NA'],
9091,NCT02632929,Limb salvage,effective wound healing,2015-05-30,COMPLETED,OBSERVATIONAL,['NA'],Diabetic Foot Ulcer Quality of life Short Form survey
9092,NCT03324191,Effect of tea extract on serum triacylglycerol concentration following a high fat meal,Effect of tea extract on whole body lipid oxidation following a high fat meal,2017-10-10,COMPLETED,INTERVENTIONAL,['NA'],
9093,NCT00743327,Evaluation for the development of incident diabetes,"Evaluation for other cardiovascular risk factors, markers of inflammation and immunological changes",2008-10,TERMINATED,OBSERVATIONAL,['NA'],
9094,NCT01322711,Evaluation of effect of Atorvastatin Therapy in Hypercholesterolemic Patients (n=30) and Diabetic Patients (n=30),,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
9095,NCT05726006,To examine the prevalence of antibiotic resistance of invasive GBS isolates among non-pregnant people in Malaysia.,Detection of Sequence Type (ST),2020-02-01,RECRUITING,OBSERVATIONAL,['NA'],
9096,NCT01455909,Change in HbA1c,,2013-02,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
9097,NCT04374578,Effect on glycemic variability,Effect on Glycemic Control,2020-05-08,COMPLETED,OBSERVATIONAL,['NA'],
9098,NCT00222781,"Compare triple tracer PET imaging of skeletal muscle in lean, obese and T2DM",Mathematical modeling of PET data.,2004-01,COMPLETED,OBSERVATIONAL,['NA'],
9099,NCT04198441,Time to Maximum Wound Closure,,2020-06-02,UNKNOWN,INTERVENTIONAL,['NA'],
9100,NCT02866435,"Change from baseline (i.e., normal glucose levels) cerebral blood flow, measured in ml/min/100g, at hypoglycemia",,2016-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
9101,NCT00229710,Body weight,"Central obesity (waist circumference, hip circumference, waist/hip ratio)",2005-02,TERMINATED,INTERVENTIONAL,['PHASE3'],
9102,NCT04286555,Systolic blood pressure (SBP),Symptoms experienced by participants as assessed by a questionnaire,2021-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
9103,NCT00937872,Define the intravenous pharmacokinetics of SRT2104.,Potential systemic metabolite burden of SRT2104 following administration.,2008-11-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
9104,NCT03715010,Measure of glucose AUC during 2H OGTT (Frame: 10 weeks),Measure of body composition (Time Frame: 10 weeks),2016-03-18,COMPLETED,INTERVENTIONAL,['NA'],
9105,NCT02677779,Bacterial Load,Bleeding: Proportion of Patients With Bleeding Necessitating Haemostasis,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
9106,NCT00521378,Daily glucodynamic profile of Oral HDV-Insulin,,2007-09-17,COMPLETED,OBSERVATIONAL,['NA'],
9107,NCT00776763,Growth Factors and Other Cytokines Measurements,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
9108,NCT00766857,Cardiac Magnetic Resonance (CMR) will be used to assess global cardiac function (LV ejection fraction).,Exercise capacity and performance will be assessed by a 6-minute walking test,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
9109,NCT01773798,Area under the glucose infusion rate curve,Area under the serum IAsp concentration-time curve,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
9110,NCT00222508,,,2001-04,COMPLETED,OBSERVATIONAL,['NA'],
9111,NCT00995930,Change From Baseline in Plaque Burden (Aortic Vessel Wall Area and Carotid Vessel Wall Area),Pharmacokinetics: ACZ885 Serum Concentrations,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
9112,NCT02831075,Area of diabetic foot ulcers,Walking distance (treadmill) if possible,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
9113,NCT04042285,Wound volume,Tissue integrity,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA'],
9114,NCT05556005,Change from baseline Left ventricular functions at 3 months,Change from baseline Transforming growth factor beta 1 at 3 months,2022-09-18,RECRUITING,INTERVENTIONAL,['PHASE2'],
9115,NCT04831775,"Change in attention, visual scanning and motor speed at week 22",Change in perceived cognitive function at week 22,2021-11-01,RECRUITING,INTERVENTIONAL,['NA'],
9116,NCT01494025,Change in Body Weight,,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
9117,NCT03790787,"AUCτ,ss",,2019-04-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
9118,NCT00248352,Change in 10 year cardiac risk as estimated by the UKPDS risk engine at 6 months post discharge compared to baseline measures obtained at time of discharge,Quality of life as assessed by questionnaire,2005-02,COMPLETED,INTERVENTIONAL,['NA'],
9119,NCT03353792,Brain Alternate Fuel Uptake,Change in Cognitive Function: Grooved Pegboard Test,2017-11-01,TERMINATED,INTERVENTIONAL,['NA'],
9120,NCT01859117,Adverse Events,Toe-brachial index (TBI),2013-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
9121,NCT03590041,Diabetes Distress - Change in Patient Reported Outcomes (PROs),Change in Patient HbA1c,2019-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
9122,NCT01223196,Whole Body Insulin Sensitivity During the Euglycemic Insulin Clamp,Effect of Pioglitazone on TNF (Tumor Necrosis Factor) Alpha Converting Enzyme (TACE) Activity in Skeletal Muscle.,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4'],Percentage (%) of Haemoglobin A1C
9123,NCT04025996,"Cross-sectional analyses will be performed to look at the association between diabetic retinopathy with left ventricular diastolic function, coronary flow reserve and urinary albumin excretion.",,2018-02-20,UNKNOWN,OBSERVATIONAL,['NA'],
9124,NCT01127997,Area under the curve of plasma glucose after meal,the mechanism of second-meal phenomenon,2010-03,COMPLETED,OBSERVATIONAL,['NA'],
9125,NCT02244736,Differences of endothelial function at baseline and during OGTT among the 3 groups.,Insulin resistance and endothelial function,2013-02,COMPLETED,OBSERVATIONAL,['NA'],
9126,NCT05449496,Post-transplant complications rates,Dietary complications,2022-06-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
9127,NCT01463813,Cancer,,2012-09,COMPLETED,INTERVENTIONAL,['NA'],
9128,NCT01252979,Heteroplasmy,,2010-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
9129,NCT00537277,Percentage of Subjects Achieving the Treatment Target of Glycosylated Haemoglobin (HbA1c) Below 7.0%,Number of Treatment Emergent Serious Adverse Events (SAEs),2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
9130,NCT01507311,Insulin secretory burst mass,Adverse events,1999-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
9131,NCT04088929,Impact of Pure Green CBD tablets on diabetic neuropathy pain using a daily self-reported pain scale score.,Impact on the use of sublingual tablets as the route of administration,2019-09-30,COMPLETED,INTERVENTIONAL,['PHASE2'],
9132,NCT02154074,level of blood insulin,vital signs,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],
9133,NCT05918653,Biomedical profile of diabetic patients,,2022-12-15,COMPLETED,OBSERVATIONAL,['NA'],
9134,NCT02308683,Post treatment mean HsCRP,Post treatment mean hgba1c,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
9135,NCT01029327,,,2009-06,COMPLETED,OBSERVATIONAL,['NA'],
9136,NCT02021890,improved physical fitness (physical activity exceeding 10 MET-hour/week,10% increase in 6-min walk test,2011-09,COMPLETED,INTERVENTIONAL,['NA'],
9137,NCT04386200,Change from baseline in Body Weight,Change from baseline in Quality of life by 36-item short form health survey (SF-36),2019-02-13,UNKNOWN,INTERVENTIONAL,['NA'],
9138,NCT03985384,Rate of change in non-calcified plaque volume,Rate of change in total plaque volume,2019-04-30,COMPLETED,INTERVENTIONAL,['PHASE4'],
9139,NCT05823142,Sleep Health: Timing*,Diabetes distress symptoms,2023-12-20,RECRUITING,INTERVENTIONAL,['NA'],
9140,NCT00363844,tolerability,Plasma glucose,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
9141,NCT00740363,Insulin secretion,Cyclosporine/tacrolimus blood concentrations,2008-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
9142,NCT04869917,Weight,Participant initiation of treatment to intensive lifestyle (ILI) or Metformin,2022-03-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
9143,NCT03288610,Preoperative copeptin level,Day 28 mortality rate,2017-01,COMPLETED,OBSERVATIONAL,['NA'],
9144,NCT03889496,Correlation between the tracer uptake (counts) and beta cell mass (mg),,2015-11-16,TERMINATED,INTERVENTIONAL,['NA'],
9145,NCT01034319,stage of change,program attendance,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
9146,NCT03552315,"The three-hour incremental area under the curve (iAUC) for capillary blood glucose, 0-180 minutes","The one-hour iAUC for intravenous Glucagon-like peptide 1 (GLP-1), 0-60 minutes",2018-04-24,COMPLETED,INTERVENTIONAL,['NA'],Difference in two-hour glucose (delta-glucose at 2h) from both capillary and intravenous blood.
9147,NCT01918345,For the Effectiveness Phase: Change in baseline-adjusted weight,Feasibility,2014-07,COMPLETED,INTERVENTIONAL,['NA'],Behaviour change
9148,NCT05162690,Intraepithelial nerve fiber density,corneal nerve fiber density,2022-05-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
9149,NCT00141219,Daily Pain Rating Scale (DPRS)- Mean Pain Score (ITT Population),Duration Adjusted Average Change (DAAC) of (Unadjusted) Mean Pain Score,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Daily Pain Rating Scale (DPRS)- Mean Pain Scores (Evaluable Population)
9150,NCT04353869,Compare the plasma concentrations of glutamine in patients with various levels of cardiovascular (CV) risk.,characterize the transcriptomic program through modification gene expression and epigenetic changes related to KDM6B and TET2 activity in blood monocytes from patients with various levels of CV risk,2020-11-16,RECRUITING,OBSERVATIONAL,['NA'],
9151,NCT05799222,Hemoglobin A1c reduction,Program adherence,2023-04-01,RECRUITING,OBSERVATIONAL,['NA'],
9152,NCT03330366,Changes of blood glucose during OGTT,Changes of HbA1c,2015-11-24,COMPLETED,INTERVENTIONAL,['NA'],
9153,NCT05777746,"Composite of Estimated relative CVD risk (based on change in LDL-c , SBP and HbA1c)",Rate of Vitamin B12 and ferritin deficiency,2022-11-29,RECRUITING,INTERVENTIONAL,['NA'],Physical Activity (Metabolic Equivalent Tasks)
9154,NCT04417725,Incidence and prevalence,Treatment patterns,2008-04-01,COMPLETED,OBSERVATIONAL,['NA'],
9155,NCT02403375,Percentage of Children and Adolescents of Ages 2 to 17 Years Reaching an HbA1c target of <7.5%,"Number of Subjects, Who Report a Diabetes-Related Adverse Event (i.e., Symptomatic Hypoglycemia, Severe Hypoglycemia, Diabetic Ketoacidosis)",2015-05-17,COMPLETED,INTERVENTIONAL,['NA'],
9156,NCT00327626,"Evaluate the effects of ISIS 113715 on insulin sensitivity, B-cell function, proinsulin/insulin ratio, fasting insulin, C-peptide and proinsulin.",,2006-05-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
9157,NCT03619031,Postprandial glucose response (AUC),Time to blood glucose peak,2018-05-03,COMPLETED,INTERVENTIONAL,['NA'],
9158,NCT03301545,Change in Glycosylated Hemoglobin (HbA1c),Change in Fasting Blood Lipids,2020-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
9159,NCT03395509,Baseline prevalence of carotic plaques,The cost(-effectiveness) of the screening program,2014-08-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
9160,NCT05259735,To assess the change Health related quality of life with the introduction of clinical guideline,To determine the number of participants who adhere to the guideline,2022-07-17,COMPLETED,INTERVENTIONAL,['NA'],
9161,NCT00351546,Effect on insulin sensitivity at 6 weeks,Gluconeogenesis rate after 6 weeks of treatment,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
9162,NCT05058807,5 times sit to stand test,Single leg stance test,2021-10-01,COMPLETED,INTERVENTIONAL,['NA'],
9163,NCT02929654,A1c change from baseline after 12 weeks,,2016-10-01,COMPLETED,INTERVENTIONAL,['NA'],
9164,NCT06084156,The primary pharmacokinetics parameter of AUC To assess the potential pharmacokinetic interaction between HSK7653 and metformin in health subjects.,"Pharmacodynamic responses of glucose, insulin and C-peptide will be evaluated",2019-08-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
9165,NCT00393705,Hemoglobin A1c (HbA1c) at 16 Week Endpoint,Total Daily Insulin Dose at 4 Weeks and 12 Weeks,2006-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
9166,NCT05007301,Frequency of device deficiencies,,2022-04-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
9167,NCT02259634,Quality of Life,Healthcare Utilization,2014-06,TERMINATED,INTERVENTIONAL,['NA'],
9168,NCT01440257,Subject incidence of adverse events,Change from baseline in hemoglobin A1c,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
9169,NCT05929079,Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset,Percentage of Participants with AHI <5 or with AHI 5-14 with Epworth Sleepiness Scale (ESS) ≤10 for GSA2 Subset,2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE3'],
9170,NCT03642717,Percentage of Participants With Adverse Events Leading to Discontinuation of the Drug,Number of Participants Per Final Effectiveness Assessment Category at Last Visit,2018-08-21,COMPLETED,OBSERVATIONAL,['NA'],
9171,NCT00482443,The difference in HbA1c between the patient in the DID group and in the standard education group.,"The differences between the two groups in terms of, lipid profile, blood pressure, the number of hypoglycaemic episodes, daily blood sugar fluctuation, total insulin dose, weight changes and patients' satisfaction with the treatment.",2007-03,COMPLETED,INTERVENTIONAL,['NA'],
9172,NCT05644717,Radiologic liver parameters,Frequency of adverse events in 6 months,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
9173,NCT00437398,Mean Number of Hypoglycemic Events After Transplant,Mean Glycated Hemoglobin (HbA1c) Since Transplant,2006-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9174,NCT05378672,Plasma glucose change from baseline at 30 minutes after IMP injection or at the time of rescue by intravenous (IV) glucose,Plasma glucose change from baseline at 15 minutes after IMP injection or at the time of rescue by IV glucose,2023-05-09,RECRUITING,INTERVENTIONAL,['PHASE3'],
9175,NCT02186483,"Cmax,ss, AUCτ",Vd/Fss,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
9176,NCT02220920,Change in HbA1c From Baseline,"Percentage of Participants With ""Adverse Events"" and ""Hypoglycemia and Blood Glucose Decreased""",2014-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
9177,NCT00693771,HbA1c values,Adverse events including hypoglycemia,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
9178,NCT02088827,Blood Pressure,Blood glucose levels,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],
9179,NCT01653951,hemoglobin A1c,,2011-08,COMPLETED,INTERVENTIONAL,['NA'],
9180,NCT00376038,"Blood concentrations of metformin when given with GSK189075 in T2DM subjects over 3-day course Lab tests, changes in blood pressure and heart rate and heart activity on EKG machine","Blood levels of drugs at Day 3 Evaluation of efficacy and safety markers on Days 1, 2, and 3.",2006-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
9181,NCT02014259,Area under the semaglutide plasma concentration time curve,Maximum observed SNAC plasma concentration,2013-12-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
9182,NCT02761434,Insulin sensitivity by matsuda & quicki Index,Energy substrate oxidation,2016-04-13,COMPLETED,INTERVENTIONAL,['NA'],
9183,NCT03950713,HbA1c values,Depression and Anxiety Stress Scale (DASS-21),2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],
9184,NCT02067013,Cytokine Levels,Serum Pharmacokinetics,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],
9185,NCT02386579,RANKL,P1NP,2015-02,COMPLETED,OBSERVATIONAL,['NA'],
9186,NCT00206297,Area under the curve for glucose,glucagon and gastric emptying,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
9187,NCT01568125,HbA1c,Content of dietary intake,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],
9188,NCT05553275,first neonatal blood glucose level measured in mg/dL,Number of neonates that have Macrosomia,2022-10-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
9189,NCT00569452,"Pilot trial to establish endpoints such as ""time within target range of a composite fasting day""","AUC, MAGE, HbA1c, body weight change",2006-01,COMPLETED,INTERVENTIONAL,['NA'],
9190,NCT06291155,Glomerular basement membrane (GBM) width and mesangial expansion,Kidney Transcript Changes,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
9191,NCT03616392,"(Part 2) Css,max of CKD-501","(Part 2) Swing[(Css,max-Css,min)/Css,min] of CKD-501",2018-07-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
9192,NCT05176197,Change in HbA1c,Hedonic survey,2022-02-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Compliance - fatty acid profile
9193,NCT02797730,PedsQL Family Impact score to assess Family Quality of Life,satisfaction score,2016-05,COMPLETED,INTERVENTIONAL,['NA'],
9194,NCT01030341,Hypoglycemic Episodes,Change in Gastroparesis Cardinal Symptom Index (GCSI) Total and Mean Score and Patient Assessed Gastro-Intestinal Quality of Life (PAGI-QOL) Score,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
9195,NCT04025775,Time in the target glucose range (5.6 to 10.0 mmol/l),AUC of glucose below 3.5 mmol/l,2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],Average inter-dialytic weight gain
9196,NCT04660643,Percent Change from Randomization (Week 36) in Body Weight,Change from Baseline in IWQOL-Lite-CT Physical Function Composite Score,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
9197,NCT00481429,"The performance of baseline biochemical biomarkers in plasma and urine in distinguishing patients who respond to rosiglitazone from those that do not, as classified by a change in HbA1C at 12 weeks.",Effect of treatment on a variety of other novel potential predictive biomarkers and markers of insulin sensitisation in diabetic patients.,2007-05,WITHDRAWN,OBSERVATIONAL,['NA'],
9198,NCT02215252,Daily Pain Numeric Rating Scale (NRS),Plasma Concentration of PF-05089771,2014-11-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
9199,NCT00884611,Percentage of Nights With CGM (Continuous Glucose Monitor) Sensor Values < 60 mg/dL,Mean Morning Blood Glucose (BG),2007-05,COMPLETED,INTERVENTIONAL,['NA'],
9200,NCT01569893,Glycated hemoglobin (HbA1c) levels,Number of visits with specialists in diabetic center,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
9201,NCT01679197,Liver Histopathology,Body Weight,2012-10-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
9202,NCT02190669,Document the glycemic response of individuals without diabetes and with type 1 or type 2 diabetes,,2014-06,COMPLETED,OBSERVATIONAL,['NA'],
9203,NCT00568035,Determine the safety of a three times daily application of QR-333 as compared to placebo.,Determine the efficacy of QR-333 on symptoms of diabetic neuropathy and the impact of QR-333 on the daily activities (including pain and sleep disturbance) of subjects with symptomatic diabetic neuropathy as compared to placebo.,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
9204,NCT03376802,Sleep energy expenditure,Pharmacokinetics,2018-04-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
9205,NCT03737240,Change in Hemoglobin A1c (HbA1c),Total Daily Insulin Dose,2019-01-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
9206,NCT01779375,M/I,Clamp Measure of Insulin Sensitivity,2013-06-16,COMPLETED,INTERVENTIONAL,['PHASE3'],OGTT Measures of ß-cell Function and Glucose Tolerance
9207,NCT02770079,Change in insulin sensitivity,Changes in the microbiota,2016-05,COMPLETED,OBSERVATIONAL,['NA'],
9208,NCT03185078,VAS,,2019-01-25,COMPLETED,INTERVENTIONAL,['NA'],
9209,NCT01607385,Gastrointestinal Symptom Rating Scale,"Pharmcokinetic measures of GSK2330672, GSK1614235, GSK2313533, and GSK2313537.",2012-05-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
9210,NCT00609856,Effect of pioglitazone vs. insulin glargine on beta-cell function and insulin sensitivity,Effect of pioglitazone vs. insulin glargine on BNP,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
9211,NCT00290394,Ambulatory blood pressure monitors used to determine the subjects blood pressure before and after the treatment. At the end of three months period wit rosiglitazone treatment diastolic blood pressure decreased.,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
9212,NCT05662462,The primary clinical outcome is the proportion of participants with an A1c <6.5% in the third trimester before delivery,Doctor-Patient Communication Scale,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
9213,NCT00419835,effect of treatment on proteinuria after 8 months of follow-up,incidence of hyperkalemia,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
9214,NCT05550688,Weight Change after smoking cessation on incident T2DM in NAFLD-free individuals,Mediation analysis of smoking relapse on incident T2DM,2007-01-01,COMPLETED,OBSERVATIONAL,['NA'],
9215,NCT01511159,Ratio of the areas under the plasma NN 90-1170 curves,Adverse events,2001-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
9216,NCT02013557,Percentage of patients that receive the 2-hour 75-g oral glucose tolerance test,Percentage of patients that receive any type of postpartum diabetes screening,2014-01,TERMINATED,INTERVENTIONAL,['NA'],
9217,NCT06146933,Analysis of system accuracy based on DIN EN ISO 15197,,2023-11-01,COMPLETED,INTERVENTIONAL,['NA'],
9218,NCT04094740,changes in serum hemoglobin A1c level,Adverse events,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],
9219,NCT03476967,Cup area,,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
9220,NCT00116545,flow mediated brachial artery vasoactivity,carbohydrate and lipid metabolism,1997-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
9221,NCT00982644,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
9222,NCT00231192,serum fructosamine,quality of life,2005-10,WITHDRAWN,INTERVENTIONAL,['NA'],
9223,NCT03429543,Percentage of Patients With Treatment Failure up to or at Week 26,Percentage of Patients Who Achieve HbA1c <7.0% at the End of 26 Weeks,2018-03-20,COMPLETED,INTERVENTIONAL,['PHASE3'],
9224,NCT00207207,Level of diabetic control as measured by 7-month HbA1c.,Number of hypoglycemic episodes.,2003-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
9225,NCT03819790,Time in range within 12-hours (6 AM -6 PM) at week 13,HCP treatment satisfaction score,2018-10-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
9226,NCT05623111,Changes in daily neuropathic pain scores,Sensory function,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
9227,NCT00497172,in-stent LL,Target lesion or target vessel revascularization,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
9228,NCT00482079,To asses the effectiveness of MK0431 compared to placebo,To test the safety and tolerability of MK0431 in patients with type 2 diabetes,2003-05-13,COMPLETED,INTERVENTIONAL,['PHASE2'],
9229,NCT05804097,Major Amputations,"TcpO2 before, during and after HBOT",2021-10-08,RECRUITING,INTERVENTIONAL,['PHASE4'],
9230,NCT04978441,"correlation between baseline personality characteristics, changing emotions throughout the day, and glycemic levels in patients with T1DM",,2020-02-17,COMPLETED,OBSERVATIONAL,['NA'],
9231,NCT01517269,Change in baseline of Diabetes Knowledge,Change in Baseline of Parent anxiety,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
9232,NCT02201602,Mean blood glucose level,Glycemic variability,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
9233,NCT04918784,Number of Participants With 100% Re-epithelialization,Number of Treatment Applications,2021-05-05,COMPLETED,INTERVENTIONAL,['NA'],Incidence of Adverse Events
9234,NCT02199470,We aimed to evaluate the extent of β-cell function by determining fasting levels of C-peptide and those after meal stimulus.,,2013-04,COMPLETED,OBSERVATIONAL,['NA'],
9235,NCT00955747,Change in Hemoglobin A1C Level From Baseline,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
9236,NCT04706377,serum vitamin B12 levels,Adverse events,2018-02-01,COMPLETED,INTERVENTIONAL,['NA'],
9237,NCT02738879,Percentage of Participants Who Experienced One or More Adverse Events (AEs),Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol at Week 30 and No Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) up to Week 30,2016-05-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
9238,NCT05268250,youth time in range,Brief Resilience Scale,2024-02-23,RECRUITING,INTERVENTIONAL,['NA'],
9239,NCT03310502,Skeletal muscle insulin sensitivity,Coronary flow reserve,2002-04-17,RECRUITING,OBSERVATIONAL,['NA'],
9240,NCT00767000,Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event,Percentage of Participants Achieving an HbA1c of <7.0% at Week 54 Who Maintain an HbA1c of <7.0%,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
9241,NCT02806700,Patient Activation,HbA1c,2016-06,COMPLETED,INTERVENTIONAL,['NA'],
9242,NCT03387787,Random blood glucose <9.9 mmol/l in percent,"Time of glucose measurements derived from CGM in the following ranges: 0-<2.2 mmol/l, 2.201-<3.9 mmol/l, 3.901-<5.5 mmol/l, 5.501-<7.8 mmol/l, 7.801-<9.9 mmol/l, 9.901-<16.6 mmol/l, ≥16.601 mmol/l",2018-01-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
9243,NCT04108455,Adverse Neonatal Events,Triglycerides,2019-03-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
9244,NCT01715649,Hemoglobin A1c,Knowledge,2012-11,COMPLETED,INTERVENTIONAL,['NA'],Participant engagement with telehealth technology
9245,NCT02713568,Area Under the Receiver Operating Curve (AUROC) for prediction of macrosomia (≥ P95),Comparative prediction rate for neonatal hyperbilirubinaemia,2016-03-08,COMPLETED,INTERVENTIONAL,['NA'],
9246,NCT00597350,Area under the curve for insulin and glucose,Any adverse event experienced by the subjects,2007-11,COMPLETED,OBSERVATIONAL,['NA'],
9247,NCT00142701,,,1999-04,COMPLETED,INTERVENTIONAL,['NA'],
9248,NCT05776563,Change in magnetic resonance spectroscopy (MRS) to assess brain glucose changes,,2024-03-01,RECRUITING,INTERVENTIONAL,['NA'],
9249,NCT02627690,Modification of Diet in Renal Disease (MDRD),number of deaths,2014-11-03,COMPLETED,OBSERVATIONAL,['NA'],
9250,NCT01185561,Center for Epidemiologic Studies Depression (CES-D) Score,State-Trait Anger Expression Inventory (STAXI) Anger Expression Sub-test Score,2007-03,COMPLETED,INTERVENTIONAL,['NA'],
9251,NCT00896077,"Safety (based on AEs, vital signs assessments, resting 12-lead ECG evaluations, physical examination findings and clinical laboratory test results)","Pharmacodynamic (PD) assessments (blood will be collected for determination of serum cytokine, chemokine, insulin and FFA levels at time points noted previously)",2009-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9252,NCT05626712,Number of Participants with Adverse Events,C-peptide during a 4-hour MMTT,2023-04-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9253,NCT00757276,Diagnosis of diabetes insipidus(DI) centralis versus psychogenic DI,,2008-06,COMPLETED,OBSERVATIONAL,['NA'],
9254,NCT01921322,Time to Target,Glycemic Variability,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
9255,NCT00749047,Reduction in proteinuria,Reduction in non-fasting plasma glucose concentration,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
9256,NCT02437747,Clinical parameter of probing pocket depth,Clinical parameter of relative attachment level,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
9257,NCT02284815,Insulin per kg from baseline to 12 months follow-up,Immune system (Th1 and Th2 cytokines) change from baseline to 12 months follow-up,2012-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
9258,NCT00437489,Change in HbA1c From Baseline,Hypoglycemia Event Rate Per Month,2007-06,TERMINATED,INTERVENTIONAL,['PHASE4'],
9259,NCT02898714,Quality of life,Work and school absenteeism,2016-07,COMPLETED,OBSERVATIONAL,['NA'],
9260,NCT03766438,Glycemic control as measured by hemoglobin A1c. Hemoglobin A1c will be measured from whole blood samples obtained and analyzed in a blinded fashion.,"Total cholesterol, HDL cholesterol, and triglycerides will be measured from the same blood sample used to derive the outcome measure. LDL-cholesterol will be calculated for each participant based on these values.",2019-02-14,COMPLETED,INTERVENTIONAL,['NA'],
9261,NCT01386671,Glycosylated hemoglobin (HbA1c),Dismutase superoxide,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
9262,NCT02897557,Percentage of time in severe hyperglycemic range (defined as >/=250 mg/dL),Standard deviation and coefficient of variation of CGM values,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
9263,NCT02800668,weight loss in kg,effect on blood pressure measured in mmHg,2011-10,COMPLETED,OBSERVATIONAL,['NA'],
9264,NCT02300779,Efficacy of the bowel preparation,Predictors of inadequate bowel preparation,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
9265,NCT00110500,To determine the maximum tolerated dose (MTD) of a single treatment by intramuscular injection by SB-509.,"To evaluate the lower extremity clinical effects of SB-509 treatment on lower limb diabetic neuropathy by symptoms, neurological examination, and lower extremity electrophysiological testing.",2005-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
9266,NCT01089179,,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],
9267,NCT03737422,prediabetes,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],
9268,NCT04700813,pathogenic mutations causing type 2 diabetes,,2019-09-13,UNKNOWN,OBSERVATIONAL,['NA'],
9269,NCT05237219,Change in hemoglobin A1c level,Change in 24-hour blood pressure,2022-05-01,WITHDRAWN,INTERVENTIONAL,['NA'],
9270,NCT03323216,Interleukin 6 (IL-6) [µg/L],,2018-04-01,UNKNOWN,OBSERVATIONAL,['NA'],
9271,NCT00354237,"improvement of peak VO2,",improvement of ventilatory threshold,2005-07,COMPLETED,INTERVENTIONAL,['NA'],
9272,NCT00315588,Insulin Independence.,"Reduction in Severe Hypoglycemia, Improvement in Hypoglycemia Awareness",2000-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
9273,NCT05593926,HbA1c levels,To investigate usability,2022-11-16,COMPLETED,INTERVENTIONAL,['NA'],
9274,NCT05730998,urinalysis,urine culture,2022-09-01,COMPLETED,INTERVENTIONAL,['NA'],
9275,NCT01080157,"Validation of SCOUT DS algorithm, ROC performance equivalency to FPG and A1c for detection of abnormal glucose tolerance.","Receiver operator characteristic area under the curve, sensitivity, specificity, and postive & negative predictive values of the SCOUT DS, FPG, and A1C tests for detection of abnormal glucose tolerance, and the intra- & inter-day SCOUT DS test",2010-03,COMPLETED,OBSERVATIONAL,['NA'],
9276,NCT00344370,NCEP LDL-C Target Attainment,Percent Change From Baseline in LDL-C,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
9277,NCT00558883,effect of treatment of leucocyte count before and after test meal,"identification of gene arrays are registered of relevant pharmacodynamic structures and metabolism ways. Histological examinations of bioptats; Blood: hsCRP, PAI1; Lymphocyte subpopulations; blood lipids, plasma glucose fasting and postprandial",2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
9278,NCT04928872,"Prediction models of postprandial plasma amino acid patterns in relation to the macronutrient content of predefined meals as assessed by plasma concentrations of amino acids, glucose, and/or triglycerides","Discordance of glucose measurement after an intake of the predefined meal as measured by a fingerstick, continuous glucose monitor, and certified laboratory",2018-06-20,COMPLETED,OBSERVATIONAL,['NA'],
9279,NCT03259217,complete healing,rate of ulcer recurrence,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],
9280,NCT00760955,Change from Baseline for a composite measure of Maximal Nerve Conduction Velocity of the Peroneal and Median Motor Nerves and the Median and Sural Sensory Nerves.,Change in Fasting C-peptide.,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
9281,NCT02796456,Biological measure : Maternal apelinemia (Plasma Concentration),Placenta weight,2016-04,COMPLETED,OBSERVATIONAL,['NA'],
9282,NCT01552018,Inflammatory biomarkers,Gene expression of DPP-4 in adipose tissue and leukocytes,2012-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
9283,NCT04809220,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,Change From Baseline in Body Weight,2021-04-13,COMPLETED,INTERVENTIONAL,['PHASE3'],
9284,NCT01865474,Fibrinogen level reduction,Change of Thromboxane-B2 level,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
9285,NCT01671293,Change From Baseline in Weight Parameter,Change of Baseline in Waist Circumference,2011-09,COMPLETED,INTERVENTIONAL,['NA'],
9286,NCT05172089,Aim 4,,2021-01-31,TERMINATED,OBSERVATIONAL,['NA'],
9287,NCT03544645,compare the impact of audiovisual educational materials verses printed educational materials,,2017-07-16,COMPLETED,INTERVENTIONAL,['NA'],
9288,NCT02456636,Mean Weight Change Over 24 Months; Adjusted,Mean Change in Stress Measured by PSS; Unadjusted Except for Affiliation,2016-02-15,COMPLETED,INTERVENTIONAL,['NA'],
9289,NCT03096535,Difference in brown adipose tissue (BAT) activity after cooling versus no cooling.,Difference in resting energy expenditure after cooling versus no cooling,2017-04-02,COMPLETED,INTERVENTIONAL,['NA'],
9290,NCT05008276,Glomerular Filtration Rate (GFR),Renal oxygenation,2021-09-27,RECRUITING,OBSERVATIONAL,['NA'],
9291,NCT03291249,Abnormal physical findings,change in HOMA/HOMA-IR scores,2017-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Mean serum concentrations of adiponectin
9292,NCT03126981,Insulin sensitivity index (SI),Interleukin-6 (IL-6),2017-04-20,COMPLETED,INTERVENTIONAL,['NA'],
9293,NCT03239717,Reduction of BCAA intake,Glucose tolerance,2017-11-28,COMPLETED,INTERVENTIONAL,['NA'],
9294,NCT00328601,,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
9295,NCT01406717,Count and Percentage of Subjects With Potentially Immune-related Treatment-emergent Adverse Events (TEAEs),Change From Baseline in Total Cholesterol,2013-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
9296,NCT02879383,"Change From Baseline at 12 Weeks in MR-PDFF, DMR vs Sham",,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],
9297,NCT02758899,Absolute Disc Glycosylation Levels,Rates of Fusion,2014-03,TERMINATED,OBSERVATIONAL,['NA'],
9298,NCT03112382,serum zinc,change from baseline in total serum Calcium at three months,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
9299,NCT01003236,Change from baseline in urinary albumin-creatinine ratio,Change from baseline in serum creatinine,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
9300,NCT05505864,Objectively measured total sedentary behaviour,Validate the modified SIT-Q (no unabbreviated name) questionnaire,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],
9301,NCT04879251,Number of patients with diabetes who have a higher BP (blood pressure) value (Change from baseline after 1 and 2 year of COVID 19 pandemic),,2021-04-26,COMPLETED,OBSERVATIONAL,['NA'],
9302,NCT05667220,Fasting blood glucose change,Fecal DPP4 activity change,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
9303,NCT02039544,Change in Scores of TCM clinical symptom and the clinical scoring system of Toronto (TCSS),Change in Nerve conduction velocity,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],Number of participants with adverse events
9304,NCT05947916,The difference of Time in Range (TIR),"Number of newborns with neonatal birth injury, shoulder dystocia, neonatal jaundice, neonatal respiratory distress syndrome (RDS)",2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],Adverse event record
9305,NCT02791867,Reduction in glycated Haemoglobin measured: HBA1c,Reduction in serum triglyceride level (mmol/l),2014-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9306,NCT02940379,Assessment of metoprolol PK parameter: AUC,Assessment of PK parameter: t1/2z,2016-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
9307,NCT01276912,HbA1c >= 6.5%,HbA1c >= 7.0%,2011-01,UNKNOWN,INTERVENTIONAL,['NA'],
9308,NCT03520413,Hemoglobin A1c,Patient Health Questionnaire-8,2018-12-21,COMPLETED,INTERVENTIONAL,['NA'],
9309,NCT02750280,Incidence of wound healing,Incidence of ulcer recurrence,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
9310,NCT00861809,Safety and tolerability of GSK962040 (Change from baseline in clinical chemistry and hematology parameters),Food intake,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
9311,NCT00665145,Stem cells circulating in peripheral blood,Safety and Efficacy of SB-509,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
9312,NCT05396443,"Change in diet quality of adolescent participants, as measured by the Healthy Eating Index Scores",Change in high blood pressure status,2022-08-15,RECRUITING,INTERVENTIONAL,['NA'],
9313,NCT03502304,Lipoproteins,Six minutes walking test,2017-06-10,COMPLETED,INTERVENTIONAL,['NA'],
9314,NCT02261168,Day-night rhythm in skeletal muscle mitochondrial respiration,Change in liver volume and liver lipid concentration during the day,2014-11,COMPLETED,INTERVENTIONAL,['NA'],
9315,NCT05295160,Concentration of fasting blood glucose < 126 mg/deciliter,Composition of the microbiome,2020-09-25,COMPLETED,INTERVENTIONAL,['NA'],
9316,NCT04636411,Inflammation,Total or ionized Mg,2020-11-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
9317,NCT01152385,Change in Haemoglobin A1c (HbA1c),Change in High-sensitivity C-reactive Protein (Hs-CRP),2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
9318,NCT02041598,Change in Baseline Hemoglobin A1c at 6-Months,Change in Baseline Lipid Profile at 6-Months,2009-07-01,COMPLETED,INTERVENTIONAL,['NA'],
9319,NCT00034255,,,2001-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9320,NCT01472185,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
9321,NCT00902161,Recovery Time (Rt[65] From Insulin-induced Hypoglycemia,Number of Participants Who Discontinued Study Treatment Due To AEs,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
9322,NCT00484198,Change in Hemoglobin A1c From Baseline Through Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus,Drug-Related Treatment-Emergent Adverse Events Reported by ≥1% Participants Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus,2007-04-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
9323,NCT05127291,Dual-task effect,,2023-05-20,COMPLETED,INTERVENTIONAL,['NA'],
9324,NCT00612794,To assess the safety and tolerability of exenatide administered once weekly by subcutaneous (SC) injection in subjects with type 2 diabetes mellitus.,To explore the pharmacodynamics of exenatide administered once weekly by SC injection in subjects with type 2 diabetes mellitus regarding the following: *fasting and postprandial glucose concentrations; *HbA1c; *Body weight.,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
9325,NCT02083133,Hypoglycemia,,2013-10-01,COMPLETED,OBSERVATIONAL,['NA'],
9326,NCT00467688,Daily time spent in the hypoglycemic glucose range during continuous glucose measurement with and without real time access to glucose values and glucose alarms,Time spent in euglycemic and hyperglycemic glucose range Satisfaction with CGMS Diabetes related distress Treatment satisfaction Anxiety and depressive symptoms,2007-02,COMPLETED,INTERVENTIONAL,['NA'],
9327,NCT02627911,"Percentage of time spent in the tight glycemic control area 80-140 mg / dl during the night, continuously measured for 3 days with CGM","Measurement of AUC during physical activity , the two hours, then to lunch time , during dinner and throughout the night",2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
9328,NCT03581968,Percentage of time of sensor glucose levels spent in target range,Number of participants experiencing hypoglycemia requiring oral treatment during:,2018-07-02,COMPLETED,INTERVENTIONAL,['NA'],
9329,NCT03811561,Presence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression.,"Change in Lipids: Total-cholesterol, High density lipoprotein (HDL)-cholesterol, low density lipoprotein (LDL)-cholesterol and triglycerides.",2019-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
9330,NCT01440439,"Glucose excursion (which, as defined below, is the change in blood glucose between the start and finish of one hour of exercise)",Blood glucose,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
9331,NCT01060332,"Body Constitution Questionnaire, BCQ",Diabetes Impact Measurement Scales,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],
9332,NCT03315663,Effectiveness of Sweetch's PIP compared to usual care to lower A1C,Evaluation of whether intervention reduces blood pressure.,2017-07-01,WITHDRAWN,INTERVENTIONAL,['NA'],
9333,NCT06046976,MicroRNA 21 (Mir-21) expression,Superoxide Dismutase(SOD) enzyme activity (%),2022-06-13,COMPLETED,INTERVENTIONAL,['NA'],
9334,NCT05844644,The change in glycemic control as measured by change in weight (percentage of total weight) from baseline at Days 90 and 180 following the G4LP and supplementation with Release.,The change in quality of life from baseline at days 90 and 180 following the G4LP and supplementation with Release.,2023-04-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Clinically relevant changes in red cell distribution width (RDW) after 180 days.
9335,NCT03038789,"Descriptive analysis of the percentage (%) of adverse events (AEs), serious adverse events (SAEs), unexpected adverse events∙adverse drug reactions and AEs of special interest (AESI)",Number of Participants With Abnormal Laboratory Values,2017-04-20,COMPLETED,OBSERVATIONAL,['NA'],
9336,NCT00877864,The primary outcome will be A1c at the end of 6 months supervised exercise period.,,2010-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
9337,NCT04262479,GAD65A titer in serum,Change in maximum C-peptide during Mixed Meal Tolerance Test (MMTT),2020-03-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
9338,NCT01427569,The percent reduction in wound area at week 4 compared to the baseline visit,The percentage of lesions that demonstrate at least 50% reduction in area by the end of week 4 compared to baseline visit,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
9339,NCT05808972,Number of participants with composite endpoint achievement,Total insulin dose received,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
9340,NCT03732209,Change in delay discounting,Change in waist and hip circumference,2019-03-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Perceived treatment effectiveness and ease of use
9341,NCT00005441,,,1993-04,COMPLETED,OBSERVATIONAL,['NA'],
9342,NCT01006915,To determine if lower extremity nerve decompression in patients suffering from symptomatic diabetic peripheral neuropathy significantly alleviates pain.,Quality of Life,2010-03,COMPLETED,INTERVENTIONAL,['NA'],
9343,NCT00012675,,,na,WITHDRAWN,OBSERVATIONAL,['NA'],
9344,NCT04009889,HOMA-IR value in week 36-40,,2018-04-05,COMPLETED,INTERVENTIONAL,['NA'],
9345,NCT00776607,Change in fasting serum C-peptide level over 24 months and (2) change in HbA1c level over 24 months in patients with LADA.,Hypoglycaemic events,2007-04,UNKNOWN,INTERVENTIONAL,['NA'],
9346,NCT06135935,The primary outcome will be area under curve for the plasma glucose response over 120 minutes after consumption of the ice creams.,CGM monitor readouts over 24 hours after consumption of the ice creams.,2023-11-12,RECRUITING,INTERVENTIONAL,['NA'],
9347,NCT06186063,Relative changes in the plasma levels of N-terminal propeptide of type I procollagen (P1NP),Changes in plasma concentrations of osteocalcin,2024-02-12,RECRUITING,INTERVENTIONAL,['NA'],
9348,NCT01600664,Quality of life,Hyperglycemia events,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
9349,NCT02306343,assessment of skin irritation,area under the curve,2011-11,UNKNOWN,INTERVENTIONAL,['NA'],
9350,NCT02787785,All-Cause Mortality,Sudden Death in various subgroups,2017-04-17,COMPLETED,INTERVENTIONAL,['NA'],S-ICD device complications
9351,NCT02032459,Maternal Vitamin D Status,Vitamin D Status in relations to pregnancy complications,2007-04,COMPLETED,OBSERVATIONAL,['NA'],"Relationship of Vitamin D to maternal diet, etc."
9352,NCT00000532,,,1992-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
9353,NCT03792607,RNA sequencing analysis both in CD4+ and CD8+ cells,ROC curves to evaluate putative DNA methylation/microRNA interactions as prognostic biomarkers of cardiovascular dysfunction in T2D patients,2019-02-14,UNKNOWN,OBSERVATIONAL,['NA'],
9354,NCT01206400,pioglitazone effect on testosterone level,,2010-09,UNKNOWN,OBSERVATIONAL,['NA'],
9355,NCT00947557,Hemoglobin A1c (HbA1c),Fasting Plasma Glucose (FPG),2009-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
9356,NCT00311870,change in glomerular filtration rate from study start to study end,change in urinary albumin excretion rate,1993-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
9357,NCT03867656,P1NP,Heart rate,2019-02-26,COMPLETED,INTERVENTIONAL,['NA'],
9358,NCT03353350,Change in Glycated Hemoglobin (HbA1c) (%),Treatment Emergent Adverse Events (TEAEs),2017-12-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
9359,NCT04699864,Manual Analysis of Retinal Images - Severity of Diabetic Macular Edema (DME),Performance of NeoRetina Algorithm - Diabetic Macular Edema (DME),2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
9360,NCT00005761,,,2000-05-23,COMPLETED,OBSERVATIONAL,['NA'],
9361,NCT04854330,Cardiac output,VEGF,2021-04-26,UNKNOWN,INTERVENTIONAL,['NA'],
9362,NCT04218305,1- Study of human serum fetuin-A and whether it is involved in insulin resistance,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],
9363,NCT04668612,Time in range (TIR) during 2 weeks receiving dual-wave bolus versus standard bolus for dinner.,Time above range (TAR) during 2 weeks receiving dual-wave bolus versus standard bolus,2020-09-04,UNKNOWN,INTERVENTIONAL,['NA'],
9364,NCT05593133,Dynamic Gait index,,2021-01-05,COMPLETED,INTERVENTIONAL,['NA'],
9365,NCT02883127,HbA1c,"Maternal after measurement of subcutaneous skin folds (biceps, triceps, suprailiac and subscapular).",2015-08-01,COMPLETED,OBSERVATIONAL,['NA'],
9366,NCT00462202,Observed ACR level from the first visit to the end of study,,2007-04,TERMINATED,INTERVENTIONAL,['PHASE3'],
9367,NCT01549769,Area under the curve,Maximum observed concentration,2012-04-30,TERMINATED,INTERVENTIONAL,['PHASE1'],
9368,NCT03437018,classification of diabetic retinopathy (DR),medical time necessary for examination and analyse,2019-10-10,COMPLETED,OBSERVATIONAL,['NA'],
9369,NCT04511416,changes in executive function Z-score,"changes in biomarkers, including fasting glucose (mmol/L) and insulin (mIU/L), insulin resistance (HOMA-IR index)",2022-02-15,RECRUITING,INTERVENTIONAL,['PHASE3'],
9370,NCT04813146,Serum HbA1c concentration,,2021-02-05,UNKNOWN,INTERVENTIONAL,['NA'],
9371,NCT03590626,Change in liver fat,Change in Biochemical Markers,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],
9372,NCT02280733,death,Wound related quality of life,2005-01,RECRUITING,OBSERVATIONAL,['NA'],
9373,NCT01634997,Hemoglobin A1c,,2012-06,UNKNOWN,OBSERVATIONAL,['NA'],
9374,NCT04694326,Diabetes Unawaraness Prevalance,,2017-04-20,COMPLETED,OBSERVATIONAL,['NA'],
9375,NCT03208465,Percent change in global myocardial perfusion reserve (MPR) index,Absolute change in global MPR index,2017-08-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
9376,NCT03046498,Measure change in number of program offerings implemented in the community,,2017-02-02,COMPLETED,INTERVENTIONAL,['NA'],
9377,NCT01714505,"Safety, Frequency of Hypoglycemia","Efficacy, Time Spent in Target Range",2012-10,COMPLETED,INTERVENTIONAL,['NA'],
9378,NCT01510665,Change in maternal biomarkers in pregnancy in the third trimester,Pregnancy complications,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
9379,NCT00344500,Change in Predicted Trajectory of Mean Body Fat Percentage Per GLMM Analysis,,2005-10,COMPLETED,INTERVENTIONAL,['NA'],
9380,NCT04823312,Number of subjects with Duo Extended set failures due to unexplained hyperglycemia (i.e. suspected occlusion) at the end of Day 7.,"Number of subjects with a rate of infusion set survival of 7 days or greater, excluding those that kinked on insertion or accidentally pulled out.",2021-03-18,UNKNOWN,INTERVENTIONAL,['NA'],
9381,NCT00542204,Hemoglobin A1C,"Patient psychosocial well-being (e.g., diabetes-related emotional distress)",2008-03,COMPLETED,INTERVENTIONAL,['NA'],
9382,NCT01143727,Wound Appearance,Percent Change in Wound Area,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
9383,NCT00951899,Total Disposition Index,Lipid Values,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
9384,NCT00468442,Insulin independence,"reduction in insulin requirements, HbA1c, MAGE, LI, HYPO score, fasting glucose, beta score, quality of life",2006-11,TERMINATED,INTERVENTIONAL,['PHASE2'],
9385,NCT04229667,Proportion of patients demonstrating a change in self-reported medication adherence actions (30-day),"Proportion of patients demonstrating a change in disease control (defined as random blood sugar <200 mg/dL mmHg), among patients with diabetes at intake (defined as random blood sugar >=200 mg/dL at intake)",2020-01-31,TERMINATED,OBSERVATIONAL,['NA'],
9386,NCT02294123,Insulinemic index,,2013-09,COMPLETED,INTERVENTIONAL,['NA'],
9387,NCT01989962,"Cultural safety, bias and discrimination--change is being assessed",Patient experiences of healthcare service (Canadian Institute of Health Information (CIHI) Patient Experience Survey)--change is being assessed,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Referrals (to whom and date)--change is being assessed
9388,NCT00011531,,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
9389,NCT01017848,development of diabetes using a predicting formula,,2009-11,COMPLETED,OBSERVATIONAL,['NA'],
9390,NCT05533632,Number of Adverse Events,Change From Baseline in Heart Rate (Pulse) After 24 Weeks of Treatment,2022-03-29,COMPLETED,INTERVENTIONAL,['PHASE4'],
9391,NCT05897216,AUCt of CKD-383,,2023-07-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
9392,NCT01040676,Hemoglobin A1c,Waist Circumference,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
9393,NCT04952779,Incidence of Adverse Events (AEs) by preferred term,Change in Post Prandial Blood/Plasma Glucose (PPBG/PPPG),2021-06-02,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
9394,NCT05397028,Efficacy of plant-based meal replacement system on A1-C levels,Efficacy of plant-based meal replacement system on insulin levels,2022-12-08,TERMINATED,INTERVENTIONAL,['NA'],
9395,NCT05779644,Abdominal fat distribution,,2023-02-23,RECRUITING,INTERVENTIONAL,['NA'],
9396,NCT00004363,,,1995-12,COMPLETED,OBSERVATIONAL,['NA'],
9397,NCT03786978,Short term readmission rate,Economic evaluation,2015-09-09,COMPLETED,INTERVENTIONAL,['NA'],
9398,NCT00984750,Arterial blood pressure and dyslipidemia,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
9399,NCT04142710,Change in yearly health and care cost per person from baseline at 12 months,Mean change in the patients' duration of municipal emergency day care unit visits from baseline at 18 months,2019-02-09,COMPLETED,INTERVENTIONAL,['NA'],
9400,NCT00698802,HbA1c,Total daily insulin dosages,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
9401,NCT00506194,Short-term intensive insulin therapy can decrease the insulin resistance and improve the Beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia.,Improve long term glycemic control,2005-10,COMPLETED,INTERVENTIONAL,['NA'],
9402,NCT00064727,,,2003-07-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
9403,NCT03983200,Nerve conduction velocity examination,Glycosylated serum albumin,2019-06-15,UNKNOWN,INTERVENTIONAL,['NA'],
9404,NCT03092063,Change in Diabetes Self-Management Behaviors (Revised Summary of Diabetes Self-Care Activities),Glycemic control,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],
9405,NCT06142006,SGLT2i and/or GLP-1 agonist use after DSS EHR template use,GFR,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],
9406,NCT00143156,The primary efficacy parameter is the endpoint End of Week 12 weekly mean pain score derived from the pain diary.,"End of Week 12 responder rates, Brief Pain Inventory - short form, sleep interference scores, Medical Outcome Study - Sleep Scale, Hospital Anxiety and Depression Scale, Patient Global Impression of Change, Neuropathic Pain Inventory Symptom Inventory.",2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
9407,NCT04462081,Percentage of Liver Fat as Measured by MRI-PDFF,,2013-01,COMPLETED,OBSERVATIONAL,['NA'],
9408,NCT02839512,Change in glycosylated hemoglobin A1c,Weight loss (%TBWL),2014-10,COMPLETED,INTERVENTIONAL,['NA'],
9409,NCT02562573,Number of subjects with abnormal laboratory values and/or adverse events that are related to treatment,Change from baseline on fasting plasma glucose,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
9410,NCT00078052,cardiovascular disease,,2003-09,COMPLETED,OBSERVATIONAL,['NA'],
9411,NCT03956290,Percentage of patients who reduced eating duration by 4 hours,% of participants who achieve ≥ 5% weight loss,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],
9412,NCT05173675,Hemoglobin A1C (HbA1c),Diabetes distress measured by the 2-item Diabetes Distress Screening Scale,2022-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
9413,NCT01313286,Maximum Observed Drug Concentration (Cmax),,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
9414,NCT04473209,serum resistin,clinical attachment loss,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],
9415,NCT04057521,Annual outpatient visit healthcare utilization per patient per 1000 patient years,Annual total healthcare expenditures per patient,2016-04-01,COMPLETED,INTERVENTIONAL,['NA'],
9416,NCT01349387,Comparison of expression of isoforms A and B of the insulin receptor using quantitative RT PCR,,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
9417,NCT05648383,Change from Baseline in glycated hemoglobin [HbA1c] at 24 months (2nd follow-up),Change from Baseline in waist circumference [WC] at 24 months (2nd follow-up),2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],Change form Baseline in the BMI z-score of children at 24 months (2nd follow-up)
9418,NCT05161429,3-point major adverse cardiac events (MACE),Non-cardiovascular outcomes,2021-07-01,RECRUITING,OBSERVATIONAL,['NA'],
9419,NCT01064583,painfree walking distance,endothelial function,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9420,NCT01179165,Prevalence of cardiac abnormalities/disease according to different examination modalities,"Feasibility of transthoracic coronary Doppler examination/Coronary Flow Reserve, and diagnostic yield related to MRI",2011-01,COMPLETED,OBSERVATIONAL,['NA'],
9421,NCT04862390,Hypoglycemia incidence with fasting,Time below range (TBR),2021-03-28,COMPLETED,OBSERVATIONAL,['NA'],
9422,NCT02161276,The decline glycosylated hemoglobin A1C and blood glucose level,The clinical composite safety evaluation of Tangning Tongluo Capsule in the treatment of type II diabetes participants,2014-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9423,NCT00871572,Mean Change in Glycosylated Hemoglobin A1c (HbA1c),Change From Baseline to Endpoint for Total Cholesterol,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
9424,NCT01204216,Specific Aim 1: To Determine the Stability of MRBC (Mean RBC Age)Over Time at Stable Glycemia. The Hypothesis is MRBC Will be Stable in Subjects Without Diabetes and in Subjects With Diabetes at Stable Glycemic Control.,Specific Aim 2: To Determine the Impact of Glycemic Control on MRBC.,2010-09-01,TERMINATED,INTERVENTIONAL,['NA'],
9425,NCT03251755,PSQI,ABI,2017-05-24,COMPLETED,INTERVENTIONAL,['NA'],
9426,NCT04526613,"Prevalence of malnutrition, DM and helminth infections in LTBI individuals and their effects on biosignatures",,2021-04-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
9427,NCT01683266,Change In HbA1c From Baseline to Month 6 Endpoint,Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
9428,NCT00947635,Cholesterol and fatty acid synthesis,Blood lipid levels,2005-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9429,NCT02526069,Acceptability and feasibility of using SweetSpot,Well-being,2015-05,TERMINATED,INTERVENTIONAL,['NA'],Change in Valued Living (BEVS)
9430,NCT06308549,Diabetes Distress,Events of ketoacidosis/severe hypoglycaemia,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],MyDiaMate usage data
9431,NCT00475345,"Incidence of nocturnal hypoglycemia (< 4mmol/L) occurring between 11pm and 7am, as determined with the Continuous Glucose Monitoring System (CGMS) and hemoglobin A1c","Nadir nocturnal BG, timing and duration of nocturnal hypoglycemia, fasting BG, lipid profile, psychosocial factors, total insulin dose, insulin sensitivity and body composition (weight, BMI, % fat, waist circumference).",2000-08,COMPLETED,INTERVENTIONAL,['NA'],
9432,NCT05759468,The primary endpoint is the change from baseline in UACR over the 6-month intervention period.,Assess the change in measure of fasting glucose as a measure of glycemic control over the 6 months intervention period.,2023-04-13,RECRUITING,INTERVENTIONAL,['PHASE2'],
9433,NCT01041859,Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12,Change From Baseline in the EuroQoL-5 Dimension (EQ-5D) Health Status Index at the Week 12 Endpoint,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
9434,NCT04018482,"Comfort of Povidone Iodine vs Avenova 1-2 hours post treatment based on an 11-point numerical scale (0-10, with 0 being no pain, and 10 being extreme pain)",Change in colony forming unit (CFU) growth pre- and post-treatment with Povidone Iodine or Avenova to determine if Avenova is non-inferior to Povidone Iodine for ocular disinfection.,2019-07-16,COMPLETED,INTERVENTIONAL,['PHASE4'],
9435,NCT04093752,Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Rate of Hypoglycemia With Blood Glucose < 54 mg/dL or Severe Hypoglycemia,2019-12-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
9436,NCT00499148,positive AUC for plasma glucose,positive AUC for serum insulin; adjusted peak values for plasma glucose and serum insulin; baseline plasma glucose and serum insulin concentrations; adjusted values for plasma glucose and serum insulin at individual postprandial time points.,2006-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
9437,NCT01968876,Change from baseline in number of pills taken over number of pills prescribed at 12 weeks,,2013-10-30,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],
9438,NCT01599143,PSS-10,Toronto Mindfulness Scale (TMS),2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
9439,NCT01018628,"To determine the pharmacokinetic profile of SRT2379 (25, 75, 250, 500, 1000, 2000, 3000 mg/day [fasted] and 500 mg/day [fed]) in healthy male volunteers after single and multiple dose administration in the fasted and fed states.",To identify other possible biomarkers suitable for future clinical assessment of oral SIRT1 activators.,2009-12-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
9440,NCT03790839,12-lead ECG,iAUC0-4h of GLP-1,2019-01-31,COMPLETED,INTERVENTIONAL,['PHASE1'],
9441,NCT04983277,UK Prospective Diabetes Study risk score,,2021-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
9442,NCT04544553,Attendance rates in patients with diabetic macular edema receiving short messaging services,,2019-01-24,COMPLETED,INTERVENTIONAL,['NA'],
9443,NCT01831804,AUC(0-t) of GSK1278863 (Part B),,2013-06-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
9444,NCT01476475,Change in HbA1c From Baseline to Week 24,Percentage of Participants With Documented Symptomatic and Severe Symptomatic Hypoglycemia,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
9445,NCT00432965,Incidence of Complete Ulcer Closure Closure.,,2002-05,COMPLETED,INTERVENTIONAL,['NA'],
9446,NCT01119846,Part C: Summary of Change From Baseline in Fasted Insulin,"Part C: Summary of AUC0-24, AUC0-t of GSK1292263 and Sitagliptin When Co-administered",2009-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
9447,NCT03487692,Hemoglobin A1C,CAHPS Provider Communication,2018-10-18,COMPLETED,INTERVENTIONAL,['NA'],Health center provider/staff satisfaction
9448,NCT03598738,HbA1c change,,2015-12-01,COMPLETED,INTERVENTIONAL,['NA'],
9449,NCT04320719,number of patients with treatment,biological characteristics of patients,2018-11-01,COMPLETED,OBSERVATIONAL,['NA'],
9450,NCT00682916,"without any altering of dietary habits or exercise routine, individuals shall lose or maintain body weight during the active phase as compared to the placebo phase.",blood lipid levels during the active phase will be improved relative to the placebo phase.,2007-04,COMPLETED,INTERVENTIONAL,['NA'],
9451,NCT06049225,Self-efficacy,Glycemic Management,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Health Dashboard Usability
9452,NCT00325611,Quality and cost of care,Lower total costs 6 months past hospitalization,2002-04,COMPLETED,INTERVENTIONAL,['NA'],
9453,NCT01159938,Postprandial Pulse Wave Velocity (PWV) in Type 2 Diabetes Mellitus (T2DM) Participants at 240 Minutes (Mins) Post-Breakfast,Change in Postprandial Pulse Wave Velocity (PWV),2010-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
9454,NCT04706286,Cmax of CKD-393,,2021-02-18,UNKNOWN,INTERVENTIONAL,['PHASE1'],
9455,NCT00259727,Insulin secretion after a single dose of HIV protease inhibitor versus placebo (insulin secretion assessed by using the hyperglycemic clamp technique),Hepatic glucose production during a somatostatin infusion in the fasting and hyperinsulinemic state after a single dose of HIV protease inhibitor,2006-01,COMPLETED,OBSERVATIONAL,['NA'],
9456,NCT03663803,changes in physical activity.,cholesterol,2011-01-19,COMPLETED,INTERVENTIONAL,['NA'],
9457,NCT00468403,Proportion of subjects with insulin independence,"Lipid profiles (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol)",2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
9458,NCT03055468,Depression Clinical Remission,,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
9459,NCT00548158,ETDRS visual acuity,retinal thickness measured by OCT,2004-10,COMPLETED,OBSERVATIONAL,['NA'],
9460,NCT00001344,,,1993-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
9461,NCT01440790,Incremental Area Under the Curve over 4 hours in serum TRAP (total peroxyl radical-trapping potential),Change from baseline in serum TRAP over 6 hours,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
9462,NCT03352518,Generation and validation of predictive calibration models,Safety assessment of the intervention by the paucity of adverse events,2017-12-28,COMPLETED,INTERVENTIONAL,['NA'],
9463,NCT06204107,"Cmax of Empagliflozin, sitagliptin, metformin","Vd/F of Empagliflozin, sitagliptin, metformin",2023-11-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
9464,NCT02493374,Mitigation of Type 2 Diabetes,,2016-05,WITHDRAWN,OBSERVATIONAL,['NA'],
9465,NCT05383391,"Studying patients' knowledge, practice and barriers of foot self-care among diabetic patients attending Sohag University Hospital",,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
9466,NCT00238472,Change from baseline in postprandial glomerular filtration rate at 12 weeks,Change in insulin AUC (0-240 minutes) at 12 weeks,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
9467,NCT02316483,HBA1C >8.5% on total and gene-specific methylation.,,2013-12,COMPLETED,OBSERVATIONAL,['NA'],
9468,NCT00099151,,,2002-03,COMPLETED,INTERVENTIONAL,['NA'],
9469,NCT03443986,Peripheral circulation,Plantar pressure distribution,2018-02-26,UNKNOWN,INTERVENTIONAL,['NA'],
9470,NCT05342740,Basic clinical and demographic information of participants in groups,,2022-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
9471,NCT01947699,Glucose levels throughout the day,,2013-09,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
9472,NCT01822431,number of participants with abnormal results,,2011-06,UNKNOWN,OBSERVATIONAL,['NA'],
9473,NCT00728143,Glycemic Index,Palatability,1989-08,COMPLETED,INTERVENTIONAL,['NA'],
9474,NCT00266643,Subscale of the UKU side effect rating scale to be measured during the switch period. The weeks during which the switch occurs are blinded.,"Weekly: Leeds Sleep Evaluation Questionnaire, Brief Profile of Mood States, Clinical Global Impression of Severity. Visits 2, 7, 11: Treatment Satisfaction Questionnaire for Medic",2005-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
9475,NCT01278121,Changes in microarray gene expression,"Inflammatory markers, hormonal dietary responses and blood lipids",2011-02,COMPLETED,INTERVENTIONAL,['NA'],
9476,NCT00590044,Number of Hypoglycemia Episodes After the Transition Period From Intravenous Insulin to Subcutaneous Insulin Between 2 Treatment Groups,Difference in Time in Hours to Resolution of DKA Between the 2 Groups,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
9477,NCT04288778,Percentage of Participants With Adverse Drug Reactions (ADRs),Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE4'],
9478,NCT00361946,,,2006-08,COMPLETED,OBSERVATIONAL,['NA'],
9479,NCT04974528,Change in HbA1c,Change in HbA1c,2021-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Change in percent predicted Forced Expiratory Volume in 1 Second (FEV1)
9480,NCT02200627,Adverse event incidence,,2014-09,COMPLETED,OBSERVATIONAL,['NA'],
9481,NCT00819975,Triglyceride levels,Incretin levels,na,COMPLETED,INTERVENTIONAL,['NA'],
9482,NCT03687320,Incidence of complete (100%) wound closure,Time to complete (100%) wound closure,2019-12-02,UNKNOWN,INTERVENTIONAL,['NA'],
9483,NCT01460095,one year change in glycated haemoglobin (HbA1c),One-year change in urinary albumin excretion,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
9484,NCT06297239,prevalence of high level of Lp(a),,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],
9485,NCT01888133,Change in steps/day,Change in A1c,2013-04,TERMINATED,INTERVENTIONAL,['NA'],
9486,NCT02166372,Evaluate the natural course of the diabetes of obese patients over a period of 10 years,,2014-03,RECRUITING,OBSERVATIONAL,['NA'],
9487,NCT02646072,Level of aqueous inflammatory cytokines post treatment as assessed using Bio-plex Pro Assays,Changes from baseline in central subfield retinal thickness as assessed by optical coherence tomography,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
9488,NCT05183685,"HbA1c, defined as the amount of blood sugar attached to hemoglobin.","Number of attendances at a general practitioners' office, emergency department, hospital, and general out-patient clinic",2022-12-10,RECRUITING,INTERVENTIONAL,['NA'],Maintenance. It measures the sustained effect of the program. Cost-effectiveness will be measured by calculating the cost used in both groups.
9489,NCT00358033,"The number of patients who had non-compliance to ADA target goals in smoking, LDL cholesterol, blood pressure or Hb A1c.",,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
9490,NCT02752113,Effect of empagliflozin plus linagliptin vs metformin plus insulin glargine on basal NO activity of renal vasculature (response of RPF (renal plasma flow) to L-NMMA (NG-monomethyl-L-arginine) infusion),"changes in albuminuria (urinary albumin to creatinine ratio [UACR]), assessed in the 24-hour urine",2016-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
9491,NCT03635970,TcPO2,,2018-05-18,COMPLETED,INTERVENTIONAL,['NA'],
9492,NCT04300764,Change in mean daily step count during hospitalization,Change in life space assessment,2026-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
9493,NCT03159221,Change in Body Mass Index (weight status) at 6 months and at 12 months,Teen Quality of Life,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
9494,NCT00758927,Percentage change of plasma small dense LDL measured by ultracentrifuge-non denaturing polyacrylamide gel electrophoresis,The percentage change of plasma HDL sub-fraction measured by ultracentrifuge-non denaturing polyacrylamide gel electrophoresis,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],
9495,NCT00465478,Exogenous insulin requirement; Hemoglobin A1C; Glucose and C-peptide level;,"lipid profile, autoantibody， Quality of life",2006-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9496,NCT03071432,Change from baseline in dynamic cerebral autoregulation after induction of anesthesia,Clinical outcome,2016-08-30,COMPLETED,INTERVENTIONAL,['NA'],
9497,NCT02898428,Hypoglycemia,,2016-04,COMPLETED,OBSERVATIONAL,['NA'],
9498,NCT01674049,Blood Glucose,Serum insulin,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
9499,NCT05277532,Time in Glucose target range (4-10 mmol/L) for tissue glucose from CGM.,Time below Glucose target range (< 4 mmol/L) for tissue glucose from CGM.,2022-05-18,RECRUITING,INTERVENTIONAL,['NA'],
9500,NCT03125369,% of patient achieve HbA1c<6%,BMI change (kg/m^2),2015-08,UNKNOWN,INTERVENTIONAL,['NA'],
9501,NCT02012478,hemoglobin A1C,PAM scale,2014-02,COMPLETED,INTERVENTIONAL,['NA'],Summary of Diabetes Self-Care Activities
9502,NCT00124553,All measures to be compared at end of study (6 months),All measures to be compared at end of study (6 months),2006-08,UNKNOWN,INTERVENTIONAL,['NA'],
9503,NCT03010956,"Differences in flow mediated dilation (FMD) at baseline and 3, 6 and 12 months after the modification of the antidiabetic medication.",Endothelial glycocalyx and coronary flow reserve.,2014-11,COMPLETED,OBSERVATIONAL,['NA'],
9504,NCT04190849,Survival,Asymptomatic progression of liver disease,2017-11-14,RECRUITING,OBSERVATIONAL,['NA'],
9505,NCT05159622,Change in Water Consumption for Parents,Parent 100% Fruit Juice Consumption,2019-05-07,COMPLETED,INTERVENTIONAL,['NA'],Hip Circumference for Parents
9506,NCT00685698,Clinical Success (in ITT Population),"Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)",2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
9507,NCT01498614,Prevalence of depression,Level of A1C,2009-03,TERMINATED,INTERVENTIONAL,['NA'],
9508,NCT04519853,"Patient reported tolerability of dietary intervention, Likert scale",Change in intestinal fatty acid binding protein (I-FABP),2021-10-25,COMPLETED,INTERVENTIONAL,['NA'],
9509,NCT02044848,Stimulated C-peptide in Response to a Standard Mixed Meal Tolerance Test,,2014-02,TERMINATED,INTERVENTIONAL,['PHASE2'],
9510,NCT00782639,Baseline and Change From Baseline Measurements for the One Participant With Contrast-Induced Nephropathy (CIN) at the 48 to 72 Hours After Injection of Contrast Media Visit,Number of Participants Who Died From Acute Renal Failure,2009-03,TERMINATED,INTERVENTIONAL,['PHASE4'],
9511,NCT02779790,Blood pressure - diastolic blood pressure,,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],
9512,NCT00239187,To assess the safety and tolerability of repeated subcutaneous doses of E1 in combination with G1 in patients with type 2 diabetes,To evaluate the pharmacokinetics (PK) profile and clinical effects of repeated subcutaneous doses of E1 in combination with G1 in patients with type 2 diabetes,2005-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
9513,NCT03320694,maternal glycemic control,Neonatal hypoglycemia,2016-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
9514,NCT00265473,Serious Adverse Events Related to Immunosuppressive Therapy.,Insulin Independent Multiple-donor Subjects.,2005-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9515,NCT02065544,Hemoglobin A1c,Aerobic Fitness,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
9516,NCT00149435,Cardiac health,,2005-09,COMPLETED,OBSERVATIONAL,['NA'],
9517,NCT05962983,change in hemoglobin A1c% (HbA1c%),change in waist circumference (inches),2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],eating motives
9518,NCT02129868,Time spent with plasma glucose concentration in the target glucose range from 3.9 to 8.0 mmol/l.,Absolute relative difference between matched pairs of subcutaneous glucose sensor and reference plasma glucose.,2014-04,COMPLETED,INTERVENTIONAL,['NA'],nature and severity of any other adverse events
9519,NCT03076697,Disease diagnosis based on photography,Automated disease diagnosis,2015-04-16,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
9520,NCT00995995,Cost-effectiveness of rosiglitazone,,2008-10,COMPLETED,OBSERVATIONAL,['NA'],
9521,NCT03788915,Weight change,HbA1C change,2018-04-16,UNKNOWN,INTERVENTIONAL,['NA'],Retention rate change
9522,NCT01364766,CGM usefulness score,Diabetes Comfort score,2010-09,COMPLETED,OBSERVATIONAL,['NA'],
9523,NCT04591639,Rate of change in myocardial T1 values with manganese enhanced cardiac MRI,Measures of glucose control like glycated haemoglobin (HbA1c) in millimoles per mole,2020-08-19,RECRUITING,INTERVENTIONAL,['NA'],
9524,NCT04916470,Change in body weight,Number of treatment emergent severe or clinically significant hypoglycaemia episodes,2021-06-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
9525,NCT04857411,Change in Diastolic Blood Pressure,Newest Vital Sign (NVS),2021-04-19,COMPLETED,INTERVENTIONAL,['NA'],
9526,NCT01348867,To assess the effectiveness of the nurse consultant led clinic in improving glycemic parameters in patients with type 2 diabetes,A comparison of the patients' utility of healthcare services,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
9527,NCT02827903,change of HbA1c,,2016-01-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
9528,NCT05379296,Change from Baseline Serum insulin at 12 months,Change from Baseline C-reactive protein at 12 months,2022-01-01,WITHDRAWN,INTERVENTIONAL,['NA'],
9529,NCT02674893,Modifications in wanting,Anthropometric modifications,2014-02-04,TERMINATED,INTERVENTIONAL,['PHASE4'],
9530,NCT01660009,Flow induced Dilation of the Brachial Artery (FMD%),Mitochondrial superoxide production,2012-06,TERMINATED,INTERVENTIONAL,['NA'],
9531,NCT03068065,Intrahepatic fat,WC,2014-05,COMPLETED,INTERVENTIONAL,['PHASE4'],"Number of Participants with gliclazide, liraglutide or metformin adverse events as a measure of safety and tolerability"
9532,NCT05026528,HbA1c,,2021-11-30,RECRUITING,INTERVENTIONAL,['NA'],Patient-reported outcome and experience measures
9533,NCT03074383,Change in glycated hemoglobin from baseline at 12 months,Variation of Summary of Diabetes Self-Care Activities Questionnaire (SDSCA) from baseline at 12 months,2017-03-20,COMPLETED,INTERVENTIONAL,['NA'],
9534,NCT01608776,Wound Reduction,,2012-05,TERMINATED,INTERVENTIONAL,['PHASE4'],
9535,NCT03104543,"Undertreatment of Hypertension (>=140/90 mmHg), Dyslipidemia (LDL >=160 mg/dL or Triglyceride >=150 mg/dL), and/or Glucose Intolerance (if Prediabetes, Hemoglobin A1c >=5.7% or Fasting Glucose >=100; if Diabetes, Hemoglobin A1c >=7%)",Primary Care Provider Attitudes,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],
9536,NCT03510078,Cardiac ischemic events,Length of hospitalization,2018-04-17,RECRUITING,INTERVENTIONAL,['NA'],
9537,NCT05000996,Estimated 10-year risk of atherosclerotic cardiovascular disease,Blood inflammatory proteins,2021-08-19,RECRUITING,OBSERVATIONAL,['NA'],
9538,NCT05883267,Anxiety assessment - trait anxiety,VR Satisfaction and effectiveness assessment,2023-05-10,RECRUITING,INTERVENTIONAL,['NA'],
9539,NCT05498610,"Cmax,NNC0480-0389,SD Maximum plasma concentration of NNC0480-0389 after a single dose","Cmax,sema,SD The maximum plasma concentration of semaglutide after a single dose",2022-08-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
9540,NCT01930136,The percent change in glomerular filtration rate (GFR) at month 6 versus baseline and the rate of GFR decline from month 6 to study end,,2013-05,COMPLETED,INTERVENTIONAL,['NA'],
9541,NCT04592263,Patient Reported Outcome,,2019-08-01,COMPLETED,OBSERVATIONAL,['NA'],
9542,NCT03042520,Number of participants with hepatocellular carcinoma (HCC) development during 5-year follow-up period after sofosbuvir-based treatment,Renal disease,2016-08,UNKNOWN,OBSERVATIONAL,['NA'],
9543,NCT03056014,Change from baseline in level of oxidative stress with varying doses of omega 6 fish oil(PUFA) at 2 weeks.,,2018-11-01,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],
9544,NCT00035568,,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
9545,NCT03407222,change in daily step count after 12 weeks of intervention,low-density lipoprotein cholesterol,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
9546,NCT04152408,Incidence of (Serious) Adverse Events,User satisfaction assessed by the Likert scale,2017-01,COMPLETED,INTERVENTIONAL,['NA'],
9547,NCT05106231,laboratory-analysed HbA1C improvement (HbA1c level below 42mmol/mol or 6.5%),Diabetes knowledge improvement (scores in percentage),2023-05-01,COMPLETED,INTERVENTIONAL,['NA'],
9548,NCT01649297,HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 16,Fasting Plasma Glucose (FPG) Change From Baseline at Week 16,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
9549,NCT04824209,Variation in pro-diabetes inflammation markers over time upon endodontic intervention.,,2021-02-09,COMPLETED,OBSERVATIONAL,['NA'],
9550,NCT02672839,Pharmacokinetics Analysis- Maximum Concentration (Cmax),Severity of all Adverse Events graded according to the Common Terminology Criteria for Adverse Events (CTCAE),2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
9551,NCT01204294,Incidence of Adverse Events (AEs),Glycosylated Haemoglobin A1c (HbA1c),2010-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
9552,NCT02731716,Improvement in Provider Performance,Primary Care Spending,2016-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
9553,NCT04866823,Acceptability of Study Measures,Change in Time Below Range (Hypoglycemia),2021-10-20,COMPLETED,INTERVENTIONAL,['NA'],
9554,NCT00069368,Urinary Outcomes,,2003-07,COMPLETED,OBSERVATIONAL,['NA'],
9555,NCT01558271,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks,Change From Baseline in Electrocardiogram Parameters at 26 Weeks and 52 Weeks,2012-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
9556,NCT03543449,Operative mortality,Perioperative time-weighted average glucose,2018-04-23,UNKNOWN,OBSERVATIONAL,['NA'],
9557,NCT02175537,Waist circumference,Health Profile Survey,2014-06,COMPLETED,INTERVENTIONAL,['NA'],Social Network Relationships
9558,NCT00605111,HbA1c,FPG,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
9559,NCT00386100,Change From Baseline in HbA1c at Week 80,"Percent Change From Baseline in Bone Alkaline Phosphatase (BSAP) at Weeks 20, 56, and 80",2006-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
9560,NCT02184676,Autoreactive T lymphocytes,Incidence of autoantibodies,2015-05-28,COMPLETED,INTERVENTIONAL,['NA'],
9561,NCT01452178,Cardiovascular events - longitudinal outcome measure.,,2005-11,COMPLETED,OBSERVATIONAL,['NA'],
9562,NCT03324451,Change in Glycosylated Hemoglobin (HbA1c) Levels,Change in Body Mass Index,2018-03-01,COMPLETED,INTERVENTIONAL,['NA'],
9563,NCT00100178,Mean Stimulated C-peptide Area Under the Curve,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
9564,NCT01789957,Change in body weight from Day 1 of Protocol 2993-112 to Week 52 (or termination),,2002-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
9565,NCT01507116,Self-reported health and Quality of Life (QoL) (measured by the study questionnaire),Patient-centred diabetes care reported by people with diabetes and health care professionals measured by the study questionnaire,2012-03,COMPLETED,OBSERVATIONAL,['NA'],
9566,NCT02919059,Effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period regarding central systolic blood pressure,Effect of dapagliflozin relative to glimepiride at 24 weeks with inadequate glycemic control regarding augmentation index,2016-12-13,UNKNOWN,INTERVENTIONAL,['PHASE4'],
9567,NCT06024928,Percent Time in Range,Mean glucose reading measured by Continuous Glucose Monitor (CGM),2023-11-01,RECRUITING,INTERVENTIONAL,['NA'],
9568,NCT04443842,Glycemic control,Change in physical activity level,2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],Change in health service utilisation
9569,NCT05473806,Changes in Liver Stiffness Measurement at 24 weeks compared to baseline.,Analysis of predictors of HbA1c improvement after 24 weeks compared to baseline.,2020-09-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
9570,NCT02122835,exercise capacity,nitrite flux during exercise,2012-02,WITHDRAWN,INTERVENTIONAL,['NA'],
9571,NCT05343767,To compare the hypoglycemic effect of two doses of a herbal medicinal product (NW Low-Glu) to that of Metformin as measured by the mean change in HbA1c levels in patients newly diagnosed with type II diabetes mellitus.,To compare the mean change in the 2h-post prandial glucose levels between each experimental arm and active-control arm (efficacy),2018-09-12,COMPLETED,INTERVENTIONAL,['NA'],To investigate the effect of NW Low-Glu on weight.
9572,NCT02760303,Metabolic Control,Diabetes Quality of Life,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
9573,NCT05981547,Glucose variability,A analysis of CGM glucose data for progression of glycaemia in a sub group,2023-11-22,RECRUITING,OBSERVATIONAL,['NA'],
9574,NCT00337324,"Daytime and night-time pain scores assessed at baseline, after FREMS/placebo, and 4 month follow-up",Partial tissue tension of oxygen and carbon dioxide by oxymetry,2002-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
9575,NCT02558491,Glucose Variability (Coefficient of Variation),Total Rescue Carbohydrates (CHO) (Grams),2015-09,COMPLETED,INTERVENTIONAL,['NA'],
9576,NCT04650945,"Glucose time in range (3,9-10 mmol/l) (% pr day)",Time with active isCGM,2021-01-04,TERMINATED,INTERVENTIONAL,['NA'],
9577,NCT04315857,Time spent with an interstitial blood glucose level below 0.70 g/l and above 2.5 g/l,,2020-06-09,COMPLETED,OBSERVATIONAL,['NA'],
9578,NCT01034111,Safety and Tolerability of Sitagliptin After 4 Weeks of Treatment,Change From Baseline in Fasting Plasma Glucose at Week 4,2010-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
9579,NCT03340467,Survival rate,Attachment site reactions,2018-08-01,WITHDRAWN,INTERVENTIONAL,['NA'],
9580,NCT06096311,Qualitative Results from Interviews,,2022-04-01,RECRUITING,OBSERVATIONAL,['NA'],
9581,NCT00796848,To evaluate the effectiveness of continuous glucose monitoring in the reduction of hypoglycemia unawareness.,To assess the levels of epinephrine production in youth diagnosed with hypoglycemia unawareness with and without continuous glucose monitor wear.,2009-03,WITHDRAWN,INTERVENTIONAL,['NA'],
9582,NCT05963594,"Incremental area under the curve (iAUC) of post-prandial glycemic excursion induced by Oligomalt relative to maltodextrin over the observation period: iAUC 0-1 hour, iAUC 0-2 hours, iAUC 0-3 hours.",Plasma peptide tyrosine (PYY),2023-01-23,COMPLETED,INTERVENTIONAL,['NA'],Plasma peptide tyrosine (PYY)
9583,NCT05687968,Fasting glucose,Triglyceride (TG),2023-01-16,RECRUITING,INTERVENTIONAL,['NA'],
9584,NCT04016415,Change in Hemoglobin A1c from Baseline to 6 months,Change in Perceived Stress Scale-10 from Baseline to 6 months,2020-07-28,RECRUITING,INTERVENTIONAL,['NA'],
9585,NCT01970462,Difference in Fasting Glucose,,2014-01,TERMINATED,INTERVENTIONAL,['PHASE4'],Hypoglycemia
9586,NCT04982640,Acceptability as indicated by participant satisfaction ratings,Body Mass Index,2022-10-24,RECRUITING,INTERVENTIONAL,['NA'],
9587,NCT00286429,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Body Weight (Week 26).,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
9588,NCT01409239,Difference Between Heart Rate Variability Between Intravenous and Subcutaneous Group,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
9589,NCT00500175,incident foot ulcers,temperature spikes on foot zones,2007-01,UNKNOWN,INTERVENTIONAL,['NA'],
9590,NCT02974491,Evaluating adequacy of the dialysis treatment,,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
9591,NCT02585674,Percentage of patients reaching fasting SMPG target range 90-130 mg/dL (5.0-7.2 mmol/L) at Week 16 (mean of the last 5 readings recorded over the last 2 weeks) without a severe hypoglycemic episode during the 16-week on-treatment period,Assessment of device Ease of Use using Ease of Use questionnaire,2015-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
9592,NCT04927702,"For Participants With Venous Leg Ulcers, number of participants with 100 Percent Epithelialization (Closure) of Wound",Number of Product Applications,2021-07-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Number of participants with coverage of product by payor (insurance)
9593,NCT05026775,Rate of Initiation,Reduction of Cardiovascular Risk,2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Rate of Mortality
9594,NCT00543361,This study will assess the lipid lowering effectiveness of MK0767 compared to metformin over the course of 52 weeks.,MK0767 will be safe and well tolerated.,2003-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
9595,NCT05570305,Change from baseline in albuminuria after 4 weeks combined zibotentan and dapagliflozin treatment versus four weeks treatment with zibotentan alone.,Change in systolic and diastolic blood pressure,2022-10-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],Change in copeptin
9596,NCT01095666,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]),2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
9597,NCT01793974,Identify variations in the human genome associated with LADA by genotyping cases and comparing allele frequencies to an existing control database,Identify associations between genetic variants with certain measurable risk profiles that can be used to judge the health status or well being of a LADA case.,2011-07,COMPLETED,OBSERVATIONAL,['NA'],
9598,NCT03344341,Absolute change from baseline in HbA1c at Week 24,Percentage of patients with reduction of SBP ≥3 mmHg,2017-12-15,TERMINATED,INTERVENTIONAL,['PHASE4'],The difference of the number between tablets taken and tablets prescribed
9599,NCT05866380,Major adverse cardiovascular events,,2022-03-23,RECRUITING,OBSERVATIONAL,['NA'],
9600,NCT00594399,12 Month Fasting Glucose,"Physical Activity, Endurance",2008-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
9601,NCT01515579,"Cmax, maximum concentration",Adverse events,2006-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
9602,NCT01277965,Number of episodes of symptomatic or non-symptomatic hypoglycaemia,Duration of hypoglycaemia,2010-03,COMPLETED,INTERVENTIONAL,['NA'],
9603,NCT00916838,,,2003-01,COMPLETED,OBSERVATIONAL,['NA'],
9604,NCT00222807,,,2003-08,COMPLETED,OBSERVATIONAL,['NA'],
9605,NCT03686423,Apparent Diffusion Coefficient (ADC) in the Tibial Nerve,,2018-11-28,COMPLETED,INTERVENTIONAL,['NA'],
9606,NCT03234387,Maximal oxygen uptake (aerobic fitness),Insulin concentration,2017-11-17,TERMINATED,OBSERVATIONAL,['NA'],
9607,NCT03627039,"Cardiovascular composite (stroke, myocardial infarction, heart failure)",Costs,2018-09-01,UNKNOWN,OBSERVATIONAL,['NA'],Tracer outcomes
9608,NCT00444600,Change in Visual Acuity From Baseline to 1 Year Grouped by Diffuse vs. Focal Edema as Characterized by the Investigator,Mean Change in Optical Coherence Tomography Retinal Volume From Baseline to 1 Year,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Major Ocular Adverse Events During First Year of Follow-Up
9609,NCT01028391,"Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Hemoglobin A1c (HbA1c) at Week 54","Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Fasting Plasma Glucose (FPG) at Week 54",2007-09-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
9610,NCT01951859,Decrease in area or closure of wounds/fissures due to Homeopathic Anti-inflammatory Topical Cream,,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],
9611,NCT05190198,Modified Toronto Clinical Neuropathy Score (mTCNS),,2022-01-15,COMPLETED,INTERVENTIONAL,['NA'],
9612,NCT01671189,Glycemic Control (hemoglobin A1c),Appointment Adherence Rate,2012-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
9613,NCT04161937,HbA1C,,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
9614,NCT05979142,Composite standard,,2011-09,COMPLETED,OBSERVATIONAL,['NA'],
9615,NCT02033876,Change in Area Above Basal (AAB) for Glucose,Change in FGF-19,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
9616,NCT05951946,"Cmax,ss",,2023-07-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
9617,NCT04280549,Protease Activated Receptor-1 Activation,,2018-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
9618,NCT04979559,Oral glucose tolerance test mean change from baseline,Likelihood ratio of screening instrument compared to American Diabetes Association criteria,2021-05-25,UNKNOWN,INTERVENTIONAL,['NA'],Participant's acceptance of mobile health application
9619,NCT04908904,Area under the curve for glucose,Area under the curve for GIP,2021-05-27,COMPLETED,INTERVENTIONAL,['NA'],
9620,NCT00903799,clinical efficacy,medico-economic evaluation of ENTERRA therapy,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
9621,NCT01261143,TSS,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
9622,NCT01513525,Area under the Curve (AUC) of liraglutide for each injection site,Adverse events,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
9623,NCT01274364,Percentage of patients who attain 2 or more of the 'ABC' targets,Default rates at end of study,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
9624,NCT02956759,Proportion of eyes progressing to any degree of PDR,Sensitivity & specificity of the diagnosis of any degree of PDR among study ophthalmologists,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],Patient vision-related quality of life (VRQOL); composite and individual domain scores of the NEI VFQ25 questionnaire.
9625,NCT03700034,"Mean number of four selected ANC components delivered by the healthcare providers per visit, observed over two visits- the trial enrolment visit and the next routine ANC appointment.",Mean number of quality antenatal care components delivered in the enrolment visit,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
9626,NCT03620266,Plasma levels of LDL cholesterol,Body composition with multi-frequency biothesiometry,2021-09-30,RECRUITING,INTERVENTIONAL,['NA'],
9627,NCT01202526,Change in insulin sensitivity after RYGB,Change in insulin secretion in response to oral glucose after RYGB,2010-09,COMPLETED,OBSERVATIONAL,['NA'],Change in insulin secretion after iv glucose-glucagon after RYGB
9628,NCT01955031,"To assess effectiveness of our telemonitoring program in Diabetes care, HbA1C assays will be compared between the two groups.The change of HbA1c between day 0, month 1,month 3, month 6, month 9 and month 12","For the telemonitoring arm, acceptability and satisfaction of the telemonitoring system by the health professionals with the number and time of connections leading to a medical decision (phone call or medical appointment) and a questionnaire",2013-11,COMPLETED,INTERVENTIONAL,['NA'],
9629,NCT02855684,Change in HbA1c from baseline,Change in daily basal insulin dose,2016-08-24,COMPLETED,INTERVENTIONAL,['PHASE3'],
9630,NCT05457088,Dietary intake of macro- and micro-nutrients,Protein carbonyls in plasma,2021-11-01,RECRUITING,INTERVENTIONAL,['NA'],
9631,NCT05076292,Incidence rate of hypoglycemia (PG < 3.9 mmol/l),Point accuracy with the Clarke Error Grid Analysis (CEGA) (using SMBG and YSI as the reference value),2021-11-23,COMPLETED,INTERVENTIONAL,['NA'],
9632,NCT02652754,Measurement of aCT1 peptide (Active Pharmaceutical Ingredient in Granexin) levels in blood,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
9633,NCT00935922,Improved lipid profile,,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
9634,NCT03179137,Myocardial production of reactive oxygen species,Anti-cardiolipin antibodies in the blood of patients with symptoms of cardiac ischemia,2016-10-01,UNKNOWN,OBSERVATIONAL,['NA'],
9635,NCT01252056,nephropathy development,Adverse events,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
9636,NCT01776788,the glycemic remission rate in different groups,the time of glycemic remission in different groups,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
9637,NCT00862589,glucagon suppression,,2006-10,COMPLETED,INTERVENTIONAL,['NA'],
9638,NCT04234763,Postprandial 1H-NMR metabolites,Dietary Glycemic load(GL),2019-08-01,UNKNOWN,INTERVENTIONAL,['NA'],
9639,NCT03629301,Change in body weight,Number of participants achieving 5% of weight loss,2018-09-17,COMPLETED,INTERVENTIONAL,['NA'],
9640,NCT03622762,Soluble RAGE concentration,Aspartate aminotransferase,2018-07-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],Weight and visceral fat %
9641,NCT03717896,plasma bicarbonate levels,hospital resource usage,2018-11-21,RECRUITING,INTERVENTIONAL,['PHASE2'],Cognitive function: Test of Premorbid Functioning
9642,NCT00852982,HbA1c,waist circumference,2006-04,UNKNOWN,INTERVENTIONAL,['NA'],
9643,NCT02579070,Percentage of patients developing a foot ulcer,Rate of change of score in quality of life from baseline and up to the final visit using the EQ-5D-5L,2016-02-08,COMPLETED,INTERVENTIONAL,['NA'],
9644,NCT01589653,Change in HbA1c From Baseline,Change in Patient Reported Outcomes: Treatment-Related Impact Measures for Diabetes (TRIM-D)-Treatment Burden,2012-05-26,COMPLETED,INTERVENTIONAL,['PHASE4'],
9645,NCT04078854,Change in hemoglobin A1c (HbA1c) levels,Number of patients with mobility problems,2020-07-08,TERMINATED,INTERVENTIONAL,['NA'],
9646,NCT06065540,CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg versus 1.0 mg): Relative change in body weight,"CagriSema (2.4 mg/2.4 mg and 1.0 mg/1.0 mg) versus semaglutide (2.4 mg and 1.0 mg), placebo and cagrilintide 2.4 mg: Number of severe hypoglycaemic episodes (level 3)",2023-09-27,RECRUITING,INTERVENTIONAL,['PHASE3'],
9647,NCT00041444,,,2002-06,COMPLETED,OBSERVATIONAL,['NA'],
9648,NCT00793481,Changes in Microvascular,,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
9649,NCT05504239,Changes from baseline HbA1c at week 24,Changes from baseline in BMI at week 24,2022-10,RECRUITING,INTERVENTIONAL,['PHASE3'],
9650,NCT02906709,Percentage of Participants Who Discontinued Study Drug Due to an AE Including Data After Glycemic Rescue (Omarigliptin [Phase A+B]; Placebo→Omarigliptin [Phase B Only]),Percentage of Participants Achieving Hemoglobin A1c Goals (<6.5%) at Week 52 (Phase A+B),2016-10-17,COMPLETED,INTERVENTIONAL,['PHASE4'],
9651,NCT01016457,HbA1C,Mean glucose level,2008-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
9652,NCT06042153,Change in TIR (70-180 mg/dl),Total score of Kidney disease QoL short form,2023-12-05,RECRUITING,INTERVENTIONAL,['PHASE4'],
9653,NCT04509791,the area under the stimulated C-peptide response curve,"continuous glucose monitoring (CGM) measurements ( time in range, time above time below)",2020-11-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
9654,NCT03006510,The proportion of patients (in each group) who ultimately have a hypoglycemic event,,2017-01,COMPLETED,INTERVENTIONAL,['NA'],
9655,NCT01584063,Physical Activity,"Metabolic (e.g., glucose)",2004-02,COMPLETED,INTERVENTIONAL,['NA'],
9656,NCT02472951,Insulin sensitivity,,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
9657,NCT05637437,Health Related Quality of Life,Systolic and Diastolic Blood Pressure,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
9658,NCT03049592,Utilization of LARC,Acceptability of contraceptive counseling intervention by patients and clinicians,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
9659,NCT05976191,Blood Glucose Measurement Patient Satisfaction Form,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],
9660,NCT04678284,Acceptability of Intervention,Diabetes Medication Adherence,2021-03-24,COMPLETED,INTERVENTIONAL,['NA'],
9661,NCT00595569,"Metabolic control (HbA1c, severe hypoglycemic events), psychological effects, diabetes knowledge","Changes in insulin doses, changes in weight",2002-04,COMPLETED,OBSERVATIONAL,['NA'],
9662,NCT05376930,"Changes from baseline in Adverse events (AEs) and adverse events of special interest (AESIs)* at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP","Proportion of subjects achieving HbA1c target of < 7% at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP",2021-09-16,COMPLETED,INTERVENTIONAL,['PHASE3'],
9663,NCT00225888,Subjects' hemoglobin A1c (A1c) values,Subjects' self-care behaviors,2004-10,TERMINATED,INTERVENTIONAL,['NA'],
9664,NCT02458495,Glycemic control (Change in participant's HbA1c level),"Time spent on website, 3 month assessment",2015-08,COMPLETED,INTERVENTIONAL,['NA'],
9665,NCT01651065,Weight,"Hemoglobin A1c (%, HbA1c)",2011-06,COMPLETED,INTERVENTIONAL,['NA'],Temporally investigate the causal induction of cascading changes in body weight between follow-ups on subsequent weight changes in other participants.
9666,NCT03676309,colesterol,Endothelial function,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
9667,NCT04114357,Change in the gut microbiome profile,Changes in Beta cell Health.,2020-06-22,COMPLETED,INTERVENTIONAL,['PHASE3'],Changes in phenotype of Mucosal Associated invariant T (MAIT) cells
9668,NCT03550378,Percent Change From Baseline in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4 Hrs) as Measured by Mixed-meal Tolerance Test (MMTT) to Day 32,Number of Participants With Positive Anti-drug Antibodies (ADA) Titre to MEDI0382,2018-06-29,COMPLETED,INTERVENTIONAL,['PHASE2'],
9669,NCT01006603,Proportion of Patients Reaching HbA1c <7% After 52 Weeks of Treatment Without Confirmed or Severe Hypoglycaemia.,Change From Baseline to Week 52 in β-cell Function (as Measured by Homeostasis Model Assessment-β [HOMA-β],2009-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
9670,NCT00306644,Change from baseline of the composite intima-media thickness (IMT) in the carotid artery following 52 weeks of treatment.,Plaque occurrence & stenosis within the right carotid artery.,2002-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
9671,NCT05141214,Short-term behavior modification,Satisfaction Survey,2023-02-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
9672,NCT02180620,glucose concentrations,triglyceride concentrations,2013-09,COMPLETED,INTERVENTIONAL,['NA'],GLP-1 concentrations
9673,NCT05065372,Glomerular filtration rate,Insulin sensitivity,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE1'],
9674,NCT00174824,level recoded integer ETDRS retinopathy scale,the incidence of hypoglycemia,2001-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
9675,NCT05472597,Incidence of metabolic syndrome,,2022-11-29,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
9676,NCT01167881,The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment.,The Change in Diastolic Blood Pressure (DBP) From Baseline After 52 Weeks of Treatment.,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
9677,NCT01923181,Change in HbA1c (Glycosylated Haemoglobin),Number of Confirmed Hypoglycaemic Episodes Recorded,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
9678,NCT03715582,peak values of troponin and CKMB after PCI,occurrence of death,2018-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
9679,NCT01690169,Number of treatment emergent adverse events (TEAEs),"tmax, the time to maximum plasma concentration of NNC0113-0987",2012-09-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
9680,NCT00479986,"Short-term effect of Pioglitazone on Markers of vascular risk (MMP-9, hsCRP, monocyte activation)","Metabolic control (HbA1c, Glucose)",2005-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
9681,NCT00304733,wound surface area reduction,time to wound healing (days),2001-08,UNKNOWN,INTERVENTIONAL,['NA'],
9682,NCT01522157,P-Triglycerides,P-HDL-Cholesterol,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
9683,NCT00943501,Number and type of adverse events,Pharmacodynamics: Fasting Plasma Glucose (FPG) and insulin,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
9684,NCT01448070,"Area under the curve (glucose infusion rate (GIR)), 0-8h",Physical examinations and vital signs,2002-10-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
9685,NCT00975286,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,"Change From Baseline in Treatment Satisfaction Score (Sum of Items 1, 4, 5, 6, 7 and 8 of DTSQ) at Week 24",2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia
9686,NCT06214780,Change in time in range,Change in Percentage of time of varibles modes of automatization,2024-01-22,RECRUITING,OBSERVATIONAL,['NA'],
9687,NCT03626155,Mean 24-hour glucose,Respiratory Exchange Ratio (RER),2018-06-01,COMPLETED,INTERVENTIONAL,['NA'],
9688,NCT01497132,Beta cell function,Hypercalcemia,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
9689,NCT02518503,Number of participants with Incident type 2 diabetes,,2012-07,COMPLETED,OBSERVATIONAL,['NA'],
9690,NCT06003530,Treatment related adverse events,Wound healing,2022-01-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
9691,NCT04854135,To Determine the Feasibility of Initiating a Continuous Glucose Monitoring in Patients With Diabetes at Hospital Discharge,Mean Change in Self-efficacy at 3 Months,2021-04-13,TERMINATED,INTERVENTIONAL,['NA'],
9692,NCT03014011,Psychomotor Speed,,2017-06-13,COMPLETED,INTERVENTIONAL,['NA'],
9693,NCT05917587,blood flow response to insulin,Percentage of nitric oxide-dependent dilation,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
9694,NCT03156361,Glucose area under the curve,total units Insulin,2017-05-18,COMPLETED,INTERVENTIONAL,['PHASE2'],
9695,NCT03616171,Number of Participants Enrolled in the Intervention Arm Who Complete the Study,Number of Participants Extending Sleep,2017-08-30,COMPLETED,INTERVENTIONAL,['NA'],
9696,NCT01455727,Hgb A1c change,Taiwan Geriatric Depression Scale(GDS) Score change,2011-08,COMPLETED,INTERVENTIONAL,['NA'],
9697,NCT05518448,EGP,Plasma β-OHB,2022-05-03,RECRUITING,INTERVENTIONAL,['NA'],
9698,NCT02099838,Change of HbA1c From Baseline at Week 12,Change of LDL From Baseline at Week 12,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Change of DBil From Baseline at Week 12
9699,NCT01316094,changes in Hemoglobin A1c (HbA1c),"safety assessed by the incidence of adverse events, vital signs, laboratory tests and 12-lead ECGs",2011-01-18,COMPLETED,INTERVENTIONAL,['PHASE3'],
9700,NCT01753362,HbA1c,Glucose Concentrations,2012-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
9701,NCT01177813,Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 24 Weeks,Change From Baseline to Week 24 in Systolic and Diastolic Blood Pressure (SBP and DBP),2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Confirmed Hypoglycaemic Adverse Events
9702,NCT02759055,Predicted Annual Rate of Change in 10 Year Risk of Fatal or Nonfatal Heart Attack or Stroke,,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
9703,NCT06272851,comparison between choroidal thickness,,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
9704,NCT04291313,The prevalence of gestational diabetes (GDM),Prevalence of post partum hemorrhage > 500 ml,2020-06-08,UNKNOWN,INTERVENTIONAL,['NA'],
9705,NCT05962710,System Performance,,2023-01-27,TERMINATED,OBSERVATIONAL,['NA'],
9706,NCT01240837,Blood glucose concentrations,,2010-11,COMPLETED,INTERVENTIONAL,['NA'],
9707,NCT02604524,Time in range when using closed-loop compared with SAP.,Reduction of hypoglycemia episodes when using closed-loop,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
9708,NCT05205928,Percentage of time of plasma glucose levels spent in target range (semaglutide vs placebo),"Glucagon, C-peptide, Paracetamol absorption after mixed meal tolerance test (in first 15 participants)",2022-10-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
9709,NCT00309127,Death and/or ESRD defined as need for dialysis or plasma creatinine 500mmol/l,"Number of hospital admissions, total number of days of hospital stay and attendance at the Accident and Emergency Department",2003-05,COMPLETED,INTERVENTIONAL,['NA'],
9710,NCT03394157,excess weight loss,Resolution of diabetes,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
9711,NCT01520818,HbA1c (glycosylated haemoglobin A1c),Quality of Life (QoL) assessed via Diabetes Health Profile (DHP-2),2000-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
9712,NCT01951339,Changes From Baseline in 31P Measurement: pH,Change in (Non-invasively Measured) Deoxygenated Hemoglobin Concentration in the Vastus Lateralis During Exercise,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
9713,NCT04964128,"Percentage of Time in Range (Phase 2, Software Release Tag 2.0)",,2021-07-22,COMPLETED,INTERVENTIONAL,['NA'],
9714,NCT01477957,Energy metabolism,Insulin sensitivity,2012-09,RECRUITING,OBSERVATIONAL,['NA'],
9715,NCT03723772,"AUCI287,τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state",Positive cross-reactive anti-human insulin antibodies,2018-11-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
9716,NCT03103867,Time in glucose target,hypoglycaemia fear in patients and caregivers,2017-02-23,COMPLETED,INTERVENTIONAL,['NA'],
9717,NCT04626531,The Diabetes Quality of Life Scale,Website Analysis and Measurement Inventory,2016-01-10,COMPLETED,INTERVENTIONAL,['NA'],
9718,NCT00127634,To assess change in baseline to endpoint in HbA1c in type 1 diabetic patients.,To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to glycemic control as assessed by the 8-point self-monitored blood glucose profiles,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
9719,NCT01680328,Injection Pain (VAS mm),Estimated Mean Differences in the Volume of Backflow (uL) in the Thighs After Different Injection Volumes and Speeds as Compared to Needle Insertion,2012-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
9720,NCT00212641,Fasting Blood Glucose at 8 weeks,Pharmacodynamic parameters at all time points,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
9721,NCT05512624,Pill Count Medication Adherence,,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],Incidence of seizure
9722,NCT01519674,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Change From Baseline in Patient Reported Outcome by Use of the Treatment Related Impact Measure - Diabetes.,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
9723,NCT02789033,Biopsies,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
9724,NCT01286922,Insulin Sensitivity,Cardiorespiratory Fitness,2009-07,COMPLETED,INTERVENTIONAL,['NA'],
9725,NCT03862521,"Change in hormone (epinephrine, norepinephrine, glucagon) response to hypoglycemia",Change in lipid profile from baseline to 6 months,2018-08-01,COMPLETED,INTERVENTIONAL,['NA'],
9726,NCT03734107,Diabetes-related hospitalizations,,2018-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
9727,NCT00006192,,,2000-08,COMPLETED,OBSERVATIONAL,['NA'],
9728,NCT02239354,Change in C-peptide,,2014-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9729,NCT00717977,Glucose Variability Measure: Amplitude of Glycemic Excursions by Time of Day,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
9730,NCT03772964,"Ex Vivo Cytokine Response of Peripheral Blood Mononucleocytes (PBMC) to Inflammatory Stimuli Compared to Baseline, Throughout Exposure, and Following Exposure to Metformin.",Measure Biogenesis of PBMCs.,2019-01-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9731,NCT04763772,Step counts by Actigraphy.,,2021-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
9732,NCT02380521,Subclinical atherosclerosis (as measured by cIMT) in patients with T2DM treated with exenatide once weekly,Endothelial dysfunction (as measured by flow mediated dilation of brachial artery) in patients with T2DM treated with exenatide once weekly,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
9733,NCT02479022,Number of treatment-emergent adverse events,Area under the glucose infusion rate-time curve,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
9734,NCT02827630,Week 4 Change in Systolic Blood Pressure,Number of Treatment-Related Adverse Events,2015-05,COMPLETED,INTERVENTIONAL,['NA'],Provider Reported Outcomes: Results from a provider satisfaction [to DH] questionnaire administered at the end of using DH.
9735,NCT06296550,HbA1c,Diabetes Distress Scale,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
9736,NCT00979225,Rates of aggregate adherence by study group to all applicable pharmacotherapy rules during the study period.,Inpatient hospitalization rates.,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
9737,NCT02712632,HbA1c reduction.,,2016-06-20,COMPLETED,OBSERVATIONAL,['NA'],
9738,NCT00637338,"To describe the safety and tolerability of escalating, multiple, subcutaneously injected doses of PF-04603629 administered to subjects with T2DM.","To evaluate the effect of multiple, escalating, subcutaneously injected doses of PF-04603926 on additional exploratory efficacy biomarkers related to this drug's target in subjects with T2DM.",2008-04,TERMINATED,INTERVENTIONAL,['PHASE1'],
9739,NCT05977218,HbA1c (mmol/mol),Self-reported quality of life,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],24-hour dietary recall
9740,NCT00804232,Primary Outcome Measure: the child's metabolic control as shown in HbA1C,"Quality of life, Satisfaction with care, Family impact and family climate, psychological variables, parental absenteeism from work; time use which is conditional on the child's diabetes etc), formal health care utilisation",2008-01,UNKNOWN,INTERVENTIONAL,['NA'],
9741,NCT01487369,Antibody titre findings,HbA1c (glycosylated haemoglobin),2002-04,COMPLETED,OBSERVATIONAL,['NA'],
9742,NCT01548885,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) Across the Overall Tested Glucose Range,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) Across the Low Glucose Range (<70mg/dL),2012-03,COMPLETED,INTERVENTIONAL,['NA'],
9743,NCT04230694,Number of Hypoglycemia Events during hospitalization,Number of Hyperglycemia Events during hospitalization,2021-09-20,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
9744,NCT03287297,Blood Glucose Level,,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA'],
9745,NCT00053534,,,2003-01,COMPLETED,OBSERVATIONAL,['NA'],
9746,NCT02040038,Change in Physical Activity,Change in Lipid Levels,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
9747,NCT00367055,Median Change From Baseline in the Insulin Secretory Capacity After a 36-month Treatment,Mean Change From Baseline in Insulin Sensitivity Index at Months 18 and 36,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
9748,NCT01620437,"Cmax, maximum insulin aspart concentration",Adverse events,2003-11-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
9749,NCT01410292,glycemic control,measures of satiety and appetite,2011-03,UNKNOWN,INTERVENTIONAL,['NA'],
9750,NCT01508481,Incidence of diabetes,Insulin resistance,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
9751,NCT02620774,Tazobactam Tissue Penetration,Number of Participants With Adverse Events,2016-02-19,COMPLETED,INTERVENTIONAL,['PHASE1'],
9752,NCT02198846,change of HbA1c,Percent of patients who reach target goal of HbA1c (<7.0%),2014-06,UNKNOWN,INTERVENTIONAL,['NA'],
9753,NCT05694351,"Contextual appropriateness (questionnaire, 5-items Likert scale, higher score is best)",Well-being,2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],
9754,NCT04307797,Part B - Changes in absolute concentrations of PCr and ATP defined by AHA 17- segment territory as a measure of cardiac energy status (determined by 31P-MRS),Part A/B - gastric inhibitory polypeptide,2022-01-18,UNKNOWN,INTERVENTIONAL,['PHASE4'],
9755,NCT03627377,Hemoglobin A1c or HbA1c,Smoking - Change in Smoking through Recall,2018-12-28,UNKNOWN,INTERVENTIONAL,['NA'],
9756,NCT01309620,Markers of oxidative damage,Vascular indices,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
9757,NCT03880838,Diastolic Blood Pressure From One Year Before to One Year After Intervention,Five Years Before to Two Years After Intervention in Depressed Mood and Anhedonia as Assessed by the Patient Health Questionnaire-2 (PHQ-2) (Extended Time Frame),2019-06-20,COMPLETED,INTERVENTIONAL,['NA'],
9758,NCT00709475,"Incidence of serious adverse drug reactions, evaluated via number of major hypoglycaemic events",Fasting glucose level control compared to baseline as measured by FBG,2008-05,COMPLETED,OBSERVATIONAL,['NA'],
9759,NCT02330848,Diet Quality assessed using the Alternative Healthy Eating Index (AHEI),Physical Activity assessed by the International Physical Activity Questionnaire (IPAQ),2012-02,COMPLETED,INTERVENTIONAL,['NA'],
9760,NCT01215331,Glycemic control,Acceptability of the treatment,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
9761,NCT00480493,Worry,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
9762,NCT01889095,Number Of Hypoglycemic events,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
9763,NCT00592397,"Changes in microarray gene expression profiles in blood and subcutaneous abdominal fat tissue from healthy obese men, as a consequence of changes in dietary macro nutrient composition.",Time to stabilization of gene expression changes due to dietary intervention.,2006-03,COMPLETED,INTERVENTIONAL,['NA'],
9764,NCT03155412,Adipogenic capacity of preadipocytes,Lipid metabolism,2016-01,COMPLETED,OBSERVATIONAL,['NA'],
9765,NCT00664027,To determine the effects of RTA 402 on glomerular filtration rate (as estimated by the MDRD formula) when administered for 28 days at dose of 25 mg followed by a dose of 75 mg for another 28 days in patients with diabetic nephropathy (stratum 2).,To determine the safety and tolerability of RTA 402 when the dose is escalated after 28 days in patients with diabetic nephropathy from 25 mg to 75 mg and continued for another 28 consecutive days.,2008-04-30,COMPLETED,INTERVENTIONAL,['PHASE2'],
9766,NCT03871660,Hyperglycaemia,,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],
9767,NCT03419195,Change in muscular mitochondrial function,,2018-02-07,COMPLETED,INTERVENTIONAL,['NA'],
9768,NCT01141192,"Fasting glucose level before, mid-way through, and after the vitamin D3 supplement or placebo trial.",Serum 25-OH D levels in response to vitamin D3 supplement or placebo across a range of adiposity,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
9769,NCT03011008,Mean amplitude of glycemic excursions (MAGE),Life quality evaluation,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
9770,NCT01213212,"Glomerular Filtration Rate (GFR), absolute and percent change, at 6 months vs baseline.",Metabolic and inflammatory parameters.,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
9771,NCT01357304,Physical activity level,"Quality of life, measured using the EQ-5D questionnaire",2011-03,COMPLETED,INTERVENTIONAL,['NA'],
9772,NCT02491801,"Blood Glucose (Study 1, 2 and 3)",,2015-03,COMPLETED,INTERVENTIONAL,['NA'],"Food Intake Measured at 120 minutes (Study 1), and at 15 and 30 minutes (Study 3)"
9773,NCT03242031,cost of treatment,,2017-06-21,RECRUITING,INTERVENTIONAL,['NA'],
9774,NCT03980990,Lactic Acidosis,All cause mortality at hospital discharge,2019-06-17,UNKNOWN,INTERVENTIONAL,['PHASE4'],
9775,NCT06288555,The accuracy of the Ipswich touch test,,2023-12-21,COMPLETED,OBSERVATIONAL,['NA'],
9776,NCT05791968,Continuous glucose monitoring,Body composition (weight and body fat),2023-09,RECRUITING,INTERVENTIONAL,['NA'],
9777,NCT04658693,Functional Gait Assessment (FGA),Neuropathic Pain Syndrome Inventory (NPSI),2021-03-02,RECRUITING,INTERVENTIONAL,['NA'],
9778,NCT04164784,HbA1c,UCAR,2019-12-10,UNKNOWN,INTERVENTIONAL,['NA'],
9779,NCT05349916,Postprandial glycemic response,Postprandial insulin response,2021-12-07,COMPLETED,INTERVENTIONAL,['NA'],
9780,NCT05235672,GADA in serum of subjects with T2D,,2021-01-30,COMPLETED,OBSERVATIONAL,['NA'],
9781,NCT04109547,Change From Baseline in Glycosylated Haemoglobin (HbA1c),Number of Participants With Anti-semaglutide Binding Antibodies Cross Reacting With Native GLP-1,2019-10-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
9782,NCT01017523,Blood glucose control (hemoglobin AIc),Diabetes-related quality of life outcome (distress),2010-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
9783,NCT00643851,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Adjusted Mean Change From Baseline in Total Body Weight (kg) in Subjects With Baseline Body Mass Index (BMI) ≥ 27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF]),2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
9784,NCT04416204,Hepatic Glycogen Content and Rates of Gluconeogenesis in Subjects With Type 2 Diabetes,Rates of Gluconeogenesis in Healthy Subjects,2020-08-21,COMPLETED,INTERVENTIONAL,['NA'],
9785,NCT04347291,Change in Psychosocial Well-being (Patient Participants) Sustained Post-intervention Effect,Change in Support Burden (Support Person Participants) Sustained Post-intervention Effect,2020-04-28,COMPLETED,INTERVENTIONAL,['NA'],Change in Support Person Involvement Alignment (Support Person Participants - Outcome & Mediator)
9786,NCT00924105,Incidence of adverse events,Biological measures of glycemia and inflammation,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
9787,NCT03017703,Insulin sensitivity measured by a insulin clamp,Vascular function,2016-12-01,COMPLETED,INTERVENTIONAL,['NA'],
9788,NCT05643521,The primary outcome is the 1H-Magnetic Resonance Spectroscopy (MRS) determined liver TG content.,"Secondary outcomes are fasting and postprandial plasma glucose, insulin, and plasma TG concentrations after 2 days VLCD or LC compared with 2 days of eucaloric conventional diet.",2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Explorative outcomes
9789,NCT02229240,Change from baseline in glycosylated hemoglobin (HbA1c) at Week 26,"Assessment of clinical laboratory tests, lipids, vital signs, ECGs and physical examinations",2015-08,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
9790,NCT05676593,Rate of change in glycated hemoglobine at 3 months,Eating behavior questionnaire,2023-05-03,RECRUITING,INTERVENTIONAL,['NA'],
9791,NCT05838872,Accuracy Evaluation: The Degree of Agreement (%) of the Minuteful - Kidney Urine Analysis Test System as Compared to the Comparator Device,Usability Evaluation: User Performance Analysis,2021-12-09,COMPLETED,INTERVENTIONAL,['NA'],
9792,NCT00241956,,,2005-10,TERMINATED,OBSERVATIONAL,['NA'],
9793,NCT04485351,Compare glycated hemoglobin levels of patients with diabetes from the University Hospital of Nancy between the period preceding and following the lockdown related to the COVID-19 pandemic.,"Describe the proportion of patients who (1) was tested for SARS-CoV-2 by PCR, (2) developped COVID-19 confirmed by PCR and (3) was hospitalized due to the severity of COVID-19.",2020-07,UNKNOWN,OBSERVATIONAL,['NA'],
9794,NCT00505284,Mean Change in Average Pain Scores From Baseline at Each Study Week,Analysis of Rescue Analgesic Medication Use (Acetaminophen) During Double-Blind Dosing Period,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
9795,NCT01855087,Blood glucose level,,na,COMPLETED,OBSERVATIONAL,['NA'],
9796,NCT02669693,Post-prandial blood glucose concentration,,2015-12,COMPLETED,INTERVENTIONAL,['NA'],
9797,NCT03138616,Change in glucose metabolism,change in metabolism of calcium and phosphorus,2016-11-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
9798,NCT04398030,"The Primary Endpoint is the Rate of Decline (s) Over Wear Time (DOI, Day 3, Day 5, Day 7) of the Natural Logarithm of the Area Under the Glucose Infusion Rate Curve [ln (AUC0-300(GIR))].",Mean Differences (Within Treatments Over Time Between Day 0 and Day 7) in Time-to-50% (Late) Maximum Insulin Concentration [t50%(Late)],2020-07-17,COMPLETED,INTERVENTIONAL,['NA'],
9799,NCT02844153,Percentage of patients receiving metformin,occurrence of lactic acidosis,2014-03,UNKNOWN,OBSERVATIONAL,['NA'],
9800,NCT00542113,Diabetes knowledge and prevention of parents of elementary school children,Self-reported parental physical activity,2001-09,COMPLETED,INTERVENTIONAL,['NA'],
9801,NCT00856908,Clinically Relevant Change of Laboratory Variables,"S-C-Peptide (AUC0-24)/24, Change From Baseline to End of Treatment",2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
9802,NCT03531021,Adolescent Food Habits Checklist,Change in weight,2018-05-03,COMPLETED,INTERVENTIONAL,['NA'],
9803,NCT05694169,Primary Endpoints is as follows:,Second Secondary Endpoint,2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE1'],
9804,NCT03129581,Weight,Body composition,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],
9805,NCT04190212,Glucose variability,Changes in blood biomarker concentrations,2021-11-18,RECRUITING,INTERVENTIONAL,['NA'],Link between glucose variability and atrial fibrillation symptom severity
9806,NCT01957592,Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,2014-10,WITHDRAWN,OBSERVATIONAL,['NA'],
9807,NCT05277558,Executive Function,,2022-05-24,RECRUITING,OBSERVATIONAL,['NA'],
9808,NCT03447925,Measures of the sites with plantar keratosis,,2017-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
9809,NCT02082132,Frequency of MODY,Comparison of clinical and biochemical characteristics of other subtypes of diabetes,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],
9810,NCT06147245,Change in HbA1c (mmol/mol),Screening for diabetic nephropathy - Urine albumin (mg)/creatinine (g) ratio,2023-10-09,RECRUITING,INTERVENTIONAL,['NA'],Participants' acceptance of intervention
9811,NCT01055093,Change of insulin sensitivity (M-Value),Incidence of any diabetic complication,2005-09,RECRUITING,OBSERVATIONAL,['NA'],
9812,NCT00502710,Absolute change in hemoglobin A1c (HbA1c),"Adverse events (AEs), vital signs, laboratory parameters.",2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
9813,NCT05463237,24-28. Visceral Adipokine Levels in Pregnant Women with Gestational Diabetes Between Weeks,,2022-10-31,COMPLETED,OBSERVATIONAL,['NA'],
9814,NCT02060916,To evaluate the efficacy of the food supplement PAZ320 on post-prandial glucose excursion,Number of Subjects with Adverse Events as a Measure of Safety and Tolerability,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
9815,NCT03673111,Incidence of Treatment-Emergent Adverse Events (safety and tolerability),Body weight,2017-05-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
9816,NCT01718457,percent change in BMI,percent in Triglycerides levels,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],change in C-peptide levels
9817,NCT03509870,serious adverse events attributable to intervention,healing,2018-06-01,TERMINATED,INTERVENTIONAL,['PHASE1'],
9818,NCT02375139,Maximum of concentration (Cmax) of Evogliptin and Metformin,Area Under Curve(AUC)inf of Evogliptin and Metformin,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
9819,NCT00320060,,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
9820,NCT03571659,1. Decrease in number of leaking Mas on FFA 2. Decrease in diffuse leakage on FFA,,2014-12-22,COMPLETED,OBSERVATIONAL,['NA'],
9821,NCT02219750,HbA1c,total insulin dose,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4'],C peptide
9822,NCT03031886,energy expenditure,,2016-01-20,COMPLETED,INTERVENTIONAL,['NA'],Nitrogen production
9823,NCT00214565,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),Validate the Work Productivity and Activity Impairment-Diabetes Questionnaire (WPAI Diabetes) and the Diabetes Productivity Impairment Questionnaire (DPIQ) (US only).,2004-08,TERMINATED,INTERVENTIONAL,['PHASE3'],
9824,NCT01373814,cardiac function,lipidomics,2010-09-03,COMPLETED,OBSERVATIONAL,['NA'],
9825,NCT05306990,Mean Change from baseline in Low Density Lipoprotein Cholesterol (LDL-C),,2017-04-20,COMPLETED,INTERVENTIONAL,['NA'],
9826,NCT00762138,Assess the incidence of hematological immunologic other ae's association with the application of AutoloGel on exuding wounds such as leg ulcers pressure ulcers and diabetics ulcers and during the management of mechanically or surgically debrided wounds,Absence of coagulopathies caused by inhibitors to coagulation Factor V as determined by a significant prolongation of the (PT) time. Depletion of Factor V activity with a positive Bethesda Assay,2008-09,TERMINATED,INTERVENTIONAL,['NA'],
9827,NCT02696070,Changes in Small Nerve Fiber Density by Assessment of a Skin Biopsy Comparing Baseline to Day 60,,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
9828,NCT03204149,Safety,Wound Healing,2017-06-14,TERMINATED,INTERVENTIONAL,['NA'],
9829,NCT05711043,Proportion of subjects with a clinically relevant reduction of insulin dose after 12 months,Cost-effectiveness,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
9830,NCT02457897,Hemoglobin A1C,Muscle Glucose Uptake,2015-04-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
9831,NCT02513277,Plasma glucose,Depression,2013-02,COMPLETED,OBSERVATIONAL,['NA'],
9832,NCT01654341,Changes in summary ordinal score on the Short Physical Performance Battery test,Mortality,2013-12,COMPLETED,INTERVENTIONAL,['NA'],
9833,NCT05913726,Clinician preparation time,Clinician learning,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],
9834,NCT05800509,Number and percentage of participants with interventional health education as accessed by the medical record of their infants' body weight in kilograms.,,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
9835,NCT04786054,BED,NR3C1 Presence of variants of the GR gene (rs56149945; rs41423247),2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],
9836,NCT04303754,Postprandial blood glucose,Appetite,2020-06-24,COMPLETED,INTERVENTIONAL,['NA'],
9837,NCT00657995,the incidence of severe hypoglycemia (< 40 mg/dl) during the intensive care period following pancreatic resection in patients monitored using the artificial pancreas,the total amount of insulin required for glycemic control after pancreatic resection,2007-04,COMPLETED,INTERVENTIONAL,['NA'],
9838,NCT01460368,Part B: Mean Change From Baseline in 12-lead Electrocardiogram (ECG) Corrected QT Intervals (LY2409021),Part B: Mean Change From Baseline in 12-lead Electrocardiogram (ECG) Corrected QT Intervals (Moxifloxacin),2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
9839,NCT00860613,metabolic control,cost effectiveness,2004-02,COMPLETED,INTERVENTIONAL,['NA'],
9840,NCT00423488,"Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint, After 6 Weeks of Treatment",,2005-07-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
9841,NCT03003507,Glycemic Variability,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
9842,NCT01771614,Pancreatic endocrine function,Oxidative stress,2016-08,WITHDRAWN,INTERVENTIONAL,['NA'],
9843,NCT01907516,Compliance With Home Blood Glucose Reporting,Subject Satisfaction,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
9844,NCT02285881,"The between groups difference in the proportion of patients which achieve the treatment goals for HbA1c, blood pressure, and total cholesterol",The difference in coping style between baseline and 24 months within and between both groups as measured with the Diabetes Coping Measurement Questionnaire.,2012-03,COMPLETED,INTERVENTIONAL,['NA'],Process evaluation of the shared decision making ability of the general practitioners by using the Shared Decision Making Questionnaire.
9845,NCT01495975,Glycemic Control,Unplanned Readmission or ED Visit,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
9846,NCT02155855,hemoglobin A1c,Frequency of contact with diabetes care team,2014-12,COMPLETED,INTERVENTIONAL,['NA'],
9847,NCT02917031,Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV) Index Measured by Magnetic Resonance Imaging (MRI) at 24 Weeks,Number of Participants With Adverse Events,2017-01-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
9848,NCT04235829,Correlation between early % total weight loss and % total weight loss 7 years following surgery.,Reduction or cessation in the treatment for either type 2 diabetes mellitus and hypertension 7 years following surgery..,2012-04-01,COMPLETED,OBSERVATIONAL,['NA'],
9849,NCT02520336,Postpartum Diabetes screening in GDM patients,,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],
9850,NCT00287820,c-peptide,TD Scores,2004-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
9851,NCT02490553,airway obstruction,diabetes mellitus,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
9852,NCT06139133,Gestational diabetes mellitus with 75g OGTT,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
9853,NCT00320021,Change in Serum Creatinine from baseline to week 26,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
9854,NCT00097279,HbA1c,8-point plasma glucose profiles,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
9855,NCT02647736,Half life of Copeptin,,2012-09,COMPLETED,INTERVENTIONAL,['NA'],
9856,NCT01025999,Determine if the improvements in glycemic control occurring early after RYGB can be reversibly inactivated and activated through delivery or exclusion of nutrients in the bypassed proximal small intestine.,"To evaluate whether improvements in glucose control occurring early after RYGB are related to altered insulin secretion, insulin sensitivity, or both.",2010-01,COMPLETED,OBSERVATIONAL,['NA'],
9857,NCT05945862,Triglycerides,Lifestyle,2023-07-17,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
9858,NCT01708044,Incremental area under the concentration-time curve (AUC(0-3 h)) of plasma glucose concentrations for each treatment,Safety,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
9859,NCT05400694,Insulin,Food pleasantness,2021-10-01,COMPLETED,INTERVENTIONAL,['NA'],
9860,NCT04125160,HbA1c evaluated by the total mean glucose from continuous glucose monitoring,Hypoglycaemic events,2019-11-12,COMPLETED,OBSERVATIONAL,['NA'],
9861,NCT00308737,FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care,Change in Weight From Baseline at Month 24,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
9862,NCT02646878,24 hour calibration requirement,,2016-01,WITHDRAWN,INTERVENTIONAL,['NA'],
9863,NCT03799796,Time-in-Range,Online peer support engagement,2019-01-06,COMPLETED,INTERVENTIONAL,['NA'],
9864,NCT02120794,Overall Mean Change in A1C,"Mean Change in A1C From Baseline to 1 Year, Stratified by Different A1c Subgroups",2014-06,COMPLETED,INTERVENTIONAL,['NA'],
9865,NCT00642616,Change in Post-bronchodilator FEV1 From Baseline to Week 52,Change in HbA1C From Baseline to Week 52,2009-03,TERMINATED,INTERVENTIONAL,['PHASE3'],
9866,NCT05905575,Change in health-related quality of life,Change in blood pressure control,2023-06-09,RECRUITING,INTERVENTIONAL,['NA'],
9867,NCT01233063,Change in added sugar,,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
9868,NCT03904901,Anxety,BMI,2018-07-20,UNKNOWN,INTERVENTIONAL,['NA'],
9869,NCT04256720,Clustering of common lifestyle behaviours,Examine associations socio-demographic factors and lifestyle behaviours,2018-12-10,RECRUITING,OBSERVATIONAL,['NA'],
9870,NCT03426540,best corrected visual acuity,central retinal thickness,2017-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
9871,NCT02528162,Scale (1-4) with questionnaire on anxiety (six-item short form STAI),The frequency of an HbA1c ≥6.5%,2015-10,COMPLETED,OBSERVATIONAL,['NA'],
9872,NCT03707171,Changes of cognitive function assessed by cognitive function scale after 12 weeks.,Change of waist-to-hip ratio,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
9873,NCT04190693,Serious Adverse Events,,2019-02-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
9874,NCT03315780,Change From Baseline in Glucose Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC[0-4h]),Number of Participants Who Develop Hypoglycemic Events,2017-10-28,COMPLETED,INTERVENTIONAL,['PHASE4'],
9875,NCT00238862,Persistent corneal re-epithelialization (= lasting success),,2005-10,COMPLETED,INTERVENTIONAL,['NA'],
9876,NCT02356224,SHR3824 and its metabolites of concentrations to characterize SHR3824 harmacokinetics.,The number of patients with adverse events as a measure of safety and tolerability,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
9877,NCT05804513,Growth hormone area under the curve.,Aldosterone peak,2023-04-17,RECRUITING,INTERVENTIONAL,['PHASE4'],Heart rate
9878,NCT05375630,Grip Strength,Vitamin K status,2022-03-21,RECRUITING,INTERVENTIONAL,['NA'],
9879,NCT04004793,Incidence of patients with diabetes remission,Net change in Albuminuria,2020-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
9880,NCT02233140,Change in dynamic peak plantar pressure (sub-metatarsal 2) in barefoot walking from baseline to 4 weeks.,Change in dynamic peak plantar pressure (sub-metatarsal 2) in barefoot walking from 1 month to 3 months.,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],
9881,NCT01469715,Absolute Relative Difference (ARD),,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
9882,NCT06311799,Difference in WIC enrollment,RDN visit adherence,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
9883,NCT00572806,Blood glucose value,Hypoglycaemic episodes,2003-02-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
9884,NCT00596687,Mean Blood Glucose Concentration,# Participants With Hypoglycemic Events,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
9885,NCT03829982,Postprandial glucose (mg/dL),Core body temperature (CBT) and skin temperature,2018-07-13,COMPLETED,INTERVENTIONAL,['NA'],
9886,NCT05742373,Changes in sirtuin molecule tissue expression,Change in dietary nutritional intake,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],
9887,NCT01820871,fasting serum glucose and HbA1c,Lipid profile,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
9888,NCT01614769,Incremental Weighted Average Blood Glucose Concentration Over 3 Hours of Hypoglycemic Recovery,,2012-07-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
9889,NCT03871049,blood sugar,,2020-01-10,COMPLETED,INTERVENTIONAL,['NA'],
9890,NCT04505566,Severity of Diabetic Retinopathy (DR),Progression of Diabetic Macular Edema,2020-11-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
9891,NCT02817152,"Probing depth change from baseline to 30, 90, and 180 days through periodontal probing","Plaque index change from baseline to 30, 90, and 180 days through periodontal probing",2014-02,COMPLETED,INTERVENTIONAL,['NA'],Glycated hemoglobin
9892,NCT01278823,Test the effect of gastric bypass surgery on glycemic control in obese type 2 DM patients,Determine the effects of gastric bypass surgery on pancreatic beta cell function and incretin hormone secretion in obese type 2 dm patients,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
9893,NCT00000466,,,1987-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
9894,NCT04125082,Hypoglycemia,Quality of Life Questionnaires,2019-02-27,UNKNOWN,INTERVENTIONAL,['PHASE4'],
9895,NCT02099123,Major cardiovascular events,Revascularisation procedure,2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],New onset diabetes
9896,NCT02454153,Change in Continuous Glucose Monitoring System Standard Deviation,Change in Continuous Glucose Monitoring System Mean Glucose,2014-12,COMPLETED,INTERVENTIONAL,['NA'],
9897,NCT01131052,Mean of Weekly Fasting Blood Glucose Concentration,Mean of Glycosylated Hemoglobin (hbA1c),2011-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
9898,NCT02834078,Change in Glycated hemoglobin,Change in Body Mass Index,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
9899,NCT02664740,The relative reduction in wound surface area (%),The presence/absence of anti-phage antibodies in plasma samples,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9900,NCT03844646,Amount of Weight Lost (kg),Number of Participants Reporting at Least 5 Days of Moderate Physical Activity of 30 Minutes or More,2019-08-01,TERMINATED,INTERVENTIONAL,['NA'],
9901,NCT00058981,,,2002-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
9902,NCT01326130,Diabetes and Hypertension control,Effects on physician practice,2011-04,UNKNOWN,INTERVENTIONAL,['NA'],
9903,NCT02541734,Renal uptake as measured by uptake of 111In-exendin-4 on SPECT images and without co-infusion of Gelofusine.,Pancreas uptake as measured by uptake of 111In-exendin-4 on SPECT images,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9904,NCT01087203,Change From Baseline in Average Diabetic Peripheral Neuropathy (DPN) Pain Score at Week 16,Serum Nerve Growth Factor (NGF),2010-03-30,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Subcutaneous Doses of Study Medication
9905,NCT04915716,blood glucose concentration,blood glucose concentration,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA'],
9906,NCT01483651,Area Under the Curve for Glucose Above Baseline,,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
9907,NCT05280925,Change in body mass index from baseline (Week 0) to Week 24,"Ease of Use and Treatment Effectiveness Questionnaire, Likert scale",2022-07-20,RECRUITING,INTERVENTIONAL,['NA'],Change in delay discounting from baseline (Week 0) to Week 24
9908,NCT03756688,Penile Length Change Between Baseline and Month 6,Erectile Function Among Groups - Evaluating Change From Baseline to 6 Months.,2018-11-07,COMPLETED,INTERVENTIONAL,['NA'],
9909,NCT01336673,Proportion of patients who experience at least one gastrointestinal side effect,Change of Hemoglobin A1c level from baseline after at least 12 weeks of Glucophage XR® therapy,2011-06,TERMINATED,OBSERVATIONAL,['NA'],
9910,NCT04243850,measured glomerulair filtration rate (mGFR),proximal sodium excretion,2020-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
9911,NCT03594565,Difference in skin irritation before and after regular application of nsFP according to the modified Draize scale.,Change in glycated hemoglobin 6 months after nsFP use,2016-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
9912,NCT02444845,Number of patients with anemia secondary to CKD,Use of treatment modalities for the management of anemia secondary to CKD,2011-05,COMPLETED,OBSERVATIONAL,['NA'],
9913,NCT01517373,Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12,Number of Participants With Abnormal Laboratory Values,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
9914,NCT05923827,Change in HbA1c,Percentage of time <54 mg/dL,2023-09-11,RECRUITING,INTERVENTIONAL,['NA'],
9915,NCT04894344,blood pressure,Physical activity,2020-10-28,COMPLETED,INTERVENTIONAL,['NA'],
9916,NCT03110796,"% of Wound Area Regression (WAR), as a measure of efficacy",,2017-07-31,UNKNOWN,INTERVENTIONAL,['NA'],
9917,NCT03777956,Pain intensity,Use of escape medicine (paracetamol) during treatment period.,2019-01-15,TERMINATED,INTERVENTIONAL,['PHASE2'],
9918,NCT03405532,Renal O2 extraction,Renal blood flow,2018-01-11,SUSPENDED,OBSERVATIONAL,['NA'],
9919,NCT02516150,AOCGIR (Area Over the Curve for Glucose Infusion Rate),Maximum Change in GIR (Glucose Infusion Rate) From Baseline,2016-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
9920,NCT02087995,"The Percentage of Agreement of the Continuous Glucose Monitoring System Glucose Values Comparing to a Laboratory Reference, Yellow Sprint Instrument (YSI) Measurement.",,2013-12,COMPLETED,INTERVENTIONAL,['NA'],
9921,NCT04907110,Ex vivo muscle mitochondrial function,Exercise efficiency,2021-08-10,COMPLETED,INTERVENTIONAL,['NA'],
9922,NCT01486680,Remission of type 2 diabetes mellitus/ glycaemic control,Quality of Life,2011-09,COMPLETED,INTERVENTIONAL,['NA'],Weight loss (excess weight loss and actual weight loss)
9923,NCT00989898,The primary outcome measure is overnight glucose control as measured by plasma glucose concentration between midnight and 8:00 a.m. in the two Time Schedules (closed-loop control starting at 1800 or 2100).,,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
9924,NCT05714683,Number (Incidence) of adverse events (AEs),Dose of Rybelsus,2024-12-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
9925,NCT02365740,gastric emptying measure,postprandial glucose variability after double-wave insulin bolus,2014-11,UNKNOWN,INTERVENTIONAL,['NA'],
9926,NCT00387582,Prevention of vision loss at one year as evidenced by ETDRS visual acuity.,Reduction in retinal thickening based on Optical Coherence Tomography.,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
9927,NCT03447964,Comparison of plasma total ceramides concentration in type 2 diabetic patients versus type 1 diabetic patients.,- Correlation between sphingolipids species concentrations and macrovascular complications (cardiovascular disease history),2017-04-04,COMPLETED,OBSERVATIONAL,['NA'],
9928,NCT02497651,Postprandial response of glucagon-like peptide-1 (GLP-1),GLP-1 receptor expression in the skin,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
9929,NCT02310555,Remission diabetes mellitus type II,Adverse effects in the long term,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],
9930,NCT04877119,Predictive SFLT-1 / PLGF ratio cat-off point for preeclampsia,Correlation between SFLT-1 / PLGF ratio and placental histopathology,2019-10-14,UNKNOWN,OBSERVATIONAL,['NA'],
9931,NCT01368081,Number of Patients With Drug Related Adverse Events,Change From Baseline in HbA1c,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Confirmed Hypoglycaemic Adverse Events
9932,NCT02769091,Percentage of Participants with Adverse Events,Change from baseline in liver fibrosis measured using transient elastography (with Fibroscan),2016-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
9933,NCT01931631,Hemoglobin A1c,Beck Depression Inventory II (BDI-II),2014-01,SUSPENDED,INTERVENTIONAL,['NA'],
9934,NCT04431687,"AUCtau,ss of CKD-501, D759, D150","Vd,ss/F of CKD-501, D759, D150",2020-06-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
9935,NCT02462863,Improvement of type 2 diabetes,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA'],
9936,NCT01612520,the absolute change in HbA1c,,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
9937,NCT03675919,remission rate,outpatient costs,2018-09-15,COMPLETED,INTERVENTIONAL,['NA'],
9938,NCT04658082,difference between core lab and non invasive glucose measurements,,2020-10-07,COMPLETED,INTERVENTIONAL,['NA'],
9939,NCT00153023,"Change from baseline (Visit 6) in 24 hour proteinuria, after one year of treatment (study end) with telmisartan 80 mg versus valsartan 160 mg.","Change from baseline in BP endpoints (SBP, DBP and pulse pressure)",2003-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
9940,NCT04562025,Adverse Events,Change in HbA1c,2020-09-25,UNKNOWN,INTERVENTIONAL,['NA'],
9941,NCT00401089,SANS,BMI Body Mass index,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9942,NCT04570111,Adherence to the study diet,Infant weight,2021-01-22,TERMINATED,INTERVENTIONAL,['NA'],
9943,NCT00638313,"To evaluate the safety and tolerability of escalating, single subcutaneous doses of PF-04603629 administered to adult subjects with T2DM.",No secondary outcomes listed in the protocol.,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
9944,NCT00283842,Change in Mean Pain Severity Score From Baseline to 13 Weeks,Number of Patients With ≥50% Reduction in Mean Pain Severity Score.,2006-03,TERMINATED,INTERVENTIONAL,['PHASE3'],
9945,NCT03568409,"Improvement of the overall glycemic control after 6 months of treatment with ABO-GLYC, as a result of reduction of HbA1c and/or post-prandial glycemic peak.",Control of the glycemia.,2017-06-01,COMPLETED,INTERVENTIONAL,['NA'],
9946,NCT01771887,adhesion,Self-management behaviors,2013-02,COMPLETED,INTERVENTIONAL,['NA'],self-efficacy
9947,NCT03854695,Assess serum IgG titers,Characterize microbiology,2019-02-01,WITHDRAWN,OBSERVATIONAL,['NA'],Assess microbiome
9948,NCT04975022,GIRmax,tGIRmax,2019-12-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
9949,NCT01292798,Overall Mean Change in Visual Acuity Scores at Month 6 Compared to Baseline,Qualitative Assessment of Diabetic Macular Edema (DME),2011-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
9950,NCT02509065,Number of Subjects Discordant for Reaching a BG < 60 mg/dl for > 2 Consecutive Plasma Glucose Measurements During Inpatient Exercise Visit,Total Glucagon Dosing by the Bihormonal Bionic Pancreas From the Start of Exercise Until the End of the Visit,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
9951,NCT01598610,Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (<75mg/dL) or Within +/- 20% (>=75mg/dL) of Laboratory Glucose Method,Number of Subject Responses 'Strongly Agree' 'Agree' or 'Neutral' With Questionnaire Statements,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
9952,NCT00256646,"The primary outcome measure is to define these unique processes and to elucidate underlying biochemical, metabolic, and genetic determinants of vascular disease complications in diabetes.",,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
9953,NCT00855166,Adjusted Mean Change in Total Body Weight,Proportion of Participants With Body Weight Decrease ≥5%,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Adjusted Percent Change in Bone Mineral Density (BMD) at Total Hip
9954,NCT05174728,Placental mitochondrial function at delivery,Placental lipid metabolism,2017-07-20,SUSPENDED,OBSERVATIONAL,['NA'],
9955,NCT01963728,Change in Hemoglobin A1C (Glycosylated Hemoglobin),Mean Blood Glucose Values,2013-11-27,TERMINATED,INTERVENTIONAL,['PHASE4'],
9956,NCT03232034,Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min).,Blood pressure,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],
9957,NCT06054035,Change in albuminuria,Numbers of patients showing resolution of chronic kidney disease (CKD),2023-10-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Interaction between diabetes risk cluster and intervention for change in albuminuria
9958,NCT01224054,Food tolerance in patients submitted to bariatric surgery,,2008-07,COMPLETED,OBSERVATIONAL,['NA'],
9959,NCT04840446,Adhesiveness and survivability of the adhesives,Assess user preference or acceptance of the adhesives worn during the study,2021-02-08,COMPLETED,OBSERVATIONAL,['NA'],
9960,NCT01300260,Insulin Area Under the Curve (AUC) - Second Phase Response,Insulin Maximum Concentration (Cmax),2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Area Under the Insulin Concentration-time Curve (AUC)
9961,NCT04083456,Physical Activity,Self-Efficacy for Managing Chronic Disease,2019-11-01,RECRUITING,INTERVENTIONAL,['NA'],FitBit Use Adherence
9962,NCT04469790,Continuous glucose monitor measures,Cardiac autonomic nervous system measures,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],
9963,NCT03455816,Quality of life assessment: Diabetes Quality of Life (DQoL) questionnaire.,Scale of adherence to treatment in patients with diabetes type 1,2017-07-07,UNKNOWN,INTERVENTIONAL,['NA'],
9964,NCT01262898,Gastric Half Emptying Time (GEt1/2),"Change From Baseline in Whole Bowel Transit Time, 100 % Gastric Emptying Time (Truncated at 240 Minutes), Small Bowel Transit Time, Colonic Transit Time as Determined by Wireless Motility Capsule (WMC)",2011-05-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
9965,NCT05813249,NAFLD regression,Fibrosis regression,2023-02-15,COMPLETED,INTERVENTIONAL,['PHASE4'],
9966,NCT01346098,incidence of complications after pancreatic surgery,Incidence of endocrine and exocrine pancreatic insufficiency,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
9967,NCT03490318,"Sensitivity of the new pathway (ophthalmic grader pathway) in detecting active DMO/PDR, using the standard care pathway as the reference standard.","Proportions of patients unable to undergo imaging, with inadequate quality images or indeterminate findings.",2017-10-26,COMPLETED,OBSERVATIONAL,['NA'],
9968,NCT01584856,,,2006-05,UNKNOWN,OBSERVATIONAL,['NA'],
9969,NCT05248841,Maximum GIR (GIRmax),Number of subjects with adverse events (AEs),2022-03-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
9970,NCT04520191,Number of participants with problems in their health care due to COVID-19 related isolation,,2021-01-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
9971,NCT06220773,The change of HbA1c from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A+BR1019B-1+BR1019C-1,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
9972,NCT02004366,Differences in Glycemic Control,Outpatient Mortality,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
9973,NCT01897857,the compensatory changes in ulnar artery blood flow after radial artery cannulation,,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
9974,NCT01848379,Change from Baseline in Clinical Attachment Level (CAL) at 6 and 12 Months,Glycated Hemoglobin (HbA1c),2012-01,UNKNOWN,INTERVENTIONAL,['NA'],Cellular Immune responses
9975,NCT02055547,Average Concentration (Cave) of MK-8521 Corresponding to Slope of Insulin Secretion Rate/Glucose (ISR/G) During Graded Glucose Infusion (GGI) at Tmax After a Single Dose of MK-8521 (Part 3),Apparent Terminal Half-life (t1/2) for Plasma Concentration of Participants Treated With a Single Dose of MK-8521 (Part 3),2013-05-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
9976,NCT03794973,Treatment effect on log-transformed MMTT C-peptide area under the curve (AUC),Immunologic,2019-12-14,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
9977,NCT03240978,change of fasting glucose,rate of non-responsiveness in the alleviation of insulin resistance to exercise intervention,2016-09,SUSPENDED,INTERVENTIONAL,['NA'],
9978,NCT04621890,Change in A1C (ΔA1C90-day) from baseline visit (visit 1) to 90-day visit (visit 2),Change in health-related empowerment from baseline visit (visit 1) to 90-day visit (visit 2) and to 180-day visit (visit 3).,2022-02-14,RECRUITING,INTERVENTIONAL,['NA'],
9979,NCT02078440,Pharmacokinetics,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
9980,NCT04802395,SGLT2/ GLP1,,2021-03-02,RECRUITING,OBSERVATIONAL,['NA'],
9981,NCT03669536,Short Portable Mental Status Questionnaire (SPMSQ),,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA'],Anemia
9982,NCT00236600,The percent change in body weight from the enrollment visit to week 60.,"Change from baseline to week 60 in absolute change in body weight, body mass index, waist circumference, fasting lipid profile; safety evaluations over study.",2000-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
9983,NCT00627029,Medicare program expenditures,Claims-based and patient-reported quality of care,2000-09,UNKNOWN,INTERVENTIONAL,['NA'],
9984,NCT02910271,Prevalence of PAD in asymptomatic patients with T1DM assessed by ankle-branchial index.,Prevalence of asymptomatic atherosclerotic carotid disease in patients with asymptomatic PAD.,2016-05,COMPLETED,OBSERVATIONAL,['NA'],
9985,NCT05728567,Inflammatory factors,,2017-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
9986,NCT05373212,CmaxTOTAL,Local tolerability,2022-05-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
9987,NCT05442853,Time in target blood glucose range (BG 70-180mg/dL),Pain Score,2022-11-02,RECRUITING,INTERVENTIONAL,['NA'],
9988,NCT05737771,Cmax of DWC202213,,2023-01-25,RECRUITING,INTERVENTIONAL,['PHASE1'],
9989,NCT03494010,Duration of use of hybrid closed-loop (HCL) system,fasting glucose levels,2018-08-31,WITHDRAWN,OBSERVATIONAL,['NA'],
9990,NCT00848315,The primary outcome is improvement in metabolic control (HbA1c).,Efficacy of the intervention,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
9991,NCT00893685,"Health related quality of life as assessed by the SF-36 questionnaire, at the beginning, at midterm and at the end of the trial period",Number of permanent transfers to elderly homes,2009-05,UNKNOWN,INTERVENTIONAL,['NA'],
9992,NCT05729776,"TIR, TBR and TAR evaluation(glucose metrics by glucose sensor) after the consumption of pizza meal vs control meal","TIR, TBR and TAR evaluation(glucose metrics by glucose sensor) after ""Medtronic pizza management"" and""Tandem T slim pizza management""",2022-12-01,COMPLETED,OBSERVATIONAL,['NA'],
9993,NCT00985712,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Endpoint,30-Day Adjusted Rates of Self-Reported Hyperglycemic Episodes at Any Time From Baseline Through Week 24,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
9994,NCT01554644,Relative (%) area wound size change versus baseline in respondents to treatment following a 12-week treatment period,Change of clinical wound infection during treatment period,2012-03,WITHDRAWN,INTERVENTIONAL,['NA'],
9995,NCT06192108,Change from Baseline in Hemoglobin A1c: (HbA1c),Change from Baseline in Diabetes Treatment Satisfaction Questionnaire-Change (DTSQc) Scores,2024-01-10,RECRUITING,INTERVENTIONAL,['PHASE3'],
9996,NCT00596505,The changes of visual acuity,,2007-04,COMPLETED,OBSERVATIONAL,['NA'],
9997,NCT03796975,Change of liver enzyme after 24 weeks treatment as assessed by blood test,Change of weight and waistline after 24 weeks treatment as assessed by standard measurement,2018-06-28,COMPLETED,INTERVENTIONAL,['PHASE4'],
9998,NCT03816605,Expression of IRS-1 and GLUT-1 in different group,,2014-04,COMPLETED,OBSERVATIONAL,['NA'],
9999,NCT01399138,Change from Baseline in Systolic and Diastolic Blood Pressure at 6 weeks,Change from Baseline in insulin sensitivity at 6 weeks,2010-07,WITHDRAWN,INTERVENTIONAL,['NA'],
10000,NCT01759121,the probability of vitreous haemorrhage,change of ischemia area,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],
10001,NCT01569841,Average Time Within Glycaemic Target Range (Above 70 mg/dL and Below 130 mg/dL),Number of Treatment Emergent Confirmed Hypoglycaemic Episodes,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
10002,NCT00111540,Change in lipids from Visit 1 to each protocol visit,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
10003,NCT02370927,Insulin concentrations,Lactate concentration,2016-05,COMPLETED,INTERVENTIONAL,['NA'],
10004,NCT00715351,Body weight change,Changes in daily blood glucose values,2007-05,COMPLETED,OBSERVATIONAL,['NA'],
10005,NCT00447213,Change in HbA1c from baseline,Preference for the study therapies,2007-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10006,NCT06176443,Metabolic improvements of type 2 diabetes,Change of body mass index,2020-01-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
10007,NCT02565979,Change in Glucose Tolerance,Change in Quality of sleep,2016-04,COMPLETED,INTERVENTIONAL,['NA'],
10008,NCT06256497,Clinical effectiveness,,2023-06-27,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
10009,NCT01323322,"To disentangle the relationship between race, SES, and health outcomes.",,2009-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
10010,NCT02916589,"Changes in the extent of gingivitis, as determined by the severity of gingival bleeding, Before and after study procedures.","Change in levels of proinflammatory cytokines in serum and gingival fluid in relation to ginigival bleeding, Before and after study procedures.",2016-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10011,NCT01672762,Change in HbA1c,"Safety assessed by the incidence of adverse events, vital signs, lab-tests and 12-lead ECGs",2012-05-25,COMPLETED,INTERVENTIONAL,['PHASE3'],
10012,NCT00415428,,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
10013,NCT01947595,postprandial glycaemia (2h plasma glucose level of the 75 g oral glucose tolerance test (OGTT)),distribution of body fat confirmed by MR-Imaging and proton magnetic resonance spectroscopy by 3 T whole body imager,2012-03,COMPLETED,INTERVENTIONAL,['NA'],"metabolic and genetic characterization to determine the non-response to lifestyle intervention confirmed by case history, clinical examination, venous blood sampling, DNA isolation, standardised questionnaires,BIA, ergospirometry"
10014,NCT01822548,Absolute Change in the Endothelial Progenitor Cell (EPC) Number,Absolute Change in HbA1C Compared to Baseline,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
10015,NCT01179048,"Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)",Time From Randomisation to Each Individual Component of the Composite Microvascular Outcome and to the Retinopathy and Nephropathy Composite Outcomes Separately.,2010-08-31,COMPLETED,INTERVENTIONAL,['PHASE3'],
10016,NCT03540758,Endogenous glucose production (EGP),,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
10017,NCT02063048,Absolute weight loss in pounds,Patient Engagement Measures,2014-04,COMPLETED,INTERVENTIONAL,['NA'],
10018,NCT01425424,"Prediabetes, Prehypertension and Vitamin D supplementation- A practice based clinical intervention",,2012-04,TERMINATED,INTERVENTIONAL,['NA'],
10019,NCT06000462,"Inter-arms differences in mean BMI, waist circumference, waist hip ratio, body weight (kilogram, kg), Body fat (%), and Muscle mass (%)",Frequency of adverse event from dapagliflozin,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10020,NCT01597713,Number of adverse events,Area under the serum insulin concentration-time curve (Trial part 2),2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
10021,NCT00547482,Glycemic control as measured by HbA1c: Difference in mean reduction between Control and Treatment Groups will be evaluated.,Device/procedure-related adverse events;hypoglycemic events; Proportion of subjects with HbA1c less than 7.0;reduction of weight for both groups;improvement of glycemic control as measured by HbA1c,2007-09,TERMINATED,INTERVENTIONAL,['NA'],
10022,NCT05265312,Number of participants referred to Medical Nutrition Therapy,Number of participants who complete a follow-up PCP/team visit,2022-05-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
10023,NCT02636491,normal glucose level,glucose sensor readings,2015-12,COMPLETED,INTERVENTIONAL,['NA'],
10024,NCT01394952,"Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)",Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of First Hospitalization for Unstable Angina,2011-07-22,COMPLETED,INTERVENTIONAL,['PHASE3'],
10025,NCT01068041,Urinary Albumin/Creatinine Ratio (UACR),Urine Albumin Serum Creatinine and the estimated GFR (glomerular filtration rate) HbA1c,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
10026,NCT00905203,skeletal muscle oxygenation response,,2009-02,UNKNOWN,INTERVENTIONAL,['NA'],
10027,NCT04623151,5-item Foot Care Detection Behaviour Scale,,2017-08-16,COMPLETED,INTERVENTIONAL,['NA'],
10028,NCT02041832,First episode of atrial fibrillation,Correlation between echocardiographic parameters and incidence of atrial fibrillation,2013-10,COMPLETED,INTERVENTIONAL,['NA'],Correlation between biomarkers and incidence of atrial fibrillation
10029,NCT01804842,Rmax (0-24) of Plasma Glucose,,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10030,NCT03216460,Percentage of time in hyperglycemic range (defined as ≥ 250 mg/dL),Coefficient of variation,2019-02-04,COMPLETED,INTERVENTIONAL,['NA'],
10031,NCT03132129,Prevalence of early heart failure in type 2 diabetes,Remission of type 2 diabetes,2017-10-24,RECRUITING,OBSERVATIONAL,['NA'],
10032,NCT03197870,Percentage of Subjects With an Improvement in Study Eye Severity of Diabetic Retinopathy (DR) (ETDRS DR Severity Score or DRSS) of ≥ 2 Steps,Summary of Subjects Developing Center-involved DME or PDR or Worsening of >=2 Steps DRSS at Week 48 Based on Central Image Reading Center Evaluation,2017-06-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
10033,NCT03675165,Diabetes Symptomatology (assessed using the Diabetes Symptoms Checklist - Revised),,2018-08-28,COMPLETED,INTERVENTIONAL,['NA'],Diabetes Risk (calculated using the Canadian Diabetes Risk Questionnaire)
10034,NCT05566028,Change from baseline in HbA1c,Change from baseline in Fasting plasma glucose,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
10035,NCT00222924,To measure the functional capacity of mitochondria in skeletal muscle of those with T2DM and those at increased risk of developing T2DM,To assess whether exercise and diet can improve mitochondrial function and morphology.,2003-12,COMPLETED,INTERVENTIONAL,['NA'],
10036,NCT02220751,clinical attachment level,Salivary proteins levels,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Density loss
10037,NCT03070704,Incidence of treatment emergent Adverse Events (AEs),Number of patients withdrawn due to ineffective therapy,2017-08-16,WITHDRAWN,OBSERVATIONAL,['NA'],
10038,NCT05038176,A1c,,2022-02-12,COMPLETED,INTERVENTIONAL,['NA'],
10039,NCT00670722,HbA1c after switch from human insulin to modern insulin treatment,Number of adverse drug reactions (ADR),2008-01,COMPLETED,OBSERVATIONAL,['NA'],
10040,NCT01181830,Blood pressure,Inflammation,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
10041,NCT02285985,Change from baseline in the secretion of cytokines/adipokines by adipose tissue,change in reactive hyperemic index,2013-02,COMPLETED,INTERVENTIONAL,['PHASE4'],change in percent arteriole dilation
10042,NCT03234751,IV infusion of nesiritide at a 3pmol/kg rate,,2017-07-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
10043,NCT01771445,IL6,Copeptin,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
10044,NCT01757756,fasting HDL cholesterol,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
10045,NCT03390959,Gait,Plantar Sensitivity,2017-05-10,UNKNOWN,INTERVENTIONAL,['NA'],
10046,NCT02294110,sensorial loss with pin prick test,,2014-11,COMPLETED,OBSERVATIONAL,['NA'],
10047,NCT05504096,Risk prediction model of diabetes using PPG features on the wearables,Validate that in-ear and wrist-worn wearables both provide relative accurate heart rate and heart rate interval measurements.,2021-10-08,COMPLETED,INTERVENTIONAL,['NA'],
10048,NCT06056687,Matrix metalloproteinase 2 (MMP-2),,2023-03-01,COMPLETED,INTERVENTIONAL,['NA'],
10049,NCT05607810,Severity of ocular and non-ocular AEs,"Incidence of clinically significant findings via physical examinations, ocular examinations, imaging, and laboratory evaluation",2022-08-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
10050,NCT00969956,Time to retinopathy,Waistlines,2012-04,TERMINATED,OBSERVATIONAL,['NA'],
10051,NCT03236415,Percentage of uncovered struts at time of follow-up optical coherence tomography,Major adverse cardiac events,2017-08,WITHDRAWN,INTERVENTIONAL,['NA'],Subgroup analysis between 4 and 6 weeks
10052,NCT03893266,Collection of the needs of type 1 diabetic patients in therapeutic education in order to reconcile diabetes and work.,,2019-04-26,COMPLETED,OBSERVATIONAL,['NA'],
10053,NCT01184703,HbA1c,LDL-cholesterol,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
10054,NCT05579743,Proportion of participants who successfully complete a weekly wound scan,,2023-01-06,RECRUITING,INTERVENTIONAL,['NA'],
10055,NCT01040468,The primary objective of this study is to compare the rates of diabetes remission over one year.,"To examine the attitudes that patients, health care professionals, and insurance providers have toward the use of bariatric surgery to treat type 2 diabetes.",2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
10056,NCT00637273,Change in HbA1c From Baseline to Week 26,Assessment on Event Rate of Treatment-emergent Hypoglycemic Events,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
10057,NCT03458494,Glucose,CRP,2018-02-15,UNKNOWN,INTERVENTIONAL,['NA'],
10058,NCT02075567,Number of Participants with no Adverse Events as a Measure of Safety and Tolerability,Hormonal Response,2014-01,COMPLETED,INTERVENTIONAL,['NA'],Blood Lactate Concentration
10059,NCT05888454,HbA1c levels (%),Change in dose of pharmacological interventions for T2DM,2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],
10060,NCT02124408,change in glycated hemoglobin levels,control of diabetic complications,2013-11,UNKNOWN,INTERVENTIONAL,['NA'],
10061,NCT00910507,Stage of Exercise Behavior,,2007-09,COMPLETED,INTERVENTIONAL,['NA'],
10062,NCT00548782,decreased insulin secretion,,2007-09,COMPLETED,INTERVENTIONAL,['NA'],
10063,NCT03952130,Change From Baseline in Hemoglobin A1c (HbA1c),Percentage of Participants With HbA1c <7% and ≤6.5%,2019-05-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
10064,NCT01807221,Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90,Change From Baseline in EQ-5D-3L Questionnaire Scores at Specified Visits,2013-06-17,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline in Heart Rate at Specified Visits
10065,NCT05704309,Cognitive Diagnoses,White matter microstructure,2022-11-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
10066,NCT04964921,Determination of autonomic dysfunction by subject,Establish the absence of any relationship of autonomic dysfunction (AD) to any other vital signs parameters.,2021-12,UNKNOWN,OBSERVATIONAL,['NA'],
10067,NCT05960019,Change in HbA1c,Change in FBG,2024-01-17,RECRUITING,INTERVENTIONAL,['NA'],Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
10068,NCT00333853,Hemoglobin A1c (HbA1c),Measured hypoglycemia,2003-08,COMPLETED,INTERVENTIONAL,['NA'],
10069,NCT05854875,Change in glucagon levels,,2019-09-22,COMPLETED,INTERVENTIONAL,['NA'],
10070,NCT02066831,HbA1c,quality of life,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
10071,NCT05866406,Insulin sensitivity,Adipose tissue gene expression,2023-11-01,RECRUITING,INTERVENTIONAL,['NA'],
10072,NCT04592055,A1c,,2020-03-20,UNKNOWN,OBSERVATIONAL,['NA'],
10073,NCT03249974,Accuracy of Enlite sensor,skin reactions wih Enlite sensor,2017-07-05,COMPLETED,OBSERVATIONAL,['NA'],
10074,NCT03681704,ACR,,2018-11-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
10075,NCT03010241,"The clinical symptoms and signs of patients were recorded by Michigan Diabetic Neuropathy Score(MDNS), and the changes of Michigan Diabetic Neuropathy Score(MDNS) were compared between the two groups before and after medication",Clinical symptoms and signs change The clinical symptoms and signs of the patients were compared before and after taking the medicine.,2017-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
10076,NCT04087369,COPD control measure,Alcohol use,2019-12-01,WITHDRAWN,INTERVENTIONAL,['NA'],Projected scale cost(Maintenance)
10077,NCT03408678,Insulin sensitivity and secretion,Body fat distribution,2017-01-23,COMPLETED,OBSERVATIONAL,['NA'],
10078,NCT01403571,Weight,Fatty Acids (% composition),2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
10079,NCT04180332,Catalase estimation,Antioxidant estimation,2017-08-10,COMPLETED,INTERVENTIONAL,['NA'],
10080,NCT03730168,concentration of serum intereukin6,concentration of serum tumour necrosis factor,2018-05-13,COMPLETED,INTERVENTIONAL,['NA'],
10081,NCT03867500,Difference in incorporation of 13-palmitate and D9-palmitate into intramyocellular lipid intermediates between overnight saline control study and overnight/insulin clamp niacin infusion study.,Effects of niacin on adipocyte lipolysis proteins,2018-11-01,SUSPENDED,INTERVENTIONAL,['EARLY_PHASE1'],
10082,NCT05940376,time to epithelial healing,any adverse effect of topical insulin or need for amniotic membrane transplantation,2023-07-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
10083,NCT04792268,Number of wards and clinician end-users recruited to the study,Rates of communication with GP/CMHT regarding diabetes or dysglycaemia follow up,2022-05-01,COMPLETED,INTERVENTIONAL,['NA'],Assessment of the implementation of the eCDSS on inpatient ward settings
10084,NCT02019264,Time From Randomization to First Occurrence of MACE+,Change From Baseline in Echocardiographically-Determined Pulmonary Arterial Systolic Pressure,2014-01-24,COMPLETED,INTERVENTIONAL,['PHASE4'],
10085,NCT04876053,HbA1c,,2021-10-22,RECRUITING,INTERVENTIONAL,['NA'],
10086,NCT06331429,Change Social Skills (Baseline-Pre-Post),Change Resilience (Baseline-Pre-Post),2024-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Glycaemic control (Baseline-Pre-Post)
10087,NCT00930865,Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs,"Explore potential pharmacodynamic (serum/urine electrolytes) effects of bumetanide + dapagliflozin following multiple doses of 1 mg bumetanide + 10 mg dapagliflozin, administered together, either simultaneously or after adaptation to either agent alone",2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
10088,NCT01845870,determination of urinary albumin,determination of serum vitamin D metabolites,2012-02,COMPLETED,OBSERVATIONAL,['NA'],
10089,NCT02750930,Number of Participant With Positive Results of Anti-albiglutide Antibody Production Over Time,,2016-10-07,TERMINATED,INTERVENTIONAL,['PHASE4'],
10090,NCT00851019,Hemoglobin A1c change from baseline,All adverse events,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
10091,NCT05843019,P kortisol,,2023-04-12,RECRUITING,OBSERVATIONAL,['NA'],
10092,NCT00984841,Diabetes summary quality measure,,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
10093,NCT01571609,insulin secretion,Indirect calorimetry,2012-08,COMPLETED,INTERVENTIONAL,['NA'],
10094,NCT03334773,Hemoglobin A1c levels (HbA1c),Diabetes management self-efficacy,2017-01-16,COMPLETED,INTERVENTIONAL,['NA'],
10095,NCT01121172,Serum Apelin Levels,Frequency of G212A Polymorphism of Apelin Receptor in Obese Children and Adolescents,2010-05,COMPLETED,OBSERVATIONAL,['NA'],
10096,NCT00143247,Change in Carbon Monoxide Diffusing Capacity (mL/Min/mm Hg) by Time on Exubera Treatment,Number of Decliners in Carbon Monoxide Diffusing Capacity (ml/Min/mm Hg) by Duration of Exubera Treatment,2003-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
10097,NCT01957930,Ischemic Foot Ulcer,,1984-01,COMPLETED,INTERVENTIONAL,['NA'],Microvascular Endothelial Function
10098,NCT04303819,Plasma total bile acids in fasting state,Body mess index,2020-01-05,COMPLETED,OBSERVATIONAL,['NA'],
10099,NCT02108197,glucose tolerance,,2014-04,COMPLETED,INTERVENTIONAL,['NA'],
10100,NCT03473704,Depression symptoms,Another disease,2017-01-19,UNKNOWN,INTERVENTIONAL,['NA'],
10101,NCT00847730,Ease of Use Assessment,,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
10102,NCT02346175,Plasma glucose concentration of SHR3824,The number and type of adverse events reported,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
10103,NCT01637935,Incident Diagnosis of Bladder Cancer (10-year Analysis),Stage of Bladder Cancer (10 Year Analysis),2004-07,COMPLETED,OBSERVATIONAL,['NA'],
10104,NCT03658564,VAS,HOMA,2018-09-30,UNKNOWN,INTERVENTIONAL,['NA'],
10105,NCT01369823,The levels of HbA1c will be investigated on patients combining the pump therapy with continuous glucose monitoring over a period of three months.,To evaluate the % sensor usage,2009-06,UNKNOWN,OBSERVATIONAL,['NA'],
10106,NCT00845182,HbA1c,"Effect Pioglitazone, Exenatide, and Pioglitazone Plus Exenatide • Insulin Sensitivity • Inflammatory Cytokines • Glucagon and Free Fatty Acids • Plasma Lipids",2007-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
10107,NCT05036876,Change in mean daily blood glucose concentration in hospitalized patients,"Average blood glucose (mg/dL), percentage time in target, percentage time below target, and percentage time above target in a subgroup of study participants.",2021-10-10,COMPLETED,INTERVENTIONAL,['NA'],
10108,NCT00371800,HbA1c,Compliance,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10109,NCT06053177,"The prevalence of undiagnosed fatty liver disease with evidence of fibrosis, obstructive sleep apnoea and heart failure in people with type 2 diabetes and prediabetes",Multi-morbidity screening,2023-01-25,RECRUITING,OBSERVATIONAL,['NA'],
10110,NCT03914547,Parents Hypoglycemia Fear,,2019-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
10111,NCT01140893,Change from baseline to 6 months of centrally measured HbA1c,Change from baseline in mean blood glucose value,2010-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10112,NCT05469659,Urine albumin-to-creatinine ratio (UACR),Albuminuria class,2021-09-22,RECRUITING,INTERVENTIONAL,['PHASE2'],
10113,NCT00416741,,,2005-02,COMPLETED,OBSERVATIONAL,['NA'],
10114,NCT05666570,The reduction in wound size of the target wound between baseline and end of study,Rate of Device Related Adverse Events,2022-05-18,TERMINATED,OBSERVATIONAL,['NA'],
10115,NCT01498926,Maximum serum insulin concentration,Adverse events,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
10116,NCT05464784,Mean change from baseline in fasting serum triglyceride levels at Week 24,Mean change from baseline in lipids,2022-08-22,RECRUITING,INTERVENTIONAL,['PHASE2'],
10117,NCT01950650,Reasons for insulin omission/non-adherence reported by patient and physician,Impact of insulin treatment on life domains (patient survey),2010-03,COMPLETED,OBSERVATIONAL,['NA'],
10118,NCT00108485,Change in Proteinuria,,2005-04,TERMINATED,INTERVENTIONAL,['PHASE3'],
10119,NCT01156246,To assess the effect of food on the pharmacokinetics of dapagliflozin and metformin.,To examine the safety and tolerability of the fixed-dose combination tablet of dapagliflozin and metformin.,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
10120,NCT05424107,HbA1c levels,Decalogue of healthy eating,2018-09-04,COMPLETED,INTERVENTIONAL,['NA'],
10121,NCT05090202,Heart failure hospitalization.,,2022-12-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
10122,NCT00318422,HbA1c,"Glycemic control parameters (fasting plasma glucose, -glucose profiles)",2006-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
10123,NCT00922376,Blood sugar levels (HbA1c),Self management,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
10124,NCT03666117,Prevalence of Hepatomegaly in children and adolescents,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
10125,NCT00065559,,,2003-04,TERMINATED,INTERVENTIONAL,['NA'],
10126,NCT00436475,"Chang in Disposition Index, a Measure of Beta Cell Function",Change in Hemoglobin A1c,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10127,NCT04949867,Percentage of time with glucose values < 3.9 mmol/l as measured by the continuous glucose monitor,Sleep efficiency measured by ActiGraph GT9X Link,2021-05-20,COMPLETED,INTERVENTIONAL,['PHASE4'],
10128,NCT00118560,maximal exercise times on treadmill and calf ergometer,,2005-06,COMPLETED,INTERVENTIONAL,['NA'],
10129,NCT05350514,"Standardized uptake value ratio for cerebral to cerebellar comparison in young adults with Type 1 diabetes, Type 2 diabetes, and young adults without diabetes","Atlas based region of interest fractional anisotropy in young adults with Type 1 diabetes, Type 2 diabetes, and young adults without diabetes",2022-07-19,COMPLETED,OBSERVATIONAL,['NA'],
10130,NCT02940158,Postprandial Blood Insulin,,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
10131,NCT03330054,Frequency Of Eye problems In Type 2 Diabetes with Chronic Kidney Disease,,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA'],
10132,NCT02832999,Insulin sentivity,body weight,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Inflammation
10133,NCT05305287,Effect of pioglitazone on hepatic mitochondrial TCA cycle fluxes,Effect of pioglitazone on hepatic gene regulatory networks,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
10134,NCT05266625,Adverse Events,Adverse Events,2022-02-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
10135,NCT05488119,Tracking people who complete the study,Changes in diabetes technology usage,2025-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
10136,NCT02721602,Acceptability of the intervention measured via family feedback indicating at least 90% approve of the sessions on post-intervention surveys.,Blood glucose control in parent with Type 2 diabetes,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
10137,NCT03246295,Urinary samples were analyzed,Urinary samples were analyzed,2015-10-20,UNKNOWN,OBSERVATIONAL,['NA'],
10138,NCT04120974,Change in Glycemic Control,Change in Blood Glucose Levels,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],Effect on Behaviour: Injection in Lipohypertrophy Areas
10139,NCT01324011,Change in body weight,Change in psychosocial factors,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
10140,NCT03793283,Concentration of Hemoglobin A1C (HbA1C).,Safety related adverse events.,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],
10141,NCT03971955,Blood collection,,2019-07-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
10142,NCT05528393,PRL,OGTT,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],
10143,NCT05628259,Diabetes Self-Management Scale,Triglyceride,2023-02-01,COMPLETED,INTERVENTIONAL,['NA'],
10144,NCT02020343,Meal triglyceride (TG) absorption,,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
10145,NCT00101673,Change from baseline in HbA1c at 12 weeks,Change from baseline in body weight at 12 weeks,2004-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
10146,NCT02971241,Young students survey,,2015-10,COMPLETED,INTERVENTIONAL,['NA'],
10147,NCT02961088,Global measures of adiposity with established clinical relevance - body weight,Measures of adiposity by established imaging techniques - visceral adipose tissue [VAT],2016-08,UNKNOWN,OBSERVATIONAL,['NA'],
10148,NCT05932966,Comparison of glycemic control obtained under closed loop according to the system used: SG versus CIQ,daily insulin dose,2023-07-06,RECRUITING,OBSERVATIONAL,['NA'],
10149,NCT05361148,Pancreas exocrine function,abnormal prior pro-insulin/insulin ratio and diabetes (subset),2021-10-12,RECRUITING,OBSERVATIONAL,['NA'],
10150,NCT03642470,HbA1c,psychological health (Child Behavior),2018-06-05,COMPLETED,OBSERVATIONAL,['NA'],
10151,NCT00884013,percent of patients eligible for quality measures (ABCS),use of EHR clinical reminders,2009-01,COMPLETED,OBSERVATIONAL,['NA'],
10152,NCT03121508,The Diabetes Self-Management Questionnaire,,2017-04-24,WITHDRAWN,INTERVENTIONAL,['NA'],
10153,NCT06262854,The composite primary endpoint of this study will be the incidence osteomyelitis recurrence or new osteomyelitis in adjacent sites or tissue infection at the site of osteomyelitis.,Direct medical costs,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
10154,NCT01171976,Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12,EuroQoL (EQ-5D) Thermometer Score: Change From Baseline at Month 12 and Month 24,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
10155,NCT00458016,Fasting Plasma Glucose Concentration,"Fasting serum triglycerides and free fatty acids, fasting serum insulin.",2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
10156,NCT04324684,rate of recovery,organ failure,2020-03-31,COMPLETED,OBSERVATIONAL,['NA'],
10157,NCT04541797,Cut-off value for myocardial perfusion index to predict ≥10% increase in myocardial blood flow as result of empagliflozin.,Improvement in exercise tolerance through performing a cardiopulmonary exercise test.,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],
10158,NCT02462421,Change in Fractional Excretion of Uric Acid (the Difference Between Data After Administration of Canagliflozin Minus Data Before Administration of Canagliflozin),Canagliflozin-induced Change in Fasting Plasma Glucose,2015-06-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
10159,NCT00921011,vessel wall changes over time that precede plaque buildup,development of cardiovascular disease,2009-05,COMPLETED,OBSERVATIONAL,['NA'],
10160,NCT00539851,,,2005-11,COMPLETED,OBSERVATIONAL,['NA'],
10161,NCT01760447,Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-54,Percentage of Participants Initiating Insulin Glargine During Weeks 20-54,2011-12-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Baseline A1C
10162,NCT02867254,Sample collection from the periodontal pocket,,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
10163,NCT01150617,Reduction of restenosis after peripheral angioplasty,Identification of new peripheral markers predictive of restenosis,2008-12,TERMINATED,INTERVENTIONAL,['PHASE4'],
10164,NCT02298803,Change in Corrected QT Interval During Day Time Hypoglycaemia,deltaQTc,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
10165,NCT03713684,Change From Baseline to Week 30 in HbA1c,Number of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year,2018-11-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
10166,NCT01390259,Hypoglycemic Events,Mean Glucose,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
10167,NCT02137512,"Time Spent <70 mg/dL - Main Phase, Night Only","Time Spent >300 mg/dL - Main Phase, Day Only",2014-08,COMPLETED,INTERVENTIONAL,['NA'],Reported Serious Adverse Events - Extension Phase
10168,NCT00998712,endothelial function,,2009-08,UNKNOWN,OBSERVATIONAL,['NA'],
10169,NCT04160156,Glucose Standard Deviation (mmol/L),,2018-06-05,COMPLETED,OBSERVATIONAL,['NA'],
10170,NCT02861144,Change of HbA1c,,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
10171,NCT05584293,Real world data from medical devices and clinical outcome in a registry,,2020-09-11,RECRUITING,OBSERVATIONAL,['NA'],
10172,NCT06309082,H-CEUS score,,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
10173,NCT05148130,blood biochemistry indices,,2018-09-11,UNKNOWN,OBSERVATIONAL,['NA'],
10174,NCT00005130,,,1984-01,COMPLETED,OBSERVATIONAL,['NA'],
10175,NCT05473364,Preservation of Serum Potassium,,2023-03-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10176,NCT01336738,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Percentage of Participants With Greater Than or Equal to (>=) 1% or >= 2% Body Weight Loss From Baseline,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
10177,NCT03500640,Change in bodyweight,Change in physical function,2018-03-27,COMPLETED,INTERVENTIONAL,['NA'],Change in mood
10178,NCT03481218,Personality traits associated with diabetes management,Differences in quality of life based on glycaemic control,2018-01-30,COMPLETED,OBSERVATIONAL,['NA'],
10179,NCT05251506,glycated hemoglobin level,success rate of measurement of blood glucose by laser lancing device,2021-08-10,UNKNOWN,INTERVENTIONAL,['NA'],
10180,NCT01549600,fasting serum glucose,,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
10181,NCT01669616,To compare the accuracy of SCOUT DS versus random capillary glucose and several diabetes risk assessment questionnaires for detection of HbA1c-defined dysglycemia.,,2012-08,COMPLETED,OBSERVATIONAL,['NA'],
10182,NCT01383356,Area Under the Curve 0 to Last Measurable Value (AUC0-t),Area Under the Curve 0 to Inf (AUC0-inf),2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
10183,NCT06312553,Acceptability,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
10184,NCT01425580,Left ventricle longitudinal function and/or functional reserve during rest and/or after exercise using tissue Doppler echocardiography,Global LV function (echocardiography) expressed as ejection fraction (EF),2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
10185,NCT02629497,platelet reactivity,Oxylipin production,2015-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
10186,NCT04456465,moderate and severe pain (VAS score ≥4),Anxiety screening/assessment: GAD-7 scale,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],
10187,NCT01990469,Change of HbAlc from baseline at Week 24,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
10188,NCT03950219,HbA1c,,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA'],
10189,NCT00157339,"To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c.",To explore the impact of Human Insulin Inhalation Powder on peak flow and peak flow variability in the study with asthma patients.,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
10190,NCT03674957,Bone mineral density,"Early life health conditions from linked administrative health records, from the Manitoba Population Healthy Research Data Repository",2016-03,TERMINATED,OBSERVATIONAL,['NA'],
10191,NCT05939921,To assess the effect of metformin on Pancreatic fat and hepatic fat in T2DM patients.,,2022-05-01,COMPLETED,INTERVENTIONAL,['NA'],
10192,NCT01581658,Maximum Concentration,,2012-04-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
10193,NCT02741037,Longitudinal % change in body weight,Longitudinal change in mother-daughter processes of mutual influence,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
10194,NCT01286350,Hemoglobin A1c,Health-related quality of life,2014-05,COMPLETED,INTERVENTIONAL,['NA'],Cost of intervention delivery
10195,NCT06269107,Change in glycated haemoglobin (HbA1c),Number of severe hypoglycaemic episodes (level 3),2024-02-15,RECRUITING,INTERVENTIONAL,['PHASE3'],
10196,NCT00666861,,,2008-04,TERMINATED,OBSERVATIONAL,['NA'],
10197,NCT02407626,Biomarker NT-proBNP,"Expression of TNF/IL1beta and microRNA (miR144, miR125b, miR208a)",2015-09,TERMINATED,INTERVENTIONAL,['NA'],
10198,NCT03514420,Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27),Number of Participants With Treatment-emergent Adverse Events (TEAEs),2018-06-15,COMPLETED,INTERVENTIONAL,['PHASE2'],
10199,NCT05174052,The effect of Dapagliflozin on change in burden of atrial fibrillation,Effect of Dapagliflozin on change in AF Effect on Quality of Life Survey,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Effect of Dapagliflozin on change in Validated Echocardiographic Indices & Biomarkers of Atrial Myopathy
10200,NCT04902807,Generate a diagnosis and therapeutic-decision tools,3- Ancillary study (pilot study),2021-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
10201,NCT01653210,High Blood Glucose Index (HBGI),Glycemic Changes During Luteal Phase,2012-08,COMPLETED,OBSERVATIONAL,['NA'],
10202,NCT02092896,Change from baseline in gastric emptying rate,Change from baseline in hypoglycemic symptom score,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Frequency of Hypoglycemic episodes
10203,NCT01901926,"Change in HbA1C levels from base line at 3, 6 and 9 months",Periodontal Pocket Depth,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],C-Reactive Protein
10204,NCT02954016,The proportion of subjects affected by serious adverse device effects (SADEs) as defined by International Standards Organization (ISO) standard 14155:2011.,12 Month Weight Loss in Kilograms,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],
10205,NCT02793154,Part B: Assessment of Nausea by VAS Score,Part B: Number of Par. With Nausea AEs Presenting Outside the Timing of the WLT and GCSI-DD,2016-09-26,TERMINATED,INTERVENTIONAL,['PHASE4'],
10206,NCT02580877,Change in mIAA Autoantibody Titer From Baseline,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
10207,NCT06312579,Gait speed,Community mobility,2024-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
10208,NCT01638351,Maximal muscle strength,Muscle oxygenation,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
10209,NCT04060732,Severe hypoglycemia rate,Feasibility of the device,2017-05-05,COMPLETED,OBSERVATIONAL,['NA'],
10210,NCT04287179,Change in glycosylated haemoglobin (HbA1c),Number of treatment emergent adverse events (TEAEs),2020-03-09,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
10211,NCT05752955,Decrease anaemia prevalence in women,Dysglycaemia after a pregnancy affected by GDM,2022-06-06,RECRUITING,INTERVENTIONAL,['NA'],Cost of care
10212,NCT01155518,Insulin Resistance,,2010-06,TERMINATED,INTERVENTIONAL,['PHASE2'],
10213,NCT04278417,Change from Baseline in BCVA,Proportion of subjects with center-involved DME up to Week 96,2020-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
10214,NCT05457192,Glycosylated Hemoglobin (HbA1c) level,Spatiotemporal gait parameters,2022-07,RECRUITING,OBSERVATIONAL,['NA'],
10215,NCT04203823,Percentage of Time in Euglycemia - Cohort C,,2020-07-20,COMPLETED,INTERVENTIONAL,['NA'],
10216,NCT00567398,Change From the Baseline Value in HbA1c at Month 3 and 6,Change From Baseline of Left Ventricular (LV) Ejection Fraction as Determined by MRI at Month 6,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
10217,NCT02689765,Change in fasting glucose and HbA1C,Calculated pancreatic β-cell function and insulin resistance,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
10218,NCT05590858,pericoronary Fat attenuation index (FAI),level of pro-inflammatory cytokines such as IL-2 and IL-6.,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],
10219,NCT01424306,Fasting Plasma Interleukin-6 on Day 9 of Each Diet Period,Adipose Tissue Inflammation - Tissue Expression of IFN-gamma mRNA,2011-10,COMPLETED,INTERVENTIONAL,['NA'],
10220,NCT05199714,Each participant's percentage of time glucose levels spent in the target range,Total bolus insulin delivery for each participant,2022-02-21,COMPLETED,INTERVENTIONAL,['NA'],Safety Endpoints
10221,NCT02123732,Change in HbA1C concentrations and fasting glucose levels,,2014-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10222,NCT04205942,change in microbial load,treatment related side effects - proliferative skin reaction,2016-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],treatment related side effects - proliferative skin reaction
10223,NCT03361098,Differences in neuronal activity in the central reward and satiety circuits in response to food-related stimuli by BOLD fMRI signal,Laboratory parameters,2017-09-18,COMPLETED,INTERVENTIONAL,['PHASE4'],Exploratory: Microbiome
10224,NCT00005193,,,1986-09,COMPLETED,OBSERVATIONAL,['NA'],
10225,NCT04008836,Number of Participants With Accurate BGMS Fingerstick Results,Number of Participants With Accurate BGMS Venous Blood Results,2019-06-10,COMPLETED,INTERVENTIONAL,['NA'],
10226,NCT00327210,Feasibility,Improved knowledge,2005-05,COMPLETED,INTERVENTIONAL,['NA'],
10227,NCT03047278,Pharmacokinetic parameter (AUC),Pharmacokinetic parameter (Elimination half-life),2015-11-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
10228,NCT02305862,To evaluate whether 26 weeks of treatment with 5/20mg rosuvastatin results in regression of carotid atherosclerotic plaques as measured by CE-MRI,To evaluate the change from baseline in creatine kinase at 26 weeks,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],
10229,NCT06287437,Percent Change in Body Weight from 24 weeks,Energy intake at 24 weeks,2024-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Change of body weight at 24 weeksl from baseline
10230,NCT03341299,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC),Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Curve,2017-11-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
10231,NCT00404950,,,2005-07,COMPLETED,OBSERVATIONAL,['NA'],
10232,NCT02794155,Change in HbA1c,Mean Mixed Meal Tolerance Test,2016-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
10233,NCT02950142,Appropriateness,Laboratory test volume,2017-12-01,COMPLETED,INTERVENTIONAL,['NA'],Downstream or cascade clinical activities
10234,NCT01889446,Post prandial insulin levels,,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],
10235,NCT04746781,4 weeks of engagement in the Diabetes prevention program,Changes in Risk perceptions,2021-02-17,COMPLETED,INTERVENTIONAL,['NA'],
10236,NCT04729023,Best correct visual acuity,Working delay time,2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],
10237,NCT05317845,Proportion of patients with Established Atherosclerotic Cardiovascular Disease (eASCVD) pooled across all countries and separately for each country in scope,Proportion of T2D patients with high risk of Atherosclerotic cardiovascular disease (ASCVD) and without eASCVD,2022-04-21,COMPLETED,OBSERVATIONAL,['NA'],
10238,NCT00005134,,,1988-09,COMPLETED,OBSERVATIONAL,['NA'],
10239,NCT00138593,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
10240,NCT04281992,Incidence of Wound Closure,Incidence of bacteria distribution,2020-01-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10241,NCT01536613,Change in body weight,Occurrence of adverse events (non-serious and serious),2004-09,COMPLETED,OBSERVATIONAL,['NA'],
10242,NCT05094505,Changes from pre- to pos intervention on glycated haemoglobin,Changes from pre- to pos intervention in angiogenesis,2021-10-01,COMPLETED,INTERVENTIONAL,['NA'],Changes from pre- to pos intervention on lipid profile
10243,NCT00666172,"Measure endothelial function determined by brachial artery reactivity to stress, at baseline/following 6m program participation comparison of change between subj randomized to exercise with weight-loss intervention vs. those randomized to exerci...",,2008-04-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
10244,NCT02808715,"Number of participants with deleterious mutations in the PRDM-16 locus, using standard genomic methods",,2014-05,COMPLETED,OBSERVATIONAL,['NA'],
10245,NCT01813773,Incidence and severity of adverse events of intravitreal aflibercept injection in the treatment of PDR.,Proportion of subjects with avoidance of vitrectomy,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10246,NCT05713058,Glycemic control,Body weight loss,2019-03-01,COMPLETED,INTERVENTIONAL,['NA'],Beta cell function
10247,NCT05767372,Evaluation of oxygen saturation (SPO2) and heart rate (HR),Evaluation of forced expiratory volume at one second (FEV1) and maximum voluntary ventilation (MVV),2023-03-01,COMPLETED,INTERVENTIONAL,['NA'],
10248,NCT00069056,,,2003-09-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
10249,NCT01353118,"Composite of Fasting Glucose, Glycosylated Haemoglobin c and Rates of Type 2 Diabetes Mellitus Remission.",A Composite of Microvascular Complications,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
10250,NCT02611596,hsCRP,prevalence of hs cTnT > 99th percentile,2016-11,WITHDRAWN,INTERVENTIONAL,['NA'],
10251,NCT00006159,,,1994-03,COMPLETED,INTERVENTIONAL,['NA'],
10252,NCT04388228,percentage registered diagnoses of DM 2 in the EHR,percentage registered diagnoses of heart failure,2022-01-30,WITHDRAWN,INTERVENTIONAL,['NA'],Diabetes follow-up quality indicator
10253,NCT04245982,histological tissue evaluation,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],
10254,NCT01364350,effects of TODAY treatment assignment on long-term glycemic control,microvascular complications,2011-03,COMPLETED,OBSERVATIONAL,['NA'],
10255,NCT00006432,,,2000-01,COMPLETED,INTERVENTIONAL,['NA'],
10256,NCT00387166,"Stress, psychosocial risk and resilient factors, socio-cultural factors, and bio-behavioral markers of cardiovascular risk",,2006-10,COMPLETED,OBSERVATIONAL,['NA'],
10257,NCT00784433,Glycemic control,CVD status,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
10258,NCT02753803,AUC,,2016-07-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
10259,NCT04031599,Relative decrease in glucose levels during exercise compared to pre-breakfast levels (sub-study),Mean time (minutes) to the first hypoglycemic event (sub-study),2020-07-10,COMPLETED,INTERVENTIONAL,['NA'],
10260,NCT02348099,Presence of Subclinical Lipohypertrophy,,2015-03,UNKNOWN,OBSERVATIONAL,['NA'],
10261,NCT02501772,urinary spot albumin creatine excretion ratio (UACR) change,,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],
10262,NCT03312764,HbA1c reduction,Decreased cardiovascular risk,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],Implementation Context
10263,NCT04149067,0.5% in Hb1Ac and 1.5 kg in body weight,Evaluate the security of the treatment,2017-06-05,COMPLETED,OBSERVATIONAL,['NA'],
10264,NCT02412774,Weight loss,HA1C,2015-04,COMPLETED,INTERVENTIONAL,['NA'],
10265,NCT00758069,Change From Baseline in 24-hour Weighted Mean Plasma Glucose,Change From Baseline in Plasma Glucose,2005-07-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
10266,NCT02112721,Follow up Insulin Sensitivity Measure using Euglycaemic glucose clamp,Follow up Acute Insulin Secretory Response- Intravenous Glucose Tolerance Test,2014-05,COMPLETED,INTERVENTIONAL,['PHASE4'],Follow Up Pain Impact Questionnaire (PIQ-6 questionnaire)
10267,NCT03442595,Percent Change in A1C,Composite of Risk for Hospitalizations and Emergency Room Visits Within 90 Days From Baseline,2016-07-01,COMPLETED,OBSERVATIONAL,['NA'],
10268,NCT01454700,difference in change in urine albumine excretion from baseline to end of study (12 months),difference in carotid intima media thickness (CIMT),2011-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
10269,NCT01664650,homeostasis model assessment for insulin resistance (HOMA-IR),Adverse events,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10270,NCT05644548,Vascular density of the retina,the foveal avascular zone (FAZ) size of the retina,2022-03-01,RECRUITING,OBSERVATIONAL,['NA'],
10271,NCT03959865,HbA1c,Persistence,2018-12-19,UNKNOWN,OBSERVATIONAL,['NA'],
10272,NCT04760626,Change in HbA1c (glycated haemoglobin),"Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3)",2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
10273,NCT01305005,,,2011-03,COMPLETED,OBSERVATIONAL,['NA'],
10274,NCT03422471,Modified Oxford Method Assessment of Baroreflex Function,,2017-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
10275,NCT02783807,Clinical Evaluation of Retina Camera Images from both Healthy and Diseased Subjects,,2015-10,COMPLETED,INTERVENTIONAL,['NA'],
10276,NCT03977662,Incidence of Insulin independence,Beta cell function as assessed by Insulin-Modified Frequently-Sampled Intravenous Glucose ToleranceTest (FSIGT),2019-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10277,NCT00738140,To evaluate the effect of intensive lifestyle modification on insulin sensitivity in men receiving GnRH agonist therapy for prostate cancer.,To evaluate the effects of intensive lifestyle modification on other markers of cardiovascular disease risk.,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
10278,NCT01097681,Plasma concentration of ASP1941,"Safety assessed by adverse events, vital signs, laboratory tests and 12-lead ECGs",2010-02-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
10279,NCT00005745,,,1998-01,COMPLETED,OBSERVATIONAL,['NA'],
10280,NCT05477511,Rate of DM in the young adult offspring,"Rate of impaired glucose regulation, obesity and adiposity, hypertension and various insulin indices",2020-08-28,RECRUITING,OBSERVATIONAL,['NA'],
10281,NCT00714129,Stable isotopic and magnetic resonance measures to determine the changes in lipid and carbohydrate metabolism after dietary intervention,"DEXA, insulin sensitivity and energy expenditure changes due to dietary intervention",2007-09,COMPLETED,INTERVENTIONAL,['NA'],
10282,NCT00210262,rate of ACE inhibitor use in index patients,Rate of retinopathy screening in all patients,2002-10,COMPLETED,INTERVENTIONAL,['NA'],
10283,NCT05057403,3-point MACE incidence rate,Non-alcoholic fatty liver disease prevalence,2022-05-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
10284,NCT04217369,Time in Range,Laboratory HbA1c,2020-05-04,UNKNOWN,INTERVENTIONAL,['NA'],
10285,NCT01884545,Triglycerides,Social Isolation,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
10286,NCT03403582,Postprandial blood lipids,Postprandial inflammation,2014-12,COMPLETED,INTERVENTIONAL,['NA'],
10287,NCT05162014,Incidence Rate of Acute Pancreatitis,,2021-12-20,COMPLETED,OBSERVATIONAL,['NA'],
10288,NCT01117311,Disposition Index,Gastric Emptying Half-time,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
10289,NCT00770081,Assessment of treatment emergent adverse events (including hypoglycemia events and other events of special interest),To assess hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) reduction from baseline after 52 weeks of treatment,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
10290,NCT05437913,Change in Self-report psychological variables: interoceptive awareness (teens),Possible adverse effects,2021-09-06,UNKNOWN,INTERVENTIONAL,['NA'],
10291,NCT00590226,Mean AM BG (mg/dl),Number of Patients With Hypoglycemic Events,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
10292,NCT01472614,Reduction of A1c level,Adverse events,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
10293,NCT05486390,HbA1c,Healthcare cost,2023-02-17,RECRUITING,INTERVENTIONAL,['NA'],
10294,NCT01224886,Oxidative capacity,Physical fitness,2010-10,RECRUITING,INTERVENTIONAL,['NA'],
10295,NCT01357252,Change from baseline in HbA1c,Responder rates - proportion of subjects reaching predefined HbA1c targets,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
10296,NCT04881383,The sensitivity of the risk prediction function in detecting DM and pre-DM in primary care,Negative predictive value (NPV) of the risk prediction function in detecting DM and pre-DM in primary care,2020-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
10297,NCT00669864,Change in HbA1c (Glycosylated Haemoglobin A1c),"Hypoglycaemic Episodes, Diurnal/Nocturnal",2007-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
10298,NCT02003014,Number of Participants Reporting One or More Serious Adverse Drug Reactions,Change From Baseline Homeostasis Model Assessment of Insulin Resistance (HOMA-IR),2009-02,COMPLETED,OBSERVATIONAL,['NA'],
10299,NCT04257409,Fitness - senior fitness,Metabolism - myokines,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
10300,NCT00571506,determine if treatment with rosiglitazone or pioglitazone affects platelet function as assessed by spontaneous and agonist-induced platelet aggregation,"adipocytokine concentrations (adiponectin, leptin), hemostatic parameters (fibrinogen, plasminogen activator inhibitor-1), high-sensitivity C-reactive protein",2004-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
10301,NCT06292468,Spatiotemporal gait parameters,,2023-07-07,COMPLETED,INTERVENTIONAL,['NA'],
10302,NCT03594240,Change in plasma homocysteine,Change in HbA1c level,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
10303,NCT00760344,Change from baseline in glycosylated hemoglobin,Body weight.,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
10304,NCT03720912,Change in HbA1c Level,FoH-C Frequency of Help,2018-10-22,COMPLETED,INTERVENTIONAL,['NA'],
10305,NCT02105597,Change in self-reported medication adherence,Change in health status,2014-08,WITHDRAWN,INTERVENTIONAL,['NA'],
10306,NCT04390711,Carbamylated-HDL levels alteration between the control and the T2DM patients with and without concomitant CAD.,,2018-09-01,COMPLETED,OBSERVATIONAL,['NA'],
10307,NCT03698786,Plasma Acylated ghrelin concentration,Plasma Leptin concentration,2017-05-24,COMPLETED,OBSERVATIONAL,['NA'],
10308,NCT04157673,Prospective memory,Working Memory,2019-09-01,COMPLETED,INTERVENTIONAL,['NA'],
10309,NCT02299791,Patients Indicated for ACE/ARB and Statin Who Had an Active Prescription for Both,,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
10310,NCT03151837,Oral Glucose Tolerance Test,Hemoglobin(Hb),2017-05-10,COMPLETED,INTERVENTIONAL,['NA'],
10311,NCT02974816,Change in HbA1c from baseline,Number of hospitalizations(Change from baseline),2017-05-15,COMPLETED,INTERVENTIONAL,['NA'],
10312,NCT00910923,To assess the safety and tolerability of JNJ-38431055,"To assess the pharmacodynamic effects of JNJ-38431055 on plasma glucose and insulin, during a Meal Tolerance Test (MTT)",2008-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
10313,NCT00362128,Number of Participants With Hypertension,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
10314,NCT00284232,HbA1c %,Confidence in new instrument quality,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
10315,NCT02183558,Gestational Diabetes Mellitus,Anthropometric measures in offspring,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
10316,NCT00044707,To determine the effect of pramlintide on the PK of an oral medication,safety and tolerability as measured by analysis of laboratory values and adverse events,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
10317,NCT02144948,Decrease in HbA1c levels,change in gastrointestinal condition,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
10318,NCT01268345,blood glucose value,,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
10319,NCT00795015,Percent of blood glucose values in the target range 80-120 mg/dl,"Percent of patient days with a low blood glucose, defines as less than 60 mg/dl",2006-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
10320,NCT00699322,Glucose variability,"oxidative stress markers (oxidized LDL, N-carboxymethyl-lysine(CML), nitrotyrosine, 8-iso-prostaglandinF2α, 8-OhDG)",2008-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],
10321,NCT02929901,Hepatic steatosis,gut microbiota,2016-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10322,NCT02686476,Change in Liver Fat,subcutaneous fat,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
10323,NCT06000735,Blood glucose time-in-range (TIR),,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
10324,NCT03106870,Number of Participants With Glycemic Control Over Period From 20 Weeks to 36 Weeks Gestation,Number of Participants With Neonates Who Were Hypoglycemic,2016-06,COMPLETED,INTERVENTIONAL,['NA'],
10325,NCT03228459,Assessment of the impact of arterial ultrasound on cardiovascular events and mortality in a low/moderate cardiovascular risk population.,Association of spirometry alterations and cardiovascular events in a low/moderate cardiovascular risk population,2015-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
10326,NCT05626725,Change in blood glucose levels from start of exercise to nadir during or up to 30 min post exercise.,Total insulin delivery during (at least 15-min) of habitual PA and 30-min after,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],
10327,NCT00521105,"Medical outcomes: HbA1c, rates of severe hypoglycemia, rates of DKA","Associated costs to the family (time away from school and work, travel, etc)",2005-08,COMPLETED,INTERVENTIONAL,['NA'],
10328,NCT04904718,Change in glucose control with the use of DreaMed,,2021-12,WITHDRAWN,INTERVENTIONAL,['NA'],
10329,NCT05831085,The event rate of major adverse cardiac or cerebrovascular events,The number of anti-anginal medications used,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
10330,NCT03746769,"Proportion of subjects who are insulin independent, free from severe hypoglycemia and have HbA1c less than or equal to 6.5% (""complete response"")","Proportion of subjects who are free of severe hypoglycemic episodes (SHE) and have a HbA1c less than or equal to 7.0% (""partial response"").",2019-07-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Improvement in Personal Glycemic State (PGS) score calculated from continuous glucose monitoring
10331,NCT05914857,2h plasma glucose on an oral glucose tolerance test (OGTT),"Creatinine, calculated eGFR, and Albumin/Creatinine Ratio (ACR)",2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
10332,NCT01638299,Evaluation of the performance of the HHM system response to meal insulin while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.,Number of Safety Events and any additional information that can be used for product development,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
10333,NCT01487421,HbA1c (glycosylated haemoglobin),Adverse Drug Reactions (ADRs) including Serious Adverse Drug Reactions (SADRs),2003-07,COMPLETED,OBSERVATIONAL,['NA'],
10334,NCT02181244,glycosylated hemoglobin,plasma LDL cholesterol,2013-05,COMPLETED,INTERVENTIONAL,['NA'],tumor necrosis factor alpha
10335,NCT00446459,The Number of Subjects With a 10% Decrease in PRA Level at Month 8.,The Number of Transplants With a Negative Crossmatch at Transplant.,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
10336,NCT03951753,Change From Baseline in Total Clamp Disposition Index (cDI),Change From Baseline in Food Intake During Ad Libitum Meal,2019-06-28,COMPLETED,INTERVENTIONAL,['PHASE1'],
10337,NCT04901143,Time in range,,2021-07-17,COMPLETED,INTERVENTIONAL,['NA'],
10338,NCT01611935,Number of Blood Products Transfused,Total Number of Complications,2013-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
10339,NCT01082120,To evaluate the effect of AZD1656 on the steady state pharmacokinetics of Pioglitazone and vice versa by assessment of AUC (0-24) and Cmax.,"To evaluate the pharmacokinetics of the Pioglitazone metabolite hydroxyl pioglitazone, when pioglitazone is administered with and without AZD1656, by assessment of AUC(0-24), Cmax and tmax.",2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
10340,NCT00222521,Hemoglobin A1c,Quality of life survey,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
10341,NCT00600236,,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
10342,NCT02111967,Measurements of serum vitamin B12 and serum holotranscobalamin concentrations,Questionnaire results,2014-03,COMPLETED,OBSERVATIONAL,['NA'],
10343,NCT05184322,Number of treatment emergent adverse events (TEAEs),Incidence of anti-XW004 antibodies at end of study,2022-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
10344,NCT04660240,Rate of Target Lesion Failure (TLF),Technical Success,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],
10345,NCT01907854,Change in HbA1c (Glycosylated Haemoglobin),Number of Treatment Emergent Adverse Events (TEAEs),2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
10346,NCT02667769,Plasma glucose day- and night profiles,,2014-08,UNKNOWN,INTERVENTIONAL,['NA'],
10347,NCT04166760,Difference in iAUC for insulin between WHE and speWHE,continuous glucose measurement (CGM),2020-01-06,COMPLETED,INTERVENTIONAL,['NA'],
10348,NCT01671514,"Change from baseline in pre-specified biomarker levels in blood, skeletal muscle, and urine",,2012-07,COMPLETED,INTERVENTIONAL,['NA'],"Change from baseline in quality of life, health, and nutrition questionnaires"
10349,NCT02357420,Change From Baseline to Week 12 in Weekly Vomiting Episodes,Change From Baseline to Week 12 for Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-time,2015-01-29,COMPLETED,INTERVENTIONAL,['PHASE2'],
10350,NCT02836704,Percentage of patients with at least one episode of hypoglycemia,Number of severe hypoglycemic events,2016-09-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
10351,NCT05668507,Change in Diabetes Distress,Change in % Time in Range,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
10352,NCT03066440,Length of acidosis,Length of stay in the hospital,2018-09-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
10353,NCT00950313,Increase in response rates to invitation to 2nd stage blood test,Increase in yield of OGTT positive results through filtering of high risk participants that pass 1st and 2nd stage screens,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
10354,NCT05307731,"The changes of glycosylated hemoglobin, compared with baseline",any adverse events,2022-03-15,RECRUITING,INTERVENTIONAL,['PHASE4'],
10355,NCT01473017,Anxiety and/or depression in Type 2 Diabetes,Quality of life,2011-11,UNKNOWN,INTERVENTIONAL,['NA'],
10356,NCT01871207,Ocular concentration of Erythropoietin and VEGF.,,2011-05,COMPLETED,OBSERVATIONAL,['NA'],
10357,NCT01200849,Understanding of prescription medication,Change in HbA1c or blood pressure readings,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
10358,NCT00849537,Macula diameter,Diabetic retinopathy,2008-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10359,NCT03192475,Change in Bodyweight,Change in Mood,2013-01-28,COMPLETED,INTERVENTIONAL,['NA'],
10360,NCT00387972,Change from baseline in blood glucose regulation after 26 weeks of treatment,"Change from baseline in glycemic parameters, insulin, body weight and waist circumference, and safety measures",2006-05,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10361,NCT05702073,Change in HbA1c,Change in scores of diabetes treatment satisfaction questionnaire status version (DTSQs),2023-03-31,RECRUITING,INTERVENTIONAL,['PHASE3'],
10362,NCT03055702,Attendance Rate of the scheduled clinic appointment,,2016-11-01,UNKNOWN,INTERVENTIONAL,['NA'],
10363,NCT04052919,transthoracic echocardiography,Physical activity questionaire,2018-02-01,COMPLETED,INTERVENTIONAL,['NA'],
10364,NCT00573950,The effect on pulse wave velocity (PWV),"the effect on atherosclerotic and inflammatory markers such as adiponectin, hsCRP",2007-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
10365,NCT01855386,Percentage of patients with NAFLD and gestational diabetes.,"Insulin sensitivity expressed as the Matsuda Index, measured during an oral glucose tolerance test (OGTT).",2013-01,TERMINATED,OBSERVATIONAL,['NA'],
10366,NCT05550870,Cholesterol in mg/dl,,2022-01-24,COMPLETED,INTERVENTIONAL,['NA'],
10367,NCT00686634,Hemoglobin A1c (HbA1c) Change From Baseline,Number of Adverse Events,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
10368,NCT04608890,"Percentage of patients with a change in eye movement test in each class Resistance, Velocity, Pursuit, Wideness and OKN measured by the eye-tracking based test",Percentage of patients with a change in eye movement test in the Velocity class,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],
10369,NCT04948918,Change in estimated glomerular filtration rate renal function (eGFR),Change in peak linear blood flow velocity in the trunk and in segmental renal arteries,2020-09-20,COMPLETED,INTERVENTIONAL,['NA'],
10370,NCT04976881,Knowledge of reproductive risks,Folic acid use,2022-05-06,RECRUITING,INTERVENTIONAL,['NA'],
10371,NCT04690309,Metabolic control in patients treated with human insulin preparations insulin vs insulin analogues.,Metabolic control in patients treated with human insulin preparations insulin vs insulin analogues.,2018-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
10372,NCT05070949,Self-compassion,Stress and depressive symptoms,2021-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
10373,NCT01275027,HgA1c reduction,Diabetes medication,2011-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
10374,NCT05130463,Change from baseline in HbA1c after 24 weeks of treatment,Number of Participants with Final effectiveness evaluation,2022-03-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
10375,NCT06292000,Peripheral insulin sensitivity,Sleep outcomes,2024-02-01,RECRUITING,INTERVENTIONAL,['NA'],
10376,NCT01477034,Tumor Necrosis Factor alpha expression in adipose tissue,Fasting plasma lipopolysaccharide binding protein (LBP),2011-11,COMPLETED,INTERVENTIONAL,['NA'],
10377,NCT03323827,ANT Acetylation,,2016-11,UNKNOWN,OBSERVATIONAL,['NA'],
10378,NCT05303051,Assess the performance of the DNN score in different ethnicity and skin tones,Retrain the DNN algorithm,2023-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
10379,NCT00046150,Frequency of catheter occlusions,"Unexplained hyperglycemia, parameters of glycemic control",2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
10380,NCT00363519,tolerability,Plasma glucose,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
10381,NCT01289119,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Percentage of Participants With a Decrease in HbA1c ≥2.0%,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
10382,NCT03877406,HbA1c,Insulin resistance,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
10383,NCT00875394,Change From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24,,2007-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
10384,NCT01702883,The primary measure will be adherence as measured by pharmacy refills in each group.,,2012-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
10385,NCT04392570,To compare the serum osmolarities of patients with type 2 diabetes who are fasting for 17 hours and who are not fasting.,,2019-05-15,COMPLETED,OBSERVATIONAL,['NA'],
10386,NCT00420901,Endothelial function responders - Improvement in endothelial function,Changes in vascular inflammatory markers,1999-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
10387,NCT04007003,Change in Insulin Use,Change in Needle Re-Use,2018-06-26,TERMINATED,INTERVENTIONAL,['NA'],
10388,NCT03754608,Diagnostic Odds ratio for the MRI vascular cognitive impairment biomarker.,Correlation between the biomarker and cognition,2018-11-07,COMPLETED,OBSERVATIONAL,['NA'],
10389,NCT04534530,Cost-effectiveness analysis of routine screening for ischemic heart disease in T2DM patients,Budget impact analysis for Health Insurance of the most efficient strategy,2023-06-05,RECRUITING,OBSERVATIONAL,['NA'],
10390,NCT02117622,Incidence of adverse events (AEs) by preferred term,Incidence of confirmed hypoglycaemia,2015-07-24,COMPLETED,OBSERVATIONAL,['NA'],
10391,NCT01072578,Calculation of derivation of pharmacokinetic variables,To examine the safety and tolerability of the combination of dapagliflozin and metformin,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
10392,NCT03716141,Wound Healing,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],
10393,NCT05459519,Changes in rate of platelet aggregation,Number of Participants with safety endpoint,2022-07-20,RECRUITING,INTERVENTIONAL,['NA'],
10394,NCT01154244,insulin resistance assessed using HOMA-IR,proportion of obesity in patients,2009-09,COMPLETED,OBSERVATIONAL,['NA'],
10395,NCT00807651,Exogenous insulin dose,HbA1c level,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
10396,NCT01880242,Target Lesion Failure,Clinical Procedure Success,2014-05-13,COMPLETED,OBSERVATIONAL,['NA'],
10397,NCT01044368,The primary endpoint is the A1c level or the change in A1c level,"The secondary endpoints include severe hypoglycemia defined as requiring external aid, hospital admissions for any CVD related intervention, and adverse events such as unplanned hospitalizations for any cause that last more than 24 hours",2010-01,SUSPENDED,INTERVENTIONAL,['NA'],
10398,NCT00642915,Estimate the efficacy of combination therapy with Lantus plus Amarylin controlling blood glucose in Japanese patients with type 2 diabetes having failed oral antidiabetic drug therapy,Document the ability to preserve the endocrine pancreatic function with Lantus plus Amaryl combination therapy,2003-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
10399,NCT05377918,Anxiety,,2022-01-31,COMPLETED,INTERVENTIONAL,['NA'],
10400,NCT05225467,Blood ketone difference,Difference in ketone development between patient with and without diabetes mellitus.,2022-03-15,COMPLETED,OBSERVATIONAL,['NA'],Other
10401,NCT03642483,HbA1c,psychological health (Child Behavior),2018-06-05,COMPLETED,OBSERVATIONAL,['NA'],
10402,NCT05596383,Homeostatic Model Assessment for Insulin Resistance (HOMA-IR),fasting insulin,2022-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
10403,NCT01088711,Number of Participants Withdrawing From Study Therapy Due to an AE,Plasma Glucose Concentration,2010-03-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
10404,NCT02479516,Elevated HBA1c,Blood Pressure,2015-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Health Behaviour questionnaire
10405,NCT04242511,TB medication levels,,2021-05,UNKNOWN,OBSERVATIONAL,['NA'],
10406,NCT00101803,Change from baseline in HbA1c at 24 weeks,Patients with reduction in HbA1c >/= to 0.7% after 24 weeks,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
10407,NCT04878120,Low blood glucose index (LBGI),Total number and amount of carbohydrate administered as rescue treatments,2021-05-14,COMPLETED,INTERVENTIONAL,['NA'],
10408,NCT00936663,Fasting Blood Glucose,Hypoglycemia,2009-07-06,TERMINATED,INTERVENTIONAL,['PHASE4'],AUC for C Peptide
10409,NCT00327054,The primary end point for the trial is serum low-density lipoprotein (LDL) cholesterol concentration measured at six weeks after intervention.,Changes in serum creatinine after six weeks intervention,2006-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10410,NCT00232583,Beta-cell Function - C-peptide AUC (Area Under the Curve),Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment,2003-11,COMPLETED,INTERVENTIONAL,['NA'],
10411,NCT00530686,1)Presence or absence of hypoglycemic unawareness 2) To assess incidence of hypoglycemic episodes 3) To assess insulin requirements in patients who did not become insulin independent.,To assess the achievement of insulin independence at 12 month and 24 month post transplant in patients who underwent allo islet cell transplantation.,2008-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
10412,NCT01971554,Number of Participants Who Discontinued Study Drug Due to an AE,Change From Baseline in 24-Hour Weighted Mean Glucose (24h-WMG) at Day 15,2013-10-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
10413,NCT03621384,Association between BsmI Polymorphisms in Vitamin D Receptor Gene and Diabetic Kidney Disease,,2014-11,COMPLETED,OBSERVATIONAL,['NA'],
10414,NCT00841347,The influence of sleep extension on leptin level for the obese teens group.,"Study the correlation between delta waves activity and psychological, behavioural, anthropometric and physiological markers of obesity and its co morbidities",2009-02,COMPLETED,INTERVENTIONAL,['NA'],
10415,NCT01877213,Diabetes-related readmissions,Duration of rehospitalizations,2013-06,UNKNOWN,INTERVENTIONAL,['NA'],
10416,NCT03389100,18F-MK6240 standardized update value ratio (SUVR),,2018-07-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],
10417,NCT04326192,SUVmax,Ipsi- and contralateral BAT during SCS-activation,2021-02-19,RECRUITING,INTERVENTIONAL,['NA'],
10418,NCT00073294,,,na,WITHDRAWN,INTERVENTIONAL,['NA'],
10419,NCT02402439,Insulin independence,Incidence of adverse events,2016-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
10420,NCT01678235,Postprandial glycemia,Difference between the maximum and baseline glycemia,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],Questionnaire: Glycemic Index Knowledge
10421,NCT05504005,Consensus Error Grid (CEG) for venous plasma glucose and glucose values measured by mμSORS at each time point of OGTT.,Incidence of Treatment-Emergent Adverse Events,2022-08-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
10422,NCT02119819,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12,Change From Baseline in Insulin Levels,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
10423,NCT05099198,Time until failure to maintain metabolic control,HbA1C change from baseline,2018-09-01,COMPLETED,OBSERVATIONAL,['NA'],
10424,NCT02821026,"The proportion of subjects with HbA1c ≤ 6.5% at 1 year AND free of severe hypoglycemic events from Day 28 to Day 365, inclusive, after the islet transplant",The incidence of discontinuation of immunosuppression,2016-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10425,NCT05365425,Volume of carotid artery plaque,changes of gut microbiota,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
10426,NCT04657003,Percentage of Participants Who Achieve ≥5% Body Weight Reduction from Randomization,Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
10427,NCT00953498,Action of glitazone on the endothelium-dependent vasodilatory effects of HDL lipoproteins,Look for possible differences between pioglitazone and rosiglitazone for their effects on HDL lipoproteins and phospholipase A2,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
10428,NCT03542071,Child: Neonatal body fat%,Percentage of participants on GDM medication,2018-07-20,TERMINATED,INTERVENTIONAL,['NA'],
10429,NCT04705779,Change in Veggie Meter Score,Change in Glycosylated Hemoglobin,2021-05-20,RECRUITING,INTERVENTIONAL,['NA'],
10430,NCT01720719,Liver fat content(%),Muscle enzymes,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],
10431,NCT00292357,Healing velocity,,na,UNKNOWN,INTERVENTIONAL,['PHASE1'],
10432,NCT00500370,Change in Body Weight,Change in Glycosylated Hemoglobin (HbA1c),2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
10433,NCT00252772,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),Patient-reported outcomes: Well-Being Questionnaire (W BQ12),2004-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
10434,NCT06134934,Experiences with and acceptability of intervention design(s),Costs,2024-01-09,RECRUITING,INTERVENTIONAL,['NA'],
10435,NCT01310452,The change in liver fat content and visceral fat mass,Safety profile,2011-01,UNKNOWN,INTERVENTIONAL,['NA'],
10436,NCT00509925,"Total Energy Expenditure, Dietary Record Method","Hypoglycaemic Episodes, Diurnal/Nocturnal",2007-07,TERMINATED,INTERVENTIONAL,['PHASE4'],
10437,NCT04271189,Assess the T2DM remission rate in patients with newly diagnosed T2DM treated with either POLYCHEM or with SDC for 16 weeks.,Quantify the effects of either POLYCHEM or SDC on the main determinants of glucose regulation,2020-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10438,NCT03781232,Generation and validation of predictive models by Mean Absolute Relative Difference (MARD) measures,,2018-11-22,COMPLETED,INTERVENTIONAL,['NA'],
10439,NCT02054897,Change in HbA1c (Glycosylated Haemoglobin),Subjects Who Achieve (Yes/no):HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists Target,2014-02-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
10440,NCT02278913,Glycemic control,Mortality,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
10441,NCT01484353,HBAIC before and after intervention,Blood pressure,na,WITHDRAWN,INTERVENTIONAL,['NA'],
10442,NCT04508751,Fetal Liver PDFF,Maternal Hepatic Fat PDFF,2020-08-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
10443,NCT02461225,Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS),Change in Pain Rating on the Visual Analog Scale (VAS),2016-03-01,COMPLETED,INTERVENTIONAL,['NA'],
10444,NCT03812614,Change from baseline in patient glycemic control at 6 months,Change in self-efficacy of support person,2019-09-23,COMPLETED,INTERVENTIONAL,['NA'],Change in self-efficacy of support person
10445,NCT02088203,Levels of bioactive components from the Russian Tarragon Nutrasorb in the blood and urine,Glucose tolerance measured with an OGTT,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
10446,NCT04335396,presence of incresed non-HDL cholesterol level of the sera,Prevalence of polyneuropathy,2018-05-28,UNKNOWN,OBSERVATIONAL,['NA'],
10447,NCT05267457,Gestational diabetes mellitus,,2012-08-01,COMPLETED,OBSERVATIONAL,['NA'],
10448,NCT03706378,Insulin,,2017-08-18,COMPLETED,INTERVENTIONAL,['NA'],
10449,NCT05167513,Diabetes Quality of Life assessment using DQOL-13 questionnaire,Change from baseline in HbA1c % and fasting blood sugar FBS (mg/dl) to the last-observation on treatment,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
10450,NCT01128153,"Change in HbA1c From Baseline to Week 24, Last Observation Carried Forward (LOCF)","Proportion of Participants Achieving a Therapeutic Response: HbA1c Less Than 7% at Week 24, Last Observation Carried Forward (LOCF)",2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
10451,NCT01015937,,,2008-03,COMPLETED,INTERVENTIONAL,['NA'],
10452,NCT05918523,Primary Endpoint: Long-term safety of REACT,Third Secondary Endpoint: Time from first injection to renal transplant.,2023-12-11,RECRUITING,OBSERVATIONAL,['NA'],
10453,NCT04825639,Prevalence of Acute Kidney Injury in the sepsis and DKA cohorts,Compare chloride levels in the AKI and non AKI groups,2021-03-15,COMPLETED,OBSERVATIONAL,['NA'],
10454,NCT03012074,Number of participants with type II diabetes who adhere to using mobile technologies to self-monitor multiple types of diabetes-related data,Medication adherence Survey,2017-03-02,COMPLETED,INTERVENTIONAL,['NA'],"Explore health care providers' perspectives on using real-time data, by conducting one-time, individual interviews over a 2 month period."
10455,NCT03744039,Description Charcot foot's treatment,Register of Charcot foot,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],
10456,NCT02234440,Reduction of portal pressure,Safety profile of the drugs like Random Blood Sugar (RBS) and serum lactate monitoring regularly.,2014-09-01,COMPLETED,INTERVENTIONAL,['NA'],
10457,NCT03436875,Microbiota,,2023-01-01,WITHDRAWN,OBSERVATIONAL,['NA'],
10458,NCT01964612,self-monitoring and self-control scale,health anxiety scale,2012-07,UNKNOWN,OBSERVATIONAL,['NA'],
10459,NCT00097084,HbA1c,Insulin Treatment Satisfaction,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
10460,NCT01163006,fat oxidation,24h glucose pattern,2010-03,COMPLETED,INTERVENTIONAL,['NA'],
10461,NCT00651014,Percentage of patients reaching LDL-C goal of < 2.5 mmol/L (97 mg/dL) at endpoint.,"Safety/tolerability: adverse events, laboratory test results, vital signs.",2004-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
10462,NCT00706680,"Percentage of patients developing New Onset Diabetes post transplant, as identified by an oral glucose tolerance test",Incidence of acute rejection,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
10463,NCT04007107,Intensity of Injection Site Pain,,2019-06-27,COMPLETED,INTERVENTIONAL,['PHASE2'],
10464,NCT01804777,Blood Pressure,Hypertension,2013-03,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],
10465,NCT05995262,HbA1c levels,,2023-04-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
10466,NCT04505618,Correlation of Imaging,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA'],
10467,NCT04573296,Change in body weight,change in liver function tests,2020-02-26,COMPLETED,INTERVENTIONAL,['NA'],Vitadio usability for HCPs
10468,NCT06213896,To determine the accuracy of diagnosis with artificial intelligence algorithm,To determine the sensitivity and specificity of EyeCheckup v2.0 to detect retinal and optic disc diseases,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],
10469,NCT04638556,Nerve conduction velocity,,2019-09-03,UNKNOWN,OBSERVATIONAL,['NA'],
10470,NCT03552562,Total retinal blood flow (DVA and FDOCT),,2018-11-21,UNKNOWN,INTERVENTIONAL,['NA'],Autonomic and sensomotoric neuropathy measurements
10471,NCT00609102,Blood glucose,HbA1c levels,2008-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
10472,NCT02529969,Triglyceride,C-Reactive Protein,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10473,NCT05803473,Time in range,Recurrent hypoglycemic events,2023-04-11,RECRUITING,INTERVENTIONAL,['NA'],Questionnaires
10474,NCT01778751,Diabetes Control,Depressive Symptoms,2013-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
10475,NCT06321029,Feasibility of intervention and delivery modality,Diabetes Therapy-Related Quality of Life Questionnaire,2023-10-19,RECRUITING,INTERVENTIONAL,['NA'],
10476,NCT05766735,Change in Metformin at 13.5-months of follow-up,,2023-08-08,RECRUITING,INTERVENTIONAL,['NA'],
10477,NCT04243629,Time in target range,Number of hypoglycemia events,2021-11-12,RECRUITING,INTERVENTIONAL,['NA'],
10478,NCT00362323,TG / HDL-C ratio,Lipid and glycemic parameters,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
10479,NCT00563628,Retinal thickness after treatment,,2007-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
10480,NCT00140543,At 1 year:Incidence of biopsy-proven (kidney) rejection episodes.,* % of steroid free patients: at 6 months and 1 year.,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
10481,NCT05573685,To estimate the effect size for changes in pain experience (interference) in the Treatment App group compared to the Digital Control App group,To estimate the effect size for changes in confidence in dealing with chronic pain in the Treatment App group compared to the Digital Control App group,2022-10-10,COMPLETED,INTERVENTIONAL,['NA'],
10482,NCT00737633,Change in HbA1c From Baseline to Week 72,Percent Weight Change From Baseline to Week 72,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2'],
10483,NCT00921882,Oral glucose tolerance test,Acceptability of screening test,2008-06,COMPLETED,OBSERVATIONAL,['NA'],
10484,NCT00877968,Post-prandial glycemic response,"Appearance, taste, texture, smell and overall acceptability",2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
10485,NCT03026426,Proportion of participants with a reduction of 50% or more in the Patient Health Questionnaire (PHQ-9) score at the 3-month assessment,Proportion of participants who improve level of activity at the 3- and 6-month assessments,2017-01-24,COMPLETED,INTERVENTIONAL,['PHASE3'],
10486,NCT05608187,Compare incidence of serious adverse events (SAEs) between treatment groups,Presence of viable L. reuteri containing the pSIP_CXCL12 plasmid in wounds,2022-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],"Analysis of L. reuteri containing the pSIP_CXCL12 plasmid in blood, feces, and perilesional skin"
10487,NCT01049750,Evaluation of diabetic neuropathy in patients with erectile dysfunction,Glycemic control,2009-06,COMPLETED,OBSERVATIONAL,['NA'],
10488,NCT01964703,serum glucose (fasting and post 75g oral glucose tolerance test),serum insulin,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4'],"HOMA IR, QUICKI, HOMA beta, lipid profile, inflammatory markers"
10489,NCT04891887,Health related quality of life,Body weight,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
10490,NCT03635437,Adverse events possibly or probably related to GABA treatment,Change in diabetes treatment satisfaction questionnaire,2018-09-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10491,NCT02750527,number of familial hypercholesterolemia or pre-type-1-diabetes,,2016-09,COMPLETED,OBSERVATIONAL,['NA'],
10492,NCT05107154,Pediatric Quality of Life (PedsQL),Glycemic Control,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
10493,NCT05764200,24 hour intestinal gas concentrations,Urine metabolites,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
10494,NCT00262145,glucose and lipid uptake,lipid metabolism,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
10495,NCT03311802,fasting plasma glucose,,2015-03-11,COMPLETED,OBSERVATIONAL,['NA'],
10496,NCT01324557,Glycosylated hemoglobin (HbA1c) measurement,The frequency of hypoglycemic episodes,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
10497,NCT06065930,Fasting Neuropilin-1 concentration in subcutaneous interstitial fluid,Metabolites in urine including acylcarnitines measured by Mass Spectrometry,2023-05-05,RECRUITING,OBSERVATIONAL,['NA'],
10498,NCT01159353,Area under the plasma glucose concentration curve (AUC) between 0 and 1 hour after insulin injection AUC(0-1h),Hypoglycaemia and adverse events,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
10499,NCT02895139,Reduction of forefoot pressure to below safety threshold,Clinician confidence in orthotics service,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
10500,NCT01937416,Cell transplantation related side effect,Skin microcirculation measurement,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
10501,NCT05093517,Muscle Insulin sensitivity,,2021-11-10,SUSPENDED,INTERVENTIONAL,['EARLY_PHASE1'],
10502,NCT00701935,Percentage Change in Abdominal Visceral Fat From Baseline to 6 Months,Assessment of Event Rate of Treatment- Emergent Hypoglycemic Event,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2'],
10503,NCT00495885,change from baseline to 12 weeks for Sleep Maintenance Insomnia using patient reported Wake After Sleep Onset (pr-WASO),"Change from baseline to 12-week of ""General Productivity"" domain from Functional Outcomes of Sleep Questionnaire (FOSQ).",2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
10504,NCT06108076,Cardiac Efficiency after chronic dosing (Left-ventricular function),Patient Reported Outcomes Measure Information System (PROMIS) - Physical Function,2024-02,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
10505,NCT01576328,Primary objective of the study is to assess the safety and tolerability of MPC therapy,,2012-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10506,NCT04739241,Change in HbA1c levels,Change in the scores of the Diabetes Quality Of Life Questionnaire (EsDQOL) from recruitment to month 12.,2014-01-24,COMPLETED,INTERVENTIONAL,['PHASE4'],
10507,NCT01585454,Gestational Weight Gain,Complications of Pregnancy and Delivery,2012-03-27,WITHDRAWN,OBSERVATIONAL,['NA'],
10508,NCT02073227,Plasma concentration of metformin following administration of a single dose of study drug,Percentage of participants with adverse events as a measure of safety and tolerability,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
10509,NCT03904056,Fluorescein leakage area of active new vessels (FLA),Electroretinography,2014-01-01,COMPLETED,INTERVENTIONAL,['NA'],
10510,NCT05456477,Ratio of incremental area under the curve (iAUC) for C-peptide to iAUC for glucose,Interleukin-6,2022-10-07,COMPLETED,INTERVENTIONAL,['NA'],
10511,NCT03725917,Change in the integrity of the skin (Ulceration),Changes in the integral pressure-time,2019-03-25,UNKNOWN,INTERVENTIONAL,['NA'],
10512,NCT02250794,mean blood glucose for the duration of the hospital stay,frequency of hypoglycemia,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE4'],Acute kidney injury
10513,NCT00147836,"glycemic control, the improvement of β-cell l function and the remission rate after short intensive therapy in newly diagnosed type 2 diabetic patients","the effects of different interventions (oral anti-hyperglycemic agents, multiple daily injections and continuous subcutaneous insulin infusion) on glycemic control, β-cell function and the remission rate in newly-diagnosed type 2 diabetic patients",2004-09,COMPLETED,INTERVENTIONAL,['NA'],
10514,NCT05859958,Discharge disposition,,2022-11-10,COMPLETED,OBSERVATIONAL,['NA'],
10515,NCT04381598,Bio-marker (Ghrelin) levels in Gingival crevicular fluid.,Probing depth,2019-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
10516,NCT04011267,Change from Baseline of the Fuzzy classification of the diabetic neuropathy severity at 12-weeks,Quality Adjusted Life Years,2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],
10517,NCT02594748,Change from baseline in Audit of Diabetes Dependent Quality of Life at 3-month follow up.,Change from baseline in Blood sugar at 3-month follow up.,2015-07,SUSPENDED,INTERVENTIONAL,['NA'],
10518,NCT04151849,Urinary aldosterone at 3 months,Urinary aldosterone at 12 months,2019-11-07,COMPLETED,OBSERVATIONAL,['NA'],Ferritin
10519,NCT04663685,Participant experience,Number of adverse events,2020-10-05,UNKNOWN,INTERVENTIONAL,['NA'],
10520,NCT00399425,Stage in Wagner's classification,Quality of life,2001-06,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10521,NCT02877680,Acceptability - Number of Participants That Felt The Intervention Was Well-Received,"Parent-Adolescent Relationship Intervention Process Measure, Adolescent Report",2017-07-31,COMPLETED,INTERVENTIONAL,['NA'],
10522,NCT01489644,Fasting repaglinide and metformin Cmax (maximum drug concentration) following individual administration,Vital signs,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
10523,NCT02304588,Frequency of Adverse Events,Relative Wound Area Regression of 40% or More at 6 Week,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Reduced pain
10524,NCT05301816,Global impression of change in health status,,2022-07-05,RECRUITING,INTERVENTIONAL,['NA'],Device Safety
10525,NCT04185662,HbA1c,,2019-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
10526,NCT05787067,Evaluation of Participants' Insulin Injection Administration Skill Levels,,2021-12-30,COMPLETED,INTERVENTIONAL,['NA'],
10527,NCT00575588,Hemoglobin A1c (HbA1c) Change From Baseline to Week 52,Mean Slope of the Regressions of Change From Week 24 to Week 52 in HbA1c,2007-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Mean Slope of the Regressions of Change From Week 24 to Week 104 in HbA1c
10528,NCT04126759,Validation of predictive algorithms for determining blood glucose levels,Number of encountered Device Deficiencies,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],
10529,NCT01859494,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/-15mg/dL (<75mg/dL) or Within +/-20% (>=75mg/dL) of Laboratory Glucose Method,Number of Subject Responses That 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
10530,NCT04857398,Area under the serum insulin icodec concentration-time curve during one dosing interval at steady state,Terminal half-life for insulin icodec at steady state,2021-04-28,COMPLETED,INTERVENTIONAL,['PHASE1'],
10531,NCT02248779,insulin sensitivity,,2014-09-22,COMPLETED,OBSERVATIONAL,['NA'],
10532,NCT01581073,"Composite renal outcome of chronic dialysis, kidney transplantation, eGFR 6 mL/min/1.73m2 or less, or eGFR less than 50% of initial value.",Number of Participants with Adverse Events baseline,2012-02-16,COMPLETED,INTERVENTIONAL,['PHASE3'],
10533,NCT00111670,Absolute change from baseline in HbAlc\n\n,"AEs, vital signs, laboratory tests, body weight, waist/hip ratio, ECG\n",2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
10534,NCT01961388,The mean change in post-meal glucose levels from baseline at the end of observation period of up to 16 weeks,Incidence rate of adverse drug reactions in acarbose and metformin treated groups during 16 weeks observation period,2015-08,WITHDRAWN,OBSERVATIONAL,['NA'],
10535,NCT00384488,Weight loss,Reduction in progression to type 2 DM,2004-05,COMPLETED,INTERVENTIONAL,['NA'],
10536,NCT03503045,Overtreatment for glycemia,Deintensification of treatment,2017-04-01,COMPLETED,OBSERVATIONAL,['NA'],
10537,NCT05207995,Adverse effects associated with the therapy,,2022-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10538,NCT04980027,Percentage of participants with Treatment Emergent Adverse Events (TEAEs),Change in DTSQs scores from Baseline to Week 12 and Week 24,2021-06-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
10539,NCT00786175,,,2008-10,WITHDRAWN,OBSERVATIONAL,['NA'],
10540,NCT02663544,Change in glucose tolerance,Change in pancreatic beta-cell function: glucose sensitivity,2016-01,COMPLETED,INTERVENTIONAL,['NA'],Change in the homeostasis model assessment (HOMA) insulin resistance index
10541,NCT01197092,HbA1c Test (Glycated hemoglobin),"Vitamins B1,B2,B6,B 12, Vitamin D",2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],
10542,NCT02061618,Hemoglobin A1c,Physical Activity,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
10543,NCT03293914,"Difference in the daily rate of change of Glycated hemoglobin (HbA1C) during the year prior to baseline, compared to the period from baseline to post-intervention",Timeliness,2017-09-18,COMPLETED,INTERVENTIONAL,['NA'],
10544,NCT03455985,Change in HbA1c From Baseline to 24 Weeks,Fasting Glucose,2018-05-01,TERMINATED,INTERVENTIONAL,['NA'],
10545,NCT01449773,Change in the in vivo kinetics of intestinally derived apoB-48-containing lipoproteins between the two 8-week interventions,"Change in the plasma surrogates of cholesterol absorption (campesterol, beta-sitosterol) and synthesis (lathosterol) between the two 8-week interventions",2008-04,COMPLETED,INTERVENTIONAL,['NA'],
10546,NCT00811317,Average Blood Glucose Over the Closed-loop Control Period,Insulin and Glucagon Levels During Closed Loop and Open Loop Admissions of Diabetic Subjects Compared to the Comparable 24 Hour Period During the Admission of Non-diabetic Subject,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
10547,NCT02138045,Evoked brain potentials (using standard electroencephalographic brain imaging).,OCT,2014-05,COMPLETED,INTERVENTIONAL,['NA'],Weight/body mass index
10548,NCT03422185,"What is the true burden of hypertension, diabetes, and hyperlipidaemia?","Is infection, notably HIV infection or its therapy, associated with increased risk of NCDs?",2013-05,COMPLETED,OBSERVATIONAL,['NA'],
10549,NCT03414320,Accepting mathematical model,,2018-01-11,COMPLETED,INTERVENTIONAL,['NA'],
10550,NCT04626570,Percentage of patients without food addiction,Evolution of quality of life,2021-01-20,RECRUITING,INTERVENTIONAL,['NA'],
10551,NCT00190502,C-peptide production,Insulin dose,2000-11,UNKNOWN,INTERVENTIONAL,['NA'],
10552,NCT04516694,HbA1c,Time in Range,2020-09-10,COMPLETED,INTERVENTIONAL,['NA'],
10553,NCT02817243,The area under the plasma concentration-time curve (AUC) of Simvastatin,The number of volunteers with adverse events as a measure of safety and tolerability,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],
10554,NCT02528019,Effects of treatment on the nominal change in arterial stiffness from baseline after 6 months of treatment as measured by cardio-ankle vascular index,Change from baseline in circulating inflammatory markers,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
10555,NCT02732886,Proportion of subjects with a target ulcer which achieves complete wound closure in 8 weeks,Change amount and change rate of the target ulcer size after using the investigational device,2016-03-29,COMPLETED,INTERVENTIONAL,['NA'],
10556,NCT01684943,For Continuous Insulin Monitoring: Time to Maximum Plasma Insulin and Time to Maximum Continuous Insulin Monitoring Insulin,Multiplex PK: Average Number of Hypoglycemia Events Over the Last Month at Baseline Categorized According to Baseline Use of Insulin Analog Found to Have the Most Favorable PK Profile for Each Individual,2010-07,COMPLETED,INTERVENTIONAL,['NA'],
10557,NCT06014437,"Incidence of complete wound closure during treatment and follow-up (12 weeks). (Outpatient follow-up 2-3 times per week, standardized photographs and measurement of wound size)",,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
10558,NCT00099723,Blood work,,2004-10,TERMINATED,INTERVENTIONAL,['PHASE1'],
10559,NCT03361709,Mean change in corneal endothelial cell density before and after phacoemulsification,Intraocular pressure,2018-01-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
10560,NCT01589445,Comparison of Changes in Fasting Serum Insulin (FSI)With Pioglitazone and Metformin,Comparison of Changes in Lipid Profiles With Pioglitazone and Metformin,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
10561,NCT04238494,Fat involution and trophicity in rectus femoris,measure the serum interleukin IL-1b and IL-18 rate,2019-10-18,UNKNOWN,INTERVENTIONAL,['NA'],
10562,NCT00721552,Glucose tolerance as assessed by the area under the curve for glucose (AUCgluc) during a standardized meal test.,Beta-cell function as determined by hyperglycemic clamp tests and modeling analysis from mixed-meal tests.,2008-10,COMPLETED,INTERVENTIONAL,['NA'],
10563,NCT05254535,Proportion of Patients Who Complete Annual Diabetic Eye Screening,Mean Implementation Cost,2023-03-28,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
10564,NCT02933853,Area under the serum insulin aspart concentration-time curve,Maximum glucose infusion rate,2016-10-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
10565,NCT00676260,Capillary filtration capacity.,Vascular Endothelium Growth Factor.,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
10566,NCT01089192,,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],
10567,NCT00722397,Blood draw to be processed and analyzed to yield genetic data.,Laboratory values.,2008-08,COMPLETED,OBSERVATIONAL,['NA'],
10568,NCT05585502,Muscle and tendon stiffness differences between T2D patients and controls,Correlation between tissue glycation indicators (RAGE) and muscle-tendon stiffness in T2D patients and controls,2022-12-10,RECRUITING,INTERVENTIONAL,['NA'],
10569,NCT00394303,"Perioperative cerebrovascular event defined as any new, temporary or permanent, focal or global neurological deficit.",Re-hospitalizations,2007-02,TERMINATED,INTERVENTIONAL,['PHASE4'],
10570,NCT00120341,"changes in sensation using, vibration perception threshold testing, monofilament testing, and the Michigan Neuropathy Screening Instrument",,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
10571,NCT06127823,Percentage of insulin-treated,Admission to neonatal intensive care unit (NICU),2024-01-03,RECRUITING,INTERVENTIONAL,['NA'],Total net costs
10572,NCT03299153,total cholesterol,Diastolic BP,2016-12-21,COMPLETED,INTERVENTIONAL,['PHASE4'],
10573,NCT00837590,Vascular Function,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE1'],
10574,NCT01512030,What is the long term development of diabetic neuropathy? Is there a significant deterioration or improvement in nerve conduction during the follow up period?,Nephropathy,2011-12,COMPLETED,OBSERVATIONAL,['NA'],
10575,NCT04476108,Change From Baseline in Average Pain Intensity as Measured by the NRS,Change From Baseline on the EuroQol-5D 5 Level Questionnaire (EQ-5D-5L) (United States),2020-07-15,COMPLETED,INTERVENTIONAL,['PHASE2'],
10576,NCT01161030,,,2008-08,COMPLETED,INTERVENTIONAL,['NA'],
10577,NCT01399580,Change from baseline to each post-baseline visit up to Week 8 in log-transformed Urinary Albumin to Creatinine Ratio (UACR),The change from baseline to each post-baseline assessment of thoracic bioimpedance,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
10578,NCT03651180,"Incidence of the composite endpoint of cardiac death, definite and probable stent thrombosis, re-PCI, Target Vessel Revascularization and bleeding in the two groups of study","Incidence of every single adverse event (cardiac death, definite and probable stent thrombosis, re-PCI, Target Vessel Revascularization and bleeding) in the two groups of study",2018-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
10579,NCT01030952,Change in Area Under Curve of 0-4 Hours Postprandial Glucose (AUCpp0-4hours) in Standardized Meal Test Using Continuous Glucose Monitoring System (CGMS),Change in Percent of 24 Hour Hyperglycemic Measurements,2009-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
10580,NCT02398383,Glucagon levels,Glucagon levels,2015-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
10581,NCT03167918,Changes in pulmonary function parameters,"Changes in glycosylated hemoglobinA1c, fasting plasma glucose, 2-hour postprandial blood glucose,",2014-07-21,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Changes in retrobulbar hemodynamics (RI)
10582,NCT02794792,Change from baseline in HbA1c with ipragliflozin once daily added on to metformin compared to placebo added on to metformin,Percentage of patients with AEs of special interest,2016-05-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
10583,NCT01694940,There is no primary outcome measure for this study,,2010-12,RECRUITING,OBSERVATIONAL,['NA'],
10584,NCT00605007,The primary outcome of the study is to determine the mortality rate of COPD patients with corticosteroid-induce hyperglycemia.,,2006-02,COMPLETED,OBSERVATIONAL,['NA'],
10585,NCT01183468,C-peptide 2-hour AUC in Response to a Mixed-meal Tolerance Test at Week 52,,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1'],
10586,NCT05936151,Change from Baseline in Glomerular Filtration Rate (GFR),Change from Baseline in Change in 24-hour (hr) Urinary Electrolytes (milligrams/24hr (mg/24h)),2023-07-20,RECRUITING,INTERVENTIONAL,['PHASE2'],
10587,NCT03753997,Change in HbA1c from baseline to 52 weeks follow-up,score of Diabetes Treatment satisfaction questionnaire - change (DTSQc) at week 52,2019-01-01,RECRUITING,INTERVENTIONAL,['NA'],Change in systolic and diastolic blood pressure from baseline to week 52
10588,NCT01701570,Rating of perceived exercise effort (RPE) during exercise (Borg RPE scale),Serum lactate during exercise,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
10589,NCT00671346,Possible effects of B-vitamin treatment on risk of developing cancer during the trial periods (completed by 2004 and 2005) and during post-trial follow-up.,"The possible effects of B-vitamin treatment on major cardiovascular events, all cause mortality and cause specific death during the trial periods (completed by 2004 and 2005) and during post-trial follow-up.",1998-12,UNKNOWN,OBSERVATIONAL,['NA'],
10590,NCT00214214,to determine if Campath-1H can be used in patients recently diagnosed with type I DM,to determine if Campath-1H can eliminate or lower insulin requirements,2005-10,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
10591,NCT05318326,HbA1c change from baseline at week 24,Fasting lipids From Baseline at Week 24 and Week 52,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
10592,NCT05514535,Change in Glycated Haemoglobin (HbA1c),Change in Score of Short Form 36 Version 2 (SF-36 v2),2022-08-29,RECRUITING,INTERVENTIONAL,['PHASE3'],
10593,NCT04154904,Comparison of the Mean Relative Difference When Including Patterns in Hypoglycemia Prediction.,,2020-08-11,COMPLETED,INTERVENTIONAL,['NA'],
10594,NCT06174779,The proportion of subjects achieving body weight loss ≥ 5% from baseline,Change of IWQoL-Lite-CT(Physical function domain) from baseline,2023-12-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
10595,NCT02953262,Any My HealtheVet Patient Portal Use,Use of Secure Messaging,2019-07-22,COMPLETED,INTERVENTIONAL,['NA'],
10596,NCT01984606,The change from baseline in HbA1c after 52 weeks of treatment.,The change in Diastolic Blood Pressure (DBP) from baseline after 52 weeks of treatment,2015-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
10597,NCT01693302,Blood glucose area under the curve,Glucose values two hours after the beginning of the meal,2007-08,COMPLETED,INTERVENTIONAL,['NA'],
10598,NCT05389566,Co-existence of peripheral neuropathy and impaired dynamic postural control in people with diabetes,The impact of peripheral neuropathy on postural control (In quite stance),2022-05-06,RECRUITING,OBSERVATIONAL,['NA'],Muscle strength and peripheral neuropathy
10599,NCT00126126,Amputee Mobility Predictor,Six-minute Walk Test,2005-01,COMPLETED,INTERVENTIONAL,['NA'],
10600,NCT05455242,Change in Behavior Automaticity,,2021-01-16,COMPLETED,INTERVENTIONAL,['NA'],
10601,NCT01836523,Change From Baseline in Total Daily Insulin Dose,Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
10602,NCT05780905,bloodbrain barrier Ktrans,Inflammatory markers,2023-04-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
10603,NCT00135226,Number of Participants With First Occurrence of Any Major Bleed (Aspirin Comparison Only),Number of Participants With Any Incident Gastrointestinal (GI) Tract Cancer (Aspirin Comparison Only),2005-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Number of Participants With Event: Other Arrhythmia (Omega-3 Comparison Only)
10604,NCT00067951,Hemoglobin A1c (HbA1c) reduction after 24 weeks of treatment.,"Change in FPG, insulin,C-peptide, insulin sensitivity,beta cell function, free fatty acids, lipids. Change in weight, vital signs, clinical laboratory tests, and adverse experiences.",2003-10-17,COMPLETED,INTERVENTIONAL,['PHASE3'],
10605,NCT00744926,Absolute change from baseline in HbA1c,"Responder rates for HbA1c (target <=7.0%, <=6.5%); relative change in glucose, insulin, C-peptide and glucagon during a meal tolerance test; beta cell function.",2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
10606,NCT04421755,Cooking skills,,2019-07-16,COMPLETED,INTERVENTIONAL,['NA'],
10607,NCT04725591,"The primary outcome is the time spent of the glucose level in the widened target range 3.9-10.0 mmol/L over the 2 last weeks of each cross-over period, as recorded by continuous subcutaneous glucose monitoring (CGM).",• Scoring of a questionnaire to evaluate the acceptance,2023-01-19,RECRUITING,INTERVENTIONAL,['NA'],
10608,NCT04682457,Change in C-peptide over a year,Change in dried blood spot C-peptide,2019-11-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
10609,NCT01874392,Test the Safety of the AP Device While the Subject is Under Close Medical Supervision in the Clinical Research Center (CRC) Setting.,Test the Benefits of the AP Device Combined With the Technosphere® Insulin Powder System,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
10610,NCT01153243,Levels of inflammatory markers,"Levels of Vitamin D, PTH and Calcium",2007-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
10611,NCT00682240,Retinal morphological changes with time secondary to laser treatment as assessed with optical coherence tomography (OCT).,"changes in retinal function as an effect of treatment, documented by visual acuity testing and microperimetry. The change in vascular leakage will be assessed by performing fluorescein angiography, flare counts will be performed monthly.",2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
10612,NCT03130699,Systolic blood pressure (SBP); mmHg units,Adherence to Refills and Medications Scale (ARMS) - patient-reported outcome,2017-06-22,COMPLETED,INTERVENTIONAL,['NA'],Pay for Performance (P4P) Clinical Metrics
10613,NCT01952535,"Safety and tolerability of HMS5552 will be assessed by adverse event monitoring, physical examinations, 12 lead ECGs, vital sign, and safety laboratory measurements.","Pharmacodynamic variables will include maximum change (%) in fasting plasma glucose level, AUC0-4 of fasting plasma glucose , AUC of percent reduction in fasting plasma glucose from baseline versus time curve, time of minimum glucose level",2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
10614,NCT00594152,Rate of loss of creatinine clearance,Change in cardiac function,1993-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
10615,NCT02192424,"Baseline-adjusted beta-cell function at 2 years, measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2).",Baseline-adjusted glycemic control at 2-years.,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3'],insulin sensitivity
10616,NCT01694173,"• Increment in glucagon stimulated C - peptide levels at the end of 6 months of ABMSCT, as compared to baseline",• Any reduction in requirement of insulin dosage measured as a percentage decrease from baseline • Improvement of HbA1c levels as compared to baseline,2010-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10617,NCT04411342,Prevalence of Normoalbuminuric chronic kidney disease,,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA'],
10618,NCT00274274,HbA1c,Duration of education,2005-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
10619,NCT03820050,System Performance,,2019-01-29,COMPLETED,OBSERVATIONAL,['NA'],
10620,NCT02506647,Pharmacokinetic effects,Safety assessment as measured by incidence and severity of adverse events,2015-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
10621,NCT03802942,Total number of patients with at least 1 documented low (equal or below 70 mg/dL) glucose levels,30-day readmission rate,2019-07-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
10622,NCT01424891,NF-kappa B binding activity,Inflammatory markers,2004-04,COMPLETED,INTERVENTIONAL,['NA'],
10623,NCT03623113,Change in mean amplitude of glycaemic excursions (MAGE),Change in intake of dietary fibre,2018-09-28,COMPLETED,INTERVENTIONAL,['NA'],Change in urinary biomarkers of carbohydrate intake
10624,NCT03077893,Quantitative Sensory Testing (QST),Nerve Conduction Velocity (NCV) - Amplitude,2017-03-09,COMPLETED,INTERVENTIONAL,['NA'],
10625,NCT00938275,Characterize and compare the pharmacokinetic profile of a single 500 mg dose of SRT2104 administered as an oral suspension and as a capsule formulation.,Assess the safety and tolerance of SRT2104.,2009-01-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
10626,NCT05456347,Visceral fat mass change.,Triglycerides change.,2021-07-01,COMPLETED,INTERVENTIONAL,['NA'],TNF-alpha change.
10627,NCT05098301,evaluate the performances of an insulin titration algorithm,measure time-in-range evolution adjustment of insulin therapy parameters,2021-11-30,COMPLETED,OBSERVATIONAL,['NA'],
10628,NCT06127355,Maternal fasting glucose concentration at 36 weeks,Infant birth weight,2021-03-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
10629,NCT02002143,Patients' control (decreased levels) of HemoglobinA1C (clinical),Patient Self-Management,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],
10630,NCT00920725,Hours to achieve blood glucose less than 200mg/dl,,2005-01,COMPLETED,INTERVENTIONAL,['NA'],
10631,NCT02098980,Insulin Resistance,,2014-05,UNKNOWN,INTERVENTIONAL,['NA'],
10632,NCT05438251,Time to the ulcer grade down,Percentage of ulcer improvement,2022-08-04,RECRUITING,INTERVENTIONAL,['PHASE4'],
10633,NCT00696163,Change in Quality of Life from baseline (using QoLD questionnaire),Efficacy,2008-04,COMPLETED,OBSERVATIONAL,['NA'],
10634,NCT01490918,The Change of Glycated Hemoglogin(HbA1c) From Baseline to 16 Weeks of Treatment,"Changes in Glucagon During Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),",2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],"Changes in MAGE of Glucose During CGMS Between 2 Group(Group 1 vs Group 2),"
10635,NCT04168541,Area under the blood glucose curve (ACU 0-240 minutes),Insulinogenic index [Change in Ins30/Change in Glu30],2018-02-05,COMPLETED,INTERVENTIONAL,['NA'],
10636,NCT04743453,"Evaluate the mean ΔmGFR, between baseline and one year after randomization.",,2021-08-17,UNKNOWN,INTERVENTIONAL,['PHASE4'],
10637,NCT04552470,Number of Participants With Absolute Electrocardiogram (ECG) Values and Increased ECG Values From Time-Matched Baseline,Terminal Phase Half-Life (t1/2) of PF-06882961,2020-10-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
10638,NCT03146845,Change in the Cardiff Wound Impact Schedule-Physical Symptoms of Daily Living (CWIS-PSDL) Scale Score From Baseline to the Week 6 Visit,Healthcare Resource Use - Number of Dressing Changes Required for Each Type of Wound Debridement,2017-06-15,COMPLETED,INTERVENTIONAL,['NA'],
10639,NCT02262208,Glycemic variability by continuous glucose monitoring system,Oxidative stress,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],
10640,NCT03848637,Area under the plasma concentration of Metformin-time curve from time zero to time of last measurable concentration,Apparent volume of distribution of Metformin,2019-04-14,UNKNOWN,INTERVENTIONAL,['PHASE1'],
10641,NCT04285710,Bacterial Quantification Over Time,Subject Phototherapy Treatment Satisfaction: questionnaire,2021-06,WITHDRAWN,INTERVENTIONAL,['NA'],
10642,NCT04039503,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Percentage of Participants Achieving an HbA1c Target Value of <5.7%,2019-08-30,COMPLETED,INTERVENTIONAL,['PHASE3'],
10643,NCT03377244,Mean Percent Body Weight (Pounds) Change,Change in Perceived Family Support for Exercise and Dietary Habits,2018-09-30,COMPLETED,INTERVENTIONAL,['NA'],
10644,NCT04666818,MODD= Adimensional coefficient calculated as mean of the daily serum glucose difference.,Cesarean section,2020-11-26,COMPLETED,OBSERVATIONAL,['NA'],
10645,NCT03125772,Composite safety endpoint of Target Vessel Failure (TVF) rate at 12 months post-index procedure: • Cardiac Death related to target vessel • Target Vessel Myocardial Infarction (TV-MI) • Target Vessel Revascularization (TVR),Stent Thrombosis Rate,2011-06,COMPLETED,INTERVENTIONAL,['NA'],Procedural complication rate
10646,NCT02105103,The primary objective is to evaluate the Accu-Chek Insight Insulin Pump and associated pump devices in routine practice. This will be expressed by the rate of error messages per 100 patient years (confirmed by pump uploads).,"Evaluate type and frequency of pump signals, i.e. reminders, errors, warnings, alarms, maintenance messages",2013-10,COMPLETED,INTERVENTIONAL,['NA'],
10647,NCT03827382,metabolic control,Quality of life by SF-36 Questionnaire,2019-02-01,RECRUITING,INTERVENTIONAL,['NA'],
10648,NCT04258293,Platelet Count,,2020-02-06,RECRUITING,OBSERVATIONAL,['NA'],
10649,NCT01554631,Ratio of postprandial Area under curve from 0 to 4 hours (AUC(0-4)) of blood glucose following sucrose load with Glucobay (Day 1) and without Glucobay (Day 0),Safety parameters,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
10650,NCT00006163,,,1997-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
10651,NCT00417716,Optical Coherence Tomography,,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],
10652,NCT04206748,# of Neonates with hyperbilirubinemia-requiring therapy.,Effect of SMBG checks on pregnancy,2019-11-12,RECRUITING,INTERVENTIONAL,['NA'],
10653,NCT01135433,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",2010-05-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
10654,NCT01766362,Macular thickness,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
10655,NCT01011868,Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 18 Weeks of Treatment,"The Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 18, 54, and 78 Weeks of Treatment",2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Confirmed Hypoglycemic Events
10656,NCT02029989,Metabolic Syndrome (MetS),,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
10657,NCT02221323,AUCINS.0-4h and AUCGIR.0-4h,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
10658,NCT03305822,Pharmacokinetics (PK): Insulin Lispro Area Under the Plasma Concentration Curve Zero to 10 Hours (AUC[0-10) Following Each Treatment Arm,Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm,2017-10-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
10659,NCT01569243,physical activity,Engagement to program,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
10660,NCT00455858,Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 20,Occurence of Hypoglycaemic Episodes,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
10661,NCT03952000,Endothelial function changes in response to exercise and feeding,Superoxide dismutase 3,2019-01-03,COMPLETED,INTERVENTIONAL,['NA'],
10662,NCT00543491,,,2003-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
10663,NCT00320086,"Number of Subjects With Normal Urinary Protein Excretion in Healthy and Diabetic Children, Assessed Over 1 Day.",,2005-08,COMPLETED,OBSERVATIONAL,['NA'],
10664,NCT00763347,Change from baseline in glycosylated hemoglobin.,Clinical laboratory evaluation (urinalysis).,2006-11,TERMINATED,INTERVENTIONAL,['PHASE2'],
10665,NCT05101330,Assessing PML understanding at Week 2. (Pilot Trial B),,2021-11-01,WITHDRAWN,INTERVENTIONAL,['NA'],
10666,NCT04484883,Resting Energy Expenditure (REE),,2019-06-01,COMPLETED,OBSERVATIONAL,['NA'],
10667,NCT02009878,Time of Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration.,"Change From Baseline in Cumulative Urine Volume at 0-6 Hours, 0-12 Hours and 0-24 Hours.",2013-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10668,NCT02612805,Changes in levels of glycated hemoglobin,"Physical activity levels, evaluated by International Physical Activity Questionnaire (IPAQ) - Short Form.",2015-11,COMPLETED,INTERVENTIONAL,['NA'],
10669,NCT03792321,Effects of testosterone replacement therapy on vascular morphology - intima-media thickness (IMT),Effects of testosterone replacement on hematocrit,2014-01-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
10670,NCT01294553,Number of Participants With an Adverse Event,Number of Participants With the Indicated Unexpected Adverse Events,2004-06,COMPLETED,OBSERVATIONAL,['NA'],
10671,NCT02695173,Incidence of urinary tract infections (UTI) complications,Incidence of pyelonephritis,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],
10672,NCT03607201,Mortality,,2017-08-01,COMPLETED,OBSERVATIONAL,['NA'],TIMI Score
10673,NCT01515657,Time to 99% Inhibition of Serum Thromboxane (TxB2),,2012-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
10674,NCT02384018,C-peptide level after mixed meal tolerance test,The absence of severe hypoglycemic episodes,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
10675,NCT01678742,Difference in the incremental area under the curve (iAUC) for peptide YY (PYY) after food ingestion between high-protein and standard diet groups,Difference in the iAUC for glucose-dependent insulinotropic polypeptide (GIP) after food ingestion between high-protein and standard diet groups,2012-08,COMPLETED,INTERVENTIONAL,['NA'],Difference in the iAUC for glucagon after food ingestion between high-protein and standard diet groups
10676,NCT01813305,Number of Participants With Complete Ulcer Closure During the Treatment Period,Percentage Change in Ulcer Size for Each Post-treatment Visit,2014-07-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Respiratory Rate Change From Baseline to Week 24
10677,NCT05139914,Insulin-mediated endothelial nitric oxide synthase (eNOS) phosphorylation measured in endothelial cells (ECs) at 14 weeks,Circulating C-reactive protein (CRP) biomarkers of vascular health at 14 weeks,2022-05-31,RECRUITING,INTERVENTIONAL,['PHASE4'],
10678,NCT04479826,Time in ranges,,2020-07-16,COMPLETED,INTERVENTIONAL,['NA'],
10679,NCT00625859,Blood samples and urine samples,Hunger and craving will be assessed using two assessment tools: (1) a questionnaire to assess hunger and craving; and (2) a Visual Analogue Scale (VAS) to assess hunger.,2008-01-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
10680,NCT03084965,Change in HbA1c,,2017-05-12,COMPLETED,OBSERVATIONAL,['NA'],
10681,NCT01623375,Area under the serum insulin degludec concentration-of i.v. administration,"Volume of distribution of insulin degludec, estimated during the terminal phase",2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
10682,NCT01630759,Management decision comparison,Number of downloads missed,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
10683,NCT05172947,Serum neopterin levels,"Measurement of serum level of LDL, cholesterol, HDL, Triglyceride",2021-12-05,COMPLETED,INTERVENTIONAL,['NA'],
10684,NCT01862029,Change in Insulin Sensitivity - Post-roflumilast,,2013-05-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10685,NCT04143269,Subjective gastrointestinal symptoms,Nerve conduction study - amplitudes,2020-01-20,COMPLETED,INTERVENTIONAL,['NA'],
10686,NCT03596203,Pain level,Changes in pain medication,2018-11-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
10687,NCT03944200,Maximum plasmaconcentration of drug in plasma(Cmax),Terminal elimination half-life(t1/2),2019-02-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
10688,NCT02527525,glycemic variability,,2016-04,COMPLETED,INTERVENTIONAL,['NA'],
10689,NCT00313183,To assess the safety and tolerability of Symlin in adolescent subjects with type 1 diabetes,To evaluate the effects of Symlin compared to placebo in adolescent subjects with type 1 diabetes on various pharmacodynamic endpoints,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
10690,NCT02827890,"Css,max of Sitagliptin","swing[(Css,max-Css,min)/Css,min] of Sitagliptin",2016-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
10691,NCT00541372,"Preference of the patient and amount of experienced hypoglycaemic events, bruises, backflow of insulin, bleeding and pain (VAS-scale)","HbA1c levels 1,5 anhydroglucitol and fructosamine levels Insulin dose",2007-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
10692,NCT03504683,Peak glucose and mean amplitude of glycemic excursions (MAGE) glucose values,Inflammatory biomarkers,2020-08-17,RECRUITING,INTERVENTIONAL,['NA'],Sleep Quality
10693,NCT05418465,Rate of change in Estimated Glomerular Filtration Rate (eGFR) compared to baseline,Change in 24-hour urine protein ration from baseline.,2022-01-26,RECRUITING,INTERVENTIONAL,['NA'],Incidence of adverse reactions
10694,NCT05000463,Pain Assessment,,2022-02-25,UNKNOWN,INTERVENTIONAL,['NA'],
10695,NCT01295788,Adherence to CGM (hours per week),Perception of Barriers/Facilitators to RT-CGM Use,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
10696,NCT00309244,Change From Baseline in HbA1c to Week 52,Severe Hypoglycemia Event Rate,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
10697,NCT04154046,New ulcers incurred,Incidence of new ulcers on feet,2019-11-01,COMPLETED,INTERVENTIONAL,['NA'],
10698,NCT01296516,Incidence of glucose intolerance,Weight loss,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
10699,NCT06255288,Procedural uncertainties - Number of patients willing to participate.,Drop out rates,2024-01-23,RECRUITING,INTERVENTIONAL,['NA'],
10700,NCT02776397,Oxidative Stress,Non HDL-Cholesterol,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],
10701,NCT04464213,Rate of adverse event,Rate of cure rate,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
10702,NCT05035849,Glycemic variations,Glycemic variations,2020-01-30,COMPLETED,INTERVENTIONAL,['NA'],
10703,NCT01527565,"Cmax, maximum insulin aspart concentration",Adverse events,2003-01-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
10704,NCT02148991,Blood pressure measurement,Quality of Life questionnaire rating,2014-07,COMPLETED,OBSERVATIONAL,['NA'],Treatment compliance questionnaire rating
10705,NCT00860288,To evaluate the efficacy of vildagliptin as add-on therapy to metformin in patients with T2DM by assessing changes in HbA1c with vildagliptin added to metformin to that of placebo added to metformin after 24 weeks of treatment,To evaluate the long-term efficacy of vildagliptin compared to sitagliptin over the entire study duration as add-on therapy to metformin in patients with T2DM.,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10706,NCT02906579,Change From Time-Matched Baseline (Placebo Cycle) in Platelet Function Assessments: Collagen/Epinephrine Time to Aggregation,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
10707,NCT00456885,Change in Body Mass Index,REE,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
10708,NCT05227196,"Cmax,0-24h.semaglutide,SS Maximum semaglutide plasma concentration at steady state","Ctau,24h,semaglutide,SS Semaglutide plasma concentration 24 hours after last dose at steady state",2022-02-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
10709,NCT00644501,"Preservation of endogenous insulin secretion/beta-cell function, as measured by mixed-meal tolerance test stimulated C-peptide secretion.",improved metabolic control and the insulin dose required to maintain it.,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
10710,NCT02600091,Recruitment/Retention Rates,Acceptability,2015-10-30,COMPLETED,INTERVENTIONAL,['NA'],
10711,NCT01900834,Variation in CD8 (cluster of differentiation) +T-cell specificity profiling,Variation in HbA1c (glycosylated haemoglobin),2013-07,COMPLETED,OBSERVATIONAL,['NA'],
10712,NCT02262611,Change in diastolic blood pressure,Global assessment of tolerability by investigator on a 4-point scale,2003-01,COMPLETED,OBSERVATIONAL,['NA'],
10713,NCT02033889,Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach),Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach),2013-12-13,COMPLETED,INTERVENTIONAL,['PHASE3'],
10714,NCT01675310,Gestational diabetes mellitus,insulin resistance,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
10715,NCT01296438,Area under the serum insulin aspart concentration-time curve,Area under the serum insulin aspart concentration-time curve,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
10716,NCT00210275,Change in Behavioral intention related to referring patient for retinopathy screening,Change in Perceived Behavourial Control (Theory of Planned Behaviour),2005-07,UNKNOWN,INTERVENTIONAL,['NA'],
10717,NCT00351832,Change from baseline on HbA1c at 12 weeks,Change from baseline on fasting lipids at 12 weeks,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
10718,NCT01044875,Visual acuity measurement by logarithm of the minimum angle of resolution (logMAR),Patient pain score during laser procedure,2009-09,UNKNOWN,INTERVENTIONAL,['NA'],
10719,NCT02886208,BMI,,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
10720,NCT04949022,Time in range (glucose between 3.9-10 mmol/l) before and during hybrid close loop insulin pump treatment,HbA1c before and during hybrid close loop insulin pump treatment,2021-08-23,UNKNOWN,INTERVENTIONAL,['NA'],Sensor glucose coefficient of variation before and during hybrid close loop insulin pump
10721,NCT03764631,Number of Participants With Dehydration,Number of Participants With Dehydration During Ramadan Periods,2018-09-26,COMPLETED,OBSERVATIONAL,['NA'],
10722,NCT01581099,Improvement in Metabolic Profile,,2013-04,COMPLETED,OBSERVATIONAL,['NA'],
10723,NCT01597154,Glycemic control determined by a standard fasting measure of glycosylated hemoglobin using internationally recognized DCCT assay,Cardiovascular structure and function,2012-09,COMPLETED,INTERVENTIONAL,['NA'],
10724,NCT04926740,Time to DKA resolution (efficacy outcome),Major adverse kidney events,2021-10-12,COMPLETED,INTERVENTIONAL,['NA'],
10725,NCT01489163,postpartum body weight,postpartum glycemia,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
10726,NCT02293837,Change From Baseline in 2-Hour C-peptide Mean Area Under the Curve (mAUC) in Pediatric Participants,Number of Participants Who Experienced Hypersensitivity Adverse Events,2015-03-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
10727,NCT03808090,Urinary oxalate excretion,,2013-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
10728,NCT05478707,Microvascular blood volume (MBV),"Skeletal muscle oxygenation, deoxyhemoglobin (HHb)",2023-10-05,RECRUITING,INTERVENTIONAL,['PHASE2'],
10729,NCT02076568,Change from baseline in diabetes-specific empowerment on the adapted Diabetes Empowerment Scale at the 2-week and 6-month follow-up,Change from baseline in depressive symptoms on the CES-D at the 2-week and 6-month follow-up,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
10730,NCT00562250,Maximum plasma concentration and exposure to glimepiride and dapagliflozin when administered alone and administered together,Recorded adverse events,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
10731,NCT02092597,Exocrine pancreas function,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
10732,NCT02209051,Proportion of patients with complete wound closure (i.e. complete skin re-epithelialization without drainage or dressing requirements) at 6 weeks after initiation of study treatment,Changes in Quality of Life assessment,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
10733,NCT01733901,All-cause mortality,Medication adherence,2012-11,UNKNOWN,INTERVENTIONAL,['NA'],
10734,NCT00401622,Change in A1C From Baseline to Week 52 Between the OneTouch® Ultra®2 and Control BGMS.,Change in Daily Glycemic Excursions Between the OneTouch® Ultra®2 and Control BGMS.,2006-10-01,COMPLETED,INTERVENTIONAL,['NA'],
10735,NCT02735837,Periodontal pocket,glycated hemoglobin (HbA1c),2015-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10736,NCT00282971,Percentage Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in FEV1 at Week 24 LOCF,2006-03-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
10737,NCT01521962,Change in glycosylated hemoglobin (HbA1c; Japan Diabetes Society value),,2012-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
10738,NCT05343065,The percentage of time a participant's glucose value is between 70 and 180 mg/dL will not be inferior to baseline.,,2022-07-05,COMPLETED,INTERVENTIONAL,['NA'],
10739,NCT05633628,HbA1c,The Patient Preferences for Patient Participation (4Ps),2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],
10740,NCT05275608,Change in metabolic control,Change in inflammatory status,2022-11-07,RECRUITING,INTERVENTIONAL,['NA'],
10741,NCT02159846,Allergy or hypersensitivity to preparation,,2013-08,COMPLETED,OBSERVATIONAL,['NA'],
10742,NCT00006505,Insulin independence,change in lipid profiles,2000-11-16,COMPLETED,INTERVENTIONAL,['PHASE2'],
10743,NCT01364402,Incidence of Contrast Induced Nephropathy(CIN),Hospital mortality,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],
10744,NCT04014569,Percentage of sensor glucose readings within range of 70-180 mg/dl,Number of Diabetic Ketoacidosis events,2018-05-02,TERMINATED,INTERVENTIONAL,['NA'],Number of physician override advisor recommendations
10745,NCT02077218,"Feasibility, defined by the percentage of patients that enroll onto the study, successful completion of all study measurements, ability of studies to be interpreted, and achievement of the recruitment goal",,2014-02,COMPLETED,INTERVENTIONAL,['NA'],Expression of Lp-PLA2
10746,NCT03525899,Time to macular hole closure,Best corrected visual acuity,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],
10747,NCT03808311,Major cardiovascular events,Kidney outcomes,2019-02-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Cost-effectiveness
10748,NCT04794907,Risk Stratification,,2022-12-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
10749,NCT03685357,"RBDSQ (""Rapid eye movement Sleep"" Behavior Disorder Screening Questionnaire)",,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA'],
10750,NCT04178603,Muscle glucose uptake during exercise and enhanced insulin sensitivity in recovery from exercise.,Posttranslational modification of proteins in muscle biopsies.,2018-07-05,COMPLETED,INTERVENTIONAL,['NA'],Changes in gene-expression in muscle as a result of exercise and during subsequent insulin stimulation.
10751,NCT00643474,Change from baseline in HbAlc level; percentage of subjects reaching or maintaining the risk target (represented by a combination of LBGI<=2.5 together with HBGI<=5).,"Changes in HBGI & LBGI; blood glucose test frequency, blood glucose profile, diabetes therapy, urinary 8-isoPGF2alpha, blood pressure, creatinine clearance, lipid profile & BMI; QoL & Locus of Control analysis; hypoglycemic episodes; study-related SAEs.",2008-03,COMPLETED,INTERVENTIONAL,['NA'],
10752,NCT01846533,Osteoprosis in type 2 diabetic patients- a cohort study,,2013-05,UNKNOWN,OBSERVATIONAL,['NA'],
10753,NCT01072331,"Change From Baseline in Plasma Glucose Area Under the Curve (AUC) 0 to 2h (Breakfast, Lunch and Dinner)",Change From Baseline in Fasting Plasma Glucose,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
10754,NCT03209466,Ulcerated area,,2017-05-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
10755,NCT00827710,Percent of patients with BP < 130/80,Percent of patients with BP checked in past year,2007-12,COMPLETED,INTERVENTIONAL,['NA'],
10756,NCT05979519,Percentage Change in fasting blood glucose,Change in blood pressure,2023-09-26,RECRUITING,INTERVENTIONAL,['NA'],
10757,NCT02916563,Number of Successful Glucose Readings,,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
10758,NCT04642261,Change in liver fat content,Changes of diastolic blood pressure,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
10759,NCT01357148,Number of Participants Taking Concomitant Medications,,2009-03,TERMINATED,OBSERVATIONAL,['NA'],
10760,NCT00469105,A1C,Patient satisfaction,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
10761,NCT02663388,"Evaluation of folate mediated one-carbon metabolic pathway parameters (Folates, Vitamin B12, Methionine, Homocysteine) on severe obesity-related complications before and after bariatric surgery",Evaluation of DNA Methylation on severe obesity-related complications before and after bariatric surgery,2016-01,RECRUITING,OBSERVATIONAL,['NA'],
10762,NCT01240200,Diabetes Treatment Satisfaction Questionnaire: Change (DTSQc) Score,Number of Hypoglycemic Events,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
10763,NCT04203173,Resource Utilization and Cost,Self-Care Behavior Brooks Medication Adherence Scale (BMAS),2019-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
10764,NCT02786134,Change in Global Myocardial Blood Flow in Response to Vasodilator,,2016-04,COMPLETED,INTERVENTIONAL,['NA'],
10765,NCT02115347,AUC From Hour 0 to Infinity (AUCinf) for Ertugliflozin,Number of Participants Who Experienced an Adverse Event,2014-09-19,COMPLETED,INTERVENTIONAL,['PHASE1'],
10766,NCT03446261,Change from baseline to week 8 in ApoB/ApoA1 ratio,Change from baseline to week 8 in FPG,2018-02-23,COMPLETED,INTERVENTIONAL,['PHASE4'],
10767,NCT03099928,Qualitative data,Change in optimism,2015-03-01,COMPLETED,OBSERVATIONAL,['NA'],
10768,NCT04406792,Participants with gestational diabetes that complete the recommended screening for Type 2 Diabetes Mellitus (T2DM),Participants with gestational diabetes who develop T2DM,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
10769,NCT01770964,change in pain severity rating,,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
10770,NCT03670797,Oral mucosal alterations,Salivary glands function,2018-12-25,COMPLETED,OBSERVATIONAL,['NA'],
10771,NCT05393843,plasmatic glycated haemoglobin,therapy for diabetes,2018-05-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
10772,NCT00637546,Gait parameter: comfortable speed,Fear of falling (Falls efficacy scale),2007-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10773,NCT04100070,Impact on glycaemic control all along the study,Impact on glycaemic control upon age classes,2019-09-02,UNKNOWN,INTERVENTIONAL,['NA'],
10774,NCT05521256,Number of adverse events,"For i.v. cohort and oral cohort- AUC0-∞,6856,SD/dose: Area under the NNC0113-6856 plasma concentration-time curve from 0 to infinity after a single dose divided by the dose administered",2022-08-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
10775,NCT03377335,Subclinical atherosclerosis,microRNAs,2017-12-22,UNKNOWN,INTERVENTIONAL,['PHASE4'],
10776,NCT02662569,Percent Change From Baseline in LDL-C at Week 12,Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12,2016-04-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
10777,NCT00795704,Hemoglobin A1C,Change From Baseline in Self-Monitoring Blood Glucose (SMBG) Averages,2008-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10778,NCT00605137,Incidence of hypoglycaemic episodes,Insulin doses,2004-05-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
10779,NCT05753124,Birth weight (in percentiles),Maternal and infant blood and urine samples,2015-05,RECRUITING,OBSERVATIONAL,['NA'],
10780,NCT03617081,Number of treatment emergent adverse events (TEAEs),"Cmax,SNAC,SD; the maximum plasma concentration of SNAC in plasma after a single dose of oral NNC0113-2023",2018-08-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
10781,NCT03195140,Hypoglycemia < 70 mg/dL,High Blood Glucose Index (HBGI),2017-08-11,COMPLETED,INTERVENTIONAL,['NA'],
10782,NCT03437902,"Lipid profile in diabetic patients (TC,TG,HDL-c,LDL-c).",Quality of life of diabetic patients and this will be evaluated by using Quality of Life Questionnaire (Short Form 36 questions (SF-36)) .,2018-02-24,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
10783,NCT01665716,OVADIA 2: Age at menopause,,2011-07,COMPLETED,OBSERVATIONAL,['NA'],
10784,NCT04214665,AUC0-t,(AUC0-inf - AUC0-t) / AUC0-inf,2014-12-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
10785,NCT01697592,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During the Overall Study,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,2012-10-24,COMPLETED,INTERVENTIONAL,['PHASE3'],
10786,NCT01038102,Hepatic steatosis by MRT,Changes in adipose tissue gene expression and lipogenic enzyme activity,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
10787,NCT00390962,,,2006-11,COMPLETED,OBSERVATIONAL,['NA'],
10788,NCT01865318,Area under the glucose infusion rate curve,Area under the serum insulin degludec curve,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
10789,NCT03211858,Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26,"Percentage of Participants With Treatment-Induced, Treatment-Boosted and Treatment-Emergent Anti-insulin Aspart Antibodies (AIAs)",2017-08-02,COMPLETED,INTERVENTIONAL,['PHASE3'],"Change in Daily Insulin Dose From Baseline to Day 1, Week 26 and Week 52"
10790,NCT04943861,Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) scores,,2023-11-14,RECRUITING,INTERVENTIONAL,['NA'],
10791,NCT02971618,HbA1c (glycosylated haemoglobin),change of systolic and diastolic blood pressure,2017-02-21,COMPLETED,OBSERVATIONAL,['NA'],
10792,NCT00399724,Incidence of severe hypoglycaemia,"Quality of Life and treatment satisfaction before, during and at the end of treatment using the Diabetes Treatment Satisfaction Questionnaire",2002-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
10793,NCT01074489,Blood glucose levels,,2010-02,COMPLETED,OBSERVATIONAL,['NA'],
10794,NCT02461641,Mean adjusted heal rate,Length of time to 100% healing of foot ulcer,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
10795,NCT00141492,,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
10796,NCT00943787,Maximum Epinephrine Response (LBGI Groups),Maximum Epinephrine Response (ADRR Groups),2006-01,COMPLETED,INTERVENTIONAL,['NA'],
10797,NCT01805700,Changes in blood glucose level in all patients as a measure of tolerability,"Changes in heart rate, systolic and diastolic blood pressure in all patients.",2010-01,COMPLETED,INTERVENTIONAL,['NA'],
10798,NCT01910441,Mean Amplitude of Glycemic Excursions (MAGE),,2013-07,TERMINATED,INTERVENTIONAL,['PHASE4'],
10799,NCT02388984,"The total effective rate of Fundus changes, the severity of diabetic retinopathy change from baseline at the end of week 24 compared to placebo",The severity of macular edema change from baseline at the end of week 24 compared to placebo,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],
10800,NCT02485327,Assessment of PD parameter: area under the glucose infusion rate curve (GIR) necessary to maintain euglycemia during the euglycemic clamp over 8 hours,Assessment of PD parameter: time to GIRmax (GIR-Tmax),2015-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
10801,NCT00886340,Number of Participants Who Met Weight Loss Goal of 5% Weight Loss,Quality of Life,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
10802,NCT02561546,glycosylated hemoglobin (A1C),postprandial glucose (PPG),2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
10803,NCT05229705,Trail Making Test,Timed Up and Go Test,2022-09-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
10804,NCT02680873,resolution of diabetes,,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
10805,NCT01089855,The decrease of neuropathic pain in diabetic patients using Brief Pain Inventory scale (BPI),Evaluate the quality of life,2009-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
10806,NCT04790617,Acute care service use,Medication adherence,2021-03-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
10807,NCT03794531,Number of participants with self-reported medically-diagnosed chronic diseases,Difference in the number of participants with self-reported medically-diagnosed chronic diseases living urban vs. rural area,2019-03-01,RECRUITING,OBSERVATIONAL,['NA'],"Risk of clinically-measured metabolic syndrome (e.g. high blood pressure, elevated adiposity, elevated blood glucose, and out-of-normal-range blood lipids), according to dietary and psychosocial risk factors"
10808,NCT04460326,Postprandial Glucose Control,Percent of Postprandial Time Spent With Hypoglycemia,2020-12-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
10809,NCT02272296,Tmax (min),T-INSAUC50% (min),2015-02,COMPLETED,INTERVENTIONAL,['PHASE4'],Tolerability
10810,NCT02342535,Change in Physical Activity (Minutes/Week),,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
10811,NCT03943979,Stability of changes in food intake,Change in neuropsychological test:Symbol digit modalities test (SDMT; Smith A. 1982).,2016-02-25,COMPLETED,INTERVENTIONAL,['PHASE2'],
10812,NCT02121340,Hemoglobin A1c,,2014-05,COMPLETED,INTERVENTIONAL,['NA'],Diabetes self management
10813,NCT01714011,Tapering off of previous psychoactive medication.,The proportion of reversed metabolic syndrome components among schizophrenia patients after treated with either aripiprazole or ziprasidone,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4'],Total cholesterol and LDL cholesterol among schizophrenia patients after treated with either aripiprazole or ziprasidone.
10814,NCT05908513,Change of body weight over time points,,2021-10-15,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
10815,NCT01197742,Documentation of the characteristics consecutive patients with acute STEMI or NSTEMI in daily hospital routine in Germany,Verification of the implementation of a therapy according to the guidelines for STEMI / NSTEMI in daily hospital routine,2007-10,COMPLETED,OBSERVATIONAL,['NA'],
10816,NCT05274880,Cmax of CKD-393,,2022-06-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
10817,NCT00563394,Reduction in clinical signs and symptoms of the infection,Wound Depth,1994-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
10818,NCT01434901,The effects of Bethanechol on insulin secretion rates,,2011-08-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
10819,NCT05286632,Evaluation of changes in Perceived Stress,,2022-07-18,RECRUITING,INTERVENTIONAL,['NA'],
10820,NCT03011021,Adverse effects,Life quality evaluation,2017-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10821,NCT04874532,Diabetes Self-Management,Qualitative experience with hypoglycemia and its prevention,2021-06-04,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
10822,NCT03344692,Total area under the post-prandial triglycerides concentration-time curve from meal-time until 8h (AUC0-8h) after standardized high fat meal.,Effect of treatment with alirocumab versus placebo on fasting and post-prandial and glucose homeostasis following a standardized high-fat meal,2019-02-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
10823,NCT01843855,Change in Total Disposition Index from Study 1 (pre-RYGB) to Study 2 (post-RYGB),,2011-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
10824,NCT03596177,Percent Change in Body Weight From Baseline to Day 59,Number of Participants With Positive Anti-drug Antibodies (ADAs) to MEDI0382,2018-09-26,COMPLETED,INTERVENTIONAL,['PHASE2'],
10825,NCT03523403,Gut microbiota profile,Plasma insulin levels,2017-10-12,COMPLETED,INTERVENTIONAL,['NA'],
10826,NCT02733185,"A composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina",,2016-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
10827,NCT03157960,Changes in uric acid (µmol/L),,2012-02-01,COMPLETED,INTERVENTIONAL,['NA'],
10828,NCT02846662,Number of participants with 50% reduction in PHQ-9 score a 3-month assessment,"Proportion of participants who improve level of activity, as evaluated by the short form of the Behavioral Activation for Depression Scale (BADS)",2016-09-19,COMPLETED,INTERVENTIONAL,['PHASE3'],
10829,NCT00728286,Thrombus area,Factors affecting thrombus area,2008-10,COMPLETED,OBSERVATIONAL,['NA'],
10830,NCT01212328,Multiple CVD risk factor control targets,Prescriber and patient acceptability of the Digital Support software and care coordinator with management guidelines.,2010-10,UNKNOWN,INTERVENTIONAL,['NA'],
10831,NCT02205372,Frequency and nature of treatment-emergent adverse events and serious adverse events.,Change from baseline in blood pressure,2014-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10832,NCT02276131,Successful completion of frequent and risk-related tasks (Measure: Percent of tasks successfully completed),,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
10833,NCT01487070,Evidence of advancement of tractional detachment post injection of Macugen before surgical intervention.,Evaluate regression of neovascularization and progression of macular traction utilizing OCT and Fundus photographs,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
10834,NCT01311076,TGIRmax: Time to Reach the Maximum Glucose Infusion Rate (GIRmax) Pharmacodynamic Parameter.,Incidence of Hypoglycemia.,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
10835,NCT02979756,Macrosomia,Lifestyle impact of GDM,2016-11-14,COMPLETED,INTERVENTIONAL,['NA'],
10836,NCT05273073,Mean difference of homeostasis model assessment of insulin resistance (HOMA-IR),"Changes in gut microbial profiles (i.e., gut microbial composition, alpha diversity, beta diversity, and functional analysis)",2018-03-01,COMPLETED,INTERVENTIONAL,['NA'],
10837,NCT05595681,Time to complete ulcer healing,Amount of index ulcers completely healed,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE1'],Other endpoints
10838,NCT01787318,Peak Post-Prandial Glucose Excursions,Area Under Curve meal-related insulin excursion following meals,2013-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
10839,NCT00501683,Urine & Fecal collection at Day -1 & days 1-5.,"Adverse events (AEs), vital signs, ECGs and clinical laboratory assessments at each day for up to 10 days",2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
10840,NCT03874754,Change in Mental Well Being,Change in Brain-Derived Neurotrophic Factor Level (in Sweat),2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],
10841,NCT02248714,Change From Baseline in Glucose Coefficient of Variation(CV),Change From Baseline in HOMA-IR,2014-03,COMPLETED,INTERVENTIONAL,['NA'],
10842,NCT01098357,Incidence of complete wound closure,Safety Safety Measures,2010-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10843,NCT04831060,Characterization of a panel of cytokines in gingival fluid of patients with periodontitis versus without periodontitis,Characterization of proteases (MMP) present in gingival fluid and unstimulated saliva,2023-02-15,RECRUITING,OBSERVATIONAL,['NA'],
10844,NCT01257815,The change in mean Best Corrected Visual Acuity (BCVA),Proportion of patients with 10 and 15 letter improvement or loss in BCVA,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
10845,NCT01114321,The primary outcome is the plasma glucose concentration measured 120 min after the oral glucose surcharge intake.,Urinary glucose measurement,2010-05,UNKNOWN,INTERVENTIONAL,['NA'],
10846,NCT05527574,Changes in frailty status in response to the exercise intervention,Changes in cognitive health,2019-11-30,RECRUITING,INTERVENTIONAL,['NA'],
10847,NCT02447601,Plasma concentrations of simvastatin and simvastatin acid.,Incidence of adverse events and serious adverse events,2015-03-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
10848,NCT04791371,Change in insulin sensitivity,,2022-06-17,RECRUITING,INTERVENTIONAL,['NA'],
10849,NCT05081583,Metformin area under the concentration vs. time curve (AUC) ratio (exposure/baseline),Midazolam half-life ratio (exposure/baseline),2021-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
10850,NCT04918732,Prevalence of NAFLD in risk groups followed by the general practitioner,To assess the work productivity and absenteism of the patient.,2021-05-05,RECRUITING,INTERVENTIONAL,['NA'],
10851,NCT01340079,Change from Baseline in hemoglobin a1c at 8 weeks after completion of the intervention.,Change from Baseline in physical activity at 8 weeks after completion of the intervention.,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10852,NCT05182580,Number of Completed Care Encounters Among All Clinic Patients (With and Without Diabetes) Per Retina Specialist Clinic Hour,Number of Participants Who Were Very Satisfied or Satisfied With Autonomous AI,2022-03-20,COMPLETED,INTERVENTIONAL,['NA'],
10853,NCT00890331,Parental involvement and Disease care behaviors,"Glycohemoglobin levels, Adverse effects and Blood glucose variability",2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
10854,NCT01792284,Hemoglobin A1c (HbA1c) at 12 Weeks,Percentage of Participants With HbA1c <7.0% and ≤6.5% at 12 Weeks,2013-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
10855,NCT01476995,Agreement of ClearView Scan versus Active Diagnosis,Sensitivity and Specificity of ClearView Scan versus Active Diagnosis,2010-09,COMPLETED,OBSERVATIONAL,['NA'],
10856,NCT00823680,Absolute change in mean daily plasma glucose,"Adverse events, lab parameters, vital signs, body weight",2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
10857,NCT04698486,Fatty acid oxidation in Heart (µmol/min),VLDL-triglyceride uptake in adipose tissue (percent),2020-07-03,COMPLETED,INTERVENTIONAL,['NA'],
10858,NCT03173963,Effect of empagliflozin on change in cortical interstitial fractional volume [Vv(Int/cortex) over the 3-year study period.,Effect of empagliflozin on development or progression of diabetic retinopathy determined by changes from baseline to 3 years of at least 2 Early Treatment of Diabetic Retinopathy Study levels in grading of standardized retinal photographs.,2017-05-27,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
10859,NCT03263351,Insulin secretion,Daily cortisol output,2017-10-01,RECRUITING,INTERVENTIONAL,['NA'],
10860,NCT01854723,Difference in A1C between groups at 6 months,Difference in number of visits with clinical pharmacist,2013-04,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
10861,NCT06147323,Changes in quality of life,,2023-11-13,RECRUITING,INTERVENTIONAL,['NA'],
10862,NCT01557504,Number of Participants Who Discontinued Study Drug Due to an AE,,2012-07-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
10863,NCT03675464,Number of participants with Hypertension,Genetic variations linked to lipolysis,2018-09-20,UNKNOWN,OBSERVATIONAL,['NA'],
10864,NCT01486043,Length of Insulin Therapy (Days),Hemoglobin A1c,2011-12,TERMINATED,INTERVENTIONAL,['NA'],
10865,NCT02050399,Cardiovascular responses during isometric exercise,,2013-08,COMPLETED,INTERVENTIONAL,['NA'],
10866,NCT00285896,"Area under curve (AUC)for plasma glucose, insulin, insulin secretion velocity and glucagon for the periods 0-48 hours(day 1-2) and 0-180 min (day 3). And also the lowest plasma glucose during the period 0-180 min day 3 and mean blood pressure",,2005-12,COMPLETED,INTERVENTIONAL,['NA'],
10867,NCT00712842,Pattern ERG,Blood glucose,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
10868,NCT04155619,Insulin secretion,"Glycemic (""Peripheral"") Rhythm Phase",2021-04-26,RECRUITING,INTERVENTIONAL,['NA'],
10869,NCT04419467,Percent Change From Baseline in Urinary Albumin-to-creatinine Ratio (ACR),Percentage of Subjects Positive for Anti-drug Antibodies,2020-09-14,COMPLETED,INTERVENTIONAL,['PHASE2'],
10870,NCT02394158,Development of Gestational Diabetes at any point during the course of pregnancy,Cost effectiveness of the intervention,2015-01-27,UNKNOWN,INTERVENTIONAL,['PHASE4'],Fetal hyperinsulinaemia
10871,NCT02888691,Percentage of Time Spent in Euglycemia,TNF-alpha,2016-08,COMPLETED,INTERVENTIONAL,['NA'],Ketones
10872,NCT02091323,fasting plasma glucose(FPG),hemoglobin A1c (HbA1c),2014-03,UNKNOWN,INTERVENTIONAL,['NA'],weight loss
10873,NCT05826678,Hypoglycemic Confidence Scale (HCS) change over 6 month study period,Family/social-level factors impacting technological device for care management,2022-09-22,RECRUITING,INTERVENTIONAL,['NA'],
10874,NCT01293578,Patient Satisfaction and knowledge,Physician adoption and satisfaction with the decision aid.,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
10875,NCT01864603,HIV Incidence,Total Costs of Programming (ART),2013-04,COMPLETED,INTERVENTIONAL,['NA'],
10876,NCT05296642,Change in Pain Pressure Threshold (PPT),Change in Heat Pain Threshold (HPT),2022-08-01,WITHDRAWN,INTERVENTIONAL,['NA'],
10877,NCT00229931,"Main Outcome Measures Will be Quantitative Changes in OCT Central Thickness, Visual Acuity, and Number of Snellen Acuity Lines Gained/Lost.","Rate of Elevated Intraocular Pressures, Retinal Detachment, Infection, and Vitreous Hemorrhage.",2005-11,COMPLETED,INTERVENTIONAL,['NA'],
10878,NCT01525225,"Number of Participants With Adverse Events (AEs) , Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Death",Number of Participants With Marked Chemistry or Hematology Laboratory Abnormalities,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1'],
10879,NCT05400863,change in BMI z-score between the two groups at 12 weeks,improvement of A1C due to metformin between the 2 groups at 12 weeks,2022-04-21,RECRUITING,INTERVENTIONAL,['NA'],metformin-induced rise in GDF15 in both groups at 12 weeks
10880,NCT03363100,A1c,,2017-12-05,COMPLETED,INTERVENTIONAL,['NA'],
10881,NCT00836329,Proportion of participants with new neuropsychological deficits (20% decline on two or more neuropsychological tests),"Neuropsychological deficits (i.e., predictive utility of neuropsychological performance on presence, number, and volume of lesions)",2008-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
10882,NCT03440736,Percentage of patients achieving Psoriasis Area and Severity Index (PASI) Score of 90 at week 28,"Percentage change from Baseline in Participant's self-assessed pain, itching and scaling",2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE4'],
10883,NCT05752292,Completion of recommended postpartum diabetes screening.,Uptake of a lifestyle program for diabetes prevention.,2023-04-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
10884,NCT03260998,corrected QT dispersion,,2017-08,UNKNOWN,OBSERVATIONAL,['NA'],
10885,NCT05226182,Usability and acceptance of the application in patients and healthcare professionals,"Possible change,impact on personal clinical parameters: bodyweight",2021-10-01,UNKNOWN,INTERVENTIONAL,['NA'],
10886,NCT01280188,Change from Baseline in 24-hour Urine Volume,Participants with Adverse Events Summarized by Incidence and Severity,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
10887,NCT03516864,Tissue oxygenation is detected on both the MIMOSA Imager and Kent camera.,,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA'],
10888,NCT02774733,The correlation between the pulmonary function parameters and the retrobulbar circulation parameters in 48 T2DM patients,"HbA1c, FPG, 2hPG, WC,BMI, DBP, SBP, and blood-fat in 48 T2DM patients",2015-08,COMPLETED,OBSERVATIONAL,['NA'],
10889,NCT00960973,AIRg (acute insulin response to glucose) using FSIGT (frequently sampled intravenous glucose tolerance test),insulin sensitivity (FSIGT),2009-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
10890,NCT03886974,Needs assessment for transition of care,,2018-09-07,COMPLETED,OBSERVATIONAL,['NA'],
10891,NCT01023165,Researchers will assess whether restoring metabolic integrity to diabetic patients improves quality of life and complications associated with diabetes,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],
10892,NCT00633282,"Improved metabolic parameters(glucose, lipid, liver enzymes, etc.)",the ratio of withdrawing because of inefficiency,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
10893,NCT00737347,change in body weight,change in body composition,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
10894,NCT02641548,Time to healing of deep heel fissures,Number of participants with complications,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],
10895,NCT03506022,Prevalence of obstructive sleep apnea syndrome confirmed by polysomnography an apnea hypopnea Index ≥ 15,,2018-01-12,COMPLETED,INTERVENTIONAL,['NA'],
10896,NCT05676619,Interrater reliability (Intraclass Correlation Coefficient) of 3D foot scans repeated at baseline (change),,2023-02-16,RECRUITING,INTERVENTIONAL,['NA'],
10897,NCT02605200,Change in the Pediatric Quality of Life Inventory Transplant Module (PedsQL),Change in the Behavior Assessment System for Children (BASC) Score,2016-07-07,COMPLETED,INTERVENTIONAL,['NA'],
10898,NCT03047447,Hemoglobin A1c,Ketones (Blood),2016-02-25,COMPLETED,INTERVENTIONAL,['NA'],
10899,NCT05687890,Changes in urine protein creatinine ratio (UPCR) at Week 12,"Percentage of subjects achieving UPCR ≥30%, ≥40%, and ≥50% reduction from baseline",2023-05-23,RECRUITING,INTERVENTIONAL,['PHASE2'],
10900,NCT04527965,Between-group changes in liver fat content between baseline and month 12,Between-group changes in FIB-4 between baseline and month 12,2020-08-11,COMPLETED,INTERVENTIONAL,['NA'],Between-group changes in plasma lipids (ceramides) using a targeted lipidomic approach between baseline and month 12
10901,NCT06267391,HbA1c,Incidence of adverse events,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
10902,NCT01055808,Changes in Health Related Quality of Life (ITR-QOL) in insulin treated type 2 diabetes at baseline and 12 weeks after a significant change in insulin treatment regimen,Change from baseline in use of concomitant oral hypoglycemic drugs,2010-01,COMPLETED,OBSERVATIONAL,['NA'],
10903,NCT00444899,HbA1c,,2007-03,COMPLETED,INTERVENTIONAL,['NA'],
10904,NCT01537016,"To identify EPA wounds using WOUNDCHEK™ Protease Status diagnostic test, and to compare the healing outcomes of two treatment regimes (PROMOGRAN®, a protease modulating therapy and current standard of care) on chronic wounds with EPA.",Reduction in wound area and cost effectiveness,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],
10905,NCT03507829,incidence of NODAT,"Mental component summary (MCS) and physical component summary (PCS) derived from the Kidney Disease Quality of Life Short Form (KDQoL-SFTM) at 6, 12 and 24 months after kidney transplantation",2012-11-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
10906,NCT02716064,"The experience of patients, family members, primary health care providers, volunteers and community organizations with the TAPESTRY-CM program",Developmental decision evaluation - I,2014-12,COMPLETED,INTERVENTIONAL,['NA'],
10907,NCT03010215,Score change of the AOFAS Hallux metatarsophalangeal interphalangeal scale,Change in clinical evaluation with VAS,2010-01,UNKNOWN,INTERVENTIONAL,['NA'],
10908,NCT02987335,Rate of Glucose Disposal (RD).,Insulin Secretion,2010-12,COMPLETED,OBSERVATIONAL,['NA'],
10909,NCT01480895,Change in HOMA.,BMI changes after delivery.,2007-03,COMPLETED,INTERVENTIONAL,['NA'],
10910,NCT00561704,"GFR, HbA1c and the adiponectin concentration.",,2007-04,COMPLETED,INTERVENTIONAL,['NA'],
10911,NCT04716790,Wound Size,Health-related quality of life,2021-04-20,UNKNOWN,INTERVENTIONAL,['NA'],
10912,NCT00495794,Change in Systolic Blood Pressure,LDL Control,2008-08,COMPLETED,INTERVENTIONAL,['NA'],
10913,NCT02935712,Safety of AZD8601 by assessing number of subjects with clinically significant urinalysis (Part B),,2016-12-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
10914,NCT01101269,Change in renal blood flow (RBF),Change in Proteinuria,2010-02,TERMINATED,INTERVENTIONAL,['NA'],
10915,NCT00924430,"Simvastatin and simvastatin acid: Cmax, tmax, AUC0-t, AUC, lz, and t1/2, as well as CL/F and Vz/F for simvastatin only","Safety and tolerability assessments including adverse events, clinical laboratory tests, electrocardiogram (ECG) and vital signs",2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
10916,NCT04022993,Antibody Response,Achievement of Glycated Hemoglobin < 7%,2018-07-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
10917,NCT01906294,"routine treatment data (composite of e.g. diagnostics, kind and dosage of pharmacological diabetes treatment)",,2013-08,TERMINATED,OBSERVATIONAL,['NA'],
10918,NCT01120899,Number of Study Eyes Demonstrating an Increase or Decrease in Best-corrected Visual Acuity (BCVA) of 15 or More Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 6 Months Compared to Baseline,"Number of Fellow Eyes Demonstrating a Decrease in the Area of Late Leakage, as Measured by Fluorescein Angiography (FA), at 24 Months Compared to Baseline",2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10919,NCT02616263,Change in metatarsal phalangeal joint angle (degrees) in people with diabetes from baseline and at a 3-year period,,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
10920,NCT05685875,Severe malaria,Severe malaria with kidney failure,2022-06-07,RECRUITING,OBSERVATIONAL,['NA'],
10921,NCT04222738,Variation of mitral E' velocity,Variation of lipid profile.,2016-12-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
10922,NCT02081001,Time to Reach 50% of Maximum Glucagon Concentration (Glucagon T50%-Early),Infusion Site Discomfort Score at 30 Minutes,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
10923,NCT04591691,"Proportion of participants with complete wound healing by week 12, defined as complete wound closure where there is skin re-epithelialization without drainage or dressing requirements",,2020-10-14,RECRUITING,OBSERVATIONAL,['NA'],
10924,NCT02065895,Glucose Area Under the Curve (AUC) Breakfast,Peak and Nadir Postprandial Glucose Concentration,2013-12,COMPLETED,INTERVENTIONAL,['NA'],Nighttime Time-in-target 5.0-8.33mmol/l (Controller Set-point Plus and Minus 15 mg/dL)
10925,NCT03917576,Maximum heart rate,Heart rate post each HIIT-interval,2018-01-04,COMPLETED,INTERVENTIONAL,['NA'],
10926,NCT00672451,Albumin Concentration in Urine,Rate of Decline of GFR,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
10927,NCT02877771,Agreement between algorithm-recommended pump action,,2016-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Reference blood glucose
10928,NCT02111096,Change From Baseline to 6 Months in Hepatic Fat Fraction,Number of Participants With Hypoglycemic Events,2014-04,TERMINATED,INTERVENTIONAL,['PHASE2'],
10929,NCT04645992,Intraoccular pressure measurement,Intraoccular pressure measurement,2020-11-20,UNKNOWN,INTERVENTIONAL,['NA'],
10930,NCT01316068,Change from Baseline in urine albumin/creatinine ratio,Change from Baseline in urine albumin/creatinine ratio and serum creatinine,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
10931,NCT00029848,Change in body weight,Metabolic parameters,2001-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
10932,NCT05262257,Mini-Mental State Examination(MMSE),glycated hemoglobin(HbA1c、GHb),2022-04-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
10933,NCT02648217,Change in HbA1c (%) (Glycosylated Haemoglobin),Number of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes,2016-01-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
10934,NCT05612269,Reducing the risk of cancer among Diabetics with SGLT2 inhibitors,measurement of inflammatory factors like interleukin-6,2022-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
10935,NCT01722474,"To compare the ability of the non-invasive ASI Device to determine arterial stiffness as compared to SphygmoCor, CR-2000 CV Profiler and VP-1000.",,2012-10,TERMINATED,INTERVENTIONAL,['NA'],
10936,NCT00404027,PPOS scores,Hemoglobin A1c,2007-06-04,COMPLETED,OBSERVATIONAL,['NA'],
10937,NCT04709549,Ideal Cardiovascular Health,Binge Eating,2021-02-10,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
10938,NCT02808351,Contrast-induced nephropathy,Major adverse renal events,2016-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
10939,NCT00205660,Change in Whole Body Sensitivity (mg/kg/Min),,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
10940,NCT02753491,decreasing 300 cal daily food intake,loosing weight,2015-10,COMPLETED,INTERVENTIONAL,['NA'],
10941,NCT03166423,Incidence rate of healing until 60 days or less,Incidence of treatment-emergent adverse events (Safety and Tolerability) of a formulation of snail slime and natural extracts in ulcer wounds in diabetics foot,2015-11-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10942,NCT00391196,Percent change in body weight from baseline.,Change from baseline HbA1c to 1 year;,2006-11,TERMINATED,INTERVENTIONAL,['PHASE3'],
10943,NCT05875519,Glycemic level recorded before local anesthesia administration and 30 minutes following local anesthesia injection using glucometer,Healing score of the extraction socket,2023-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
10944,NCT04024306,Number of patients who developed Steroid-induced diabetes mellitus,Number of patients who didn't develop steroid-induced diabetes mellitus,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],
10945,NCT01103245,Plasma Glucose,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
10946,NCT05619237,Quality Improvement,Patient satisfaction - overall satisfaction,2022-12-06,COMPLETED,INTERVENTIONAL,['NA'],
10947,NCT02048189,Mixed measurement of insulin secretion and insulin resistance,Decrease in the time spent in baseline and prandial hyperglycemia,2012-03-08,TERMINATED,INTERVENTIONAL,['PHASE4'],
10948,NCT00834496,The primary objective is that acute cellular rejection following a switch to sirolimus will be comparable to the historical rate at our center under calcineurin inhibitors of around 5% for post liver transplant recipients.,,2009-01,WITHDRAWN,OBSERVATIONAL,['NA'],
10949,NCT00542724,Change in HbA1c,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
10950,NCT01250639,,,2010-08,UNKNOWN,OBSERVATIONAL,['NA'],
10951,NCT02848053,Incidence of diabetes,Number of participants with abnormal blood glucose values (in mmol/L),2016-08,UNKNOWN,OBSERVATIONAL,['NA'],
10952,NCT01306214,Change From Baseline in HbA1c After 18 Weeks of Treatment,Change From Baseline in HbA1c After 52 Weeks of Treatment,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
10953,NCT01628445,Change in A1c,Postprandial glucose reduction through measurement of 7 point glucose profile,2012-08,TERMINATED,INTERVENTIONAL,['PHASE3'],
10954,NCT03481374,VO2 max,,2016-07-01,COMPLETED,INTERVENTIONAL,['NA'],
10955,NCT00869908,Number of serious adverse drug reactions and major hypoglycaemic events reported as serious adverse drug reactions,Change in PPG (postprandial glucose),2008-11,COMPLETED,OBSERVATIONAL,['NA'],
10956,NCT04552002,Waist circumference,Microbiome sequencing,2020-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
10957,NCT00240253,To evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes.,"To evaluate the effects of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes on markers of cardiovascular risk, fasting serum lipids, fasting plasma glucose, waist circumference, and patient-reported outcomes.",2005-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
10958,NCT00525330,The primary objective of this trial is to demonstrate the hemoglobin A1c (HbA1c)-lowering effects of KRP-104 in patients with type 2 diabetes inadequately controlled on metformin alone.,To assess the safety and tolerability of KRP-104;,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
10959,NCT02294370,glucose levels in tissue fluid,capillary glucose,2013-12,COMPLETED,OBSERVATIONAL,['NA'],
10960,NCT06273631,Change of time in range (TIR),Change in autoimmunity from baseline,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
10961,NCT05865717,Physical activity which will be measured using a questionnaire developed by the American College of Lifestyle Medicine and Loma Linda University,Prevalence of Chronic Diseases according to each profession and BMI,2023-02-15,COMPLETED,OBSERVATIONAL,['NA'],
10962,NCT01910805,Change in Diabetes Risk Awareness from baseline to 12 months postpartum,Change in physical activity levels from baseline to 12 months postpartum,2014-08,COMPLETED,INTERVENTIONAL,['NA'],Change in physical activity levels from baseline to 6 months postpartum
10963,NCT02347514,glycosylated hemoglobin,Summary of Diabetes Self-Care Activities (SDSCA),2014-11,COMPLETED,INTERVENTIONAL,['NA'],
10964,NCT01477853,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 16,2011-10-24,TERMINATED,INTERVENTIONAL,['PHASE3'],
10965,NCT04428658,Glycemic control,Patient-reported outcomes,2022-09-15,RECRUITING,INTERVENTIONAL,['NA'],
10966,NCT05506800,Incidence and mortality rate of cancer,Reproductive health,2016-03-03,SUSPENDED,OBSERVATIONAL,['NA'],
10967,NCT00021788,,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
10968,NCT01767012,Amount of aqueous flare measured with a Laser flare meter,Anterior capsule opacification (measured as brightness of anterior capsular reflect on slitlamp photographs),2010-08,COMPLETED,INTERVENTIONAL,['PHASE4'],IOL tilt measured with a Purkinje-meter
10969,NCT04343872,Change in Glycosylated Hemoglobin (HbA1c),,2020-12-10,COMPLETED,INTERVENTIONAL,['NA'],
10970,NCT06006689,Change in UACR(urinary albumin ⁃ to ⁃ creatinine ratio).,TCM syndrome,2023-09-04,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in MCP-1.
10971,NCT01816165,State 3 Mitochondrial Oxygen Consumption,Vascular Markers,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Counterregulatory Hormones
10972,NCT01790438,Change From Baseline to 26 Weeks in Hemoglobin A1c (HbA1c),Change From Baseline to 26 Weeks in European Quality of Life (EQ-5D-3L) - Visual Analog Scales (VAS) Scores,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
10973,NCT02324491,"Safety and tolerability assessed by adverse events, laboratory evaluations, ECGs, vital signs, physical examinations",Change in Patient Reported Outcomes (PRO) scores,2014-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
10974,NCT00834626,Percentage of Participants Having Remission of Type 2 Diabetes,Percentage of Participants Achieving Remission in Hypertension,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
10975,NCT03658031,Incidence rate of T2DM,,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
10976,NCT04026750,Change From Baseline in Peak Glucagon Response to Hypoglycemia,Number of Patients Returning to Blood Glucose =>70 mg/dL,2019-09-15,TERMINATED,INTERVENTIONAL,['PHASE1'],
10977,NCT06051565,Degree of vascular stenosis,Serum transferrin saturation,2021-11-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
10978,NCT03338855,Corrected Glucose Disposal Rate (cGDR) Measured as Change in Rate of Disposal (Delta RD) Basal vs High Insulin After 5 Weeks of Treatment,,2018-03-05,COMPLETED,INTERVENTIONAL,['PHASE4'],Fibroblast Growth Factor 21 (FGF21) Area Under the Curve (AUC) in Plasma After 5 Weeks of Treatment
10979,NCT00384215,To determine whether glycemic control as measured by HbA1c is different between insulin glargine [rDNA Origin] injection and pioglitazone when added to subjects who fail monotherapy with SU or metformin.,Compare cost of therapy for hyperglycemia treatment,2001-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
10980,NCT05007262,diabetic retinopathy(DR)progression rate,Efficacy of traditional Chinese medicine syndrome.,2021-08-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
10981,NCT01101945,"To demonstrate safety and tolerability of dutogliptin/PHX1149Tas assessed by vital signs, adverse event reporting, and routine clinical laboratory assessments",To demonstrate maintenance or lowering of HbA1c and fasting blood glucose,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2'],
10982,NCT05243628,Change in HbA1c,Change in Coefficient of variation (CV),2022-03-31,COMPLETED,INTERVENTIONAL,['PHASE4'],Change in Percent Predicted Forced Expiratory Volume in 1 Second
10983,NCT02329366,"To identify objective, quantitative biological and molecular markers that correlate with healing outcomes for diabetic foot ulcers (DFUs) using debrided tissue of patients with wounds",,2014-12,COMPLETED,OBSERVATIONAL,['NA'],
10984,NCT04312802,Anaerobic threshold (AT) measurement correlation with cardiac perfusion,,2018-03-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
10985,NCT02268214,Adjusted Mean Change in HbA1c From Baseline at Week 24,Subjects With HbA1c Reduction From Baseline to Week 24 (LOCF) >= 0.5% and Without Severe Hypoglycemia Events,2014-11-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
10986,NCT03751839,failure load in kN,measurement of serum periostin in ng/ml,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],
10987,NCT01789593,Digit Symbol Substitution Test (DSST) score,Paced Auditory Serial Addition Task (PASAT) score,2013-01-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
10988,NCT05838755,"Change from baseline in the weekly average of average daily pain intensity at Week 12, assessed on the Numeric Rating Scale (NRS)","Number of participants with greater than or equal to ≥ 50 % reduction from baseline in the weekly average of average daily pain intensity at Week 12, assessed on the NRS",2023-09-20,RECRUITING,INTERVENTIONAL,['PHASE2'],
10989,NCT01816997,Glucose homeostasis,Chronic complications of diabetes,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
10990,NCT04418869,Change in plasma glucose during exercise and recovery,Change in cardiac output.,2014-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
10991,NCT02759484,Blood Pressure Control,Intermediate Behavior: Medication Adherence,2015-03,COMPLETED,INTERVENTIONAL,['NA'],Intervention Costs
10992,NCT01349166,supervised physical training on cardiometabolic and inflammatory biomarkers,relationships between cortisol secretion and the postprandial inflammatory responses depending on the level of glucose tolerance,2008-02,UNKNOWN,INTERVENTIONAL,['NA'],
10993,NCT01703234,Flow Mediated Dilatation,FGF-23,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
10994,NCT01281098,Regression of retinal neovascularization,Need for vitrectomy due to occurrence of vitreous hemorrhage or retinal detachment,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
10995,NCT03914924,Disease-related knowledge,Cardiometabolic Health Parameter: cardiac autonomic control,2020-01-20,RECRUITING,INTERVENTIONAL,['NA'],Morbidity associated with diabetes
10996,NCT04525573,Fat Reduction,General Health Improvement,2020-08-07,WITHDRAWN,OBSERVATIONAL,['NA'],
10997,NCT03495284,Fasting blood glucose,Triglycerides,2018-02-19,COMPLETED,INTERVENTIONAL,['NA'],
10998,NCT05585268,Proportion of patients with one or more PIMs deprescribed,Mean number of total medications,2022-10-03,COMPLETED,INTERVENTIONAL,['NA'],
10999,NCT04980040,Percentage of Participants With Unexpected Adverse Drug Reactions (ADRs),Percentage of Participants With Overall Improvement and Final Effectiveness Assessment,2014-04-19,COMPLETED,OBSERVATIONAL,['NA'],
11000,NCT02554643,Attenuation of expression of proinflammatory genes verified by qPCR-array technique ranging from at least 5% in pre and post-intervention measurements,Enhance physical performance verified by oxygen consumption measurement on treadmill,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
11001,NCT02993809,Survival without major amputation,Thermography,2018-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],
11002,NCT01255163,Number of Participants With Incidence of Nausea,Body Mass Index (BMI),2010-11-21,TERMINATED,INTERVENTIONAL,['PHASE2'],
11003,NCT02083991,Cumulative incidence of New Onset of Diabetes After Transplantation(NODAT),Cumulative frequency of infections,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
11004,NCT03954418,Amniotic fluid,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA'],
11005,NCT02096874,Peripheral retinal ischemia,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
11006,NCT00754143,Safety and tolerability of FG-3019,Change from baseline in first morning urinary albumin creatinine ratio (ACR),2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
11007,NCT01730014,Incidence of adverse events (AE),The maximal GIR (glucose infusion rate) observed,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
11008,NCT05293015,EFFICACY: TIR（Time in Range）,QUALITY OF LIFE:living quality,2022-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
11009,NCT02181127,Continuous Glucose Monitor (CGM) Glucose Total Area Over the Curve and Less Than 60 mg/dl,Episodes of Nausea Per Day on Glucagon vs Placebo,2014-11,COMPLETED,INTERVENTIONAL,['NA'],
11010,NCT04317703,bioequivalence study,,2020-08-19,COMPLETED,INTERVENTIONAL,['PHASE1'],
11011,NCT04493814,Association between quantity of Visceral adipose Tissu and Liver Stiffness,Build an algorithm with Visceral adipose Tissue mesured and biological markers to predict fibrosis.,2020-07,UNKNOWN,OBSERVATIONAL,['NA'],
11012,NCT04935749,Epidemiology,,2021-07-01,RECRUITING,OBSERVATIONAL,['NA'],
11013,NCT05874141,Number of participants with Cancer,Correlate the presence of each co-morbidity with the extent of diabetes control,2023-11-15,RECRUITING,INTERVENTIONAL,['NA'],
11014,NCT00393510,Number of Participants With Limb Salvage,Time of Ulcer Healing,2000-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
11015,NCT01784965,Change in Weight Reported at 14 Weeks,Insulin Resistance in the Liraglutide vs.Placebo Group After Calorie Restriction,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
11016,NCT00886665,Short-form (sf)- McGill pain questionnaire (SF-MPQ),Nerve conduction study,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],
11017,NCT05648903,Intervention primary outcome- Change in Hba1c (mmol/l),Intervention secondary outcomes- diabetes remission,2022-01-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Other study outcomes- engagement with the programme
11018,NCT00175734,To determine what hemoglobin level is best for diabetic dialysis patients. Specific parameters: endothelial cell function and related expansile capacity of blood vessels. *Assessed through labs and pulse wave velocity test,"Pulse rate, BP, respiratory rate, peripheral oxygen saturation, ECG during 6-min walk-test and Health Related Quality of Life Assessment as measured by questionnaires",2005-08,UNKNOWN,INTERVENTIONAL,['NA'],
11019,NCT02620072,Dysglycemia or diabetes,Progression to diabetes,2015-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events
11020,NCT06026813,Plantar pressure,Balance,2024-03-07,RECRUITING,OBSERVATIONAL,['NA'],
11021,NCT05055804,"Standard OTC Glucose, A1C & Laboratory Results in Comparison to ELG Device During Non-Fasting Event",,2021-08-11,UNKNOWN,INTERVENTIONAL,['NA'],
11022,NCT03932630,Percentage of time in target glucose range (3.9 - 10.0 mmol/L),Percentage of time when pump was in Auto-mode,2019-12,WITHDRAWN,INTERVENTIONAL,['NA'],
11023,NCT01087645,Number and severity of adverse events (AEs) recorded,The uptake in blood of oral NN9925,2010-03-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
11024,NCT01910194,AUCISEC(0-10min),,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
11025,NCT02036619,The glucose tolerance status 3 months postpartum in women with recent GDM.,The prevalence of women with a fasting plasma glucose ≥ 92-99mg/dl in early pregnancy to have a normal 75g OGTT between 26-28 weeks of pregnancy.,2014-04,COMPLETED,OBSERVATIONAL,['NA'],
11026,NCT00187564,4. Trolox equivalent antioxidant capacity (TEAC) (measurement of total antioxidant status),2. Urine albumin/creatinine ratio,2004-08,COMPLETED,INTERVENTIONAL,['NA'],
11027,NCT00601250,HbA1c Change From Baseline at Week 24,2 Hour Post-Prandial Glucose (PPG) Increment Over Fasting Plasma Glucose (FPG) at Week 24,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
11028,NCT00833027,Change From Baseline in HbA1c at Week 24,Change From Baseline in HbA1c at Week 12,2008-03-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
11029,NCT04473430,"Differences in mean percentage time-in-hypoglycemia (< 70 mg/dL) during the intervention phase, compared to control in both phases (i.e. intervention-control vs. control-intervention).",Number of hospitalization or emergency room visits for diabetes ketoacidosis,2020-11-05,COMPLETED,INTERVENTIONAL,['NA'],
11030,NCT00552175,Change From Baseline at Week 12 in Average Pain Severity Rating Using Diaries for the Combined Duloxetine Arms (40 mg + 60 mg),Change From Baseline in Beck Depression Inventory-II (BDI-II) Total Score at Week 12,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
11031,NCT01180283,Evidence that lodenafil carbonate improves erectile function in patients with diabetes type 2.,Adverse events in type 2 diabetes patients taking lodenafil carbonate and laboratory tests changes after this treatment.,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
11032,NCT05259475,Change in liver fat content.,Change in the composition of gut microbiota from baseline due to the diet intervention.,2021-08-20,COMPLETED,INTERVENTIONAL,['NA'],
11033,NCT04899791,Change in blood cholesterol levels,Change in body weight,2021-05-24,COMPLETED,INTERVENTIONAL,['NA'],
11034,NCT02620644,Retinal Ganglion Cell Complex in microns by Optical Coherence Tomography measurements,,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
11035,NCT03907189,Correlation of foot temperature data and daily activity in patients with emergent inflammation.,Correlation of foot temperature data and daily activity in patients without inflammation to the plantar foot.,2019-03-25,UNKNOWN,OBSERVATIONAL,['NA'],Usage rate for the activity monitor
11036,NCT05359341,Proportion of cured patients in the sitagliptin group versus the proportion of cured patients in the empagliflozin group,The change in lipid profile in patients in sitagliptin group versus empagliflozin group,2020-09-20,COMPLETED,INTERVENTIONAL,['NA'],Percentage of adverse effects appeared in patients in sitagliptin group versus percentage of adverse effects appear in patients in the empagliflozin group.
11037,NCT00334399,,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],
11038,NCT03159559,myocardial perfusion reserve index (MPRI),,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11039,NCT05287906,Gastric inhibitory polypeptide,,2022-04-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
11040,NCT02010827,Differences in Endogenous glucose production during the three days measured as total Area under the curve (tAUC),"differences in appetite, hunger, satiety between the three days",2013-11,COMPLETED,OBSERVATIONAL,['NA'],
11041,NCT02896140,Change in Hemoglobin A1C (A1C),Change in c-reactive protein level,2016-04,COMPLETED,OBSERVATIONAL,['NA'],
11042,NCT05132660,Electroretinogram,HbA1c,2022-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['EARLY_PHASE1'],
11043,NCT02053116,Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo,Change from baseline in very low density lipoprotein (VLDL),2014-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
11044,NCT00256256,FDG-uptake in the brain and heart visualized by Positron emission tomography with and without GLP-1,Laboratory values (insulin secretion and counter-regulatory hormones),2005-11,COMPLETED,INTERVENTIONAL,['NA'],
11045,NCT06030544,HbA1c,Presence of sediment in urine,2022-02-25,RECRUITING,INTERVENTIONAL,['PHASE2'],
11046,NCT00167934,Effects of Medication on Insulin Secretion at Skeletal Muscle (Glucose Disposal),,2004-12,COMPLETED,INTERVENTIONAL,['NA'],
11047,NCT03115112,Change in HbA1c From Baseline to Week 24,Change in SBP in Subjects From Baseline at Week 24,2017-10-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
11048,NCT01218256,Muscle strength,Glycemic control,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
11049,NCT03029702,Proportion of participants who report suitability of the study procedures,Cord blood c-peptide,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE4'],
11050,NCT04821921,Hemoglobin A1c (HbA1c),,2021-04-09,COMPLETED,OBSERVATIONAL,['NA'],
11051,NCT01260376,Effects of exercise and antilipolysis on FFA and VLDL-TG kinetics,,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
11052,NCT00251875,7. user metrics,,2005-07,UNKNOWN,INTERVENTIONAL,['NA'],
11053,NCT00752440,Inspiratory muscle strength,Variability of heart rate,2006-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11054,NCT00590434,"proportion of patients with complications including perforation, bleeding, MI or CVA within 24 hours of colonoscopy in >80 vs. <80 agr group",Five year disease free survival and five year mortality rates after the diagnosis of colon cancer in older (>80 yrs) vs. younger group (<80 yrs),2006-08,COMPLETED,OBSERVATIONAL,['NA'],
11055,NCT06258473,Hypertension and Diabetes control,Hypertension and diabetes care cascade,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE1'],
11056,NCT02608905,Monocyte Inflammatory Protein Nuclear Factor Kappa-B (NFkappaB) (%),Arterial Flow Mediated Dilatation (%),2015-11,TERMINATED,INTERVENTIONAL,['PHASE4'],
11057,NCT02538705,Area of diabetic foot ulcers,Transcutaneous oxygen pressure,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
11058,NCT00317707,cardiovascular deaths and hospitalization for cardiovascular causes,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
11059,NCT00939289,CGM System(s) performance (relative to YSI and/or SMBG) evaluated by standard accuracy metrics,"Documentation of all reported Adverse Device Effects, Serious Adverse Device Events, and Unanticipated Adverse Device Effects",2008-07,COMPLETED,OBSERVATIONAL,['NA'],
11060,NCT04937348,"Anthropometrics: body weight [kg], length [cm], head circumference [cm].",Impact of maternal adipokines on breast milk composition.,2019-12-13,COMPLETED,OBSERVATIONAL,['NA'],
11061,NCT02001753,Changes of endothelium-dependent arterial dilation before and after CMR in type 2 diabetes,Changes of endothelial progenitor cells before and after CMR in peripheral blood,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
11062,NCT03315598,Change from baseline Numeric rating scale pain score (0-10) at 8 weeks,5-pointed patient satisfaction scale,2017-05-15,COMPLETED,INTERVENTIONAL,['NA'],
11063,NCT04780425,Change in mean glaciated heamoglobin (HbA1c) at three months,Change in mean WHO quality of life (WHOQoL BREF) score at three months,2021-01-26,COMPLETED,INTERVENTIONAL,['NA'],
11064,NCT00638209,Insulin effect on cortical function (spectral analysis),,2008-02,UNKNOWN,INTERVENTIONAL,['NA'],
11065,NCT02389127,Level of HbA1c in T2DM and cirrhosis,,2015-07,COMPLETED,OBSERVATIONAL,['NA'],
11066,NCT03407508,HbA1c,Gingivitis,2018-10-17,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11067,NCT02077452,"Safety and tolerability of HMS5552 will be assessed by adverse event monitoring, physical examinations, 12 lead ECGs, vital sign, and safety laboratory measurements.","Insulin, C-peptide, glucagon and glucagon-like peptide 1 up to 6hr post-dose following single dose and steady state (fasting and postprandial)",2014-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
11068,NCT03279263,Changes in HbA1c between active treatment groups and placebo at Week 12,Changes in Body Weight,2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
11069,NCT01738802,Change in the markers of oxidative stress and inflammation,Hemoglobin A1c,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
11070,NCT01500928,Device-related adverse outcome,Product quality (MTBF),2011-07,UNKNOWN,INTERVENTIONAL,['NA'],
11071,NCT05232305,Anthropometric Measurements - Hip Circumference,Anthropometric Measurements - Hip Circumference,2022-03-01,UNKNOWN,INTERVENTIONAL,['NA'],
11072,NCT06207838,Between group difference in the percentage of time spent within range with sensor glucose (SG) between 70-180 mg/dL (TIR) (3.9-10.0 mmol/L).,Difference in physical capacity indices listed in screening visit: Four Square Step,2023-09-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
11073,NCT04642911,Overall survival of subject with diabetes 2 type with gene therapy drug product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study,,2020-10-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
11074,NCT02302079,Percent change from baseline in excess central subfield thickness (CST) in the study eye as assessed by spectral domain-optical coherence tomography (SD-OCT) at Month 3,Absolute and percent change from baseline in excess CST in the study eye as assessed by SD-OCT at Months 1 and 2,2015-01-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
11075,NCT02209662,Complete wound closure within 12 weeks,Improvement in wound healing for the patient to return to function over the 12 weeks,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],
11076,NCT02907346,Change in A1c,,2016-09-01,COMPLETED,INTERVENTIONAL,['NA'],
11077,NCT02984644,Change in EGP With Pancreatic Clamp: Study 3,Change in Glucagon Using Pancreatic Clamp: Study 3,2017-09-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
11078,NCT03076112,Glycated hemoglobin,25-hydroxyvitamin D,2017-04-25,COMPLETED,INTERVENTIONAL,['PHASE3'],
11079,NCT06127433,Intergroup remission rate at 24 week,,2023-03-07,RECRUITING,INTERVENTIONAL,['PHASE4'],
11080,NCT02625636,Number of patients with adverse events,Assessment of PK parameter (recombinant glucagon and SAR438544): partial AUCs (AUC0-t),2015-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
11081,NCT04275804,Ulcer size,Foot function,2022-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
11082,NCT04650165,DR severity level,mfERG assessement,2021-06-01,RECRUITING,OBSERVATIONAL,['NA'],
11083,NCT00950716,Lipid levels,"Cognitive-psychological-behavioral assessments: a) Depression Anxiety and Stress Scale (DASS21). b) Diabetes Empowerment Scale (C-DES). c) Summary of Diabetes Self Care Activities (SDSCA, Chinese version).",2009-09,COMPLETED,INTERVENTIONAL,['NA'],
11084,NCT04905823,Adverse events,Values of continuous glucose monitoring,2021-03-31,COMPLETED,OBSERVATIONAL,['NA'],
11085,NCT02783612,Assessing the compliance of the research group compared to the control group.,,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],
11086,NCT00370721,visual acuity,pan retinal photocoagulation,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],
11087,NCT02224417,HbA1c levels,Glucose testing within range,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
11088,NCT01773473,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,"Change From Baseline in 1,5-Anhydroglucitol (1,5-AG) at Week 26",2013-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
11089,NCT01622634,Metabolic Syndrome Risk Factors,Satiety,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
11090,NCT04979377,Prevalence of hyperandrogenic PCOS in T1DM,Influence of hyperandrogenism on chronic complications,2020-03-09,RECRUITING,OBSERVATIONAL,['NA'],
11091,NCT01145547,Mean Area Under the Curve for Rise in Breakfast Post-prandial.,,2009-04,COMPLETED,INTERVENTIONAL,['NA'],
11092,NCT01536431,Safety,T cell (immune) response to islet cell antigens,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11093,NCT00318461,Change in Glycosylated A1c (HbA1c) at Week 104,Hypoglycaemic Episodes at Week 104,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
11094,NCT01599338,"Change in appetite, desire to eat, pleasure in eating","Change in plasma ghrelin, leptin, and HbA1c levels",2011-01,COMPLETED,INTERVENTIONAL,['NA'],
11095,NCT05729282,Continuous glucose monitoring (CGM) profile,Fasting serum/plasma apolipoprotein B (ApoB) (relative/change),2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Deuterium tracer enrichment in body water (measured in saliva)
11096,NCT00545337,Change of HbA1c,"Blood glucose parameters, hypoglycemic episodes and dosage of the mealtime and basal insulins",2004-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
11097,NCT00933972,Creatinine clearance; Pk parameters; adverse events,Blood glucose; meal tolerance test,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
11098,NCT02004678,time to reach maximum plasma concentration (Tmax),number of patients experiencing laboratory adverse events,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
11099,NCT00333151,HbA1c,Glycaemic control,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
11100,NCT00095030,Change in baseline HbA1c after 52 weeks,Change in lipids after 52 weeks; safety and efficacy when administered with metformin after 52 weeks,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
11101,NCT02653300,Change in MRI-Proton Density Fat Fraction (MRI-PDFF),Mean Fibrosis Score CAP™ (FibroMax),2018-09-20,COMPLETED,INTERVENTIONAL,['PHASE2'],
11102,NCT01526733,Early Insulin Exposure (%AUC[0-60]),Duration of Insulin Action (AUMC[0-360]/AUC[0-360]),2011-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
11103,NCT01714674,Cardiac troponin T,Blood pressure,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],
11104,NCT02194790,The difference of rate of estimated glomerular filtration(eGFR) decline,Change from baseline in Hemoglobin A1C,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
11105,NCT00870194,Change in HbA1c (Percent),Incidence of Confirmed Hypoglycemia(Overall),2009-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
11106,NCT00108615,Effects of pioglitazone and metformin on ectopic lipid accumulation,Effects of pioglitazone and metformin on beta cell responsiveness,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
11107,NCT04572802,Gensini score,,2020-10-10,COMPLETED,OBSERVATIONAL,['NA'],
11108,NCT02207374,Number of Treatment Emergent Adverse Events (TEAEs),Change in Glycosylated Haemoglobin A1c (HbA1c),2014-08-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
11109,NCT02739971,"Change from baseline in AGEs markers in serum (carboxymethyl lysine, CML and Methylglyoxal ,MG ) at 6 months",retention rate to the diet,2016-06,COMPLETED,INTERVENTIONAL,['NA'],Change in microbial diversity and composition of fecal microbiome following AGE reduction in diet
11110,NCT05098600,Measurement of Vitamin D levels,Identification and prevalence of possible exacerbating factors in patients with Alopecia Areata,2021-10-15,COMPLETED,OBSERVATIONAL,['NA'],
11111,NCT01648582,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks,Change From Baseline in EQ-5D Visual Analog Scale Score,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
11112,NCT02597257,11-point Numeric Rating Scale,11-point Numeric Rating Scale,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
11113,NCT02268292,Metabolic syndrome,Arterial stiffness,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
11114,NCT00012623,,,na,COMPLETED,OBSERVATIONAL,['NA'],
11115,NCT03775057,Percentage of patients reaching fasting SMPG target without a severe hypoglycemic episode during the 16-week on-treatment period,Assessment of emotional well-being using WHO-5 well-being index,2018-08-22,UNKNOWN,INTERVENTIONAL,['NA'],
11116,NCT02248077,Complete Ulcer Closure,,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
11117,NCT04823442,BAT glucose uptake,Changes in pancreatic and gut hormones,2021-01-21,COMPLETED,INTERVENTIONAL,['NA'],
11118,NCT05642143,"Evaluation of differences in bone turnover markers between T2D patients with and without previous fractures by biochemical analysis of different bone markers (CTX, P1NP, osteocalcin (OC), ucOC, sclerostin, osteoglycin and osteopontin).",Compare muscle mass and strength in T2D patients with and without neuropathy,2023-02-24,RECRUITING,OBSERVATIONAL,['NA'],The correlation between levels of Advanced Glycation End Products (AGEs) (assessed by skin autofluorescence) and bone material strength (assessed by microindentation).
11119,NCT03288233,Average end expiratory alveolar concentration of CO (ppm) 5 hours after lunch,,2015-04,UNKNOWN,OBSERVATIONAL,['NA'],
11120,NCT02631083,Substrate oxidation,,2014-11-14,COMPLETED,INTERVENTIONAL,['NA'],
11121,NCT00290979,Non-inferiority in the efficacy and safety of HMR1964 as compared with Insulin lispro,6-month safety data,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
11122,NCT02204670,Hepatic Triglyceride Content,Post-prandial glucose,2014-07,COMPLETED,OBSERVATIONAL,['NA'],
11123,NCT01697228,Hemoglobin A1c,Baseline differences between vitamin D deficient & sufficient subjects,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
11124,NCT01076088,Change From Baseline in Hemoglobin A1C (A1C) at Week 24,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,2010-11-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
11125,NCT02544321,Hyperemia Peripheral Arterial Tonometry (RH-PAT): Reactive Hyperemia Index (RHI),Metabolic Markers - Insulin,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
11126,NCT02169518,Paraoxonase activity is measured using a semi-automated microtitre plate method.,,2012-07-05,RECRUITING,OBSERVATIONAL,['NA'],
11127,NCT01663298,FGF2 methylation level,Wound healing indices (WHI),2010-08,COMPLETED,OBSERVATIONAL,['NA'],
11128,NCT02989831,Difference in center of pressure displacement (balance) between the two conditions.,Difference in anteroposterior velocity of the centre of pressure displacements between the two conditions (insoles 'on' or 'off'),2014-04,COMPLETED,INTERVENTIONAL,['NA'],
11129,NCT05705869,Diagnosis of heart failure within 6 months,People diagnosed with HFrEF receiving GDMT within 6 months,2022-12-22,RECRUITING,INTERVENTIONAL,['NA'],"The number of patients in the NT-proBNP/echocardiography group with echocardiographic features of potential amyloid as assessed by the US2.ai algorithm report conclusion of ""amyloid to be considered"""
11130,NCT05427890,Differences in behaviour intention between arms,Empirical evidence of using PMT constructs in developing interventions,2022-06-20,COMPLETED,INTERVENTIONAL,['NA'],Objective Risk Score
11131,NCT03193229,Total number of steps per day,Pace of steps per day,2017-05-15,COMPLETED,INTERVENTIONAL,['NA'],Sedentary minutes per day
11132,NCT02967653,"Raw Urine Osmolality value at 12 week follow-up, adjusted for baseline (UOsm in mOsm/Kg)","Raw Self-Reported Fluid Intake value 12 week follow-up, adjusted for baseline",2017-07-13,COMPLETED,INTERVENTIONAL,['PHASE2'],"Subgroup Analyses - Raw Urine Osmolality value at 12 week follow-up, adjusted for baseline in patients UOsm <300mOsm/Kg"
11133,NCT04316052,International Restless Leg Syndrome Study Group Rating Scale: (International tool for finding the severity of RLS),The Pittsburgh Sleep Quality Index (PSQI).,2020-02-15,COMPLETED,INTERVENTIONAL,['NA'],Epworth Sleepiness Scale (ESS)
11134,NCT04018365,HbA1c change at Week 24 of the treatment from baseline,Postprandial glucose for 2 hours over time,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
11135,NCT06141980,Efficacy outcome_Proportion of subjects achieving HbA1c target of < 7.0 %,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
11136,NCT04965506,The change in HbA1c from baseline to 20 weeks,Number of participants with treatment-related adverse events,2021-09-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
11137,NCT02542059,Beta cell mass measured by uptake of 68Ga-exendin in the pancreas on PET images,Comparing uptake of 68Ga-exendin in the pancreas with blood glucose and insulin measured after glucose ingestion and arginine infusion,2015-08,RECRUITING,OBSERVATIONAL,['NA'],
11138,NCT02966626,Change in HbA1c,Change in body mass index,2017-01,COMPLETED,OBSERVATIONAL,['NA'],
11139,NCT00236626,Mean change in insulin sensitivity from baseline to Month 9.,"Mean change, baseline to Month 9, in body weight and composition, Body Mass Index (BMI), lipid profile, fasting glucose; blood pressure; safety evaluations (adverse events) during study.",2000-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
11140,NCT01740921,change of baseline skin maximum hyperaemia at 4 months,change of baseline capillary density at 4 months,2011-01,COMPLETED,INTERVENTIONAL,['NA'],change of baseline adipose tissue inflammation at 4 months
11141,NCT01128829,The Effect of Sucralose on Insulin Concentration (Area Under the Curve; AUC),,2010-05,COMPLETED,INTERVENTIONAL,['NA'],
11142,NCT01542463,Fasting plasma glucose (FBG),Hypoglycaemic episodes,2004-09,COMPLETED,OBSERVATIONAL,['NA'],
11143,NCT01649570,Incidence of hypoglycaemia,"Glycaemic control parameters: Glycosylated haemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and post-prandial plasma glucose (PPPG)",2002-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
11144,NCT04518566,Patient activation score as measured by patient activation measure,HbA1c,2021-05-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
11145,NCT01733134,Dyspnea,Rehospitalization,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
11146,NCT02937987,Change of Weight,,2016-04,COMPLETED,OBSERVATIONAL,['NA'],
11147,NCT02740829,Endogenous glucose production following intranasal glucagon compared to placebo,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
11148,NCT00543738,,,2003-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
11149,NCT01736228,to establish the efficacy and safety of DIABECELL,Improvement in the quality-of-life of xenotransplant recipients,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
11150,NCT04200586,Change in myocardial perfusion reserve index,,2020-04-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11151,NCT02567994,Change of HbAlc from baseline at Week 24,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
11152,NCT01434186,Mean Change in HbA1c From Baseline to Week 16,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
11153,NCT03741972,Change in cardiac biomarkers,Improve in the 6-minute walk,2018-12-21,COMPLETED,OBSERVATIONAL,['NA'],
11154,NCT03620773,Glomerular Filtration Rate (GFR),Aortic Stiffness & Wall Shear Stress,2018-10-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Epigenetic profiling
11155,NCT00005262,,,1990-07,COMPLETED,OBSERVATIONAL,['NA'],
11156,NCT03631121,Change of glycemic variation,,2018-08-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11157,NCT04208282,Primary,Exploratory outcomes,2017-07-01,COMPLETED,INTERVENTIONAL,['NA'],Adverse Events
11158,NCT03132181,Mode of action,Metabolism,2017-04-24,COMPLETED,INTERVENTIONAL,['PHASE2'],
11159,NCT00611884,Change in Glycosylated Haemoglobin (HbA1c),Physical Examination,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
11160,NCT03230786,Change from baseline in blood HbA1c at 12 weeks versus placebo.,Proportion of subjects reaching a level of HbA1c below 7.0% (53 mmol/mol) at 12 weeks versus placebo,2017-08-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
11161,NCT00786825,Brain Glycogen Turnover Rate,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
11162,NCT01874366,Food Effect,Time to peak plasma concentration (t-max),2013-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],
11163,NCT04191525,HOMA-IR,Waist perimeter,2018-09-10,COMPLETED,INTERVENTIONAL,['NA'],Mediterranean diet adherence score
11164,NCT02773875,Amount of time sensor glucose levels are >250 mg/dl,Percent of time in range between 70-180 mg/dl,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],
11165,NCT05980455,Scoring Change in Nausea Severity by GCSI-DD,Mean Change from Baseline in Quality of Sleep Scores,2023-07-10,RECRUITING,INTERVENTIONAL,['NA'],
11166,NCT05506215,Percentage of ulcer closed at 12 weeks,The type and number of serious adverse events experienced,2022-07-10,TERMINATED,INTERVENTIONAL,['NA'],
11167,NCT02189135,Number of patients with hypoglycaemia in usual care versus telemedicine during Ramadan,Glycaemic control of patients measured with HbA1c in patients under usual care versus telemedicine from baseline to end of treatment,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
11168,NCT02308059,Pain scores on the visual analog scale,Neuropathic pain scores on the Leeds Assessment of Neuropathic Symptoms and Signs pain scale,2012-04,COMPLETED,OBSERVATIONAL,['NA'],
11169,NCT03443635,High or Medium (Versus Low) Mediterranean Diet Adherence,Food Costs,2018-02-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11170,NCT00607230,concentration of autoreactive t-cells,"Concentration of TNF, TNF-receptors, other cytokines, and c-peptide levels",2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
11171,NCT00781313,The primary aim is to ascertain the emergency preparedness among our families with diabetes mellitus and to obtain a percentage of unprepared to the ones who are prepared.,,2008-06,COMPLETED,OBSERVATIONAL,['NA'],
11172,NCT04465877,"Change From Baseline in AUEC0-4 for Plasma Postprandial Glucose (PPG) Compared to Placebo on Days 1, 14 and 28",,2020-06-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
11173,NCT01068652,Glycosylated Haemoglobin (HbA1c),Mean of 8-point Plasma Glucose (PG) Profile After 50 Weeks of Treatment,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
11174,NCT01317576,Blood sampling to determine the concentration of cardiovascular risk factors in the blood before and after exercise,"Muscle biopsy to measure muscle mitochondrial density, muscle mitochondrial function and muscle lipid metabolism",2011-03,COMPLETED,INTERVENTIONAL,['NA'],
11175,NCT02092220,Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 11,Number of Participants With Skin Rash,2014-04,COMPLETED,INTERVENTIONAL,['NA'],CGM Mean Absolute Relative Differences (MARD) Versus Time-stamped Blood Glucose (BG) Values From Meter Downloads
11176,NCT04074317,Area Under the Curve 0-180 Minutes for Plasma Glucose >180 mg/dL,Insulin Area Under the Concentration (AUC) Curve,2019-08-22,COMPLETED,INTERVENTIONAL,['PHASE2'],
11177,NCT02259088,Mean Average Change From Baseline in Best-Corrected Visual Acuity (BCVA) (Letters) to Month 1 Through 12,Mean Number of Ranibizumab Re-treatments Received in the Study Eye From Month 3 Onward,2014-11-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
11178,NCT05747872,Change in ulcer surface area,,2022-03-10,COMPLETED,INTERVENTIONAL,['NA'],
11179,NCT02011633,"metformin, rosuvastatin AUClast","Metformin, rosuvastatin AUCinf",2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
11180,NCT01867307,Change From Baseline of Renal Tubular Maximum Reabsorptive Capacity for Glucose (TmG) at End of Empagliflozin Treatment (Day 14),,2013-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
11181,NCT03591458,Ratio of Self-Reported Hypoglycemic Episodes to Total Hypoglycemic Episodes,Hypoglycemia Fear Survey Score,2018-08-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
11182,NCT05921097,Comparison of axon-reflex flare responses with QST,Comparison of axon-reflex flare responses with NC-Stat DPNCheck,2023-06-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],DPN severity and pain
11183,NCT01507272,AUC (area under the curve),"t½, terminal half-life",1999-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
11184,NCT05606471,Muscle protein breakdown rate,Right vastus lateralis muscle fibre pennation angle,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE4'],
11185,NCT00929838,Hemoglobin A1c (HbA1c) at 12 Months Post Randomization,,2008-08,COMPLETED,INTERVENTIONAL,['NA'],
11186,NCT04088851,"The gluconeogenic flux rates from pyruvate (lactate, alanine) and glycerol are higher in patients with T2D compared to the healthy control group.",,2019-09-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
11187,NCT00225277,Nominal Change From Baseline in Percent Atheroma Volume,Number of Subjects Experiencing Any of the Composite Endpoint C Cardiovascular Events,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Cardiovascular Events as Adjudicated by the Clinical Endpoint Committee
11188,NCT02258945,Eating behaviours of adult patients with Type 1 diabetes using continuous subcutaneous insulin infusion therapy measured using food diaries and food surveys.,Cardiometabolic risks of adult patients with Type 1 diabetes who are using insulin pump therapy.,2014-04,COMPLETED,OBSERVATIONAL,['NA'],
11189,NCT00403884,Visual acuity,reduction of retinal edema,2004-10,UNKNOWN,INTERVENTIONAL,['NA'],
11190,NCT02759289,Change in platelet activity in response to arsenic exposure measured by Regression models,,2015-11,COMPLETED,OBSERVATIONAL,['NA'],
11191,NCT00177138,"Time-to-event analysis will be used to analyze categorical end points that include graft failure, patient survival, biopsy documented rejection episode and non-compliance.","The continuous outcome variable, weekly or bi-weekly serum creatinine levels, will be analyzed using a two-way repeated-measures analysis of variance.",2004-07,TERMINATED,INTERVENTIONAL,['PHASE4'],
11192,NCT02289066,markers of bone turnover (bone specific alkaline phosphatase and C terminal,Evaluation of the relationship between periodontal disease and diabetes control and complications,2013-11,COMPLETED,OBSERVATIONAL,['NA'],
11193,NCT00434499,Improvement in insulin resistance,Improvement in endothelial dysfunction,2007-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
11194,NCT01829477,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,2013-04,TERMINATED,INTERVENTIONAL,['PHASE3'],
11195,NCT05838586,iAUC of SBP,Net iAUC of HR,2023-07-31,RECRUITING,INTERVENTIONAL,['NA'],
11196,NCT01774058,"The measurement of the blood flow volume is done with the Sono TT FlowLab (em-Tec GmbH, Munich) ultrasound instrument on the common femoral artery in diabetics and non-diabetics after ilomedin administration.",,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
11197,NCT01855490,Effect of exenatide on metabolic responses to an oral (as a mixed meal) or intravenous glucose challenge in subjects with established T1D with or without residual insulin production.,"Effect of exenatide on insulin secretion, glucagon secretion, GLP-1 and GIP levels, and gastric emptying in these patients with T1D. - effect of exenatide on residual insulin production",2012-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
11198,NCT02632747,Glomerular Filtration Rate (GFR) Under Euglycaemic Conditions After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril.,"Filtration Status (Glomerular Filtration Rate (GFR) < 120 mL/Min/1.73m², Yes/no) After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril",2016-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
11199,NCT04971655,State-Trait Anxiety Inventory (STAI),,2021-08-04,UNKNOWN,INTERVENTIONAL,['NA'],
11200,NCT01492153,Change in body weight,Adverse events (AEs) including hypoglycaemic episodes,2003-02-11,COMPLETED,OBSERVATIONAL,['NA'],
11201,NCT04175496,Postprandial insulin response,,2019-12-01,COMPLETED,INTERVENTIONAL,['NA'],
11202,NCT01180608,cerebral neurobiological effect of pregabaline as treatment for neuropathic pain,cerebral neurobiological changes in relationship with dose dependent therapeutic effect of treatment with pregabaline,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],
11203,NCT01108978,Evaluation absolute and percentage reductions in low-density lipoprotein cholesterol (LDL-C) by fasting biochemistry examination,"Evaluation of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides by fasting biochemistry examination",2010-05,TERMINATED,INTERVENTIONAL,['PHASE4'],
11204,NCT02008851,Number of adverse events related to study procedures or investigational product,Number of renal-specific adverse events,2013-12,TERMINATED,INTERVENTIONAL,['PHASE1'],Changes in renal function over time
11205,NCT01746563,Macular Evaluation,Structural Macular Evaluation,2011-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11206,NCT02111291,Time to Well-established Granulation Tissue,Adverse Event,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
11207,NCT02246712,"Kinetic parameters (AUC, Cmax, Tmax, apparent total clearance, and apparent volume of distribution) of tramadol enantiomers were estimated.",Pain scores on the visual analog scale,2008-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
11208,NCT02490124,Contrast Enhanced Ultrasound,,2014-12,COMPLETED,OBSERVATIONAL,['NA'],
11209,NCT03776448,Fasting venous blood glucose,Gastrointestinal symptoms,2019-01,UNKNOWN,INTERVENTIONAL,['NA'],
11210,NCT03785379,Change from baseline Glycated Hemoglobin (HbA1c) at 6 months,Change from baseline Glycated Hemoglobin (HbA1c) at 12 months,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
11211,NCT05552872,Survival at 7 Days,SOFA Indexs,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],
11212,NCT02799953,changes in systolic and diastolic blood pressure,changes in answering hypertension knowledge questions,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
11213,NCT00933530,"Characterize the pharmacokinetic profile of SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, and 3.0 g/day) when administered as a single dose and when administered as once daily for 7 consecutive days.",,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
11214,NCT01691287,Metabolic Control measured as HbA1c level,Number of Diabetic Keto Acidosis events,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
11215,NCT06101901,Rate of patients who remain in a diabetic kidney disease clinical trial to trial completion,,2024-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
11216,NCT01890954,Percent of Time Spent Near Normoglycemia,,2013-08,COMPLETED,INTERVENTIONAL,['NA'],
11217,NCT05701254,"Compare cortical bone tissue levels of pentosidine (AGE), pyridinoline (normal enzymatic collagen crosslinks), and matrix-bound water between T1DM and controls.",Compare cortical bone tissue heterogeneity in nanoindentation measures of modulus and hardness between T1DM and controls.,2019-06-18,RECRUITING,OBSERVATIONAL,['NA'],
11218,NCT04379427,Performance and accuracy of heart rate,,2019-03-25,COMPLETED,INTERVENTIONAL,['NA'],
11219,NCT00368693,Complete ulcer closure will be defined as complete re-epithelialization without the presence of any callus and/or exudate.,,2005-08,TERMINATED,INTERVENTIONAL,['PHASE3'],
11220,NCT00123643,Flow Mediated Dilation,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
11221,NCT01357135,Percentage of Participants With Strict Changes in Initial Dual Therapy,,2009-07-15,COMPLETED,OBSERVATIONAL,['NA'],
11222,NCT04317430,Estimated glomerular filtration rate (eGFR),Change of Urinary podocalyxin level,2020-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Change of Urinary 8-hydroxy-2' -deoxyguanosine (8-OHdG) level
11223,NCT04029298,Change in hemoglobin A1c,Adherence to treatment,2023-03-01,WITHDRAWN,INTERVENTIONAL,['NA'],
11224,NCT05949008,Change in total body weight from baseline,Percent change in % body fat from baseline,2023-11-22,RECRUITING,INTERVENTIONAL,['PHASE4'],
11225,NCT00018122,,,na,UNKNOWN,OBSERVATIONAL,['NA'],
11226,NCT03270592,"Health related quality of life, EQ-5D",EQ-VAS,2009-09-17,COMPLETED,INTERVENTIONAL,['NA'],
11227,NCT04213547,Qualitative data from focus group,BMI,2020-09-16,RECRUITING,INTERVENTIONAL,['NA'],
11228,NCT05925010,postprandial blood glucose,difference between fasting blood glucose value and postprandial blood glucose value,2023-01-02,RECRUITING,INTERVENTIONAL,['NA'],
11229,NCT06021119,peak postprandial plasma glucose (PPG) level in mg/dl,Time in range %,2023-03-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
11230,NCT05603273,wound size and depth,blood flow,2023-12-13,RECRUITING,INTERVENTIONAL,['NA'],
11231,NCT01091909,postoperative complications,Delayed wound healing,2010-03,COMPLETED,INTERVENTIONAL,['NA'],
11232,NCT05314036,Establishment of proposed Wellness Transformation Network clinical trial procedures.,Time course and curve analysis of Meal Induced Glycemia (MIG) scores response after the test meal administration.,2022-01-17,COMPLETED,INTERVENTIONAL,['NA'],
11233,NCT00412347,,,2006-08,COMPLETED,OBSERVATIONAL,['NA'],
11234,NCT01143168,Rate of reducing exogenous insulin requirement; Hemoglobin A1c; Fast blood glucose (FBG) and postmeal blood glucose (PBG); C-peptide levels.,Serious adverse event frequency and severity,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],
11235,NCT04098575,Percentage of Participants With Antidiabetic and Cardiovascular Co-medication,Fasting Plasma Glucose (FPG),2019-09-16,COMPLETED,OBSERVATIONAL,['NA'],
11236,NCT01698528,Glycemic Control as Determined by the Change in Absolute HbA1c Level,Time Health Care Providers and Subjects Spend on Managing the Insulin Titration,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
11237,NCT01130012,Number of at risk participants developing GDM during pregnancy,The effect of intervention on fetal growth,2005-04,COMPLETED,INTERVENTIONAL,['NA'],
11238,NCT04085705,Presence of contact allergy for wound dressings,Presence of eczema,2019-09-17,UNKNOWN,OBSERVATIONAL,['NA'],Past ulcers
11239,NCT00650806,Percent Change in Body Weight From Baseline to Week 12,Change in Waist/Hip Ratio From Baseline to Week 12,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
11240,NCT00538642,Insulin Sensitivity,LDL Cholesterol,2007-08,COMPLETED,INTERVENTIONAL,['NA'],
11241,NCT01814787,Number of Children With Documented Risk Factors for Type 2 Diabetes,,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
11242,NCT04808804,RNFL thickness,,2021-06,UNKNOWN,OBSERVATIONAL,['NA'],
11243,NCT04093284,Blood glucose profile,Sensitivity Questionnaire of Patients,2019-09-12,UNKNOWN,INTERVENTIONAL,['NA'],
11244,NCT03053518,Observed Incremental Area Under the Curve (iAUCobs),,2017-06-30,TERMINATED,INTERVENTIONAL,['NA'],
11245,NCT00102297,Pharmacokinetics,Bioactivity on urinary and plasma markers,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
11246,NCT03445247,changes of proteinuria,changes of systolic and diastolic blood pressure,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
11247,NCT05099939,Change in lung function,CFRD diagnosis,2021-11-25,RECRUITING,OBSERVATIONAL,['NA'],
11248,NCT05786001,Oxygenation in lower limb angiosomes assessed by hyperspectral imaging.,,2023-04-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
11249,NCT00644241,"Increment in glucagon stimulated C - peptide levels at the end of 6 months of ABMSCT, as compared to baseline",Improvement of HbA1c levels as compared to baseline,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
11250,NCT01313949,To assess the effectiveness of the training program in improving glycemic parameters in diabetic patients before and after the training.,"To assess the efficacy of the training in improving the participants' knowledge of diabetes, as compared to the control patients.",2009-02,COMPLETED,INTERVENTIONAL,['NA'],
11251,NCT00131755,Glycemic control (measured by blood glucose),Side effects,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
11252,NCT03286816,the effect of exogenous lactate on brain lactate concentrations during euglycemia and hypoglycemia between T1DM patients with normal awareness of hypoglycemia and T1DM patients with impaired awareness of hypoglycemia,Changes in immune cell cytokine production capacity in response to hypoglycemia compared to euglycemia and in response to lactate infusion compared to placebo,2016-11,COMPLETED,INTERVENTIONAL,['NA'],
11253,NCT02734745,accuracy of freestyle Libre flash monitoring,Evaluate the accuracy of the Free Style Libre for each day of use and during hyperglicemia ( >180 mg / dl ),2016-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
11254,NCT01664637,Change from baseline in symptoms associated with diabetic gastroparesis,"Adverse events (AEs), vital signs, ECGs, clinical laboratory parameters",2012-08,TERMINATED,INTERVENTIONAL,['PHASE2'],
11255,NCT01239849,Percentage of subjects in the total LDL cholesterol group achieving their LDL cholesterol target after 8 weeks of treatment.,"5. Safety of atorvastatin through laboratory assessment, physical examination, vital signs, and adverse events.",2009-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11256,NCT00466518,Changes in pharmacokinetics,Determine tolerability of sitagliptin therapy in post-kidney transplant patients.,2007-04,COMPLETED,INTERVENTIONAL,['NA'],
11257,NCT00263861,Glycemic control as measured by Glycosylated Hemoglobin Assay,,2005-03,COMPLETED,INTERVENTIONAL,['NA'],
11258,NCT01634282,Incidence and severity of adverse events,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
11259,NCT02883842,Change in glucose level measured by HbA1C level,Change in low-density lipoprotein cholesterol (LDL-C) level,2016-08,COMPLETED,INTERVENTIONAL,['NA'],
11260,NCT04670666,Change from baseline in glycated hemoglobin (HbA1c) levels.,Incidence and severity of adverse events recorded during the study.,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
11261,NCT01608932,Number of emergency hospitalisations,"Anxiety and depression status as measured by Hospital Anxiety and Depression Scale, HADS.",2012-04,COMPLETED,INTERVENTIONAL,['NA'],
11262,NCT06283264,1-Prevalence of coeliac disease among diabetic type 2 patient 2-its effect on glycemic control,,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
11263,NCT00117780,Mean HbA1c,Hypoglycaemia,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
11264,NCT00368394,"Outcome:In T1DM, glulisine, like RHI, displays dose proportionality in exposure over the dose range 0.075 to 0.3 U/kg, which partly only translates into dose proportionality in glucodynamics.",,2004-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
11265,NCT04112875,Changes in Endothelium-dependent and endothelium-independent vasodilation,Body composition by DXA,2016-04,COMPLETED,INTERVENTIONAL,['NA'],
11266,NCT01106651,Change in HbA1c From Baseline to Week 26,Percent Change in Total Hip Bone Mineral Density (BMD) From Baseline to Week 26,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
11267,NCT01087567,The need for rescue therapy,"A1c,C-peptide. Time to normoglycemia and rescue therapy. Mean glucose, mean FBG, HOMA-B, HOMA-IR. Hypoglycemic events (minor and major. Tolerability based on side effects.",2010-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
11268,NCT01414920,Change from Baseline in Glycosylated Hemoglobin (HbA1c),Change from Baseline in Fasting Plasma Glucose,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
11269,NCT02472717,The change in the proportion of patients achieving an ACR 20% improvement response in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to placebo,"The effect(s) of liraglutide on the enumeration of circulating T-cell subpopulations, and on activation of circulating T-cell subpopulations",2015-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],The effect of liraglutide on levels of infiltrating dermal T cells and cytokines in psoriatic skin plaques from patients with psoriatic arthritis receiving liraglutide therapy for 12 weeks compared to those receiving placebo
11270,NCT00130312,Safety and tolerance of sulodexide therapy long-term,Change in urinary protein/albumin excretion,2005-08,TERMINATED,INTERVENTIONAL,['PHASE4'],
11271,NCT02648854,Cmax of Metformin,Vd/F of Metformin,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
11272,NCT01250106,Insulin resistance,body weight,2010-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11273,NCT04523454,Questionnaire - Number of women who have had the importance of a planned pregnancy explained to them,,2020-10-02,COMPLETED,OBSERVATIONAL,['NA'],
11274,NCT03909841,Cognition,Quality of Life: The Chinese (Hong Kong) 12-item Short-Form Health Survey version 2,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],
11275,NCT01250340,Changes of isoprostanes after study drug administration.,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11276,NCT05692778,Experiences of using an eHealth tool supporting the foot assessment,Long term effect,2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],
11277,NCT06125119,Diabetyping,Diabetyping,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Self-reported experiences with capillary blood sampling in an at home setting
11278,NCT04856683,Prediction of frailty,Inappropriate therapeutic regimen,2020-08-10,RECRUITING,OBSERVATIONAL,['NA'],
11279,NCT00221715,"Bypass permeability 5 years after surgery, assessed trough Doppler ultrasonography",leg salvage,2002-07,COMPLETED,INTERVENTIONAL,['NA'],
11280,NCT05577390,The Impact of INF® Therapy and Standard Physical Therapy on Heart Rate Variability,The impact of INF® Therapy and Standard Physical Therapy on inflammation,2024-01-08,RECRUITING,INTERVENTIONAL,['NA'],
11281,NCT04416269,Mean daily BG concentration,Patient antihyperglycemic drug preference survey,2020-08-07,RECRUITING,INTERVENTIONAL,['PHASE4'],
11282,NCT01049152,-Hemodialysis tolerability -Hypoglycemia numbers -Hyperglycemia numbers -Inflammation markers,variations of glycemia during the night; insulin-sensitivity,2009-07-31,COMPLETED,OBSERVATIONAL,['NA'],
11283,NCT04614168,The change in plasma glucagon levels (pmol/L) measured during normoglycaemic and hypoglycaemia,Four Choice Reaction Time Test,2021-07-26,UNKNOWN,INTERVENTIONAL,['NA'],
11284,NCT02153879,HDL particles size and number assessed by nuclear magnetic resonance (NMR) and reported as nm and micromol/L,"Apolipoprotein A1 (Apo A1), apolipoprotein A2 (Apo A2), paraoxonase (PON) HDL concentration (g/l - mg/l)",2009-02,COMPLETED,INTERVENTIONAL,['PHASE4'],Lecithin-cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP) activity (AU - pmol/h*μl) and mass (microg/ml)
11285,NCT02406586,Change in Flow-mediated Dilation,Change in Expression of Inflammatory Biomarker C-Reactive Protein (CRP),2009-07,COMPLETED,INTERVENTIONAL,['NA'],
11286,NCT00626080,"Cerebral blood flow, in brain regions associated with appetite control, as determined by H2O-PET",Weight change,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
11287,NCT00719108,The area under the GIR-time curve at steady state from 240 to 300 minutes (AUCGIR-SS),"PD Endpoints: Area under the GIR-time curve from 0 to 7 hours, GlR at steady state. PK Endpoints: AUCINS-SS, AUCINS0-7h, CLtot, VSS, t1/2 ,Terminal rate constant Safety Endpoints: AE, Lab assessments, Vital signs, Phy Exam, ECG & Hypoglycemia.",2008-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
11288,NCT02370680,change in platelet aggregation,Safety as measured by the number and system class of adverse events reported in each treatment arm,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1'],urinary metabolites of prostacyclin and thromboxane
11289,NCT05738655,Hormone analysis,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],
11290,NCT02077348,"Insulin and growth hormone signalling, expressed as CHANGE in phosphorylation of intracellular target proteins and CHANGE in mRNA expression of target genes in muscle- and fat-tissue.",Ghrelin,2014-05,COMPLETED,INTERVENTIONAL,['NA'],
11291,NCT02678390,Plasma Ketone Concentrations,Plasma Insulin Concentrations,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
11292,NCT04171557,All-cause Mortality,Cause specific mortality: Cardiovascular,2019-11-20,UNKNOWN,OBSERVATIONAL,['NA'],All-cause Mortality
11293,NCT04270097,Genetic risk variants associated with increased risk of T2D in Emiratis,,2016-03-23,UNKNOWN,OBSERVATIONAL,['NA'],
11294,NCT00672204,The Proportion of Insulin-independent Subjects With Full Islet Graft Function,,2007-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11295,NCT04708574,Change in nutrition assessment from baseline to post intervention,Change in steps per day from baseline to post intervention,2006-03-08,COMPLETED,INTERVENTIONAL,['NA'],
11296,NCT01713348,Time in Range,HbA1c,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
11297,NCT01586481,Healing duration of the diabetic foot ulcer,Compliance of patients to footwear,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
11298,NCT05568277,Diabetes Self-Efficacy Scale,,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
11299,NCT03211182,blood sugar,Metabolic syndrome,2012-03-07,UNKNOWN,INTERVENTIONAL,['NA'],
11300,NCT05497232,Patient survival & pancreas graft survival & renal graft survival,,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],
11301,NCT00311818,"Frequency of subjects with HbA1c: ≤ 6.5 %, 6.5 %< HbA1c ≤ 7.0 %, 7.0 %<HbA1c ≤ 8.0 % and HbA1c > 8.0 %","Frequency of subjects with hypoglycemic events (overall, severe, nocturnal, symptomatic)",2003-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
11302,NCT03768973,Changes in intrapulmonary shunt fraction,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],
11303,NCT00442156,OCT-measured retinal thickness and visual acuity,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
11304,NCT05984238,Percentage of patients off insulin at 24 weeks [efficacy],Secondary efficay endpoint 1 - HbA1c 48 weeks,2023-08-03,RECRUITING,INTERVENTIONAL,['NA'],
11305,NCT02801942,"Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in iLN",Number of Participants Who Appreciated Receiving Study Feedback,2016-07-25,COMPLETED,INTERVENTIONAL,['NA'],
11306,NCT00013117,,,na,COMPLETED,INTERVENTIONAL,['NA'],
11307,NCT02465515,Time to First Occurrence of Major Adverse Cardiovascular Events (MACE) During Cardiovascular (CV) Follow-up Time Period,Change From Baseline in Heart Rate,2015-07-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
11308,NCT05543564,BCVA,,2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],
11309,NCT05362058,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L),2022-06-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
11310,NCT02621580,"The rate of structural and functional changes to the retinal thickness following PASCAL PRP in severe PDR patients, assessed by optical coherence tomography.",,2012-09,COMPLETED,INTERVENTIONAL,['NA'],
11311,NCT05984771,Measurement of electrochemical skin conductance,vitamin B12 levels,2021-01-10,COMPLETED,INTERVENTIONAL,['NA'],
11312,NCT01647776,Efficacy of sDNA testing for the detection of advanced adenomas,"To investigate the association of activated (phosphorylated) IRS1, AKT and mTOR with colon adenomas.",2012-04-01,COMPLETED,OBSERVATIONAL,['NA'],
11313,NCT01805830,HbA1c,HOMA-IR,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
11314,NCT01283113,Visceral fat level,,2010-08,COMPLETED,OBSERVATIONAL,['NA'],
11315,NCT04011020,Incidence of Treatment Adverse Events in T1D Subjects,Efficacy of SCE therapy in immune modulation,2022-09-20,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
11316,NCT01922817,Magnitude of epinephrine release at 2.5mmol/L,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
11317,NCT06275412,Glycemic Control,Diabetes-Specific Family Support,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Intervention Satisfaction
11318,NCT05781334,Proportion of patients prescribed SGLT2i (sodium glucose co-transporter-2 inhibitors),,2023-06-09,RECRUITING,INTERVENTIONAL,['NA'],Number of participants with heart failure readmission
11319,NCT02024516,adiponectin change,Body Mass Index change,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],
11320,NCT03433248,GFR,Blood Pressure (Dinamap®),2017-11-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],Glucagon (mg/L)
11321,NCT03538106,Risk factors associated with a cesarean delivery in patients with diabetes type 1,Risk factors associated with an emergency cesarean delivery in patients with diabetes type 1,2016-11,COMPLETED,OBSERVATIONAL,['NA'],
11322,NCT01172093,presence of OSA,glycemic control,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
11323,NCT01227538,Assessment of whether two-hour urinary C-peptide response to mixed-meal (measured as area under the curve on the graph) can be used assess residual beta-cell function in the first 5 years after diagnosis of Type 1 diabetes.,To assess whether urinary C-peptide response to mixed-meal is reproducible in non-observed setting.,2011-04,COMPLETED,OBSERVATIONAL,['NA'],
11324,NCT02977884,Healthcare expenses,Absenteeism: Sick days on record at Ohio University Human Resources,2012-08,COMPLETED,INTERVENTIONAL,['NA'],
11325,NCT01248364,"Change From Baseline in Glucose Metabolism (Pre-meal and Postprandial Glucose), PPG iAUC 5h, at Day 28","Change From Baseline in Rate of Endogenous Glucose Production: iAUC 5h, at Day 28",2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
11326,NCT03834207,Acceptability & usefulness of the C3-Cloud system,,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA'],
11327,NCT05874726,Tissue sample repository,,2023-07-19,RECRUITING,OBSERVATIONAL,['NA'],
11328,NCT01225939,Compare the pharmacokinetics (Cmax and AUC) of the oral solution and the oral solid formulation of AZD8329.,"Investigate the safety and tolerability of AZD8329 administered as two different oral formulations.(Safety variables: Adverse events, Vital Signs, Clinical chemistry, Electrocardiogram (p ECG))",2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
11329,NCT00605787,Plasma lipids,Safety blood parameters,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
11330,NCT02540733,Barthel index,,2012-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
11331,NCT02727348,Blood pressure or heart rate changes more than 30% of baseline after spinal or block is considered significant,S-LANSS score in who receive FSNB versus SAB.,2014-05,COMPLETED,INTERVENTIONAL,['NA'],
11332,NCT05343494,Fidelity - sessions attended,Intervention acceptability,2022-04-04,COMPLETED,INTERVENTIONAL,['NA'],Qualitative interviews
11333,NCT00763412,CRP,C-Peptide,2006-11,COMPLETED,INTERVENTIONAL,['NA'],
11334,NCT01144065,Comparison of hair cortisol and testosterone levels between the patients with acute MI and the 2 control groups,Correlation of hair cortisol and testosterone with the burden of coronary atherosclerosis in the MI group,2010-08,COMPLETED,OBSERVATIONAL,['NA'],
11335,NCT06177054,insulin need per kg,Hyperechogenicity detected by ultrasound,2023-12-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
11336,NCT01182701,"Determine the effectiveness of a cognitive/behavioral intervention program in improving health outcomes of quality of life, general health, glycemic control, and depression.",Determine the effectiveness of a cognitive/behavioral intervention program in enhancing adherence to self-management strategies.,2004-08,COMPLETED,INTERVENTIONAL,['NA'],
11337,NCT05199090,Change-from-baseline in weight,,2022-02-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
11338,NCT00754988,Mean changes in HbA1c,"Safety: Adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies.",2008-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
11339,NCT05597605,"Primary Initial Performance Objectives: Confirm the ability to (c) recharge the SENSOR, ED and CHARGER.",Secondary Performance Objective: Assessment of procedural success for the implantation and explantation procedure,2022-09-21,COMPLETED,INTERVENTIONAL,['NA'],Exploratory Analysis: Histopathology analysis of the biopsy
11340,NCT00162344,Examine the prevalence of ischemic heart disease in population of patients with diabetes mellitus and atypical chest pain.,"Determine the relative value of ETT, Duke Treadmill Score (DTS), MPI, ejection fraction (EF), clinical risk factors, and C-Reactive Protein (CRP) values for identifying patients at risk for cardiac events.",2003-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
11341,NCT00487526,control of type 2 diabetes in non obese adults,"CCK FFA,Cholesterol,Ghrelin,C-peptide,HbA1c,Gastrin,GIP,Triglycerides,Insulin",2007-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],
11342,NCT01703611,HbAIc decrease,Weight change,2012-12,COMPLETED,INTERVENTIONAL,['NA'],Blood pressure
11343,NCT02460718,patient activation,composite measure of healthcare utilization,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
11344,NCT00256633,The primary outcome measure will be to determine if DNA characteristics are associated with CV risk in type 2 diabetes mellitus.,,2007-04,COMPLETED,OBSERVATIONAL,['NA'],
11345,NCT02290301,Time-to-event for the primary composite MACE(Major Adverse Cardiovascular Events) endpoint,,2013-06-28,COMPLETED,OBSERVATIONAL,['NA'],
11346,NCT01881828,"Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c.",Change in Blood Pressure,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Change in Vascular Dysfunction
11347,NCT01928420,Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score,APO-E genotyping,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Pharmacokinetic analysis
11348,NCT05562206,Accuracy,Visual Analog Scale (VAS) for site discomfort,2022-08-30,RECRUITING,INTERVENTIONAL,['NA'],
11349,NCT03128229,Proximal tubular injury,Proposed mediators of tubular dysfunction and injury,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],
11350,NCT01839448,Presence/absence of abnormal glucose metabolism,Oral glucose tolerance test results if necessary,2014-03-27,COMPLETED,OBSERVATIONAL,['NA'],Number of pregnancies
11351,NCT05422846,ulcer depth (mm),sleep quality score,2022-08-01,COMPLETED,INTERVENTIONAL,['NA'],kinesiophobia score
11352,NCT03590158,Glycaemia,Objective sleep,2018-07-17,COMPLETED,INTERVENTIONAL,['NA'],Plasma proteome
11353,NCT03940300,Improve cardio-metabolic health in adults with (non-insulin treated) type 2 diabetes or at risk for type 2 diabetes as measured by hemoglobin A1c.,Improve glycemic control measured by continuous glucose monitoring (CGM),2019-01-28,TERMINATED,INTERVENTIONAL,['NA'],Participant experience with the program evaluated by questionnaire
11354,NCT05046873,"AUC0-∞,NNC0480-0389,SD: Area under the NNC0480-0389 plasma concentration-time curve after a single dose","Cmax,NNC0480-0389,SD: Maximum plasma concentration of NNC0480-0389 after a single dose",2021-09-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
11355,NCT06295874,Patient Introduction Form,Patient Follow-up Form,2023-01-05,RECRUITING,INTERVENTIONAL,['NA'],Comfort Rating Scale
11356,NCT00762957,Change from baseline in glycosylated hemoglobin.,Change from baseline in urinary albumin to creatinine ratio.,2004-11,TERMINATED,INTERVENTIONAL,['PHASE3'],
11357,NCT05569876,Diagnostic accuracy of the HypoVoice approach to detect hypoglycemia based on voice data quantified as area under the receiver operating characteristic curve (AUROC),Physiological parameters indicative of hypoglycemia,2022-11-11,COMPLETED,INTERVENTIONAL,['NA'],Change in cognitive performance across the glycemic trajectory.
11358,NCT05018585,Change in hemoglobin A1c (HbA1c).,Number of episodes per patient of diabetic ketoacidosis between baseline and Month 24.,2022-05-19,RECRUITING,INTERVENTIONAL,['PHASE3'],
11359,NCT01823510,Thrombus Formation,Platelet Reactivity Index (PRI),2013-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
11360,NCT02413762,Macrovascular complication of diabetes mellitus - prevalence and incidence,Progression to NAFLD or NASH,2015-03,COMPLETED,OBSERVATIONAL,['NA'],
11361,NCT02855645,Plasma Blood Sugar,,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
11362,NCT02644759,Exogenous insulin dose,HbA1c level,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11363,NCT00372463,Self-efficacy,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
11364,NCT04807218,Change in hemoglobin A1c (Percent),Change in number and/or doses of anti-hyperglycemic medications • doses of anti-hyperglycemic medications,2021-03-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Acceptability of referral over time
11365,NCT00970424,Hemoglobin A1c Level (HbA1c),Fasting Plasma Glucose Level (FPG),2009-08,TERMINATED,INTERVENTIONAL,['PHASE3'],
11366,NCT00391040,"HbA1c decrease, reduction of hypoglycemia, acute complications","treatment satisfaction, ability for diabetes management, diabetes knowledge",2003-11,COMPLETED,INTERVENTIONAL,['NA'],
11367,NCT05734989,Number of patients referred to PCPs (Primary Care Providers) for CKD screening,,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
11368,NCT02078635,Change from baseline of the maximum vessel wall volume of the carotid arteries,initiation of statin therapy,na,WITHDRAWN,INTERVENTIONAL,['NA'],Palatability of the test / control diets
11369,NCT00801164,"The primary study endpoints are periodontal evaluation including clinical attachment level, pocket depth, plaque index, suppuration and gingival index score.","Secondary endpoints include glycated hemoglobin A1c (HbA1c) and systemic biomarkers (LPS, TNF-a, CRP, IL-6, serum insulin and glucose). Tertiary outcome measures include staining, calculus, opportunistic Candida infection, and patient satisfaction.",2008-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
11370,NCT00772265,Mean AUC0-24h and Cmax,"PK endpts: AUC0-4h, AUC0-6h, AUC0-12h, AUC6-12h, AUC6-24h,tmax,and elimination rate constant. PD endpoints: AUCGIR0-4h, AUCGIR0-6h, AUCGIR0-12h,AUCGIR0-24h, AUCGIR6-12h, AUCGIR6-24h, GIRmax and tGIRmax Safety : AEs,haematology,biochem,phy exam.",2010-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
11371,NCT00490867,Forearm blood flow,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
11372,NCT03386344,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,Percentage of Participants With Adverse Events (AEs),2018-02-19,TERMINATED,INTERVENTIONAL,['PHASE3'],
11373,NCT05862818,Difference in plasma triglyceride level between Meal Conditions and Shift Work,Difference in plasma free fatty acids level between Meal Conditions and Shift Work,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
11374,NCT04931836,Chain in Serum Short Chain Fatty Acids (SCFA),Body Composition,2021-07-29,RECRUITING,INTERVENTIONAL,['NA'],
11375,NCT01848990,Change From Baseline to 12 Months in HbA1c,Mean Times Per Week Participants Said They Were Eating to Avoid Going Low Due to Late Insulin Action,2013-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
11376,NCT04668703,change in diabetic retinopathy severity score (DRSS),"change in the aqueous concentrations of VEGF, PIGF, interleukin- (IL-) 2, IL-5, IL-6, and IL-8",2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
11377,NCT01950663,Per Patient Referral Accuracy,,2013-09,COMPLETED,INTERVENTIONAL,['NA'],
11378,NCT00359762,Time to Treatment Failure,Hypoglycemia Rate Per Year in Period III,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
11379,NCT02263677,Change in Liver steatosis,,2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
11380,NCT02089451,Area under the serum insulin aspart concentration-time curve (only for subcutaneous administration),Maximum observed serum insulin aspart concentration (only for subcutaneous and intramuscular administration),2014-03-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
11381,NCT03868683,Glucose [,Insulin,2018-08-20,COMPLETED,INTERVENTIONAL,['NA'],
11382,NCT03649243,allergenic to propolis analysis,obtaining biopses,2015-10,COMPLETED,OBSERVATIONAL,['NA'],
11383,NCT03903757,RNA sequencing analysisin adipose tissues,Linear regression to correlate epigenetic biomarkers with HOMA index,2019-12,UNKNOWN,OBSERVATIONAL,['NA'],
11384,NCT03859817,Variations in ketone levels,Changes in glycated hemoglobin (HbA1c),2019-04-16,UNKNOWN,OBSERVATIONAL,['NA'],
11385,NCT05990374,Effects of different GLP-1 on blood glucose,Effects of different GLP-1 on body fat mass,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],
11386,NCT03194945,proportion of subjects with optimal glycemic control,Incidence of adverse events,2017-11-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11387,NCT02768948,number of differentiation marker,,2017-05-05,COMPLETED,INTERVENTIONAL,['NA'],
11388,NCT04797429,HbA1c [%] (change over a period of 7 months intervention and 7 months follow-up with 4 measurement dates),Biochemical parameters,2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
11389,NCT00959595,Touch thresholds in the sole of the foot (Semmes-Weinstein monofilaments),fMRI,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
11390,NCT01743599,Retrograde ejaculation (a minimum of a total of 1 million sperm in postejaculatory urine),Erectile dysfunction,2008-02,COMPLETED,OBSERVATIONAL,['NA'],
11391,NCT05013008,Mean Change in Plasma Biomarker Levels After 36 Months of Treatment Versus 4 Months of Treatment in a Set of 27 Pre-defined Biomarkers,,2021-08-18,COMPLETED,INTERVENTIONAL,['PHASE2'],
11392,NCT00237237,Change from baseline in HbA1c at 52 weeks,Patients with reduction in HbA1c >/= to 7% after 52 weeks,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
11393,NCT02610088,Vascular function assessed by Flow-mediated vasodilation (FMD),Carotid intima-media thickness (cIMT) assessed by ultrasound,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
11394,NCT02273193,Fasting Glucose will be obtained during the first trimester of pregnancy,Hemoglobin A1c will be obtained during the second trimester of pregnancy (between 24-28 weeks),2014-10-14,COMPLETED,OBSERVATIONAL,['NA'],
11395,NCT04098679,IQ,Adiposity,2019-09-30,RECRUITING,OBSERVATIONAL,['NA'],
11396,NCT02858076,E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline),Retinal Neovascularization on Clinical Exam,2016-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
11397,NCT03991299,Change in Body Weight at 1 Month,,2021-04-29,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11398,NCT01586780,"Blood glucose, insulin, amino acids, ghrelin and incretins",Subjective satiety,2009-08,COMPLETED,INTERVENTIONAL,['NA'],
11399,NCT02910141,HbA1c,Weight or BMI,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
11400,NCT01852214,P2Y12 Reaction Units,Platelet Reactivity Index,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
11401,NCT00753766,Percent of Screened Participants That Are Eligible and Choose Participation,Percentage of Participants Who Need to Return to the Operating Room,2005-10,TERMINATED,INTERVENTIONAL,['NA'],
11402,NCT00842010,Inpatient Mortality,Frequency of steroid use,2006-03,COMPLETED,OBSERVATIONAL,['NA'],
11403,NCT01527552,"Cmax, maximum insulin aspart concentration",Adverse events,2002-11-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
11404,NCT02251834,Blood Pressure,A1C,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
11405,NCT03253237,Glycemic variability in individuals with type 2 diabetes mellitus in primary care measured by continuous glucose monitor device,,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
11406,NCT04892199,The primary endpoint is the change from baseline in glycated haemoglobin A1c (HbA1c).,Insulin sensitivity and beta cell function,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
11407,NCT04340908,Difference in NTproBNP between the treatment and control study arms,Post operative atrial fibrillation,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11408,NCT01985711,Change in Patient Health Questionnaire-9 items (PHQ-9) score,Change in general self-efficacy,2014-05,UNKNOWN,INTERVENTIONAL,['NA'],
11409,NCT01339143,Glycemic Variability,hypoglycemia,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11410,NCT01890122,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination),Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥2.0%,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
11411,NCT01302743,Decrease in LDL Cholesterol,,2010-11,TERMINATED,INTERVENTIONAL,['NA'],
11412,NCT01192152,Metformin Cmax,"Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities",2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
11413,NCT03078933,Wound Closure rate,,2017-03-20,UNKNOWN,INTERVENTIONAL,['NA'],
11414,NCT04725799,Measurement of Glucose Concentration,,2018-05-24,COMPLETED,OBSERVATIONAL,['NA'],
11415,NCT03165786,Hypoglycemia Fear Scale Score (HFS_2),Glycemic variability,2016-10-26,COMPLETED,INTERVENTIONAL,['NA'],
11416,NCT04584242,Changes from baseline LSM (Liver Stiffness measurement) at week 24 (±7days),Prognostic factor of the Improvement of HbA1 between baseline and week 24 (±7days) within and between arms,2020-09-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11417,NCT00251680,Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol,Physical Examination,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
11418,NCT02663245,Glycaemic control measured by HbA1c,evaluation of quality of life using spanish version of diabetes quality of life questionnaire (EsDQOL),2015-12,COMPLETED,INTERVENTIONAL,['NA'],
11419,NCT06067685,Correlation coefficient between triglyceride levels and birthweight,Correlation coefficient between triglyceride levels and cord c-peptide levels,2023-08-10,RECRUITING,OBSERVATIONAL,['NA'],
11420,NCT04917393,Rate of SADEs,Change in Glycemic control - fasting glucose,2021-09-13,RECRUITING,INTERVENTIONAL,['NA'],
11421,NCT01248442,Increase and function of peripheral regulatory T-cells,calcium levels,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
11422,NCT01988987,Result of an early postpartum 75-gram oral glucose tolerance test (GTT) result,Result of a postpartum 75-gram oral glucose tolerance test (GTT),2013-02-22,COMPLETED,OBSERVATIONAL,['NA'],
11423,NCT01801254,postprandial blood glucose and triglycerides,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
11424,NCT05904262,Foot Sole Sensation Evaluation,Muscle strength,2023-06-06,COMPLETED,OBSERVATIONAL,['NA'],
11425,NCT02149992,overall mean glucose,metabolic differences,2014-11,UNKNOWN,INTERVENTIONAL,['NA'],steady state
11426,NCT02589210,"The proportion of product related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events",Cost effectiveness of treatment,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
11427,NCT04757519,Change in Weight at 6 Months,Impact of Weight on Quality of Life,2021-02-18,RECRUITING,INTERVENTIONAL,['NA'],
11428,NCT01261052,Measurement of the Effectiveness of APD and FMPD/APD Intervention in Adapting to Reduced Insulin Sensitivity,Measurement of APD and FMPD/APD Interventions in Controlling Post-prandial Blood Glucose With Reduced Insulin Sensitivity.,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
11429,NCT00151697,Body weight,adverse effects,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
11430,NCT00991549,"a reduced percentage of the calories introduced in the form of fat of at least 6.6%, in absolute value, in at least 25% of the subjects","relation between weight loss and change in insulin sensitivity, beta cell function, and insulin-mediated suppression of plasma non-esterified fatty acids",2004-12,COMPLETED,INTERVENTIONAL,['NA'],
11431,NCT03773731,EC50 of insulin in terms of intraplatelet VASP (vasodilator-stimulated phosphoprotein)-phosphorylation: group differences after 12 weeks of training,Fatty Liver Index (FLI),2019-01-04,UNKNOWN,INTERVENTIONAL,['NA'],
11432,NCT00631345,Fasting Glucose,Physical Activity,2007-08,COMPLETED,INTERVENTIONAL,['NA'],
11433,NCT05628532,Percentage of time spent in 70 - 180 mg/dL glycemic range,Scoring of Diabetes Distress Scale (DDS),2023-02-03,RECRUITING,INTERVENTIONAL,['NA'],
11434,NCT02282046,implant complications,resonance frequency analysis,2014-05,COMPLETED,OBSERVATIONAL,['NA'],
11435,NCT01788527,Glycemic Control in pregnant group,Study Contacts,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
11436,NCT03985293,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16,Number of Participants With Treatment Emergent ECG Abnormalities,2019-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],
11437,NCT04407182,Symptom resolution,Time to return to normal activity,2020-05-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in myocardial enzymes
11438,NCT03795389,DM199 urine concentrations of KLK1,Urine Kidney Injury Molecule-1 (Kim1),2019-02-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Blood glucose
11439,NCT03334214,"Percentage of Participants With Adverse Events, Graded by Severity, That Were Related to Treatment With IONIS DGAT2Rx",Absolute Change in Hemoglobin A1C (HbA1C),2017-11-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
11440,NCT03038373,Evidence of clinically definition of remission of type 2 diabetes by by fasting blood glucose level < 7.0 mmol and HbA1c <6.5%,,2012-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
11441,NCT00482183,"The primary angiographic end point is in-stent luminal late loss, as determined by quantitative angiography.","Secondary end points include the percentage of in-stent stenosis of luminal diameter, the rate of restenosis.",2003-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
11442,NCT01293461,"To assess the safety and tolerability of CBX129801 when administered SC by adverse events, injection site assessments, clinical laboratory tests, vital signs, physical examinations, and electrocardiograms.",To evaluate the technique of vibration perception threshold (VPT) in patients with type 1 diabetes (Part 2 only),2011-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11443,NCT02036450,Time to adjudicated stroke or systemic arterial embolism,Time to death by any cause,2014-01,COMPLETED,INTERVENTIONAL,['NA'],Change from baseline in quality of life
11444,NCT01396954,,,2007-11,UNKNOWN,OBSERVATIONAL,['NA'],
11445,NCT02806830,Comparison of the overall scores of the ocular discomfort questionnaire after the 2 first intravitreal injection in naïve patients,,2016-04,COMPLETED,INTERVENTIONAL,['NA'],
11446,NCT00698048,Vasopressin and copeptin levels,,2008-08,COMPLETED,OBSERVATIONAL,['NA'],
11447,NCT00142922,fitness,Diabetes Related emaitonal distress,2002-10,COMPLETED,INTERVENTIONAL,['NA'],
11448,NCT03091517,Change in HbA1c levels (Effectiveness),Degree of user satisfaction with the GlycoLeap program (Maintenance),2017-06-22,COMPLETED,INTERVENTIONAL,['NA'],
11449,NCT00932087,Level of plasma isoprostane and lipoperoxides,TXA2 and PF4 levels after platelet activation of control platelet exposed to LDL,2009-02,COMPLETED,OBSERVATIONAL,['NA'],
11450,NCT01111370,the Proportion of G4 CGM System in Agreement With the Reference Standard,,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
11451,NCT01978405,The changes of endothelium-dependent arterial dilation before and after contrast administrated,,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11452,NCT03591900,number of thalassemic patients with impaired glucose tolerance,control of diabetic thalassemic patients on insulin pump,2014-04,COMPLETED,INTERVENTIONAL,['NA'],
11453,NCT03816618,Ulcer size,,2020-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
11454,NCT03570632,Rate of hypertensive disorders of pregnancy,Neonatal morbidity,2019-07-08,RECRUITING,INTERVENTIONAL,['PHASE4'],Neonatal body composition
11455,NCT01623388,Evaluate blood sugar variability in Type I diabetics for differences in epigenetic signatures between Type I diabetics with little glycemic variability as compared to those with more pronounced glycemic changes.,,2013-01,WITHDRAWN,OBSERVATIONAL,['NA'],
11456,NCT02473926,Change From Baseline in Objective Physical Activity at 4 Months,Change From Baseline in Physical Function at 4 Months,2015-12,COMPLETED,INTERVENTIONAL,['NA'],
11457,NCT05163587,lipid profile,body composition,2021-03-26,COMPLETED,INTERVENTIONAL,['NA'],
11458,NCT00246844,,,2005-10-26,COMPLETED,OBSERVATIONAL,['NA'],
11459,NCT04567550,To evaluate the effect of RGX-314 on DR by the Early Treatment Diabetic Retinopathy Study (ETDRS)-Diabetic Retinopathy Severity Scale (-DRSS) at week 48,To evaluate the incidences of ocular inflammation following SCS RGX-314 administration,2020-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],
11460,NCT01447524,Change from baseline in insulin secretion at 7 days.,,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
11461,NCT01130727,flow-mediated dilation (FMD),plasma levels of flavonols,2010-05,COMPLETED,INTERVENTIONAL,['NA'],
11462,NCT00334113,7-Day Physical Activity Recall (PAR),,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
11463,NCT06153537,Change in glycated haemoglobin (HbA1c),Change in laboratory measured FPG,2023-11-29,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
11464,NCT03092960,Number and Percentage of Men Achieving 5% Weight Loss or More,Change in Psychosocial Well-being: Number and Percentage of Participants Who Had no Problems With Anxiety and Depression Domain in Utility-based Quality of Life Measured by EuroQol EQ-5D,2017-04-03,COMPLETED,INTERVENTIONAL,['NA'],
11465,NCT03262363,Change from Renal Function at 6 months,,2018-08-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
11466,NCT00855439,Confirmed Clinical Neuropathy (CCN),Cardiac Autonomic Neuropathy,2008-06,COMPLETED,INTERVENTIONAL,['NA'],Intra-epidermal Nerve Fiber Density
11467,NCT01103817,Change in Endothelial Function after Treatment with Vitamin D,Comparison of Urinary Albumin/Creatinine Ratio,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
11468,NCT00385333,Fluorescence anisotropy,The difference in fluorescence anisotropy values within subjects under room air and 100% oxygen exposure (one minute exposure time).,2006-09-29,COMPLETED,INTERVENTIONAL,['PHASE2'],
11469,NCT04343131,Percentage of time spent with glucose levels between 70-140 mg/dl,,2014-11,COMPLETED,INTERVENTIONAL,['NA'],
11470,NCT06286878,Platelet aggregation using ADP,Platelet aggregation using ASPI at 30 (± 5) days after study therapy,2021-12-08,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Analyze the primary objective of the study in the following pre-specified subgroups:
11471,NCT03585153,Pancreas Volume Index,Urinary C-peptide/creatinine,2014-02-19,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
11472,NCT01694212,Change of Central Macular Thickness,IL-12 concentration,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
11473,NCT00005131,,,1985-07,COMPLETED,OBSERVATIONAL,['NA'],
11474,NCT05593081,Change in serum hemoglobin A1c level,The incidence of chronic complications of diabetes mellitus,2022-05-20,RECRUITING,OBSERVATIONAL,['NA'],
11475,NCT05910840,Change from Baseline Hemaglobin A1c (HbA1c) at 18 months,Cost effectiveness (QOL),2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],"Experience with Support-t platform (Barriers, facilitators, satisfaction, fidelity) - Health Care Provider"
11476,NCT00575172,"Cardiovascular events 1)Sudden death 2)New development or recurrence of apoplexy or TIA 3)New development or recurrence of AMI or and angina pectoris 4)Newly developed ASO, amputation of leg due to ASO","1)Total mortality 2)Changes in the mean IMT of common carotid arteries 3)Changes in the pulse wave velocity (PWV) (rt & 1t baPWV), ABI",2003-03,COMPLETED,OBSERVATIONAL,['NA'],
11477,NCT05357742,Hemoglobin A1c (HbA1c),Self-Care Behavior,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],
11478,NCT01554618,Percentage of Patients Positive for Anti-Drug Antibodies (ADAs) to Exenatide up to Week 24,Plasma Exenatide Concentrations to Week 52 Among Patients Who Received Open-Label Exenatide (Treatment Period),2011-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
11479,NCT01351857,The proportion of subjects who fail to attend at least one outpatient adult endocrinology visit during the second year after transition to adult diabetes care.,In the 2 year transfer to adult care-Frequency of A1C (glycated hemoglobin test),2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
11480,NCT03167684,Glycemic control (mean 24-hour and nocturnal glucose),Systemic inflammation,2017-05-01,UNKNOWN,INTERVENTIONAL,['NA'],Subjective sleep quality
11481,NCT05205005,Glygocalyx integrity - perfused boundary region,Popliteal artery flow mediated dilation,2022-05-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
11482,NCT06236607,Glucose time-in-range (TIR) of 70-180 mg/dL,Diabetic Ketoacidosis events,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
11483,NCT00339781,,,2005-02,COMPLETED,OBSERVATIONAL,['NA'],
11484,NCT03922087,Number of participant with gestational complications.,Number of participant with postnatal depression.,2018-11-20,COMPLETED,OBSERVATIONAL,['NA'],
11485,NCT00971815,Changes in the 24-hour AUC of free plasma cortisol,Plasma-Inflammation markers,2009-05,COMPLETED,INTERVENTIONAL,['NA'],
11486,NCT01060917,skin tissue glucose concentration,"serum and urine electrolyte concentrations (sodium, potassium, chloride, calcium, magnesium, urea, osmolarity, pH, lactate, p(O2), standard bicarbonate, p(CO2), blood glucose concentration",2003-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11487,NCT05548699,Daily stress levels over time,Alcohol misuse over time,2023-05-02,RECRUITING,OBSERVATIONAL,['NA'],Stressful life events
11488,NCT02030249,Bone mass,Muscle (handgrip) strength,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],Urinary N-terminal telopeptide
11489,NCT06184815,Changes in Glycemic Control Measured by A1c,Changes in Glycemic Control Measured by severe hypoglycemia,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
11490,NCT03882463,Time spent hypoglycemia,Number of hypoglycemia,2019-04-30,COMPLETED,INTERVENTIONAL,['NA'],
11491,NCT02548702,Change from baseline in number of participants reporting one or more sessions of sport per week measured by the UK Single Item Questionnaire,Change from baseline in control of blood glucose concentration as measured by HPA1c (mmol/mol),2015-10,UNKNOWN,INTERVENTIONAL,['NA'],
11492,NCT02081352,Incidence of wound closure,Quality of wound healing,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],Rate of wound healing in crossover arm
11493,NCT02316821,"Change in glomerular filtration rate (GFR) measured by inulin clearance after 16 weeks of study drug administration, compared to baseline GFR",Profiles of pharmacokinetics of plasma RTA 402 concentration: Trough (Pre-dose) and peak (2-4 hours post dose) concentrations of study drug at steady state,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
11494,NCT00542620,Glycosylated Haemoglobin A1c (HbA1c),"Percentage of Children Assessing Insulin Therapy Injection Pain as ""Very Happy Face""",2007-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
11495,NCT05124834,Analysis of system accuracy based on DIN EN ISO 15197,,2022-01-15,COMPLETED,INTERVENTIONAL,['NA'],
11496,NCT00280046,HbA1c,Quality of Life,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
11497,NCT03689608,Postprandial glucose AUC,Postprandial triglyceride,2018-09-26,COMPLETED,INTERVENTIONAL,['NA'],Change in autophagic flux (DIRECT-Fast4flux)
11498,NCT05430139,Reference Intervals,,2022-10-31,RECRUITING,OBSERVATIONAL,['NA'],
11499,NCT02749032,GLP-1 feedback inhibition,Incidence of Treatment-Emergent Adverse Events - Safety and tolerability,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
11500,NCT03837405,diet adherence between intervention arms as measured by 24- hour diet recall--dichotomous,Weight change,2018-12-12,COMPLETED,INTERVENTIONAL,['NA'],Mindfulness
11501,NCT02980978,A1c (Laboratory Assessment),,2016-04,COMPLETED,INTERVENTIONAL,['NA'],Aspirin Use (as Noted in EMR)
11502,NCT00271700,- Lab glucose values (percent of routine glucose readings between 60 and 180 mg/dL),- Quality of insulin orders using explicit criteria,2010-05,COMPLETED,INTERVENTIONAL,['NA'],
11503,NCT01296633,Medication regimen knowledge,Patient-provider communication assessment,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
11504,NCT05259449,Assessed changes from Body composition: Fatmass and Fat-free mass.,Assessed changes from cardiorespiratory fitness,2022-03-10,RECRUITING,INTERVENTIONAL,['NA'],
11505,NCT03428308,Number of follow-up visits,Change in blood cholesterol (blood test),2018-04,UNKNOWN,INTERVENTIONAL,['NA'],Success of intersectoral cooperation
11506,NCT04582435,"AUCIco,τ,SS, Area under the serum insulin icodec concentration-time curve during one dosing interval at steady state","t½,Ico,SS, Terminal half-life for insulin icodec at steady state",2020-10-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
11507,NCT03368807,Average Number of Days Per Month With a Missed Bolus Insulin Dose With Blinded CGM,Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Unblinded CGM,2017-12-11,COMPLETED,OBSERVATIONAL,['NA'],
11508,NCT04137705,Assessment of repeatability (precision under the same conditions in the same subjects: 2 separate MRI acquisitions on the same scanner) of body composition and multiple organ metrics.,Assessment of the reproducibility (precision under different measurement conditions: same participants scanned on separate MRI scanners at both 1.5T and 3T) of multiparametric MRI for the assessment of body composition and multiple organ metrics.,2019-11-04,RECRUITING,OBSERVATIONAL,['NA'],Assessment of the mean differences in body composition and multiple organ metrics between healthy participants and those with type 2 diabetes acquired with multiparametric MRI.
11509,NCT01964963,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Fasting Blood Glucose,2011-08-03,COMPLETED,OBSERVATIONAL,['NA'],
11510,NCT01651117,Change in Glucose Control (Stage 2: Non-mentors v. Mentors),Change in Depression Symptoms (Stage 2: Non-mentors v. Mentors),2012-09-01,COMPLETED,INTERVENTIONAL,['NA'],
11511,NCT02459353,Glycemic Variability (Standard Deviation),blood pressure DBP,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
11512,NCT00962962,Fasting Plasma Glucose,Measures of Glucose control,2009-07,COMPLETED,INTERVENTIONAL,['NA'],
11513,NCT00155610,,,na,TERMINATED,OBSERVATIONAL,['NA'],
11514,NCT03921203,ApoB48 levels in blood and interstitial fluid,,2019-04-17,COMPLETED,OBSERVATIONAL,['NA'],
11515,NCT03964571,Reduction in size of wound,Reduction in size of wound,2019-10-09,RECRUITING,INTERVENTIONAL,['NA'],
11516,NCT03248206,Change from baseline result of Manual tactile test at 12 weeks,Change from baseline result of peak torque of shoulder internal rotation assessing by Bi-planar isokinetic dynamometer (BID) at 12 weeks,2017-08-23,COMPLETED,INTERVENTIONAL,['NA'],
11517,NCT04305431,Facilitators and Barriers,Second Phase Secondary Outcome,2021-02-25,RECRUITING,INTERVENTIONAL,['NA'],
11518,NCT02274103,HbA1c,"Adherence to diabetes treatment using the Diabetes Self Management Profile (DSMP) (Harris et al, 2001).",2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
11519,NCT02864914,Incidence of diabetic ketoacidosis (DKA),Incidence of severe genital infections,2016-03-15,COMPLETED,OBSERVATIONAL,['NA'],
11520,NCT02051504,Maximal oxygen uptake,Prefrontal cortex oxygenation during exercise,2010-03,COMPLETED,OBSERVATIONAL,['NA'],Body composition
11521,NCT05847413,Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL at 12 weeks.,,2020-05-30,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
11522,NCT05125445,change in margianl bone level,,2021-02-11,COMPLETED,INTERVENTIONAL,['NA'],
11523,NCT00747409,postprandial blood glucose at the end of the study and its change from baseline.,diastolic myocardial function,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11524,NCT01365416,,,2011-12-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
11525,NCT00410033,"Insulin aspart specific, human insulin specific and cross reacting antibodies",Incidence of hypoglycaemic episodes,1989-12,COMPLETED,INTERVENTIONAL,['NA'],
11526,NCT02137863,"Changes in glomerular renal function after percutaneous coronary angiography as measured by neutrophil gelatinase-associated lipocalin, cystatin c, blood urea nitrogen, creatinin",complete blood count,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
11527,NCT00257257,Absolute change in HbA1C from baseline to Month 6.,"Fasting glucose, fasting insulin, C-peptide, HOMA analysis, body weight, HDL-cholesterol, triglycerides, blood pressure, safety (physical examination, vital signs, laboratory tests, adverse events).",2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
11528,NCT02856633,Successful diagnosis of patient's condition by Vitaliti software as compared to patient's Medical Record,,2016-07,COMPLETED,OBSERVATIONAL,['NA'],
11529,NCT05130385,Evaluation of the sensitivity and specificity of High-Res-OCT for retinal fluid,Evaluation of the segmentation quality of the retinal layers using High-Res-OCT,2021-11-30,RECRUITING,OBSERVATIONAL,['NA'],Correlation of pathological changes with fundus color photographs
11530,NCT00257218,Incidence of diabetes mellitus,insulin sensitivity,2006-01,UNKNOWN,INTERVENTIONAL,['NA'],
11531,NCT03938389,Change from Baseline to 26 weeks in β-cell function (first-phase insulin secretion),Change in Central Aortic Pressure (mmHg) from Baseline to 26 weeks,2020-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
11532,NCT04054284,Number of patients with adverse event,Fasting Glucose,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],Waist Circumference
11533,NCT00467376,Adverse events,"blood glucose parameters, hypoglycemic episodes and dosage of the mealtime and Lantus.",2007-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
11534,NCT01637350,,,2012-08,UNKNOWN,OBSERVATIONAL,['NA'],
11535,NCT03070678,Area under the concentration-time curve from 0 to infinity (AUC0 ∞),Total 24-hour UGE (urinary glucose excretion) after each dose with sotagliflozin,2017-03-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
11536,NCT00997191,Best Corrected Visual acuity,Central Macular Thickness,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
11537,NCT03892265,"Prevalence of CVD risk factors and diseases and their association with social and environmental determinants in an established longitudinal cohort of ~3,000 Haitian adults",Incidence of CVD risk factors and CVD during ~7 years of follow-up and their association with social and environmental determinants,2019-03-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
11538,NCT00943917,Mean Change in HbA1c (ITT),,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
11539,NCT03237975,Short form of the sense of coherence questionnaire (SOC-13),Diabetes Self-Efficacy Scale (DSES),2017-03-27,UNKNOWN,INTERVENTIONAL,['NA'],
11540,NCT05932953,"Prevalence of children,with current skin intolerance (eczema symptoms measured by questionnaire) to an insulin pump and/or blood glucose sensor assessed by an autoquestionnary.",Search for risk factors associated with skin side effect,2022-05-15,RECRUITING,OBSERVATIONAL,['NA'],
11541,NCT03916016,Blood Pressure,Blood glucose concentration,2015-12-09,COMPLETED,INTERVENTIONAL,['NA'],
11542,NCT00700856,"A composite endpoint including: all-causes mortality, non fatal myocardial infarction (MI) - including silent MI- , non fatal stroke, unplanned coronary revascularization",events of heart failure evaluated according to the American Heart Association and the American Diabetes Association consensus on glitazones and heart failure,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11543,NCT01172977,Functional outcome six months after the cerebral ischemia,Mortality,2010-08,COMPLETED,OBSERVATIONAL,['NA'],
11544,NCT02543684,serum insulin changes over time,,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
11545,NCT03303196,Mean Plasma Glucose Level.,,2018-04-09,COMPLETED,INTERVENTIONAL,['NA'],
11546,NCT03864705,Plasma metformin levels,,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA'],
11547,NCT05952219,Cmax,,2023-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
11548,NCT03258242,Mean change from baseline in Chinese medicine syndrome score chart at 48 weeks,Frequency and severity of ocular and non-ocular adverse events over time,2017-08-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],Change of retinal blood flow density
11549,NCT03821636,Rate of type 2 diabetes remission,change in prealbumin levels,2019-06-16,RECRUITING,INTERVENTIONAL,['NA'],
11550,NCT06147518,Percentage of patients with glycemic control at 24 weeks (HBA1c <7.0 %),Number of patients with Mortality/ Liver transplantation in both groups,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
11551,NCT01116531,Concentration of O-desmethyltramadol,Concentration of O-desmethyltramadol,2010-04,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
11552,NCT00607087,Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion,Total Daily Bolus Insulin Dose,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
11553,NCT00849342,Change in body weight and BMI,Change in blood pressure,2008-12,COMPLETED,OBSERVATIONAL,['NA'],
11554,NCT06044064,Incidence of PDAC at 3 years,• Incidence of PDAC at baseline • Incidence of resectable PDAC at baseline • Incidence of resectable PDAC at 3 years,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
11555,NCT04215445,Comparison of change in retinal and choroidal vascular perfusion density in proteinuric and non-proteinuric chronic kidney disease patients treated with SGLT2-inhibitor,,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11556,NCT03542682,Time to Maximum Glucose Infusion Rate,Area Under the Curve for the Glucose Infusion Rate,2018-05-30,COMPLETED,INTERVENTIONAL,['NA'],
11557,NCT04439630,postprandial insulin concentrations,subjective appetite variables,2020-07-01,COMPLETED,INTERVENTIONAL,['NA'],
11558,NCT02010684,Change From Baseline in Depression Measures at 6 Months,Change From Baseline in Self-Efficacy (Diabetes Empowerment Scale) at 6 Months,2009-04,COMPLETED,INTERVENTIONAL,['NA'],
11559,NCT02251431,ACR,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
11560,NCT01875341,Primary end-point: change in daytime and night-time mean systolic blood pressure,plasma renin and aldosterone,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
11561,NCT01249742,Patients' Evaluation of Quality of Care,Degree of use of intervention,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
11562,NCT03553030,Major Adverse Cardiac Events (MACE).,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],
11563,NCT04507061,Mean change in urinary albumin-to-creatinine ratio (UACR) from baseline to the average of multiple time points during treatment,Number of subjects with early discontinuations,2020-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
11564,NCT03898076,The difference of Predictive A1c level from CGM data with Real A1c level from EMR,,2020-06-01,COMPLETED,OBSERVATIONAL,['NA'],
11565,NCT04451837,Hba1c,,2020-09-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
11566,NCT00634998,Changes in aldose reductase enzyme levels,Changes in Neuropathic Pain Scale (NPS) measurement and quantitative sensory testing in the lower extremities via touch discrimination with Semmes-Weinstein monofilaments and vibratory sensation testing,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
11567,NCT03619356,Change in spectral THG strength distribution,Quantify the extent of diseases in spectral THG strength distribution,2018-02-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
11568,NCT05170880,HbA1c levels,,2019-02-11,COMPLETED,INTERVENTIONAL,['NA'],
11569,NCT04345016,rate of diabetic foot ulcer recurrence in after phase of trial,rate of lower extremity amputations in after phase of trial,2017-04-13,COMPLETED,INTERVENTIONAL,['NA'],
11570,NCT01865331,Frequency of adverse events (AEs),Area under the glucose infusion rate curve,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
11571,NCT05477030,Glycated Hemoglobin (HbA1c),Endothelial disfunction,2022-02-23,RECRUITING,INTERVENTIONAL,['NA'],
11572,NCT03698396,Incidence of procedure related adverse events,Insulin independence achieved,2019-08-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11573,NCT00883259,Incidence of gestational DM in high-risk patients,Intrauterine deaths,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11574,NCT05798442,Reduced BMI and visceral obesity,Reduced alcohol consumption and tobacco smoking,2024-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
11575,NCT01986881,Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study),Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study),2013-11-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
11576,NCT02536859,Area under the glucose infusion rate curve,Area under the glucose infusion rate curve,2015-08-31,COMPLETED,INTERVENTIONAL,['PHASE1'],
11577,NCT02160639,"Change from baseline fasting glucose at 3, 9, 15, and 27 months","Change from baseline food security at 3, 9, 15, and 27 months",2015-01,UNKNOWN,INTERVENTIONAL,['NA'],
11578,NCT01627340,Number of Subjects Seroprotected for Anti- Hepatitis B Surface Antigen (Anti-HBs) Antibodies,Number of Subjects Reporting Any Serious Adverse Events (SAEs),2012-07-24,COMPLETED,INTERVENTIONAL,['PHASE4'],
11579,NCT02614768,Percentage of Test-to-Reference Measurement Pairs With an Absolute Relative Difference (ARD) ≤15%,,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
11580,NCT01630850,HbAlc <7.0% and an absence of severe hypoglycemic events,,2012-05,RECRUITING,INTERVENTIONAL,['NA'],
11581,NCT00476437,Incidence of hypoglycaemic episodes,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
11582,NCT02228629,Comparison of peak pressure sub-metatarsal 2 and hallux in usual house shoes versus the CrocsRx clogs,,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],
11583,NCT00814294,The primary objective of this trial is to compare the reduction in mean glycated hemoglobin levels (HbA1c) between 2 doses of oral HDV-I and placebo in type 2 diabetic patients on background metformin therapy at the end of 18 weeks of treatment.,"To evaluate the effects of oral HDV-I versus placebo on frequency of hypoglycemic events, body weight, and lipid levels",2008-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
11584,NCT05347459,Prevention of decline in cognitive function associated with type 2 diabetes,Better cognitive performance in the intervention group at baseline,2022-03-02,RECRUITING,OBSERVATIONAL,['NA'],Reduced serum inflammatory markers in intervention group
11585,NCT01288729,Length of Wear of Infusion Site,,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
11586,NCT02932436,difference in E/E' ratio between 12 weeks after baseline and at baseline,difference in E/E' ratio (change from baseline (V1) to 12 weeks follow-up) in the subgroup of patients with HbA1c 6.5%-6.9%,2016-10-10,COMPLETED,INTERVENTIONAL,['PHASE4'],association analysis for selected SNPs
11587,NCT02217943,Composite Measure of Glycemic Control - Recurrence,Assess the changes in SF-36 Health Survey,2014-07-01,COMPLETED,INTERVENTIONAL,['NA'],
11588,NCT05549583,Area under the plasma concentration versus time curve (AUC) 0-t,"Number of participants with adverse events (AEs), abnormal clinical laboratory test results, physical examination findings and glycemia.",2018-04-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
11589,NCT00568620,Insulin sensitivity,Incretin effect,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
11590,NCT05325710,FINDRISC score,,2022-03-20,RECRUITING,INTERVENTIONAL,['NA'],
11591,NCT00638560,PGC-1alpha mRNA expression in skeletal muscle PPARgamma mRNA expression in skeletal muscle Serum malondialdehyde concentration,body weight glucose infusion rate during the steady state of an euglycemic-hyperinsulinemic clamp VO2max,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
11592,NCT00660075,"Measurement of the Area Under the Curve of Plasma Triglycerides (TG) Levels During Postprandial Period (Time 0,2,4,6,8 Hours)",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
11593,NCT04365517,Biochemical parameter of acute lung disease,Cytokine-inflammatory profile,2021-12-29,UNKNOWN,INTERVENTIONAL,['PHASE3'],
11594,NCT02757183,Usage and Adoption of the smart phone based mobile health application,Adherence to Prescribed Medication,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],
11595,NCT03106727,Antenatal Care,CHW Retention,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],
11596,NCT01047813,Blood glucose levels,Stress levels,2009-09,UNKNOWN,OBSERVATIONAL,['NA'],
11597,NCT05414396,Changes in biomarkers,,2018-03-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
11598,NCT04221399,Concentration of serum glucose,,2020-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
11599,NCT03626324,Successful Home-use Performance,,2018-07-25,COMPLETED,INTERVENTIONAL,['NA'],
11600,NCT01862237,Left Ventricular Mass measured by echocardiography,Magnetic Resonance Imaging (MRI) parameters.,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],
11601,NCT01869101,Diabetes prevention treatment decisions by physician,Subject initiation and persistence with diabetes prevention interventions,2013-06,UNKNOWN,OBSERVATIONAL,['NA'],BMI
11602,NCT01273311,,,2010-12-22,COMPLETED,OBSERVATIONAL,['NA'],
11603,NCT03229850,Insulin Levels,,2021-02-01,SUSPENDED,INTERVENTIONAL,['NA'],
11604,NCT04543422,Toronto Clinical Scoring System,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],
11605,NCT01923597,Effect of green tea (epigallocatechin gallate) in albuminuria in diabetic patients and nephropathy.,Effect of green tea (epigallocatechin gallate) on plasma lipids in patients with diabetic nephropathy.,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Effect of Green Tea (epigallocatechin gallate) in the glomerular filtration rate in patients with diabetic nephropathy.
11606,NCT02422043,self-efficacy (Self-efficacy of Diabetes Management),socio-cognitive profile,2015-01-28,COMPLETED,INTERVENTIONAL,['NA'],
11607,NCT00328302,Mesangial expansion,24 hour ambulatory blood pressure,2000-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11608,NCT04119167,Level of fasting blood sugar,,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
11609,NCT03105219,Urinary albumin excretion,Retinol binding protein,2017-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
11610,NCT02165579,"(1.) wound healing,",(5.) recurrent ulcers.,2014-06,COMPLETED,OBSERVATIONAL,['NA'],
11611,NCT01515592,Antibody against liraglutide,24-hour profiles of serum insulin,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
11612,NCT06184373,Comparative experience of OGTT and CGM,Medical care,2024-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Infant outcomes
11613,NCT05719155,AUClast,,2023-02-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
11614,NCT00000160,,,1972-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
11615,NCT03889236,Percentage change from baseline in the Microvascular Health Index in the fasting mimicking diet or food supplement group compared to the placebo group,Percentage change from baseline in specific urinary heparan sulfate domains in the fasting mimicking diet or food supplement group compared to the placebo,2018-05-03,COMPLETED,INTERVENTIONAL,['NA'],
11616,NCT00055042,,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
11617,NCT01470807,estimation of the failure rates of system components,percent time of active CTR,2011-10,COMPLETED,INTERVENTIONAL,['NA'],
11618,NCT02821585,Change in Waist Circumference,Glycemic variability,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
11619,NCT03398590,Acceptability,Calorie intake,2017-04-12,COMPLETED,INTERVENTIONAL,['NA'],
11620,NCT01056497,insulin secretion and insulin sensitivity To determine whether ALA ameliorates or prevents impairment of insulin secretion and insulin sensi,To determine the role of oxidative stress and inflammation in the pathogenesis of lipotoxicity,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
11621,NCT02631928,"PK: Cins.max, maximum observed insulin concentration",Changes in Electrocardiogram recordings,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
11622,NCT01393860,Measure: Change in blood pressure,Measure: Change in potassium levels,2010-12,COMPLETED,OBSERVATIONAL,['NA'],
11623,NCT04383639,Postprandial insulin,"Satiety measured by a Visual Analogue Scale (see ""Description"" for details)",2021-05-03,COMPLETED,INTERVENTIONAL,['NA'],
11624,NCT02771093,Changes From Baseline in the Standard Deviation (SD) of 24-hour Blood Glucose Values,Number of Participants Reporting One or More Treatment-emergent Adverse Events,2016-09-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
11625,NCT00135083,"To show non-inferiority between treatment groups (insulin glargine plus insulin glulisine administered once a day, twice a day, or 3 times a day) in the change in glycemic control as measured by hemoglobin A1C.",,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
11626,NCT00086502,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24,Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
11627,NCT00976924,blood glucose value,,2009-07,COMPLETED,INTERVENTIONAL,['NA'],
11628,NCT02552277,"Percent change in the epidermal nerve fiber density (ENFD) at 6 months, compared to baseline",Adverse Events (AEs),2015-10-27,COMPLETED,INTERVENTIONAL,['PHASE2'],
11629,NCT00967993,The Primary Outcome of This Trial Will be the Change in Serum Phosphorus From Baseline to End of Treatment After a Four Week Treatment Period.,"The Incidence of Treatment-emergent Adverse Events (New or Worsened From Study Drug Initiation) Will be Summarized by Body System, Severity, Type of Adverse Event, and Presumed Relationship to the Study Drug.",2010-01,COMPLETED,OBSERVATIONAL,['NA'],
11630,NCT04073914,Change in Parent Stress using the Perceived Stress Scale (PSS),,2017-06-29,COMPLETED,INTERVENTIONAL,['NA'],
11631,NCT02084251,Safety/Adverse Event Outcome Measure,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
11632,NCT00869414,Change in the Mean Minutes Per 24 Hour Day in the Hyperglycemic Range of > 180 mg/dL.,,2009-07,TERMINATED,INTERVENTIONAL,['NA'],
11633,NCT01305551,"Evidence of BE on single-dose pharmacokinetic parameters half-life (T-HALF) derived from Saxagliptin, 5-Hydroxy Saxagliptin and Metformin plasma concentration versus time data.","Active metabolite of Saxagliptin, 5-Hydroxy Saxagliptin, from 5 mg Saxagliptin/500 mg Metformin XR FDC tablet & from 5 mg Onglyza administered together with 500 mg Glifage® XR in single-dose fed & fasted state pharmacokinetics in healthy subjects",2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
11634,NCT00612040,Change in Glycosylated Haemoglobin (HbA1c),Physical Examination,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
11635,NCT00283751,HbA1c,Change in body weight,2003-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
11636,NCT02779816,Visual analog scale for ease of use,,2017-05-01,TERMINATED,INTERVENTIONAL,['NA'],
11637,NCT01045590,Change from baseline in the ratio (IAAT:SAT) between the intra-abdominal adipose tissue area (IAAT) and abdominal subcutaneous adipose tissue area [SAT] after 12 months treatment with oral glibenclamide plus rosiglitazone compared to oral glibenclamide p,Comparisons will be made between glibenclamide plus rosiglitazone and glibenclamide plus placebo treatment groups on Change from baseline after 6 and 12 months treatment with respect the following,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
11638,NCT03785301,HbA1c,FGM accuracy,2018-12-20,UNKNOWN,INTERVENTIONAL,['NA'],
11639,NCT01336777,Adipose Cell Size,Gene Expression,2009-08,UNKNOWN,OBSERVATIONAL,['NA'],
11640,NCT04073576,Performance of the AHCL system,Safety of the AHCL system,2019-05-20,UNKNOWN,INTERVENTIONAL,['NA'],
11641,NCT00964964,Total number of periods where carbohydrate supplementation is needed during the treatment,Number of periods with low blood sugar during treatment,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
11642,NCT02297399,Tolerability of the bowel preparation (analogue visual scale),Adverse events,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
11643,NCT03099837,Influence of prenatal and early postnatal factors on child health,,2013-01-10,UNKNOWN,OBSERVATIONAL,['NA'],
11644,NCT02355158,Summary of Neuropathic Pain Symptom Inventory (NPSI),,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
11645,NCT01497574,Area under the insulin concentration curve (AUC),Adverse events,2005-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
11646,NCT03441750,Rate of newly diagnosed diabetes,,2017-04-25,COMPLETED,INTERVENTIONAL,['PHASE4'],
11647,NCT02175732,HbA1c,Depression,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
11648,NCT04090580,Impact of dapagliflozin in glycemic variability,Impact of dapagliflozin in waist circumference,2019-08-27,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11649,NCT00982293,The primary outcome measure is the improvement in Subject's hemoglobin A1c level after 13 weeks of treatment compared to baseline.,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
11650,NCT01014832,Frequency of hypoglycemia,,2008-12,COMPLETED,INTERVENTIONAL,['NA'],
11651,NCT00949416,,,2009-06,UNKNOWN,OBSERVATIONAL,['NA'],
11652,NCT04665128,Reducing the glucose levels of hyperglycemic patients in the emergency department may improve clinical outcomes and have a positive effect on post-discharge prognosis.,,2020-12-15,UNKNOWN,OBSERVATIONAL,['NA'],
11653,NCT00351585,Durability of this effect after a 2-week washout,Chance from baseline in glucagon secretion at 12 weeks,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
11654,NCT02135068,Nadir blood glucose levels during exercise,Mean daytime and nighttime glucose values,2015-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
11655,NCT00985361,Hemoglobin A1c,,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
11656,NCT01356953,Blood Pressure - Ambulatory blood pressure monitoring (ABPM),,2008-10,COMPLETED,INTERVENTIONAL,['NA'],
11657,NCT00790660,Evaluation of safety through clinical safety labs and adverse events,Evaluation of routine PK and PD parameters,2008-10-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
11658,NCT05557227,"Time to hypoglycemia Secondary endpoints: Blood glucose variability, volume of intravenous glucose needed to maintain glucose above 5 mmol/l, respiratory exchange ratio.",Time in Range,2022-12-15,RECRUITING,INTERVENTIONAL,['NA'],
11659,NCT03588234,Food literacy level,Fast food consumption,2018-06-28,COMPLETED,OBSERVATIONAL,['NA'],
11660,NCT05006508,Change of long-term blood glucose concentration measured as glycated hemoglobin at end of follow-up,Change of Patient Health Questionnaire 9-item scale,2021-08-16,RECRUITING,INTERVENTIONAL,['NA'],
11661,NCT06329882,Change in glycemic profile,,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11662,NCT01673191,Mean Change in Intraocular Pressure,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
11663,NCT00189774,,,na,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
11664,NCT05445284,Retention feasibility,Diabetes-related emergency department visits,2023-10-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
11665,NCT02423850,Wound healing change quantified using digital imaging method,Wound duration is compared to outcome of the wound,2015-08,COMPLETED,OBSERVATIONAL,['NA'],Quality of life (Questionaires) using 36-Item Short Form Survey (SF-36) is compared to outcome of the wound
11666,NCT01755468,"Baseline-adjusted beta-cell function at 2 years, measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2).",Baseline-adjusted glycemic control at 2-years.,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3'],insulin sensitivity
11667,NCT02102737,Correlation between measure of insulin resistance measurement by scintigraphy and hyperinsulinemic euglycemic clamp,strain by speckle tracking echocardiography,2014-05-13,COMPLETED,INTERVENTIONAL,['PHASE2'],
11668,NCT00388050,"Treatment Action, adherence",Acceptability,2006-07,COMPLETED,INTERVENTIONAL,['NA'],
11669,NCT03304158,Mean fasting blood glucose level,,2017-06-01,COMPLETED,INTERVENTIONAL,['NA'],
11670,NCT01892124,Change in Body Mass Index,Changes in Blood Pressure,2013-11,COMPLETED,INTERVENTIONAL,['NA'],Changes in Food Habits
11671,NCT01855399,Percent Glycosylated Hemoglobin,,2014-09-09,COMPLETED,INTERVENTIONAL,['NA'],
11672,NCT01369082,Duration of sustained islet allograft function,Donor-specific alloantibodies,2011-05,COMPLETED,OBSERVATIONAL,['NA'],
11673,NCT00240383,"To compare, after 24 weeks of oral administration of double-blind treatment, the change from baseline in hemoglobin A1c (HbA1c) achieved with the highest dose and subsequent doses of BMS-298585 versus the lowest dose of BMS-298585 in subjects with Type 2","To assess, after 12 and 24 weeks of oral administration of double-blind therapy, the percent change from baseline in fasting lipids (total cholesterol,low density lipoprotein cholesterol,HDL-C, TG, non-HDL chol",2002-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
11674,NCT01608724,Absolute Change From Baseline in Haemoglobin A1c (HbA1c),Change From Baseline in 2-hour Postprandial Plasma Glucose (2h-PPG),2012-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
11675,NCT02988011,Gene expression in adipose tissue,Epigenetic changes assessed as DNA methylation,2016-02-28,UNKNOWN,INTERVENTIONAL,['NA'],
11676,NCT04016662,CGM Measured Time <70 mg/dL,Hypoglycemia Unawareness,2020-09-28,COMPLETED,INTERVENTIONAL,['PHASE4'],Patient Reported Questionnaires
11677,NCT00862849,Intra-participant Variability in Percent of Total Area Under the Plasma Insulin Concentration-Versus-Time Curve Attained by Time T (%AUC[0-T]),Number of Treatment Emergent Adverse Events (TEAEs) Related to Study Drug,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
11678,NCT02211495,Number of Day Until 50% Healing of Leg Ulcer,"Quality of Life (PAID, EQ5D, VAS, SF-12)",2014-07,COMPLETED,INTERVENTIONAL,['NA'],
11679,NCT01649167,,,2009-02,COMPLETED,OBSERVATIONAL,['NA'],
11680,NCT02622113,Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events),Percentage Change in Body Weight,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
11681,NCT01318564,Patients' Adherence to Unit Dose Packaging Devices,,2011-03,COMPLETED,OBSERVATIONAL,['NA'],
11682,NCT04222686,Variation of exercise-induced urinary albumin excretion,Change in uricemia concentration,2017-12-20,COMPLETED,INTERVENTIONAL,['PHASE4'],
11683,NCT03433677,Rate of Infusion Set Failures,Number of Participants With Severe Hypoglycemic Events,2018-02-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
11684,NCT00213213,"- Infant pain score during the newborn screening test, assessed by the Premature Infant Pain Profile (PIPP), or individual parameters of PIPP (facial grimace, heart rate, oxygen saturation)",- Serum Glucose concentrations in infants of diabetic mothers,2003-07,UNKNOWN,INTERVENTIONAL,['NA'],
11685,NCT04161859,Prevalence of the use of nutraceutical in clinical practice,,2017-05-01,COMPLETED,OBSERVATIONAL,['NA'],
11686,NCT02695121,Incidence of bladder cancer,Incidence of compsite cancer outcomes,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],
11687,NCT05067231,Genetic Variants in the NPPA and NPPB gene of the Natriuretic Peptide family associated with the Cardiovascular and Metabolic Diseases,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],
11688,NCT02251418,Ulcer area,Ulcer area,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
11689,NCT01436201,Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
11690,NCT02834923,Sugar-sweetened beverages,Weight,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
11691,NCT05264727,Change in Glucagon Suppression (G50) caused by amino acids vs. saline,glucagon suppression (G50) is greater in obese compared to lean people without T2DM,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE4'],
11692,NCT04881890,Adherence with food tracking,Change in body weight per participant over the study period,2020-10-05,COMPLETED,INTERVENTIONAL,['NA'],Change in physical symptoms
11693,NCT02506296,Difference in response to a standard DPPIV therapy,differences in time spent in hypoglycaemia,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
11694,NCT01146678,Lixisenatide maximum plasma/serum peak concentration (LIX-Cmax),Time to GIRmax (GIR-Tmax),2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
11695,NCT01408628,Frequency of Hypoglycemia,Severity of Self-reported Hypoglycemia,2011-08,COMPLETED,INTERVENTIONAL,['NA'],
11696,NCT02419859,Glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood),Hypoglycemic events,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
11697,NCT01019486,Coronary Blood Flow Assessment With Regadenoson Stress by Cardiac MRI Between Non-diabetic and Type 1 Diabetic Subjects.,Myocardial Perfusion Index,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
11698,NCT01578837,Change in Mean 24 hour Systolic Ambulatory Blood Pressure at 12 weeks,Change in lipids at 12 weeks,2014-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11699,NCT03697109,"In all patients, assessment of safety based on treatment-emergent adverse events (TEAEs) as graded by CTCAE v5.0.",In patients with uncontrolled hypertension the mean change in SBP or DBP from Baseline to visit OL22/ET,2018-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
11700,NCT03077997,Diabetes Distress (As measured by the Diabetes Distress Scale),EuroQol 5D5L,2017-03-15,TERMINATED,INTERVENTIONAL,['NA'],
11701,NCT05092477,Illness Perceptions Questionnaire (IPQ scores),Beliefs about Medicines Questionnaire (BMQ scores),2022-01-27,COMPLETED,INTERVENTIONAL,['NA'],
11702,NCT00527995,Improvement of flow mediated dilatation of the brachial artery following a single dose of 100mg Sildenafil.,Change in hemodynamics and cardiovascular parasympathetic and sympathetic nerve function using time domain and frequency domain indexes of heart rate variability (HRV) and baroreflex sensitivity (BRS) following a single dose of 100mg Sildenafil.,2001-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
11703,NCT00194298,SUV measurement from PET scan,,2002-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
11704,NCT06150508,Lipid profile,Lifestyle questionnaire,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Satisfaction rate
11705,NCT01623648,Plasma glucose,Change in body weight,2013-02,UNKNOWN,INTERVENTIONAL,['NA'],
11706,NCT04530383,Change in BK channel gene expression,Pharmacokinetics of metformin,2022-02-14,RECRUITING,INTERVENTIONAL,['PHASE2'],
11707,NCT05275803,Microorganism,IL-1β、IL-6、TNF-α,2023-06-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
11708,NCT04871958,Blood glucose Time-In-Range (TIR) during hospital stay,Accesses to the isolation room,2021-03-19,TERMINATED,INTERVENTIONAL,['NA'],
11709,NCT02871089,Area under the meal stimulated C-peptide curve (AUC) during a mixed meal tolerance test (MMTT),Lipid profile,2017-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Qualitative Human Factor Assessment
11710,NCT00721019,Total body insulin sensitivity,Glycerol turnover and free fatty acid concentrations,2008-07,COMPLETED,INTERVENTIONAL,['NA'],
11711,NCT04027023,impact of a temporary personalized poly-pharmaceutical treatment on the disease stage in patients with type 2 diabetes,Electrolytic balance,2019-10-30,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11712,NCT02705274,Proportion of visual acuity improvement using Snellen chart or equivalent from baseline and 1 year,Proportion of eyes Need for Vitrectomy,2016-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
11713,NCT00099320,Change from Baseline to Week 16 in fasting serum glucose (FSG) and glucose,Changes in lipids between Baseline and Week 16,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
11714,NCT02027740,Change in LDL-c,HbA1C,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
11715,NCT02681718,Difference in Hemoglobin A1C (Text Message vs. Control),Percentage of participants who visited a physician due to a diabetes related follow-up,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
11716,NCT05969106,Incremental Cost Efficiency Rate (ICER),,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],Glucose control at start of the study
11717,NCT00981448,Change in acute insulin response from IVGTT.,change in urinary zinc,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
11718,NCT05846191,Mean different in concentration of serum pentraxin-3 and high sensitive CRP levels in study groups.,,2023-12-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
11719,NCT02914821,Sugar-Sweetened Beverages Sold by Universal Product Code (UPC),Changes in types of beverages purchased,2016-09-01,TERMINATED,INTERVENTIONAL,['NA'],
11720,NCT00980356,To assess whether monotherapy with Vildagliptin improve glycemic control in kidney transplanted patients with newly diagnosed NODAT as judged in OGTT 3 months after treatment start compared to placebo.,To assess differences in the change in HbA1c and fasting plasma glucose after 3 months after treatment start and to assess the safety and efficacy of Vildagliptin in renal transplanted patients.,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
11721,NCT01121289,Area under the serum NN1218 concentration-time curve,Area under the serum NN1218 concentration-time curve,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
11722,NCT02694263,HbA1c + weight loss,Flash Glucose Monitoring - MAGE,2016-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
11723,NCT04226846,Comparison between Bios device readings and glucose values,,2019-12-09,UNKNOWN,OBSERVATIONAL,['NA'],
11724,NCT01730885,"Mean absolute relative deviation (MARD) from paired reference values of BGStar®, iBGStar® and comparator BG meter measurements at stable hypoglycaemic, euglycaemic and hyperglycaemic levels and overal",,2012-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
11725,NCT00389415,Adverse events profile after 52 weeks of treatment,Change from baseline to endpoint in body weight at 52 weeks,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
11726,NCT02590822,Increase in circumferential PEDSR rate as measured by CMR at 12 weeks.,Exercise Questionnaire,2015-10-02,RECRUITING,INTERVENTIONAL,['NA'],
11727,NCT00380913,The Average Pain Score at target site.,Safety will be assessed through the collection of AEs and vital signs.,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
11728,NCT00299871,HbA1c levels at baseline and endpoint (at 13 weeks).,"Fructosamine, fasting plasma glucose, fasting serum insulin, proinsulin, C-peptide, glucagon.",2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
11729,NCT03257228,Insulin like growth factors in patients with OLP and diabetes mellitus,,2014-11-01,COMPLETED,OBSERVATIONAL,['NA'],
11730,NCT05420714,Average change in glycemic control 3 months after Pro-CGM use,Percentage of positive patient response to the Pro-CGM Questionnaire,2022-08,WITHDRAWN,INTERVENTIONAL,['NA'],
11731,NCT03665350,Change in blood glucose variability,Changes in Hemoglobin A1c (HbA1c).,2018-11-08,TERMINATED,INTERVENTIONAL,['PHASE2'],
11732,NCT04331444,"Difference between change in TIR (3.9-10 mmol/l) in percent, assessed via blinded CGM device, between CGM group (A) and SMBG group (C)",Difference between number of participants using CGM vs. not using CGM increasing 5 % or more in TIR,2020-08-01,COMPLETED,INTERVENTIONAL,['NA'],Evaluating which blood glucose measured by SMBG best reflect TIR
11733,NCT03532620,Change from baseline in hemoglobin A1c levels,Changes from baseline in carotid intima-media thickness,2018-08-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],Incidence of adverse events (AEs)
11734,NCT01515059,Glycaemic shift,Change in palatability via VAS,2012-09,TERMINATED,OBSERVATIONAL,['NA'],
11735,NCT02220907,Number of Participants With Adverse Events,Percentage Change in Body Weight From Baseline,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
11736,NCT04011397,Change in enjoyment,Change in systolic and diastolic blood pressure,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
11737,NCT06180616,Body weight,FIB-4,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
11738,NCT04515745,Ever applied for public disability program benefits (Social Security Disability Insurance (SSDI) or disability-related Supplemental Security Income (SSI)),Application for Social Security Disability Insurance (SSDI) or disability-related Supplemental Security Income (SSI) benefits.,2016-12-19,COMPLETED,OBSERVATIONAL,['NA'],Ever participated in labor force conditional on enrollment in disability programs.
11739,NCT03146156,Neonatal adiposity comparison between intervention and usual care group,Maternal metabolic status,2017-03-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
11740,NCT05812547,To evaluate the average change in blood glucose levels with the use the Lumen device,To evaluate the change in need for neonatal intensive care unit (NICU) admission,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
11741,NCT00411554,Change From Baseline in HbA1c at Week 12,Change From Baseline in 2 Hour Postprandial Glucose at Week 12,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
11742,NCT04068285,walking speed,,2019-11-04,COMPLETED,INTERVENTIONAL,['NA'],
11743,NCT05920434,Pain severity,Vibration sense,2020-07-19,COMPLETED,INTERVENTIONAL,['NA'],The quality of life
11744,NCT00361023,,,2006-01,COMPLETED,INTERVENTIONAL,['NA'],
11745,NCT05890807,Parodontitis based on clinical observation of the patient's oral cavity (direct method),D. Visible clinical signs associated with periodontitis on the photos taken. Plaque,2023-03-20,RECRUITING,INTERVENTIONAL,['NA'],Charlson score
11746,NCT04210609,Wound closure rate at 20 weeks,"Time to 50%, 75%, 100% wound closure",2021-10-04,UNKNOWN,INTERVENTIONAL,['NA'],
11747,NCT02938806,Analysis of gut microbial composition and diversity by 16S rRNA sequencing,Analysis of urine metabolite concentrations measured by mass spectrometry,2016-06,COMPLETED,OBSERVATIONAL,['NA'],
11748,NCT01601990,Change of HbAlc,HbA1c Responder Rate,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
11749,NCT00355823,,,2006-08,COMPLETED,OBSERVATIONAL,['NA'],
11750,NCT03430141,Nutrition Intervention,Chronic disease prevalence,2016-10-31,COMPLETED,INTERVENTIONAL,['NA'],
11751,NCT03196362,Remission rate,Adverse events,2016-12-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11752,NCT01346527,Left ventricular strain,Maternal palmitate rate of appearance during hyperinsulinemia,2011-04,COMPLETED,OBSERVATIONAL,['NA'],
11753,NCT01973231,Change in Glycosylated Haemoglobin (HbA1c) From Baseline,Number of Treatment Emergent Adverse Events (TEAEs),2013-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
11754,NCT01690481,MRI brain volumes,Neuropsychological scores,2006-12,COMPLETED,OBSERVATIONAL,['NA'],
11755,NCT00742976,change in weight; change in extracellular volume,"sodium excretion in urine, 24 hour blood pressure, body composition change,urine osmolality, urine albumin excretion, GFR, HbA1c, Blood lipid profile, NT-proBNP, plasma Albumin, Plasma metanephrines, aldosterone, active renin, angiotensin II",2008-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
11756,NCT04449692,Difference between study visits in time (min) in hypoglycemia (plasma glucose < 3.9 mmol/l) from 0-180 minutes post-intervention,Difference between study visits in incidence rate of vomiting from 0-180 minutes post-intervention,2020-07-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
11757,NCT02915263,Change in Neuropathic Pain Severity as Measured by the Pain Visual Analogue Scores (VAS).,Change in Autonomic Neuropathy as Measured by Standardized Autonomic Nervous System Testing.,2017-09-11,TERMINATED,INTERVENTIONAL,['PHASE2'],
11758,NCT05252793,Healthy Lifestyle Behaviors Scale II Score Change,Self-Efficacy Questionnaire,2022-01-01,COMPLETED,INTERVENTIONAL,['NA'],
11759,NCT02689570,coronary artery calcifications,diastolic dysfunction,2011-06,UNKNOWN,OBSERVATIONAL,['NA'],
11760,NCT00699023,Incremental AUC after a fat-rich meal of cholesterol concentration in chylomicron and VLDL fractions,Concentration and Composition of different lipoprotein subclasses in the fasting condition.,2008-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
11761,NCT03946631,Sensitivity of early postpartum overt diabetes screening by 2-hour glucose tolerance testing in postpartum women.,,2019-08-20,TERMINATED,OBSERVATIONAL,['NA'],
11762,NCT04962048,Change of toleration / wellbeeing due to intervention of PSNP with Numeric Rating Scale,Change of microcirculation with thermal imaging (TH),2021-05-28,TERMINATED,INTERVENTIONAL,['NA'],
11763,NCT02280863,"Count of Participants With no More Than One Meter Glucose Value <50 mg/dL and no Values <40 mg/dL, no More Than Two Episodes With Meter Glucose Values Remaining >300 mg/dL for More Than 1 Hour, and no Ketonemia, Seizures, or Loss of Consciousness","Percentage of Fingerstick Meter Glucose Value Tests >300 mg/dL, Adult Cohort - Integrated System Interface and Adolescent Cohort",2014-07,COMPLETED,INTERVENTIONAL,['NA'],
11764,NCT02905487,Blood levels of C- Reactive Protein in mother and her child,Blood level of C-peptide in mother,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],
11765,NCT01832935,Number Of Hypoglycemic events,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
11766,NCT06227247,Receipt of intervention (Exercise Session Completion),,2024-02-01,RECRUITING,INTERVENTIONAL,['NA'],
11767,NCT01156779,Assessment of safety,Pharmacokinetics and Pharmacodynamics,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
11768,NCT03370484,Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min).,Subjective ratings of appetite (au),2017-10-01,COMPLETED,INTERVENTIONAL,['NA'],
11769,NCT05193578,HbA1c (mmol/mol),Absolute change in systolic and diastolic blood pressure (mmHg),2022-01-12,RECRUITING,INTERVENTIONAL,['PHASE2'],
11770,NCT05998837,Biopsy changes in the expression and location of senescence markers by immunohistochemistry,Outcomes of blood presssure control,2021-04-13,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
11771,NCT01682954,Body Weight,,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
11772,NCT01342939,Incretin effect,Plasma glucagon response,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
11773,NCT05510245,Fraction of unbound drug in plasma; Cu/C where Cu represents unbound concentration and C represents total concentration,Number of Participants With Treatment emergent Clinically Significant Abnormal ECG,2022-08-29,TERMINATED,INTERVENTIONAL,['PHASE1'],
11774,NCT05253521,The change in the frequency / absolute number of circulating ALDHhiSSChi granulocyte precursor cells between individuals of South Asian origins and White individuals of European origin,The change in the frequency / absolute number of circulating ALDHhiSSClo cells with primitive provascular progenitor cell phenotype between individuals of South Asian origins and White individuals of European origin,2022-01-08,COMPLETED,OBSERVATIONAL,['NA'],Changes in the concentration of serum inflammatory markers individuals of South Asian origins and White individuals of European origins
11775,NCT00220337,"Number of Subjects With Urine Protein Status 'Positive +++' at Baseline, Categorized by Urine Protein Status at Last Visit",Change in Quality of Life From Visit 2 (Baseline) to Termination Visit,2004-12-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
11776,NCT03178591,The average of systolic blood pressure at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group.,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
11777,NCT04183868,Change of myocardial metabolic rate of glucose,Change of lipid profile,2016-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
11778,NCT03531944,Change in HbA1c level,Cost effectiveness analysis,2018-06-06,COMPLETED,INTERVENTIONAL,['NA'],
11779,NCT00687960,Post-Prandial Metabolism,,2006-11,COMPLETED,INTERVENTIONAL,['NA'],
11780,NCT06083116,"Steady-state pharmacokinetics parameters of Hydrochlorothiazide: Css, max",Adverse events,2019-08-28,COMPLETED,INTERVENTIONAL,['PHASE1'],
11781,NCT03616275,Changes from Baseline Autonomic function (Heart rate variability) at 3 and 6 months,Changes from Baseline salivary cortisol at 3 and 6 months,2017-10-17,COMPLETED,INTERVENTIONAL,['NA'],
11782,NCT02881164,Satiety,,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
11783,NCT00160056,,,2005-04,COMPLETED,INTERVENTIONAL,['NA'],
11784,NCT01410097,Short Physical Performance Battery (SPPB) Score,Modified Mini-Mental Status Exam (3MS),2009-09,COMPLETED,INTERVENTIONAL,['NA'],
11785,NCT01464073,body fat mass reduction,biological parameter,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
11786,NCT03111433,change in soluble interacellular adhesion molecule level,,2017-03-19,COMPLETED,INTERVENTIONAL,['PHASE2'],
11787,NCT01122108,"Patient Acceptability of Colesevelam HCl Powder for Oral Suspension vs. Generic Cholestyramine Via the Bile Acid Sequestrant Acceptability (BASA) Scale, Based Upon an Anticipated Equivalent Cholesterol Lowering Doses of Each Comparator Drug.",,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4'],Weighted vs. Unweighted Composite BASA Scale Scores
11788,NCT03838380,hemoglobin A1c levels,Mode of delivery,2017-02-01,COMPLETED,INTERVENTIONAL,['NA'],
11789,NCT02343146,Glycemic Control/HbA1c,Child eating as measured by Remote Food Photography by the parent,2015-12,COMPLETED,INTERVENTIONAL,['NA'],
11790,NCT00437008,A high-AGE meal causes a more pronounced postprandial endothelial dysfunction comparing to a low-AGE meal in people with type 2 diabetes mellitus.,To investigate whether treatment with Benfotiamine 1050mg/day for 3 days has a protective effect on endothelial function after a high-AGE meal,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
11791,NCT05872620,Mean Percent Change from Baseline in Body Weight,Mean Change from Baseline in Short Form 36 Version 2 Health Survey Acute Form (SF-36v2) Domain Scores,2023-06-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
11792,NCT01175473,Change From Baseline in Area Under the Plasma Glucose Concentration Curve From Time 0.5 Hours to 4.5 Hours (GLU-AUC0:30-4:30h) at Day 28,Percentages of Patients by Ranges of Oxyntomodulin Levels,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
11793,NCT03470415,epicardial fat thickness measurement,Electrocardiogram,2018-05,UNKNOWN,OBSERVATIONAL,['NA'],
11794,NCT01231178,Body weight,Body composition,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
11795,NCT01841229,Glycated hemoglobin (HbA1c),Homeostasis model assessment of insulin resistance (HOMA-IR),2012-10,UNKNOWN,OBSERVATIONAL,['NA'],
11796,NCT05631431,primary objective,,2021-10-15,RECRUITING,INTERVENTIONAL,['PHASE2'],
11797,NCT03909802,Wound size,,2019-07-06,COMPLETED,INTERVENTIONAL,['NA'],
11798,NCT05994651,The effect of using the tidal model on the psychological well-being of individuals with diabetes will be evaluated.,,2023-07-10,COMPLETED,INTERVENTIONAL,['NA'],
11799,NCT05234086,Proportion of patients with completely closed ulcers,,2020-01-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],
11800,NCT03987633,Ethnic disparities in treatment failure,Identification of candidate genetic variants associated with observed disparities in treatment failure.,2021-02-01,RECRUITING,OBSERVATIONAL,['NA'],
11801,NCT03746093,Changes in HbA1c levels from baseline to visit 2 and 3,Changes in fasting serum triglycerides from baseline to visit 2 and 3,2018-11-07,UNKNOWN,INTERVENTIONAL,['NA'],
11802,NCT04432025,Proportion of patients reaching end point for glycemic control,Change in quality of life,2021-04-01,RECRUITING,INTERVENTIONAL,['NA'],
11803,NCT03888053,Presence of anti-BB-101 antibodies,To evaluate plasma concentration of BB-101,2018-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
11804,NCT03182842,Time within 3.9 and 10 mmol/l,,2017-06-17,COMPLETED,INTERVENTIONAL,['NA'],
11805,NCT05845190,homocystiene,cholestrol,2022-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
11806,NCT01756716,Frequency and nature of treatment-emergent adverse events and serious adverse events.,Plasma concentrations of MT-3995 and its major metabolite,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
11807,NCT02057211,∆-change of C-peptide Area Under the Curve (AUC) (0-120 min) for a mixed meal tolerance test at two year follow-up when compared to pre-treatment values at enrolment.,,2014-04,TERMINATED,INTERVENTIONAL,['PHASE2'],
11808,NCT01483352,Percentage of Participants Categorized by Ability of the Port to Deliver Insulin Intraperitonally,Design Validation Participant Questionnaire - Percentage of Participants With a Positive Response,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
11809,NCT04620265,Change from baseline spatial and temporal gait parameters at 3 months,,2020-03-01,COMPLETED,INTERVENTIONAL,['NA'],
11810,NCT03617146,Diabetes distress score,"Self-care behaviors (medication adherence, dietary practices, and physical activity behaviors)",2018-06-15,TERMINATED,INTERVENTIONAL,['NA'],
11811,NCT02626936,Percentage of time below 4.0 mmol/L,Total glucagon delivery,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
11812,NCT00219089,Change from baseline in mean sitting diastolic blood pressure after 8 weeks,Diastolic blood pressure less than 90 mmHg or reduction of 10 mmHg or greater from baseline after 8 weeks,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
11813,NCT05197829,Problem Areas in Diabetes,Number of Sensor Checks per Day,2022-01-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
11814,NCT03960424,Hemoglobin A1C,Diabetes Quality of life,2019-09-30,COMPLETED,INTERVENTIONAL,['NA'],
11815,NCT03054454,Nights spent in hospital with a diabetes-related foot problem.,number of below knee amputations attributed to diabetic foot disease,2017-04,UNKNOWN,INTERVENTIONAL,['NA'],
11816,NCT05592860,HbA1c,Change in blood pressure,2021-07-10,COMPLETED,INTERVENTIONAL,['NA'],
11817,NCT02451722,Reduction of Peak Pressure,Comfort of wear,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
11818,NCT00762242,change from baseline (pre-forearm ischemia) in circulating metabolites compared with post-ischemic forearm measurements,,2007-05,TERMINATED,OBSERVATIONAL,['NA'],
11819,NCT03842475,Diabetes remission (complete),Change in ectopic fat,2018-10-01,RECRUITING,OBSERVATIONAL,['NA'],Changes in gut microbiome
11820,NCT04717050,Change in Metabolic Dysregulation (MetD) After Completion of Phase 1 Progressive Combine Training (PCT) -metabolic syndrome (MSY),Metabolic Dysregulation (MetD) Status During 4 month follow up period - metabolic syndrome (MSY),2021-08-12,RECRUITING,INTERVENTIONAL,['NA'],
11821,NCT01632007,Glycosylated hemoglobin (HbA1c),,2012-05-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
11822,NCT04150107,Average Exogenous Total Insulin Compared to Baseline,Daytime Low Blood Glucose Index (LBGI) Compared to Baseline,2019-10-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
11823,NCT02028078,Tracer to Tracee Ratio (the absolute relative difference ARDi ),Tracer to tracee Ratio,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to reach each hypoglycaemic level
11824,NCT03659461,change in blood insulin response to sitagliptin,,2017-10-01,COMPLETED,INTERVENTIONAL,['NA'],
11825,NCT03541096,Difference in brown adipose tissue (BAT) activity after cooling between Winter Swimmers (WS) and No-Winter Swimmers (NWS).,Difference in glycemic control after winter swimming,2018-11-07,UNKNOWN,INTERVENTIONAL,['NA'],
11826,NCT04123587,the list of previously found candidate variants which are observed in the slufonylurea-dependent patients but not in the non-dependent patients,,2019-09-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
11827,NCT02630706,Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation),Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation),2015-12-16,COMPLETED,INTERVENTIONAL,['PHASE3'],
11828,NCT02231684,Area under the semaglutide plasma concentration curve,Number of treatment emergent adverse events (TEAEs),2014-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
11829,NCT03037190,Preservation of beta cells function,Prevention of Celiac DIsease,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],
11830,NCT02211742,postprandial glucose homeostasis,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
11831,NCT01970033,Change From Baseline in HbA1c (Hemoglobin A1C) at Week24,"Change From Baseline in Body Weight at Week 4,8,12、24、38、52",2012-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],
11832,NCT04276428,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose,2020-02-28,COMPLETED,INTERVENTIONAL,['PHASE1'],
11833,NCT04763746,"Train Lifelight algorithms on a more diverse population, including patients with Fitzpatrick scale 1, 4, 5 and 6 skin tones.",,2021-06-01,COMPLETED,OBSERVATIONAL,['NA'],
11834,NCT05033275,Babies with sacral agenesis identified with screening of asymptomatic babies with a spinal ultrasound,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA'],
11835,NCT05885828,Blood glucose profile,Changes in lipid metabolism,2023-07-17,RECRUITING,INTERVENTIONAL,['NA'],
11836,NCT03624023,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),Change of Wound Volume for Individual Subject Measured by 3D Camera and Analysis Software up to 12 Weeks.,2019-12-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11837,NCT02888951,Volume of Gastric Contents,"Episodes of intra-operative regurgitation, vomiting or aspiration",2016-08,UNKNOWN,OBSERVATIONAL,['NA'],
11838,NCT02210871,Area under the semaglutide plasma concentration-time curve,Number of treatment emergent adverse events (TEAEs),2014-08-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
11839,NCT04298424,HbA1C,Self-Efficacy Score,2020-02-14,UNKNOWN,INTERVENTIONAL,['NA'],
11840,NCT00726674,Decrease in HbA1c level,Safety measures,2008-08,COMPLETED,OBSERVATIONAL,['NA'],
11841,NCT01369277,Renal clearance (CLr),,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
11842,NCT06051058,To determine the effect of the Care Transitions App on post-discharge adverse events,To determine the effect of the Care Transitions App on the 30-day readmission rate,2024-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
11843,NCT00950599,Change From Baseline in A1C at Week 12 in the 0-40 mg Cohort,"Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Follow-up Period in the 0 & 100 mg Cohort",2003-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
11844,NCT00391027,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in Urinary Free 8-iso Prostaglandin F2-alpha (α) in a Subset of Subjects,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
11845,NCT04375943,"E velocity, A velocity,E' velocity",,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],
11846,NCT04399434,glucolipid metabolism and insulin sensitivity in pregnant women,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
11847,NCT05773183,To compare differences in steroid metabolomics in men with prostate cancer pre- and post-androgen deprivation therapy (ADT),To compare differences in metabolic phenotype in (i) hypogonadal men compared to healthy men (ii) hypogonadal men pre and post testosterone replacement therapy (iii) men with prostate cancer post initiation of Androgen Deprivation Therapy,2023-03-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
11848,NCT04018326,Final UCVA,,2013-05-01,COMPLETED,OBSERVATIONAL,['NA'],
11849,NCT00810589,"Duration of action, time from onset of action until end of action","GIRmax, maximum glucose infusion AUCGIR,0-32h, AUCGIR,0-12h, AUCGIR,12-32h, tinf=0, Cmax,ins, tmax,ins, AUCins,0-24h AUCins,0-∞ AUCins,0-12h AUCins,12-24h",2008-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
11850,NCT00814372,Change in HbA1c from baseline and compared to placebo,Change in fasting plasma glucose (FPG) from baseline and vs. placebo,2008-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
11851,NCT01453842,Plasma GLP-1,Plasma paracetamol,2011-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
11852,NCT00654056,Insulin sensitivity,Changes in insulin signaling proteins?,2008-03,COMPLETED,INTERVENTIONAL,['NA'],
11853,NCT03331614,Reduction in Subjective Pain,Quality of Life,2017-10-15,UNKNOWN,INTERVENTIONAL,['NA'],
11854,NCT00488033,"Number of Participants With Combination of All Cause Death, Non-fatal Myocardial Infarction (MI), and Hospitalization for Unstable Angina",Number of Participants With Limb Amputation or Peripheral Vascular Revascularization Procedure,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
11855,NCT01508923,24-hour glucose profiles after three fixed meals,Adverse events,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
11856,NCT02284893,Mean Change in HbA1c,Mean Change in Fasting Plasma Glucose (FPG),2014-09-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
11857,NCT04957914,Incidence of Documented Hypoglycemia,,2021-07-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
11858,NCT05243589,"WHO Quality of Life Scale (WHOQOL BREF)( assessing change in quality of life at baseline, 4th and 6th week of intervention.",,2021-02-26,COMPLETED,INTERVENTIONAL,['NA'],
11859,NCT04790760,Difference in time-matched glucose levels between the right arm and the left arm,Difference in time below range between the right arm and the left arm,2021-03,UNKNOWN,INTERVENTIONAL,['NA'],Change in bone mass
11860,NCT03083600,Plasma Glycated Haemoglobin (HbA1c) (mmol/mol),Blood pressure (mmHg),2017-05-22,TERMINATED,INTERVENTIONAL,['NA'],
11861,NCT01338922,Diabetes burden (main carer),Diabetes treatment satisfaction,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
11862,NCT00462371,quality of life,impact of disease,2002-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
11863,NCT01847937,Increase in magnetic resonance signal intensity of segmented nerves,Correlation of magnetic resoance signal intensity value and nerve conduction thresholds,2013-05,COMPLETED,OBSERVATIONAL,['NA'],
11864,NCT01871415,Change in HbA1c,Safety: Incidence of adverse events,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
11865,NCT05857319,Effectiveness of the national RNPC weight reduction program on the change of treatments (drug or instrumental treatments) or in the comorbidities of overweight/obesity.,Dropout rate,2023-07-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
11866,NCT05046483,Change of cardiac function,"Incidence of further cardiovascular diseases (CVD) and STEMI-related complications, new onset of prediabetes and diabetes mellitus and associated comorbidities",2018-12-30,RECRUITING,OBSERVATIONAL,['NA'],
11867,NCT02854111,The correct diagnosis of diabetes mellitus,The correct diagnosis of impaired glucose tolerance,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
11868,NCT05611112,Mental health - Depression,Health literacy,2022-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
11869,NCT02508779,"Reduced consequences of extreme BG (e.g., diabetic ketoacidosis, SH)",Improved internal locus of control (as confirmed by the Perceived Competence for Diabetes Scale and the Treatment Self-Regulation Questionnaire),2015-07,COMPLETED,INTERVENTIONAL,['NA'],
11870,NCT00418288,The acute effect of GLP-1 on glucose uptake in the heart,The acute effect of GLP-1 on lumped constant in the brain,2007-01,COMPLETED,INTERVENTIONAL,['NA'],
11871,NCT03120871,Insulin sensitivity (Si),Urinary follicle stimulating hormone (FSH),2017-05-12,COMPLETED,OBSERVATIONAL,['NA'],
11872,NCT01011062,insulin sensitivity measured as glucose disposal during clamp,plasma adipokines and their expressions in SAT,2004-01,COMPLETED,INTERVENTIONAL,['NA'],
11873,NCT01105884,complete healing of the wound,,2009-10,WITHDRAWN,INTERVENTIONAL,['NA'],
11874,NCT00543556,,,2001-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
11875,NCT01474161,"Safety parameters (Study Parts II, III and IV)","Pharmacokinetics parameters (Study Parts II, III and IV)",2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
11876,NCT04843527,Impact on time above 180 mg/dL,,2021-04-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
11877,NCT00622960,body weight,"glycemic control (glucose, insulin, and HbA1c)",2004-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
11878,NCT04371497,differential HbA1c before and after insulin switch,Continuous Glucose Monitoring before and after insulin switch,2011-06-01,COMPLETED,OBSERVATIONAL,['NA'],
11879,NCT00641056,Change in HbA1c From Baseline to Week 26,Assessment on Event Rate of Treatment-emergent Hypoglycemic Episodes,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
11880,NCT02378675,Difference of adipocytokines between women with GDM and women with normal glucose tolerance.,,2012-08,COMPLETED,OBSERVATIONAL,['NA'],
11881,NCT01131182,Proportion of Participants With at Least One Symptomatic Hypoglycemic Event,Proportion of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event,2010-06-13,COMPLETED,INTERVENTIONAL,['PHASE4'],
11882,NCT01724814,Incidence and severity of treatment emergent adverse events,Peak Plasma Concentration(Cmax) of HM12460A following a single dose in Parts 1-3,2012-12-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
11883,NCT03636867,Incidence of amputation,Incidence of revascularization of peripheral arteries,2018-08-07,COMPLETED,OBSERVATIONAL,['NA'],Incidence of major cardio and cerebrovascular adverse events (MACCE)
11884,NCT02344186,Changes in unfolded protein response markers,Beta cell function,2014-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
11885,NCT01001962,New onset of hypertension,Mortality cardiovascular,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11886,NCT06053047,Relative risk reduction in the incidence of new Diabetic Foot Ulcers (DFUs),Relative risk reduction in resource utilization,2024-01-22,RECRUITING,INTERVENTIONAL,['NA'],Healthcare Provider acceptance of Bluedrop Monitoring System (BMS)
11887,NCT05413239,Time in Range (TIR),Attitudes toward diabetes device use,2022-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Diabetes incorporation/identity
11888,NCT02607280,Change From Baseline in Average Daily Pain Score (ADPS) at Each Week,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
11889,NCT01506310,Serum fasting glucose values.,The mean birth-weight of newborns,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
11890,NCT00423059,Factor VIII,complication rate,2006-12,COMPLETED,INTERVENTIONAL,['NA'],
11891,NCT01264016,Percent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,Number of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Comprehension),2010-11,COMPLETED,INTERVENTIONAL,['NA'],
11892,NCT00432887,glucose tolerance,plasma caffeine concentration,2004-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
11893,NCT04221152,"Adverse events, Adverse drug reactions, and Presence/absence of the use of rescue treatment drugs",Postprandial glucose for 2 hours over time,2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
11894,NCT03059056,Area under the curve,,2017-02-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
11895,NCT01781975,Area Under the Stimulated C-peptide Curve (AUC) Mean Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 1 Year Visit,Number of Adverse Events,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
11896,NCT01105455,Serum glucose concentration 1hr after glucose challenge test,Acceptability of study foods,2010-03,COMPLETED,INTERVENTIONAL,['NA'],
11897,NCT05917808,Change in 2 hour glucose in OGTT,Change in homeostasis model assessment (HOMA) Index between 1st and second OGTT,2023-05-29,RECRUITING,INTERVENTIONAL,['NA'],
11898,NCT05806294,Blood pressure,Changes in resting energy expenditure,2022-11-17,RECRUITING,INTERVENTIONAL,['NA'],Changes in hospital admissions rates for ischemic stroke events
11899,NCT02667652,body mass idex,blood fat,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
11900,NCT05713396,AV,TPF/FT,2017-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
11901,NCT04838600,"Incidence of clean wound bed at End of Treatment, as assessed by investigator","Relative change in devitalized tissue and wound size at End of Treatment, compared to Baseline, assessed by planimetry",2021-06-07,TERMINATED,OBSERVATIONAL,['NA'],
11902,NCT04805996,HbA1c,Diabetes complications follow up,2021-03-23,COMPLETED,INTERVENTIONAL,['NA'],
11903,NCT03637075,Effects of nasal insulin vs. placebo on the insulin sensitivity of the human brain as well as effects on regional availability of dopamine receptors.,Effects of nasal insulin vs. placebo on changes in autonomic nervous system,2017-02-20,RECRUITING,INTERVENTIONAL,['NA'],
11904,NCT03412253,Cure of type II DM.,,2013-11-01,SUSPENDED,INTERVENTIONAL,['NA'],
11905,NCT02614625,Sensitivity as the proportion of anatomical structures that are detectable with the two instruments,Corneal sublayer thickness and retinal sublayer thickness obtained with the two study instruments,2014-12,UNKNOWN,OBSERVATIONAL,['NA'],
11906,NCT03997032,Plasma homocysteine level,Retinal vessel diameters,2017-07-31,COMPLETED,INTERVENTIONAL,['NA'],Intraocular pressure
11907,NCT01221207,Number of Participants Who Achieve Full Wound Healing.,,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
11908,NCT02091193,Change in Endothelial Function with Krill Oil Supplementation as Compared with Baseline and Placebo,"Change in Lipid Profile (HDL, LDL, Total Cholesterol), Glucose, Hemoglobin A1C with Krill Oil Supplementation Compared with Baseline and Placebo",2012-03,COMPLETED,OBSERVATIONAL,['NA'],"Effects of Longer Term Krill Oil Supplementation compared to Baseline on Endothelial function, lipid profile, Hemoglobin A1C, glucose, c-peptide and total antioxidant capacity."
11909,NCT00801450,central subfield macular thickness,Intraocular pressure,2007-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11910,NCT03182231,Pancreatic uptake of 68Ga-NODAGA-exendin-4,Beta cell function,2016-10-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11911,NCT04126603,Gene Expression of CD34+ Endothelial Progenitor Cell number,Biochemistry: LDL over HDl Ratio,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
11912,NCT00295256,"Outcomes measures are mean fasting glucose levels, mean systolic pressure and mean diastolic pressure",,2006-02,COMPLETED,INTERVENTIONAL,['NA'],
11913,NCT03078101,The difference of Ang 1-7 increase from baseline between a 3-month treatment with empagliflozin on top of ACEi treatment compared to ACEi treatment alone,Mean changes in salt sensitivity after 3 months of empagliflozin treatment,2017-04-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of hospitalizations during the study.
11914,NCT02414217,Change in Objective Diabetes Numeracy from Baseline to ≈6 weeks,Change in Glycemic Control from Baseline to ≈3 months,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
11915,NCT01181882,Platelet function,Lysophospholipids,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
11916,NCT00402012,Change in skeletal muscle mitochondrial number (electron microscopy + qPCR of mtDNA) and mitochondrial gene expression in T2DM patients treated with pioglitazone (vs. placebo),intra hepatic and intra myocellular lipid by MRS; mitochondrial content by MRS (ATP max) post weight loss period,2006-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
11917,NCT02660593,Blood Sugar level,,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],
11918,NCT02548585,Change From Baseline in Body Weight to the EOT (Cohort 4),"Percent Change From Baseline in Incretin AUC0-4h After MMT to EOT (Cohorts 1, 2, 3, and 4)",2015-12-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11919,NCT02589028,Area under the curve (AUC) of plasma glucose level after breakfast,Area under the curve of plasma glucagon level after breakfast,2015-10,COMPLETED,INTERVENTIONAL,['NA'],
11920,NCT02828995,Diabetes Medication Adherence,Diabetes Patient Weight (in Pounds),2016-07-08,COMPLETED,OBSERVATIONAL,['NA'],
11921,NCT00525629,Insulin Resistance,,2007-02,COMPLETED,INTERVENTIONAL,['NA'],
11922,NCT01469143,Area under the serum insulin aspart concentration-time curve,Time to maximum observed serum insulin aspart concentration,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
11923,NCT04601311,diabetes distress,diabetes distress,2020-11-11,UNKNOWN,INTERVENTIONAL,['NA'],Proportion of participants with one or more serious adverse events in the intervention period
11924,NCT03041844,Change in wound size,Microcirculatory blood flow index change,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],
11925,NCT00147342,,,2005-05,COMPLETED,OBSERVATIONAL,['NA'],
11926,NCT01615978,Adverse events,24-hour profiles of plasma glucose,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
11927,NCT03154060,Mean Absolute Relative Difference,Precision Absolute Relative Deviation,2017-05-19,COMPLETED,INTERVENTIONAL,['NA'],
11928,NCT03950505,A degree of liver fibrosis,Clinical glucometabolic parameters :Anthropometric parameters,2020-05-29,UNKNOWN,INTERVENTIONAL,['PHASE4'],
11929,NCT02337218,Gait Test (LegSys System),,2014-11,COMPLETED,INTERVENTIONAL,['NA'],
11930,NCT05657769,HbA1C Changes,Lab outcome VI (triglyceride),2022-11-12,RECRUITING,INTERVENTIONAL,['NA'],
11931,NCT03625856,HbA1c changes,Depression score changes,2018-11-30,COMPLETED,INTERVENTIONAL,['NA'],
11932,NCT01925989,Sleep Respiratory Quotient (RQ) in Type 1 Diabetes Mellitus (T1DM),"Change in RQ, Pre-breakfast to Post-breakfast Meal, in T1DM",2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
11933,NCT01065909,,,2009-05,COMPLETED,OBSERVATIONAL,['NA'],
11934,NCT00679939,Adjusted Percent Change in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) From Week 52 +10 Days to Week 76+10 Days,Percent Change in Sex Hormone Binding Globulin (SHBG) From Week 52 to Week 76,2008-04-21,COMPLETED,INTERVENTIONAL,['PHASE4'],Percent Change in Free Estradiol From Week 52 to Week 76
11935,NCT01580852,Glucose Levels,HbA1c levels,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
11936,NCT01483560,Change in Averaged Mean Far Wall Common Carotid Artery Intima-media Thickness (cIMT),Change in Endothelial Function,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
11937,NCT02080741,Telomere length,Level of expression of candidate genes,2014-09-23,TERMINATED,INTERVENTIONAL,['NA'],Analysis of the specific psychological interview EMIC
11938,NCT01038518,"5-year change in prevalence of biomarkers of chronic diseases (e.g. diabetes, asthma, allergy) and micronutrient status (e.g. vitamin D status).",significant interaction (on a additive scale) between Vitamin D status and genetic variants in the Vitamin D receptor in relation to selected chronic disease biomarkers,2010-11,COMPLETED,OBSERVATIONAL,['NA'],
11939,NCT04581447,Proportion of patients with partial or complete T2D remission criteria,Level of glicentin,2021-01-07,RECRUITING,INTERVENTIONAL,['PHASE3'],
11940,NCT05066893,Change in HbA1c,,2020-11-05,RECRUITING,INTERVENTIONAL,['NA'],
11941,NCT02371239,Mean 24 hour glucose concentration,Homeostatic model assessment 2 (HOMA2),2015-02,COMPLETED,INTERVENTIONAL,['NA'],
11942,NCT05662657,To evaluate the prevalence of post-traumatic stress disorder (PTSD) in adult with Type 1 Diabetes,To evaluate whether there is a correlation between PTSD and the patient participation to a therapeutic education program,2022-11-30,RECRUITING,OBSERVATIONAL,['NA'],
11943,NCT01725672,AUC(0-t) and AUC(0-inf) for metformin and glimepiride,Number of subjects with adverse events (AE)s,2012-09-27,TERMINATED,INTERVENTIONAL,['PHASE1'],
11944,NCT06305143,improvement of visual acuity,,2024-04-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
11945,NCT00856882,,,2007-10,COMPLETED,INTERVENTIONAL,['NA'],
11946,NCT02304627,Area under the serum insulin 338 concentration-time curve,Maximum observed plasma capric acid concentration,2014-11-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
11947,NCT05649553,Change in HbA1c,Changes in quality of life,2022-09-15,COMPLETED,INTERVENTIONAL,['NA'],
11948,NCT05098470,Contribution of gluconeogenesis (GNG) to endogenous glucose production (EGP),Glucokinase activity,2022-03-07,RECRUITING,INTERVENTIONAL,['PHASE3'],
11949,NCT05596773,Occurrence of clinically relevant events (number),,2023-02-22,RECRUITING,OBSERVATIONAL,['NA'],Adherence to clinical algorithms provided via the eHealth application
11950,NCT06032221,Device Feasibility - Patient feedback on device use,,2023-07-14,RECRUITING,INTERVENTIONAL,['NA'],
11951,NCT03938233,Total cardiovascular risk,Body mass index (BMI),2020-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Smoking
11952,NCT00432679,Change From Baseline in Glycosylated Hemoglobin (HbA1c) After 16 Weeks of Treatment in Rosiglitazone Group and Placebo Group,Percentage of Participants With Changes in HbA1c and FPG Meeting Specified Criteria After 16 Weeks of Treatment,2006-05-24,COMPLETED,INTERVENTIONAL,['PHASE3'],
11953,NCT02440217,Myocardial metabolic responses to stress in humans,,2015-05,UNKNOWN,OBSERVATIONAL,['NA'],
11954,NCT03495765,The primary endpoint for the study will be the mean change in best-corrected visual acuity (BCVA) from baseline to the mean level at Month 12.,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
11955,NCT01255085,Energy Intake,Subjective Appetite,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
11956,NCT00024583,,,2001-09,COMPLETED,OBSERVATIONAL,['NA'],
11957,NCT01220336,"Composite clinical outcome measure- improvement in either HgA1C, SBP, or LDL","Composite clinical outcome measure- improvement in either HgA1C, SBP, or LDL",2011-04,COMPLETED,INTERVENTIONAL,['NA'],
11958,NCT00377442,AUC0-6h of plasma glucose from pre-dose to 6h post-dose.,"AEs, laboratory parameters.",2006-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
11959,NCT02076555,Change from baseline in diabetes-specific empowerment on the adapted Diabetes Empowerment Scale at the 2-week and 6-month follow-up,Change from baseline in depressive symptoms on the CES-D at the 2-week and 6-month follow-up,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
11960,NCT01135914,Mean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 12,Time Trade-Off Questionnaire - 25 (TTO) Composite Score at Month 12,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
11961,NCT01441323,insulin sensitivity,adiposity,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
11962,NCT02840630,Change in Glycated Hemoglobin (HbA1c),Change in Vitamin D,2016-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
11963,NCT02739984,Percent Change From Baseline in LDL-C at Week 12,Percent Change From Baseline in VLDL-C at Week 12,2016-05-17,COMPLETED,INTERVENTIONAL,['PHASE3'],
11964,NCT01276743,• Difference of distribution of PTPN22 C1858T alleles between patients and controls of Greek origin,• The association between the PTPN22 C1858T polymorphism among patients and presence of autoantibodies,2010-02,COMPLETED,OBSERVATIONAL,['NA'],
11965,NCT01754259,Change in Post-exercise Coronary Vasodilator Reserve,Change in LV Diastolic Function,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
11966,NCT04261933,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),2020-02-13,COMPLETED,OBSERVATIONAL,['NA'],
11967,NCT01125969,Hemoglobin A1c,Cost-effectiveness of change in Hemoglobin A1c,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
11968,NCT01280409,Weight Change,Satisfaction With Medication as Assessed by a 5-point Likert Scale,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
11969,NCT05485961,Time to first occurrence of CV death or MI (Phase 3),Total number of hospitalizations (Phase 3),2022-10-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
11970,NCT03957811,Effect of whole body vibration on TcPO2 levels,,2017-04-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],
11971,NCT00989534,,,2003-01,COMPLETED,INTERVENTIONAL,['NA'],
11972,NCT03338153,Major adverse cardiac event,target lesion revascularization,2007-10,COMPLETED,OBSERVATIONAL,['NA'],
11973,NCT02526615,insulin sensitivity in skeletal muscle,insulin stimulated intestinal glucose uptake,2000-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
11974,NCT01535612,"Patients ability to successfully assemble, fill, prime, apply and use the PaQ™ device",Dermal Irritation,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
11975,NCT06068686,NT-proBNP Concentration (pg/ml),Fasting blood glucose (mg/dl),2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],
11976,NCT06203275,Change in HOMA-IR .,The secondary outcome is the change in expression of GRK2,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
11977,NCT05570734,Psychological Distress - Anxiety,,2023-02-27,RECRUITING,INTERVENTIONAL,['NA'],
11978,NCT00366379,Percentage of patients at each dose who achieve FPG <100mg/dL.,"AEs, laboratory parameters.",2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
11979,NCT02039986,Change from baseline in insulin secretion capacity at 16 weeks,Composite change from baseline in relationships of insulin secretion and protein and interleukin levels at 16 weeks,2014-01-06,COMPLETED,OBSERVATIONAL,['NA'],
11980,NCT05359432,Serum triglycerides,,2020-07-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
11981,NCT00822367,"To determine the nutritional supplements glycemic response in patients with DM, defined as the maximum glucose excursion, area under the curve, and 2 and 3 hour BG levels fol",,2006-05,COMPLETED,INTERVENTIONAL,['NA'],
11982,NCT00630825,Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus,Pharmacokinetics (PK) of LY2189265 - Area Under the Concentration Time Curve (AUC),2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
11983,NCT01399489,Change from Baseline in Arterial stiffness (pulse wave velocity),Change in Resting blood pressure after 16 weeks of training,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
11984,NCT00402909,Change from baseline in hemoglobin (Hb)_A1c,Proportion of patients achieving reduction in HbA1c of 0.5%,2006-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
11985,NCT04909983,Response rate of active treatment versus standard of care,Time to resolution of Irritative contact dermatitis,2021-05-19,TERMINATED,INTERVENTIONAL,['NA'],
11986,NCT01163721,Change From Baseline in Fasting Serum Glucose at Week 12,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
11987,NCT01533688,Measure the % of Participants With Effective (How Well the Colon is Cleansed Using the Validated Boston Bowel Preparation Scale) for Various Bowel Preparations for Colonoscopy.,Measure of Patients Who Develop (Tolerance)Side Effects of Taking Bowel Preparations.,2011-10,COMPLETED,INTERVENTIONAL,['NA'],
11988,NCT00699413,Body Mass Index,Hunger,2008-02,TERMINATED,INTERVENTIONAL,['PHASE4'],
11989,NCT02328040,"Blood Glucose Measures in Subjects Treated With Sitagliptin, Compared to the Placebo","Measure of Glucagon Concentration in Subjects Treated With Sitagliptin, Compared to Placebo",2014-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
11990,NCT01069341,Adverse Event (AE),Mean Change in Intraocular Pressure (IOP),2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
11991,NCT04065724,Ulcer area,Participant satisfaction measured by Numeric Rating Scale(NRS),2013-02,COMPLETED,INTERVENTIONAL,['NA'],
11992,NCT00968812,Change in HbA1c From Baseline to Week 52,Change in HbA1c From Baseline to Week 104,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
11993,NCT03478202,Change from baseline in weight,Change from baseline in fasting Insulin level,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],
11994,NCT00991575,Fatal and non fatal cardiovascular disease (CVD) and stroke,Vessel area stenosis,2009-04-01,COMPLETED,OBSERVATIONAL,['NA'],
11995,NCT00554697,Diabetes Mellitus Type II and Tissue Oxygenation,,2007-11,TERMINATED,OBSERVATIONAL,['NA'],
11996,NCT05453838,Blood glucose - Product A versus Product B,GL new product,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
11997,NCT00826774,Weight,Homeostasis model assessment of insulin resistance (HOMA-IR),2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
11998,NCT02846571,HbA1C ≤ 7% or a ≥ 2.5 decrease from baseline (before transplant),,2019-12-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
11999,NCT04254380,Treatment developed AIAs or important increase in AIA titers,Percentage of subjects who achieve an HbA1c of ≤ 7.0% at visit Week 26,2019-12-04,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
12000,NCT02095418,To evaluate incidence of NODAT in patients of two arms,"To evaluate patient overall survial, OS",2014-02,UNKNOWN,INTERVENTIONAL,['NA'],
12001,NCT02417012,Change in Hba1c,Change in glucose lowering medication,2015-04,COMPLETED,INTERVENTIONAL,['NA'],Change in low grade inflammation
12002,NCT01519505,Incident cases of type 2 diabetes,Cost-effectiveness,2005-03,UNKNOWN,INTERVENTIONAL,['NA'],
12003,NCT01049633,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],
12004,NCT04077216,trans-meal blood glucose,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],
12005,NCT02375737,Adherence to the program's intervention,Clinical effectiveness/impact on cholesterol,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
12006,NCT02294526,Change from baseline in fasting insulin at 6 months,Change from baseline in blood pressure at 6 months,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
12007,NCT04476433,Change of Perceived level of disease threat (Baseline-Pre-Post),Change Psychological well-being (Baseline-Pre-Post),2019-02-04,COMPLETED,INTERVENTIONAL,['NA'],Exocrine pancreatic test ( Baseline-Pre-Post)
12008,NCT05952999,Patient Perception of Digital Care at discharge,Number of participants with Hospital Acquired Infections,2023-08-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Clinical Sustainability Assessment Tool
12009,NCT01548235,Incidence of SADR (serious adverse drug reactions) including major hypoglycaemia,"Overall, daytime and nocturnal frequency of hypoglycaemic events",2006-02,COMPLETED,OBSERVATIONAL,['NA'],
12010,NCT03152552,Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 12,Change From Baseline in Bone Mineral Density (BMD) at Weeks 12 and 36,2017-07-25,TERMINATED,INTERVENTIONAL,['PHASE2'],
12011,NCT04947163,Audit of Diabetes Dependent Quality of Life:,30sec sit-to-stand (30secSTS),2021-07-01,COMPLETED,INTERVENTIONAL,['NA'],
12012,NCT03344549,Know the renal function,Adherence to treatment,2017-12-28,COMPLETED,INTERVENTIONAL,['NA'],
12013,NCT04295005,Indirect healthcare cost,,2020-11-16,COMPLETED,OBSERVATIONAL,['NA'],
12014,NCT05454709,Time in range,AP related parameters - algorithm,2023-12-29,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
12015,NCT00907608,Death,"Number of hospital admissions, total number of days of hospital stay and attendance at the Accident and Emergency Department",2007-12,TERMINATED,INTERVENTIONAL,['NA'],
12016,NCT03731533,Weight,Minutes per day of exercise,2018-12-01,WITHDRAWN,INTERVENTIONAL,['NA'],
12017,NCT05875259,"Cmax,ss",,2023-05-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
12018,NCT01980017,Percentage of Participants Who Self Report of Not Smoking (Even a Puff) in the Last 7 Days + CO <10ppm,Cost-effectiveness of Smoking Cessation Interventions.,2013-07,COMPLETED,INTERVENTIONAL,['NA'],Implementation Costs - Clinic
12019,NCT05449678,Time in range (TIR),Adherence,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
12020,NCT03223129,Glucose kinetics,Metabolomics,2018-01-09,COMPLETED,INTERVENTIONAL,['NA'],
12021,NCT05683106,Change from Baseline Pre-ulcerative lesions and ulcers at 12 and 24 weeks,Change from Baseline Comfort at 12 weeks,2023-09-06,RECRUITING,INTERVENTIONAL,['NA'],
12022,NCT05403502,Adverse drug reactions,CGM hypoglycemia outcomes: Rate of hypoglycemia events,2022-08-31,COMPLETED,INTERVENTIONAL,['NA'],Patient Reported Outcomes: ITSQ
12023,NCT01557634,Time in target,Glucose variability,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
12024,NCT05816577,Bristol Stool Chart,Microbiome composition,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Fasting blood short chain fatty acids
12025,NCT00005462,,,1991-09,COMPLETED,OBSERVATIONAL,['NA'],
12026,NCT01545401,Change in the proportion of patients achieving glycaemic and BP control,Other secondary outcome measures,2012-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
12027,NCT04902326,Change in hemoglobin A1C from baseline to 12 months,Proportion of days covered by Metformin,2021-09-16,COMPLETED,INTERVENTIONAL,['NA'],
12028,NCT00574639,Change in Epinephrine Levels,,2007-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
12029,NCT04857957,CNTX-6016 Pharmacokinetics - tmax,,2021-04-14,COMPLETED,INTERVENTIONAL,['PHASE1'],CNTX-6016 Efficacy - PDN Cohort
12030,NCT01972893,To evaluate Safety and tolerability of ZYD1,Pharmacokinetics (PK) and Pharmacodynamic (PD) effect after single and multiple subcutaneous dose administrations in healthy adult male volunteers Gender effect study.,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
12031,NCT01334125,Baseline Adjusted Hemoglobin A1c Over Time,"Number of Participants With Minor, Major, and Nocturnal Hypoglycemia",2011-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
12032,NCT01455896,"time to first occurrence of any event included in the MACE cardiovascular composite endpoint (CV death, non fatal MI, non fatal stroke, or hospitalization for unstable angina),",,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
12033,NCT02812303,Difference in differences in Blood pressure (BP) goal achievement over the follow-up period comparing PHC and non-PHC practices,Difference in differences in proportion of patients completing colorectal cancer screening over the follow-up period comparing PHC and non-PHC practices,2014-07,COMPLETED,OBSERVATIONAL,['NA'],
12034,NCT01069965,Change from Baseline in Glycosylated Hemoglobin at Week 13,Cardiovascular and metabolic biomarkers at Baseline and 13 weeks,2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
12035,NCT03465878,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) Following Each Treatment Arm for Each Study Part,Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve Following Each Treatment Arm for Each Study Part,2018-03-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
12036,NCT02429258,Change in 24-hour Mean Weighted Glucose (MWG) From Baseline to End of Treatment (Week 4) Using the Continuous Glucose Monitoring (CGM) System,Change in Static Insulin Secretion Rate (10^-9 Min^-1) From Baseline to Week 4 - ITT Population,2015-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
12037,NCT01365793,the Number of Participants With Glasgow Coma Score (GCS) < 14 Within the First 24 Hours of Treatment for Diabetic Ketoacidosis (DKA),Intelligence Quotient (IQ) Testing,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
12038,NCT02763150,Incidence of Gestational Diabetes Mellitus,Minutes per week of moderate physical activity,2017-12-15,COMPLETED,INTERVENTIONAL,['NA'],
12039,NCT02974244,Changes from baseline in weight (kg),Frequency of diarrhea and constipation,2014-10-28,COMPLETED,OBSERVATIONAL,['NA'],
12040,NCT03481829,Infant BMI,Child BMI,2022-04-14,RECRUITING,OBSERVATIONAL,['NA'],
12041,NCT03329118,The number of volunteers with adverse events as a measure of safety and tolerability.,,2017-11-24,UNKNOWN,INTERVENTIONAL,['PHASE1'],
12042,NCT01307072,Preoperative status,Postoperative status,2008-09,COMPLETED,OBSERVATIONAL,['NA'],
12043,NCT01824277,Change in A1C over the study period.,Changes in the patient perioperative outcomes,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
12044,NCT03467932,Change From Baseline of HbA1C (Glycated Hemoglobin),Change Over Time in Hb1Ac,2018-05-29,COMPLETED,INTERVENTIONAL,['PHASE2'],
12045,NCT02333734,Oral Glucose tolerance test (OGTT),Physical fitness,2014-07,COMPLETED,INTERVENTIONAL,['NA'],blood flow
12046,NCT02914496,HbA1c,The Summary of Self-Care Activities,2016-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12047,NCT01473654,Physical Activity,hemoglobin a1c,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
12048,NCT04162067,HbA1c,Clinical outcomes stratified by age group,2020-01-06,COMPLETED,OBSERVATIONAL,['NA'],"HbA1c in the subgroup of patients using CSII therapy, stratified by patients considered ""atypical"" for pumping by Canadian regulatory authorities"
12049,NCT05215730,Change in wound size,Physiological parameter - Average time to wound closure,2021-07-07,COMPLETED,INTERVENTIONAL,['NA'],
12050,NCT03330301,Bone facture,Mental diseases,2012-04-01,COMPLETED,OBSERVATIONAL,['NA'],Congenital disorders
12051,NCT05741489,Nocturnal Hypoglycemia Event Rate,Comorbidities,2022-08-10,COMPLETED,INTERVENTIONAL,['NA'],
12052,NCT01627210,Evaluate the Dexcom G4 system utility and usability during home use.,,2012-05,COMPLETED,OBSERVATIONAL,['NA'],
12053,NCT01292993,Plasma concentration of LX4211 and metformin after concurrent single-dose administration,Glucose-dependent insulinotropic peptide,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
12054,NCT02941367,Percentage of patients with at least 1 documented symptomatic hypoglycemia event (plasma glucose ≤70 mg/dL; 3.9 mmol/L),"Percentage of patients with HbA1c <7%, no weight gain and no documented symptomatic hypoglycemia (plasma glucose ≤70 mg/dL; 3.9 mmol/L)",2017-02-23,COMPLETED,INTERVENTIONAL,['PHASE4'],
12055,NCT05669560,Change of HbA1C measured in percentage.,Change in Clinical attachment levels(mm).,2023-01-20,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],
12056,NCT05319600,Change from Baseline in Physical Activity,Change in insulin requirements,2022-03-23,COMPLETED,INTERVENTIONAL,['NA'],
12057,NCT03483467,The primary outcome is wound healing (defined as full epithelialisation without drainage maintained for 2 weeks) within 12 weeks of starting study treatment.,Effectiveness of participant blind,2018-03-11,COMPLETED,INTERVENTIONAL,['NA'],
12058,NCT00960076,Change in HbA1c Level From Baseline to Week 18 (LOCF),Percent of Subjects Reaching Goal (HbA1c <7%) at Week 18 (LOCF) - Percent of Subjects (1),2009-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
12059,NCT03361878,Metformin AUC,Lactate,2014-05-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
12060,NCT01490099,"Cmax, maximum serum insulin detemir concentration",Adverse events,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
12061,NCT01590771,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone,2012-07-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
12062,NCT04769375,Evaluation of pelvic girdle questionnaire,,2021-04-01,COMPLETED,OBSERVATIONAL,['NA'],
12063,NCT03215173,Change in postpartum weight retention,Change in Readiness to Change,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],
12064,NCT01829555,change from baseline in number of self-monitoring of blood glucose tests conducted,change from baseline in hemoglobin A1c levels,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
12065,NCT00275223,,,2004-09,COMPLETED,OBSERVATIONAL,['NA'],
12066,NCT01107132,,,2010-05,UNKNOWN,OBSERVATIONAL,['NA'],
12067,NCT01717911,The primary outcome was the comparison of A1C change.,Beta-cell function and insulin sensitivity and the proportion of subjects who reached the treatment target (A1C <7.0% or <6.5% at 6 months).,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12068,NCT04115657,Postprandial insulin,Appetite control,2019-05-02,COMPLETED,INTERVENTIONAL,['NA'],
12069,NCT02295696,HbA1c,Self-management,2014-11,UNKNOWN,INTERVENTIONAL,['NA'],
12070,NCT03526237,Change in BMI,Change in Diet and exercise Behaviors,2015-04-24,COMPLETED,INTERVENTIONAL,['NA'],
12071,NCT01414660,interleukin 7,metabolic parameters,2010-06-09,COMPLETED,OBSERVATIONAL,['NA'],
12072,NCT00412165,"To evaluate the effect, at 12 months, of the 3 intensities of the PACEi-DP intervention on Body Mass Index (BMI) among male & female adolescents.",behavioral measures of diet and physical activity.,2006-02,COMPLETED,INTERVENTIONAL,['NA'],
12073,NCT00985179,health behavior (physical activity & fruits and vegetables),perceived occupational efficiency,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
12074,NCT05203640,Blood glucose,carbohydrate supplementation,2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],
12075,NCT04791618,Life Simple 7(LS7 the metrics for defining ideal cardiovascular health) score at 6-month follow-up,Change in Tobacco Use,2017-05-01,UNKNOWN,INTERVENTIONAL,['NA'],Change in Carotid Intima Media Thickness (CIMT)
12076,NCT03239119,Change in HbA1c from Baseline to Week 30,Change in 7-SMBG from Baseline to Week 16，Week 24 and Week 30,2017-11-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],
12077,NCT03682237,Time in normoglycemia,Urinary albumin/excretion rate,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],
12078,NCT01427660,Changes in decisional conflict,Medication adherence and intensification,2011-09,COMPLETED,INTERVENTIONAL,['NA'],
12079,NCT04647175,Blood glucose total area under the curve (tAUC),Microbiomics,2020-11-23,UNKNOWN,INTERVENTIONAL,['NA'],
12080,NCT04228341,Glucose,Insulin,2019-02-13,COMPLETED,INTERVENTIONAL,['NA'],
12081,NCT04782999,Insulin secretion during iv stimulation,Alpha cell function,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
12082,NCT06211270,Integration,Body Mass Index,2023-11-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
12083,NCT00949286,Death from any cause,Myocardial infarction (non-fatal and fatal),2010-01,COMPLETED,OBSERVATIONAL,['NA'],
12084,NCT00332826,The primary safety outcome will be measurements of post bronchodilator FEV1 throughout the treatment period,,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
12085,NCT03610984,Effects of structured education on β-cell endocrine function progression of T1D patients.,Effects of structured education on metabolic control.,2016-10-01,COMPLETED,OBSERVATIONAL,['NA'],
12086,NCT01627509,,,2012-05,UNKNOWN,OBSERVATIONAL,['NA'],
12087,NCT01629251,Primary efficacy endpoint,Secondary efficacy endpoints,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
12088,NCT02394886,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Wound size and depth measurement,2014-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
12089,NCT03851432,Change in Hemoglobin A1c (HbA1c) From Baseline to Week 24 (Core period),Percentage of Patients Who Have Received Rescue Therapy at Week 24 (Core period) and Week 52 (Extension period),2019-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],
12090,NCT04097691,Injection of subcutaneous glucose 10% in small shots is effective in improving neuropathic signs using the Michigan Neuropathy Screening Instrument (MNSI),,2019-07-14,COMPLETED,OBSERVATIONAL,['NA'],
12091,NCT02438189,Comparison of percent time in range overnight between the two treatment arms,Change in HbA1c from clinical baseline to study completion,2015-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
12092,NCT06326034,Quality of Life Assessment tool,,2022-05-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
12093,NCT05460884,Changes in maximal incremental plasma glucose level (iCmax) between baseline and endpoint within intervention groups vs. control.,Changes in plasma insulin levels between baseline and endpoint within the intervention group vs. control,2020-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12094,NCT01638585,Duration of survival without major amputation in urokinase group compared to group with standard therapy,new lesions on the contralateral leg,2011-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
12095,NCT01170832,Heart rate (HR) Variability Studies,Positron Emission Tomography (PET) scan,2010-05,COMPLETED,OBSERVATIONAL,['NA'],
12096,NCT01376557,Change From Baseline in HbA1c to Week 12,Change From Baseline in Triglycerides at Week 12,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
12097,NCT05524909,"Changes in Moderate to Vigorous Physical Activity Minutes between baseline and Immediate post-intervention, between baseline and 12-month post-intervention, and between baseline and 6-month follow-up","Changes in five activity indicators (steps, 'sedentary minutes', 'lightly active minutes', calories burn, and sleep time)",2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12098,NCT00965315,,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],
12099,NCT03146975,"Changes in beta defensins 1, 2 and 3",Changes in percentage of diseased sites,2014-03-02,COMPLETED,INTERVENTIONAL,['NA'],
12100,NCT00840164,,,2009-02,UNKNOWN,OBSERVATIONAL,['NA'],
12101,NCT01295229,Feasibility,Efficacy and Mechanisms,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
12102,NCT06181721,Percentage of time in hyperglycemic range (defined as > 13.9 mmol/L (>250 mg/dL)),Average number of hypoglycemic treatments when CGM is less than 3.9mmol/L,2023-09-05,COMPLETED,INTERVENTIONAL,['NA'],
12103,NCT00412178,HbA1c,Compliance,2004-12,TERMINATED,INTERVENTIONAL,['NA'],
12104,NCT04164641,Number of re-ulceration occurrences,Percentage of patients who do not experience re-ulceration after custom orthosis,2019-12-09,RECRUITING,INTERVENTIONAL,['NA'],
12105,NCT02026310,"24 weeks after treatment, HbA1c values' change compared with baseline",hypoglycemia events,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
12106,NCT01681290,Bilateral change in sensory nerve conduction velocity,Quality of life questionnaire,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
12107,NCT01773668,Performance data,Physical duration,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
12108,NCT01291875,Changes in HbA1c and serum inflammatory markers of inflammation after periodontal intervention,,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
12109,NCT06332690,Modification of inflammatory biomarkers on OCT and perfusion density parameters on OCT-A at 4 months after surgery (Change measure),"Initial clinical characteristics in patients with a gain in BCVA (Best Corrected Visual Acuity) of ≥ 5, ≥ 10, and ≥ 15 ETDRS (Early Treatment Diabetic Retinopathy Study) letters.",2023-10-17,RECRUITING,OBSERVATIONAL,['NA'],
12110,NCT00647595,Central adiposity,neonatal adiposity,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
12111,NCT00324675,Proteinuria,HbA1c,2006-08,COMPLETED,INTERVENTIONAL,['NA'],
12112,NCT05699408,Change in HbA1c,Change in scores of diabetes treatment satisfaction questionnaire status version (DTSQs),2023-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
12113,NCT02496780,post-prandial protein turnover,,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
12114,NCT01677936,Postprandial Glucose Levels,Systolic Blood Pressure,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
12115,NCT03953092,Adverse events will be evaluated,maximum plasma concentration (Cmax),2019-05-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
12116,NCT02836015,Hemoglobin A1c,BMI,2016-05-13,COMPLETED,INTERVENTIONAL,['NA'],
12117,NCT02797392,Change in proportion of citizens at increased risk of lifestyle related disease from baseline to the 12 weeks follow up,GP reported Personal belief,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
12118,NCT00570310,Daily Evening Patient Reported Pain Intensity Scores,'Time to Efficacy Failure' During the Randomized Withdrawal Portion of the Study,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
12119,NCT00497133,,,2007-07,COMPLETED,OBSERVATIONAL,['NA'],
12120,NCT02006342,Time to Anion Gap Closure,Number of Participants Who Developed Hypoglycemia,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
12121,NCT02082301,Primary outcome: sensitivity of immediate post partum screen,Secondary outcome: physiology,2012-10,COMPLETED,OBSERVATIONAL,['NA'],
12122,NCT01324388,"Mean, 24-hour Blood Pressure (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol","Pharmacokinetics, Maximum Concentration (Cmax) of Metoprolol When Administered With LY2189265",2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
12123,NCT03606694,First phase of insulin secretion,Blood pressure,2019-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
12124,NCT05689684,change in levels of postprandial blood glucose,body weight,2022-11-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12125,NCT00325910,Combined endpoint of all cause mortality and all cause hospitalization at 6 months,Development of Lactic Acidosis,2006-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
12126,NCT03232333,Percentage of Participants,,2017-07-21,COMPLETED,OBSERVATIONAL,['NA'],Short Form - 36: Bodily Pain
12127,NCT03036254,Change in Cognitive outcome,IADL questionnaire,2017-10-08,RECRUITING,INTERVENTIONAL,['NA'],
12128,NCT00263276,Mean change from baseline in HbA1c compared to placebo.,"Mean change from baseline in fasting plasma glucose, evaluate proportion of subjects who achieve a therapeutic response (HbA1c <7%); change from baseline in urinary glucose excretion",2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
12129,NCT03579615,Time spent in the target glucose range,AUC of glucose below 3.0mmol/l (54mg/dl),2020-12-23,COMPLETED,INTERVENTIONAL,['NA'],
12130,NCT01617603,Difference in Insulin Resistance (HOMA) Between Treatments After 12 Weeks of Product Intake,Oxidative Stress After 12 Weeks of Product Intake,2009-04,COMPLETED,INTERVENTIONAL,['NA'],
12131,NCT03546972,Feasibility of adding hunger training (HT) to Diabetes Prevention Program (DPP) as assessed by completion rates,Changes in proposed behavioral mediators through survey,2017-12-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12132,NCT03793023,Change in HbA1c,Safety Outcome,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],
12133,NCT05421845,incidence of gestational diabetes mellitus,maternal physical activity information,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
12134,NCT01315171,Cognitive function tests,Brain activity,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
12135,NCT02411253,"AUC (T0-T120) of serum C-peptide, determined after a mixed meal tolerance test at month 12, compared to baseline.",Adverse event.,2015-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
12136,NCT04362241,To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure.,Rescue Therapy,2020-08-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12137,NCT01881724,Change in HbA1c from baseline,sleep duration,2013-05,UNKNOWN,INTERVENTIONAL,['NA'],
12138,NCT06273059,The overall objective of this study is to identify and describe genetic variation of young-onset DM in Indonesia.,To describe genetic variation in young-onset DM with diabetic complications in various systems:,2022-09-12,RECRUITING,OBSERVATIONAL,['NA'],
12139,NCT03278483,Toxicity (liver function),,2019-02-28,COMPLETED,INTERVENTIONAL,['PHASE4'],
12140,NCT03895515,Change in percentage of time spent in glycaemic target range (TIR),Change in Glycated Haemoglobin A1c (HbA1c),2020-01-03,COMPLETED,OBSERVATIONAL,['NA'],
12141,NCT03553862,Incidence of hypoglycaemia,"Work Productivity and Activity Impairment questionnaire, General Health version (WPAI-GH)",2018-05-11,COMPLETED,INTERVENTIONAL,['NA'],
12142,NCT00891124,"Proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline",The treatment goal of risk factors is based on ADA guideline.,2009-05,COMPLETED,OBSERVATIONAL,['NA'],
12143,NCT02931292,Percent excess body mass index loss (%EBMIL),percent of complications,2005-06,COMPLETED,OBSERVATIONAL,['NA'],
12144,NCT03415074,CKD progression,Occurence of the adverse events,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],
12145,NCT00853151,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 6-Month Endpoint,Change From Baseline in Homeostatic Model Assessment (HOMA) at 3-Week and 6-Month Endpoints,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
12146,NCT04431141,"AUCτ,ss of teneligliptin and empagliflozin",t1/2β of teneligliptin and empagliflozin,2020-09-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
12147,NCT03895996,"The incidence and severity of local i.v.-site reactions,",Changes from baseline in HbA1c,2019-06-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
12148,NCT06080425,body weight measured at the five post-baseline follow-up points,Diabetes Distress,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],
12149,NCT02714972,Comparison of percent time in range overnight between the two treatment arms,"Amount of total (manual, automatic, combined) and insulin boluses",2016-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
12150,NCT00036504,,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
12151,NCT01456130,Number of Participants With Treatment Emergent Adverse Events (TEAEs),Change From Baseline in Fasting Glucose,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
12152,NCT02954822,"AUCτ,ss for Evogliptin and Glimepiride",,2016-11-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
12153,NCT00971048,Adequate Management of the Wound Assessed by a Left Movement (Improvement) in the Modified Bates Jensen Wound Assessment Tool.,Moist Wound Environment as Per the Bates-Jensen Wound Assessment Tool (BWAT),2009-09,COMPLETED,INTERVENTIONAL,['NA'],
12154,NCT04132531,Change in the frequency of circulating cells with aldehyde dehydrogenase activity.,Change in the frequency of circulating cells with aldehyde dehydrogenase activity and cell surface marker expression.,2018-05-01,COMPLETED,OBSERVATIONAL,['NA'],Changes in the concentration of oxidative stress and inflammatory markers
12155,NCT05645068,coefficient of variation of the superficial retinal capillary plexus,,2023-02-28,RECRUITING,INTERVENTIONAL,['NA'],
12156,NCT02606617,Change of control rate of blood glucose(%),Change of clinic blood pressure and 24h mean blood pressure(mmHg).,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12157,NCT03766802,Glycated Hemoglobin (HbA1c),Accelerometer,2018-02-05,UNKNOWN,INTERVENTIONAL,['NA'],Triglyceride
12158,NCT03143764,examine cycling distance,examine changes in cardiorespiratory fitness,2014-09-01,COMPLETED,INTERVENTIONAL,['NA'],
12159,NCT04721158,More Frequent Glycemic Control Monitoring,,2021-01-17,COMPLETED,INTERVENTIONAL,['NA'],
12160,NCT04145479,postprandial triglyceride,,2021-03-01,UNKNOWN,INTERVENTIONAL,['NA'],
12161,NCT03754036,Insulin sensitivity,Physical activity level,2019-01-05,COMPLETED,INTERVENTIONAL,['NA'],
12162,NCT01319240,The area under liraglutide concentration-time curve,Number of hypoglycaemic episodes,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
12163,NCT02109315,Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed measuring flow-mediated vasodilation (FMD) of the brachial artery.,Oxidative stress markers,2014-05,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
12164,NCT03608163,Difference in peak epinephrine levels between first and third hypoglycemic episodes,Symptoms of low blood sugar (hypoglycemia),2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
12165,NCT04835194,The correlation between clinical phenotypes and combined endpoint,"Time to first cardiovascular mortality in patients with heart failure with preserved ejection fraction and concurrent hypertension, diabetes.",2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],"The correlation between simultaneous risk factor control (HbA1c (%), and LDL-c (mmol/L), and blood pressure (mmHg)) and mortality in patients with diabetes, hypertension and heart failure with preserved ejection fraction"
12166,NCT02620878,Percentage of Time Spent in Target Range (70-180 mg/dl or 3.9-10.0 mmol/L),Percentage of Time Artificial Pancreas is Active,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
12167,NCT02349516,To explore the effect of Squalamine Lactate eye drops on Best Corrected Visual Acuity in subjects with diabetic macular edema,"To assess the safety and tolerability of Squalamine Eye Drops, measured by ophthalmic examination, the recording and evaluation of clinical AEs",2015-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
12168,NCT00155142,,,2004-09,UNKNOWN,OBSERVATIONAL,['NA'],
12169,NCT03333772,Acceptability,Change from baseline in Glycated hemoglobin (HbA1C) at post-intervention,2017-11-15,COMPLETED,INTERVENTIONAL,['NA'],
12170,NCT03087253,Prevalence of diabetes mellitus,Incidence of severe morbidities and causes of mortality,2018-02-27,RECRUITING,OBSERVATIONAL,['NA'],
12171,NCT01945138,Study Period: Serum BG Standard Deviation,Day 28 Follow-Up: C-Peptide,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
12172,NCT06152588,Change in HbA1c (mmol/mol),Use of antidiabetic medication,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Dietary fibers (gram)
12173,NCT00627744,Improvement in beta-cell function measured by means of the insulinogenic index (ΔI30/ΔG30) obtained from an oral glucose tolerance test (OGTT),Improvement in incretin-independent beta-cell function measured as the Acute Insulin Response (ΔAIRG) during an intravenous glucose tolerance test.,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
12174,NCT02983214,Number of participants who suffer from bleeding events as defined by the Bleeding Academic Research Consortium (BARC) criteria during the entire follow-up period.,"Number of participants who suffer from the secondary safety end points which are palpitations, tachycardia, headache, diarrhea, urticaria, neoplasms, blood disorders, drug interruption.",2016-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
12175,NCT02927561,To compare the sensitivity and specificity of automated grading system versus human grading in detecting diabetic retinopathy,,2015-06,COMPLETED,OBSERVATIONAL,['NA'],
12176,NCT06221241,Change of the Average Daily Pain Score (ADPS) from baseline to Week 12. [ADPS is the weekly average pain score based on the 11-point numeric rating scale (NRS)],Adverse Events,2024-03-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
12177,NCT04136951,To learn if using PREVENT tool results in high nurses' system usability perception measured by the System Usability Scale (SUS).,,2023-02-01,COMPLETED,INTERVENTIONAL,['NA'],
12178,NCT05314140,Proportions of diabetic patients with high coronary artery calcium score,Description of adverse events regarding to the coronary artery calcium score,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
12179,NCT01073826,Glucagon like peptide- 1 (GLP-1),,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
12180,NCT00887302,Metabolics of RYGB with Gastrostomy - Glucose,,2009-03-25,COMPLETED,OBSERVATIONAL,['NA'],
12181,NCT02064335,Physical fitness,,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
12182,NCT01465620,Change from Baseline in NTSS6 score at 3 months,change from baseline of thermal and vibration thresholds,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
12183,NCT01238406,Sleep efficacy,Total wake up time per night,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
12184,NCT01680653,Duration of Nocturnal Hypoglycemia,Duration of Glucose Readings <70 mg/dl,2012-05,COMPLETED,INTERVENTIONAL,['NA'],Prolonged Episodes of Hypoglycemic Events
12185,NCT01251497,,,2009-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
12186,NCT03628963,Patient Activation,Acceptability,2018-09,UNKNOWN,INTERVENTIONAL,['NA'],
12187,NCT04835636,HbA1c,Weight change,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],
12188,NCT01278485,Number of Participants With Hemoglobin A1c <7.0% at the Time of Enrollment,Number of Participants Reporting Body Weight Fears in the 12 Months Prior to Enrollment,2011-05,COMPLETED,OBSERVATIONAL,['NA'],
12189,NCT01480934,Development of Posterior capsule opacification.,"duration of diabetes, stage of diabetic retinopathy",2005-06,COMPLETED,OBSERVATIONAL,['NA'],
12190,NCT04395378,Glucose concentration (mmol/L),Plasma albumin concentration (g/dL),2019-12-05,SUSPENDED,OBSERVATIONAL,['NA'],Glucose concentration from the pilots log books for the previous 6 months
12191,NCT03713502,Prevalence of pre-diabetes,,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA'],
12192,NCT00378508,C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) at Baseline,Baseline Hemoglobin A1c,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
12193,NCT03363386,Change in fasting blood glucose level,,2016-12,COMPLETED,INTERVENTIONAL,['NA'],
12194,NCT06173765,Change in primary clinical marker of inflammation IL-6,Change in fasting Lipids,2022-08-31,RECRUITING,INTERVENTIONAL,['NA'],
12195,NCT00347542,Oral Glucose Insulin Sensitivity (OGIS),Blood Pressure,2006-07,COMPLETED,INTERVENTIONAL,['NA'],
12196,NCT04723628,Glycemic Control,Perceived Diabetes Self-Management Scale (PDSMS),2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],
12197,NCT02862860,Amplitude of glycemic variations,,2012-05-29,COMPLETED,INTERVENTIONAL,['NA'],
12198,NCT04208230,Association between Type 2 diabetes status and marrow fat at the distal tibia,,2017-01-03,COMPLETED,OBSERVATIONAL,['NA'],
12199,NCT00110370,(A1C less than 7%) with once-daily insulin glargine in combination with OADs.,"body weight, SAE's and study drug related AEs.",2004-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
12200,NCT01289145,Self-reported physical activity frequency and duration,Social Cognition,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
12201,NCT05482321,Primary outcome 4,Secondary outcome 6,2023-02-27,RECRUITING,OBSERVATIONAL,['NA'],
12202,NCT01940614,Overall diagnostic accuracy,Predictive value of absent bright spot in posterior pituitary enlargement,2013-07,COMPLETED,OBSERVATIONAL,['NA'],
12203,NCT04545151,Area under the stimulated C-peptide response curve,Continous glucose monitoring (CGM),2021-02-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life: HypoFear questionnaire
12204,NCT05851651,Infant Feeding pattern,Women's prevalence of Impaired Glucose Tolerance,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],"Women's experience, perception, and attitude for AME practices"
12205,NCT01275131,"Early Exposure to Insulin (%AUC[0-60]), Stage 3","Duration of Insulin Action (AUMC[0-360]/AUC[0-360]), Stage 3",2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
12206,NCT04702048,Mean change in photoreceptor cell spacing,Proportion of participants who receive intravitreal aflibercept,2021-02-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
12207,NCT02292433,Accumulation Ratio (Rac) on Day 7 for PF-04937319,Change From Baseline in Pre-Meal C-Peptide at Day 7,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
12208,NCT01990300,Changes From Baseline in Glycosylated Hemoglobin (HbA1c),Changes From Baseline in Fasting Blood Glucose (FBG),2011-11-28,COMPLETED,OBSERVATIONAL,['NA'],
12209,NCT04172077,"Examine the effects of patients' attachment styles (secure, mixed and fearful) on their type one diabetes management represented by A1C level",b)Compare diabetes management self-efficacy and attachment style in parents,2019-09-18,COMPLETED,OBSERVATIONAL,['NA'],
12210,NCT04339296,Self-reported Medication Adherence,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA'],
12211,NCT02844517,The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.,,2016-11,COMPLETED,INTERVENTIONAL,['NA'],
12212,NCT02961179,Change from baseline to 6 weeks in insulin sensitivity between high dairy and dietary counselling phases,Change from baseline to 6 weeks in metabolomics profiles between high dairy and dietary counselling phases,2017-01,COMPLETED,INTERVENTIONAL,['NA'],
12213,NCT04709419,Change in Tissue Oxygenation,Number of Participants with Complete Wound Closure,2022-10-27,TERMINATED,INTERVENTIONAL,['NA'],Number of Patients with Maintained Wound Closure
12214,NCT00665808,treatment satisfaction (DTSQs and DTSQc),Pregnancy,2007-10,COMPLETED,OBSERVATIONAL,['NA'],
12215,NCT03012113,The effect of Mirabegron treatment on BAT activity measured by MRI in South Asians compared with white Caucasians.,The effect of Mirabegron treatment on sympathetic output in South Asian and white Caucasian individuals.,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12216,NCT00420511,Preservation of Beta-cell Function Measured by Area-under-the-curve (C-peptide/Glucose)/HOMA-IR,Proportion of Patients Achieving Sustained Normoglycemia Off Medication at 1-week Post-insulin Therapy,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
12217,NCT03881657,Blood pressure,Life functioning,2015-11-24,COMPLETED,INTERVENTIONAL,['NA'],
12218,NCT05568134,"Agreement between plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose",Perceived benefits and burdens of CGM use,2023-07-17,RECRUITING,OBSERVATIONAL,['NA'],
12219,NCT01226537,Fasting glucose 2) HbA1c 3) Lipid profile 4) Taurine 5) Insulin 6) Urine Micro albumin 7) Eye test,,2012-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
12220,NCT05227677,The achievement rate of HbA1c (≤7%),The extent of change of HbA1c,2022-08-15,RECRUITING,INTERVENTIONAL,['NA'],
12221,NCT04964752,the percentage of MARD (Mean Absolute Relative Difference),Sensor Stability,2021-07-30,UNKNOWN,INTERVENTIONAL,['NA'],
12222,NCT01262586,Change in Glycemic profiles between vildagliptin and glimepiride,Glucose Fluctuation before and during treatment,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
12223,NCT02526524,Change in HbA1c (%) at 16 Weeks,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
12224,NCT05826054,Maximum tolerated dose (MTD),,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE1'],
12225,NCT04917926,Glycaemic control,Level of physical activity,2021-06-21,RECRUITING,INTERVENTIONAL,['NA'],Frequency of health service utilisation
12226,NCT00334503,,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],
12227,NCT06010992,Glycemic control,Serum levels of asprosin,2023-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
12228,NCT00822211,Change from baseline in HbA1c after 24 weeks,Change from baseline in fasting plasma glucose at 24 weeks,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
12229,NCT01102699,CPC mobilization after a single G-CSF dose,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
12230,NCT02145988,Resting ankle-brachial index (ABI),Adverse events,2015-06-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
12231,NCT00975052,Weighted average active GLP-1 (glucagonlike peptide-1) concentrations,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
12232,NCT00954694,"The primary endpoint of the study is the qualitative measurement, by use of a questionnaire, of attitude and interest toward exercise in participants by assessing if they choose to seek and perform other modes of exercise.","Secondary endpoints are the quantitative measurement of the change in weight, waist-to-hip ratio, heart rate, blood pressure, 6-minute walk test, and A1C levels.",2009-08,UNKNOWN,INTERVENTIONAL,['NA'],
12233,NCT06225154,Serum and saliva IL-1β levels (pg/ml),HbA1c ( %),2015-02,COMPLETED,INTERVENTIONAL,['NA'],Clinical Attachment Level (mm)
12234,NCT00997152,Change in Fasting Plasma Glucose (FPG) levels,"Safety (biochemistry, hematology, urinalysis and adrenal-related markers) and tolerability (adverse events)",2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
12235,NCT02681809,Number of Subjects With Total PVD by the Month 3 Visit,Number of Subjects With Ocular Treatment-emergent Adverse Events in the Study Eye,2015-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
12236,NCT01337947,arterial vascular stiffness,nitric oxide dependent vasodilation,2011-04,COMPLETED,OBSERVATIONAL,['NA'],
12237,NCT03210896,"Chemical components in breath will be captured into absorbent tubes followed by GCMS analysis, to determine if there are potential biomarkers in exhaled breath that can be directly correlated with blood glucose concentration.",Demographic and lifestyle data will be recorded to see if they correlate with breath chemical composition.,2017-07-10,COMPLETED,INTERVENTIONAL,['NA'],
12238,NCT01908816,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Ranibizumab Injection,2013-09-26,COMPLETED,INTERVENTIONAL,['PHASE3'],
12239,NCT00979719,physical activity,"social-cognitive predictors of behavior (self-efficacy, action control etc.)",2009-10,COMPLETED,INTERVENTIONAL,['NA'],
12240,NCT02622295,Post-training Bone Turnover: Osteocalcin,Post-training Subject-report Measures: EQ-5D,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
12241,NCT01586065,Number of High Glucose Correction Doses Administered.,Pre- and Post-meal (2-3 Hour) Glucose Levels,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
12242,NCT00447629,Safety,Pharmacokinetics,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
12243,NCT02924311,Mean change in Best Corrected Visual Acuity from baseline to month 12 in treatment naïve patients and previously treated patients,Number of participants with ocular and non-ocular safety events,2016-09-21,COMPLETED,OBSERVATIONAL,['NA'],Number of patients with prior intraocular steroids (DME Monitoring)
12244,NCT04345497,HbA1c Level,Hyperglycemic Episodes,2020-08-26,COMPLETED,INTERVENTIONAL,['NA'],
12245,NCT02936115,Proportion of Patients that achieve a 50% or greater reduction in wound size by 8 weeks,Number of patients with worsening of index wound defined by ≥ 50% increase in wound size,2016-07,TERMINATED,INTERVENTIONAL,['PHASE4'],
12246,NCT03670043,Birmingham Irritable Bowel Syndrome (IBS) Symptom Questionnaire,,2019-03-19,COMPLETED,INTERVENTIONAL,['PHASE4'],
12247,NCT00674050,PK parameters of serum insulin,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
12248,NCT05463289,Proportion screened for diabetic retinopathy,Diagnostic Accuracy,2022-07-11,RECRUITING,INTERVENTIONAL,['NA'],
12249,NCT02386930,HbA1c%,physical exercise in minutes per day,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
12250,NCT00120536,Change from baseline in HbA1c at 24 weeks,Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs. low baseline HbA1c,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
12251,NCT02230631,The percentage of patients experiencing at least 1 hypoglycaemic event,Difference in the reported incidence rates of hypoglycaemia,2014-10,COMPLETED,OBSERVATIONAL,['NA'],
12252,NCT04953442,Percentage of participants that are satisfied with participation in the study,Average of minutes of sleep per night,2021-04-15,RECRUITING,INTERVENTIONAL,['NA'],Autonomous motivation for physical activity as assessed using Behavioural Regulation in Exercise Questionnaire-2 (BREQ-2)
12253,NCT01945242,Number of Participants Reporting One or More Serious Adverse Drug Reactions,Change From Baseline in Fasting Insulin,2011-03,COMPLETED,OBSERVATIONAL,['NA'],
12254,NCT04017221,Incidence rate of lower extremity amputation,Incidence rate of Fournier's gangrene,2018-10-01,COMPLETED,OBSERVATIONAL,['NA'],
12255,NCT02999386,All cause Mortality,Hospital length of stay,2016-10,COMPLETED,OBSERVATIONAL,['NA'],
12256,NCT01718080,Overweight and Lean Children Sugar Metabolism Before and During Puberty,,2012-10,COMPLETED,OBSERVATIONAL,['NA'],
12257,NCT00270439,Insulin sensitivity as measured by the minimal model and HOMA score,Decreased use of oral hypoglycemics,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
12258,NCT02934425,Net incremental area under the curve (AUC) appetite VAS ratings,Composite daily hunger and fullness VAS ratings,2016-08,COMPLETED,INTERVENTIONAL,['NA'],
12259,NCT02663713,platelet reactivity measured in P2Y12 reaction units (PRU) at the end of the 2 study periods (pre-crossover and post-crossover).,"• VerifyNow P2Y12 assay % inhibition, using the TRAP-induced (BASE channel) response at the end of the 2 study periods",2017-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
12260,NCT00107107,To examine the long-term effect of subcutaneously (SC) injected pramlintide on body weight,To examine the effects of long term pramlintide treatment on HbA1c in subjects with type 1 diabetes completing protocol 137-150.,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
12261,NCT00603239,Change in Glycosylated Hemoglobin (HbA1c),Change in Euroqol - 5 Domain Quality of Life (EQ-5D) Score,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
12262,NCT01161862,Mean Plasma Blood Glucose Achieved by the Bionic Pancreas (mg/dl),Nadir Blood Glucose in Each Arm,2010-07,COMPLETED,INTERVENTIONAL,['NA'],
12263,NCT04550403,prevalence of intensive care unit admission and/or in-hospital mortality among COVID-19 inpatients,number of days of hospitalization in patients with and without diabetes,2020-07-30,COMPLETED,OBSERVATIONAL,['NA'],
12264,NCT00476788,Mean Glycated Hemoglobin (A1c),Number of Reported Adverse Events,2007-04,COMPLETED,INTERVENTIONAL,['NA'],
12265,NCT00021879,,,2001-03,COMPLETED,OBSERVATIONAL,['NA'],
12266,NCT00201110,A1C,Lipid panel,2004-07,COMPLETED,INTERVENTIONAL,['NA'],
12267,NCT05113693,"Cmax of CKD-501, D759, H053",,2021-11-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
12268,NCT00004647,,,1993-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
12269,NCT02737891,Effects of Co-administration of Tesofensine/Metoprolol Treatment vs. Placebo on 24-hour Mean Heart Rate,Change From Baseline to End of Treatment in Body Weight,2016-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
12270,NCT05870202,Acceptability,Change in HbA1c,2023-03-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
12271,NCT01545388,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG),2012-02-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
12272,NCT01730196,Weight change,hemoglobin A1C,2009-09,COMPLETED,INTERVENTIONAL,['NA'],waist circumference
12273,NCT00580294,Brief Pain Inventory,,2007-11,COMPLETED,INTERVENTIONAL,['NA'],
12274,NCT00407680,HbA1c,Serum angiotensinogen,2006-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12275,NCT02123251,Changes in HDL From Baseline to the End of Intervention (December 2015),Change From Baseline to End of Intervention (December 2015) in Physical Component Summary Measure of the Short Form (SF-36v2) Health Survey,2014-05,COMPLETED,INTERVENTIONAL,['NA'],
12276,NCT01435980,Clinical events,Blood testing,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12277,NCT00145353,Meal-regulated insulin time two peaks after the two intervention periods,,2004-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12278,NCT02806349,HbA1c,fasting insulin,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],ALT
12279,NCT01206712,Investigation of ß-cell function via comparison of AUC0-300 minutes of intact Proinsulin in T2DM patients treated with LANTUS + Metformin (MET) vs. T2DM patients treated with Sulfonylurea (SU) + Metformin,"Investigation of insulin, intact proinsulin, glucose and PAI-1 levels over a 5 h period after uptake of a standardized meal comparing four different population groups",2009-11,COMPLETED,OBSERVATIONAL,['NA'],
12280,NCT02313363,change of HbA1c,change of the scores of Summary of Diabetes Self-Care Activities (SDSCA),2013-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],number of events of hypoglycemia
12281,NCT01272193,Change in Glycosylated Haemoglobin (HbA1c),Change in Body Weight,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
12282,NCT06277362,Safety Composite,Rutherford class,2020-01-31,RECRUITING,OBSERVATIONAL,['NA'],
12283,NCT05115175,Feasibility of the Scaled Mindfulness-Based Intervention as Assessed by Participant Feedback,,2019-07-14,COMPLETED,INTERVENTIONAL,['NA'],
12284,NCT05013346,Islet auto-antibody titre and positivity proportions,Type 1 diabetes genetic risk score,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA'],
12285,NCT01619345,Anatomical location (stomach or proximal small bowel) of tablet at complete tablet erosion (CTE),Time to CTE,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
12286,NCT00472342,Improvements of adipokine levels,Prevention of diabetes,2007-03,UNKNOWN,INTERVENTIONAL,['NA'],
12287,NCT04222660,Change in cornea nerve density,Determination of tibial nerve conduction velocity,2021-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12288,NCT05643144,Level of Situation Awareness (Aim 2),Glucose variability (Aim 1),2023-03-20,RECRUITING,INTERVENTIONAL,['NA'],
12289,NCT06227520,Wound Healing,Ulcer Reoccurrence,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
12290,NCT06325111,Identification of oral microbiome characteristics associated to T1D glycaemic control,,2023-05-29,RECRUITING,OBSERVATIONAL,['NA'],
12291,NCT02726425,Change in disease control (HbA1c),Health Service Utilization,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
12292,NCT01334203,The primary efficacy endpoint is the change from baseline in exercise treadmill duration in the peak ETT at week 12 or last visit.,Change from baseline in exercise treadmill duration in the trough ETT at week 12,2011-05,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
12293,NCT06218342,Liver stiffness measurement (LSM),Body weight,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
12294,NCT00479973,"The primary objective measures will consist of fasting blood glucose, insulin and HA1C.","Total-C, TG, HDL, LDL, BP, weight, BMI, waist/hip ratio, self-monitoring blood glucose, HOMA-IR, AST, ALT, total protein, albumin, alk phos, total/direct bilirubin, creatinine, BUN, PT, PTT, fibrinogen, adverse effects, Diabetes-39, SF-36",2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],
12295,NCT03452657,Proportion of eyes with a ≥ 2-step improvement in the ETDRS Diabetic Retinopathy Severity Scale (DRSS) score,Proportion of eyes that meet the protocol-defined failure criteria,2018-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],
12296,NCT02313090,HbA1c,low density lipoprotein cholesterol,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
12297,NCT03664414,Change in the glomerular filtration rate,Change in health-related quality of life,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12298,NCT06140303,Incidence of index ulcers closed,Time to closure,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
12299,NCT00435565,,,na,COMPLETED,OBSERVATIONAL,['NA'],
12300,NCT04547348,Time until remission,Incidence of Adverse Events and Serious Adverse Events,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
12301,NCT04235439,GIRmax,Safety and Local Tolerability,2019-04-23,COMPLETED,INTERVENTIONAL,['PHASE1'],
12302,NCT01084928,body weight,Percent of Total Calories from Fat,2010-04,COMPLETED,INTERVENTIONAL,['NA'],
12303,NCT05816733,Rate of atrial fibrillation recurrence,Cardiovascular complex adverse events,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
12304,NCT00552942,diabetic indices,"interleukin and cytokine levels, weight loss",2006-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],
12305,NCT00837941,analgesic efficacy measured by patients self reported pain level after single dose administration,The onset of analgesic efficacy following single dose of pregabalin and duloxetine hydrochloride versus placebo,2009-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
12306,NCT02928250,effect on on urinary albumin excretion (UAE),"total antioxidant capacity (TAC), malondialdhyde (MDA).",2015-08,COMPLETED,INTERVENTIONAL,['NA'],
12307,NCT06115265,Weight in kg,CAC scores,2023-09-05,RECRUITING,INTERVENTIONAL,['NA'],
12308,NCT01307514,,,2008-11,UNKNOWN,OBSERVATIONAL,['NA'],
12309,NCT01492205,Overall acceptance of the NovoLet® system among healthcare professionals (nurses and doctors),Incidence of adverse drug reactions,2005-09,COMPLETED,OBSERVATIONAL,['NA'],
12310,NCT04027712,b amyloid predicts cardiovascular mortality in diabetic with coronary artery,,2014-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
12311,NCT00150410,Glycosylated hemoglobin,insufficient clinical response.,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
12312,NCT01370681,Geometric mean AUCt,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
12313,NCT02087215,number of the participants with complete epithelization of diabetic foot ulcer,number of participants in whom local infective complications develop in diabetic foot ulcer patients,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],improvement of inflammatory parameters in diabetic foot ulcers
12314,NCT04559815,Change in Glycated haemoglobin (HbA1c),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",2020-11-08,COMPLETED,OBSERVATIONAL,['NA'],
12315,NCT04225507,Change from baseline 2-hour glucose levels at 6 months,Change from baseline morning blood pressure at 6 months,2021-04-13,RECRUITING,INTERVENTIONAL,['NA'],
12316,NCT03802825,Percent of Participants With A1C < 8%,Mean A1C Change,2019-03-01,COMPLETED,INTERVENTIONAL,['NA'],
12317,NCT06040463,Change in A1c,CHW Support Adherence,2023-10-23,RECRUITING,INTERVENTIONAL,['NA'],
12318,NCT01298375,Euglycemic-hyperinsulinemic clamp for measurement of insulin sensitivity and metabolic flexibility,Evaluating mitochondrial function through measurement of phosphocreatine (PCr) recovery by phosphorus magnetic resonance spectroscopy (31P-MRS) within the skeletal muscle,2011-03,RECRUITING,OBSERVATIONAL,['NA'],
12319,NCT01330563,CKD-501 AUC,CKD-501 Tmax,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
12320,NCT01086306,To compare the incidence of hospitalizations with infections associated with T Lymphocyte dysfunction,Inpatient diagnoses of respiratory tract infections,2010-01,COMPLETED,OBSERVATIONAL,['NA'],
12321,NCT03738449,Area under the plasma concentration of Metformin-time curve from time zero to time of last measurable concentration,Apparent volume of distribution of Metformin,2019-01-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
12322,NCT01247753,Change in body weight,Change in physical activity,2011-03-01,COMPLETED,INTERVENTIONAL,['NA'],
12323,NCT04230889,Interstitial Glucose Response,Postprandial Glucose,2017-02-06,COMPLETED,INTERVENTIONAL,['NA'],Medications
12324,NCT00106457,,,2005-02,COMPLETED,OBSERVATIONAL,['NA'],
12325,NCT03217591,Percent Change From Baseline in Urine Albumin Creatinine Ratio (UACR) Over Weeks 8 and 12,,2017-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
12326,NCT02601482,Glycemic control,HOMA-2 insulin resistance index,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],
12327,NCT00438503,"Effect og glucose in dialysis water on blood pressure, plasma glucose and hormones in plasma",Relationship between changes in blood pressure and and changes in hormones,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
12328,NCT00286455,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Glucagon (Week 26).,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
12329,NCT01107314,,,2010-02,COMPLETED,OBSERVATIONAL,['NA'],
12330,NCT00432835,Symptom of Gastric Emptying Time (GET) Associated With Gastroparesis,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
12331,NCT03069196,"Progression of Micro-vascular, Macro-Vascular and Pulmonary Complications.",Association of Risk factors with prevalence of complications.,2016-06-10,UNKNOWN,OBSERVATIONAL,['NA'],
12332,NCT04869098,Glycaemic response,respiratory quotient,2021-04-27,RECRUITING,INTERVENTIONAL,['NA'],
12333,NCT01499082,Change in HbA1c From Baseline to Month 6 Endpoint,Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Change in HbA1c From Month 6 to Month 9
12334,NCT03749889,Birth Outcome Questionnaire,,2018-09-04,TERMINATED,INTERVENTIONAL,['NA'],
12335,NCT03203278,Glycaemic control,Glycaemic control,2017-11-06,COMPLETED,INTERVENTIONAL,['NA'],
12336,NCT02383784,Body fat content determined by tetrapolar bioelectrical impedance .,,2007-03,COMPLETED,INTERVENTIONAL,['NA'],
12337,NCT05967923,Range of motion of the shoulder,Shoulder and hand disability,2023-07-05,RECRUITING,INTERVENTIONAL,['NA'],
12338,NCT00577824,Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24,"Change in 1,5-anhydroglucitol",2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
12339,NCT00789945,To determine the changes in A1C.,To determine changes in postprandial glucose excursion during the meal's 5 hour postprandial period.,2008-12,COMPLETED,INTERVENTIONAL,['NA'],
12340,NCT05461274,Rate of patients who remain in diabetic neuropathy clinical trial to trial completion,,2024-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
12341,NCT02604875,measurement of copeptin values in mmol/l within 24 hours to assess the amount of release in a day curve.,,2015-11,COMPLETED,OBSERVATIONAL,['NA'],
12342,NCT01164501,HbA1c Change From Baseline in Patients With Moderate Renal Impairment,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Hypoglycaemic Events
12343,NCT04739124,"Correlation between appropriation factors, intention to use, Freestyle Libre use and glycemic control",,2021-06-10,COMPLETED,OBSERVATIONAL,['NA'],
12344,NCT01999322,Number of Microscopically Confirmed Episodes of Infusion Set Occlusions,Number of Premature Infusion Set Changes,2013-11-19,COMPLETED,INTERVENTIONAL,['PHASE3'],
12345,NCT00174668,Total daily insulin dose,Physical examination,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
12346,NCT00704795,"Glucagon responses (as assessed by area under curve (AUC)) during 50-g oral glucose tolerance test (OGTT) and isoglycemic iv glucose infusion, respectively.",GI-mediated glucose tolerance as assessed by the amount of glucose ingested as compared to the amount of glucose needed to mimic the OGTT curve during the iv glucose infusion.,2008-06,UNKNOWN,OBSERVATIONAL,['NA'],
12347,NCT05211375,Complete remission rate of type 2 diabetes,Late complication rate,2022-01-03,RECRUITING,INTERVENTIONAL,['PHASE3'],
12348,NCT02442544,Glycemic control (serum hemoglobin A1c),Glycemic control (as measured by serum hemoglobin A1c),2015-09,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Change in gut permeability (quantification of specific sugars in urine)
12349,NCT05530369,Neuropathy,Mean glucose (mg/dl),2014-09-01,COMPLETED,OBSERVATIONAL,['NA'],
12350,NCT03650023,Glucose levels,The areas under the curve (AUC) of glucose,2018-05-09,COMPLETED,INTERVENTIONAL,['NA'],
12351,NCT01891955,Fasting glucagon,Fasting HbA1c,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
12352,NCT00453375,"The primary endpoint in this study is safety.Safety parameters include: stimulated C-peptide response levels, opthalmologic examination, laboratory assessments, 24-hr urine protein, allergic reactions and adverse events including hypoglycemia.","The secondary endpoints are pharmacodynamic parameters. Parameters include plasmid levels and insulin mRNA levels in blood and urine, Stimulated C-peptide response and Immunological response.",2006-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
12353,NCT02548767,Change of de novo lipogenesis: palmitate tracer-to-tracee ratios by gas chromatography-mass spectrometry.,Change of Very low density lipoprotein (VLDL)-triglyceride (TG) kinetics,2016-02,COMPLETED,INTERVENTIONAL,['NA'],Change of blood levels of uric acid
12354,NCT04602039,This project aimed to examine changes in insulin resistance in participants using dairy colostrum as a food supplement,This project aimed to examine changes in inflammatory markers in participants using dairy colostrum as a food supplement,2016-07-21,COMPLETED,INTERVENTIONAL,['NA'],
12355,NCT01116180,Cognitive function and brain cortical activity assessed by EEG,Cardiac conduction evaluated by a three channel digital Holter Monitor.,2010-04,COMPLETED,INTERVENTIONAL,['NA'],
12356,NCT02397265,Percentage of Time in Target Range Over 24 Hour,,2014-12-03,COMPLETED,INTERVENTIONAL,['NA'],
12357,NCT02100488,Intra-subject postprandial glycemic variability,CV_AUC-PG_3-8h,2014-03,COMPLETED,INTERVENTIONAL,['NA'],Time into range
12358,NCT00138554,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
12359,NCT02210000,Percentage of Responders Based on the Fullness/Early Satiety Subscale (Responders) as Assessed by Gastrointestinal Cardinal Symptom Index-Daily Diary (GCSI-DD) at Week 12,Trough Plasma Concentration of Camicinal on Day 28 and Day 84,2014-08-27,COMPLETED,INTERVENTIONAL,['PHASE2'],
12360,NCT05145140,Diabetic Foot Ulcer relapse rate,C-reactive protein(CRP),2022-01-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],
12361,NCT03624803,"To describe baseline characteristics of patients starting Dapagliflozin together with other anti-diabetic medications , alone or in combination. And to describe if Dapagliflozin was given as 2nd line , 3rd line or later in combination therapy.",To record the change in blood pressure (mmHg) from baseline.,2019-03-09,COMPLETED,OBSERVATIONAL,['NA'],
12362,NCT03452085,xerostomia,patients preference for treatment AS or TT,2017-09-23,COMPLETED,INTERVENTIONAL,['NA'],
12363,NCT06332378,Hemoglobin A1C,,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
12364,NCT05241522,Standard uptake value in the kidney,,2021-08-06,RECRUITING,INTERVENTIONAL,['PHASE1'],
12365,NCT03784443,Number of Lucentis Injections received in the study eye,Number of focal laser treatments,2019-09-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
12366,NCT05320276,Frequency of patients with chronic diseases seen in the emergency department who have not been offered an educational program,Identification of reasons for refusal to participate,2022-02-28,COMPLETED,OBSERVATIONAL,['NA'],
12367,NCT03061981,"[Safety and Tolerability] 12-lead ECGs, Vital signs. Physical examinations, Clinical laboratory testing and Adverse event assessments",Renal clearance (CLR),2017-03-29,COMPLETED,INTERVENTIONAL,['PHASE1'],Key metabolites of DA-1241 in Cohort 6
12368,NCT02233491,Glucose metabolism,Hospitalization,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
12369,NCT05495451,Feasibility of an intensive multidisciplinary program based on lifestyle changes in patients diagnosed with type 2 diabetes.,"Evolution of the HOMA-IR between the start of the program, the middle of the intervention (3 months) and the end of the intervention (6 months).",2022-01-21,COMPLETED,INTERVENTIONAL,['NA'],
12370,NCT01530178,Better Targeted Blood Glucose Levels,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
12371,NCT04607096,Change in first phase insulin secretion.,Change in subcutaneous adipose tissue.,2021-04-08,UNKNOWN,INTERVENTIONAL,['NA'],Change in insuin clearance.
12372,NCT01724060,Change in Energy Intake From Baseline,Change in Macronutrient Composition From Baseline,2012-09,COMPLETED,OBSERVATIONAL,['NA'],
12373,NCT03877068,Number of Clinically Significant Hypoglycemia Events While Hospitalized,Glycemic Variability Calculated by Mean Amplitude of Glycemic Excursions (MAGE) After Discharge,2019-06-26,COMPLETED,INTERVENTIONAL,['NA'],
12374,NCT02822534,The steady-state urine concentration (Css) of SP2086 acid,The number of volunteers with adverse events as a measure of safety and tolerability,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],
12375,NCT02942056,Type 2 DM control,obesity,2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
12376,NCT03153007,"Assessment of signs and symptoms, impacts on functioning and HRQoL among subjects with DFU",,2017-08-11,COMPLETED,OBSERVATIONAL,['NA'],
12377,NCT06234787,To determine the cumulative incidence or risk of potential hypoglycemia during ICU admission,"To describe the theoretical cumulative incidence of potential hypoglycemia with alternative thresholds of 70, 75, 85, or 90 mg/dL",2023-11-30,RECRUITING,OBSERVATIONAL,['NA'],
12378,NCT06321302,Occurrence of a ≥2-step improvement compared with baseline in Diabetic Retinopathy Severity Scale (DRSS) level in the study eye at Week 52,Occurrence of ocular AEs of special interest in the study eye between baseline and EOS,2024-05-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
12379,NCT01179555,Pt. 1 Dilated Fundus Exam (DFE),Pt. 2 Appointment Adherence Characteristics,2010-10,COMPLETED,INTERVENTIONAL,['NA'],Pt. 2 Cost-effectiveness
12380,NCT00086515,Change From Baseline in Hemoglobin A1C (A1C) at Week 24,Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24,2004-06-30,COMPLETED,INTERVENTIONAL,['PHASE3'],
12381,NCT02795910,Systolic blood pressure,Ischemic heart disease treatment,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
12382,NCT02995863,Presence of diabetic foot ulcer,Toe - Brachial Index (TBI),2016-12-10,COMPLETED,INTERVENTIONAL,['NA'],
12383,NCT05642377,Pharmacokinetic Assessment by Apparent Volume of Distribution of HGR4113,Pharmacodynamic Assessment by Change in Plasma C-peptide,2022-11-22,RECRUITING,INTERVENTIONAL,['PHASE1'],
12384,NCT00740012,Glucose (continuous glucose monitoring),"Hormones (norepinephrine, cortisol, glucagon, growth hormone, prolactin), Pulse, Blood glucose",2007-03,COMPLETED,INTERVENTIONAL,['NA'],
12385,NCT03452605,BOLD fmri response,,2015-11-20,COMPLETED,INTERVENTIONAL,['NA'],
12386,NCT02235298,Epicardial Fat Thickness,Left Ventricular Mass (LVM),2015-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
12387,NCT01871558,Percentage of Patients Who Reported at Least One Symptomatic Hypoglycemic Event During the 24 Week Randomized Period in Both Treatment Arms,Percent of Participants That Reach Therapeutic Goal (HbA1c ≤ 7%) at Week 24 Without Any Hypoglycaemic Episode (Symptomatic or Not) and Without Any Weight Gain (Variation ≥3% Compared to Baseline),2013-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
12388,NCT02372955,arterial stiffness,composite intravascular volume status,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12389,NCT04068805,Change in self-reported HbA1C level,Change in positive affect [Patient-Reported Outcomes Measurement Information Systems - Positive Affect Subscale(PROMIS)],2020-08-31,TERMINATED,INTERVENTIONAL,['NA'],
12390,NCT02453711,Relative Change in Body Weight (%),Anti-semaglutide Antibodies During and After Treatment,2015-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
12391,NCT02545842,Percentage of patients with HbA1c <7% achievement,Percentage of patients experienced hypoglycemic events,2015-09-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
12392,NCT02066155,Hemoglobin A1C,BMI,2013-01,COMPLETED,INTERVENTIONAL,['NA'],Diabetes-related distress
12393,NCT06202742,Subjective Sleep Quality,Objective sleep parameters,2024-03-08,RECRUITING,INTERVENTIONAL,['NA'],
12394,NCT05717933,thyroid abnormalities among children and adolescents with type 1 diabetes mellitus when its first detected and its relationship with disease-related variables.,,2023-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
12395,NCT05885659,Variability of glycemic levels,Anthropometric data,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],
12396,NCT04166032,Mean Absolute Relative Difference (MARD) of Glucose Values Between the ANICGM and FDA-approved Glucose Monitoring Device,,2019-11-06,COMPLETED,INTERVENTIONAL,['NA'],
12397,NCT01790412,prevention gestational diabetes,Maternal weight gain,2009-02,COMPLETED,INTERVENTIONAL,['NA'],Other pregnancy outcomes
12398,NCT00757601,Number of Participants Who Discontinued Treatment Due to an AE,Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006,2008-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
12399,NCT03156179,fractional calcium absorption,Estimated calcium retention,2015-09-01,COMPLETED,OBSERVATIONAL,['NA'],
12400,NCT03974464,Show that the negativity of S-100b protein and copeptin eliminates stroke in the face of vertigo,,2016-05-01,COMPLETED,OBSERVATIONAL,['NA'],
12401,NCT00700908,Change in HbA1c,Change in adherence to SMBG frequency,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
12402,NCT06185192,Fasting Insulin levels,"Species prevalence in stool, blood, and saliva",2023-12-13,RECRUITING,INTERVENTIONAL,['NA'],
12403,NCT02156037,HbA1c,Depression,2009-07,COMPLETED,INTERVENTIONAL,['NA'],
12404,NCT02497313,Glucagon-like peptide-1 (GLP-1): Incremental and total area under the Concentration-Time Curve,Appetite as assessed by Visual analog scale score,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
12405,NCT00263835,Change in hemoglobin A1c.,"Change in blood pressure, cholesterol, and weight.",2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
12406,NCT01707160,Area under the Curve,Adverse events,1995-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
12407,NCT05994586,Discomfort related to metformin side effects,HbA1c level,2023-05-25,RECRUITING,INTERVENTIONAL,['NA'],
12408,NCT05700877,Rates of a composite cardiovascular endpoint,Cost-effectiveness,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE4'],Cardiovascular risk markers 4
12409,NCT04890886,Assessment of the distribution of adipose tissue,Thermal assessment,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],
12410,NCT03547440,Metabolic control,Akkermansia muciniphila quantification in stool,2015-03-18,UNKNOWN,OBSERVATIONAL,['NA'],Metabolic control 2
12411,NCT00985881,Gait variability,,2007-04-01,COMPLETED,INTERVENTIONAL,['NA'],
12412,NCT04880850,Change in Glycated haemoglobin (HbA1c),Change in body weight,2021-05-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
12413,NCT04981067,Median effective anesthetic concentration 90 (MEAC 90),Any adverse events,2021-08-24,RECRUITING,INTERVENTIONAL,['NA'],
12414,NCT01636349,muscular adaptations,glycaemic control,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
12415,NCT04637841,Evaluation of relaxation time,Evaluation of skin temperature,2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],
12416,NCT04185454,Osteocalcin ratio,Lipid profil 2,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],
12417,NCT01347814,Gastric emptying half time,Appetite sensations,2008-02,COMPLETED,INTERVENTIONAL,['NA'],
12418,NCT04645732,"EQ-5D-5L, the descriptive index",Mortality,2021-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Vigorous Intermittent Lifestyle Physical Activity (VILPA): Time spent on VILPA intensity activities
12419,NCT02960373,Glycemic index (GI),,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],
12420,NCT03554486,Percentage of Time in Range: Sensor Glucose Readings <70 mg/dl,Mean Sensor Glucose in mg/dl,2018-07-23,COMPLETED,INTERVENTIONAL,['PHASE4'],
12421,NCT05047237,Point estimates of Feasibility Measures: Time,Implementation Metric- Value,2021-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12422,NCT01316016,,,2009-04,COMPLETED,INTERVENTIONAL,['NA'],
12423,NCT02359214,Pulsewave Velocity,Systolic Blood Pressure,2014-04,COMPLETED,INTERVENTIONAL,['NA'],Plasma Angiotensin II
12424,NCT00822471,"Improvement in the percent of subjects correctly identifying guideline-recommended treatment targets for the ""ABC's of Diabetes"", where A = A1C < 7%; B = BP <130/80mmHg and; and C = LDL-C < 100mg/dl.",Decrease the percentage of participants with self-reported ED visits and hospitalizations for severe hypoglycemia and hyperglycemia.,2003-01,COMPLETED,INTERVENTIONAL,['NA'],
12425,NCT00737022,Macular appearance,Post-operation best-corrected visual acuity,2005-05,COMPLETED,OBSERVATIONAL,['NA'],
12426,NCT04604223,Difference in the incidence at 4 weeks of a composite outcome comprised of:,Incidence at 4 weeks of a composite of extrapulmonary disease comprised of :,2021-01-18,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12427,NCT02647905,CGM Relative Difference to Laboratory Reference Reported as MARD,,2016-01,COMPLETED,INTERVENTIONAL,['NA'],CGM System Agreement With Reference Control
12428,NCT03627715,The Change in Albumin/Creatinine Ratio with Adjunct use of Propagermanium Compared to Placebo in Participants with DKD who are Receiving Irbesartan,The Effect of Treatment with Propagermanium on Measures of Proteinuria as measured by ACR,2018-11-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
12429,NCT00621140,HbA1c Change From Baseline at Week 24,Adjusted Means for 2h Post Prandial Blood Glucose (PPG) Change From Baseline at Week 24,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
12430,NCT00437970,Medication side effects,Endothelial dysfunction.,2008-04,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
12431,NCT06057805,CGM metric of mean glucose compared to OGTT result,CGM variability measure MAGE will be compared to fructosamine test,2024-02-06,RECRUITING,INTERVENTIONAL,['NA'],Tolerability to dexcom adhesive
12432,NCT02641743,plasma glucose concentration,plasma free fatty acid concentration,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
12433,NCT05968924,Adherence to use of SmartMat,Use of health care facilities,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
12434,NCT05951569,Measure of Loop Safety by Self-Report of Hospitalization Events,,2023-06-20,COMPLETED,OBSERVATIONAL,['NA'],HbA1c
12435,NCT00032487,Primary Major Macrovascular Events,Secondary Endpoint,2000-12-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
12436,NCT02486172,Glycaemic control,Body weight,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],Sustainability of the program
12437,NCT00271284,Efficacy data : fasting blood glucose concentration,Tolerance data : undesirable events including episodes of hypoglycaemia,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
12438,NCT05521893,Average postprandial glucose concentration,Incidence of caesarean section,2020-03-12,COMPLETED,INTERVENTIONAL,['NA'],
12439,NCT02985242,"Microaneurysm formation rate over 12 months, i.e. number of newly developed microaneurysms within 12 months",Change in ambulatory blood pressure,2017-06-12,TERMINATED,INTERVENTIONAL,['PHASE4'],
12440,NCT04370600,Bicarbonate concentration,,2020-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],
12441,NCT00946257,Safety and tolerability after a single dose of otelixizumab in T1DM patients,,2009-07-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
12442,NCT03961516,Pancreatic Fat and Glycemic measures,Pancreatic Fat by Modulator Status,2019-05-01,COMPLETED,OBSERVATIONAL,['NA'],
12443,NCT06296485,Hypoglycemia aggregate outcome,Hypoglycemia Distress,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Caregiver Action
12444,NCT02245633,ADAMTS13 levels in diabetic hemodialysis patients,VWF levels in diabetic hemodialysis patients,2014-09,UNKNOWN,OBSERVATIONAL,['NA'],miRNA expression in plasma from diabetic hemodialysis patients
12445,NCT06006312,the prevalence of pancreatic exocrine insufficiency,Insulin level,2023-08,RECRUITING,OBSERVATIONAL,['NA'],
12446,NCT04442451,Capillary density,,2024-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
12447,NCT02811289,whole body organ glucose partitioning,Electrocardiogram,2016-08-05,COMPLETED,INTERVENTIONAL,['NA'],
12448,NCT01341067,Change in HgbA1c,Change in Basal Insulin Dose From Baseline Values,2011-04,COMPLETED,OBSERVATIONAL,['NA'],
12449,NCT03769675,Positive Pain,Extensor Digitorum Brevis Muscle Nerve Conduction,2018-11-20,COMPLETED,INTERVENTIONAL,['NA'],
12450,NCT05749029,Change in Diabetes Distress Scale (DDS) scores from baseline (week 0) to post-intervention (week 4).,Change in Compassionate Engagement and Action Scale (CEAS) scores at baseline (week 0) to follow-up (week 8).,2023-05-01,COMPLETED,INTERVENTIONAL,['NA'],
12451,NCT04219085,Composite Primary Outcome,hypertensive disorders of pregnancy.,2020-09-01,RECRUITING,INTERVENTIONAL,['NA'],
12452,NCT01461616,Growth Hormone(ng/ml),"insulin concentration (mmol/L) after a single injection of either NPH insulin, insulin Detemir or insulin glargine",2012-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
12453,NCT00393718,Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment,Hypoglycaemic Episodes,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
12454,NCT00813410,glucose concentration at the subcutaneous insulin delivery site,,2007-02,COMPLETED,INTERVENTIONAL,['NA'],
12455,NCT00543595,,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
12456,NCT00770640,Change of total daily Insulin Dose.,Change from Baseline in intact Parathyroid Hormone.,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
12457,NCT02231736,The quality of HbA1c influences micronuclei formation in binucleated cells,Type 2 diabetes duration of the subjects influences chromosomal damage,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],
12458,NCT00744458,Percentage of patients with regular follow-up one year after the treatment was started,Treatment response of patients with arterial hypertension (blood pressure),2008-08,COMPLETED,INTERVENTIONAL,['NA'],
12459,NCT02655757,Changes in late lumen loss of target lesion,Incidence rate of MACE,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
12460,NCT03654586,Total calories purchased in last two weeks of study,Newest vital sign measure,2018-07-30,TERMINATED,INTERVENTIONAL,['NA'],
12461,NCT00770939,Percentage of patients with a 50% reduction of wound area after 4 and 8 weeks,Granulation rate,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
12462,NCT01006889,Hepatic Steatosis,Change in Anthropometric Variables (BMI).,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
12463,NCT06296836,Mean glucose levels,Mortality,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Mean glucose levels while receiving metformin in the continuation arm and while not receiving metformin in the discontinuation arm
12464,NCT02380339,Reduction of fear of hypoglycemia in type 1 diabetic patients as measured by reduction of 2 point on the HFS-W). pre-treatment and after two months post completion of treatment.,,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA'],
12465,NCT05830994,Changes in gastric emptying,Incidence of Treatment-Emergent Adverse Events rated by the ASGE lexicon for adverse events,2023-04-12,RECRUITING,INTERVENTIONAL,['NA'],
12466,NCT00111800,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Descriptive Statistics of Dipeptidyl Peptidase-IV (DPP-IV) Inhibition Performed as Part of the Population PK,2005-04-28,COMPLETED,INTERVENTIONAL,['PHASE2'],
12467,NCT00837512,Onset Time (Tmax),,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
12468,NCT04923386,Change in AUC glucose level above expected baseline,Change in fasting blood glucose levels above expected baseline,2021-06-15,COMPLETED,OBSERVATIONAL,['NA'],
12469,NCT00781495,To detect an association between insulin-induced weight gain and physical activity levels,To assess the relationship between insulin-induced weight gain and cardiovascular risk profile,2008-12,UNKNOWN,OBSERVATIONAL,['NA'],
12470,NCT03242252,Change From Baseline in HbA1c at Week 26,Percentage of Participants With Treatment-emergent Adverse Events (TEAEs),2017-08-16,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Hypoglycemic Events
12471,NCT04825366,Change in the Gold score,Number of severe hypoglycemia,2021-08-03,RECRUITING,INTERVENTIONAL,['NA'],
12472,NCT05326204,Fetal weight,perinatal complications,2021-12-30,RECRUITING,OBSERVATIONAL,['NA'],
12473,NCT03218735,Number of children with birthweight above 4500 grams,Number of children admitted to NICU,2017-07-12,WITHDRAWN,INTERVENTIONAL,['NA'],
12474,NCT01068717,"Time to Achieve the Observed Maximum Plasma Concentration (Tmax) for Saxagliptin and Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States","Number of Participants With Clinically Significant Abnormalities in Body Temperature, Blood Pressure, or Heart Rate",2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
12475,NCT01384058,"Change of the concentration of apolipoprotein B (ApoB) in dense Low Densitiy Lipoprotein (dLDL) from baseline with ezetimibe, simvastatin or the combination of both drugs",Change of the concentrations of triglycerides,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
12476,NCT05577104,the time to STSG surgery,the wound neutrophil extracellular traps (NETs) formation,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],
12477,NCT02865525,Number of events 'hospitalization and death' for 2 patient groups defined through the questionnaire QUILAM score,Number of events 'hospitalization and death' for 2 patient groups separate with different cut off,2013-03,COMPLETED,OBSERVATIONAL,['NA'],
12478,NCT04136730,Glycated Haemoglobin concentration (mmol/mol),Short performance physical battery test,2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],Quality of life score
12479,NCT05893576,Calculate the ratio of bioavailability between the new formulation and original formulation of HRS9531 according to the equation F (relative bioavailability) =AUCT·DR/AUCR·DT×100%,Incidence and severity of adverse events,2023-05-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
12480,NCT01930110,The number of patients experiencing exercise-induced hypoglycemia requiring dextrose infusion (< 3.3 mmol/L symptomatic or < 3.0 mmol/L regardless of symptoms).,The amount of dextrose infused,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
12481,NCT04213651,Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing,,2020-03-02,UNKNOWN,OBSERVATIONAL,['NA'],
12482,NCT03430310,Pancreas lipid,Insulin secretion,2018-10-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12483,NCT01526980,Glucose average in 24-hour blood glucose profiles,Adverse events,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
12484,NCT00959101,AUC0-t and Cmax (after repaglinide 2.0 mg and metformin 500 mg as co-administered tablets and combination tablet dosing under fed state),Repaglinide AUC(0-24 & 0-∞) and Cmax after combination tablet (repaglinide 1.0 mg/metformin 500 mg) during fed state,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
12485,NCT01162876,Pharmacodynamics,Safety issues,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
12486,NCT01821053,preeclampsia,light for gestational age,2013-06,COMPLETED,OBSERVATIONAL,['NA'],
12487,NCT02266758,Number of Cesarean Section Deliveries,Number of Infant Bone Fractures or Nerve Palsies associated with delivery,2014-06-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Number of pregnant women with anxiety or depression
12488,NCT01868191,Change from baseline in intraepidermal nerve fiber density,Change in neuropathic deficits,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],
12489,NCT03112343,the proportion of patients who reach his/her optimal insulin dose within 12 weeks of enrolling in the study without severe hypoglycemia or unscheduled clinic visits.,the number of self-monitoring blood glucose measurements,2017-09-26,COMPLETED,INTERVENTIONAL,['NA'],
12490,NCT03529123,Change in HbA1c,Change in SMPG profiles,2018-06-19,COMPLETED,INTERVENTIONAL,['PHASE3'],
12491,NCT03166852,Frequency of training,Interview,2016-04-27,COMPLETED,INTERVENTIONAL,['NA'],
12492,NCT00246987,Change in HbA1c from baseline to Week 24,Changes achieved from baseline in FPG after 24 weeks. Changes achieved from baseline in 3 hour post-prandial AUC for glucose and insulin levels after 24 weeks vs. placebo.,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
12493,NCT02864160,Change in Patient Hemoglobin A1C from Baseline to 6 Months,Change in Health Coach Interpersonal Communication from Baseline to 6 Months as Assessed by the RIAS,2014-09,COMPLETED,INTERVENTIONAL,['NA'],Change in Program Reach to End of Year 5
12494,NCT02719132,Composite endpoint including quality of life score,Proportion of patients,2016-07,WITHDRAWN,INTERVENTIONAL,['PHASE4'],laboratory values changes
12495,NCT01628289,Retinopathy profile in the two groups,Subjects' attendance of the screening,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
12496,NCT02748239,A1c values,Depression,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
12497,NCT00541437,,,2006-05,COMPLETED,OBSERVATIONAL,['NA'],
12498,NCT05198765,Change in weight trajectory during 18-month post-intervention follow-up period,Intentions to engage in weight loss,2023-04-19,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
12499,NCT04833062,Addition of the UAPI to the CPR,,2022-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
12500,NCT00848757,Change in Blood Pressure,Physical Activity Levels (Self-reported),2009-03,COMPLETED,INTERVENTIONAL,['NA'],
12501,NCT02903199,Postprandial capillary glucose,24 h Interstitial Glucose,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],
12502,NCT02821052,Incidence of AEs (adverse event),Change in Glycosylated haemoglobin A1c (HbA1c),2016-07-01,COMPLETED,OBSERVATIONAL,['NA'],
12503,NCT02932826,Number of Participants with Adverse events as a Measure of Safety and Tolerability,Autoimmune Status,2016-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
12504,NCT00420095,Glycosylated Hemoglobin (HbA1c) Value at 12 Week Endpoint,Hypoglycemia Rate Per Participant Per 30 Days,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
12505,NCT03916640,AUCIns 0-8h,Safety and tolerability (Adverse Events recording),2019-01-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
12506,NCT05743907,HbA1c(%),,2023-03-24,RECRUITING,INTERVENTIONAL,['PHASE4'],
12507,NCT00432276,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Mean HDL Particle Size,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
12508,NCT02427802,Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection),Ulcer Closure (Percent of Patients With Target Ulcer Closure),2015-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
12509,NCT00869609,Change in Weight,Change in Waist Circumference,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
12510,NCT04599738,Change in insulin response from baseline for 180 minutes,Satiety by visual analogue scale for 4 hours,2017-03-06,COMPLETED,INTERVENTIONAL,['NA'],
12511,NCT05380232,All-cause mortality,Major adverse cardiovascular events (MACE),2006-03,COMPLETED,OBSERVATIONAL,['NA'],
12512,NCT01695278,Change in hemoglobin A1c,Task related self-efficacy for initiating and maintaining diabetes self-management,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Diabetes self-management behaviors
12513,NCT06278181,asymptomatic malaria,symptomatic malaria,2023-09-21,RECRUITING,OBSERVATIONAL,['NA'],strongyloides infection
12514,NCT03851627,Liver fat,diabetes management satisfaction questionnaire,2022-01-25,RECRUITING,INTERVENTIONAL,['PHASE4'],amount of pancreatic fat
12515,NCT00562029,Measure: Resolution of Type 2 Diabetes Mellitus,Measure: Safety and efficacy of duodenal-jejunal bypass,2007-11,COMPLETED,INTERVENTIONAL,['NA'],
12516,NCT04392557,side effects,lipid metabolism/atheroscelorisis,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12517,NCT00191464,HbA1C,Apolipoproteins [substudy],2003-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
12518,NCT03504059,Changes in the composite ICH score of adolescents from baseline to year 2 and 4,Changes in the composite ICH score of adolescents from baseline to adulthood,2017-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12519,NCT03182426,Rate of Serious Adverse Event/Medical Event of Special Interest,T-cell phenotyping,2017-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
12520,NCT04764279,Partial Remission of Diabetes,Reduction in Visceral Adiposity,2021-06,UNKNOWN,INTERVENTIONAL,['NA'],
12521,NCT04020068,Improvement of patient care,,2019-04-08,UNKNOWN,OBSERVATIONAL,['NA'],
12522,NCT04069611,Probing Pocket Depth (PPD),Patient Satisfaction,2020-01-30,RECRUITING,INTERVENTIONAL,['NA'],
12523,NCT01396564,Short-term comparison of metformin and pioglitazone in pediatric patients with T2D,Comparison of long-term effects of metformin vs pioglitazone,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
12524,NCT04726163,Percentage of time spent in the range 70-180 mg / dl (TIR),Time spent bellow glycaemia < 70mg/dl,2021-01-29,TERMINATED,INTERVENTIONAL,['NA'],
12525,NCT01374178,Pharmacokinetics: Area Under the Concentration-Time Curve (AUC),Number of Participants With Clinically Significant Effects,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
12526,NCT04466007,Complication rate after treatment administration,% amputations,2021-01-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],VascuQol-6 questionnaire
12527,NCT05097534,Change from baseline HbA1c,Change from baseline medication Adherence,2021-12-07,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
12528,NCT03557138,Kinetic behavior of glucose reabsorption,positron emission tomography (PET),2017-02-22,UNKNOWN,INTERVENTIONAL,['NA'],
12529,NCT00662519,Number of participants with adverse events,Increase T regulatory cells (Treg) from the bone marrow,2008-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
12530,NCT02053077,"Efficacy: Blood Glucose During Hospital Stay, an Expected Average of 1 Week",Usability: Coverage of the GlucoTab,2014-02,COMPLETED,OBSERVATIONAL,['NA'],
12531,NCT00005760,,,2000-05,COMPLETED,OBSERVATIONAL,['NA'],
12532,NCT05470842,"Proportion of participants with captured hypoglycaemia; within that group, the time spent in the hypoglycaemic range","Emergency department re-attendances and/or hospital re-admissions for falls, fractures, heart attacks, ischaemic strokes and death within 30 days",2023-06-06,COMPLETED,INTERVENTIONAL,['NA'],
12533,NCT01288326,Percentage of participants reaching the treatment target of a HbA1c (glycosylated haemoglobin A1c) decrease of at least 1%,Frequency of hypoglycaemic episodes (frequency of episodes with low blood sugar),2011-02,COMPLETED,OBSERVATIONAL,['NA'],
12534,NCT04632862,HbA1c level at Week 24 after administration of the IP,"HbA1c level < 7% at Weeks 6, 12, 18, and 24 after administration of the IP",2020-11-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
12535,NCT04160078,Number of Participants With PSS Score Indicating High Stress,Blood Pressure,2019-12-18,COMPLETED,INTERVENTIONAL,['NA'],
12536,NCT02029846,Time to Achieve Glycemic Target (HbA1c <7.5%).,Overall Hypoglycemia Measured by Glucose Meter,2013-04,TERMINATED,INTERVENTIONAL,['PHASE4'],Diabetes Quality of Life
12537,NCT05415878,Offloading adherence,Cumulative plantar tissue stress,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Correlates of joint pain
12538,NCT01270191,The time of monotherapy failure and monotherapy failure rate,"Comparison of A1C change, the proportion of subjects who reached the treatment target",2010-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12539,NCT04864483,Incidence of early day hypoglycemia,Patient satisfaction and preference,2021-03-21,COMPLETED,INTERVENTIONAL,['NA'],
12540,NCT05005741,haemoglobin A1c(HbA1c),Homeostasis model assessment for β cell(HOMA-β),2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
12541,NCT05359796,the development or progression of diabetic retinopathy,the changes of carotid intima-media thickness(IMT),2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],
12542,NCT05388721,Environmental contaminants 2,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],
12543,NCT03327896,Provider Ranking as Assessed by Health Care Quality Metrics,Colorectal Cancer Screening (Patient level),2017-01-15,UNKNOWN,OBSERVATIONAL,['NA'],
12544,NCT00707460,Pilot Study: no formal primary outcome measure. There is no noted safety issue for this study; although adverse/side effects and/or symptoms will be closely monitored by the RPN and community research staff.,"Future dietary intervention feasibility will be assessed by 24-hour recalls/ diet records, appointment attendance, participant and community staff feedback, and questionnaire completion.",2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
12545,NCT00486187,Change in adiponectin level in the rosiglitazone vs. metformin/sulfonylurea arms,"Secondary end-points include changes in leptin, resistin, hs-CRP, IL-6, MMP-9, ICAM-1, insulin sensitivity (as estimated by the HOMA technique), HbA1c, and lipid levels in the rosiglitazone vs. metformin/sulfonylurea arms",2006-04,COMPLETED,INTERVENTIONAL,['NA'],
12546,NCT01469481,radioactivity t1/2,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
12547,NCT04143945,Intensity of Injection Site Pain,,2019-10-28,COMPLETED,INTERVENTIONAL,['PHASE2'],
12548,NCT04450810,Clinical attachment level,,2014-06-01,COMPLETED,OBSERVATIONAL,['NA'],
12549,NCT06305377,Glucometric data,,2024-03-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
12550,NCT05105321,Rate of composite cardiometabolic endpoints,Changes of body mass index,2021-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
12551,NCT03455101,Glycemia control status of Turkish adult patients with diabetes mellitus,Weight control status of Turkish adult patients with diabetes mellitus.,2017-04-01,COMPLETED,OBSERVATIONAL,['NA'],
12552,NCT03543644,75g OGTT derived plasma glucose iAUC,75g OGTT derived Matsuda whole body insulin sensitivity index [Matsuda ISI OGTT],2018-05-31,COMPLETED,INTERVENTIONAL,['NA'],Urinary and blood proteomic panel
12553,NCT03490253,Physical Activity,Patient Health Questionnaire-8 (PHQ-8),2020-02-05,COMPLETED,INTERVENTIONAL,['NA'],
12554,NCT01618162,Change in Glycosylated Haemoglobin (HbA1c),Number of Adverse Events (AEs),2012-08-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
12555,NCT03701087,incidence of gestational diabetes recurrence,,2018-08-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
12556,NCT02782195,To measure the rate of glucose absorption after a standard evening meal,,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
12557,NCT00808795,"Incidence of CIN, defined as increase in serum creatinine concentration>=0.5mg/dL(44.2micromol/L) or >=25% above baseline.",Change in Glomerular filtration rate(GFR),2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
12558,NCT04972539,Cmax,,2020-08-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
12559,NCT05816759,AUCt of CKD-383,,2023-05-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
12560,NCT02362607,Blood Glucose Control Status Measured by HbA1c,Patient Satisfaction Measured by Questionnaire,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
12561,NCT03818581,Subjective Total Sleep Time,Insomnia Severity Index,2019-03-15,COMPLETED,INTERVENTIONAL,['PHASE4'],
12562,NCT04656236,Differences in lipolysis rate,"Differences in circulating concentrations of 3-hydroxybutyrate, glucose, free fatty acids, insulin, glucagon and C-peptide",2021-01-01,COMPLETED,INTERVENTIONAL,['NA'],
12563,NCT01017302,Safety and Tolerability of various doses of RO5095932,"Pharmacodynamics: glucose, insulin, C-peptide",2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
12564,NCT03666546,Capillary blood glucose levels as baseline corrected AUC: AUCbaseline_c (0-180 minutes) [Baseline corrected area under curve from 0 to 180 minutes for blood glucose concentration (= Area under curve from 0 to 180 minutes minus baseline*180 minutes)],"Incremental area under curve from 0 to 180 minutes for blood glucose concentration, i.e., above baseline levels for blood glucose concentration after oral intake of Laevolac crystals/liquid or control products (iAUC(0-180min))",2018-11-26,COMPLETED,INTERVENTIONAL,['PHASE4'],Blood glucose concentration at 240 minutes - only when blood glucose is >10 mmol/L (>180 mg/dL) at 180 minutes
12565,NCT00160927,,,2003-01,UNKNOWN,OBSERVATIONAL,['NA'],
12566,NCT02702375,Gout,,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],
12567,NCT04214704,Percentage reduction in HbA1c,Subjective assessment of probability of using Genteel for SMBG,2020-02-04,COMPLETED,INTERVENTIONAL,['NA'],
12568,NCT02088658,Hemoglobin A1c,Resource Utilization & Cost,2013-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12569,NCT00421850,Metabolic Outcomes (Systolic Blood Pressure),Satisfaction (Provider and Health Team),2001-07,COMPLETED,INTERVENTIONAL,['NA'],
12570,NCT01357889,Maximum Observed Plasma Concentration (Cmax) of Albiglutide in the BE Phase,Number of Participants With a Change From Baseline of Clinical Concern in Electrocardiogram (ECG) Values by Any On-therapy Visit,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
12571,NCT03984929,Patient Activation,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA'],
12572,NCT05988346,normalization of LV diastolic dysfunction,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],
12573,NCT06082973,Number of Level 1 (<70 mg/dL) and Level 2 (<54 mg/dL) hypoglycemic events,Total number of carbohydrates ingested,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
12574,NCT04049110,Mean Amplitude of Glucose Excursions (MAGE) after physical exercise,"Area under the curve for glucagon before, during and after physical exercise",2020-08-25,COMPLETED,INTERVENTIONAL,['PHASE3'],"Area under the curve for somatostatin before, during and after physical exercise"
12575,NCT01805414,Relative change in Blood sugar,,2012-09,COMPLETED,INTERVENTIONAL,['NA'],
12576,NCT02926937,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 (Sotagliflozin 400 mg Versus Placebo),Change From Baseline in HbA1c at Week 26 (Sotagliflozin 200 mg Versus Placebo),2016-11-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Hypoglycemic Events (Sotagliflozin 200 mg Versus Placebo)
12577,NCT06238778,hypoglycemia percentage of time,blood chemistry values,2024-01-23,RECRUITING,INTERVENTIONAL,['PHASE2'],
12578,NCT03703440,Hemaglobin A1c (HbA1c),Cost effectiveness (self-efficacy),2019-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12579,NCT05560256,Building Capacity in Human-Centered Design: Developing a Diabetes mHealth Application for and with Kenyan Adolescents,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],
12580,NCT02778269,Number of power-line interference on the ECG,"Number of congruences concerning identified arrhythmias of this validation study and the previous study ""Predicting Hypoglycaemia and Arrhythmias in the vulnerable Patient with Diabetes and Chronic Kidney Disease"".",2016-06,COMPLETED,INTERVENTIONAL,['NA'],
12581,NCT06150495,"Retinal vessel density (VD, %)",,2019-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
12582,NCT00361868,HbA1c/TG,Lipid and glycemic parameters.,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
12583,NCT00604253,HbA1c,Insulin antibodies,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
12584,NCT05097339,Change in ketone concentration during and after morning Aerobic and Symptom Limited Maximal Exercise Test,,2019-05-10,COMPLETED,OBSERVATIONAL,['NA'],
12585,NCT02592421,Change in Endogenous Glucose Production (EGP),Change in Glucagon During EGP Measurement,2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
12586,NCT00813020,"AUC0-8 (NN9535), the area under the plasma NN9535 plasma-concentration-time curve in the interval 0-8 after investigational medicinal product administration",Cmax of the plasma NN9535 curve,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
12587,NCT05626842,Primary study objective- HbA1c,Secondary study objective- participant experience,2021-01-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12588,NCT03574558,Number of hypoglycemic below 54 mg/dl,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA'],
12589,NCT04022499,Weight loss,Attendance,2019-08-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12590,NCT01379690,Hip Fracture,,2011-04,COMPLETED,OBSERVATIONAL,['NA'],
12591,NCT02688920,"Thickness of the duodenal mucosa using OCT, and EUS if possible","Thickness of the duodenal submucosa using OCT if possible, and EUS",2016-03,COMPLETED,OBSERVATIONAL,['NA'],"Thickness of the duodenal muscularis using OCT if possible, and EUS"
12592,NCT02299960,Test-retest-reliability EndoPAT,Clinical feasibility of circulating endothelial cells and EndoPAT,2014-08,COMPLETED,OBSERVATIONAL,['NA'],
12593,NCT05421390,Change in whole-body insulin sensitivity,Change in C-reactive protein,2022-06-10,RECRUITING,INTERVENTIONAL,['NA'],Change in subcutaneous adipose tissue gene expression signature
12594,NCT03288571,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Evaluation of the preliminary efficacy of the injection on kidney's protein to creatinine ratio,2019-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
12595,NCT02341664,"Lipid-lowering therapy use among a contemporary, nationally representative, community-based sample of adult patients receiving primary and subspecialty care in the US.",,2015-05,COMPLETED,OBSERVATIONAL,['NA'],
12596,NCT03708887,Change in blood lipids from baseline,Change in gut microbiota from baseline,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12597,NCT01572610,Adverse Event collection and assessment,,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2'],
12598,NCT00475202,,,na,UNKNOWN,OBSERVATIONAL,['NA'],
12599,NCT02957721,Change in A1C,Blood Pressure (BP),2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],
12600,NCT01419535,Change in Insulin Sensitivity Index,Adipose-tissue Insulin Sensitivity Index (Adipo-SI),2011-11-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
12601,NCT02419612,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52,Time to Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.,2015-08-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
12602,NCT04776811,Mean absolute relative difference (MARD),"Correlation between CGM metrics, HbA1c and fructosamine",2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],
12603,NCT05279729,Long term diabetes improvement via A1c,mhealthy app preference assessed by questionnaire,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],
12604,NCT01972412,Telephone Support for self-monitoring of persons with diabetes mellitus using the Chronic Care Model,,2013-04,UNKNOWN,INTERVENTIONAL,['NA'],
12605,NCT04946188,Validation of predictive model for determining blood glucose levels,,2020-07-21,COMPLETED,INTERVENTIONAL,['NA'],
12606,NCT04127383,Perceived quality of care (PACIC): Patient Assessment of Chronic Illness Care,Productivity losses,2019-11-01,COMPLETED,INTERVENTIONAL,['NA'],
12607,NCT04858386,Excessive Fetal Growth,Adverse Pregnancy Outcomes,2017-11-01,TERMINATED,OBSERVATIONAL,['NA'],
12608,NCT01798706,Absolute Change in HbA1c From Baseline to Week 24,Percentage of Participants With Gastrointestinal Disorders,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
12609,NCT05819749,Acceptability of intervention,Diabetes medication adherence,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],
12610,NCT03316690,Change in postprandial glycemic control as assessed by mean blood glucose concentration during a 4 hour mixed-meal tolerance test,Training rate of perceived exertion,2017-10-20,COMPLETED,INTERVENTIONAL,['NA'],
12611,NCT03547427,Relative glucagon counterregulation (GCR) response,Rate of gastric emptying,2018-05-20,TERMINATED,INTERVENTIONAL,['NA'],
12612,NCT01536808,Telomere shortening,Cardiovascular events,2009-04,COMPLETED,INTERVENTIONAL,['NA'],
12613,NCT03285386,Time constant for muscle deoxygenation kinetics (assessed by near-infrared spectroscopy),Time constant for heart rate kinetics,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],
12614,NCT02024971,Number of Participants With Adverse Drug Reactions,Change From Baseline in Fasting Insulin,2010-07,COMPLETED,OBSERVATIONAL,['NA'],
12615,NCT00719251,Quality of life with the EQ-5D.,"Sociodemographic data like gender and age, were recorded. Additionally clinical history, deformities, alcohol dependence or smoking history, previous and present pharmacologic treatment and corticosteroids were included.",2004-03,COMPLETED,INTERVENTIONAL,['NA'],
12616,NCT02254291,Number of Treatment Emergent Adverse Events (TEAEs),Change in Glycosylated Haemoglobin A1c (HbA1c),2014-10-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
12617,NCT04148482,Hunger perception before and after test meals consumption using visual analogue scales,Appetite satiety hormones levels by immunoassay kits,2021-06-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
12618,NCT05262595,"AUC (NNC0471-0119,0-30min,basal-corrected)/AUC (NNC0471-0119,0-t,basal-corrected)","GIRmax,basal-corrected: Maximum observed basal-corrected GIR",2022-03-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
12619,NCT06243172,"Cortisol oscillations (amplitude, peak, mesor, phase, period length (TAU))","Glucagon-like peptide-1 (GLP-1) oscillations (amplitude, peak, mesor, phase, period length (TAU))",2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Cardiovascular autonomic neuropathy
12620,NCT00940251,antidiabetic activity,"Improvement in metabolic, insulin level, HbA1c,kidney and lipid profile",2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
12621,NCT00235469,"To investigate the efficacy of 200, 400, and 600 mg/day of lacosamide compared with placebo in reducing pain in subjects with painful distal diabetic neuropathy.","To investigate the effect of lacosamide on subjects' perception of pain, sleep, activity, quality of life, as well as to investigate the pharmacokinetics and safety of lacosamide.",2004-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
12622,NCT04590872,Number of successful manufactured products,Change in blood glucose levels,2022-06-16,RECRUITING,INTERVENTIONAL,['PHASE1'],
12623,NCT01944449,Fasting circulating levels of HbA1c,Body Weight,2013-09,COMPLETED,INTERVENTIONAL,['NA'],
12624,NCT00130845,time to progression of diabetic retinopathy,time to moderate vision loss,2000-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
12625,NCT01758757,Incidence of retinal breaks,Incidence of neovascular glaucoma,2007-09,COMPLETED,INTERVENTIONAL,['NA'],
12626,NCT00297401,Change in the renal and peripheral pressor response to Angiotensin II pre and post-treatment with ruboxistaurin.,Secondary analyses will consist of the change in endothelial function and vascular compliance pre- and post-treatment with ruboxistaurin.,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
12627,NCT00991055,The change from baseline in HbA1Cand FPG,Insulin resistance (HOMA-IR index),2008-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12628,NCT00108459,,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
12629,NCT04769687,inflammation,fragility,2020-11-21,RECRUITING,INTERVENTIONAL,['PHASE2'],
12630,NCT00924599,Gestational diabetes not present in pregnancy,,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
12631,NCT00751114,HbA1c: Change From Baseline to Study Endpoint,Number of Patients With at Least One Episode of Severe Symptomatic Hypoglycemia,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
12632,NCT00696605,,,2008-07,COMPLETED,OBSERVATIONAL,['NA'],
12633,NCT05029271,Endpoints are exploratory and descriptive related to time in glycemic range.,,2023-04-17,COMPLETED,INTERVENTIONAL,['NA'],
12634,NCT00935064,Expiration/Inspiration Ratio Before and After Treatment,,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
12635,NCT02713321,Diabetes-related preventable hospitalizations,Number of months of Medicaid coverage,2017-01-24,COMPLETED,OBSERVATIONAL,['NA'],
12636,NCT05893784,Fatigue Severity Scale,,2022-01-20,COMPLETED,INTERVENTIONAL,['NA'],
12637,NCT01436916,Change in insulin sensitivity using OGIS (oral glucose insulin sensitivity index),Change in fasting and post prandial blood glucose,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
12638,NCT03542929,Changes in lactate levels,Borg's Rating of Perceived Exertion Scale (RPE) or Modified Borg Scale,2017-11-20,COMPLETED,INTERVENTIONAL,['NA'],
12639,NCT02637609,Measuring patients' priorities for barriers and facilitators for diabetes self-management using Best-Worst Scaling,,2013-07,UNKNOWN,OBSERVATIONAL,['NA'],Self-reported difficulty in understanding and answering the survey questions
12640,NCT05350553,Methylglyoxal Evaluation,Neuropathy Status using the Michigan Neuropathy Screening Index,2022-05-02,UNKNOWN,OBSERVATIONAL,['NA'],
12641,NCT02923960,Plasma Glucose Concentration,Serum Insulin Concentration,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
12642,NCT06062576,2-week reduction rate of wound area,,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
12643,NCT00328965,To investigate the clinical effectiveness of lacidipine on elevated systolic blood pressure (SBP) in Korean patients aged 35 to 75 years.,To investigate the clinical effectiveness of lacidipine on elevated diastolic blood pressure and endothelial function by flow-medicated vasodilation and measurement of markers of inflammation in Korean patients aged 35 to 75 years with type 2 diabetes.,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
12644,NCT01879501,Vision-related quality of life,"Perceived self-efficacy, emotional well being, and vision-specific distress",2013-01,UNKNOWN,INTERVENTIONAL,['NA'],
12645,NCT00228579,Visceral adipose tissue volume,Insulin sensitivity,2003-06,COMPLETED,OBSERVATIONAL,['NA'],
12646,NCT04161976,PK: Maximum Observed Insulin Lispro Concentration (Cmax),Duration Until Catheter Failure,2019-12-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
12647,NCT03426566,Abnormal Plantar Pressure Distribution,BMI,2012-09,COMPLETED,OBSERVATIONAL,['NA'],
12648,NCT05011292,Percentage of parents who report that they do not give their young children fruit juice,Percentage of parents who viewed an intervention video report that they enjoyed it or learned something from it,2021-08-10,COMPLETED,INTERVENTIONAL,['NA'],
12649,NCT00546741,To determine the effect of metformin on the exposure of dapagliflozin and the effect of dapagliflozin on the exposure of metformin in healthy subjects after a single dose of each treatment,To assess the safety and tolerability of dapagliflozin when administered alone or with metformin after a single dose of each treatment,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
12650,NCT03003793,Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls,,2015-11,COMPLETED,OBSERVATIONAL,['NA'],
12651,NCT03221205,Strain,Mean value of arterial pressure,2014-10-15,COMPLETED,INTERVENTIONAL,['NA'],
12652,NCT04336176,Pressure Time Integral,Modified Monitoring Orthopaedic Shoes questionnaire,2018-03-22,COMPLETED,INTERVENTIONAL,['NA'],
12653,NCT04965935,Systolic blood pressure,Adverse Events (AEs),2021-07-15,RECRUITING,INTERVENTIONAL,['PHASE3'],
12654,NCT06296992,Retention for follow-up measurements,Quality of Life (PedsQL 4.0),2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Motivation for Physical Activity (EMI-2)
12655,NCT03693560,Change in Adiponectin level.,Percent Change in (total cholesterol / High-density lipoprotein (HDL) cholesterol) for each patient before and after 3 months combination treatment for each group .,2018-10-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
12656,NCT05488210,Muscle mass (%),Sensory perception,2022-07-01,UNKNOWN,OBSERVATIONAL,['NA'],
12657,NCT00403026,"Electrophysiological changes (ERG, VEP)","Ocular side effects (infection, RD, IOP rise, cataract)",2006-08,UNKNOWN,INTERVENTIONAL,['NA'],
12658,NCT01382459,,,2011-07,UNKNOWN,OBSERVATIONAL,['NA'],
12659,NCT02330549,Change From Baseline in Adipose Tissue Insulin Resistance (Adipo-IR ) Index,Number of Participants With Abnormal Physical Examination Findings,2015-07-17,COMPLETED,INTERVENTIONAL,['PHASE2'],
12660,NCT02040441,Albuminuria,Slope of estimated GFR,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
12661,NCT02707406,Incidence of adverse events collected throughout the trial compared between the two groups,Difference in score of quality of life assessment determined by Cardiff Wound Impact Schedule (CWIS),2016-02,COMPLETED,INTERVENTIONAL,['NA'],
12662,NCT03012529,Amputation-Free Survival,First occurrence of ipsilateral amputation related to index osteomyelitis,2018-01-22,RECRUITING,INTERVENTIONAL,['PHASE4'],
12663,NCT06315361,Prevalence of significant fibrosis by non invasive tests,Identification of MACE,2019-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
12664,NCT02156843,Time to composite endpoint of >=50% SCr increase from baseline or ESRD,Time to the composite endpoint >=100% SCr increase or ESRD,2014-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Change in SCr
12665,NCT01407315,Accuracy of the GlucoMenDay,Safety of the GlucoMenDay System,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
12666,NCT05754008,Differences between study arms in HbA1c change 6-months following enrollment,Participant-reported measures: Diabetes stigma,2023-03-31,RECRUITING,INTERVENTIONAL,['NA'],
12667,NCT06260722,Change from Baseline in Hemoglobin A1c (HbA1c) (%),Change from Baseline in Systolic Blood Pressure (SBP),2024-02-21,RECRUITING,INTERVENTIONAL,['PHASE3'],
12668,NCT05273840,the proportions of participants regressing back to normal glucose level,body weight,2021-06-11,RECRUITING,INTERVENTIONAL,['NA'],changes in triglyceride level (blood lipids)
12669,NCT01481623,"Identification and genetic, clinical and metabolic characterization of monogenic diabetes forms",Clinical and biological characterization of total or partial deficiency of the genes responsible for monogenic diabetes,2012-09,UNKNOWN,INTERVENTIONAL,['NA'],
12670,NCT02605148,Change in glucose metabolism,Incidence of Treatment-Emergent Adverse Events,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],
12671,NCT04725890,Device- or Procedure-related SAE Rate,Changes in blood pressure,2021-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Procedure time
12672,NCT01647308,Total apoC-III,Insulin Sensitivity,2012-07,TERMINATED,INTERVENTIONAL,['PHASE2'],
12673,NCT05494450,evaluate the safety and performance of Exufiber Ag+ in medium to high exuding chronic wounds,,2022-01-01,TERMINATED,INTERVENTIONAL,['NA'],
12674,NCT00384085,Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - ITT Population With All Sites) (Sensitivity Analysis),Adjusted Hypoglycemic Event Rates (Event/Patient-year),2006-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
12675,NCT04529590,Rate of cardiovascular death,Rate of all-cause death,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],
12676,NCT01885234,glycated hemoglobin,HOMA,2011-12,COMPLETED,INTERVENTIONAL,['NA'],First ventilatory threshold
12677,NCT02668601,hypothalamic CBF,,2010-08,COMPLETED,OBSERVATIONAL,['NA'],
12678,NCT06061237,Functional reach test,Muscle mass,2022-09-19,COMPLETED,INTERVENTIONAL,['NA'],
12679,NCT02175784,Change in HbA1C from baseline,"Safety assessed by the adverse events, vital signs. and laboratory tests",2014-03-31,COMPLETED,INTERVENTIONAL,['PHASE4'],
12680,NCT02284269,Incidence of adverse events,The change from baseline in Fasting Plasma Glucose,2014-10,UNKNOWN,OBSERVATIONAL,['NA'],
12681,NCT01988246,Number of Participants With Ocular and Non-Ocular Adverse Events,Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score,2013-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change From Baseline in Retinal Thickness
12682,NCT00605592,A decrease in the average daily insulin requirement post-islet cell transplantation.,,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
12683,NCT01238380,Identification of patients with monogenic diabetes,To develop a health economic model of the care pathway leading to testing of monogenic diabetes.,2010-12,COMPLETED,OBSERVATIONAL,['NA'],
12684,NCT04945109,Changes in glycemic control,questionnaire 4,2021-10-19,COMPLETED,INTERVENTIONAL,['NA'],
12685,NCT01809184,Number of adverse events (AEs),Area under the glucose infusion rate (GIR)-time curve,2013-03-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
12686,NCT05395806,Change in fatigue level,Change in cardiovascular risk level,2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12687,NCT00544206,mean glucose level,"fasting capillary blood glucose level;percentage change from baseline in the dose and amount of antihyperglycemic medication(s), including insulin",2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
12688,NCT03592667,Ambulatory arterial stiffness index,Glomerular filtration rate,2019-02-14,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12689,NCT02960295,Compliance With Requirements for Frequency of Glucose Measures,Glucose Concentrations,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
12690,NCT05117424,Coronary lesion severity,Cardiovascular events,2018-11-01,RECRUITING,OBSERVATIONAL,['NA'],Lipoprotein function assessment
12691,NCT04121572,To utilize capnography as a noninvasive tool for the detection and monitoring of DKA,To find the ability of EtCO2 in ruling in or out DKA,2019-10-10,RECRUITING,OBSERVATIONAL,['NA'],To evaluate the different severity grades of DKA using EtCO2 Monitoring
12692,NCT02199769,Resulted Diabetes Screening Test,Diabetes Diagnosis,2014-07-01,COMPLETED,INTERVENTIONAL,['NA'],
12693,NCT02172313,Area under the semaglutide plasma concentration time curve,Area under the SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) plasma concentration time curve,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
12694,NCT02000817,Number of Participants With Abnormal Vital Sign Results,Number of Participants With Anti-drug Antibody Binding,2014-03-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
12695,NCT00012662,,,na,COMPLETED,INTERVENTIONAL,['NA'],
12696,NCT00734669,Number of hypoglycemic events,"Secretion of hormones increasing blood glucose, effect of exercise on hypoglycemic events, postprandial glucose excursions, heart rate and forearm blood flow at hypoglycemia",2008-07,COMPLETED,OBSERVATIONAL,['NA'],
12697,NCT00341614,Total kcal and fat kcal at 3 months,Bone-mineral density at 3 months,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
12698,NCT01935765,Compare the prevalence of sleep apnea syndrome by polysomnography between type 1 diabetic patients and healthy volunteers,Precise clinical symptoms in DT1 patients with Sleep apnea syndrome,2013-09,COMPLETED,INTERVENTIONAL,['NA'],
12699,NCT02624804,Treatment related adverse events,Number of patients unable to complete therapy,2017-06-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
12700,NCT02816710,Intraoperative Bleeding,Need for Reoperation,2016-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
12701,NCT04146740,Blood glucose level,Edinburgh Post Natal Depression scale (Punjabi version),2019-03-12,COMPLETED,INTERVENTIONAL,['NA'],
12702,NCT00380822,,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],
12703,NCT05760677,The recovery of menstrual cycle,The changes in body weight,2022-10-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1'],
12704,NCT03789526,changes in ultrasound images of the Tenoasynovitis.,,2018-12-11,COMPLETED,INTERVENTIONAL,['NA'],
12705,NCT00662714,HbA1c,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
12706,NCT02138331,Total daily insulin dose,Pancreatic β-cell Mass,2014-04,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Hemoglobin A1c
12707,NCT00391209,Demonstrate that a simple approach for adding AIR® Inhaled Insulin to oral antihyperglycemic medication can achieve glycemic control similar to a more aggressive approach.,"Patient reported outcome from ""Expectations About Insulin Therapy Questionnaire""",2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
12708,NCT02189005,Safety of Dietary Supplement PreCrea 600 mg twice-daily,Efficacy of Dietary Supplement PreCrea 600 mg twice-daily in lowering Fasting Plasma Glucose (FPG),2013-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Safety of Dietary Supplement PreCrea 600 mg twice-daily with Liver Function
12709,NCT00706017,Incidence of SADR (serious adverse drug reactions ) incl major hypo (hypoglycaemic events),Weight,2007-09,COMPLETED,OBSERVATIONAL,['NA'],
12710,NCT00273572,Parameters of the metabolic syndrome,Attainment of weight reduction and physical activity targets,2004-12,COMPLETED,INTERVENTIONAL,['NA'],
12711,NCT02897349,Percentage Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment,Percentage of Participants With Any Severe Hypoglycaemic AE,2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE3'],
12712,NCT01242215,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",2010-09-17,COMPLETED,INTERVENTIONAL,['PHASE3'],
12713,NCT02650830,bile acid profile,,2015-09-12,COMPLETED,OBSERVATIONAL,['NA'],
12714,NCT00086450,"5-year Composite Endpoint of All-cause Mortality, Non-fatal Myocardial Infarction, and Stroke",Rates of Individual MACCE Endpoints,2004-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],
12715,NCT03021746,Change in A1C Blood Glucose level,,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
12716,NCT02444364,Change in Bone Turnover,,2015-05,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],
12717,NCT01207284,Peak pressure at lateral forefoot,Activities-Specific Balance Confidence Scale (ABC),2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
12718,NCT01538511,Area under the plasma insulin concentration curve from 0 to 24 hours,Frequency of adverse events,2006-06-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
12719,NCT01308164,Time spent in the normal range,Number of recommendations for changes in setting per patient and per iPRO wear,2011-03,COMPLETED,INTERVENTIONAL,['NA'],
12720,NCT00877526,"Percentage of diabetic patients having dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications, respectively","Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)",2009-05,COMPLETED,OBSERVATIONAL,['NA'],
12721,NCT00962026,Incidence and severity of infection in study participants,"Changes in participants' HbA1c levels, insulin doses, and beta cell preservation",2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
12722,NCT03462940,Change in vascular function,Change in lipid levels,2018-04-02,TERMINATED,INTERVENTIONAL,['NA'],
12723,NCT04957589,Muscle Protein Breakdown (MPB) (3MH),Skeletal Muscle & Creatine Pool Assessment (D3-C),2020-01-01,COMPLETED,INTERVENTIONAL,['NA'],
12724,NCT02384109,Uptake of evidence-based diabetes prevention (lifestyle change or metformin),Change in systolic blood pressure,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
12725,NCT00865397,Change in HbA1c,Change in waist and hip circumference,2009-02,COMPLETED,OBSERVATIONAL,['NA'],
12726,NCT01022411,fasting glucose,HbA1c,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
12727,NCT00973960,The primary efficacy endpoint is an assessment of glycemic control at week 24 or last assessment measured via HbA1c.,The safety endpoint will be the incidence and severity of anticipated and unanticipated adverse events (device and non-device related).,2009-09,COMPLETED,OBSERVATIONAL,['NA'],
12728,NCT04419948,Incremental Area Under the Serum Concentration Versus Time Curve (AUC) of Triglycerides,Incremental Area Under the Plasma Concentration Versus Time Curve (AUC) of Protein Carbonyls,2019-05-16,UNKNOWN,INTERVENTIONAL,['NA'],
12729,NCT01415726,Inflammation control,Metabolic control,2011-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
12730,NCT00820313,Biomarkers of Cardiovascular Disease,Dietary Intake,2006-10,UNKNOWN,INTERVENTIONAL,['NA'],
12731,NCT05937737,Total Reactive Antioxidant Potential (TRAP),,2020-04-20,COMPLETED,INTERVENTIONAL,['NA'],
12732,NCT01121315,"Composite end-point consisting of Cardiovascular Disease, elective coronary revascularisation and mortality",Number of consultations in primary care. Number of hospitalisations,2010-05,COMPLETED,OBSERVATIONAL,['NA'],
12733,NCT00400036,Insulin signaling in skeletal muscle at 4 weeks,glucose tolerance at 4 weeks,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
12734,NCT02699541,"Participants' diabetes self-Management activities: diet habits, physical activity and medications Management",Diabetes Self-Management Self-Efficacy.,2016-04,COMPLETED,INTERVENTIONAL,['NA'],
12735,NCT02061579,Changes in Self-Reported Physical Activity Level Across Study Visits,Changes in Patient Satisfaction During Intervention Period,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
12736,NCT01571310,Postprandial Glucose Response,Postprandial Free Fatty Acids Response,2012-07,COMPLETED,INTERVENTIONAL,['NA'],
12737,NCT03644134,Change in HbA1c,,2013-09-26,COMPLETED,INTERVENTIONAL,['NA'],
12738,NCT00135109,"To investigate the efficacy of 200, 400, and 600mg/day of lacosamide compared with placebo in reducing pain in subjects with painful distal diabetic neuropathy.","To investigate the effect of lacosamide on subjects' perception of pain, sleep, activity, and quality of life, as well as to investigate the pharmacokinetics and safety of lacosamide.",2004-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
12739,NCT04440449,Frailty Scale Using Fried's Phenotype Method Based on Five Frailty Characteristics,SPPB Chair Stands,2019-07-15,COMPLETED,INTERVENTIONAL,['NA'],
12740,NCT00836940,Change from baseline in HbA1c compared with placebo at the end of 12 week treatment period,Waist circumference,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],
12741,NCT04794478,Dexcom Continuous Glucose Monitoring System Performance,System Related Adverse Device Effects,2021-02-19,COMPLETED,INTERVENTIONAL,['NA'],
12742,NCT04994288,HbA1c,salvage treatment,2021-09-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
12743,NCT02167620,"Improvement in HbA1C derived from Oral glucose tolerance test (Matsuda, index of insulin sensitivity; area under glucose curve; insulin secretion sensitivity index-2 (ISSI-2))",Improvements in hippocampal volume,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
12744,NCT04271228,HbA1c,Total daily consumed carbohydrates,2020-02-15,COMPLETED,INTERVENTIONAL,['NA'],"Time required to review insulin pump and sensor data, make and send recommendations or length of visit"
12745,NCT00866658,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During 24-Week Period,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia
12746,NCT03941652,Basic version of the eMOM GDM application has developed,Usability of professional eMOM GDM application,2019-05-27,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Nutrition dataset
12747,NCT01050465,seeking information using MedlinePlus,,2009-05,COMPLETED,INTERVENTIONAL,['NA'],
12748,NCT02870816,The number of participants out of 60 with complete healing of their diabetic foot ulcers as measured by complete epithialization of the foot wound comparing the two active treatment groups,Cost effectiveness of each treatment modality.,2016-08-31,COMPLETED,INTERVENTIONAL,['NA'],
12749,NCT03214107,Percentage of time of capillary glucose levels spent between 4-10 mmol/L,Mean glucose levels,2017-08-03,COMPLETED,INTERVENTIONAL,['NA'],
12750,NCT02231021,Change in glycohemoglobin(HbA1c) from baseline,The number of subject with any change of findings in electrocardiogram from baseline,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
12751,NCT04902235,Change in oxytocin concentration,Alexithymia assessment,2021-07-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
12752,NCT04049500,Usability will be assessed using a 5-point Likert scale,,2021-09,WITHDRAWN,OBSERVATIONAL,['NA'],
12753,NCT04970108,Systolic blood pressure (SBP),Adverse events,2023-08,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
12754,NCT00005485,Cardiovascular Disease,Mortality,2000-09-19,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
12755,NCT01022112,Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value),Safety and Tolerability,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
12756,NCT04488848,Interleukin-6,,2019-04-11,UNKNOWN,INTERVENTIONAL,['NA'],
12757,NCT01242059,Energy Intake,Subjective Appetite,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
12758,NCT01991197,The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.,The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Change in Serum Leptin From Baseline to 16 Weeks.,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Dipeptidyl Peptidase-4 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).
12759,NCT02680054,Time of Peak Glucose Level Following Test Meal,Number of Participants With Hypoglycaemia Events Following the Insulin Dosing,2016-02,TERMINATED,INTERVENTIONAL,['PHASE4'],Acceptability of Giving Insulin at Different Times Related to Test Meal
12760,NCT04562714,Time in Range (TIR),Mean number of glucose checks,2020-09-08,COMPLETED,INTERVENTIONAL,['NA'],Exploratory analysis 4: Frequency of glucose testing
12761,NCT00302055,Weight Loss,Rate of Community Program Participation,2006-03,COMPLETED,INTERVENTIONAL,['NA'],
12762,NCT03323788,Response of muscle mRNA to acute exercise,,2016-11,UNKNOWN,OBSERVATIONAL,['NA'],
12763,NCT01951768,Clinical Cure,Pathogen Eradication,2013-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
12764,NCT00954109,Blood Flow in Response to Oral Glucose Tolerance Tests,,2009-08,COMPLETED,INTERVENTIONAL,['NA'],
12765,NCT04433598,Glycemic control,Health literacy (HL),2019-06-09,COMPLETED,INTERVENTIONAL,['NA'],
12766,NCT00358124,"Other efficacy variables were the change from baseline in FPG, serum lipids and weight.",Health-related quality of life was compared between the baseline visit and the follow-up assessments,2001-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
12767,NCT00190320,reduction of neonatal traumatism risk,reduction of maternal morbidity and caesarean,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
12768,NCT02794506,Change of glycosylated hemoglobin (HbA1c),Change of serum N- epsilon (carboxymethyl) lysine level,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
12769,NCT01204775,Mean Change in HbA1c From Baseline to Week 16,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
12770,NCT00989924,The smooth index of corrected QT interval (SIQTC) measured by MCG,,2009-10,UNKNOWN,OBSERVATIONAL,['NA'],
12771,NCT05639088,Attendance at clinic visits,Change in Quality of Life,2023-08-24,RECRUITING,INTERVENTIONAL,['NA'],Transition Status
12772,NCT02838693,Changes in insulin sensitivity in Asian populations with normal glucose tolerance and prediabetes over 3 years. Data will be presented at the end of 5.5years.,To discover and/or validate biomarkers that predict which subjects will progress from NGT to prediabetes and/or from prediabetes to diabetes. Data will be presented at the end of 5.5years.,2016-03,UNKNOWN,OBSERVATIONAL,['NA'],
12773,NCT06143423,Severity of serious adverse events (SAEs),Anti-Drug Antibody (ADA),2023-05-24,RECRUITING,INTERVENTIONAL,['PHASE1'],
12774,NCT00119054,Blood Pressure and Hemaglobin A1c,Knowledge Compliance Self-efficacy Quality of life Satisfaction with care,2005-09,COMPLETED,INTERVENTIONAL,['NA'],
12775,NCT06079450,Hypoglycemic Confidence Scale,hospitalization rate,2022-06-10,COMPLETED,OBSERVATIONAL,['NA'],
12776,NCT04149951,Glycated Hemoglobin (HbA1c),Fullness,2020-06-03,COMPLETED,INTERVENTIONAL,['NA'],Dose response analysis
12777,NCT01726075,"Changes in the Implicit Time assessed by mfERG (IT-mfERG) at month 6, 12, 18 and 24",DR severity assessed by ETDRS scale CFP - 30º/35º-7 fields at month 24,2013-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","ophthalmological examination: Refractive Error, Slit Lamp Exam, Ophthalmoscopy (Vitreous, Retina, Macula, Choroid, Optic Nerve), Intra-Ocular Pressure (IOP) Measurement at month 24"
12778,NCT00944697,Short Form McGill Pain Score.,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
12779,NCT06278571,Number of participants with body mass index profile in control target,The proportion of patients with adequate knowledge of diabetes,2023-01-30,RECRUITING,INTERVENTIONAL,['NA'],
12780,NCT04976283,Change in radiologic liver parameters,Change in Lipid profile,2021-09-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],Change in Systolic and Diastolic blood pressure
12781,NCT01369602,Amount of drug excreted (Ae),,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
12782,NCT01965639,Mortality,Change in patient-reported outcomes,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
12783,NCT01299012,Improved Blood Glucose comtrol in Type 1 Diabetes Patients with Liraglutide,,2010-10,COMPLETED,OBSERVATIONAL,['NA'],
12784,NCT04224428,Percent change in urinary albumin creatinine ratio (UACR),Urinary monocyte chemoattractant protein-1 (MCP-1),2020-01-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
12785,NCT03771053,Change from Baseline coronary plaque volume percentage(PAV) at 12 months,Inflammation marker,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
12786,NCT02291666,Metabolic ratio,Renal clearance,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
12787,NCT05299918,Cardiac Autonomic Neuropathy assesed by Othostatic BP change,,2014-07-15,COMPLETED,OBSERVATIONAL,['NA'],
12788,NCT00004984,Rate of Type 1 Diabetes Per Year,,1994-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
12789,NCT04711980,Changes in total score on the Michigan Diabetic Neuropathy Score (MDNS) of Scale,Changes in total score on the Clinical Symptoms Score of Scale,2021-06,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
12790,NCT00774800,Area Under the Insulin Concentration-time Curve for the First Hour (AUC0-60),Area Under the Blood Glucose Time-Concentration Curve Blood Glucose (AUC[BG]),2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
12791,NCT00123604,Flow Mediated Dilation,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
12792,NCT05932251,glucose-disposition-index,Neonatal body length,2023-06-19,RECRUITING,OBSERVATIONAL,['NA'],
12793,NCT02189694,Percentage of time of glucose levels spent below 4.0 mmol/L.,Hypoglycemic risk assessed by the number of patients experiencing at least one hypoglycemic event (> 15 minutes) below 3.1 mmol/L,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
12794,NCT00982254,Glucose Infusion Rate (GIR),Adverse Events,2001-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
12795,NCT00425490,C-peptide total and incremental area under the curve.,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
12796,NCT05333835,Mean Change From Baseline in HbA1c at Week 26,Number of Hypoglycaemic Episodes at Week 26,2022-07-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
12797,NCT04629586,Gather longitudinal data from individuals living with type 1 diabetes.,,2018-12-13,RECRUITING,OBSERVATIONAL,['NA'],
12798,NCT01792518,HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment,The Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 24 Weeks of Treatment,2013-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
12799,NCT03503370,Time to new foot complication among all randomized participants,Susceptibility to chlorhexidine among bacterial pathogens on the feet,2019-01-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to new foot complication among participants with a healed foot complication at randomization.
12800,NCT05797935,To assess and estimate the difference in pancreatic fat content in the patients of Type 2 Diabetes Mellitus at baseline and after taking dapagliflozin for 24 weeks,To estimate the correlation between two advanced MR techniques commonly used for quantification of pancreatic fat(PDFF and MR Spectroscopy),2021-08-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
12801,NCT04361799,The proportion of time spent in the target glucose range from 5.6 to 10.0 mmol/L based on sensor glucose levels during the time from hospital admission for elective surgery until discharge.,Total daily insulin requirements,2020-09-25,COMPLETED,INTERVENTIONAL,['NA'],Proportion when closed-loop was active
12802,NCT00674271,Plaque burden in carotid arteries,Genotyping genes for pattern recognition molecules,2008-05,UNKNOWN,OBSERVATIONAL,['NA'],
12803,NCT01770483,"Sustained Viral Response,",Normalization of Alanine Transferase Test,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
12804,NCT00208598,,,2003-01,COMPLETED,OBSERVATIONAL,['NA'],
12805,NCT00184639,Fasting plasma glucose,Hypoglycaemia,2004-08-16,COMPLETED,INTERVENTIONAL,['PHASE3'],
12806,NCT02612402,increase in daily physical activity,glycemic control,2014-07,UNKNOWN,INTERVENTIONAL,['NA'],
12807,NCT00290043,"Outcome measures: Post-prandial glucose and insulin concentrations. Outcome: In T1DM, insulin glulisine provides a better mimic of the physiological postprandial glucose disposal than RHI.",,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
12808,NCT03321032,Target lesion failure at 2-years follow-up,Non-target lesion revascularization,2017-12-19,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12809,NCT00994357,Prevalence of LGA in children of diabetic women.,The occurrence of low grade inflammation and endothelial dysfunction in pregnant women with diabetes.,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
12810,NCT02443922,Beta Cell Function as measured by the arginine stimulation test in response to two therapies for type 2 diabetes mellitus,,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],
12811,NCT05214235,Visual Analogue Scale (VAS) at 1 Year after Surgery,Number of Participants with Spinal Fusion at 1 Year after Surgery,2022-02-07,RECRUITING,OBSERVATIONAL,['NA'],
12812,NCT04096794,changes in serum hemoglobin A1c level,Adverse effects,2016-09,RECRUITING,OBSERVATIONAL,['NA'],
12813,NCT00464880,To investigate whether renin-inhibition using aliskiren 300 mg daily could be a treatment alternative to the angiotensin II receptor antagonist irbesartan 300 mg with an equivalent potential for reno-protection,"To investigate whether aliskiren, irbesartan or the combination reduce biomarkers of inflammation and cardiovascular risk",2005-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
12814,NCT02426541,Adjusted Change From Baseline in Skeletal Muscle Insulin-stimulated Gluocose Uptake,Adjusted Change in Liver Insulin-stimulated Glucose Uptake From Baseline to Week 8,2015-03-23,COMPLETED,INTERVENTIONAL,['PHASE4'],
12815,NCT04042207,"Percentage of CGM time in glucose range 70-180 mg/dl, during 24 hours periods for the third and fourth week for each treatment period","Percentage of CGM time in glucose range 70-180 mg/dl, during 24 hours periods",2019-09-03,COMPLETED,INTERVENTIONAL,['NA'],
12816,NCT00818779,Plasminogen Activator Inhibitor 1,Serum Level of Nitric Oxide,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
12817,NCT05742685,Diabetes medication adherence,Glycemic control,2023-08-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
12818,NCT00826007,Hypoglycemia Incidence,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],
12819,NCT00024921,,,na,COMPLETED,OBSERVATIONAL,['NA'],
12820,NCT00395031,"Reduced Glucose, Cholesterol and Lipid Levels",Improvement in quality of life & Positive and Negative Symptoms,2003-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
12821,NCT03228602,Latency of the gustatory evoked potential,,2016-07-11,TERMINATED,INTERVENTIONAL,['NA'],
12822,NCT04217902,Description of individual experiences of patients and health care professionals in diabetes care.,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],
12823,NCT02005432,fluorescein angiography leakage area,,2012-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12824,NCT00138580,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
12825,NCT01783717,Insulin sensitivity.,waistline/hipline ratio,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],
12826,NCT02419898,Recruitment feasibility,Acceptability of the data collection procedures to participants.,2013-04,UNKNOWN,OBSERVATIONAL,['NA'],
12827,NCT02278926,Glucose control,Glucose control,2012-01,COMPLETED,OBSERVATIONAL,['NA'],
12828,NCT02606357,Change from baseline in HbA1c,- Time to reach control,2015-11-22,COMPLETED,INTERVENTIONAL,['PHASE4'],
12829,NCT02009410,Recovery rate of 13CO2 (carbon dioxide with stable isotope of carbon),Change in clinical global impression of disease symptoms,2013-11,WITHDRAWN,INTERVENTIONAL,['PHASE4'],routine safety laboratory
12830,NCT01490372,Metabolic syndrome,Inflammatory markers,2011-08,COMPLETED,OBSERVATIONAL,['NA'],
12831,NCT00178633,Change in Weight,Change in Left Ventricular Mass,2004-05,COMPLETED,OBSERVATIONAL,['NA'],
12832,NCT05047471,risk factors of albuminuria: Increase in Low density lipoprotein cholesterol (LDL-C),OR of the incidence of the adverse events,2021-12-25,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],MD the Percentage change from baseline of other laboratory test parameters of interest
12833,NCT01284465,HbA1c,Risk factors for co-morbidity and daily self-management behaviors,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
12834,NCT05670769,Diabetes Self-Care Activities Questionnaire,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
12835,NCT04711382,Time in Range,Coefficient of variation,2018-01-29,COMPLETED,OBSERVATIONAL,['NA'],
12836,NCT02328326,"Change in Cardiac Event 5-year Risk Score, as Measured by UKPDS Risk Engine",Change in Diabetes Self-Management Behavior - Check Feet,2016-11-16,COMPLETED,INTERVENTIONAL,['NA'],Change in Supporter Distress About Patient Participant's Diabetes
12837,NCT03227094,Predictive value (positive and negative),Cost evaluation of methods,2017-11-13,COMPLETED,INTERVENTIONAL,['NA'],
12838,NCT00482768,glycosylated hemoglobin,Change in risk of coronary heart disease,2007-06,COMPLETED,INTERVENTIONAL,['NA'],
12839,NCT04587297,number of meals,,2020-12-08,COMPLETED,OBSERVATIONAL,['NA'],
12840,NCT04344210,Variation in HbA1c levels,Comparison of sleep pattern changes between groups,2020-04-17,COMPLETED,INTERVENTIONAL,['NA'],
12841,NCT06115304,Appetite regulating hormones measured by specific immunoassays,,2023-10-05,RECRUITING,INTERVENTIONAL,['NA'],Peptidomicsmeasured in blood and cerebrospinalfluid using mass spectrometry
12842,NCT02973100,Change From Baseline in Hemoglobin A1c (HbA1c),"Pharmacokinetics: Area Under the Concentration-Time Curve at Steady State From Time Zero to 168 Hours (AUC[0-168], ss) of Dulaglutide",2016-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
12843,NCT05500352,"Change in the global work during hypoglycemia in individuals with type 1 diabetes, type 2 diabetes, and without diabetes, respectively.","Change in mechanical dyssynchrony during hyperglycemia in individuals with type 1 diabetes, type 2 diabetes and without diabetes, respectively.",2022-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12844,NCT04141111,Glycemic control,Therapeutic changes,2015-03-22,COMPLETED,INTERVENTIONAL,['NA'],
12845,NCT05147259,Onset of appearance,Assessment of development of Anti-drug Antibodies (ADAs),2021-11-29,UNKNOWN,INTERVENTIONAL,['PHASE1'],
12846,NCT03754465,Proportions of subjects who achieved complete wound closure,Durability of complete wound closure,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
12847,NCT03576430,Change in Hemoglobin A1C,Diabetes treatment satisfaction questionnaire (DTSQ),2018-05-31,UNKNOWN,INTERVENTIONAL,['NA'],resting pulse rate
12848,NCT05279326,"Change in glycaemic management, to be assessed by blood analysis","Change in the participants' satisfaction, to be assessed by questionnaire",2023-12,RECRUITING,INTERVENTIONAL,['NA'],
12849,NCT01801150,Glycemic control,To determine additional effects of CPAP on insulin resistance in patients with type 2 diabetes and SAHS.,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Influence of body distribution and activity on metabolic control
12850,NCT03913962,Maximal lipid oxidation rate during submaximal incremental exercise,Blood sample calprotectin,2019-05-02,RECRUITING,INTERVENTIONAL,['NA'],
12851,NCT02548494,Blood glucose,Urinalysis for levels of ketones & glucosuria,2015-11,TERMINATED,INTERVENTIONAL,['NA'],Hypoglycemic events
12852,NCT02335931,Disease progression in the previously affected foot,Altered levels of bone resorption markers,2014-09,COMPLETED,OBSERVATIONAL,['NA'],Diabetes regulation
12853,NCT02036138,To assess the efficacy of intensive medical therapy alone versus medical therapy combines with LRYGB or LSG in controlling type 2 DM in non-morbid obese patients (BMI 30-34.9),To assess the safety of intensive medical therapy alone versus medical therapy combines with LRYGB or LSG in diabetic non-morbid obese patients (BMI 30-34.9).,2015-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
12854,NCT00808860,HbA1C (glycosylated hemoglobin),"body weight (BMI, hip-weight ratio)",2008-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
12855,NCT02981121,Cumulative incidence of Diabetes Mellitus after randomization,Change on HOMA2%B,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12856,NCT02482675,Vascular Endothelial Function,Arachidonic Acid,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
12857,NCT05081765,correlation between glucose level and C through.olaparib in the blood of the patients with ovarian cancer,,2021-09-20,UNKNOWN,OBSERVATIONAL,['NA'],
12858,NCT01477567,Number of Participants With One or More Drug-related Adverse Events (AEs) or Any Serious AEs,Number of Participants Forming Antibody to LY3009385,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
12859,NCT05624034,EGG findings,Factors affecting the condition,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],
12860,NCT01707147,Percentage of Patients With Incidence of Adverse Events Who Had Taken at Least One Dose of Trajenta,Change From Baseline After 24 Weeks in Fasting Plasma Glucose (FPG),2012-11-16,COMPLETED,OBSERVATIONAL,['NA'],
12861,NCT04981847,Hemoglobin A1c,Blood pressure,2021-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12862,NCT02718326,Percentage of Participants With a ≥ 2-step Change at Week 52 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline,Area Under the Curve (AUC) for Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52,2016-03-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
12863,NCT05219994,Insulin change in response to OGTT,,2020-09-09,COMPLETED,INTERVENTIONAL,['NA'],
12864,NCT01282060,Link between HbA1c level and the overall mortality rate at 5 years.,Role of other cardiovascular risk factors,2009-03,UNKNOWN,OBSERVATIONAL,['NA'],
12865,NCT06124443,Assesment of prevalence of congenital heart defects among infants of diabetic mother compared to that in infants of non-diabetic mothers.,,2024-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
12866,NCT00845858,The Primary Efficacy Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD) Total Score.,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],The Pre-specified Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD) Total Score by Gender.
12867,NCT01064414,Change in HbA1c From Baseline to Week 26,Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
12868,NCT05435157,Residual gastric volume,Antral cross-sectional area,2022-03-09,RECRUITING,OBSERVATIONAL,['NA'],
12869,NCT02688933,Percentage of Time of Mean Glucose Concentration Within the Target Range of 70-180 mg/dL as Obtained From CGM,Coefficient of Variation (CV%) in Mean CGM Glucose,2016-05-05,COMPLETED,INTERVENTIONAL,['PHASE4'],Change From Baseline in Daily Insulin Dose at Week 16
12870,NCT06094231,Changes in HbA1c,Time in range,2023-09-25,RECRUITING,INTERVENTIONAL,['NA'],
12871,NCT05545722,diabetes self-management skill scale,Diabetes strengthening scale,2021-04-01,COMPLETED,INTERVENTIONAL,['NA'],
12872,NCT04094649,"Change in blood glucose Area Under the Curve (AUC, mg/dL ● hours) from baseline to 3 hours after an Oral Glucose Tolerance Test (OGTT) with Ultrasonic Vagus Nervous Stimulation (uVNS).hyperglycemia",Change in whole blood lipospolysaccharide-induced TNF-Alpha (pg/mL) production from base line to 4 hours post stimulation.,2019-08-01,SUSPENDED,INTERVENTIONAL,['NA'],
12873,NCT01565824,Well-Being Questionnaire (W-BQ12),,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
12874,NCT02595580,difference between Glucopred and the reference method,,2016-01,TERMINATED,INTERVENTIONAL,['NA'],
12875,NCT02547935,Adjusted Mean Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24,Adjusted Mean Change From Baseline in HbA1c: Comparison of Dapagliflozin 10 mg and Placebo at Week 24,2015-09-21,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
12876,NCT02852759,Change of Glucose Tolerance measured by OGTT,Change of glucose infusion rate by hyperinsulinemic euglycemic clamp,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
12877,NCT05317130,Incidence of sports injuries and illnesses 4 years following study start,Health literacy 12 months following study start.,2022-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
12878,NCT03849755,Change in the percentage of time in glucose target range (glucose levels 3.9-10 mmol/l or 70 - 180 mg/dl),Evaluation of usability of PEPPER system by conducting the usability test,2018-11-15,COMPLETED,INTERVENTIONAL,['NA'],
12879,NCT01173094,Occlusion of the below-knee artery or bypass,Restenosis measured by Duplex Ultrasound or CTA,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
12880,NCT03182322,The activation of an immune response (antibody or CD4+ T cell) against insulin.,,2018-05-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Transcriptome of peripheral blood cell populations
12881,NCT06245369,Change in Healthy Eating Index,Change in Body weight,2024-04-01,RECRUITING,INTERVENTIONAL,['NA'],
12882,NCT02921906,Insulin levels,Paracetamol levels,2016-06,COMPLETED,INTERVENTIONAL,['NA'],
12883,NCT04256304,The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus,,2018-12-28,COMPLETED,INTERVENTIONAL,['NA'],Health Literacy Scale for Turkish Diabetic Patients
12884,NCT02710370,Change from baseline (time of operation) in metabolite profile.,Generation of intestinal organoids from Roux limb biopsies.,2016-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
12885,NCT00004407,,,1998-02,TERMINATED,INTERVENTIONAL,['NA'],
12886,NCT05695417,Safety and Tolerability,Diabetic Retinopathy Severity Scale (DRSS) changes,2023-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],
12887,NCT00729456,Ulcer recurrence.,Amputation. Quality of life. Mood. Well-being. Compliance.,2003-04,COMPLETED,INTERVENTIONAL,['NA'],
12888,NCT01812291,Depressive Mood - Hamilton Rating Scale for Depression (HAMD),Diabetes Self-Care Behavior - The Diabetes Self-Management Questionnaire (DSMQ),2012-02,COMPLETED,INTERVENTIONAL,['NA'],Major Depressive Disorder
12889,NCT03389490,Glycemic variability,Heart rate variability,2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
12890,NCT06021691,delayed language development in children,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA'],
12891,NCT01507285,Area under the Curve,Adverse events,1999-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
12892,NCT05372471,HbA1c change,Hypoglycemia level 1 and 2,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],
12893,NCT04436666,pain relief,,2020-07-15,COMPLETED,INTERVENTIONAL,['NA'],
12894,NCT05000840,HcA1c at 6 months for participants with HbA1c < 7.5%,Changes in HbA1c over time- Patient-Reported Variable #4,2021-10-20,RECRUITING,OBSERVATIONAL,['NA'],
12895,NCT02093234,Change From Baseline in the Unmet Behaviors/Goals That Were Not Achieved at Year 1,Change in Medication Adherence,2014-04,COMPLETED,INTERVENTIONAL,['NA'],
12896,NCT02079415,Congenital malformations,Length of hospital stay,2011-01,COMPLETED,OBSERVATIONAL,['NA'],Admission to neonatal intensive care unit
12897,NCT02575001,Significant between group differences in metabolic control,Significant differences in psychological scores between groups,2015-07,COMPLETED,OBSERVATIONAL,['NA'],
12898,NCT06292871,Satisfaction levels,Proportion of participants with optimal blood glucose control,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Proportion of participants delivering healthy live birth
12899,NCT04499846,Compliance rate to the statin treatment,Compliance rate to the statin treatment according to treatment duration.,2020-06-11,COMPLETED,OBSERVATIONAL,['NA'],
12900,NCT01296308,Neuropathy-related Quality of Life (QOL-DN),Waist-to-Hip Ratio (WHR) and Body Mass Index (BMI),2011-03,COMPLETED,OBSERVATIONAL,['NA'],
12901,NCT02908152,Hepatic steatosis,AST,2017-02-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
12902,NCT03351530,"The change of hs-CRP between diabetes mellitus patients, periodontal disease patients and healthy people after receiving periodontal therapy and using mouthwash",,2017-05-18,UNKNOWN,OBSERVATIONAL,['NA'],
12903,NCT01316783,Metabolic disorders,,2011-05-06,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
12904,NCT00567905,Homeostasis model assessment for insulin resistance (HOMA-IR) was used as the major outcome measurement.,"HbA1C, blood sugar, creatinine, aminotransferases aspartate, aminotransferases alanine, uric acid, and plasma lipoproteins (triglyceride, cholesterol, cholesterol-HDL (HDL) and cholesterol-LDL (LDL)) cholesterol; BMI,WC---.",2007-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
12905,NCT00646438,The purpose of this study is to see how safe and effective strict glucose control is when extended beyond 3 days and hospital discharge for one year.,Another purpose is to see how well patients can comply with the daily management of intensive glucose control for one-year as well as the study follow-up schedule.,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],
12906,NCT00841048,"Safety and Tolerability (Adverse events, vital signs, ECGs, physical examination, laboratory variables",Pharmacodynamic measurements allowing to assess AZD4017 effect in different tissues,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
12907,NCT02636192,Number of Participants with a recorded diagnosis of Diabetic Ketoacidosis (DKA),,2015-07-31,COMPLETED,OBSERVATIONAL,['NA'],
12908,NCT05040412,Intubation time,Intubation difficulty,2020-01-25,COMPLETED,INTERVENTIONAL,['NA'],
12909,NCT00631007,Change From Baseline in Hemoglobin A1c (HBA1c) at Week 24 With Last Observation Carried Forward,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 With Last Observation Carried Forward.,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
12910,NCT05294458,"Relative bioavailability of a high concentration cotadutide SC formulation in comparison to low concentration formulation, in the fasted state",Evaluate immunogenicity for cotadutide administered as low and high concentration SC formulations and an IV formulation,2022-03-28,COMPLETED,INTERVENTIONAL,['PHASE1'],Temperature needed at the injection site to homogenize at the point of injection
12911,NCT05609175,Area under the receiver operator characteristics curve (AUROC) in detecting nocturnal level 1 hypoglycemia based on motion data obtained by radar signals,"AUROC in classifying motion patterns according to thermal camera measurements based on motion data, physiological data, and Artificial Intelligence",2023-02-14,RECRUITING,OBSERVATIONAL,['NA'],
12912,NCT02387164,Type 1 Diabetes Status Overall,Change From Baseline in GADA Month 24,2015-03-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
12913,NCT00460941,Percentage of patients withdrawn because of gastrointestinal effects,"Mean changes in 24h blood glucose Area Under the Curve (AUC), Fasting Plasma Glucose (FPG), fructosamine, Hemoglobin A1c (HbA1c), body weight, Adverse Events (AEs), laboratory parameters.",2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
12914,NCT01323114,Hemoglobin A1C,,2011-04,UNKNOWN,INTERVENTIONAL,['NA'],
12915,NCT00763022,Change in Baseline in Glycosylated hemoglobin.,Urinary albumin/creatinine ratio.,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
12916,NCT03786718,User Experience - Qualitative,Change in Patient Activation,2018-12-27,COMPLETED,INTERVENTIONAL,['NA'],
12917,NCT00691249,Post-Prandial metabolism,Satiety,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
12918,NCT04174508,Average annual number of new cases of diabetes according to World Health Organization (WHO) criteria,,2020-03-24,RECRUITING,OBSERVATIONAL,['NA'],
12919,NCT02622282,Change in Physical Activity,Change in Quality of Life,2016-05,COMPLETED,INTERVENTIONAL,['NA'],
12920,NCT02151461,Change From Baseline to Day 28 in Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr,Change From Baseline to Day 28 in Fasting Plasma Insulin Concentration,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
12921,NCT04871438,HbA1c,Glucose Monitoring Satisfaction Score (GMSS),2021-11-10,RECRUITING,INTERVENTIONAL,['NA'],Exercise duration
12922,NCT00711503,Δ 2-h AUC C-peptide response,"Incremental and/or peak C-peptide response, Time to peak C-peptide, insulin requirement per kg body weight per day,frequency of insulin free state with maintenance of HbA1c <7.5%, HbA1c, Means of fasting glucose values, circulating IL-6 and CRP",2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
12923,NCT00789282,A higher proportion of patients with type 2 diabetes enrolled in the 'enhanced care' arm compared with the patients enrolled 'usual' care' arm will achieve an absolute reduction in their HbaA1c of 1.0% or greater during the study period.,A higher proportion of patients with type 2 diabetes in the 'enhanced care' arm compared with the patients enrolled in 'usual care' arm will achieve a 10% or greater reduction in HbA1c values during the study period.,2008-02,TERMINATED,INTERVENTIONAL,['NA'],
12924,NCT03457818,Change in Cortical Porosity (Ct.Po) (%) by High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Imaging From Baseline to 6 and 12 Months.,"Change in Dual-energy X-ray Absorptiometry (DXA) (gm/cm2) at Lumbar Spine, Femoral Neck, Total Hip and Radius From Baseline to 6 and 12 Months.",2018-11-07,TERMINATED,INTERVENTIONAL,['PHASE2'],Change in Skin Autofluorescence (SAF) (Unitless) From Baseline to 6 and 12 Months.
12925,NCT00948493,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],
12926,NCT05352230,Compliance,Time in Range (TIR) of 70 to 180 mg/dL,2023-04-15,RECRUITING,INTERVENTIONAL,['PHASE1'],
12927,NCT03847753,Risk of Cancers,,2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],
12928,NCT03739099,Percent of time spent in the 70-180 mg/dl glucose range assessed on daily CGM data,Score of the Artificial Pancreas Acceptance Questionnaire,2018-11-05,UNKNOWN,INTERVENTIONAL,['NA'],
12929,NCT04921306,insulin-stimulated fluorodeoxyglucose (18F-FDG) uptake in quadriceps muscle.,insulin-stimulated 18F-FDG uptake in BAT,2021-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],skeletal muscle GLUT4 translocation
12930,NCT05598203,Change in diabetic retinopathy and baseline diabetic kidney disease at 12 months,Change in baseline blood pressure at 12 months,2022-09-06,RECRUITING,INTERVENTIONAL,['NA'],Change in baseline adherence to recommendations at 12 months
12931,NCT00614120,Change in Glycosylated Haemoglobin A1c (HbA1c),Hypoglycaemic Episodes,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
12932,NCT00895986,Improved frequency of recommended self-care behaviors (Self-Care Inventory-R),"Major mediating/moderating variables include Problem Areas in Diabetes, Brief Symptom Inventory, Coping Styles, and Confidence in Diabetes",2008-12,COMPLETED,INTERVENTIONAL,['NA'],
12933,NCT00286442,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Body Weight (Week 26).,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
12934,NCT00106561,percent reduction in 24 hour urine protein excretion,,2002-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
12935,NCT01539811,Wound Healing,,2012-02,TERMINATED,INTERVENTIONAL,['NA'],
12936,NCT02731859,Weight reduction,Reduction of daily caloric intake,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],
12937,NCT03912766,change of serum sodium after surgery,,2016-02-01,COMPLETED,OBSERVATIONAL,['NA'],
12938,NCT04129528,Stimulated C-peptide AUC by mixed meal tolerance test (MMTT).,Stimulated C-peptide AUC by MMTT.,2019-11-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
12939,NCT00799448,HbA1c,Adverse events,2003-09-16,TERMINATED,INTERVENTIONAL,['PHASE4'],
12940,NCT00782847,deterioration of kidney function in diabetic nephropathy,HbA1c,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
12941,NCT03659799,Decrease in plasma glucose levels during exercise,Total amount of carbohydrates needed to treat hypoglycemic events,2019-04-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
12942,NCT03243383,Incidence of initial hospital readmission,Change in A1c level,2017-09-07,COMPLETED,INTERVENTIONAL,['NA'],
12943,NCT03372018,Body Weight,Beck Depression Inventory,2018-08-07,COMPLETED,INTERVENTIONAL,['NA'],
12944,NCT01717937,Measurement of to be determined physical characteristics of retinovascular structures seen on phase variance optical coherence tomography (PV-OCT) and fluorescein angiography(FA).,Changes over time in the to be determined measured physical characteristics of retinovascular structures seen on PV-OCT and FA.,2013-02,TERMINATED,OBSERVATIONAL,['NA'],
12945,NCT05083559,Percent of Time With Sensed Glucose Between 70-180 mg/dl,Mean Amount of Insulin Delivered Per Day (in Units),2021-12-08,COMPLETED,INTERVENTIONAL,['NA'],
12946,NCT05579314,"Mean change from baseline in clinical laboratory values, vital signs, clinical findings from physical exam and ECG abnormalities",,2022-09-26,RECRUITING,INTERVENTIONAL,['PHASE1'],
12947,NCT03650127,Coronary heart disease/Type 2 diabetes/Venous thromboembolism diagnosis,,2018-02-02,UNKNOWN,OBSERVATIONAL,['NA'],
12948,NCT00976729,"Safety and tolerability of NOX-E36 by means of adverse events, vital signs, laboratory parameters, 12-lead ECG and immunogenicity assessment",Pharmacodynamic profile,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
12949,NCT04988581,Phase 2,The secondary outcomes,2021-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
12950,NCT02036372,Median glucose,Glucose,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
12951,NCT00813228,Changes in plasma TGF-Beta 1 levels.,"Changes in plasma or stimulated PBMC cytokines levels, changes in stimulated PBMC proliferation, changes in peripheral blood gene expression and changes in immune phenotyping.",2009-01-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
12952,NCT06261944,Dichotomised diabetes risk status,Sensitivity and specificity,2024-03-13,RECRUITING,INTERVENTIONAL,['NA'],
12953,NCT03124043,Change in HbA1c,Change in Treatment Satisfaction,2015-04,COMPLETED,INTERVENTIONAL,['NA'],
12954,NCT03717688,GLP-1,Glucagon,2018-05-17,COMPLETED,INTERVENTIONAL,['PHASE4'],GIP
12955,NCT02034266,Change in corneal nerve fibre length,R-R interval,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Serum fatty acid profile
12956,NCT01400971,Number of Participants With Insulin-Related Treatment Change From Initial Insulin Therapy,Number of Participants Who Achieved Their Personalized HbA1c Target by the End of the Study,2011-07,COMPLETED,OBSERVATIONAL,['NA'],
12957,NCT00446992,LDL,,2006-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
12958,NCT04579341,glycemic control,,2018-01-21,UNKNOWN,INTERVENTIONAL,['NA'],
12959,NCT02004327,Maximum Concentration of DW1029M in plasma,Apparent volume of distribution of DW1029M in Plasma,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
12960,NCT02597400,The primary pharmacokinetics parameters of Cmax To assess the potential pharmacokinetic interaction between HMS5552 and metformin in subjects with T2DM,"Pharmacodynamic responses (serum levels) of glucose, insulin and C-peptide will be evaluated.",2015-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
12961,NCT04656106,Change in HbA1c (Glycosylated Hemoglobin),Change in body weight,2021-04-27,COMPLETED,OBSERVATIONAL,['NA'],
12962,NCT05717127,Pancreatic beta-cell function,Fasting glucose,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],Satiety
12963,NCT04789798,BMI,The number of patients who added insulin to their oral antidiabetic medication or switched to oral antidiabetic medication by discontinuing insulin,2013-10-21,COMPLETED,INTERVENTIONAL,['NA'],Urine microalbuminurea
12964,NCT05483803,Sub-study 2: Changes on caregiver's positive mood,Behavioral outcome: Usability,2022-10-01,COMPLETED,INTERVENTIONAL,['NA'],
12965,NCT02505451,Regional longitudinal strain,,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
12966,NCT06325917,glycemic control,diabetes self management behaviors,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12967,NCT05605821,Evaluation of the association between diabetic disease control and the degree of hepatic fibrosis,Percentage of patients at risk of severe fibrosis in a population of type 2 diabetics followed in a tertiary diabetes service.,2024-01-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
12968,NCT05280184,Change in daily insulin Bolus score,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],
12969,NCT00869362,Hemoglobin A1c,Average Intervention Effect Over 12 Months After Hospital Discharge,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
12970,NCT00831194,"Self reported stress, weight loss, and salivary alpha amylase.","Positive correlation between levels of salivary alpha amylase (sAA) and weight loss, BMI and levels of sAA, levels of sAA and maladaptive coping.",2009-03,COMPLETED,INTERVENTIONAL,['NA'],
12971,NCT04707508,Serum glycosylated hemoglobin A1c,Blood pressure,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
12972,NCT05208164,Sleep Impairment,Inflammatory Markers,2021-04-01,RECRUITING,INTERVENTIONAL,['NA'],
12973,NCT04943614,Functional reach test,,2020-12-01,COMPLETED,INTERVENTIONAL,['NA'],
12974,NCT00848822,This study could help find if there are particular times of day or times during sleep that change glucose the most.,This study may help make recommendations about the best time to test glucose values and better help children with Type 1 Diabetes Mellitus control their glucose levels.,2009-02,COMPLETED,OBSERVATIONAL,['NA'],
12975,NCT01554358,cardimetablic risk,approximately 40 SNPs,2009-08,UNKNOWN,INTERVENTIONAL,['NA'],
12976,NCT02789319,Analytical accuracy and clinical performance criteria,Device issues,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4'],Results
12977,NCT03377127,Hemoglobin A1c at 12 Months,No-show,2018-02-19,COMPLETED,INTERVENTIONAL,['NA'],
12978,NCT03660345,BCVA,,2018-09-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
12979,NCT02284009,Mean Change From Baseline in Time Normalized Stimulated (From Mixed Meal Tolerance Test [MMTT]) 2-hour Plasma C-peptide Area Under the Curve (AUC) at Week 52,Population Estimates of PK Parameters: First-order Absorption Rate Constant [Ka],2014-10-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
12980,NCT03135327,Tear film thickness,Conjunctival blood flow velocity by functional slit-lamp (FSLB),2007-01-01,RECRUITING,INTERVENTIONAL,['NA'],
12981,NCT03973515,Area under the plasma concentration versus time curve (AUC),The change for plasma insulin,2019-08-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
12982,NCT01303302,Comparison of the differences in HbA1c levels,Improvement in weigth and metabolic parameters,2008-04,COMPLETED,INTERVENTIONAL,['NA'],
12983,NCT01616784,The change in HbA1c after 2 years in those participants whose baseline HbA1c was at or above 7.5% (58mmol/mol).,Quality of adjusted life years,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
12984,NCT02366377,The number of volunteers with adverse events as a measure of safety and tolerability,Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],
12985,NCT02021695,DNA methylation and gene expression in blood monocytes and lymphocytes,,2013-09,COMPLETED,OBSERVATIONAL,['NA'],
12986,NCT02039258,Plasma concentration of metformin following the single dose of CANA/MET XR FDC after fed and fasted conditions,Percentage of participants with adverse events as a measure of safety and tolerability,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
12987,NCT05703880,Descriptive summary of comedications of patients who initiate finerenone and have CKD and T2D in the US.,Incidence rate of proliferative diabetic retinopathy in patients who initiate finerenone with prior non-proliferative diabetic retinopathy,2023-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
12988,NCT05680155,Change from baseline in HbA1c,Pharmacokinetics: plasma trough level of XW003,2022-12-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
12989,NCT02845219,Area under the levonorgestrel plasma concentration-time curve during a dosing interval (0-24 hours) at steady state,Maximum observed levonorgestrel plasma concentration during a dosing interval 0-24 hours) at steady state,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
12990,NCT00243984,"BMI on days 1, 84, 168, and 175.","C reactive protein on days 1, 84, and 168.",2005-03,SUSPENDED,INTERVENTIONAL,['PHASE3'],
12991,NCT00232375,The primary endpoint was insulin-dependency (IDDM: integrated C-peptide values [sigma C-peptide] <4 ng/ml).,,1996-01,COMPLETED,INTERVENTIONAL,['NA'],
12992,NCT04092738,Change in Waist circumference,Change in subjective occupational physical activity,2019-03-04,UNKNOWN,INTERVENTIONAL,['NA'],"Sociodemographic variables (age, gender, socio economic status)"
12993,NCT02372630,JNK-1 Protein in MNC,Insulin Sensitivity by Hyperinsulinemic-euglycemic Clamp,2014-05-23,COMPLETED,INTERVENTIONAL,['PHASE4'],
12994,NCT02008682,Change From Baseline in Glycosylated Haemoglobin (HbA1c),Number of Confirmed Hypoglycaemic Episodes,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
12995,NCT03049839,Reduction of body weight average at year-end structured intervention compared with the baseline.,Reduced of waist circumference average at year-end structured intervention program compared with baseline.,2017-08-01,UNKNOWN,INTERVENTIONAL,['NA'],
12996,NCT00157638,"Symptom improvement (constipation, pain)",Health services utilization,2004-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
12997,NCT04767750,"Measurement of the gene expression levels of LncRNA H19 & IGF-1R mRNA, normalized to the housekeeping gene GAPDH expression level, in HCC and T2DM in comparison with healthy controls using Real-Time Quantitative PCR (by the 2^-ΔΔCT method).",,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],
12998,NCT05022316,diabetes control,completion of medication adherence documentation,2022-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
12999,NCT02443415,Acute change in brain morphology,Change in neurocognitive assessment,2015-02,COMPLETED,OBSERVATIONAL,['NA'],
13000,NCT00460304,The mean ICR from Vist 3a-e and 4a-e will be compared. Percentage reduction of ICR will be calculated. From these the mean ICR will be calculated.,The mean post-meal glucose from the four hour period after beginning a meal will be averaged for each bolus wave form. Then the three wave form mean glucose results will be compared.,2007-09,COMPLETED,INTERVENTIONAL,['NA'],
13001,NCT03839667,change in HbA1C level (%),cardiovascular risk,2019-01-07,COMPLETED,INTERVENTIONAL,['NA'],
13002,NCT02929953,prematurity prevalence among T1D patients,Medications exposure in premature who developed T1DM compared with prematures who did not develop diabetes,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
13003,NCT05301855,The fifth part of the questionnaire is the Beliefs about medicine which is assessed using the Arabic version of the Beliefs about Medicines Questionnaire Specific (BMQ-Specific).,,2022-03,RECRUITING,OBSERVATIONAL,['NA'],
13004,NCT02540642,To compare the change in HbA1c levels (%) with vitamin B12 supplementation in poorly controlled type 2 diabetic patients,To compare the change in serum homocysteine level (micromol/L) with vitamin B12 supplementation in poorly controlled type 2 diabetic patients,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
13005,NCT00952198,Characterize the pharmacokinetics (PK) of the study drug and metabolites in terms of plasma concentrations.,Characterize the pharmacodynamic (PD) activity of the study drug on biomarkers.,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
13006,NCT04520971,time in range,number with composite neonatal outcome,2021-01-15,COMPLETED,INTERVENTIONAL,['NA'],
13007,NCT05477134,The difference in arginine availability,The difference in insulin sensitivity and the effect of intravenous arginine bolus on insulin sensitivity,2023-02-06,RECRUITING,INTERVENTIONAL,['NA'],
13008,NCT00552409,Change in Urine Albumin Excretion,,2007-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
13009,NCT00471549,Relative reduction in circulating osteoprotegerin levels,Relative reduction in adhesion molecules (ICAM and VCAM),1991-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
13010,NCT00854347,Prevalence of diabetes and prediabetes.,Evaluate insulin needs capacity to predict subsequent diagnosis of diabetes and prediabetes,2005-11,COMPLETED,OBSERVATIONAL,['NA'],
13011,NCT04993326,Type 2 Glycemic Control - HbA1c of 7% or less,"Understand of COVID-19 Risks, Protection and Prevention",2022-01-10,WITHDRAWN,INTERVENTIONAL,['NA'],
13012,NCT02146157,Change from Baseline in fasting blood glucose,Change from Baseline in waist-to-hip ratio,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
13013,NCT05339841,Long-term CV clinical outcome at 7 years follow-up,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - history of vaccination (questionnaire),2022-06-10,RECRUITING,INTERVENTIONAL,['NA'],Ancillary study of UO-14 (IRCCS San Raffaele Roma): mean corpuscular hemoglobin (MCH) in the CV-PREVITAL Exercise sub-study cohort
13014,NCT05179798,Percentage of postprandial capillary glucose values above target (>7.0 mmol/L),Patient satisfaction evaluated through a questionnaire,2022-01-12,RECRUITING,INTERVENTIONAL,['NA'],
13015,NCT03596450,Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0 Percentage (%) (53 Millimoles Per Mole [mmol/Mol]) at Year 1 (Yes/No),Percentage of Medication Possession Ratio (MPR) for Study Drug Medication Adherence For The Two Years of The Study,2018-07-13,COMPLETED,INTERVENTIONAL,['PHASE4'],
13016,NCT00708981,Delay in development in end-stage renal failure in subjects with Advanced Diabetic Nephropathy (CKD stages 3 and 4),,2007-05,COMPLETED,INTERVENTIONAL,['NA'],
13017,NCT00099918,Change from baseline in HbA1c at 24 weeks,Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs. low baseline HbA1c,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
13018,NCT00392678,Change in HbA1c Baseline to End of Trial in TINSAL-T2D Stage 1,"Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index",2006-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
13019,NCT02284230,Plasma glucose during oral glucose tolerance test at week 26,Plasma liraglutide,2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
13020,NCT03710811,Circulating immunity cell profiles,skeletal muscle parameter,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],fasting blood glucose
13021,NCT03516474,Lower rates of DFU recurrence in patients monitored using mHealth,,2018-05-15,UNKNOWN,OBSERVATIONAL,['NA'],
13022,NCT04687215,Vascular improvement on lower extremities with the Doppler Flowmetry,Vascular improvement on lower extremities by performing the flow mediated arterial dilation test,2022-01-27,RECRUITING,OBSERVATIONAL,['NA'],
13023,NCT03889522,Examine the relationship between artificial sweeteners and hemoglobin A1c,,2019-05-01,COMPLETED,OBSERVATIONAL,['NA'],
13024,NCT04205617,Change in Hemoglobin A1c,Change in diastolic blood pressure,2019-12-14,COMPLETED,INTERVENTIONAL,['NA'],
13025,NCT00278057,,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
13026,NCT04918004,Hba1c mmol/mol,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],
13027,NCT00464555,Proportion of participants with insulin independence,Quality of life measures,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
13028,NCT01932671,Combined endpoint of cardiovascular events,All cause mortality,2012-08,UNKNOWN,OBSERVATIONAL,['NA'],
13029,NCT04416737,Glucagon response to induced hypoglycemia,Glucose Values,2021-11-01,COMPLETED,INTERVENTIONAL,['NA'],
13030,NCT01109927,Glucagon stimulated C-peptide,,1995-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
13031,NCT01375686,"Validation of SCOUT DS algorithm, ROC performance equivalent to FPG, A1c for detection abnormal glucose tolerance.",,2011-06,COMPLETED,OBSERVATIONAL,['NA'],
13032,NCT02621736,Change of copeptin at baseline and after 28 days during routine desmopressin therapy,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],
13033,NCT01459120,Absolute number of clients newly tested HIV-positive who enrolled into HIV/AIDS care,Absolute number of clients with a positive Tuberculosis-screening who return their sputum-bottles and who have at least one AFB-positive smear.,2011-10,COMPLETED,INTERVENTIONAL,['NA'],
13034,NCT02846831,Percentage of time of glucose levels spent between 3.9 and 10 mmol/L.,Number of patients calling for technical issues related to the closed-loop system,2019-01-24,COMPLETED,INTERVENTIONAL,['PHASE2'],
13035,NCT05355038,effect of lifestyle modification among GDM on pregnancy outcome,,2020-11-11,COMPLETED,INTERVENTIONAL,['NA'],
13036,NCT05787873,Cmax of SIPS-2209-1,Vd/F of SIPS-2209-1,2022-08-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
13037,NCT00876928,Percent of Subjects Who Develop Diabetes,Disposition Index,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
13038,NCT00136916,Summary of ≥ 20 % Decliners in DLco,Insulin Antibodies,2002-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
13039,NCT00138619,Change from baseline in HbA1c at 104 weeks,Change in HOMA B between 24 weeks and 104 weeks,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
13040,NCT01620463,Adverse events,24-hour glucagon profile in plasma,2002-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
13041,NCT00978263,Change From Baseline in Glycosylated Hemoglobin at month 6,Change From Baseline in Body Weight (month 12),2009-02,COMPLETED,INTERVENTIONAL,['NA'],
13042,NCT00360334,Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg),Severe Hypoglycemic Rate Per 30 Days,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
13043,NCT06120322,"To identify the factors contributing to chronic inflammation within the intestine and in peripheral organs, in particular focusing on biopsies markers","Taking advantage of the measurements collected in Outcome 1, the investigators will use a machine learning-based multi-omics approach to easily recognize patient differences, stratification and characterization",2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
13044,NCT03345667,Assessment of color vision in diabetic patients before and after the use of anti-vegf in the treatment of diabetic macular edema,Frame between the injections,2017-08-01,COMPLETED,OBSERVATIONAL,['NA'],
13045,NCT05172622,The evaluation of the number of adverse events and the number and percentage of subjects,,2020-11-24,UNKNOWN,INTERVENTIONAL,['PHASE1'],
13046,NCT05974020,Plantar Pressure Distribution,Foot Posture,2023-08-04,COMPLETED,INTERVENTIONAL,['NA'],
13047,NCT06103799,Peri-implant bone resorption,Patient satisfaction,2023-01-01,COMPLETED,INTERVENTIONAL,['NA'],
13048,NCT05120544,Change in HbA1c,Change in hypertension knowledge,2022-04-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
13049,NCT04838145,Insulin secretion,Presence of enterovirus,2018-08-30,COMPLETED,INTERVENTIONAL,['PHASE2'],
13050,NCT03058926,"Protocol and Regulatory Compliance for Consortium Studies for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",,2017-01-19,UNKNOWN,OBSERVATIONAL,['NA'],
13051,NCT02074423,"Blood glucose incremental Area Under the Curve between 0 and 120 minutes after consumption of a standard meal, compared between MealShape and the placebo",Insulin incremental Area under the Curve between 0 and 60 minutes compared between MealShape and Placebo after consumption of a standard meal,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
13052,NCT01743781,The acceptance rate of comprehensive eye examination in both groups,knowledges of eye disease and attitude of eye examination,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
13053,NCT02580266,Cellular phenotype,,2015-09,WITHDRAWN,OBSERVATIONAL,['NA'],
13054,NCT03423862,Predicting the honeymoon period,Establishing the relationship between baseline inflammation and other measures,2017-10-01,COMPLETED,OBSERVATIONAL,['NA'],
13055,NCT02872974,Carotid intima-media thickness,Cardiovascular risk factors,2016-08,COMPLETED,OBSERVATIONAL,['NA'],
13056,NCT02173834,Difference in sympathetic stimulation to BAT between lean and obese individuals,Difference in correlation between sympathetic stimulation of BAT as assessed with 123I-MIBG SPECT scans and metabolic BAT activity as assessed with 18F-Fluorodeoxyglucose(FDG)- positron emission tomography(PET)-CT scan in lean and obese individuals,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
13057,NCT01557907,Insulin levels,Number of participants with adverse events,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
13058,NCT01488136,Adrenaline response(pmol/L) at 2.5mmol/L of glucose,"Glucose Thresholds (calculated when counter-regulatory hormone release is greater than 2SD of hormone level at euglycaemia 4.0mmol/L blood sugar) of each of the counter-regulatory hormones (adrenaline, noradrenalin, glucagon)",2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Symptom scores and Cognitive function scores at 2.5mmol/L
13059,NCT02024542,Tensile Strength of White Adipose Tissue,,2011-02,RECRUITING,OBSERVATIONAL,['NA'],
13060,NCT03918148,Urinary albumin to creatinine ratio excretion,estimated Glomerular filtration rate (eGFR),2018-01-15,RECRUITING,OBSERVATIONAL,['NA'],Lipid profile
13061,NCT03091712,Change in HbA1c,Proportion of accepted MIDS recommended insulin degludec doses,2017-05-05,COMPLETED,INTERVENTIONAL,['NA'],
13062,NCT01497938,The Event Area Under the Curve (AUC) Was Used to Demonstrate the Reduction of Nocturnal Hypoglycemia With the Low Glucose Suspend (LGS) Feature (LGS ON),,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
13063,NCT00724087,Total energy expenditure,Glycerol turnover and free fatty acid concentration,2008-07,COMPLETED,INTERVENTIONAL,['NA'],
13064,NCT02011529,Hemoglobin A1c,LDL cholesterol,2013-11,COMPLETED,INTERVENTIONAL,['NA'],Brief Psychiatric Rating Scale (BPRS)
13065,NCT00328627,Change From Baseline to Week 26 in HbA1c,Change From Baseline to Week 26 in Mean HDL Particle Size,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
13066,NCT04866212,academic achievement,,2020-04-30,UNKNOWN,OBSERVATIONAL,['NA'],
13067,NCT02236364,Photographic Images of the eye,,2014-08,TERMINATED,INTERVENTIONAL,['NA'],
13068,NCT00660374,HbA1c,HbA1c,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
13069,NCT06025721,Treatment Engagement Measured by Sessions Attended,Cardiovascular health (AHA Life's Essential 8),2024-01-05,RECRUITING,INTERVENTIONAL,['NA'],
13070,NCT02004561,Change in Glucose Tolerance,Changes in nutritional health,2012-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Fat distribution
13071,NCT02290860,abnormal glucose tolerance,,2014-12,COMPLETED,INTERVENTIONAL,['NA'],
13072,NCT00516620,Body Weight,"Biomarkers of diet and obesity-related chronic diseases (serum lipids, homocysteine and C-reactive protein) and genotypes",2005-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
13073,NCT04497792,HbA1C level,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
13074,NCT02736084,Intervention Acceptability,Changes in MOS SAS Scores,2013-08,COMPLETED,INTERVENTIONAL,['NA'],
13075,NCT03536377,change in Hba1C,change in blood pressure medication,2019-02-11,UNKNOWN,INTERVENTIONAL,['NA'],
13076,NCT00737152,To determine cardiovascular side effects such as coronary artery disease (CAD) and congestive heart failure (CHF) in patients treated with RAS 130 along with diet and exercise.,To determine the effect of RAS 130 on reduction of blood glucose level with or without diet and exercise,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],
13077,NCT05631561,The changes of Hba1c from baseline at 6 months post procedure,Quality of life assessment (EQ-5D-5L) at pre-procedure and 6 months post procedure,2022-12-27,RECRUITING,INTERVENTIONAL,['NA'],
13078,NCT03096002,independent bouts of physical activity,independent bouts of physical activity,2017-06-12,UNKNOWN,OBSERVATIONAL,['NA'],dietary adherence
13079,NCT04560296,Change in Self-care ability of Chronic disease,HbA1c,2020-09-15,UNKNOWN,INTERVENTIONAL,['NA'],
13080,NCT00575783,,,2005-08,COMPLETED,OBSERVATIONAL,['NA'],
13081,NCT03378895,Individualized Prevention Program participation rate,Variation of the risk score in at least one of the three behavioral domains; The risk score will be calculated from the results reported on a self-administered questionnaire,2017-12-01,COMPLETED,INTERVENTIONAL,['NA'],
13082,NCT03503942,Diabetes incidence,Metformin adherence,2017-12-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
13083,NCT04283994,EHR documentation of Goals of Care discussions,Goal concordance,2021-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Key Implementation Factors
13084,NCT00469586,HbA1c change from baseline,Hypoglycaemia,2007-04-26,TERMINATED,INTERVENTIONAL,['PHASE3'],
13085,NCT04575181,Change in flow mediated dilation,"Number of clinically significant hypoglycaemic episodes s (level 2) ((below 3.0 mmol/L (54 mg/dL), confirmed by BG meter)",2020-10-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
13086,NCT00331370,"Primary outcome would be abnormal retinal geometry defined as the composite outcome of a) abnormal arteriolar length: diameter, b) narrowed branching angles, or c) disturbed junction exponents.",,2006-05,UNKNOWN,INTERVENTIONAL,['NA'],
13087,NCT02248857,Prescription Understanding,Medication Adherence: Pharmacy Records,2014-12,COMPLETED,INTERVENTIONAL,['NA'],Changes in Low-density Lipoprotein Cholesterol (LDL)
13088,NCT01722682,Insulin secretion under stimulation,Islet function,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
13089,NCT00638131,change from baseline to week 16 in renal inflammation. The following urinary inflammatory/oxidative stress parameters will be measured: - TNF,change from baseline to week 16 in renal functioning. The following renal function parameter will be measured: - 24h UAE;,2009-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
13090,NCT01041365,Insulin Sensitivity,Vascular Function,2009-12,COMPLETED,OBSERVATIONAL,['NA'],
13091,NCT00065676,Does quercetin effect glucose absorption,,2010-04-30,COMPLETED,INTERVENTIONAL,['PHASE2'],
13092,NCT02459834,Plasma glucose iAUC,Mean plasma glucose and insulin responses,2015-11,COMPLETED,INTERVENTIONAL,['NA'],
13093,NCT03209089,clinical characteristics of T2DM patients managed by GPs,,2017-08-07,COMPLETED,OBSERVATIONAL,['NA'],
13094,NCT05168488,Capillary glucose (change during exercise),percent time in hypoglycemia,2021-11-16,COMPLETED,INTERVENTIONAL,['NA'],
13095,NCT02244385,Blood Pressure,Uteroplacental assessment,2011-07,COMPLETED,OBSERVATIONAL,['NA'],Urinary podocyte markers
13096,NCT01901952,Hemoglobin A1c,Medications,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
13097,NCT00333554,"At least a 20% reduction in the level of the major inflammatory cytokine, IL1-beta, achieved in the plasma of the treatment group",95% of families will continue to attend follow-up visits,2006-06,COMPLETED,INTERVENTIONAL,['NA'],
13098,NCT00688363,Haemoglobin A1c after one year,the number of serious hypoglycaemic episodes (hypoglycaemic episodes when the patient needs help from other people),2003-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
13099,NCT04082351,HbA1c,,2016-07-03,COMPLETED,INTERVENTIONAL,['NA'],
13100,NCT03225209,Change in Glycemic control,Change in Physical activity,2018-01-31,COMPLETED,INTERVENTIONAL,['PHASE2'],
13101,NCT01129297,Study the influence of phenotypic characteristics on gene expression of tissues involved in glucose metabolism,Genotype-Phenotype correlation,2006-06-13,RECRUITING,OBSERVATIONAL,['NA'],
13102,NCT02288351,Elevated Glut-1 gene and protein expression levels,Glut-1 level change in fasting glucose,2014-11,WITHDRAWN,INTERVENTIONAL,['NA'],
13103,NCT03397225,Hemoglobin A1c,,2013-11-15,COMPLETED,INTERVENTIONAL,['NA'],
13104,NCT03768245,Mean Change From Baseline In Power At 12 Weeks,,2016-07-01,COMPLETED,INTERVENTIONAL,['NA'],
13105,NCT02474147,Functional brain imaging of reward circuitry,Serum concentrations of oxidative stress markers,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
13106,NCT05007990,Natural History,,2022-09-08,RECRUITING,OBSERVATIONAL,['NA'],
13107,NCT01206725,Early diastolic tissue velocity (e'),Early diastolic tissue velocity (e'),2010-09,COMPLETED,INTERVENTIONAL,['NA'],
13108,NCT02317796,Change in PPG AUC0-3h in a MMTT between Days 1 and 29.,Differences between placebo and MLR-1023 dose groups in PPG AUC0-3h Days 1 and 29.,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
13109,NCT00971139,Impacts of the OPPC service on organizational processes/organizational change such as care processes,"Characteristics of high/low volume users, patient-caregiver communication and use patterns",2009-11,COMPLETED,INTERVENTIONAL,['NA'],
13110,NCT02302716,Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c),Percentage of Participants With Hypoglycemic Events,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
13111,NCT04216485,Gestational weight gain,Incidence of Gestational Diabetes Mellitus,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
13112,NCT02172716,Change from baseline in the expression on mDCs,"periodontal probing depth, periodontal attachment level, bleeding on probing, visible plaque and gingival bleeding.",2014-05,COMPLETED,INTERVENTIONAL,['NA'],
13113,NCT02130401,Measurement of glycosylated hemoglobin (A1c),Feasibility and acceptability of the device as an intervention for the diabetes population,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
13114,NCT01455857,Change in HbA1c,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
13115,NCT05951660,Changes from baseline to follow up in the total score of Changes in Sexual Function Questionnaire-14 (CSFQ-14),Changes from baseline to follow up in shared decision making,2023-08-24,RECRUITING,INTERVENTIONAL,['NA'],
13116,NCT04152811,Change in Hemoglobin A1c over 4.5 months,Change in Health Related Quality of Life over 4.5 months using SF-12 Survey,2019-07-05,COMPLETED,INTERVENTIONAL,['NA'],
13117,NCT04116203,Plasma Triglycerides and apoB-lipoprotein remnants in non-fasting and fasted state,"Plasma hormones, testosterone, SHBG, Estrogen",2016-06-30,SUSPENDED,INTERVENTIONAL,['PHASE1'],
13118,NCT03120299,Change in blood metabolomics profile of lipid species from baseline,Pharmacogenomics analysis,2017-05-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
13119,NCT05570357,HbA1C,Lipid profile,2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
13120,NCT03582878,Pancreas graft survival,Kidney graft survival,2004-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
13121,NCT02728453,change in left ventricular mass,change in body fat mass,2016-04-27,TERMINATED,INTERVENTIONAL,['PHASE4'],number of participants with lower urinary tract infections or genital fungal infections
13122,NCT04635670,Change in albuminuria based on urinary albumin-creatinine ratio (UACR),Change in autonomous neuropathy evaluated by VagusTM,2020-06-29,COMPLETED,INTERVENTIONAL,['NA'],Change in Gut microbiome characterization assessed by 16S RNA sequencing
13123,NCT02949687,"glycated hemoglobin(HbA1c) level of 6.0% or less, without the use of diabetes medications",,2016-09-20,WITHDRAWN,INTERVENTIONAL,['NA'],
13124,NCT00172757,,,2002-01,UNKNOWN,OBSERVATIONAL,['NA'],
13125,NCT00467168,Lipids including triglyceride and cholesterol in four subfractions of ppTRLs.,Lipids lipoproteins in the postprandial plasma,1998-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
13126,NCT03248466,hospital stay,Transcutaneous oxygen partial pressure,2017-08-30,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
13127,NCT02179385,Clinical composite,Change in Self Efficacy Score,2014-06,UNKNOWN,INTERVENTIONAL,['NA'],Change in Quality of life score
13128,NCT05663736,HbA1c,CK-MB,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
13129,NCT03800680,Change in HbA1c levels at Month 12,Incremental cost-effectiveness ratios based on QALY at Month 12,2019-10-19,COMPLETED,INTERVENTIONAL,['NA'],
13130,NCT05108350,Pharmacokinetics parameters of SHR3824 and Metformin in the fasted and fed state: AUC0-inf (if applicable),The incidence and severity of adverse events/serious adverse events,2021-11-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],
13131,NCT01106573,,,2010-06,UNKNOWN,OBSERVATIONAL,['NA'],
13132,NCT04445714,To assess the safety of fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) patients,To assess the efficacy of fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) patients,2021-04-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
13133,NCT00861445,The primary objective of this trial is to evaluate the efficacy of SPM 927 in reducing pain in subjects with diabetic distal sensory polyneuropathy,Examine the pharmacokinetics of SPM927 (assessment at all site visits during entire trial participation),2001-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
13134,NCT00715780,Incidence of major hypoglycaemic episodes,Percentage of patients reaching the target of HbA1c less than 6.5%,2008-06,COMPLETED,OBSERVATIONAL,['NA'],
13135,NCT02168348,Percentage of healed lesions,Number of malnourished patients according to HAS 2003 and 2007 criteria,2013-11-26,COMPLETED,OBSERVATIONAL,['NA'],Number of malnourished patients at 12 and 24 weeks
13136,NCT03152994,fasting blood glucose(FBG),Exercise capacity (composite outcome measure),2017-04-01,COMPLETED,OBSERVATIONAL,['NA'],Symptom Evaluation(composite outcome measure)
13137,NCT01843114,Total retinal blood flow,Retinal blood velocities,2015-01-12,COMPLETED,INTERVENTIONAL,['NA'],
13138,NCT00816218,Vascular Endothelial Function,Insulin Resistance,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
13139,NCT02015988,Percentage change from baseline in triglycerides (TG) at week 12,Percentage changes from baseline in uric acid at week 52,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Number of adverse events (AE) caused discontinuations of investigational products
13140,NCT01334606,Glycemic Control as Measured by Percent (%) Absolute Change in Fructosamine,,2011-03,TERMINATED,INTERVENTIONAL,['NA'],
13141,NCT00574665,Endothelial function and fibrinolytic balance,,2006-10,COMPLETED,INTERVENTIONAL,['NA'],
13142,NCT03050229,Reduction of nocturnal blood pressure measured by ABPM,The correlation between blood pressure and body weight,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
13143,NCT03057470,Reduction In Plasma Glucose (YSI),"Investigate Glycemic Response of a 0%, 50%, 100% and 150% Bolus Insulin Correction of Post-exercise Hyperglycemia Compared to no Bolus Insulin Correction",2016-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13144,NCT01310556,Frequency of unknown glucose metabolism disorders in patients with coronary artery disease,Fasting and 120 minute glucose levels have relation with vessels' stenosis.,2009-06,COMPLETED,OBSERVATIONAL,['NA'],
13145,NCT01476501,Change in serum vitamin D from baseline to 3 and 6 months,Change in bone health from baseline to 3 and 6 months,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
13146,NCT03542084,Glycemic Control,A1c testing frequency,2018-09-04,COMPLETED,INTERVENTIONAL,['NA'],
13147,NCT01889628,Glycaemic response,,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
13148,NCT00668239,diffuse macular oedema,morphofunctional assessment of retina,2004-09,COMPLETED,INTERVENTIONAL,['NA'],
13149,NCT02221466,Peripheral arterial tonometry (PAT),Nitric oxide and cytokine expression,2014-02,COMPLETED,OBSERVATIONAL,['NA'],
13150,NCT01424319,The change from baseline to each post-baseline visit in log-transformed UACR (urinary albumin to creatinine ratio),The proportion of subjects who achieve various percent of reduction in UACR (Urinary Albumin to Creatinine Ratio) from baseline to final,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
13151,NCT05138432,Change in Hemoglobin A1c,Change in HDL cholesterol,2021-11-29,RECRUITING,INTERVENTIONAL,['NA'],
13152,NCT03877523,Change in macrophages activation after 30-days Cocarnit administration,,2018-10-03,COMPLETED,INTERVENTIONAL,['NA'],
13153,NCT02315235,Changes in pain for a week after the procedure,The evaluation of changes in the specific neuro-sensory system,2014-05,WITHDRAWN,INTERVENTIONAL,['NA'],The secondary effect of the procedure for the peripheral nerves and blood vessels
13154,NCT00005133,,,1988-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
13155,NCT06217614,Changes in subjective dry mouth score,Salivary Nitric oxide levels,2022-08-01,COMPLETED,INTERVENTIONAL,['NA'],
13156,NCT00755833,Change in HbA1c,Number of ADRs (adverse drug reaction),2008-09,COMPLETED,OBSERVATIONAL,['NA'],
13157,NCT04603937,Non-inferiority of KSI-301 to Aflibercept measured by changes in BCVA.,Safety and Tolerability of KSI-301 mg compared to aflibercept 2 mg measured by the number of ocular and systemic adverse events.,2020-09-30,TERMINATED,INTERVENTIONAL,['PHASE3'],
13158,NCT02606838,Number of Subjects With Numeric Meter Results When Users Obtain Fingerstick Capillary Blood Using the Styx Lancing Device ( 28 Gauge Lancets),Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements Regarding the Styx Lancing Device,2015-11,COMPLETED,INTERVENTIONAL,['NA'],
13159,NCT02140645,Binary EMR Characteristic: Pancreatitis,,2014-05,COMPLETED,OBSERVATIONAL,['NA'],
13160,NCT01065155,"Cardiovascular target organ damage (renal, cardiac and vascular) and new cardiovascular events",,2010-02,COMPLETED,OBSERVATIONAL,['NA'],
13161,NCT02384356,"Health Status using general health-related quality of life, perceived health, and PHQ8","Demographics, use of formal care and access, substance use, NCD diagnoses, self-care behavior, knowledge/perceptions, and anthropometric measures",2014-06,COMPLETED,OBSERVATIONAL,['NA'],
13162,NCT05003154,Concentration of glycosylated hemoglobin A1c,Proportion of patients with abnormal resulets of postnatal oral glucose tolerance test,2021-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
13163,NCT04278664,"HbA1c, maternal glycemic control",,2015-07,TERMINATED,OBSERVATIONAL,['NA'],
13164,NCT01213277,Primary endpoint is to see whether they are fast glycators,A secondary endpoint includes adverse events such as unplanned hospitalizations for any cause that last more than 24 hours,2010-10,SUSPENDED,INTERVENTIONAL,['NA'],
13165,NCT05574699,Change in the number of social needs identified during the visit,Change in the number of hospitalization events and emergency department (ED) visits between intervention and control arms,2023-04-30,RECRUITING,INTERVENTIONAL,['NA'],
13166,NCT01269047,"Post-prandial Blood Glucose Concentration in Both Pramlintide and Exenatide Treated Groups in Acute and Chronic Setting, Compared to Insulin Monotherapy in Type 1 Diabetes Mellitus.",Difference in HbA1C Between the Treatment and the Control Groups,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
13167,NCT01185743,gene expression profiling,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
13168,NCT06097689,Changes in spectral fingerprints measured by the Lab Demo 1.0 at fluctuations of venous blood glucose levels,Oxygen saturation,2023-11-24,RECRUITING,INTERVENTIONAL,['NA'],
13169,NCT03063138,Wound volume,,2015-08-01,COMPLETED,OBSERVATIONAL,['NA'],
13170,NCT00643435,"Resident physician use of self-efficacy enhancing patient interviewing techniques, assessment via coding of audio recordings from standardized patient encounters",,2006-02,COMPLETED,INTERVENTIONAL,['NA'],
13171,NCT00341406,adipose cell size distribution,,2003-09-04,COMPLETED,OBSERVATIONAL,['NA'],
13172,NCT00250731,diabetes regimen adherence,diabetes self-efficacy,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
13173,NCT00818571,Measure: pharmacokinetics of vildagliptin and its metabolites,"Measure: safety assessments will include vital signs, electrocardiograms and adverse events",2008-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
13174,NCT04515576,Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD):Change from baseline to Day 29 in Fasting Glucose (FG),2020-08-25,COMPLETED,INTERVENTIONAL,['PHASE1'],
13175,NCT01963559,Cutaneous blood flow,Effect of neuropathy on PIV impairment,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
13176,NCT00050479,,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
13177,NCT01883024,"Patient agreement with the IPRA© advices: global rate of agreement, according to advice subtypes, according to blood glucose levels, according to the situations (pre or post-meal, bedtime)",Assessment of patient satisfaction,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
13178,NCT02598544,Adipose tissue inflammation,Concomitant medication,2013-05,COMPLETED,INTERVENTIONAL,['NA'],
13179,NCT01179815,Mortality,Diabetes related influence on quality of Life,2010-01,RECRUITING,OBSERVATIONAL,['NA'],
13180,NCT00171574,Change from baseline in urine protein excretion after 20 weeks,Change from baseline in diastolic blood pressure after 20 weeks,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
13181,NCT01793168,"To accelerate research into rare disorders by connecting individuals who are interested in research and who have been diagnosed with a rare disorder (or a disorder of unknown prevalence, or who are undiagnosed) with researchers who study rare diseases.",,2010-07,RECRUITING,OBSERVATIONAL,['NA'],
13182,NCT00005137,,,1992-07,COMPLETED,INTERVENTIONAL,['NA'],
13183,NCT03545178,Hypoglycemia prediction (for Substudy B),Change of mean amplitude of glucose excursion (MAGE) day 0-3 compared to day 4-28 and day 0-7 compared to day 8-28 prior to consultation (for Substudy A),2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],Change of mean of daily differences (MODD) day 0-3 compared to day 4-28 and day 0-7 compared to day 8-28 prior to consultation (for Substudy A)
13184,NCT05015283,"One year after operation, the complete remission rate of type 2 diabetes mellitus [HbA1c < 6%, fasting plasma glucose < 5.6 mmol/L, no need to use any hypoglycemic drugs]",Dumping syndrome and hypoglycemia symptoms,2022-02-01,RECRUITING,INTERVENTIONAL,['NA'],
13185,NCT01941277,A decrease in Insulin Resistance (IR) as measured by a change in IR.,,2014-08,TERMINATED,INTERVENTIONAL,['NA'],
13186,NCT03216226,Percentage of Patients With ADA,Pharmacodynamics - An Increase in the Plasma Glucose Concentration of ≥20 mg/dL Within 30 Minutes After Treatment,2017-06-28,COMPLETED,INTERVENTIONAL,['PHASE3'],
13187,NCT02675608,Change in HAI titer from day 0 to day 30 (+/- 4 days),Inflammatory Soluble Factor and Cellular Analysis additional measurements,2015-08,COMPLETED,OBSERVATIONAL,['NA'],
13188,NCT03277742,Blood glucose control,,2017-09-20,WITHDRAWN,INTERVENTIONAL,['NA'],
13189,NCT05553912,HbA1c at Month 6,Quality of communication assessed using 3 questions from the CAHPS Clinician and Group survey,2022-11-02,RECRUITING,INTERVENTIONAL,['NA'],Clinician satisfaction survey
13190,NCT01659697,occurence of diabetes,change in Body Mass index and Physical activity,2012-08,UNKNOWN,OBSERVATIONAL,['NA'],
13191,NCT05950516,Change in HbA1c,Percentage of Participants That Achieved Body Weight Loss ≥5%,2023-07-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
13192,NCT04161846,Post Training Presentation Delivery Skills,Change in Physical Activity,2019-08-08,COMPLETED,INTERVENTIONAL,['NA'],Adherence
13193,NCT03156985,Incidence of adverse events,,2017-08-16,COMPLETED,OBSERVATIONAL,['NA'],The incidence of interested adverse events
13194,NCT02167061,Maximum of concentration (Cmax) of Evogliptin and Metformin,Time prior to the first measurable concentration (tlag) of Metformin (only in Part 2 trial),2014-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
13195,NCT03554200,effect of Empagliflozin 10mg qd versus placebo on cardiac output in patients with acute heart failure,Effect of Empagliflozin 10 mg daily on Left ventricular diastolic function,2018-06-11,TERMINATED,INTERVENTIONAL,['PHASE2'],
13196,NCT00920881,,,2005-11,COMPLETED,OBSERVATIONAL,['NA'],
13197,NCT01123980,Change in Glycosylated Haemoglobin (HbA1c),Number of Hypoglycaemic Episodes,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
13198,NCT00677599,"Change in cardiovascular disease risk indictaors - including carotid intima-media thickness (CIMT), total plaque volume (TPV) (at the carotid bifurcation), pulse wave velocity (PWV) and biomarkers of risk in blood samples .",,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
13199,NCT01236404,Safety/Tolerability,Pharmacodynamic Response,2010-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
13200,NCT01145092,Insulin Sensitivity,skeletal muscle lipid content,2006-02,COMPLETED,INTERVENTIONAL,['NA'],
13201,NCT00566358,"Changes in the secretion pattern of incretins, insulin and glucagon after intervention, as measured by standardized mixed meal tolerance test",Regression of carotid intima-media thickness,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
13202,NCT02938572,The ratio of suppression of endogenous glucose production relative to total glucose lowering effect,Number of treatment emergent adverse events,2016-10-19,COMPLETED,INTERVENTIONAL,['PHASE1'],
13203,NCT05495386,To collect continuous glucose monitoring (CGM) data to develop a hypoglycaemia notification algorithm.,To evaluate the surgeon satisfaction of H02 in participants with type 1 diabetes.,2022-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],
13204,NCT01407276,Apparent Terminal Half-life (t1/2) of Omarigliptin,Number of Participants Withdrawn From Study,2011-08-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
13205,NCT02456064,HbA1c,,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
13206,NCT04723160,consistent rate of diagnoses,full coincidence rate of software's diagnoses,2020-08-10,COMPLETED,OBSERVATIONAL,['NA'],
13207,NCT04496401,To characterise the bioavailability of Envarsus® and compare it to the bioavailability of tacrolimus,Assessment of biological and clinical tolerance/ safety: Incidence of serious adverse events,2020-09-28,COMPLETED,INTERVENTIONAL,['PHASE4'],
13208,NCT05706506,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Weight,2023-03-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
13209,NCT01955694,The percentage of subjects with a relative decrease in N-terminal prohormone B-type natriuretic peptide of more than 30% from baseline to Visit 10,Change in serum potassium,2013-11-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
13210,NCT00079638,Mean percent change in LDL-C from Baseline to Week 12,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
13211,NCT02040246,HbA1c change from baseline,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
13212,NCT00397553,HbA1c,Post-prandial glycemia (2 hour after breakfast),2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
13213,NCT05917093,Change in Blood Glucose,Adherence to Refills and Medicines Scale for Diabetes (ARMS-D) Score,2024-03,RECRUITING,INTERVENTIONAL,['NA'],Patient's Perceived Involvement in Care Scale (PICS)
13214,NCT05218304,"To know the prevalence of the main risk factors chronic diseases (obesity, diabetes, high blood pressure, high cholesterol and kidney failure) in the adult population of New Caledonia aged 18 to 64 using the WHO STEPS survey method.",Seroprevalence of infectious diseases,2021-07-26,SUSPENDED,INTERVENTIONAL,['NA'],
13215,NCT02940275,Perfused small vessel density of sublingual small vessels measured by Cytocam,Total small vessel density of sublingual small vessels measured by Cytocam,2016-10-17,COMPLETED,OBSERVATIONAL,['NA'],
13216,NCT03947333,Change in Patient Activation at 3 Months,System Usage Data for My Diabetes Care - Utilization of Embedded Features and Functionality (Intervention Group Only),2020-03-09,COMPLETED,INTERVENTIONAL,['NA'],
13217,NCT02343926,Change from baseline in HbA1c,Number of serious adverse events,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
13218,NCT01553526,Target Lesion Failure (TLF),Clinical Procedural Success,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],
13219,NCT03170518,Percentage of Participants with Adverse Events as a Measure of Safety and Tolerability,Percent Change in Body Weight From Baseline at Week 26 and Week 52,2017-07-21,COMPLETED,INTERVENTIONAL,['PHASE3'],Change in Urinary Albumin/Creatinine Ratio (ACR) From Baseline at Week 26 and Week 52
13220,NCT04238936,Interleukin-1 (IL-1) receptor antagonist,,2020-01-20,COMPLETED,OBSERVATIONAL,['NA'],
13221,NCT01844050,Change from Baseline Total score of diabetes symptoms at 4 weeks,Change from Baseline blood glucose at 2 hours after meal at 4 weeks,2008-09,COMPLETED,INTERVENTIONAL,['NA'],
13222,NCT02132637,Percentage of Participants With Clinically Significant Hypoglycemia,Beta Cell Function,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
13223,NCT00390728,"Sub-study: The fear of hypoglycaemia as measured by the Hypoglycaemia Fear Survey questionnaire (HFS-98) assessed at baseline, 3 months and study end point or upon withdrawal of the subject from the study.",Proportion of patients reaching HbA1c target as per participation with the Prescription Plan,2002-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
13224,NCT01422668,Glycemic Index of Khalas dates with and without coffee,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
13225,NCT02770235,erectile dysfunction and AGE levels,,2014-03-17,COMPLETED,INTERVENTIONAL,['NA'],
13226,NCT02904512,Number of Participants With Hypoglycemic Events (< 70mg/dL),,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
13227,NCT04406402,High asymmetric dimethylarginine (ADMA) change,Glycated hemoglobin (HbA1c) change,2006-12-05,COMPLETED,INTERVENTIONAL,['NA'],
13228,NCT02984605,glycated hemoglobin,,2016-12,UNKNOWN,INTERVENTIONAL,['NA'],
13229,NCT04569214,Assess the PAZ320 effect on postprandial blood glucose levels in type II diabetic patients.,Number of Subjects with Adverse Events as a Measure of Safety and Tolerability,2012-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
13230,NCT05014204,Primary Safety Endpoint,Changes in glucose-lowering medication usage,2021-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Procedural Time
13231,NCT02868983,PROMIS-29 v2,Asthma Symptom Utility Index,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],Covid-19 patient measures
13232,NCT00057499,"Clinical endpoints including adverse events, local reactions, routine physical exams, insulin dose, and laboratory tests",T cells' secretion of IL-4 and Interferon (IFN)-gamma,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
13233,NCT04443153,Glycemic Outcomes,High Blood Glucose Index,2020-09-04,RECRUITING,INTERVENTIONAL,['NA'],
13234,NCT02956044,AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity),Urinary Glucose Excretion up to 0-72 hr,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
13235,NCT01672255,Change in Catecholamines,,2012-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
13236,NCT02264288,"Safety (adverse events [type, frequency, and severity of AEs, and relationship of AEs to study drug], laboratory abnormalities, and hospitalizations",Leg rest pain score,2014-10-23,TERMINATED,INTERVENTIONAL,['PHASE2'],
13237,NCT02931630,Postprandial triglyceride response,Microbiota,2016-05,COMPLETED,INTERVENTIONAL,['NA'],
13238,NCT04141423,Anti-insulin Tregopil antibodies,PD Endpoints - CGM profile,2019-10-28,TERMINATED,INTERVENTIONAL,['PHASE1'],
13239,NCT01451918,Examine the effect of resveratrol on ApoB 100 and ApoB 48 production in humans,Assess the change in insulin sensitivity with resveratrol treatment,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
13240,NCT01719029,Glucose area-under-the-curve,Infant Adiposity,2007-08,COMPLETED,INTERVENTIONAL,['NA'],
13241,NCT01223612,Functional and anatomical change in the retina,OCT macular thickness,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
13242,NCT06074913,Temperature of the back of the hand,2-hour postprandial blood glucose (2hPG),2023-07-07,RECRUITING,INTERVENTIONAL,['NA'],
13243,NCT02857764,Incidence of Below-Knee Lower Extremity Amputation in Canagliflozin New Users Versus non-SGLT2i Aha New Users,,2016-02-15,COMPLETED,OBSERVATIONAL,['NA'],
13244,NCT02363803,Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS),Change in Spontaneous Pain Intensity as a Function of Baseline HPT,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
13245,NCT00090519,Occurrence of Sustained Moderate Visual Loss (SMVL) in a Diabetic Retinopathy (DR) Study Eye,Number of Participants With Adverse Events,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
13246,NCT00362193,Glycemic relapse: increase in HbA1c by 1% over baseline and >8%,Fasting Lipid Panel,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
13247,NCT04914559,Area under the blood glucose curve,Insulinogenic index,2021-05-17,COMPLETED,INTERVENTIONAL,['NA'],
13248,NCT01992588,CSII bolus related baseline corrected area under the serum insulin aspart concentration-time curve,CSII bolus related baseline corrected area under the glucose infusion rate curve,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
13249,NCT00192803,ACE and ACE2 activities in monocytes,,na,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13250,NCT04189848,Intensity of Injection Site Pain,,2019-12-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
13251,NCT01130207,Changes in microflora after bariatric surgery,,2010-05,COMPLETED,OBSERVATIONAL,['NA'],
13252,NCT00805506,To collect sufficient glucose data by means of continuous glucose monitoring for the purpose of detecting clinically relevant alterations in blood glucose throughout a typical or modal day.,,2006-02,COMPLETED,OBSERVATIONAL,['NA'],
13253,NCT00231647,Percent change in body weight from baseline to Week 16.,"Changes in body weight, body mass index,anthropometric measurements (waste and hip circumference and their ratio),fasting blood glucose and lipid profile from baseline to Week 16; safety evaluations including incidence of adverse events during the study.",2004-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
13254,NCT01154478,incremental AUC after a test meal of triglycerides concentration in chylomicrons and VLDL fraction,endothelial function,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
13255,NCT02330042,Number of participants with measureable macular edema by OCT imaging,,2014-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
13256,NCT01202474,Percentage of patients achieving HbA1c level < 8% (in patients 6-12 year-old) and HbA1c level < 7.5 % (in patients 13-17 year-old),Change in daily dose of glargine and glulisine,2011-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
13257,NCT05847907,Complications,Implant stability quotient (ISQ),2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
13258,NCT04288362,Change in HbA1c levels,"Change in healthcare cost in terms of total healthcare cost of polyclinic, emergency department, hospital admissions and specialist outpatient clinic visits",2019-03-25,COMPLETED,INTERVENTIONAL,['NA'],Change in Diabetes Retinal Photography rates
13259,NCT03718832,HbA1c,Healthy behaviors observed in paid claims HEDIS measures,2019-04-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Heterogeneity: HbA1c by causal tree
13260,NCT01563419,the time spent to complete dialing up insulin pens,the recommendation for the use of a magnifier,2011-10,COMPLETED,INTERVENTIONAL,['NA'],
13261,NCT04772729,Glycaemia difference in time in range (TIR) 70-180mg/dl,Difference in the basal rate of insulin,2021-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13262,NCT05323162,Preservation of residual beta cell insulin secretion capacity,Dietary intake,2022-04,UNKNOWN,INTERVENTIONAL,['NA'],
13263,NCT05789810,Fear Severity,,2022-09-10,COMPLETED,INTERVENTIONAL,['NA'],
13264,NCT02682901,Change in Hands ESC From Baseline to Endpoint After 24 Weeks of Intervention With Bromocriptine QR vs Placebo,,2015-10-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
13265,NCT04457752,Complete Wound Closure,Changes in bacterial Load,2020-09-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
13266,NCT01053234,Prothrombin fragment 1+2,C-reactive protein,2007-02,COMPLETED,INTERVENTIONAL,['NA'],
13267,NCT02003898,Mean Change in A1C From Baseline to 1 Year,"Mean Change in A1C From Baseline to 1 Year, Baseline A1c > 9%",2013-11-26,COMPLETED,INTERVENTIONAL,['NA'],
13268,NCT05986097,HbA1c change,Change in insulin resistance,2023-08-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
13269,NCT05214547,Change from 4 weeks Shoulder Pain at 6 weeks,Change from 4 weeks Shoulder Function at 6 weeks,2022-02-25,UNKNOWN,INTERVENTIONAL,['NA'],Change from baseline Shoulder Muscle Tone at 6 weeks
13270,NCT00836225,To evaluate the safety and tolerability of single and multiple doses of ISIS-SGLT2Rx administered subcutaneously,Pharmacokinetic profile all doses and Pharmacodynamics for multi-dose groups,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
13271,NCT01610674,Barrier analysis,feasibility study,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
13272,NCT04829084,Increased number of DR patients at REMEH for eye screening,,2021-02-26,COMPLETED,INTERVENTIONAL,['NA'],
13273,NCT00383578,Change from baseline in HbA1c,Change from baseline in body weight,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
13274,NCT01238224,"Capillary recruitment, muscle glucose uptake and circulating glucose levels following a meal",Vascular function and circulating biomarkers.,2009-11,TERMINATED,INTERVENTIONAL,['PHASE1'],
13275,NCT02012166,Post-infusion Incremental Glucose Area Under the Plasma Concentration Versus Time Curve [AUC0-240 min] Study Part 2,Number of Participants Who Discontinued Study Treatment Due To AEs,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
13276,NCT04599075,Neonatal Hypoglycemia,Umbilical Cord Blood Level of Insulin,2021-03-15,COMPLETED,INTERVENTIONAL,['PHASE4'],
13277,NCT01021930,Comparison of the surface coverage between DM and Non-DM at 6 months after Cypher and YINYI stent implantation using OCT.,MACE,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13278,NCT01572415,Comparison of SCOUT DS to Random Capillary Glucose,,2011-09,COMPLETED,OBSERVATIONAL,['NA'],
13279,NCT00311077,To evaluate the serum insulin glulisine concentration and insulin lispro concentration,Adverse events collection,2004-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
13280,NCT00863967,Cardiovascular events,Disease activity score,2003-10,UNKNOWN,OBSERVATIONAL,['NA'],
13281,NCT01595269,Changes in A1C,Changes in Diabetes self-care activities,2007-04,COMPLETED,INTERVENTIONAL,['NA'],
13282,NCT05402358,The RAND 36-item Health Survey 1.0,Focus group and individual interviews with health professional participants,2020-06-01,COMPLETED,OBSERVATIONAL,['NA'],
13283,NCT03434860,HOMA-IR,cytokines levels,2016-01-15,COMPLETED,INTERVENTIONAL,['NA'],
13284,NCT02880267,"Proportion of blood glucose values, compared between CGM and a lab glucose analyzer that are matched relative to a proportion of blood glucose values, compared between CGM and a lab glucose analyzer matched to an accuracy measurement of %20/20 mg/dL",,2016-05,COMPLETED,INTERVENTIONAL,['NA'],
13285,NCT01269008,Better meal and post meal sugars on the closed loop device using the study medications.,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
13286,NCT01583790,Weightloss of patients,Improvement of co-morbidities after surgery,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],
13287,NCT04805541,Number of subject eyes whose EyeCheckup results match the reading center grading for identifying vision threatening diabetic eye disease (severe NPDR or PDR or surrogate markers for CSME).,,2022-02-01,RECRUITING,OBSERVATIONAL,['NA'],
13288,NCT00146484,* Hemoglobin A1c over the first 24 months of diabetes,* Family Functioning (Family Environment Scale)over the first 24 months of diabetes,1996-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
13289,NCT02922179,serious hypoglycemic events,Serious cardiac events,2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],A1C control
13290,NCT03631134,Changes of glycemic variation,Change of insulin dose,2018-08-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13291,NCT05526430,Dose Limiting Toxicity (DLT),Visual Analog Scale (VAS),2022-09-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
13292,NCT00677937,Reduction in incidence of diabetes at 3 years,"change in hba1c, fasting and post glucose levels, cardiovascular risk (framingham), presence of MetS (NCEP ATP III)",2009-05,COMPLETED,INTERVENTIONAL,['NA'],
13293,NCT04595968,Frequency of all device related Serious Adverse Events,Frequency of hypoglycemic episodes,2021-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
13294,NCT03315143,"Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF)","Total Number of Occurrences of CV Death, Non-fatal Myocardial Infarction and Non-fatal Stroke",2017-12-19,TERMINATED,INTERVENTIONAL,['PHASE3'],
13295,NCT02258373,"Percentage of Time in Range of 70 to 180 mg/dl, Measured With CGM",Number of Participants With >=1 Serious Adverse Event Other Than SH,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
13296,NCT03772600,Difference in time in range (70-180 mg/dL) between the control and experimental group,Between group difference in number of patients having allergic reactions to the sensors,2019-01-29,COMPLETED,INTERVENTIONAL,['NA'],Number of patients who stop using the Dexcom G6® CGM and the reason to stop
13297,NCT01247649,Correlation between continuous glucose measurements using study device and YSI(yellow springs instrument),,2010-11,TERMINATED,INTERVENTIONAL,['NA'],
13298,NCT01301092,Maximum Concentration (Cmax) of LY2189265: Subcutaneous (SC) to Intravenous (IV),)Maximum Concentration (Cmax) of LY2189265: Intramuscular (IM) to Subcutaneous (SC),2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
13299,NCT00901979,Effect of LCQ on measures of glucose control,Safety and tolerability,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
13300,NCT05536232,Peptide C evolution,Circulating rate of cytokines,2022-10-17,RECRUITING,INTERVENTIONAL,['NA'],
13301,NCT00680745,Adjusted Mean Change in HbA1c Levels,Adjusted Mean Change in Fasting Plasma Glucose (FPG),2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
13302,NCT04646408,Educational,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],
13303,NCT01243138,"Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension","Ascertain the most commonly used medications in those that have been previously diagnosed as diabetic, hypertensive or dyslipidaemic.",2011-07,COMPLETED,OBSERVATIONAL,['NA'],
13304,NCT04765254,Investigation of bad prognosis cause for covid-19 diabetic patients,,2021-02-20,UNKNOWN,OBSERVATIONAL,['NA'],
13305,NCT03447301,HbA1c (glycated hemoglobin),Weight,2018-02-25,UNKNOWN,INTERVENTIONAL,['NA'],
13306,NCT02533648,muscle oxidative stress in diabetic patients,Tolerance of the treatment measured by any adverse events during treatment and between each visit.,2011-09-16,COMPLETED,INTERVENTIONAL,['PHASE3'],
13307,NCT04129021,Visualization of a structure of interest and measuring the short-term and long-term reproducibility of the data collected compared to routine systems,,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA'],
13308,NCT00511602,HbA1c change from baseline (week 2) to end of treatment (week 12),"Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations",2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
13309,NCT01393275,alteration of HbA1c-level (haemoglobin A1c),follow up of all parameters mentioned above,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
13310,NCT02857491,perioperative hemorrhage of the surgical eye,best-corrected visual acuity,2014-07,COMPLETED,INTERVENTIONAL,['NA'],grade of surgical difficulty
13311,NCT03063580,Area under the concentration-time curve from 0 to infinity (AUC0 ∞),Total 24-hour UGE (urinary glucose excretion),2017-02-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
13312,NCT00961974,"Glycemic control, assessed by hemoglobin A1c","Frequency of hospitalizations, emergency department visits, and episodes of severe hypoglycemia",2002-04,COMPLETED,INTERVENTIONAL,['NA'],
13313,NCT00924534,Change from baseline in Creatinine kinase level to Day 35,Change from baseline in High density lipoprotein cholesterol level to Day 28,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
13314,NCT04814849,number of participants reporting financial burden,number of participants reporting emotional and/or psychosocial burden,2017-12-01,COMPLETED,OBSERVATIONAL,['NA'],
13315,NCT05480228,The frequency (i.e. number of participants) with treatment emergent adverse events (TEAEs) reported in the time period defined by first administration of IP until 7 days after the last dose of IP.,Occurrence of 50% reduction of WAP from Baseline to Week 13.,2022-09-21,RECRUITING,INTERVENTIONAL,['PHASE2'],To assess the effect of NRD135S.E1 in comparison to placebo with respect to the actigraphy step count.
13316,NCT01196325,Quantitative inner retinal blood flow,Mean angle opening distance and trabecular-iris spur area,2009-07,UNKNOWN,OBSERVATIONAL,['NA'],
13317,NCT03406975,Percentage of Excess Weight Loss (EWL),Change in Eating Behaviors,2017-12-20,COMPLETED,INTERVENTIONAL,['NA'],
13318,NCT02285218,new hepatokines,,2014-04,UNKNOWN,OBSERVATIONAL,['NA'],
13319,NCT06011798,Mean change from baseline in BCVA by ETDRS letter,Assess safety outcome - TEAE,2023-08-23,RECRUITING,INTERVENTIONAL,['PHASE2'],
13320,NCT03451630,Change in Hospital Readmission Rate,Gaps in care,2018-04-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
13321,NCT01749176,HbA1c,,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
13322,NCT04118257,Change in glucose iAUC,Change in serum fructosamine,2017-02-10,COMPLETED,INTERVENTIONAL,['NA'],
13323,NCT01069393,Improvement in HbA1c (glycosylated haemoglobin),Qualitative evaluation via in-depth interviews to assess patients' experiences of the intervention,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
13324,NCT05464524,"Established the role of tested environmental factors and lifestyle choices on the incidence, recurrence, and severity of diabetic foot ulcers in adults living with diabetes in England.",Established changes to DFU status and quality of life over the 12 week follow up period.,2023-10-19,RECRUITING,OBSERVATIONAL,['NA'],
13325,NCT03073330,Incidence of gestational diabetes diagnosed on each screening test of each arm.,Apgar score,2016-06,UNKNOWN,INTERVENTIONAL,['NA'],
13326,NCT03258268,HbA1c,Hypoglycemia,2017-08-07,COMPLETED,INTERVENTIONAL,['NA'],
13327,NCT05328726,Dose limiting toxicity,Glycosylated Hemoglobin,2022-03-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
13328,NCT02727790,"Number of participants with hypoglycemia, and/ or adverse events that are related to treatment",Changes in mean interstitial glucose levels measured by CGM,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
13329,NCT01323075,The duration of sensory block in minutes.,"Occurrence of neurological complications, yes/no",2011-05,COMPLETED,OBSERVATIONAL,['NA'],
13330,NCT02052817,Change from baseline measured wound area,,2013-12,UNKNOWN,INTERVENTIONAL,['NA'],
13331,NCT06265935,SF-36 Quality of Life Scale:,Visual Similarity Scale for Fatigue,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
13332,NCT05108987,Body Weight,Flow-mediated dilation,2021-09-25,RECRUITING,INTERVENTIONAL,['NA'],
13333,NCT00005347,,,1992-02,COMPLETED,OBSERVATIONAL,['NA'],
13334,NCT05530486,Change in complete ulcer healing,,2023-06-30,RECRUITING,INTERVENTIONAL,['NA'],
13335,NCT03233178,"Change in ALT in patients with T2DM initiating SGLT2 inhibitors, Liraglutide or Sitagliptin compared to control",Change in triglycerides from baseline to follow-up,2017-01,COMPLETED,OBSERVATIONAL,['NA'],
13336,NCT00753181,Average daily blood glucose level,"Percentage of time in specified glucose ranges; Glycemic excursions; Change in plasma glucose, insulin, free fatty acids, triglycerides, 1,5-anhydroglucitol, and fructosamine; Dietary intake variables",2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
13337,NCT02055755,Questionnaire relevant to wound healing,Develop new parameters for clinical decision support based on data collected in this study.,2013-04,WITHDRAWN,OBSERVATIONAL,['NA'],
13338,NCT01198730,Diabetes,Mortality,2009-04,RECRUITING,OBSERVATIONAL,['NA'],
13339,NCT02803892,Change from Baseline C-peptide after the MMTT,Adverse Events (AEs) and Serious Adverse Events (SAEs),2016-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
13340,NCT03113916,Waist Circumference in Centimeters,Number of Vegetable Servings Per Day (Transformed Using the Natural Log),2014-06-23,COMPLETED,INTERVENTIONAL,['NA'],Recruit Participants for Sustainability Phase
13341,NCT01358994,,,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
13342,NCT05892848,"level of serum ostecalcin, sclerostin in patients with type 1 diabetes ann d their age and sex matched control",,2023-06-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
13343,NCT00330473,To assess blood sugar control as measured by HbA1c,To assess patient-reported outcomes based on the DTSQ Questionnaire,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
13344,NCT01791465,Serum Interleukin 6 (IL-6) at Levels at Baseline and 16 Weeks,Waist to Hip Ratio at Baseline and 16 Weeks,2013-03,TERMINATED,INTERVENTIONAL,['PHASE4'],"Peripheral Endothelial Tonography, as Measured by the Non-invasive EndoPAT System Using the LnRHI (Natural Log of Reactive Hyperemia Index), at Baseline and 16 Weeks"
13345,NCT04937816,Incidence Rate of Lower Limb Amputation (LLA),Incidence Rate of Adverse Events Related to Amputation,2021-06-01,COMPLETED,OBSERVATIONAL,['NA'],
13346,NCT02314637,Number of Participants With Adverse Events,Change From Baseline in Fasting Plasma Glucose at Week 52,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
13347,NCT04917965,Coagulation Index,,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
13348,NCT01790711,The Efficiency of FMT on T2DM,Durability,2012-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
13349,NCT01739712,Academic performance,,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
13350,NCT03680794,sCD160 concentration in the aqueous humor,Stromal cell-derived factor 1 (SDF-1),2018-06-27,RECRUITING,INTERVENTIONAL,['NA'],
13351,NCT05502016,"Glycemic control, measured by change in mean HbA1c (%) from baseline",,2023-06-30,RECRUITING,INTERVENTIONAL,['NA'],
13352,NCT00463671,The aim of the present study was to investigate whether changes in oxidative stress and NO bioavailability are responsible for the different effects of HBOT on tissue oxygenation in diabetic patients suffering from foot ulcers.,,2003-12,COMPLETED,INTERVENTIONAL,['NA'],
13353,NCT00318032,"To contribute to the ADDITION-Europe study, to assess screening and intensive treatment on 5 year cardiovascular outcomes",To assess the economic and psychological cost of screening,2004-08,UNKNOWN,INTERVENTIONAL,['NA'],
13354,NCT05541120,Percentage of participants in each group who have HbA1c < 7%,Mean change in PAM-13 at 9 months,2022-10-18,WITHDRAWN,INTERVENTIONAL,['NA'],
13355,NCT00462046,LDL-c,Blood pressure,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
13356,NCT05096078,Blood count test 8,WMS Number Range Test,2020-10-16,UNKNOWN,INTERVENTIONAL,['NA'],
13357,NCT04948112,Average percent time in glucose range,Neonatal hypoglycemia,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Perceived benefit questionnaire (GMS)
13358,NCT03945656,Clinically significant hypoglycaemia (Double dose): Clinically significant hypoglycaemia (Plasma glucose [PG] less than 3.0 mmol/L [54 mg/dL]) after 2 times the individualised optimal basal dose of insulin,"Clinically significant hypoglycaemia (Triple dose) - Clinically significant hypoglycaemia [PG less than 3.0 mmol/L (54 mg/dL)], after 3 times the individualised optimal basal dose of insulin",2019-05-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
13359,NCT04176120,Complete wound healing,Patient-reported mobility,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
13360,NCT00815932,Changes in the Latency of P300,Changes in Pain Thresholds for Tactile and Thermal Stimuli will be calculated as the difference between ratings obtained form pain threshold measurements before- and after tDCS,2016-09,WITHDRAWN,INTERVENTIONAL,['NA'],
13361,NCT00690287,Pharmacodynamic variables,Pharmacokinetic variables,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
13362,NCT04368741,Glycated albumin level,,2019-10-15,UNKNOWN,INTERVENTIONAL,['NA'],
13363,NCT00099853,Change from baseline in HbA1c after 24 weeks,Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs low baseline HbA1c,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
13364,NCT04200625,Epicardial Fat thickness,,2019-09-24,COMPLETED,OBSERVATIONAL,['NA'],
13365,NCT04436796,Non-inferiority for CGM Time <54 mg/dL,Basal: Bolus Insulin Ratio,2020-08-05,COMPLETED,INTERVENTIONAL,['NA'],Any Adverse Event Rate Per 100 Person-years
13366,NCT03200535,Enrollment in Diabetes Prevention or Weight Management Class (Online),Enrollment in Diabetes Prevention or Weight Management Class (in Person),2017-06-26,COMPLETED,INTERVENTIONAL,['NA'],
13367,NCT04817644,"Area under the salcaprozate sodium (SNAC) milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,milk)","Time to maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (tmax,E1247,D10,plasma)",2021-09-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
13368,NCT05029076,"Adverse Event, Serious Adverse Event and Drug Combination",The Number of participants with abnormal laboratory examinations,2019-05-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
13369,NCT01162772,catecholamine,Homeostasis model assessment-estimated insulin resistance,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],
13370,NCT00831389,Incidence of Nocturnal Hypoglycemia Following Exercise,Percentage of Time Plasma Glucose (PG) is Below the Euglycemic Range.,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
13371,NCT04328233,Change in fasting glucose concentration,Duration of eating period,2019-10-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
13372,NCT00476658,,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],
13373,NCT05571436,Diabetes self-management behavior,Self-efficacy related to diabetes self-management,2022-10-17,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
13374,NCT01169779,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia
13375,NCT06114134,Hemoglobin A1C (HbA1C),Antropometric Indices,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
13376,NCT04001725,Metformin in preventing precocious (14 days) dexamethasone-induced diabetes,Amino acid profile,2019-10-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],
13377,NCT00220831,A combination of CVD mortality non fatal MI and Stoke at a 4 year follow up.,"etc…), all cause mortality, heart failure, at a 4 year follow up.",2005-04,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
13378,NCT00065130,Postprandial glycemic control,Adverse events,2000-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
13379,NCT01437072,HbA1c (Glycosylated Haemoglobin) level,The presence of retinopathy,2010-11,COMPLETED,OBSERVATIONAL,['NA'],
13380,NCT04656093,Beliefs about Medicines Questionnaire (BMQ scores),Illness Perceptions Questionnaire (IPQ scores),2021-01-15,COMPLETED,INTERVENTIONAL,['NA'],
13381,NCT02092870,Percent change in wound size from baseline at 12 weeks,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
13382,NCT00288392,- Time to healing,Safety,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
13383,NCT02062047,Changes in clinical attachment level (CAL) in sites with initial PD ≥7mm from baseline to 12 months.,Changes in the levels of osteoprotegerin (OPG) in gingival crevicular fluid,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
13384,NCT01320345,Occurrence of clinical significant retinopathy progression.,Frequency of foot ulcer and non-traumatic amputation.,2016-11-03,RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of Life questionnaire
13385,NCT02826655,Peripheral Retina Structure Differences between Healthy Controls and participants with diabetic retinopathy.,,2016-06,TERMINATED,INTERVENTIONAL,['NA'],
13386,NCT01308437,Change in HbAlc from baseline to 6 months of treatment between Wosulin arm and Novolin arm(as surrogate indicator of change in insulin antibodies titers between the two treatment arms).,"Correlation of the immunogenicity with hypoglycemia, local allergic reactions and systemic allergic reactions will be evaluated.",2011-03,TERMINATED,INTERVENTIONAL,['PHASE3'],
13387,NCT03749642,Change of the average daily pain score based on the 11-point Numeric Rating Scale (NRS).,Frequency of adverse events,2018-11-22,COMPLETED,INTERVENTIONAL,['PHASE2'],
13388,NCT04254016,Variation of mitral E' velocity,Variation of lipid profile.,2016-11-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
13389,NCT04238702,Effective Renal Plasma Flow (ERPF),Vascular function,2020-11-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
13390,NCT00100204,,,2004-12-21,COMPLETED,OBSERVATIONAL,['NA'],
13391,NCT01175408,The primary endpoint is the A1c level or the change in A1c level,A secondary endpoint includes adverse events such as unplanned hospitalizations for any cause that last more than 24 hours,2010-09,COMPLETED,INTERVENTIONAL,['NA'],
13392,NCT06013826,Fear,,2022-02-17,COMPLETED,INTERVENTIONAL,['NA'],
13393,NCT05854862,TIR,Incidence of hypoglycemia,2013-08-01,RECRUITING,OBSERVATIONAL,['NA'],
13394,NCT02690168,Percent Enrichment of Bicarbonate as Measured by Magnetic Resonance Spectroscopy (MRS),Change in Leptin Levels,2016-02,COMPLETED,OBSERVATIONAL,['NA'],
13395,NCT00279266,Daily pain evaluations on a visual analog pain scale,Changes in sleep disturbance in secondary to pain as rated by a visual analog scale,2006-01,WITHDRAWN,INTERVENTIONAL,['NA'],
13396,NCT02405949,"Predictive value of the genetic test in identifying individuals who will have a good response to bariatric surgery, in terms of type 2 diabetes remission after the surgery.",,2013-07,COMPLETED,OBSERVATIONAL,['NA'],
13397,NCT01524159,fibrinogen,Creatinine,2011-06,COMPLETED,INTERVENTIONAL,['NA'],
13398,NCT01584232,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks,Percentage of Participants With Hypoglycemic Episodes,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
13399,NCT01420497,"glycemic values,",urinary excretion rate,2008-08,COMPLETED,INTERVENTIONAL,['NA'],
13400,NCT01970163,Effect of DermACELL on the proportion of chronic wounds of the lower extremity that have healed.,Proportion of wounds closed at 12 weeks and weekly thereafter for up to 24 weeks,2013-10,COMPLETED,INTERVENTIONAL,['NA'],"Incidence of treatment-emergent adverse events (AE), changes in vital signs, ankle-brachial index (ABI) and physical examination findings."
13401,NCT03369626,Level of engagement with the assigned mobile app,Change in self-reported diabetes medication type or dose,2017-07-26,COMPLETED,INTERVENTIONAL,['NA'],
13402,NCT05314855,Amplitude of SCN activity rhythm (peak-trough change in SCN activity),,2023-01-04,RECRUITING,OBSERVATIONAL,['NA'],
13403,NCT02798198,The correlation between the pulmonary function and the renal hemodynamics in 37 T2DM patients without DKD,"The albumin excrete rate (AER), urinary albumin/creatinine ratio (UACR)in the healthy people and T2DM patients and comparing the differences between the two groups",2015-09,COMPLETED,OBSERVATIONAL,['NA'],
13404,NCT03171623,Safety and tolerability of single dose of SY-004,C-peptide secretion following single dose of SY-004,2017-04-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
13405,NCT02247635,"Reduction in the prevalence of metabolic syndrome (obesity, diabetes, hypertension, dyslipidemia)",Reduction of hypercholesterolemia,2008-11,COMPLETED,INTERVENTIONAL,['NA'],
13406,NCT00368134,Change in HbA1c after 12 weeks,Safety Profile after 12 weeks treatment,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
13407,NCT03545802,Compliance over the course of the training programme,change in glycaemic control,2017-05-20,COMPLETED,INTERVENTIONAL,['NA'],
13408,NCT03804983,change between Percent Time in Range at home pre/post intervention at home,Change in Total amount of carbohydrates corresponding to hypoglycemia treatment at camp,2019-01-15,COMPLETED,INTERVENTIONAL,['NA'],
13409,NCT00704132,Change From Baseline in Glucose 5-Hour Incremental AUC at Week 6,,2007-02-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
13410,NCT04578431,Blood from mother,,2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],
13411,NCT05301478,Plantar pressure,,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],
13412,NCT04352907,Continous Glucose Sensor values (CGM),Vasopressor Use,2020-11-06,RECRUITING,OBSERVATIONAL,['NA'],
13413,NCT03176524,Assessments of local tolerability at injection site,Time to plasma glucose increase of ≥20 mg/dL from baseline,2017-06-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
13414,NCT01310491,HbA1c change over time (participants with T2DM only),Satisfaction and usability of the technology and equipments.,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
13415,NCT04227769,Change in insulin concentration in blood during the cephalic phase of insulin secretion in obese patients with type 2 diabetes,Change in autonomic function,2020-01-13,RECRUITING,INTERVENTIONAL,['PHASE2'],
13416,NCT04173117,Recruitment and retention rates,The number of participants who experience any Major Adverse Cardiovascular Events (MACE),2020-02-28,TERMINATED,INTERVENTIONAL,['NA'],
13417,NCT02695095,incidence of acute liver injury,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],
13418,NCT00174681,Percentage of subjects achieving HbA1c < 7% at the end of the study.,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
13419,NCT01982630,Accumulation Ratio of the Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2,Apparent Terminal Half Life (t1/2) of MK-8521 on Day 14 for Non-Diabetic Overweight/Obese Participants in Part 2,2013-11-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
13420,NCT03771261,Change from Baseline Body weight at 4 months,Change from Baseline Insulin Sensitivity at 4 months,2018-06-15,COMPLETED,INTERVENTIONAL,['NA'],
13421,NCT01400295,Contrast-Induced Nephropathy,An early abnormal increase in serum cystatin C,2010-12,COMPLETED,OBSERVATIONAL,['NA'],
13422,NCT05832996,The efficacy of cooled versus room temperature artificial tears in reducing post intravitreal injection ocular discomfort as measured by pain scale survey.,,2022-03-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
13423,NCT02014207,blood glucose,food intake,na,COMPLETED,INTERVENTIONAL,['NA'],subjective appetite
13424,NCT03252132,Muscle strength (isokinetic strength),,2017-08-10,COMPLETED,INTERVENTIONAL,['NA'],
13425,NCT01688778,Changes in HbA1c,Use of medication,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Number of visits at GP
13426,NCT02669732,First-phase and Second-phase secretion C-peptide,plasma concentration of DS-8500a,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
13427,NCT03391349,"mRNA expression of L-plastin,lipocalin and adiponection","Quantify the levels of L-plastin, lipocalin and adiponectin",2016-10-20,COMPLETED,OBSERVATIONAL,['NA'],
13428,NCT01432275,Overall User Preference for the FreeStyle InsuLinx System Compared to Current Method.,Preference Questionnaire (Insulin Calculator Not Activated),2011-09,COMPLETED,INTERVENTIONAL,['NA'],
13429,NCT02330406,Change in glycated hemoglobin,Change in fatty acid fraction,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
13430,NCT03111238,Complete relief of ischemic rest pain without developing ischemic lesions on the index leg.,,2017-04-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
13431,NCT00512707,Change From Baseline in Erectile Function Domain Score of the International Index of Erectile Function (IIEF),Change From Baseline in Positive Affects Ratio (PAR) of Derogatis Affects Balance Scale (DABS),2006-11,COMPLETED,INTERVENTIONAL,['PHASE4'],Change From Baseline in Sex Hormone Binding Globulin (SHBG)
13432,NCT03207841,"Change in HDL, LDL, total cholesterol and triglycerides",Change in Spinal Cord Injury-Quality of Life (SCI-QOL) Score,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],
13433,NCT02854696,Incremental cost- utility ratio at 1 year,Assessment of total cost of islet cell transplantation,2016-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
13434,NCT05165615,Percentage of time in target ranges,The 5-item World Health Organization well-being index (WHO-5 index),2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
13435,NCT02204657,Glycemic Control by Measurement of HbA1c,Hypoglycemia,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
13436,NCT02365363,Exercise intensity,Substrate Oxidation,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
13437,NCT02076347,Percentage of patients in each arm who obtain monitoring of vitamin B12 as recommended,Percentage of patients with newly identified vitamin B12 deficiency who have prior evidence of neuropathy upon chart review,2014-02,COMPLETED,INTERVENTIONAL,['NA'],
13438,NCT00435240,"waist circumference at baseline, 3 months and 6 months","C-reactive protein at baseline, 3 months and 6 months",2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
13439,NCT01928381,"Brief Pain Index - Item 5, Average Daily Pain Score (Range 0-10) Higher Values Indicate Worse Pain",,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
13440,NCT00964418,Area under the glucose infusion rate curve during one dosing interval at steady state (for NN1250),Area under the NN1250 concentration-time curve during one dosing interval at steady state,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
13441,NCT00642278,Change in HbA1c From Baseline to Week 12,Percent Change in Body Weight From Baseline to Week 12,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
13442,NCT03982693,Prevention of major cardiovascular endpoints,Changes in PAD Quality of Life,2019-03-19,RECRUITING,INTERVENTIONAL,['PHASE3'],
13443,NCT00024518,C-Peptide Level,Hemoglobin A1C,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
13444,NCT03557892,HbA1c,Local Reactions,2018-04-01,COMPLETED,INTERVENTIONAL,['NA'],
13445,NCT01316861,Glycosylated hemoglobin (HbA1c),Safety will be evaluated by the Adverse events occurence,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
13446,NCT00947024,Bioequivalence based on AUC and Cmax,,1993-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
13447,NCT04809285,Percentage of Time in Range,,2021-04-06,COMPLETED,INTERVENTIONAL,['NA'],
13448,NCT01640223,Percentage of data collected,,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
13449,NCT01497912,Fibrin network permeability,skin microvascular reactivity,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
13450,NCT00495235,Prevalence Rate of Insulin Resistance,,2005-10,COMPLETED,OBSERVATIONAL,['NA'],
13451,NCT04149392,Frequency of diabetes medication changes that take place at the follow up visit,Mortality rate,2019-12-16,WITHDRAWN,INTERVENTIONAL,['NA'],
13452,NCT03777722,Change in depression,Light exposure using the Daysimeter,2018-11-01,RECRUITING,INTERVENTIONAL,['NA'],
13453,NCT01136798,Total Amount of Slow Wave Activity,Mean 24-h Blood Glucose Levels,2010-06-01,COMPLETED,INTERVENTIONAL,['NA'],
13454,NCT02114008,Residual gastric volume (RGV) in morbidly obese diabetics. A comparison of 3 hour versus 8 hour fasting,,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
13455,NCT01373489,Hemoglobin A1c (HbA1c) at 6 Months Post Randomization,,2011-07,COMPLETED,INTERVENTIONAL,['NA'],
13456,NCT04340648,Performance and accuracy in pulse monitoring,,2019-06-03,COMPLETED,INTERVENTIONAL,['NA'],
13457,NCT05922852,urinary protein changes,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],
13458,NCT04364685,HbA1c,Quality of life-39,2017-01-25,COMPLETED,INTERVENTIONAL,['NA'],
13459,NCT02834858,Area of diabetic foot ulcers,Walking distance (treadmill) if possible,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
13460,NCT05514080,Glucose outcomes: percentage of time spent in specific glucose ranges (ex: 3.9-10.0 mmol/L),,2019-12-06,COMPLETED,INTERVENTIONAL,['NA'],
13461,NCT00458081,Relative change in the microalbuminuria level.,Safety (including neuropsychiatric events) and Laboratory assessments.,2007-03,TERMINATED,INTERVENTIONAL,['PHASE3'],
13462,NCT02354027,The area under the plasma concentration-time curve (AUC) of metformin,The number of volunteers with adverse events as a measure of safety and tolerability.,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
13463,NCT05188014,Blood glucose,percent of time in hyperglycemia,2022-03-15,RECRUITING,INTERVENTIONAL,['NA'],Carbohydrate supplementation
13464,NCT02278068,Primary Safety Outcome as assessed by Incidence of serious adverse device effects,Adverse Event Rate,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
13465,NCT00286962,incidence of hypoglycemia; data taken from patient diaries during either study arm.,"daily glucose excursions; measured with continuous glucose monitoring system (CGMS) at baseline, halfway through and at the end of both study arms",2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
13466,NCT02426138,Healthy Eating Index 2010 Score,Diabetes Distress Scale,2015-04-01,COMPLETED,INTERVENTIONAL,['NA'],Total Cholesterol
13467,NCT00233649,,,2004-05,COMPLETED,OBSERVATIONAL,['NA'],
13468,NCT03607617,SDH data adoption,DM Key tests,2018-09-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
13469,NCT00850135,Correlation Between Glucose AUC and Birth Weight.,"Pregnancy and Delivery Characteristics for Participants With AUC-130 <= 22,000 and AUC-130 > 22,000",2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
13470,NCT01053026,1. Vascular function testing,"Circulating biomarkers including hs-CRP, adiponectin, myostatin, MMP, etc",2009-12,COMPLETED,OBSERVATIONAL,['NA'],
13471,NCT04632277,Serum Cholesterol,Serum Creatinine.,2020-08-25,COMPLETED,INTERVENTIONAL,['NA'],Body mass index
13472,NCT00569400,Change of human insulin antibodies,Frequency of adverse events,2003-05-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
13473,NCT01220856,The Percentage of Insulin-independent Patients Following Single Infusion Islet Cell Transplantation at Day 75 +/- 5,,2010-07-28,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Pre-transplant in Cytokine Levels - IL-6
13474,NCT01545492,difference in 'change in z score for weight' at 12 m(+/- 2m),differences in DNA methylation,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],
13475,NCT05482958,Glycemic control amongst people with established T2DM.,Change in glycemic control.,2022-07-29,RECRUITING,OBSERVATIONAL,['NA'],
13476,NCT04317404,Post-injection glucose levels,KOOS Knee survey,2020-11-01,COMPLETED,OBSERVATIONAL,['NA'],
13477,NCT02343471,Effect on apolipoprotein B48 of whey protein as pre-meal after a high-fat meal in healthy subjects and subjects with type 2 diabetes measured as incremental Area Under the Curve (iAUC -15 - 360 min).,Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the Curve (AUC -15 - 360 min).,2015-03,COMPLETED,INTERVENTIONAL,['NA'],Responses of satiety visual analog scale (VAS) measured as incremental Area Under the Curve (AUC -15 - 360 min)
13478,NCT01582243,Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,The Percentage of Patients Achieving the Two Glycemic Goals After 12- and 24-week Treatment,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
13479,NCT02489773,Compare the Pearson Correlation of Glycated Albumin (GA) and Fructosamine Within All Subjects With the Performance Goal of 0.8,"Kendall Correlation Analysis of Changes in GA, HbA1c, and 7-day Interval MBG in the First 3 Months in Group 1",2015-06,COMPLETED,OBSERVATIONAL,['NA'],
13480,NCT06143449,Provide data on disease management.,,2015-10-01,RECRUITING,OBSERVATIONAL,['NA'],
13481,NCT05788965,"Feasibility, safety, tolerability",,2023-04-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
13482,NCT04601519,Objective sleep fragmentation,Sleep fragmentation by subgroups,2021-07-01,UNKNOWN,OBSERVATIONAL,['NA'],
13483,NCT05654727,BDNF,,2021-07-01,COMPLETED,OBSERVATIONAL,['NA'],
13484,NCT02813759,Satiety,,2015-07,COMPLETED,INTERVENTIONAL,['NA'],
13485,NCT06143267,Total glucagon response,Food intake,2022-12-06,RECRUITING,INTERVENTIONAL,['NA'],
13486,NCT00767260,area under the curve of c-peptide,area under the curve of serum insulin,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
13487,NCT03774186,Fear of Hypoglycemia Score,Fetal Outcomes: Number of Participants With Neonatal Hypoglycemia Infants,2019-03-21,COMPLETED,INTERVENTIONAL,['NA'],
13488,NCT04051866,Glycated Hemoglobin A (HbA1c),Gingival Probing bleeding,2022-12-02,WITHDRAWN,INTERVENTIONAL,['NA'],
13489,NCT00464776,Investigate the antiproteinuric effect of increasing doses of Aliskiren compared to matching placebo.,To investigate whether there is a change in biomarkers of inflammation and cardiovascular risk.,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
13490,NCT05027334,Fasting blood glucose (FBG),Weight,2017-07-01,COMPLETED,INTERVENTIONAL,['NA'],
13491,NCT01671735,weight loss,,2012-09,WITHDRAWN,INTERVENTIONAL,['NA'],
13492,NCT01547897,Effect of NOX-E36 on albuminuria as measured by ACR (albumin to creatinine ratio; mg/g),Effect of NOX-E36 on eGFR,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
13493,NCT05136287,Weight loss,Number of participants experiencing adverse events,2022-02-01,COMPLETED,OBSERVATIONAL,['NA'],
13494,NCT01529216,HbA1c,HbA1c,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
13495,NCT04013581,Change of HbA1c,Change of liver enzymes,2019-08-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
13496,NCT02327039,"Change from baseline in reverse cholesterol transport, measured as cholesterol efflux capacity of patient's plasma",Safety as measured by monitoring of adverse events,2015-03,COMPLETED,INTERVENTIONAL,['PHASE4'],Exploratory analyses - changes from baseline in impedance cardiography analysis
13497,NCT04040595,Mean adipocyte size (µm2) assessed using Image J software.,"Adipose tissue expression of genes that are determinants of adipose inflammation (IL-1beta, IL-6, and 8, TNFalpha, MCP-1/CCL2).",2019-03-07,COMPLETED,INTERVENTIONAL,['NA'],
13498,NCT02449330,Change of the ratio of peak velocity of early transmitral diastolic filling by echocardiography (E) to early diastolic mitral annular velocity by tissue Doppler echocardiography (E/e'),Change of plasma levels of NT-proBNP,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13499,NCT01976689,Left ventricular hypertrophy,,2012-03,COMPLETED,OBSERVATIONAL,['NA'],
13500,NCT05015504,estimated hemoglobin A1c levels,body weight,2022-02-10,RECRUITING,INTERVENTIONAL,['NA'],
13501,NCT01762046,Metformin response,Vitamin D,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],
13502,NCT03483129,Percentage of eligible patients recruited into the study assessed by study attendance and surgery patient records,Change in the urinary concentration of metabolites of high health importance assessed by FIE-MS,2018-04-25,COMPLETED,INTERVENTIONAL,['NA'],
13503,NCT04097600,"AUC0-24h,sema,SS; area under the semaglutide plasma concentration-time curve during a dosing interval at steady state","t½,sema,SS; terminal half-life of semaglutide at steady state",2019-09-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
13504,NCT06024590,The primary endpoint is the percentage of index ulcers healed at 12 weeks,Wound complication rate,2023-10-03,RECRUITING,INTERVENTIONAL,['PHASE4'],
13505,NCT02158442,"Efficacy of Timentin Delivered by PILP Procedure (Treatment Group) Versus Intravenous Delivery (Control Group) at Reducing Microbiological Load in Subjects With Diabetes, and Significant Wound Infection of the Lower Limb.",,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
13506,NCT00705952,"Whether weight loss achieved through a programme of intensive lifestyle management can result in enhanced production of Glucagon-Like Peptide-1 together with improvements in glycaemic control, in patients with new onset type 2 diabetes.","To examine the changes in hormonal regulators of energy homeostasis (leptin, adiponectin, ghrelin) and cardiovascular risk factors occurring with this intervention.",2008-01,COMPLETED,INTERVENTIONAL,['NA'],
13507,NCT03162926,Incidence of all adverse events reported for subjects,,2017-07-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
13508,NCT02265276,Change in the NAFLD fibrosis score,Change in HbA1c,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
13509,NCT05785780,Up-to-date CRC screening,Rate of CRC Screening Uptake by Glucose Control (Controlled vs. Uncontrolled) Among Participants with Type 2 Diabetes,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],Implementation Fidelity
13510,NCT04439474,HBA1C,,2018-10-10,COMPLETED,INTERVENTIONAL,['NA'],
13511,NCT00214253,post-transplant islet function,Suitability of cadaver donor pancreases for islet transplantation,2002-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
13512,NCT05174390,Number of participants with the diagnosis of atrial fibrillation,Patient-reported symptoms (descriptive category variables) of atrial fibrillation using a questionnaire in a digital application,2021-09-20,UNKNOWN,OBSERVATIONAL,['NA'],
13513,NCT05980754,biochemical parameters including level of insulin,pancreatic fat content,2024-05-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
13514,NCT04407650,Glycaemic control,Biomedical neonatal outcomes,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13515,NCT03685773,Endogenous glucose production (EGP),Change in Arterial Spin Labeling (ASL) signal,2019-04-21,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
13516,NCT00660790,Change of Intima Media Thickness (IMT),,2008-04,COMPLETED,OBSERVATIONAL,['NA'],
13517,NCT02772497,Proportion of visual acuity improvement using Snellen chart or equivalent,Number of eyes with retinal toxicity after ziv aflibercept treatment,2016-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
13518,NCT04486547,Change from baseline social motivation level of adolescents at 6 months,,2018-10-15,COMPLETED,INTERVENTIONAL,['NA'],
13519,NCT04336969,Change in rise of HbA1c,Change in education exposure to safe exercise strategies,2020-06-18,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],"T1D Patients receiving 4T education and care monitored on a step-down cadence in study 2, will achieve an HBA1c non-inferior to weekly review"
13520,NCT00233298,"Differences in response among healthy, healthy obese, pre-diabetic or 3 diabetes",,2005-05-26,COMPLETED,OBSERVATIONAL,['NA'],
13521,NCT03378024,The correlation of changes of albuminuria and the outcome of PAD,,2016-12-01,UNKNOWN,OBSERVATIONAL,['NA'],
13522,NCT05188586,Specificity,Stage Shift,2022-12-06,RECRUITING,INTERVENTIONAL,['NA'],
13523,NCT03962010,Change in HbA1c,,2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
13524,NCT04234334,Plasma Zeaxanthin,Plasma glucose,2020-01-13,COMPLETED,INTERVENTIONAL,['NA'],
13525,NCT00850161,The primary endpoint is to determine whether intranasal administration of Nasulin™ will stimulate glucose disposal and suppress endogenous glucose production.,,2009-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
13526,NCT03444467,Number of treatment emergent adverse events (TEAEs),Change from baseline in Activated Partial Thromboplastin time (APTT),2018-02-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
13527,NCT05039307,Change from baseline in the adherence to a healthy lifestyle score at 12 months,Change from baseline in systolic and diastolic blood pressure at 12 months,2021-10-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
13528,NCT01029392,Change in Hemoglobin A1c,Change in Insulin Requirements,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
13529,NCT04547439,Melatonin and Cortisol Rhythm,,2021-02-03,RECRUITING,INTERVENTIONAL,['PHASE2'],
13530,NCT05443204,MFG discharge - hypoglycaemic events,Postprandial glucose intersticial monitoringdiabetes specific supplement,2022-07-07,RECRUITING,INTERVENTIONAL,['NA'],
13531,NCT00000539,,,1992-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
13532,NCT00641719,Number of Participants Who Experienced an Adverse Event (AE),Change From Baseline to One Year Endpoint in Beck Depression Inventory-II (BDI-II) Total Score,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
13533,NCT00726713,Change From Baseline in Vibration Perception Threshold (VPT) at 24 Weeks,(Exploratory) Change From Baseline in Levels Potential Antioxidant (PAO) at Week 24,2008-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
13534,NCT03258840,HbA1c,Serum Lpa,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
13535,NCT03133156,Changes in human adipose tissue characteristics following exercise training.,,2017-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
13536,NCT04182451,Efficacy of Meso Wound Matrix,Health Economics,2019-12-05,COMPLETED,INTERVENTIONAL,['NA'],
13537,NCT01729299,post-prandial insulin secretion,gastric emptying,2013-04,UNKNOWN,INTERVENTIONAL,['NA'],
13538,NCT01890226,Change in Composite Quality Score,Change in Health-related Quality of Life,2014-11,COMPLETED,INTERVENTIONAL,['NA'],
13539,NCT03513055,the relationship between SDBG and injection score,the relation between insulin antibodies and glucose excursions,2018-05-07,UNKNOWN,INTERVENTIONAL,['NA'],
13540,NCT05950477,"In 100 subjects with type 1 diabetes it will be evaluated the relationship between time in range, assessed though continuous glucose monitoring, and the score of the depression questionnaire CES-D",,2023-06-12,RECRUITING,OBSERVATIONAL,['NA'],
13541,NCT00173134,,,2005-05,UNKNOWN,OBSERVATIONAL,['NA'],
13542,NCT01514292,CGM Relative Differences to Laboratory Reference,,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
13543,NCT01079234,Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,Extension Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
13544,NCT00693537,,,na,COMPLETED,INTERVENTIONAL,['PHASE4'],
13545,NCT00049907,,,2002-09,COMPLETED,OBSERVATIONAL,['NA'],
13546,NCT01431430,Patient death,Renal lithiasis,2012-01-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
13547,NCT05541484,Ketone levels measured in blood and breath in persons with T1D in persons with T1D,Ketone levels in persons with T1D during usual care versus usual care plus SGLT2i treatment,2022-10-14,RECRUITING,INTERVENTIONAL,['PHASE4'],Ketone levels in persons with T1D undergoing insulin withdrawal
13548,NCT01765517,effects of probiotics on endotoxin levels in patients with T2DM,effects of probiotics on gut microflora,2013-10,COMPLETED,INTERVENTIONAL,['NA'],Effects of probiotics on insulin resistance
13549,NCT01221194,Number of Participants Who Developed Foot Ulcer During Study Time Frame,,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
13550,NCT00288132,Hemoglobin A1c,Waist Circumference,2005-09,COMPLETED,INTERVENTIONAL,['NA'],
13551,NCT01383772,Risk of failing visual field criteria to hold a driving licence.,Visual field assessment prior to planned pan retinal photocoagulation,2012-06,COMPLETED,INTERVENTIONAL,['NA'],
13552,NCT04318184,"""Change"" is being assessed for Triglyceride","""Change"" is being assessed for BMI",2018-01-02,COMPLETED,INTERVENTIONAL,['NA'],
13553,NCT00268541,Adipose tissue gene expression at 8 weeks,Body composition/adiposity at 8 weeks,2004-09,COMPLETED,INTERVENTIONAL,['NA'],
13554,NCT05525884,Diagnosis of significant hepatic fibrosis,High HOMA-IR,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],
13555,NCT00742521,catecholamine measures,,2001-03,COMPLETED,INTERVENTIONAL,['NA'],
13556,NCT01500590,change of estimated GFR calculated by MDRD equation and onset of microalbuminuria,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13557,NCT03975309,Montreal Cognitive Assessments (MoCA),Number Span Test (Forward/Backward),2019-09-09,COMPLETED,OBSERVATIONAL,['NA'],
13558,NCT05705271,Number of participants with hyperkalemia events,Change in urine albumin-to-creatinine ratio (UACR) from baseline to 4 months,2023-02-08,RECRUITING,INTERVENTIONAL,['PHASE4'],
13559,NCT05095922,Blood pressure,,2023-03-28,RECRUITING,INTERVENTIONAL,['PHASE4'],
13560,NCT03797885,"Proportion of type 2 diabetes mellitus (T2DM) patients with cardiovascular risk factors (CVRFs) and/or established cardiovascular disease (CVD), regardless the date of diagnosis",Type of pharmacological treatment,2019-01-15,COMPLETED,OBSERVATIONAL,['NA'],
13561,NCT00873405,"Weight loss, BMI reduction and waist circumference reduction","Glucose homeostasis, metabolic control.",2006-06,UNKNOWN,INTERVENTIONAL,['NA'],
13562,NCT02816073,Regression of neovascularization,Retreatment rate,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
13563,NCT01565317,Change in Sural nerve conduction velocity,Change in Sural Nerve Amplitude potential,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
13564,NCT03634098,"To study in type 2 diabetic participants with liver biopsy, the performance of a composite biomarker (3rd generation test) for the diagnosis of NASH",Constitution of a bio-collection,2018-10-25,COMPLETED,INTERVENTIONAL,['NA'],
13565,NCT00237094,,,2005-06,COMPLETED,INTERVENTIONAL,['NA'],
13566,NCT00633763,Difference in fallypride binding in the pancreas of long-standing T1DM patients versus healthy controls,,2008-02,COMPLETED,OBSERVATIONAL,['NA'],
13567,NCT00839865,The primary objective is to determine the effect of this ointment on the incidence of complete wound closure.,"Secondary objectives include: evaluating the acceleration of ulcer closure or facilitation of surgical closure, reduction of ulcer surface area over time, reduction in complications, the quality of life and it's safety.",2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],
13568,NCT00005146,,,1979-05,COMPLETED,OBSERVATIONAL,['NA'],
13569,NCT01823367,Changes in weight,Changes in diet,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
13570,NCT00431977,Cardiac death,All-caused death,2006-11,COMPLETED,INTERVENTIONAL,['NA'],
13571,NCT03536364,Effect of food order on postprandial glucose excursions as measured by incremental area under the curve (iAUC) for glucose ((mg/dl)*180) in the setting of 3 commonly followed meal patterns in overweight/obese patients with pre-diabetes,Effect of food order on satiety as measured by a visual analog scale (cm) in the setting of 3 commonly followed meal patterns in overweight/obese patients with pre-diabetes,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],
13572,NCT03130426,The first occurrence of diabetes relapse,Glycated hemoglobin (HbA1C),2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE3'],
13573,NCT03815955,Positive and Negative Affect,,2019-03-14,COMPLETED,INTERVENTIONAL,['NA'],
13574,NCT04678557,Cohort 2: The Change in AUC (Area Under Curve) From Baseline to Week 26 in C-peptide During 4-hour MMTT,,2019-06-25,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
13575,NCT01020955,Insulin sensitivity,body composition,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
13576,NCT03400618,The difference in mean glucose level,Hypoglycemia confidence score,2018-03-01,COMPLETED,INTERVENTIONAL,['NA'],Ketoacidosis
13577,NCT05487534,Glucose variability and insulin resistance (CGMS - 10 days),Attentional Cueing Procedure,2023-04-26,RECRUITING,OBSERVATIONAL,['NA'],
13578,NCT01125553,Maximum observed serum insulin aspart concentration,Time to maximum observed serum insulin aspart concentration,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
13579,NCT02362737,Change help-seeking behaviors (Medication adherence and doctor/ER visits).,Change HbA1c.,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],
13580,NCT00241085,Change from baseline in urinary protein excretion after 30 weeks,"Change from baseline in circulating markers of blood vessel inflammation, insulin resistance, serum creatinine, diabetic control, and proportion of patients who return to normalization of protein excretion after 30 weeks",2002-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
13581,NCT00874159,Percentage of diabetic patients having diabetic eye complications,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, nephropathy and retinopathy)",2009-04,COMPLETED,OBSERVATIONAL,['NA'],
13582,NCT01045005,Doppler Blood flow velocity waveforms measured at rest and after administration of oxygen and carbon dioxide,Radial Artery pressure waveforms,2006-01,WITHDRAWN,INTERVENTIONAL,['NA'],
13583,NCT01965496,To assess HbA1C levels after 14 weeks continuous treatment,To assess Fasting blood glucose levels,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],To assess the body weights after the treatment
13584,NCT04413578,HbA1c Range,Healthcare Cost,2018-12-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
13585,NCT05536804,Change from Baseline in Kidney Oxygenation in Participants With or Without T2D,Percent Change from Baseline in Urine Albumin-to-Creatine Ratio (UACR),2023-02-08,RECRUITING,INTERVENTIONAL,['PHASE2'],
13586,NCT03015220,Number of Treatment-emergent Adverse Events (TEAEs),Diabetes Therapy-Related Quality of Life (DTR-QoL): Total Score and Scores for the 4 Domains,2017-01-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
13587,NCT05073302,Rate of inflammation in the DL implant site,Cellular composition demonstrated by immunohistochemistry,2022-03-22,RECRUITING,INTERVENTIONAL,['PHASE1'],
13588,NCT06241664,Sensitivity and Specificity,,2024-01-31,RECRUITING,INTERVENTIONAL,['NA'],
13589,NCT04866667,New-onset cardiovascular events,Microvascular complications,2021-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
13590,NCT01845831,Change in HbA1C,Hospital Mortality Rate,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
13591,NCT05498688,Plasma fatty acid composition,Subjective appetite,2022-08-25,RECRUITING,INTERVENTIONAL,['NA'],
13592,NCT02118714,Percentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 26,Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Inhibin B,2015-04-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
13593,NCT05990530,Residual β-Cell function (RBCF),Quality of life score,2023-02-22,RECRUITING,INTERVENTIONAL,['PHASE2'],
13594,NCT04143737,Change in average daily steps- measured by Pedometer,Change in Leadership self-efficacy scale,2016-03-07,COMPLETED,INTERVENTIONAL,['NA'],
13595,NCT00687063,Weight change from baseline,Insulin dose and frequency at the end of the study,2008-04,COMPLETED,OBSERVATIONAL,['NA'],
13596,NCT03101865,Time in target (3.9 to 10.0mmol/l) (70 to 180 mg/dl),AUC of glucose below 3.5mmol/l (63mg/dl),2017-08-08,COMPLETED,INTERVENTIONAL,['NA'],Percentage of time of CGM availability
13597,NCT01511692,The energy intake at a standardised buffet meal with a preload paradigm quantified using Foodworks 2.10,Adverse events,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
13598,NCT04090008,Percent reduction in the ulcer size,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],
13599,NCT02072902,Hazard ratios for all-site and site specific cancer,,2012-03,COMPLETED,OBSERVATIONAL,['NA'],
13600,NCT01193387,Maximum observed Insulin Degludec concentration,Area under the Insulin Degludec concentration-time curve,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
13601,NCT01869881,ACR(Urine Albumin/Creatinine ratio),PCR(Protein to Creatinine ratio in Urine),2013-02-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
13602,NCT00508014,"Mean change in blood pressure, glycated hemoglobin, and LDL-cholesterol between baseline and follow-up","Use of aspirin, ACE inhibiters/ARBs (diabetic patients), pneumonia vaccine updated, diabetic foot exam, diabetic microalbumuria check, retinal exam, smoking cessation counseling, dental visit, and self management goal",2006-12,COMPLETED,INTERVENTIONAL,['NA'],
13603,NCT06111508,Change in Time in Range,Frequency of Dose Changes,2023-11-29,RECRUITING,INTERVENTIONAL,['NA'],
13604,NCT02377362,Number of Participants With One or More Treatment Emergent Adverse Events (Parts B),Change From Baseline in Hip Circumference (Part B),2015-03,TERMINATED,INTERVENTIONAL,['PHASE1'],
13605,NCT00171561,Blood measures of hypertension after 24 weeks,Change in serum markers of endothelial function and oxidative stress after 24 weeks,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
13606,NCT00324350,Number of Participants With at Least One Fall,Number of Participants With > 2 cm of Height Loss,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
13607,NCT03364868,The development of diabetes,Abnormal glucose tolerance (AGT) defined by dysglycemia or diabetes.,2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
13608,NCT01963546,Stress Indicators,Vital Signs,2014-03,UNKNOWN,INTERVENTIONAL,['NA'],
13609,NCT03235908,Copeptin level,operational function (functioning) after 12 months compared to baseline assessed by questionnaire,2017-05-01,COMPLETED,OBSERVATIONAL,['NA'],
13610,NCT05411965,Pharmacokinetic variables - Cmax,Pharmacokinetic variables - t1/2 of Pioglitazone M-IV,2022-04-28,COMPLETED,INTERVENTIONAL,['PHASE1'],
13611,NCT04501107,AUCLIS.0-1h,AUCGIR.4-8h,2020-08-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
13612,NCT02986256,Number of hospitalization days related to diabetic foot ulcers after one year of follow-up,Patient satisfaction score,2017-01-04,COMPLETED,INTERVENTIONAL,['NA'],
13613,NCT03416855,Percentage of patients with AEs at week 26,Changes from baseline in PPBG/PPPG after 26 weeks treatment,2018-01-31,COMPLETED,OBSERVATIONAL,['NA'],
13614,NCT03858062,Time in target,Glucose measurement performance,2019-03-10,COMPLETED,INTERVENTIONAL,['NA'],Glucagon dose
13615,NCT05319275,mTCNS total score change from baseline at week 24,Changes in Nerve Conduction Amplitude from baseline at week 24,2020-07-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
13616,NCT01792635,Number of Participants With Change From Baseline and Absolute Values in Electrocardiogram (ECG) Meeting Categorical Summarisation Criteria in Part B,Ra in Part B in PF-05175157 200 mg BID Group,2012-12,TERMINATED,INTERVENTIONAL,['PHASE2'],
13617,NCT03036774,Number of patients with full stomach,Intraoperative hypoxemia,2017-02-14,COMPLETED,INTERVENTIONAL,['NA'],
13618,NCT06236581,Change from baseline on percent time in range from continuous glucose monitor at post-intervention,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
13619,NCT04917692,Number of episodes of diabetic ketoacidosis per patient,Number of episodes of hypoglycemia per patient,2021-07,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
13620,NCT01464320,Change in glomerular filtration rate,Change in urinary albumin excretion,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
13621,NCT01580813,Evaluate the Impact of Acipimox on Exercise Parameters in People With Type 2 Diabetes: Peak VO2,Triglycerides,2011-06,COMPLETED,INTERVENTIONAL,['NA'],
13622,NCT03476876,Wound Saturation of Oxygen at 16 Weeks,Number of Participants With Wound Complications at 16 Weeks,2018-04-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
13623,NCT04657939,Change in myocardial perfusion after treatment,Peripheral endothelial function,2020-12-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
13624,NCT03684642,Change From Baseline to Week 56 in HbA1c,Number of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year,2018-09-26,TERMINATED,INTERVENTIONAL,['PHASE3'],
13625,NCT03360604,Change in cognitive performance on a Letter Memory Task,Fullness,2018-04-04,COMPLETED,INTERVENTIONAL,['NA'],
13626,NCT03060577,Percentage Change in LDL-C From Baseline of the ORION-1 Study to Day 210 in ORION-3 (Inclisiran Arm),"Number of Participants Reaching on Treatment LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL (Inclisiran Arm)",2017-04-27,COMPLETED,INTERVENTIONAL,['PHASE2'],
13627,NCT01167959,Changes in gut hormones,,2009-06,COMPLETED,OBSERVATIONAL,['NA'],
13628,NCT00547027,weekly physical activity,physical activity stage of change,2006-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
13629,NCT04359771,Change in the Best Corrected Visual Acuity (BCVA),,2018-01-22,COMPLETED,INTERVENTIONAL,['PHASE4'],
13630,NCT03849261,AUClast of Metformin,CL/F of Metformin,2019-01-14,UNKNOWN,INTERVENTIONAL,['PHASE1'],
13631,NCT02353273,"Pharmacokinetic parameters of Salvigenin and Asiaticoside A as listed below. (AUC0-∞, AUC0-t, Cmax)(Cmax,ss, AUC0-τ)","Pharmacokinetic parameters of Salvigenin and Asiaticoside A as listed below, if appropriate. (Tmax,ss)",2015-07-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
13632,NCT00954577,"Reduction in diabetes risk factors including insulin secretory capacity, insulin sensitivity, body fat content, dyslipidemia, and circulating concentrations of pro-inflammatory cytokines.",Improvement in self-esteem and in health-related behaviors.,2006-07,UNKNOWN,OBSERVATIONAL,['NA'],
13633,NCT05680129,Change from baseline in HbA1c,Pharmacokinetics: plasma trough level of XW003,2023-01-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
13634,NCT02935868,"Salivary peroxidase - collection of stimulated saliva in 10 minutes, measurement by a spectrophotometer.","Plaque index - measured by visual observation and classification in scores (1 for presence, 0 for absence)",2013-11,COMPLETED,OBSERVATIONAL,['NA'],
13635,NCT02700477,Post prandial blood sugar levels,Glycosylated haemoglobin (HbA1C)(%),2013-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
13636,NCT02052037,Glycemic Index,Physical Activity,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
13637,NCT03076424,Intestinal Microbiome Composition,Hemoglobin A1-c,2017-03-08,COMPLETED,OBSERVATIONAL,['NA'],
13638,NCT02382536,In-line fluid pressure,Leakage,2014-08,COMPLETED,OBSERVATIONAL,['NA'],Number of subjects with adverse events
13639,NCT04023344,Antibody Response,Treatment Satisfaction,2018-03-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
13640,NCT02917057,Changes from baseline in weight (kg),Frequency of Vomiting,2015-08-01,COMPLETED,OBSERVATIONAL,['NA'],
13641,NCT06228313,VivaChek Ino glucose concentration,,2022-06-01,COMPLETED,OBSERVATIONAL,['NA'],
13642,NCT02311504,presence of diabetic retinopathy,,2014-01,COMPLETED,OBSERVATIONAL,['NA'],
13643,NCT00449839,Absorbed Insulin Aspart,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
13644,NCT03737942,neuromuscular monitoring,,2018-11-15,UNKNOWN,OBSERVATIONAL,['NA'],
13645,NCT02011100,chronic systemic inflammation,level of glucose intolerance,2013-12,COMPLETED,INTERVENTIONAL,['NA'],muscle carnosine content
13646,NCT02616666,Proportion of patients achieving clinical success as measured by a 4-item composite endpoint.,"To assess differences between dapagliflozin and SOC in the healthcare resource utilization up to 52 weeks following randomization and separately, up to 104 weeks following randomization",2016-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
13647,NCT00164658,Change in stage of adoption of health behaviors and referral for additional screening and follow up for high risk participants at 6 month post evaluation,Primary care physicians' provision of preventive services in response to family medical history.,2005-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
13648,NCT05335083,Mean 24 hour glucose difference between the CPAP on and CPAP off conditions,Insulin sensitivity,2023-01-31,RECRUITING,INTERVENTIONAL,['NA'],
13649,NCT04272359,Long-term diabetes complications,Insulin parameters after shift to new-generation hypoglycaemic therapeutic regimens,2019-05-06,UNKNOWN,OBSERVATIONAL,['NA'],
13650,NCT01067092,% of persons with blood pressure less than 130/80,Summary of Diabetes Self-Care Activities,2005-05,COMPLETED,INTERVENTIONAL,['NA'],
13651,NCT03058029,Percent change in body weight,Change in HbA1c,2017-02-22,UNKNOWN,INTERVENTIONAL,['NA'],Proportion of subjects with weight loss ≥7.5%
13652,NCT02370719,Change in HbA1c from baseline to 12 months,Summary of Diabetes Self-Care Activities,2015-06-28,TERMINATED,INTERVENTIONAL,['NA'],
13653,NCT01475201,change in arterial stiffness,change in diastolic blood pressure,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
13654,NCT05679037,The change in carotid artery intima-media thickness (CIMT),Fast blood glucose measuremt,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
13655,NCT01171456,Effect of metformin versus placebo on the development of GDM,Effects on maternal and fetal pregnancy outcomes of pre-conception metabolic intervention with metformin.,2010-04,WITHDRAWN,INTERVENTIONAL,['NA'],
13656,NCT05476627,Number of Participants with all cause death,Advanced Intelligence Assessment with Mini-Mental State Examination (MMSE),2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],
13657,NCT00935532,Change in HbA1c From Baseline to Endpoint (Week 26),Assessment on Event Rate of Treatment-emergent Minor Hypoglycemic Events,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
13658,NCT00398060,Weight,"Blood pressure (diastolic, systolic)",2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
13659,NCT03339453,Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia,PK: Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon,2017-11-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
13660,NCT01956773,Number of Participants With Uptake of Genetic Counseling for Those at Risk of Hereditary Conditions at 1 Year,Number of Providers Who Were Successfully Using MeTree in Their Clinical Work Flow,2014-04-11,COMPLETED,INTERVENTIONAL,['NA'],
13661,NCT02687893,Mean duration of time with sensed glucose less than 70 mg/dl post-exercise,Mean duration of time with capillary blood glucose > 180 mg/dl,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
13662,NCT03761719,Neurocognitive test domain scores,,2018-07-30,COMPLETED,OBSERVATIONAL,['NA'],
13663,NCT04984044,Change from baseline Michigan Neuropathy Screening Instrument (MNSI) scores at 8 weeks.,Change from baseline Serum 25(OH) D level at 8 weeks.,2020-11-07,COMPLETED,INTERVENTIONAL,['NA'],
13664,NCT01618045,Monocyte Function,Lipid Profile,2012-05,COMPLETED,OBSERVATIONAL,['NA'],
13665,NCT04266054,Glycemic control as measured by hemoglobin A1c. Hemoglobin A1c will be measured from whole blood samples obtained and analyzed in a blinded fashion.,triglycerides will be measured from the same blood sample used to derive the outcome measure.,2019-12-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
13666,NCT02181621,Within-patient Change From Baseline in Log^10 Biofilm-protected Bacteria Count (Colony Forming Units [Cfu]/Gram[g]),Presence of Biofilm by Clinical Judgment Versus Presence of Biofilm by Laboratory Test,2014-08,TERMINATED,INTERVENTIONAL,['NA'],
13667,NCT04706637,Change of 24 hour urine creatinine,Adverse events,2021-02-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13668,NCT01138124,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,,2010-03,COMPLETED,OBSERVATIONAL,['NA'],
13669,NCT03164187,Percentage of patients achieving HbA1c level ≤ 7 %,Mean daily dosage of Diabeton MR,2016-09-01,COMPLETED,OBSERVATIONAL,['NA'],
13670,NCT01912092,"Clinical signs of local infection (Presence of erythema, pain, tenderness, warmth or induration)",Wound surface area,2013-04,COMPLETED,INTERVENTIONAL,['NA'],
13671,NCT01123083,Change From Baseline in 2 Hour Mixed Meal-stimulated C-peptide Area Under Curve (AUC) (Normalized for 120-minute Time Interval) at Month 12,"Composite Rank Sum: C-Peptide AUC, HbA1c and Exogenous Insulin Use at 6 and 12 Months",2010-05-17,COMPLETED,INTERVENTIONAL,['PHASE3'],
13672,NCT00513201,Glycemic control in lyspro vs regular insulin in cirrhotic patients,Tolerance to treatment and reduced postprandial hypoglycemia episodes,na,COMPLETED,INTERVENTIONAL,['PHASE4'],
13673,NCT01107717,Difference in HbA1c level,hypoglycemic events,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
13674,NCT00270842,Gait and Balance Measures,Fall Self Efficacy,2006-01,COMPLETED,INTERVENTIONAL,['NA'],
13675,NCT05260021,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline PedsQL (3.2) Diabetic Module,2022-04-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
13676,NCT04018833,Functional change,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],
13677,NCT01497535,Maximum glucose infusion rate (GIRmax),Adverse events,2004-05-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
13678,NCT03062475,GDM,pre-eclampsia,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA'],
13679,NCT02783677,Digital infrared thermal imaging (DITI),,2013-01,UNKNOWN,OBSERVATIONAL,['NA'],
13680,NCT04051294,Insulin level,Blood pressure,2019-01-03,COMPLETED,INTERVENTIONAL,['NA'],
13681,NCT02594397,the score of GCSI,motilin concentrations,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],
13682,NCT05508061,Percentage of time the glucose level is above 10 mmol/l for the study participants,AP-related parameters: algorithm activity,2022-10-19,COMPLETED,INTERVENTIONAL,['NA'],
13683,NCT02935855,Efficacy on coagulation parameters,Safety and tolerability parameters,2015-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
13684,NCT04746599,Pain reduction,Limb salvage,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
13685,NCT01778738,Beta-cell function,Vitamin and mineral deficiencies,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
13686,NCT00823381,global skeletal muscle gene expression profile,safety and tolerability,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
13687,NCT03945747,Change in estimated insulin sensitivity,Change in DXA scan,2019-08-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
13688,NCT01412554,Exploring Insulin Sensitivity After 10-20 Years of Follow-up,Ultrasound Abdomen,2011-08,COMPLETED,OBSERVATIONAL,['NA'],
13689,NCT01907958,Stabilisation or improvement of urine albumin excretion status by at least one stage,Microalbuminuria (or further stages of CKD) after 12 months,2013-04,UNKNOWN,OBSERVATIONAL,['NA'],"Demographics, medical history and medication Diabetes and hypertension status Blood pressure measurements"
13690,NCT02762578,Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin),Device Specific Questionnaires II (Would You Recommend the Pen?),2016-05-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
13691,NCT03912363,Neonatal blood glucose value,Incidence of composite neonatal outcome,2019-11-01,RECRUITING,INTERVENTIONAL,['NA'],
13692,NCT04627636,- Visual analogue scale for pain (VAS-P) for pain assessment,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],
13693,NCT04621396,Type 2 Diabetes,,2013-09,RECRUITING,OBSERVATIONAL,['NA'],
13694,NCT01301339,Do Air Force personnel who fail the Air Force physical fitness test have a higher incidence of pre-diabetes than those who pass the test?,"And for those who fail, do they have higher cardiovascular risks as correlated with fasting lipid panel.",2011-07,COMPLETED,OBSERVATIONAL,['NA'],
13695,NCT00144937,Lowering of LDL cholesterol concentrations and blood pressure levels (at 12 months). Increase in use of antiplatelet agents (at 12 months),All the above-mentioned primary and secondary outcomes will be evaluated at 12 months,2003-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13696,NCT03528174,Mean Absolute Relative Difference of Sensed Glucose Values,Mean Draize Scale for Erythema for the Right Sensing Cannula at End of Study for All Subjects,2018-04-16,COMPLETED,INTERVENTIONAL,['NA'],
13697,NCT02062034,Oxidative Stress markers,Progression and regression of non-proliferative diabetic retinopathy,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Security profile
13698,NCT01614496,Time spent with glucose in the target range,,na,COMPLETED,INTERVENTIONAL,['NA'],
13699,NCT03300934,Time spent in glucose target (%) (3.9 - 10 mmol/l),User experience after the 4 week treatment,2017-07-01,COMPLETED,INTERVENTIONAL,['NA'],
13700,NCT03166124,Pharmacokinetics: Insulin Lispro Area Under the Concentration Versus Time Curve (AUC) for Each Treatment Arm,Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm,2017-05-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
13701,NCT00501397,"urine collections for volume, glucose, & creatinine at Day 1 Session 1, Days 5 & 6 Session 3.","Vitals: Screening,Days -1 & 1 Session 1,Days 1-4 Session 2,Days 5-6 Session 3,followup",2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
13702,NCT03240874,Number of Participants Who Used the SweetMama Application,Difference in Hemoglobin A1c From Enrollment to Delivery,2017-08-02,COMPLETED,INTERVENTIONAL,['NA'],Clinical Outcomes of Pregnancy - Number of Babies With Neonatal Intensive Care Unit Admission
13703,NCT01234727,,,2010-12,COMPLETED,OBSERVATIONAL,['NA'],
13704,NCT05104333,Neutralizing antibody level,Adverse events following vaccination,2021-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13705,NCT05414968,Change from Baseline Pain Assessment,,2023-03-22,RECRUITING,INTERVENTIONAL,['NA'],
13706,NCT01845324,width of fetal interventricula heart septum,glucose control in patients with normal and abnormal interventricular septal width,2013-05,UNKNOWN,OBSERVATIONAL,['NA'],
13707,NCT04653207,Change in postprandial blood glucose over 180 minutes period,Change in postprandial plasma insulin over 180 minutes period,2018-03-01,COMPLETED,INTERVENTIONAL,['NA'],
13708,NCT02132442,Change in hepatic triglyceride content (HTGC),Hemoglobin A1c,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
13709,NCT00940082,"the gender, height, weight, blood pressure, course of the disease of each patient was recorded","Left ventricular mass index (LVMI), relative wall thickness (RWT) were calculated and High-sensitive C-reactive protein (HsCRP), homocysteine and TNF-α were detected",2007-06,UNKNOWN,OBSERVATIONAL,['NA'],
13710,NCT00704574,"Incidence of serious adverse drug reactions, including major hypoglycaemic events",Variability in FPG (Fasting Plasma Glucose),2008-01,COMPLETED,OBSERVATIONAL,['NA'],
13711,NCT05977205,Glycemic control,Fear of COVID-19 infection,2020-05-02,COMPLETED,OBSERVATIONAL,['NA'],
13712,NCT01336023,Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.,Mean Actual Daily Insulin Dose,2011-05-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
13713,NCT00674466,Reduction of HbA1c From Baseline,Reduction in Fasting Body Weight From Baseline,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
13714,NCT01030471,Diabetes-Related Family Conflict Scale (DFCS)-Measure of family conflict around diabetes-specific tasks,Hemoglobin A1c value,2009-09,WITHDRAWN,INTERVENTIONAL,['NA'],
13715,NCT05430204,Number of fetal or neonatal deaths,Number of participants who formula fed their babies,2023-03-07,RECRUITING,INTERVENTIONAL,['NA'],
13716,NCT01563120,glycemic control,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
13717,NCT04811989,General foot health,Representations about diabetic foot,2021-03-08,COMPLETED,INTERVENTIONAL,['NA'],Sociodemographic data
13718,NCT04860908,Presence of anti COVID 19 antibodies in maternal and cord blood,,2021-04-26,UNKNOWN,OBSERVATIONAL,['NA'],
13719,NCT01529385,Microcirculation for Dorsum of Foot,Physical Activity Level,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
13720,NCT01758471,euglycemia,,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13721,NCT03396484,DQ8 Antigen Presentation,,2020-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
13722,NCT05166512,Change from baseline in body weight (kilograms (kg) and percent of baseline bodyweight),Change from baseline in food security status over the past 30 days using the 10-item United States Department of Agriculture (USDA) adult food security survey module,2022-02-02,COMPLETED,INTERVENTIONAL,['NA'],Program satisfaction among DPP Cooks participants (qualitative)
13723,NCT03258281,Change From Baseline in Adenosine Diphosphate (ADP) Stimulated P-selectin Expression,Change in ADP-stimulated Cluster of Differentiation (CD)-147 MFI,2018-05-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
13724,NCT06066801,the remission of DFO,Incremental cost effectiveness ratio,2024-03-14,RECRUITING,INTERVENTIONAL,['NA'],
13725,NCT02473809,Change in collagen I cross-linked C-terminal telopeptide measured in serum,Change in procollagen type I N-terminal propeptide measured in serum,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
13726,NCT00043797,,,na,UNKNOWN,INTERVENTIONAL,['PHASE2'],
13727,NCT02068443,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) National Glycohemoglobin Standardization Program (NGSP) at the End of Treatment (EOT) Period,Number of Participants Who Had Clinically Relevant Changes in 12-Lead Electrocardiogram (ECG) Findings,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
13728,NCT02554851,The proportion of participants with 100% healing at the end of follow-up,,2017-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
13729,NCT05492448,Changes in ratio of forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC).,Changes in scores of modified Bristol stool form scale.,2022-09-19,RECRUITING,INTERVENTIONAL,['NA'],
13730,NCT03523143,TESGO composite outcome,The growth and development of the offspring,2018-06-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
13731,NCT00264914,"Safety : Physical examination, vital signs, adverse events, electrocardiogram, hematology, serum chemistry",Serum sodium,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
13732,NCT01876849,"Long-term safety of twice-daily exenatide treatment, as defined by the occurrence of adverse events.",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
13733,NCT03078049,Total costs,Index medication dose increase,2017-03-31,COMPLETED,OBSERVATIONAL,['NA'],
13734,NCT00985257,Percent of Blood Glucose (BG) Results Within +/-15mg/dL or +/-20% of Laboratory Glucose Method,,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
13735,NCT04335656,Change in composite inflammatory index after probiotic supplementation,scRNA-seq analyses of peripheral blood mononuclear cells,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
13736,NCT04120571,Blood glucose (CGM),Blood glucose (OGTT),2019-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
13737,NCT05403853,Performance of the LumiraDx POC HbA1c assay when compared to a current CE marked reference method in patients being assessed for diagnosis or monitored for diabetes.,,2022-04-19,COMPLETED,INTERVENTIONAL,['NA'],
13738,NCT00353561,Mycological cure on the 15th day of therapy and defined as the absence of Candida growth on fungal culture of high vaginal swab,"Relief in clinical symptoms and signs of vulvovaginal candidiasis including vaginal discharge, pruritus, burning sensation and vaginal congestion",2004-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
13739,NCT01977417,Aim 1: Vascular Endothelial Function in Obese Prediabetic Adults Before and After 1 Month of Salsalate or Placebo.,,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2'],
13740,NCT00829569,insulin sensitivity,oxidative stress,2004-01,COMPLETED,INTERVENTIONAL,['NA'],
13741,NCT01836796,HbA1c,Urine albumine excretion rate,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
13742,NCT06055829,Glucose level,,2022-10-24,COMPLETED,OBSERVATIONAL,['NA'],
13743,NCT05168306,Difference in bodyweight from the control arm at 6 months,,2021-12-05,TERMINATED,INTERVENTIONAL,['NA'],
13744,NCT01143948,optimal glycemic control in inpatient cirrhotics,Incidence of hypoglycemic episodes,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13745,NCT01999218,Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104,Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach,2013-12-16,COMPLETED,INTERVENTIONAL,['PHASE3'],
13746,NCT01090752,Effects of Pioglitazone on 24h Blood Pressure Control,Effects of Pioglitazone on Salt Sensitivity,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
13747,NCT00799695,"a change in the proportion of diabetic patients who acted as a result of the phone contact, and obtained a retina eye exam.",,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
13748,NCT01106625,Change in HbA1c From Baseline to Week 26,Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
13749,NCT05244200,Fasting plasma glucose (FPG),Body Weight.,2022-01-20,UNKNOWN,INTERVENTIONAL,['NA'],
13750,NCT04424290,Multiple dosing (MD) part: Number of patients with drug related adverse events (AEs) from drug administration till end of study (EOS),MD part: Number of patients with ocular AEs at EOS,2020-06-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
13751,NCT01511185,AUC (area under the curve) of Insulin Secretion Rate (ISR) over the 90-216 mg/dL glucose interval,Adverse events,2001-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
13752,NCT05232708,"Cmax,sema,0.5mg: maximum observed semaglutide concentration-time after single dose of s.c. semaglutide 0.5 mg administration",,2022-01-19,COMPLETED,INTERVENTIONAL,['PHASE1'],
13753,NCT00005374,,,1994-01,COMPLETED,OBSERVATIONAL,['NA'],
13754,NCT01858597,The Concentration of Serum FGF19,Expression of FGF19 in Term Placenta,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
13755,NCT04830462,OGTT (oral glucose tolerance test),Changes in body composition,2021-04-15,COMPLETED,INTERVENTIONAL,['PHASE4'],
13756,NCT03814694,Change in glycated hemoglobin (HbA1c) during 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet.,Change in fasting plasma triglycerides during 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet.,2019-01-29,COMPLETED,INTERVENTIONAL,['NA'],Change in health-related quality of life (HRQoL) after 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet.
13757,NCT02806973,PD: Baseline-Adjusted Glucose Maximum Concentration (BGmax),,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1'],PK: Area Under the Curve Extrapolated to Infinity (AUC[0-inf]) of Glucagon
13758,NCT01229891,Serum 25-hydroxyvitamin D,Serum High Density Lipoprotein (HDL),2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
13759,NCT00245206,"Change in LDL cholesterol, HDL cholesterol, and triglycerides",,2005-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
13760,NCT05712720,Change in Central Subfield Thickness,Repeat-dose AUC of RZ402,2023-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
13761,NCT02984709,Glycemic Control (A1C),Self Care Inventory,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
13762,NCT02447185,intraoperative bleeding,the change of inflammatory factors in vitreous body,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],
13763,NCT01396772,Average number of vegetable and fruit servings consumed per day,average number of physical activity minutes per day,2011-05,UNKNOWN,INTERVENTIONAL,['NA'],
13764,NCT06188481,Change from baseline in HbA1c in %,Change from baseline in well-being,2024-01-23,RECRUITING,INTERVENTIONAL,['NA'],
13765,NCT03284216,Exercise-induced change in blood glucose control.,Hyperglycemia-induced change in cognitive function.,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],
13766,NCT02040012,"To investigate the number of adverse events of single and multiple ascending doses AZP-531 in healthy volunteers, in overweight/obese volunteers, in patients with type 2 diabetes mellitus.",To determine the plasma pharmacokinetic (PK) profile of AZP-531 after single and multiple doses,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],To obtain exploratory data on the effects of AZP-531 on the pharmacodynamic (PD) markers
13767,NCT01452815,Change from baseline in symptoms associated with diabetic gastroparesis,Clinical Chemistry and Hematology Parameters,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
13768,NCT03194009,Physical Activity,Cost-utility of Metformin. Measured using cost per QALYS,2017-08-10,UNKNOWN,INTERVENTIONAL,['NA'],
13769,NCT01322256,The difference between AUCs for PET/CT scan and scintigraphy,,2012-10,TERMINATED,INTERVENTIONAL,['NA'],
13770,NCT05761301,Part B: Frequency of Adverse Events,Part B: Plasma Concentrations of ALN-KHK and Potential Major Metabolite(s),2023-03-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
13771,NCT00194805,glycosylated hemoglobin (A1C) levels.,"Study participants who receive the web-based telehealth intervention will have fewer depression symptoms and higher quality of life, social support, at the 12 month (long-term) follow-up than participants in the control group.",2003-09,COMPLETED,INTERVENTIONAL,['NA'],
13772,NCT05261841,Change from Baseline HbA1c at 6 and 12 months,,2021-06-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
13773,NCT04862858,"Percentage of individuals who initiate guideline-based SGLT2i or GLP-1 RA medications with cardiovascular benefit, excluding combination products, based on administrative claims data","Percentage of individuals who initiate guideline-based SGLT2i or GLP-1 RA medications with cardiovascular benefit, including combination products, based on administrative claims data",2021-08-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
13774,NCT00400491,glycated hemoglobin,insulin sensitivity,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
13775,NCT04057248,HbA1C Value at 3 Months From Subject Start of Study Compared to Baseline,Triglycerides Value at 3 Months From Subject Start of Study,2018-07-09,COMPLETED,INTERVENTIONAL,['NA'],
13776,NCT04523064,Acute kidney injury,Myocardial Infarction Type 5,2020-09-22,RECRUITING,INTERVENTIONAL,['PHASE4'],
13777,NCT03340311,Glucose log completeness,Patient satisfaction,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],
13778,NCT04831723,Normal range of capillary blood glucose in newborns at day 5 of life,Validation of laboratory procedures,2021-07-09,COMPLETED,OBSERVATIONAL,['NA'],
13779,NCT06124560,Area under the plasma concentration versus time curve (AUC) 0-inf (Metformin only),Number of participants with adverse events (AEs),2022-10-28,COMPLETED,INTERVENTIONAL,['PHASE1'],
13780,NCT05949320,Eating Behaviour Questionnaire from the EatSmart Restaurant Star+ Campaign,,2023-04-03,RECRUITING,INTERVENTIONAL,['NA'],
13781,NCT02407899,Absolute changes from baseline in Fasting C-peptide levels at week 104.,"Absolute changes of body weight and BMI level from baseline and at week 26, 52, 78 and 104.",2015-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
13782,NCT01916096,Blood Volume Measurements,,2012-02,COMPLETED,OBSERVATIONAL,['NA'],
13783,NCT04270604,"Establishment of a diverse bank of biological samples, stem cell lines, derivatives, and associated information.",,2012-02-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
13784,NCT01788033,C-peptide level,Number of Adverse Events,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
13785,NCT04533152,DFU risk score,Survival without major microvascular events (MICE),2021-11-24,RECRUITING,OBSERVATIONAL,['NA'],
13786,NCT03022344,Progression of contrast enhanced cardiac CT in relation to baseline and follow-up cardiovascular risk factors and biomarkers.,Blood pressure (mmHg),2014-11,UNKNOWN,INTERVENTIONAL,['NA'],
13787,NCT05355285,Change in anterior cingulate cortex glutamate concentration from Baseline Euglycemia to Hyperglycemia,Change in plasma insulin concentration from Baseline Euglycemia to Hyperinsulinemic Euglycemia,2011-01,COMPLETED,INTERVENTIONAL,['NA'],Self Referential Emotional Task (SRET) response time
13788,NCT01365013,Incidence of Diabetes,Implementation of the program,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
13789,NCT00260130,"satiation and satiety on liquid verses solid foods with concurrent measurements of appetite, dietary intake, energy expenditure and body weight/composition.",cephalic phase testing at week 8,2005-02,COMPLETED,INTERVENTIONAL,['NA'],
13790,NCT01691755,Change from baseline in hemoglobin HbA1c,Safety: incidence of adverse events,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
13791,NCT01606007,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24,Adjusted Mean Change From Baseline in Body Weight at Week 24,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
13792,NCT01297049,Blood glucose control with changes in Glycated hemoglobin (HbA1c) values,Audit of Diabetes Dependence Quality of Life (ADDQoL-19),2010-04,COMPLETED,INTERVENTIONAL,['NA'],
13793,NCT05996601,Medication adherence of participants using a 4-item medication adherence scale,,2023-08-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
13794,NCT03997526,Complete healing,Minor amputation - contralateral limb,2020-07-15,TERMINATED,OBSERVATIONAL,['NA'],
13795,NCT03925714,Number of patients with improved insulin resistance,,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
13796,NCT06033872,a. To compare the first incidence rate of hypoglycemia or severe hypoglycemia between intervention and control groups in Ramadan,"Healthcare utilizations costs - Medical services, drugs and devices utilized, outpatient and inpatient visits, cost of intervention sessions, telemonitoring and equipment, indirect costs related to health care utilisation, and caregiver costs.",2021-01-25,COMPLETED,INTERVENTIONAL,['NA'],
13797,NCT05092945,Brown Adipose Tissue (BAT) Glucose uptake,Changes in insulin level and secretion,2021-05-18,RECRUITING,INTERVENTIONAL,['NA'],
13798,NCT03553524,Compare the efficacy of the morning and afternoon HIIT in lowering blood glucose values in participants with type 2 diabetes.,Respiratory exchange ratio (RER),2021-10-30,WITHDRAWN,INTERVENTIONAL,['NA'],
13799,NCT03878277,Renal Perfusion,Tubular Injury Markers,2019-07-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
13800,NCT01693510,Gestational weight gain within IOM guidelines,Bone outcomes,2012-11-12,COMPLETED,INTERVENTIONAL,['NA'],
13801,NCT02658591,Change in gut hormone levels measured in the blood,Ad libitum food (pizza meal) intake as measured by the amount of pizza (in grams) consumed during the 20 minute period,2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
13802,NCT01803711,Hospital Anxiety and Depression Scale,Leeds Sleep Evaluation Questionnaire (LSEQ),2013-02,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
13803,NCT05261867,"Composite of cardiovascular death, recurrent AMI, and hospitalization for HF (MACE).",Any coronary revascularization,2017-01,RECRUITING,OBSERVATIONAL,['NA'],
13804,NCT00426920,AUC,AUC,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],
13805,NCT01521624,Serum concentrations of various markers of oxidative stress,,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
13806,NCT02571608,Recruitment rate,Length of Hospital Stay,2022-01-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
13807,NCT01143714,Change in Wound Area,Number of Sharp Debridements Performed During the 4-week Treatment Phase and the 8-week Follow-up Period (12 Weeks Total),2010-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
13808,NCT05874323,correlation of RAGE gene polymorphism rs1800625 with the incidence of type I diabetes,"the relation between MiRNA-34, MiRNA-146, to TID severity and activity.",2023-01-01,COMPLETED,INTERVENTIONAL,['NA'],
13809,NCT00837122,A,,2009-02-03,RECRUITING,OBSERVATIONAL,['NA'],
13810,NCT02131961,Proportion of contact cast systems intact by day 14,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
13811,NCT01270633,Percent of study ulcers healed,Cost of Treatment,2010-12,TERMINATED,INTERVENTIONAL,['NA'],
13812,NCT04972890,Changes in microRNA 126 expression after stem cells injection,Number of participants with side effects after intracavernosal injection,2020-10-27,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
13813,NCT02036528,Complete wound clearing of infection,DFU Area % Change,2014-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
13814,NCT02194608,Change from baseline in body mass index,Number of severe/symptomatic hypoglycemic episodes,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
13815,NCT02786823,HbA1c,Serum C reactive protein (CRP),2017-05-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
13816,NCT01914146,1. Presence or absence of orthostatic hypotension,3. The nadir of systolic blood pressure (SBP) and diastolic blood pressure (DBP) during tilt table test.,2015-04,WITHDRAWN,INTERVENTIONAL,['NA'],
13817,NCT00497198,Change From Baseline in Hemoglobin A1c(HbA1c) at Week 12,Change From Baseline in Low Density Lipoprotein Cholesterol(LDL-c) at Week 12,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
13818,NCT03154398,the percentage of patients progress to advanced diabetic nephropathy,,2017-05-01,COMPLETED,OBSERVATIONAL,['NA'],
13819,NCT05086445,Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change from Baseline in Body Weight,2021-11-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
13820,NCT05540704,Feasibility as measured by participant attrition less than 20%,Change in NIH PROMIS Scale - Anxiety,2023-04-04,RECRUITING,INTERVENTIONAL,['NA'],
13821,NCT04641650,Difference between estimated Hba1c (or Glucose Management Index (GMI)) with FreeStyle Libre Pro sensor and laboratory Hba1c,Glucose total coefficient of variation (CV),2021-07-21,UNKNOWN,OBSERVATIONAL,['NA'],
13822,NCT04716244,Identification of four consistent themes on thematic qualitative analysis,,2021-01-20,RECRUITING,OBSERVATIONAL,['NA'],
13823,NCT05766449,"Risk factors of chronic hepatitis B patients with non-alcoholic fatty liver disease progressing to cirrhosis, liver cancer or liver failure","Incidence of cirrhosis, cancer and liver failure in patients with chronic hepatitis B and non-alcoholic fatty liver disease",2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],
13824,NCT01062529,Plasma levels of glucose,Serum levels of free fatty acids (FFA),2009-10,COMPLETED,INTERVENTIONAL,['NA'],
13825,NCT01755442,Mean 24-hour systolic blood pressure,Safety end points will include ECGs.,2012-11,TERMINATED,INTERVENTIONAL,['PHASE1'],
13826,NCT04624672,RATE OF PARTIAL REMISSION OF DIABETES,RATE OF COMPLETE REMISSION OF DIABETES,2021-08-25,TERMINATED,INTERVENTIONAL,['PHASE4'],
13827,NCT02511067,Anatomic Retinal Changes,Rescue Therapy,2016-10-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
13828,NCT05272670,Foot Care Self-Efficacy Scale,Health promotion satisfaction,2022-02-15,RECRUITING,INTERVENTIONAL,['NA'],
13829,NCT00207389,GIP area under the curve after OGTT,Other GI peptides and hormones after OGTT,2004-03,TERMINATED,OBSERVATIONAL,['NA'],
13830,NCT02612493,Insulin dosage,Change in lipids,2006-01,COMPLETED,OBSERVATIONAL,['NA'],
13831,NCT01143870,Change in Percent of Glycosylated Hemoglobin 6 Months Following Enrollment,Change in Hemoglobin A1C Over 12 Months From Enrollment,2010-04,COMPLETED,INTERVENTIONAL,['NA'],
13832,NCT01474525,"Mean blood glucose, based on the highest post-prandial blood glucose reading for each day, by trimester","Provider usage: number of logins onto the system, average amount of time spent on the system per week",2010-01,UNKNOWN,INTERVENTIONAL,['NA'],
13833,NCT03071068,"Incidence of acute (up to the 7-day follow-up visit) ocular (serious) adverse events ([S]AEs) in the study eye, after each injection and across injections per subject","Mean change from baseline in CST, by study visit, based on spectral domain optical coherence tomography (SD-OCT), as assessed by the central reading centre (CRC)",2016-12-22,COMPLETED,INTERVENTIONAL,['PHASE2'],
13834,NCT00972322,Number of Participants Discontinuing Study Drug Due to an AE,,2009-08-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
13835,NCT01869348,Change in Physical Activity From Baseline to 12 Weeks,Change in Weight From Baseline to 12 Weeks,2014-06,COMPLETED,INTERVENTIONAL,['NA'],Acceptability
13836,NCT03671161,Number of ketoacidosis episodes,Any changes in Weight,2016-01-01,COMPLETED,INTERVENTIONAL,['NA'],
13837,NCT03042039,Total number of hospital admissions per participant measured at end of study (at approx 12 months),Change in Disease specific health status measurement (6) as measured with BMI of all patients with chronic heart failure between start and end of study (12 months),2015-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
13838,NCT01152372,"Glucose (labeled and unlabeled), insulin and c-peptide will be measured to calculate insulin sensitivity, endogenous glucose production and insulin secretion",Characterize the patterns of intermediate metabolites in healthy subjects and subjects with type 2 diabetes mellitus,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
13839,NCT00467246,Reduction of recurrence of ketoacidosis and hyperglycaemia.,To investigate time to treatment in patients presenting with a hyperglycaemic emergency,na,WITHDRAWN,INTERVENTIONAL,['NA'],
13840,NCT00627146,"The difference in change in daily insulin need between baseline and month 48, between placebo and ChAgly CD3 treated patients",,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
13841,NCT03835195,Differences in HbA1C value after the intervention,Difference in the body mass index after the intervention,2018-06-01,COMPLETED,INTERVENTIONAL,['NA'],
13842,NCT01608607,Body weight,,2012-05,UNKNOWN,OBSERVATIONAL,['NA'],
13843,NCT03936010,"Relative hazard of composite outcome of Stroke, MI, and Mortality",,2017-09-22,COMPLETED,OBSERVATIONAL,['NA'],
13844,NCT01513798,Fat mass,Substrate utilization during submaximal exercise,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
13845,NCT03424044,Percent of Time With Sensed Glucose < 70 mg/dl,Mean Amount of Glucagon Delivered in One Day,2018-03-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
13846,NCT02151695,Percentage of patients with regression of retinal neovascularization between baseline and 12th month.,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
13847,NCT03423108,HbA1c,Lower body maximal muscle strength,2018-09-10,UNKNOWN,INTERVENTIONAL,['NA'],
13848,NCT02620332,Assessment of MultiPepT1De safety profile,Assessment of T lymphocyte immune response to islet cell antigens,2015-10-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
13849,NCT03665870,Fear of Hypoglycemia,Knowledge of Diabetes,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],
13850,NCT00787475,HgA1C level,Measurement of systolic blood pressure,2008-09,COMPLETED,INTERVENTIONAL,['NA'],
13851,NCT01340911,Number of participants with adverse events and incidence of adverse events will be used as a measure of safety and tolerability of multiple doses of SRT3025 in healthy male subjects.,Plasma levels of SRT3025 may be compared to the number and types of adverse events experienced by subjects receiving multiple doses of SRT3025 to assess any relationship between plasma SRT3025 levels and adverse events.,2011-06-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
13852,NCT05204706,Number of women withdrawn or loss to follow up,Number of women randomised,2022-01-24,RECRUITING,INTERVENTIONAL,['NA'],Length of stay at the hospital ward
13853,NCT01511172,Fasting plasma/serum glucose,Other adverse events,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
13854,NCT04858854,Fasting serum glucose,Fasting insulin,2021-10-10,COMPLETED,INTERVENTIONAL,['NA'],
13855,NCT00005399,Incident coronary heart disease and stroke events,all-cause and cause-specific mortality,1996-08,COMPLETED,OBSERVATIONAL,['NA'],
13856,NCT00563043,changes in ERG implicit time,,2007-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13857,NCT01364675,Cardiovascular Events,Incidence of Individual Cardiovascular Disease,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],
13858,NCT00682448,Weight Gain,Hemoglobin A1C,2007-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
13859,NCT00615121,Discover novel gene expression pattern in peripheral arterial disease,,2004-06,COMPLETED,OBSERVATIONAL,['NA'],
13860,NCT05226897,HbA1c,C-peptide,2021-07-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
13861,NCT03438617,Change from Baseline HbA1c at 12 and 18 months,Change from Baseline Depression at 12 and 18 months,2017-03-08,COMPLETED,INTERVENTIONAL,['NA'],
13862,NCT04452331,Contextualization of Care,hospital admission rate,2021-10-05,RECRUITING,INTERVENTIONAL,['NA'],
13863,NCT03182712,Changes on hs-CRP (High-sensitivity C reactive protein),Changes on Total Antioxidant activity,2007-02,COMPLETED,INTERVENTIONAL,['NA'],
13864,NCT02557022,Body weight analysis,,2014-09,UNKNOWN,OBSERVATIONAL,['NA'],
13865,NCT00614341,Pain reduction in diabetic patients with chronic diabetic neuropathy,Improvement in sensation and overall foot condition,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
13866,NCT06240910,Berge balance scale,Functional reach test,2023-07-17,RECRUITING,INTERVENTIONAL,['NA'],Michigan neuropathy screening instrument questionnaire
13867,NCT03059069,changes in Hamilton Depression Rating Scale (HDRS),changes in Mini-mental state examination (MMSE) score,2016-06-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13868,NCT01970046,Change From Baseline in HbA1c (Hemoglobin A1C) at Week24,"Change From Baseline in Body Weight at Week 4,8,12、24、38、52",2013-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],
13869,NCT03403283,Increase in acid sphingomyelinase (ASM) expression and activity in bone marrow-derived endothelial progenitor cells (EPCs),,2014-01,RECRUITING,OBSERVATIONAL,['NA'],
13870,NCT05110846,Change in hemoglobin A1c (HbA1c),Fasting plasma glucose,2022-02-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],
13871,NCT04509245,Change in insulin sensitivity,Change in öiver fat,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],
13872,NCT00574808,Quality of care process index = ∑ of recommended services received by patient/ ∑ of the recommended services for which the patient was eligible,Quality of care outcome index = ∑ of recommended targets reached / ∑ of the number of targets for which the patient is eligible based on the number of conditions suffered by the patient,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
13873,NCT00792662,Hemoglobin A1C as a Marker for Glycemic Control,Instrumental Activities of Daily Living (IADL) Scale,2008-11-18,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
13874,NCT00910780,Changes in per cent of body fat,Psychiatric safety and tolerability,2009-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
13875,NCT05095038,Fasting blood glucose,Change in subjective assessment of investigational product,2022-02-10,TERMINATED,INTERVENTIONAL,['NA'],
13876,NCT05912647,Change in mean hemoglobin A1c score,Mean scores on the Adherence to Refills and Medications Scale for Diabetes,2024-02-03,RECRUITING,INTERVENTIONAL,['NA'],
13877,NCT00965549,Glycosylated Haemoglobin (HbA1c),"Hypoglycaemia (total, severe and nocturnal)",2009-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
13878,NCT00958711,Bacterial Burden,Ease of Dressing Use,2009-01,TERMINATED,INTERVENTIONAL,['NA'],
13879,NCT00381186,insulin resistance,exercise change,1999-02,COMPLETED,INTERVENTIONAL,['NA'],
13880,NCT03202563,Changes from baseline MAGE(Mean amplitude of glycemic excursion) at week 12,Changes from baseline Nitrotyrosine at week 12,2017-08-09,COMPLETED,INTERVENTIONAL,['PHASE4'],Changes of baseline Body weight at week 13
13881,NCT03228732,Change in the level of catecholamines in plasma,,2017-12-19,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
13882,NCT05526131,val66met polymorphism of BDNF gene,,2021-02-17,COMPLETED,INTERVENTIONAL,['NA'],
13883,NCT03782805,Change from Baseline TNF-alpha at 6 months,Change from Baseline Parathyroid hormone (PTH) at 6 months,2018-05-09,COMPLETED,INTERVENTIONAL,['NA'],
13884,NCT04550806,Area under the curve of GA combined with body composition for GDM diagnosis,GDM prediction model establishment,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],
13885,NCT02322554,Healing,,2005-01,UNKNOWN,OBSERVATIONAL,['NA'],
13886,NCT00099957,Postprandial serum total triglycerides at 4 weeks,Postprandial apo B-48 and apo B-100 in the two lipoprotein fractions - chylomicrons and VLDL1+VLDL2+IDL (VLDL/IDL) at 4 weeks,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
13887,NCT05727579,To investigate the modifying effect of sodium intake on Ertugliflozin on blood pressure,To investigate the effect of Ertugliflozin on the hypertensive effects of high dietary sodium intake,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Biomarkers
13888,NCT03563638,Serum PTX3 levels in early pregnancy,,2015-10-01,COMPLETED,OBSERVATIONAL,['NA'],
13889,NCT04258904,Incidence of dermatological complications,Trans Epidermal Water Loss (TEWL):,2020-03-10,COMPLETED,INTERVENTIONAL,['NA'],
13890,NCT01889277,Plasma concentrations of MT-3995 and its major metabolite,Change from baseline in Urine albumin-to-creatinine ratio (UACR) and blood pressure,2013-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
13891,NCT05539066,Compliance rate of BMI (Body Mass Index),Incidence of hypoglycemia,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
13892,NCT05132725,TTG-IgA,BMI,2021-11-15,UNKNOWN,INTERVENTIONAL,['NA'],
13893,NCT00000151,,,1979-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
13894,NCT04192422,Neonatal sensor glucose time in target,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],
13895,NCT03025607,Change in Autonomous Motivation to Prevent T2DM,Change in psychosocial measures,2017-05-03,COMPLETED,INTERVENTIONAL,['NA'],
13896,NCT01349855,"Safety in terms of adverse and serious adverse events, vital signs, ECG, safety laboratory",Pharmacokinetic parameter : AUC,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
13897,NCT00786487,Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion,,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
13898,NCT03371355,Percent Change From Baseline in Fasting Triglycerides Level at the Primary Analysis Time Point,Number of Participants With Treatment-emergent Adverse Events (TEAEs),2017-12-21,COMPLETED,INTERVENTIONAL,['PHASE2'],
13899,NCT02180555,Glucose metabolism disturbance,Patient characteristics predicting adverse outcome,2012-02,UNKNOWN,OBSERVATIONAL,['NA'],
13900,NCT01768208,The primary objective of the study is to evaluate the changes in the metabolomic parameters before and after Saxagliptin treatment in type 2 diabetic patients.,,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13901,NCT00406458,"Visual analog scale for pain intensity (VASPI), Nerve Conduction Velocity (NCV), Total Neuropathy Score (TNS), Epidermal Nerve Fiber Density (ENFD) & Epidermal Nerve Fiber Density Regeneration (ENFDR)",Safety,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
13902,NCT02131675,C-peptide level,Duration of diabetes,2012-10,COMPLETED,OBSERVATIONAL,['NA'],
13903,NCT03908125,Time in Range,,2019-03-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
13904,NCT01813929,Flow-mediated Brachial Artery Dilation,Cardiac Function,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4'],Mitochondrial Oxidant Generation
13905,NCT00965510,"Scores on PHQ9, PAM and health indicators",Satisfaction with care coordination model.,2009-09,TERMINATED,INTERVENTIONAL,['NA'],
13906,NCT00961207,Reduction in albuminuria/proteinuria,"Safety of Triple RAAS inhibition with ACE-I, ARB and DRI",2009-08,TERMINATED,INTERVENTIONAL,['PHASE4'],
13907,NCT06097351,Statistical analysis and target gene prediction of misexpressed mirnas and enrichment pathway analysis,,2020-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
13908,NCT00316758,"AEs, laboratory parameters, ECG.","Mean change from original baseline in HbA1c, FPG, lipid profile.",2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
13909,NCT04184440,changes of OGTT,changes of short chain fatty acids,2020-03,UNKNOWN,INTERVENTIONAL,['NA'],
13910,NCT04712266,hyperglycemic excursions,,2020-09-15,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
13911,NCT02488733,Rate of patients achieving diabetes resolution,"Renal (onset of nephropathy or microalbuminuria), cardiovascular (defined as the occurrence of myocardial infarction, congestive heart failure or stroke), and ocular damage (development of diabetic retinopathy), and diabetes-related peripheral neuropathy",2015-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
13912,NCT00383110,Health Care System Distrust Scale,LDL-cholesterol,2004-11,COMPLETED,OBSERVATIONAL,['NA'],
13913,NCT01889355,Enhanced Meter Feature Usability,,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
13914,NCT04812782,Change of Endothelial function from pre meal to post meal period,Gastric emptying rate,2018-02-12,COMPLETED,INTERVENTIONAL,['NA'],
13915,NCT00011141,,,na,COMPLETED,INTERVENTIONAL,['NA'],
13916,NCT03081676,Insulin secretion,Amount glucose used to maintain the glucose clamp,2017-03-08,COMPLETED,INTERVENTIONAL,['NA'],
13917,NCT00271739,Serum Lipids Levels; Low-density Lipoprotein (LDL)-Cholesterol,,2000-12,COMPLETED,INTERVENTIONAL,['NA'],
13918,NCT01959529,"Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke",Change in Glycosylated Haemoglobin (HbA1c),2013-10-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
13919,NCT03998267,Difference in mean HbA1c,Lipids,2019-08-22,UNKNOWN,INTERVENTIONAL,['NA'],Exploratory outcome
13920,NCT04074668,Mitochondrial Function,Kidney Injury Biomarkers,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],Epigenetic profiling
13921,NCT03784027,Time in target (3.9 to 10.0 mmol/l) (70 to 180 mg/dl),Percentage of time of CGM availability,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],
13922,NCT02463084,Change in cerebrospinal fluid levels of Alzheimer's disease biomarkers (CSF beta-amyloid 42),Change in brain perfusion,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
13923,NCT01600690,Change in EPC levels,Change in hsCRP,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
13924,NCT00122447,AIM 1: Change in Flow Mediated Dilation (FMD) (%),AIM 1: Change in hsCRP (High Sensitivity C-reactive Peptide) Level,2005-05,COMPLETED,INTERVENTIONAL,['NA'],AIM 2: Difference in FMD (Measure of Endothelial Function)
13925,NCT01432509,Type 2 Diabetes occurrence,Others cardiovascular risk factors,2011-09,COMPLETED,INTERVENTIONAL,['NA'],
13926,NCT04674254,Change in vascular density of the retinal capillary plexuses,Change in orbital blood flow,2021-03-30,COMPLETED,INTERVENTIONAL,['PHASE4'],
13927,NCT02919345,Change in flow mediated dilation (FMD) and its related endpoint (FMD post reperfusion lesion),Change in body composition (% of fat mass and % free fat mass),2017-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Change in Waist Circumference
13928,NCT04377399,Microcirculation,Neuropathic symptom score,2018-01-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
13929,NCT00718614,choroidal blood flow,heart rate variability,2007-06,TERMINATED,INTERVENTIONAL,['NA'],
13930,NCT00817622,Changes in leptin and adiponectin after 12 Weeks,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
13931,NCT01959334,Number of Participants With At Least One Adverse Event,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
13932,NCT03935191,Dexcom G6 CGM Accuracy,Dexcom G6 CGM Safety,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA'],
13933,NCT04503174,Percent of Boluses Using the Auto Population Feature Resulting in Fewer Readings Less Than 70 mg/dL Than Those Not Using the Feature,"Diabetes Impact and Satisfaction Scale (DIDS), Impact Score",2020-08-04,COMPLETED,OBSERVATIONAL,['NA'],
13934,NCT04352738,Intrahepatic free glucose concentration,First-pass hepatic extraction of glucose,2021-04-15,COMPLETED,OBSERVATIONAL,['NA'],Changes in intrahepatocellular lipid (IHCL)
13935,NCT06054659,Time to DFU healing,Relationship of glycemic variability and the likelihood of healing,2024-02-20,RECRUITING,INTERVENTIONAL,['NA'],
13936,NCT01231984,Glycemic Control as Measured by HbA1c (4 mm vs. 12.7 mm),"Number of Serious, Unexplained Hyperglycemic Events, Reported as Number of Events by Needle.",2010-10,COMPLETED,INTERVENTIONAL,['NA'],
13937,NCT02909829,AUCinc: The incremental area under the curve (as compared to pre-meal glucose value) of the postprandial glucose excursions for the lunch meal.,1. Glucose concentration as measured by CGM at 5 hours (300 min) post-meal. Glucose concentration as measured by CGM at 5 hours (300 min) post-meal,2017-10-31,COMPLETED,INTERVENTIONAL,['NA'],
13938,NCT00348712,Treatment difference in HbA1c,Hypoglycaemia,2006-10-30,TERMINATED,INTERVENTIONAL,['PHASE3'],
13939,NCT00402727,Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population,Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the Microbiological Valid (MBV) Population,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
13940,NCT05491577,Results of the FAAM-F questionnaire at Month 24,K. Sanders Classification of the Charcot Foot,2023-01-23,RECRUITING,OBSERVATIONAL,['NA'],Front view X-ray of the ankle(s) under loading
13941,NCT02577120,Ceramiseal and EpiCeram restore barrier function to wounds in patients,,2019-01-09,RECRUITING,INTERVENTIONAL,['PHASE4'],
13942,NCT03450863,Change in Glycated Haemoglobin (HbA1c),Change in fasting plasma glucose (FPG),2018-03-22,COMPLETED,OBSERVATIONAL,['NA'],
13943,NCT01350388,Change in Urinary Concentrations of Transforming Growth Factor-beta1 (TGF-beta1) From Baseline to 24 Weeks,Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma From Baseline to 24 Weeks,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
13944,NCT02070926,Time to major adverse events,,2006-01,COMPLETED,OBSERVATIONAL,['NA'],
13945,NCT01478763,,,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
13946,NCT02605772,redunction of Hemoglobin A1c (HbA1c) Levels (%) in two groups respectively after three months intervention,Difference of Homeostasis model assessment of insulin resistance (HOMA-IR) and Homeostasis model assessment beta cell function index (HOMA-β) between two groups after three months intervention,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
13947,NCT00549536,To evaluate the difference in 24h blood pressure measurement and insulin sensitivity between the treatment and the control group.,To evaluate differences in the transmembrane sodium/hydrogen exchanger activity between the active treatment and the control group.,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
13948,NCT03091673,Change in Plasma Glucose,Plasma Glucagon Tmax,2017-03-27,COMPLETED,INTERVENTIONAL,['PHASE3'],
13949,NCT02494375,Association between HbA1c and sleep characteristics,Body composition (BMI fat and lean mass percentage),2015-06-28,UNKNOWN,INTERVENTIONAL,['NA'],
13950,NCT03509532,MACE,,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],
13951,NCT04612257,Time in range,Total insulin delivery,2019-06-18,TERMINATED,INTERVENTIONAL,['NA'],
13952,NCT00242372,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),To validate the Work Productivity and Activity Impairment-Diabetes Questionnaire (WPAI-Diabetes) and the Diabetes Productivity Impairment Questionnaire (DPIQ) in patients with type 2 diabetes and to explore the effects of tesaglitazar (0.5 mg) on pati,2004-08,TERMINATED,INTERVENTIONAL,['PHASE3'],
13953,NCT06224790,15% improvement in eGFR,Safety - Adverse Effects of Drugs,2024-03-10,RECRUITING,INTERVENTIONAL,['PHASE4'],
13954,NCT05348863,HbA1c,Physical activity using accelerometry,2022-10-28,RECRUITING,INTERVENTIONAL,['NA'],
13955,NCT04729296,The primary outcome is the elapsed time from random treatment assignment to the development of diabetes (T1D) or time of last contact among those randomized,,2021-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
13956,NCT00428571,Diabetic control as assessed by HbA1c,Utilization of resources and productivity losses,2007-05,TERMINATED,INTERVENTIONAL,['NA'],
13957,NCT05933460,Diastolic Blood pressure,Continuous glucose monitoring statistic data,2022-03-01,COMPLETED,INTERVENTIONAL,['NA'],
13958,NCT06092827,Satisfaction towards physical activity intervention,Questionnaire on motivation to practice physical activity,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Hemoglobin (safety parameter)
13959,NCT05003908,Safety (adverse events),Efficacy: Insulin dose reduction,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE1'],
13960,NCT05613985,To assess the ulcer after 2 weeks of study treatment by evaluation of the following primary endpoint:,The key secondary objective is to evaluate the ulcer after 4 weeks of study treatment by evaluation of the following endpoint:,2021-09-14,RECRUITING,INTERVENTIONAL,['NA'],
13961,NCT05527535,Efficiency of AI in diabetic retinopathy screening,Satisfaction of patients and health care personnel in AI-based screening,2022-10-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
13962,NCT00454597,"To compare the Blood levels of of glucose, curve of tolerance wing glucose, hemoglobin glycosylated, insulin, triglyceride, cholesterol, HDL, LDL, leptin and Adiponectin before and after the procedure","To evaluate the metabolic conditions of the subjects of both groups to the 15 days and the month, 6, 12 and 24 months later to the procedure",2007-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
13963,NCT02956577,Changes in Global Longitudinal Strain (GLS) stratified by Coronary Artery Calcium Score (CAC) in patients with diabetes during one year of follow-up,Changes in GLS in patients with long-term diabetes and no macrovascular disease,2016-03-16,COMPLETED,OBSERVATIONAL,['NA'],LA function stratified by micro- and macrovascular status
13964,NCT00496457,Effect of TRO19622 versus Placebo on the mean 24h neuropathic pain score on the Likert numerical rating scale.,Adverse events,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
13965,NCT02218931,"Composite fetal outcomes: stillbirth, small for gestational age or admission to neonatal intensive care unit",Development of a cohort for medium and long term follow up of mothers and babies after birth through applications to other grant giving bodies.,2014-09-12,COMPLETED,INTERVENTIONAL,['NA'],
13966,NCT03333642,Remission of type 2 Diabetes at 24 months,Control of type 2 diabetes,2017-11-27,UNKNOWN,INTERVENTIONAL,['NA'],Measurement of surgical adverse events
13967,NCT00334841,,,2006-07,UNKNOWN,OBSERVATIONAL,['NA'],
13968,NCT04743479,Hazard ratio (HR),Diagnostic yield,2020-12-01,RECRUITING,OBSERVATIONAL,['NA'],
13969,NCT00960674,HbA1c,Quality of life by SF-36,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
13970,NCT01013766,"Pharmacokinetic parameters: AUC, Cmax, Tmax, t1/2, tlag, Cl/F, and V/F",Relationship between pharmacokinetic and pharmacodynamic parameters,2009-08-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
13971,NCT02378909,Improvement in ulcer size at monthly intervals up to 12 months follow up.,Proportion of wounds healed at monthly intervals up to 12 months followup,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],
13972,NCT05937321,Time in Range,Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes,2023-11-02,RECRUITING,INTERVENTIONAL,['NA'],World Health Organisation-Five Well-Being Index
13973,NCT03594591,Changes in arterial wall microcirculation (vasa-vasorum density),Changes in retinal microcirculation (Foveal Avascular Area),2018-01-02,UNKNOWN,OBSERVATIONAL,['NA'],
13974,NCT00115973,HbA1c,Frequency of hypoglycemic events,2005-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
13975,NCT04800471,Change in hyperglycemia,Change in Glucose Variability,2021-08-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
13976,NCT05698875,Mean glucose (mmol/l),"Range times (Time in range, time above range, time below range)",2023-02-14,COMPLETED,INTERVENTIONAL,['NA'],
13977,NCT05329610,Adherence to the intervention,Blinding to the intervention,2022-04-05,COMPLETED,INTERVENTIONAL,['NA'],Fractional shortening (%)
13978,NCT03837119,urinary tract infection,,2018-04-04,COMPLETED,OBSERVATIONAL,['NA'],
13979,NCT02588898,Polyneuropathy grade estimated using a score including a combination of data from questionnaire and electrophysiology investigations,Plasma cobalamin levels,2009-09,COMPLETED,OBSERVATIONAL,['NA'],
13980,NCT00780195,catecholamines,,1998-07,COMPLETED,INTERVENTIONAL,['NA'],
13981,NCT03386864,mitochondrial oxygen flux,,2016-04,COMPLETED,OBSERVATIONAL,['NA'],
13982,NCT01242202,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",2010-10-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
13983,NCT02153190,Percent time spent in target range (3.9-10.0 mmol/L or 70-180 mg/dL) during each study period,Low Blood Glucose Index (LBGI),2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
13984,NCT01917227,HbA1c,,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
13985,NCT04759144,Time in target (3.9 to 10.0mmol/L) (70 to 180 mg/dL),Human factors assessment,2021-03-12,COMPLETED,INTERVENTIONAL,['NA'],
13986,NCT01876914,Total retinal blood flow & visual acuity,The degree of parafoveal ischemia as identified by OCT and visual acuity,2013-06,COMPLETED,OBSERVATIONAL,['NA'],
13987,NCT01979081,Physical Functioning Inventory,Patient Specific Functional Scale (PSFS),2013-01,COMPLETED,OBSERVATIONAL,['NA'],Brief Pain Inventory
13988,NCT05208827,Gestational diabetes,Weight gain during pregnancy,2022-01-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
13989,NCT04101045,Fractional hepatic DNL,,2019-11-21,TERMINATED,INTERVENTIONAL,['NA'],
13990,NCT04495231,Presence of metabolic syndrome,"Cardiovascular risk as estimated by Progetto Cuore Score (english translation: ""Heart Project Score"")",2007-09-01,COMPLETED,OBSERVATIONAL,['NA'],
13991,NCT03393208,Maximum Observed Plasma Concentration (Cmax) of Metformin (GIR Tablet Active Ingredient),"Number of Participants With Clinically Significant Abnormalities in Vital Signs, Laboratory Parameters, Physical Examination Findings and 12-lead Electrocardiogram (ECG) Findings",2018-01-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
13992,NCT06323161,Change in Glycated Haemoglobin (HbA1c),Number of Clinically Significant Hypoglycaemic Episodes (level 3),2024-03-26,RECRUITING,INTERVENTIONAL,['PHASE3'],
13993,NCT03017482,percent of time patients are on the closed loop system,Percent time in range,2017-07-15,COMPLETED,OBSERVATIONAL,['NA'],Diabetic Ketoacidosis
13994,NCT01919684,Safety and tolerability of single oral doses of LGD-6972 in healthy subjects and in subjects with T2DM.,The effect of food on the bioavailability and PK profile of LGD-6972 and its potential metabolites after a single oral 40 mg dose in healthy subjects.,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
13995,NCT05843175,Percentage of time spent in the euglycemic range for the 24 hours after each experimental condition,Placenta efficiency,2023-06-22,RECRUITING,INTERVENTIONAL,['NA'],Sleep quality (questionnaire)
13996,NCT02656069,Hypoglycemia Rescue: Alternate Glucose Response Definition,Global Assessment of Hypoglycemia,2017-03-15,COMPLETED,INTERVENTIONAL,['PHASE3'],
13997,NCT02438670,Time spent in safe blood glucose range,Glucose level extremes and need for outside intervention,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
13998,NCT05089617,Adverse events will be evaluated,maximum plasma concentration (Cmax),2022-01-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
13999,NCT02510885,Number of Participants With Image Quality Sensitive Enough to Identify Specific New Vessel Morphology,,2015-07,TERMINATED,INTERVENTIONAL,['NA'],
14000,NCT02137070,Change in BOLD fMRI signal,,2014-08,COMPLETED,OBSERVATIONAL,['NA'],
14001,NCT01234649,Insulin Secretion-Sensitivity Index (IS-SI),Alanine Aminotransferase /Aspartate Aminotransferase (ALT/AST) Ratio,2011-08-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
14002,NCT00701051,Skeletal Muscle Capillarization (Pre/Post Intervention),Body Composition (%Fat),2006-10,COMPLETED,INTERVENTIONAL,['NA'],
14003,NCT03835208,mean amplitude of glucose excursions (MAGE),C-peptide,2019-02-25,UNKNOWN,INTERVENTIONAL,['NA'],3-hydroxy-butyrate
14004,NCT00698698,,,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],
14005,NCT01371955,comparison of prevalence of homozygous polymorphism between the DN-group and the non-DN group,delay between diabetes diagnosis and ND onset by genetic polymorphism,2011-01,COMPLETED,OBSERVATIONAL,['NA'],HbA1c
14006,NCT02235194,Area under the curve for Glucose,Gut peptide hormones,2014-08,COMPLETED,INTERVENTIONAL,['NA'],
14007,NCT00732407,arterial stiffness and platelet function,"oxidative stress parameters (oxidized LDL and Isoprostanes), markers of inflammatory status (highly sensitive CRP test) and 24 hours blood pressure monitoring",2008-09,UNKNOWN,INTERVENTIONAL,['NA'],
14008,NCT06067178,Change in systolic blood pressure (mmHg),,2023-12-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Costs per attained blood pressure target among individuals in the health dialogue group vs. the opportunistic screening group
14009,NCT02118376,Dual energy X-ray absorptiometry,lab testing,2014-08,UNKNOWN,INTERVENTIONAL,['NA'],lab testing
14010,NCT04682977,Executive functioning using the Executive Function Performance Test,Participation in life activities and roles using the Late Life Functioning and Disability Index,2021-08-11,UNKNOWN,INTERVENTIONAL,['NA'],
14011,NCT04915339,Episodic memory performances,Client satisfaction questionnaire,2021-06,UNKNOWN,INTERVENTIONAL,['NA'],
14012,NCT00282360,silent ischemia,symptomatic myocardial ischemia,1999-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
14013,NCT02539355,Change in adipose tissue macrophage cell surface expression of metabolic activation marker ABCA1 as measured by relative mean fluorescence intensity (rMFI),Change in fasting plasma total adiponectin assessed by ELISA,2015-08,COMPLETED,INTERVENTIONAL,['NA'],Changes in gut microbiota assessed by stool sample analysis
14014,NCT04988321,Change in bodily and emotional perception of pain (BEEP) score,Change in corticospinal excitability (CE),2021-09-03,COMPLETED,INTERVENTIONAL,['NA'],
14015,NCT03362112,Lipoprotein-associated Phospholipase A2,C Peptide,2015-01-30,COMPLETED,OBSERVATIONAL,['NA'],
14016,NCT03936660,Implementing a clinic-level multifaceted intervention,Measurement of average time from baseline to patient event.,2019-07-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
14017,NCT04588896,1-hour glucose from OGTT,Socio-cognitive measures,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
14018,NCT00952445,,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
14019,NCT03910361,Changes from baseline intrahepatic fat (%),,2019-04-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
14020,NCT03738852,Brain glucose levels,,2018-11-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
14021,NCT01527981,Changes in depression severity,Changes in glucose levels,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
14022,NCT00311064,too large infants (> 2 standard deviation [SD]),induction of labour,2006-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
14023,NCT01671969,Urinary albumin excretion,,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
14024,NCT03555591,Number of Participants Who Had One or More Adverse Drug Reactions,Percentage of Participants Achieving Good Glycemic Control (Reduction in HbA1c Values < 6.0 Percent),2016-05-01,COMPLETED,OBSERVATIONAL,['NA'],
14025,NCT05790421,Toe Strength Dynamometer,,2022-04-02,COMPLETED,INTERVENTIONAL,['NA'],
14026,NCT00675857,Change from baseline to Week 26 in HbA1c levels,Change in fasting serum glucose levels,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
14027,NCT04735835,Glucose and HbA1c,Covid-19 symptom assessment,2020-07-20,RECRUITING,INTERVENTIONAL,['NA'],Hip Circumference (in sub-cohort)
14028,NCT01779141,Percent of Sensor Glucose Values in 70-140 mg/dL,Unhealthy Babies,2013-05,COMPLETED,OBSERVATIONAL,['NA'],
14029,NCT04654390,Change from Visit 2(Randomization) in HbA1c level at Week 24 after administation of the IP,"Proportions of subjects who achieved HbA1c level < 7% at Weeks 6, 12, 18, and 24 after administration of the IP",2020-12-30,COMPLETED,INTERVENTIONAL,['PHASE3'],
14030,NCT02122874,Serum glucose levels (mg/dl),Homeostasis model assessment (HOMA),2013-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
14031,NCT03766750,Reduction of glycated hemoglobin levels measured between the first visit and the last visit.,Incidence and severity of adverse events recorded during the study.,2021-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
14032,NCT04349696,Blood glucose concentration change from baseline at 2 hours after drug administration,,2014-02-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
14033,NCT02232126,30-day Hospital Readmission,30-day Readmission Among Intervention Participants,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
14034,NCT03787563,Number of Subject with adverse events,Flash Glucose Measurements,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
14035,NCT00299169,mean LDL levels,the proportions of participants taking statins at the end of the trial,2006-09,TERMINATED,INTERVENTIONAL,['PHASE4'],
14036,NCT03074214,Major adverse cardiovascular events (MACE),myocardial infarct size,2017-03-06,UNKNOWN,OBSERVATIONAL,['NA'],
14037,NCT02039141,"Change in Quality of Life Measured at Baseline, 3-months, 6-months, and 12-months",Change in Social support from family and friends on healthy eating and exercise.,2012-04,COMPLETED,INTERVENTIONAL,['NA'],Initial incremental cost effectiveness of intervention vs. standard care
14038,NCT04634838,Percent reduction of wound size,Number of infectious episodes,2021-02-02,TERMINATED,INTERVENTIONAL,['NA'],
14039,NCT05576116,Patients achieving normoglycemia,Proportion of participants with morbid obesity post PAK,2022-09-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
14040,NCT00134550,Recurrence rate of foot ulcers (during 26 weeks of study),Cost of DFU treatment from debut to healing (IDUS substudy),2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
14041,NCT00536744,The Primary Variable for Effectiveness of the dermaPACE Device Will be Assessed by Comparing the Incidence of Complete Wound Closure of the dermaPACE and Control Groups 12 Weeks Post Initial Application.,"Time to Wound Closure, Wound Closure Area and Volume Between Active and Control 12 Weeks Post Initial Application, Subject Pain Assessment Between Active and Control 24 Weeks Post Initial Application",2007-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
14042,NCT01796834,HbA1C Blood Test,Blood Pressure,2012-08,COMPLETED,INTERVENTIONAL,['NA'],patient evaluation of MBSR intervention
14043,NCT00252720,Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale,Rate of Change in Urinary Albumin Excretion Rate (UAER).,2001-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
14044,NCT01597882,Grip strength,Sickness behaviour scale,2012-10,COMPLETED,OBSERVATIONAL,['NA'],
14045,NCT00315718,HbA1c values,Blood pressure (systolic/diastolic),2002-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
14046,NCT03457012,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),2018-03-29,COMPLETED,OBSERVATIONAL,['NA'],
14047,NCT00398944,Patients who underwent the recommended procedures during the last 12 months,,2006-11,COMPLETED,INTERVENTIONAL,['NA'],
14048,NCT00494767,Body fat and fat-free mass as determined by a new investigational MR technique compared to 4C Model methodologies.,"Drug levels in blood over time (Day 42 PK parameters are AUC, Cmax, tmax)",2006-09-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
14049,NCT03745885,Pharmacokinetic: t½ of Supaglutide,,2018-12-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
14050,NCT03399357,Humoral immune response measure,,2017-05-31,UNKNOWN,OBSERVATIONAL,['NA'],
14051,NCT00235443,Number of Subjects With Adverse Events (AEs) Reported Spontaneously by the Subject or Observed by the Investigator.,Change From Baseline in Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS),2004-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
14052,NCT03202732,HbA1c,Mortality,2017-10-09,COMPLETED,INTERVENTIONAL,['NA'],
14053,NCT03598400,Severe hypoglycaemia,area under the curve of episodes of hypoglycaemia and hyperglycaemia,2018-08-01,COMPLETED,INTERVENTIONAL,['NA'],
14054,NCT01796366,Number of treatment emergent adverse events,Area under the glucose infusion rate-time curve,2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
14055,NCT01515228,In-segment late luminal loss,Stent thrombosis (by ARC definition),2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
14056,NCT01708083,Difference in polymorphids and/or mRNA expression in different types of fat tissue in patients with normal weight or obesity with or without diabetes type 2,,2010-01,COMPLETED,OBSERVATIONAL,['NA'],
14057,NCT02303405,Hemoglobin A1c,Adverse Events,2014-11,TERMINATED,INTERVENTIONAL,['PHASE2'],
14058,NCT03871621,Left ventricular mass index,Plasma biomarker: fatty acid binding protein 4 (FABP-4),2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
14059,NCT00970294,"Recruitment, Retention, Adherence",Glycemic Control,2007-07,COMPLETED,INTERVENTIONAL,['NA'],
14060,NCT00027287,,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
14061,NCT05767450,Glycemic control by Time-in-Range (TIR) monitoring,Measurement by flow cytometry of differences in the percentages of innate lymphoid cells,2022-12-16,RECRUITING,INTERVENTIONAL,['NA'],
14062,NCT00824330,Arterial baroreflex sensitivity,Increase in Gosling's pulsatility index,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
14063,NCT01668485,Whole body glucose counterregulation,Gluconeogenesis from lactate,2001-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
14064,NCT03642184,eGFR,Adverse events,2018-07-14,TERMINATED,INTERVENTIONAL,['PHASE4'],
14065,NCT02486237,Number of patients with microvascular and cardiovascular complications,Number of patients with microvascular and cardiovascular complications stratified by diabetes pharmacologic treatment,2015-09,COMPLETED,OBSERVATIONAL,['NA'],
14066,NCT01976858,To determine serum concentrations of PEX168,To determin HbA1c levels of PEX168,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],To assess number of participants with Adverse Events as a Measure of Safety and To assess number of participants with Adverse Events as a Measure of Safety and Tolerability
14067,NCT00147745,Acute Effect of a Single Dose of Colesevelam on Oral Glucose Absorption From Baseline to First Dose,Change in Hemoglobin A1C Due to Effect of Colesevelam From Baseline to 12 Weeks,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
14068,NCT05540197,Early islet graft function,Insulin concentration,2022-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
14069,NCT05759884,central macular thickness (CMT),nonperfusion (NP),2022-02-01,RECRUITING,INTERVENTIONAL,['NA'],
14070,NCT05270343,Residual β-Cell function (RBCF),Daily Insulin Dosage,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
14071,NCT02226822,Classes of diabetic medications at baseline and changes up to 3 years,Treatment choice,2014-09-20,COMPLETED,OBSERVATIONAL,['NA'],
14072,NCT05258240,Single leg standing test,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA'],
14073,NCT02143440,When the glucose level decreased to about 10 mmol/L,,2012-03,UNKNOWN,INTERVENTIONAL,['NA'],
14074,NCT03811132,HbA1c,Marker of inflammation #4: interleukin-1 receptor antagonist (IL-1Ra),2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],Fear of diabetes complications
14075,NCT06005987,Compliance,Percentage of in-range blood glucose levels,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14076,NCT01211197,Metformin: Maximum Measured Concentration (Cmax),"Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator.",2010-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
14077,NCT02610179,The serum glucose levels will be measured in response to oral glucose challenge and compared between Twizzlers and glucola beverage.,Cost-effectiveness,2015-04,RECRUITING,INTERVENTIONAL,['NA'],
14078,NCT02344732,Mean corneal epithelial wound healing time (in days),Duration of diabetes mellitus (measured in years) and its influence on wound healing time,2013-10,COMPLETED,INTERVENTIONAL,['NA'],
14079,NCT04403789,Change from Baseline Fasting Plasma Glucose (mmol/L) at 12 Weeks,Change from Baseline Physical Activity (AX3 Device) at 12 Weeks and 16 weeks,2021-03-28,COMPLETED,INTERVENTIONAL,['NA'],
14080,NCT01242228,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",2010-10-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
14081,NCT00979823,Number of risky prescribing events,"Secondary analyses will evaluate the actual use of the tool by residents, direct costs of the program, and resident satisfaction.",2010-09,COMPLETED,INTERVENTIONAL,['NA'],
14082,NCT00017953,First Occurrence of a Severe Cardiovascular Event,First Occurrence of Major Clinical Events,2001-06,COMPLETED,INTERVENTIONAL,['NA'],
14083,NCT01540396,Diagnosis of gestational diabetes,Maternal birth trauma,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
14084,NCT04807452,Toronto Clinical Neuropathy Scoring System,,2020-03-30,COMPLETED,INTERVENTIONAL,['NA'],Berg Balance Scale
14085,NCT03290144,Change in FEV1,Change in Body Mass Index (BMI),2015-02-02,UNKNOWN,OBSERVATIONAL,['NA'],
14086,NCT02763007,Proportion of subjects achieving HbA1c <7% after 36 month treatment,change of HOMA-beta(homeostasis model assessment of beta cell) from baseline to 36 month,2016-05-18,TERMINATED,INTERVENTIONAL,['PHASE4'],
14087,NCT04469855,Number of adverse events (AEs),Change in patient-reported outcomes (PROs) using the Diabetes Therapy-Related QOL (DTR-QOL) questionnaire - satisfaction with treatment,2020-07-27,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
14088,NCT02738671,Functional MRI of the brain tracking testing.,Change from baseline Functional magnetic resonance imagine,2016-01,COMPLETED,OBSERVATIONAL,['NA'],
14089,NCT03376698,Change in serum high-sensitivity CRP (mg/dl),Change in plasma myeloperoxidase level (ng/ml),2017-06-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Concentration of colhicine in white blood cell (ng/1*10^9 cells)
14090,NCT03917238,Pancreatic uptake of gallium-68-NODAGA-exendin-4,,2019-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
14091,NCT04082091,Early Impact Measure of Intervention for Detection,Change in Physiological Characteristics of Intervention Participants - Physical Activity,2019-09,UNKNOWN,OBSERVATIONAL,['NA'],
14092,NCT03734367,Change in the emotional skills of adolescents with type 1 diabetes that will be related to a glycosylated index between normal values,,2019-01,UNKNOWN,INTERVENTIONAL,['NA'],
14093,NCT00900146,Change From Baseline in Dynamic Phase Secreted Insulin Per Unit of Glucose Concentration (Φd) Over 4 Months (Period III),Percentage Change From Baseline in Fasting Lipids Profile at Month 4 (Period II),2009-04,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
14094,NCT00698789,"Safety and tolerability as determined by monitoring of AEs, vital signs, ECGs, physical examinations, and clinical laboratory blood and urine parameters.",Change from Baseline in fasting plasma glucose and population pharmacokinetics of INCB019602 in type 2 diabetic patients.,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2'],
14095,NCT05189015,angiotensin(1-7),LDL,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
14096,NCT00830011,Pain intensity score (NRS),pain-related disability (MPI) and emotional functioning,2004-09,COMPLETED,INTERVENTIONAL,['NA'],
14097,NCT01375660,Oral Glucose Insulin Sensitivity (OGIS),Incident Diabetes,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
14098,NCT06115213,Emergency room visits,New diagnosis of peripheral artery disease,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],
14099,NCT00476281,nutritional and respiratory parameters,abnormal glucose tolerance,2008-04,COMPLETED,INTERVENTIONAL,['NA'],
14100,NCT03830281,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 16,Percentage of Participants With at Least 1 Event of Unexplained Hyperglycemia >300 mg/dL Confirmed by SMBG That Leads to an Unplanned Infusion Set Change,2019-02-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
14101,NCT03851055,Fasting blood glucose mg/dl,fructosamine mg/dl,2017-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
14102,NCT02089477,The primary outcome is amount of time duing interval walking (in minuts) with InterWalk per week after 3 month,VO2-peek test in the InterWalk Application,2014-03,COMPLETED,INTERVENTIONAL,['NA'],
14103,NCT01182935,Number of subjects with type 2 diabetes diagnosed with oral glucose tolerance test (OGTT),The relation between serum 25(OH)D levels and blood glucose levels at OGTT,2010-04,COMPLETED,OBSERVATIONAL,['NA'],
14104,NCT00591903,,,2007-12-14,COMPLETED,OBSERVATIONAL,['NA'],
14105,NCT05404789,Time of data entry completion during Emergency Scenario,,2021-09-27,COMPLETED,INTERVENTIONAL,['NA'],
14106,NCT02152384,"Pharmacodynamics (PD): Plasma Glucose Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h), Above Pre Meal Baseline for Insulin Lispro",Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
14107,NCT00887874,"Percentage of diabetic patients having dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications, respectively","Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)",2009-05,COMPLETED,OBSERVATIONAL,['NA'],
14108,NCT04883372,glycated hemoglobin,Time spent below target (TBR),2021-05-22,COMPLETED,OBSERVATIONAL,['NA'],
14109,NCT05129345,Aim 3: Number of strategies modified in the self-management support and education,,2022-06-07,RECRUITING,OBSERVATIONAL,['NA'],
14110,NCT03273738,metabolic changes in type 2 diabetes,,2018-10-02,UNKNOWN,OBSERVATIONAL,['NA'],
14111,NCT06058338,Hemoglobin A1c,Program satisfaction,2023-05-31,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Program feasibility
14112,NCT01587638,Rate of New Onset Diabetes (NOD),,2009-04,COMPLETED,OBSERVATIONAL,['NA'],
14113,NCT00071448,HbA1c (glycosylated haemoglobin A1c),FPG (fasting plasma glucose),2002-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
14114,NCT05228860,HgbA1c,Food Assistance Programs,2023-09-18,RECRUITING,INTERVENTIONAL,['NA'],
14115,NCT00937222,The primary outcome measure is HDL-C,"Serum lipids, glucose, HbA1c, anthropometrics and blood pressure",2009-06,COMPLETED,INTERVENTIONAL,['NA'],
14116,NCT05364723,distribution of diabetic retinopathy in eastern morocco,,2022-05-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
14117,NCT00456105,Glycemic control,Readmission,2006-07,TERMINATED,INTERVENTIONAL,['NA'],
14118,NCT05220917,Hospitalization for Heart Failure (HHF) Hospitalization for Heart Failure (HHF),Coronary revascularization,2021-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Switching patterns
14119,NCT06147752,Change of homeostasis model assessment-insulin resistance（HOMA-IR）,Change of hepatic steatosis value,2023-03-28,RECRUITING,INTERVENTIONAL,['NA'],
14120,NCT00797771,"User satisfaction regarding the ""Adi"" pump functioning will be evaluated by questionnaire. The questionnaire will be administrated during the last study visit",Number of severe hypoglycemic events,2008-12,COMPLETED,INTERVENTIONAL,['NA'],
14121,NCT00309608,HbA1c Change From Baseline at Week 12,Fasting Blood Plasma Glucose Level (FPG) Change From Baseline at Week 12,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
14122,NCT00534547,Treatment success based on patients' glycemic control,"Physiologic Measurements, Comorbidity improvement, Improvement in QOL",na,WITHDRAWN,INTERVENTIONAL,['NA'],
14123,NCT00410722,Fasting insulin,Cancer cell proliferation,2006-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],
14124,NCT02154126,Accuracy (mean absolute relative difference) compared to be reference device should be less than 20%,,2014-05,COMPLETED,INTERVENTIONAL,['NA'],
14125,NCT00501020,The primary efficacy variable was HbA1c change from baseline (visit 3) after 24 weeks of treatment with either RSG+MET combination therapy or Metformin monotherapy.,"Secondary efficacy variables included: the change from baseline (visit 3) at week 24 (visit) in FPG, immunoreactive insulin, HbA1c and FPG responders, Questionnaire-Tolerability of GI side-effects, and Questionnaire - Quality of Life.",2001-06-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
14126,NCT02923063,Quadriceps muscle work efficiency,Perceived Stress (NIH),2020-01-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Walking economy during 6 minute walk
14127,NCT05973734,Number of patients who receive Treg infusions (Arm1) or Donor Derived Vertebral Bone Marrow (Arm2) and islet transplantation (feasibility),Quality of life (QOL) assessment,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],
14128,NCT00336674,Diagnosis of Diabetes AT 5 years according to American Diabetes Association / World Health Organization (ADA/WHO) criteria.,Immune function,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
14129,NCT06143566,Oxygen uptake during peak exercise (Peak VO2),Urine albumin to creatinine ratio,2024-03-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Medication Adherence
14130,NCT03341429,%WL,HRQoL,2018-08-22,COMPLETED,INTERVENTIONAL,['PHASE4'],
14131,NCT01942694,Time to Development of Diabetes,Identification of Characteristics Associated With the Variability in Achieved 25OHD Concentration.,2013-10,COMPLETED,INTERVENTIONAL,['NA'],Quality of Life and Mood Scores in Pre-diabetes Population Using a Validated Instrument (PROMIS-29 Profile v2.0 and a General Question on Perception of Overall Health From the PROMIS Scale 1.2).
14132,NCT06248190,Improved control of at least one condition that was not optimally controlled at baseline,Heathcare utilisation and cost,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],
14133,NCT05260983,Phenomenological Body Shame Scale - Revised,Short-form State-Trait Anxiety Inventory,2021-08-28,COMPLETED,INTERVENTIONAL,['NA'],1-item Expected Diabetes Prevention Self-Efficacy Scale
14134,NCT00530309,Plasma concentrations and PD parameters over time and at the end of study,Other metabolic parameters at the end of study,2007-08-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
14135,NCT05099887,Percent of Wound closure,,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
14136,NCT00422630,Change in insulin sensitivity over time,Diet satisfaction,2007-10,COMPLETED,INTERVENTIONAL,['NA'],
14137,NCT04637217,Correlation between neurodegeneration and retinal vessels characteristics,Correlation between choroidal parameters and diabetes control,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],
14138,NCT00593255,2-hours postprandial plasma glucose (PPPG),Hypoglycaemic episodes,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
14139,NCT02064023,Composite obstetrical/perinatal endpoint consisting of specific elements (see description),Mean maternal HbA1c during pregnancy,2014-04,TERMINATED,INTERVENTIONAL,['NA'],Number of episodes of severe hypoglycemia
14140,NCT02348190,protein kinase C enzyme activity in tissue samples,protein kinase C enzyme activity in T cells,2003-06,COMPLETED,INTERVENTIONAL,['NA'],
14141,NCT04378972,pro-inflammatory cytokines analysis,,2019-09-16,COMPLETED,OBSERVATIONAL,['NA'],
14142,NCT00536796,Cholesterol levels,,2007-09,COMPLETED,OBSERVATIONAL,['NA'],
14143,NCT05695573,Determine the urinary exosomal UMODmRNA gene expression,,2019-07-05,COMPLETED,OBSERVATIONAL,['NA'],
14144,NCT06160934,Client Satisfaction Questionnaire,Time in Range,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14145,NCT05974566,Change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP),Change in renal function level,2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
14146,NCT06086067,Time spent at each glucose range,Progesterone,2023-09-15,COMPLETED,INTERVENTIONAL,['NA'],
14147,NCT06329375,Food insecurity at 30-days post initial discharge,Hospitalization,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14148,NCT01407003,"Safety and tolerability of single and multiple dose(s) of LIK066: number of patients with adverse events and changes from baseline in vital signs, ECG and clinical labs (blood chemistry, hematology and urinalysis).",Change in fasting and post-challenge plasma glucose after a single dose and 2 weeks of treatment,2011-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
14149,NCT04113239,Genotypes of participants,Food frequency questionnaire,2019-11-27,COMPLETED,OBSERVATIONAL,['NA'],
14150,NCT02742987,Flow-mediated Dilation of the Brachial Artery,Number of Patients With Platelet Reactivity >256 P2Y12 Reaction Units,2014-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
14151,NCT03032991,Electroencephalography (EEG),Metabolomic,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],Physical Activity
14152,NCT03958760,Triglyceride (TG) (mmol/L),The proportion of re-hospitalization,2021-02-28,COMPLETED,OBSERVATIONAL,['NA'],
14153,NCT00099931,Change from baseline in HbA1c at 24 weeks,Patients with endpoint <7% after 24 weeks,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
14154,NCT02088268,effect of PRP on diabete wound closure,,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
14155,NCT02596932,Mean neonatal blood glucose levels,Maternal hypoglycemia,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
14156,NCT01593137,"assess the effect of treatment with liraglutide compared to glimepiride, as add-on to metformin, for one year on circulating levels of EPCs in patients with type 2 diabetes poorly controlled.","Safety parameters of glycaemic control: HbA1c, FPG",2012-05,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
14157,NCT00171600,"Change from baseline in urine albumin excretion rate from collected urine samples, after 16 and 20 weeks",Change from baseline in kidney function after 16 and 20 weeks,2005-07,TERMINATED,INTERVENTIONAL,['PHASE4'],
14158,NCT01178957,Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) secretion,,2012-04,COMPLETED,OBSERVATIONAL,['NA'],
14159,NCT02201004,Change in HbA1c from baseline,Number of subjects with adverse events,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
14160,NCT03260868,Change From Baseline in Glycated Hemoglobin A1c (HbA1c) to Week 24,"Number of Participants With At Least One Hypoglycemic Events (Any, Severe Documented Symptomatic, Probable Symptomatic, Asymptomatic, Pseudo-hypoglycemia: Any Time of the Day) During 24 Week Treatment Period",2017-09-19,TERMINATED,INTERVENTIONAL,['PHASE4'],
14161,NCT03529188,HFS-Parent score,HbA1C,2018-08-03,UNKNOWN,OBSERVATIONAL,['NA'],
14162,NCT02131766,USS Virginia Time Within Target,Morning Glucose Levels,2014-06,COMPLETED,INTERVENTIONAL,['NA'],
14163,NCT04057417,Major adverse cardiovascular events,Cardiovascular disease-related risk factors,2018-01-05,UNKNOWN,INTERVENTIONAL,['NA'],Trail counts
14164,NCT03748251,Continuous glucose sensor data,Content of carbohydrates,2018-02-14,COMPLETED,INTERVENTIONAL,['NA'],Content of amino acids
14165,NCT04038125,Evaluate re perfusion following Ozurdex use.,,2019-08-22,UNKNOWN,INTERVENTIONAL,['PHASE4'],
14166,NCT02337972,Change of conjunctival flora and bacterial resistance,,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],
14167,NCT04201496,CGM-measured time in the target range 70-180mg/dl (TIR) during the day,Number of hyperglycemic episodes as defined by contiguous CGM above 300 mg/dL,2020-02-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
14168,NCT04973111,Change in insulin secretion rate and ambient glucose levels,Change in blood glucose levels at each level of glucose infusion,2021-07-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
14169,NCT01686932,Hypoglycemic Profile of Vildagliptin Compared to Sitagliptin Over 4 Days After 8 Weeks of Treatment in Period 1 & 2,Number of Occurrence of Pre-defined ECG Findings During 4 Days of Continuous ECG Monitoring at Baseline and in the 8th Week of Periods 1 and 2,2012-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
14170,NCT01385865,Blood glucose change with meal tolerance test,"Lipid profile (triglyceride, total cholesterol, low-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, high-density lipoprotein cholesterol)",2011-01,COMPLETED,INTERVENTIONAL,['NA'],
14171,NCT02726256,"HOMA-IR, HOMA-β",,2007-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
14172,NCT00961324,Area under the glucose infusion rate curve during one dosing interval at steady state,Area under the NN1250 concentration-time curve during one dosing interval at steady state,2009-07-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
14173,NCT02328911,Change in self-reported pain.,Change in quality of life.,2015-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
14174,NCT02225691,Baseline change in HbA1c at month 3 and 6 between paired testing and control arms for each of the 3 patient segments.,Proportion of patients who achieve good glycemic control (HbA1c≤7%),2014-12,UNKNOWN,INTERVENTIONAL,['NA'],Baseline change in self-care scores (based on Diabetes Self-Efficacy Scale Questionnaire)
14175,NCT06183476,Sleep,Glucose levels,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14176,NCT04905589,Diurnal glucose Incremental area under curve (iAUC) concentrations,Peptide tyrosine tyrosine (PYY) Incremental area under curve (iAUC),2021-04-30,COMPLETED,INTERVENTIONAL,['NA'],
14177,NCT01031680,Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit,Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
14178,NCT01655810,Change from baseline in carotid intima-medial thickness,Urinary Calcium,2012-08-13,COMPLETED,INTERVENTIONAL,['NA'],
14179,NCT02009488,"Change from baseline in beta-cell glucose sensitivity, determined as a slope of ISR vs. plasma glucose concentration during MMTT","Change from baseline in renal threshold for glucose (RTG), estimated using an MMTT-based method",2014-09-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
14180,NCT03533738,Insulin response,,2017-10-12,COMPLETED,INTERVENTIONAL,['NA'],
14181,NCT06025292,Whole Body Protein Balance,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14182,NCT00044447,Change in HbA1C from baseline to Week 26.,Incidence of hypoglycemia.,2001-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
14183,NCT05343962,PROMIS Scale v1.2 - Global Health9. Spanish version,PROMIS-10_Q01. Spanish version.,2022-03-01,UNKNOWN,OBSERVATIONAL,['NA'],
14184,NCT00845130,Quantify the Effect of Chronic Hyperglycemia on Cellular Uptake of Vitamin C Across the Blood-brain Barrier,,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
14185,NCT00774553,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables, weight and ECG)",Pharmacodynamic variables,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
14186,NCT06124573,Area under the plasma concentration versus time curve (AUC) 0-inf (Metformin only),Number of participants with adverse events (AEs),2022-11-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
14187,NCT01918488,24-hour urinary sodium excretion induced by amiloride,Office blood pressure measurements,2013-10,UNKNOWN,INTERVENTIONAL,['NA'],
14188,NCT05492890,Maternal outcome,Neonatal outcomes,2022-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
14189,NCT03272854,Graft Failure,Non-Cardiovascular Mortality,2001-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Venous Thrombosis
14190,NCT05219409,Rate of new diagnoses of Type 1 Diabetes Mellitus per year,Number of participants with adverse effects on Sitagliptin,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Monitor Stage 2 patients with a CGM system (continuous blood glucose detection)
14191,NCT04585139,HbA1c,,2020-10-06,COMPLETED,INTERVENTIONAL,['NA'],
14192,NCT02109094,Plasma Leptin Level,,2014-02,COMPLETED,OBSERVATIONAL,['NA'],
14193,NCT03136471,Glycemic Control (HbA1c) for Telehealth visits for COVID-19 patients,,2017-01,COMPLETED,OBSERVATIONAL,['NA'],
14194,NCT05169502,Genome wide expression profile of circulating cells in blood samples from each cohort group,,2021-12-08,RECRUITING,OBSERVATIONAL,['NA'],
14195,NCT01916174,Maximum observed plasma liraglutide concentration after single dose,Terminal elimination half-life of liraglutide after single dose,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
14196,NCT05298111,Changes in fasting and postprandial blood glucose,Changes in food intake,2021-10-01,COMPLETED,INTERVENTIONAL,['NA'],Habitual physical activity
14197,NCT06292026,time to wound closure,,2022-03-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
14198,NCT01791114,Insulin Sensitivity,Metabolic profile,2012-01,COMPLETED,INTERVENTIONAL,['NA'],Thermoregulation
14199,NCT03434119,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26,"Percentage of Participants With Hypoglycemic Events (Any Hypoglycemia, Severe Hypoglycemia, Documented Hypoglycemia) During the On-Treatment Period",2018-02-20,TERMINATED,INTERVENTIONAL,['PHASE3'],
14200,NCT04424706,total MMP-9 levels,,2020-06-30,UNKNOWN,OBSERVATIONAL,['NA'],
14201,NCT01363141,Change in Blood Glucose and Insulin levels in 1 year as compared to baseline,Change in markers of cardiovascular disease in 1 year as compared to baseline,2010-12,COMPLETED,INTERVENTIONAL,['NA'],
14202,NCT05337306,Health Literacy Questionnaire Subscale 2: having sufficient information to manage my health,Perceived Diabetes Self-Management Scale score,2023-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
14203,NCT00706511,Polysomnography - Sleep Efficiency,IVGTT (Intravenous Tolerance Test) - Disposition Index (DI),2007-12,COMPLETED,INTERVENTIONAL,['NA'],
14204,NCT00541515,Blood glucose levels,,2007-10,COMPLETED,INTERVENTIONAL,['NA'],
14205,NCT05685810,Kidney disease,Insulin resistance,2018-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
14206,NCT02910674,"Percent of Participants Responding 'YES' on the Question ""Did You Successfully Obtain Measurement Result Using the Dario™ BGMS?""",,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
14207,NCT00428207,Glycemic Stability,Frequency of Catheter Change,2007-02,TERMINATED,INTERVENTIONAL,['NA'],
14208,NCT05016375,Explore bathing and spa behaviour by applying the social-ecological model to interpretivist thematic analysis.,Explore how passive heating might impact physical activity by applying the social-ecological model to interpretivist thematic analysis.,2022-06-28,COMPLETED,OBSERVATIONAL,['NA'],
14209,NCT01622777,Nerve growth factor,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
14210,NCT06264258,Change in glucose average and variability,Change in game play patterns over time,2024-03-01,RECRUITING,INTERVENTIONAL,['NA'],
14211,NCT05286450,Distribution of Participants Responses as Regards DSMQ Health Care Use Domain,,2022-03-15,COMPLETED,OBSERVATIONAL,['NA'],
14212,NCT01341899,Changes in C-peptide levels during standard-meal tolerance test from baseline to different time points after transplantation,mortality and dysfunction of other endocrine glands,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
14213,NCT02054650,Change in low back pain severity,Change in biomarker concentrations,2014-05,TERMINATED,INTERVENTIONAL,['NA'],
14214,NCT02243072,Metabolic Control: Hemoglobin A1c (HbA1c),"Regimen Adherence: Diabetes Management Scale (DMS), Glucose Meter Downloads",2014-12,COMPLETED,INTERVENTIONAL,['NA'],
14215,NCT03815305,Change in SRRC,,2018-07-30,UNKNOWN,INTERVENTIONAL,['PHASE4'],
14216,NCT05188703,Number of participants who completed a follow-up eye exam 12+ months after baseline eye exam,,2022-07-25,RECRUITING,INTERVENTIONAL,['NA'],
14217,NCT06020235,Efficacy,Pharmacokinetics,2024-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Wound healing
14218,NCT00794430,Investigate the safety and tolerability of V3381 in patients with diabetic neuropathic pain at doses of up to 400 mg bid,Determine the efficacy of V3381 in the treatment of diabetic peripheral neuropathic pain at does of up to 400 mg bid,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
14219,NCT03967639,Smoking habits of patients undergoing cardiac surgery,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],
14220,NCT02964104,Number of treatment emergent adverse events (TEAE),"AUCGIR,0-24h,SS, area under the glucose infusion rate-time curve at steady state",2016-11-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
14221,NCT03728296,Occurrence of treatment related adverse events as assessed by CTCAE v4.0,,2019-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
14222,NCT05769127,Change in body weight for DPP participants,change in liver elastography in DPP participants,2023-04-26,RECRUITING,INTERVENTIONAL,['NA'],
14223,NCT03960333,circulating CD4+T cells in Type 2 Diabetic pre/post Metformin,,2019-04-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
14224,NCT06180837,Insulin Sensitivity,Cardiac Event Risk Test 1 (CERT 1),2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14225,NCT05341063,Health Literacy Scale,,2021-10-10,COMPLETED,INTERVENTIONAL,['NA'],
14226,NCT04507867,Overall Mortality at Day 40,Number of Participants With Distension on Day 3,2020-09-07,COMPLETED,INTERVENTIONAL,['NA'],Number of Deceased Participants Stratified by Urea Level
14227,NCT02745470,Whole brain connectivity,intake of food in the buffet,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
14228,NCT00897169,"Beta-cell function index estimated by a model-based analysis fit to the complete OGTT C-peptide and glucose profiles (12 time points), and including diabetes progression (as assessed by the glucose concentration 2 hours after an oral glucose load)",Evaluation of comparability of OGTT and clamp data based on modelling data of insulin sensitivity from steady-state clamp insulin and glucose concentrations and OGTT insulin and glucose profiles (12 time points),2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
14229,NCT02313220,Body weight (kg),Body weight (%),2014-12,COMPLETED,INTERVENTIONAL,['PHASE2'],"Adverse events /serious adverse events, vital signs and collection of clinical chemistry/haematology parameters."
14230,NCT01474018,Change in A1c,Total Daily Insulin Dose,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
14231,NCT02041234,number of subjects achieving LDL level of <100mg/dl without lipid lowering medication,Weight loss,2014-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
14232,NCT01267175,Usability of the X54 Insulin Pump Meets Expectations,Usability of the Training Material Meets Expectations,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
14233,NCT03611322,"Cmax,sema,Week5: the maximum plasma semaglutide concentration after first maintenance dose of subcutaneous semaglutide 1 mg administration following a four week escalation period",Number of site-initiated technical complaints with or without co-reported adverse events,2018-08-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
14234,NCT02441023,Metabolic control,Body mass index (BMI),2013-03,COMPLETED,INTERVENTIONAL,['NA'],
14235,NCT02505321,Level of Circulatory Lipids following Triglyceride stimulation test (OTTT) (mmol/L),Incremental Area under the Curve NEFA levels (µmol/L),2015-05-29,COMPLETED,INTERVENTIONAL,['NA'],
14236,NCT04645641,System Performance,System Related Adverse Device Effects,2020-10-12,UNKNOWN,INTERVENTIONAL,['NA'],
14237,NCT03809858,Number of missed meal boluses,Diabetes Distress Scale (DDS) Scores,2019-05-29,COMPLETED,INTERVENTIONAL,['NA'],
14238,NCT01831921,Hemoglobin A1c,Triglycerides,2014-01,COMPLETED,INTERVENTIONAL,['NA'],Homeostasis Model of Insulin Resistance (HOMA IR)
14239,NCT02158741,Summary of Diabetes Self-Care Activities,SF12v2,2014-09,COMPLETED,INTERVENTIONAL,['NA'],Health Assessment forms
14240,NCT00007696,,,1998-04,COMPLETED,OBSERVATIONAL,['NA'],
14241,NCT04088201,Interstitial fluid glucose readings,Acceptablility of sensor,2019-09-26,UNKNOWN,INTERVENTIONAL,['NA'],
14242,NCT00324207,,,2006-02,COMPLETED,OBSERVATIONAL,['NA'],
14243,NCT00363233,Total cholesterol at 3 months,LDL and triglycerides at 3 months; Blood glucose and HbA1C at 3 months,2006-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
14244,NCT02490969,All-cause mortality,,2015-09,COMPLETED,OBSERVATIONAL,['NA'],
14245,NCT02647515,intraocular pressure,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
14246,NCT02691234,"To assess initial closure rate of the wound 4 weeks after the last treatment session, as compared to the control group receiving conventional standard of care.",,2016-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
14247,NCT02034513,Number of Treatment Emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period,FPG (Fasting Plasma Glucose),2014-01-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
14248,NCT06069258,Movement behaviour,Adverse events,2023-10-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
14249,NCT03042325,Percentage of Participants with Glycosylated Hemoglobin < 7.0%,,2017-07-30,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
14250,NCT02432859,"The wound fluid level of VEGF, VEGFR-2, HIF-1α and NO (pg/ml)",Wound surface area(cm2),2013-11,COMPLETED,INTERVENTIONAL,['NA'],
14251,NCT01076608,,,2003-09,COMPLETED,OBSERVATIONAL,['NA'],
14252,NCT05188027,Blood glucose,carbohydrate supplementation,2021-11-16,RECRUITING,INTERVENTIONAL,['NA'],
14253,NCT03118739,Urinary Albumin to Creatinine Ratio (UACR),MRI Variables - LV Mass,2017-05-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Baseline Flow Mediated Dilatation (Reactive Hyperemia)
14254,NCT00989339,endothelial function,carbohydrate metabolism,2009-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
14255,NCT02578563,Change from baseline in the HbA1c level after 1 year,Change from baseline in Waist circumference at 12 months,2016-02-12,COMPLETED,OBSERVATIONAL,['NA'],
14256,NCT01040819,Plasma 15-epi-lipoxin A4,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
14257,NCT02324036,Attainment of concrete behavioral goal (assessed in a two-week follow-up phone call to the patient),"Improvement in ""red flag"" outcome (assessed from the patient's medical record as the change in the measured value of the outcome measure identified as a high priority outcome)",2014-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
14258,NCT05222815,Change in Diabetes Distress,,2022-08-29,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
14259,NCT04372810,Tibiotarsal joint range of motion,Static balance,2017-08-09,COMPLETED,INTERVENTIONAL,['NA'],
14260,NCT02307968,leaking,,2014-10,COMPLETED,OBSERVATIONAL,['NA'],
14261,NCT02147925,Intrahepatic lipids (IHL),Change in hemoglobin A1c(HbA1c),2014-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
14262,NCT05181449,To compare the percentage of patients in the TPT and Usual Care groups who have a HbA1c less than 6.5 and are not on any glucose lowering medications (excluding Metformin up to 2000 mg/day) at 12 months (360 days).,To compare the percentage of patients in the TPT and Usual Care groups who have a HbA1c less than at 6.5 and are not on any glucose lowering medications at 12 months (360 days).,2022-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
14263,NCT02011620,Improvement in endothelial function as measured by laser doppler imaging.,Improvement in bone metabolism,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
14264,NCT00005248,,,1989-08,COMPLETED,OBSERVATIONAL,['NA'],
14265,NCT05787457,Metabolic phenotype of type 2 diabetes mellitus across groups,Genetic Differences,2014-07-31,TERMINATED,OBSERVATIONAL,['NA'],
14266,NCT01291160,Number of 100% Wound Closure,,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
14267,NCT02539160,Platelet Reactivity Measured by Vasodilator Stimulated Phosphoprotein (VASP) Platelet Reactivity Index (PRI %),Platelet Reactivity Measured by VerifyNow P2Y12,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
14268,NCT01124656,Incidence of Adverse Events.,Change from Baseline for Glycosylated Hemoglobin.,2006-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
14269,NCT01345227,Adverse events related to the procedure of intra bone marrow islet infusion,Beta-cell function,2009-08,COMPLETED,INTERVENTIONAL,['NA'],
14270,NCT03842267,Changes from baseline HbA1c at week 24,,2019-05-13,COMPLETED,INTERVENTIONAL,['PHASE3'],
14271,NCT03018444,Postprandial GLP-1 secretion,Resting Energy Expenditure,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
14272,NCT06071325,Types and Amount of Diabetes Waste,,2023-09-19,RECRUITING,OBSERVATIONAL,['NA'],
14273,NCT05769335,Glucose area under curve (AUC) after 3 meals,Change in fat mass,2023-03-15,RECRUITING,INTERVENTIONAL,['NA'],
14274,NCT05376969,"Changes from baseline in Adverse events (AEs) and adverse events of special interest (AESIs)* at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP","Proportion of subjects achieving HbA1c target of < 7% at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP",2021-05-25,COMPLETED,INTERVENTIONAL,['PHASE3'],
14275,NCT00428727,Ulcer reduction percentage,Presence of adverse events related to the application of the patches,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
14276,NCT02008435,Percent body weight loss,Exercise stress test (EST),2013-04,COMPLETED,INTERVENTIONAL,['NA'],Habit formation indices of fat grams and calorie tracking
14277,NCT04181853,genetic molecules,,2020-02-05,COMPLETED,INTERVENTIONAL,['NA'],
14278,NCT02965443,Percentage of subjects achieving a HbA1c ≤ 7.5% and having a reversal from a BBIT to a BOT regimen,changes in fear of hypoglycemia between groups,2018-02-02,TERMINATED,INTERVENTIONAL,['PHASE4'],changes in clinical chemistry/haematology parameters between groups
14279,NCT01590433,Change in Body Weight,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
14280,NCT04349670,Complications,Correlation of symptoms,2020-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
14281,NCT04131608,Iron deficiency detected by Hemoglobin level in g/dl HBA1C level in diabetic patients,,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA'],
14282,NCT03296436,complete ulcer closure,recurrent ulcer-related complications,2020-01,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],
14283,NCT04426422,gut micribiota,glycemic control,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
14284,NCT00173628,,,1990-01,UNKNOWN,OBSERVATIONAL,['NA'],
14285,NCT01418703,Hypoglycemic Events,Mean Glucose,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
14286,NCT00612014,Change from baseline in the mean Gastroparesis Cardinal Symptom Index score (24 hour recall version) across the four days of dosing. Baseline is the average of the scores collected across the 4 days just prior to admission for dosing.,Cumulative GSA score after each dosing event and after all dosing events,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
14287,NCT04813133,Serum High Density Lipoproteins (HDL),,2021-02-05,UNKNOWN,INTERVENTIONAL,['NA'],
14288,NCT00952991,Gastrointestinal Symptoms,Glucagon Secretion,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
14289,NCT00872456,"Composite of major CVD events (non fatal MI, Stroke and CVD death)",Revascularization procedures,2005-03,COMPLETED,OBSERVATIONAL,['NA'],
14290,NCT02038517,Relationship of insulin secretion and sensitivity with the development of abnormalities of glucose metabolism after OLT,Relationship of insulin secretion and sensitivity with the development of the metabolic syndrome after OLT,2013-06,RECRUITING,OBSERVATIONAL,['NA'],Morbidity and mortality after OLT
14291,NCT03820349,MRI outcome,Cognitive function,2018-05-07,COMPLETED,OBSERVATIONAL,['NA'],
14292,NCT01079325,To compare the effect of SB-509 versus placebo in subjects with moderately severe diabetic neuropathy (DN) on sural Nerve Conduction Velocity (NCV) at six-months,To evaluate the safety of SB-509 in subjects with moderately severe diabetic neuropathy,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
14293,NCT03361631,To evaluate the occurrence of clinical adverse event (tolerance) to intracavernous injection of autologous MSC in patients 18 to 50 years of age with complicated type 1 diabetes mellitus with erectile dysfunction refractory to oral treatment.,Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the Injection rate actually achieved,2018-06-30,UNKNOWN,INTERVENTIONAL,['PHASE1'],
14294,NCT02002611,Assess Cmax of R-warfarin,Assess Vd/F of R-warfarin,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
14295,NCT02791035,Correlation between change of HbA1c and urinary glucose excretion,Percentage of subjects achieving the target HbA1c(<6.5%),2016-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
14296,NCT03439072,Number of Subjects With a Positive Glucose Response,Glucagon Preparation and Administration Time,2018-01-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
14297,NCT01018173,Time to cardiovascular composite primary endpoints,"Metabolic and renal function parameters: HbA1c, fasting plasma glucose, body weight, lipid profile, albumin/creatinine ratio (ACR), albuminuria, glomerular filtration rate (GFR)",2010-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
14298,NCT00924053,Vz/F,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
14299,NCT00879125,glycemic control,Correction of lipid profiles,1999-11,COMPLETED,OBSERVATIONAL,['NA'],
14300,NCT02043886,Catecholamines,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
14301,NCT05210517,Fractional uric acid excretion,urinary glucose levels,2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
14302,NCT03912961,Number of subjects where the image readout by retina specialists match the readouts by EyeStar AI system for identifying diabetic eye disease,Number of subjects with ocular diseases other than diabetic retinopathy between the readout by the EyeStar AI system and those by the retina specialists,2019-01-21,COMPLETED,OBSERVATIONAL,['NA'],
14303,NCT06251635,Resting State Functional Connectivity (assessed through Functional MRI),Processing Speed,2024-02-28,RECRUITING,INTERVENTIONAL,['NA'],
14304,NCT00138515,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
14305,NCT03981328,LGA newborns,Health-related quality of life,2020-08-26,RECRUITING,INTERVENTIONAL,['NA'],
14306,NCT01715428,carotid intima-media thickness,changes in atherogenic lipoproteins,2012-06,COMPLETED,OBSERVATIONAL,['NA'],
14307,NCT02715193,"Changes from baseline in 24-hour insulin requirements on Day 1 relative to the two 24 hour periods post-treatment on Days 3 and 4, between the REMD-477 and placebo treated subjects, needed to maintain targeted glycemic control.",Changes from baseline over time of lipase,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
14308,NCT05100576,Change of HbA1c level,Difference in the decisions between the two type of visits,2021-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
14309,NCT04878406,Number of treatment emergent adverse events (TEAEs),"Cmax,semaglutide,SD: Maximum plasma concentration of semaglutide upon a single-dose",2021-05-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
14310,NCT04308590,Rate of safety based TEAEs,Proportion of patients with normalization of the mean SBP,2020-07-27,RECRUITING,INTERVENTIONAL,['PHASE3'],
14311,NCT03713268,Estimate of subretinal fluid volume before and after surgery for retinal detachment based on surgical view versus based on OCT output,,2018-09-30,RECRUITING,OBSERVATIONAL,['NA'],
14312,NCT01386099,Beta-cell function,Body weight,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
14313,NCT00128154,Increase in insulin sensitivity,weight and/or body composition,2004-01,COMPLETED,INTERVENTIONAL,['NA'],
14314,NCT01396161,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),Urinary Recovery,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
14315,NCT00605839,Quality of Parent-child Relationship,,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
14316,NCT01377961,A1C,"For Arm 1 :AUCglucose,Plasma Lipids concentrations,BMI,Plasma lycopene and isoflavones concentration,EPCs count and function,Chlamydia Trachomatis titers in serum",2010-09,WITHDRAWN,INTERVENTIONAL,['NA'],
14317,NCT02219646,Endothelin-1,Flow Mediated Dilation,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2'],carotid Intima Media Thickness
14318,NCT01572740,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16,Number of Confirmed Hypoglycaemic Episodes,2012-04-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
14319,NCT04742751,Drug adherence/Pill Counts,Glycemic Control,2022-03-02,RECRUITING,INTERVENTIONAL,['PHASE2'],
14320,NCT00829296,Change in Central Systolic Blood Pressure (SBP),Change in Pulse Pressure Amplification,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
14321,NCT05569525,Glycated hemoglobin (HbA1c),Glucose coefficient of variability (CV),2022-11-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14322,NCT01212198,Incidence of diabetes in patients with high risk for diabetes and gestational diabetes in Koreans,,2005-05,UNKNOWN,OBSERVATIONAL,['NA'],
14323,NCT02404870,AUC of FGF23,"1, 25 vitamin D",2014-09-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
14324,NCT02328521,Neointimal area,number of major adverse cardiovascular events,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],
14325,NCT05344066,Number of stillbirths,The acceptability of the dietary interventions will be explored qualitatively,2022-11-24,RECRUITING,INTERVENTIONAL,['NA'],Mode of delivery
14326,NCT02620917,Number of Patients With Glycated Hemoglobin on Target,"Number of Patients With HbA1c on Target Using Advanced Pump's Functions, CGM and CHO Counting",2015-11-01,COMPLETED,OBSERVATIONAL,['NA'],
14327,NCT04937296,HBA1c (Glycated hemoglobin),Triglyceride-glucose index,2022-01-12,COMPLETED,INTERVENTIONAL,['NA'],
14328,NCT05018416,Procedural and investigational product-related treatment-emergent adverse events (TEAEs) obtained through 18 months after the last REACT injection.,,2021-07-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
14329,NCT04283617,Intracerebral concentrations of glucose between T2DM patients,Multitasking Test (MTT),2021-10-12,WITHDRAWN,INTERVENTIONAL,['NA'],
14330,NCT02126358,LDL-C change rate,LDL-C change rate,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
14331,NCT06239129,Effect of medications or conditions on kidney function decline,Adverse health events associated to laboratory abnormalities,2006-01-01,COMPLETED,OBSERVATIONAL,['NA'],
14332,NCT02223065,Dapagliflozin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]),,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
14333,NCT02526810,mean amplitude of glycemic excursions( MAGE),the level of blood 8-hydroxy-2-deoxyguanosine(8-OHdG),2015-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],the incidence of severe hypoglycemia
14334,NCT05974592,Foot Care Behavior Scale (USAS),Diabetic Foot Evaluation Form (DADF),2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],
14335,NCT04620668,Changes in stress as measured by the Perceived Stress Scale (PSS-10),Changes in life satisfaction as measured by the Satisfaction with Life Scale,2021-10-01,COMPLETED,INTERVENTIONAL,['NA'],
14336,NCT04874012,HbA1c,Body mass index (BMI),2021-06-12,RECRUITING,INTERVENTIONAL,['PHASE2'],
14337,NCT02816762,Change form baseline in albuminuria levels,To identify the CPAP-responder subgroup of OSA patients with diabetic nephropathy,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
14338,NCT01198678,Evaluate capability to follow glucose concentration changes over 15 consecutive days,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
14339,NCT01868581,Maximum serum insulin degludec concentration (Cmax) (for IDegAsp),,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
14340,NCT03613805,device accuracy,changes in fear of hypoglycaemia,2018-03-14,COMPLETED,INTERVENTIONAL,['NA'],
14341,NCT04283318,change of 2h glucose levels,Changes in body composition,2018-06-13,COMPLETED,INTERVENTIONAL,['NA'],
14342,NCT04622722,2-hour postprandial glucose,Gastrointestinal tolerance,2018-08-22,COMPLETED,INTERVENTIONAL,['NA'],
14343,NCT03324737,Weight at 4 months post-delivery,Breastfeeding Status,2017-11-16,COMPLETED,INTERVENTIONAL,['NA'],
14344,NCT00437164,changes in fluid related parameters as measured by hematocrit and hemoglobin levels and body weight,"safety/tolerability, as measured by adverse events, clinical laboratory, edema & glycemic measures, ophthalmic assessments; & changes in weight, waist & hip circumference",2006-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
14345,NCT01742624,"Incidence of efficacy failure (treated-BCAR, biopsy-confirmed acute rejection, graft loss rate, death, or follow-up failure)","Safety assessed by the incidence of adverse events, physical exam, and labo-tests",2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
14346,NCT02003274,1. Composite plasma glucose and hormone responses to a mixed meal; 2. Glucose control coefficients,Composite plasma free fatty and amino acid responses to a mixed meal,2013-10,UNKNOWN,INTERVENTIONAL,['NA'],
14347,NCT01627184,Glycemic Control during Exercise,System Utility and Usability,2012-05,COMPLETED,OBSERVATIONAL,['NA'],
14348,NCT05013294,Glycated hemoglobin,Waist-hip ratio,2021-08-23,COMPLETED,INTERVENTIONAL,['NA'],
14349,NCT03399565,HDL-C,,2016-01-18,UNKNOWN,OBSERVATIONAL,['NA'],
14350,NCT06013865,Discontinuation of Empagliflozin,Blood Pressure,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
14351,NCT01315808,Study the rate of change of HbA1c in normal population with known risk factors of diabetes,Diabetes prediction model based on the rate of change in HbA1c,2011-03,TERMINATED,OBSERVATIONAL,['NA'],
14352,NCT00272012,Change in HbA1c.,Adverse events.,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
14353,NCT00608816,catecholamine levels,,na,WITHDRAWN,INTERVENTIONAL,['NA'],
14354,NCT05452551,Logarithmic decrement,,2021-07-06,COMPLETED,OBSERVATIONAL,['NA'],
14355,NCT00013286,,,1999-10,COMPLETED,OBSERVATIONAL,['NA'],
14356,NCT01168258,Genotype frequency of SNP in the study genes of DME participants and control participants.,"Secondary outcomes are ophthalmic measurements, including visual acuity, FA and OCT data, to investigate associations between detected genetic polymorphisms and response to conventional diabetic retinopathy treatment.",2010-07-07,TERMINATED,OBSERVATIONAL,['NA'],
14357,NCT05635266,Biospecimen & Clinical Data Collection,,2021-10-26,RECRUITING,OBSERVATIONAL,['NA'],
14358,NCT01606371,Number of participants with one or more drug related adverse events (AEs) or any serious AEs,Glucose excursion after meals,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
14359,NCT01913145,Usability and HbA1c Method Comparison Study Using Lay-Person Micro-Blood Specimens,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
14360,NCT01472406,% of time within zone [80-140] mg/dL except 5 hours post-prandial and during exercise and 3 hours post-exercise,% of time within zone [70-150] mg/dL during the 3 hours following exercise,2011-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
14361,NCT01980459,The magnesium cellular levels will provide a stronger correlation with antiinflammatory indicators compared to the circulating serum levels of magnesium.,Magnesium supplementation will lower parameters of inflammation in hypomagnesemic diabetic patients.,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
14362,NCT03227484,effect of treatment with 25 mg empagliflozin daily versus placebo on regional brain insulin sensitivity,effect of treatment with empagliflozin versus placebo on energy expenditure,2017-06-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
14363,NCT05262946,Cumulative Somatosensory Impairment Index,Validated Spanish version of Short-Form Late-Life Function and Disability Instrument,2016-01-01,COMPLETED,INTERVENTIONAL,['NA'],
14364,NCT05155410,Glucose Control: Change in Fructosamine,Waist circumference,2022-02-15,COMPLETED,INTERVENTIONAL,['NA'],Cravings
14365,NCT03806166,Definitive treatment failure (infection recurrence),Quality of life measured by EuroQol 5 Dimensions 5 Levels Score and EuroQol Visual Analogue Score,2019-02-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
14366,NCT00254085,Blood glucose fluctuations,number of hypoglycemia,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
14367,NCT01774474,Change in central subfield mean macular thickness as a measurement of efficacy,No. of subjects developing clinically significant macular edema as a measurement of efficacy,2013-07-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Change in central subfield mean macular thickness as a measurement of efficacy
14368,NCT03605810,Performance of classification to predict eGFR,,2018-07-15,COMPLETED,OBSERVATIONAL,['NA'],
14369,NCT01224366,HbA1c reduction,Incidence of hypoglycemia and severe hypoglycemia (overall and subpopulations),2010-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
14370,NCT01177384,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,2011-01-25,COMPLETED,INTERVENTIONAL,['PHASE3'],
14371,NCT04055064,Change in dietary intake of nutrients,Change in Ankle Brachial Index(ABI),2017-05-23,COMPLETED,INTERVENTIONAL,['NA'],
14372,NCT03725709,Exam metabolic profiles of CSF and plasma in diabetes. (Metabolites analysis of CSF and plasma),,2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],
14373,NCT01720290,Change in HbA1c (glycosylated haemoglobin A1c),Incidence of hypoglycemic episodes,2002-07-25,COMPLETED,INTERVENTIONAL,['PHASE4'],
14374,NCT00813280,glucose levels,type of insulin treatment,2008-06,COMPLETED,OBSERVATIONAL,['NA'],
14375,NCT04481997,Reasons for prolonging DAPT over 1 year,Diabetes control (HbA1c values),2021-01-11,UNKNOWN,OBSERVATIONAL,['NA'],
14376,NCT05128097,Retrospective study of the management of the main geriatric risks in the University HÔptaux de Strasbourg,,2020-06-01,UNKNOWN,OBSERVATIONAL,['NA'],
14377,NCT00576368,"Glycemic status (Fasting Blood Glucose, Fasting Plasma Glucose, and HbA1C as done in routine medical practice)",,2003-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
14378,NCT03723785,"AUCI287,0-840h,SD: Area under the serum insulin 287 concentration-time curve after a single dose",Positive cross-reactive anti-human insulin antibodies,2018-11-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
14379,NCT01756274,Percent of Blood Glucose Results Within +/-15 mg/dL(<75 mg/dL) and Within +/-20% (>=75 mg/dL) of the Reference Instrument BG Value,Percent of BG Results (Per Population) Within +/-15 mg/dL (<100 mg/dL)and Within +/-15% (>=100 mg/dL) of the Reference Instrument BG Value,2012-12,COMPLETED,INTERVENTIONAL,['NA'],"Number of Blood Samples From Babies in the Neonatal Intensive Care Unit (NICU) That Produced Meter Results Beyond What Random Chance Would Predict (i.e., Outside 95% Limits for Studentized Residuals)"
14380,NCT05908812,Differences in glycated hemoglobin and/or insulin resistance in diabetic patients with non-sarcopenic obesity vs patients with sarcopenic obesity,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA'],
14381,NCT02317484,HbA1c change level,Body composition and visceral fat change levels,2014-11,COMPLETED,OBSERVATIONAL,['NA'],
14382,NCT00607906,vital signs assessments:,Correlation between drug concentrations & blood sugar levels:,2007-11-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
14383,NCT02631902,Health-Related Quality of Life,Body Mass Index,2015-10,COMPLETED,INTERVENTIONAL,['NA'],
14384,NCT01920256,Change in baseline A1C (glycated hemoglobin) at 12 months,Change in baseline insulin satisfaction at 12 months,2013-08,COMPLETED,INTERVENTIONAL,['NA'],Cost
14385,NCT06111833,Genetic testing for evaluate the different types of MODY,Sudomotor function,2023-05-22,RECRUITING,OBSERVATIONAL,['NA'],
14386,NCT02910518,Assessment of PK parameter: area under the concentration time curve,Number of patients with treatment emergent adverse events,2017-02-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
14387,NCT02025296,proportion of patients achieving the target of HbA1c <7% without hypoglycemia,Lifestyle,2013-12,COMPLETED,INTERVENTIONAL,['NA'],
14388,NCT01699932,Change in HbA1c,Hypoglycemia,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
14389,NCT01396187,Number of Participants With Blood Glucose Abnormalities,Average Plasma Concentration (Cav) of PF-05231023 at Steady State,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
14390,NCT02540486,Percentage of subjects reaching fasting plasma glucose (FPG) target,Serious adverse events,2013-12,COMPLETED,INTERVENTIONAL,['NA'],List of concomitant medications initiated after randomization
14391,NCT03696368,GDM Diagnosis,,2019-01-04,RECRUITING,OBSERVATIONAL,['NA'],
14392,NCT01605149,,,2012-07,COMPLETED,OBSERVATIONAL,['NA'],
14393,NCT00690456,Change from baseline in HbA1c,Percent change from baseline in HDL-C and Triglycerides,2008-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
14394,NCT02178176,Adherence to oral hypoglycemic agents: Medication Event Monitoring System,,2013-09,COMPLETED,INTERVENTIONAL,['NA'],
14395,NCT00509236,Number of Participants With Clinical Adverse Events,Change From Baseline in Hemoglobin A1c for Sitagliptin Versus Glipizide Treatment,2007-10-19,COMPLETED,INTERVENTIONAL,['PHASE3'],
14396,NCT01906099,Fasting blood glucose (mg/dl),Triglyceride (mg/dl),2012-09,COMPLETED,INTERVENTIONAL,['NA'],
14397,NCT01354990,Number of Participants With Concomitant Conditions,,2009-02,COMPLETED,OBSERVATIONAL,['NA'],
14398,NCT04100473,Primary Pharmacodynamic Endpoint - PD 2,Secondary Pharmacodynamic Endpoint - PD3,2018-04-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
14399,NCT02532829,Plasma GLP-1 and P-YY measurements by ELISA in participants treated by different bariatric and metabolic surgical techniques.,Plasma insulin levels in participants treated by different bariatric and metabolic surgical techniques.,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],"Plasma Liver Function Tests (SGOT, SGPT and GGT levels) in participants treated by different bariatric and metabolic surgical techniques."
14400,NCT05731544,Change in HbA1c,To assess the effect on HbA1c,2022-08-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
14401,NCT05662475,Sirtuin 1 concentration in GCF,,2021-11-15,COMPLETED,INTERVENTIONAL,['NA'],
14402,NCT01006018,Insulin Secretion,,2011-07,TERMINATED,INTERVENTIONAL,['NA'],
14403,NCT03329261,Major Cardiovascular Events (MACE),Incidence of Adverse Events,2017-12-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
14404,NCT06195488,determine stomach fullness,Incidence of risk factors,2022-10-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
14405,NCT02673762,A multi marker test score based on a pre-specified model is measured in each patient. The test score is on a scale of 0 to 1.0 and relates to the probability of disease.,Housekeeping gene Ct values on PCR analysis will be measured in individual patients,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],
14406,NCT06263348,Incidences of ADRs and SAEs,Response rate,2023-12-20,RECRUITING,INTERVENTIONAL,['PHASE4'],
14407,NCT05899166,Decline in Beta-cell Function,"Qualitative patient perspectives, interview - child",2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Study termination for dyslipidemia
14408,NCT00817271,P-Glucose levels,"Pharmacodynamics (P-Glucose, S-Insulin and S-C-peptide)",2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
14409,NCT02471963,Effect of empagliflozin after 6 weeks of treatment on macrocirculation,Biomarkers,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
14410,NCT02898493,Internal Consistency (IC) assessed as Cronbach's Alpha Value,Test-retest Reliability,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],
14411,NCT04180813,Proportion of T2DM patients with high medication adherence at Week 24,Patient satisfaction by Diabetes Treatment Satisfaction Questionnaire (DTSQ) among linagliptin and acarbose initiators. The DTSQ would be completed at routine physician visits since initiation of the drug,2020-03-04,TERMINATED,OBSERVATIONAL,['NA'],
14412,NCT04289727,Change in bone mineral density by Dual X-ray Absorptometry (DXA),,2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],
14413,NCT00490178,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
14414,NCT00805974,Ambulatory blood pressure monitoring on 24 hours,Glycemic measurements on 24h (D0-D1).,2005-10,TERMINATED,INTERVENTIONAL,['NA'],
14415,NCT00566592,Rate of glucose recovery from hypoglycemia.,Hormone and substrate concentrations,2005-01,COMPLETED,INTERVENTIONAL,['NA'],
14416,NCT01869608,Diagnosis of abnormal glucose tolerance,Patient's satisfaction,2014-04,COMPLETED,INTERVENTIONAL,['NA'],
14417,NCT01241864,HbAlc <6.5% and an absence of severe hypoglycemic events,HbAlc < 6.5% and an absence of severe hypoglycemic events measured after last transplant,2010-12,RECRUITING,INTERVENTIONAL,['PHASE2'],
14418,NCT02274844,Change in Low-Density Lipoprotein (LDL) Cholesterol,Change in Diabetes Medication Counts,2016-04,COMPLETED,INTERVENTIONAL,['NA'],Change in Medication Beliefs- Concerns (Concerns About the Negative Effects of Medications)
14419,NCT06305416,Changes in Central Subfield Thickness (CST) from Baseline,Evaluation and comparison of safety between reference vs. test drug.,2024-03-20,RECRUITING,INTERVENTIONAL,['PHASE3'],
14420,NCT01926938,"markers of endothelial activation, coagulation and inflammation",,2003-05,COMPLETED,OBSERVATIONAL,['NA'],
14421,NCT05071235,Quality of life (QoL) follow up,Change in visual analogue scale (VAS),2019-08-27,COMPLETED,INTERVENTIONAL,['NA'],
14422,NCT04074148,glycated haemoglobin (HbA1c) percent,,2019-10-25,COMPLETED,INTERVENTIONAL,['NA'],
14423,NCT05107388,Incidence rate of hyperglycemia,,2021-12,UNKNOWN,INTERVENTIONAL,['NA'],
14424,NCT04847414,change in BMI,HOMA-IR,2021-04-10,UNKNOWN,OBSERVATIONAL,['NA'],
14425,NCT05202067,Medication adherence,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],
14426,NCT02001337,To create a prospective cohort of subjects with increased probability of being diagnosed with pancreatic cancer and identify pancreatic cancer in this cohort.,,2013-05,COMPLETED,OBSERVATIONAL,['NA'],
14427,NCT05944640,TIR,Mean sensor glucose concentration,2022-04-01,RECRUITING,OBSERVATIONAL,['NA'],
14428,NCT00005669,Changes in Body Weight as Determined by Body Mass Index-standard Deviation Score (BMI-SDS).,Change in Body Fat by Bod Pod,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
14429,NCT03062774,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Determine PB-119 blood concentration,2014-11-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
14430,NCT01702051,Beta cell function,Incidence of complications after pancreatic surgery,2012-02,RECRUITING,OBSERVATIONAL,['NA'],Incidence of each individual postoperative complication
14431,NCT04182503,Incidence of gestational hypertension,,2019-08-12,UNKNOWN,OBSERVATIONAL,['NA'],
14432,NCT02785198,Wound healing change quantified by digital photo planimetry,"The biochemical changes during wound healing, is assessed by biochemical markers in peripheral venous blood samples.",2016-04,TERMINATED,INTERVENTIONAL,['NA'],
14433,NCT01176149,Improvement of metabolic control,Percentage of patients reaching target HbA1c (i.e. <7.0%),2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
14434,NCT02803918,Number of patients with anti-lixisenatide antibodies,Assessment of pharmacodynamic parameter: plasma glucose AUC-0-4.5 hours,2017-05-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
14435,NCT05887817,Change in CAVI,Change in urinary L-FABP,2023-09-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
14436,NCT03291171,Change in self-reported sedentary behaviour,change in coping planning,2017-10-15,COMPLETED,INTERVENTIONAL,['NA'],
14437,NCT01398267,"Glomerular filtration rate (mGFR), measured as iohexol clearance",High density lipoprotein-cholesterol (HDL-C) blood levels,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
14438,NCT01350219,Autoimmune control,Analysis of islet beta cell function,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],
14439,NCT01765270,Troponin I (TnI) Area Under the Curve (AUC),Need for Antiarrhythmic Therapy,2013-03,TERMINATED,INTERVENTIONAL,['PHASE4'],
14440,NCT01061216,Insulin measurements will be used to compute PK model parameters: absorption rate(s) and elimination rate using an appropriate transport model.,Feasibility of RCS for longer-term ID infusion,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
14441,NCT02138188,"Change from baseline glycosylated haemoglobin (HbA1c) at 6th, 12th and 24th months after transition to CSII.",Measures of Coping Strategies at Baseline,2013-09,UNKNOWN,OBSERVATIONAL,['NA'],
14442,NCT00651196,histomorphometry measurements,Bone mineral density,2008-01,COMPLETED,OBSERVATIONAL,['NA'],
14443,NCT05689099,"Cmax,sema,0.5mg: maximum observed semaglutide concentration-time after single dose of subcutaneous semaglutide 0.5 mg administration",,2023-01-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
14444,NCT06014684,Peripheral Insulin sensitivity,24h substrate metabolism,2023-07-13,RECRUITING,INTERVENTIONAL,['NA'],Blood glucose levels measured continuously over 7 days.
14445,NCT02128854,Diet Score on the Rapid Eating and Activity Assessment for Participants,Quality of Life Using the Medical Outcomes Study Short Form,2014-08-14,COMPLETED,INTERVENTIONAL,['NA'],
14446,NCT00832624,Change From Baseline in HbA1c (Hemoglobin A1c) at Week 18,,2008-11-26,TERMINATED,INTERVENTIONAL,['PHASE4'],
14447,NCT00729040,Total steps,content of posts (qualitative),2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
14448,NCT05551988,Predictors of amputation in diabetic foot ulcer patient,Antibiotic resistance level,2021-06-01,COMPLETED,OBSERVATIONAL,['NA'],
14449,NCT05362071,Glycaemic control,Subjective perception of well-being,2022-05-02,COMPLETED,INTERVENTIONAL,['NA'],
14450,NCT00663949,decreasing urinary protein,,2006-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
14451,NCT02172092,Extracellular volume,Distribution of strong and weak acids,2014-08,COMPLETED,INTERVENTIONAL,['NA'],
14452,NCT02343107,dietary score (International Diet Quality Index),Blood pressure,2014-03,COMPLETED,INTERVENTIONAL,['NA'],
14453,NCT03991026,Change in Body mass index (kg/m^2),Change in Blood pressure (mmHg),2019-06-18,COMPLETED,INTERVENTIONAL,['NA'],
14454,NCT01702311,Mean Fasting Blood Glucose,Number of Subjects With BG > 300 mg/dL,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
14455,NCT00123227,Plaque volume change over 12 months as assessed by cardiovascular magnetic resonance (CMR),Change in plaque gadolinium enhancement as a measure of fibrous cap inflammation and plaque neovascularisation,2002-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],
14456,NCT00738023,Changes in Systolic Blood Pressure During Initial Intralipid Infusion,Changes in Systolic Blood Pressure During Intralipid Infusion Post-rosiglitazone Intervention,2004-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
14457,NCT02358109,The Incremental Cost Effectiveness Ratio (ICER),Quality Adjusted Life Years (QALYs),2014-01,COMPLETED,INTERVENTIONAL,['NA'],Hemogram profile
14458,NCT00819884,"24-hr glucose (Calculated plasma glucose AUC0-24, change in fasting plasma glucose)",Pharmacodynamics (S-Insulin AUC0-24 and C-peptide AUC0-24),2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
14459,NCT04913909,Change in blood fructosamine levels in Type 2 diabetic patients an Oral probiotic use,,2015-09-10,COMPLETED,INTERVENTIONAL,['NA'],
14460,NCT03022058,Presence of significant qEEG hypoglycaemia indicators when comparing normo- and hypoglycaemic EEG as measured by the EarEEG systems for subjects where hypoglycaemia-induced changes have been observed in the scalp EEG (visit 4),,2017-06-22,COMPLETED,INTERVENTIONAL,['NA'],
14461,NCT06092476,Efficacy endpoint 2,Mechanistic: Change in Cystatin Value,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14462,NCT02413086,Grades of wound healing,SF-36,2015-04,UNKNOWN,INTERVENTIONAL,['NA'],
14463,NCT00455988,,,2006-09,UNKNOWN,OBSERVATIONAL,['NA'],
14464,NCT01858233,The IBEP Study,The IBEP Study,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
14465,NCT02084498,Change in HbA1c,Frequency of serious hypoglycemic events,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Treatment Satisfaction
14466,NCT00295659,,,2001-01,COMPLETED,OBSERVATIONAL,['NA'],
14467,NCT00138671,Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusion Capacity (DLco),Severe Hypoglcyemic Event Rates,2003-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
14468,NCT05461495,BMI,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],
14469,NCT04517201,Fasting plasma glucose of T2D patients,Total insulin dose,2020-11-04,UNKNOWN,INTERVENTIONAL,['NA'],
14470,NCT00461006,Relative change from baseline in glomerular filtration rate,"Adverse events (AEs), laboratory parameters.",2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
14471,NCT05881200,Change in insulin resistance,,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],
14472,NCT01835678,effect of linagliptin compared to placebo on basal production and release of nitric oxide (NO) from renal vasculature,determine the relationship between changes of renal endothelial function with metabolic changes and changes of isoprostanes,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
14473,NCT01153100,Reduction in rebound hyperglycemia (blood glucose levels over 180 mg/dl),Reduction in time to get back to control of glycemia (140-180 mg/dl) if rebound hyperglycemia occurs,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
14474,NCT00433758,Clarke Error Grid,,2006-12,UNKNOWN,INTERVENTIONAL,['NA'],
14475,NCT03025399,"the changes of degree of retinal microvascular lesions before and after treatment (no, mild non proliferative phase, moderate non proliferative phase, severe non proliferative phase, proliferative phase)",Change of Vision (analysis of visual acuity before and after medication using EDTRS international visual acuity chart),2017-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],
14476,NCT02568514,Change in inpatient mortality,Change in Hospital Consumer Assessment of Healthcare Providers and Systems (HCAPs) scores,2016-08,WITHDRAWN,INTERVENTIONAL,['NA'],
14477,NCT05970237,Target blood glucose achievement rate,,2023-07-26,RECRUITING,OBSERVATIONAL,['NA'],
14478,NCT00831519,oxidative stress,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],
14479,NCT03172260,HbA1c,Kidney function,2017-02-08,COMPLETED,OBSERVATIONAL,['NA'],
14480,NCT00811889,To determine the safety and tolerability of bardoxolone methyl when administered for 12 months (52 weeks)following randomization to type 2 diabetic patients with CKD (eGFR 20 - 45 mL/min/1.73m2).,To determine the change in eGFR from baseline in patients with type 2 diabetes and CKD (baseline eGFR = 20 - 45 mL/min/1.73m2) after receiving bardoxolone methyl for 12 months (52 weeks) following randomization.,2009-04-30,COMPLETED,INTERVENTIONAL,['PHASE2'],
14481,NCT02409511,Complementary markers for improving the performance of MA,To test whether the enhancement of this specific marker of kidney injury is able to identify those patients in which MA really means diabetic nephropathy.,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],
14482,NCT04838561,"INsulin delivery Systems: Perceptions, Ideas, Reflections and Expectations Questionnaire Post Intervention (Youth and Parent Versions)",Estimated HbA1c (%),2021-03-15,COMPLETED,OBSERVATIONAL,['NA'],"INsulin delivery Systems: Perceptions, Ideas, Reflections and Expectations Questionnaire (Baseline and Post Intervention)"
14483,NCT05177094,Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS),Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm),2022-01-26,COMPLETED,INTERVENTIONAL,['PHASE2'],
14484,NCT03195257,C-terminal telopeptide of type I collagen (CTX).,N-terminal propeptide of type 1 procollagen (P1NP).,2012-11-17,COMPLETED,INTERVENTIONAL,['NA'],
14485,NCT03782441,Safety evaluation: paucity of adverse events,Device usability,2019-11-05,COMPLETED,INTERVENTIONAL,['NA'],
14486,NCT06304844,Determine the number of participant with eGFR<60 ml/min/1.73 m2 or albuminuria (urinary albumin-to-creatinine ratio (ACR) ⩾3 mg/mmol) in patients with type 2 DM and MAFLD,,2024-04-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
14487,NCT02312050,The change in eGFR from Screening to measurements taken at Week 26,Incidence of major cardiac events,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
14488,NCT01691846,Change from baseline in hemoglobin HbA1c,Safety: incidence of adverse events,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
14489,NCT02867436,Change in C-peptide area under the curve measured by mixed-meal tolerance test (MMTT) between group on GFD and standard gluten-containing diet.,Differences in fecal microbiome between children on normal diet and children on gluten-free diet over the first year of diabetes duration;,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],
14490,NCT03437525,Change from Baseline HbA1c at 6 and 12 months,Change from Baseline Insulin Attitudes at 6 and 12 months,2017-03-08,COMPLETED,INTERVENTIONAL,['NA'],
14491,NCT00489645,• To examine the influence of acute glycaemia (normoglycaemia and hyperglycaemia) on gastric emptying kinetics in patients with type 1 diabetes and non diabetic subjects when treated with subcutaneous (SC) injections of pramlintide.,"• Gastric peristalsis derived from high-resolution scintigraphy by means of Fast Fourier Transform (FFT) analysis. • Effects on gastric emptying and on the rate of appearance of ingested glucose appearance, postprandial glucose sequestration, endoge",2005-01,COMPLETED,INTERVENTIONAL,['NA'],
14492,NCT04894461,Pain assessment measured with the Neuropathy Pain Scale (NPS),Serum Albumin levels,2021-11-01,UNKNOWN,INTERVENTIONAL,['NA'],
14493,NCT01158040,Neonatal hypoglycemia (neonatal capillary blood glucose lowers then 40 mg/dL),Mean maternal blood glucose during labor,2010-08,UNKNOWN,OBSERVATIONAL,['NA'],
14494,NCT01285076,Number of Participants With Hypoglycemic Episodes,Self-reported Barrier Questionnaire,2011-01,COMPLETED,OBSERVATIONAL,['NA'],
14495,NCT04595474,Proportion of subjects with advanced fibrosis,Lipid profile,2021-01-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
14496,NCT01606085,Diabetes health related quality of life measures,Diabetes (DM) self efficacy,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
14497,NCT00419302,Glycemic response to a meal challenge,Safety variables,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
14498,NCT03151343,Invasive hemodynamics,Daily activity,2017-03-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
14499,NCT00562133,the postprandial time course of nitrotyrosine after injection of insulin glulisine compared with regular human insulin,"postprandial time course of blood glucose, insulin, intact proinsulin, ADMA, MMP-9, FFA, ox-LDL, per ox Status, IL-18, postprandial time course of microvascular blood circulation measured with laserdopplerflux at 37 °C and 44 C",2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
14500,NCT01275794,To assess frequency of target levels of HbA1c ≤ 7% in patients with T2D during OAD monotherapy,To compare the results of OAD monotherapy in different groups of patients,2010-12,COMPLETED,OBSERVATIONAL,['NA'],
14501,NCT02451631,Change in HbA1c (%),Change in FBG(Fasting Blood Glucose),2015-04,UNKNOWN,INTERVENTIONAL,['NA'],
14502,NCT00477581,Effect of Exenatide on postprandial glucose,"Assessment of effect of exenatide to the effect of sitagliptin the acetaminophen absorption test, and 6-point self-monitored blood glucose (SMBG) profiles",2007-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
14503,NCT00360893,,,1994-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
14504,NCT01411930,Insulin sensitivity,Hepatic glucose production,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
14505,NCT02859779,Needs and expectations of adolescents with type 1 diabetes for skills to be developed during the educational sessions,Needs and expectations of parents of adolescents with type 1 diabetes for skills to be developed during the educational sessions,2017-02-04,COMPLETED,INTERVENTIONAL,['NA'],
14506,NCT00118950,HaemoglobinA1c,"Adverse events and safety variables (e.g. hypoglycaemia, haemoglobin, white blood cell count, cobalamine and folate).",2001-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
14507,NCT03676595,Change of Berg Balance Scale (BBS) score,Change of Unipedal Stance Test (UST) time,2013-11-20,COMPLETED,INTERVENTIONAL,['NA'],
14508,NCT03179423,Safety and tolerability of GNbAC1 in patients with recent onset type 1 diabetes: Serious Adverse Events (SAE) and Adverse Events (AE),,2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE2'],
14509,NCT00330200,Evaluate the effects on hemoglobin A1c (HbA1c),Assess the effects of ISIS 113715 on insulin suppression of local rates of lipolysis (microdialysis),2005-11-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
14510,NCT05218915,Glycemic variability,Diabetes Treatment Satisfaction,2022-01-28,RECRUITING,INTERVENTIONAL,['PHASE4'],
14511,NCT05465317,"Composite outcome including: 40% decline in estimated glomerular filtration rate (eGFR), incident end-stage kidney disease (ESKD), all-cause mortality",Genital Mycotic infection,2022-08-08,COMPLETED,OBSERVATIONAL,['NA'],
14512,NCT06046417,Percentage of time of glucose levels spent in the target range (3.9-10.0 mmol/L).,Thematic interview analysis,2023-11-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Safety Endpoints
14513,NCT00700960,HbA1c,,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
14514,NCT02823808,Cumulative treatment failure (HbA1c≥7.0%) rate for glycemic control,Change in glucagon,2017-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],
14515,NCT01380873,△Cmax of plasma glucose,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
14516,NCT01345435,Changes in Hemoglobin A1c,Medication compliance,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
14517,NCT02846779,Insulin Persistence,Number of Hospitalizations,2016-07,COMPLETED,INTERVENTIONAL,['NA'],
14518,NCT02906917,Change in HbA1c (%) - Week 26,Incidence of TEAEs,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE3'],
14519,NCT04695158,Physical Activity Level for Group III,The levels of Routine Blood Samples for Group III,2021-01-06,UNKNOWN,OBSERVATIONAL,['NA'],
14520,NCT05769439,evidence-based DhMRs concerning incident obesity,,2021-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
14521,NCT00832741,blood glucose,gastric emptying,2008-05,COMPLETED,OBSERVATIONAL,['NA'],
14522,NCT03196336,hospitalization,"severe evolving complication (ischemic or proliferative retinopathy, severe renal insufficiency, severe hypoglycemia, coronaropathy or evolving foot lesion)",2015-03,COMPLETED,INTERVENTIONAL,['NA'],
14523,NCT01438814,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) After 14 Weeks Treatment,Change From Baseline in HbA1c Over Time,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
14524,NCT00570466,Dietary intake of servings of fruit and vegetables as measured by three 24-hour dietary recalls; and minutes of moderate to vigorous physical activity as measured by 5 days of accelerometry.,"Height, weight, waist circumference, propylthiouracil (PROP) sensitivity status and nutrition and physical activity psychosocial questionnaires.",2008-01,COMPLETED,INTERVENTIONAL,['NA'],
14525,NCT04403217,Changes in fasting insulin (μU/mL) levels from baseline to visit 2 and 3,Changes in waist perimeter (cm) from baseline to visit 2 and 3,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
14526,NCT04662866,Endogenous glucose production during fasting,,2021-02-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Intraabdominal fat
14527,NCT04529824,Diabetes Status,Fitbit-derived sedentary time,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],Healthcare medical costs
14528,NCT01552213,Number of Patients With a Diagnosis of Gestational Diabetes at 26 Weeks Gestation.,Number of Participants With Intrauterine Fetal Demise,2012-03,COMPLETED,INTERVENTIONAL,['NA'],
14529,NCT00323414,Number of Participants With Improvement of >= 2 Points in NAFLD Activity Score (NAS),HbA1C Levels,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
14530,NCT00941161,"fasting glucose, HbA1c","total cholesterol, C-LDL, C-HDL, triglycerides, VLDL, insulin",2009-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
14531,NCT04412798,Capillary glycaemic responses,Systolic/diastolic blood pressure,2020-05-01,UNKNOWN,INTERVENTIONAL,['NA'],
14532,NCT03890172,Change of ulcer size,time of wound healing,2019-07-30,UNKNOWN,OBSERVATIONAL,['NA'],
14533,NCT00946517,Parenting styles,Adherence to therapy,2009-07,TERMINATED,OBSERVATIONAL,['NA'],
14534,NCT01040104,Time to wound healing / Scar maturation,,2009-07,COMPLETED,OBSERVATIONAL,['NA'],
14535,NCT01420692,"The Changes in the Peripheral Blood Levels of TNF-α, IL-6, MCP-1, sICAM-1, sVCAM-1, vWF, E-selectin, P-selectin, Endothelin-1, PAI-1, tPA and HMW Adiponectin at 12th and 24th weeks compared to the baseline level, as Measures of Inflam. and Coagulation","Calculation of Body-mass Index, Body Fat Mass, Level of Insulin Resistance and the Insulin Secretion Capacity of Pancreatic Beta Islet Cells as Measures to Identify the Effects of Gliclazide and Insulin Detemir Treatments on Diabetes Progression",2010-06,COMPLETED,INTERVENTIONAL,['NA'],
14536,NCT01620489,Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin),Estimated Mean Ratio to Baseline and Observed Coefficient of Variation in Renal Function-estimated Glomerular Filtration Rate (eGFR) (to Check How Well the Kidneys Are Functioning Using Modification of Diet in Renal Disease (MDRD) Formula),2012-06-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
14537,NCT00399711,HbA1c,Percentage of subjects achieving sudden levels of HbA1c,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
14538,NCT00534183,Study of metabolic profile,Study of obesity and diabetes,2006-06,COMPLETED,INTERVENTIONAL,['NA'],
14539,NCT02583061,Glucose tolerance status,,2003-09,RECRUITING,OBSERVATIONAL,['NA'],
14540,NCT00154401,HbA1c,Safety and tolerability,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
14541,NCT02863887,Percent weight loss,Change in Pulse,2016-06,COMPLETED,INTERVENTIONAL,['NA'],
14542,NCT01373346,Operation Related Mortality,Albumin : Good Response Group,2010-02,COMPLETED,INTERVENTIONAL,['NA'],
14543,NCT04551625,"High amplitude, antegrade contractions assessed with HRCM",Distance of capsule movement.,2020-10-15,UNKNOWN,OBSERVATIONAL,['NA'],
14544,NCT00372060,Change From Baseline in Hemoglobin A1c (HbA1c ) at Week 12,Change From Baseline in Fasting Plasma Glucose at Week 12,2006-08-21,COMPLETED,INTERVENTIONAL,['PHASE3'],Change From Baseline in Hemoglobin A1c (HbA1c ) at Week 52
14545,NCT01638780,"insulin sensitivity (overall, muscle- and liver specific)",heart function,2012-05,UNKNOWN,INTERVENTIONAL,['NA'],
14546,NCT03217175,Number of Subjects With Plasma Glucose < 60 mg/dl,Time From Exercise Start to Plasma Glucose < 60 mg/dl,2017-08-18,TERMINATED,INTERVENTIONAL,['NA'],
14547,NCT03601494,visual analog scale of pain,Nerve conduction velocity,2017-02-01,COMPLETED,INTERVENTIONAL,['NA'],
14548,NCT03794960,Treatment Effect,Immunologic,2019-12-14,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
14549,NCT01586897,"Medication Safety Monitoring - ACE/ARB, Thiazide",,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
14550,NCT05176847,Change in body weight,Change in minutes a week of moderate to vigorous physical activity (MVPA),2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
14551,NCT00590876,fMRI,,2008-12,COMPLETED,OBSERVATIONAL,['NA'],
14552,NCT00267683,HbA1c,Percentage of subjects achieving the treatment target of HbA1c value < 6.5%,2005-12,TERMINATED,INTERVENTIONAL,['PHASE3'],
14553,NCT01377688,Blood pressure and /or Estimated Glomerular Filtration Rate (eGFR),,2011-10,COMPLETED,OBSERVATIONAL,['NA'],
14554,NCT00678080,The Number of Participants Who Achieved a Hemoglobin A1C <7%,Number of Participants With Newborns Who Needed Neonatal Dextrose,2008-09,COMPLETED,INTERVENTIONAL,['NA'],
14555,NCT05268926,urinary albumin/creatinine ratio,number of SAE's and AE's,2022-02-03,TERMINATED,INTERVENTIONAL,['PHASE2'],
14556,NCT03949504,Concentration of glucose in plasma,,2019-01-09,COMPLETED,OBSERVATIONAL,['NA'],
14557,NCT02147496,Food intake,Appetite hormones,2011-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Subjective Appetite
14558,NCT01127269,Percentage of patients with Glycosylated Haemoglobin (HbA1c) <7% with no severe documented nocturnal hypoglycemia episode.,Hypoglycemic episodes,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
14559,NCT01028963,Subject incidence of adverse events,Effect on fasting plasma glucose concentration,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
14560,NCT02094521,Area under the NNC0113-0987 plasma concentration time curve,Maximum observed NNC0113-0987 plasma concentration,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
14561,NCT03865342,Change in weight,Change in hemoglobin A1c,2016-09,COMPLETED,INTERVENTIONAL,['NA'],Change in quality of life
14562,NCT00665106,Ocular safety,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
14563,NCT01363284,Prediction of duloxetine pain relief efficacy by pre-treatment extent of the CPM response,Treatment-related increase in CPM response,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
14564,NCT02293720,Measure the incidence of device related serious adverse events requiring an early removal,,2015-04,WITHDRAWN,INTERVENTIONAL,['NA'],
14565,NCT06037512,Analysis of system accuracy based on DIN EN ISO 15197,,2023-04-13,COMPLETED,INTERVENTIONAL,['NA'],
14566,NCT01964976,Number of Participants Reporting One or More Serious Adverse Drug Reactions,Change From Baseline in Fasting Insulin Level,2011-07,COMPLETED,OBSERVATIONAL,['NA'],
14567,NCT00302224,"To evaluate the safety and tolerability of 14 daily doses; To determine the pharmacokinetic (PK) profile in plasma of DIO-902 after a single dose, and after fourteen daily doses; To evaluate the pharmacodynamic effects of fourteen daily doses","To explore the impact of treatment with the enantiomer of ketoconazole on markers of inflammation and coagulation as well as on lipomic profiles, pre- and post-treatment",2005-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
14568,NCT01136512,Vitamin B12 level,methylmalonic acid,2007-08,COMPLETED,OBSERVATIONAL,['NA'],
14569,NCT02640768,Composite performance score computed as the sum of the performance scores of all 5 domains of appropriateness and efficacy in both the intervention and the control wards,discharge condition in the intervention and control wards,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
14570,NCT00035542,,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
14571,NCT00744965,Mean Fetal Weight at Birth,Need for Insulin Therapy,2008-09-16,COMPLETED,INTERVENTIONAL,['PHASE4'],
14572,NCT04118374,Change in endothelial function - diet 2,,2019-03-29,RECRUITING,INTERVENTIONAL,['NA'],
14573,NCT02963662,The levels of adipokines and inflammatory cytokines in the fasting state at preoperation in patients with BMI ≥35 kg/m2 or BMI ≥28 kg/m2 and T2D or metabolic syndrome.,"The adipokines and inflammatory cytokines levels in the fasting state at 1 month, 3 months, 6 months and 12 months after surgery",2015-10,COMPLETED,INTERVENTIONAL,['NA'],
14574,NCT02750410,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline in Daily Total Insulin Dose,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
14575,NCT00605020,HbA1c,Change in weight,2003-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
14576,NCT05809817,Metabolic control,,2023-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
14577,NCT01425645,Proportion of study subjects achieving a 7% weight loss,,2012-01,COMPLETED,INTERVENTIONAL,['NA'],
14578,NCT02605564,Area Under the Curve (AUC) of C-peptide on mixed meal tolerance test,,2016-01-19,TERMINATED,INTERVENTIONAL,['NA'],
14579,NCT03073070,Measurement of RBC survival in diabetic children using biotin-labeled RBCs,,2017-11-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
14580,NCT03653533,Occurrence of hypoglycemia between a phase with no SmartGuard® function and a phase with SmartGuard® function,,2019-01-07,TERMINATED,INTERVENTIONAL,['NA'],
14581,NCT03919617,Rate of Resting Energy Expenditure (REE),,2019-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
14582,NCT01353495,Size of Index Wound Based on Calculations Wound Width x Length x Depth 2. Size of Index Wound Based on Calculations Wound Width x Length x Depth,,2010-04,COMPLETED,INTERVENTIONAL,['NA'],
14583,NCT01579292,Body mass index,Fasting plasma glucose,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
14584,NCT03188094,probability of eligible patients at a practice site to lose 5% or more of their body weight six months following the index office visit.,improved blood pressure following the index office visit,2018-12-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
14585,NCT03208010,Change from baseline in body mass index (BMI) at 36 months,Text Messages Intervention - Follow-up Phone Call Interview,2017-04-01,COMPLETED,INTERVENTIONAL,['NA'],
14586,NCT00457470,Change of retinal thickness at Day 15 or Day 25 depending on dosing regimen,; Proportion of eyes experiencing an improvement in the degree of retinopathy at Day 28,2007-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
14587,NCT01434030,Desire to Receive Advice From Personal Glucose Advisory System (PGASystem),Willingness to Follow PGASystem Advice,2010-04,COMPLETED,INTERVENTIONAL,['NA'],
14588,NCT01917656,Change in Fructosamine From Start of Ramadan to End of Ramadan,"Number of Treatment Emergent Adverse Events (TEAEs) During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period.",2014-01-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
14589,NCT02421510,Change From Baseline in A1C at Week 24,Percent Change From Baseline in Body Weight at Week 24,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
14590,NCT02642159,Percent Change From Baseline in Non-HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum,Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Week 12 and 24 : Overall ITT Analysis,2016-03-15,COMPLETED,INTERVENTIONAL,['PHASE4'],
14591,NCT00208637,Dietary intake as measured by 3-day weight diet records,All measures to be compared at end of study (6 months),2002-08,COMPLETED,INTERVENTIONAL,['NA'],
14592,NCT03232437,Precision (as measured by %CV) of HbA1c measurements,,2017-06-14,COMPLETED,OBSERVATIONAL,['NA'],
14593,NCT00501930,"Clinical laboratory tests, ECGs, adverse events",clinical lab tests,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
14594,NCT00629213,Incidence of newly diagnosed type 2 diabetes,newly diagnosed hypertension,na,COMPLETED,INTERVENTIONAL,['PHASE3'],
14595,NCT00354536,blood plasma levels of GSK716155,blood plasma levels of GSK716155,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
14596,NCT02023918,Insulin Sensitivity,Lipolysis,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
14597,NCT02064309,"Safety of device, as evaluated by incidence of adverse events or serious adverse events judged probable or highly probable related to the device","8. Number of patients with non-fasting c-peptide concentrations >0.003 nmol/l at 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 and 26 weeks post-transplantation; i.e. Kaplan-Meier analysis of survival time for islet grafts.",2014-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",7. Score in diabetes treatment satisfaction questionnaire in transplanted patients at 12 and 26 weeks post-transplantation when compared to before transplantation and 6 months after explantation.
14598,NCT02849288,Assessment of safety outcomes and serious adverse events and device related adverse effects.,System functionality as evidenced by the availability of CGM data,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
14599,NCT00900887,"ocular topic antiinflammatory therapy (ketorolac, nepafenac or placebo) applied 3 times a day in the treated eye for a week after selective photocoagulation",visual capacity under subjective refractive correction measured in decimal equivalent,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
14600,NCT04061746,12 month Change in C-peptide area under the curve after a 2-hour MMTT,Change in 24-hour insulin dose per kilogram between baseline and 1 year measurements,2020-02-27,RECRUITING,INTERVENTIONAL,['PHASE1'],Changes in serum cytokine levels after treatment
14601,NCT02503527,Blood glucose variability (within patient standard deviation of blood glucose values per day),"Gastro-intestinal intolerance (AEs, complications)",2015-08,TERMINATED,INTERVENTIONAL,['NA'],
14602,NCT04119947,The Safety and tolerance of SY-009，Collecting Number of subjects with adverse events as assessed by CTCAE V5.0,C-peptide secretion following single dose of SY-009,2019-03-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
14603,NCT05293587,Participant satisfaction,Change in Aerobic Fitness from Baseline at 8 weeks,2021-09-13,COMPLETED,INTERVENTIONAL,['NA'],Structured Assessment of FEeasibility
14604,NCT01843387,The primary objective of the study is to assess the safety and tolerability of MPC therapy,Exploratory assessment of the efficacy of MPC therapy,2013-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
14605,NCT05325294,Primary Effectiveness Endpoint for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL),Secondary Effectiveness Endpoint 2 for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL),2022-05-05,COMPLETED,INTERVENTIONAL,['NA'],
14606,NCT04569396,Fatty Liver Index,,2016-01-12,COMPLETED,OBSERVATIONAL,['NA'],
14607,NCT04448496,Mean change of best corrected visual acuity,Changes of total area (mm^2)of nonperfusion within the ETDRS grid using fluorescein angiography and optical coherence tomography angiography,2020-06-22,UNKNOWN,INTERVENTIONAL,['PHASE4'],
14608,NCT02227745,efficiency in visual function with dorzolamide after photocoagulation,,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],
14609,NCT02809911,Lower Extremity - Pain Sensitivity to Various Experimentally Induced Pain Stimuli,,2016-06,COMPLETED,INTERVENTIONAL,['NA'],
14610,NCT04226820,exercise test wilt hand held dynamometer,Blood pressure analysis,2020-02-01,RECRUITING,INTERVENTIONAL,['NA'],
14611,NCT00803296,Incretin effect,Insulin resistance,2006-01,COMPLETED,OBSERVATIONAL,['NA'],
14612,NCT05473494,Diabetic Foot Care Self-Efficacy Scale,Foot Care Behavıor Scale,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],
14613,NCT04089202,Glycemic control based on A1c,Cost effectiveness analysis (CEA),2020-02-03,TERMINATED,INTERVENTIONAL,['NA'],
14614,NCT05454176,Cost analysis of CGM,,2022-08-15,RECRUITING,INTERVENTIONAL,['PHASE4'],
14615,NCT01542424,HbA1c (glycosylated haemoglobin),Incidence of adverse events,2006-03,COMPLETED,OBSERVATIONAL,['NA'],
14616,NCT01023919,To investigate the difference of surface coverage pattern between diabetic patients and non-diabetic patients after DES (Cypher stent or YINYI stent)implantation,To investigate the differences of surface coverage pattern，malapposition and the incidence of thrombosis between Cypher stent and YINYI in non-diabetic patients,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
14617,NCT05124808,Number of participants with composite neonatal morbidity,Infant adiposity,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],
14618,NCT04311164,Glycated Hemoglobin A1c (HbA1c),"Educational, time and risk preferences",2020-05-15,COMPLETED,OBSERVATIONAL,['NA'],
14619,NCT05152277,Number of Adverse Events,Glucose concentration,2021-12-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
14620,NCT03339336,Change from Randomization in Weekly Mean ADP Score,Maximum Observed Concentration (Cmax) at Steady State,2018-05-31,TERMINATED,INTERVENTIONAL,['PHASE2'],
14621,NCT04674332,time needed to achieve glycemic control,,2019-09-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
14622,NCT05594446,Collection of anthropometric measurements of the foot : European shoe size,,2022-09-09,COMPLETED,OBSERVATIONAL,['NA'],
14623,NCT05069545,Change in time in range (3.9-10 mmol/L),DHSS-HCP(Health Care Professional),2021-10-12,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
14624,NCT03972904,Insulin resistance index changes,Glycated albumin changes,2019-06-20,UNKNOWN,INTERVENTIONAL,['NA'],BMI changes
14625,NCT05439928,Time to Resolution of Metabolic Acidosis,Cost savings,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14626,NCT04243200,Repeat ambulance calls and attendances for hypoglycaemia within 14 days.,"To assess whether the ""Hypos can strike twice"" intervention can reduce repeat ambulance calls and attendance for hypoglycaemia within 30 and 90 days.",2020-09-14,COMPLETED,OBSERVATIONAL,['NA'],
14627,NCT01570660,whole body insulin sensitivity,intrahepatocellular lipid content,2002-02,COMPLETED,INTERVENTIONAL,['NA'],
14628,NCT04017832,Change From Baseline to Week 26 in Glycated Haemoglobin (HbA1c) (%),Number of Participants With Treatment-emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes During Exposure to Trial Product,2019-07-29,COMPLETED,INTERVENTIONAL,['PHASE3'],
14629,NCT00276250,The Number of Insulin-independent Subjects at Day 75 (± 5 Days) Following the First Islet Cell Transplantation,"Number of Subjects With Normal Renal Function, as Measured by Serum Creatinine Levels",2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
14630,NCT01986231,Assess Difference in Hepatic Glycogen Measured in the Fasting State Before vs. After Repeated Glucagon Administration,Assess Difference in Hepatic Glycogen Measured in the Fed State Before vs. After Repeated Glucagon Administration,2011-01,COMPLETED,INTERVENTIONAL,['NA'],
14631,NCT05542420,The proportion of patients prescribed cardiovascular disease (CVD) medications,,2022-10-19,COMPLETED,OBSERVATIONAL,['NA'],
14632,NCT05831384,Overall diabetes distress score,"The The patient's glycated haemoglobin (Hba1c) result, expressed as a %, taken during the standard check-up on the day of admission to hospital result (Hba1c)",2023-05-11,COMPLETED,OBSERVATIONAL,['NA'],
14633,NCT03221868,Change in HbA1c,Change in QoL,2016-08,COMPLETED,INTERVENTIONAL,['NA'],
14634,NCT04026165,eGFRcr Slope,eGFRcys Slope,2019-07-24,COMPLETED,INTERVENTIONAL,['PHASE2'],
14635,NCT03222791,Mean change in Glucose Tolerance Test from the baseline level,Change in HOMA-IR from baseline,2017-02-01,COMPLETED,INTERVENTIONAL,['NA'],Patients compliance evaluation using a compliance questionnaire
14636,NCT06273657,HbA1c,Diabetes Treatment Satisfaction,2024-02-07,RECRUITING,INTERVENTIONAL,['NA'],
14637,NCT04467255,Six-minute walk test,Surface multichannel electromyographic variables.,2018-05-03,RECRUITING,INTERVENTIONAL,['NA'],
14638,NCT01319487,change from baseline of central retinal thickness as determined by logOCT,Change in macular volume and retinal thickness from baseline to Week 12 and Week 24,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
14639,NCT00194506,Hemoglobin A1c,Utilization,2002-08,COMPLETED,INTERVENTIONAL,['NA'],
14640,NCT01409213,Change From Baseline for Mean Fasting Blood Glucose (FBG),,2009-08,COMPLETED,OBSERVATIONAL,['NA'],
14641,NCT01220349,Measurement of the alteration of left ventricular myocardial strain (≤ 18% in absolute value) by echocardiography and the relationship to micro-angiopathy.,"Analyses of this association (alteration of myocardial strain and micro-angiopathy) in relation with the duration of diabetes, and other co-factors such as dyslipidemia, unstable diabetes, and coexisting macro-angiopathy.",2011-01,COMPLETED,INTERVENTIONAL,['NA'],
14642,NCT02685384,Change of health insurance status,Change of Medicaid expenditures,2012-01,COMPLETED,OBSERVATIONAL,['NA'],
14643,NCT01404676,Change in mean amplitude of glycemic excursion(MAGE) for 12 weeks(12weeks - 0 week).,Change from baseline in oxidative stress markers and inflammatory markers at 12 weeks. Change from baseline in endothelial cell function at 12 weeks.,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
14644,NCT02958995,Hazard Ratio for Risk of 10 Common Cancers Associated With Diabetes,,1997-01-01,COMPLETED,OBSERVATIONAL,['NA'],
14645,NCT03041571,Patient provider orientation scale score (PPOS),Medical honors students focus group,2017-03-01,WITHDRAWN,OBSERVATIONAL,['NA'],
14646,NCT01005264,Decrease in ulcer size,Complete healing rate at the end of the study,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
14647,NCT02919839,blood glucose,,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],
14648,NCT03322631,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Change From Baseline to 8 Weeks in Fasting Plasma Glucose,2017-11-15,COMPLETED,INTERVENTIONAL,['PHASE1'],
14649,NCT05696015,"Change from baseline discharge telehealth orientation and application of the Diabetes Self-Care Activity Questionnaire (QAD) at within 72 hours after discharge, 10 days after and within 30 days after discharge",,2023-03-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14650,NCT02538120,Neurovascular microcirculatory response,,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
14651,NCT04304560,Diastolic Function,Galectin -3,2020-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],
14652,NCT03376607,Change in HbA1c,Alcohol intake per week,2019-01-11,UNKNOWN,INTERVENTIONAL,['NA'],The differences the HBCPs note from patient to patient
14653,NCT06059287,Extra-cellular volume fraction,Native T2 mapping,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14654,NCT05992415,Adherence to Follow-up Eye Care,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14655,NCT04523363,Birth Weight,Placental Pathology,2025-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],
14656,NCT02050191,attitudes and perceptions re: feasibility of web portal,,2006-07,COMPLETED,INTERVENTIONAL,['NA'],
14657,NCT01468987,Change From Baseline in Hemoglobin A1c (HbA1c) at 26 Weeks,Rapid Assessment of Physical Activity (RAPA) at 26 Weeks,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
14658,NCT00346996,Severe hypoglycaemia,hypoglycaemia during daytime,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
14659,NCT04060745,Changes in glucose metabolism between non-activated and cold-activated BAT,Changes in metabolic profiles in cold versus thermoneutral conditions,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA'],
14660,NCT04242758,Urinary Phthalates concentration,Albumin excretion,2019-06-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
14661,NCT05128747,Evaluate the effectiveness of one of the most common dietary approches;DASH diet in controlling lipid profile in diabetic patients.,,2022-03-01,UNKNOWN,INTERVENTIONAL,['NA'],
14662,NCT00262977,Patient reported aspirin use daily or every other day.,,2004-09,COMPLETED,INTERVENTIONAL,['NA'],
14663,NCT00811044,Genes affecting the development of Type 2 diabetes will be identified,Any differences between genetic groups in the metabolism of glucose/sugar will be studied to the extent that the data allow,2000-10,WITHDRAWN,OBSERVATIONAL,['NA'],
14664,NCT02328508,wound healing,glycemic control,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
14665,NCT04232631,Evaluating the effectiveness of 3 devices to measure perfusion to predict wound healing,,2021-04-28,RECRUITING,OBSERVATIONAL,['NA'],
14666,NCT01620450,Maximum insulin aspart concentration (Cmax IAsp),Adverse events,2004-11-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
14667,NCT01215994,,,2009-03,UNKNOWN,OBSERVATIONAL,['NA'],
14668,NCT00775840,The change from Baseline in N-terminal pro-B-type Natriuretic Peptide biomarker.,"Progression of preserved (Left Ventricular Ejection Fraction greater than or equal to 45%) to impaired systolic dysfunction (Left Ventricular Ejection Fraction less than 45%), based on echocardiographic results.",2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
14669,NCT01666938,level of physical activity,Metabolic Control,2012-04,COMPLETED,INTERVENTIONAL,['NA'],
14670,NCT01884792,Blood sugar area under the curve,Accelerometer counts,2013-03,COMPLETED,INTERVENTIONAL,['NA'],
14671,NCT02051842,Oxidative stress,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Oxidative stress
14672,NCT03444584,Percent Change From Baseline to Day 28 in Plasma Glucose AUC0-4hrs as Measured by MMTT,Change From Baseline in the Percentage of 24-hrs Glucose Readings That Falls Within Clinically Significant Hypoglycemic Range to the End of Each Dosing as Measured by CGM,2018-05-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
14673,NCT05601349,Rate of patients who received comprehensive Rehabilitation,,2020-01-01,COMPLETED,INTERVENTIONAL,['NA'],
14674,NCT05335889,Proportion of participants who are fully compliant with eButton use,,2022-07-18,COMPLETED,OBSERVATIONAL,['NA'],
14675,NCT03881956,Pre-test and post-test scores,Postpartum characteristics of neonates,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],
14676,NCT01812590,Pancreatic endocrine function,,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
14677,NCT05754567,Childhood executive function,Significant associations between maternal pre-existing diabetes and ADHD (Attention Deficit Hyperactivity Disorder),2023-09-07,RECRUITING,OBSERVATIONAL,['NA'],Maternal CGM (Continuous Glucose Monitor) percentage time in target
14678,NCT01131091,The primary objective is to determine the effect of renal insufficiency on the pharmacokinetics of a single 400 mg dose of SK 0403.,The secondary objective is to determine the safety and tolerability of a single 400 mg dose of SK 0403 in subjects with renal insufficiency.,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
14679,NCT04420936,Change in body weight,Change in blood pressure,2021-09-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
14680,NCT02673203,Glucose Nadir,Nutirion Intake: Protein,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
14681,NCT04616027,Fraction of unbound drug in plasma [fu],Incidence of treatment emergent Electrocardiogram [ECG] abnormalities,2021-01-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
14682,NCT02908087,Serum C-peptide AUC,Insulin dose,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
14683,NCT01087541,Glycosylated Haemoglobin A1c at 6 Months,Systolic and Diastolic Blood Pressure,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
14684,NCT05037695,NGAL values in pre-specified periods,Death,2021-07-21,UNKNOWN,INTERVENTIONAL,['PHASE4'],
14685,NCT04806685,Hemoglobin A1c,Insomnia Severity Index,2021-03-15,COMPLETED,INTERVENTIONAL,['NA'],
14686,NCT01512940,Percent excess weight loss,Resolution of comorbidities,2011-10,UNKNOWN,INTERVENTIONAL,['NA'],
14687,NCT04637880,25- Hydroxyvitamin D and relation to development of preeclampsia,25 Hydroxyvitamin D in newborn,2012-07,COMPLETED,OBSERVATIONAL,['NA'],
14688,NCT05588583,Wound progress of the total effect of treatment using Mepilex Up,Evaluation of all reported adverse events and device deficiencies,2022-10-31,RECRUITING,INTERVENTIONAL,['NA'],
14689,NCT01326299,Positive AUC from 0 to 240 minutes for plasma glucose.,Plasma glucose concentrations,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
14690,NCT01233622,HbA1c Reduction,Responder Rate,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
14691,NCT04132089,20 participants baseline diabetes self-management score will be measured at baseline and after the utilization (9 weeks) of the mHealth application capABILITY.,Participants who receive a Spark trigger message will login and use capABILITY quicker (time measured in seconds) than those participants who receive Facilitator trigger message.,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],
14692,NCT02620592,"Safety and tolerability assessed by monitoring adverse events, clinical, laboratory, electrocardiogram, and vital signs examinations.",Glucagon,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
14693,NCT01674348,Change in HbA1c from baseline,Number of subjects with adverse events,2011-04,TERMINATED,INTERVENTIONAL,['PHASE2'],"Pharmacokinetic profile (Cmax, Tmax and AUC)"
14694,NCT00834262,Number of all hypoglycaemic episodes,"Average post-breakfast (2h), post-lunch (2h), post-dinner (2h) blood glucose level",2009-04,COMPLETED,OBSERVATIONAL,['NA'],
14695,NCT02215642,Disease-specific survival,Overall survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],Disease-free survival
14696,NCT00143013,,,2004-10,UNKNOWN,OBSERVATIONAL,['NA'],
14697,NCT03832725,Remission of Type 2 Diabetes,Metabolom Markers,2018-03-01,RECRUITING,INTERVENTIONAL,['NA'],
14698,NCT02229175,Retinal thickness,Number of injections of bevacizumab needed,2021-01-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
14699,NCT02547311,Cost effectiveness,,2012-10,COMPLETED,INTERVENTIONAL,['NA'],
14700,NCT01135771,demonstrate the accuracy of the OptiScanner in measuring blood glucose levels in otherwise healthy diabetic subjects when compared to blood glucose levels simultaneously measured on the YSI,The secondary objective of the study is to demonstrate a blood glucose measurement range of 60 to 500 mg/dL at the hematocrit levels referenced as normal,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
14701,NCT02862067,SGLT2 inhibition effects on cardiorespiratory fitness (CRF).,,2016-07,COMPLETED,OBSERVATIONAL,['NA'],
14702,NCT00529165,HbA1c,Quality of Life,2007-07,COMPLETED,INTERVENTIONAL,['NA'],
14703,NCT05593653,Insomnia Severity Index Score,Fasting Plasma Glucose,2023-01-06,RECRUITING,INTERVENTIONAL,['PHASE4'],
14704,NCT00895440,Identify patients with peripheral neuropathy with the Neuropad indicator test,,2009-07,COMPLETED,OBSERVATIONAL,['NA'],
14705,NCT02435277,Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations,Change in Fasting Plasma Glucose,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
14706,NCT03490773,Difference in immune function in Cpeptide negative and positive,Difference in HLA type in Cpeptide negative and positive groups,2014-11-01,COMPLETED,OBSERVATIONAL,['NA'],
14707,NCT03772067,Clock genes mRNA expression,Body Weight,2018-12-28,UNKNOWN,INTERVENTIONAL,['NA'],
14708,NCT02365233,Change in Hepatic Lipid Content From Baseline Visit to Six Month Follow up Visit,,2013-05-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
14709,NCT00389636,Time to complete wound healing within 12 weeks,Excess pain,2006-09,UNKNOWN,INTERVENTIONAL,['NA'],
14710,NCT01464346,"Mean Daily Agreement (Percent of Sensor Values Within 30% of Reference Value) With Minimum Calibration, Combined Abdomen and Buttock Insertion Sites","Mean Daily Agreement (Percent of Sensor Values Within 30% of Reference Value) With 3-4 Calibrations Per Day, Combined Abdomen and Buttock Insertion",2011-11,COMPLETED,INTERVENTIONAL,['NA'],"Mean Absolute Relative Difference (MARD) Between Sensor and YSI for Buttock Insertion Site, With Calibration Every 12 Hours"
14711,NCT01458158,Association of matrix metalloproteinases with atherosclerosis in patients with chronic kidney disease,Matrix metalloproteinases and atherosclerosis associated with pro-inflammatory and oxidative stress markers in chronic kidney disease,2011-10,UNKNOWN,OBSERVATIONAL,['NA'],
14712,NCT01199848,Postprandial Insulin Levels for 6 Hours,Strawberry Dose-response Effect on Postprandial Oxidative Stress (Ox-LDL) in Insulin-resistant Men and Women in an Acute Postprandial Paradigm,2010-09-15,COMPLETED,INTERVENTIONAL,['NA'],
14713,NCT00500955,The primary efficacy endpoint was percent change from baseline in ACR after 32 weeks of treatment.,"Secondary efficacy endpoints included change from baseline (visit 3) at week 32 (visit 7) in the following: serum TGF, creatinine clearance (calculated), PAI-1, CRP, IL-6, vWF, sVCAM, fibrinogen, TNF alpha, ET-1, heart rate and blood pressure",2000-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
14714,NCT02191644,Lp-PLA2 Activity in PBMC,PBMC metabolites,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],LDL particle size
14715,NCT01887067,Change in office systolic & diastolic blood pressure from baseline to 6 months,Change in glucose metabolism,2013-06,TERMINATED,INTERVENTIONAL,['NA'],
14716,NCT05547594,Changes in Short Physical Performance Battery (SPPB) at different time points from baseline to 1 year after surgery,Changes in Patient Health Questionnaire-9 (PHQ-9) at different time points from baseline to 1 year after surgery,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Postsurgical complications
14717,NCT01601704,Percentage of Participants With a Confirmed Occurrence of Major Adverse Cardiovascular Event (MACE),Percentage of Participants With a Confirmed Occurrence of Stroke (Nonfatal or Fatal),2012-06,TERMINATED,INTERVENTIONAL,['PHASE3'],
14718,NCT00760448,"Baseline-adjusted hypoglycaemic symptoms score at nadir plasma glucose concentration based on the Edinburgh Hypoglycaemia Scale: autonomic symptoms, neuroglycopenic symptoms and general malaise",,2004-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
14719,NCT00513643,AUC GIR 360-720 min,"PD endpoints like GIR max, t max/GIR, AUC GIR 0-120 min, AUC GIR 0-720 min, t >2/GIR, early and late t 50%/GIR",2002-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
14720,NCT02653209,On treatment HbA1c in patients with an eGFR <90 mls/min/1.73m2 compared to patients with an eGFR >90 mls/min/1.73m2.,HbA1c on therapy against predefined test of gender heterogeneity,2016-11-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
14721,NCT03883503,Difference in copeptin levels between the interventions,Difference in Response to lottery Experiment before and after the intervention,2019-02-25,COMPLETED,INTERVENTIONAL,['NA'],
14722,NCT04726631,the percentage of maternal glycosylated Hemoglobin,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],
14723,NCT05221580,Change in Glycosylated Haemoglobin (HbA1c),Treatment satisfaction questionnaire (Diabetes Treatment Satisfaction Questionnaire (DTSQ)),2022-03-18,COMPLETED,OBSERVATIONAL,['NA'],
14724,NCT01461434,Time to first diagnosis of atrial fibrillation,Stroke,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
14725,NCT00698269,Change in HbA1c,Number of adverse drug reactions (ADR),2008-02,COMPLETED,OBSERVATIONAL,['NA'],
14726,NCT00858676,"sudden cardiac death, fatal or non-fatal myocardial infarction, coronary revascularization, admission due to heart failure, fatal or non-fatal stroke",,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
14727,NCT06295289,TIR,MBG,2023-10-16,RECRUITING,INTERVENTIONAL,['NA'],postoperative infection
14728,NCT00529594,The group taking the etoricoxib feel less pain then the group taking placebo,,2006-08,COMPLETED,INTERVENTIONAL,['NA'],
14729,NCT01611363,"Part B: Assessment of the relationship between the exposure to ipragliflozin in plasma, urinary glucose excretion and plasma glucose levels in subjects with T2DM","Part B: Safety and tolerability following multiple doses of ipragliflozin assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and signs and symptoms of hypoglycemia",2011-10-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
14730,NCT01729546,Evaluation of System Accuracy according to ISO 15197,,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
14731,NCT04310137,Change in walking behavior (step timing),Waist circumference,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA'],
14732,NCT05387434,Change in Body Weight From 0-6 Months,Average Program Attendance,2021-03-03,COMPLETED,INTERVENTIONAL,['NA'],
14733,NCT03840161,CoG accuracy in monitoring glucose levels (invasively) during a standardized meal experiment.,Treatment satisfaction questionnaire,2018-07-16,COMPLETED,OBSERVATIONAL,['NA'],
14734,NCT04339283,Change form Baseline Pulse on the 28th day,Change from Baseline Body Mass Index on the 28th day,2019-09-01,COMPLETED,INTERVENTIONAL,['NA'],
14735,NCT02790931,Fast gait speed,EQ-5D score of the quality of life,2016-08,COMPLETED,INTERVENTIONAL,['NA'],
14736,NCT00942318,HbA1c,"self monitoring blood glucose measurements (frequency, mean and standard deviation, number of hypoglycaemic and hyperglycaemic events)",2009-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
14737,NCT06182891,Evaluation of the biomarkers of the epithelial-mesenchymal transition process,Evaluation of adverse event,2021-10-30,COMPLETED,INTERVENTIONAL,['NA'],
14738,NCT04984421,Change in fidelity (R) assessed by questionnaire to parents,Change in parents' risk of type 2 diabetes assessed by FINDRISC questionnaire,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],
14739,NCT03182569,Comfort measured by a visual analogue scale for pain,Metabolic stability according to lab determinations,2016-12-11,COMPLETED,INTERVENTIONAL,['NA'],
14740,NCT00132132,Percentage of Participants With BMI Reduction,,2005-08,COMPLETED,INTERVENTIONAL,['NA'],
14741,NCT02887625,HbA1c,change in body weight,2015-02,UNKNOWN,INTERVENTIONAL,['NA'],
14742,NCT06117137,Number of participants with tight controlled diabetes melitus,Number of participant with changing in inflammatory biomarkers,2023-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
14743,NCT02018497,"Relationship between blood pressure group, adaptability group and comorbidities","Relationship between adaptability group, habits and anthropometric, metabolic, endocrine, Electrocardiogram, Holter, ambulatory blood pressure monitoring (ABPM)",1995-01,RECRUITING,OBSERVATIONAL,['NA'],Description of the blood pressure hemodynamic profile at a medical office and their prognostic implications.
14744,NCT00786890,"Cardiovascular risk factors: anthroprometric parameters, blood pressure and lipid profiles",,2008-11,UNKNOWN,OBSERVATIONAL,['NA'],
14745,NCT04750837,size of the ulcer reduce to zero cm,,2020-01-16,COMPLETED,INTERVENTIONAL,['PHASE2'],
14746,NCT02743598,Neurocognitive performance- change in domain averages on a standard neuropsychological profile,Change from baseline serum LDL,2016-09,TERMINATED,INTERVENTIONAL,['PHASE4'],
14747,NCT00946504,Bioequivalence based on AUC and Cmax,,1992-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
14748,NCT02325531,"Rate Ratio of the Percent of the Clinics' Patients ""Indicated"" for ACE/ARB With Guideline-appropriate Prescription for ACE/ARBs",Rate Ratio of the Change in the Percent of the Clinic's 'Indicated' Patients With Correct Intensity Statin Prescribing,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
14749,NCT04070963,Diabetes incidence,Association of HbA1C levels with post operative complications,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA'],
14750,NCT01800851,Energy expenditure,Insulin resistance,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
14751,NCT04885621,hemoglobin A1C levels,Weight/BMI,2021-05-01,COMPLETED,OBSERVATIONAL,['NA'],
14752,NCT01681160,change from baseline in BATES-JENSEN WOUND ASSESSMENT score at 3days and change from baseline in BATES-JENSEN WOUND ASSESSMENT score at 6 days,,2009-01,COMPLETED,INTERVENTIONAL,['NA'],
14753,NCT01571297,Effect of RM-131 on gastric emptying time,Safety and tolerability of RM-131,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
14754,NCT06180811,Emergency Room Visit,Cost-Related Medication Underuse,2024-01,RECRUITING,INTERVENTIONAL,['NA'],
14755,NCT00553787,Percentage of Subjects With a Weight Loss of at Least 5% at Week 56 With LOCF,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
14756,NCT03447340,Healthy food intake,Diastolic Blood pressure,2016-11-09,COMPLETED,INTERVENTIONAL,['NA'],
14757,NCT01564459,Percentage of Participants Who Were Discontinued Form the Study Due to an AE,Change in Pain Intensity Scores - All Responders,2012-03-26,COMPLETED,INTERVENTIONAL,['PHASE2'],
14758,NCT03380338,Change in capillary recruitment,Changes in continous cardiovascular monitoring,2016-05-11,COMPLETED,INTERVENTIONAL,['NA'],
14759,NCT04678661,Change From Baseline in Glycemic Control at 3 Months,Number of Participants Who Experienced Severe Hypoglycemic Events.,2021-02-15,TERMINATED,INTERVENTIONAL,['NA'],Type of Escalation of Care
14760,NCT05378295,Peripheral insulin sensitivity,body weight,2021-11-05,RECRUITING,INTERVENTIONAL,['NA'],
14761,NCT05566197,Body Fat Percentage,,2022-07-15,RECRUITING,INTERVENTIONAL,['NA'],
14762,NCT00895427,,,2009-02,COMPLETED,OBSERVATIONAL,['NA'],
14763,NCT05545657,Baseline brain functional MRI scan,Longitudinal changes of brain functional MRI scan,2022-10-18,RECRUITING,OBSERVATIONAL,['NA'],
14764,NCT00110435,Percent reduction in LDL-C from baseline after 6 weeks of treatment,Percent of patients attaining LDL-C <70 mg/dl after 6 weeks of treatment,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
14765,NCT05156021,Changes in Intraocular Pressure from baseline to 12 months after surgery,Changes in Ocular and Systemic Adverse Events from baseline to 12 months after surgery,2021-12-12,COMPLETED,INTERVENTIONAL,['NA'],
14766,NCT01073137,Otoacoustic emissions change with blood sugar levels,,2006-06,UNKNOWN,OBSERVATIONAL,['NA'],
14767,NCT05730582,Cost effectiveness as measured by cost per case found,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14768,NCT06131918,Objective improvement in Diabetic Neuropathy,Levels of Superoxide dismutase and Glutathione peroxidase,2023-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
14769,NCT02053584,BGMS Accuracy Assessment When Used by Layperson,Evaluation of the Ease of Use of the Dario BGMS by the Lay-person,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
14770,NCT03722199,FMD -Flow mediated dilatation test,blood pressure analysis,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],exercise test with hand held dynamometer
14771,NCT02657018,Change from baseline daily physical activity at 24 weeks,Adherence to the intervention,2016-08,COMPLETED,INTERVENTIONAL,['NA'],Perceived acceptance of intervention
14772,NCT04810780,Primery Effectivness Endpoint,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA'],
14773,NCT06185465,Difference in scoring the positive rate of bacterial biofilm before the first treatment and on the 7th day of treatment in Group A and Group B,Detection rate of bacteria/drug-resistant bacteria on the wound and their correlation with the detection rate of bacterial biofilm,2024-01-03,RECRUITING,INTERVENTIONAL,['NA'],
14774,NCT03231839,change in glucose metabolism,body composition,2009-02-01,COMPLETED,INTERVENTIONAL,['NA'],
14775,NCT02960659,Change in Absolute Gluconeogenesis From Baseline to 12 Weeks,Change in Palmitate Turnover From Baseline to 12 Weeks,2017-05-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
14776,NCT04150926,Insulin concentration,,2019-08-15,COMPLETED,INTERVENTIONAL,['NA'],
14777,NCT03084822,Physical activity self-efficacy (using Self-Efficacy and Exercise Habits Survey),Cardiovascular health knowledge,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
14778,NCT00252733,Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.,Rate of Change in Urinary Albumin Excretion Rate (UAER).,2001-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
14779,NCT03943940,Adverse events,Insulin dose and drug dosage,2019-04-24,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
14780,NCT04572165,Occurrence of first time malignant neoplasm of pancreas,,2021-01-26,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
14781,NCT03066570,"Quality of Life as measured with Norfolk Quality of Life Questionnaire, Diabetic Neuropathy Version (Norfolk-QOL-DN)",,2017-06-01,COMPLETED,INTERVENTIONAL,['NA'],
14782,NCT00688974,Glucose control,Diabetes remission,2004-05,COMPLETED,OBSERVATIONAL,['NA'],
14783,NCT03824002,Change from Baseline Reactive Hyperemia Index at 3 and 9 months,Change from Baseline Pulse Wave Velocity at 3 and 9 months,2017-04-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
14784,NCT03869931,Triglyceride concentration following 30 days of fenofibrate treatment,Change in ETDRS scale following 30 days of fenofibrate treatment,2019-03-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],
14785,NCT00172796,,,2005-04,UNKNOWN,OBSERVATIONAL,['NA'],
14786,NCT03188484,Atrial fibrillation (AF) diagnosis,,2016-05,COMPLETED,OBSERVATIONAL,['NA'],
14787,NCT03039075,Changes of HbA1c,"Changes of LDL, HDL, TG, TC",2016-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
14788,NCT05620225,Comparison of therapy-related AEs between the 2 Study arms,Neurological Exam - percentage of treatment arm with a change in neurological status,2022-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
14789,NCT01237522,Renal clearance of metformin,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
14790,NCT05191160,Liver fat,Glucose tolerance - 2-hour plasma glucose (2h-PG),2021-11-02,RECRUITING,INTERVENTIONAL,['NA'],Adherence biomarkers - Objective biomarkers of SSBs (urinary fructose)
14791,NCT00272831,Fatal or severe bleeding,"Number of hospital admissions, total number of days of hospital stay and attendance at the Accident and Emergency Department",2005-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
14792,NCT05930210,The ulcer complete closure rate,The proportion of subjects with complete ulcer closure,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE3'],
14793,NCT02096705,Adjusted Mean Change in HbA1c From Baseline to Week 24,Adjusted Mean Change in Absolute Calculated Mean Total Daily Dose of Insulin (TDDI) From Baseline to Week 24,2014-03-31,COMPLETED,INTERVENTIONAL,['PHASE3'],
14794,NCT02880592,Time to initial closure of diabetic foot ulcer,Incidence of adverse events,2016-08,COMPLETED,INTERVENTIONAL,['NA'],
14795,NCT01803126,To study the role of biofilm in the hardening of the arteries. The study will evaluate the hardening of the arteries found in legs that have been amputated because of vascular disease and/or diabetes.,,2012-06,COMPLETED,OBSERVATIONAL,['NA'],
14796,NCT03973931,Medication adherence,Healthcare utilization costs (Costs),2019-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
14797,NCT02716610,Maximum glucose infusion rate (GIRmax),Bioavailability,2013-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
14798,NCT05973799,Glucose infusion rate,Peripheral glucose uptake,2019-10-10,RECRUITING,INTERVENTIONAL,['NA'],Growth Hormone
14799,NCT01396941,Insulin sensitivity,,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
14800,NCT04823208,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change from Baseline in Body Weight,2021-05-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
14801,NCT02139254,Number of women with gestational diabetes,Delivery Mode,2013-08,COMPLETED,OBSERVATIONAL,['NA'],
14802,NCT06318442,Difference in Glucose tolerance,Difference in insulin sensitivity,2024-04-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Tissue specific changes in AMPK determined from adipose and muscle biopsies
14803,NCT00489190,Dynamics compared with the initial level of glycemia and insulin dosages.,"Evaluation of frequency of glycemia episodes. Also undesirable events, Influence on indexes of general clinical analysis of blood and biochemical analysis of blood.",2005-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
14804,NCT05228561,The effect of mobile application supported diabetes education on blood sugar,,2022-03-15,UNKNOWN,INTERVENTIONAL,['NA'],
14805,NCT00312780,Reduction in albumin excretion relative to creatinine,Pharmacokinetics and renal elimination,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
14806,NCT01731808,feasibility of an intensive nurse led education program,,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
14807,NCT00850239,"Primary objective is to demonstrate the efficacy of dutogliptin, as evidenced by placebo-corrected changes in HbA1c relative to baseline.",• Demonstrate changes in fasting plasma glucose,2009-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
14808,NCT06076720,Comparison of changes in the Low Vision Quality-of-Life Questionnaire (LVQOL) scores at different time points,Comparison of changes in visual scanning test at different time points,2023-10-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14809,NCT05083013,Need for ventilatory support,Incidence of other complications,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA'],
14810,NCT00301249,,,1999-10,COMPLETED,OBSERVATIONAL,['NA'],
14811,NCT01101867,Mean Glucose,"1,5-anhydroglucitol Change",2010-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
14812,NCT02633722,Postprandial glucose response to meal test,Glycaemic response over 1 week by continuous glucose monitoring,2016-01,COMPLETED,INTERVENTIONAL,['NA'],
14813,NCT02280486,Proportion of subjects achieving glycemic response defined as Glycosylated hemoglobin (HbA1c) < 7.0%,"Safety and tolerability of saxagliptin vs. glimepiride measured by adverse events, serious adverse events (SAEs); laboratory assessments (biochemistry, lipids, blood and urine routine tests",2015-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
14814,NCT03813927,Wound healing,Vitamin D blod level status,2016-04-01,COMPLETED,INTERVENTIONAL,['NA'],
14815,NCT05063253,Changes in glycosylated hemoglobin (HbA1c) from baseline to week 20,The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (Nab).,2021-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
14816,NCT01640873,Fasting Plasma Glucose (FPG),Change From Baseline at 2 Hours Oral Glucose Tolerance Test,2012-09-19,COMPLETED,INTERVENTIONAL,['PHASE1'],
14817,NCT05226416,hospitalization for any cause,rate of demand for medical care,2022-02-21,COMPLETED,OBSERVATIONAL,['NA'],
14818,NCT04689685,Accuracy of the RADAR model: Diagnostic accuracy of wearable based physiological data in detecting dysglycemia (glucose > 13.9mmol/L and glucose < 3.9 mmol/L) quantified as the area under the receiver operator characteristics curve (AUC-ROC),24. Analysis of user requirements for smartwatch based dysglycemia warning systems,2021-02-19,COMPLETED,OBSERVATIONAL,['NA'],
14819,NCT03793855,GC,DQ,2019-05-06,COMPLETED,INTERVENTIONAL,['NA'],ADD
14820,NCT01194882,Change in glycosylated hemoglobin (HbA1c),Antibody assessments (anti-Insulin antibodies),2010-11-16,COMPLETED,INTERVENTIONAL,['PHASE3'],
14821,NCT05023993,Feasibility of a nutrition and exercise program in childhood cancer survivors (CCS),,2022-06-23,RECRUITING,INTERVENTIONAL,['NA'],
14822,NCT04657783,Major adverse cardiovascular events (MACE),All cause mortality,2020-06-10,RECRUITING,OBSERVATIONAL,['NA'],
14823,NCT01452113,plasma glucagon concentration,GIP,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
14824,NCT06268145,ECC5004 PK parameters: tmax,ECC5004 PK parameters: AUC(extr),2024-02-06,RECRUITING,INTERVENTIONAL,['PHASE1'],
14825,NCT00381992,"The prevalence of hepatitis B, hepatitis C, hypertension, hyperlipidemia, diabetes and obesity, HIV, N. gonorrhoeae, and C. trachomatis",,2005-09,COMPLETED,OBSERVATIONAL,['NA'],
14826,NCT05440591,Carotid Femoral Pulse Wave Velocity,Advanced glycation end products,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
14827,NCT01316341,Fasting Plasma Glucose (FPG) Change From Baseline,"Clinical Relevant Abnormalities for Protocol-Specified Significant Adverse Events, Hypoglycaemic Events, Vital Signs, Blood Chemistry, Rescue Therapy, Body Weight and Waist Circumference",2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
14828,NCT03219320,Numeric Rating Scale (NRS) Average Pain Intensity,Numeric Rating Scale (NRS) Average Pain Intensity in Patients Who Did Not Use a Concomitant Medication at Baseline,2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE2'],
14829,NCT04689958,Improvement in Brief Pain inventory at week 8,,2020-11-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
14830,NCT02402933,Number of Participants Awakening or Returning to a Normal Status Within 30 Minutes Following Studied Drug of Administration,Percentage of Participants With Adverse Events Through the Nasal Score Questionnaire,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Change in Blood Glucose Level Over Time
14831,NCT04235959,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration.,PK: Cmax of Tirzepatide (Cohort 2),2020-10-21,COMPLETED,INTERVENTIONAL,['PHASE1'],
14832,NCT05272059,Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs),Time to Reach Maximum Blood Concentrations (Tmax) of MHS552,2023-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
14833,NCT00718874,decreased insulin secretion,decreased markers of inflammation; decreased estradiol concentration,2008-06,COMPLETED,INTERVENTIONAL,['NA'],
14834,NCT00922649,Number of daily basal rates at Week 16,Change from baseline to week 16 in Patient Reported Outcomes (PROs),2008-02-01,COMPLETED,INTERVENTIONAL,['NA'],
14835,NCT04332302,Genotyping of HLA (rs2854275),Change from Baseline Balance at 12 weeks,2020-01-15,UNKNOWN,INTERVENTIONAL,['NA'],
14836,NCT00332085,Hemoglobin A1c,Oral Glucose Tolerance Test,2006-01,TERMINATED,INTERVENTIONAL,['PHASE1'],
14837,NCT00042458,- To investigate the safety of pramlintide treatment employing dose titration upon initiation of pramlintide followed by insulin dose optimization in subjects with type 1 diabetes.,- To examine the pattern of daily insulin use over the course of the study.,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
14838,NCT05691738,Falling Risk,Diaposan (Vibration) Evaluation,2022-10-03,COMPLETED,INTERVENTIONAL,['NA'],
14839,NCT04902638,Hyperglycaemia time,,2020-07-01,UNKNOWN,INTERVENTIONAL,['NA'],
14840,NCT02694796,Achievement of Physical activity recommendations,Captured physical activity,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
14841,NCT03784703,leptin (ng/mL),Triglycerides,2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
14842,NCT03593135,HbA1c (Glycosylated Hemoglobin),fasting lipid profile,2017-07-15,COMPLETED,INTERVENTIONAL,['NA'],
14843,NCT03769870,"AUCτ,ss(Area under the concentration-time curve at steady state)",,2019-01-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
14844,NCT04369664,Change in platelet activity (LTA) before and after cholesterol reduction,,2020-08-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
14845,NCT02429024,A1c change from baseline in subjects using the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system compared to subjects using only the OneTouch Verio® Flex (without Bluetooth) for 24 weeks.,OneTouch Reveal Mobile APP interaction and usage via APP analytics over 24wks.,2015-05,COMPLETED,INTERVENTIONAL,['PHASE4'],Healthcare efficiency survey by the HCP
14846,NCT00005380,,,1993-09,COMPLETED,OBSERVATIONAL,['NA'],
14847,NCT01736930,Mornings With Urine Ketones Characterized as Moderate or Large - Algorithm 3,Percentage of Sensor Glucose Values 71 to 180 mg/dL - Algorithm 3,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
14848,NCT01076478,To determine the relationship of peripheral neuropathy with peripheral vascular disease using the WIQ and the ABI from baseline to W12.,To assess the safety of Cilostazol therapy.,2004-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
14849,NCT05791188,Serum chloride,,2023-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
14850,NCT05644730,Primary Efficacy Outcome,Percent Time in the Desired Control Range,2022-11-08,RECRUITING,INTERVENTIONAL,['NA'],Glucose readings from CGM's versus from blood
14851,NCT02099409,Time spent in normal glucose range ( mg/dl),time spent in high glucose range (>180mg/dl),2014-01,COMPLETED,INTERVENTIONAL,['NA'],
14852,NCT02347709,Measure the degree of loss of epidermal nerve fibers near a lower extremity diabetic wound using Intra-epidermal Nerve Fiber Density analysis.,,2014-12,WITHDRAWN,OBSERVATIONAL,['NA'],
14853,NCT01648296,The Primary Endpoint is to Determine if PET/CT Measurements of Myocardial FA Metabolism Performed With [18F]FluorbetaOx Correlated With Those Performed With [11C]Palmitate and Calculation of Human Dosimetry.,To Determine Human Dosimetry Based on the Human Biodistribution of [18F](+/-)NOS in Both Normal Healthy Volunteers and Dilated Non-ischemic Cardiomyopathy Patients.,2012-09-13,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
14854,NCT05309850,Incidence of type 2 diabetes,,2022-04-05,RECRUITING,INTERVENTIONAL,['NA'],
14855,NCT03370497,Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min).,Subjective ratings of appetite (au),2017-10-01,COMPLETED,INTERVENTIONAL,['NA'],
14856,NCT02869659,Chang in Epigengene score (and related individual transcriptional and methylation measures),change in homeostatic model assessment (HOMA) estimates of insulin resistance,2016-11-01,COMPLETED,INTERVENTIONAL,['NA'],
14857,NCT00501592,Insulin Resistance and Glucose Homeostasis,Hepatocellular Function,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
14858,NCT04279587,Change in Hemoglobin A1c,Change in Behavioral Pediatrics Feeding Assessment,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14859,NCT00278980,Change in sensory nerve conduction velocity from baseline to 6 mo of treatment,- Safety and tolerability of C-peptide,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
14860,NCT03479866,Hunger and appetite assessment,,2018-06-04,UNKNOWN,INTERVENTIONAL,['NA'],Carotid plaque
14861,NCT03864562,Gastric emptying rate,Recruitment rate,2019-03-01,COMPLETED,OBSERVATIONAL,['NA'],
14862,NCT04200313,HbA1c,Other Secondary Efficacy Endpoint: Mean Participant-reported Grams of Carbohydrate Taken Specifically to Prevent or Treat Hypoglycemic Events Per 24 Hours,2020-03-31,COMPLETED,INTERVENTIONAL,['NA'],Safety Outcome Measure: Worsening of HbA1c by >0.5%
14863,NCT00624364,HbA1c,Adverse events,2004-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
14864,NCT00123136,improve quality of life,"serial changes in EDX, QST, autonomic functions, biopsy",2005-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
14865,NCT04243174,"Feasibility of mobile phone text messaging intervention for people with T2DM: Number of Participants recruited, completed the study, dropped out",Self-report questionnaire (International Physical Activity Questionnaire - IPAQ),2020-01-23,COMPLETED,INTERVENTIONAL,['NA'],
14866,NCT03925519,"Analysis of blood sugar, glycated hemoglobin (HbA1c)",Analysis of Nitric Oxide,2013-01-25,COMPLETED,OBSERVATIONAL,['NA'],
14867,NCT00915200,Urinary Albumin excretion,tolerance and safety,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
14868,NCT05668442,Adverse events,Questionnaires,2020-11-21,COMPLETED,OBSERVATIONAL,['NA'],
14869,NCT04619303,Difference in best corrected visual acuity change between treatment arms,Adverse Events,2017-02-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
14870,NCT02623465,(Part B) PK: AUC of Insulin Lispro Glucose Following a Mixed Meal,(Part B) PD: AUC of Glucose Following a Meal,2018-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
14871,NCT00676819,Glucose infusion rate,"Cmax,ins: the maximal serum insulin (or serum insulin aspart) concentration",2002-01-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
14872,NCT03182972,Medication reconciliation: Percentage unreconciled medications,,2016-08-02,COMPLETED,INTERVENTIONAL,['NA'],
14873,NCT03131687,Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c) Bayesian Dose Response,Pharmacokinetics (PK): Model Predicted Concentration at Steady State (Css) of Tirzepatide,2017-05-24,COMPLETED,INTERVENTIONAL,['PHASE2'],
14874,NCT05628090,Proportion of patients persisting on insulin glargine (Lantus® or Toujeo®) at the end of 6th month,Proportion of patients on Toujeo® who switched to other therapy at the end of 6th month,2022-11-30,COMPLETED,OBSERVATIONAL,['NA'],
14875,NCT02996539,Association between HRV and renal function (eGFR and UACR),Clinical characteristics of patients,2013-02,COMPLETED,OBSERVATIONAL,['NA'],
14876,NCT00129259,Change in Mean C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT),Change in Average Total Insulin Dose Per Body Weight,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
14877,NCT01150955,Metabolic parameters,Pathways of substrate metabolism.,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
14878,NCT03816280,Central venous oxygen saturation,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],
14879,NCT05346679,BMI,,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],
14880,NCT02451436,Sleep Duration,hs-CRP,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
14881,NCT00734591,Rate of Primary Lung Cancer Mortality,Rate of Primary Lung Cancer Diagnosis,2008-08,COMPLETED,OBSERVATIONAL,['NA'],
14882,NCT04134143,Number of participants with adverse events through study completion,,2019-11-07,TERMINATED,INTERVENTIONAL,['PHASE1'],
14883,NCT03046927,Residual beta-cell function (RBCF),Duration of Partial Clinical Remission (PCR),2017-10-19,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
14884,NCT00085969,Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28,Change in postprandial blood glucose concentrations from Baseline to Day 28,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
14885,NCT01060241,The primary endpoint is the A1c level or the change in A1c level,"The secondary endpoints include severe hypoglycemia defined as requiring external aid, hospital admissions for any CVD related intervention, and adverse events such as unplanned hospitalizations for any cause that last more than 24 hours",2010-02,SUSPENDED,INTERVENTIONAL,['NA'],
14886,NCT00847327,Glycemic variability,Hemoglobin A1C,2008-04,COMPLETED,INTERVENTIONAL,['NA'],
14887,NCT02299050,Glucose Metabolism During Mixed Meal Tolerance Test,Arterial Stiffness (AS),2014-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
14888,NCT05344859,Change in Hemoglobin A1C level between screening and 6 months,,2023-05-15,RECRUITING,INTERVENTIONAL,['NA'],
14889,NCT06242548,Ketonemia variation among groups over time during mountains outings,weight measurements for each of the 4 mountains outings,2023-06-02,COMPLETED,INTERVENTIONAL,['NA'],
14890,NCT03061214,Change in HbA1c,Occurence of Cross Reacting Antibodies With in Vitro Neutralising Effect to Endogenous GLP-1 (Yes/no),2017-08-28,COMPLETED,INTERVENTIONAL,['PHASE3'],
14891,NCT03281083,Liver fat content,Abdominal fat,2014-03-28,TERMINATED,INTERVENTIONAL,['PHASE2'],
14892,NCT04102657,Difference in body-fat percentage before and after 12-14 days of designated diet,Time below range (Interstitial BG <70 mg/dL) between designated diet groups,2019-09-20,UNKNOWN,INTERVENTIONAL,['NA'],
14893,NCT01135927,Area under the NN1250 GIR (glucose infusion rate) curve,Area under the serum insulin detemir concentration-time curve,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
14894,NCT04074954,Amount of activity conducted by the patient after receiving surgery,,2023-03-23,WITHDRAWN,OBSERVATIONAL,['NA'],
14895,NCT02643771,Percentage of bleeding on probing,Clinical attachment level (mm),2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
14896,NCT01642108,HbA1c,Glucagon secretion,2012-07,UNKNOWN,INTERVENTIONAL,['NA'],
14897,NCT02462785,Change in Carbohydrate Counting Accuracy Measured Using a Standardized Meal & Snack Tray Test at Baseline and 3-months Post-Education,Change in Carbohydrate Counting Knowledge Tested Using the PedCarbQuiz (PCQ) at Baseline and 3-months Post-Education,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
14898,NCT00434954,Incidence of Hypoglycemia (Percentage of Participants With at Least One Hypoglycemic Episode),Patient Reported Outcomes: Quality of Life (SF-12),2007-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
14899,NCT03447080,Change in postprandial blood glucose over 180 minutes period,Change in postprandial plasma insulin over 180 minutes period,2017-06-02,COMPLETED,INTERVENTIONAL,['NA'],
14900,NCT04564391,change of fasting insulin sensitivity in mixed-meal test,change of urea concentration in serum(mmol/l),2020-09-21,RECRUITING,INTERVENTIONAL,['NA'],change in uric Acid concentration in Serum (µmol/l)
14901,NCT04000789,Conjunctival Goblet Cell Density,,2019-07,UNKNOWN,INTERVENTIONAL,['NA'],
14902,NCT03273881,Neonatal hypoglycemia,NICU admission,2017-10-31,RECRUITING,INTERVENTIONAL,['NA'],
14903,NCT02089438,Postprandial glucose,Postprandial glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),2014-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
14904,NCT04628481,Change from baseline in HbA1c,Estimated Glucose Disposal Rate (eGDR),2020-12-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
14905,NCT01707784,Markers of stress,,2012-10,COMPLETED,OBSERVATIONAL,['NA'],
14906,NCT04564846,Difference in Area Under the Curve (AUC(0-16)) of endogenous glucose production between placebo and ORMD-0801,Mean changes in ketones from baseline to Day 29 of the treatment period.,2020-11-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
14907,NCT03343730,Rate of Diabetic Retinopathy Detection,,2018-02-27,UNKNOWN,INTERVENTIONAL,['NA'],
14908,NCT00169624,Flow dependent and independent Brachial artery vasoreactivity assessed using Doppler technology at 3 month vs baseline,Myocardial perfusion improvement following improved vasoreactivity assessed using myocardial perfusion imaging at 3 month vs baseline,2005-10,TERMINATED,INTERVENTIONAL,['PHASE3'],
14909,NCT00312104,HbA1c,Hypoglycaemia,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
14910,NCT00501072,Clinical effectiveness: percentage of time spent in euglycaemia,"Incidence of hypoglycaemia; Number of SMBG performed, Number of adjustments of insulin therapy, Patient satisfaction, agreement of paired SMBG and RT-CGMS measurements.",2007-11,COMPLETED,INTERVENTIONAL,['NA'],
14911,NCT02742597,Evaluation of Intervention Effectiveness - Change in Patient-Centredness,Evaluation of Intervention Effectiveness - Change in Demographics,2016-01-12,COMPLETED,INTERVENTIONAL,['NA'],
14912,NCT04160988,Specificity,Percentage of Participant Images With Insufficient Quality as Judged by VeriSee DR,2019-12-16,COMPLETED,OBSERVATIONAL,['NA'],
14913,NCT03135535,Change in Skin Perfusion From Baseline to 4 Weeks,Change in Stride Velocity From Baseline to 4-week,2017-05-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
14914,NCT01054118,GLP-1 levels after a standard meal,Assess incremental glucose changes after a meal tolerance test (MTT),2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
14915,NCT01112709,Muscular Strength,Body Composition,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
14916,NCT02476760,Hospitalization for acute pancreatitis,,2014-03,COMPLETED,OBSERVATIONAL,['NA'],
14917,NCT05237128,Change in HbA1c,Change in HbA1c,2022-03-22,RECRUITING,INTERVENTIONAL,['NA'],
14918,NCT03835312,Concentration of serum C-peptide,Occurrence of graft versus host disease,2019-02-20,RECRUITING,INTERVENTIONAL,['NA'],
14919,NCT03609294,AUClast,,2018-07-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
14920,NCT01841697,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event,Percentage of Participants Achieving an A1C Goal <6.5% After 24 Weeks of Treatment,2013-06-13,COMPLETED,INTERVENTIONAL,['PHASE3'],
14921,NCT06002048,Montreal Cognitive Assessment (MoCA),,2023-07-19,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
14922,NCT01680978,Cardiac energetics: Change in PCr/ATP ratio using phosphorus magnetic resonance spectroscopy (MRS),Change in cardiac/hepatic triglyceride content assessed my MRS,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
14923,NCT06147583,Sensitivity,False positive per day,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14924,NCT02930044,Duration of intravenous insulin infusion,Incidence of low serum glucose (hypoglycemia) within 24 hours,2016-10,COMPLETED,INTERVENTIONAL,['NA'],
14925,NCT03709108,Safety and feasibility of the SI-informed bolus calculator: Low Blood Glucose Index,,2018-11-19,COMPLETED,INTERVENTIONAL,['NA'],
14926,NCT00857558,changes in HbA1C from baseline,adverse event,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
14927,NCT00599885,Comparison of telmisartan and valsartan on neointima volume with IVUS at 8 months after zotarolimus-eluting stent implantation.,"Comparison of telmisartan and valsartan on the levels of RBP-4 and inflammatory markers (hsCRP, IL-6, TNF-α, adiponectin).",2007-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
14928,NCT00781534,,,2003-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
14929,NCT01578382,Martorell HYTILU and calciphylaxis show both decreased tissue protection mechanisms against tissue calcification,Martorell hypertensive ischemic leg ulcer and calciphylaxis are both characterized by non-infectious inflammation,2011-09,COMPLETED,OBSERVATIONAL,['NA'],
14930,NCT05773677,incidence of maternal obstetric complications:,differences in early or late enrollment of patients,2022-10-10,RECRUITING,INTERVENTIONAL,['NA'],
14931,NCT00134264,The time to first occurrence of a major cardiovascular disease event,Various composites of major cardiovascular disease events and other lipid parameters,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3'],
14932,NCT01468675,Number of Subjects Who Discussed Disease Risk With Primary Care Provider,,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
14933,NCT01517490,"Changes in visual acuity, diabetic retinopathy grading and OCT",,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],
14934,NCT02635646,Individual Insulin Resistance and Insulin Secretion,2h OGTT Glucose,2015-10,COMPLETED,INTERVENTIONAL,['NA'],
14935,NCT04745780,Glycated hemoglobin,Hypoglycemic events,2021-02-10,COMPLETED,INTERVENTIONAL,['NA'],
14936,NCT05846802,Measure of symptom severity of gastroparesis and functional dyspepsia using the change in total score from the Patient Assessment of Upper Gastrointestinal Disorders Symptoms (PAGI SYM) from baseline to 48 weeks.,"Changes in gastric emptying, as measured by gastric emptying scintigraphy (GES) at baseline and 48 weeks",2024-05-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Presence or absence of Carnett's sign for abdominal wall pain at baseline.
14937,NCT04057677,Mitochondrial Respiration,Physical function,2019-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
14938,NCT05543850,Time in range,Satisfaction,2022-10-28,COMPLETED,INTERVENTIONAL,['NA'],Glucagon dose
14939,NCT06170905,Postprandial glucose excursion,Glicentin course,2024-02-01,RECRUITING,INTERVENTIONAL,['NA'],
14940,NCT04079881,AUC Postprandial Glucagon,AUC Postprandial Glucose,2020-02-13,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
14941,NCT01469104,Change in plasma glucose concentration,Change in serum insulin concentrations,2009-08,COMPLETED,INTERVENTIONAL,['NA'],
14942,NCT01425359,Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment,Patient's Global Impression of Change (PGIC) Scale Score,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
14943,NCT00072891,,,na,COMPLETED,INTERVENTIONAL,['NA'],
14944,NCT00819091,Change From Baseline in HbA1c (Glycosylated Hemoglobin) at Week 18,Change From Baseline in Fasting Plasma Glucose at Week 12,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
14945,NCT06237322,Blood Glucose Measurement taken with alternate PPG software device,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
14946,NCT00997178,Change in Glycosylated Hemoglobin (HbA1c),Need for Diabetes Rescue Therapy,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
14947,NCT01912170,Fasting insulin,"birth weight, length of children",2013-08,UNKNOWN,INTERVENTIONAL,['NA'],"blood lipids, inflammatory markers"
14948,NCT00013975,,,2001-03,COMPLETED,OBSERVATIONAL,['NA'],
14949,NCT03297762,CGM use,Hgb A1c,2018-05-07,TERMINATED,INTERVENTIONAL,['NA'],
14950,NCT01542242,Hemoglobin A1C,Total Body Adipose Tissue Distribution (whole body Computed Tomography),2012-02,TERMINATED,INTERVENTIONAL,['PHASE4'],
14951,NCT00105755,Reduce the risk for lower extremity ulceration and amputation in veterans at high risk for these complications.; Incidence of diabetic foot ulcers over 18 months. Incidence of foot infections over 18 months. Incidence of Charcot fractures.,Improve quality of life. Health Related Quality of Life (change over 18 months),2003-01,COMPLETED,INTERVENTIONAL,['NA'],
14952,NCT02440061,β-cell function (DI-meal),,2018-05,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
14953,NCT03629704,28 day prognosis,Incidence of hypoglycemia,2018-08-03,UNKNOWN,OBSERVATIONAL,['NA'],
14954,NCT01720303,Change in HbA1c,Change in body weight,2002-09-19,COMPLETED,INTERVENTIONAL,['PHASE4'],
14955,NCT05449795,Number of results from the Contour Next and Contour Plus Elite BGMSs reference values within ±20% of reference values,,2022-11-29,COMPLETED,OBSERVATIONAL,['NA'],
14956,NCT00987285,"Improvement in health behaviors (e.g., dietary patterns, physical activity, medication taking) and biologic outcomes (HbA1c, lipid ratio, blood pressure, and smoking status).","Diabetes-specific quality of life (Diabetes Distress Scale), patient activation (PAM scale), and perceived social-environmental support (the Chronic Illness Resources Survey) at 4- and 12-month follow-ups.",2007-01,COMPLETED,INTERVENTIONAL,['NA'],
14957,NCT02159638,Difference between the two CGM systems compared to capillary glucose value,Evaluation of two CGM systems from questionnaire,2013-05,COMPLETED,INTERVENTIONAL,['NA'],
14958,NCT00915486,Percentage reduction in ulcer surface area,"Changes in vital signs, body weight, physical examination and laboratory parameters",2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
14959,NCT01599442,duration of survival without major amputation,total mortality,2010-06,TERMINATED,OBSERVATIONAL,['NA'],
14960,NCT02561130,Number of Participants Achieving Drug-free Diabetes Remission in the Experimental Group Compared to the Control Group,Number of Participants With Severe Hypoglycemic Episodes,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
14961,NCT03225339,Weight loss,Patient reported outcomes,2017-07-16,COMPLETED,INTERVENTIONAL,['NA'],Waist Circumference
14962,NCT01548222,Percentage of time CGM glucose is <70mg/dl,Weight gain,2012-02,COMPLETED,OBSERVATIONAL,['NA'],
14963,NCT04554199,Cognitive function assessment in controlled type 2 diabetic patients wearing RPD.,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],
14964,NCT01495052,changes from baseline in insulin resistance Hematology index detection Hematology index detection Hematology index detection Hematology index detection Hematology index detection,changes from baseline in WHR,2011-08,COMPLETED,INTERVENTIONAL,['NA'],
14965,NCT04787952,The potential associations between BAT activity and transcriptome profile,The potential associations between BAT activity and fT4 concentrations,2016-10-01,COMPLETED,OBSERVATIONAL,['NA'],
14966,NCT04709120,death,Rate of cases of health status worsening occured during hospitalisation,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],
14967,NCT05566717,Primary Endpoint,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],
14968,NCT01341587,Change in HbA1c,,2011-04,TERMINATED,INTERVENTIONAL,['NA'],
14969,NCT06135987,Number of patients with complete healed chronic wound (venous leg ulcer and Diabetic foot ulcer) at 12 weeks,Defectuosity of the device,2022-06-24,RECRUITING,OBSERVATIONAL,['NA'],
14970,NCT04521049,to classify renal responders to saxagliptin using tubular markers,,2019-03-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
14971,NCT01271023,Overall frequency of hyperglycemia,Percent of subjects with a nadir blood glucose <=60 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
14972,NCT01786408,Non-Inferiority of Analyte Levels,,2013-03,WITHDRAWN,INTERVENTIONAL,['NA'],
14973,NCT06079463,Beck Anxiety Scale,World Health Organization Quality of Life Scale,2023-10-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
14974,NCT04999722,Change from Baseline Glycated hemoglobin at 12 months,Change from Baseline Diabetic nephropathy at 12 months,2021-08-25,UNKNOWN,INTERVENTIONAL,['NA'],
14975,NCT05737576,Area under the concentration-time curve (AUC0-0.5h),Incidence and severity of adverse events (AEs),2023-03-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
14976,NCT02696252,"proportion of blood glucose values, compared between CGM and a lab glucose analyzer that are matched relative to a diabetes accuracy measurement of %20/20 mg/dL",,2016-01,COMPLETED,OBSERVATIONAL,['NA'],
14977,NCT04201600,Aggregate Language Score,Instrumental Activities of Daily Living (IADL) total score,2022-03-01,RECRUITING,OBSERVATIONAL,['NA'],
14978,NCT00838825,resource utilization,metabolic outcome,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
14979,NCT00970099,insulin sensitivity and insulin signaling,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
14980,NCT01047982,difference in HOMA values,"incidence of pregnancy complications: hypertension, preterm delivery. macrosomia, shoulder dystocia, etc.",2010-03,COMPLETED,INTERVENTIONAL,['NA'],
14981,NCT03234322,Difference of participant's physical activity at twelve months after the routine health check between the groups.,Acceptance of participants according to the application of a diabetes risk score for routine use in clinical practice.,2017-09-13,COMPLETED,INTERVENTIONAL,['NA'],Change on participant's individual diabetes risk.
14982,NCT01745900,Continuing validation of near infrared spectroscopy-based glucose meter algorithm,,2012-12,UNKNOWN,OBSERVATIONAL,['NA'],
14983,NCT05512871,Mobile health application feasibility,Change in intake of meals,2022-09-19,COMPLETED,INTERVENTIONAL,['NA'],
14984,NCT03958838,Change from Baseline HbA1c and at 12 months,Change in Peer Support Engagement and Health Care Utilization and 12 months,2019-05-25,COMPLETED,INTERVENTIONAL,['NA'],
14985,NCT02970344,Change in psychological distress,Assessing change in Physical Activity,2017-04-20,COMPLETED,INTERVENTIONAL,['NA'],
14986,NCT01235260,The number and rate of deaths from cancer in patients who have used becaplermin and patients who have not used not used becaplermin.,The number of becaplermin doses associated with risk of incident cancer and/or cancer death.,2010-03,COMPLETED,OBSERVATIONAL,['NA'],
14987,NCT00939939,incremental area under the triglyceride curve (iAUC-TG),hs-CRP,2010-03,TERMINATED,INTERVENTIONAL,['PHASE4'],
14988,NCT00608439,Total Symptom Score,Quantitative Sensory Test,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
14989,NCT05921019,the Brief Pain Inventory-Short Form,Nerve conduction velocity (NCV),2022-08-31,RECRUITING,INTERVENTIONAL,['NA'],
14990,NCT01501032,Percent of subjects with a peak blood glucose >400 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount,Percent of subjects with a nadir blood glucose <=60 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount,2013-10,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
14991,NCT02725593,Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24,Percentage of Participants With Baseline Glycated Haemoglobin (HbA1c) >= 7% Who Achieved HbA1c Level < 7% at Week 24,2016-06-22,COMPLETED,INTERVENTIONAL,['PHASE3'],
14992,NCT02274740,Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min),Change in baseline coronary flow reserve to assess the effect of lixisenatide on microvascular dysfunction,2015-04,TERMINATED,INTERVENTIONAL,['PHASE2'],
14993,NCT00795860,Insulin sensitivity,whole body and skeletal muscle oxidative capacity,2003-06,COMPLETED,INTERVENTIONAL,['NA'],
14994,NCT01358435,Mean AUC0-24h and Cmax,"PK endpts: AUC0-4h, AUC0-6h, AUC0-12h, AUC6-12h, AUC6-24h,tmax,and elimination rate constant. PD endpoints: AUCGIR0-4h, AUCGIR0-6h, AUCGIR0-12h,AUCGIR0-24h, AUCGIR6-12h, AUCGIR6-24h, GIRmax and tGIRmax Safety : AEs,haematology,biochem,phy exam",2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
14995,NCT05545800,Amplitude of glycemic excursions,Percentage of adverse events,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
14996,NCT04502212,Change From Baseline in Rate of Glucose Disappearance (Rd),Incidence of Adverse Device Effects (ADEs) With a Severity Score of 5: Treatment Emergent Adverse Events (TEAEs) by System Organ Class and Preferred Term,2020-07-30,COMPLETED,INTERVENTIONAL,['NA'],Change From Baseline in Inflammatory Biomarkers: Interleukin-6
14997,NCT03407989,estimated GFR decline ml/min/y,"Diabetes-specific health-related quality of life baseline measures, CKD stage, and eGFR decline.",2014-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
14998,NCT04942756,Evaluate CGM by using FSL2 in preventing severe hyperglycemia peaks,,2021-06-30,UNKNOWN,INTERVENTIONAL,['NA'],
14999,NCT01969318,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 12,"Change From Baseline in Body Weight at Week 4,8,12",2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
15000,NCT01293669,Changes in fasting plasma glucose (FPG),Change in AUC insulin from Day 1 (Baseline) at Week 4,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
15001,NCT05571878,"The change in brain imaging outcomes, measuring brain insulin resistance, following intranasal insulin or placebo challenges, compared between the participants with depression and healthy controls.",Correlation between brain insulin resistance with cognitive functioning at baseline and 6-month study follow up,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],"Correlation between brain insulin resistance, and hepatic and visceral adiposity"
15002,NCT02750774,Gestational Diabetes Mellitus (GDM) occurrence,Neonatal Intensive Care Unit (NICU) admission,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],
15003,NCT03244241,Difference in mean daily plasma glucose between the two groups,Number of post-discharge infections or re-admissions 1 month after discharge,2017-04-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
15004,NCT06305195,deep breath test interpretation,Framingham risk score (FRS),2023-08-23,RECRUITING,OBSERVATIONAL,['NA'],
15005,NCT00817778,Clinically Relevant Change of Laboratory Variables,"S-C-Peptide (AUC0-24)/24, Change From Baseline to End of Treatment",2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
15006,NCT02669524,Difference in postprandial glucose excursions,Fibroblast growth factor-21,2015-10,COMPLETED,INTERVENTIONAL,['NA'],
15007,NCT00011206,,,2001-01,COMPLETED,OBSERVATIONAL,['NA'],
15008,NCT01102673,"PK Endpoints: AUC(0-inf), AUC(0-last), AUC(0-24), Cmax, Tmax, CL/F, Vz/F and half-life (t1/2), as the data permit.",none-see my comment,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
15009,NCT05667051,Percentage of bleeding on probing sites (BOP%),,2022-04-05,COMPLETED,OBSERVATIONAL,['NA'],
15010,NCT01594801,Safety,,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
15011,NCT02768935,level of expression markers,,2017-10-30,COMPLETED,INTERVENTIONAL,['NA'],
15012,NCT05039970,Number of Sessions Attended,Participants' game rating/Net Promoter Score or questionnaire.,2021-09-07,COMPLETED,INTERVENTIONAL,['NA'],Fitness tracker integration with the game.
15013,NCT05424965,Activity of Wnt signaling pathway in placental tissue,,2018-03-23,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
15014,NCT01493258,Change in CERSG Knowledge Score from baseline to 24-hr and to 6-month follow up,CERSG Acceptance,2010-08,WITHDRAWN,INTERVENTIONAL,['NA'],
15015,NCT04868851,Drop out,Parent survey on intervention acceptability (Here for Health),2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],
15016,NCT02744300,Weight loss,Number of participants with either: a HbA1c value greater than or equal to 5.7; or a 2 hour value on a 75 g oral glucose tolerance test of greater than or equal to 140,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
15017,NCT02682342,change in mitochondrial network complexity of endothelial cells as measured by mitochondrial network fragment ratio,,2016-03-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
15018,NCT00779363,Device Functionality Evaluation,Percentage of body weight loss,2004-06,COMPLETED,INTERVENTIONAL,['NA'],
15019,NCT01771042,Change in whole-body norepinephrine kinetics,Change in muscle sympathetic nerve activity,2013-04,UNKNOWN,INTERVENTIONAL,['NA'],Change in insulin sensitivity
15020,NCT04427189,Change of HbA1c level,DKA rate,2008-04,RECRUITING,OBSERVATIONAL,['NA'],
15021,NCT01468519,Change in total International Index of Erectile Function (IIEF) score from baseline to six months,Global assessment question on erectile function,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
15022,NCT06034548,Clinical outcomes - BP,Behavioral outcome - exercise; questions,2018-08-27,COMPLETED,INTERVENTIONAL,['NA'],
15023,NCT01257334,the change from baseline in HbA1c,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],
15024,NCT04098562,Changes of Inflammation Marker at 3 Week,,2019-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
15025,NCT00970723,"The primary outcome will be the percentage of patients having a sustained 50% or more-decrease in retinal thickening at 1 year, assessed with OCT in the study eye.",Comparison of blood pressure in each group at one year,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
15026,NCT04864977,Percentage of Participants with Type 2 Diabetes Who Achieve Nadir Glucose in Range 70-125 milligram/deciliter (mg/dL),Percentage of Participants who successfully use Continuous Glucose Monitoring (CGM),2021-08-16,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
15027,NCT04698122,Biological samples collection for establishment of the first National Microbiome Biobank,,2021-05-27,COMPLETED,OBSERVATIONAL,['NA'],
15028,NCT02462369,microalbuminuria improvement in T2DM treated with saxagliptin,incidence of hypoglycaemia of saxagliptin or glimepiride,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],
15029,NCT05145439,Transcutaneous Oxygen Pressure (TcPO2),Ankle Brachial Index (ABI),2023-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
15030,NCT02524938,Change in estimated glomerular filtration rate (eGFR),Change in 8hydroxy 2'deoxyguanoside (8OhdG),2016-06-01,TERMINATED,INTERVENTIONAL,['NA'],
15031,NCT02026024,mean amplitude of glycaemic excursions (MAGE),,2013-10,COMPLETED,OBSERVATIONAL,['NA'],
15032,NCT02919397,Weight (kg),Sleep duration (average hours per night),2016-10-01,COMPLETED,INTERVENTIONAL,['NA'],
15033,NCT02596204,Change in Hemoglobin A1c,Change in Hemoglobin A1c,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
15034,NCT03406000,Mean change in HbA1c,Number of hypoglycemic events per patient-year,2018-01-22,COMPLETED,INTERVENTIONAL,['PHASE4'],
15035,NCT01155050,Change in Waist Circumference,Change in Fasting Plasma Glucose,2010-01,COMPLETED,INTERVENTIONAL,['NA'],
15036,NCT01607190,CSME needing treatment either photocoagulation or ITV.,"Microaneurysm(MA) activity (number of MA, MA formation and MA disappearance rates and MA turnover)",2012-11,COMPLETED,OBSERVATIONAL,['NA'],
15037,NCT03760965,Change in hemoglobin A1c (HbA1c),Adverse events,2018-11-27,TERMINATED,INTERVENTIONAL,['PHASE3'],
15038,NCT00552994,In stent neointimal hyperplasia,Peri-stent remodeling - Edge response to Cypher Select plus and Xience V stent - Malapposition - Angiographic late lumen loss,2007-08,COMPLETED,INTERVENTIONAL,['NA'],
15039,NCT02565706,Quantity of Fruit and Vegetable Intake,Response to Survey Items Assessing Knowledge of Area Farmers' Markets,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
15040,NCT02415556,Verbal Memory Composite z Score,Weight (kg).,2015-10-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Cerebral Blood Flow on Magnetic Resonance Imaging (MRI).
15041,NCT03444142,Blood pressure,Waist Circumference,2017-11-17,UNKNOWN,INTERVENTIONAL,['PHASE4'],
15042,NCT03102424,Change in HbA1c values to evaluate of the effect of DW1330,Change from baseline in OAD drugs description,2017-04-10,COMPLETED,INTERVENTIONAL,['NA'],Change from baseline of inflammatory biomarkers
15043,NCT06074731,Morphological changes using Swept Source Optical Coherence Tomography,,2017-06-01,RECRUITING,OBSERVATIONAL,['NA'],
15044,NCT01571622,Glucose response,"Insulin GLP-1, GIP and DPP4",2012-04,COMPLETED,INTERVENTIONAL,['NA'],
15045,NCT01065766,"Percentage of Participants With an Overall Efficacy Evaluation by the Investigator of Improved, Stable, or Worse at Week 24",,2009-03,COMPLETED,OBSERVATIONAL,['NA'],
15046,NCT04914819,Number of Participants Losing 5 Percent or More of Weight From Baseline to 16-week Follow-up,Intervention Arm: Number of Weeks With Daily Data Reporting for at Least 5 of 7 Days,2021-06-18,COMPLETED,INTERVENTIONAL,['NA'],
15047,NCT00487240,Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint,Insulin Dose (Total and By Component [Basal and Bolus]),2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
15048,NCT00118937,HbA1c - difference between final visit and baseline.,Extra blood- and urine-samples will be stored at -80 degrees Celsius for potential extra analyses after closure of the study. DNA will be stored for later pharmaco-genetic analysis.,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
15049,NCT05231642,Glucose AUC,PAI-1,2021-11-30,COMPLETED,INTERVENTIONAL,['NA'],
15050,NCT01739283,plasma glucagon area under curve values,"plasma gut hormones and nutrients (absolute, incremental and area under curve values)",2012-07,COMPLETED,INTERVENTIONAL,['NA'],glucose (g/kg body weight) needed to be infuse to keep clamp
15051,NCT00987662,Reduction of 24h BP and arterial stiffness in obese hypertensives,Drug specific effect on reduction in central fat deposition and the leptin to adiponectin ratio,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
15052,NCT03338517,Ulcer surface area,,2016-08-04,COMPLETED,INTERVENTIONAL,['NA'],
15053,NCT02413385,Average steps per day,Body mass index,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
15054,NCT05333185,Blood Glucose Levels,Regulating the Nutrition of Children according to their blood sugar level,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],
15055,NCT05601583,Total Scan Time,,2023-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],
15056,NCT03273140,Better Sense of Coherence,Better Quality of life,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],
15057,NCT02127762,"Change from baseline in pain-related disability, as measured by the Brief Pain Inventory. Pain interference scale at 3-month post-intervention.","Change from baseline in glycemic control, as measured by blood levels of Hemoglobin A1c.",2012-09,COMPLETED,INTERVENTIONAL,['NA'],
15058,NCT00970593,Change From Baseline in Predose Fasting Glucose Levels at Day 15,,2009-09-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Plasma Concentration Versus Time Summary of Multiple Dose of OAP-189
15059,NCT01024218,Device preference,Comparison of the frequency of adverse events (needle stick injuries),2004-12-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
15060,NCT00121667,Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24,Baseline and Change From Baseline at Week 24 in Postprandial Glucose (PPG) Area Under the Curve (AUC),2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Confirmed Hypoglycemia During the ST + LT Treatment Period
15061,NCT02723968,Measurement of the sensitivity and the specificity of HOMA-%IR (homeostasis model assessment index of insulin resistance) for the diagnosis of diabetes mellitus in comparison to a continuous glucose monitoring system.,Correlation between IGTT and HbA1C dosage (glycated haemoglobin A1C).,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
15062,NCT00143104,"To assess in patients with type 1 diabetes mellitus the effects, if any, on lung lining, fluid cell count and differential within subjects after 12 weeks of inhaled insulin therapy compared to 12 weeks of subcutaneous short-acting therapy.","(1) Albumin and fibrinogen concentrations, and airway appearance in the above subjects. (2) routine safety, tolerance, and efficacy in the above subjects.",2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
15063,NCT02861261,HbA1c,"Inflammation markers (hs-CRP, TNF-alfa, IL-6, and IL-8 etc. in ng/ml)",2016-08-18,UNKNOWN,INTERVENTIONAL,['PHASE3'],
15064,NCT03904485,Assessment of myocardial injury,,2019-04-01,UNKNOWN,OBSERVATIONAL,['NA'],
15065,NCT06124586,effect of an immediate (within first 48h) PTA intervention on microbiome composition,Effect of the immediate PTA intervention on related complications,2024-02-01,RECRUITING,INTERVENTIONAL,['NA'],
15066,NCT04123093,Wound Surface Area,Adverse Events - Wound Care Subjects,2019-08-09,TERMINATED,INTERVENTIONAL,['NA'],
15067,NCT00537264,Health-related quality of life outcomes,,2007-11,COMPLETED,INTERVENTIONAL,['NA'],
15068,NCT05529589,Change of visual acuity,B-mode ultrasound imaging,2023-02-10,RECRUITING,OBSERVATIONAL,['NA'],
15069,NCT00793390,breast cancer,,2008-11-17,COMPLETED,OBSERVATIONAL,['NA'],
15070,NCT05413330,Change in diabetic retinopathy grade as a measurement of efficacy,No. of subjects with Adverse Events as a measurement of safety,2020-09-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
15071,NCT05596747,Incidence and Severity of Hypoglycemia,PD: Change from Baseline in 7-Point Glucose,2022-11-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
15072,NCT00985114,Percent (%) of Subjects Who Achieve a ≥ 0.5% Reduction in HbA1C at 24 Weeks or Last Visit From Baseline.,,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
15073,NCT02706821,Fasting and postprandial plasma glucose,Monocyte chemoattractant protein-1 (MCP-1),2014-02,COMPLETED,INTERVENTIONAL,['NA'],
15074,NCT06256419,Genotype identification in patients with T2DM,Incidence and severity of possible adverse reaction within 6 month after GLP-1 RA treatment,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],
15075,NCT02039245,Plasma concentration of metformin following the dose of 2 CANA/MET XR FDC tablets,Percentage of participants with adverse events as a measure of safety and tolerability,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
15076,NCT00357955,"Percentage of Participans With A1c<7%, LDL Cholesterol <100mg/dL, Systolic Blood Pressure <130mm Hg and Diastolic Blood Pressure <80 mm Hg",,2004-08,COMPLETED,INTERVENTIONAL,['NA'],
15077,NCT06088615,Accuracy of non-invasive glucose measurement in comparison to invasive glucose measurement,,2023-11-08,RECRUITING,OBSERVATIONAL,['NA'],
15078,NCT06077708,Periodontal Clinical Parameters,Biochemical Data,2022-08-23,COMPLETED,INTERVENTIONAL,['NA'],
15079,NCT02117765,Primary Safety Endpoints (composite outcome measure),Exploratory (composite outcome measure),2015-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
15080,NCT03198832,Probing depth change,Clinical Attachment Level,2016-05-02,COMPLETED,INTERVENTIONAL,['NA'],
15081,NCT02585505,Increase in glucagon stimulated C peptide level,,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
15082,NCT00821899,"Evaluate glycosylated hemoglobin 1,3,6, and 12 months after autologous bone marrow blood administration.","Evaluate GADab titers and treatment tolerance 1,3,6, and 12 months after autologous bone marrow blood administration.",2009-01,COMPLETED,INTERVENTIONAL,['NA'],
15083,NCT05135130,"Frequency of wound infection, gangrene, and amputation",,2021-10-04,UNKNOWN,OBSERVATIONAL,['NA'],
15084,NCT02242149,Evidence of improvement in glycemic control and improvement in liver steatosis,Changes of adipocytokines and cytokeratin-18,2014-10-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
15085,NCT01768546,Change from Baseline Weight Measure at Week 16,Change from Baseline Weight Measure at Month 12,2012-02,COMPLETED,INTERVENTIONAL,['NA'],
15086,NCT03355040,number of Neonatal death,Number of Anal sphincter tear for the patient,2016-04-01,COMPLETED,OBSERVATIONAL,['NA'],
15087,NCT02043405,Change in insulin sensitivity,Change in membrane localized diacylglycerol species,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
15088,NCT01206101,Proportion Of Insulin-independent Subjects After Receiving Only One (Single-Donor) Islet Cell Transplant,Glucose Level Variability And Hypoglycaemia Duration Derived From The Continuous Glucose Monitoring System (CGMS),2012-03-21,TERMINATED,INTERVENTIONAL,['PHASE2'],
15089,NCT01241695,postprandial blood glucose (iAUC) (0-240 min),daily compliance,2010-11,COMPLETED,INTERVENTIONAL,['NA'],
15090,NCT01548729,Metabolic efficiency at 1 year,Adverse events,2012-02-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
15091,NCT04958980,Concentration of participants at increased risk for diabetes complications related to increased waist circumference,,2021-08,UNKNOWN,INTERVENTIONAL,['NA'],
15092,NCT03048747,Percentage of Subjects With Normalized Serum Sodium Concentration on the Day After Final IMP Administration,Change in Serum Sodium Concentration,2017-03-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
15093,NCT04466904,To assess the number and incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of IBI362 compared with placebo,Number of Participants With Anti-IBI362 Antibodies,2020-09-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
15094,NCT00725036,Long term pulmonary safety profiles,Treatment satisfaction,2002-09-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
15095,NCT05749679,Change in annual glomerular filtration rate (GFR) slope,change of Albuminuria,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
15096,NCT05271864,Oxygen Saturation,Heart rate,2022-11-01,COMPLETED,OBSERVATIONAL,['NA'],
15097,NCT04286399,Combined endpoint based on the first occurrence of cardiovascular death or major adverse cardiovascular event,,2019-07-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
15098,NCT00287066,18F-labeled glucose uptake in muscle,Glucose turnover overnight Insulin pharmacokinetics,2006-02,TERMINATED,INTERVENTIONAL,['PHASE3'],
15099,NCT05433415,Change from Block Kids 2004 Food Frequency Questionnaire (BKFFQ) at 12 and 24 weeks,Change fron Quality of Mother Interaction at 12 and 24 weeks,2023-03-06,RECRUITING,INTERVENTIONAL,['NA'],Change from Weight Efficacy Lifestyle Questionnaire at 12 and 24 weeks
15100,NCT03770767,Birth weight standard deviation score,"Neonatal morbidity (neonatal hypoglycaemia, jaundice, respiratory distress and duration of stay in neonatal intensive care unit) and infant morbidity evaluated as hospitalization during the first 3 months of life (after discharge in the neonatal period)",2019-11-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
15101,NCT02006459,plasma Glucagon,"Satiety, hunger, appetite",2013-09,COMPLETED,OBSERVATIONAL,['NA'],
15102,NCT03248271,Nadir of diastolic blood pressure during the Tilt Table Test,Presence or absence of a positive Tilt Table Test (vasovagal syncope),2017-10-01,WITHDRAWN,OBSERVATIONAL,['NA'],
15103,NCT02882945,Test of allelic frequencies,Evaluation of serum CRP(C-reactive protein) levels,2015-05,COMPLETED,OBSERVATIONAL,['NA'],
15104,NCT00184613,Variation in morning FPG,Variation of pre-dinner plasma glucose collected in hospital on the last 3 days,2005-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
15105,NCT03819634,Time to Infusion Set Failure,,2019-01-25,COMPLETED,INTERVENTIONAL,['NA'],
15106,NCT04905628,Dexcom Continuous Glucose Monitoring (CGM) System Performance,System Related Adverse Device Effects,2021-07-08,UNKNOWN,OBSERVATIONAL,['NA'],
15107,NCT02770885,Fluid intake in ml,Thirst perception,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
15108,NCT01724515,Mitochondrial Respiration,Phosphorylation of proteins,2012-09,COMPLETED,INTERVENTIONAL,['NA'],
15109,NCT04801485,the incidence of gestational diabetes,the perinatal outcomes-3,2021-01-01,COMPLETED,INTERVENTIONAL,['NA'],
15110,NCT03330756,glycaemic control,Cardiac / ventricular hypertrophy,2017-10-23,UNKNOWN,INTERVENTIONAL,['NA'],
15111,NCT01787903,Time spent in the euglycemic range,Changes in hypoglycemia awareness score,2013-02,COMPLETED,INTERVENTIONAL,['NA'],RT-CGM satisfaction
15112,NCT00609895,Compare % of subjects with glucose > or = to 56 mg/dL at any point of 8-point glucose profiles during 3 consecutive days,"To evaluate overall safety and tolerability based on adverse event reporting, laboratory tests, and clinical examinations",2004-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
15113,NCT00966407,"Genotype for specific genes related to obesity, metabolic syndrome, and/or type 2 diabetes; Fasting serum biomarkers; Hand grip strength, muscle strength of upper and lower extremities; Fitness measurements; Body composition measures",Perception of physical fitness; Relationship between physiological measures and genotype variation,2007-02,COMPLETED,OBSERVATIONAL,['NA'],
15114,NCT01774981,Part A and Part B: Number of Participants With One or More Treatment Emergent Adverse Events (AEs) or Any Serious AEs,Part B: Change From Baseline in Albuminuria Over Time,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
15115,NCT02538848,"Incidence, severity and causality of adverse events",,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
15116,NCT02667964,FGF-21 change after physical activity,,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],
15117,NCT01463904,,,2007-04,UNKNOWN,OBSERVATIONAL,['NA'],
15118,NCT02612714,serum testosterone,sexual function evaluation,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
15119,NCT01530789,Percentage of patient using the system,satisfaction level of the telemedecin nurse,2011-05,TERMINATED,OBSERVATIONAL,['NA'],
15120,NCT03112538,between group difference of HbA1c changes from baseline to 6 months,Treatment satisfaction using Diabetes Treatment Satisfaction Questionnaire DTSQs,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
15121,NCT02687776,myocardial injury in non-cardiac surgery (MINS),composite events composed of all-cause mortality and/or major adverse cardiac and cerebrovascular events (MACCE),2016-02,UNKNOWN,OBSERVATIONAL,['NA'],
15122,NCT02230501,HbA1c,antidiabetic medication,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
15123,NCT01530165,Incidence of Type 2 Diabetes,The impact of city planning on prevalence of obesity and type 2 diabetes,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],
15124,NCT01223547,Change in HbA1c,Weight,2010-10,COMPLETED,INTERVENTIONAL,['NA'],
15125,NCT02163278,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Pharmacodynamic parameters,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
15126,NCT01623882,Percentage of wounds closed,,2012-06,WITHDRAWN,OBSERVATIONAL,['NA'],
15127,NCT01426737,Mean amplitude of glycemic excursion as described by Service et al. (1970) calculated from the glucose excursions of the CGMS profiles using MiniMedSolution Software (MedtronicMiniMed).,,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],
15128,NCT01354288,HbA1c 12 months after therapeutic education,Evolution of the parental and child quality of life 12 and 24 months after therapeutic education (evaluated by questionnaire),2011-12-07,COMPLETED,INTERVENTIONAL,['NA'],
15129,NCT00723853,"Biochemical markers (glucose tolerance, lipid panel, insulin, hemoglobin A-1-C)","Cost Assessment (costs incurred to attend meetings, eat healthier, exercise more)",2008-04,COMPLETED,INTERVENTIONAL,['NA'],
15130,NCT00858351,Subjective Pain,Temperature,2007-11,COMPLETED,INTERVENTIONAL,['NA'],
15131,NCT01775878,glycosylated hemoglobin,blood pressure,2009-05,COMPLETED,INTERVENTIONAL,['NA'],
15132,NCT00022750,,,2000-10,COMPLETED,INTERVENTIONAL,['NA'],
15133,NCT05580705,Patient Satisfaction Level,,2022-09-22,COMPLETED,INTERVENTIONAL,['NA'],
15134,NCT02097316,"Time spent in glycemic area 70-180 mg / dl, measured continuously for 5 days with a continuous glucose monitoring (CGM) DEXCOM G4",Time spent in the strict glycemic area 80-140 mg / dl,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Time spent above 180mg/dl;
15135,NCT01474889,Endogenous Glucose Production,Autonomic Symptom Response to Hypoglycemia,2011-10,COMPLETED,INTERVENTIONAL,['NA'],
15136,NCT04088981,Rate of glycemic control,Body weight,2024-07,SUSPENDED,INTERVENTIONAL,['NA'],Endothelial function
15137,NCT01602913,"Incidence of T2DM defined as having at least 2 diagnostic codes indicating T2DM after the index date, or 1 diagnostic code and 1 prescription of oral anti-diabetic medications or insulin (or Byetta and Victoza) after the index date",,2011-12,COMPLETED,OBSERVATIONAL,['NA'],
15138,NCT03786406,Diagnosed with carotid artery disease,High risk of CVD (above 20% over 10 years) according to the risk engine from the United Kingdom Prospective Diabetes Study (UKPDS),2018-12-03,COMPLETED,OBSERVATIONAL,['NA'],
15139,NCT00139516,,,2001-09,COMPLETED,INTERVENTIONAL,['NA'],
15140,NCT01936025,lowest dose of DXM,additive BG lowering effects,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
15141,NCT01936935,Matsuda Insulin Sensitivity Index (MISI),Plasma high-sensitivity C-reactive protein (hs-CRP),2012-09,COMPLETED,INTERVENTIONAL,['NA'],Mean peak postprandial glucose
15142,NCT00457093,"In the time period 2400 to 0600 hours (the Basal Period) when post-meal food is least likely to affect the glucose level, detect the mean percentage pf time the glucose level is between 70-119 mg/dL","Establish the mean percentage of time spent in the glucose ranges of 40-70 mg/dL, 120-179 mg/dL, 180-240 mg/dL and >240 mg/dL in the Basal Period and for the entire day, and the average glucose for the entire 24 hour period.",2006-10,COMPLETED,INTERVENTIONAL,['NA'],
15143,NCT04982705,Percentage of subejcts with clinically significant change from baseline in safety laboratory test results,Apparent volume of distribution following oral administration (Vd/F),2021-07-07,RECRUITING,INTERVENTIONAL,['PHASE1'],HbA1c level
15144,NCT03258918,Percentage of participants who achieve weight loss goal,Study attrition,2017-09-11,COMPLETED,INTERVENTIONAL,['NA'],Change in physical symptoms
15145,NCT00960661,Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30,Minor Hypoglycemia Rate Per Year,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
15146,NCT00276406,Ascending Colon Emptying Half-time (AC t1/2) Measured in Hours,QTc Interval Before and After Treatment,2006-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
15147,NCT00238524,Investigate the efficacy of lacosamide compared with placebo in reducing pain in subjects with painful distal diabetic neuropathy will be determined by pain score ratings assessed in a patient's diary and at clinic visits.,"Investigate effect of lacosmide on subjects' perception of sleep, activity, quality of life, and safety, determined by rating scales assessed in a patient's diary and at the clinic visits.",2003-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
15148,NCT03258853,Percentage of Time in Glucose Target Range (70-180 mg/dl) as Determined by Continuous Glucose Monitor (CGM) on Days 3-14,Number of Subjects With Time in Range (70-180 mg/dl) of 70% or Greater,2021-08-26,COMPLETED,INTERVENTIONAL,['NA'],
15149,NCT01536236,Visual Analog Scale (VAS),Short Form 36 (SF-36) Quality of Life Questionnaire,2011-10,WITHDRAWN,INTERVENTIONAL,['NA'],
15150,NCT05096325,Difference in the number of occlusion alarms generated by the new software algorithm compared to the currently implemented occlusion detection system.,Qualitative assessement of the state of the adhesive tapes after study completion,2022-01-03,COMPLETED,OBSERVATIONAL,['NA'],
15151,NCT01536665,Geometric mean glucagon concentration during hypoglycaemia (nadir glucose (target 2.5 mmol/L) ),Time from termination of insulin infusion at nadir to reach plasma glucose 4.0,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
15152,NCT00348972,Safety / tolerability: hypoglycemia,Fasting supine levels of counterregulatory hormones,2002-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
15153,NCT03244449,Whole-body glucose disposal,HOMA-IR (Homeostasis Model Assessment - Insulin Resistance),2014-08-26,COMPLETED,OBSERVATIONAL,['NA'],
15154,NCT03590561,Change in brain metabolites,Change in insulin secretion,2018-06-13,COMPLETED,INTERVENTIONAL,['NA'],
15155,NCT03734887,Change of Medication Adherence Rate,Program Acceptability assessed by a random sub-sample of interviews,2019-10-31,TERMINATED,INTERVENTIONAL,['NA'],
15156,NCT01319656,Evaluation of effects,,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
15157,NCT06119204,Weight loss,EuroQol 5 Dimension 5 Level (EQ-5D),2024-01-26,RECRUITING,INTERVENTIONAL,['NA'],
15158,NCT03987191,Time Spent With CGM Glucose Levels >180mg/dl Between Two Groups,Work Productivity and Activity Impairment (WPAI:SHP Version 2 Questionnaire) Between Two Groups,2020-01-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
15159,NCT05752045,Referable Diabetic Retinopathy screening sensitivity/specificity,Laterality determination algorithm accuracy for laterality assessment,2023-06-28,RECRUITING,INTERVENTIONAL,['NA'],
15160,NCT04881019,Gylcemic response profiles,,2021-06-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
15161,NCT00240370,Compare change from basline in HbA1c after 24 weeks and 50 weeks of treatment with muraglitazar + metformin vs. pioglitazone + metformin,hs-CRP from baseline to W24,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
15162,NCT03875729,The area under the time-concentration curve (AUC) of C-peptide after a mixed meal tolerance test (MMTT) at Week 78,Incidence and titers of anti-teplizumab antibodies after treatment courses,2019-04-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
15163,NCT03730480,Fingerstick Contour Next BGMS and Contour TV3 Results Compared to the Reference Analyzer,Subjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMS,2018-09-06,COMPLETED,INTERVENTIONAL,['NA'],
15164,NCT02081573,Acceptability Questionnaire.,Body Mass Index,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
15165,NCT04258813,Diversity supplement primary outcome: 90-day postoperative cardiovascular complications,Provider-reported care coordination,2021-06-14,RECRUITING,INTERVENTIONAL,['NA'],PCP-reported care coordination
15166,NCT03294044,Success in clinical outcomes of primary disease Diabetes from baseline to 3 months,Quality of life (Euro-QoL),2017-10-27,COMPLETED,INTERVENTIONAL,['NA'],
15167,NCT02328235,Metabolic Flexibility measured ex vivo in skeletal muscle using radio labeled carbon isotopes,Intestinal Permeability using a 4 sugar probe test and mass spectrometry,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
15168,NCT03028506,large for gestational age infants,,2015-01,COMPLETED,OBSERVATIONAL,['NA'],
15169,NCT03466866,number of incident diabetes-related ED visits and/or hospitalizations,Diabetes self-care behaviors,2018-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
15170,NCT01026675,oral glucose challenge test plasma glucose value,oral glucose challenge test plasma glucose cut-off value,2009-04,COMPLETED,OBSERVATIONAL,['NA'],
15171,NCT01055626,Differences in body fat,Differences in cardiovascular risk factors,2005-01,UNKNOWN,OBSERVATIONAL,['NA'],
15172,NCT02558296,Change in HbA1c From Baseline to Week 24,Change in Systolic Blood Pressure From Baseline to Week 24 in Subjects Hypertensive at Baseline,2015-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Proportion of Participants With Incidence of Hospitalization for Heart Failure
15173,NCT03191396,Change in HbA1c,Change in Pulse Rate,2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE3'],
15174,NCT06013228,Fatigue,,2023-08-30,RECRUITING,OBSERVATIONAL,['NA'],
15175,NCT01188863,Half-life of the drug in plasma,Glucagon-like Peptide 1,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
15176,NCT04623567,Change from Baseline Triglyceride at 12 weeks,Change from Baseline TCM Symptom Score at 12 weeks,2021-12-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Compositional and Functional Changes from Baseline Metabolites in blood and feces at 12 weeks
15177,NCT04722991,DRSS improvement ≥2 steps at 48 weeks of treatment in the study eye,Frequency of treatment emergent adverse events,2021-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
15178,NCT04078516,"Diagnostic value of CCM, PTT, AF and MRI",Validation of PainDETECT in diabetes,2019-08-12,COMPLETED,OBSERVATIONAL,['NA'],Exploratory measures
15179,NCT05418946,Variation in glycated hemoglobin (HbA1c) values (% -point) from baseline to 4 months from enrollment,Evaluation of albuminuria (mg/g creatinine),2022-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
15180,NCT01283308,Diabetes Incidence,Program Acceptability,2009-05,COMPLETED,INTERVENTIONAL,['NA'],
15181,NCT03629912,Timed Up and Go (TUG) Test: Change in Dynamic Balance,Diastolic Blood Pressure,2018-08-13,COMPLETED,INTERVENTIONAL,['NA'],
15182,NCT02531035,Percentage of Participants With A1C <7.0% at Week 24 and No Episode of Severe Hypoglycemia and No Episode of Diabetic Ketoacidosis (DKA) After Randomization,Percent Change From Baseline in Mean Daily Bolus Insulin Dose,2015-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
15183,NCT05883098,Healing by 12 weeks,Infection rate,2022-07-01,COMPLETED,INTERVENTIONAL,['NA'],
15184,NCT03827902,Change in HbA1c,Cost of glycemic management during study,2019-07-09,WITHDRAWN,OBSERVATIONAL,['NA'],Frequency of hypoglycemic events
15185,NCT00491400,Brachial Artery Flow-mediated Dilation,Serum Lipids,2005-09,TERMINATED,INTERVENTIONAL,['NA'],
15186,NCT01840189,nocturnal hypoglycemic events,o Subjective health status,2013-04-24,TERMINATED,INTERVENTIONAL,['PHASE2'],
15187,NCT01232179,no leakage in widefield fluorescin angiography,,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],
15188,NCT03367351,Adherence to CGM,CGM Self-Efficacy,2018-03-09,COMPLETED,INTERVENTIONAL,['NA'],
15189,NCT01887691,change in continuous glucose profile,change in Sleep effectiveness biomarkers,2012-10,TERMINATED,INTERVENTIONAL,['PHASE1'],
15190,NCT05515939,Change in Hemoglobin A1c (HbA1c),Clinical Evaluation of Treatment,2022-09-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
15191,NCT00539448,Evaluating the Glycemic control of the regimen : Change in A1C levels,Average daily dose : - For both insulin Glulisine & insulin Glargine. - FBG and PPBG if possible ?,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
15192,NCT01662921,show that insulin glulisine is non-inferior to insulin lispro in a basal/bolus regimen to treat hyperglycemia in patient with gestational diabetes mellitus,Compare incidence of hypoglycemic episodes <60 mg/dL with symptoms,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Compare incidence of primary cesarean section
15193,NCT02527265,Insulin Maximum Observed Concentration (Cmax),Assessment of Fumaryl Diketopiperazine (FDKP) Elimination Half-life (t1/2),2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE2'],
15194,NCT02664064,% Weight Loss,HbA1c,2016-01,COMPLETED,INTERVENTIONAL,['NA'],Program engagement
15195,NCT06213337,Development of foot care self-efficacy in diabetic patients,,2023-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
15196,NCT05277805,Relational empowerment,,2020-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
15197,NCT04183413,Systolic blood pressure among adults with hypertension,"21. Knowledge on diabetes and hypertension among adults with diabetes, prediabetes, or hypertension",2021-11-01,RECRUITING,INTERVENTIONAL,['NA'],
15198,NCT01338376,HbA1c,The incidence of Hypoglycemia,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],
15199,NCT05970601,Effect of a single oral high-sodium chloride load or a partial substitution by potassium chloride on hypoxia-induced dilatation of brachial artery.,Effect of a single oral high-sodium chloride load or a partial substitution by potassium on systemic inflammation markers.,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Effect of a single oral high-sodium chloride load or a partial substitution by potassium on metabolomics in stool.
15200,NCT02198989,HbA1c,Insulin resistance measured as HOMA-IR,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
15201,NCT02967224,Change in HbA1c (percentage %),Change in fasting plasma glucose,2015-11-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
15202,NCT05737810,Attitudes regarding insulin icodec,,2023-03-27,COMPLETED,OBSERVATIONAL,['NA'],
15203,NCT03155087,the incidence of T2DM,metformin efficacy----the decrease level of HbA1c,2013-06,COMPLETED,OBSERVATIONAL,['NA'],
15204,NCT04041375,Change in Diabetes Distress Screening Scale (DDS17),Change in Use of community resources,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],Change in Use of VHA resources
15205,NCT00162240,compare change from baseline in HbA1c after 24 weeks of treatment with muraglitazar + metformin vs placebo + metformin,"change in FPG from basline to W24, proportion of subjects receiving therapeutic response at W24, percent change of fasting lipid levels from baseline to W11/12, change in hs-CRP from baseline to W24",2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
15206,NCT02328118,"composite outcome including amotio retinae,vitreous hemorrhage within 12 months after vitrectomy",the change of inflammatory factors in vitreous body,2015-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
15207,NCT05338463,Incidence of treatment-related Adverse Events associated with Fespixon cream,Time to complete ulcer healing,2021-12-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
15208,NCT05426018,Changes of HbA1c compared with baseline at 12 weeks,Blood drug concentration level,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],
15209,NCT02061969,Mean Fasting Blood Glucose Level,Mortality,2014-04-25,COMPLETED,INTERVENTIONAL,['PHASE4'],
15210,NCT05510583,"Assessment of the non-inferiority of the occurrence of maternal, fetal, and neonatal complications for patients of both groups",Comparison of the rate of patients put on insulin in both groups,2022-08-02,COMPLETED,OBSERVATIONAL,['NA'],
15211,NCT05543265,Rate of primary care provider visit attendance,Rate of patient-reported primary care visit attendance,2022-11-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
15212,NCT05467514,To assess the effect of liraglutide on carotid intima media thickness in patients with type 1 diabetes mellitus.,"To assess the effect of liraglutide on cardiovascular risk factors, cardiometabolic markers. eGDR (Estimated glucose disposal rate)",2022-07-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
15213,NCT04602650,Fecal Microbial Gene Sequencing,Neurological History Questionnaire,2021-01-14,COMPLETED,OBSERVATIONAL,['NA'],
15214,NCT04131257,Change in the incidence of diabetes among individuals with pre-diabetes,"Change in the ""Adoption at the clinic level""",2019-12,UNKNOWN,INTERVENTIONAL,['NA'],
15215,NCT02772887,Blood pressure,Placental growth factor (PlGF),2016-08,TERMINATED,INTERVENTIONAL,['NA'],
15216,NCT00396851,,,2007-01,UNKNOWN,INTERVENTIONAL,['NA'],
15217,NCT00401453,daily insulin requirements and glycemic control,"c-reactive protein, prostaglandin F2 alpha, cholesterol, HDL and LDL.",2007-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
15218,NCT04811183,Evolution in the adherence,,2021-06-04,UNKNOWN,OBSERVATIONAL,['NA'],
15219,NCT00592969,HbA1c,Adverse events,2003-12-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
15220,NCT04741074,Kidney Transplant Eligibility,Receipt of Kidney Transplant,2021-07-23,TERMINATED,INTERVENTIONAL,['PHASE3'],Proportion Experiencing Acute Pancreatitis Events
15221,NCT02497170,Hemoglobin A1c,,2015-09,COMPLETED,INTERVENTIONAL,['NA'],
15222,NCT06125561,oral health-related quality of life,Clinical attachment loss,2023-10-01,RECRUITING,OBSERVATIONAL,['NA'],
15223,NCT04723134,Number of Wounds with Complete Healing,,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],
15224,NCT05691452,Changes of sit-to-stand transitions,Changes of 24-hour glucose levels assessed by continuous glucose monitors,2023-01-24,RECRUITING,INTERVENTIONAL,['NA'],
15225,NCT01335763,The change in HbA1c from baseline to week 26,Health economic evaluation,2011-04,COMPLETED,INTERVENTIONAL,['NA'],
15226,NCT03496298,Time to First Occurrence of Major Adverse Cardiovascular Events (MACE): Event Rate Per 100 Participant-years for First Occurrence of Major Cardiovascular (CV) Event - Non-Inferiority Analysis,Time to First Occurrence of Composite Renal Endpoint: Event Rate Per 100 Participant-years for First Occurrence of Composite Renal Endpoint,2018-04-27,TERMINATED,INTERVENTIONAL,['PHASE3'],
15227,NCT04073927,Intestinal inflammation,Kidney function,2019-08-05,UNKNOWN,INTERVENTIONAL,['NA'],
15228,NCT05400525,Changes in immune response,Dietary Habits,2022-06-15,COMPLETED,INTERVENTIONAL,['NA'],
15229,NCT01167231,"Safety, tolerability of acarbose and its effect on body weight, waist circumference and blood pressure","Effect of acarbose on HbA1c, fasting and postprandial glycemia and on lipid profile",2007-05,COMPLETED,OBSERVATIONAL,['NA'],
15230,NCT05543967,Longitudinal changes of odor-induced brain fMRI activation,Longitudinal changes of functional MRI scan,2022-10-18,RECRUITING,OBSERVATIONAL,['NA'],
15231,NCT05916729,Presence of Candida albicans after therapy at fourth reexamination,,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
15232,NCT05427682,Plasma concentrations of rongliflozin,Incidence of Adverse Events [safety],2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],
15233,NCT03360058,"Measure the effectiveness of an online training programme, practice implementation toolkit and face to face training for primary care staff",Training uptake,2017-10-07,COMPLETED,INTERVENTIONAL,['NA'],
15234,NCT04445181,Proportion of patients with CKD in a large T2D population,"Proportion of healthcare provider prescriptions of SGLT2i used to treat glycemia management, hypertension, heart failure, coronary artery disease, CKD or other condition",2020-07-01,COMPLETED,OBSERVATIONAL,['NA'],
15235,NCT03916601,(Cohort 2) Assessment of PK parameter: Maximum insulin concentration (INS-Cmax),Assessment of PD parameter: Time to GIRmax (GIR-tmax),2017-12-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
15236,NCT03656744,Absolute Change in Liver Fat Content (LFC) as Measured by MRI-PDFF,Number of Participants Reporting an Adverse Events From Baseline Through Week 18,2018-11-26,COMPLETED,INTERVENTIONAL,['PHASE2'],
15237,NCT01786421,Determination of diurnal triglyceridemia depend on alcohol intake,Gender differences in diurnal triglyceridemia by alcohol consumption,na,COMPLETED,OBSERVATIONAL,['NA'],
15238,NCT05543434,Clinical attachment level gain,Radiographic Evaluation,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],
15239,NCT05933018,to evaluate presence of fatty liver in type 1 diabetes,presence of metabolic syndrome in type 1 Diabetes Mellitus,2023-01-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
15240,NCT05564728,Qualitative perspective on a conversational agent/chatbot app usage experience among patients and carers at the end of the trial (1 month).,Usability of a conversational agent/chatbot among patients and carers at the end of the trial (1 month).,2023-06-23,COMPLETED,OBSERVATIONAL,['NA'],
15241,NCT00813215,Incremental AUC og the triglyceride response,Gene expression of genes involved in lipid metabolism and inflammation,2009-01,UNKNOWN,INTERVENTIONAL,['NA'],
15242,NCT02119572,"Change from Baseline HbA1c at 6 months,12 months",cost,na,UNKNOWN,INTERVENTIONAL,['NA'],
15243,NCT02225457,Change from baseline in insulin sensitivity,Change from baseline in muscle and adipose tissue gene expression,2013-12,UNKNOWN,INTERVENTIONAL,['NA'],
15244,NCT01461577,Efficacy assessment of insulin glargine measured by changes of HbA1c levels from baseline,Number of patients with treatment-emergent adverse events,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4'],
15245,NCT05801627,HbA1c change from baseline at week 24,eatic β-cell function change (calculated by HOMA-β ) from baseline at week 24 and week 52,2020-05-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
15246,NCT03925909,Rate of change in microbiome,Rate of change in plasma glucose concentration,2019-05-01,TERMINATED,INTERVENTIONAL,['NA'],
15247,NCT01272219,Proportion of Subjects With Onset of Type 2 Diabetes,Change From Baseline in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes),2011-06-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
15248,NCT05804565,Power Calculation for Definitive RTC,Patient-Reported Quality of Life,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],
15249,NCT01881074,Local Inflammatory Markers,Systemic Inflammatory Markers,2012-06,COMPLETED,OBSERVATIONAL,['NA'],
15250,NCT03830840,"Success (evaluated by Yes/No format) recruiting and establishing an observational cohort of 1,000 Latino families with at least one family member living with type 2 diabetes by deploying the methods proven feasible by Mil Familias Operational Pilot.",National survey of children's health (NSCH) for all children and youth,2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],Physical activity measured by two wearable physical activity monitors for 1 week
15251,NCT01353937,Quality of Life,cEPCs by FACS analysis,2014-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
15252,NCT03195153,"Assessment of platelet reaction units Absolute changes in platelet reactivity (expressed as P2Y(12) reaction units by the point-of-care VerifyNow assay [Accumetrics, San Diego, California] After 30 days of treatment with each drug",,2017-03-28,UNKNOWN,INTERVENTIONAL,['PHASE4'],
15253,NCT05222633,Central subfield thickness,,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA'],
15254,NCT02022254,Area under the R-warfarin plasma concentration-time curve,Incremental area under the INR (international normalised ratio) -curve,2013-12-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
15255,NCT00322478,Patient Satisfaction,Standard Deviation of A1c and SMBG,2006-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
15256,NCT05706298,Change in time in target glycaemic range,Change in carbohydrate intake,2022-12-07,RECRUITING,INTERVENTIONAL,['NA'],
15257,NCT01485913,"Compare the intermediate evolution of the HbA1c (3, 6 and 12 months)","Compare the evolution of the bio-clinical parameters at 3.6, and 12 months: weight, BMI, blood pressure, waist measurement",2011-07-01,COMPLETED,INTERVENTIONAL,['NA'],
15258,NCT05831059,Numeric Rating Scale,,2022-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
15259,NCT01235026,Plasmatic Interleukin-6 (IL-6),Plasmatic usCRP,2010-11,UNKNOWN,INTERVENTIONAL,['NA'],
15260,NCT02783196,Clock Gene expression,Overall glycemia,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],
15261,NCT03766256,Choice of evidence-based diabetes prevention (lifestyle change or metformin),Decisional conflict,2019-03-01,COMPLETED,INTERVENTIONAL,['NA'],
15262,NCT04280315,TEWL,Sebum content in skin,2020-02-18,COMPLETED,OBSERVATIONAL,['NA'],
15263,NCT03583593,Time of healing,Insulin control,2014-05-23,COMPLETED,INTERVENTIONAL,['PHASE2'],
15264,NCT03817463,"Number of participants with myocardial infraction (MI), stroke, all cause mortality",Cost of care,2019-04-15,COMPLETED,OBSERVATIONAL,['NA'],
15265,NCT04666636,Change in glycohemoglobin,,2020-12-07,RECRUITING,INTERVENTIONAL,['PHASE2'],
15266,NCT02992431,15D,visits to physician,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],
15267,NCT04577274,Change from baseline Insulin at 240 minutes,Creatinine concentration analysis,2020-11-04,COMPLETED,INTERVENTIONAL,['NA'],
15268,NCT06060392,Change in liver fat content,Change in LDL-cholesterol,2023-10-30,RECRUITING,INTERVENTIONAL,['NA'],
15269,NCT01433419,Adverse events,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
15270,NCT05429229,Change from baseline in lipoperoxides levels in tear film at 30 days.,Change from baseline in tear secretion in mm with Schirmer I test at 30 days.,2021-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Change from baseline severity of dry eye symptoms according the punctuation in Ocular Surface Disease Index (OSDI) at 30 days
15271,NCT02530840,Diabetes Control as Expressed by the Change in HbA1c %,,2014-07,UNKNOWN,INTERVENTIONAL,['NA'],
15272,NCT01349374,"Nothing will be measured, the aim of the study is the obtention of skin micro-samples collected from healthy volunteers and diabetic patients (type 2 and MODY), intended to be used afterwards to obtain stem cell lines.",,2011-01,TERMINATED,INTERVENTIONAL,['NA'],
15273,NCT01772446,Compare the percentage of patients in the intervention group versus the control group who get a HbA1c below 7%,"Evaluate whether the intervention is more effective (reducing HbA1c below 7%) in patients with predictive risk index <1.5, or in patients with predictive risk index> 1.5.",2013-06,COMPLETED,INTERVENTIONAL,['NA'],
15274,NCT02325193,"average AUC/day in hypoglycaemic range < 70mg/dl (3,9mmo/l)",Number of PLGM activities,2015-03,COMPLETED,OBSERVATIONAL,['NA'],
15275,NCT01382264,Improved glycemic control as determined by A1C in a population of patients with inadequately controlled type 2 diabetes mellitus.,Satisfaction with treatment and quality of life.,2011-07,UNKNOWN,INTERVENTIONAL,['NA'],
15276,NCT02284425,Incidence and severity of treatment emergent adverse events (TEAEs),Concentration of REGN1193 in serum over time,2014-10,TERMINATED,INTERVENTIONAL,['PHASE1'],
15277,NCT00729898,"Incidence of serious adverse drug reactions, including major hypoglycaemic events",Weight changes,2008-03,COMPLETED,OBSERVATIONAL,['NA'],
15278,NCT01177709,Weight (wt) in Pounds (Lbs)..,Insulin Level,2008-05,TERMINATED,INTERVENTIONAL,['NA'],
15279,NCT05852626,Number of patients who achieved individualized target HbA1c,Foot evaluation,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
15280,NCT03179332,AUCGIR(0-60min),Clinical safety laboratory,2017-06-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
15281,NCT03390322,Incidence of procedure related SAEs.,Change to HbA1c levels,2017-07-28,RECRUITING,INTERVENTIONAL,['NA'],
15282,NCT04469270,Efficacy of Engensis compared to Placebo on painful DPN in the feet and lower legs comparing the Average Daily Pain Score from the Day 0 Visit to the Day 180 Visit on the Brief Pain Inventory for Participants with Diabetic Peripheral Neuropathy,To evaluate the possibility of humoral responses to Engensis,2020-10-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],"To determine whether IM administration of Engensis has the potential for improving quality of life, sensation, proprioception, and deep tendon reflexes by measuring the improvement in Bedside Sensory Testing at Day 180 compared to Baseline"
15283,NCT02947503,Development of T2D and obesity during Phase C,Secondary outcome measures phase C,2019-11-26,RECRUITING,INTERVENTIONAL,['PHASE3'],
15284,NCT01469559,Hypoglycemia monitoring,Short Form-36 (SF-36) Quality of life scale,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
15285,NCT01613755,Peak plasma concentration (Cmax) of metformin,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
15286,NCT05502562,Change in Glycated haemoglobin A1c (HbA1c),HbA1c reduction greater than or equal to (>=) 1%-points and body weight reduction of greater than or equal to (>=) 3%,2023-02-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
15287,NCT00843609,"Reduction in time spent in hypoglycaemia, defined as continuous glucose <3.5mmol/l (63mg/dl) (with or without symptomatic hypoglycaemia).",Quality of Life measures (Fear of Hypoglycaemia score and subject satisfaction questionnaire);,2008-10,COMPLETED,INTERVENTIONAL,['NA'],
15288,NCT01609881,"Vitreous and anterior chamber levels of prostaglandins, other cytokines, and Acuvail",Secondary Outcome,2012-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],
15289,NCT00608179,catecholamines,,2002-08,COMPLETED,INTERVENTIONAL,['NA'],
15290,NCT01434862,Percent of Blood glucose tests within target range of 70 to 180 mg/dl,Percent of Continuous Glucose Monitoring (CGM) System estimated blood glucose within target range of 70 to 180 mg/dl,2011-02,TERMINATED,INTERVENTIONAL,['NA'],
15291,NCT04094194,LDL-cholesterol (randomized and non-randomized controlled trials),Incident Stroke (Prospective Cohort Studies),2017-12-01,UNKNOWN,OBSERVATIONAL,['NA'],
15292,NCT02939768,Mitochondrial superoxide dismutase (MnSOD) activity,,2016-08,COMPLETED,INTERVENTIONAL,['NA'],
15293,NCT00069446,Incidence of clinically significant hypotension.,Percent reduction in total ulcer surface area.,2003-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
15294,NCT03118336,epicardial adipose tissue volume,myocardial PCr/ATP ratio,2017-06-16,COMPLETED,INTERVENTIONAL,['PHASE3'],
15295,NCT03080337,Compliance with glucose testing over time,Cost-effectiveness (dollars per hour),2017-03-17,TERMINATED,INTERVENTIONAL,['NA'],
15296,NCT00321256,and 12 months following transplantation.,Morbidity and quality of life will also be assessed.,2003-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
15297,NCT04991168,Number of missing and decayed teeth on the oral examination and clinical signs in diabetology.,,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA'],
15298,NCT01508806,Area under the Curve (AUC),Adverse events,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
15299,NCT02218138,Homeostasis model assessment of insulin resistance,Center for Epidemiological Studies-Depression Scale,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
15300,NCT03520153,Hepatic glucose fluxes (gluconeogenesis and glycogenolysis),Tumor necrosis factor alpha (TNF-alpha),2018-08-07,WITHDRAWN,OBSERVATIONAL,['NA'],Maturity-Onset Diabetes of Young (MODY) genetic testing
15301,NCT01704261,Percentage of Participants Who Discontinued From the Study Due to an AE,Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% at Week 24,2012-10-18,COMPLETED,INTERVENTIONAL,['PHASE3'],
15302,NCT05892341,Effectiveness of AQUACEL® Ag+ Extra™ and Cutimed® Sorbact® on wound management,Safety assesment,2022-12-05,COMPLETED,INTERVENTIONAL,['NA'],Quality of Life assesment
15303,NCT05585190,Insulin sensitivity (HOMA-IR),vascular endothelial function (superficial femoral and brachial arteries) and resilience to a high-glucose load,2023-02-06,RECRUITING,INTERVENTIONAL,['NA'],Acceptability Questionnaire
15304,NCT03758144,change in glycemic control,Gastrointestinal symptom questionnaire,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA'],change in weight
15305,NCT06293417,major adverse cardiovascular events and diabetic microvascular events for 48 months,change in TC/HDL-C ratio at 48month from baseline,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
15306,NCT00707954,"Safety: Adverse Events, Adverse Drug Reactions",Pharmacodynamics- 1)Urinary Glucose Excretion; 2)Plasma Glucose Concentration; 3)Insulin Concentration in Serum; 4)Insulinogenic Index;and 5)Hemoglobin A1c and Glycoalbumin,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
15307,NCT00474838,Change of pancreatic beta cell function,Time to reach target goal of blood glucose level,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
15308,NCT02910089,Glycosylated Hemoglobin (HbA1c):,Patients Achieving HbA1c,2016-10-20,COMPLETED,INTERVENTIONAL,['PHASE4'],
15309,NCT04971889,Change from Baseline HbA1c,Change from baseline Systolic Blood Pressure,2021-08-03,RECRUITING,INTERVENTIONAL,['NA'],Change from baseline Situational Obstacles to Dietary Adherence Questionnaire
15310,NCT01947556,T-BG≥10,T-INSAUC50%,2014-03,COMPLETED,INTERVENTIONAL,['NA'],time exogenous glucose requirement
15311,NCT01148862,The Primary Treatment Comparison is the Evaluation of the Severity (Milligrams Per Deciliter) of Induced Hypoglycemia.,,2010-06,COMPLETED,INTERVENTIONAL,['NA'],
15312,NCT00737763,The primary endpoint for this study will be the difference from baseline in the body's ability to respond to a Mixed Meal Tolerance Test at 12 months after enrollment.,,2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
15313,NCT02169050,Oral Glucose Insulin Sensitivity (OGIS),Inflammatory markers in plasma,2011-05,COMPLETED,OBSERVATIONAL,['NA'],
15314,NCT01269580,post revascularization cardiovascualr mortality,post revascularization amputation,2009-02,UNKNOWN,OBSERVATIONAL,['NA'],post revascularization restenosis
15315,NCT00198146,"Area under the curve, Glucagon Stimulation Testing for c-peptide measurements at 0, +6min and +10min intervals over 2 years",Insulin requirements (units/kg/day),2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
15316,NCT01037647,VLDL-TG production and clearance rates,VLDL-TG subcutaneous adipose tissue storage,2008-05,COMPLETED,OBSERVATIONAL,['NA'],
15317,NCT03313661,The level of fasting and post prandial BG level,,2017-10-14,UNKNOWN,INTERVENTIONAL,['PHASE3'],
15318,NCT02750501,Change From Baseline of Erythrocyte Omega-3 Index % (DHA+EPA),Plasma Composition (%) Ratio of n6/n3 Fatty Acids.,2016-07-20,COMPLETED,INTERVENTIONAL,['NA'],GI Symptoms
15319,NCT01531114,the superiority antiplatelet effect in terms of PR level of loading dose (LD) of Prasugrel (60 mg) versus LD of Ticagrelor (180 mg) in diabetic patients with STEMI undergoing primary PCI at 2 hours post drug administration.,PR level measured at 6 and 12 hours post study drugs administration.,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
15320,NCT04715776,"From baseline to 3 months after using dietary supplements (compare yourself with yourself), follow up for a total of 12 months",,2018-12-10,UNKNOWN,INTERVENTIONAL,['NA'],
15321,NCT01260337,Change in weight at 3 and 6 months,Change in HbA1C at 3 and 6 months,2010-03,COMPLETED,INTERVENTIONAL,['NA'],
15322,NCT04982575,Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide),"Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0mmol/L (54mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)",2021-08-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
15323,NCT03878459,Decrease in HbA1c,insulin dose,2019-08-08,RECRUITING,INTERVENTIONAL,['PHASE4'],
15324,NCT06104969,Standard of Care Adherence,Change from baseline to later of Week 52 or Confirmation Visit in PROMIS Sleep Disturbance,2023-06-15,RECRUITING,OBSERVATIONAL,['NA'],
15325,NCT03673904,statistical significant elevation of high sensitive CRP in diabetics and prediabetes,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],
15326,NCT01006057,Area under the insulin degludec concentration-time curve,Renal clearance of insulin degludec after single-dose,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
15327,NCT03702374,Changes in concentration of total antioxidant capacity (TAC) after intervention from baseline.,Diabetic retinopathy severity progress at the end of intervention from baseline,2018-09-26,COMPLETED,INTERVENTIONAL,['PHASE3'],
15328,NCT01472159,"Change in glycemic control, assessed by hemoglobin A1c","Change in psychosocial factors (e.g., self-efficacy, fear of hypoglycemia, quality of life, diabetes-specific family conflict, diabetes responsibility sharing, diabetes-specific burden, anxiety, depressive symptoms)",2011-10,COMPLETED,INTERVENTIONAL,['NA'],
15329,NCT02741674,Reoperation/Rehospitalization Rate,Composite Adverse Event,2016-02,COMPLETED,OBSERVATIONAL,['NA'],
15330,NCT01991093,Multiple electrode aggregometry in detection of clopidogrel resistance,,2014-06,COMPLETED,OBSERVATIONAL,['NA'],
15331,NCT02268929,The mean HbA1c change by Generalized Estimating Equations (GEE) methods,Effects of integrated Personalized Diabetes Management (PDM) by means of Generalized Estimating Equations [GEE] methods,2014-10-14,COMPLETED,INTERVENTIONAL,['NA'],
15332,NCT04753294,Change in wound progress,Wear time,2021-06-14,COMPLETED,INTERVENTIONAL,['NA'],
15333,NCT03463629,Change in glucose level as indicated by HbA1c levels,Change in blood pressure,2018-03-21,COMPLETED,INTERVENTIONAL,['NA'],Glucose level as indicated by HbA1c levels
15334,NCT06245980,Heart failure readmission,cardiovascular death,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],
15335,NCT03350984,Differences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin.,Number of Participants With Sustained Glycemic Control During Hospital Stay,2017-11-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
15336,NCT02482584,Change in arterial stiffness measured by office carotid-femoral pulse wave velocity (cf-PWV) from start to end of 12 weeks intervention,Change from start to end of 13 weeks intervention in insulin sensitivity measured by hyperinsulinemic euglycemic clamp,2015-04,UNKNOWN,INTERVENTIONAL,['NA'],
15337,NCT04682795,Time In Range,Insulin dose,2021-09-01,UNKNOWN,INTERVENTIONAL,['NA'],Insulin treatment compliance
15338,NCT00428532,,,2007-03,UNKNOWN,INTERVENTIONAL,['NA'],
15339,NCT05674799,BMI in early pregnancy,Glycemia in early pregnancy,2023-04-08,RECRUITING,INTERVENTIONAL,['NA'],Rate of neonatal hypoglycemia requiring treatment
15340,NCT00960635,,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
15341,NCT04617275,Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity,CFB in Body Weight at Week 12 (Non-diabetic Participants With Obesity),2021-01-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
15342,NCT02609633,Change From Baseline in Diabetes-Related Distress Among Parents/Caregivers According to the Problem Areas in Diabetes (PAID) Child and Teen (C&T) Parent Questionnaire Score at Month 6,Percentage of Participants With Overall Treatment Satisfaction With the Use of Accu-Chek® CONNECT Diabetes Management System According to a Questionnaire,2015-12-28,COMPLETED,INTERVENTIONAL,['NA'],
15343,NCT00393770,Insulin sensitivity,Lipid profile.,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
15344,NCT05681533,Epicardial fat volume,,2021-03-31,RECRUITING,OBSERVATIONAL,['NA'],
15345,NCT06264427,Number of participants with obstructive sleep apnea,CPAP treatment effect on daytime sleepiness measured with the functional outcome of sleep questionnaire (FOSQ-10).,2022-07-15,RECRUITING,INTERVENTIONAL,['NA'],
15346,NCT00673296,Interval between the treatment and clearing of premacular hemorrhage,"Snellen best-corrected visual acuity measurements, intraocular pressure, slit-lamp examination and non-contact lens biomicroscopic examination.",2007-01,UNKNOWN,INTERVENTIONAL,['NA'],
15347,NCT01838083,Area under the serum insulin concentration curve within 24 hours (INS-AUC0-24) after dosing on Day 6,"Safety as measured by adverse events/serious adverse events, ohypoglycemia events, physical examinations, clinical laboratory, electrocardiograms, vital signs, injection site reactions and anti-insulin antibodies.",2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
15348,NCT05102071,Occurrence of first hospitalization for congestive heart failure (HHF),All cause cost,2021-11-01,WITHDRAWN,OBSERVATIONAL,['NA'],
15349,NCT03022721,Development of diabetic complications,,2016-09,RECRUITING,OBSERVATIONAL,['NA'],
15350,NCT00795691,Change in Body Weight at month 12,Quality of life as assessed using the Diabetes Quality of Life Scale at month 12,2004-05,COMPLETED,INTERVENTIONAL,['NA'],
15351,NCT00948584,The primary objective was to compare the mean changes of A1C from baseline to end point between two groups.,Secondary objectives included the proportion of patients to achieve A1C level below 7.0%; incidence of hypoglycemic episodes; change in body weight; and insulin dose.,2007-11,COMPLETED,INTERVENTIONAL,['NA'],
15352,NCT02162407,Steady state glucose infusion rate (GIR) / interstitial insulin steady state concentration,Insulin concentration profiles,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
15353,NCT05689658,Minutes of Moderate Physical activity,Glycemia,2023-03-15,COMPLETED,INTERVENTIONAL,['NA'],
15354,NCT02811055,Difference from baseline in Plasma aldosterone concentration,Difference from baseline in HOMA index,2017-07-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],
15355,NCT05147194,Ratio of UACR levels at 6 months to baseline UACR,Ratio of UACR levels at 1 months to baseline UACR,2022-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],
15356,NCT01096940,To evaluate the effect of AZD1656 on the steady state pharmacokinetics of simvastatin (including simvastatin acid) and vice versa by assessment of AUC(0-24) and Cmax.,"To evaluate the safety and tolerability of AZD1656 alone and in combination with simvastatin by assessments of adverse events, laboratory variables, electrocardiogram, blood pressure, pulse, results of physical examination, and weight.",2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
15357,NCT06061861,6-month change in glycosylated hemoglobin level,Change in self-reported readiness to change,2023-10-01,RECRUITING,INTERVENTIONAL,['PHASE3'],
15358,NCT01905020,Percentage of time in target range,Number of hypoglycemic events requiring treatment,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
15359,NCT01492166,Change in prandial glucose increment (PGI),Occurrence of Adverse Drug Reactions (ADR),2006-11,COMPLETED,OBSERVATIONAL,['NA'],
15360,NCT03980353,Identification of community integration obstacles for children with type 1 diabetes,,2019-08-01,COMPLETED,OBSERVATIONAL,['NA'],
15361,NCT02889172,Beck Depression Inventory,Simplified Medication Adherence Questionnaire,2015-02,TERMINATED,INTERVENTIONAL,['NA'],
15362,NCT01722266,Change in Mean Weekly Glucose Concentrations,Change in Glucagon Concentrations,2012-11-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
15363,NCT00812032,An exploratory study with three co-primary response variables which are directly related to platelet COX-1 inhibition: arachidonic acid-induced platelet aggregation in whole blood and PRP and in the Cone-and-Plate(let) Assay (CPA),"Indirectly COX-related platelet aggregation induced by collagen or ADP, and thromboxane metabolite excretion.",2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
15364,NCT03368209,Calibration models for device predictive purposes,,2015-12-04,TERMINATED,INTERVENTIONAL,['NA'],
15365,NCT05894746,Amino acid metabolism,Fibrinogen,2023-05-04,RECRUITING,INTERVENTIONAL,['NA'],multiomics explorative analyses
15366,NCT00570154,,,2007-11-27,COMPLETED,OBSERVATIONAL,['NA'],
15367,NCT01892319,"Proportion of pregnancies (Levemir® treatment), compared to pregnancies (other basal insulin treatment regimens), resulting in none of the following events: Major congenital malformations, Perinatal death, Neonatal death",Proportion with changes (progression/regression) of major congenital malformations,2013-09-30,COMPLETED,OBSERVATIONAL,['NA'],
15368,NCT02220036,Serum creatinine,high sensitive C-Reactive Protein,2014-06,UNKNOWN,INTERVENTIONAL,['NA'],
15369,NCT04707157,Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS),Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm),2021-05-06,TERMINATED,INTERVENTIONAL,['PHASE2'],
15370,NCT05645419,Number of Participants with myocardial infarction,,2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
15371,NCT04430946,Gut peptide hormone responses,Meal induced thermogenesis,2020-08-25,RECRUITING,INTERVENTIONAL,['NA'],
15372,NCT01223131,Absolute change of glycosylated hemoglobin (HbA1c),Anti-glargine and anti-human insulin antibody assessment,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
15373,NCT05612698,fasting plasma glucose,body composition (measured by bioimpedance),2023-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
15374,NCT01165684,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 32,Hypoglycaemic Episodes (Rate of All Treatment Emergent Hypoglycaemia Episodes),2010-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
15375,NCT01890993,Change in HbA1c (glycosylated haemoglobin),Change in systolic blood pressure,2013-08,COMPLETED,OBSERVATIONAL,['NA'],
15376,NCT04259801,Number of treatment emergent adverse events (TEAE) in Part 2,The maximum concentration of semaglutide after administration of the 12th dose of semaglutide,2020-02-17,COMPLETED,INTERVENTIONAL,['PHASE1'],
15377,NCT05980026,change in UACR (mg/g creatinine) level,change in HbA1c(%),2022-01-10,COMPLETED,INTERVENTIONAL,['NA'],
15378,NCT05430061,Gastric half emptying time,Height and Weight,2017-07-27,COMPLETED,INTERVENTIONAL,['NA'],
15379,NCT01954459,Point accuracy of the continuous glucose monitor plus Insupatch (CGM+IP) by mean absolute relative difference (MARD) calculation of sensors with and without IP use.,,2013-09,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],
15380,NCT01277471,Change in Insulin Resistance,Oxidative stress markers and AGEs,2010-12,COMPLETED,INTERVENTIONAL,['NA'],
15381,NCT02303730,Change in liver fat content（%） measured by MRS,"Change in body weight,waist circumference and hip circumference",2015-03,COMPLETED,INTERVENTIONAL,['PHASE4'],Incidence of adverse events（AEs）and Severe adverse events(SAEs)
15382,NCT00422955,Change in transcapillary escape rate of L125 albumin following 16 weeks treatment,"Change in plasma volume, pedal oedema, extracellular fluid volume following 16 weeks treatment.",2003-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
15383,NCT01098539,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Plasma Concentrations (Conc.) of Albiglutide at Week 8 and Week 16,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
15384,NCT04218734,Change in HbA1c (%) from baseline to week 24,Change in body weight from baseline to week 12 and week 24,2020-01-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
15385,NCT00431717,,,2006-11,COMPLETED,OBSERVATIONAL,['NA'],
15386,NCT01478399,Pharmacokinetics,Safety/Tolerability,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
15387,NCT02002130,Compare the effect of oral GABA or oral GABA/GAD combination administration on pancreatic beta cell function by quantitative C-peptide secretion,Compare the effect of oral GABA or oral GABA/GAD administration on diabetes related autoantibodies,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
15388,NCT01482481,HbA1c level,Body Mass Index (BMI),2008-01,COMPLETED,OBSERVATIONAL,['NA'],
15389,NCT01901913,Area under the curve above 180 mg/dl (10 mmol/l),"Percentage of time spent above 180, 250, (10, 13.9 mmol/l)",2013-10,COMPLETED,INTERVENTIONAL,['NA'],
15390,NCT01626586,Diabetes-related Outcomes,Diabetes-related medical outcome data,2012-05,COMPLETED,INTERVENTIONAL,['NA'],
15391,NCT01993121,Changes from baseline in cardiovascular exercise performance,Changes from baseline in diastolic function will be measured,2002-09,COMPLETED,INTERVENTIONAL,['NA'],
15392,NCT00918879,Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c),Proportion of Patients (Expressed in Percentage of Total Participants) Achieving a Therapeutic Glycemic Response Defined as HbA1c < 7.0% at Week 24,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
15393,NCT03341117,"Modification in the antioxidant enzymatic system activity (total antioxidant capacity, catalase, glutathione peroxidase , superoxide dismutase) in patients with type 2 diabetes after the administration of acetylsalicylic acid",Modification in fasting glucose in patients with type 2 diabetes after the administration of Acetylsalicylic acid,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
15394,NCT00451620,The objective of this study is to determine whether GlucoNorm has a greater effect than Glyburide on insulin levels and postprandial glucose levels in elderly people with type 2 diabetes who are diet controlled.,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
15395,NCT02752828,Change from baseline in HbA1c,Measurement of anti-insulin antibodies from baseline,2016-05-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
15396,NCT05198544,Evaluate Wound healing in Wagner 1 and 2 grade DFUs by wound size,Occurrence of adverse events through case report forms,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Bacterial burden measured by Imaging
15397,NCT04080596,AUClast,,2017-10-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
15398,NCT04196140,Time in range 70-180 mg/dL,Body Mass Index (BMI) (kg/m2),2019-12-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Coefficient of variation
15399,NCT01871324,the efficacy will be evaluated using Diabetes Quality of Life questionnaire before and after the program.,the efficacy will be evaluated using behavioral changes related to diabetes questionnaire before and after the program.,2013-09,WITHDRAWN,INTERVENTIONAL,['NA'],"the efficacy will be evaluated using HbA1c values, glucose levels before and after the program"
15400,NCT00325429,Adverse events profile after 52 weeks of treatment,Change from baseline to endpoint in body weight at 52 weeks,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
15401,NCT03025919,area under the ROC curve,sensitivity and specificity of screening,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],
15402,NCT02147041,composite of anthropometric measures,Quality of life evaluation,2012-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
15403,NCT02586129,Change in HbA1c,,2015-11-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
15404,NCT00425919,Fasting Plasma Glucose,"Mean changes of HbA1c, Fasting Insulin, HOMA-IR and QUICKI indices, Body weight, waist measurements, total cholesterol, LDL-C, HDL-C, total/HDL, apolipoprotein A-1 & B, triglycerides, free fatty acids, hs C-reactive protein, adiponectin, edema.",2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],
15405,NCT03898206,Postprandial glucose,Blood pressure,2019-02-26,UNKNOWN,INTERVENTIONAL,['NA'],
15406,NCT05081440,primary outcome,secondary outcome,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA'],
15407,NCT00909051,"Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C; exploratory analysis according to patient groups (concomitant cardiovascular disease groups, BMI)",,2009-03-24,COMPLETED,OBSERVATIONAL,['NA'],
15408,NCT04461236,Change in whole-body protein metabolism in type 2 diabetic obese subjects,Changes in quality of life as measured by Short Form (36) Health Survey (SF36) in type 2 diabetics obese subjects,2019-05-30,UNKNOWN,INTERVENTIONAL,['NA'],Group differences in Bi-manual Coordination Task between type 2 diabetics and non-diabetic subjects
15409,NCT03648307,Glucose tolerance,,2008-07,COMPLETED,OBSERVATIONAL,['NA'],
15410,NCT00738907,Pancreatic tracer binding as standardized uptake value (SUV) or binding potential (BPnd),,2006-11,COMPLETED,OBSERVATIONAL,['NA'],
15411,NCT01681173,Change of 2h-postprandial blood glucose from IGT to diabetes mellitus type 2 or normal glucose tolerance (NGT),Determination of gene expression in adipose tissue,2010-05,COMPLETED,INTERVENTIONAL,['NA'],
15412,NCT00770653,The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.,Change From Baseline in Erythrocyte Deformability (60.00).,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
15413,NCT04741685,TIR,Hypoglycemia perception 2,2021-02-15,COMPLETED,OBSERVATIONAL,['NA'],
15414,NCT00090506,,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
15415,NCT04873232,To evaluate the efficacy of IM administration of Engensis on pain in Participants with painful DPN in the feet and lower legs as compared to Placebo,To evaluate the safety of IM administration of Engensis in Participants with painful DPN in the feet and lower legs,2021-05-17,RECRUITING,INTERVENTIONAL,['PHASE3'],
15416,NCT02625649,Number of patients with HbA1c<48 mmol/mol.,Number of patients with two-step change from preoperative level on the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) scale,2016-01,COMPLETED,OBSERVATIONAL,['NA'],
15417,NCT01792323,tmax(GIR); time to maximum glucose infusion rate,"GIRmax, maximum glucose infusion rate",2011-08,COMPLETED,INTERVENTIONAL,['PHASE1'],"tmax(ins), time to maximum observed plasma insulin lispro concentration"
15418,NCT01470937,Progression of fasting glucose >140 mg/dL,,1998-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
15419,NCT02575599,The Patient Activation Measure (PAM),Glycosylated haemoglobin (HbA1c),2018-09-01,UNKNOWN,INTERVENTIONAL,['NA'],
15420,NCT01707979,near infrared spectroscopy,,2012-09,COMPLETED,OBSERVATIONAL,['NA'],
15421,NCT01089166,,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],
15422,NCT05669599,Percent Change From Baseline to Week 52 in Body Weight,Percent Change From Baseline in Free Fatty Acids (FFA),2023-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
15423,NCT00813085,Comparison of change in diabetes quality of care between intervention and usual care group.,"Change in diabetes risk factor variables, satisfaction with care and technology, quality of life and health care utilization, health data privacy issues.",2002-04,COMPLETED,INTERVENTIONAL,['NA'],
15424,NCT00645268,The IIEF Erectile Function (EF) Domain score,Flow mediated brachial artery dilation (FMD) as an index of generalized endothelial function,2002-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
15425,NCT03563456,Antioxydants,Personal history as independent factor,2017-06-05,COMPLETED,INTERVENTIONAL,['NA'],
15426,NCT00540462,"Measure sugar levels, HbA1c levels, and medication needed. OGTT, MGTT.","Comparing the DM controls between Medical and Surgical treatment In surgery groups, compare the bypass surgery and sleeve gastrectomy",2007-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],
15427,NCT05322122,Feasibility and performance measured by anastomosis success,Quality of life improvement,2021-11-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
15428,NCT05341388,BDNF concentrations,36 item Short Form Survey (SF-36),2021-03-01,TERMINATED,OBSERVATIONAL,['NA'],
15429,NCT00282945,"This study will examine whether biomarkers of B-cell function measured early in the study (1, 3, and/or 6 months) will predict long-term changes in B-cell function (as represented by HOMA-B).",,2006-01,TERMINATED,INTERVENTIONAL,['NA'],
15430,NCT04612933,Change from baseline of Time in Range (TiR),Change from baseline of time spent below target glucose range (TbR) level 2,2021-06-28,RECRUITING,INTERVENTIONAL,['NA'],Semi-structured interviews
15431,NCT03367455,Associations of serum potassium and KCNJ11 variants with incident diabetes as represented by odds ratio,,2015-05,COMPLETED,OBSERVATIONAL,['NA'],
15432,NCT05899439,Genetic risk of type 1 diabetes,,2005-01-01,RECRUITING,OBSERVATIONAL,['NA'],
15433,NCT02488785,Hemoglobin A1c,,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
15434,NCT03168867,Glycemic Control,Household Chaos (Self-reported),2017-09-25,COMPLETED,INTERVENTIONAL,['NA'],
15435,NCT04611737,height,Depression Anxiety Stress Scales,2020-11-03,COMPLETED,INTERVENTIONAL,['NA'],
15436,NCT02390245,Diagnostic Image Confirmation by Ophthalmologist,Adherence to Follow-up Ophthalmic Care.,2014-09,COMPLETED,INTERVENTIONAL,['NA'],
15437,NCT01871870,Verification of the Automation and Telemetry Components,Deviation From Target Blood Glucose,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
15438,NCT00989378,Amount of Slow Wave Activity determines insulin sensitivity.,,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
15439,NCT03169959,Maximum observed plasma concentration (Cmax),Laboratory assessments of urinalysis,2017-05-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
15440,NCT04611152,Changes in BCVA to Assess Non-inferiority of KSI-301 to Aflibercept.,Safety and Tolerability of KSI-301 mg compared to aflibercept 2 mg measured by the number of ocular and systemic adverse events.,2020-09-30,TERMINATED,INTERVENTIONAL,['PHASE3'],
15441,NCT03973762,Se and Sp under investigation target 3,Se and Sp under investigation target 1/2/4/5,2019-05-31,COMPLETED,INTERVENTIONAL,['NA'],
15442,NCT01319734,improving the renal function,Vitamin C can improve the visual fields,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],
15443,NCT03584217,Glomerular filtration rate (GFR),Renal perfusion,2018-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Epigenetic profiling
15444,NCT03407677,rotation of insulin injections,Accuracy of the ROTO track® injection log,2018-08-27,COMPLETED,INTERVENTIONAL,['NA'],glycaemic control
15445,NCT02632292,In-stent late lumen loss,Anginal status assessed by the Seattle Angina Questionnaire,2016-01,TERMINATED,INTERVENTIONAL,['NA'],
15446,NCT05563090,Tongue imaging device,Health Evaluation - Existing symptoms,2022-09-17,RECRUITING,OBSERVATIONAL,['NA'],
15447,NCT05349903,Postprandial plasma gut hormone response,Breath hydrogen (fermentability),2021-11-10,COMPLETED,INTERVENTIONAL,['NA'],
15448,NCT00662831,Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing,Transcutaneous Local Tissue Oxygenation (pO2),2008-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Number of Clinically Relevant Minor Hemorrhages and Trivial Hemorrhages
15449,NCT02127047,Change in beta-cell function as derived from change in C-peptide and glucose levels during the mixed meal test,Change in fractalkine,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
15450,NCT02846545,Active Treatment Period: C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 4 Hour Mixed Meal Tolerance Test (MMTT) at Week 52,Titers of Antibodies to Golimumab,2016-08-26,COMPLETED,INTERVENTIONAL,['PHASE2'],
15451,NCT04891159,"Adoption of a shared decision making measured by the total score obtained on the 9 items of the shared decision making questionnaire (SDM-Q-9), translated into French.",,2021-09,UNKNOWN,OBSERVATIONAL,['NA'],
15452,NCT03421119,HbA1c,Liver enzymes,2019-06-20,UNKNOWN,INTERVENTIONAL,['PHASE3'],
15453,NCT02890745,"Urinary excretion of 8-oxo-7,8-dihydroguanosine (nmol/24h)","Plasma levels of iron, ferritin, transferrin and transferrin saturation",2016-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
15454,NCT05709444,"To determine the incidence of overall adverse events, related adverse events, a composite of adverse events of special interest, serious adverse events, and the incidence of BMT discontinuation.",To measure the efficacy of SQ BMT in combination with RAAS inhibition therapy to achieve a <1.0 ml/min/year drop in eGFR after six months,2022-12-26,RECRUITING,INTERVENTIONAL,['PHASE2'],
15455,NCT03108521,Glycosylated Hemoglobin A1c (HbA1c),Change in C-peptide,2016-04-21,COMPLETED,INTERVENTIONAL,['PHASE4'],
15456,NCT02898467,Neutrophile activation assessed by free DNA levels in atherothrombotic plaques,Atherothrombosis characterization assessed by histological analysis,2016-10,UNKNOWN,OBSERVATIONAL,['NA'],Banking of biological samples
15457,NCT00655863,Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 16.,Change From Baseline in Endothelial Function Through Pulse Wave Tonometry,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
15458,NCT02161588,Area under the semaglutide plasma concentration-time curve,Number of treatment emergent adverse events (TEAEs) recorded,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
15459,NCT05624775,Change in cooking self-efficacy by the Nourishing the Community Through Culinary Medicine survey (NCCM),Change in Triglyceride,2022-02-01,COMPLETED,INTERVENTIONAL,['NA'],
15460,NCT05716724,Change in glycated haemoglobin (HbA1c),Timing of intake of oral semaglutide as reported in patient diary,2023-01-25,COMPLETED,OBSERVATIONAL,['NA'],
15461,NCT02364323,percentage of patients attaining ≥ 3 pre-defined treatment targets from the following treatment targets: 1) BP <130/80 mm Hg 2) HbA1c <7% 3) Calculated LDL-cholesterol <2.6mmol/l 4) Fasting TG <2mmol/l 5) Use of ACEI or ARB,Patient behavior measured on the Summary of Diabetes Self-care Activities (SDSCA),2015-02-17,COMPLETED,INTERVENTIONAL,['NA'],
15462,NCT00790530,Completion of dilated eye examination,Completion of microalbumin testing,2006-06,COMPLETED,INTERVENTIONAL,['NA'],
15463,NCT02563015,Lean mass,25(OH)D,2016-03-07,TERMINATED,INTERVENTIONAL,['NA'],
15464,NCT00640549,Changes in concentration of LDL subfractions LDL-5 and LDL-6 compared with screening (visit 1),Changes in size of LDL subfractions compared with screening (visit 1),2003-03,TERMINATED,INTERVENTIONAL,['PHASE4'],
15465,NCT01378117,Mean Blood Glucose Levels Among the Three Groups at the Time of Hospitalization to 1st Day After Therapy,Percent of Blood Glucose Readings Within Target Range Between 70 and 140 mg/dL Among the Three Groups After 24 Hrs of Randomized Treatment,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
15466,NCT03664726,Reinforcing Value of Food,Change in Working Memory Span,2018-02-12,COMPLETED,INTERVENTIONAL,['NA'],
15467,NCT00643773,Body Composition,Muscle characteristics,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
15468,NCT02320253,Percent Weight Change From Baseline,Depression Score: Change From Baseline.,2014-11,COMPLETED,INTERVENTIONAL,['NA'],Health Economics
15469,NCT02432924,Change in physical activity level (PAL),QIntervention: Change in cardiovascular disease and type 2 diabetes risk,2014-10,COMPLETED,INTERVENTIONAL,['NA'],
15470,NCT05666479,Accuracy of Real-Time Continuous Glucose Monitoring,Assess Irreversible Damage/Interference of Real-Time Continuous Glucose Monitoring Devices Caused by Electrocautery,2022-09-09,RECRUITING,OBSERVATIONAL,['NA'],
15471,NCT04326166,Change in HbA1c,Change in FPG,2020-03-25,UNKNOWN,OBSERVATIONAL,['NA'],
15472,NCT00517283,To detect the mean difference in half gastric emptying time for a solid meal between any treatment and placebo,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
15473,NCT02028091,"Pulse wave arrival time difference between finger and toe, duration of diabetes",,2012-09,COMPLETED,OBSERVATIONAL,['NA'],
15474,NCT03095846,5. Difference in brown adipose tissue (BAT) activity after cooling between Winter Swimmers (WS) and No-Winter Swimmers (NWS).,Difference in resting energy expenditure after cooling versus no cooling,2017-04-02,COMPLETED,INTERVENTIONAL,['NA'],
15475,NCT03577184,Change from baseline in Random blood sugar (RBS) and fasting blood sugar (FBS) levels at week 12 in participants receiving Vildagliptin combination with Metformin,Number of participants who experienced an Adverse Event,2018-07,WITHDRAWN,OBSERVATIONAL,['NA'],
15476,NCT00889226,Proportion of Patients Achieving LDL- C<100mg/dL,The Change of LDL-C,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
15477,NCT01009021,Pain recorded using a Visual Analog Scale,,2008-03,COMPLETED,INTERVENTIONAL,['NA'],
15478,NCT05965973,"Change in the expression of key genes in hepatic fibrogenesis including transforming growth factor beta 1, a-smooth muscle actin, type-1 collagen, connective tissue growth factor",Identify bacteria strains involved in the control of blood glucose such as C elegans.,2023-06-09,RECRUITING,INTERVENTIONAL,['NA'],
15479,NCT01207349,%HbA1c,anthropometry,2002-08,COMPLETED,OBSERVATIONAL,['NA'],
15480,NCT01526720,Genetic basis of beta cell function,Genetic basis of insulin sensitivity,2003-10,UNKNOWN,OBSERVATIONAL,['NA'],
15481,NCT05691712,Mean Change from Baseline in HbA1c (Tirzepatide 10 or 15 milligram [mg]),"Percentage of Participants with HbA1c ≤6.5%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood glucose <3.9 mmol/L [70 mg/dL] or Severe Hypoglycemia)",2023-02-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
15482,NCT02077179,Metabolic Syndrome Z Score,Adherence to the HIP Program; Percent of Dietary Logs Completed,2014-09,TERMINATED,INTERVENTIONAL,['NA'],
15483,NCT02601989,insulin sensitivity,"Endothelial function in peripheral arteries measured with EndoPAT, measured as difference in reactive hyperemia",2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],
15484,NCT04163055,The rate of CWH of DFUs will be estimated as a proportion and compared between the two groups using a chi square test. The superiority of AF-guided intervention (Arm 2) will be established if the null hypothesis is rejected.,Quality of Life improvement due to the device as assessed Diabetic Foot Ulcer Scale,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
15485,NCT03660683,CD 34+ Cell Migratory Function,Arterial Stiffness - Augmentation Pressure,2018-10-22,TERMINATED,INTERVENTIONAL,['PHASE4'],Serum Glucose
15486,NCT03506230,Differences in HbA1c after six months,Whether or not HbA1c test was performed at 3 months,2018-11-25,UNKNOWN,INTERVENTIONAL,['NA'],Differences in the number of GP visits
15487,NCT05962372,Cardiometabolic Improvement Score (CIS),Change in levels of metabolic risk factors,2024-01-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
15488,NCT04090307,Effects of TLC group prenatal care on infant skinfold thickness,Determine the effect of TLC on psychosocial stress and depression using the Munich Chronotype Questionnaire (MCTQ),2019-11-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
15489,NCT04920253,Wound Closure,Healed Proportion,2021-11-29,RECRUITING,INTERVENTIONAL,['NA'],AWC Failure
15490,NCT02031081,Change In Cumulative Meal-related Symptoms,Gastric Emptying Rate,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
15491,NCT01373476,Ocular fundus,Optic coherence tomography (OCT),2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
15492,NCT01269502,Recurrency of diabetic foot ulcer,,2009-06,COMPLETED,INTERVENTIONAL,['NA'],
15493,NCT03774095,Gastrointestinal tolerability,,2018-06-11,UNKNOWN,INTERVENTIONAL,['NA'],
15494,NCT02936843,Skin Biopsy - Intraepidermal Nerve Fiber Density (IENFD) - Distal Thigh,,2016-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
15495,NCT00476151,Placebo vs. Active Comparison of the Change From Average Pain at Baseline to Average Pain at 4 Weeks.,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
15496,NCT03449654,Change in vascular inflammation,Carotid intima media thickness,2017-10-26,COMPLETED,INTERVENTIONAL,['PHASE4'],Autonomic nervous system function
15497,NCT03509324,fasting plasma glucose after insulin therapy,,2015-03-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
15498,NCT04701424,Time in the target glucose range (3.9 to 10.0 mmol/l),Total insulin dose,2020-12-16,COMPLETED,INTERVENTIONAL,['NA'],Percentage of time of CGM availability
15499,NCT03887936,Finite element analysis of bone to measure bone strength,Osteoblast and osteoclast progenitor cells which are cells found in bone,2019-10-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
15500,NCT02183324,"Number of patients with clinically relevant changes in clinical laboratory tests (haematology, clinical chemistry, and urinalysis)",DPP-IV activity at different time points,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
15501,NCT03760068,Treatment Emergent Antibody Response (TEAR),Change in 7-point Self-monitored Blood Glucose (SMBG) Profile From Baseline,2018-11-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
15502,NCT01086319,"Hospitalizations with any hypersensitivity reaction, including anaphylaxis, angioedema, generalized urticaria, SJS, TEN, and other severe skin reactions (i.e., acute generalized exanthematous pustulosis and drug rash with eosinophilia/systemic symptoms)",Hospitalized for for toxic epidermal necrolysis (TEN),2009-08,COMPLETED,OBSERVATIONAL,['NA'],
15503,NCT03520972,Change of glycosylated hemoglobin(HbA1c),Self-monitoring of blood glucose (SMBG),2018-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Blood lipid
15504,NCT01136785,Change in Mean Serum Insulin Derived From 24 Hour Blood Sampling,Change in 24-h Mean Level of Plasma Norepinephrine,2009-11,COMPLETED,INTERVENTIONAL,['NA'],
15505,NCT02350374,"The individual variation of CHO amount at each main meal : Breakfast, Lunch, Snacks, Dinner",,2014-11-17,COMPLETED,INTERVENTIONAL,['NA'],
15506,NCT05569772,type 2 diabetes,diabetes remission,2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE3'],
15507,NCT02779452,Change in neurodevelopment,Change in DHA level in cord blood,2013-12,COMPLETED,OBSERVATIONAL,['NA'],
15508,NCT02138097,Subsequent Insulin Initiation for MarketScan Patients,Persistence at 12 Months for MarketScan Patients,2014-05,COMPLETED,OBSERVATIONAL,['NA'],
15509,NCT05110404,fasting lipid profile,,2021-12-25,COMPLETED,INTERVENTIONAL,['NA'],
15510,NCT01817569,Adverse event incidence.,Mean change in lipid metabolism.,2011-02-13,COMPLETED,OBSERVATIONAL,['NA'],
15511,NCT01643811,Proportion of patients who quit previous medication for hypertension because of improved disease,"difference of serum levels of c-peptide, Ghrelin, GIP, GLP-1, glucagon, insulin between before and after operation",2012-04,COMPLETED,OBSERVATIONAL,['NA'],
15512,NCT02726217,Acceptability of the intervention protocol will be evaluated using a satisfaction survey.,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA'],
15513,NCT00511875,Change in Early Treatment Diabetic Retinopathy Study (ETDRS),Change in Arteriovenous Ratio Diameter,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
15514,NCT04820270,Immunization,PRA level,2018-08-20,UNKNOWN,INTERVENTIONAL,['NA'],
15515,NCT04924686,NOD2 ligands in fecal and plasma,,2020-05-10,UNKNOWN,OBSERVATIONAL,['NA'],
15516,NCT05739214,percent of wound size measurement methods,percent of wounds complete closure,2022-08-01,COMPLETED,INTERVENTIONAL,['NA'],
15517,NCT00717457,Change in HbA1c,Beta cell function (proinsulin/insulin ratio),2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
15518,NCT00001723,Change in BMI Standard Deviation Score,Effect of Race on Change in Weight (kg),1998-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
15519,NCT02624817,Metabolic control,Insulin secretory response to a glucagon test,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
15520,NCT05291026,Primary outcome measure,Secondary outcome measure II,2018-12-15,COMPLETED,INTERVENTIONAL,['NA'],
15521,NCT01715090,Mean change in HbA1c,Detection of important factors for patient compliance to internet-based self-care interventions,2012-12,COMPLETED,INTERVENTIONAL,['NA'],
15522,NCT01603121,Safety and Tolerability of Study Drug,Evaluation of Early Efficacy of Study Drug,2012-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
15523,NCT02675335,mean ulcer size after a treatment period of 12 weeks,,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
15524,NCT05466643,Changes from Baseline HbA1c,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
15525,NCT01630980,Metabolic syndrome measures,,2012-05,COMPLETED,OBSERVATIONAL,['NA'],
15526,NCT02088034,Body Weight,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
15527,NCT01703221,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During the Overall Study,Change From Baseline for Fasting Plasma Glucose (FPG) at Week 24,2012-10-24,COMPLETED,INTERVENTIONAL,['PHASE3'],
15528,NCT05763303,assessment of change in measurements of glycated hemoglobin (HbA1c),assessment of change in measurement of body mass index (BMI),2023-10-25,RECRUITING,INTERVENTIONAL,['NA'],
15529,NCT02442024,Change from baseline fructosamine after 1 and 2 months of diet,Change from baseline lipid profile after 1 and 2 months of diet,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],
15530,NCT02882737,"The primary endpoint is peak plasma glucose achieved within 2 hours after the 200 μg subcutaneous glucagon injection. In the primary analysis, the investigators will compare the peak plasma glucose after exercise and after resting.",The fused data from the two sensors.,2016-09,COMPLETED,INTERVENTIONAL,['NA'],
15531,NCT02015780,Change from Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16,Change from Baseline in Total Daily Dose of Insulin at Week 52,2013-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
15532,NCT00608387,Glycosylated hemoglobin (HbgA1c),Overall cost-effectiveness,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
15533,NCT06227650,Percentage of time spent in the target,Microangiopathic events,2024-02-06,RECRUITING,OBSERVATIONAL,['NA'],
15534,NCT01492218,Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score,Technical complaints of NovoLet® device,2004-03-15,COMPLETED,OBSERVATIONAL,['NA'],
15535,NCT04731272,Early-phase insulin secretion,Glucose tolerance,2021-04-20,RECRUITING,INTERVENTIONAL,['PHASE2'],
15536,NCT02273258,Area under the body weight standardized glucose infusion rate (GIR) versus time curve from 0 to 12 hours post administration (GIR-AUC0-12),"Number of patients with AEs, SAEs, laboratory, vital signs and electrocardiographic abnormalities , injections site reaction assessment (ISR), and if any, hypoglycemia",2013-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
15537,NCT01512849,Effect of Renal Function on Percent Inhibition of Renal Glucose Reabsorption (RGR) of TA-7284,Clinical Laboratory Tests,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
15538,NCT02229383,Change in HbA1c From Baseline to Week 28,Change in Seated Systolic Blood Pressure From Baseline to Week 28,2014-09-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
15539,NCT00015626,,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],
15540,NCT01524874,Change in mean serum 25-hydroxycholecalciferol concentration,Change in mean cardiometabolic risk factors,2010-08,COMPLETED,INTERVENTIONAL,['NA'],
15541,NCT01485614,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin),Participants With Worsening in Dental Status at Week 54,2012-02-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
15542,NCT00986349,Change in Anti-diabetes Medications,Total Weight Change (kg) at Week 52 Compared to Baseline Weight,2010-06,COMPLETED,INTERVENTIONAL,['NA'],Fasting Plasma Glucose Over Time for All Subjects
15543,NCT02600845,Treatment Satisfaction: Diabetes Treatment Satisfaction Questionnaire (DTSQc) Score at Week 24,Percentage of Blood Glucose Tagged Data,2015-12-30,COMPLETED,INTERVENTIONAL,['NA'],
15544,NCT03997656,body weight,health-related quality of life,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],
15545,NCT00103857,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24,Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 104,2005-03-17,COMPLETED,INTERVENTIONAL,['PHASE3'],
15546,NCT03994289,Postprandial glucose AUC,,2019-02-20,COMPLETED,INTERVENTIONAL,['NA'],
15547,NCT01831154,The Effect of Intraoperative Tight Glycemic Control on Postoperative C-Reactive Protein Plasma Levels in Patients Undergoing Open Heart Surgery,Intraoperative Glycemic Stability in Patients Undergoing Open Heart Surgery Compared Between Three Glycemic Protocols.,2010-05,COMPLETED,INTERVENTIONAL,['NA'],
15548,NCT01368328,Insulin Sensitivity as assessed with homeostatic model assessment (HOMA),urea and creatinine,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],
15549,NCT04324229,Incidence of type 2 diabetes,,2020-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
15550,NCT01850134,Hunger,Prospective Consumption,2013-06,WITHDRAWN,INTERVENTIONAL,['NA'],
15551,NCT01854463,glycemic control,arterial stiffenss,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4'],non-alcoholic fatty liver diseases and bone turnover marker
15552,NCT00806338,"Safety and Tolerance of multiple intravenous doses of trodusquemine (MSI-1436) in obese or overweight type 2 diabetics. Safety will be evaluated by physical exams, vital signs assessments, 12-lead ECGs, clinical lab tests and adverse event profile.",Effect on exploratory biomarkers,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
15553,NCT00725257,Hemoglobin A1c,Time to introduction of an oral hypoglycemic agent,2004-06,COMPLETED,INTERVENTIONAL,['NA'],
15554,NCT05170984,Rate of wound closure,Changes in the Pain Visual Analogic Scale,2022-02-10,RECRUITING,INTERVENTIONAL,['NA'],
15555,NCT00573781,"Changes in glucose metabolism, changes in transcriptomic and metabolomic profiles",Interaction between the diet and genetic factors within treatment groups,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
15556,NCT01503112,Glycaemic response (HbA1c change post treatment),Weight change over 6 months treatment,2011-05,COMPLETED,OBSERVATIONAL,['NA'],
15557,NCT01883258,Change in vascular endothelial function,Change in maximal oxygen consumption,2013-05,COMPLETED,INTERVENTIONAL,['NA'],
15558,NCT00006438,,,1997-01,COMPLETED,INTERVENTIONAL,['NA'],
15559,NCT00288236,Absolute change in HbA1C from baseline to Week 48,"Fasting glucose, total daily insulin dose, body weight, waist circumference, HDL-cholesterol, triglycerides, safety (physical examination, vital signs, laboratory tests, adverse events).",2006-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
15560,NCT03808376,Safety Endpoint - Incidence of device-related or sensor insertion/removal procedure-related serious adverse,,2018-12-27,COMPLETED,INTERVENTIONAL,['NA'],
15561,NCT00097786,Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
15562,NCT03549754,6. Provide real world data on renal outcomes and other microvascular complications in patients with type 2 diabetes and Heart Failure,,2018-02-17,RECRUITING,OBSERVATIONAL,['NA'],
15563,NCT03656887,Number of hypoglycemic events (<70 mg/dl) detected by capillary blood glucose measurement or clinical signs suggestive of hypoglycemia.,,2019-01-08,COMPLETED,OBSERVATIONAL,['NA'],
15564,NCT04136067,Number of treatment-emergent adverse events (AEs),Maximum observed serum NNC0268-0965 concentration after the last dose,2019-10-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
15565,NCT00603291,Co-primary Endpoint- Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss From Baseline to Week 52,Percent Change in Body Weight From Baseline to Week 52,2007-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
15566,NCT01849731,Glycosylated Haemoglobin levels,,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
15567,NCT00350779,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 18,Change From Baseline in 2-hour PMG (Post-meal Glucose) at Week 54,2006-06-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
15568,NCT01574820,"major cardiovascular events, including myocardial infarction, overt heart failure, and surgery or coronary intervention for CAD",Biomarkers measurements,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
15569,NCT00592670,Catecholamine measures,,2005-03,COMPLETED,INTERVENTIONAL,['NA'],
15570,NCT01509157,Parental fear of hypoglycemia,Hypoglycemic events-number and severity of episodes,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
15571,NCT03267264,Overall User Preference -Combined Groups,User Experience - Each Individual Study Group,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],
15572,NCT04935554,Change in HbA1c from baseline until week 12,Change in mental health by questionnaire SCL-90r until week 12,2020-08-17,COMPLETED,INTERVENTIONAL,['NA'],
15573,NCT00291772,Area under the curve for glucose,glucagon and gastric emptying,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
15574,NCT03439345,Progression to referable diabetic retinopathy/maculopathy,Cost-effectiveness (incremental cost per QALY gained),2018-07-23,COMPLETED,INTERVENTIONAL,['PHASE4'],Minor and major non-traumatic lower limb amputation (minor [defined as distal to the ankle] or major [defined as through or proximal to the ankle])
15575,NCT03060694,controlled attenuation parameter; liver stiffness measure,,2016-09,COMPLETED,OBSERVATIONAL,['NA'],
15576,NCT01810952,Average Daily Glucose Levels on Days 1-5 After the Initiation of the Treatment Protocol.,Glucose Values <70 mg/dL.,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
15577,NCT05589467,height in centimeters,,2020-01-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
15578,NCT00574782,,,2003-09,COMPLETED,OBSERVATIONAL,['NA'],
15579,NCT01898923,Number of Participants With Complete Ulcer Closure,Incidence of Infection of the Target Ulcer,2012-11-23,COMPLETED,INTERVENTIONAL,['PHASE3'],
15580,NCT03955289,Improved healing rate to time to healing,"Decreased complications in diabetic foot ulcers, i.e. infection, hospital admission, amputation",2019-01-15,COMPLETED,OBSERVATIONAL,['NA'],
15581,NCT01302028,Effect of grade of renal impairment on the pharmacokinetics of ASP1941,"Assessment of safety through evaluation of adverse events, physical examination, vital sins, lab-tests and 12-lead ECG",2010-01-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
15582,NCT02722239,Adverse Events,,2016-03-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
15583,NCT02092051,Difference in HbA1c between week 26 and week 69,Difference in the mean number of severe hypoglycaemic events between weeks 1-26 and weeks 43-69 defined as unconsciousness due to hypoglycaemia or need of assistance from another person to resolve the hypoglycaemia,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
15584,NCT00741923,"body weight, waist circumference, blood glucose, satiety hormones, and blood lipids, inflammation factor, and glycated haemoglobin",,2007-11,COMPLETED,INTERVENTIONAL,['NA'],
15585,NCT03211832,Partnerships to Support EBDM,Inter-agency Connectedness,2017-07-05,COMPLETED,INTERVENTIONAL,['NA'],
15586,NCT02906319,HbA1c levels,,2015-09,COMPLETED,OBSERVATIONAL,['NA'],
15587,NCT00928889,Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4),Change From Baseline in Glycosylated Serum Albumin (GSA) at the End of the Study (Week 4),2009-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
15588,NCT00607867,Change in Overnight Fasting Glucose Concentration at 5 Weeks From Baseline,Change in Fasting Triglycerides at 5 Weeks From Baseline,2008-04,TERMINATED,INTERVENTIONAL,['NA'],
15589,NCT01157403,C peptide release test,,2010-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
15590,NCT06285487,Changes in Glycemic Control,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
15591,NCT02184455,Percentage of Wound Area Reduction Compared to Baseline,Percent Change in Wound Area From Baseline,2016-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
15592,NCT01867216,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change From Baseline in C-Peptide Area Under the Effective Concentration Curve (AUEC₀-₁₂) During Mixed Meal Tolerance Test at Day 28,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
15593,NCT05979987,Opening link within SMS Text message,Completion rate of one screening/test,2023-07-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
15594,NCT02929355,Rate of vascular events between day one and the last day of follow-up reviewed by patient examination,Rate of carotid atherosclerosis progression measured by duplex ultrasonography in percentage of stenosis,2012-01,COMPLETED,OBSERVATIONAL,['NA'],
15595,NCT01247896,"The single dose PK of PF-05190457 will be described by estimating parameters of AUC(0-infinity), AUC(0-last), AUC(0-24), Cmax, Tmax, CL/F, Vz/F and half-life (t1/2), as the data permit","Gastric half-emptying time (GET½), the duration of the lag phase (Tlag), gastric emptying coefficient (GEC)",2010-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
15596,NCT03681249,24H urine total protein,,2018-11-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
15597,NCT05921461,PedCheck parameters that demonstrate correlation between HOVR and Ankle Brachial Index (ABI) and Toe Brachial Index (TBI).,Evaluation of usability based on collected data using standard pain scoring questionnaires.,2022-05-01,COMPLETED,OBSERVATIONAL,['NA'],
15598,NCT03520855,Diapason questionnaire (Aide aux Jeunes Diabètes),Evaluation of well-being with DQOLY,2019-04-03,RECRUITING,INTERVENTIONAL,['NA'],
15599,NCT04503551,Percentage of participants with a ≥2-step improvement from baseline on the ETDRS-DRSS at Week 52,Reported incidence of device deficiencies,2020-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
15600,NCT01390610,Derive optimum Self Monitored Blood Glucose (SMBG) testing patterns from CGM data. CGM data will be graphically and statistically represented by an Ambulatory Glucose Profile (AGP).,,2011-06,COMPLETED,OBSERVATIONAL,['NA'],
15601,NCT05660941,Time in range,Time above and below significant sensor glucose levels,2023-07-21,RECRUITING,INTERVENTIONAL,['NA'],
15602,NCT05127538,Dynamic Balance,,2021-12-10,COMPLETED,INTERVENTIONAL,['NA'],
15603,NCT01467674,HbA1c,Clinical Periodontal Status,2008-01,COMPLETED,OBSERVATIONAL,['NA'],
15604,NCT01086280,"Major cardiovascular events defined as a composite of acute MI, stroke or death due to acute MI, stroke, CHF, dysrhythmia, sudden death, or coronary revascularization. Alternative outcomes include DVT, PE, and arterial vascular disease",All-cause death,2010-01,COMPLETED,OBSERVATIONAL,['NA'],
15605,NCT03926806,Glycemic control,Change of GLP-1 response,2016-11-25,COMPLETED,INTERVENTIONAL,['NA'],
15606,NCT02806960,PD: Baseline-Adjusted Glucose Maximum Concentration (BGmax),,2014-06,TERMINATED,INTERVENTIONAL,['PHASE1'],
15607,NCT01422590,AUC of DPP-4 activity,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
15608,NCT01831752,blood glucose correlation coefficient,,2013-02,COMPLETED,OBSERVATIONAL,['NA'],
15609,NCT06082063,MACE + HHF,"Diabetic ketoacidosis, safety",2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Long term risk of DKA
15610,NCT05221359,Safety: Percentage of patients who will experience at least one relevant adverse event (AE) judged by the investigator as probably or highly probably related to ExOlin® for the whole duration of the study (extension phase included),Quality of Life: Overall score and subscores of the Diabetes Quality of Life (DQOL) questionnaire,2022-05-05,RECRUITING,INTERVENTIONAL,['NA'],
15611,NCT02980627,Metabolic Control (Change in HbA1c),Decrease in Overall Eating Disorder symptomatology,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
15612,NCT01677546,HbA1c (Glycated hemoglobin),Frequency of bolus calculator using,2011-01,COMPLETED,INTERVENTIONAL,['NA'],Body mass index- standard deviation (BMI- sds)
15613,NCT00035984,Change in HbA1c from Baseline to Week 30,Change in body weight from Baseline to each intermediate visit and Week 30,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
15614,NCT03128320,Change in transcutaneous oxygen pressure (TcPO2),Number of subjects with TEAEs in different severity,2017-05-25,COMPLETED,INTERVENTIONAL,['PHASE2'],
15615,NCT02500485,The number of volunteers with adverse events as a measure of safety and tolerability.,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],
15616,NCT05915975,Change in Glycemic Control,Change in Diabetes Self-Management,2023-11-07,RECRUITING,INTERVENTIONAL,['NA'],
15617,NCT06246851,Intradermal (in type 2 diabetics) vs intradermal (in non-type 2 diabetics),Intradermal or aerosol BCG re-vaccination safety in healthy volunteers,2024-02,RECRUITING,INTERVENTIONAL,['NA'],Examination of immunological and microbiological markers
15618,NCT06005519,change in body fat percentage in long time period,,2018-12-01,COMPLETED,INTERVENTIONAL,['NA'],
15619,NCT01137474,Adjusted Mean Change From Baseline in Hemoglobin (HbA1c) at Week 12,Adjusted Mean Change From Baseline in Serum Uric Acid Levels at Week 12,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
15620,NCT03734718,Blood glucose,Number of symptomatic hypoglycemic events,2019-06-01,COMPLETED,INTERVENTIONAL,['NA'],
15621,NCT02502253,"Evaluate BDPP effect on cognition with measures of memory, executive function, and attention measures (composite)",,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
15622,NCT01396330,Mean and maximum change from baseline in glucose level (mmol/l),,2011-09,COMPLETED,INTERVENTIONAL,['NA'],
15623,NCT05936203,Insulin doses delivered,,2023-01-11,COMPLETED,INTERVENTIONAL,['NA'],
15624,NCT01261494,HbA1c,Insulin resistance Index [fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR)],2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
15625,NCT03468283,hemoglobin A1c levels,the Problem Areas in Diabetes,2012-08-07,COMPLETED,INTERVENTIONAL,['NA'],
15626,NCT01371318,Lower extremity amputation secondary to diabetic foot ulcer,,2011-07,COMPLETED,INTERVENTIONAL,['NA'],
15627,NCT00774904,"GFR, HbA1c and the adiponectin concentration",,2007-04,COMPLETED,INTERVENTIONAL,['NA'],
15628,NCT01406262,QTc interval,Number of participants with adverse events,2011-07-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
15629,NCT03539133,Rehospitalization due to heart failure,Restenosis rate,2017-10-18,RECRUITING,OBSERVATIONAL,['NA'],
15630,NCT05104437,Neutralizing antibody level,Adverse events following vaccination,2021-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
15631,NCT00676741,Metabolic control measured as HbA1c,Number of adverse drug reactions (ADR),2008-02,COMPLETED,OBSERVATIONAL,['NA'],
15632,NCT06288412,"Time below range, glucose less than (<) 3.0 millimoles per liter (mmol/L) (54 milligrams per deciliter [mg/dL]) within 24 hours after start of exercise (TBR3.0mmol/L,exe)","Number of hypoglycaemic episodes for 18 hours in reference week (26 to 44 hours after dosing) (Hypo18h,ref)",2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE1'],
15633,NCT05309057,Body weight,Markers of inflammation - CRP,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA'],
15634,NCT00332488,Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue,Change in HbA1c From Baseline to Week 24 (Subjects Who Stayed on Original Treatment),2004-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
15635,NCT02298192,Change From Baseline in HbA1c,Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes,2014-11-21,COMPLETED,INTERVENTIONAL,['PHASE3'],
15636,NCT01974674,restoration of normal glycemic control without insulin,degenerative complications of diabetes,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],
15637,NCT01274052,,,2007-03,COMPLETED,OBSERVATIONAL,['NA'],
15638,NCT05093569,to determine the accuracy of K'Watch Release 0.x CGM system glucose readings at day 1 as compared to standard references.,Safety of the K'Watch system characterizing device-related pain intensity (Visual Analogue Scale scores from 0-10) recorded during the study.,2021-11-15,UNKNOWN,OBSERVATIONAL,['NA'],
15639,NCT03721848,Health Behavior-Amount of Red Meat Intake (Assessing Change),Primary Care PTSD (Assessing Change),2017-04-30,COMPLETED,INTERVENTIONAL,['NA'],
15640,NCT00362765,Endogenous Glucose Production (EGP) and Glucose Disposal Rate (GDR) by two-step hyperinsulinemic euglycemic clamp (HEC),"Gluconeogenesis, Glycogenolysis, Skeletal muscle and liver fat content, Abdominal fat content, Body energy expenditure and respiratory quotient, Lipids and glycemic parameters",2006-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
15641,NCT04791826,Frequency of prescription of SGLT-2i medication at outpatient clinic visits,Adherence of prescription of SGLT-2i medication at outpatient clinic visit,2021-03-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Frequency of incident HF
15642,NCT02536950,Mean glucose,% time < 60 mg/dl,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
15643,NCT02877355,Area under the semaglutide plasma concentration-time curve,Maximum observed SNAC plasma concentration,2016-08-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
15644,NCT04531462,Change in HbA1c From Baseline After 52 Weeks of Treatment,Change of Time in the 5-time Chair Stand Test From Baseline to Week 52,2020-10-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
15645,NCT04076800,Insulin daily doses,HbA1c,2019-08-01,RECRUITING,INTERVENTIONAL,['NA'],
15646,NCT00375388,"To investigate the quality of the metabolic control of diabetes and related variables (daily dose of insulin, body weight).",To perform a socio-economic evaluation.,1998-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
15647,NCT01761318,Left ventricular filling pressure (= early peak filling rate / peak mitral annulus longitudinal motion),Myocardial T1 - mapping,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4'],Hypoglycaemic episodes
15648,NCT05261776,Blood glucose level,,2021-03-15,COMPLETED,INTERVENTIONAL,['NA'],
15649,NCT02501746,Change in Systolic Blood Pressure,Change in cardiovascular disease (CVD) risk Score,2017-02-06,COMPLETED,INTERVENTIONAL,['NA'],
15650,NCT00812487,Hospital Readmission,Mean Glucose,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
15651,NCT01786707,Number of Participants With a Reduction of HbA1c of >0.5%,The Number of Subjects With a Reduction of >1% in HbA1c,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
15652,NCT06200519,Persistence of diastolic function changes into infancy,,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
15653,NCT03150199,Number of PP-MI Sessions Completed by Participants,Change in Diabetes Self-Care,2017-07-25,COMPLETED,INTERVENTIONAL,['NA'],Change in Hemoglobin A1c
15654,NCT04667143,Mean change from baseline in HbA1c at Week 24,,2021-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],
15655,NCT00933062,To assess the plasma pharmacokinetic profile of SRT2104 following administration of single and multiple oral doses (once a day for seven days) at a single dose level (2.0 g/day) to healthy male volunteers in the fed state.,To assess the safety and tolerability of SRT2104 following administration of single and multiple oral doses (once a day for seven days) at a single dose level (2.0 g/day) to healthy male volunteers in the fed state.,2009-03-23,COMPLETED,INTERVENTIONAL,['PHASE1'],
15656,NCT00138606,Change from baseline in HbA1c at 52 weeks,Change from baseline in mean daily number of insulin injections at 52 weeks,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
15657,NCT05200819,"Risk-marker signatures for severe COVID-19 disease, longer-term complications in patients surviving COVID-19.",,2020-12-02,COMPLETED,OBSERVATIONAL,['NA'],
15658,NCT02693964,Difference in carotid intima media thickness between postmenopausal women with type 1 diabetes and controls,Correlation between biomarkers with cardiovascular risk measures (carotid intima media thickness),2016-03,COMPLETED,OBSERVATIONAL,['NA'],
15659,NCT05613556,Frequency and location of high-pressure plantar areas,,2022-04-01,COMPLETED,OBSERVATIONAL,['NA'],
15660,NCT00130208,Number of Subjects With Greater Than 50% Reduction in Microalbuminuria,Change in Serum Albumin From Baseline to End of 26 Weeks,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
15661,NCT01864174,"Number of Participants With Death, Serious Adverse Events (SAEs), SAEs Related to Study Therapy, SAEs Leading to Discontinuation, Adverse Events (AEs) Related to Study Therapy, and AEs Leading to Discontinuation",Percent of Participants With HbA1c < 7%,2013-06-20,COMPLETED,INTERVENTIONAL,['PHASE4'],
15662,NCT05630417,Blood Parameters Follow-up Form,Blood Parameters Follow-up Form,2022-03-15,COMPLETED,INTERVENTIONAL,['NA'],
15663,NCT00879970,Number of Participants With the Indicated Components of the Composite Outcome for Vitamin D,"Mean Score on Montreal Cognitive Assessment (MoCA) Test, as an Assessment of Cognitive Function (CF)",2009-05,TERMINATED,INTERVENTIONAL,['PHASE4'],
15664,NCT01515202,"Safety and tolerability, as measured by the number, frequency and intensity of adverse events, vital sign measurements, ECGs, physical examinations, and clinical laboratory tests","Pharmacodynamics, as measured by Serum concentration of cortisol and cortisone after an oral dose of cortisone and biomarkers for HPA axis activity (urinary free cortisol and cortisone, salivary cortisol, ACTH, DHEA-S and 4-androstenedione)",2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
15665,NCT05163002,Differences between baseline A1c (%) and 90 days after the last educational session.,Difference in mean glycaemia (mg /dL) between baseline and 90 days following the last educational session,2021-05-10,UNKNOWN,INTERVENTIONAL,['NA'],
15666,NCT04412200,Cytokine secretion,AUC of stimulated C peptide,2020-06-01,RECRUITING,INTERVENTIONAL,['NA'],
15667,NCT03017287,Correlation between GlucoMe and HCT recommendations,Target HbA1C/glucose achievement,2017-01,TERMINATED,INTERVENTIONAL,['NA'],
15668,NCT03502174,FreeStyle Libre Flash Glucose Monitoring System Related adverse device effects,,2018-04-05,COMPLETED,OBSERVATIONAL,['NA'],
15669,NCT06293664,Difference in the total or incremental area under the curve of glucose and insulin concentration at an OGTT during saline vs. α-MSH infusion,"Difference in the total or incremental area under the curve of the concentration of metabolites (C-peptide, Glucagon, Gut hormones, α-MSH) during OGTT with saline or α-MSH infusion.",2024-03-04,RECRUITING,INTERVENTIONAL,['NA'],Adverse events (including flushing)
15670,NCT00331604,Treatment difference in HbA1c,Hypoglycaemia,2006-08-31,TERMINATED,INTERVENTIONAL,['PHASE3'],
15671,NCT00759720,Change from Baseline in Glycosylated hemoglobin level.,"Low-density lipoprotein fractionation [L-DL particles (total), intermediate-density lipoprotein, large L-DL, small L-DL (total), medium-small L-DL, very-small L-DL, mean L-DL size].",2003-11,TERMINATED,INTERVENTIONAL,['PHASE3'],
15672,NCT03761615,Time in range glucose levels as determined by CGM,Carbohydrate consumption,2018-11-13,COMPLETED,OBSERVATIONAL,['NA'],Length of hospital stay
15673,NCT05041621,Comparison of 5 hours postprandial percentage of time below 3.9 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations,Mobile app usability questionnaire: score is the average of 16 items and each item scores ranges 0-6 (average of higher scores means higher usability),2021-07-07,COMPLETED,INTERVENTIONAL,['NA'],
15674,NCT02350478,Changes in Endothelial Function (FMD - Flow Mediated Dilatation) From Baseline to 12 Weeks,Changes in Biochemical Markers (svCAM-1),2013-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
15675,NCT03928379,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug,PD: Change from Baseline in Fasting Plasma Insulin,2019-10-27,COMPLETED,INTERVENTIONAL,['PHASE1'],
15676,NCT03958591,the proportions of treatment simplification,,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
15677,NCT02947555,Association of lens autofluorescence with atherosclerotic vascular events,Association of lens autofluorescence with antropoetric parameters,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA'],
15678,NCT04548232,Hepatic steatosis,Fertility,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],
15679,NCT01364129,Proportion of Participants that Receive Annual Eye Exam,,2006-08,COMPLETED,INTERVENTIONAL,['NA'],
15680,NCT01007097,Change from Baseline in Glycosylated Hemoglobin at Week 12.,Incidence of Hypoglycemia During Double-Blind Treatment Period.,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2'],
15681,NCT01960062,Change in Hemoglobin A1c,Office visit time,2011-10,WITHDRAWN,INTERVENTIONAL,['NA'],
15682,NCT05413005,Clinically important hypoglycemic episodes,Serum IgM levels,2022-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
15683,NCT01709201,Percent days abstinent,Medical complications,2013-07,WITHDRAWN,INTERVENTIONAL,['NA'],Medical complications 90 days post baseline
15684,NCT02634528,"PK: Cins.max, maximum observed insulin concentration",Changes in Electrocardiogram recordings,2016-11-16,COMPLETED,INTERVENTIONAL,['PHASE1'],
15685,NCT05716607,glycemic variability,immunoglobulins,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
15686,NCT03932721,Difference in the percentage change in flow mediated dilation (FMD),Difference in the percentage change in FMD reserve,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Difference in Plasma C-Reactive Protein Change in mg/dL from randomization to 16 weeks of treatment.
15687,NCT00974272,Triglyceride concentration in serum,"serum or plasma lipoproteins, apolipoproteins and inflammatory markers; endothelial function",2006-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
15688,NCT04347252,hepatic glucose production,Change in Beta-hydroxybutyrate concentrations,2019-09-24,COMPLETED,INTERVENTIONAL,['PHASE1'],
15689,NCT04126291,Change in knowledge,Change in practice related to pediatric weight management,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],
15690,NCT03591939,rate of patients with positive T-regulatory cells in blood,,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA'],
15691,NCT05587348,Odds of attending 1 DSMES class,Change in Diabetes Self-Efficacy from baseline to 6 months,2023-09-12,RECRUITING,INTERVENTIONAL,['NA'],
15692,NCT05540132,Time to completion of distance bike challenge,Glycemic variability in the 12 hours following the exercise test,2023-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
15693,NCT02804698,Framingham cardiovascular disease risk,,2016-08,COMPLETED,INTERVENTIONAL,['NA'],
15694,NCT03230175,Number of Subjects With Complete Wound Healing,Percent Change in Wound Surface Area,2017-10-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
15695,NCT05396378,Increase of blood glucose following the oral glucose dose,Maternal subjective well being after oral glucose dose during the preoperative fasting period,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
15696,NCT00891995,C-peptide Average Area Under the Curve (AUC) in Response to a Mixed Meal at 1 Year Following Enrollment.,BMI Percentile,2010-09,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
15697,NCT01978704,mean plasma glucose concentrations,postprandial plasma glucose concentrations,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
15698,NCT02951260,Overall aerobic work performed during an exercise bout with self-selected intensity,Physical fitness (VO2max),2016-10,COMPLETED,INTERVENTIONAL,['NA'],Oxidative phosphorylation in skeletal muscle fibers
15699,NCT01645995,Changes in body weight and body composition,"Changes in cardiovascular risk factors (blood pressure, inflammatory markers)",2012-03,COMPLETED,INTERVENTIONAL,['NA'],
15700,NCT02917226,fasting blood glucose,,na,UNKNOWN,INTERVENTIONAL,['NA'],
15701,NCT03359629,Percentage of Measurements With < 15% Error,,2017-09-27,COMPLETED,OBSERVATIONAL,['NA'],
15702,NCT01154413,Reduction in hypo/hyperglycemia episodes,"Lower mean glycemia, reduced time of stay in hospital",2007-12,COMPLETED,INTERVENTIONAL,['NA'],
15703,NCT01135394,Change in Insulin Resistance,Number of Genes Determined to be Correlated With Change in Insulin Sensitivity,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
15704,NCT00321321,Insulin Secretion,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
15705,NCT00191178,Instruments used/tests performed:hand held computers to rate a series of 13 symptoms;hand held computers to administer a series of cognitive-motor performance tests;blood glucose testing,"blood glucose rate of change;eight-point self-monitored blood glucose profile;episodes of hypoglycemia, including episodes of severe hypoglycemia",2003-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
15706,NCT05802121,Side effects and tolerability,Bone health: Vitamin K2,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
15707,NCT02998008,echocardiography,,2017-01-02,TERMINATED,INTERVENTIONAL,['NA'],
15708,NCT06318611,Chronotype,Glycemic control,2022-05-01,COMPLETED,OBSERVATIONAL,['NA'],
15709,NCT03282136,"all cause mortality, and cardiac cause mortality.",hospital admissions for HF,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
15710,NCT02430870,Percentage of Participants Who Have Severe Hypoglycemia at Least Once Post-dose During Dosing For Part 2,AUCtau: Area Under the Plasma Concentration-time Curve From Time 0 Over the Dosing Interval for TAK-648 for Part 2,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
15711,NCT04585581,Plasma glucose concentration,Infant bone mass,2020-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Infant bone mass
15712,NCT03662984,Myocardial insulin sensitivity,Cholesterol profile,2018-11-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
15713,NCT00546728,Change in Reactive Hyperemic Index Over the 3-month Treatment Period,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
15714,NCT05290233,Lean mass,processing speed,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],
15715,NCT02115932,Change in EQ5D HUI from baseline at 2 and 6 months,Cost-utility of intervention measured by cost per Quality-Adjusted Life Year (QALY) gained,2014-07-30,COMPLETED,INTERVENTIONAL,['NA'],Change in gait from baseline at 2 and 6 months
15716,NCT00308139,Sub-study Relative Bioavailability of Exenatide When Administered Using the Exenatide Once Weekly Dual Chambered Pen and the Exenatide Once Weekly Single Dose Tray (Single Dose Tray-11 Weekly Doses Switch to Dual Chamber Pen-11 Weekly Dose),Assessment on Event Rate of Treatment-emergent Hypoglycemic Events With Non-SU Use at Screening,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
15717,NCT01285518,Number of Participants With Abnormal Cardiac Rhythms Recorded by Telemetry,Volume of Distribution at Steady State (Vss) of PF-05231023,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
15718,NCT01030796,Caffeine abstinence,HbA1c,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
15719,NCT00343343,Deposition of sterile air depositions.,Amount of backflow,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
15720,NCT00315952,"To perform positron emission tomography (PET) imaging of [18F]-fluoro-deoxy-glucose (FDG) uptake by muscle, following administration of a single dose of inhaled compared to infused insulin in volunteers with type 1 diabetes",To determine overnight rates of glucose production and plasma glucose after a single pre-dinner dose of inhaled compared to IV infused insulin in volunteers with type 1 diabetes,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
15721,NCT04832464,Berg Balance Scale,Michigan Neuropathy Screening Instrument,2021-03-30,UNKNOWN,INTERVENTIONAL,['NA'],
15722,NCT04698720,Immune cells,Representations regarding the DFU,2019-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Heart rate
15723,NCT02749435,Mean Change from baseline to Month 6 in HbA1c,Proportion of patients in both cohorts who intensify antihyperglycaemic treatment from Visit 1,2016-05-03,TERMINATED,OBSERVATIONAL,['NA'],Change from baseline to Month 6 in Morisky 8-item scale (adherence)
15724,NCT01486888,Maximum serum insulin concentration (Cmax),Adverse events,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
15725,NCT02675855,Complete closure of index wound,Number of patients with worsening of wound by ≥50% increase in size,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
15726,NCT01327404,,,2009-10,UNKNOWN,OBSERVATIONAL,['NA'],
15727,NCT05483777,Wound Observation and Evaluation Form,,2023-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
15728,NCT03512665,Homeostasis Model Assessment - Insulin Resistance (HOMA-IR),Change in plasma FGF-21,2018-04-07,COMPLETED,INTERVENTIONAL,['NA'],
15729,NCT03602378,"Stress in parents of children with developmental disability and chronic disease, and healthy children.","Advanced glycation end products in parents of children with developmental disability, chronic disease and parents of healthy children.",2018-04-02,UNKNOWN,OBSERVATIONAL,['NA'],
15730,NCT04001283,Metabolic protein expression in cardiac biopsies and vascular offcuts,,2013-01-21,UNKNOWN,INTERVENTIONAL,['PHASE2'],
15731,NCT00376870,In-Segment Late Loss,Stent thrombosis,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],
15732,NCT01976923,Visual acuity change,Proportion of eyes gaining at least 15 letters of BCVA,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Molecules in the vitreous humor and epiretinal membranes
15733,NCT05587413,Change of HbA1C between the control group and interventional group.,,2022-11-02,RECRUITING,INTERVENTIONAL,['NA'],
15734,NCT06333977,"Incidence, severity of adverse events",Renal Clearance (CLR) in urine,2022-03-25,COMPLETED,INTERVENTIONAL,['PHASE1'],HbA1c
15735,NCT02079805,Change in Insulin Resistance Index (HOMA-R) From Baseline at the End of the Treatment Period (Week 12),Number of Participants With Treatment-Emergent Adverse Events,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
15736,NCT03766854,"AUCI287τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state","GIRmax,0-24h,SS - Maximum observed glucose infusion rate at steady state",2018-12-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
15737,NCT04829903,Adverse effects,,2020-01-02,COMPLETED,INTERVENTIONAL,['NA'],
15738,NCT04953221,The change in the average weekly NRS score of pain from baseline,The change from baseline in the SF-36 Quality of Life Scale score,2021-07-01,UNKNOWN,OBSERVATIONAL,['NA'],
15739,NCT01973400,"Total Symptoms Score (TSS) (pain, paresthesia, burning, and numbness)of patients with diabetes type 1 and 2 neuropathy.",Neuropathy Impairment Score (NIS) of patients with diabetes type 1 and 2 neuropathy,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],"Mini Mental State Examination (MMSE) score, Montreal Cognitive Assessment (MoCA) test."
15740,NCT03489083,Heat Shock Response Change.,Visceral Adipose Tissue Change.,2016-02-01,COMPLETED,INTERVENTIONAL,['NA'],
15741,NCT04647617,5-time chair stand test,WHOQOL-BREF World Health Organization Quality of Life Taiwan version,2020-08-24,COMPLETED,INTERVENTIONAL,['NA'],
15742,NCT04537637,Change in Glycated haemoglobin (HbA1c ),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",2020-08-28,COMPLETED,OBSERVATIONAL,['NA'],
15743,NCT01554020,Fasting glucose,Blood pressure,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
15744,NCT03549845,Healthcare Utilization Composite - Change in CVD-related emergency department visits and hospitalizations,Participant experience of the CHAP intervention,2018-09-17,COMPLETED,INTERVENTIONAL,['NA'],Cardiovascular Risk - Change in diabetes risk score
15745,NCT05921344,Consensus Error Grid (CEG) for venous plasma glucose and glucose values measured by mμSORS at each time point of OGTT.,Incidence of Treatment-Emergent Adverse Events,2023-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
15746,NCT00754624,Annual Rate of Change in FEV1 From Baseline to End of Study,High Resolution Computerized Tomography Scans of the Chest,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
15747,NCT02617693,Difference in waist circumference,"Change in stress levels, as measured by the Depression Anxiety and Stress Scale 21-items (DASS-21) used in National Health Surveys in Malaysia",2015-11-23,COMPLETED,INTERVENTIONAL,['PHASE4'],
15748,NCT00289705,BMI development,"Medical risk factors, incidence of diseases (such as diabetes, hypertension etc), quality of life, socioeconomic development, eating pattern.",2006-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],
15749,NCT01623934,Diagnosis of gestational diabetes mellitus,,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],
15750,NCT01096277,Endothelial function,Effect on EPCs,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
15751,NCT01490112,Change in weight,Adverse events: Serious and non-serious,2005-01,COMPLETED,OBSERVATIONAL,['NA'],
15752,NCT04593173,Analysis of Value of 2D and 3D Left Ventricular Strains in Echocardiography in Type 2 of diabetic Patients,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],
15753,NCT00333723,Efficacy of rosiglitazone combined with glyburide to glyburide monotherapy in reducing glycosylated hemoglobin (HbA1c).,"Efficacy of rosiglitazone combined with glyburide to glyburide monotherapy upon FPG, c-peptide, HOMA and responder rates.",2000-07-28,COMPLETED,INTERVENTIONAL,['PHASE4'],
15754,NCT01770639,Treatment failure within the first year after surgery,Foot angles,2013-01,COMPLETED,OBSERVATIONAL,['NA'],
15755,NCT05581966,Data Collection,,2023-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
15756,NCT03283774,Cost analysis,,2015-01,COMPLETED,OBSERVATIONAL,['NA'],
15757,NCT04215328,Weight change between groups,Changes in gut hormone levels,2014-11-01,COMPLETED,INTERVENTIONAL,['NA'],
15758,NCT06086912,"After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Maximum Concentration (Cmax)",Immunogenicity indicators: anti-INS068 antibodies,2023-11-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
15759,NCT04805970,Measure and characterize organ volume change in patients with and without diabetes through use of summary statistics.,,2021-03-24,RECRUITING,OBSERVATIONAL,['NA'],
15760,NCT03088566,Patients reported experience measure (PREM),Patients reported outcome measure (PROM),2017-08-15,COMPLETED,INTERVENTIONAL,['NA'],
15761,NCT01556984,The changes of endothelial function,,2012-10,COMPLETED,OBSERVATIONAL,['NA'],
15762,NCT05952739,Diabetes mellitus complicating pregnancy,,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],
15763,NCT00329862,"Reduction and or elimination of co-morbidities @ 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 weeks",,2006-05,TERMINATED,INTERVENTIONAL,['NA'],
15764,NCT03249077,Weight,HbA1c (24-month for digital DPP),2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],Motivation for continuing
15765,NCT00849316,Incidence of major hypoglycaemic episodes,Number of all minor (daytime and nocturnal) hypoglycaemic events,2009-02,WITHDRAWN,OBSERVATIONAL,['NA'],
15766,NCT02084654,First-phase insulin response,glucose lowering effect,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],insulin-mediated glucose uptake (insulin sensitivity)
15767,NCT01704612,the duration of sensory block in hours,the duration of motor sciatic block,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4'],"occurrence of neurological omplications, yes/no"
15768,NCT01183715,Single dose pharmacokinetics of PF-05161704 and its metabolite PF-05200145,Preliminary pharmacodynamics of PF-05161704,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],
15769,NCT03269084,Clinical diagnosis of type 1 diabetes,,1994-11-07,RECRUITING,OBSERVATIONAL,['NA'],
15770,NCT01304836,Diagnosis of new onset Diabetes Mellitus as per ADA criteria at any point up to 24 weeks after kidney transplantation,Change from Baseline in HbA1C levels,2011-01-22,COMPLETED,INTERVENTIONAL,['PHASE4'],
15771,NCT03740074,App utility,Personal Activity Intelligence (PAI) Score,2018-10-02,COMPLETED,INTERVENTIONAL,['NA'],
15772,NCT03341793,Changes in myokine (muscle secretome) secretion induced by bariatric surgery,,2017-11-14,UNKNOWN,INTERVENTIONAL,['NA'],
15773,NCT06147414,% of inconclusive results,Estimated delay for result in standard care diagnosis condition,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
15774,NCT01191866,,,2009-09,UNKNOWN,OBSERVATIONAL,['NA'],
15775,NCT04029402,Renal function change,,2019-07-01,RECRUITING,OBSERVATIONAL,['NA'],
15776,NCT01839344,Glucose tolerance following a maltose tolerance test,Area under the Glucose Curve (AUC),2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Reactive Hyperemia Index (RHI)
15777,NCT03318601,Correlation between copetine and other biomarkers,Copetine concentrations,2016-05-09,UNKNOWN,INTERVENTIONAL,['NA'],
15778,NCT00560417,Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF]),Total Daily Insulin Dose at Endpoint (LOCF),2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
15779,NCT00743808,Systolic blood pressure,Measure changes in action taken related to improving blood pressure management as percent of providers reporting changing (initiating or adjusting) blood pressure medication,2006-12,COMPLETED,OBSERVATIONAL,['NA'],
15780,NCT01002521,Genetic Phenotyping (Haptoglobin and TRAPS),Quality of Life,2009-12,UNKNOWN,OBSERVATIONAL,['NA'],
15781,NCT00642174,Inhibition of Platelet Aggregation (IPA) 4 Hours After Loading Dose Assessed by Accumetrics VerifyNow™ P2Y12 Assay,Inhibition of Platelet Function as Measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
15782,NCT04186195,Children's type 1 diabetes glycemic control,Parent's type 1 diabetes glycemic status,2020-11-03,COMPLETED,OBSERVATIONAL,['NA'],
15783,NCT03064347,Difference in AUC of GLP-1 on meal tolerance tests Enteric Coated vs. Uncoated Nutrient.,Difference in Peak GLP-1 on meal tolerance tests Enteric Coated vs. Uncoated Nutrient.,2017-02-22,COMPLETED,INTERVENTIONAL,['NA'],
15784,NCT03774511,Homeostatic Model Assessment of Insulin Resistance (HOMA-IR),Visceral adipose fat,2017-07-09,COMPLETED,INTERVENTIONAL,['NA'],
15785,NCT00823849,"Primary Efficacy Evaluation: Comparing with the basic line information, the change value of arteriosclerosis related biomarker in 4 groups after 12 weeks of treatment.",,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
15786,NCT05887999,Pharmacodynamics (PD): Area under the concentration versus time curve from time 60 to 120 minutes (AUC60-120min) of plasma glucagon during the insulin-induced hypoglycemia,Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT,2023-06-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
15787,NCT03817749,Glucose control,Change from baseline caspase-1 activation at 14 days,2019-02-06,COMPLETED,INTERVENTIONAL,['NA'],
15788,NCT03977727,1-Hour Change in Postprandial Plasma Glucose (PPG),Pump Occlusions,2019-06-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
15789,NCT03077360,Percent Change in Body Weight Compared to Baseline Measurement,,2017-02-01,COMPLETED,INTERVENTIONAL,['NA'],
15790,NCT06336486,Visual Analog Scale(VAS),36-Item Short Form Health Survey(SF-36),2018-12-04,COMPLETED,INTERVENTIONAL,['NA'],
15791,NCT06146322,Food intake,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],
15792,NCT06111586,Change from baseline to W52 in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration,Change from baseline to W52 and W104 in DTSQs Total and item scores (caregivers of all participants 12-17 y.o.),2023-12-11,RECRUITING,INTERVENTIONAL,['PHASE2'],
15793,NCT05292833,The percentage of patients adhering to the Mediterranean Diet,Describe the difficulties/barriers to the initiation of the Mediterranean Diet,2023-07-06,RECRUITING,OBSERVATIONAL,['NA'],
15794,NCT01617434,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26,Number of Severe Hypoglycaemic Episodes During The Randomised Treatment Period,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
15795,NCT01935167,log ACR,Cystatin C,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
15796,NCT00627484,Change in Insulin Sensitivity,Change in Resting Energy Expenditure,2005-03-01,COMPLETED,OBSERVATIONAL,['NA'],
15797,NCT03254524,Emergency Deparrtment (ED) visit by a patient,Hospital Selection,2014-08-20,COMPLETED,OBSERVATIONAL,['NA'],
15798,NCT06132334,Physical activity level,Upper extremity functional exercise capacity (percentage of the expected value (%)),2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
15799,NCT02634333,Change in Visual Acuity From Baseline,Development of PDR and/or DME (Whichever Came First),2016-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
15800,NCT03279107,Change in plasma blood insulin from fasting baseline value (Time Frame: Up to 180 minutes).,Change in subjective appetite ratings from fasting baseline value (Time Frame: Up to 180 minutes).,2017-08-25,COMPLETED,INTERVENTIONAL,['NA'],
15801,NCT01588418,Effect of Exenatide on Brain (Total Gray Matter) Glucose Metabolism,Effect of Exenatide on the Liver and Adipose Tissue Glucose Uptake,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
15802,NCT02226640,Perform 'deep' clinical and molecular phenotyping of 360 adults- Diabetic and Non-Diabetic,,2010-11,COMPLETED,OBSERVATIONAL,['NA'],
15803,NCT06064669,healthy live birth,Cumulative live birth,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
15804,NCT03607435,Calibration of the KBS-1 Test Article using the POC Control data for comparison.,Calibration of the RBA-1 Test Article using the hospital lab test Control data and POC blood glucose monitor Control data for comparison.,2018-08-02,UNKNOWN,INTERVENTIONAL,['NA'],
15805,NCT04428645,Mean Change in the Percent of Time With Sensed Glucose Between 70 - 180 mg/dl,Change in Coefficient of Variation of Sensor Glucose Based on the Dexcom G6 CGM Data.,2020-07-21,COMPLETED,INTERVENTIONAL,['NA'],
15806,NCT01088451,Differences in mean blood glucose concentrations and the pattern of fluctuation on control and study days; and changes in the glycated hemoglobin A1c after the study period. Occurrence of side effects especially hypoglycemic episodes.,"The difference in postprandial areas under the curve when comparing conventional therapy and experimental combined prandial insulin therapy in the 5 to 6 hours following meal ingestion, taking into account the glycemic index profile of the meal.",2009-12,UNKNOWN,INTERVENTIONAL,['NA'],
15807,NCT04105608,Changes in serum GLP-1 concentration,Hunger-satiety scores (millimeters),2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],
15808,NCT03987438,The risk of diabetes mellitus (DM) in patients with impaired glucose tolerance,Changes in glycosylated hemoglobin levels.,2019-08-03,UNKNOWN,INTERVENTIONAL,['NA'],
15809,NCT03661177,Lipid panel,Cultural identity change,2020-01-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
15810,NCT00767884,Changes in optic nerve head topography before and after panretinal photocoagulation,,2008-10-29,TERMINATED,OBSERVATIONAL,['NA'],
15811,NCT02123563,plaque and gingival indices,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
15812,NCT00879710,Changes in LDL Cholesterol,Changes in Cholesterol Absorption or Synthesis Rates From the Baseline,2008-08,COMPLETED,INTERVENTIONAL,['NA'],
15813,NCT06273124,Primary Outcome,,2024-03-07,RECRUITING,INTERVENTIONAL,['NA'],
15814,NCT03487029,muscle oxigeneration,Physical activity level,2018-03-02,COMPLETED,INTERVENTIONAL,['NA'],
15815,NCT01429818,%ΔMBF,Adverse effects,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
15816,NCT01895712,Target Vessel Failure (TVF),Target lesion revascularization (TLR),2013-08,COMPLETED,OBSERVATIONAL,['NA'],
15817,NCT03910205,Interleukin-18 level,Tnf-alpha level,2019-04-08,COMPLETED,OBSERVATIONAL,['NA'],
15818,NCT04499820,density of the deep capillary plexus in optical coherence tomography angiography (OCTA),Diet questionnaire,2020-06-26,RECRUITING,INTERVENTIONAL,['NA'],
15819,NCT03699189,HbA1c,The quality of life,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
15820,NCT05373199,AUCGIR 6-24h,Local tolerability,2022-05-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
15821,NCT03594344,Intact skin with no abnormal openings at the site of primary amputation,The Foot and Ankle Ability Measure (FAAM),2018-07-04,RECRUITING,INTERVENTIONAL,['NA'],
15822,NCT02040571,Continuous glucose monitoring (CGM) time spent in target glycaemic range (4.0-8.0 mmol/L) from 2000h-0800h in clinical trial centre (phase 1 of the study).,Cognitive Assessment: CogState assessment battery outcome measures will be generated. Each battery test point will record participant response times and accuracy rates for all tasks performed.,2014-01,COMPLETED,INTERVENTIONAL,['NA'],
15823,NCT05348499,Diabetes Distress Score-T1 score in people with type 1 diabetes,Thematic analysis of semi-structured interviews to explore the impact of HCL systems on different aspects of life and daily functioning of people with type 1 diabetes and their partners.,2021-11-14,RECRUITING,OBSERVATIONAL,['NA'],
15824,NCT00184600,HbA1c (Glycosylated Haemoglobin) at Month 36,Number of Participants Having an 'Other' Adverse Event,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
15825,NCT00006165,,,na,COMPLETED,INTERVENTIONAL,['NA'],
15826,NCT01377155,Days to reach the titration target,The frequency of reported and documented (<70 mg/dl) hypoglycemic events per 24 hour period,2011-06,COMPLETED,INTERVENTIONAL,['NA'],
15827,NCT05517863,percent of wounds complete closure,percent of days needed for surface area reduction,2022-03-01,COMPLETED,INTERVENTIONAL,['NA'],
15828,NCT00798161,HbA1c Change From Baseline at Week 24,Use of Rescue Therapy,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
15829,NCT02569060,Change from Baseline HbA1c at 6 Months,Change from Baseline Food stability,2015-10,COMPLETED,INTERVENTIONAL,['NA'],Change from Baseline Diabetes Self-Care
15830,NCT01616433,Glucose,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
15831,NCT06192121,Diabetes Self-Care Activities,,2023-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
15832,NCT05782881,"Composite cardiovascular disease (cardiovascular death, non fatal myocardial infarction, non fatal stroke, hospitalization for heart failure, and readmission for acute coronary syndrome)",Blood pressure( both diastolic and systolic will be measured),2023-01-15,RECRUITING,INTERVENTIONAL,['NA'],
15833,NCT04878393,Number of adverse event (AEs),Number of serious adverse reactions (SARs),2021-04-30,COMPLETED,OBSERVATIONAL,['NA'],
15834,NCT00005905,,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
15835,NCT01617824,M1/M2 polarization balance,Endothelial progenitor cell levels,2012-09,COMPLETED,INTERVENTIONAL,['PHASE4'],
15836,NCT02397447,Insulin Sensitivity (Matsuda Index) After 90 Days,AUC-insulin After 90 Days,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
15837,NCT03353376,change in in Hba1c levels,change in non HDL Cholesterol,2010-09-13,COMPLETED,INTERVENTIONAL,['NA'],change in number in hospital admission
15838,NCT06121856,Performance evaluation: blood glucose monitoring system accuracy: BGMS vs reference instrument using arterial blood,,2023-02-07,COMPLETED,OBSERVATIONAL,['NA'],
15839,NCT05365529,Glycemic regulation assessed by HbA1c,Quality of life Assessment via Short Form-36 Questionnaire (SF-36),2022-05-16,RECRUITING,INTERVENTIONAL,['NA'],Long term TRE adherence
15840,NCT03024944,Amount of Tau Accumulation by Measuring Standardized Uptake Value Ratio (SUVR),,2017-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
15841,NCT00743002,"To evaluate the safety and tolerability of TT223 as a treatment for Type 2 diabetes at 1 mg, 2 mg and 3 mg.",To determine the pharmacokinetic (PK) parameter profile of TT223 in a subset of patients.,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
15842,NCT01906359,6-hour postprandial changes from fasting in glucose-dependent insulinotropic polypeptide (GIP),6-hour changes from fasting hunger rating using visual analogue scale (VAS),2012-09,COMPLETED,INTERVENTIONAL,['NA'],
15843,NCT06160063,Evaluation of Literacy Scale for Acute Complications of Diabetesfor Children with Type 1 Diabetes (8-12 years),,2023-01-16,COMPLETED,INTERVENTIONAL,['NA'],
15844,NCT04167761,Rate of isoproterenol-stimulated lipolysis to measure metabolic flexibility in epicardial adipose tissue samples.,Distribution of adipose cell size in epicardial tissue.,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],
15845,NCT02518945,Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo.,Change in Blood Ketone Bodies,2015-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
15846,NCT05773495,Change in Diabetic Screening Rate,Follow Up Rate For In-Person Eye Care Among Screen Positives,2024-03-19,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
15847,NCT05599893,Glycemic level,Health related quality of life,2021-01-01,COMPLETED,INTERVENTIONAL,['NA'],
15848,NCT02144441,Trial feasibility metric: reasons for disenrollment,Hypoglycemia,2014-06,WITHDRAWN,INTERVENTIONAL,['NA'],
15849,NCT01847144,Change in fasting glucose,Additional changes in biochemical results,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
15850,NCT01963130,"This study investigated the effect of the used type 2 DM drug, vildagliptin, a DPP-4 inhibitor, on portal hemodynamics.","This study investigated the effect of the used type 2 DM drug, vildagliptin, a DPP-4 inhibitor, on hepatosteatosis.",2012-07,COMPLETED,OBSERVATIONAL,['NA'],
15851,NCT03010475,Area under the rosuvastatin plasma concentration-time curve,Maximum observed rosuvastatin plasma concentration,2017-01-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
15852,NCT01825148,pancreatic uptake of radiolabeled Exendin,,2012-12,COMPLETED,OBSERVATIONAL,['NA'],
15853,NCT05041673,Change in steatosis as measured using CAP score (fibroscan) and MRI,Changes in fibrosis grade,2021-02-23,UNKNOWN,INTERVENTIONAL,['NA'],
15854,NCT02230488,Prevent <31 day readmission,improve overall glycemic management,2014-09,TERMINATED,INTERVENTIONAL,['NA'],Patient satisfaction
15855,NCT05256615,Sleep (minutes per night),Infant Apgar Scores,2020-01-01,RECRUITING,INTERVENTIONAL,['NA'],
15856,NCT02382159,Variation of the Lipid parameter pattern patients who are treated by lipid-lowering drug.,Variation for lipid parameter when the patients who are treated for 3±1 months by lipid-lowering drug.,2010-10,COMPLETED,OBSERVATIONAL,['NA'],Setting the sub-group by the result of lipid parameter
15857,NCT01762644,Insulin Independence and Hemoglobin A1c (A1C) < 6.5%,Average daily insulin requirement per week,2015-08,WITHDRAWN,INTERVENTIONAL,['PHASE3'],
15858,NCT01649219,Glucose and lipid metabolism,Changes in muscle metabolism,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
15859,NCT02250222,Number of participants with one or more drug related adverse events or serious adverse events,PK profile (maximum concentration (Cmax) of LGD-6972 after repeat oral doses in NHS and in subjects with T2DM,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],"Change from baseline in fasting plasma active and total GLP-1 measured during an OGTT on Day 14 of treatment with LGD-6972 at 0.5, 1, 1.5, 2, 3, and 4 hours post-glucose load in one dose group of subjects with T2DM"
15860,NCT03767699,Gestational Weight Gain,,2013-11,COMPLETED,OBSERVATIONAL,['NA'],
15861,NCT03155594,Changes in care,Accuracy of device,2017-05-09,UNKNOWN,INTERVENTIONAL,['NA'],
15862,NCT04900636,Impact on quality of life,Metabolic control,2021-05-01,COMPLETED,INTERVENTIONAL,['NA'],
15863,NCT05035082,Change in Glycosylated hemoglobin A1c (HbA1c),"Diabetes Treatment Satisfaction Questionnaire, change version (DTSQc), Relative treatment satisfaction total score",2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE4'],
15864,NCT02464800,Visual acuity,Retinal reattachment,2007-04,COMPLETED,OBSERVATIONAL,['NA'],
15865,NCT01461499,Reduction in Albuminuria,Change in the Serum Insulin Level,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
15866,NCT03914326,"Time to first occurrence of a major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death/non-fatal myocardial infarction/non-fatal stroke",Time to first occurrence of a severe hypoglycaemic episode,2019-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
15867,NCT02167243,To assess if the intervention reduces A1c,,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
15868,NCT01637727,Long term effects of gestational diabetes mellitus in a population of parous women,Long term effects of gestational diabetes mellitus in a population of parous women,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],
15869,NCT00659282,Incidence of major hypoglycaemic events reported as serious adverse drug reactions,,2006-09-11,COMPLETED,OBSERVATIONAL,['NA'],
15870,NCT00544934,glycated albumimin concentration,urine albumin,2007-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
15871,NCT01223560,,,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
15872,NCT05857085,evaluation of arterial stiffness with peak wave velocity ( PWV),evaluation of endothelial progenitor cells EPC count,2021-12-15,COMPLETED,INTERVENTIONAL,['PHASE4'],changes of glycemia endpoints glucovariability/time in range
15873,NCT01869790,Area under the curve (AUC),,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
15874,NCT00241124,Change from baseline in systolic 24 hour blood pressure after 12 weeks,"Adverse events, serious adverse events, laboratory values, physical examinations, vital signs for up to 26 weeks",2004-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
15875,NCT01084369,Improvement in endothelial dependent and endothelial-independent vasodilatation,Markers of endothelial function,2013-10-11,TERMINATED,INTERVENTIONAL,['PHASE4'],
15876,NCT05392166,pancreatic enzymes elevation in diabetic children .,,2022-05-13,RECRUITING,INTERVENTIONAL,['NA'],
15877,NCT01333514,Probability of Hypoglycemia,Probability of Hyperglycemia,2011-04,TERMINATED,INTERVENTIONAL,['PHASE4'],
15878,NCT05540405,Glycated hemoglobin (HbA1c),Skeletal muscle mass,2023-01-24,COMPLETED,INTERVENTIONAL,['NA'],
15879,NCT04618406,Change in the number of wound complications,Number of participants requiring re-amputation,2021-11-01,RECRUITING,INTERVENTIONAL,['NA'],
15880,NCT04346524,Maternal complications during pregnancy,Fetal complications during pregnancy,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA'],
15881,NCT05613920,Changes in blood glucose levels over time,pregnancy outcomes,2022-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Apgar score of newborn
15882,NCT01146314,Improvement of health status of overweight children,Improvement of health behaviors and psychosocial adjustment,2006-09,COMPLETED,INTERVENTIONAL,['NA'],
15883,NCT00892151,Number of Participants Rated Successful (<=3) at Performing Specific Tasks,Number of Participants Who Rated Clarity and Usefulness of User Instructions as >=3,2009-04,COMPLETED,INTERVENTIONAL,['NA'],
15884,NCT03854656,Change in body weight (kg),Satisfaction with the intervention (qualitative methods),2019-02-25,COMPLETED,INTERVENTIONAL,['NA'],
15885,NCT00838344,medication adherence,medication adherence challenges,2008-04,UNKNOWN,INTERVENTIONAL,['NA'],
15886,NCT05195567,Analysis of system accuracy based on DIN EN ISO 15197,,2022-02-17,COMPLETED,INTERVENTIONAL,['NA'],
15887,NCT00236639,The percent change in body weight from the baseline (randomization) to Week 60 (after one year of maintenance therapy).,"Changes from either baseline to Week 60 and/or Week 112, or enrollment to Week 60 and/or Week 112 in absolute body weight, Body Mass Index (BMI), body measurements, fasting lipid profile.",2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
15888,NCT04698200,Change of systolic and diastolic blood pressure,Skin and body temperature,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
15889,NCT03610412,The effect of cinnamomum cassia on body weight,The effect of cinnamomum cassia potentiates the IGF1 insulin response on body fat%.,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
15890,NCT05515744,Incidence of neonatal intensive care unit (NICU) > 1 day (24 hours) stay,Duration of maternal hospital stay,2023-01-20,RECRUITING,INTERVENTIONAL,['NA'],
15891,NCT02152852,Improvement in HbA1c,Physical and mental functioning,2011-11,COMPLETED,INTERVENTIONAL,['NA'],
15892,NCT01268488,Numbers of Fingerstick Blood Glucose (BG) Results Within +/- 5 to 15mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,Numbers of Forearm Blood Glucose (BG) Results Within +/- 5 to 15 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,2010-12,COMPLETED,INTERVENTIONAL,['NA'],
15893,NCT02832739,Level of and potential changes in technology acceptance in participants,Level of and potential changes in eHealth Literacy in participants,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],
15894,NCT03490136,Prevalence of type 2 diabetes,Changes in dietary habits,2016-05,COMPLETED,OBSERVATIONAL,['NA'],
15895,NCT01510509,Major adverse cardiac events,Late luminal loss,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],
15896,NCT00564668,Safety,HbA1c,2004-06-19,COMPLETED,INTERVENTIONAL,['PHASE3'],
15897,NCT00270985,HbA1c,Il-6,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
15898,NCT05372445,Gut microbiota metabolic pathways changes,Gut microbiota diversity changes,2022-05-30,RECRUITING,INTERVENTIONAL,['NA'],
15899,NCT00282451,HbA1c,Postprandial glucose concentration increments (calculated based on 7-point blood glucose profiles),2006-02,COMPLETED,INTERVENTIONAL,['PHASE4'],
15900,NCT01832311,level of vascular endothelial growth factor in aqueous humor,degree of corneal edema,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
15901,NCT03136939,the rate of positive reactivation against the IGRP epitopes,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],
15902,NCT01307917,"compare endothelial function by studying reactive hyperemia, nitric oxide, and proinflammatory factors in adolescents (12-21 years old) with diabetes vs. healthy sex- and age-matched control subjects.","examine the effects of flavonoids on vascular function, urine nitric oxide, and proinflammatory factors in patients with diabetes mellitus",2009-07,WITHDRAWN,INTERVENTIONAL,['NA'],
15903,NCT02073474,Incidence rates of adverse events.,Number of MS patients discontinuing medications for MS symptoms other than anti-spasticity medications.,2011-02,COMPLETED,OBSERVATIONAL,['NA'],
15904,NCT01437592,Area under the serum insulin degludec concentration-time curve,Time to maximum observed serum insulin degludec concentration,2011-09-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
15905,NCT00105898,Change in HbA1c at 12 months,"Change in blood pressure, lipid profile and diabetes-related stress (self-report) at 12 months; cost-effectiveness analysis of the interventions.",2005-02,COMPLETED,INTERVENTIONAL,['NA'],
15906,NCT02174562,"Percent of Participants With Improvement in Hemoglobin A1c by 0.5%""",Adherence as Measured By Percentage of Doses Taken as Prescribed,2014-07,COMPLETED,INTERVENTIONAL,['NA'],
15907,NCT00870454,Mean of the last 7 daily average diabetic peripheral neuropathy (DPN) pain scores,The mean of the last 7 Daily Sleep Interference scores.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
15908,NCT00770445,Change from Baseline in Matrix Metallo Proteinase 9.,Change from Baseline in Circadian (7 point) Blood Glucose Profile (Week 12).,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
15909,NCT02387749,Change of Nerve Conduction Amplitude of Nerves Affected Measured by Nerve Conduction Study.,Change of Levels of Glycated Haemoglobin( HA1C) After Stem Cells Transfusion Measured in Percent %,2014-05,COMPLETED,INTERVENTIONAL,['NA'],
15910,NCT03668808,Continuous Glucose Monitoring - Time in Range (70-140 mg/dl),Sleep Efficiency Measured by ActiGraph,2018-11-16,COMPLETED,INTERVENTIONAL,['PHASE4'],
15911,NCT04867785,Change From Baseline in Hemoglobin A1c (HbA1c),"Population PK: Average Steady-State Plasma Concentration (Cav,ss) of LY3437943",2021-05-13,COMPLETED,INTERVENTIONAL,['PHASE2'],
15912,NCT01585818,Average mean glucose levels and variability,Glucose and Insulin Levels,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],
15913,NCT01094054,Disposition Index,Gastric emptying and intestinal transit,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4'],
15914,NCT02402985,Variance of glucose metabolism after different diet intervention,Variance of intestinal hormones,2013-09,COMPLETED,INTERVENTIONAL,['NA'],
15915,NCT00511108,Percent Change From Baseline in Index of Static Beta-cell Sensitivity to Glucose After 12 Weeks of Treatment,Change From Baseline in Glucose 5-hour Total AUC After 12 Weeks of Treatment,2007-07-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
15916,NCT03289494,"Mean postprandial incremental Area Under the Curve (iAUC), measured by CGMS",Charaterisation of acceptability to H-SDS diet in free living conditions,2017-08-30,COMPLETED,INTERVENTIONAL,['NA'],
15917,NCT03811470,All cancers,Cost-effectiveness,2017-05-31,RECRUITING,OBSERVATIONAL,['NA'],
15918,NCT01685502,Decrease rate of HbA1c,Body weight,2010-11,COMPLETED,OBSERVATIONAL,['NA'],
15919,NCT03672409,Change in knowledge measurements in diabetes by questionnaire,,2018-09-05,UNKNOWN,INTERVENTIONAL,['NA'],
15920,NCT01805245,Diabetes Distress,Mean Night Diastolic Ambulatory Blood Pressure,2012-01,COMPLETED,INTERVENTIONAL,['NA'],Mindfulness
15921,NCT05673668,Changes of islet secretory function (HOMA-β),Change of sympathetic nervous system activity,2022-12-27,RECRUITING,INTERVENTIONAL,['NA'],
15922,NCT01508858,AUC of levonorgestrel,Adverse events,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
15923,NCT06209411,Number of participants who completed OGTT during the first year postpartum,"Number of women with abnormal OGTT who get tests including hemoglobin, lipid profile, creatinine.",2024-03-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
15924,NCT04796779,Time in Range,CGM-measured Percent Below 54 mg/dL,2021-04-21,COMPLETED,INTERVENTIONAL,['NA'],"CGM-measured % >300 mg/dL During the Four Hours Following the Announced Meal, or Until the Next Meal Bolus is Given, for the Missed Meal Bolus Challenge"
15925,NCT00263939,"Health related quality of life (HRQoL) at 2wks and 4wks during the intervention, immediately post intervention and at 6 months and 1 year post intervention","self-care self-efficacy at 2wks and 4wks during the intervention, immediately post intervention and at 6 months and 1 year post intervention",2004-07,COMPLETED,INTERVENTIONAL,['NA'],
15926,NCT03553680,Change in Diabetes Distress,Change in Diabetes Self-Care,2017-10-20,COMPLETED,INTERVENTIONAL,['NA'],
15927,NCT05631444,Efficacy profile: Quality of life,,2019-01-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
15928,NCT03733743,Day-night rhythm in skeletal muscle mitochondrial respiration,Change in energy status of the heart between morning and evening,2018-07-09,COMPLETED,INTERVENTIONAL,['NA'],
15929,NCT02970656,Glycosylated Hemoglobin (HbA1c),DNA Methylation,2017-02-08,COMPLETED,INTERVENTIONAL,['NA'],
15930,NCT00598663,HbA1c at 6 Month,Diabetic Ketoacidosis Events,2008-01,COMPLETED,INTERVENTIONAL,['NA'],
15931,NCT00526552,,,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
15932,NCT02876744,Detection and measure of ischemic territories in central and peripheral retina,,2017-04-04,COMPLETED,OBSERVATIONAL,['NA'],
15933,NCT00855010,Bone Turnover Marker - Plasma 25-hydroxyvitamin D,Disposition Index,2009-02,COMPLETED,INTERVENTIONAL,['NA'],
15934,NCT00668109,Sexual encounter profile question 3 observed within 15 minutes to 4 hours for vardenafil and 22 to 26 hours for the tadalafil group,Safety and tolerability,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3'],
15935,NCT04190160,The Diabetes Treatment Satisfaction (DTSQ),Cognitive function (MMSE),2018-11-19,COMPLETED,INTERVENTIONAL,['NA'],
15936,NCT02114554,Prognostic factors for poor outcome,,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],
15937,NCT04779645,Change in Cardiovascular Disease (CVD) Risk Markers.,,2021-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
15938,NCT00038727,"Major Adverse Cardiovascular Events (MACE): Myocardial Infarction (MI), Stroke, or Cardiovascular Death (CVD)",Mortality,2002-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
15939,NCT03371940,Change in depression status - Diagnosis of Major Depressive Disorder,Cost effectiveness analyses,2012-01-01,COMPLETED,INTERVENTIONAL,['NA'],
15940,NCT02955875,Medications knowledge at 9 months,Cost-effectiveness of pharmaceutical care at 9 months,2015-01,COMPLETED,INTERVENTIONAL,['NA'],
15941,NCT01555164,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
15942,NCT02060201,Area under the concentration-time curve from time zero extrapolated to infinite time [(AUC(INF)] for Saxagliptin and Dapagliflozin,"Safety measured by the occurrence of deaths, adverse events (AEs), serious adverse events (SAEs), results of clinical laboratory tests, vital sign measurements, physical examination findings, and 12-lead electrocardiogram (ECG) results",2014-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
15943,NCT00069602,Accuracy of the GlucoWatch G2 Biographer and CGMS sensors,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
15944,NCT01608425,Surgical procedures,Ulcer healing,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],
15945,NCT03089333,Change in Systolic Blood Pressure,Change in microalbuminuria,2016-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
15946,NCT00259701,,,2005-06,COMPLETED,OBSERVATIONAL,['NA'],
15947,NCT05247437,Changes in weight from baseline (week 0) to posttreatment (week 9),Changes in the scores on the Weight loss self-efficacy scale,2022-02-19,UNKNOWN,INTERVENTIONAL,['NA'],
15948,NCT02079870,Ad libitum energy intake during a lunch meal (following a standardised breakfast meal),Incidence of adverse events,2014-03-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
15949,NCT02883751,Wound closure,Cost-benefit ratio of ulcer treatment following minor amputations,2017-01,WITHDRAWN,INTERVENTIONAL,['NA'],
15950,NCT00888238,Insulin Secretion Rate (ISR) During 190 - 340 Minutes Post-dose,Glucose Infusion Rate (GIR) During 190 - 340 Minutes Post-dose,2009-05-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
15951,NCT03647306,MI-IS,,2018-02-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
15952,NCT00231660,The percent change in body weight and change in HbA1c from baseline (Week 0) to one year after maintenance therapy (Week 60).,"Changes from baseline or from enrollment to Week 60 in BMI and HRQOL measures; safety evaluations, such as adverse events and vital signs throughout study.",2000-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
15953,NCT03091686,Participants' intentions to reduce occupational sitting time,Participants confidence to reduce occupational sitting time,2017-08-17,COMPLETED,INTERVENTIONAL,['NA'],
15954,NCT05516576,"Remission of diabetes after endoscopic gastroplasty with endomina, in patients with type-2 diabetes and class I obesity",,2023-09-29,RECRUITING,INTERVENTIONAL,['NA'],
15955,NCT01856907,Normalization of Glucose Levels,Waist-to-Height Ratio,2013-09-28,COMPLETED,INTERVENTIONAL,['PHASE4'],Liver Enzymes as Safety Measure
15956,NCT05711108,Biochemical hypoglycemia,Symptoms of hypoglycemia reported to the staff by the resident in between or at the time of fingerstick glucose monitoring (information derived from nursing notes),2022-01-19,RECRUITING,OBSERVATIONAL,['NA'],
15957,NCT01787214,Within-day glucose variability,Net glycemia at 4 hours,2013-06,TERMINATED,INTERVENTIONAL,['NA'],
15958,NCT03179657,Nonalcoholic fatty liver disease (NAFLD),Cognitive function,2008-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
15959,NCT02458131,Change in BMI,"Change in knowledge, attitudes, beliefs and behaviors related to diabetes and weight loss",2016-11-11,COMPLETED,INTERVENTIONAL,['NA'],
15960,NCT01910727,Change in percent of total calories from fat from baseline through 12 months follow-up,Increased numbers of individuals having been screen for diabetes between baseline and 12 months follow-up,2011-12,COMPLETED,INTERVENTIONAL,['NA'],
15961,NCT02744963,Appropriate medicine adherence,Healthcare costs including medication costs,2016-06,UNKNOWN,INTERVENTIONAL,['NA'],Count of healthcare encounters
15962,NCT03068273,CGM patient acceptability questionnaire - patient-reported outcome,Hyperglycemia (>250 mg/dL): rate comparison (type 2 diabetes),2015-05,COMPLETED,INTERVENTIONAL,['NA'],
15963,NCT00653302,% of responders with HbA1c<7% and/or a final decrease of HbA1c>15% compare to the basal value (HbA1c final - HbA1c basal).,AE/SAE evaluation,2003-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
15964,NCT01332370,medical resource utilization,,2009-12,COMPLETED,OBSERVATIONAL,['NA'],
15965,NCT05015894,"AUC0-∞,NNC0480-0389,SD, area under the NNC0480-0389 plasma concentration time curve after a single dose","Cmax,NNC0480-0389,SD, Maximum observed NNC0480-0389 plasma concentration after a single dose",2021-08-30,COMPLETED,INTERVENTIONAL,['PHASE1'],
15966,NCT04209075,Gastrointestinal (GI) Tolerability Score,Stool Short Chain Fatty Acids (SCFA),2020-03-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
15967,NCT05872269,Frequency and severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs),Change in BMI,2023-07-20,RECRUITING,INTERVENTIONAL,['PHASE4'],
15968,NCT00700622,Change From Baseline in HbA1c to Week 16,,2008-05,TERMINATED,INTERVENTIONAL,['PHASE3'],
15969,NCT03877783,retention rate,Memory function,2020-10-19,UNKNOWN,INTERVENTIONAL,['NA'],
15970,NCT02528695,Glucose uptake in adipose tissue measured by uptake of 18F-FDG on PET images,,2014-11,COMPLETED,INTERVENTIONAL,['NA'],
15971,NCT03482869,Maximal walking distance,,2018-03-30,UNKNOWN,INTERVENTIONAL,['NA'],
15972,NCT02513875,fasting glucose (mg/dL),TC (mg/dL),2013-02,COMPLETED,INTERVENTIONAL,['NA'],
15973,NCT01783275,Splanchnic glucose uptake,Endogenous glucose production,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
15974,NCT05745441,24-hour total fat oxidation,14-hour post-dinner cumulative dietary fat oxidation,2023-07-05,RECRUITING,INTERVENTIONAL,['NA'],
15975,NCT03993366,Time in hyperglycemia,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA'],Gastrointestinal symptoms
15976,NCT03199638,"HbA1c, Glycated Hemoglobin",Insulin Sensitivity Score (ISS),2016-04-01,COMPLETED,INTERVENTIONAL,['NA'],
15977,NCT03703869,Change in HbA1c at month 6,Body weight,2018-03-06,COMPLETED,OBSERVATIONAL,['NA'],
15978,NCT02291874,Fasting plasma glucose,"Adverse events (AEs), vital signs, and laboratory tests",2014-10-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
15979,NCT03204799,Metagenomic profile change,blood glucose change,2016-12-17,UNKNOWN,OBSERVATIONAL,['NA'],
15980,NCT02889510,Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1),Changes From Baseline on Measurements of Respiratory Function Defined by Residual Functional Capacity (RFC),2016-10-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
15981,NCT03268941,Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Values,Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 in Part 1,2017-09-26,COMPLETED,INTERVENTIONAL,['PHASE2'],
15982,NCT02856113,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in CD26 (CD8+T Cells) Surface Antigen Levels at Weeks 26 and 52,2016-10-14,COMPLETED,INTERVENTIONAL,['PHASE3'],
15983,NCT00931372,Area under the insulin secretion curve,Area under the insulin secretion curve,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
15984,NCT03312179,MACE,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],
15985,NCT05544266,"Phenotypic and genotypic characterization of previously unknown forms of diabetes using Whole Genome Sequencing (WGS), and deeper phenotyping methods",,2020-09-30,RECRUITING,OBSERVATIONAL,['NA'],
15986,NCT02813343,Glucose control (HbA1c levels),Standardized PROMs/PREMs,2016-04,COMPLETED,INTERVENTIONAL,['NA'],
15987,NCT05236660,Foot ulcer recurrence during the 12-months follow-up (as the primary clinical outcome),Quality-adjusted life years,2022-03-02,RECRUITING,INTERVENTIONAL,['NA'],
15988,NCT05418699,HbA1c level,Coefficient of variation,2022-09-26,RECRUITING,OBSERVATIONAL,['NA'],
15989,NCT05195944,Change in HbA1c level (%),Number of treatment-emergent adverse events,2022-10-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4'],Change in alanine aminotransferase (ALT) level
15990,NCT01877603,The relation between plasma irisin and endothelium-dependent vasodilation,,2013-07,COMPLETED,OBSERVATIONAL,['NA'],
15991,NCT01413035,To assess efficacy of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus,To evaluate the incidence and severity of adverse events of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus,2011-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
15992,NCT01031108,To examine the effects of SRT2104 (2.0 g administered once daily for 28 days) on reversing vasomotor and fibrinolytic dysfunction in both type 2 diabetes mellitus patients and otherwise healthy smokers in a fed state.,"To explore the effects of SRT2104 on potential biomarkers of activity for glucose control (HbA1c, glycated albumin and fructosamine) and/or Sirt1 activation.",2010-05-28,COMPLETED,INTERVENTIONAL,['PHASE1'],
15993,NCT06253351,HbA1c after HCL,nephropathy,2024-03-13,RECRUITING,OBSERVATIONAL,['NA'],
15994,NCT02582736,Hospitalization for a hyperglycemic emergency,,2012-04,COMPLETED,OBSERVATIONAL,['NA'],
15995,NCT04025762,Time spent in the target sensor glucose range,"Total, basal and bolus insulin dose",2019-09-01,COMPLETED,INTERVENTIONAL,['NA'],Sleep quality assessment
15996,NCT04698018,"AUCIAsp,0-30min, area under the serum insulin aspart concentration-time curve from 0 to 30 minutes",Number of treatment emergent hypoglycaemic episodes,2021-04-20,COMPLETED,INTERVENTIONAL,['PHASE1'],
15997,NCT05790681,"Time to maximum observed serum insulin icodec concentration after a single dose (tmax,Ico,SD)","Model-based area under the serum insulin icodec concentration-time curve during one dosing interval at steady state (AUC,Ico,τ,SS,model)",2023-04-25,RECRUITING,INTERVENTIONAL,['PHASE1'],
15998,NCT01987258,Glycemic control,Excess post-exercise oxygen consumption (EPOC),2013-06,COMPLETED,INTERVENTIONAL,['NA'],
15999,NCT05714059,Primary Effectiveness Endpoint for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL),Secondary Effectiveness Endpoint 2 for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL),2023-02-28,COMPLETED,INTERVENTIONAL,['NA'],
16000,NCT04234373,Effect of a low-carb dietary intervention on glycemic control as defined by blood glucose level at 2h after an oral glucose tolerance test.,Effect of a low-carb dietary intervention on liver fat fraction as measured with MRI,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],
16001,NCT01163591,"The optimal eZscan unit to detect the presence of diabetic nephropathy as defined by eGFR and ACR using ROC analysis, sensitivity and specificity values.","A prediction algorithm using age, sex, body mass index and eZcan score will be developed to predict eGFR as continuous and categorical variables using Cox regression analysis.",2009-01,COMPLETED,OBSERVATIONAL,['NA'],
16002,NCT04342845,Problem Areas in Diabetes Questionnaire,Stages of Change score,2016-05-01,COMPLETED,INTERVENTIONAL,['NA'],
16003,NCT03122041,The main outcome was change in HOMA-β index (Homeostasis model assessment for beta cell function index).,The secondary outcome was change in plasma glucose level at 120 minutes (G120) after glucose load in oral glucose tolerant test (OGTT).,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
16004,NCT03119142,Adherence to the Mediterranean diet,Inflammation,2017-05-02,COMPLETED,OBSERVATIONAL,['NA'],
16005,NCT03771066,Change in rate of glucose appearance,Change in concentration of clostridia,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],
16006,NCT04939753,Nephrogenic Diabetes Insipidus prevalence,Timing of symptoms of NDI,2021-05-26,COMPLETED,OBSERVATIONAL,['NA'],
16007,NCT01121276,Area under the blood glucose concentration-time curve,Area under the blood glucose concentration-time curve,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
16008,NCT00095446,Treatment satisfaction with insulin pump therapy,infusion set in-use times,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
16009,NCT03922022,Rate of recruitment,EQ-5D-5L,2019-05-21,COMPLETED,INTERVENTIONAL,['NA'],
16010,NCT03869411,maximum rate of oxygen consumption,blood cholesterol,2019-08-15,COMPLETED,INTERVENTIONAL,['NA'],
16011,NCT05716503,Patient satisfaction of aesthetic outcome,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],
16012,NCT03008239,Adverse Events reporting,Blood maltose concentrations,2017-11-14,UNKNOWN,INTERVENTIONAL,['NA'],
16013,NCT05392959,the longitudinal change of the Index of Microvascular Resistance (IMR).,,2022-06-06,RECRUITING,INTERVENTIONAL,['PHASE4'],
16014,NCT02065349,"Change in mean of 24-hour average pain intensity, Numeric pain rating scale (NPRS)","Composite of pharmacokinetics of ASP8477 concentration: Trough concentration (Ctrough), observed maximum concentration (Cmax), Area under the curve (AUC)0-6",2014-02-24,COMPLETED,INTERVENTIONAL,['PHASE2'],
16015,NCT01537120,24 Hour Weighted Mean Glucose (WMG) At 2 Weeks,HbA1C At 12 Weeks,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],
16016,NCT03740919,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26,Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values at Week 26,2019-04-07,COMPLETED,INTERVENTIONAL,['PHASE3'],
16017,NCT00171119,Change from baseline in urine albumin excretion rate after 24 weeks,Percent of patients returning to normal urine albumin excretion rate after 24 weeks,2004-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
16018,NCT03757910,Brain Tau SUVR,White Matter Hyper Intensity Volume,2019-10-01,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],
16019,NCT01812694,Gestational weight gain,Gestational Diabetes,2013-03-28,COMPLETED,INTERVENTIONAL,['PHASE3'],
16020,NCT00992797,"Insulin sensitivity measured with euglycemic, hyperinsulinemic clamp",Metabolomics analyses.,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],
16021,NCT00419562,Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo,Rate of Type 1 Diabetes in Secondary Stratum (Stratum 3+4) When Treated With Oral Insulin Versus Placebo,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3'],
16022,NCT00851903,HbA1c Response Rate: Percentage of Patients Achieving Glycosylated Haemoglobin A1c (HbA1c) < 7% at Study Endpoint (End of Treatment Period),Change in Body Weight From Baseline to Study Endpoint,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
16023,NCT02242825,Change from Baseline in diastolic blood pressure (DBP),Number of patients with adverse events,2006-01,COMPLETED,OBSERVATIONAL,['NA'],
16024,NCT06012799,Rate of NODAT,,2021-05-15,RECRUITING,OBSERVATIONAL,['NA'],
16025,NCT01566006,proteinuria,,2012-04,UNKNOWN,INTERVENTIONAL,['NA'],
16026,NCT03215953,Severe adverse events related to use of offloading device,Lifestyle limitation,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA'],
16027,NCT03783598,Canada activity performance measure (COPM),Demographic questionnaire,2015-12-02,COMPLETED,INTERVENTIONAL,['NA'],
16028,NCT00349362,The effect of 6 months of testosterone replacement on diabetes control measured by HbA1c in hypogonadal men with type 2 diabetes treated with insulin.,The effect of the CAG repeat polymorphism in exon 1 of the androgen receptor gene on the response of the study population to testosterone.,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
16029,NCT02429232,Change from baseline in bone turnover markers,Change from baseline in urine biomarkers,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
16030,NCT03448367,Safety of the FreeStyle Libre Flash Glucose Monitoring System,,2018-02-27,TERMINATED,OBSERVATIONAL,['NA'],
16031,NCT02276196,"Changes from baseline following 8-week treatment with a glucagon-like peptide(GLP)-1 receptor agonist versus insulin glulisine on renal hemodynamics, measured as glomerular filtration rate (GFR) / effective renal plasma flow (ERPF)",Blood Pressure,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4'],Arterial stiffness
16032,NCT05029115,recurrence rate of AF within a year in ablated participants,Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) score,2021-10-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
16033,NCT00374270,difference in change in systolic BP between the intervention and usual care groups,proportion of patients that are prescribed an ACE inhibitor or angiotensin receptor antagonist between groups,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4'],
16034,NCT02472236,Composite measure the plasma concentrations of Digoxin.,Incidence of adverse events and serious adverse events,2015-06-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
16035,NCT02318706,Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain,Change in Visual Analog Scale From Baseline (Week 14) to Week 66 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3'],
16036,NCT02954601,Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM),Calculate the Difference Between Values of Pre-treatment and End-of-treatment Mean Daytime CGM Glucose,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
16037,NCT02498002,ACADM Gene Expression in Subcutaneous Adipose Tissue,Post-Prandial Protein Oxidation,2015-05,COMPLETED,INTERVENTIONAL,['NA'],
16038,NCT02506972,Incremental area under the blood glucose response curve,Time to baseline,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
16039,NCT04446026,Hb1Ac,Fasting glucose,2020-07-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
16040,NCT01133600,Pharmaco-economic,Quality of Life/patient satisfaction,2010-08,TERMINATED,INTERVENTIONAL,['PHASE4'],
16041,NCT04141787,Clinical cure rate of deep-seated methicillin sensitive Staphylococcal infections,Adverse event rate,2019-07-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],Duration of therapy
16042,NCT06327191,"To determine whether treatment with metformin during pregnancy, in women with GDM, leads to a reduction in adiposity in the offspring at follow up as measured by anthropometric measurements and sum of skinfolds.",,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
16043,NCT05478525,Number of participants with adverse events [safety and tolerability of GLY-200],Change from baseline in 3-hours postprandial plasma insulin profile,2022-08-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
16044,NCT00547183,Effectiveness measured by IIEF score of questions 1-5 and 15 plus the percentages of positive responses to questions 2 and 3 in the SEP diary,"Change in the GAQ, SEP, IIEF, SEAR, and RSE scores.",2004-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
16045,NCT00537498,"Number of patients being alive, having no major amputation and healed ulceration","Each of overall survival, major amputation rate, survival free of major amputation rate, rate of ulcer healing, and safety",2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],
16046,NCT04240652,Diabetic macular edema,Albumin-creatinine-ratio (mg/mmol),2018-06-05,RECRUITING,OBSERVATIONAL,['NA'],
16047,NCT02519309,Change from Baseline Body Weight,Change from Baseline Body Weight,2015-08,COMPLETED,INTERVENTIONAL,['NA'],
16048,NCT02373319,Pre-post changes in blood lipid levels,Pre-post changes in body mass index,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
16049,NCT00528372,Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) (Last Observation Carried Forward [LOCF]): Group 2,Number of Participants With Changes From Baseline in Electrocardiogram (ECG) Findings (Last Observation Carried Forward {LOCF]),2007-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
16050,NCT03378765,BMI,,2018-01-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
16051,NCT00403741,"Score on Treatment Self-Regulation Questionnaire(TSRQ)at Treatment Self-Regulation Questionnaire (TSRQ) at 3 months, 9 months and 15 months after assesment's day of the education period.","HbA1c et lipid profile at 3 months, 9 months and 15 months after assesment's day of the education period.",2007-01,COMPLETED,INTERVENTIONAL,['NA'],
16052,NCT05949281,Change in fasting serum/plasma concentrations of C-reactive protein (CRP) measured by a high-sensitivity assay (hsCRP) (mg/L),Safety-related events,2023-08-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in interleukin messenger ribonucleic acid (mRNA) expression measured by quantitative polymerase chain reaction
16053,NCT04600167,First diagnosis of TB,"Occurrence of possible, probable, or definite TB, or death",2022-06-17,RECRUITING,INTERVENTIONAL,['PHASE3'],
16054,NCT00185601,HbA1c,Health care utilization,2006-02,COMPLETED,INTERVENTIONAL,['NA'],
16055,NCT00118976,albuminuria,Tertiary: differences in response to treatment in patients with different ACE/ID and other renin angiotensin system genotypes.,2005-03,COMPLETED,INTERVENTIONAL,['NA'],
16056,NCT03627182,Change from baseline in Glycosylated Hemoglobin (HbA1c),Evaluate safety of CKD-501 from number of participants with adverse events,2018-04-26,UNKNOWN,INTERVENTIONAL,['PHASE3'],
16057,NCT04277598,Wound area reduction after 4 weeks treatment with APO-2,Evaluation of Quality of Life: questionnaire,2020-10-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
16058,NCT04567225,Time to Anion Gap Closure,Incidence of Hypoglycemia,2020-10-01,TERMINATED,INTERVENTIONAL,['PHASE4'],
16059,NCT06003634,Number of Participants with Change in A1c,Social Network Scale,2023-11-20,RECRUITING,OBSERVATIONAL,['NA'],
16060,NCT04445168,Moderate to vigorous physical activity (MVPA),Health-related quality of life,2020-08-31,UNKNOWN,INTERVENTIONAL,['NA'],
16061,NCT03909555,Difference in the proportions of chronic complications,Difference of quality of life,2019-06-01,UNKNOWN,OBSERVATIONAL,['NA'],New biomarkers which may indicate the occurrence of chronic complications of diabetes
16062,NCT02378493,Antibiogram results,The capacity of the S. aureus strains isolated to create biofilms in the presence of antibiotics,2015-12-16,COMPLETED,OBSERVATIONAL,['NA'],Perception threshold for vibrations at the ankle (Hz)
16063,NCT00484068,nutritional status,,2003-01,COMPLETED,INTERVENTIONAL,['NA'],
16064,NCT00469287,,,2007-06,COMPLETED,OBSERVATIONAL,['NA'],
16065,NCT05956106,Blood pressure will be assessed before and after the trial.,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],
16066,NCT03064321,Average Glucose Control for Last 3 Months Assessed by A!C level,Sleep Quality,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],Insomnia Severity
16067,NCT03847129,Static two-point discrimination (S2PD) test,,2015-08-20,COMPLETED,INTERVENTIONAL,['NA'],
16068,NCT04726657,Fructosamine,time below 70,2016-01-18,COMPLETED,INTERVENTIONAL,['NA'],
16069,NCT02367131,Percentage of Patients With Adverse Drug Reactions (ADRs),Change From Baseline in Fasting Plasma Glucose at the Last Observation During the Observation Period,2015-02-24,COMPLETED,OBSERVATIONAL,['NA'],
16070,NCT02547519,The activation of an antibody response against insulin.,GAD and IA-2 autoantibodies,2015-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse events
16071,NCT00609986,Acute/Active Rejection,Severe Hyperglycemia,2007-07,COMPLETED,INTERVENTIONAL,['NA'],
16072,NCT01456650,Change in plasma fasting glucose,HbA1c levels,2011-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
16073,NCT00123435,Weight loss,Quality of life and participant satisfaction,2005-07,COMPLETED,INTERVENTIONAL,['NA'],
16074,NCT00554671,Hemoglobin A1c,Health-care Costs to the VHA,2008-05,COMPLETED,INTERVENTIONAL,['NA'],
16075,NCT03476460,Incidence of contrast nephropathy during the first 48 hours after contrast administration,Determination of biomarkers of contrast nephropathy during the first 48 hours after contrast administration,2014-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
16076,NCT02747277,Frequency of CD19 and IgM low B cells in cord blood of babies born from autoimmune mothers,,2016-05,COMPLETED,OBSERVATIONAL,['NA'],
16077,NCT03740698,% Time in Target Range Defined as 3.9-10mmol/l,,2021-02-01,TERMINATED,INTERVENTIONAL,['NA'],
16078,NCT02162212,Arm elevation.,"Disability of the Arm, Shoulder, and Hand (DASH) questionnaire",2014-09,COMPLETED,INTERVENTIONAL,['NA'],
16079,NCT06137222,Incidence of adverse events (AEs) and serious adverse events (SAEs). Primary safety endpoint,Wound size (area in cm2) reduction from baseline/treatment initiation,2023-12-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
16080,NCT05888259,pressure-time integrals,,2021-09-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
16081,NCT05141929,Change from Self Rated Abilities for Health Practices levels in pregnant women with GDM,Rate of maternal-fetal-neonatal complications in pregnant women with GDM,2020-06-01,COMPLETED,INTERVENTIONAL,['NA'],
16082,NCT02023320,Change in HbA1c from baseline,Change in serum C-peptide from baseline,2013-11,COMPLETED,INTERVENTIONAL,['NA'],
16083,NCT01897688,To demonstrate the safety and efficacy of islet transplantation under alemtuzumab induction for treatment of Type-1 Diabetes (T1D) in subjects with hypoglycemia unawareness and a history of severe hypoglycemic episodes.,To relate clinical transplant outcomes based upon islet quantity/quality to organ donor characteristics.,2012-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
16084,NCT05684406,evaluate the potential of peripheral blood mtDNA-CN as biomarker in type 2 diabetic patients,evaluate the potential of leukocyte telomere length as biomarker in type 2 diabetic patients,2023-01,RECRUITING,OBSERVATIONAL,['NA'],
16085,NCT02796950,Levels of GLP-1 in plasma,Insulin sensitivity by measuring blood glucose after an OGTT,2016-06,COMPLETED,INTERVENTIONAL,['NA'],"Secretion of the hormones ghrelin, leptin and GIP (gastric inhibitory polypeptide) by measuring hormone levels in plasma"
16086,NCT03363594,To evaluate total body fat content across various BMI categories in the study population,To correlate HbA1C level with various BMI categories,2017-12-11,COMPLETED,OBSERVATIONAL,['NA'],
16087,NCT00381342,Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 24,"Changes in fasting and 30, 60, 120 and 180-minute glucose measurements",2006-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
16088,NCT02833415,Change in Glycerol Enrichment,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE4'],
16089,NCT00992043,glycated hemoglobin,,2009-10,COMPLETED,INTERVENTIONAL,['NA'],
16090,NCT04432090,Incremental AUC for glucagon during hypoglycemia (above baseline levels during euglycemia),,2021-04-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],
16091,NCT04762719,Uptake of 11C-ER 176 in the Stomach Muscle,Percentage of Immune Cells With CD45 Expression,2021-05-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
16092,NCT00068094,,,2005-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
16093,NCT05067270,"Visual Analog Scale (VAS) Pain Score in the Abdominal, Arm, Thigh, and Buttock Areas",,2021-10-22,COMPLETED,INTERVENTIONAL,['PHASE1'],
16094,NCT05293808,Effects of different doses of aspirin on platelet aggregation,Valuation of RAC1 levels in platelets,2014-05-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
16095,NCT03779139,Clarke score,,2019-08-01,RECRUITING,INTERVENTIONAL,['NA'],
16096,NCT05203575,HbA1c after Cycle 2,Sleep quality after Cycle 2,2022-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
16097,NCT04753099,parental competence with managing child's care,,2020-10-09,COMPLETED,INTERVENTIONAL,['NA'],
16098,NCT02509624,PK Parameter: Cmax of Selonsertib and Its Metabolite GS-607509,Percentage of Participants Experiencing Any Treatment-Emergent and Grade ≥ 3 Laboratory Abnormalities,2015-08-18,COMPLETED,INTERVENTIONAL,['PHASE1'],
16099,NCT00484419,Mean Percentage of Change in HbA1c From Week 0(Baseline) to Week 16 Endpoint,Mean Percentage of Change in LDL-C Levels From Week 0(Baseline) to Week 16 (Least Squares Mean),2007-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
16100,NCT05544825,75-g Oral Glucose Tolerance Test (120 minute glucose),High-density lipoprotein cholesterol,2022-07-01,COMPLETED,INTERVENTIONAL,['NA'],
16101,NCT00894322,Time to Maximum Concentration (Tmax) of 2 mg Exenatide (Cohort 2) in Participants With Diabetes in Pharmacokinetic Evaluable Population,Mean Change From Baseline at Week 12 in Fasting Plasma Glucose in Participants With Diabetes (Cohort 2) for the ITT Population,2009-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
16102,NCT05427084,TBR (Tissue-to-blood ratio) of the most-diseased segment (MDS) of the ascending aorta,Change in monocyte marker expression,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
16103,NCT01700075,full recovery from atherosclerotic diseases,normalised laboratory and instrumental data,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
16104,NCT03766334,Average blood glucose fluctuations at endpoint and baseline,Waist circumference(endpoint)-Waist circumference(baseline),2018-12-05,WITHDRAWN,INTERVENTIONAL,['NA'],
16105,NCT02087826,Response to the Mixed Meal Tolerance Test,Response to Metformin,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Response to a Mixed Meal Tolerance Test after Metformin
16106,NCT05386927,Urine metabolomics,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],
16107,NCT05597709,Analysis of risk factors for clinical outcomes in patients with T2DM,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],
16108,NCT01973374,Compliance with Obstetric and Diabetes Care,Neonatal Outcomes,2013-01,COMPLETED,INTERVENTIONAL,['NA'],
16109,NCT03048227,Time spent with glucose,Score of Quality of Life questionnaire (IDSRQ),2017-04-21,TERMINATED,INTERVENTIONAL,['NA'],
16110,NCT03295578,Wellbeing,Qualitative user experiences,2017-10-02,COMPLETED,INTERVENTIONAL,['NA'],BMI
16111,NCT01726491,DNA methylation of genes in insulin resistance,mRNA expression of genes,2012-08,COMPLETED,OBSERVATIONAL,['NA'],
16112,NCT02701569,Glycated hemoglobin,Treatment satisfaction as measured by the World Health Organization-Diabetes Treatment Satisfaction Questionnaire,2014-07,COMPLETED,INTERVENTIONAL,['NA'],Depressive symptoms as measured by the Beck's Depression Inventory
16113,NCT03778580,Bone formation in serum by P1NP,Advanced glycation endproducts,2018-03-01,COMPLETED,INTERVENTIONAL,['NA'],
16114,NCT05231174,AUROC of the self-evaluation tool,,2023-05-01,COMPLETED,INTERVENTIONAL,['NA'],
16115,NCT01337141,Optimise metabolic control,Treatment adherence,2011-05,COMPLETED,INTERVENTIONAL,['NA'],
16116,NCT06141811,Evaluation of incidence of adverse events,,2023-04-25,RECRUITING,OBSERVATIONAL,['NA'],
16117,NCT04120844,Problem Areas in Diabetic (PAID) Questionnaire,Stages of Change score,2016-05-01,COMPLETED,INTERVENTIONAL,['NA'],
16118,NCT00407771,"The magnitude of platelet aggregation inhibition before randomization, 10 minutes (t=0) and 8 hours (t=8) post tirofiban administration using the Ultegra RPFA assay.",Major adverse cardiac events (MACE) at 24 hours and 30 days post PCI.,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],
16119,NCT01921192,homocysteine,folic acid,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],vitamin B12
16120,NCT00231023,,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
16121,NCT02756117,Change in plasma 2-AAA from baseline to peak post-lysine ingestion (anticipated 2-4 hours post-ingestion),Change in urinary 2-AAA from baseline to peak post-lysine ingestion (anticipated 2-4 hours post-ingestion),2016-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
16122,NCT01454024,Number of adverse events and technical complaints,HbA1c (haemoglobin A1c),2011-11,COMPLETED,OBSERVATIONAL,['NA'],
16123,NCT05791929,Area Under ROC curve generated by the statistical model able to discriminate between healing and not healing ulcers,The AUC of the models estimated according to different sites of ulcers.,2023-04-13,WITHDRAWN,OBSERVATIONAL,['NA'],
16124,NCT06060743,insulin information sheet,Insulin Injection Skill Observation Form,2022-11-01,COMPLETED,INTERVENTIONAL,['NA'],
16125,NCT01145599,"Identify ""progressors""","Identify correlations between ""progressors"" and study outcomes.",2010-09,COMPLETED,OBSERVATIONAL,['NA'],
16126,NCT05900505,"To compare participant satisfaction with NSRCH (social navigator) vs. standard care (social worker), as measured by the Client Satisfaction Questionnaire (CSQ).","To compare change in Quality of Life (QOL) of participants (pre/post intervention) referred to NSRCH (social navigator) vs standard care (social worker), as measured by the WHOQOL-BREF.",2023-06-26,RECRUITING,INTERVENTIONAL,['NA'],To compare the resource cost of the social navigator compared to the social worker.
16127,NCT03565809,Diabetes control,hospitalization for falls and femoral fracture,2017-05-02,COMPLETED,OBSERVATIONAL,['NA'],
16128,NCT02131272,Change in HbA1c (Glycosylated Haemoglobin),Incidence of Adverse Events (AEs),2014-06-11,TERMINATED,INTERVENTIONAL,['PHASE3'],
16129,NCT02941874,Normal values of IRAP concentration will be calculated by making the average of the three dosages of IRAP measured at base line.,Temporal reproducibility of the concentration of IRAP,2017-04-07,COMPLETED,OBSERVATIONAL,['NA'],kinetic profile of the concentration of IRAP during OGTT
16130,NCT04430608,Time In Range (TIR) for blood glucose,Course of hospital stay.,2020-05-25,UNKNOWN,INTERVENTIONAL,['NA'],
16131,NCT03661684,AUC for glucose during OGTT,AUC for Insulin during OGTT,2016-06-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],
16132,NCT03022682,Complete recruitment of IDEO cohort participants to spur novel and creative interactions between investigators that have transformative potential in obesity research.,Adipose tissue inflammation and fibrosis,2015-02,RECRUITING,OBSERVATIONAL,['NA'],
16133,NCT03645382,Change from baseline fat mass at 12-week.,Change from baseline visceral/subcutaneous fat area ratio of L1 and L4 at 12-week.,2017-02-21,COMPLETED,INTERVENTIONAL,['NA'],Change from baseline blood pressure (BP; mmHg) at 12-week.
16134,NCT00933881,Improvement in heart rate control post-GDM,Improvement in SDB post-GDM,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
16135,NCT01051089,"HbA1c, serum adipokine levels",VO2max,2009-06,UNKNOWN,INTERVENTIONAL,['NA'],
16136,NCT04025489,Investigation of gene polymorphism and other markers in 500 subjects,Effect of vitamin d supplementation on raging and other metabolic measures.,2020-03-01,RECRUITING,INTERVENTIONAL,['NA'],
16137,NCT01847092,Changes in Urine Albumin to Creatinine Ratio (UACR),Change in Estimated Glomerular Filtration Rate (mL/Min/1.73 m2) From Baseline to Week 12 Endpoint,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
16138,NCT04613700,Duration of ad libitum meal,Gallbladder motility,2020-03-01,COMPLETED,INTERVENTIONAL,['NA'],
16139,NCT05071898,Rate of glucose disappearance,Weight loss,2022-04-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Glucose effectiveness (Sg)
16140,NCT01552005,Retention rate of Saxagliptin and to describe discontinuation rate and reasons,Saxagliptin utilization according to patient's profile and disease characteristics,2012-05,COMPLETED,OBSERVATIONAL,['NA'],
16141,NCT05624970,insulin sensitivity,A body shape index (ABSI),2022-11-09,RECRUITING,INTERVENTIONAL,['NA'],
16142,NCT05722873,Trabecular bone microarchitecture,Insulin sensitivity,2023-10-25,RECRUITING,INTERVENTIONAL,['NA'],
16143,NCT03259321,Type 2 diabetes,Fish and polyunsaturated fatty acids intake,1989-01-01,COMPLETED,OBSERVATIONAL,['NA'],
16144,NCT05651724,Predictive power of non-invasive tests for detection of high-risk patients,Patient Reported Outcomes: Disease-specific health-related Quality of Life (HR-QoL),2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Assess if implementation of the patient care pathway as proposed in this study increases awareness and knowledge of NAFLD and NASH management among participating physicians and clinicians
16145,NCT01507337,Area under the liraglutide plasma concentration time curve (AUC 0-t),Adverse events,2004-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
16146,NCT05802862,Change From Baseline in Hemoglobin A1c (HbA1c),Number of Treatment-emergent Adverse Events (TEAE) and Serious Adverse Events(SAE),2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
16147,NCT00477204,Change in LDL-c From Baseline to 6 Months in Subjects With Type 1 Diabetes Taking Vytorin or Zocor.,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
16148,NCT01713764,Hemoglobin A1c,Hemoglobin A1c,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],
16149,NCT00935805,Blood pressure,Fasting blood glucose,2006-07,UNKNOWN,OBSERVATIONAL,['NA'],
16150,NCT02556840,Birth weight for gestational age,Anxiety score (short form of the Spielberger State - Trait Anxiety Inventory,2016-04-25,COMPLETED,INTERVENTIONAL,['NA'],
16151,NCT01525238,Geometric Mean of Apparent Volume of Distribution at Terminal Phase After Extravascular Administration (Vz/F) of Dapagliflozin,Number of Participants With Marked Urinalysis Abnormalities,2012-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
16152,NCT04924504,Association between insulin sensitivity Versus structural and functional changes in the placenta,Changes from baseline in the central aortic pressure waveform,2021-05-01,RECRUITING,OBSERVATIONAL,['NA'],
16153,NCT05151770,Algorithm efficacy,Influence of the insulin administration on algorithm results,2021-12-30,COMPLETED,OBSERVATIONAL,['NA'],
16154,NCT04643171,superoxide dismutase,lipid hydroperoxidase,2020-11-19,UNKNOWN,INTERVENTIONAL,['NA'],
16155,NCT01014884,Determine the impact of multidisciplinary team interventions in reducing the rate of non-elective hospitalizations over a 12 month period compared to usual care,Determine the impact of multidisciplinary team interventions versus usual care on the length of stay (LOS) of each non-elective hospitalization,2009-11,TERMINATED,INTERVENTIONAL,['NA'],
16156,NCT02562313,Pharmacokinetics: AUClis 0-30min,Local tolerability,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
16157,NCT05307172,the rate of annual decline in glomerular filtration rate (GFR year n+1 - GFR year n) measured by iohexol clearance,The occurrence of severe liver damage,2022-05-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
16158,NCT00920764,Mean change from baseline to each post-baseline observation on UACR over the course of treatment period versus standard of care,Change from baseline to each weekly measurement in NGAL,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
16159,NCT04219462,the Five-Version of International Index of Erectile function,,2019-12-02,UNKNOWN,INTERVENTIONAL,['NA'],
16160,NCT03231709,Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period,Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group),2017-08-18,COMPLETED,INTERVENTIONAL,['PHASE4'],
16161,NCT03928899,caesarean section rate,rate of labor pain,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA'],
16162,NCT05362474,Change in Albuminuria at 3 months,,2022-07-01,TERMINATED,INTERVENTIONAL,['PHASE3'],
16163,NCT03138174,To meet the requirements of ISO 15197:2015,,2017-03-23,COMPLETED,OBSERVATIONAL,['NA'],
16164,NCT02063321,Prevalence of Diabetic Macular Edema or clinically significant Diabetic Macular Edema,Range of visual deterioration and occurence of blindness in relation to general treatment (insulin vs. OAD or combination therapy),2012-12,UNKNOWN,OBSERVATIONAL,['NA'],
16165,NCT04626453,Oxyhemoglobin differences,blood glucose level in mg/dL,2020-10-29,COMPLETED,INTERVENTIONAL,['NA'],
16166,NCT00703989,prostacyclin synthase activity,,2005-02,COMPLETED,INTERVENTIONAL,['NA'],
16167,NCT05854069,Gaps in CGM use,CGM satisfaction during the intervention period,2023-04-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Satisfaction with data-sharing relationships
16168,NCT04441216,Between-group differences in glycemic excursion during 75g OGTT as indicated by area under the curve (AUC) plasma glucose concentration during 12-week on-treatment and 12-week off treatment period,Prevalence of euglycaemic chinese subject after 12-week on-treatment and 12-week off treatment period,2020-08-02,RECRUITING,INTERVENTIONAL,['NA'],
16169,NCT00545857,C-peptide response to a Sustacal meal,Hemoglobin A1c,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
16170,NCT04902378,Glycemic control as reflected by percent glucose time-in-range,Proportion of participants who experience device-related adverse events,2021-06-15,RECRUITING,INTERVENTIONAL,['NA'],
16171,NCT04642534,Correlation of in vitro circadian parameters (amplitude and magnitude) with clinical metabolic health outcomes (body weight),"Glucose excursion (time-in-range, coefficient of variation)",2020-02-12,COMPLETED,OBSERVATIONAL,['NA'],Metabolomic parameters of energy metabolism
16172,NCT02591576,Long term excess mortality,,2003-01,COMPLETED,OBSERVATIONAL,['NA'],
16173,NCT02923089,Postprandial plasma insulin,,2017-01,COMPLETED,INTERVENTIONAL,['NA'],
16174,NCT01818557,Neonatal weight,Macrosomia,2013-05,COMPLETED,INTERVENTIONAL,['NA'],
16175,NCT01708096,Insulin sensitivity,Weight reduction,2009-10,COMPLETED,INTERVENTIONAL,['NA'],Insulin signaling and glucose transport in skeletal muscle
16176,NCT04758364,gait speed,,2021-02-20,COMPLETED,OBSERVATIONAL,['NA'],
16177,NCT00934414,To compare the relative bioavailability and bioeffect of TI Inhalation Powder in subjects with type 2 diabetes who smoke and who do not smoke to determine relative insulin bioavailability,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
16178,NCT01486381,"Standard safety parameters: Haematology, biochemistry and vital signs",BMI (Body Mass Index),2002-03-20,COMPLETED,INTERVENTIONAL,['PHASE3'],
16179,NCT04079413,Immunogenicity,Achievement of Glycated Hemoglobin < 7%,2019-06-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
16180,NCT04812392,Change in glycemic control during a reduced physical activity state,,2021-04-01,COMPLETED,INTERVENTIONAL,['NA'],
16181,NCT00042471,Effect of varying needle length on bioavailability of Pramlintide,Effect of varying needle length on safety and tolerability of Pramlintide,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
16182,NCT05619198,Percentage of time spent in sensor-derived time in range (3.9-10.0 mmol/L) during and after a bout of exercise,Physical activity level assessed by Actigraph GT3x,2022-12-19,RECRUITING,INTERVENTIONAL,['NA'],
16183,NCT00593476,Changes in weight at 12 weeks.,"Changes in HbA1c, lipids, inflammatory markers (hs-CRP), fasting glucose, blood pressure, waist circumference and survey measures at 12 weeks.",2007-03,COMPLETED,INTERVENTIONAL,['NA'],
16184,NCT06198881,Number of vaginal deliveries among the population studied,,2023-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
16185,NCT02202668,Transcutaneous Raman spectra of subcutaneous deep wound soft tissue and underlying bone,Wound temperature post-Transcutaneous Raman Spectroscope,2014-09,TERMINATED,INTERVENTIONAL,['NA'],
16186,NCT03479242,Functional skin closure in DFU in relation to biofilm infection,,2019-01-25,TERMINATED,OBSERVATIONAL,['NA'],
16187,NCT01982253,Change From Baseline in HbA1c at Week 12.,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12,2013-10,TERMINATED,INTERVENTIONAL,['PHASE2'],
16188,NCT04460885,Change in HbA1c,"Time spent > 10 mmol/L (180 mg/dL) using continuous glucose monitoring (CGM) system, Dexcom G6",2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE3'],
16189,NCT00046501,to measure change in glycemic control as measured by hemoglobin A1c (A1c).,"Clinical values: physical examination, vital signs, change in age-adjusted body mass index (BMI)",2002-11,COMPLETED,INTERVENTIONAL,['PHASE3'],
16190,NCT05297110,rate of fasting glycemia level reduction,rate of adverse effects,2021-08-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
16191,NCT01257464,Insulin release,Incretin Response,2010-09,TERMINATED,INTERVENTIONAL,['PHASE2'],
16192,NCT05354947,Number of Hepatic Adverse Events - Elevation of liver transaminases AST / ALT.,Number of Metabolism and nutrition disorders - Hypoglycemia,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],
16193,NCT03338803,Change in Glycosylated Hemoglobin (HbA1c) Across Renal Function Categories,Percentage of Adults With T2DM Who Achieve HbA1c < 7.0% Across Renal Function Categories,2017-11-21,COMPLETED,OBSERVATIONAL,['NA'],
16194,NCT01365507,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
16195,NCT03781102,Change in Body Mass Index (BMI) Percentile,Change in demographic and social and environmental risk factors for T2D,2019-07-01,SUSPENDED,INTERVENTIONAL,['NA'],
16196,NCT05479435,Hearth Rate,Body Mass Index (BMI),2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],
16197,NCT01185496,,,2010-08,COMPLETED,OBSERVATIONAL,['NA'],
16198,NCT05290246,Change in glycemic measures- HbA1c (12w),Intervention burden (24w),2022-05-27,RECRUITING,INTERVENTIONAL,['NA'],
16199,NCT06192940,Insulin Injection,Acute Diabetes Events,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
16200,NCT02420392,Difference of incretin sensitivity of pancreatic beta cell measured by hyperglycemic clamp with GLP-1 and GIP infusion,Difference of Area under the curve of insulin/C-peptide level during GIP infusion under hyperglycemic clamp between diabetes patients and normal glucose tolerance subjects,2015-02,COMPLETED,INTERVENTIONAL,['NA'],
16201,NCT00223782,Plantar Pressure,,2004-05,COMPLETED,INTERVENTIONAL,['NA'],
16202,NCT01948986,Change From Baseline in 24 Hour Fluid Balance,Urinary Glucose Excretion Over 24 Hours (UGE0-24hr) for Ertugliflozin,2013-10-01,COMPLETED,INTERVENTIONAL,['PHASE1'],
16203,NCT00067886,,,2003-03,COMPLETED,OBSERVATIONAL,['NA'],
16204,NCT01653899,To assess the safety of the IDN-6556 caspase inhibitor in adult Type 1 diabetic participants receiving their first islet transplant,2. To obtain preliminary data on the efficacy of IDN-6556 to maintain adequate immunological protection against both allo- and autoimmunity of islet transplant recipients.,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
16205,NCT00060918,Change from baseline in HbA1c at 5 months,"Blood pressure at 3 and 5 months. Body weight at 3 and 5 months. Lab values (glucose, insulin, triglycerides, cholesterol, and albumin:creatinine ratio) at 3 and 5 months.",2001-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
16206,NCT01677104,skin blood flow,,2012-08,COMPLETED,INTERVENTIONAL,['NA'],
16207,NCT05245110,Changes from baseline Health-related quality of life at 12 weeks,,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
16208,NCT03890991,Diabetes self-care activities measured using the Revised Summary of Diabetes Self-care Activities,Proportion of participants who adhere to yearly eye and foot screening,2019-02-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
16209,NCT01669473,Medication adherence,"Clinical outcomes-systolic blood pressure, HbA1, and LDL cholesterol.",2013-06,COMPLETED,INTERVENTIONAL,['NA'],
16210,NCT01934608,Medication adherence to each of the chronic medications as measured by the proportion of days covered (PDC) measure,"Secondary outcomes will be continuous gaps (e.g. 15, 30, or 60 days) in medication use.",2013-09,COMPLETED,INTERVENTIONAL,['NA'],
16211,NCT05288452,Primary Outcome for the HIV Cohort: Change in HbA1c level between baseline and 6 months,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],
16212,NCT01040806,HbA1c level,LDL cholesterol level,2009-08,COMPLETED,INTERVENTIONAL,['NA'],
16213,NCT03027934,Aggregation Response,Reticulated Platelet Reactivity Index (PRI),2017-08-28,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
16214,NCT02089152,Culture-confirmed melioidosis,Overall melioidosis,2014-04-01,COMPLETED,INTERVENTIONAL,['NA'],
16215,NCT04322240,measurement of Compound Muscle Action Potential (CMAP) distal latency,,2020-04-02,COMPLETED,INTERVENTIONAL,['NA'],
16216,NCT05822349,change in anxiety level,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],
16217,NCT02302963,Change in Hypoglycemia During Closed Loop Control (Assessed by Low Blood Glucose Index [LBGI]),,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
16218,NCT04190277,Difference in percentage of time spent in hypoglycemia (<70mg/dL) during 12 weeks between closed-loop and open-loop,"Questionnaire of usability (for 50 subjects from Arm 1, including 15 adolescents and 35 adults)",2020-01-07,TERMINATED,INTERVENTIONAL,['NA'],
16219,NCT04878419,Recruitment Rate,Correlation of outcome expectation on degree of change in participants Time in Range after the educational intervention.,2021-06-17,COMPLETED,INTERVENTIONAL,['NA'],Correlation of childhood opportunity index (COI) with degree of change in participants' Time In Range after the educational intervention.
16220,NCT00013208,,,na,COMPLETED,INTERVENTIONAL,['NA'],
16221,NCT04333823,Measured Glomerular Filtration Rate (mGFR),Total Daily Insulin Dose (TDID),2020-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Exercise Session - Blood Glucose Variability
16222,NCT01863147,Left ventricular mass and left ventricular volume,Endothelial function and augmentation index (AIx),2013-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
16223,NCT04831385,"The primary outcome measure will be changes in glycemic control, as measured by HbA1c, from baseline.",,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
16224,NCT05570162,Adherence to Flash 1,Percentage of patients attaining the the International Consensus on Time in Range (ICTR),2022-11-01,COMPLETED,INTERVENTIONAL,['NA'],
16225,NCT00765817,Change in Glycosylated Hemoglobin (HbA1c),Percentage of Subjects Experiencing Minor Hypoglycemia,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
16226,NCT00703027,,,2002-10,COMPLETED,OBSERVATIONAL,['NA'],
16227,NCT06224803,Concentration of HbA1c,Concentration of Blood Sugar,2020-08-26,COMPLETED,INTERVENTIONAL,['NA'],
16228,NCT00536965,HbA1c profile,,2007-07,COMPLETED,OBSERVATIONAL,['NA'],
16229,NCT00550979,endothelial function,,2007-09,UNKNOWN,OBSERVATIONAL,['NA'],
16230,NCT04420728,Effect of Auto vs. Manual Mode of MiniMed 670G on Time in Target Range Assessed via CGM,"Assess Feasibility of Auto-mode MiniMed 670G via study recruitment, retention and completion rates.",2020-07-15,COMPLETED,INTERVENTIONAL,['NA'],Impact of Weaning on Total Daily Insulin Requirement Assessed by Child Food and Liquid Intake Questionnaire
16231,NCT04080960,hemoglobin A1C,,2019-05-01,COMPLETED,OBSERVATIONAL,['NA'],
16232,NCT03817099,Rate of participants completed the study,Efficacy potential on body mass index,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA'],
16233,NCT02913703,Effect of preprandial ghrelin on glucose tolerance,Effect of preprandial ghrelin on insulin sensitivity (as measured by Matsuda index),2017-01-11,COMPLETED,INTERVENTIONAL,['PHASE1'],
16234,NCT00318786,Hemoglobin A1C (HbA1C),"HbA1C, after 28 weeks of treatment; Plasma glucose levels",2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],
16235,NCT03163511,Change in C-peptide for Cohort 2 subjects,,2017-07-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
16236,NCT04776239,Post-PCI coronary artery endothelial function as assessed via FFR,Number of participants with Target Vessel Failure,2021-08-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
16237,NCT04035044,Analytical verification of Allegro - Urine Albumin comparison,,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],
16238,NCT00639808,12-lead ECG data,Scintigraphy to measure rate of gastric emptying after ingestion of a radio-labeled meal,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1'],
16239,NCT03362580,Educational level,,2017-12-12,COMPLETED,OBSERVATIONAL,['NA'],
16240,NCT00006068,,,na,UNKNOWN,INTERVENTIONAL,['NA'],
16241,NCT01291719,glucose control in target range,hypoglycemia,2008-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
16242,NCT00780559,Change in 6-Minute-Walk Test Measured in Feet Between Baseline and 12 Months,Intraepidermal Nerve Fiber Density (IENFD) at the Proximal Thigh,2009-11-01,COMPLETED,INTERVENTIONAL,['NA'],Change in Physical Activity (PA) at 12 Months as Measured by the CHAMPS (Community Health Activities Model Program for Seniors) Activity Scale
16243,NCT01840982,"1. Glycemic index(GI) 2. Glucose, insulin AUC(incremental area under the curve) 3. C-peptide","Homeostatic model assessment-insulin resistance(HOMA-IR), quantitative insulin sensitivity check index(QUICKI), Insulinogenic index(IGI)",2010-10,COMPLETED,INTERVENTIONAL,['NA'],
16244,NCT02885428,diagnostic of the silent myocardial ischemia,,2015-04-15,TERMINATED,OBSERVATIONAL,['NA'],
16245,NCT01576887,Number of Adverse Events,Area under the curve,2012-07-31,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
16246,NCT04495972,Insulin sensitivity,Level of 2-hour blood glucose Area Under the Curve (AUC),2021-01-15,COMPLETED,INTERVENTIONAL,['NA'],
16247,NCT04838743,Change in local laboratory measured HbA1c (Glycated haemoglobin ),Change in daily dose of Xultophy®,2021-04-23,COMPLETED,OBSERVATIONAL,['NA'],
16248,NCT01667003,Target Lesion Failure (TLF),Clinical Procedural Success,2012-08,COMPLETED,OBSERVATIONAL,['NA'],
16249,NCT00968708,Percentage of Participants With Primary Major Adverse Cardiac Events (MACE),Percentage of Participants With Secondary Major Adverse Cardiac Events (MACE),2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
16250,NCT03498534,Development of active TB,,2012-09,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
16251,NCT06057454,Measurement of adverse events from the date of the first dose through 12 weeks of R-5280 tolerance,Measurement of clinical activity and to determine the gut microbiome profile in youth with recently diagnosed Type 1 Diabetes,2023-12-05,RECRUITING,INTERVENTIONAL,['PHASE1'],
16252,NCT03930758,Bone-specific alkaline phosphatase,Novel Pedar,2009-10-08,COMPLETED,INTERVENTIONAL,['NA'],
16253,NCT02399332,Change in HbA1C from baseline at one year,Change in medication adherence from baseline at one year,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
16254,NCT02213159,Total dose of morphine consumed in Post Anesthesia Care Unit (PACU),overall satisfaction at one month,2014-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
16255,NCT03887403,Assess the effectiveness of the intervention to increase adherence to OAD treatment.,,2016-03,COMPLETED,INTERVENTIONAL,['NA'],
16256,NCT00154414,HbA1c,Safety and tolerability,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],
16257,NCT05628311,HbA1c change from baseline at week 24,To assess changes in PD parameters fasting C-peptide at different time points before and after administration.,2023-01-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],
16258,NCT05011032,Erythrocyte sedimentation rate (ESR),,2021-08-12,WITHDRAWN,INTERVENTIONAL,['NA'],
16259,NCT03057444,Change of short chain fatty acid concentration in the gut,Change from baseline in anthropometry at four weeks and eight weeks after consumption resistant starch type III,2017-02-10,COMPLETED,INTERVENTIONAL,['NA'],Change from baseline in GLP-1 (Glucagon-like peptide-1) at four weeks and eight weeks after consumption resistant starch type III
16260,NCT00171743,,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
16261,NCT03703999,HbA1c,insulin use,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],
16262,NCT04267367,Change in HbA1c level,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA'],
16263,NCT01076634,"Area under the glucose infusion rate curve during one dosing interval at steady-date""",Area under the serum Insulin Degludec concentration-time curve,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
16264,NCT00854984,The obstacles to providing access and support to a generic online self help computerised cognitive behavioural therapy (CBT) programme for such patients.,"A change in depression (BDI-2), anxiety , social function (WASAS), quality of life (Euroqol 5D) or illness perception (IPQ-R) from participation in a self help programme.",2009-02,UNKNOWN,INTERVENTIONAL,['NA'],
16265,NCT01328561,,,2011-03-17,TERMINATED,OBSERVATIONAL,['NA'],
16266,NCT02351466,Changes in total and regional gray and white matter volumes and white matter microstructure.,Changes in Neurocognitive metrics including IQ as well as executive and visual-spatial memory.,2015-03,COMPLETED,OBSERVATIONAL,['NA'],
16267,NCT02192450,Symptomatic nocturnal hypoglycaemia,Quality of life incl. pre-depression scale,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4'],
16268,NCT01430143,Change from baseline in insulin sensitivity at 12 weeks,Diameter of t-tubuli in skeletal muscle,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
16269,NCT00447382,Change From Baseline in Insulin Detemir - Human Insulin Cross-reacting Antibodies,Adverse Events,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
16270,NCT02690883,the percentage change of 24h-UAER(urinary albumin excretion rates) from baseline at Week 24,Change in Blood pressure,2016-04-08,COMPLETED,INTERVENTIONAL,['PHASE4'],
16271,NCT04565418,Change in 24 rhythm in whole-body energy metabolism (fat oxidation),Change in 24h rhythm in serum cholesterol,2021-01-26,COMPLETED,INTERVENTIONAL,['NA'],
16272,NCT01273675,,,2010-09,UNKNOWN,OBSERVATIONAL,['NA'],
16273,NCT00857376,This study will provide information on the effect of a dose range of ALA on oxidative stress biomarkers.,To determine whether ALA improves vascular function through its effects on oxidative stress,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
16274,NCT01707134,Number of hypoglycaemic events,HbA1c (glycosylated haemoglobin),1997-09,COMPLETED,INTERVENTIONAL,['PHASE3'],
16275,NCT04761016,Blood pressure,Medication use,2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
16276,NCT02305914,Change in the Levels of fecal elastase-1,outpatient clinic and phone questionnaire,2014-11,UNKNOWN,OBSERVATIONAL,['NA'],
16277,NCT01500850,Fasting Intact Proinsulin,Hypoglycemic events.,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],
16278,NCT02258932,Eating behaviours of adult patients with Type 1 diabetes using continuous subcutaneous insulin infusion therapy measured using food diaries and food surveys.,Cardiometabolic risks of adult patients with Type 1 diabetes who are using insulin pump therapy.,2013-12,COMPLETED,OBSERVATIONAL,['NA'],
16279,NCT05611541,Postprandial 2 hour blood glucose value,Level of compliance with the weekly diet,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],
16280,NCT06119737,Thyroid Stimulating Hormone,,2021-05-02,COMPLETED,INTERVENTIONAL,['NA'],
16281,NCT03096392,"The amount of time, in minutes, glucose levels are within range (70-180 mg/dL)",Total doses of insulin used (in number of units of insulin injected) during the study,2017-04-18,COMPLETED,INTERVENTIONAL,['PHASE2'],
16282,NCT00915772,Clinical Relevant Drug-related Abnormal Findings in Physical Examination and ECG as Reported as AE,Change in HbA1c From Baseline Over Time,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
16283,NCT01315977,Activation of Antioxidant Response Element After Consumption of Green Tea,,2011-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
16284,NCT02199834,Change of HbA1c,Change in depressive symptom,2013-02,COMPLETED,INTERVENTIONAL,['NA'],
16285,NCT00823953,serum fructosamine at end of trial phase in each of the groups,"Insulin resistance by the hyperinsulinemic, euglycemic clamp in a subset at the end of trial phase",2008-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
16286,NCT01941290,Target Lesion Failure (TLF),Clinical Procedure Success,2013-10,COMPLETED,OBSERVATIONAL,['NA'],
16287,NCT00522158,,,na,COMPLETED,INTERVENTIONAL,['PHASE4'],
16288,NCT02688218,Mean Change in Sensor Glucose in Subjects With Type 1 Diabetes,,2016-02,COMPLETED,INTERVENTIONAL,['NA'],
16289,NCT01296100,The proportion of patients who reach normal levels of all glycaemic parameters.,Difference in reduction of 10 year-estimated cardiovascular risk score of 10% between the standard therapy control group and the lifestyle intervention groups (WHO CVD prediction chart).,2011-02,COMPLETED,INTERVENTIONAL,['NA'],
16290,NCT02358668,Change in Serum Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo,Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation of Blood Glucose Over 24 Hours on Continuous Glucose Monitoring System Repeated Measures Analysis,2015-03-30,COMPLETED,INTERVENTIONAL,['PHASE2'],Changes in Complete Blood Count in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo
16291,NCT00133809,The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation,The Number of Subjects Exhibiting Fasting C-peptide Levels ≥ 0.5 ng/mL,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
16292,NCT04558710,Coefficient of variation,Time Above Range,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],
16293,NCT02821871,Cumulative percentage drainage of SP2086 in fecal,The number of volunteers with adverse events as a measure of safety and tolerability,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],
16294,NCT01057628,change from baseline in HbA1c,"safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",2010-01-13,COMPLETED,INTERVENTIONAL,['PHASE3'],
16295,NCT03232983,Pharmacokinetics: Insulin Lispro Area Under the Concentration Versus Time Curve (AUC) Following LY900014 Administration,Total Amount of Glucose Infused (Gtot) Over Duration of the Clamp Procedure,2017-08-14,COMPLETED,INTERVENTIONAL,['PHASE1'],
16296,NCT03088410,Homeo-static Model Assessment-Insulin Resistance (HOMA-IR),,2016-08-22,COMPLETED,INTERVENTIONAL,['PHASE4'],
16297,NCT00121641,A1C Changes From Baseline at Week 24 - Open Label Cohort,Baseline and Change From Baseline at Week 24 in Postprandial Glucose (PPG) Area Under the Curve (AUC) - Open Label Cohort,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Changes From Baseline in Heart Rate During the ST + LT Period - Open Label Cohort
16298,NCT00771069,Attainment rate to the target blood pressure.,Treatment pattern and factors that affect BP control,2008-11,COMPLETED,OBSERVATIONAL,['NA'],
16299,NCT04420507,the gut and oral microbiome of healthy pregnant women,The glucose level during pregnancy,2017-05-15,COMPLETED,OBSERVATIONAL,['NA'],
16300,NCT00605189,Compare Energy Charge Between Wound Treatment Therapies,,2007-07,TERMINATED,INTERVENTIONAL,['NA'],
16301,NCT06297603,Change from Baseline in Hemoglobin A1c (HbA1c) (%),Change from Baseline in Systolic Blood Pressure (SBP),2024-04-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],
16302,NCT03354806,Foot tissue oxygenation on day 2,Foot tissue oxygenation in hyperaemia-induced condition on day 2,2018-06,WITHDRAWN,INTERVENTIONAL,['NA'],
16303,NCT03592784,Feasibility of the Food Order Intervention,Birthweight,2018-06-18,TERMINATED,INTERVENTIONAL,['NA'],
16304,NCT04067440,Characterization of microbiome,,2019-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],
16305,NCT06208618,Diabetes management self-efficacy,Belief in a healthy lifestyle,2024-01-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],
16306,NCT02117518,"Identification, isolation, propagation and targeting of autoreactive T cells from T1D patients",,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],
16307,NCT05960565,Area under the glucose curve,Pharmacokinetics of glucagon,2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2'],
16308,NCT01251016,Patient Selection,,2010-07,UNKNOWN,OBSERVATIONAL,['NA'],
16309,NCT05264376,"Change over time in Perceived Well-Being as assessed by the World Health Organization Well-Being Index (WHO-5; deWit et al., 2007).",,2022-03-21,COMPLETED,INTERVENTIONAL,['NA'],
16310,NCT03999385,Change in diabetes self-management,Change in Eating Disorder Symptomatology,2019-06-24,UNKNOWN,INTERVENTIONAL,['NA'],
16311,NCT04734132,Glycated hemoglobin (HbA1C),Conversion rate from prediabetes to normal,2019-01-22,COMPLETED,INTERVENTIONAL,['NA'],Microbiota composition
16312,NCT03670225,Determine if Invia Motion Endure supports acceptable progress towards the goal of therapy for DFU and PI/PU wounds,Evaluation of ease of use and satisfaction,2018-10-16,COMPLETED,INTERVENTIONAL,['NA'],Adequate management of the exudate
16313,NCT02178787,To Compare Profiles of TCD-blood Flow Velocities (TCD_BFV).,To Compare Profiles of UTlight Blood Flow (UT_BF) and Regional Oximetry (UT_Ox).,2014-04,COMPLETED,OBSERVATIONAL,['NA'],
16314,NCT03415256,Skin blood flow,balance,2018-11,WITHDRAWN,INTERVENTIONAL,['NA'],
16315,NCT01134224,Area under the glucose infusion rate curve (only for IDegAsp),Area under the insulin aspart concentration-time curve (only for BIAsp 30),2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],
16316,NCT00478127,,,na,COMPLETED,OBSERVATIONAL,['NA'],
16317,NCT04236895,PD endpoint,Safety endpoints,2018-07-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
16318,NCT04109235,Change in HbA1C,Physical Activity (minutes per week),2020-02-13,RECRUITING,INTERVENTIONAL,['NA'],
16319,NCT03239457,Proportion of patients with 100% of the lesion area covered by granulation tissue.,Adverse events,2015-12,COMPLETED,OBSERVATIONAL,['NA'],
16320,NCT04653961,Sensor glucose percentage of time in hyperglycemia above 250 mg/dl,Number of Serious Adverse Events,2020-06-01,RECRUITING,INTERVENTIONAL,['NA'],The amount of bolus insulin dose
16321,NCT04428723,Analysis of hormonal responses during mixed meal testing.,Relationship between hormonal responses and microbiome.,2020-08-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Safety outcome- hyperglycemia and hypoglycemia during the study
16322,NCT03748420,Mean Change in A1c,Clinic-based Medical Care Costs,2020-08-19,COMPLETED,INTERVENTIONAL,['NA'],
16323,NCT02798172,"The primary endpoints were changes from baseline to week 26 in pulmonary function parameters [VC%, FVC%, FEV1%, PEF%, MVV%, TLC%, FEV1/FVC%, DLCO%, and DLCO/VA%] between pretherapy and posttreatment.","In addition, safety endpoints were assessed (AEs, clinical laboratory tests, vital signs, and electrocardiographic readings)",2014-05,COMPLETED,INTERVENTIONAL,['NA'],The changes of BMI from baseline to week 26 in intervention group (n=44) and control group (n=37).
16324,NCT01523041,Area under the insulin aspart curve in the interval from 0-24 hours,"tmin, time to minimum concentration",1999-11-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
16325,NCT02762708,Changes in the Gut Microbiome Following RYGB or Caloric Restriction,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],
16326,NCT04714216,Percentage of time sensor glucose is within target glucose range,Patient Survey,2021-06-29,COMPLETED,INTERVENTIONAL,['NA'],
16327,NCT02742701,Predictive performance of glycosuria measured on urine collected between 10 am and 16 am on the blood glucose level at 6 pm,"Type, frequency and intensity of symptoms in relation to the blood glucose level",2016-04,UNKNOWN,OBSERVATIONAL,['NA'],
16328,NCT01083043,Serum levels of endothelial dysfunction biomarkers and glycemic variability,Metabolic parameters and glycemic variability,2006-12,COMPLETED,OBSERVATIONAL,['NA'],
16329,NCT04073524,Level of quality of life - total score,Level of self perceived stress,2018-06-01,UNKNOWN,INTERVENTIONAL,['NA'],
16330,NCT05890950,Proportion of participants who discontinued study medication due to an AE,t1/2 of plasma K-833,2023-03-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
16331,NCT06014879,Demographic and Medical Information Questionnaire,,2023-08-07,RECRUITING,INTERVENTIONAL,['NA'],
16332,NCT01963663,Serum concentration of YKL-40,,2012-11,COMPLETED,INTERVENTIONAL,['NA'],
16333,NCT00878813,Major disability or death,"severe cerebrovascular re-event (i.e. new TIA, and stroke)",2009-03,COMPLETED,OBSERVATIONAL,['NA'],
16334,NCT03319784,Change in blood glucose level,American Shoulder and Elbow Surgeon (ASES) Shoulder Score,2018-09-05,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
16335,NCT04468152,We hypothesize that neck circumference correlated significantly with DME.,We hypothesize that the sRAGE levels were higher in the DME group.,2018-07-07,COMPLETED,INTERVENTIONAL,['NA'],
16336,NCT04269070,Change in 2-hour postprandial area-under-the-curve blood glucose at 2 weeks,Change in baseline workplace stepping time at 2 weeks,2021-03-25,COMPLETED,INTERVENTIONAL,['NA'],Change in central aortic diastolic and systolic blood pressure at 2 weeks
16337,NCT02656212,Change from baseline in major safety endpoints: Hepatic Function,Change from baseline: C-Peptide,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
16338,NCT00579371,Incidence of insulin independence with a single islet transplant,Metabolic functional assessments of the islet graft,2004-03-17,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
16339,NCT00891943,"Changes in weight, waist circumference and percent body fat at 12 months.","BMI, blood pressure, resting heart rate; obesity and weight related quality of life, Rosenberg measure of self-esteem changes at 12 months.",2009-06,UNKNOWN,INTERVENTIONAL,['NA'],
16340,NCT04230382,OGTT,,2020-01-20,COMPLETED,OBSERVATIONAL,['NA'],S-Magnesium
16341,NCT04997512,Mortality at 2 years,Scores from GOLD score,2021-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
16342,NCT01555008,Change from baseline in postprandial glucose,Area Under Curve (AUC),2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],
16343,NCT06268821,HbA1c,Frequency of hypoglycaemia events,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],
16344,NCT04421001,Total insulin daily dose per kg per day,"treatment satisfaction, scale up to 10, higher is better",2020-10,UNKNOWN,INTERVENTIONAL,['NA'],
16345,NCT03620890,Number of Neonates With Composite Adverse Neonatal Outcome,Number of Neonates Who Had Jaundice Requiring Therapy,2018-09-04,COMPLETED,INTERVENTIONAL,['PHASE4'],
16346,NCT05864183,comparison between the measurement of HbA1c in normal non prediabetics and prediabetics at Sohag university hospital .,,2023-04-15,RECRUITING,OBSERVATIONAL,['NA'],
16347,NCT01520831,Area under the GIR (Glucose Infusion Rate) profile (AUC GIR) in the interval 0-120 minutes,"t½, terminal half-life",1999-04,COMPLETED,INTERVENTIONAL,['PHASE1'],
16348,NCT02652026,Change from baseline in Glycosylated Hemoglobin (HbA1c),,2013-06,COMPLETED,INTERVENTIONAL,['NA'],
16349,NCT00399204,,,2006-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],
16350,NCT03625752,Changes in pain as measured by the Visual Analog Scale (VAS),Adverse events,2019-06-06,RECRUITING,INTERVENTIONAL,['NA'],
16351,NCT01464437,To evaluate the dose-effect relationship of AMG 151 compared to placebo on fasting plasma glucose in subjects with type 2 diabetes treated with metformin,Adverse events,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
16352,NCT04639414,Histological resolution of NASH without worsening of fibrosis,Hepatic steatosis grade,2021-03-26,RECRUITING,INTERVENTIONAL,['PHASE4'],
16353,NCT01607294,assess the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes,"assess safety using adverse event reports, physical exams, vital signs, ECGs and clinical laboratory parameters",2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
16354,NCT00445003,Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks,Change in Optical Coherence Tomography Retinal Volume,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
16355,NCT00847262,"Metabolic profiles, including lipid profile and blood glucose",Incidents of side effects between groups,2008-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
16356,NCT03674866,Change in Glycated Haemoglobin (HbA1c),Reason(s) for discontinuing insulin degludec,2018-10-29,COMPLETED,OBSERVATIONAL,['NA'],
16357,NCT04881110,Peripheral transcutaneous oxygen pressure,Female sexual function,2021-04-28,UNKNOWN,INTERVENTIONAL,['PHASE4'],
16358,NCT01157923,Time spent in the normal range,Number and type of changes in any pump setting per iteration,2010-07,COMPLETED,INTERVENTIONAL,['NA'],
16359,NCT02650050,Number of intra-vitreal anti-VEGF injections,Time to reduction of the macular thickness,2016-01-19,TERMINATED,INTERVENTIONAL,['NA'],
16360,NCT02463097,Change in A1C,Number of Diabetic Ketoacidosis (DKA) Events,2015-06,COMPLETED,INTERVENTIONAL,['NA'],
16361,NCT05218395,To assess the risk of Persistent organic pollutant exposure to type 2 diabetes,To assess the risk of Persistent organic pollutant exposure to thyroid cancer,2021-12-20,RECRUITING,OBSERVATIONAL,['NA'],
16362,NCT01549444,Renin and Aldosterone levels corelated to BP measurements,Blood pressure measurements,2012-03,COMPLETED,OBSERVATIONAL,['NA'],
16363,NCT02699307,Change in physical activity: Community Healthy Activities Model Program for Seniors (CHAMPS) survey,Change in social participation:validated questionnaires from the Patient-Reported Outcomes Measurement Information System (PROMIS) assessment center,2016-06,COMPLETED,INTERVENTIONAL,['NA'],
16364,NCT04484779,Total and Domain Specific Score of the mHealth App Usability Questionnaire (MAUQ) for Standalone mHealth Apps Used by Patients,Likelihood of Site to Recommend the IIM System,2020-07-14,COMPLETED,INTERVENTIONAL,['NA'],
16365,NCT03013985,Mean Daily Blood Glucose Concentration After Hospital Discharge,Hospital Mortality,2017-05-17,COMPLETED,INTERVENTIONAL,['PHASE4'],
16366,NCT04834518,Frequency of Diabetic Ketoacidosis on the clinical presentation of Type 1 Diabetes,The rate of progression from pre-symptomatic T1D to clinical diabetes,2021-04-01,RECRUITING,OBSERVATIONAL,['NA'],
16367,NCT02409017,Mean maternal glucose,,2015-04,TERMINATED,INTERVENTIONAL,['NA'],
16368,NCT01795833,Number of Participants With Progression to Type 2 Diabetes,Total Physical Activity,2013-06-03,COMPLETED,INTERVENTIONAL,['NA'],
16369,NCT05620927,Impaired awareness of hypoglycemia (IAH) - Clarke's Questionnaire,occurrence of cognitive impairment,2022-11-24,RECRUITING,OBSERVATIONAL,['NA'],
16370,NCT04830969,Change in Probing Pocket Depth at the 6-month Post-SRP Completed at Baseline,Change in Distance to the Healthy Plane Based on the Subgingival Plaque Microbiome at 6 Months,2016-11-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
16371,NCT04181424,Glycemic control (HbA1c),Blood Pressure,2019-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],
16372,NCT01471275,Glycosylated hemoglobin,Adverse events recorded,2011-11,UNKNOWN,INTERVENTIONAL,['NA'],
16373,NCT03499704,Mean Change from Baseline in HbA1c at Week 26,Number of Participants who Achieved an HbA1c Goal Target of Less than (<) 6.5 Percent (%) at Week 26,2020-02-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],
16374,NCT01595750,Endotelial function,"Serum endothelial dysfunction markers:TWEAKs, FasL, ADMA",2012-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],
16375,NCT00994955,best-corrected visual acuity,"change of retinal thickness, presence of hard exudates and leakage in FFA, specificity and sensitivity of optoacoustic measurements",2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",
16376,NCT01168076,,,2001-12,COMPLETED,OBSERVATIONAL,['NA'],
16377,NCT06113588,Diabetes-related distress (patient and family member),Patient medical outcomes,2023-06-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],
16378,NCT02411578,Number of Hypoglycemic Events ≥50 mg/dl 15 Minutes AND ≥ 70 mg/dl 30 Minutes After Initial Treatment,CGM Coefficient of Variation,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2'],
16379,NCT00276939,Hemoglobin A1c,Dietary Acceptability,2003-09,COMPLETED,INTERVENTIONAL,['NA'],
16380,NCT03940183,HbA1c,Body Mass Index,2019-07-08,COMPLETED,INTERVENTIONAL,['PHASE3'],
16381,NCT02035371,Area under the serum insulin aspart concentration-time curve,Maximum observed serum insulin aspart concentration,2014-01-13,COMPLETED,INTERVENTIONAL,['PHASE1'],
16382,NCT01626053,Changes in A1c levels for pretest and post test (Preset baseline and post-test 2 years,,2009-03,COMPLETED,INTERVENTIONAL,['NA'],
16383,NCT05845242,"Correlation of the above features with the chance of developing ulcers (Risk 0, Risk 1, Risk 2 and Risk 3).","Assessing the practical needs for transferring measurements to a different environment (e.g., home) by interviewing the clinicians involved in the consortium.",2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],
16384,NCT06057623,Change of the isometric force,Change of Rate of Perceived Exertion,2023-06-15,RECRUITING,OBSERVATIONAL,['NA'],
16385,NCT00389896,HDL-C raising effects after 6 weeks,Effect on other lipids and lipoproteins at 6 weeks,2001-07-26,COMPLETED,INTERVENTIONAL,['PHASE3'],
16386,NCT04308291,Time in range (TIR),Glycemic parameters changes,2021-02-15,COMPLETED,OBSERVATIONAL,['NA'],
16387,NCT02846857,Percentage of time of glucose levels below 3.9 mmol/L,Percentage of time when the closed-loop was automatically switched to insulin pump therapy,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],
16388,NCT03437044,P2Y12 Reaction Units (PRU),Platelet Reactivity Index (PRI),2018-03-14,COMPLETED,INTERVENTIONAL,['PHASE4'],
16389,NCT04442698,Delta Hemoglobin A1c Levels (HbA1c),,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],
16390,NCT03266952,Incidence of Stroke,Scoring cognitive impairment,1993-01,COMPLETED,OBSERVATIONAL,['NA'],Incidence of diabetes
16391,NCT00771004,Incidence of Cardiac Troponin I elevation (greater than 1 upper limit of normal) post-percutaneous coronary intervention with stent implantation.,Time course of Adiponectin Laboratory Procedure.,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],
16392,NCT00502138,Fasting and postprandial pramlintide pharmacokinetics,Hemoglobin A1c,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
16393,NCT02037321,Non-alcoholic fatty liver disease (NAFLD) analysis,,2013-05,UNKNOWN,OBSERVATIONAL,['NA'],
16394,NCT04455633,Change from Baseline in Average Daily Pain Score (ADPS),Safety: # of AEs reported,2020-07-07,COMPLETED,INTERVENTIONAL,['PHASE2'],
16395,NCT04207619,Percent 13C enrichment of bicarbonate measured via carbon-13 magnetic resonance spectroscopy (13C-MRS),Change in serum epinephrine levels,2020-02-19,RECRUITING,INTERVENTIONAL,['NA'],
16396,NCT03385135,Endothelium-dependent vasodilation,Major adverse cardiac events (MACE),2017-12,UNKNOWN,INTERVENTIONAL,['NA'],
16397,NCT01025856,postprandial lipids metabolism,adipose tissue lipolytic activities,2009-09,COMPLETED,INTERVENTIONAL,['NA'],
16398,NCT00993304,"AUC0-8h (triglyceride), the area under the triglyceride-concentration-time curve in the interval 0-8 hours following a meal with a high fat content","Glucose, insulin, C-peptide and glucagon: AUC0-8 hours after meal with a high fat content",2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],
16399,NCT00634543,Change From Baseline in Pain Intensity Score at Day 43,Change From Baseline in Short Form-36 (SF-36) Score at Day 43,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4'],
16400,NCT04062890,Blood Pressure,,2019-12-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],
16401,NCT00369148,glycohemoglobin,blood pressure,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4'],
16402,NCT01245166,The changes from baseline in HbA1c to the end of treatment period,"the change from baseline to the end of treatment in FBG, PBG, lipid profiles, and body weight. The safety evaluation will include: 1) Adverse events; 2) Laboratory data; 3) Physical examination; 4) Vital signs; 5) 12- lead ECG",2010-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],
16403,NCT00446264,Composite Criteria: Insulin Independence and Glycosylated Hemoglobin (HbA1c) Under 6.5% at One Year,Number of Adverse Events,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
16404,NCT04515758,Participant and Instructor Age,Change in Exercise-related Self-Efficacy,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],
16405,NCT05887544,Concentration of Indole-3-lactic acid in blood,Concentration of 3-Phenyllactic acid in urine,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],Exploratory analyses
16406,NCT01708902,The Change From Baseline in HbA1c After 12 Weeks of Treatment in APG,The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
16407,NCT00628524,"Parameters of triglyceride tolerance and glucose tolerance in correlation to cardiovascular events, cardiovascular mortality, total mortality.","Waist-to-Hip ratio, nutrition protocol, physical activity, non-invasive endothelial function, body fat composition, other biomarkers of lipid and glucose metabolism.",2008-02,COMPLETED,OBSERVATIONAL,['NA'],
16408,NCT02779413,Number of Adverse Events (AE),Weight gain,2016-06-02,COMPLETED,OBSERVATIONAL,['NA'],
16409,NCT03076528,Balance change from Baseline to 4 weeks quantified by body sway,Change of Incidents of foot problems,2016-11-06,COMPLETED,INTERVENTIONAL,['PHASE2'],
16410,NCT00396071,Change in C-peptide IAUC (0-4hr),Change in postprandial GLP-1,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],
16411,NCT01498276,Intergenerational transfer of diet-related behaviors,Efficacy of utilizing mothers to educate family members of disease risk and motivate healthy behaviors.,2012-01-03,COMPLETED,OBSERVATIONAL,['NA'],
16412,NCT03263494,Change in HbA1c from baseline to 26 weeks adjusted for baseline,Pittsburgh Sleep Quality Index,2018-01-25,COMPLETED,INTERVENTIONAL,['PHASE3'],
16413,NCT05501223,Number of medications used at baseline compared to number of medications used at follow-up. Resulting in a rate of medications used at baseline compared to follow-up i.e. no. medication at follow-up/no. at baseline.,EQ5D index score. (a Euro Quality of Life 5-dimension 5-level (EQ-5D-5L) scale). The score is retrieved by using the validated EQ5D questionnaire which translates to a corresponding EQ5D index score using country specific value sets.,2020-11-01,RECRUITING,INTERVENTIONAL,['NA'],
16414,NCT04331535,Time-to-new diagnosis of common complex disease,Medication adherence,2020-07-17,RECRUITING,INTERVENTIONAL,['NA'],Health status and quality of life
16415,NCT01042977,Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit,Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 8 (LOCF) in Participants With Baseline SBP>=130 mmHg,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
16416,NCT05553184,"Change in Brown Adipose Tissue thermogenesis (formoterol induced, cold-induced and effect of nicotinic acid)",Protein expression of subcutaneous abdominal white adipose tissue,2022-07-05,COMPLETED,INTERVENTIONAL,['NA'],
16417,NCT01859793,Brachial Artery Flow Mediated Dilation,Circulating Inflammatory Markers VCAM-1,2013-06,COMPLETED,INTERVENTIONAL,['PHASE4'],
16418,NCT05031871,AUC0-inf：Area under the curve from time 0 to infinity；,ADA：anti-drug antibody,2021-09-02,COMPLETED,INTERVENTIONAL,['PHASE1'],
16419,NCT01217307,Improvement in Left Ventricular Ejection Fraction,"Cardiac MRI After 4 Months, Per Protocol Analysis",2011-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
16420,NCT04470635,Vascular endothelial growth factor level,Thiol/disulphide measurement,2020-07-25,COMPLETED,OBSERVATIONAL,['NA'],
16421,NCT04495114,Preoperative glucose,,2017-08-31,COMPLETED,INTERVENTIONAL,['NA'],
16422,NCT01386541,Assessment of the safety/tolerability of multiple dosing of BYK324677 given once daily (SID) or twice daily (BID) in healthy volunteers.,Exploratory assessment of the pharmacodynamics (PD) of multiple dosing of BYK324677 (SID or BID) under steady state conditions in healthy volunteers.,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],
16423,NCT03968952,Number of home visits completed by Community Health Worker,Mean postpartum Diastolic Blood Pressure,2019-10-01,COMPLETED,INTERVENTIONAL,['NA'],
16424,NCT02523131,Time spent in the target glucose range from 3.9 to 10.0 mmol/l (70 to 180mg/dl) based on CGM glucose levels,Change of body weight from screening to end of study,2016-05,COMPLETED,INTERVENTIONAL,['NA'],Amount of CGM use
16425,NCT01453751,Number of adverse events reported,reduction in requirement of insulin dosage compared to baseline,2014-03,WITHDRAWN,INTERVENTIONAL,['NA'],
16426,NCT02660476,"Diabetes Complications (Nephropathy, Neuropathy, Retinopathy)",Physical activity,2014-10,TERMINATED,OBSERVATIONAL,['NA'],
16427,NCT05902650,OCTA data,,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],
16428,NCT04389775,Number of treatment emergent adverse events (TEAEs),Trough plasma XW003 concentrations before next dosing (Day 1 to last dosing),2020-03-29,COMPLETED,INTERVENTIONAL,['PHASE1'],
16429,NCT05165693,Glucose positive area under the curve (AUC),Insulin Concentrations,2022-02-23,COMPLETED,INTERVENTIONAL,['NA'],Sensory Questionnaire
16430,NCT03366168,"To demonstrate that in humans, epithelial stem cells isolated from the base of human taste buds can be propagated.",To investigate if differentiation capability of the stem cells changes as a factor of age.,2017-12-18,RECRUITING,OBSERVATIONAL,['NA'],
16431,NCT03502109,Quality of Life (QoL) by visual analog scale (VAS),ACR (albumin-creatinine ratio),2018-01-05,COMPLETED,INTERVENTIONAL,['NA'],
16432,NCT02823678,Percent resected volume of pancreas and diabetes development,Blood glucose control,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],
16433,NCT01839370,Percent of Glucose Measurements within Target Range,,2013-07,COMPLETED,INTERVENTIONAL,['NA'],
16434,NCT00879801,The rate of conversion to diabetes of IGR subjects carrier of type 2 diabetes susceptibility genes,,2003-01,COMPLETED,OBSERVATIONAL,['NA'],
16435,NCT00099892,Change from baseline in HbA1c after 24 weeks,Change from baseline in fasting lipids at 24 weeks,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3'],
16436,NCT02459535,"change in combined blood levels of glucose and insulin, expressed in calculated indices for insulin sensitivity",,2015-03,COMPLETED,INTERVENTIONAL,['NA'],
16437,NCT03686722,Maximum excretion rate (Urate max),Maximum Glucose concentration(Gmax),2017-09-09,COMPLETED,INTERVENTIONAL,['PHASE1'],
16438,NCT04245826,Total mortality,,2019-05-16,UNKNOWN,OBSERVATIONAL,['NA'],
16439,NCT04158921,The mean change in blood glucose.,The change in the number of hypoglycemic episodes.,2019-11-07,TERMINATED,INTERVENTIONAL,['NA'],
16440,NCT00856986,Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26.,Hypoglycaemic Episodes Weeks 0-52,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],
16441,NCT01361594,Hospital Mortality,Cerebrovascular Events,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],
16442,NCT00435786,,,na,COMPLETED,OBSERVATIONAL,['NA'],
16443,NCT01383304,"Combined primary endpoint: Cardiovascular death, acute myocardial infarction, ischaemic stroke",Single endpoints:cardiovascular death; acute myocardial infarction; ischemic stroke; stent thrombosis; all-cause death,2007-11,UNKNOWN,OBSERVATIONAL,['NA'],Genotype according to pre-specified genetic single nucleotide polymorphisms (SNPs)
16444,NCT00516958,"To compare the rates of clinical success (cure + improvement) of Topical Dermacyn™ vs. Oral Levofloxacin vs. Combined therapy, in patients with mild diabetic foot infections in non ischemic ulcers",To compare the treatment groups with respect to microbiological outcome. Incidence of adverse events and other safety outcomes,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],
16445,NCT05102851,CCU admission,,2021-08-01,COMPLETED,OBSERVATIONAL,['NA'],
16446,NCT05452525,AUClast,,2022-07-26,COMPLETED,INTERVENTIONAL,['PHASE1'],
16447,NCT01170403,Cardiovascular event,,2006-01,COMPLETED,OBSERVATIONAL,['NA'],
16448,NCT04189510,Efficacy of Artificial Pancreas system,,2021-04-01,WITHDRAWN,INTERVENTIONAL,['NA'],
16449,NCT05147883,Score of Quality of Life,Depression,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA'],
16450,NCT00130806,The difference in daily dose requirements of insulin after 24 weeks,"(a) HbA1C; (b) FPG; (c) Percent of patients with HbA1C <7.0%; (d) TG, HDL-C, non-HDL-C and apolipoprotein B; (e) Free Fatty Acids (FFA); (f) the incidence of hypoglycemic events at 24 weeks",2005-09,TERMINATED,INTERVENTIONAL,['PHASE3'],
16451,NCT05776420,Hemoglobin A1c,Carotenoid level,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE3'],
16452,NCT00482729,Change From Baseline in Hemoglobin A1c (A1C) at Week 18,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18,2007-06-19,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Patients With A1C < 7.0% at Week 44
16453,NCT04234867,time to development of DKA,time to decrease of ph level,2022-05-18,TERMINATED,INTERVENTIONAL,['PHASE1'],
16454,NCT03746392,Documentation of goals of care,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],
16455,NCT01763567,Device Performance: Accuracy of HGMS,,2012-03,COMPLETED,OBSERVATIONAL,['NA'],Functionality of HGMS: Alerts and Alarms - % of Hyper False Alert
16456,NCT01972477,Percent change in HDL-cholesterol level,Adverse event,2016-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",
16457,NCT01342874,altered OGTT,delivery and neonatal outcomes,2010-08,COMPLETED,OBSERVATIONAL,['NA'],
16458,NCT01629862,Absolute Change in Brachial Artery Flow-mediated Dilation (FMD).,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],
16459,NCT02115555,Glycemic Control using HBA1C,Treatment Adherence Behaviors,2014-05,COMPLETED,INTERVENTIONAL,['NA'],Satisfaction
16460,NCT01404078,Tolerability of a Double Dose of Half Strength Polycap,Blood Pressure Reduction and Lipid Lowering in Type 2 Diabetics,2010-04,COMPLETED,INTERVENTIONAL,['NA'],
16461,NCT01941238,Incidence of hypoglycemia,Rate of acute complications,2013-07,COMPLETED,OBSERVATIONAL,['NA'],
16462,NCT00341237,Disease,,2010-05-26,RECRUITING,OBSERVATIONAL,['NA'],
16463,NCT03923114,Pituitary uptake of Ga-68-NODAGA-exendin,Metabolic status (ACTH),2019-05-23,UNKNOWN,INTERVENTIONAL,['NA'],
16464,NCT05390892,"Total (first and recurrent) cardiovascular, kidney, and death events",,2022-09-26,RECRUITING,INTERVENTIONAL,['PHASE4'],
16465,NCT04948931,Spielberger State-Trait Anxiety Scale (STAI),,2021-07-28,COMPLETED,INTERVENTIONAL,['NA'],
16466,NCT06057246,Post-prandial glucose response,Sleep duration,2023-05-15,RECRUITING,INTERVENTIONAL,['NA'],
